PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Schliess, F; Reissmann, R; Reinehr, R; vom Dahl, S; Haussinger, D				Schliess, F; Reissmann, R; Reinehr, R; vom Dahl, S; Haussinger, D			Involvement of integrins and Src in insulin signaling toward autophagic proteolysis in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-VOLUME; MAP KINASE; GLUTAMINE TRANSPORT; ACTIVATION; EXPRESSION; RESISTANCE; P38(MAPK); INHIBITION; MODULATION; MECHANISMS	Cell volume changes critically determine hepatic signal transduction and metabolism. Hepatocyte swelling by insulin contributes to p38(MAPK) activation leading to inhibition of autophagic proteolysis. Recently integrins were shown to sense hypoosmotic hepatocyte swelling. Here the role of integrins, Src, and focal adhesion kinase (FAK) in insulin signaling was investigated using the intact organ model of perfused rat liver. Insulin increases [Tyr(P)(418)]Src, [Tyr(P)(397)]FAK, and dual p38(MAPK) phosphorylation by about 2-fold. Infusion of the integrin-antagonizing hexapeptide GRGDSP or the Src inhibitor PP-2 prevented activation of Src and p38(MAPK) and, consequently, proteolysis inhibition by insulin. However, insulin-induced phosphorylation of IRbeta (Tyr(1158)) and protein kinase B (PKB, Ser(473)), as well as K+-uptake and cell swelling, was not reduced by the inhibitors. Both hypoosmotic swelling and insulin increase the plasma membrane levels of activated beta(1) integrin. Inhibition of insulin-induced swelling by furosemide largely abolished activation of beta(1) integrin and phosphorylation of Src, but not of PKB. Rapamycin does not affect either insulin-induced K+-retention and cell swelling or proteolysis inhibition, indicating that swelling-dependent proteolysis inhibition occurs independently from the mammalian target of rapamycin. The data suggest that sensing of cell swelling by integrins essentially contributes to insulin signaling, thereby defining a novel way of integrin involvement in growth factor signaling.	Univ Dusseldorf, Div Gastroenterol Hepatol & Infect Dis, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schliess, F (corresponding author), Univ Dusseldorf, Div Gastroenterol Hepatol & Infect Dis, Moorenstr 5, D-40225 Dusseldorf, Germany.	Freimut.Schliess@uni-duesseldorf.de	Dahl, Stephan vom/AAF-8456-2021; Reinehr, Roland/G-6118-2016	Dahl, Stephan vom/0000-0003-0481-0601; 				Aplin AE, 1998, PHARMACOL REV, V50, P197; Beugnet A, 2003, BIOCHEM J, V372, P555, DOI 10.1042/BJ20021266; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Carloni V, 2002, HEPATOLOGY, V36, P582, DOI 10.1053/jhep.2002.35277; Carloni V, 2001, HEPATOLOGY, V34, P42, DOI 10.1053/jhep.2001.25224; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HALLBRUCKER C, 1991, EUR J BIOCHEM, V199, P467, DOI 10.1111/j.1432-1033.1991.tb16145.x; HALLBRUCKER C, 1991, PFLUG ARCH EUR J PHY, V418, P519, DOI 10.1007/BF00497781; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HAUSSINGER D, 1992, TRENDS PHARMACOL SCI, V13, P371, DOI 10.1016/0165-6147(92)90114-L; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; HAUSSINGER D, 1990, BIOCHEM J, V272, P239, DOI 10.1042/bj2700039; Hsu SL, 2001, CANCER LETT, V167, P193, DOI 10.1016/S0304-3835(01)00479-7; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Krause U, 2002, EUR J BIOCHEM, V269, P3742, DOI 10.1046/j.1432-1033.2002.03069.x; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; Kubitz R, 2001, HEPATOLOGY, V34, P340, DOI 10.1053/jhep.2001.25959; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Low SY, 1998, J PHYSIOL-LONDON, V512, P481, DOI 10.1111/j.1469-7793.1998.481be.x; Low SY, 1997, FEBS LETT, V417, P101, DOI 10.1016/S0014-5793(97)01264-7; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nejjari M, 2001, J PATHOL, V195, P473, DOI 10.1002/path.964; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Ritchie JWA, 2001, CELL PHYSIOL BIOCHEM, V11, P259, DOI 10.1159/000047812; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Schliess F, 2003, INT REV CYTOL, V225, P187, DOI 10.1016/S0074-7696(05)25005-2; Schliess F, 2001, BIOL CHEM, V382, P1063, DOI 10.1515/BC.2001.133; Sies H, 1978, Methods Enzymol, V52, P48; Tessari P, 2003, CURR OPIN CLIN NUTR, V6, P79, DOI 10.1097/00075197-200301000-00012; Torimura T, 2001, HEPATOLOGY, V34, P62, DOI 10.1053/jhep.2001.25546; Trouet D, 1999, J PHYSIOL-LONDON, V520, P113, DOI 10.1111/j.1469-7793.1999.t01-1-00113.x; vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200; vom Dahl S, 2001, CELL PHYSIOL BIOCHEM, V11, P285, DOI 10.1159/000047815; vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031; VOMDAHL S, 1991, BIOCHEM J, V280, P105, DOI 10.1042/bj2800105; VOMDAHL S, 1995, BIOCHEM J, V308, P529, DOI 10.1042/bj3080529; VOMDAHL S, 1991, BIOL CHEM H-S, V372, P411, DOI 10.1515/bchm3.1991.372.1.411; Wang N, 2001, P NATL ACAD SCI USA, V98, P7765, DOI 10.1073/pnas.141199598; Warskulat U, 1999, CELL PHYSIOL BIOCHEM, V9, P99, DOI 10.1159/000016306; Webster CRL, 2000, J BIOL CHEM, V275, P29754, DOI 10.1074/jbc.M002831200; Wettstein M, 1997, HEPATOLOGY, V26, P1560	49	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21294	21301		10.1074/jbc.M313901200	http://dx.doi.org/10.1074/jbc.M313901200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985360	hybrid			2022-12-27	WOS:000221273800091
J	Petriv, OI; Rachubinski, RA				Petriv, OI; Rachubinski, RA			Lack of peroxisomal catalase causes a progeric phenotype in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BETA-OXIDATION; LIFE-SPAN; C-ELEGANS; DAF-16; NEMATODE; GENETICS; PROTEIN; GENES; EXTENSION; SURVIVAL	Studies using the nematode Caenorhabditis elegans as a model system to investigate the aging process have implicated the insulin/insulin-like growth factor-I signaling pathway in the regulation of organismal longevity through its action on a subset of target genes. These targets can be classified into genes that shorten or extend life-span upon their induction. Genes that shorten life-span include a variety of stress response genes, among them genes encoding catalases; however, no evidence directly implicates catalases in the aging process of nematodes or other organisms. Using genetic mutants, we show that lack of peroxisomal catalase CTL-2 causes a progeric phenotype in C. elegans. Lack of peroxisomal catalase also affects the developmental program of C. elegans, since Deltactl-2 mutants exhibit decreased egg laying capacity. In contrast, lack of cytosolic catalase CTL-1 has no effect on either nematode aging or egg laying capacity. The Deltactl-2 mutation also shortens the maximum life-span of the long lived Deltaclk-1 mutant and accelerates the onset of its egg laying period. The more rapid aging of Deltactl-2 worms is apparently not due to increased carbonylation of the major C. elegans proteins, although altered peroxisome morphology in the Deltactl-2 mutant suggests that changes in peroxisomal function, including increased production of reactive oxygen species, underlie the progeric phenotype of the Deltactl-2 mutant. Our findings support an important role for peroxisomal catalase in both the development and aging of C. elegans and suggest the utility of the Deltactl-2 mutant as a convenient model for the study of aging and the human diseases acatalasemia and hypocatalasemia.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg 5-14, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca						Boulianne GL, 2001, MECH AGEING DEV, V122, P883, DOI 10.1016/S0047-6374(01)00245-7; Braeckman BP, 2002, MECH AGEING DEV, V123, P1447, DOI 10.1016/S0047-6374(02)00085-4; Chang CC, 1999, J CELL SCI, V112, P1579; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Germain V, 2001, PLANT J, V28, P1, DOI 10.1046/j.1365-313X.2001.01095.x; Gill MS, 2003, FREE RADICAL BIO MED, V35, P558, DOI 10.1016/S0891-5849(03)00328-9; Goto S, 1999, MECH AGEING DEV, V107, P245, DOI 10.1016/S0047-6374(98)00133-X; Guarente L, 1998, P NATL ACAD SCI USA, V95, P11034, DOI 10.1073/pnas.95.19.11034; Hall DH, 1995, METHOD CELL BIOL, V48, P395; Hekimi S, 2001, TRENDS GENET, V17, P712, DOI 10.1016/S0168-9525(01)02523-9; HOPE IA, 1999, C ELEGANS PRACTICAL, P62; Houthoofd K, 2002, EXP GERONTOL, V37, P1015, DOI 10.1016/S0531-5565(02)00063-3; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Houthoofd K, 2002, EXP GERONTOL, V37, P1359, DOI 10.1016/S0531-5565(02)00172-9; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Jazwinski SM, 1998, EXP GERONTOL, V33, P773, DOI 10.1016/S0531-5565(98)00027-8; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Legakis JE, 2002, MOL BIOL CELL, V13, P4243, DOI 10.1091/mbc.E02-06-0322; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; MACKAY WJ, 1989, GENETICS, V122, P643; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nakamura A, 1999, BIOCHEM BIOPH RES CO, V264, P580, DOI 10.1006/bbrc.1999.1549; OGATA M, 1991, HUM GENET, V86, P331; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Petriv OI, 2002, PHYSIOL GENOMICS, V10, P79, DOI 10.1152/physiolgenomics.00044.2002; Segrest JP, 2001, J LIPID RES, V42, P1346; Shibata Y, 2003, SCIENCE, V302, P1779, DOI 10.1126/science.1087167; Smith JJ, 2000, J BIOL CHEM, V275, P20168, DOI 10.1074/jbc.M909285199; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; Thieringer H, 2003, J CELL SCI, V116, P1797, DOI 10.1242/jcs.00380; Togo SH, 2000, EUR J BIOCHEM, V267, P1307, DOI 10.1046/j.1432-1327.2000.01091.x; van Roermund CWT, 2000, J CELL BIOL, V150, P489, DOI 10.1083/jcb.150.3.489; Van Zandyeke SM, 2002, MECH AGEING DEV, V123, P365, DOI 10.1016/S0047-6374(01)00382-7; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; WETTERAU JR, 1992, SCIENCE, V258, P999; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; WONG A, 1995, GENETICS, V139, P1247; WOODBURY W, 1971, ANAL BIOCHEM, V44, P301, DOI 10.1016/0003-2697(71)90375-7; Yanase S, 2002, MECH AGEING DEV, V123, P1579, DOI 10.1016/S0047-6374(02)00093-3	44	106	116	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19996	20001		10.1074/jbc.M400207200	http://dx.doi.org/10.1074/jbc.M400207200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996832	hybrid			2022-12-27	WOS:000221164500074
J	Picher, M; Burch, LH; Boucher, RC				Picher, M; Burch, LH; Boucher, RC			Metabolism of P2 receptor agonists in human airways - Implications for mucociliary clearance and cystic fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; INDEPENDENT ATP RELEASE; NASAL EPITHELIAL-CELLS; INTRACELLULAR CALCIUM; EXTRACELLULAR ATP; ADENYLATE KINASE; ION-TRANSPORT; ADENOSINE; VOLUME; MECHANISMS	Extracellular nucleotides are among the most potent mediators of mucociliary clearance (MCC) in human lungs. However, clinical trials revealed that aerosolized nucleotides provide only a transient improvement of MCC to patients diagnosed with cystic fibrosis (CF). In this study, we identified the mechanism that eliminates extracellular nucleotides from human airways. Polarized primary cultures of human bronchial epithelial cells were impermeable to extracellular nucleotides but rapidly dephosphorylated ATP into ADP, AMP, and adenosine. The half-life of a therapeutic ATP concentration (0.1 mM) was similar to20 s within the periciliary liquid layer. The mucosal epithelial surface eliminated P2 receptor agonists (ATP = UTP > ADP > UDP) at 3-fold higher rates than the serosal surface. We also showed that mucosal (not serosal) ectoATPase activity increases toward areas most susceptible to airway obstruction (nose < bronchi << bronchioles). Bronchial cultures from patients with CF, primary ciliary dyskinesia, or alpha 1-antitrypsin deficiency exhibited 3-fold higher mucosal (not serosal) ectoATPase activity than normal cultures. Time course experiments indicated that CF enhances ATP elimination and adenosine accumulation on the mucosal surface. Furthermore, nonspecific alkaline phosphatase was identified as the major regulator of airway nucleotide concentrations in CF, primary ciliary dyskinesia, and alpha 1-antitrypsin deficiency. The ectoATPase activity and mRNA expression of mucosally restricted nonspecific alkaline phosphatase were 3-fold higher on bronchial cultures from these patients than from healthy subjects. This study demonstrates that the duration of nucleotide-mediated MCC is limited by epithelial ectonucleotidases throughout human airways, with the efficiency of this mechanism enhanced in chronic inflammatory lung diseases, including CF.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Dept Pulm & Crit Care Med, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University	Picher, M (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, 7010 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	pichm@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 34322] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; Blackburn MR, 1998, J BIOL CHEM, V273, P5093, DOI 10.1074/jbc.273.9.5093; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Cass C E, 1999, Pharm Biotechnol, V12, P313; Clancy JP, 1999, AM J PHYSIOL-CELL PH, V276, pC361, DOI 10.1152/ajpcell.1999.276.2.C361; Clarke LL, 1999, AM J PHYSIOL-CELL PH, V276, pC777, DOI 10.1152/ajpcell.1999.276.4.C777; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Donaldson SH, 2000, MOL MED, V6, P969, DOI 10.1007/BF03401831; DONALDSON SH, 1998, P2 NUCLEOTIDE RECEPT, P413; Felix JA, 1996, AM J RESP CELL MOL, V14, P296, DOI 10.1165/ajrcmb.14.3.8845181; Foster WM, 2002, PULM PHARMACOL THER, V15, P277, DOI 10.1006/pupt.2002.0351; Gabriel SE, 2002, CURR TOP MEMBR, V53, P193; GABRIEL SE, 1997, LUNG SCI FDN, P305; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; GUNST SJ, 1988, J APPL PHYSIOL, V64, P2522, DOI 10.1152/jappl.1988.64.6.2522; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Homolya L, 1999, J BIOL CHEM, V274, P26454, DOI 10.1074/jbc.274.37.26454; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; Kunzelmann K, 2001, CLIN EXP PHARMACOL P, V28, P857, DOI 10.1046/j.1440-1681.2001.03541.x; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; Lazarowski ER, 2001, NEWS PHYSIOL SCI, V16, P1; LAZAROWSKI ER, 2001, PEDIAT PULMONOLOGY S, V22, P193; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LEHIR M, 1989, ENZYME, V41, P87, DOI 10.1159/000469058; Leung GPH, 2001, BIOL REPROD, V64, P764, DOI 10.1095/biolreprod64.3.764; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Lyczak JB, 2002, CLIN MICROBIOL REV, V15, P194, DOI 10.1128/CMR.15.2.194-222.2002; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Morse DM, 2001, AM J PHYSIOL-CELL PH, V280, pC1485, DOI 10.1152/ajpcell.2001.280.6.C1485; Musante L, 1999, J BIOL CHEM, V274, P11701, DOI 10.1074/jbc.274.17.11701; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Oberwaldner B, 2000, EUR RESPIR J, V15, P196; Olivier KN, 1996, AM J RESP CRIT CARE, V154, P217, DOI 10.1164/ajrccm.154.1.8680683; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Picher M, 2003, J BIOL CHEM, V278, P11256, DOI 10.1074/jbc.M208071200; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; RUGOLO M, 1993, J BIOL CHEM, V268, P24779; STEFANOVIC V, 1988, RENAL PHYSIOL BIOCH, V11, P89; Szkotak AJ, 2001, AM J PHYSIOL-CELL PH, V281, pC1991, DOI 10.1152/ajpcell.2001.281.6.C1991; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Taylor AL, 1999, J CLIN INVEST, V104, P875, DOI 10.1172/JCI7270; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; WIENDL HS, 1998, BIOCHIM BIOPHYS ACTA, V1431, P282; WONG LB, 1992, AM J RESP CELL MOL, V7, P447, DOI 10.1165/ajrcmb/7.4.447; WU R, 1985, AM REV RESPIR DIS, V132, P311; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	58	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20234	20241		10.1074/jbc.M400305200	http://dx.doi.org/10.1074/jbc.M400305200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14993227	hybrid			2022-12-27	WOS:000221164500100
J	Burchfield, JG; Lennard, AJ; Narasimhan, S; Hughes, WE; Wasinger, VC; Corthals, GL; Okuda, T; Kondoh, H; Biden, TJ; Schmitz-Peiffer, C				Burchfield, JG; Lennard, AJ; Narasimhan, S; Hughes, WE; Wasinger, VC; Corthals, GL; Okuda, T; Kondoh, H; Biden, TJ; Schmitz-Peiffer, C			Akt mediates insulin-stimulated phosphorylation of Ndrg2- Evidence for cross-talk with protein kinase C theta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWNSTREAM-REGULATED GENE-2; N-MYC; SKELETAL-MUSCLE; GLYCOGEN-SYNTHESIS; C2C12 MYOBLASTS; SEQUENCE MOTIFS; NPKC-THETA; B AKT; DIFFERENTIATION; INHIBITION	The protein kinase Akt mediates several metabolic and mitogenic effects of insulin, whereas activation of protein kinase C (PKC) isoforms has been implicated in the inhibition of insulin action. We have previously shown that both PKCtheta and PKCepsilon are activated in skeletal muscle of insulin-resistant high fat-fed rats, and to identify potential substrates for these kinases, we incubated recombinant PKC isoforms with rat muscle fractions in vitro. PKCtheta specifically phosphorylated a 48-kDa protein that was subsequently identified by mass spectrometry as Ndrg2. Ndrg2 is highly related to N-Myc downstream-regulated protein 1, which has been linked to stress responses, cell proliferation, and differentiation, although Ndrg2 itself is not repressed by N-Myc. Ndrg2 contains several potential phosphorylation sites, including three Akt consensus sequences. Ndrg2 phosphorylation was enhanced in [P-32] orthophosphate-labeled C2C12 muscle cells co-overexpressing either PKCtheta or Akt. Phosphorylation of Ndrg2 was examined further using a phospho (Ser/Thr) Akt substrate antibody. Insulin increased Ndrg2 phosphorylation in C2C12 cells in a wortmannin- and palmitate-inhibitable manner, whereas rapamycin, PD98059, and bisindoylmaleimide I had no effect, supporting a direct role for Akt. Mutation of Ndrg2 indicated that Thr-348 is the major phosphorylation site detected by the antibody and that Akt stimulates phosphorylation of this site, whereas PKCtheta phosphorylates Ser-332. PKCtheta overexpression, however, diminished the effect of insulin on Thr-348 phosphorylation without reducing Akt activation, suggesting that this is mediated through phosphorylation of Ndrg2 at Ser-332. Our data identify Ndrg2 as a novel insulin-dependent phosphoprotein and suggest that PKCtheta may inhibit insulin action in part by reducing its phosphorylation by Akt.	Garvan Inst Med Res, Cell Signalling Grp, Diabet & Obes Program, Sydney, NSW 2010, Australia; Garvan Inst Med Res, Prot Anal Lab, Sydney, NSW 2010, Australia; Osaka Univ, Grad Sch Frontier Biosci, Dev Biol Lab, Suita, Osaka 5650871, Japan	Garvan Institute of Medical Research; Garvan Institute of Medical Research; Osaka University	Schmitz-Peiffer, C (corresponding author), Garvan Inst Med Res, Cell Signalling Grp, Diabet & Obes Program, 384 Victoria St, Sydney, NSW 2010, Australia.	c.schmitz-peiffer@garvan.org.au	Schmitz-Peiffer, Carsten/J-6918-2012; Biden, Trevor/AAW-2829-2021; Corthals, Garry/G-9417-2016; Burchfield, James/C-1779-2019; Wasinger, Valerie/AAC-5004-2021	Schmitz-Peiffer, Carsten/0000-0001-7330-7255; Corthals, Garry/0000-0001-9423-5596; Burchfield, James/0000-0002-6609-6151; Wasinger, Valerie/0000-0001-5338-0869; Biden, Trevor/0000-0001-5211-0234; Hughes, William/0000-0002-7149-3987				Agarwala KL, 2000, BIOCHEM BIOPH RES CO, V272, P641, DOI 10.1006/bbrc.2000.2833; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Boulkroun S, 2002, J BIOL CHEM, V277, P31506, DOI 10.1074/jbc.M200272200; Campbell DH, 1999, CANCER RES, V59, P5376; Cazzolli R, 2002, AM J PHYSIOL-ENDOC M, V282, pE1204, DOI 10.1152/ajpendo.00487.2001; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Choi SC, 2003, FEBS LETT, V553, P413, DOI 10.1016/S0014-5793(03)01030-5; Conejo R, 2002, ONCOGENE, V21, P3739, DOI 10.1038/sj.onc.1205469; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; CORTHALS GL, 1999, PROTEOME RES 2D GEL, P197; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kurdistani SK, 1998, CANCER RES, V58, P4439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ludowyke RI, 1996, J IMMUNOL, V157, P5130; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Miles K, 2000, J CELL BIOCHEM, V79, P71, DOI 10.1002/1097-4644(2000)79:1<71::AID-JCB70>3.0.CO;2-N; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Okuda T, 1999, BIOCHEM BIOPH RES CO, V266, P208, DOI 10.1006/bbrc.1999.1780; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Qu XH, 2002, MOL CELL BIOCHEM, V229, P35, DOI 10.1023/A:1017934810825; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Schmitz-Peiffer C, 2003, IUBMB LIFE, V55, P367, DOI 10.1080/1521654031000138569; Schmitz-Peiffer C, 2002, ANN NY ACAD SCI, V967, P146; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; Shaw E, 2002, PROTEINS, V47, P163, DOI 10.1002/prot.10083; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimono A, 1999, MECH DEVELOP, V83, P39, DOI 10.1016/S0925-4773(99)00025-8; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	43	67	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18623	18632		10.1074/jbc.M401504200	http://dx.doi.org/10.1074/jbc.M401504200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985363	hybrid			2022-12-27	WOS:000221041500066
J	Kim, EJ; Sampathkumar, SG; Jones, MB; Rhee, JK; Baskaran, G; Goon, S; Yarema, KJ				Kim, EJ; Sampathkumar, SG; Jones, MB; Rhee, JK; Baskaran, G; Goon, S; Yarema, KJ			Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-acyl-modified N-acetylmannosamine analogs in Jurkat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE SIALIC-ACID; MOLECULAR-CLONING; POLYSIALIC ACID; SIDE-CHAIN; ADHESION MOLECULE; INFLUENZA-VIRUS; LEWIS-X; EXPRESSION; GENE; GD3	The supplementation of the sialic acid biosynthetic pathway with exogenously supplied N-acetylmannosamine (ManNAc) analogs has many potential biomedical and biotechnological applications. In this work, we explore the structure-activity relationship of ManNAc analogs on cell viability and metabolic flux into the sialic acid biosynthetic pathway to gain a better understanding of the fundamental biology underlying "glycosylation engineering" technology. A panel of ManNAc analogs bearing various modifications on the hydroxyl groups as well as substitutions at the N-acyl position was investigated. Increasing the carbon chain length of ester derivatives attached to the hydroxyl groups increased the metabolic efficiency of sialic acid production, whereas similar modification to the N-acyl group decreased efficiency. In both cases, increases in chain length decreased cell viability; DNA ladder formation, Annexin V-FITC two-dimensional flow cytometry assays, caspase-3 activation, and down-regulation of sialoglycoconjugate-processing enzymes established that the observed growth inhibition and toxicity resulted from apoptosis. Two of the panel of 12 analogs tested, specifically Ac(4)ManNLev and Ac(4)ManNHomoLev, were highly toxic. Interestingly, both of these analogs maintained a ketone functionality in the same position relative to the core monosaccharide structure, and both also inhibited flux through the sialic acid pathway (the remainder of the less toxic analogs either increased or had no measurable impact on flux). These results provide fundamental insights into the role of sialic acid metabolism in apoptosis by demonstrating that ManNAc analogs can modulate apoptosis both indirectly via hydroxyl-group effects and directly through N-acyl-group effects.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; Naval Med Res Ctr, Enter Dis Dept, Silver Spring, MD 20910 USA	Johns Hopkins University; Naval Medical Research Center (NMRC)	Yarema, KJ (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Clark Hall 106A,3400 N Charles St, Baltimore, MD 21218 USA.	kjyarema@bme.jhu.edu	Rhee, Jun Kyu/I-9308-2014; Sampathkumar, Srinivasa-Gopalan/C-9951-2017	Rhee, Jun Kyu/0000-0001-6161-4311; Sampathkumar, Srinivasa-Gopalan/0000-0002-0616-8977				ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Azuma Y, 2000, GLYCOCONJUGATE J, V17, P301, DOI 10.1023/A:1007165403771; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Bhunia AK, 2002, J BIOL CHEM, V277, P16396, DOI 10.1074/jbc.M200877200; Charter NW, 2002, J BIOL CHEM, V277, P9255, DOI 10.1074/jbc.M111619200; Chen HY, 2002, J EXP MED, V196, P1529, DOI 10.1084/jem.20021915; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Collins G, 2000, NETW COMPUT, V11, P20; Connolly JL, 2001, J VIROL, V75, P4029, DOI 10.1128/JVI.75.9.4029-4039.2001; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Eda S, 2004, J BIOL CHEM, V279, P5967, DOI 10.1074/jbc.M310805200; Forrest JC, 2003, J VIROL, V77, P9109, DOI 10.1128/JVI.77.17.9109-9115.2003; Foster MM, 2003, CANCER RES, V63, P2775; Hang HC, 2001, J AM CHEM SOC, V123, P1242, DOI 10.1021/ja002962b; Harduin-Lepers A, 2000, BIOCHEM J, V352, P37, DOI 10.1042/0264-6021:3520037; Hart SP, 2000, CELL DEATH DIFFER, V7, P493, DOI 10.1038/sj.cdd.4400680; Ishii A, 1998, J BIOL CHEM, V273, P31652, DOI 10.1074/jbc.273.48.31652; Jacobs CL, 2001, BIOCHEMISTRY-US, V40, P12864, DOI 10.1021/bi010862s; Jones MB, 2004, BIOTECHNOL BIOENG, V85, P394, DOI 10.1002/bit.10901; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; KAYSER H, 1992, J BIOL CHEM, V267, P16934; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R; Keppler OT, 1999, GLYCOBIOLOGY, V9, P557, DOI 10.1093/glycob/9.6.557; Kim YJ, 1996, BIOCHEM BIOPH RES CO, V228, P324, DOI 10.1006/bbrc.1996.1660; KISHIMOTO H, 1995, J EXP MED, V181, P649, DOI 10.1084/jem.181.2.649; Kitagawa H, 1996, J BIOL CHEM, V271, P931, DOI 10.1074/jbc.271.2.931; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; Lawrence SM, 2000, J BIOL CHEM, V275, P17869, DOI 10.1074/jbc.M000217200; Lee JH, 1999, J BIOL CHEM, V274, P21878, DOI 10.1074/jbc.274.31.21878; Leguizamon MS, 1999, J INFECT DIS, V180, P1398, DOI 10.1086/315001; Lemieux GA, 1999, J AM CHEM SOC, V121, P4278, DOI 10.1021/ja984228m; Lemieux GA, 2001, CHEM BIOL, V8, P265, DOI 10.1016/S1074-5521(01)00008-4; Liu TM, 2000, J BIOL CHEM, V275, P32832, DOI 10.1074/jbc.C000573200; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; Malisan F, 2002, EXP GERONTOL, V37, P1273, DOI 10.1016/S0531-5565(02)00138-9; Misasi R, 2000, AIDS RES HUM RETROV, V16, P1539, DOI 10.1089/088922200750006065; Mohsin MA, 2002, VIRUS RES, V85, P123, DOI 10.1016/S0168-1702(02)00008-4; Mong TKK, 2003, CHEMBIOCHEM, V4, P835, DOI 10.1002/cbic.200300650; MORRIS RG, 1984, AM J PATHOL, V115, P426; Murata Takeomi, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P249; Oetke C, 2001, EUR J BIOCHEM, V268, P4553, DOI 10.1046/j.1432-1327.2001.02379.x; Okajima T, 2000, J BIOL CHEM, V275, P6717, DOI 10.1074/jbc.275.10.6717; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; Rozen S, 2000, Methods Mol Biol, V132, P365; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; Sanfilippo CM, 2003, INT REV IMMUNOL, V22, P327, DOI 10.1080/08830180305211; Sarkar AK, 1997, J BIOL CHEM, V272, P25608, DOI 10.1074/jbc.272.41.25608; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; Sarkar AK, 2000, CARBOHYD RES, V329, P287, DOI 10.1016/S0008-6215(00)00200-7; Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; SEPPALA R, 1991, J BIOL CHEM, V266, P7456; Shang J, 1999, EUR J BIOCHEM, V265, P580, DOI 10.1046/j.1432-1327.1999.00733.x; Sillanaukee P, 1999, EUR J CLIN INVEST, V29, P413; Suzuki O, 2003, INT J ONCOL, V23, P769; SZELE FG, 1994, NEUROSCIENCE, V60, P133, DOI 10.1016/0306-4522(94)90209-7; Uemura S, 2003, GLYCOBIOLOGY, V13, P207, DOI 10.1093/glycob/cwg022; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Villavicencio-Lorini P, 2002, J MOL MED-JMM, V80, P671, DOI 10.1007/s00109-002-0382-y; Viswanathan K, 2003, BIOCHEMISTRY-US, V42, P15215, DOI 10.1021/bi034994s; Watanabe Y, 2002, J BIOL CHEM, V277, P18222, DOI 10.1074/jbc.M201074200; Wieser JR, 1996, FEBS LETT, V395, P170, DOI 10.1016/0014-5793(96)01029-0; Yarema KJ, 2001, GENOME BIOL, V2; Yarema KJ, 1998, J BIOL CHEM, V273, P31168, DOI 10.1074/jbc.273.47.31168; Yarema KJ, 2001, BIOTECHNIQUES, V31, P384, DOI 10.2144/01312rv02; Yarema KJ, 2001, NAT BIOTECHNOL, V19, P553, DOI 10.1038/89305	72	25	28	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18342	18352		10.1074/jbc.M400205200	http://dx.doi.org/10.1074/jbc.M400205200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966124	hybrid			2022-12-27	WOS:000221041500031
J	Pitha-Rowe, I; Hassel, BA; Dmitrovsky, E				Pitha-Rowe, I; Hassel, BA; Dmitrovsky, E			Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-ACTIVATING ENZYME; CULTURED-MAMMALIAN-CELLS; RAR-ALPHA; HISTONE DEACETYLASE; NUCLEAR-BODY; LUNG-CANCER; ACID; PROTEIN; PML; EXPRESSION	Acute promyelocytic leukemia (APL) cases expressing the t(15,17) product, promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARalpha), have clinical remissions through leukemic cell differentiation after all-trans-retinoic acid ( RA) treatment. This differentiation therapy propelled interest in uncovering molecular mechanisms for RA-dependent APL differentiation. We previously identified the ubiquitin-activating enzyme-E1-like protein (UBE1L) as an RA-regulated target gene in APL that triggers PML/RARalpha degradation and apoptosis. This study reports that conjugation of the ubiquitin-like species, interferon-stimulated gene, 15-kDa protein (ISG15), also occurs during RA-induced APL differentiation. Knock-down of UBE1L expression inhibited this conjugation. RA treatment of APL and other RA-responsive leukemic cells induced expression of UBE1L and ISG15 as well as intracellular ISG15 conjugates. Notably, ISG15 conjugation did not occur in RA-resistant NB4-R1 APL cells. Induction of UBE1L and ISG15 along with ISG15 conjugation in RA-sensitive NB4-S1 APL cells were detected following treatment with specific retinoids and type I interferon (IFN). UBE1L and ISG15 mRNAs were co-expressed in normal human tissues that were examined. In contrast, UBE1L mRNA expression was markedly repressed in several cancer cell lines. A physical association was found between UBE1L and ISG15 in vivo. This required the conserved diglycine motif in the carboxyl terminus of ISG15. Targeting UBE1L expression with small inhibitory RNA or small hairpin RNA inhibited IFN and RA-induced ISG15 conjugation. Formation of ISG15 conjugates through induction of an activating enzyme represents a novel pharmacologic mechanism for regulation of this ubiquitin-related species. Taken together, the observed rela tionship between expression of UBE1L and ISG15, their physical association and coordinate regulation, and induced ISG15 conjugation during leukemic cell differentiation implicate an important role for these proteins in retinoid response.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Norris Cotton Canc Ctr, Hanover, NH 03755 USA; Dartmouth Coll, Hitchcock Med Ctr, Lebanon, NH 03756 USA; Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; University System of Maryland; University of Maryland Baltimore	Pitha-Rowe, I (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	ipr@dartmouth.edu			NCI NIH HHS [R01-CA87546, R01-CA62275, T32-CA09658] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062275, R01CA087546, T32CA009658] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CASTAIGNE S, 1990, BLOOD, V76, P1704; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Dimberg A, 2000, BLOOD, V96, P2870; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hamerman JA, 2002, J IMMUNOL, V168, P2415, DOI 10.4049/jimmunol.168.5.2415; Harborth J, 2001, J CELL SCI, V114, P4557; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; KITAREEWAN S, 2004, IN PRESS PROMISING C, V1; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; Liu MJ, 2002, GENE, V298, P129, DOI 10.1016/S0378-1119(02)00932-0; Liu MJ, 2003, J BIOL CHEM, V278, P1594, DOI 10.1074/jbc.M208123200; LOEB KR, 1994, MOL CELL BIOL, V14, P8408, DOI 10.1128/MCB.14.12.8408; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; NasonBurchenal K, 1997, DIFFERENTIATION, V61, P321, DOI 10.1046/j.1432-0436.1997.6150321.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pitha-Rowe I, 2003, LEUKEMIA, V17, P1723, DOI 10.1038/sj.leu.2403065; Privalsky ML, 2001, CURR TOP MICROBIOL, V254, P117; Ritchie KJ, 2002, GENE DEV, V16, P2207, DOI 10.1101/gad.1010202; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	42	54	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18178	18187		10.1074/jbc.M309259200	http://dx.doi.org/10.1074/jbc.M309259200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976209	hybrid			2022-12-27	WOS:000221041500012
J	Takeo, S; Fujise, M; Akiyama, T; Habuchi, H; Itano, N; Matsuo, T; Aigaki, T; Kimata, K; Nakato, H				Takeo, S; Fujise, M; Akiyama, T; Habuchi, H; Itano, N; Matsuo, T; Aigaki, T; Kimata, K; Nakato, H			In vivo hyaluronan synthesis upon expression of the mammalian hyaluronan synthase gene in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MOLECULAR-CLONING; PROTEIN; NOTCH; RECEPTOR; GLYCOSAMINOGLYCANS; TRANSFORMATION; IDENTIFICATION; MORPHOGENESIS; BIOSYNTHESIS	Hyaluronan (HA) is a large linear polymer of repeating disaccharides of glucuronic acid and GlcNAc. Although HA is widely distributed in vertebrate animals, it has not been found in invertebrates, including insect species. Insects utilize chitin, a repeating beta-1,4-linked homopolymer of GlcNAc, as a major component of their exoskeleton. Recent studies illustrate the similarities in the biosynthetic mechanisms of HA and chitin and suggest that HA synthase ( HAS) and chitin synthase have evolved from a common ancestral molecule. Although the biochemical properties and in vivo functions of HAS proteins have been extensively studied, the molecular basis for HA biosynthesis is not completely understood. For example, it is currently not clear if proper chain elongation and secretion of HA require other components in addition to HAS. Here, we demonstrate that a non-HA-synthesizing animal, the fruit fly Drosophila melanogaster, can produce HA in vivo when a single HAS protein is introduced. Expression of the mouse HAS2 gene in Drosophila tissues by the Gal4/UAS ( upstream activating sequence) system resulted in massive HA accumulation in the extracellular space and caused various morphological defects. These morphological abnormalities were ascribed to disordered cell-cell communications due to accumulation of HA rather than disruption of heparan sulfate synthesis. We also show that adult wings with HA can hold a high level of water. These findings demonstrate that organisms synthesizing chitin ( but not HA) are capable of producing HA that is structurally and functionally relevant to that in mammals. The ability of insect cells to produce HA supports the idea that in vivo HA biosynthesis does not require molecules other than the HAS protein. An alternative model is that Drosophila cells use endogenous components of the chitin biosynthetic machinery to produce and secrete HA.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Tokyo Metropolitan Univ, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan	University of Minnesota System; University of Minnesota Twin Cities; Tokyo Metropolitan University; Aichi Medical University	Nakato, H (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, 6-160 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	nakat003@umn.edu	Matsuo, Takashi/AAR-8291-2021	Matsuo, Takashi/0000-0002-4185-6740	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD042769] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD042769, HD042769] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bono P, 2001, MOL BIOL CELL, V12, P891, DOI 10.1091/mbc.12.4.891; BRAND AH, 1993, DEVELOPMENT, V118, P401; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; deCelis JF, 1997, DEVELOPMENT, V124, P1919; Fischer K, 1935, ANGEW CHEM-GER EDIT, V48, P0394, DOI 10.1002/ange.19350482605; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Huppert SS, 1997, DEVELOPMENT, V124, P3283; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1999, CANCER RES, V59, P2499; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Purcell K, 1999, J CELL BIOL, V146, P731, DOI 10.1083/jcb.146.4.731; REISSIG JL, 1955, J BIOL CHEM, V217, P959; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1997, GENOMICS, V41, P493, DOI 10.1006/geno.1997.4696; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Spicer AP, 1997, J BIOL CHEM, V272, P8957; Thiex NJ, 2002, J AOAC INT, V85, P318; Toba G, 1999, GENETICS, V151, P725; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; Verheyen EM, 1996, GENETICS, V144, P1127; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; WOLFF T, 1991, DEVELOPMENT, V113, P825; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; Zhang M, 2000, INT J BIOL MACROMOL, V27, P99, DOI 10.1016/S0141-8130(99)00123-3	46	19	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18920	18925		10.1074/jbc.M314293200	http://dx.doi.org/10.1074/jbc.M314293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966127	hybrid			2022-12-27	WOS:000221041500102
J	Chen, SH; Dell, EJ; Lin, F; Sai, JQ; Hamm, HE				Chen, SH; Dell, EJ; Lin, F; Sai, JQ; Hamm, HE			RACK1 regulates specific functions of G beta gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR-INTERACTING PROTEIN; PHOSDUCIN-LIKE PROTEIN; SUBUNITS; CHEMOTAXIS; INHIBITION; ACTIVATION; BINDING; ALPHA; PHOSPHORYLATION	We showed previously that Gbetagamma interacts with Receptor for Activated C Kinase 1 (RACK1), a protein that not only binds activated protein kinase C (PKC) but also serves as an adaptor/scaffold for many signaling pathways. Here we report that RACK1 does not interact with Galpha subunits or heterotrimeric G proteins but binds free Gbetagamma subunits released from activated heterotrimeric G proteins following the activation of their cognate receptors in vivo. The association with Gbetagamma promotes the translocation of RACK1 from the cytosol to the membrane. Moreover, binding of RACK1 to Gbetagamma results in inhibition of Gbetagamma-mediated activation of phospholipase C beta2 and adenylyl cyclase II. However, RACK1 has no effect on other functions of Gbetagamma, such as activation of the mitogen-activated protein kinase signaling pathway or chemotaxis of HEK293 cells via the chemokine receptor CXCR2. Similarly, RACK1 does not affect signal transduction through the Galpha subunits of G(i), G(s), or G(q). Collectively, these findings suggest a role of RACK1 in regulating specific functions of Gbetagamma.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hamm, HE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Rm 442,Robinson Res Bldg, Nashville, TN 37232 USA.	Heidi.Hamm@Vanderbilt.edu	Hamm, Heidi E/G-2374-2014	Lin, Fang/0000-0003-2179-7031; chen, songhai/0000-0001-7316-7125	NCI NIH HHS [CA34590-20] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034590, R23CA034590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Chen SH, 2000, EMBO J, V19, P4265, DOI 10.1093/emboj/19.16.4265; Chen SH, 2002, BIOCHEMISTRY-US, V41, P6045, DOI 10.1021/bi012189c; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; Dell EJ, 2002, J BIOL CHEM, V277, P49888, DOI 10.1074/jbc.M202755200; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HAWES BE, 1994, J BIOL CHEM, V269, P29825; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hwang JI, 2004, P NATL ACAD SCI USA, V101, P488, DOI 10.1073/pnas.0307549100; Iaccarino G, 1999, IUBMB LIFE, V48, P257; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; LEE E, 1994, METHOD ENZYMOL, V237, P146; Litosch I, 1997, BIOCHEM J, V326, P701, DOI 10.1042/bj3260701; Liu JP, 1997, MOL CELL ENDOCRINOL, V132, P61, DOI 10.1016/S0303-7207(97)00120-2; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; McLaughlin JN, 2002, J BIOL CHEM, V277, P34885, DOI 10.1074/jbc.M205583200; Mochly-Rosen D, 1998, FASEB J, V12, P35; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Peracino B, 1998, J CELL BIOL, V141, P1529, DOI 10.1083/jcb.141.7.1529; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; Schulz R, 2001, PHARMACOL RES, V43, P1, DOI 10.1006/phrs.2000.0757; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; Wang DZ, 2002, BIOCHEMISTRY-US, V41, P7100, DOI 10.1021/bi025902m; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; Zimmermann G, 1996, J BIOL CHEM, V271, P27161, DOI 10.1074/jbc.271.43.27161	42	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17861	17868		10.1074/jbc.M313727200	http://dx.doi.org/10.1074/jbc.M313727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963031	hybrid			2022-12-27	WOS:000220870400119
J	Thakurta, AG; Gopal, G; Yoon, JH; Saha, T; Dhar, R				Thakurta, AG; Gopal, G; Yoon, JH; Saha, T; Dhar, R			Conserved nuclear export sequences in Schizosaccharomyces pombe Mex67 and human TAP function in mRNA export by direct nuclear pore interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-FORMATION; PROTEIN EXPORT; BINDING-SITES; FG-REPEAT; YEAST; REQUIRES; DOMAIN; P15; IDENTIFICATION; NUCLEOPORINS	Mex67, the homolog of human TAP, is not an essential mRNA export factor in Schizosaccharomyces pombe. Here we show that S. pombe encodes a homolog of the TAP cofactor that we have also named p15, whose function in mRNA export is not essential. We have identified and characterized two distinct nuclear export activities, nuclear export signal (NES) I and NES II, within the region of amino acids 434-509 of Mex67. These residues map within the known NTF2-like fold of TAP (amino acids 371-551). We show that the homologs of these two NESs are present and are functionally conserved in TAP. The NES I, NES II, and NES I + II of TAP and Mex67 directly bind with -phenylalanine-glycine(-FG)-containing sequences of S. pombe Nup159 and Nup98 but not with human p62. Mutants of NES I or NES II of Mex67/TAP that do not bind -FG Nup159 and Nup98 in vitro are unable to mediate nuclear export of a heterologous protein in S. pombe and in HeLa cells. Fused with the RNA recognition motifs (RRMs) of Crp79 and green fluorescent protein (GFP) (RRM-NES-GFP), the NES I and NES II of Mex67 or TAP can suppress the mRNA export defect of the Deltap15 rae1-167 synthetic lethal S. pombe strain, suggesting that the NESs can function in the absence of p15. These novel nuclear export sequences may provide additional routes for delivering Mex67/TAP to the nuclear pore complex.	NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NICHD, NIH, Bethesda, MD 20892 USA; Sungshin Womens Univ, Dept Biol, Seoul 136742, South Korea; Kangnung Natl Univ, Coll Nat Sci, Div Biol, Kangnung 210702, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Sungshin Women's University; Kangnung Wonju National University	Dhar, R (corresponding author), NCI, Ctr Canc Res, NIH, Bldg 37,Rm 6138,9000 Rockville Pike, Bethesda, MD 20892 USA.	dharr@mail.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC005643, ZIABC005643] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfa C., 1993, EXPT FISSION YEAST; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bear J, 1999, MOL CELL BIOL, V19, P6306; Black BE, 1999, MOL CELL BIOL, V19, P8616; Blevins MB, 2003, J BIOL CHEM, V278, P20979, DOI 10.1074/jbc.M302061200; Braun IC, 2002, MOL CELL BIOL, V22, P5405, DOI 10.1128/MCB.22.15.5405-5418.2002; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Forler D, 2004, MOL CELL BIOL, V24, P1155, DOI 10.1128/MCB.24.3.1155-1167.2004; Fribourg S, 2001, MOL CELL, V8, P645, DOI 10.1016/S1097-2765(01)00348-3; Grant RP, 2002, NAT STRUCT BIOL, V9, P247, DOI 10.1038/nsb773; Izaurralde Elisa, 2002, Results Probl Cell Differ, V35, P133; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; KADOWAKI T, 1994, MOL BIOL CELL, V5, P1253, DOI 10.1091/mbc.5.11.1253; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 2002, J BIOL CHEM, V277, P9242, DOI 10.1074/jbc.M110007200; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Lei EP, 2003, MOL BIOL CELL, V14, P836, DOI 10.1091/mbc.E02-08-0520; Levesque L, 2001, J BIOL CHEM, V276, P44953, DOI 10.1074/jbc.M106558200; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Simos G, 1999, CURR BIOL, V9, pR238, DOI 10.1016/S0960-9822(99)80152-3; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Suyama M, 2000, EMBO REP, V1, P53, DOI 10.1093/embo-reports/kvd009; Thakurta AG, 2002, MOL BIOL CELL, V13, P2571, DOI 10.1091/mbc.E01-11-0133; Yoon JH, 2000, MOL CELL BIOL, V20, P8767, DOI 10.1128/MCB.20.23.8767-8782.2000; Zenklusen D, 2001, FEBS LETT, V498, P150, DOI 10.1016/S0014-5793(01)02482-6	33	11	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17434	17442		10.1074/jbc.M309731200	http://dx.doi.org/10.1074/jbc.M309731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963046	hybrid			2022-12-27	WOS:000220870400069
J	Vatamaniuk, OK; Mari, S; Lang, A; Chalasani, S; Demkiv, LO; Rea, PA				Vatamaniuk, OK; Mari, S; Lang, A; Chalasani, S; Demkiv, LO; Rea, PA			Phytochelatin synthase, a dipeptidyltransferase that undergoes multisite acylation with gamma-glutamylcysteine during catalysis - Stoichiometric and site-directed mutagenic analysis of Arabidopsis thaliana PCS1-catalyzed phytochelatin synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-METAL DETOXIFICATION; BINDING PEPTIDES; THIOL PEPTIDES; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; CAENORHABDITIS-ELEGANS; PHENOTYPIC SELECTION; TRANSFERASE PEPTIDES; AMINO-ACIDS; CADMIUM	Phytochelatin ( PC) synthase has been assumed to be a gamma-glutamylcysteine dipeptidyl transpeptidase (EC 2.3.2.15) and, more recently, as exemplified by analyses of the immunopurified recombinant enzyme from Arabidopsis thaliana (AtPCS1-FLAG), has been shown to catalyze a PC synthetic reaction with kinetics that approximates a bisubstrate-substituted enzyme mechanism in which millimolar concentrations of free GSH and micromolar concentrations of heavy metal.GSH thiolates (e.g. cadmium.GS(2)) or millimolar concentrations of S-alkylglutathiones serve as cosubstrates. Here, we show, by direct analyses of the stoichiometry of AtPCS1-FLAG-catalyzed PC synthesis, the kinetics and stoichiometry of acylation of the enzyme and release of free glycine from gamma-Glu-Cys donors, and the effects of the Cys-to-Ser or -Ala and Ser-to-Ala substitution of conserved residues in the catalytic N-terminal half of the enzyme, that PC synthase is indeed a dipeptidyltransferase that undergoes gamma-Glu-Cys acylation at two sites during catalysis, one of which, in accord with a cysteine protease model, likely corresponds to or is at least tightly coupled with Cys(56). The identity of the second site of enzyme modification remains to be determined, but it is distinguishable from the first Cys(56)-dependent site, which is amenable to gamma-Glu-Cys acylation by free GSH, because its acylation not only depends on the provision of Cd2+ or GSH with a blocked, S-alkylated thiol group, but is also necessary for net PC synthesis. We conclude that des-Gly-PCs are not generated as an immediate by-product, but rather that the enzyme catalyzes a dipeptidyl transfer reaction in which some of the energy liberated upon cleavage of the Cys-Gly bonds of the gamma-Glu-Cys donors in the first phase of the catalytic cycle is conserved through the formation of a two site-substituted gamma-Glu-Cys acyl-enzyme intermediate whose hydrolysis provides the energy required for the formation of the new peptide bond required for the extension of PC chain length by one gamma-Glu-Cys repeat per catalytic cycle.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Rea, PA (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, 3800 Hamilton Walk, Philadelphia, PA 19104 USA.	parea@sas.upenn.edu						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cazale AC, 2001, FEBS LETT, V507, P215, DOI 10.1016/S0014-5793(01)02976-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; CHEAH E, 1993, PROTEIN ENG, V6, P575, DOI 10.1093/protein/6.6.575; Clemens S, 2001, EUR J BIOCHEM, V268, P3640, DOI 10.1046/j.1432-1327.2001.02293.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; Cobbett CS, 1999, TRENDS PLANT SCI, V4, P335, DOI 10.1016/S1360-1385(99)01465-X; Cobbett CS, 2000, PLANT PHYSIOL, V123, P825, DOI 10.1104/pp.123.3.825; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRILL E, 1989, P NATL ACAD SCI USA, V86, P6838, DOI 10.1073/pnas.86.18.6838; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HOWDEN R, 1995, PLANT PHYSIOL, V107, P1059, DOI 10.1104/pp.107.4.1059; Humm A, 1997, BIOCHEM J, V322, P771, DOI 10.1042/bj3220771; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KLAPHECK S, 1994, PLANT PHYSIOL, V104, P1325, DOI 10.1104/pp.104.4.1325; KONDO N, 1984, TETRAHEDRON LETT, V25, P3869, DOI 10.1016/S0040-4039(01)91190-6; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUBOTA H, 1995, PLANT SCI, V106, P157, DOI 10.1016/0168-9452(95)04020-U; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Maier T, 2003, PLANTA, V218, P300, DOI 10.1007/s00425-003-1091-7; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Mathews C.K., 2000, BIOCHEMISTRY; MEHRA RK, 1988, ARCH BIOCHEM BIOPHYS, V265, P381, DOI 10.1016/0003-9861(88)90141-5; MEHRA RK, 1988, P NATL ACAD SCI USA, V85, P8815, DOI 10.1073/pnas.85.23.8815; MEUWLY P, 1995, PLANT J, V7, P391, DOI 10.1046/j.1365-313X.1995.7030391.x; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; Oven M, 2002, J BIOL CHEM, V277, P4747, DOI 10.1074/jbc.M108254200; Rauser WE, 1999, CELL BIOCHEM BIOPHYS, V31, P19, DOI 10.1007/BF02738153; RAUSER WE, 1995, PLANT PHYSIOL, V109, P195, DOI 10.1104/pp.109.1.195; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Vatamaniuk OK, 2001, J BIOL CHEM, V276, P20817, DOI 10.1074/jbc.C100152200; Vatamaniuk OK, 2000, J BIOL CHEM, V275, P31451, DOI 10.1074/jbc.M002997200; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; Vatamaniuk OK, 2002, TRENDS BIOTECHNOL, V20, P61, DOI 10.1016/S0167-7799(01)01873-X; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2	40	98	106	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22449	22460		10.1074/jbc.M313142200	http://dx.doi.org/10.1074/jbc.M313142200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004013	Green Published, hybrid			2022-12-27	WOS:000221417100094
J	Gustafsson, AB; Tsai, JG; Logue, SE; Crow, MT; Gottlieb, RA				Gustafsson, AB; Tsai, JG; Logue, SE; Crow, MT; Gottlieb, RA			Apoptosis repressor with caspase recruitment domain protects against cell death by interfering with Bax activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; CARDIOMYOCYTE APOPTOSIS; CYTOCHROME-C; ENDOPLASMIC-RETICULUM; CARDIAC MYOCYTES; INHIBITOR; MITOCHONDRIA; EXPRESSION; RELEASE; STRESS	Myocardial ischemia/reperfusion (I/R) is associated with an extensive loss of myocardial cells. The apoptosis repressor with caspase recruitment domain (ARC) is a protein that is highly expressed in heart and skeletal muscle and has been demonstrated to protect the heart against I/R injury (Gustafsson, A. B., Sayen, M. R., Williams, S. D., Crow, M. T., and Gottlieb, R. A. (2002) Circulation 106, 735-739). In this study, we have shown that transduction of TAT-ARCL31F, a mutant of ARC in the caspase recruitment domain, did not reduce creatine kinase release and infarct size after I/R. TAT-ARCL31F also failed to protect against hydrogen peroxide-mediated cell death in H9c2 cells, suggesting that the caspase recruitment domain is important in mediating ARC's protective effects. In addition, we report that ARC co-immunoprecipitated with the pro-apoptotic protein Bax, which causes cytochrome c release when activated. TAT-ARC, but not TAT-ARCL31F, prevented Bax activation and cytochrome c release in hydrogen peroxide-treated H9c2 cells. TAT-ARC was also effective in blocking cytochrome c release after ischemia and reperfusion, whereas TAT-ARCL31F had no effect on cytochrome c release. In addition, recombinant ARC protein abrogated Bax-induced cytochrome c release from isolated mitochondria. This suggests that ARC can protect against cell death by interfering with activation of the mitochondrial death pathway through the interaction with Bax, preventing mitochondrial dysfunction and release of pro-apoptotic factors.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA	Scripps Research Institute; Johns Hopkins University	Gottlieb, RA (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM 220,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	robbieg@scripps.edu	Logue, Susan/K-7748-2019; Logue, Susan/G-3002-2010	Logue, Susan/0000-0001-7938-3558; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060590] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 60590] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; Cook SA, 1999, CIRC RES, V85, P940; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ekhterae D, 2003, AM J PHYSIOL-CELL PH, V284, pC1405, DOI 10.1152/ajpcell.00279.2002; Ekhterae D, 1999, CIRC RES, V85, pE70; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kajstura J, 1996, LAB INVEST, V74, P86; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Li PF, 2002, MOL CELL, V10, P247, DOI 10.1016/S1097-2765(02)00600-7; Long XL, 1998, J CLIN INVEST, V101, P1453, DOI 10.1172/JCI345; Misao J, 1996, CIRCULATION, V94, P1506, DOI 10.1161/01.CIR.94.7.1506; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Neuss M, 2001, J BIOL CHEM, V276, P33915, DOI 10.1074/jbc.M104080200; Newmeyer DD, 2000, CELL DEATH DIFFER, V7, P402, DOI 10.1038/sj.cdd.4400665; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; ROUSLIN W, 1983, J BIOL CHEM, V258, P9657; Saraste A, 1997, CIRCULATION, V95, P320; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829; TSUCHIDA A, 1994, CIRC RES, V75, P576, DOI 10.1161/01.RES.75.3.576; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wang B, 2003, J BIOL CHEM, V278, P14461, DOI 10.1074/jbc.M209684200; Wang DC, 1998, MOL CELL BIOCHEM, V180, P163, DOI 10.1023/A:1006815814283; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yaglom JA, 2003, J BIOL CHEM, V278, P50483, DOI 10.1074/jbc.M306903200; Yajima H, 2003, BIOCHEM BIOPH RES CO, V309, P520, DOI 10.1016/j.bbrc.2003.08.030; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	39	140	148	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21233	21238		10.1074/jbc.M400695200	http://dx.doi.org/10.1074/jbc.M400695200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004034	hybrid			2022-12-27	WOS:000221273800083
J	Oma, Y; Kino, Y; Sasagawa, N; Ishiura, S				Oma, Y; Kino, Y; Sasagawa, N; Ishiura, S			Intracellular localization of homopolymeric amino acid-containing proteins expressed in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED MENTAL-RETARDATION; INTRANUCLEAR INCLUSIONS; EXPANDED-POLYGLUTAMINE; GLUTAMINE REPEATS; MUTANT HUNTINGTIN; AGGREGATION; EXPANSION; MUTATIONS; PATTERNS; GROWTH	Many human proteins have homopolymeric amino acid (HPAA) tracts, which are involved in protein-protein interactions and also have intrinsic polymerization properties. Polyglutamine or polyalanine expansions cause several neurodegenerative diseases. To examine the properties of HPAAs, we expressed 20 kinds of 30-residue HPAA fused to the C terminus of yellow fluorescent protein in mammalian cells. Specific localization was observed depending on the HPAA. Polyarginine and polylysine aggregated in the nucleus. Polyalanine, polyhistidine, polyisoleucine, polyleucine, polymethionine, polyphenylalanine, polythreonine, polytryptophan, and polyvaline localized in the cytoplasm, and some of these HPAAs formed aggregate(s). Hydrophobic HPAAs such as polyisoleucine, polyleucine, polyphenylalanine, and polyvaline were found as one major aggregate or cumulus in the perinuclear region. Western blot analysis indicated that hydrophobic HPAA tracts appear to oligomerize and form high molecular weight complexes. These results indicate that hydrophobicity itself may trigger the oligomerization and aggregation of proteins when overexpressed in cells. Our experiments provide novel insights into the nature of the HPAAs that are often seen in human and other organisms.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan	University of Tokyo	Ishiura, S (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan.	cishiura@mail.ecc.u-tokyo.ac.jp						Becher MW, 2000, ANN NEUROL, V48, P812, DOI 10.1002/1531-8249(200011)48:5<812::AID-ANA20>3.3.CO;2-U; Blondelle SE, 1997, BIOCHEMISTRY-US, V36, P8393, DOI 10.1021/bi963015b; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dorsman JC, 2002, HUM MOL GENET, V11, P1487, DOI 10.1093/hmg/11.13.1487; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Holmes SE, 2001, NAT GENET, V29, P377, DOI 10.1038/ng760; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Kashi Y, 1997, TRENDS GENET, V13, P74, DOI 10.1016/S0168-9525(97)01008-1; Katti MV, 2000, PROTEIN SCI, V9, P1203, DOI 10.1110/ps.9.6.1203; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Laumonnier F, 2002, AM J HUM GENET, V71, P1450, DOI 10.1086/344661; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Onodera O, 1997, BIOCHEM BIOPH RES CO, V238, P599, DOI 10.1006/bbrc.1997.7337; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Rankin J, 2000, BIOCHEM J, V348, P15, DOI 10.1042/0264-6021:3480015; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shanmugam V, 2000, ANN NEUROL, V48, P798; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Stromme P, 2002, NAT GENET, V30, P441, DOI 10.1038/ng862; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	28	52	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21217	21222		10.1074/jbc.M309887200	http://dx.doi.org/10.1074/jbc.M309887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14993218	hybrid			2022-12-27	WOS:000221273800081
J	Ishida-Takahashi, R; Uotani, S; Abe, T; Degawa-Yamauchi, M; Fukushima, T; Fujita, N; Sakamaki, H; Yamasaki, H; Yamaguchi, Y; Eguchi, K				Ishida-Takahashi, R; Uotani, S; Abe, T; Degawa-Yamauchi, M; Fukushima, T; Fujita, N; Sakamaki, H; Yamasaki, H; Yamaguchi, Y; Eguchi, K			Rapid inhibition of leptin signaling by glucocorticoids in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBROSPINAL-FLUID; STAT3 ACTIVATION; PROTEIN-KINASE; RECEPTOR GENE; OBESE GENE; IDENTIFICATION; EXPRESSION; MUTATION; WEIGHT; PLASMA	Elevated secretion of glucocorticoids (GCs) or hypersensitivity to GCs has a permissive effect on the development of obesity and leads to abnormalities of body fat distribution. Recent studies demonstrated GCs act as antagonists of leptin in rodents. However, little is known about the interaction between GCs and leptin signaling. In the present study, we investigated the effects of GCs on leptin action in vitro and in vivo. GCs rapidly inhibited the leptin-induced STAT3 phosphorylation in a dose- and time-dependent manner, as assayed by Western blotting using anti-phosphospecific-STAT3 in human hepatoma cell lines (Huh7) transiently expressing long form leptin receptor. GCs also inhibited the leptin-induced JAK2 tyrosine phosphorylation but unaltered the specific binding of I-125-leptin to the cells. Parallel experiments, however, demonstrated that the inhibitory effects of GCs were not observed in either IL-6- or LIF-induced STAT3 phosphorylation. Furthermore, we examined the feeding behavior and hypothalamic leptin signaling following intracerebroventricular (icv) infusion of GCs prior to icv leptin infusion in Sprague-Dawley rats. The food intake after 24 h of icv leptin injection increased 3-fold in GCs-treated animals. In addition, central infusion of GCs resulted in a marked reduction of hypothalamic STAT3 phosphorylation in response to icv infusion of leptin. To clarify the molecular mechanism by which GCs rapidly reduce leptin-induced JAK/STAT signaling, we examined the intracellular signal transduction pathway potentially mediated by GCs. PD98059, a specific MEK inhibitor, blocked the inhibitory effects of GCs on leptin-induced JAK/STAT activation in Huh7 cells. These results suggest GCs antagonize leptin action by a rapid inhibition of the leptin-induced JAK/STAT pathway partly via MAPK cascade.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Med & Dent Sci, Div Immunol Endocrinol & Metab, Nagasaki 8528501, Japan	Nagasaki University	Eguchi, K (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Med & Dent Sci, Div Immunol Endocrinol & Metab, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.	eguchi@net.nagasaki-u-ac.jp						Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bianchi M, 2000, P NATL ACAD SCI USA, V97, P9573, DOI 10.1073/pnas.160099797; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Brattsand R, 1996, ALIMENT PHARM THERAP, V10, P81, DOI 10.1046/j.1365-2036.1996.22164025.x; Buttgereit F, 2002, STEROIDS, V67, P529, DOI 10.1016/S0039-128X(01)00171-4; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chen JP, 1999, FEBS LETT, V457, P162, DOI 10.1016/S0014-5793(99)01031-5; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Considine RV, 1996, DIABETES, V45, P992, DOI 10.2337/diabetes.45.7.992; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Considine RV, 1997, J CELL BIOCHEM, V65, P254, DOI 10.1002/(SICI)1097-4644(199705)65:2<254::AID-JCB10>3.0.CO;2-I; Degawa-Yamauchi M, 2002, FEBS LETT, V525, P116, DOI 10.1016/S0014-5793(02)03099-5; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Fong TM, 1998, MOL PHARMACOL, V53, P234, DOI 10.1124/mol.53.2.234; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halleux CM, 1998, J CLIN ENDOCR METAB, V83, P902, DOI 10.1210/jc.83.3.902; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hu XY, 2003, J IMMUNOL, V170, P4833, DOI 10.4049/jimmunol.170.9.4833; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; John C, 2002, ENDOCRINOLOGY, V143, P3060, DOI 10.1210/en.143.8.3060; King APJ, 1996, J BIOL CHEM, V271, P18088, DOI 10.1074/jbc.271.30.18088; LAMIABLE D, 1988, J CHROMATOGR-BIOMED, V434, P315, DOI 10.1016/0378-4347(88)80094-X; LealCerro A, 1996, HORM METAB RES, V28, P711, DOI 10.1055/s-2007-979884; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Mozo L, 1998, J ALLERGY CLIN IMMUN, V102, P968, DOI 10.1016/S0091-6749(98)70335-5; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Qiu I, 2001, BIOCHEM BIOPH RES CO, V287, P1017, DOI 10.1006/bbrc.2001.5691; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; STRAIN GW, 1980, METABOLISM, V29, P980, DOI 10.1016/0026-0495(80)90043-8; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Uotani S, 1999, DIABETES, V48, P279, DOI 10.2337/diabetes.48.2.279; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Zakrzewska KE, 1999, DIABETES, V48, P365, DOI 10.2337/diabetes.48.2.365; Zakrzewska KE, 1997, DIABETES, V46, P717, DOI 10.2337/diabetes.46.4.717; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	48	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19658	19664		10.1074/jbc.M310864200	http://dx.doi.org/10.1074/jbc.M310864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14993217	hybrid			2022-12-27	WOS:000221164500035
J	Kurokawa, H; Lee, DS; Watanabe, M; Sagami, I; Mikami, B; Raman, CS; Shimizu, T				Kurokawa, H; Lee, DS; Watanabe, M; Sagami, I; Mikami, B; Raman, CS; Shimizu, T			A redox-controlled molecular switch revealed by the crystal structure of a bacterial heme PAS sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT OXYGEN SENSOR; ESCHERICHIA-COLI; REGULATED PHOSPHODIESTERASE; DOMAIN; PROTEIN; BINDING; MECHANISM; CATALYSIS; PROGRAM; SITE	PAS domains, which have been identified in over 1100 proteins from all three kingdoms of life, convert various input stimuli into signals that propagate to downstream components by modifying protein-protein interactions. One such protein is the Escherichia coli redox sensor, Ec DOS, a phosphodiesterase that degrades cyclic adenosine monophosphate in a redox-dependent manner. Here we report the crystal structures of the heme PAS domain of Ec DOS in both inactive Fe3+ and active Fe2+ forms at 1.32 and 1.9 Angstrom resolution, respectively. The protein folds into a characteristic PAS domain structure and forms a homodimer. In the Fe3+ form, the heme iron is ligated to a His-77 side chain and a water molecule. Heme iron reduction is accompanied by heme-ligand switching from the water molecule to a side chain of Met-95 from the FG loop. Concomitantly, the flexible FG loop is significantly rigidified, along with a change in the hydrogen bonding pattern and rotation of subunits relative to each other. The present data led us to propose a novel redox-regulated molecular switch in which local heme-ligand switching may trigger a global "scissor-type" subunit movement that facilitates catalytic control.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Struct Biol Res Ctr, Houston, TX 77030 USA; Kyoto Univ, Grad Sch Agr, Kyoto 6110011, Japan	Tohoku University; University of Texas System; Kyoto University	Kurokawa, H (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	kurokawa@tagen.tohoku.ac.jp	Kurokawa, Hirofumi/A-7231-2010	Shimizu, Toru/0000-0002-3950-5554; Raman, C. S./0000-0002-1036-3193				Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; DeLano WL, 2002, PYMOL USERS MANUAL; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Hao B, 2002, BIOCHEMISTRY-US, V41, P12952, DOI 10.1021/bi020144l; Harper SM, 2003, SCIENCE, V301, P1541, DOI 10.1126/science.1086810; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurokawa H, 2001, J MOL BIOL, V312, P59, DOI 10.1006/jmbi.2001.4822; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Miyatake H, 2000, J MOL BIOL, V301, P415, DOI 10.1006/jmbi.2000.3954; Nakajima H, 2001, J BIOL CHEM, V276, P7055, DOI 10.1074/jbc.M003972200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park H, 2002, ACTA CRYSTALLOGR D, V58, P1504, DOI 10.1107/S0907444902011794; Pascher T, 1996, SCIENCE, V271, P1558, DOI 10.1126/science.271.5255.1558; Pei JM, 2001, PROTEINS, V42, P210, DOI 10.1002/1097-0134(20010201)42:2<210::AID-PROT80>3.0.CO;2-8; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Taguchi S, 2004, J BIOL CHEM, V279, P3340, DOI 10.1074/jbc.M301013200; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Yoshimura T, 2003, J BIOL CHEM, V278, P53105, DOI 10.1074/jbc.M304408200	39	143	145	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20186	20193		10.1074/jbc.M314199200	http://dx.doi.org/10.1074/jbc.M314199200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14982921	hybrid			2022-12-27	WOS:000221164500095
J	Levitan, A; Danon, A; Lisowsky, T				Levitan, A; Danon, A; Lisowsky, T			Unique features of plant mitochondrial sulfhydryl oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; LIVER-REGENERATION; EGG-WHITE; SACCHAROMYCES-CEREVISIAE; PHYSCOMITRELLA-PATENS; ARABIDOPSIS-THALIANA; PROTEINS; YEAST; GENE; THIOREDOXIN	The yeast and human mitochondrial sulfhydryl oxidases of the Erv1/Alr family have been shown to be essential for the biogenesis of mitochondria and the cytosolic iron sulfur cluster assembly. In this study we identified a likely candidate for the first mitochondrial flavin-linked sulfhydryl oxidase of the Erv1-type from a photosynthetic organism. The central core of the plant enzyme (AtErv1) exhibits all of the characteristic features of the Erv1/Alr protein family, including a redox-active YPCXXC motif, noncovalently bound FAD, and sulfhydryl oxidase activity. Transient expression of fusion proteins of AtErv1 and the green fluorescence protein in plant protoplasts showed that the plant enzyme preferentially localizes to the mitochondria. Yet AtErv1 has several unique features, such as the presence of a CXXXXC motif in its carboxyl-terminal domain and the absence of an amino-terminally localized cysteine pair common to yeast and human Erv1/Alr proteins. In addition, the dimerization of AtErv1 is not mediated by its amino terminus but by its unique CXXXXC motif. In vitro assays with purified protein and artificial substrates demonstrate a preference of AtErv1 for dithiols with a defined space between the thiol groups, suggesting a thioredoxin-like substrate.	Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel; Univ Dusseldorf, Inst Bot, D-40225 Dusseldorf, Germany	Weizmann Institute of Science; Heinrich Heine University Dusseldorf	Danon, A (corresponding author), Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel.	Avihai.Danon@weizmann.ac.il						ASHTON NW, 1977, MOL GEN GENET, V154, P87, DOI 10.1007/BF00265581; Brohawn SG, 2003, BIOCHEMISTRY-US, V42, P11074, DOI 10.1021/bi0301385; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; Danon A, 2002, TRENDS BIOCHEM SCI, V27, P197, DOI 10.1016/S0968-0004(02)02066-2; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gerber J, 2001, J BIOL CHEM, V276, P23486, DOI 10.1074/jbc.M100134200; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hofhaus G, 1999, EUR J CELL BIOL, V78, P349, DOI 10.1016/S0171-9335(99)80069-7; Hofhaus G, 2003, EUR J BIOCHEM, V270, P1528, DOI 10.1046/j.1432-1033.2003.03519.x; Hofhaus G, 2002, METHOD ENZYMOL, V348, P314, DOI 10.1016/S0076-6879(02)48650-8; Hoober KL, 1999, BIOCHEMISTRY-US, V38, P3211, DOI 10.1021/bi9820816; Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759; Hoober KL, 1999, J BIOL CHEM, V274, P22147, DOI 10.1074/jbc.274.32.22147; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Klissenbauer M, 2002, J EXP BIOL, V205, P1979; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; Laloi C, 2001, P NATL ACAD SCI USA, V98, P14144, DOI 10.1073/pnas.241340898; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lee JE, 2000, FEBS LETT, V477, P62, DOI 10.1016/S0014-5793(00)01767-1; Leon S, 2003, BIOCHEM J, V371, P823, DOI 10.1042/BJ20021946; Leon S, 2002, BIOCHEM J, V366, P557, DOI 10.1042/BJ20020322; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; LISOWSKY T, 1994, CURR GENET, V26, P15, DOI 10.1007/BF00326299; Lisowsky T, 1996, YEAST, V12, P1501, DOI 10.1002/(SICI)1097-0061(199612)12:15<1501::AID-YEA40>3.0.CO;2-H; Lisowsky T, 2001, DIGEST LIVER DIS, V33, P173, DOI 10.1016/S1590-8658(01)80074-8; Meiri E, 2002, MOL GENET GENOMICS, V267, P231, DOI 10.1007/s00438-002-0658-5; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Polimeno L, 1999, ITAL J GASTROENTEROL, V31, P494; Raje S, 2003, BIOCHEMISTRY-US, V42, P4560, DOI 10.1021/bi030003z; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5; VONARNIM AG, 1998, GENE, V221, P315; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; Wu CK, 2003, PROTEIN SCI, V12, P1109, DOI 10.1110/ps.0238103; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	41	66	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20002	20008		10.1074/jbc.M312877200	http://dx.doi.org/10.1074/jbc.M312877200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996837	hybrid			2022-12-27	WOS:000221164500075
J	Shajahan, AN; Timblin, BK; Sandoval, R; Tiruppathi, C; Malik, AB; Minshall, RD				Shajahan, AN; Timblin, BK; Sandoval, R; Tiruppathi, C; Malik, AB; Minshall, RD			Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; IN-VIVO; PLASMALEMMAL VESICLES; ALBUMIN TRANSCYTOSIS; PH DOMAIN; PROTEIN; BINDING; TRANSPORT; PATHWAY	Albumin transcytosis, a determinant of transendothelial permeability, is mediated by the release of caveolae from the plasma membrane. We addressed the role of Src phosphorylation of the GTPase dynamin-2 in the mechanism of caveolae release and albumin transport. Studies were made in microvascular endothelial cells in which the uptake of cholera toxin subunit B, a marker of caveolae, and I-125-albumin was used to assess caveolae-mediated endocytosis. Albumin binding to the 60-kDa cell surface albumin-binding protein, gp60, induced Src activation (phosphorylation on Tyr(416)) within 1 min and resulted in Src-dependent tyrosine phosphorylation of dynamin-2, which increased its association with caveolin-1, the caveolae scaffold protein. Expression of kinase-defective Src mutant interfered with the association between dynamin-2, which caveolin-1 and prevented the uptake of albumin. Expression of non-Src-phosphorylatable dynamin (Y231F/Y597F) resulted in reduced association with caveolin-1, and in contrast to WT-dynamin-2, the mutant failed to translocate to the caveolin-rich membrane fraction. The Y231F/Y597F dynamin-2 mutant expression also resulted in impaired albumin and cholera toxin subunit B uptake and reduced transendothelial albumin transport. Thus, Src-mediated phosphorylation of dynamin-2 is an essential requirement for scission of caveolae and the resultant transendothelial transport of albumin.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Minshall, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, M-C 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	rminsh@uic.edu		Shajahan-Haq, Ayesha/0000-0001-7616-320X; Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL 60678, T32 HL 07239, HL 71626] Funding Source: Medline; NIGMS NIH HHS [GM 58531] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071626, P01HL060678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Andersson E, 1998, J BIOL CHEM, V273, P4747, DOI 10.1074/jbc.273.8.4747; ANTOHE F, 1993, EUR J CELL BIOL, V60, P268; Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; Gilbert A, 1999, J CELL SCI, V112, P1101; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Henley JR, 1999, FASEB J, V13, pS243, DOI 10.1096/fasebj.13.9002.S243; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; John TA, 2003, AM J PHYSIOL-LUNG C, V284, pL187, DOI 10.1152/ajplung.00152.2002; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kim YN, 2002, ENDOCRINOLOGY, V143, P1726, DOI 10.1210/en.143.5.1726; LEMMON M, 2000, BIOCHEM J, V273, P27725; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; Minshall RD, 2002, HISTOCHEM CELL BIOL, V117, P105, DOI 10.1007/s00418-001-0367-x; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; Niles WD, 1999, J MEMBRANE BIOL, V167, P85, DOI 10.1007/s002329900474; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PITCHER J, 1995, J BIOL CHEM, V1270, P11070; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725; Predescu SA, 1997, AM J PHYSIOL-HEART C, V272, pH937, DOI 10.1152/ajpheart.1997.272.2.H937; Predescu SA, 2003, MOL BIOL CELL, V14, P4997, DOI 10.1091/mbc.e03-01-0041; Predescu SA, 2001, MOL BIOL CELL, V12, P1019, DOI 10.1091/mbc.12.4.1019; Scaife RM, 1997, CELL SIGNAL, V9, P395, DOI 10.1016/S0898-6568(97)00041-7; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246, DOI 10.1152/ajpheart.1992.262.1.H246; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; Vogel SM, 2001, MICROVASC RES, V61, P87, DOI 10.1006/mvre.2000.2274; Vogel SM, 2001, AM J PHYSIOL-LUNG C, V281, pL1512, DOI 10.1152/ajplung.2001.281.6.L1512	39	167	175	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20392	20400		10.1074/jbc.M308710200	http://dx.doi.org/10.1074/jbc.M308710200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15007081	hybrid			2022-12-27	WOS:000221164500118
J	Wang, L; Li, G; Sugita, S				Wang, L; Li, G; Sugita, S			RalA-exocyst interaction mediates GTP-dependent exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CORE VESICLE EXOCYTOSIS; CRACKED PC12 CELLS; BINDING PROTEIN; MEMBRANE-FUSION; CA2+-DEPENDENT EXOCYTOSIS; SACCHAROMYCES-CEREVISIAE; CA2+-ACTIVATED SECRETION; NEUROTRANSMITTER RELEASE; GUANINE-NUCLEOTIDES	Many secretory cells utilize a GTP-dependent pathway, in addition to the well characterized Ca2+-dependent pathway, to trigger exocytotic secretion. However, little is currently known about the mechanism by which this may occur. Here we show the key signaling pathway that mediates GTP-dependent exocytosis. Incubation of permeabilized PC12 cells with soluble RalA GTPase, but not RhoA or Rab3A GTPases, strongly inhibited GTP-dependent exocytosis. A Ral-binding fragment from Sec5, a component of the exocyst complex, showed a similar inhibition. Point mutations in both RalA (RalA(E38R)) and the Sec5 (Sec5(T11A)) fragment, which abolish RalA-Sec5 interaction also abolished the inhibition of GTP-dependent exocytosis. Moreover, transfection with wild-type RalA, but not RalAE38R, enhanced GTP-dependent exocytosis. In contrast the RalA and the Sec5 fragment showed no inhibition of Ca2+-dependent exocytosis, but cleavage of a SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein by Botulinum neurotoxin blocked both GTP- and Ca2+-dependent exocytosis. Our results indicate that the interaction between RalA and the exocyst complex (containing Sec5) is essential for GTP- dependent exocytosis. Furthermore, GTP- and Ca2+-dependent exocytosis use different sensors and effectors for triggering exocytosis whereas their final fusion steps are both SNARE-dependent.	Univ Toronto, Toronto Western Res Inst,Univ Hlth Network, Dept Physiol, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Sugita, S (corresponding author), Univ Toronto, Toronto Western Res Inst,Univ Hlth Network, Dept Physiol, Div Cellular & Mol Biol, MC11-432,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	ssugita@uhnres.utoronto.ca		Sugita, Shuzo/0000-0002-9182-873X; Wang, Li/0000-0002-3460-2080				Andrews HK, 2002, TRAFFIC, V3, P906, DOI 10.1034/j.1600-0854.2002.31206.x; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BITTNER MA, 1986, J BIOL CHEM, V261, P182; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; BURGOYNE RD, 1994, FEBS LETT, V344, P139, DOI 10.1016/0014-5793(94)00361-0; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; Fukai S, 2003, EMBO J, V22, P3267, DOI 10.1093/emboj/cdg329; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jiang XP, 2003, J BIOL CHEM, V278, P42867, DOI 10.1074/jbc.M304487200; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Khvotchev MV, 2003, J NEUROSCI, V23, P10531; Klenchin VA, 1998, METHODS, V16, P204, DOI 10.1006/meth.1998.0668; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MACLEAN CM, 1993, BIOCHEM J, V294, P325, DOI 10.1042/bj2940325; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; Mark BL, 1996, BIOCHEM BIOPH RES CO, V225, P40, DOI 10.1006/bbrc.1996.1128; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Murthy M, 2003, NEURON, V37, P433, DOI 10.1016/S0896-6273(03)00031-X; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; OKANO K, 1993, NEURON, V11, P165, DOI 10.1016/0896-6273(93)90280-5; Padfield PJ, 1996, BIOCHEM J, V314, P123, DOI 10.1042/bj3140123; Pinxteren JA, 2000, BIOCHIMIE, V82, P385, DOI 10.1016/S0300-9084(00)00197-8; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; REGAZZI R, 1989, J BIOL CHEM, V264, P9939; Shin OH, 2003, NEURON, V37, P99, DOI 10.1016/S0896-6273(02)01145-5; Shin OH, 2002, NAT NEUROSCI, V5, P649, DOI 10.1038/nn869; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; Tse FW, 2000, J PHYSIOL-LONDON, V526, P99, DOI 10.1111/j.1469-7793.2000.00099.x; Tucker WC, 2003, J CELL BIOL, V162, P199, DOI 10.1083/jcb.200302060; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200	55	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19875	19881		10.1074/jbc.M400522200	http://dx.doi.org/10.1074/jbc.M400522200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14978027	hybrid			2022-12-27	WOS:000221164500061
J	Cao, JS; Hawkins, E; Brozinick, J; Liu, XY; Zhang, HX; Burn, P; Shi, YG				Cao, JS; Hawkins, E; Brozinick, J; Liu, XY; Zhang, HX; Burn, P; Shi, YG			A predominant role of acyl-CoA: Monoacylglycerol acyltransferase-2 in dietary fat absorption implicated by tissue distribution, subcellular localization, and up-regulation by high fat diet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; INTESTINAL LIPID ABSORPTION; B-CONTAINING LIPOPROTEINS; TRIACYLGLYCEROL SYNTHESIS; DIACYLGLYCEROL ACYLTRANSFERASE; CHYLOMICRON SECRETION; BIOSYNTHETIC-ENZYMES; JEJUNAL VILLUS; RECEPTOR PPAR; RAT-LIVER	Acyl-CoA: monoacylglycerol acyltransferase-2 (MGAT2) catalyzes the synthesis of diacylglycerol and differs from the MGAT1 and MGAT3 in tissue distribution at the mRNA level. In addition to the small intestine, MGAT2 mRNA is also expressed at high levels in human liver, the lower gastrointestinal tract, and the mouse kidney, but the physiological significance of such expression has not yet been studied. Using an affinity-purified antibody, the present study investigated the expression of murine MGAT2 protein along the intestinal tract, determined its subcellular localization, and studied its regulation by diet and in db/db mouse. Results demonstrate a high level of MGAT2 expression in the small intestine in a proximal-to-distal gradient that correlated well with both MGAT enzyme activity and fat absorption pattern. In contrast, MGAT2 protein was not detectable in other sections of the digestive tract, including stomach, cecum, colon, and rectum, or other mouse tissues such as kidney, liver, and adipocytes. Immunohistological studies provided direct evidence that the enzyme is expressed not only in the villi, but also in the crypt regions of the small intestine, which suggests that MGAT2 expression occurs prior to the maturation of enterocytes. MGAT2 is localized in the endoplasmic reticulum (ER) in both MGAT2-transfected COS-7 and Caco-2 cells, indicating that the ER is the primary site for dietary fat re-synthesis. MGAT2 expression appeared not to be affected by diabetes in the db/db mouse, however, the total intestinal MGAT activity was significantly enhanced. Finally, an up-regulation of both MGAT2 protein expression and MGAT activity was observed in mice fed a high fat diet, implicating a role of MGAT2 in diet-induced obesity. Taken together, our data suggest a predominant role of MGAT2 in dietary fat absorption.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Div Endocrine Res, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Div Bioprod Pharmaceut Dev, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly	Shi, YG (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Div Endocrine Res, DC 0545, Indianapolis, IN 46285 USA.	shi_yuguang@lilly.com						BALLAS LM, 1980, BIOCHIM BIOPHYS ACTA, V602, P578, DOI 10.1016/0005-2736(80)90336-3; BHAT BG, 1993, ARCH BIOCHEM BIOPHYS, V300, P663, DOI 10.1006/abbi.1993.1092; BLACK DD, 1995, J PEDIATR GASTR NUTR, V20, P125, DOI 10.1097/00005176-199502000-00002; Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; Cao JS, 2003, J BIOL CHEM, V278, P25657, DOI 10.1074/jbc.M302835200; Cao JS, 2003, J BIOL CHEM, V278, P13860, DOI 10.1074/jbc.M300139200; Cartwright IJ, 1999, J LIPID RES, V40, P1858; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; COLEMAN RA, 1984, J BIOL CHEM, V259, P8934; COLEMAN RA, 1985, BIOCHIM BIOPHYS ACTA, V834, P180, DOI 10.1016/0005-2760(85)90154-7; Coudreau SK, 2003, OBES RES, V11, P1163, DOI 10.1038/oby.2003.160; Covasa M, 1999, AM J PHYSIOL-REG I, V277, pR279, DOI 10.1152/ajpregu.1999.277.1.R279; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Ginsberg HN, 1997, CLIN EXP PHARMACOL P, V24, pA29, DOI 10.1111/j.1440-1681.1997.tb03051.x; GIRON MD, 1993, ARCH BIOCHEM BIOPHYS, V302, P265, DOI 10.1006/abbi.1993.1209; HOFFMAN AGD, 1982, BIOCHIM BIOPHYS ACTA, V710, P53, DOI 10.1016/0005-2760(82)90189-8; HULSMANN WC, 1976, BIOCHIM BIOPHYS ACTA, V450, P288, DOI 10.1016/0005-2760(76)90002-3; JAMDAR SC, 1992, ARCH BIOCHEM BIOPHYS, V296, P419, DOI 10.1016/0003-9861(92)90592-K; JAMDAR SC, 1995, BBA-LIPID LIPID MET, V1255, P237, DOI 10.1016/0005-2760(94)00217-M; JOHNSON LR, 1994, PHYSL GASTROINTESTIN, P1909; JOHNSTON JM, 1970, BIOCHIM BIOPHYS ACTA, V218, P124, DOI 10.1016/0005-2760(70)90099-8; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; LEHNER R, 1993, J BIOL CHEM, V268, P8781; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; LEHNER R, 1995, J BIOL CHEM, V270, P13630, DOI 10.1074/jbc.270.23.13630; Lin L, 2001, AM J PHYSIOL-REG I, V280, pR504, DOI 10.1152/ajpregu.2001.280.2.R504; Lockwood JF, 2003, AM J PHYSIOL-ENDOC M, V285, pE927, DOI 10.1152/ajpendo.00179.2003; Loirdighi N, 1997, AM J PHYSIOL-GASTR L, V273, pG62, DOI 10.1152/ajpgi.1997.273.1.G62; Luan Y, 2002, DIABETES RES CLIN PR, V57, P75, DOI 10.1016/S0168-8227(02)00026-8; Ludwig EH, 2002, CLIN GENET, V62, P68, DOI 10.1034/j.1399-0004.2002.620109.x; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P341, DOI 10.1139/o85-050; Mansbach CM, 1998, J LIPID RES, V39, P963; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; MOSTAFA N, 1993, BIOCHIM BIOPHYS ACTA, V1169, P189, DOI 10.1016/0005-2760(93)90205-N; MOSTAFA N, 1993, J COMP PHYSIOL B, V163, P463; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; *NIH, 1985, NIH PUBL, V8623; PALTAUF F, 1971, BIOCHIM BIOPHYS ACTA, V239, P47, DOI 10.1016/0005-2760(71)90191-3; Phan CT, 2001, FRONT BIOSCI-LANDMRK, V6, pD299, DOI 10.2741/Phan; SABB JE, 1986, J NUTR, V116, P892, DOI 10.1093/jn/116.5.892; SABESIN SM, 1977, EXP MOL PATHOL, V26, P277, DOI 10.1016/0014-4800(77)90055-7; SABESIN SM, 1975, LIPIDS, V10, P840, DOI 10.1007/BF02532330; Spannagel AW, 1996, AM J PHYSIOL-GASTR L, V270, pG128, DOI 10.1152/ajpgi.1996.270.1.G128; Sukhotnik I, 2003, PEDIATR SURG INT, V19, P385, DOI 10.1007/s00383-003-1016-3; THOMSON ABR, 1994, BBA-BIOMEMBRANES, V1191, P197, DOI 10.1016/0005-2736(94)90249-6; TROTTER PJ, 1993, J BIOL CHEM, V268, P10017; TSO P, 2000, BIOCH PHYSL ASPECTS, P125; WESTERGAARD H, 1976, J CLIN INVEST, V58, P97, DOI 10.1172/JCI108465; WU AL, 1980, AM J CLIN NUTR, V33, P582, DOI 10.1093/ajcn/33.3.582; XIA T, 1993, AM J PHYSIOL, V265, pR414, DOI 10.1152/ajpregu.1993.265.2.R414; Yen CLE, 2003, J BIOL CHEM, V278, P18532, DOI 10.1074/jbc.M301633200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899	56	57	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18878	18886		10.1074/jbc.M313272200	http://dx.doi.org/10.1074/jbc.M313272200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966132	hybrid			2022-12-27	WOS:000221041500097
J	Kathe, SD; Shen, GP; Wallace, SS				Kathe, SD; Shen, GP; Wallace, SS			Single-stranded breaks in DNA but not oxidative DNA base damages block transcriptional elongation by RNA polymerase II in HeLa cell nuclear extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRACTED ARTICLE. SEE; RADIATION-INDUCED DNA; ESCHERICHIA-COLI RNA; COCKAYNE-SYNDROME; TEMPLATE STRAND; COUPLED REPAIR; COMPLEMENTATION GROUPS; TRANSCRIBED STRAND; EXCISION-REPAIR; GENE	Transcription and repair of many DNA helix-distorting lesions such as cyclobutane pyrimidine dimers have been shown to be coupled in cells across phyla from bacteria to humans. The signal for transcription-coupled repair appears to be a stalled transcription complex at the lesion site. To determine whether oxidative DNA lesions can block correctly initiated human RNA polymerase II, we examined the effect of site-specifically introduced oxidative damages on transcription in HeLa cell nuclear extracts. We found that transcription was blocked by single-stranded breaks, common oxidative DNA lesions, when present in the transcribed strand of the transcription template. Cyclobutane pyrimidine dimers, which have been previously shown to block transcription both in vitro and in vivo, also blocked transcription in the HeLa cell nuclear transcription assay. In contrast, the oxidative DNA base lesions, 8-oxoguanine, 5-hydroxycytosine, and thymine glycol did not inhibit transcription, although pausing was observed with the thymine glycol lesion. Thus, DNA strand breaks but not oxidative DNA base damages blocked transcription by RNA polymerase II.	Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont	Wallace, SS (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, 95 Carrigan Dr,Stafford Hall, Burlington, VT 05405 USA.	swallace@zoo.uvm.edu		Wallace, Susan S./0000-0002-3906-0321	NATIONAL CANCER INSTITUTE [R37CA033657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017101] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA 33657] Funding Source: Medline; NIA NIH HHS [R01AG17101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; BAILLY V, 1989, BIOCHEM J, V259, P761, DOI 10.1042/bj2590761; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bregeon D, 2003, MOL CELL, V12, P959, DOI 10.1016/S1097-2765(03)00360-5; CHEN YH, 1993, J BIOL CHEM, V268, P5849; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Feng ZH, 2002, J BIOL CHEM, V277, P12777, DOI 10.1074/jbc.M112297200; FRANKENBERGSCHWAGER M, 1990, RADIAT ENVIRON BIOPH, V29, P273, DOI 10.1007/BF01210408; Grishko VI, 1997, MUTAT RES-DNA REPAIR, V384, P73, DOI 10.1016/S0921-8777(97)00017-7; Hanawalt PC, 1999, NATO ADV SCI I A-LIF, V302, P169; HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x; Hatahet Z, 1998, CONT CANC RES, P229; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; Kuraoka I, 2003, J BIOL CHEM, V278, P7294, DOI 10.1074/jbc.M208102200; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Leadon SA, 1997, CANCER RES, V57, P3784; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; Lee SK, 2002, CELL, V109, P823, DOI 10.1016/S0092-8674(02)00795-X; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Liu J, 1998, NUCLEIC ACIDS RES, V26, P1707, DOI 10.1093/nar/26.7.1707; Liu J, 1996, BIOCHEMISTRY-US, V35, P14999, DOI 10.1021/bi961455x; Ljungman M, 1999, RADIAT RES, V152, P444, DOI 10.2307/3580230; May A, 2000, BIOCHEM BIOPH RES CO, V269, P433, DOI 10.1006/bbrc.2000.2264; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Meijer M, 1999, BIOESSAYS, V21, P596, DOI 10.1002/(SICI)1521-1878(199907)21:7<596::AID-BIES8>3.0.CO;2-5; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park JS, 2002, CELL, V109, P757, DOI 10.1016/S0092-8674(02)00769-9; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Sweder KS, 1996, GENETICS, V143, P1127; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; TANAKA K, 1981, SOMAT CELL GENET, V7, P445, DOI 10.1007/BF01542989; Thompson LH, 1998, CONT CANC RES, P335; Thorslund T, 2002, DNA REPAIR, V1, P261, DOI 10.1016/S1568-7864(02)00003-4; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Tornaletti S, 2001, J BIOL CHEM, V276, P45367, DOI 10.1074/jbc.M105282200; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wallace SS, 2003, DNA REPAIR, V2, P441, DOI 10.1016/S1568-7864(02)00182-9; Wallace SS, 1998, RADIAT RES, V150, pS60, DOI 10.2307/3579809; WALLACE SS, 1997, OXIDATIVE STRESS MOL, P49; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; Weinfeld M, 1997, RADIAT RES, V148, P22, DOI 10.2307/3579534; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; ZHOU W, 1994, BIOCHEMISTRY-US, V33, P14926, DOI 10.1021/bi00253a032; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601; ZHOU W, 1995, CELL, V82, P577, DOI 10.1016/0092-8674(95)90030-6	64	112	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18511	18520		10.1074/jbc.M313598200	http://dx.doi.org/10.1074/jbc.M313598200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978042	hybrid			2022-12-27	WOS:000221041500052
J	Kettle, AJ; Clark, BM; Winterbourn, CC				Kettle, AJ; Clark, BM; Winterbourn, CC			Superoxide converts indigo carmine to isatin sulfonic acid - Implications for the hypothesis that neutrophils produce ozone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLET OXYGEN PRODUCTION; MYELOPEROXIDASE; OXIDATION; GENERATION; POTENTIALS; OXIDANT; REDOX	Recently, it was proposed that neutrophils generate ozone (Wentworth, P. J., McDunn, J. E., Wentworth, A. D., Takeuchi, C., Nieva, J., Jones, T., Bautista, C., Ruedi, J. M., Gutierrez, A., Janda, K. D., Babior, B. M., Eschenmoser, A., and Lerner, R. A. ( 2002) Science 298, 2195-2199; Babior, B. M., Takeuchi, C., Ruedi, J., Gutierrez, A., and Wentworth, P. J. ( 2003) Proc. Natl. Acad. Sci. U. S. A. 100, 3031-3034). Evidence for the proposal was based largely on the chemistry of ozone reacting with indigo carmine to produce isatin sulfonic acid. In this investigation, we have examined the specificity of this reaction and whether it can be used as unequivocal evidence of ozone production by neutrophils. Stimulated neutrophils promoted the loss of indigo carmine and formation of isatin sulfonic acid in a reaction that was completely inhibited by superoxide dismutase. Methionine, which scavenges ozone, singlet oxygen, and hypochlorous acid, had no effect on the reaction. Neither did catalase or azide, which scavenge hydrogen peroxide and inhibit myeloperoxidase, respectively. From these results, it is apparent that superoxide was responsible for bleaching indigo carmine. Superoxide generated using xanthine oxidase and acetaldehyde also converted indigo carmine to isatin sulfonic acid in a reaction that was completely inhibited by superoxide dismutase and unaffected by catalase. When the xanthine oxidase reaction was carried out in H-2 O-18, the proportion of O-18 incorporated into the isatin sulfonic acid was the same as that found for ozone. Thus, reactions of ozone and superoxide with indigo carmine are indistinguishable with respect to isatin sulfonic acid formation. We conclude that bleaching of indigo carmine cannot be used to invoke ozone production by neutrophils. Studies using indigo carmine to implicate ozone in other biological processes should also be interpreted with caution.	Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand; Univ Canterbury, Dept Chem, Christchurch 1, New Zealand	University of Otago; University of Canterbury	Kettle, AJ (corresponding author), Christchurch Sch Med & Hlth Sci, Dept Pathol, POB 4345, Christchurch, New Zealand.	tony.kettle@chmeds.ac.nz	Kettle, Anthony J/A-8520-2008	Kettle, Anthony J/0000-0002-8218-7766				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BABIOR BM, 1975, J LAB CLIN MED, V85, P235; Babior BM, 2003, P NATL ACAD SCI USA, V100, P3031, DOI 10.1073/pnas.0530251100; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; Clark W. M., 1960, OXIDATION REDUCTION; COOK AG, 2003, J CHEM EDUC, V71, P160; d'Alessandro N, 2000, J CHEM SOC PERK T 2, P1862, DOI 10.1039/b003346o; Fridovich I, 1985, CRC HDB METHODS OXYG, P213; GABIG TG, 1979, BLOOD, V53, P1133; Grisham MB, 2000, TRENDS PHARMACOL SCI, V21, P119, DOI 10.1016/S0165-6147(99)01435-2; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Harriram A, 2003, J ENVIRON SCI HEAL A, V38, P1055, DOI 10.1081/ESE-120019863; ILAN YA, 1976, BIOCHIM BIOPHYS ACTA, V430, P209, DOI 10.1016/0005-2728(76)90080-3; KANOFSKY JR, 1989, CHEM-BIOL INTERACT, V70, P1, DOI 10.1016/0009-2797(89)90059-8; KANOFSKY JR, 1984, J CLIN INVEST, V74, P1489, DOI 10.1172/JCI111562; KANOFSKY JR, 1995, ARCH BIOCHEM BIOPHYS, V316, P52, DOI 10.1006/abbi.1995.1009; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Klebanoff S.J., 1999, INFLAMMATION BASIC P, P721; Lerner RA, 2003, P NATL ACAD SCI USA, V100, P3013, DOI 10.1073/pnas.0730791100; MICHAELI A, 1994, PHOTOCHEM PHOTOBIOL, V59, P284, DOI 10.1111/j.1751-1097.1994.tb05035.x; MUNOZ F, 2000, J CHEM SOC P2, P661; Nathan C, 2002, SCIENCE, V298, P2143, DOI 10.1126/science.1080005; Parren PWHI, 2003, TRENDS IMMUNOL, V24, P467, DOI 10.1016/S1471-4906(03)00234-5; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; PREISLER PW, 1959, J AM CHEM SOC, V81, P1991, DOI 10.1021/ja01517a051; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; Tatsuzawa H, 1999, BIOCHEM BIOPH RES CO, V262, P647, DOI 10.1006/bbrc.1999.1265; Tuynman A, 2000, J BIOL CHEM, V275, P3025, DOI 10.1074/jbc.275.5.3025; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Wentworth P, 2003, SCIENCE, V302, P1053, DOI 10.1126/science.1089525; Wentworth P, 2002, SCIENCE, V298, P2195, DOI 10.1126/science.1077642; Winterbourn CC, 2003, BIOCHEM BIOPH RES CO, V305, P729, DOI 10.1016/S0006-291X(03)00810-6	33	105	108	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18521	18525		10.1074/jbc.M400334200	http://dx.doi.org/10.1074/jbc.M400334200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978029	hybrid			2022-12-27	WOS:000221041500053
J	Raffoul, JJ; Cabelof, DC; Nakamura, J; Meira, LB; Friedberg, EC; Heydari, AR				Raffoul, JJ; Cabelof, DC; Nakamura, J; Meira, LB; Friedberg, EC; Heydari, AR			Apurinic/apyrimidinic endonuclease (APE/REF-1) haploinsufficient mice display tissue-specific differences in DNA polymerase beta-dependent base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASE; STRANDED DEOXYRIBONUCLEIC-ACID; ENZYME APEX NUCLEASE; ABASIC SITE; DAMAGE; PROTEIN; REF-1; P53; IDENTIFICATION; STIMULATION	Apurinic/apyrimidinic (AP) endonuclease ( APE) is a multifunctional protein possessing both DNA repair and redox regulatory activities. In base excision repair (BER), APE is responsible for processing spontaneous, chemical, or monofunctional DNA glycosylase-initiated AP sites via its 5'-endonuclease activity and 3'-"end-trimming" activity when processing residues produced as a consequence of bifunctional DNA glycosylases. In this study, we have fully characterized a mammalian model of APE haploinsufficiency by using a mouse containing a heterozygous gene-targeted deletion of the APE gene (Apex(+/-)). Our data indicate that Apex(+/-) mice are indeed APE-haploinsufficient, as exhibited by a 40-50% reduction (p < 0.05) in APE mRNA, protein, and 5'-endonuclease activity in all tissues studied. Based on gene dosage, we expected to see a concomitant reduction in BER activity; however, by using an in vitro G: U mismatch BER assay, we observed tissue-specific alterations in monofunctional glycosylase-initiated BER activity, e. g. liver (35% decrease, p < 0.05), testes (55% increase, p < 0.05), and brain ( no significant difference). The observed changes in BER activity correlated tightly with changes in DNA polymerase beta and AP site DNA binding levels. We propose a mechanism of BER that may be influenced by the redox regulatory activity of APE, and we suggest that reduced APE may render a cell/tissue more susceptible to dysregulation of the polymerase beta-dependent BER response to cellular stress.	Wayne State Univ, Dept Food Sci & Nutr, Detroit, MI 48202 USA; Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA; Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA	Wayne State University; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Heydari, AR (corresponding author), Wayne State Univ, Dept Food Sci & Nutr, 3009 Sci Hall, Detroit, MI 48202 USA.	ahmad.heydari@wayne.edu	Meira, Lisiane/AAA-4326-2020	Nakamura, Jun/0000-0002-1756-7199; Meira, Lisiane/0000-0003-4289-2986	NIDDK NIH HHS [1R21-DK62256] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062256] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; ALVAREZ JG, 1984, BIOL REPROD, V30, P833, DOI 10.1095/biolreprod30.4.833; Baker MA, 2003, PROTOPLASMA, V221, P145, DOI 10.1007/s00709-002-0057-0; Basnakian AG, 1996, DNA CELL BIOL, V15, P255, DOI 10.1089/dna.1996.15.255; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bogliolo M, 2002, ANTICANCER RES, V22, P2797; Cabelof DC, 2003, CANCER RES, V63, P5799; Cabelof DC, 2003, DNA REPAIR, V2, P295, DOI 10.1016/S1568-7864(02)00219-7; Cabelof DC, 2002, CARCINOGENESIS, V23, P1419, DOI 10.1093/carcin/23.9.1419; Cabelof DC, 2002, MUTAT RES-FUND MOL M, V500, P135, DOI 10.1016/S0027-5107(02)00003-9; Cappelli E, 2000, CARCINOGENESIS, V21, P1135, DOI 10.1093/carcin/21.6.1135; Cappelli E, 2003, ENVIRON MOL MUTAGEN, V42, P50, DOI 10.1002/em.10166; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; de Boer JG, 2002, MUTAT RES-FUND MOL M, V509, P201, DOI 10.1016/S0027-5107(02)00217-8; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; DUGUID JR, 1995, CANCER RES, V55, P6097; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fisher HM, 1997, J EXP ZOOL, V277, P390, DOI 10.1002/(SICI)1097-010X(19970401)277:5&lt;390::AID-JEZ5&gt;3.0.CO;2-K; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Friedberg EC, 2003, DNA REPAIR, V2, P501, DOI 10.1016/S1568-7864(03)00005-3; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P208; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Hadi MZ, 2000, NUCLEIC ACIDS RES, V28, P3871, DOI 10.1093/nar/28.20.3871; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Hofer T, 1998, CHEM RES TOXICOL, V11, P882, DOI 10.1021/tx980041x; Intano GW, 2001, NUCLEIC ACIDS RES, V29, P1366, DOI 10.1093/nar/29.6.1366; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; Izumi T, 2000, CARCINOGENESIS, V21, P1329, DOI 10.1093/carcin/21.7.1329; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kakolyris S, 1998, HISTOPATHOLOGY, V33, P561; Kumar TR, 2002, MUTAT RES-GEN TOX EN, V513, P103, DOI 10.1016/S1383-5718(01)00300-X; Lebedeva NA, 2003, BIOCHEM BIOPH RES CO, V300, P182, DOI 10.1016/S0006-291X(02)02808-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LJUNGQUIST S, 1974, J BIOL CHEM, V249, P1536; LJUNGQUIST S, 1974, J BIOL CHEM, V249, P1530; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; Marenstein DR, 2003, J BIOL CHEM, V278, P9005, DOI 10.1074/jbc.M212168200; Marsin S, 2003, J BIOL CHEM, V278, P44068, DOI 10.1074/jbc.M306160200; Meira LB, 1997, NAT GENET, V17, P145, DOI 10.1038/ng1097-145; Meira LB, 2001, CANCER RES, V61, P5552; Mohrenweiser HW, 2003, MUTAT RES-FUND MOL M, V526, P93, DOI 10.1016/S0027-5107(03)00049-6; Nakamura J, 1999, CANCER RES, V59, P2522; Nakamura J, 1998, CANCER RES, V58, P222; Olsen AK, 2001, NUCLEIC ACIDS RES, V29, P1781, DOI 10.1093/nar/29.8.1781; ONO Y, 1994, MUTAT RES, V315, P55, DOI 10.1016/0921-8777(94)90028-0; Ordway JM, 2003, MOL CELL BIOL, V23, P4257, DOI 10.1128/MCB.23.12.4257-4266.2003; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Sawyer DE, 2003, MUTAT RES-FUND MOL M, V529, P21, DOI 10.1016/S0027-5107(03)00101-5; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SEKI S, 1991, J BIOL CHEM, V266, P20797; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; SOKAL RR, 1981, BIOMETRY, P169; Sokhansanj BA, 2002, NUCLEIC ACIDS RES, V30, P1817, DOI 10.1093/nar/30.8.1817; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Tan YS, 1996, ACTA MED OKAYAMA, V50, P53; Tomkinson AE, 2001, PROG NUCLEIC ACID RE, V68, P151; VERLY WG, 1972, CAN J BIOCHEM CELL B, V50, P217, DOI 10.1139/o72-029; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; Wilson DM, 2003, FRONT BIOSCI-LANDMRK, V8, pD963, DOI 10.2741/1109; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Wilstermann AM, 2001, J BIOL CHEM, V276, P46290, DOI 10.1074/jbc.M105733200; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yu SL, 2003, MOL CELL BIOL, V23, P382, DOI 10.1128/MCB.23.1.382-388.2003; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	71	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18425	18433		10.1074/jbc.M313983200	http://dx.doi.org/10.1074/jbc.M313983200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14973123	hybrid, Green Published			2022-12-27	WOS:000221041500041
J	Ye, L; MacDougall, M; Zhang, SB; Xie, YX; Zhang, JH; Li, ZB; Lu, YB; Mishina, YJ; Feng, JQ				Ye, L; MacDougall, M; Zhang, SB; Xie, YX; Zhang, JH; Li, ZB; Lu, YB; Mishina, YJ; Feng, JQ			Deletion of dentin matrix protein-1 leads to a partial failure of maturation of predentin into dentin, hypomineralization, and expanded cavities of pulp and root canal during postnatal tooth development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTINOGENESIS IMPERFECTA; HYDROXYAPATITE FORMATION; BONE SIALOPROTEIN; COLLAGEN FIBRILS; GENE; MUTATION; PHOSPHOPROTEIN; MICE; DSPP; EXPRESSION	The dentin matrix protein-1 (DMP-1) gene is identified in odontoblasts during both embryonic and postnatal development. In vitro study suggests that this noncollagen acidic phosphoprotein plays a role in mineralization. However, deletion of the Dmp-1 gene has little effect on tooth development during embryogenesis. To address the role of DMP-1 in tooth during postnatal development, we analyzed changes of dentinogenesis in Dmp-1 null mice from 3 days after birth to 1 year. Here we show that Dmp-1 null mice postnatally develop a profound tooth phenotype characterized by a partial failure of maturation of predentin into dentin, enlarged pulp chambers, increased width of predentin zone with reduced dentin wall, and hypomineralization. The tooth phenotype of these mice is strikingly similar to that in dentin sialophosphoprotein (Dspp) null mice and shares some features of the human disease dentinogenesis imperfecta III. We have also demonstrated that DSPP levels are reduced in Dmp-1 null mice, suggesting that DSPP is probably regulated by DMP-1 during dentinogenesis. Finally, we show the absence or delayed development of the third molar in Dmp-1 null mice, which is probably secondary to defects in Dmp-1 null bone. Taken together, these studies suggest that DMP-1 is essential for later dentinogenesis during postnatal development.	Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat Dent, San Antonio, TX 78284 USA; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of Missouri System; University of Missouri Kansas City; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Feng, JQ (corresponding author), Univ Missouri, Sch Dent, Dept Oral Biol, 650 E 25th St, Kansas City, MO 64108 USA.	fengj@umkc.edu	MacDougall, Mary/ABG-8212-2021	Lu, Yongbo/0000-0003-3692-1736	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE013480, P01DE013221, R29DE009875, R01DE009875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071003] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13221, DE09875, DE13480, DE00455] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ameye L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0848com; BOSKEY AL, 1990, BONE MINER, V11, P55, DOI 10.1016/0169-6009(90)90015-8; Boskey AL, 1997, J DENT RES, V76, P1433, DOI 10.1177/00220345970760080501; BUTLER WT, 1995, INT J DEV BIOL, V39, P169; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Fedarko NS, 2000, J BIOL CHEM, V275, P16666, DOI 10.1074/jbc.M001123200; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; Feng JQ, 2003, J DENT RES, V82, P776, DOI 10.1177/154405910308201003; Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; Frazier-Bowers SA, 2002, J DENT RES, V81, P129, DOI 10.1177/154405910208100209; GARANT PR, 2003, ORAL CELLS TISSUES, P25; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; Hassan AH, 2003, CONNECT TISSUE RES, V44, P30, DOI 10.1080/03008200390151927; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; LEVIN LS, 1983, ORAL SURG ORAL MED O, V56, P267, DOI 10.1016/0030-4220(83)90008-7; LINDE A, 1989, CALCIFIED TISSUE INT, V44, P286, DOI 10.1007/BF02553763; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735; Qin CL, 2003, J BIOL CHEM, V278, P34700, DOI 10.1074/jbc.M305315200; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; Stockton DW, 2000, NAT GENET, V24, P18, DOI 10.1038/71634; Ten Cate A.R., 1998, ORAL HISTOLOGY DEV S, P128; Thompson DL, 2002, J BONE MINER RES, V17, P311, DOI 10.1359/jbmr.2002.17.2.311; van den Boogaard MJH, 2000, NAT GENET, V24, P342, DOI 10.1038/74155; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; Vieira AR, 2003, J DENT RES, V82, P162, DOI 10.1177/154405910308200303; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Zhang JH, 2002, BIOCHEM BIOPH RES CO, V293, P1412, DOI 10.1016/S0006-291X(02)00416-3; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	38	219	230	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19141	19148		10.1074/jbc.M400490200	http://dx.doi.org/10.1074/jbc.M400490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966118	hybrid			2022-12-27	WOS:000221041500127
J	Aitsebaomo, J; Wennerberg, K; Der, CJ; Zhang, CL; Kedar, V; Moser, M; Kingsley-Kallesen, ML; Zeng, GQ; Patterson, C				Aitsebaomo, J; Wennerberg, K; Der, CJ; Zhang, CL; Kedar, V; Moser, M; Kingsley-Kallesen, ML; Zeng, GQ; Patterson, C			p68RacGAP is a novel GTPase-activating protein that interacts with vascular endothelial zinc finger-1 and modulates endothelial cell capillary formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GTPASES; TRANSCRIPTION FACTOR; EXPRESSION; MIGRATION; ENCODES; FAMILY; RAC1; CHIP; GENE	The endothelium is required for maintenance of vascular integrity and homeostasis during vascular development and in adulthood. However, little is known about the coordinated interplay between transcription factors and signaling molecules that regulate endothelial cell-dependent transcriptional events. Vascular endothelial zinc finger-1 (Vezf1) is a zinc finger-containing transcription factor that is specifically expressed within the endothelium during vascular development. We have previously shown that Vezf1 potently activates transcription of the endothelin-1 promoter. We now report the identification of p68RacGAP, a novel Vezf1-interacting 68-kDa RhoGAP domain-containing protein. p68RacGAP mRNA is highly expressed in vascular endothelial cells by Northern blot analysis, and immunohistochemical staining of adult mouse tissues identified p68RacGAP in endothelial cells, vascular smooth muscle cells, and epithelial cells in vivo. Rac1 and Vezf1 both bind avidly to p68RacGAP, suggesting that p68RacGAP is not only a GTPase-activating protein for Rac1 but that p68RacGAP may also be part of the protein complex that binds to and modulates Vezf1 transcriptional activity. Functionally p68RacGAP specifically activates the GTPase activity of Rac1 in vivo but not Cdc42 or RhoA. In addition, p68RacGAP potently inhibits Vezf1/DB1-mediated transcriptional activation of the human endothelin-1 promoter and modulates endothelial cell capillary tube formation. Taken together, these data suggest that p68RacGAP is a multifunctional regulatory protein that has a Rac1-specific GTPase-activating activity, regulates transcriptional activity of the endothelin-1 promoter, and is involved in the signal transduction pathway that regulates endothelial cell capillary tube formation during angiogenesis.	Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Baylor College of Medicine	Patterson, C (corresponding author), Univ N Carolina, Carolina Cardiovasc Biol Ctr, 8200 Med Biomol Res Bldg, Chapel Hill, NC 27599 USA.	cpatters@med.unc.edu	Wennerberg, Krister/AFM-0539-2022; Wennerberg, Krister/AAH-2919-2022; Zhang, Chunlian/L-1399-2014	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA063071] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021096] Funding Source: NIH RePORTER; NCI NIH HHS [CA63071] Funding Source: Medline; NHLBI NIH HHS [HL61656] Funding Source: Medline; NIA NIH HHS [AG21096] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aitsebaomo J, 2001, J BIOL CHEM, V276, P39197, DOI 10.1074/jbc.M105166200; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KOYANONAKAGAWA N, 1994, MOL CELL BIOL, V14, P5099, DOI 10.1128/MCB.14.8.5099; Lebowitz PF, 1998, CELL ADHES COMMUN, V6, P277, DOI 10.3109/15419069809010787; Lopes NHM, 2002, CIRC RES, V91, P798, DOI 10.1161/01.RES.0000040421.54108.81; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Wherlock M, 2002, J CELL SCI, V115, P239; Xiong JW, 1999, DEV BIOL, V206, P123, DOI 10.1006/dbio.1998.9144; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770	28	23	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17963	17972		10.1074/jbc.M311721200	http://dx.doi.org/10.1074/jbc.M311721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966113	Green Published, hybrid			2022-12-27	WOS:000220870400131
J	Hecht, O; van Nuland, NA; Schleinkofer, K; Dingley, AJ; Bruhn, H; Leippe, M; Grotzinger, J				Hecht, O; van Nuland, NA; Schleinkofer, K; Dingley, AJ; Bruhn, H; Leippe, M; Grotzinger, J			Solution structure of the pore-forming protein of Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NK-LYSIN; TOXIN AEROLYSIN; NMR STRUCTURE; AMOEBAPORES; PEPTIDES; GRANULYSIN; ANTIBACTERIAL; AMEBIASIS; MEMBRANES; RESIDUES	Amoebapore A is a 77-residue protein from the protozoan parasite and human pathogen Entamoeba histolytica. Amoebapores lyse both bacteria and eukaryotic cells by pore formation and play a pivotal role in the destruction of host tissues during amoebiasis, one of the most life-threatening parasitic diseases. Amoebapore A belongs to the superfamily of saposin-like proteins that are characterized by a conserved disulfide bond pattern and a fold consisting of five helices. Membrane-permeabilizing effector molecules of mammalian lymphocytes such as porcine NK-lysin and the human granulysin share these structural attributes. Several mechanisms have been proposed to explain how saposin-like proteins form membrane pores. All mechanisms indicate that the surface charge distribution of these proteins is the basis of their membrane binding capacity and pore formation. Here, we have solved the structure of amoebapore A by NMR spectroscopy. We demonstrate that the specific activation step of amoebapore A depends on a pH-dependent dimerization event and is modulated by a surface-exposed histidine residue. Thus, histidine-mediated dimerization is the molecular switch for pore formation and reveals a novel activation mechanism of pore-forming toxins.	Univ Kiel, Inst Biochem, D-24118 Kiel, Germany; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept NMR Spect, NL-3484 CH Utrecht, Netherlands; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Zentrum Infekt Forsch, D-97070 Wurzburg, Germany; Univ Kiel, Inst Zool, D-24118 Kiel, Germany	University of Kiel; Utrecht University; University of London; University College London; University of Kiel	Grotzinger, J (corresponding author), Univ Kiel, Inst Biochem, Olshaussenstr 40, D-24118 Kiel, Germany.	jgroetzinger@biochem.uni-kiel.de	Leippe, Matthias/AAP-1677-2020; Dingley, Andrew/G-6427-2013	Dingley, Andrew/0000-0002-6838-5803; Bruhn, Heike/0000-0002-4759-7989				Anderson DH, 2003, J MOL BIOL, V325, P355, DOI 10.1016/S0022-2836(02)01234-2; ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; Andra J, 2003, DEV COMP IMMUNOL, V27, P291, DOI 10.1016/S0145-305X(02)00106-4; ANDRA J, 1994, FEBS LETT, V354, P97, DOI 10.1016/0014-5793(94)01103-6; Berninghausen O, 1997, INFECT IMMUN, V65, P3615, DOI 10.1128/IAI.65.9.3615-3621.1997; BOHEIM G, 1974, J MEMBRANE BIOL, V19, P277, DOI 10.1007/BF01869983; Bracha R, 2003, EUKARYOT CELL, V2, P295, DOI 10.1128/EC.2.2.295-305.2003; Bransburg-Zabary S, 2002, BIOCHEMISTRY-US, V41, P6946, DOI 10.1021/bi0120704; Bruchhaus I, 1996, MOL MICROBIOL, V22, P255, DOI 10.1046/j.1365-2958.1996.00111.x; Bruhn H, 2003, BIOCHEM J, V375, P737, DOI 10.1042/BJ20030250; Bruhn H, 1999, BIOL CHEM, V380, P1001, DOI 10.1515/BC.1999.124; CARRAWAY KL, 1968, BIOCHIM BIOPHYS ACTA, V160, P272, DOI 10.1016/0005-2795(68)90102-5; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GREEN MJ, 1990, BIOCHEMISTRY-US, V29, P2177, DOI 10.1021/bi00460a031; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Gutsmann T, 2003, BIOCHEMISTRY-US, V42, P9804, DOI 10.1021/bi034686u; Hanson DA, 1999, MOL IMMUNOL, V36, P413, DOI 10.1016/S0161-5890(99)00063-2; HOARE DG, 1967, J BIOL CHEM, V242, P2447; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JURSCH R, 1994, INFECT IMMUN, V62, P2249, DOI 10.1128/IAI.62.6.2249-2256.1994; KELLER F, 1989, BIOCHIM BIOPHYS ACTA, V982, P89, DOI 10.1016/0005-2736(89)90178-8; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; LEIPPE M, 1994, P NATL ACAD SCI USA, V91, P2602, DOI 10.1073/pnas.91.7.2602; LEIPPE M, 1992, EMBO J, V11, P3501, DOI 10.1002/j.1460-2075.1992.tb05432.x; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; LEIPPE M, 1994, MOL MICROBIOL, V14, P895, DOI 10.1111/j.1365-2958.1994.tb01325.x; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; Miteva M, 1999, FEBS LETT, V462, P155, DOI 10.1016/S0014-5793(99)01520-3; MUNFORD RS, 1995, J LIPID RES, V36, P1653; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pena SV, 1997, J IMMUNOL, V158, P2680; Petri WA, 2002, ANNU REV MICROBIOL, V56, P39, DOI 10.1146/annurev.micro.56.012302.160959; RAVDIN JI, 1995, CLIN INFECT DIS, V20, P1453, DOI 10.1093/clinids/20.6.1453; Ruysschaert JM, 1998, FEBS LETT, V425, P341, DOI 10.1016/S0014-5793(98)00261-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Stanley SL, 2003, LANCET, V361, P1025, DOI 10.1016/S0140-6736(03)12830-9; WALSH JA, 1986, REV INFECT DIS, V8, P228; WAXMAN E, 1993, ANAL BIOCHEM, V210, P425, DOI 10.1006/abio.1993.1220	44	75	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17834	17841		10.1074/jbc.M312978200	http://dx.doi.org/10.1074/jbc.M312978200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970207	hybrid			2022-12-27	WOS:000220870400116
J	Park, KS; Whitsett, JA; Di Palma, T; Hong, JH; Yaffe, MB; Zannini, M				Park, KS; Whitsett, JA; Di Palma, T; Hong, JH; Yaffe, MB; Zannini, M			TAZ interacts with TTF-1 and regulates expression of surfactant protein-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; RESPIRATORY EPITHELIAL-CELLS; HEPATOCYTE NUCLEAR FACTOR-3; INTERSTITIAL LUNG-DISEASE; SP-A GENE; B GENE; SECRETORY PROTEIN; BINDING PROTEIN; TRANSGENIC MICE; MOUSE LUNG	Thyroid transcription factor-1 (TTF-1/Nkx-2.1) is required for formation of the lung and differentiation of peripheral respiratory epithelial cells. TTF-1 activates transcription of target genes, including the surfactant proteins critical for lung function. A recently identified protein TAZ (transcriptional co-activator with PDZ -binding motif) contains a WW domain and a COOH-terminal PDZ-binding motif that are proposed to mediate its interactions with various transcriptional proteins. To determine the role of TAZ in the regulation of gene expression in the lung, the sites of TAZ expression and the role of TAZ in the regulation of respiratory epithelial gene expression were assessed. TAZ mRNA was detected in immortalized mouse lung epithelial cells, primary isolates of mouse alveolar type II epithelial cells, and epithelial cells of fetal lung. Sites of TAZ mRNA and protein overlapped with those of TTF-1 and surfactant protein C (SP-C) in the respiratory epithelial cells of the mouse lung. In the presence of TTF-1, TAZ synergistically activated the expression of mouse SP-C-luciferase reporter constructs. Mammalian two-hybrid assays and pull-down experiments demonstrated that the TAZ directly interacted with TTF-1. Further, deletion analysis demonstrated that TAZ binds to the NH2-terminal domain of TTF-1. TAZ binds to TTF-1, increasing the transcriptional activity of TTF-1 on the SP-C promoter. Developmental and cell-selective regulation of TAZ provides a mechanism by which the activity of TTF-1 on target genes is modulated.	Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Dept Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; MIT, Dept Biol, Ctr Canc Res, Cambridge, MA 02139 USA	Cincinnati Children's Hospital Medical Center; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Massachusetts Institute of Technology (MIT)	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org	Zannini, Mariastella/I-1735-2012; Di+Palma, Tina/AAN-6853-2021	Park, Kwon-Sik/0000-0003-3346-9086	NHLBI NIH HHS [HL61646, HL 38859] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038859, R37HL038859, P01HL061646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amin RS, 2001, J PEDIATR-US, V139, P85, DOI 10.1067/mpd.2001.114545; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Bachurski CJ, 2003, MOL CELL BIOL, V23, P9014, DOI 10.1128/MCB.23.24.9014-9024.2003; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Cassel TN, 2002, J BIOL CHEM, V277, P36970, DOI 10.1074/jbc.M201293200; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004-1013.2003; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; Di Palma T, 2003, J BIOL CHEM, V278, P3395, DOI 10.1074/jbc.M205977200; Endo T, 1997, MOL ENDOCRINOL, V11, P1747, DOI 10.1210/me.11.11.1747; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; Ghaffari M, 1997, BIOCHEM J, V328, P757, DOI 10.1042/bj3280757; Glasser SW, 2003, J BIOL CHEM, V278, P14291, DOI 10.1074/jbc.M210909200; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Krude H, 2002, J CLIN INVEST, V109, P475, DOI 10.1172/JC1200214341; Kumar AS, 2000, BBA-GENE STRUCT EXPR, V1492, P45, DOI 10.1016/S0167-4781(00)00058-0; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; Naltner A, 2000, AM J PHYSIOL-LUNG C, V279, pL1066, DOI 10.1152/ajplung.2000.279.6.L1066; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; SUDOL M, 1994, ONCOGENE, V9, P2145; Tell G, 1998, BIOCHEM J, V329, P395, DOI 10.1042/bj3290395; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Yan C, 2002, J BIOL CHEM, V277, P10967, DOI 10.1074/jbc.M109986200; Yan C, 2001, J BIOL CHEM, V276, P21686, DOI 10.1074/jbc.M011378200; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Yang YS, 2001, AM J RESP CELL MOL, V24, P30, DOI 10.1165/ajrcmb.24.1.4050; Yi M, 2002, J BIOL CHEM, V277, P2997, DOI 10.1074/jbc.M109793200; Zhang LQ, 1997, BBA-GENE STRUCT EXPR, V1350, P359, DOI 10.1016/S0167-4781(96)00180-7; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	49	134	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17384	17390		10.1074/jbc.M312569200	http://dx.doi.org/10.1074/jbc.M312569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970209	hybrid			2022-12-27	WOS:000220870400062
J	Xing, F; Hiley, SL; Hughes, TR; Phizicky, EM				Xing, F; Hiley, SL; Hughes, TR; Phizicky, EM			The specificities of four yeast dihydrouridine synthases for cytoplasmic tRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL TRANSFER-RNAS; PHENYLALANINE TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ANTICODON LOOP; GENE; IDENTIFICATION; GENOME	Dihydrouridine is a highly abundant modified nucleoside found widely in tRNAs of eubacteria, eukaryotes, and some archaea. In cytoplasmic tRNA of Saccharomyces cerevisiae, dihydrouridine occurs exclusively at positions 16, 17, 20, 20A, 20B, and 47. Here we show that the known dihydrouridine synthases Dus1p and Dus2p and two previously uncharacterized homologs, Dus3p (encoded by YLR401c) and Dus4p (YLR405w), are required for all of the dihydrouridine modification of cytoplasmic tRNAs in S. cerevisiae. We have mapped the in vivo position specificity of the four Dus proteins, by three complementary approaches: determination of the molar ratio of dihydrouridine in purified tRNAs from different dus mutants; microarray analysis of a large number of tRNAs based on differential hybridization of uridine- and dihydrouridine-containing tRNAs to the complementary oligonucleotides; and the development and use of a novel dihydrouridine mapping technique, employing primer extension. We show that each of the four Dus proteins has a distinct position specificity: Dus1p for U-16 and U-17, Dus2p for U-20, Dus3p for U-47, and Dus4p for U-20a and U-20b.	Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Rochester; University of Toronto	Phizicky, EM (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	eric_phizicky@urmc.rochester.edu			NIGMS NIH HHS [GM 52347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Bakin AV, 1998, METH MOL B, V77, P297; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; BATT RD, 1954, J AM CHEM SOC, V76, P3663, DOI 10.1021/ja01643a018; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; Bishop AC, 2002, J BIOL CHEM, V277, P25090, DOI 10.1074/jbc.M203208200; BOGUTA M, 1994, MOL CELL BIOL, V14, P2298, DOI 10.1128/MCB.14.4.2298; Brachmann CB, 1998, YEAST, V14, P115; Cavaille J, 1999, RNA, V5, P66, DOI 10.1017/S1355838299981475; Dalluge JJ, 1997, J BACTERIOL, V179, P1918, DOI 10.1128/jb.179.6.1918-1923.1997; Dalluge JJ, 1996, NUCLEIC ACIDS RES, V24, P1073, DOI 10.1093/nar/24.6.1073; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; GEHRKE CW, 1989, J CHROMATOGR, V471, P3, DOI 10.1016/S0021-9673(00)94152-9; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hani J, 1998, NUCLEIC ACIDS RES, V26, P689, DOI 10.1093/nar/26.3.689; HOPPER AK, 1982, CELL, V28, P543, DOI 10.1016/0092-8674(82)90209-4; Hopper AK, 2003, GENE DEV, V17, P162, DOI 10.1101/gad.1049103; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Jackman JE, 2003, RNA, V9, P574, DOI 10.1261/rna.5070303; Johansson MJO, 2002, RNA, V8, P324, DOI 10.1017/S1355838202027851; Jovine L, 2000, J MOL BIOL, V301, P401, DOI 10.1006/jmbi.2000.3950; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LANGLEROUAULT F, 1995, NUCLEIC ACIDS RES, V23, P3079, DOI 10.1093/nar/23.15.3079; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; MAGRATH D. I., 1967, BIOCHEM BIOPHYS RES COMMUN, V26, P32, DOI 10.1016/0006-291X(67)90248-3; Massenet S, 1999, MOL CELL BIOL, V19, P2142; MOLINARO M, 1968, J BIOL CHEM, V243, P1277; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; Noon KR, 2003, J BACTERIOL, V185, P5483, DOI 10.1128/JB.185.18.5483-5490.2003; Peng WT, 2003, CELL, V113, P919, DOI 10.1016/S0092-8674(03)00466-5; Pintard L, 2002, EMBO J, V21, P1811, DOI 10.1093/emboj/21.7.1811; Rinaldi T, 1997, CURR GENET, V31, P494, DOI 10.1007/s002940050235; Rinaldi T, 2003, GENE, V303, P63, DOI 10.1016/S0378-1119(02)01154-X; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Rubin G M, 1975, Methods Cell Biol, V12, P45; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Urbonavicius J, 2002, J BACTERIOL, V184, P5348, DOI 10.1128/JB.184.19.5348-5357.2002; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; Xing F, 2002, RNA, V8, P370, DOI 10.1017/S1355838202029825	43	75	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17850	17860		10.1074/jbc.M401221200	http://dx.doi.org/10.1074/jbc.M401221200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970222	hybrid			2022-12-27	WOS:000220870400118
J	Midura, RJ; Wang, AM; Lovitch, D; Law, D; Powell, K; Gorski, JP				Midura, RJ; Wang, AM; Lovitch, D; Law, D; Powell, K; Gorski, JP			Bone acidic glycoprotein-75 delineates the extracellular sites of future bone sialoprotein accumulation and apatite nucleation in osteoblastic cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX VESICLES; IN-VITRO; EPIPHYSEAL CARTILAGE; RAT BONE; NONCOLLAGENOUS PROTEINS; ALKALINE-PHOSPHATASE; INSITU HYBRIDIZATION; COLLAGEN FIBRILS; N-RAP; EXPRESSION	Addition of an organophosphate source to UMR osteoblastic cultures activates a mineralization program in which BSP localizes to extracellular matrix sites where hydroxyapatite crystals are subsequently nucleated (Wang, A., Martin, J. A., Lembke, L. A., and Midura, R. J. (2000) J. Biol. Chem. 275, 11082-11091). This study identifies for the first time novel extracellular spherical structures, termed biomineralization foci (BMF), containing bone acidic glycoprotein-75 (BAG-75), bone sialoprotein (BSP), and alkaline phosphatase that are the exclusive sites of initial nucleation of hydroxyapatite crystals in the UMR model. Importantly, in the absence of added phosphate, UMR cultures after reaching confluency contain two size populations of morphologically identifiable BMF precursors enriched in BAG-75 (15-25 and 150-250 mum in diameter). The shape and size of the smaller population are similar to structures assembled in vitro through self-association of purified BAG-75 protein (Gorski, J. P., Kremer, E. A., Chen, Y., Ryan, S., Fullenkamp, C., Delviscio, J., Jensen, K., and McKee, M. D. (1997) J. Cell. Biochem. 64, 547-564). After organophosphate addition, BSP accumulates within these BAG-75-containing BMF precursors, with hydroxyapatite crystal nucleation occurring subsequently. In summary, BAG-75 is the earliest detectable biomarker that accurately predicts the extracellular sites of de novo biomineralization in UMR cultures. We hypothesize that BAG-75 may perform a key structural role in the assembly of BMF precursors and the recruitment of other proteins such as alkaline phosphatase and BSP. Furthermore, we propose a hypothetical mechanism in which BAG-75 and BSP function actively in nucleation of apatite within BMF.	Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Orthopaed Res Ctr, Cleveland, OH 44195 USA; Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64108 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City	Midura, RJ (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.	midura@bme.ri.ccf.org			NIAMS NIH HHS [AR-45171] Funding Source: Medline; NIDCR NIH HHS [DE-14619, DE-11197] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE014619, R03DE011197] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; BASKEY AL, 1995, ANN NY ACAD SCI, V769, P249; BIANCO P, 1993, J HISTOCHEM CYTOCHEM, V41, P193, DOI 10.1177/41.2.8419459; Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223-002-1057-y; BONNUCI E, 1989, CONNECT TISSUE RES, V22, P43; BONUCCI E, 1992, BONE MINER, V17, P219, DOI 10.1016/0169-6009(92)90740-5; Bonucci E, 1995, Connect Tissue Res, V33, P157, DOI 10.3109/03008209509016996; BONUCCI E, 1978, CALC TISS RES, V25, P179, DOI 10.1007/BF02010766; BONUCCI E, 1988, CLIN ORTHOP RELAT R, P243; Bonucci E., 1992, CALCIFICATION BIOL S, P19; BOSKEY AL, 1992, CLIN ORTHOP RELAT R, P244; Chang YL, 2000, J BIOMED MATER RES, V52, P270, DOI 10.1002/1097-4636(200011)52:2<270::AID-JBM5>3.0.CO;2-1; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; CHEN Y, 1992, J BIOL CHEM, V267, P24871; EANES ED, 1992, CALCIFICATION BIOL S, P1; ECAROTCHARRIER B, 1989, J BIOL CHEM, V264, P20049; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; Gorski JP, 2003, J BONE MINER RES, V18, pS196; Gorski JP, 1996, CONNECT TISSUE RES, V35, P137, DOI 10.3109/03008209609029184; Gorski JP, 2004, J BIOL CHEM, V279, P25455, DOI 10.1074/jbc.M312408200; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; Gorski JP, 1997, J CELL BIOCHEM, V64, P547; Gorski JP, 1998, CRIT REV ORAL BIOL M, V9, P201, DOI 10.1177/10454411980090020401; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; HALE JE, 1987, J BIOL CHEM, V262, P1916; HALL BK, 1987, CLIN ORTHOP RELAT R, V225, P255; Herrera AH, 2000, CELL MOTIL CYTOSKEL, V45, P211, DOI 10.1002/(SICI)1097-0169(200003)45:3<211::AID-CM4>3.3.CO;2-P; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; HUNTER GK, 1994, BIOCHEM J, V302, P175, DOI 10.1042/bj3020175; IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274; INGRAM RT, 1993, J BONE MINER RES, V8, P1019; Irie K, 1998, ANAT RECORD, V252, P554; Kimura K, 2000, VITAM HORM, V58, P257, DOI 10.1016/S0083-6729(00)58027-3; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; MAJESKA RJ, 1975, BIOCHIM BIOPHYS ACTA, V391, P51, DOI 10.1016/0005-2744(75)90151-5; MCQUILLAN DJ, 1995, BONE, V16, P415; Midura RJ, 1996, GLYCOBIOLOGY, V6, P677, DOI 10.1093/glycob/6.7.677; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; Nefussi JR, 1997, J HISTOCHEM CYTOCHEM, V45, P493, DOI 10.1177/002215549704500402; PERESS NS, 1974, CALC TISS RES, V14, P275, DOI 10.1007/BF02060301; POCKWINSE SM, 1992, J CELL BIOCHEM, V49, P310, DOI 10.1002/jcb.240490315; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; RIMINUCCI M, 1995, CALCIFIED TISSUE INT, V57, P277, DOI 10.1007/BF00298883; SATO M, 1992, FASEB J, V6, P2966, DOI 10.1096/fasebj.6.11.1644260; SATOMURA K, 1991, ACTA ANAT, V142, P97; Sela J., 1992, CALCIFICATION BIOL S, P73; Shen ZX, 1995, MATRIX BIOL, V14, P773, DOI 10.1016/S0945-053X(05)80020-4; SHEPARD N, 1981, HISTOCHEMISTRY, V70, P107, DOI 10.1007/BF00493202; Shepard N., 1992, CALCIFICATION BIOL S, P41; STANFORD CM, 1995, J ORTHOPAED RES, V13, P664, DOI 10.1002/jor.1100130505; STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420; Sugawara Y, 2002, JPN J PHARMACOL, V88, P262, DOI 10.1254/jjp.88.262; Thiry M, 1999, PROG HISTOCHEM CYTO, V34, P93; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; WANG A, 1999, T 45 ANN M ORTH RES, P209; Wang AM, 2000, J BIOL CHEM, V275, P11082, DOI 10.1074/jbc.275.15.11082; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Winchester SK, 1999, J CELL PHYSIOL, V181, P479, DOI 10.1002/(SICI)1097-4652(199912)181:3<479::AID-JCP12>3.0.CO;2-D; WU LNY, 1991, J BIOL CHEM, V266, P1195; Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404; WURTHIER RE, 1985, CHEM BIOL MINERALIZE, P113; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1989, CONNECT TISSUE RES, V22, P653, DOI 10.3109/03008208909114117; Zhang RQ, 2001, BIOCHEMISTRY-US, V40, P14898, DOI 10.1021/bi0107445; Zhu JX, 2001, HISTOCHEM J, V33, P25, DOI 10.1023/A:1017587712914	69	63	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25464	25473		10.1074/jbc.M312409200	http://dx.doi.org/10.1074/jbc.M312409200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15004030	hybrid			2022-12-27	WOS:000221827900070
J	Herrmann, R; Heck, M; Henklein, P; Henklein, P; Kleuss, C; Hofmann, KP; Ernst, OP				Herrmann, R; Heck, M; Henklein, P; Henklein, P; Kleuss, C; Hofmann, KP; Ernst, OP			Sequence of interactions in receptor-G protein coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-ACTIVATED RHODOPSIN; TRANSDUCIN ALPHA-SUBUNIT; CARBOXYL-TERMINAL SEQUENCES; COVALENT CROSS-LINKING; G-BETA-GAMMA; CRYSTAL-STRUCTURE; CONFORMATIONAL SWITCH; COMPLEX-FORMATION; ADENYLYL-CYCLASE; ESCHERICHIA-COLI	Guanine nucleotide exchange in heterotrimeric G proteins catalyzed by G protein-coupled receptors (GPCRs) is a key event in many physiological processes. The crystal structures of the GPCR rhodopsin and two G proteins as well as binding sites on both catalytically interacting proteins are known, but the temporal sequence of events leading to nucleotide exchange remains to be elucidated. We employed time-resolved near infrared light scattering to study the order in which the Galpha and Ggamma C-terminal binding sites on the holo-G protein interact with the active state of the GPCR rhodopsin (R*) in native membranes. We investigated these key binding sites within mass-tagged peptides and G proteins and found that their binding to R* is mutually exclusive. The interaction of the holo-G protein with R* requires at least one of the lipid modifications of the G protein (i.e. myristoylation of the Galpha N terminus and/or farnesylation of the Ggamma C terminus). A holo-G protein with a high affinity Ggamma C terminus shows a specific change of the reaction rate in the GDP release and GTP uptake steps of catalysis. We interpret the data by a sequential fit model where (i) the initial encounter between R* and the G protein occurs with the Gbetagamma subunit, and (ii) the Ggamma C-terminal tail then interacts with R* to release bound GDP, thereby decreasing the affinity of R* for the Gbetagamma subunit. The mechanism limits the time in which both C-terminal binding sites of the G protein interact simultaneously with R* to a short lived transitory state.	Charite Univ Med Berlin, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Charite Univ Med Berlin, Inst Biochem, D-10098 Berlin, Germany; Charite Univ Med Berlin, Inst Pharmakol, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ernst, OP (corresponding author), Charite Univ Med Berlin, Inst Med Phys & Biophys, Schumannstr 20-21,Campus Mitte, D-10098 Berlin, Germany.	oliver.ernst@charite.de		Henklein, Petra/0000-0001-7468-8926				ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gautam N, 2003, STRUCTURE, V11, P359, DOI 10.1016/S0969-2126(03)00054-6; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Heck M, 2000, METHOD ENZYMOL, V315, P329; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Jian XY, 2001, J BIOL CHEM, V276, P48518, DOI 10.1074/jbc.M107129200; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; Kisselev OG, 2003, STRUCTURE, V11, P367, DOI 10.1016/S0969-2126(03)00045-5; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Marin EP, 2001, J BIOL CHEM, V276, P27400, DOI 10.1074/jbc.C100198200; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Matsuda T, 2000, METHOD ENZYMOL, V316, P465; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Morizumi T, 2003, J BIOCHEM, V134, P259, DOI 10.1093/jb/mvg139; Natochin M, 1999, J BIOL CHEM, V274, P7865, DOI 10.1074/jbc.274.12.7865; Natochin M, 2001, J NEUROCHEM, V77, P202, DOI 10.1046/j.1471-4159.2001.00221.x; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; Shukla P, 1999, J GEN PHYSIOL, V114, P609, DOI 10.1085/jgp.114.5.609; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Szundi I, 1998, BIOCHEMISTRY-US, V37, P14237, DOI 10.1021/bi981249k; Taylor JM, 1996, J BIOL CHEM, V271, P3336; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Weitmann S, 2001, BIOCHEMISTRY-US, V40, P10853, DOI 10.1021/bi011176w; Whitlock GG, 1999, NEURON, V23, P337, DOI 10.1016/S0896-6273(00)80784-9; Xu MQ, 2001, METHODS, V24, P257, DOI 10.1006/meth.2001.1187; Yan ECY, 2003, P NATL ACAD SCI USA, V100, P9262, DOI 10.1073/pnas.1531970100	50	74	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24283	24290		10.1074/jbc.M311166200	http://dx.doi.org/10.1074/jbc.M311166200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15007073	hybrid			2022-12-27	WOS:000221702500053
J	Date, T; Kato, T; Miyamoto, M; Zhao, ZJ; Yasui, K; Mizokami, M; Wakita, T				Date, T; Kato, T; Miyamoto, M; Zhao, ZJ; Yasui, K; Mizokami, M; Wakita, T			Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-A; HUMAN HEPATOCYTES; HEPATOCELLULAR-CARCINOMA; EFFICIENT REPLICATION; CULTURE; GENOME; TRANSFUSION; CLONE; ASSAY; LINE	A hepatitis C virus genotype 2a subgenomic replicon, JFH-1 replicon, was previously established using the consensus sequence of clone JFH-1 from a patient with fulminant hepatitis and, in a previous report, was indicated to replicate efficiently in Huh7. Here the replication of JFH-1 replicon was tested in HepG2, a human hepatocyte-derived cell line, and in IMY-N9, a cell line developed by fusing human hepatocytes and HepG2 cells. Following transfection with in vitro transcribed replicon RNA and selection by cultivation with G418, colonies formed in both cell lines although at efficiencies substantially lower than those of Huh7. The H2476L mutation identified in the Huh7 replicon in our previous study increased the colony formation efficiencies of the JFH-1 replicon in HepG2 and IMY-N9 cells. Higher amounts of replicon RNA were detected in IMY-N9 clones than in HepG2 clones by real time detection reverse transcription-PCR, and replicon RNA replication and viral protein expression were confirmed by Northern and Western blotting in isolated clones. Sequencing of replicon RNAs revealed that mutations found in hepatitis C virus-derived regions were not identical and that two of nine HepG2 clones and three of nine IMY-N9 clones had no or one synonymous mutation. This system with the JFH-1 replicon and three cell lines is useful not only for estimating the cellular factors affecting viral activity but also for clarifying the common gene response of the host.	Tokyo Metropolitan Inst Neurosci, Dept Microbiol, Tokyo 1838526, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Clin Mol Informat Med, Nagoya, Aichi 4678601, Japan; Chinese Acad Prevent Med, Inst Virol, Beijing 100052, Peoples R China	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Nagoya City University; Chinese Center for Disease Control & Prevention; National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control & Prevention	Wakita, T (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Microbiol, 2-6 Musashidai, Tokyo 1838526, Japan.	wakita@tmin.ac.jp						Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; BERTOLINI L, 1993, RES VIROLOGY, V144, P281, DOI 10.1016/S0923-2516(06)80041-5; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2003, J VIROL, V77, P3181, DOI 10.1128/JVI.77.5.3181-3190.2003; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Fournier C, 1998, J GEN VIROL, V79, P2367, DOI 10.1099/0022-1317-79-10-2367; Gu BH, 2003, J VIROL, V77, P5352, DOI 10.1128/JVI.77.9.5352-5359.2003; Iacovacci S, 1997, HEPATOLOGY, V26, P1328; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Ito T, 1996, J GEN VIROL, V77, P1043, DOI 10.1099/0022-1317-77-5-1043; Ito T, 2001, HEPATOLOGY, V34, P566, DOI 10.1053/jhep.2001.26752; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023; Kato T, 2003, J MED VIROL, V69, P357, DOI 10.1002/jmv.10297; Kato T, 2001, J MED VIROL, V64, P334, DOI 10.1002/jmv.1055; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LIANG TJ, 1993, HEPATOLOGY, V18, P1326, DOI 10.1016/0270-9139(93)90219-D; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Mizutani T, 1996, J VIROL, V70, P7219, DOI 10.1128/JVI.70.10.7219-7223.1996; Ohba K, 1996, FEBS LETT, V378, P232, DOI 10.1016/0014-5793(95)01441-1; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; Rumin S, 1999, J GEN VIROL, V80, P3007, DOI 10.1099/0022-1317-80-11-3007; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; Takeuchi T, 1999, GASTROENTEROLOGY, V116, P636, DOI 10.1016/S0016-5085(99)70185-X; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Zhao ZJ, 2003, J VIROL, V77, P4248, DOI 10.1128/JVI.77.7.4248-4260.2003; Zhu Q, 2003, J VIROL, V77, P9204, DOI 10.1128/JVI.77.17.9204-9210.2003	29	92	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22371	22376		10.1074/jbc.M311120200	http://dx.doi.org/10.1074/jbc.M311120200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14990575	hybrid			2022-12-27	WOS:000221417100085
J	Everitt, AB; Luu, T; Cromer, B; Tierney, ML; Birnir, B; Olsen, RW; Gage, PW				Everitt, AB; Luu, T; Cromer, B; Tierney, ML; Birnir, B; Olsen, RW; Gage, PW			Conductance of recombinant GABA(A) channels is increased in cells co-expressing GABA(A) receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; CULTURED HIPPOCAMPAL-NEURONS; CHLORIDE CHANNELS; GABARAP; CYTOSKELETON; GLYCINE	High conductance gamma- aminobutyric acid type A ( GABA(A)) channels (> 40 picosiemens ( pS)) have been reported in some studies on GABA(A) channels in situ but not in others, whereas recombinant GABA(A) channels do not appear to display conductances above 40 pS. Furthermore, the conductance of some native GABA(A) channels can be increased by diazepam or pentobarbital, which are effects not reported for expressed GABA(A) channels. GABARAP, a protein associated with native GABA(A) channels, has been reported to cause clustering of GABA(A) receptors and changes in channel kinetics. We have recorded single channel currents activated by GABA in L929 cells expressing alpha(1), beta(1), and gamma(2S) subunits of human GABA(A) receptors. Channel conductance was never higher than 40 pS and was not significantly increased by diazepam or pentobarbital, although open probability was increased. In contrast, in cells expressing the same three subunits together with GABARAP, channel conductance could be significantly higher than 40 pS, and channel conductance was increased by diazepam and pentobarbital. GABARAP caused clustering of receptors in L929 cells, and we suggest that there may be interactions between subunits of clustered GABA(A) receptors that make them open co- operatively to give high conductance " channels." Recombinant channels may require the influence of GABARAP and perhaps other intracellular proteins to adopt a fuller repertoire of properties of native channels.	Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 2601, Australia; Lund Univ, S-22184 Lund, Sweden; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research; Australian National University; Lund University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tierney, ML (corresponding author), John Curtin Sch Med Res, GPO Box 334, Canberra, ACT 0200, Australia.	louise.tierney@anu.edu.au	Luu, Tien/C-8303-2009; Cromer, Brett/AAQ-6533-2020	Cromer, Brett/0000-0003-0743-1535; Birnir, Bryndis/0000-0002-1763-0266				Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; CURMI JP, 1993, J MEMBRANE BIOL, V136, P273; Eghbali M, 2000, MOL PHARMACOL, V58, P463, DOI 10.1124/mol.58.3.463; Eghbali M, 1997, NATURE, V388, P71, DOI 10.1038/40404; FATIMASHAD K, 1992, P ROY SOC B-BIOL SCI, V250, P99, DOI 10.1098/rspb.1992.0136; GRAY R, 1985, J NEUROPHYSIOL, V54, P134, DOI 10.1152/jn.1985.54.1.134; Guyon A, 1999, J PHYSIOL-LONDON, V516, P719, DOI 10.1111/j.1469-7793.1999.0719u.x; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; Laver DR, 1997, PROG BIOPHYS MOL BIO, V67, P99, DOI 10.1016/S0079-6107(97)00008-4; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; SMITH SM, 1989, J MEMBRANE BIOL, V108, P45, DOI 10.1007/BF01870424; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264	16	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21701	21706		10.1074/jbc.M312806200	http://dx.doi.org/10.1074/jbc.M312806200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007071	hybrid			2022-12-27	WOS:000221417100004
J	Heine, C; Koch, B; Storch, S; Kohlschutter, A; Palmer, DN; Braulke, T				Heine, C; Koch, B; Storch, S; Kohlschutter, A; Palmer, DN; Braulke, T			Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; MULTIPLE SULFATASE DEFICIENCY; MANNOSE 6-PHOSPHATE RECEPTOR; BATTEN-DISEASE; CATHEPSIN-D; METACHROMATIC LEUKODYSTROPHY; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE PROTEIN; SURFACE EXPRESSION; RETENTION SIGNAL	Variant late infantile neuronal ceroid lipofuscinosis, a lysosomal storage disorder characterized by progressive mental deterioration and blindness, is caused by mutations in a polytopic membrane protein (CLN6) with unknown intracellular localization and function. In this study, transient transfection of BHK21 cells with CLN6 cDNA and immunoblot analysis using peptide-specific CLN6 antibodies demonstrated the expression of a similar to27-kDa protein that does not undergo proteolytic processing. Cross-linking experiments revealed the presence of CLN6 dimers. Using double immunofluorescence microscopy, epitope-tagged CLN6 was shown to be retained in the endoplasmic reticulum ( ER) with no colocalization with the cis-Golgi or lysosomal markers. The translocation into the ER and proper folding were confirmed by the N-linked glycosylation of a mutant CLN6 polypeptide. Pulse-chase labeling of fibroblasts from CLN6 patients and from sheep (OCL6) and mouse (nclf) models of the disease followed by immunoprecipitation of cathepsin D indicated that neither the synthesis, sorting nor the proteolytic processing of this lysosomal enzyme was affected in CLN6-defective cells. However, the degradation of the endocytosed index protein arylsulfatase A was strongly reduced in all of the mutant CLN6 cell lines compared with controls. These data suggest that defects in the ER-resident CLN6 protein lead to lysosomal dysfunctions, which may result in lysosomal accumulation of storage material.	Univ Hamburg Hosp, Childrens Hosp, Dept Biochem, D-20246 Hamburg, Germany; Lincoln Univ, Anim & Food Sci Div, Canterbury, New Zealand	University of Hamburg; University Medical Center Hamburg-Eppendorf; Lincoln University - New Zealand	Braulke, T (corresponding author), Univ Hamburg Hosp, Childrens Hosp, Dept Biochem, Martinistr 52,Bldg W23, D-20246 Hamburg, Germany.	braulke@uke.uni-hamburg.de	Palmer, David/B-7344-2008; Braulke, Thomas/AAV-9121-2020; Kohlschütter, Alfried/ABE-3495-2021; Kohlschütter, Alfried/ABH-5710-2020	Braulke, Thomas/0000-0002-2336-8532; Kohlschütter, Alfried/0000-0002-2700-0401; Storch, Stephan/0000-0002-8807-5917	NINDS NIH HHS [NS40297] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS040297] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Braulke T, 1996, Subcell Biochem, V27, P15; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; Bronson RT, 1998, AM J MED GENET, V77, P289, DOI 10.1002/(SICI)1096-8628(19980526)77:4<289::AID-AJMG8>3.0.CO;2-I; Claussen M, 1997, ENDOCRINOLOGY, V138, P3797, DOI 10.1210/en.138.9.3797; Cook RW, 2002, AUST VET J, V80, P292, DOI 10.1111/j.1751-0813.2002.tb10847.x; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; DAMKE H, 1992, BIOCHEM J, V281, P225, DOI 10.1042/bj2810225; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; FIGURA KV, 1978, EXP CELL RES, V111, P15, DOI 10.1016/0014-4827(78)90231-8; Gao HL, 2002, AM J HUM GENET, V70, P324, DOI 10.1086/338190; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; Goebel HH, 1999, MOL GENET METAB, V66, P367, DOI 10.1006/mgme.1999.2808; Haltia M, 2003, J NEUROPATH EXP NEUR, V62, P1; Hardt B, 2003, GLYCOBIOLOGY, V13, P159, DOI 10.1093/glycob/cwg013; HASILIK A, 1980, J BIOL CHEM, V255, P4937; Heine C, 2003, BIOCHEM J, V376, P369, DOI 10.1042/BJ20030598; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; Hu W, 2003, J NEUROCHEM, V86, P470, DOI 10.1046/j.1471-4159.2003.01855.x; Isosomppi J, 2002, HUM MOL GENET, V11, P885, DOI 10.1093/hmg/11.8.885; Janes RW, 1996, FEBS LETT, V399, P75, DOI 10.1016/S0014-5793(96)01290-2; Jarvela I, 1999, HUM MOL GENET, V8, P1091, DOI 10.1093/hmg/8.6.1091; Jolly RD, 1999, MOL GENET METAB, V66, P376, DOI 10.1006/mgme.1999.2821; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; Kyttala A, 2004, MOL BIOL CELL, V15, P1313, DOI 10.1091/mbc.E03-02-0120; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Lonka L, 2000, HUM MOL GENET, V9, P1691, DOI 10.1093/hmg/9.11.1691; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Maza J, 2003, CELL COMMUN ADHES, V10, P319, DOI 10.1080/15419060390263083; Meyer C, 2001, J CELL SCI, V114, P4469; Muschol N, 2002, BIOCHEM J, V368, P845, DOI 10.1042/BJ20020249; PALMER DN, 1985, BIOCHIM BIOPHYS ACTA, V834, P159, DOI 10.1016/0005-2760(85)90151-1; Palmer DN, 1997, NEUROPEDIATRICS, V28, P45, DOI 10.1055/s-2007-973666; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; PARKER KC, 1983, BIOCHEMISTRY-US, V22, P1145, DOI 10.1021/bi00274a024; Partanen S, 2003, BIOCHEM J, V369, P55, DOI 10.1042/BJ20021226; PORTER MT, 1969, P NATL ACAD SCI USA, V62, P887, DOI 10.1073/pnas.62.3.887; Ranta S, 1999, NAT GENET, V23, P233, DOI 10.1038/13868; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ren Z, 2003, J NEUROSCI, V23, P6608; ROSORIUS O, 1993, J BIOL CHEM, V268, P21470; SAVUKOSKI M, 1998, SCIENCE, V277, P1802; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Sharp JD, 2003, HUM MUTAT, V22, P35, DOI 10.1002/humu.10227; STECKEL F, 1985, EUR J BIOCHEM, V151, P141, DOI 10.1111/j.1432-1033.1985.tb09078.x; STECKEL F, 1985, EUR J BIOCHEM, V151, P147, DOI 10.1111/j.1432-1033.1985.tb09079.x; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; Teixeira C, 2003, J NEUROL, V250, P661, DOI 10.1007/s00415-003-1050-z; Teixeira CA, 2003, HUM MUTAT, V21, P502, DOI 10.1002/humu.10207; Vines DJ, 1999, FEBS LETT, V443, P131, DOI 10.1016/S0014-5793(98)01683-4; von Bulow R, 2002, J BIOL CHEM, V277, P9455, DOI 10.1074/jbc.M111993200; Wheeler RB, 2002, AM J HUM GENET, V70, P537, DOI 10.1086/338708; Zwad O, 2002, FEBS LETT, V510, P211, DOI 10.1016/S0014-5793(01)03267-7	54	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22347	22352		10.1074/jbc.M400643200	http://dx.doi.org/10.1074/jbc.M400643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15010453	hybrid			2022-12-27	WOS:000221417100082
J	Poncet, D; Larochette, N; Pauleau, AL; Boya, P; Jalil, AA; Cartron, PF; Vallette, F; Schnebelen, C; Bartle, LM; Skaletskaya, A; Boutolleau, D; Martinou, JC; Goldmacher, VS; Kroemer, G; Zamzami, N				Poncet, D; Larochette, N; Pauleau, AL; Boya, P; Jalil, AA; Cartron, PF; Vallette, F; Schnebelen, C; Bartle, LM; Skaletskaya, A; Boutolleau, D; Martinou, JC; Goldmacher, VS; Kroemer, G; Zamzami, N			An anti-apoptotic viral protein that recruits bax to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCATOR; LOCALIZED INHIBITOR; CYTOCHROME-C; MEMBRANE PERMEABILIZATION; BCL-2 HOMOLOG; CELL-DEATH; OLIGOMERIZATION; RELEASE; EXPRESSION; TERMINUS	The viral mitochondria-localized inhibitor of apoptosis (vMIA), encoded by the UL37 gene of human cytomegalovirus, inhibits apoptosis-associated mitochondrial membrane permeabilization by a mechanism different from that of Bcl-2. Here we show that vMIA induces several changes in Bax that resemble those found in apoptotic cells yet take place in unstimulated, nonapoptotic vMIA-expressing cells. These changes include the constitutive localization of Bax at mitochondria, where it associates tightly with the mitochondrial membrane, forming high molecular weight aggregates that contain vMIA. vMIA recruits Bax to mitochondria but delays relocation of caspase-8-activated truncated Bidgreen fluorescent protein (GFP) (t-Bid-GFP) to mitochondria. The ability of vMIA and its deletion mutants to associate with Bax and to induce relocation of Bax to mitochondria correlates with their anti-apoptotic activity and with their ability to suppress mitochondrial membrane permeabilization. Taken together, our data indicate that vMIA blocks apoptosis via its interaction with Bax. vMIA neutralizes Bax by recruiting it to mitochondria and "freezing" its pro-apoptotic activity. These data unravel a novel strategy of subverting an intrinsic pathway of apoptotic signaling.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; INSERM, U419, F-44035 Nantes, France; Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France; Dept Biol Cellulaire, CH-1211 Geneva 4, Switzerland; ImmunoGen Inc, Cambridge, MA 02139 USA; Hop Bicetre, F-94277 Le Kremlin Bicetre, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; University of Geneva; ImmunoGen, Inc.; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr; zamzami@igr.fr	Vallette, Francois/N-2361-2018; Cartron, Pierre Francois/K-9802-2015; KROEMER, Guido/B-4263-2013; Boya, Patricia/P-8345-2019; Boutolleau, David/GRO-1697-2022; Kroemer, Guido/AAY-9859-2020; Poncet, Delphine A/A-7190-2016; Vallette, Francois/K-9047-2015; LAROCHETTE, Nathanael/R-4298-2017	KROEMER, Guido/0000-0002-9334-4405; Boya, Patricia/0000-0003-3045-951X; Poncet, Delphine A/0000-0003-0446-5262; Vallette, Francois/0000-0002-3296-8572; Cartron, Pierre-Francois/0000-0002-3393-784X; martinou, Jean-claude/0000-0002-9847-2051; LAROCHETTE, Nathanael/0000-0002-7936-678X; Vallette, Francois/0000-0003-0802-0519; JALIL, Abdelali/0000-0003-2710-8735; Goldmakher, Viktor/0000-0001-6130-4436				Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Everett H, 2002, J EXP MED, V196, P1127, DOI 10.1084/jem.20011247; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hayajneh WA, 2001, VIROLOGY, V279, P233, DOI 10.1006/viro.2000.0726; HEIDI L, 2002, NAT MED, V8, P274; Huang QL, 2003, J MOL BIOL, V332, P1123, DOI 10.1016/j.jmb.2003.08.007; Huang QL, 2002, P NATL ACAD SCI USA, V99, P3428, DOI 10.1073/pnas.062525799; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McCormick AL, 2003, VIROLOGY, V316, P221, DOI 10.1016/j.virol.2003.07.003; McCormick AL, 2003, J VIROL, V77, P631, DOI 10.1128/JVI.77.1.631-641.2003; Messud-Petit F, 1998, J VIROL, V72, P7830, DOI 10.1128/JVI.72.10.7830-7839.1998; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Roucou X, 2002, BIOCHEM J, V363, P547, DOI 10.1042/0264-6021:3630547; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2003, CANCER RES, V63, P1483; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	51	111	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22605	22614		10.1074/jbc.M308408200	http://dx.doi.org/10.1074/jbc.M308408200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004026	hybrid			2022-12-27	WOS:000221417100112
J	Chiara, F; Bishayee, S; Heldin, CH; Demoulin, JB				Chiara, F; Bishayee, S; Heldin, CH; Demoulin, JB			Autoinhibition of the platelet-derived growth factor beta-receptor tyrosine kinase by its C-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; ACTIVATING MUTATIONS; MET PROTOONCOGENE; DOMAIN; KIT; TRANSFORMATION; MASTOCYTOSIS; ANTAGONISTS; MECHANISM; ONCOGENE	In this report, we investigated the role of the C-terminal tail of the platelet-derived growth factor ( PDGF) beta-receptor in the control of the receptor kinase activity. Using a panel of PDGF beta-receptor mutants with progressive C-terminal truncations, we observed that deletion of the last 46 residues, which contain a proline- and glutamic acid-rich motif, increased the autoactivation velocity in vitro and the V-max of the phosphotransfer reaction, in the absence of ligand, as compared with wild-type receptors. By contrast, the kinase activity of mutant and wild-type receptors that were pre-activated by treatment with PDGF was comparable. Using a conformation-sensitive antibody, we found that truncated receptors presented an active conformation even in the absence of PDGF. A soluble peptide containing the Pro/ Glu-rich motif specifically inhibited the PDGF beta-receptor kinase activity. Whereas deletion of this motif was not enough to confer ligand-independent transforming ability to the receptor, it dramatically enhanced the effect of the weakly activating D850N mutation in a focus formation assay. These findings indicate that allosteric inhibition of the PDGF beta-receptor by its C-terminal tail is one of the mechanisms involved in keeping the receptor inactive in the absence of ligand.	Univ Catholique Louvain, Christian de Duve Inst Cellular Pathol, Expt Med Unit MEXP, B-1200 Brussels, Belgium; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA	Universite Catholique Louvain; Ludwig Institute for Cancer Research; Rutgers State University New Brunswick; Rutgers State University Medical Center	Demoulin, JB (corresponding author), Univ Catholique Louvain, Christian de Duve Inst Cellular Pathol, Expt Med Unit MEXP, 74 Ave Hippocrate, B-1200 Brussels, Belgium.	jean-baptiste.demoulin@mexp.ucl.ac.be	Demoulin, Jean-Baptiste/E-5847-2010	chiara, federica/0000-0003-2396-3080; Demoulin, Jean-Baptiste/0000-0002-8016-6689				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; Chiara F, 2003, J BIOL CHEM, V278, P29352, DOI 10.1074/jbc.M302404200; Demoulin JB, 2003, BIOCHEM J, V376, P505, DOI 10.1042/BJ20030385; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Irusta PM, 2002, J BIOL CHEM, V277, P38627, DOI 10.1074/jbc.M204890200; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; LONGATI P, 1994, ONCOGENE, V9, P49; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Nagata H, 1997, INT ARCH ALLERGY IMM, V113, P184, DOI 10.1159/000237541; Noelle V, 2000, BIOCHEMISTRY-US, V39, P7170, DOI 10.1021/bi991915x; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Shimizu A, 2001, J BIOL CHEM, V276, P27749, DOI 10.1074/jbc.C100286200; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5	27	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19732	19738		10.1074/jbc.M314070200	http://dx.doi.org/10.1074/jbc.M314070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996833	hybrid			2022-12-27	WOS:000221164500043
J	Friberg, MA; Spiess, M; Rutishauser, J				Friberg, MA; Spiess, M; Rutishauser, J			Degradation of wild-type vasopressin precursor and pathogenic mutants by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROHYPOPHYSEAL DIABETES-INSIPIDUS; NEUROPHYSIN-II GENE; SIGNAL PEPTIDE MUTATION; ENDOPLASMIC-RETICULUM; PRION PROTEIN; CELL-LINE; UBIQUITIN; IDENTIFICATION; PATHWAY; MEMBRANE	Mutations in the gene encoding the antidiuretic hormone arginine vasopressin cause autosomal dominant neurogenic diabetes insipidus. Autoptic data in affected individuals suggest that the neurons expressing mutant vasopressin undergo selective degeneration. Expression studies have shown that the mutants are retained in the endoplasmic reticulum, but how this trafficking defect is linked to neurotoxicity is unknown. One possibility is that unsecreted mutant precursors, or degradation products thereof, are cytotoxic. We therefore investigated the fate of endoplasmic reticulum-retained pathogenic mutants. Our data show that the mutants are retrotranslocated to the cytosol and degraded by the proteasome. In the presence of proteasomal inhibitors, three distinct un- or deglycosylated cytosolic species of vasopressin precursors were stabilized: pre-pro-vasopressin, pro-vasopressin, and an N-terminally truncated form. In addition to the retrotranslocated forms, a fraction of the newly synthesized precursor was not translocated, but was synthesized into the cytosol due to inefficient function of the vasopressin signal peptide. As a result, cytosolic pre-pro-vasopressin and its degradation product were also recovered when wild-type vasopressin was expressed. Cytosolic forms of vasopressin might trigger cytotoxicity in vivo, as has been proposed in the case of prion protein, which also contains an inefficient N-terminal signal peptide.	Univ Basel Hosp, Div Endocrinol Metab & Clin Nutr, CH-4031 Basel, Switzerland; Univ Basel Hosp, Dept Med, Med Clin A, CH-4031 Basel, Switzerland; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel; University of Basel; University of Basel	Rutishauser, J (corresponding author), Univ Basel Hosp, Med Clin B, Petersgraben 4, CH-4031 Basel, Switzerland.	j.rutishauser@unibas.ch		Spiess, Martin/0000-0001-7139-0550				Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Amizuka N, 2000, BIOCHEM BIOPH RES CO, V273, P621, DOI 10.1006/bbrc.2000.2913; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BERGERON C, 1991, ACTA NEUROPATHOL, V81, P345, DOI 10.1007/BF00305879; Beuret N, 1999, J BIOL CHEM, V274, P18965, DOI 10.1074/jbc.274.27.18965; Boson WL, 2003, CLIN ENDOCRINOL, V58, P108, DOI 10.1046/j.1365-2265.2003.01667.x; BRAVERMAN LE, 1965, ANN INTERN MED, V63, P503, DOI 10.7326/0003-4819-63-3-503; Bullmann C, 2002, EXP CLIN ENDOCR DIAB, V110, P134, DOI 10.1055/s-2002-29091; Cescato R, 2000, J NEUROCHEM, V74, P1131; CHEVRIER D, 1991, MOL CELL ENDOCRINOL, V79, P109, DOI 10.1016/0303-7207(91)90101-W; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DiMeglio LA, 2001, MOL GENET METAB, V72, P39, DOI 10.1006/mgme.2000.3117; Evans DAP, 2000, J NEUROENDOCRINOL, V12, P685; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fluck CE, 2001, EUR J ENDOCRINOL, V145, P439, DOI 10.1530/eje.0.1450439; Gaupp R, 1941, Z GESAMTE NEUROL PSY, V171, P514, DOI 10.1007/BF02880551; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; GONKING NQ, 1997, J INVEST MED, V45, pA29; HANHART E, 1940, HDB ERBBIOLOGIE ME 2, V4, P798; Hansen LK, 1997, TRENDS ENDOCRIN MET, V8, P363, DOI 10.1016/S1043-2760(97)00157-4; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hatsuzawa K, 1997, J BIOCHEM-TOKYO, V121, P270; Hegde RS, 2003, TRENDS NEUROSCI, V26, P337, DOI 10.1016/S0166-2236(03)00143-7; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Holscher C, 2001, J BIOL CHEM, V276, P13388, DOI 10.1074/jbc.M007331200; ITO M, 1993, J CLIN INVEST, V91, P2565, DOI 10.1172/JCI116494; Ito M, 1997, J CLIN INVEST, V99, P1897, DOI 10.1172/JCI119357; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Mahoney CP, 2002, J CLIN ENDOCR METAB, V87, P870, DOI 10.1210/jc.87.2.870; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nijenhuis M, 1999, J BIOL CHEM, V274, P21200, DOI 10.1074/jbc.274.30.21200; Olias G, 1996, DNA CELL BIOL, V15, P929, DOI 10.1089/dna.1996.15.929; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Rittig S, 1996, AM J HUM GENET, V58, P107; Rittig S, 2002, J CLIN ENDOCR METAB, V87, P3351, DOI 10.1210/jc.87.7.3351; Rutishauser J, 1996, J CLIN ENDOCR METAB, V81, P192, DOI 10.1210/jc.81.1.192; Rutishauser J, 1999, MOL GENET METAB, V67, P89, DOI 10.1006/mgme.1999.2825; Santiprabhob J, 2002, MOL GENET METAB, V77, P112, DOI 10.1016/S1096-7192(02)00118-X; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Siggaard C, 1999, J CLIN ENDOCR METAB, V84, P2933, DOI 10.1210/jc.84.8.2933; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Yewdell JW, 2001, TRENDS CELL BIOL, V11, P294, DOI 10.1016/S0962-8924(01)02030-X; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	55	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19441	19447		10.1074/jbc.M310249200	http://dx.doi.org/10.1074/jbc.M310249200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996841	hybrid			2022-12-27	WOS:000221164500009
J	Imhof, I; Flury, I; Vionnet, C; Roubaty, C; Egger, D; Conzelmann, A				Imhof, I; Flury, I; Vionnet, C; Roubaty, C; Egger, D; Conzelmann, A			Glycosylphosphatidylinositol (GPI) proteins of Saccharomyces cerevisiae contain ethanolamine phosphate groups on the alpha 1,4-linked mannose of the GPI anchor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; PHOSPHOLIPID MEMBRANE ANCHOR; CELL-WALL INTEGRITY; ENDOPLASMIC-RETICULUM; 3RD MANNOSE; TRANSFERRING PHOSPHOETHANOLAMINE; MAMMALIAN-CELLS; CORE STRUCTURE; PIG-B; YEAST	In humans and Saccharomyces cerevisiae the free glycosylphosphatidylinositol (GPI) lipid precursor contains several ethanolamine phosphate side chains, but these side chains had been found on the protein-bound GPI anchors only in humans, not yeast. Here we confirm that the ethanolamine phosphate side chain added by Mcd4p to the first mannose is a prerequisite for the addition of the third mannose to the GPI precursor lipid and demonstrate that, contrary to an earlier report, an ethanolamine phosphate can equally be found on the majority of yeast GPI protein anchors. Curiously, the stability of this substituent during preparation of anchors is much greater in gpi7Delta sec18 double mutants than in either single mutant or wild type cells, indicating that the lack of a substituent on the second mannose ( caused by the deletion of GPI7) influences the stability of the one on the first mannose. The phosphodiester-linked substituent on the second mannose, probably a further ethanolamine phosphate, is added to GPI lipids by endoplasmic reticulum-derived microsomes in vitro but cannot be detected on GPI proteins of wild type cells and undergoes spontaneous hydrolysis in saline. Genetic manipulations to increase phosphatidylethanolamine levels in gpi7Delta cells by overexpression of PSD1 restore cell growth at 37 degreesC without restoring the addition of a substituent to Man2. The three putative ethanolaminephosphate transferases Gpi13p, Gpi7p, and Mcd4p cannot replace each other even when overexpressed. Various models trying to explain how Gpi7p, a plasma membrane protein, directs the addition of ethanolamine phosphate to mannose 2 of the GPI core have been formulated and put to the test.	Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Conzelmann, A (corresponding author), Univ Fribourg, Dept Med, Div Biochem, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	andreas.conzelmann@unifr.ch						Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; FRAERING P, 2001, THESIS U FRIBOURG FR; Fukushima K, 2003, J BIOL CHEM, V278, P36296, DOI 10.1074/jbc.M304341200; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; Grimme SJ, 2001, J BIOL CHEM, V276, P27731, DOI 10.1074/jbc.M101986200; Guillas I, 2000, METHOD ENZYMOL, V312, P506; HANSON BA, 1980, J LIPID RES, V21, P309; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Imhof I, 2000, GLYCOBIOLOGY, V10, P1271, DOI 10.1093/glycob/10.12.1271; INOUE N, 1993, J BIOL CHEM, V268, P6882; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; Menzel R, 1997, YEAST, V13, P1211, DOI 10.1002/(SICI)1097-0061(199710)13:13<1211::AID-YEA168>3.0.CO;2-8; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Packeiser AN, 1999, YEAST, V15, P1485, DOI 10.1002/(SICI)1097-0061(199910)15:14<1485::AID-YEA477>3.0.CO;2-4; PAYTON MA, 1991, J BACTERIOL, V173, P2006, DOI 10.1128/jb.173.6.2006-2010.1991; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J BIOL CHEM, V266, P21051; Richard M, 2002, MICROBIOL-SGM, V148, P2125, DOI 10.1099/00221287-148-7-2125; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Storey MK, 2001, BBA-MOL CELL BIOL L, V1532, P234, DOI 10.1016/S1388-1981(01)00129-9; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; Sutterlin C, 1998, BIOCHEM J, V332, P153; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; Taron CH, 2000, MOL BIOL CELL, V11, P1611, DOI 10.1091/mbc.11.5.1611; Toh-e A, 1998, GENES GENET SYST, V73, P365, DOI 10.1266/ggs.73.365; Toh-e A, 2002, GENES GENET SYST, V77, P309, DOI 10.1266/ggs.77.309; Toh-e A, 2001, GENES GENET SYST, V76, P393, DOI 10.1266/ggs.76.393; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; UEDA E, 1993, J BIOL CHEM, V268, P9998; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333	51	36	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19614	19627		10.1074/jbc.M401873200	http://dx.doi.org/10.1074/jbc.M401873200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985347	hybrid			2022-12-27	WOS:000221164500030
J	Sriram, K; Benkovic, SA; Hebert, MA; Miller, DB; O'Callaghan, JP				Sriram, K; Benkovic, SA; Hebert, MA; Miller, DB; O'Callaghan, JP			Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration - Key signaling pathway for astrogliosis in vivo?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; SERINE PHOSPHORYLATION; DOPAMINERGIC NEUROTOXICANT; CHRONIC PARKINSONISM; REACTIVE GLIOSIS; MICE DEFICIENT; DNA-BINDING; STAT3; BRAIN; EXPRESSION	Reactive gliosis is a hallmark of disease-, trauma-, and chemical-induced damage to the central nervous system. The signaling pathways associated with this response to neural injury remain to be elucidated, but recent evidence implicates the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. Here, we used the known dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), to selectively damage striatal dopaminergic nerve terminals and elicit a glial response. We then analyzed changes in gene expression and protein phosphorylation, in vivo, to identify ligands and mediators of the JAK-STAT pathway that accompany glial activation. Administration of MPTP caused rapid tyrosine (Tyr-705) phosphorylation and nuclear translocation of STAT3 in striatal astrocytes, prior to the induction of glial fibrillary acidic protein mRNA and protein. Pharmacological protection of dopaminergic nerve terminals with nomifensine abolished MPTP-mediated phosphorylation and translocation of STAT3 and prevented induction of astrogliosis. Among the Janus kinase family of tyrosine kinases, only JAK2 was associated with the phosphorylation of STAT3 after MPTP and, inhibition of JAK2 by AG490, in vivo, attenuated both the phosphorylation of STAT3 and induction of GFAP. The p44/42 mitogen-activated protein kinase (MAPK; ERK1/2) also was activated by MPTP, but was not associated with activation of STAT3, because serine (Ser-727) was not phosphorylated. The mRNA for ligands of the gp130-JAK/STAT3 signaling pathway, interleukin-6, leukemia inhibitory factor, and oncostatin M were elevated prior to activation of STAT3 and induction of astrogliosis; neuroprotection with nomifensine blocked these effects of MPTP. Taken together, our results suggest that the gp130-mediated activation of JAK2/STAT3 signaling pathway may play a key role in the induction of astrogliosis.	NIOSH, Ctr Dis Control & Prevent, HELD TMBB, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	O'Callaghan, JP (corresponding author), NIOSH, Ctr Dis Control & Prevent, HELD TMBB, Mailstop L-3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	jdo5@cdc.gov	O'Callaghan, James/O-2958-2013; Sriram, Krishnan/F-1039-2014	Sriram, Krishnan/0000-0001-7005-1872				Acarin L, 2000, J NEUROPATH EXP NEUR, V59, P151, DOI 10.1093/jnen/59.2.151; Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Brenner Michael, 1996, Methods (Orlando), V10, P351, DOI 10.1006/meth.1996.0113; Bugga L, 1998, J NEUROBIOL, V36, P509, DOI 10.1002/(SICI)1097-4695(19980915)36:4<509::AID-NEU5>3.0.CO;2-#; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CALNE DB, 1985, NATURE, V317, P246, DOI 10.1038/317246a0; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Choi JS, 2003, GLIA, V41, P237, DOI 10.1002/glia.10186; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dunn SL, 2002, GLIA, V37, P31, DOI 10.1002/glia.10010; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1982, SCAND J IMMUNOL S9, V15, P41; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; FRANCIS JW, 1995, NEUROTOXICOL TERATOL, V17, P7, DOI 10.1016/0892-0362(94)00048-I; Gautron L, 2002, NEUROSCIENCE, V112, P717, DOI 10.1016/S0306-4522(02)00115-X; Guillemin G, 1996, GLIA, V16, P71, DOI 10.1002/(SICI)1098-1136(199601)16:1<71::AID-GLIA8>3.0.CO;2-E; Guo DQ, 1998, J IMMUNOL, V160, P2742; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Kahn MA, 1997, J NEUROCHEM, V68, P1413; Koblar SA, 1998, P NATL ACAD SCI USA, V95, P3178, DOI 10.1073/pnas.95.6.3178; Krohn K, 1999, J NEUROCHEM, V72, P1353, DOI 10.1046/j.1471-4159.1999.721353.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Little AR, 2002, NEUROSCIENCE, V115, P307, DOI 10.1016/S0306-4522(02)00359-7; MacLennan AJ, 2000, NEUROSCIENCE, V99, P761, DOI 10.1016/S0306-4522(00)90236-7; MAYER RA, 1986, J NEUROCHEM, V47, P1073; Merrill JE, 1997, BRAIN BEHAV IMMUN, V11, P245, DOI 10.1006/brbi.1997.0496; MILETICH RS, 1994, ANN NEUROL, V35, P689, DOI 10.1002/ana.410350609; Miscia S, 2002, CELL GROWTH DIFFER, V13, P13; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; O'Callaghan JP, 2004, J NEUROSCI METH, V135, P159, DOI 10.1016/j.jneumeth.2003.12.006; O'Callaghan JP, 1999, ANAL BIOCHEM, V274, P18, DOI 10.1006/abio.1999.4260; OCALLAGHAN JP, 1990, BRAIN RES, V521, P73, DOI 10.1016/0006-8993(90)91526-M; OCALLAGHAN JP, 1991, NEUROTOXICOL TERATOL, V13, P275, DOI 10.1016/0892-0362(91)90073-6; OCALLAGHAN JP, 1993, ANN NY ACAD SCI, V679, P195, DOI 10.1111/j.1749-6632.1993.tb18299.x; OCALLAGHAN JP, 2002, CURRENT PROTOCOLS TO; Planas AM, 1997, J NEUROCHEM, V68, P1345; Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21; Rajan P, 1998, J NEUROSCI, V18, P3620; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; Rizk NM, 2001, ENDOCRINOLOGY, V142, P3027, DOI 10.1210/en.142.7.3027; Schaefer LK, 2000, CYTOKINE, V12, P1647, DOI 10.1006/cyto.2000.0774; Schweizer U, 2002, J CELL BIOL, V156, P287, DOI 10.1083/jcb.200107009; Skaper SD, 2001, ANN NY ACAD SCI, V939, P11; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; STROMBERG I, 1986, BRAIN RES BULL, V17, P225, DOI 10.1016/0361-9230(86)90119-X; SUNDSTROM E, 1986, EUR J PHARMACOL, V131, P289, DOI 10.1016/0014-2999(86)90585-6; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takizawa T, 2001, CYTOKINE, V13, P272, DOI 10.1006/cyto.2000.0831; Tan J, 2000, J BIOL CHEM, V275, P37224, DOI 10.1074/jbc.M002006200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wang JP, 2002, J NEUROSCI RES, V67, P423, DOI 10.1002/jnr.10145; Wen TC, 2001, NEUROSCI LETT, V303, P153, DOI 10.1016/S0304-3940(01)01711-6; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Xia XG, 2002, MOL CELL NEUROSCI, V21, P379, DOI 10.1006/mcne.2002.1180; Yanagisawa M, 2001, FEBS LETT, V489, P139, DOI 10.1016/S0014-5793(01)02095-6; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7	73	203	244	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19936	19947		10.1074/jbc.M309304200	http://dx.doi.org/10.1074/jbc.M309304200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996842	hybrid			2022-12-27	WOS:000221164500068
J	Alano, CC; Ying, WH; Swanson, RA				Alano, CC; Ying, WH; Swanson, RA			Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD(+) depletion and mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING FACTOR; EXCITOTOXIC NEURONAL DEATH; INTACT-CELLS; CYCLOSPORINE-A; ISCHEMIA-REPERFUSION; CEREBRAL-ISCHEMIA; PROTECT NEURONS; CYCLOPHILIN-D; BRAIN-DAMAGE; ADP-RIBOSE	Extensive activation of poly(ADP-ribose) polymerase-1 (PARP-1) by DNA damage is a major cause of caspase-independent cell death in ischemia and inflammation. Here we show that NAD(+) depletion and mitochondrial permeability transition (MPT) are sequential and necessary steps in PARP-1-mediated cell death. Cultured mouse astrocytes were treated with the cytotoxic concentrations of N-methyl-N'-nitro-N-nitrosoguanidine or 3-morpholinosydnonimine to induce DNA damage and PARP-1 activation. The resulting cell death was preceded by NAD(+) depletion, mitochondrial membrane depolarization, and MPT. Sub-micromolar concentrations of cyclosporin A blocked MPT and cell death, suggesting that MPT is a necessary step linking PARP-1 activation to cell death. In astrocytes, extracellular NAD(+) can raise intracellular NAD(+) concentrations. To determine whether NAD(+) depletion is necessary for PARP-1-induced MPT, NAD(+) was restored to near-normal levels after PARP-1 activation. Restoration of NAD(+) enabled the recovery of mitochondrial membrane potential and blocked both MPT and cell death. Furthermore, both cyclosporin A and NAD(+) blocked translocation of the apoptosis-inducing factor from mitochondria to nuclei, a step previously shown necessary for PARP-1-induced cell death. These results suggest that NAD(+) depletion and MPT are necessary intermediary steps linking PARP-1 activation to AIF translocation and cell death.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Dept Neurol 127, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Swanson, RA (corresponding author), Vet Affairs Med Ctr, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA.	calano@itsa.ucsf.edu		Swanson, Raymond/0000-0002-3664-5359	NINDS NIH HHS [NS11048, NS14543] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS014543, F32NS011048, P01NS014543] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Affar E, 2002, P NATL ACAD SCI USA, V99, P245, DOI 10.1073/pnas.012460399; Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Anderson CM, 2002, J NEUROSCI, V22, P9203; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Bruzzone S, 2001, FASEB J, V15, P10; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chen YM, 2001, J NEUROCHEM, V77, P1601, DOI 10.1046/j.1471-4159.2001.00374.x; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Cossarizza A, 1996, EXP CELL RES, V222, P84, DOI 10.1006/excr.1996.0011; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Di Lisa F, 2001, FEBS LETT, V492, P4, DOI 10.1016/S0014-5793(01)02198-6; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Ferrand-Drake M, 1999, NEUROSCIENCE, V90, P1325, DOI 10.1016/S0306-4522(98)00559-4; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Gagne JP, 2001, MOL CELL BIOCHEM, V224, P183, DOI 10.1023/A:1011910329010; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Mandir AS, 2000, J NEUROSCI, V20, P8005; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Pardo J, 2001, J IMMUNOL, V167, P1222, DOI 10.4049/jimmunol.167.3.1222; Petronilli V, 1998, BIOFACTORS, V8, P263, DOI 10.1002/biof.5520080314; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1996, SHOCK, V6, P79, DOI 10.1097/00024382-199608000-00001; Tanveer A, 1996, EUR J BIOCHEM, V238, P166, DOI 10.1111/j.1432-1033.1996.0166q.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Ye ZC, 1998, GLIA, V22, P237, DOI 10.1002/(SICI)1098-1136(199803)22:3<237::AID-GLIA3>3.0.CO;2-2; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	58	296	305	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18895	18902		10.1074/jbc.M313329200	http://dx.doi.org/10.1074/jbc.M313329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14960594	hybrid			2022-12-27	WOS:000221041500099
J	Gu, G; Yang, J; Mitchell, KA; O'Tousa, JE				Gu, G; Yang, J; Mitchell, KA; O'Tousa, JE			Drosophila NinaB and NinaD act outside of retina to produce rhodopsin chromophore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPHILIN HOMOLOG NINAA; VITAMIN-A FORMATION; BETA-CAROTENE; MOLECULAR-IDENTIFICATION; GENE ENCODES; EXPRESSION; MUTANT; SPECIFICITY; TRANSPORT; NEURONS	The Drosophila ninaB gene encodes a beta,beta-carotene-15,15'-oxygenase responsible for the centric cleavage of beta-carotene that produces the retinal chromophore of rhodopsin. The ninaD gene encodes a membrane receptor required for efficient use of beta-carotene. Despite their importance to the synthesis of visual pigment, we show that these genes are not active in the retina. Mosaic analysis shows that ninaB and ninaD are not required in the retina, and exclusive retinal expression of either gene, or both genes simultaneously, does not support rhodopsin biogenesis. In contrast, neuron-specific expression of ninaB and ninaD allows for rhodopsin biogenesis. Additional directed expression studies failed to identify other tissues supporting ninaB activity in rhodopsin biogenesis. These results show that nonretinal sites of NinaB beta, beta-carotene-15,15'-oxygenase activity, likely neurons of the central nervous system, are essential for production of the visual chromophore. Retinal or another C-20 retinoid, not members of the beta-carotene family of C-40 carotenoids, are supplied to photoreceptors for rhodopsin biogenesis.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	University of Notre Dame	O'Tousa, JE (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.	jotousa@nd.edu		O'Tousa, Joseph/0000-0001-9754-6816	NEI NIH HHS [EYO6808] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Barua AB, 2000, J NUTR, V130, P1996, DOI 10.1093/jn/130.8.1996; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cheng L, 1998, MOL GEN GENET, V259, P13, DOI 10.1007/s004380050783; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Duszka C, 1996, J NUTR, V126, P2550, DOI 10.1093/jn/126.10.2550; Freeman M, 1997, DEVELOPMENT, V124, P261; Hall JC, 2000, CURR OPIN NEUROBIOL, V10, P456, DOI 10.1016/S0959-4388(00)00117-3; Kiefer C, 2002, P NATL ACAD SCI USA, V99, P10581, DOI 10.1073/pnas.162182899; Lee T, 1999, DEVELOPMENT, V126, P4065; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Leuenberger MG, 2001, ANGEW CHEM INT EDIT, V40, P2614, DOI 10.1002/1521-3773(20010716)40:14<2613::AID-ANIE2613>3.0.CO;2-Z; Livera G, 2001, BIOL REPROD, V64, P1307, DOI 10.1095/biolreprod64.5.1307; Maden M, 2003, DEV DYNAM, V226, P237, DOI 10.1002/dvdy.10222; Malpel S, 2002, DEVELOPMENT, V129, P1443; Newsome TP, 2000, DEVELOPMENT, V127, P851; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Satoh AK, 1997, J CELL SCI, V110, P2943; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; St Johnston D, 2002, NAT REV GENET, V3, P176, DOI 10.1038/nrg751; STARK WS, 1990, J COMP PHYSIOL A, V166, P429, DOI 10.1007/BF00192014; STEPHENSON RS, 1983, SYM SOC EXP BIOL, P477; Stowers RS, 2002, NEURON, V36, P1063, DOI 10.1016/S0896-6273(02)01094-2; Stowers RS, 1999, GENETICS, V152, P1631; Tabuchi K, 2000, J NEUROSCI RES, V59, P94, DOI 10.1002/(SICI)1097-4547(20000101)59:1<94::AID-JNR11>3.3.CO;2-H; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; von Lintig J, 2004, J NUTR, V134, p251S, DOI 10.1093/jn/134.1.251S; von Lintig J, 2001, P NATL ACAD SCI USA, V98, P1130, DOI 10.1073/pnas.031576398; XU T, 1993, DEVELOPMENT, V117, P1223; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476; YAO KM, 1994, J NEUROCHEM, V63, P41; Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834; Yeum KJ, 2000, FREE RADICAL BIO MED, V29, P105, DOI 10.1016/S0891-5849(00)00296-3; Zaffran S, 1997, DEVELOPMENT, V124, P2087; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	39	33	34	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18608	18613		10.1074/jbc.M400323200	http://dx.doi.org/10.1074/jbc.M400323200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14982930	hybrid			2022-12-27	WOS:000221041500064
J	Phillips, E; Reeve, A; Bevan, S; McIntyre, P				Phillips, E; Reeve, A; Bevan, S; McIntyre, P			Identification of species-specific determinants of the action of the antagonist capsazepine and the agonist PPAHV on TRPV1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VANILLOID RECEPTOR-1; CAPSAICIN RECEPTOR; SENSORY NEURONS; GUINEA-PIG; COMPETITIVE ANTAGONIST; INDUCED ACTIVATION; GANGLION NEURONS; HEAT; ACID; VR1	The vanilloid receptor 1 (VR1 or TRPV1) ion channel is activated by noxious heat, low pH and by a variety of vanilloid-related compounds. The antagonist, capsazepine is more effective at inhibiting the human TRPV1 response to pH 5.5 than the rat TRPV1 response to this stimulus. Mutation of rat TRPV1 at three positions in the S3 to S4 region, to the corresponding human amino acid residues I514M, V518L, and M547L decreased the IC50 values for capsazepine inhibition of the pH 5.5 response from > 10,000 nM to 924 +/- 241 nM in [Ca2+](i) assays and increased capsazepine inhibition of the capsaicin response to levels seen for human TRPV1. We have previously noted that phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV) is a strong agonist of rat TRPV1 but not human TRPV1 in [Ca2+](i) assays (1). Mutation of methionine 547 in S4 of rat TRPV1 to leucine, found in human TRPV1 ( M547L), reduced the ability of PPAHV to activate TRPV1 by similar to20-fold. The reciprocal mutation of human TRPV1 (L547M) enabled the human receptor to respond to PPAHV. These mutations did not significantly affect the agonist activity of capsaicin, resiniferatoxin (RTX) or olvanil in [Ca2+](i) assays. Introducing the equivalent mutation into guinea pig TRPV1 (L549M) increased the agonist potency of PPAHV by > 10-fold in the [Ca2+](i) assay and increased the amplitude of the evoked current. The rat M547L mutation reduced the affinity of RTX binding. Thus, amino acids within the S2-S4 region are important sites of agonist and antagonist interaction with TRPV1.	Novartis Inst Med Sci, Novartis Inst Biomed Res, London WC1E 6BN, England	Novartis; University of London; University College London	McIntyre, P (corresponding author), Novartis Inst Med Sci, Novartis Inst Biomed Res, 5 Gower Pl, London WC1E 6BN, England.		Bevan, Stuart/A-8821-2008; Mcintyre, Peter/N-4109-2013	Bevan, Stuart John/0000-0002-8977-1797; McIntyre, Peter/0000-0001-9506-5998				BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; BEVAN S, 1992, BRIT J PHARMACOL, V107, pP235; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; BRAND L, 1987, DRUG EXP CLIN RES, V13, P259; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; FOX AJ, 1995, NEUROSCIENCE, V67, P741, DOI 10.1016/0306-4522(95)00115-Y; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jerman JC, 2000, BRIT J PHARMACOL, V130, P916, DOI 10.1038/sj.bjp.0703390; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Kollarik M, 2002, J PHYSIOL-LONDON, V543, P591, DOI 10.1113/jphysiol.2002.022848; Kuzhikandathil EV, 2001, J NEUROSCI, V21, P8697, DOI 10.1523/JNEUROSCI.21-22-08697.2001; Liu L, 2000, PHYSIOL BEHAV, V69, P363, DOI 10.1016/S0031-9384(00)00209-2; McIntyre P, 2001, BRIT J PHARMACOL, V132, P1084, DOI 10.1038/sj.bjp.0703918; Nagy I, 1999, J NEUROSCI, V19, P10647, DOI 10.1523/JNEUROSCI.19-24-10647.1999; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Ross RA, 2001, BRIT J PHARMACOL, V132, P631, DOI 10.1038/sj.bjp.0703850; Savidge J, 2002, NEUROPHARMACOLOGY, V43, P450, DOI 10.1016/S0028-3908(02)00122-3; Seabrook GR, 2002, J PHARMACOL EXP THER, V303, P1052, DOI 10.1124/jpet.102.040394; Szallasi A, 1996, EUR J PHARMACOL, V299, P221, DOI 10.1016/0014-2999(95)00864-0; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Vlachova V, 2003, J NEUROSCI, V23, P1340, DOI 10.1523/JNEUROSCI.23-04-01340.2003; Vyklicky L, 1998, J NEUROPHYSIOL, V79, P670, DOI 10.1152/jn.1998.79.2.670; Walker KM, 2003, J PHARMACOL EXP THER, V304, P56, DOI 10.1124/jpet.102.042010; WALPOLE CSJ, 1994, J MED CHEM, V37, P1942, DOI 10.1021/jm00039a006; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	30	85	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17165	17172		10.1074/jbc.M313328200	http://dx.doi.org/10.1074/jbc.M313328200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960593	hybrid			2022-12-27	WOS:000220870400036
J	Vrontou, E; Karamanou, S; Baud, C; Sianidis, G; Economou, A				Vrontou, E; Karamanou, S; Baud, C; Sianidis, G; Economou, A			Global co-ordination of protein translocation by the SecA IRA1 switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT ATP-BINDING; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCASE; SIGNAL PEPTIDES; MEMBRANE; SECYEG; DOMAIN; HYDROLYSIS; COMMUNICATION; MECHANISM	SecA, the dimeric ATPase subunit of protein translocase, contains a DEAD helicase catalytic core that binds to a regulatory C-terminal domain. We now demonstrate that IRA1, a conserved helix-loop-helix structure in the C-domain, controls C-domain conformation through direct interdomain contacts. C-domain conformational changes are transmitted to the DEAD motor and alter its conformation. These interactions establish DEAD motor/C-domain conformational cross-talk that requires a functional IRA1. IRA1-controlled binding/release cycles of the C-domain to the DEAD motor couple this crosstalk to protein translocation chemistries, i.e. DEAD motor affinities for ligands (nucleotides, preprotein signal peptides, and SecYEG, the integral membrane component of translocase) and ATP turnover. IRA1-mediated global co-ordination of SecA catalysis is essential for protein translocation.	Univ Crete, Fdn Res & Technol, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Crete, Greece; Univ Crete, Dept Biol, GR-71110 Iraklion, Crete, Greece	University of Crete; University of Crete	Economou, A (corresponding author), Univ Crete, Fdn Res & Technol, Inst Mol Biol & Biotechnol, POB 1527, GR-71110 Iraklion, Crete, Greece.	aeconomo@imbb.forth.gr	Karamanou, Spyridoula/H-7485-2018; Economou, Anastassios/P-8292-2017	Karamanou, Spyridoula/0000-0002-8803-1404; Economou, Anastassios/0000-0002-1770-507X				Baud C, 2002, J BIOL CHEM, V277, P13724, DOI 10.1074/jbc.M200047200; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Dapic V, 2000, J BIOL CHEM, V275, P25000, DOI 10.1074/jbc.M001100200; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; den Blaauwen T, 1999, FEBS LETT, V458, P145, DOI 10.1016/S0014-5793(99)01139-4; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; Ding HY, 2001, BIOCHEMISTRY-US, V40, P1835, DOI 10.1021/bi002058w; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; Economou A, 1998, MOL MICROBIOL, V27, P511, DOI 10.1046/j.1365-2958.1998.00713.x; Economou A, 2002, MOL MEMBR BIOL, V19, P159, DOI 10.1080/09687680210152609; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hirano M, 1996, BIOCHEM BIOPH RES CO, V229, P90, DOI 10.1006/bbrc.1996.1762; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; JAROSIK GP, 1991, J BACTERIOL, V173, P860, DOI 10.1128/jb.173.2.860-868.1991; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; Kourtz L, 2000, MOL MICROBIOL, V37, P1342, DOI 10.1046/j.1365-2958.2000.02078.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Singleton MR, 2003, EMBO J, V22, P4579, DOI 10.1093/emboj/cdg441; Song M, 1997, J BIOCHEM-TOKYO, V122, P1010; Triplett TL, 2001, J BIOL CHEM, V276, P19648, DOI 10.1074/jbc.M100098200; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	39	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22490	22497		10.1074/jbc.M401008200	http://dx.doi.org/10.1074/jbc.M401008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007058	hybrid			2022-12-27	WOS:000221417100099
J	Tripet, B; Howard, MW; Jobling, M; Holmes, RK; Holmes, KV; Hodges, RS				Tripet, B; Howard, MW; Jobling, M; Holmes, RK; Holmes, KV; Hodges, RS			Structural characterization of the SARS-coronavirus spike S fusion protein core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE RESPIRATORY SYNDROME; TO-CELL FUSION; VIRUS ENVELOPE GLYCOPROTEIN; AMINO-ACID SUBSTITUTIONS; HELICAL COILED-COILS; MURINE CORONAVIRUS; MEMBRANE-FUSION; IMMUNODEFICIENCY-VIRUS; CRYSTAL-STRUCTURE; HIV-1 GP41	The spike (S) glycoprotein of coronaviruses mediates viral entry into host cells. It is a type 1 viral fusion protein that characteristically contains two heptad repeat regions, denoted HR-N and HR-C, that form coiled-coil structures within the ectodomain of the protein. Previous studies have shown that the two heptad repeat regions can undergo a conformational change from their native state to a 6-helix bundle ( trimer of dimers), which mediates fusion of viral and host cell membranes. Here we describe the biophysical analysis of the two predicted heptad repeat regions within the severe acute respiratory syndrome coronavirus S protein. Our results show that in isolation the HR-N region forms a stable alpha-helical coiled coil that associates in a tetrameric state. The HR-C region in isolation formed a weakly stable trimeric coiled coil. When mixed together, the two peptide regions (HR-N and HR-C) associated to form a very stable alpha-helical 6-stranded structure ( trimer of heterodimers). Systematic peptide mapping showed that the site of interaction between the HR-N and HR-C regions is between residues 916 - 950 of HR-N and residues 1151 - 1185 of HR-C. Additionally, interchain disulfide bridge experiments showed that the relative orientation of the HR-N and HR-C helices in the complex was antiparallel. Overall, the structure of the heterostranded complex is consistent with the structures observed for other type 1 viral fusion proteins in their fusion-competent state.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hodges, RS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.	robert.hodges@uchsc.edu	Jobling, Michael G/AAJ-3814-2021	Jobling, Michael/0000-0001-7689-3093; Howard, Megan W/0000-0002-7100-6202	NIAID NIH HHS [R01 AI 48717, R01 AI 25231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025231, R01AI048717] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200; Bos ECW, 1995, VIROLOGY, V214, P453, DOI 10.1006/viro.1995.0056; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chen L, 2001, STRUCTURE, V9, P255, DOI 10.1016/S0969-2126(01)00581-0; DEGROOT RJ, 1989, VIROLOGY, V171, P493, DOI 10.1016/0042-6822(89)90619-3; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; El-Sahly HM, 2000, CLIN INFECT DIS, V31, P96, DOI 10.1086/313937; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Folz RJ, 1999, CHEST, V115, P901, DOI 10.1378/chest.115.3.901; FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985; Ghosh JK, 1998, J BIOL CHEM, V273, P27182, DOI 10.1074/jbc.273.42.27182; Gibbons DL, 2000, J VIROL, V74, P7772, DOI 10.1128/JVI.74.17.7772-7780.2000; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hayes DB, 2003, SEDIMENTATION INTERP; Holtzer ME, 1997, BIOPHYS J, V73, P1031, DOI 10.1016/S0006-3495(97)78136-0; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Knipe D, 2001, FIELDS VIROLOGY, P1187; Kobe B, 1999, P NATL ACAD SCI USA, V96, P4319, DOI 10.1073/pnas.96.8.4319; Kohn WD, 1998, J MOL BIOL, V283, P993, DOI 10.1006/jmbi.1998.2125; Luo ZL, 1999, J VIROL, V73, P8152, DOI 10.1128/JVI.73.10.8152-8159.1999; Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a; Mathews JM, 2000, J VIROL, V74, P5911, DOI 10.1128/JVI.74.13.5911-5920.2000; Matsuyama S, 2002, J VIROL, V76, P11819, DOI 10.1128/JVI.76.23.11819-11826.2002; McINTOSH K., 1974, Current Topics in Microbiology and Immunology, P85; Medinas RJ, 2002, J VIROL, V76, P9079, DOI 10.1128/JVI.76.18.9079-9086.2002; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Pinon JD, 2003, J VIROL, V77, P3281, DOI 10.1128/JVI.77.5.3281-3290.2003; Poon LLM, 2003, CLIN CHEM, V49, P953, DOI 10.1373/49.6.953; Pritsker M, 1998, P NATL ACAD SCI USA, V95, P7287, DOI 10.1073/pnas.95.13.7287; RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x; SEMCHUK PD, 1996, PEPTIDES CHEM STRUCT, P73; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939; STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGUCHI F, 1995, J VIROL, V69, P7260, DOI 10.1128/JVI.69.11.7260-7263.1995; Taguchi F, 2002, J VIROL, V76, P950, DOI 10.1128/JVI.76.3.950-958.2002; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Tomasi M, 2003, FEBS LETT, V536, P56, DOI 10.1016/S0014-5793(03)00010-3; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; TRIPET B, 2001, PEPTIDES WAVE FUTURE, P265; WATOWICH SJ, 1994, STRUCTURE, V2, P719, DOI 10.1016/S0969-2126(00)00073-3; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Yang CL, 1997, J VIROL, V71, P8490, DOI 10.1128/JVI.71.11.8490-8496.1997; Yang XZ, 2000, J VIROL, V74, P4746, DOI 10.1128/JVI.74.10.4746-4754.2000; Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116; Young JK, 1997, VIROLOGY, V238, P291, DOI 10.1006/viro.1997.8834; Zelus BD, 1998, J VIROL, V72, P7237, DOI 10.1128/JVI.72.9.7237-7244.1998; Zelus BD, 2003, J VIROL, V77, P830, DOI 10.1128/JVI.77.2.830-840.2003; Zhao X, 2000, P NATL ACAD SCI USA, V97, P14172, DOI 10.1073/pnas.260499197; Zhou GF, 2000, BIOORGAN MED CHEM, V8, P2219, DOI 10.1016/S0968-0896(00)00155-3; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	68	154	169	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20836	20849		10.1074/jbc.M400759200	http://dx.doi.org/10.1074/jbc.M400759200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14996844	Green Published, hybrid			2022-12-27	WOS:000221273800035
J	Merrick, CJ; Jackson, D; Diffley, JFX				Merrick, CJ; Jackson, D; Diffley, JFX			Visualization of altered replication dynamics after DNA damage in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; STRAND BREAK REPAIR; S-PHASE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; FORK PROGRESSION; CYCLE CHECKPOINT; ACTIVATION; YEAST; INHIBITION; TRANSCRIPTION	Eukaryotic cells respond to DNA damage within the S phase by activating an intra-S checkpoint: a response that includes reducing the rate of DNA synthesis. In yeast cells this can occur via checkpoint-dependent inhibition of origin firing and stabilization of ongoing forks, together with a checkpoint-independent slowing of fork movement. In higher eukaryotes, however, the mechanism by which DNA synthesis is reduced is less clear. We have developed strategies based on DNA fiber labeling that allow the quantitative assessment of rates of replication fork movement, origin firing, and fork stalling throughout the genome by examining large numbers of individually labeled replication forks. We show that exposing S phase cells to ionizing radiation induces a transient block to origin firing but does not affect fork rate or fork stalling. Alkylation damage by methyl methane sulfonate causes a slowing of fork movement and a high rate of fork stalling, in addition to inducing a block to new origin firing. Nucleotide depletion by hydroxyurea also reduces replication fork rate and increases stalling; moreover, in contrast to a recent report, we show that hydroxyurea induces a strong block to new origin firing. The DNA fiber labeling strategy provides a powerful new approach to analyze the dynamics of DNA replication in a perturbed S phase.	Canc Res UK, London Res Ctr Clare Hall Labs, Potters Bar EN6 3LD, Herts, England; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	Cancer Research UK; University of Manchester	Diffley, JFX (corresponding author), Canc Res UK, London Res Ctr Clare Hall Labs, Blanche Lane, Potters Bar EN6 3LD, Herts, England.	John.Diffley@cancer.org.uk	Merrick, Catherine/AAD-9154-2022	Merrick, Catherine/0000-0001-7583-2176; Diffley, John/0000-0001-5184-7680				Aboussekhra A, 1996, EMBO J, V15, P3912, DOI 10.1002/j.1460-2075.1996.tb00765.x; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; ATEN JA, 1992, HISTOCHEM J, V24, P251, DOI 10.1007/BF01046839; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; HAMLIN JL, 1978, EXP CELL RES, V112, P225, DOI 10.1016/0014-4827(78)90204-5; Henry-Mowatt J, 2003, MOL CELL, V11, P1109, DOI 10.1016/S1097-2765(03)00132-1; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; King WR, 2003, CURR GENET, V42, P313, DOI 10.1007/s00294-002-0361-4; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Painter R B, 1985, Kroc Found Ser, V19, P89; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1977, MUTAT RES, V42, P299, DOI 10.1016/S0027-5107(77)80031-6; PAINTER RB, 1985, MUTAT RES, V145, P63, DOI 10.1016/0167-8817(85)90041-0; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shimada K, 2002, GENE DEV, V16, P3236, DOI 10.1101/gad.239802; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Vernis L, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng121; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	37	176	179	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20067	20075		10.1074/jbc.M400022200	http://dx.doi.org/10.1074/jbc.M400022200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14982920	hybrid			2022-12-27	WOS:000221164500083
J	Taha, TA; Osta, W; Kozhaya, L; Bielawski, J; Johnson, KR; Gillanders, WE; Dbaibo, GS; Hannun, YA; Obeid, LM				Taha, TA; Osta, W; Kozhaya, L; Bielawski, J; Johnson, KR; Gillanders, WE; Dbaibo, GS; Hannun, YA; Obeid, LM			Down-regulation of sphingosine kinase-1 by DNA damage - Dependence on proteases and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TIME RT-PCR; CELL-DEATH; CERAMIDE; APOPTOSIS; SPHINGOSINE-1-PHOSPHATE; PATHWAY; STRESS; ACTINOMYCIN; ACTIVATION	Sphingosine kinase 1 (SK1), a key enzyme in sphingosine 1-S1P) synthesis, regulates various aspects of cell behavior, including cell survival and proliferation. DNA damaging anti-neoplastic agents have been shown to induce p53, ceramide levels, and apoptosis; however, the effects of anti-neoplastic agents on SK have not been assessed. In this study, we investigated the effects of a DNA damaging agent, actinomycin D ( Act D), on the function of sphingosine kinase ( SK1). Act D caused a reduction in the protein levels of SK1, as indicated by Western blot analysis, with a concomitant decrease in SK activity. The down-regulation was posttranscriptional, because the mRNA levels of SK1 remained unchanged. Similar decreases in SK1 protein were observed with other DNA damaging agents such as doxorubicin, etoposide, and gamma-irradiation. ZVAD, the pancaspase inhibitor, and Bcl-2 annulled the effect of Act D on SK1, demonstrating a role for cysteine proteases downstream of Bcl-2 in the down-regulation of SK1. Inhibition of caspases 3, 6, 7, and 9 only partially reversed Act D-induced SK1 loss. Inhibition of cathepsin B, a lysosomal protease, produced a significant reversal of SK1 decline by Act D, suggesting that a multitude of ZVAD-sensitive cysteine proteases downstream of Bcl-2 mediated the SK1 decrease. When p53 up-regulation after Act D treatment was inhibited, SK1 down-regulation was rescued, demonstrating p53 dependence of SK1 modulation. Treatment of cells with S1P, the product of SK1, partially inhibited Act D-induced cell death, raising the possibility that a decrease in SK1 may be in part necessary for cell death to occur. Furthermore, the knockdown of SK1 by small interfering RNA in MCF-7 cells resulted in a significant reduction in cell viability. These studies demonstrate that SK1 is down-regulated by genotoxic stress, and that basal SK1 function may be necessary for the maintenance of tumor cell growth.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Div Gen Internal Med, Charleston, SC 29401 USA; Amer Univ Beirut, Dept Biochem, Beirut, Lebanon; Amer Univ Beirut, Dept Pediat, Beirut, Lebanon	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; American University of Beirut; American University of Beirut	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu	Dbaibo, Ghassan S./X-2978-2019	obeid, lina/0000-0002-0734-0847	NCI NIH HHS [P01 CA 097132] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; French KJ, 2003, CANCER RES, V63, P5962; Hannun YA, 1997, ADV EXP MED BIOL, V400, P305; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1989, CLIN CHIM ACTA, V185, P333, DOI 10.1016/0009-8981(89)90224-6; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jayadev S, 1996, J LIPID MEDIAT CELL, V14, P295, DOI 10.1016/0929-7855(96)00538-X; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Mitas M, 2001, INT J CANCER, V93, P162, DOI 10.1002/ijc.1312; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Olivera A, 2000, METHOD ENZYMOL, V311, P215; Petak Istvan, 2001, Pathology and Oncology Research, V7, P95; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Radin NS, 2003, BIOCHEM J, V371, P243, DOI 10.1042/BJ20021878; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; Willis A. C., 2002, Current Molecular Medicine (Hilversum), V2, P329, DOI 10.2174/1566524023362474; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	34	103	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20546	20554		10.1074/jbc.M401259200	http://dx.doi.org/10.1074/jbc.M401259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14988393	hybrid			2022-12-27	WOS:000221164500134
J	Jayanthi, LD; Samuvel, DJ; Ramamoorthy, S				Jayanthi, LD; Samuvel, DJ; Ramamoorthy, S			Regulated internalization and phosphorylation of the native norepinephrine transporter in response to phorbol esters - Evidence for localization in lipid rafts and lipid raft-mediated internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN DOPAMINE TRANSPORTER; ORTHOSTATIC INTOLERANCE; SEROTONIN TRANSPORTERS; FUNCTIONAL REGULATION; SURFACE EXPRESSION; COCAINE; TRAFFICKING; MODULATION; RECEPTORS	The effects of norepinephrine in the brain and periphery are terminated primarily by active reuptake of the catecholamine via cocaine- and amphetamine-sensitive norepinephrine transporters (NETs). Activation of protein kinase C (PKC) down-regulates NET by sequestering it from the plasma membrane, although the underlying mechanism is not yet known. Previously, we showed robust expression of endogenous NETs in rat placental trophoblasts (Jayanthi, L. D., Vargas, G., and DeFelice, L. J. (2002) Br. J. Pharmacol. 135, 1927-1934). Here we report a significant reduction in native NET function and surface expression in these cells following phorbol ester (beta-PMA) treatment. The beta-PMA-mediated down-regulation of NET occurs by a rapid sequestration of NETs from the plasma membrane and is calcium-independent. Reversible biotinylation experiments revealed a significant enhancement of NET endocytosis following beta-PMA treatment. Chemical treatments and expression of dominant negative mutants of dynamin 1 and 2 failed to prevent the beta-PMA effect, suggesting a clathrin-independent pathway. In contrast, treatment with the cholesterol-disrupting agent filipin, which blocks caveolae/lipid raft-mediated internalization, completely blocked the beta-PMA-mediated NET sequestration. Discontinuous sucrose density gradient centrifugation revealed NET in the lipid raft fractions. Following beta-PMA treatment, there was reduced NET levels in the lipid raft fractions suggesting that cholesterol-rich lipid rafts mediate PKC-triggered NET internalization. Metabolic labeling and immunoprecipitation studies revealed that NET phosphorylation is stimulated several-fold by PKC activation and protein phosphatase 1/2A inhibition. Together, these findings demonstrate for the first time that in trophoblasts (i) PKC activation regulates NET function and surface expression by an enhanced internalization process that is lipid raft-mediated and (ii) PKC and protein phosphatase(s) modulation regulates NET phosphorylation.	Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA	Medical University of South Carolina	Jayanthi, LD (corresponding author), Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA.	jayanthi@musc.edu			NIMH NIH HHS [MH62612] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062612] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Apparsundaram S, 2001, J PHARMACOL EXP THER, V299, P666; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; Axelrod J, 1969, Prog Brain Res, V31, P21; Bauman AL, 2000, J NEUROSCI, V20, P7571; Bauman PA, 2002, ARCH BIOCHEM BIOPHYS, V404, P80, DOI 10.1016/S0003-9861(02)00232-1; Becher A, 2001, J NEUROCHEM, V79, P787, DOI 10.1046/j.1471-4159.2001.00614.x; Bohn LM, 2000, J NEUROSCI, V20, P9040; Carozzi AJ, 2002, J BIOL CHEM, V277, P17944, DOI 10.1074/jbc.M110879200; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Casabona G, 1997, PROG NEURO-PSYCHOPH, V21, P407, DOI 10.1016/S0278-5846(97)00011-0; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; CHEN CC, 1993, FEBS LETT, V332, P169, DOI 10.1016/0014-5793(93)80506-P; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Deken SL, 2003, J NEUROSCI, V23, P1563; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; EICHHOLTZ T, 1992, J BIOL CHEM, V267, P22490; ESLER M, 1981, HYPERTENSION, V3, P149, DOI 10.1161/01.HYP.3.2.149; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; GANGULY PK, 1986, CIRC RES, V59, P684, DOI 10.1161/01.RES.59.6.684; GONG JP, 2002, 32 ANN M SOC NEUR OR; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; Hahn MK, 2003, J NEUROSCI, V23, P4470; Ivancsits S, 2003, AM J MED SCI, V325, P63, DOI 10.1097/00000441-200302000-00002; IVERSEN LL, 1978, HDB PSYCHOPHARMACOLO, P381; JAYANTHI LD, 1993, BIOCHEMISTRY-US, V32, P12178, DOI 10.1021/bi00096a030; Jayanthi LD, 2002, BRIT J PHARMACOL, V135, P1927, DOI 10.1038/sj.bjp.0704658; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Karl PI, 1996, BIOCHEM J, V320, P831, DOI 10.1042/bj3200831; Kitayama S, 1999, J BIOL CHEM, V274, P10731, DOI 10.1074/jbc.274.16.10731; Klimek V, 1997, J NEUROSCI, V17, P8451; Lin ZC, 2003, J BIOL CHEM, V278, P20162, DOI 10.1074/jbc.M209584200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; McKeown KJ, 2003, J CLIN ENDOCR METAB, V88, P1737, DOI 10.1210/jc.2002-021369; Melikian HE, 1999, J NEUROSCI, V19, P7699; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MONTESANO R, 1979, P NATL ACAD SCI USA, V76, P6391, DOI 10.1073/pnas.76.12.6391; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Ramamoorthy JD, 1995, AM J OBSTET GYNECOL, V173, P1782, DOI 10.1016/0002-9378(95)90427-1; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; RAMAMOORTHY S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P181, DOI 10.1016/0167-4889(92)90255-A; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; Ramamoorthy Sammanda, 2002, P1; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; Ruzycky AL, 1996, PLACENTA, V17, P461, DOI 10.1016/S0143-4004(96)90028-4; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Scanlon SM, 2001, BIOCHEMISTRY-US, V40, P10507, DOI 10.1021/bi010730z; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Shannon JR, 2000, NEW ENGL J MED, V342, P541, DOI 10.1056/NEJM200002243420803; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Xu F, 2000, NAT NEUROSCI, V3, P465, DOI 10.1038/74839	62	122	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19315	19326		10.1074/jbc.M311172200	http://dx.doi.org/10.1074/jbc.M311172200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976208	hybrid			2022-12-27	WOS:000221041500145
J	Ligon, LA; Tokito, M; Finklestein, JM; Grossman, FE; Holzbaur, ELF				Ligon, LA; Tokito, M; Finklestein, JM; Grossman, FE; Holzbaur, ELF			A direct interaction between cytoplasmic dynein and kinesin I may coordinate motor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN; AXONAL-TRANSPORT; DIRECT BINDING; DYNACTIN; PROTEIN; SPECTRIN; SUBUNIT; REPEAT	Cytoplasmic dynein and kinesin I are both unidirectional intracellular motors. Dynein moves cargo toward the cell center, and kinesin moves cargo toward the cell periphery. There is growing evidence that bi-directional motility is regulated in the cell, potentially through direct interactions between oppositely oriented motors. We have identified a direct interaction between cytoplasmic dynein and kinesin I. Using the yeast two-hybrid assay and affinity chromatography, we demonstrate that the intermediate chain of dynein binds to kinesin light chains 1 and 2. The interaction is both direct and specific. Co-immunoprecipitation experiments demonstrate an interaction between endogenous proteins in rat brain cytosol. Double-label immunocytochemistry reveals a partial co-localization of vesicle-associated motor proteins. Together these observations suggest that soluble motors can interact, potentially allowing kinesin I to actively localize dynein to cellular sites of function. There is also a vesicle population with both dynein and kinesin I bound that may be capable of bi-directional motility along cellular microtubules.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Holzbaur, ELF (corresponding author), Univ Penn, Sch Med, Dept Physiol, D400 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.	holzbaur@mail.med.upenn.edu		Ligon, Lee/0000-0002-5735-3654	NIGMS NIH HHS [GM48661] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048661] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Gindhart JG, 1998, J CELL BIOL, V141, P443, DOI 10.1083/jcb.141.2.443; Gyoeva FK, 2000, J CELL SCI, V113, P2047; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; Hollenbeck PJ, 2001, J CELL BIOL, V152, pF25, DOI 10.1083/jcb.152.5.F25; Holleran EA, 2001, J BIOL CHEM, V276, P36598, DOI 10.1074/jbc.M104838200; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Khodjakov A, 1998, MOL BIOL CELL, V9, P333, DOI 10.1091/mbc.9.2.333; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Ligon LA, 2001, NAT CELL BIOL, V3, P913, DOI 10.1038/ncb1001-913; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Lin SXH, 1996, CELL MOTIL CYTOSKEL, V34, P299; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; Mary S, 2002, MOL BIOL CELL, V13, P285, DOI 10.1091/mbc.01-07-0337; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; Zhang J, 2003, MOL BIOL CELL, V14, P1479, DOI 10.1091/mbc.E02-08-0516	26	127	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19201	19208		10.1074/jbc.M313472200	http://dx.doi.org/10.1074/jbc.M313472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985359	hybrid			2022-12-27	WOS:000221041500133
J	Nelson, SW; Honzatko, RB; Fromm, HJ				Nelson, SW; Honzatko, RB; Fromm, HJ			Origin of cooperativity in the activation of fructose-1,6-bisphosphatase by Mg2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; RECOMBINANT PORCINE FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE INHIBITION; DYNAMIC LOOP; ALLOSTERIC INHIBITION; CRYSTAL-STRUCTURE; MECHANISM; 1,6-BISPHOSPHATASE; BINDING; CATALYSIS	Fructose-1,6-bisphosphatase requires a divalent metal cation for catalysis, Mg2+ being its most studied activator. Phosphatase activity increases sigmoidally with the concentration of Mg2+, but the mechanistic basis for such cooperativity is unknown. Bound magnesium cations can interact within a single subunit or between different subunits of the enzyme tetramer. Mutations of Asp(118), Asp(121), or Glu(97) to alanine inactivate the recombinant porcine enzyme. These residues bind directly to magnesium cations at the active site. Three different hybrid tetramers of fructose-1,6-bisphosphatase, composed of one wild-type subunit and three subunits bearing one of the mutations above, exhibit kinetic parameters (K-m for fructose-1,6-bisphosphate, 1.1-1.8 muM; K-alpha for Mg2+, 0.34-0.76 mM; K-i for fructose-2,6-bisphosphate, 0.11-0.61 muM; and IC50 for AMP, 3.8-7.4 muM) nearly identical to those of the wild-type enzyme. Notwithstanding these similarities, the k(cat) parameter for each hybrid tetramer is approximately one-fourth of that for the wild-type enzyme. Evidently, each subunit in the wildtype tetramer can independently achieve maximum velocity when activated by Mg2+. Moreover, the activities of the three hybrid tetramers vary sigmoidally with the concentration of Mg2+ (Hill coefficients of similar to2). The findings above are fully consistent with a mechanism of cooperativity that arises from within a single subunit of fructose-1,6-bisphosphatase.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	hjfromm@iastate.edu			NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC PA, 1978, P NATL ACAD SCI USA, V75, P2185, DOI 10.1073/pnas.75.5.2185; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; CHOE JY, 2003, J BIOL CHEM, V278, P66014; CHOE JY, 2003, J BBIOL CHEM, V278, P66020; ELMAGHRABI MR, 1992, J BIOL CHEM, V267, P6526; ELMAGHRABI MR, 1993, J BIOL CHEM, V268, P9466; Fromm H J, 1979, Methods Enzymol, V63, P467; Fromm SJ, 1999, BIOCHEM BIOPH RES CO, V265, P448, DOI 10.1006/bbrc.1999.1679; Fushinobu S, 1996, J BIOL CHEM, V271, P25611, DOI 10.1074/jbc.271.41.25611; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P1324, DOI 10.1021/bi00651a024; GIROUX E, 1994, J BIOL CHEM, V269, P31404; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; Johnson KA, 2001, BIOCHEMISTRY-US, V40, P618, DOI 10.1021/bi0016422; KE HM, 1991, BIOCHEMISTRY-US, V30, P4412, DOI 10.1021/bi00232a007; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Kurbanov FT, 1998, J BIOL CHEM, V273, P17511, DOI 10.1074/jbc.273.28.17511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAKASHIMA K, 1976, J BIOL CHEM, V251, P4315; Nelson SW, 2002, J BIOL CHEM, V277, P15539, DOI 10.1074/jbc.M112304200; Nelson SW, 2001, J BIOL CHEM, V276, P6119, DOI 10.1074/jbc.M009485200; Nelson SW, 2001, FEBS LETT, V492, P254, DOI 10.1016/S0014-5793(01)02262-1; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; Nelson SW, 2000, J BIOL CHEM, V275, P29986, DOI 10.1074/jbc.M000473200; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PONTREMOLI S, 1979, ARCH BIOCHEM BIOPHYS, V194, P481, DOI 10.1016/0003-9861(79)90642-8; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Stec B, 2000, J MOL BIOL, V299, P1303, DOI 10.1006/jmbi.2000.3799; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Van Schaftingen E., 1987, ADV ENZYMOL RELAT AR, V59, P45; XUE Y, 1994, P NATL ACAD SCI USA, V91, P12483; ZHANG R, 1995, BIOCHEMISTRY-US, V35, P3038; ZHANG RL, 1995, BIOCHEMISTRY-US, V34, P8190, DOI 10.1021/bi00025a026	41	5	6	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18481	18487		10.1074/jbc.M308811200	http://dx.doi.org/10.1074/jbc.M308811200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978036	hybrid, Green Published			2022-12-27	WOS:000221041500048
J	Palacino, JJ; Sagi, D; Goldberg, MS; Krauss, S; Motz, C; Wacker, M; Klose, J; Shen, J				Palacino, JJ; Sagi, D; Goldberg, MS; Krauss, S; Motz, C; Wacker, M; Klose, J; Shen, J			Mitochondrial dysfunction and oxidative damage in parkin-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE JUVENILE PARKINSONISM; LEWY BODY DISEASE; ALPHA-SYNUCLEIN; LIPID-PEROXIDATION; CELL-DEATH; STRESS; GENE; DOPAMINE; BRAIN; INACTIVATION	Loss-of-function mutations in parkin are the predominant cause of familial Parkinson's disease. We previously reported that parkin -/- mice exhibit nigrostriatal deficits in the absence of nigral degeneration. Parkin has been shown to function as an E3 ubiquitin ligase. Loss of parkin function, therefore, has been hypothesized to cause nigral degeneration via an aberrant accumulation of its substrates. Here we employed a proteomic approach to determine whether loss of parkin function results in alterations in abundance and/or modification of proteins in the ventral midbrain of parkin -/- mice. Two-dimensional gel electrophoresis followed by mass spectrometry revealed decreased abundance of a number of proteins involved in mitochondrial function or oxidative stress. Consistent with reductions in several subunits of complexes I and IV, functional assays showed reductions in respiratory capacity of striatal mitochondria isolated from parkin -/- mice. Electron microscopic analysis revealed no gross morphological abnormalities in striatal mitochondria of parkin -/- mice. In addition, parkin -/- mice showed a delayed rate of weight gain, suggesting broader metabolic abnormalities. Accompanying these deficits in mitochondrial function, parkin -/- mice also exhibited decreased levels of proteins involved in protection from oxidative stress. Consistent with these findings, parkin -/- mice showed decreased serum antioxidant capacity and increased protein and lipid peroxidation. The combination of proteomic, genetic, and physiological analyses reveal an essential role for parkin in the regulation of mitochondrial function and provide the first direct evidence of mitochondrial dysfunction and oxidative damage in the absence of nigral degeneration in a genetic mouse model of Parkinson's disease.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Endocrinol, Boston, MA 02115 USA; Univ Clin Charite, Inst Human Genet, D-13353 Berlin, Germany	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Shen, J (corresponding author), Harvard Univ, Sch Med, Ctr Neurol Dis, New Res Bldg 636E,77 Ave, Boston, MA 02115 USA.	jshen@rics.bwh.harvard.edu	Shen, Jie/GXH-9449-2022; Goldberg, Matthew/T-7827-2019	Goldberg, Matthew/0000-0002-5172-9841				Alam ZI, 1997, J NEUROCHEM, V69, P1326; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; Castellani RJ, 2002, NEUROSCI LETT, V319, P25, DOI 10.1016/S0304-3940(01)02514-9; Choudhary D, 1997, TOXICOL LETT, V93, P141, DOI 10.1016/S0378-4274(97)00087-8; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Cookson MR, 2003, NEUROMOL MED, V3, P1, DOI 10.1385/NMM:3:1:1; Cordeiro C, 1996, BIOCHEM SOC T, V24, pS472, DOI 10.1042/bst024472s; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Da Silva JS, 2003, J CELL BIOL, V162, P1267, DOI 10.1083/jcb.200304021; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; DEXTER DT, 1994, ANN NEUROL, V35, P38, DOI 10.1002/ana.410350107; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Foroud T, 2003, NEUROLOGY, V60, P796, DOI 10.1212/01.WNL.0000049470.00180.07; Gluck M, 2002, J NEUROCHEM, V82, P66, DOI 10.1046/j.1471-4159.2002.00938.x; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; Hayashi S, 2000, MOVEMENT DISORD, V15, P884, DOI 10.1002/1531-8257(200009)15:5<884::AID-MDS1019>3.0.CO;2-8; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Itier JM, 2003, HUM MOL GENET, V12, P2277, DOI 10.1093/hmg/ddg239; JENNER P, 1996, NEUROLOGY S3, V47, P5161; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klose J, 2002, NAT GENET, V30, P385, DOI 10.1038/ng861; Klose J, 1999, METH MOL B, V112, P67; KOLLER WC, 1986, NEUROLOGY, V36, P1147, DOI 10.1212/WNL.36.8.1147-b; Kosel S, 1999, BIOL CHEM, V380, P865, DOI 10.1515/BC.1999.106; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Morel P, 1998, NEUROCHEM INT, V33, P531, DOI 10.1016/S0197-0186(98)00062-X; Morikawa N, 1996, J NEUROCHEM, V66, P1174; Munch G, 2000, J CHEM NEUROANAT, V20, P253, DOI 10.1016/S0891-0618(00)00096-X; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Orth M, 2003, NEUROSCI LETT, V351, P29, DOI 10.1016/S0304-3940(03)00941-8; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Schapira AHV, 1998, BBA-BIOENERGETICS, V1366, P225, DOI 10.1016/S0005-2728(98)00115-7; Schmuck G, 2002, NEUROTOX RES, V4, P1, DOI 10.1080/10298420290007574; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; Serra JA, 2001, J NEURAL TRANSM, V108, P1135, DOI 10.1007/s007020170003; Sherer TB, 2002, J NEUROSCI, V22, P7006; Sherer TB, 2001, BRAIN RES, V891, P94, DOI 10.1016/S0006-8993(00)03203-0; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shin Y, 2003, BRAIN RES, V968, P102, DOI 10.1016/S0006-8993(02)04279-8; SINGER TP, 1988, TOXICOLOGY, V49, P17, DOI 10.1016/0300-483X(88)90169-2; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Sousa SC, 2003, FEBS LETT, V543, P179, DOI 10.1016/S0014-5793(03)00421-6; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Vaughan JR, 2001, ANN HUM GENET, V65, P111, DOI 10.1017/S0003480001008557; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Wang XS, 2003, J BIOL CHEM, V278, P25179, DOI 10.1074/jbc.M302706200; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Winklhofer KF, 2003, J BIOL CHEM, V278, P47199, DOI 10.1074/jbc.M306769200; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319	66	759	783	0	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18614	18622		10.1074/jbc.M401135200	http://dx.doi.org/10.1074/jbc.M401135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985362	hybrid			2022-12-27	WOS:000221041500065
J	Rochdi, MD; Laroche, G; Dupre, E; Giguere, P; Lebel, A; Watier, V; Hamelin, E; Lepine, MC; Dupuis, G; Parent, JL				Rochdi, MD; Laroche, G; Dupre, E; Giguere, P; Lebel, A; Watier, V; Hamelin, E; Lepine, MC; Dupuis, G; Parent, JL			Nm23-H2 interacts with a G protein-coupled receptor to regulate its endocytosis through an Rac1-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; MEDIATED ENDOCYTOSIS; THROMBOXANE A(2); BETA; RHO; ACTIVATION; GTP; INTERNALIZATION; TERMINUS; EFFECTOR	G protein-coupled receptors (GPCRs) represent a vast family of transmembrane proteins involved in the regulation of several physiological responses. The thromboxane A2 receptor (present as two isoforms: TPalpha and TPbeta) is a GPCR displaying diverse pharmacological effects. As seen for many other GPCRs, TPbeta is regulated by agonist-induced internalization. In the present study, we report the identification by yeast two-hybrid screening of Nm23-H2, a nucleoside diphosphate kinase, as a new interacting molecular partner with the C-terminal tail of TPbeta. This interaction was confirmed in a cellular context when Nm23-H2 was co-immunoprecipitated with TPbeta in HEK293 cells, a process dependent on agonist stimulation of the receptor. We observed that agonist-induced internalization of TPbeta was regulated by Nm23-H2 through modulation of Rac1 signaling. Immunofluorescence microscopy in HEK293 cells revealed that Nm23-H2 had a cytoplasmic and nuclear localization but was induced to translocate to the plasma membrane upon stimulation of TPbeta to show extensive co-localization with the receptor. Our findings represent the first demonstration of an interaction of an Nm23 protein with a membrane receptor and constitute a novel molecular regulatory mechanism of GPCR endocytosis.	Univ Sherbrooke, Fac Med, Serv Rhumatol, Dept Med,Div Rheumatol, Fleurimont, PQ J1H 5N4, Canada; Univ Sherbrooke, Grad Program Immunol, Fleurimont, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Biochem, Fleurimont, PQ J1H 5N4, Canada; Univ Sherbrooke, Ctr Rech Clin, Fleurimont, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke; University of Sherbrooke; University of Sherbrooke	Parent, JL (corresponding author), Univ Sherbrooke, Fac Med, Serv Rhumatol, Dept Med,Div Rheumatol, 3001 12 Ave Nord, Fleurimont, PQ J1H 5N4, Canada.	jean-luc.parent@USherbrooke.ca						Benard V, 2002, METHOD ENZYMOL, V345, P349; Cavalli V, 2001, FEBS LETT, V498, P190, DOI 10.1016/S0014-5793(01)02484-X; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Cuello F, 2003, J BIOL CHEM, V278, P7220, DOI 10.1074/jbc.M210304200; Deitcher D, 2001, TRENDS NEUROSCI, V24, P625, DOI 10.1016/S0166-2236(00)01927-5; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Ishikawa N, 2003, J BIOENERG BIOMEMBR, V35, P7, DOI 10.1023/A:1023433504713; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; Kimura N, 2000, J BIOENERG BIOMEMBR, V32, P309, DOI 10.1023/A:1005549315846; Krishnan KS, 2001, NEURON, V30, P197, DOI 10.1016/S0896-6273(01)00273-2; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Luttrell LM, 2002, J CELL SCI, V115, P455; Machesky LM, 1999, NAT CELL BIOL, V1, pE29, DOI 10.1038/10020; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nagata K, 2003, PROSTAG LEUKOTR ESS, V69, P169, DOI 10.1016/S0952-3278(03)00078-4; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; OTERO AS, 2003, J BIOENERG BIOMEMBR, V32, P269; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Qualmann B, 2003, BIOCHEM J, V371, P233, DOI 10.1042/bj20030139; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Rochdi MD, 2002, J BIOL CHEM, V277, P40751, DOI 10.1074/jbc.M207910200; Song J, 1998, J CELL SCI, V111, P2257; THOMPSON G, 1995, BIOCHEMISTRY-US, V37, P7885; von Zastrow M, 2001, BIOCHEM SOC T, V29, P500, DOI 10.1042/BST0290500	34	49	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18981	18989		10.1074/jbc.M312621200	http://dx.doi.org/10.1074/jbc.M312621200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976202	hybrid			2022-12-27	WOS:000221041500110
J	Stolpe, S; Friedrich, T				Stolpe, S; Friedrich, T			The Escherichia coli NADH: ubiquinone oxidoreductase (complex I) is a primary proton pump but may be capable of secondary sodium antiport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINONE OXIDOREDUCTASE; RESPIRATORY-CHAIN; NA+ TRANSLOCATION; CLUSTER N2; 2-DIMENSIONAL CRYSTALLIZATION; KLEBSIELLA-PNEUMONIAE; MEMBRANE-PROTEINS; MODULAR EVOLUTION; ENCODED SUBUNITS; STOICHIOMETRY	The NADH: ubiquinone oxidoreductase (complex I) couples the transfer of electrons from NADH to ubiquinone with the translocation of protons across the membrane. Recently, it was demonstrated that complex I from Klebsiella pneumoniae translocates sodium ions instead of protons. Experimental evidence suggested that complex I from the close relative Escherichia coli works as a primary sodium pump as well. However, data obtained with whole cells showed the presence of an NADH-induced electrochemical proton gradient. In addition, Fourier transform IR spectroscopy demonstrated that the redox reaction of the E. coli complex I is coupled to a protonation of amino acids. To resolve this contradiction we measured the properties of isolated E. coli complex I reconstituted in phospholipids. We found that the NADH: ubiquinone oxidoreductase activity did not depend on the sodium concentration. The redox reaction of the complex in proteoliposomes caused a membrane potential due to an electrochemical proton gradient as measured with fluorescent probes. The signals were sensitive to the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP), the inhibitors piericidin A, dicyclohexylcarbodi-imide ( DCCD), and amiloride derivatives, but were insensitive to the sodium ionophore ETH-157. Furthermore, monensin acting as a Na+/H+ exchanger prevented the generation of a proton gradient. Thus, our data demonstrated that the E. coli complex I is a primary electrogenic proton pump. However, the magnitude of the pH gradient depended on the sodium concentration. The capability of complex I for secondary Na+/H+ antiport is discussed.	Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany	University of Freiburg	Friedrich, T (corresponding author), Univ Freiburg, Inst Organ Chem & Biochem, Albertstr 21, D-79104 Freiburg, Germany.	tfriedri@uni-freiburg.de						AHMED I, 1994, BBA-BIOENERGETICS, V1188, P131, DOI 10.1016/0005-2728(94)90031-0; Albracht SPJ, 2003, BBA-BIOENERGETICS, V1557, P41, DOI 10.1016/S0005-2728(02)00393-6; Barquera B, 2002, BIOCHEMISTRY-US, V41, P3781, DOI 10.1021/bi011873o; Bogachev AV, 1996, J BACTERIOL, V178, P6233, DOI 10.1128/jb.178.21.6233-6237.1996; BONGAERTS J, 1995, MOL MICROBIOL, V16, P521, DOI 10.1111/j.1365-2958.1995.tb02416.x; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; BROWN GC, 1988, BIOCHEM J, V252, P473, DOI 10.1042/bj2520473; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; Drose S, 2002, BBA-BIOENERGETICS, V1556, P65, DOI 10.1016/S0005-2728(02)00307-9; Flemming D, 2003, J BIOL CHEM, V278, P47602, DOI 10.1074/jbc.M308967200; Flemming D, 2003, J BIOL CHEM, V278, P3055, DOI 10.1074/jbc.M208849200; FRIEDRICH T, 1989, EUR J BIOCHEM, V180, P173, DOI 10.1111/j.1432-1033.1989.tb14629.x; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; Galkin AS, 1999, FEBS LETT, V451, P157, DOI 10.1016/S0014-5793(99)00575-X; Gemperli AC, 2003, P NATL ACAD SCI USA, V100, P839, DOI 10.1073/pnas.0237328100; Gemperli AC, 2002, J BIOL CHEM, V277, P33811, DOI 10.1074/jbc.M204860200; HAMAMOTO T, 1994, MOL MICROBIOL, V14, P939, DOI 10.1111/j.1365-2958.1994.tb01329.x; HARELBRONSTEIN M, 1995, J BIOL CHEM, V270, P3816, DOI 10.1074/jbc.270.8.3816; HASSINEN IE, 1993, BIOCHIM BIOPHYS ACTA, V1144, P107, DOI 10.1016/0005-2728(93)90164-B; Hellwig P, 2000, BIOCHEMISTRY-US, V39, P10884, DOI 10.1021/bi000842a; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Hirst J, 2003, P NATL ACAD SCI USA, V100, P773, DOI 10.1073/pnas.0330050100; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; KAIM G, 1993, EUR J BIOCHEM, V218, P937, DOI 10.1111/j.1432-1033.1993.tb18450.x; Krebs W, 1999, MOL MICROBIOL, V33, P590, DOI 10.1046/j.1365-2958.1999.01506.x; Krulwich TA, 2001, BBA-BIOENERGETICS, V1505, P158, DOI 10.1016/S0005-2728(00)00285-1; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Mathiesen C, 2002, BBA-BIOENERGETICS, V1556, P121, DOI 10.1016/S0005-2728(02)00343-2; Mathiesen C, 2003, FEBS LETT, V549, P7, DOI 10.1016/S0014-5793(03)00767-1; MATHIESEN C, 2003, THESIS U LUND SWEDEN; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; Nakamaru-Ogiso E, 2003, FEBS LETT, V549, P43, DOI 10.1016/S0014-5793(03)00766-X; Nakamaru-Ogiso E, 2003, BIOCHEMISTRY-US, V42, P746, DOI 10.1021/bi0269660; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Putnoky P, 1998, MOL MICROBIOL, V28, P1091, DOI 10.1046/j.1365-2958.1998.00868.x; RAGAN CI, 1978, BIOCHEM J, V172, P539, DOI 10.1042/bj1720539; REENSTRA WW, 1980, BIOCHEMISTRY-US, V19, P1, DOI 10.1021/bi00542a001; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; Sazanov LA, 2003, J BIOL CHEM, V278, P19483, DOI 10.1074/jbc.M208959200; Schulte U, 1999, J MOL BIOL, V292, P569, DOI 10.1006/jmbi.1999.3096; Simon W, 1979, Methods Enzymol, V56, P439; Spehr V, 1999, BIOCHEMISTRY-US, V38, P16261, DOI 10.1021/bi9919605; Steuber J, 2001, BBA-BIOENERGETICS, V1505, P45, DOI 10.1016/S0005-2728(00)00276-0; Steuber J, 2003, J BIOL CHEM, V278, P26817, DOI 10.1074/jbc.M301682200; Steuber J, 2000, MOL MICROBIOL, V35, P428, DOI 10.1046/j.1365-2958.2000.01712.x; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; WIKSTROM M, 1984, FEBS LETT, V169, P300, DOI 10.1016/0014-5793(84)80338-5; YAGI T, 1987, BIOCHEMISTRY-US, V26, P2822, DOI 10.1021/bi00384a025; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; YoungMog K, 1997, BIOCHEM BIOPH RES CO, V233, P147, DOI 10.1006/bbrc.1997.6420; Zientz E, 1998, J BACTERIOL, V180, P5421, DOI 10.1128/JB.180.20.5421-5425.1998	57	68	70	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18377	18383		10.1074/jbc.M311242200	http://dx.doi.org/10.1074/jbc.M311242200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970214	hybrid			2022-12-27	WOS:000221041500035
J	Yamano, H; Kominami, K; Harrison, C; Kitamura, K; Katayama, S; Dhut, S; Hunt, T; Toda, T				Yamano, H; Kominami, K; Harrison, C; Kitamura, K; Katayama, S; Dhut, S; Hunt, T; Toda, T			Requirement of the SCFPop1/Pop2 ubiquitin ligase for degradation of the fission yeast S phase cyclin Cig2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; P25(RUM1) CDK INHIBITOR; CELL-CYCLE; F-BOX; SCHIZOSACCHAROMYCES-POMBE; MULTISITE PHOSPHORYLATION; PROTEIN-DEGRADATION; DNA-REPLICATION; SCF; PROTEOLYSIS	Two multiprotein E3 (ubiquitin-protein ligase) ubiquitin ligases, the SCF (Skp1-Cullin-1-F-box) and the APC/C (anaphase promoting complex/cyclosome), are vital in ensuring the temporal order of the cell cycle. Particularly, timely destruction of cyclins via these two E3s is essential for down-regulation of cyclin-dependent kinase. In general, G(1) and S phase cyclins are ubiquitylated by the SCF, whereas ubiquitylation of mitotic cyclins is catalyzed by the APC/C. Here we show that fission yeast S phase cyclin Cig2 is ubiquitylated and degraded via both the SCF and the APC/C. Cig2 instability during G(2) and M phase is dependent upon the SCF complex, whereas the APC/C is responsible for Cig2 destruction during anaphase and G(1), thereby ensuring a spike pattern of Cig2 levels, peaking only at S phase. Two F-box/WD proteins Pop1 and Pop2, homologues of budding yeast Cdc4 and human Fbw7, are responsible for Cig2 instability. Pop1 binds Cig2 in vivo. An in vitro binding assay shows that an internal 93 amino acid residues comprising a part of the cyclin box are necessary and sufficient for this binding. Cig2 phosphorylation is also required for interaction with Pop1. We previously showed that transcriptional oscillation of cig2(+) requires Pop1 and Pop2 function. SCFPop1/Pop2 therefore regulates Cig2 levels in a dual manner, transcriptionally and post-translationally. Our results also highlight a collaborative action of the APC/C and the SCF toward the common substrate Cig2. This type of composite degradation control may be more general as the regulatory mechanism in other complex systems.	Canc Res UK, London Res Inst, Lincolns Inn Fields Labs, Lab Cell Regulat, London WC2A 3PX, England; Canc Res UK, London Res Inst, Clare Hall Labs, Lab Cell Cycle Control, S Mimms EN6 3LD, Herts, England; Marie Curie Res Inst, Cell Cycle Control Grp, Surrey RH8 0TL, England	Cancer Research UK; Cancer Research UK	Toda, T (corresponding author), Canc Res UK, London Res Inst, Lincolns Inn Fields Labs, Lab Cell Regulat, 44 Lincolns Inn Fileds, London WC2A 3PX, England.	toda@cancer.org.uk	Kitamura, Kenji/C-4173-2018	Kitamura, Kenji/0000-0003-1046-7133				Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; Hermand D, 2003, J BIOL CHEM, V278, P9671, DOI 10.1074/jbc.M211358200; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jallepalli PV, 1998, P NATL ACAD SCI USA, V95, P8159, DOI 10.1073/pnas.95.14.8159; Katayama S, 2002, MOL BIOL CELL, V13, P211, DOI 10.1091/mbc.01-07-0333; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Kominami K, 1998, EMBO J, V17, P5388, DOI 10.1093/emboj/17.18.5388; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Krylov DM, 2003, CURR BIOL, V13, P173, DOI 10.1016/S0960-9822(03)00008-3; LEHMANN A, 2004, GENES CELLS, DOI DOI 10.111/J.1356-9597.2004.00730.X; Martin-Castellanos C, 1996, EMBO J, V15, P839, DOI 10.1002/j.1460-2075.1996.tb00419.x; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Wolf DA, 1999, CURR BIOL, V9, P373, DOI 10.1016/S0960-9822(99)80165-1; Yamano H, 2000, MOL CELL, V6, P1377, DOI 10.1016/S1097-2765(00)00135-0; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9	47	14	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18974	18980		10.1074/jbc.M311060200	http://dx.doi.org/10.1074/jbc.M311060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970237	hybrid			2022-12-27	WOS:000221041500109
J	Lee, JY; Zhao, L; Youn, HS; Weatherill, AR; Tapping, R; Feng, LL; Lee, WH; Fitzgerald, KA; Hwang, DH				Lee, JY; Zhao, L; Youn, HS; Weatherill, AR; Tapping, R; Feng, LL; Lee, WH; Fitzgerald, KA; Hwang, DH			Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MYD88-DEPENDENT SIGNALING PATHWAY; MITOGEN-INDUCIBLE CYCLOOXYGENASE; PHOSPHOLIPID OXIDATION-PRODUCTS; MICROBIAL LIPOPROTEINS; OXIDIZED PHOSPHOLIPIDS; PATTERN-RECOGNITION; CELL ACTIVATION; IMMUNE-RESPONSE; CUTTING EDGE	Toll-like receptor 4 (TLR4) and TLR2 agonists from bacterial origin require acylated saturated fatty acids in their molecules. Previously, we reported that TLR4 activation is reciprocally modulated by saturated and polyunsaturated fatty acids in macrophages. However, it is not known whether fatty acids can modulate the activation of TLR2 or other TLRs for which respective ligands do not require acylated fatty acids. A saturated fatty acid, lauric acid, induced NFkappaB activation when TLR2 was co-transfected with TLR1 or TLR6 in 293T cells, but not when TLR1, 2, 3, 5, 6, or 9 was transfected individually. An n-3 polyunsaturated fatty acid (docosahexaenoic acid (DHA)) suppressed NFkappaB activation and cyclooxygenase-2 expression induced by the agonist for TLR2, 3, 4, 5, or 9 in a macrophage cell line (RAW264.7). Because dimerization is considered one of the potential mechanisms for the activation of TLR2 and TLR4, we determined whether the fatty acids modulate the dimerization. However, neither lauric acid nor DHA affected the heterodimerization of TLR2 with TLR6 as well as the homodimerization of TLR4 as determined by co-immunoprecipitation assays in 293T cells in which these TLRs were transiently overexpressed. Together, these results demonstrate that lauric acid activates TLR2 dimers as well as TLR4 for which respective bacterial agonists require acylated fatty acids, whereas DHA inhibits the activation of all TLRs tested. Thus, responsiveness of different cell types and tissues to saturated fatty acids would depend on the expression of TLR4 or TLR2 with either TLR1 or TLR6. These results also suggest that inflammatory responses induced by the activation of TLRs can be differentially modulated by types of dietary fatty acids.	ARS, Western Human Nutr Res Ctr, USDA, Davis, CA 95616 USA; Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA	United States Department of Agriculture (USDA); University of California System; University of California Davis; University of Illinois System; University of Illinois Urbana-Champaign; Baylor College of Medicine; University of Massachusetts System; University of Massachusetts Worcester	Hwang, DH (corresponding author), ARS, Western Human Nutr Res Ctr, USDA, Meyer Hall,1 Shields Ave, Davis, CA 95616 USA.	Dhwang@whnrc.usda.gov	Fitzgerald, Katherine/ABE-6317-2020	Fitzgerald, Kate/0000-0003-3175-609X	NCI NIH HHS [CA75613] Funding Source: Medline; NIDDK NIH HHS [DK41868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Byrd-Leifer CA, 2001, EUR J IMMUNOL, V31, P2448, DOI 10.1002/1521-4141(200108)31:8&lt;2448::AID-IMMU2448&gt;3.0.CO;2-N; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hashimoto M, 2003, J BIOL CHEM, V278, P44205, DOI 10.1074/jbc.M306735200; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KRAUSS JH, 1989, EUR J BIOCHEM, V180, P519, DOI 10.1111/j.1432-1033.1989.tb14677.x; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lee JY, 2003, J LIPID RES, V44, P479, DOI 10.1194/jlr.M200361-JLR200; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Paik JH, 2000, J BIOL CHEM, V275, P28173; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; QURESHI N, 1991, INFECT IMMUN, V59, P441, DOI 10.1128/IAI.59.1.441-444.1991; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Schnare M, 2000, CURR BIOL, V10, P1139, DOI 10.1016/S0960-9822(00)00700-4; Seki E, 2001, J IMMUNOL, V166, P2651, DOI 10.4049/jimmunol.166.4.2651; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Triantafilou M, 2002, J CELL SCI, V115, P2603; Walton KA, 2003, ARTERIOSCL THROM VAS, V23, P1197, DOI 10.1161/01.ATV.0000079340.80744.B8; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Zeyda M, 2002, J BIOL CHEM, V277, P28418, DOI 10.1074/jbc.M203343200; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; Zhang HF, 2002, FEBS LETT, V532, P171, DOI 10.1016/S0014-5793(02)03669-4	55	312	349	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16971	16979		10.1074/jbc.M312990200	http://dx.doi.org/10.1074/jbc.M312990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966134	hybrid			2022-12-27	WOS:000220870400012
J	Seredick, SD; Spiegelman, GB				Seredick, SD; Spiegelman, GB			The Bacillus subtilis response regulator Spo0A stimulates sigma(A)-dependent transcription prior to the major energetic barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN COMPLEX-FORMATION; COLI RNA-POLYMERASE; SPOIIG PROMOTER; STRAND SEPARATION; SIGMA-SUBUNIT; DNA-BINDING; PROTEIN; SPORULATION; ACTIVATION; INITIATION	At the spoIIG promoter phosphorylated Spo0A (Spo0Asimilar toP) binds 0A boxes overlapping the -35 element, interacting with RNA polymerase to facilitate open complex formation. We have compared in vitro transcription from a series of heteroduplex templates containing denatured regions within the promoters. Transcription from heteroduplex templates with 12, 8, or 6 base pairs denatured was independent of Spo0Asimilar toP, but heteroduplexes with 4 or 2 base pairs denatured required Spo0Asimilar toP for maximal levels of transcription. Investigation of the thermal dependence of transcription suggested that strand separation was the primary thermodynamic barrier to transcription initiation but indicated that Spo0Asimilar toP does not reduce this energetic barrier. Kinetic assays revealed that Spo0Asimilar toP stimulated both the rate of formation of initiated complexes as well as increasing the number of complexes capable of initiating transcription. These results imply that Spo0Asimilar toP stimulates transcription at least in part by stabilizing the RNA polymerase-spoIIG complex until contacts between RNA polymerase and the -10 element induce strand separation.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Spiegelman, GB (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	spie@interchange.ubc.ca						BALDUS JM, 1995, MOL MICROBIOL, V17, P281, DOI 10.1111/j.1365-2958.1995.mmi_17020281.x; BALDUS JM, 1994, J BACTERIOL, V176, P296, DOI 10.1128/JB.176.2.296-306.1994; BIRD TH, 1993, MOL MICROBIOL, V9, P741, DOI 10.1111/j.1365-2958.1993.tb01734.x; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; Brodolin K, 2000, J BIOL CHEM, V275, P3661, DOI 10.1074/jbc.275.5.3661; Buckner CM, 1998, J BACTERIOL, V180, P3578, DOI 10.1128/JB.180.14.3578-3583.1998; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Chen YF, 1997, J MOL BIOL, V267, P47, DOI 10.1006/jmbi.1996.0853; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DOBINSON KF, 1987, BIOCHEMISTRY-US, V26, P8206, DOI 10.1021/bi00399a028; Dove SL, 2000, P NATL ACAD SCI USA, V97, P13215, DOI 10.1073/pnas.97.24.13215; GRIMES E, 1991, NUCLEIC ACIDS RES, V19, P6113, DOI 10.1093/nar/19.22.6113; Grimshaw CE, 1998, BIOCHEMISTRY-US, V37, P1365, DOI 10.1021/bi971917m; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Hatt JK, 1998, J BACTERIOL, V180, P3584, DOI 10.1128/JB.180.14.3584-3591.1998; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HAYNIE DT, 2001, BIOL THERMODYNAMICS, P98; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Hoch JA, 1995, 2 COMPONENT SIGNAL T; KEILTY S, 1987, J BIOL CHEM, V262, P6389; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; KULDELL N, 1994, J BACTERIOL, V176, P2991, DOI 10.1128/JB.176.10.2991-2998.1994; Kumar A, 2004, J BACTERIOL, V186, P200, DOI 10.1128/JB.186.1.200-206.2004; Lewis RJ, 2000, MOL MICROBIOL, V38, P198, DOI 10.1046/j.1365-2958.2000.02134.x; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; Liu MF, 2003, J BIOL CHEM, V278, P39755, DOI 10.1074/jbc.M305995200; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; NAKANISHI S, 1975, J BIOL CHEM, V250, P8202; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; Perego M, 1996, MOL MICROBIOL, V19, P1151, DOI 10.1111/j.1365-2958.1996.tb02460.x; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Perego M, 1996, TRENDS GENET, V12, P97, DOI 10.1016/0168-9525(96)81420-X; RECORD MT, 1996, ESCHERICHIA COLI SAL, V1, P792; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4721, DOI 10.1021/bi00339a002; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Rowe-Magnus DA, 1998, P NATL ACAD SCI USA, V95, P5305, DOI 10.1073/pnas.95.9.5305; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schyns G, 1997, J BACTERIOL, V179, P5605, DOI 10.1128/jb.179.17.5605-5608.1997; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; SPIEGELMAN GB, 1995, 2 COMPONENT SIGNAL T, P159; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; Studitsky VM, 2001, NUCLEIC ACIDS RES, V29, P854, DOI 10.1093/nar/29.3.854; Zapf JW, 1996, BIOCHEMISTRY-US, V35, P2926, DOI 10.1021/bi9519361; Zhao H, 2002, STRUCTURE, V10, P1041, DOI 10.1016/S0969-2126(02)00803-1; Zhou XZ, 1997, PROTEINS, V27, P597, DOI 10.1002/(SICI)1097-0134(199704)27:4<597::AID-PROT11>3.0.CO;2-F	49	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17397	17403		10.1074/jbc.M311190200	http://dx.doi.org/10.1074/jbc.M311190200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14976210	hybrid			2022-12-27	WOS:000220870400064
J	Xu, LG; Li, LY; Shu, HB				Xu, LG; Li, LY; Shu, HB			TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; KAPPA-B ACTIVATION; SIGNAL-TRANSDUCTION; KINASE 1; TNF; PATHWAYS; P38; FAMILY; JNK; C-IAP1	The tumor necrosis factor receptor-associated factor (TRAF) protein family members are critically involved in activation of NF-kappaB, JNK, and p38 activation triggered by tumor necrosis factor (TNF) receptor family members and toll/interleukin-1 receptor (TIR)-containing receptors. TRAF proteins (except for TRAF1) contain an N-terminal RING finger domain that is essential for their functions. In this report, we identified a protein designated as TRAF7, which contains a RING finger domain and a zinc finger domain that are mostly conserved with those of TRAFs. TRAF7 also contains seven WD40 repeats at its C terminus. TRAF7 specifically interacted with MEKK3 and potentiated MEKK3-mediated AP1 and CHOP activation. Depletion of TRAF7 by antisense RNA inhibited MEKK3-mediated AP1 and CHOP activation. Moreover, overexpression of TRAF7 induced caspase-dependent apoptosis. Domain mapping experiments indicated that TRAF7 potentiated MEKK3-mediated AP1 and CHOP activation and induced apoptosis through distinct domains. Our studies identified a novel TRAF family member that is involved in MEKK3 signaling and apoptosis.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Integrated Dept Immunol, Denver, CO 80206 USA; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Shu, HB (corresponding author), Natl Jewish Med & Res Ctr, Dept Immunol, 1400 Jackson St,K516C, Denver, CO 80206 USA.	shuh@njc.org		Xu, Liangguo/0000-0003-1991-2889				Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chung JY, 2002, J CELL SCI, V115, P679; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; HAN KJ, 2004, J BIOL CHEM     0122; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	21	123	129	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17278	17282		10.1074/jbc.C400063200	http://dx.doi.org/10.1074/jbc.C400063200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	15001576	hybrid			2022-12-27	WOS:000220870400049
J	Wang, JX; Wang, HZ; Zhang, YQ; Gao, HH; Nattel, S; Wang, ZG				Wang, JX; Wang, HZ; Zhang, YQ; Gao, HH; Nattel, S; Wang, ZG			Impairment of HERG K+ channel function by tumor necrosis factor-alpha - Role of reactive oxygen species as a mediator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGESTIVE-HEART-FAILURE; TRANSIENT OUTWARD CURRENTS; HUMAN VENTRICULAR MYOCYTES; OXIDATIVE STRESS; RECEPTORS; CELLS; REPOLARIZATION; CALCIUM	Congestive heart failure (CHF) is associated with susceptibility to lethal arrhythmias and typically increases levels of tumor necrosis factor-alpha (TNF-alpha) and its receptor, TNFR1. CHF down-regulates rapid delayed-rectifier K+ current (I-Kr) and delays cardiac repolarization. We studied the effects of TNF-alpha on cloned HERG K+ channel (human ether-a-go-go-related gene) in HEK293 cells and native I-Kr in canine cardiomyocytes with whole-cell patch clamp techniques. TNF-alpha consistently and reversibly decreased HERG current (I-HERG). Effects of TNF-alpha were concentration-dependent, increased with longer incubation period, and occurred at clinically relevant concentrations. TNF-alpha had similar inhibitory effects on IKr and markedly prolonged action potential duration (APD) in canine cardiomyocytes. Immunoblotting analysis demonstrated that HERG protein level was slightly higher in canine hearts with tachypacing-induced CHF than in healthy hearts, and TNF-alpha slightly increased HERG protein level in CHF but not in healthy hearts. In cells pretreated with the inhibitory anti-TNFR1 antibody, TNF-alpha lost its ability to suppress I-HERG, indicating a requirement of TNFR1 activation for HERG suppression. Vitamin E or MnTBAP (Mn(III) tetrakis(4-benzoic acid) porphyrin chloride), a superoxide dismutase mimic) prevented, whereas the superoxide anion generating system xanthine/xanthine oxidase mimicked, TNF-alpha-induced I-HERG depression. TNF-alpha caused robust increases in intracellular reactive oxygen species, and vitamin E and MnTBAP abolished the increases, in both HEK293 cells and canine ventricular myocytes. We conclude that the TNF-alpha/TNFR1 system impairs HERG/I-Kr function mainly by stimulating reactive oxygen species, particularly superoxide anion, but not by altering HERG expression; the effect may contribute to APD prolongation by TNF-alpha and may be a novel mechanism for electrophysiological abnormalities and sudden death in CHF.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3A 2T5, Canada	Universite de Montreal; Universite de Montreal; McGill University	Wang, ZG (corresponding author), Montreal Heart Inst, Res Ctr, 5000 Belanger E, Montreal, PQ H1T 1C8, Canada.	wangz@icm.umontreal.ca	Wang, Zhiguo/GRS-4339-2022; Zhang, Yiqiang/D-9613-2012; wang, zhiguo/AAN-4182-2021	Wang, Zhiguo/0000-0002-0811-2045; Zhang, Yiqiang/0000-0003-0691-6645; Nattel, Stanley/0000-0002-5565-3311				Anker SD, 1998, QJM-MON J ASSOC PHYS, V91, P199, DOI 10.1093/qjmed/91.3.199; Aukrust P, 1999, AM J CARDIOL, V83, P376, DOI 10.1016/S0002-9149(98)00872-8; BEUCKELMANN DJ, 1993, CIRC RES, V73, P379, DOI 10.1161/01.RES.73.2.379; Byrne JA, 2003, ARCH MAL COEUR VAISS, V96, P214; Choudhary Gaurav, 2002, Congest Heart Fail, V8, P148, DOI 10.1111/j.1527-5299.2002.00716.x; Deswal A, 2001, CIRCULATION, V103, P2055; ESCANDE D, 1987, AM J PHYSIOL, V252, pH142, DOI 10.1152/ajpheart.1987.252.1.H142; FERRARI R, 1995, CIRCULATION, V92, P1479, DOI 10.1161/01.CIR.92.6.1479; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; LEE JH, 1994, J CARDIOVASC ELECTR, V5, P232, DOI 10.1111/j.1540-8167.1994.tb01160.x; Liu L, 1999, INT J CARDIOL, V69, P77, DOI 10.1016/S0167-5273(99)00008-X; Lodge NJ, 1997, J MOL CELL CARDIOL, V29, P3211, DOI 10.1006/jmcc.1997.0548; London B, 2003, AM J PHYSIOL-HEART C, V284, pH431, DOI 10.1152/ajpheart.00431.2002; Marban E, 2002, NATURE, V415, P213, DOI 10.1038/415213a; McTiernan C F, 2000, Curr Cardiol Rep, V2, P189, DOI 10.1007/s11886-000-0068-4; NABAUER M, 1993, CIRC RES, V73, P386, DOI 10.1161/01.RES.73.2.386; Nuss HB, 1999, AM J PHYSIOL-HEART C, V277, pH80, DOI 10.1152/ajpheart.1999.277.1.H80; Nygren A, 1998, CIRC RES, V82, P63; Priebe L, 1998, CIRC RES, V82, P1206, DOI 10.1161/01.RES.82.11.1206; Shi H, 1999, MOL PHARMACOL, V55, P497; Suematsu N, 2003, CIRCULATION, V107, P1418, DOI 10.1161/01.CIR.0000055318.09997.1F; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; Tsuji Y, 2000, CARDIOVASC RES, V48, P300, DOI 10.1016/S0008-6363(00)00180-2; WANG H, 2003, CANCER RES, V62, P4843; Wang JX, 2001, CIRCULATION, V104, P2645, DOI 10.1161/hc4701.100513; Yue LX, 1996, AM J PHYSIOL-HEART C, V270, pH2157, DOI 10.1152/ajpheart.1996.270.6.H2157; Zhang YQ, 2003, J BIOL CHEM, V278, P10417, DOI 10.1074/jbc.M211044200; Zhang YQ, 2003, FEBS LETT, V534, P125, DOI 10.1016/S0014-5793(02)03804-8; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3	29	116	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13289	13292		10.1074/jbc.C400025200	http://dx.doi.org/10.1074/jbc.C400025200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14973143	hybrid			2022-12-27	WOS:000220478500002
J	Ahn, YO; Mizutani, M; Saino, H; Sakata, K				Ahn, YO; Mizutani, M; Saino, H; Sakata, K			Furcatin hydrolase from Viburnum furcatum blume is a novel disaccharide-specific acuminosidase in glycosyl hydrolase family 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOGENIC BETA-GLUCOSIDASE; AGLYCONE SPECIFICITY; AROMA FORMATION; WHITE CLOVER; KEY ENZYME; PRIMEVEROSIDASE; GLYCOSIDASE; LEAVES; PURIFICATION; EXPRESSION	Furcatin hydrolase (FH) is a unique disaccharide-specific acuminosidase, which hydrolyzes furcatin(p-allylphenyl 6-O-beta-D-apiofuranosyl-beta-D-glucopyranoside (acuminoside)) into p-allylphenol and the disaccharide acuminose. We have isolated a cDNA coding for FH from Viburnum furcatum leaves. The open reading frame in the cDNA encoded a 538-amino acid polypeptide including a putative chloroplast transit peptide. The deduced protein showed 64% identity with tea leaf beta-primeverosidase, which is another disaccharide glycosidase specific to beta-primeverosides (6-O-beta-D-xylopyranosyl-beta-D-glucopyranosides). The deduced FH also shared greater than 50% identity with various plant beta-glucosidases in glycosyl hydrolase family 1. The recombinant FH expressed in Escherichia coli exhibited the highest level of activity toward furcatin with a K-m value of 2.2 mM and specifically hydrolyzed the beta-glycosidic bond between p-allylphenol and acuminose, confirming FH as a disaccharide glycosidase. The FH also hydrolyzed beta-primeverosides and beta-vicianoside (6-O-alpha-L-arabinopyranosyl-beta-D-glucopyranoside) but poorly hydrolyzed beta-gentiobiosides (6-O-beta-D-glucopyranosyl-beta-D-glucopyranosides), indicating high substrate specificity for the disaccharide glycone moiety. The FH exhibited activity toward p-allylphenyl beta-D-glucopyranoside containing the same aglycone as furcatin but little activity toward the other beta-D-glucopyranosides. Stereochemical analysis using H-1 NMR spectroscopy revealed that FH is a retaining glycosidase. The subcellular localization of FH was analyzed using green fluorescent protein fused with the putative N-terminal signal peptide, indicating that FH is localized to the chloroplast. Phylogenetic analysis of plant beta-glucosidases revealed that FH clusters with beta-primeverosidase, and this suggests that the disaccharide glycosidases will form a new subfamily in glycosyl hydrolase family 1.	Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan	Kyoto University	Mizutani, M (corresponding author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.	mizutani@scl.kyoto-u.ac.jp		Mizutani, Masaharu/0000-0002-4321-0644				Adachi J., 1996, MOLPHY PROGRAMS MOL; BARRETT T, 1995, STRUCTURE, V3, P951, DOI 10.1016/S0969-2126(01)00229-5; Bones AM, 1996, PHYSIOL PLANTARUM, V97, P194, DOI [10.1034/j.1399-3054.1996.970128.x, 10.1111/j.1399-3054.1996.tb00497.x]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; Chang S. J., 1993, Plant Molecular Biology Reporter, V11, P113, DOI 10.1007/BF02670468; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Cicek M, 1999, BIOTECHNOL BIOENG, V63, P392, DOI 10.1002/(SICI)1097-0290(19990520)63:4&lt;392::AID-BIT2&gt;3.0.CO;2-M; Cicek M, 2000, J BIOL CHEM, V275, P20002, DOI 10.1074/jbc.M001609200; DUBE S, 1989, CAN J BOT, V67, P2085, DOI 10.1139/b89-264; EVANS PH, 1984, J AGR FOOD CHEM, V32, P1254, DOI 10.1021/jf00126a011; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Frangne N, 2002, PLANT PHYSIOL, V128, P726, DOI 10.1104/pp.010590; Gunata Z, 1998, J AGR FOOD CHEM, V46, P2748, DOI 10.1021/jf980084j; HASE T, 1982, B CHEM SOC JPN, V55, P3663, DOI 10.1246/bcsj.55.3663; HATTORI S, 1959, J AM CHEM SOC, V81, P4424, DOI 10.1021/ja01525a079; HUGHES MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P273, DOI 10.1016/0003-9861(92)90518-2; IMASEKI H, 1961, ARCH BIOCHEM BIOPHYS, V92, P467, DOI 10.1016/0003-9861(61)90386-1; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KASAI T, 1981, Kagawa Daigaku Nogakubu Gakujutsu Hokoku, V32, P111; LI CP, 1992, PLANT PHYSIOL, V100, P282, DOI 10.1104/pp.100.1.282; LIZOTTE PA, 1988, PLANT PHYSIOL, V86; Ly TN, 2002, J AGR FOOD CHEM, V50, P4919, DOI 10.1021/jf025529p; Ma SJ, 2001, BIOSCI BIOTECH BIOCH, V65, P2719, DOI 10.1271/bbb.65.2719; Matsushima R, 2003, PLANT J, V33, P493, DOI 10.1046/j.1365-313X.2003.01636.x; Minami Y, 1999, PLANT SCI, V142, P219, DOI 10.1016/S0168-9452(99)00015-1; Mizutani M, 2002, PLANT PHYSIOL, V130, P2164, DOI 10.1104/pp.102.011023; Ogawa K, 1997, J AGR FOOD CHEM, V45, P877, DOI 10.1021/jf960543l; OHIGASHI H, 1976, AGR BIOL CHEM TOKYO, V40, P2283, DOI 10.1080/00021369.1976.10862375; OXTOBY E, 1991, PLANT MOL BIOL, V17, P209, DOI 10.1007/BF00039495; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PLOUVIER V, 1980, CR ACAD SCI D NAT, V290, P1071; POULTON JE, 1990, PLANT PHYSIOL, V94, P401, DOI 10.1104/pp.94.2.401; Rask L, 2000, PLANT MOL BIOL, V42, P93, DOI 10.1023/A:1006380021658; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKATA K, 2000, CAFFEINATED BEVERAGE, P327; Stotz HU, 2000, PLANT PHYSIOL, V124, P1007, DOI 10.1104/pp.124.3.1007; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van de Ven WTG, 2000, PLANT CELL, V12, P1409, DOI 10.1105/tpc.12.8.1409; Verdoucq L, 2003, J BIOL CHEM, V278, P25055, DOI 10.1074/jbc.M301978200; Wirth J, 2001, J AGR FOOD CHEM, V49, P2917, DOI 10.1021/jf001398l; Wong AW, 1998, J BIOL CHEM, V273, P34057, DOI 10.1074/jbc.273.51.34057; Yamamoto S, 2002, BIOSCI BIOTECH BIOCH, V66, P801, DOI 10.1271/bbb.66.801; YASUDA T, 1994, PHYTOCHEMISTRY, V37, P133, DOI 10.1016/0031-9422(94)85012-7; YOSHIZAWA Y, 1993, BIOSCI BIOTECH BIOCH, V57, P1572, DOI 10.1271/bbb.57.1572; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zhanaeva TA, 1998, RUSS J PLANT PHYSL+, V45, P63; Zhou JM, 2002, PLANT PHYSIOL, V129, P1252, DOI 10.1104/pp.010863	51	21	23	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23405	23414		10.1074/jbc.M311379200	http://dx.doi.org/10.1074/jbc.M311379200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	14976214	hybrid			2022-12-27	WOS:000221570900076
J	Coskun, U; Radermacher, M; Muller, V; Ruiz, T; Gruber, G				Coskun, U; Radermacher, M; Muller, V; Ruiz, T; Gruber, G			Three-dimensional organization of the archaeal A(1)-ATPase from Methanosarcina mazei Go1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; A(1) ATPASE; EVOLUTION; SUBUNIT; BINDING; V-1	A modified isolation procedure provides a homogeneous A(1)- ATPase from the archaeon Methanosarcina mazei Go1, containing the five subunits in stoichiometric amounts of A(3): B-3: C: D: F. A(1) obtained in this way was characterized by three- dimensional electron microscopy of single particles, resulting in the first three- dimensional reconstruction of an A(1)- ATPase at a resolution of 3.2 nm. The A(1) consists of a headpiece of 10.2 nm in diameter and 10.8 nm in height, formed by the six elongated subunits A(3) and B-3. At the bottom of the A(3)B(3) complex, a stalk of 3.0 nm in length can be seen. The A(3)B(3) domain surrounds a large cavity that extends throughout the length of the A(3)B(3) barrel. A part of the stalk penetrates inside this cavity and is displaced toward an A- B- A triplet. To investigate further the topology of the stalk subunits C - F in A(1), cross- linking has been carried out by using dithiobis[ sulfosuccinimidyl-propionate] ( DSP) and 1- ethyl- 3-( dimethylaminopropyl)carbodiimide ( EDC). In experiments where DSP was added the cross- linked products B- F, A(x)- D, A- B- D, and A(x)- B-x- D were formed. Subunits B- F, A- D, A- B- D, and A- B- C- D could be cross- linked by EDC. The subunit- subunit interaction in the presence of DSP was also studied as a function of nucleotide binding, demonstrating movements of subunits C, D, and F during ATP cleavage. Finally, the three- dimensional organization of this A(1) complex is discussed in terms of the relationship to the F-1- and V-1- ATPases at a resolution of 3.2 nm.	Univ Saarland, Fachrichtung Biophys 2 5, D-66421 Homburg, Germany; Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA; Univ Munich, Dept Dept Biol 1, Microbiol Sect, D-80638 Munich, Germany	Saarland University; University of Vermont; University of Munich	Gruber, G (corresponding author), Univ Saarland, Fachrichtung Biophys 2 5, Univ Bau 76, D-66421 Homburg, Germany.	ggrueber@uniklinik-saarland.de	Mueller, Volker/ABE-4305-2021; Coskun, Ünal/F-4683-2011	Mueller, Volker/0000-0001-7955-5508; Coskun, Ünal/0000-0003-4375-3144				AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; Coskun U, 2002, J BIOL CHEM, V277, P17327, DOI 10.1074/jbc.M110407200; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Gruber G, 2001, J EXP BIOL, V204, P2597; Gruber G, 2001, BIOCHEMISTRY-US, V40, P1890, DOI 10.1021/bi002195t; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; Gruber G, 2000, J BIOENERG BIOMEMBR, V32, P341, DOI 10.1023/A:1005519801891; Hilario E, 1998, J MOL EVOL, V46, P703, DOI 10.1007/PL00006351; IHARA K, 1992, J EXP BIOL, V172, P475; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; KOHONEN T, 1990, P IEEE, V78, P1464, DOI 10.1109/5.58325; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemker T, 2003, FEBS LETT, V544, P206, DOI 10.1016/S0014-5793(03)00496-4; Lemker T, 2001, EUR J BIOCHEM, V268, P3744, DOI 10.1046/j.1432-1327.2001.02284.x; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marin I, 2001, J MOL EVOL, V52, P17, DOI 10.1007/s002390010130; Muller V, 2004, J BIOENERG BIOMEMBR, V36, P115, DOI 10.1023/B:JOBB.0000019603.68282.04; Muller V, 2003, CELL MOL LIFE SCI, V60, P474, DOI 10.1007/s000180300040; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Radermacher M, 2001, J STRUCT BIOL, V135, P26, DOI 10.1006/jsbi.2001.4395; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Svergun DI, 1998, BIOCHEMISTRY-US, V37, P17659, DOI 10.1021/bi982367a; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	28	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22759	22764		10.1074/jbc.M313741200	http://dx.doi.org/10.1074/jbc.M313741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14988401	hybrid			2022-12-27	WOS:000221417100127
J	Nesbit, MA; Bowl, MR; Harding, B; Ali, A; Ayala, A; Crowe, C; Dobbie, A; Hampson, G; Holdaway, I; Levine, MA; McWilliams, R; Rigden, S; Sampson, J; Williams, AJ; Thakker, RV				Nesbit, MA; Bowl, MR; Harding, B; Ali, A; Ayala, A; Crowe, C; Dobbie, A; Hampson, G; Holdaway, I; Levine, MA; McWilliams, R; Rigden, S; Sampson, J; Williams, AJ; Thakker, RV			Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; ZINC-FINGER PROTEIN; X-LINKED THROMBOCYTOPENIA; DNA-BINDING DOMAIN; 2-HYBRID SYSTEM; SENSORINEURAL DEAFNESS; NUCLEAR-LOCALIZATION; EMBRYONIC EXPRESSION; GENE-EXPRESSION; COFACTOR	The hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome is an autosomal dominant disorder caused by mutations of the dual zinc finger transcription factor, GATA3. The C-terminal zinc finger (ZnF2) binds DNA, whereas the N-terminal finger (ZnF1) stabilizes this DNA binding and interacts with other zinc finger proteins, such as the Friends of GATA ( FOG). We have investigated seven HDR probands and their families for GATA3 abnormalities and have identified two nonsense mutations (Glu-228 --> Stop and Arg- 367 --> Stop); two intragenic deletions that result in frameshifts from codons 201 and 355 with premature terminations at codons 205 and 370, respectively; one acceptor splice site mutation that leads to a frameshift from codon 351 and a premature termination at codon 367; and two missense mutations (Cys-318 --> Arg and Asn-320 --> Lys). The functional effects of these mutations, together with a previously reported GATA3 ZnF1 mutation and seven other engineered ZnF1 mutations, were assessed by electrophoretic mobility shift, dissociation, yeast two-hybrid and glutathione S-transferase pull-down assays. Mutations involving GATA3 ZnF2 or adjacent basic amino acids resulted in a loss of DNA binding, but those of ZnF1 either lead to a loss of interaction with specific FOG2 ZnFs or altered DNA-binding affinity. These findings are consistent with the proposed three-dimensional model of ZnF1, which has separate DNA and protein binding surfaces. Thus, our results, which expand the spectrum of HDR-associated GATA3 mutations and report the first acceptor splice site mutation, help to elucidate the molecular mechanisms that alter the function of this zinc finger transcription factor and its role in causing this developmental anomaly.	Univ Oxford, Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Nuffield Dept Med,Acad Endocrine Unit, Oxford OX3 7LJ, England; NIH, Pediat & Reprod Endocrinol Branch, Bethesda, MD 20892 USA; Metrohlth Med Ctr, Dept Pediat, Div Genet, Cleveland, OH 44109 USA; Churchill Hosp, Dept Clin Genet, Oxford OX3 7L3, England; Guys Kings Coll &St Thomas Hosp Med & Dent Sch, Dept Chem Pathol, London SE1 7EH, England; Auckland Hosp, Dept Endocrinol, Auckland, New Zealand; Cleveland Clin, Childrens Hosp, Dept Pediat Oncol, Cleveland, OH 44195 USA; Mayo Clin & Mayo Fdn, Div Hematol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Oncol, Rochester, MN 55905 USA; Guys Hosp, Paediat Renal Unit, London SE1 9RT, England; Univ Wales Coll Med, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales; Morriston Hosp, Dept Nephrol, Swansea SA6 6NL, W Glam, Wales	University of Oxford; National Institutes of Health (NIH) - USA; MetroHealth System; University of London; King's College London; Auckland City Hospital; Cleveland Clinic Foundation; Mayo Clinic; Mayo Clinic; Guy's & St Thomas' NHS Foundation Trust; Cardiff University; Morriston Hospital	Thakker, RV (corresponding author), Univ Oxford, Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Nuffield Dept Med,Acad Endocrine Unit, Oxford OX3 7LJ, England.	rajesh.thakker@ndm.ox.ac.uk		Levine, Michael/0000-0003-0036-7809; Bowl, Michael/0000-0001-7971-445X; Thakker, Rajesh/0000-0002-1438-3220				Alimov AP, 2003, ENDOCRINOLOGY, V144, P3138, DOI 10.1210/en.2003-0119; BILOUS RW, 1992, NEW ENGL J MED, V327, P1069, DOI 10.1056/NEJM199210083271506; Blokzijl A, 2002, CURR BIOL, V12, P35, DOI 10.1016/S0960-9822(01)00623-6; Burset M, 2001, NUCLEIC ACIDS RES, V29, P255, DOI 10.1093/nar/29.1.255; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Debacker C, 1999, MECH DEVELOP, V85, P183, DOI 10.1016/S0925-4773(99)00088-X; Fossett N, 2000, P NATL ACAD SCI USA, V97, P7348, DOI 10.1073/pnas.97.13.7348; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Freson K, 2002, HUM MOL GENET, V11, P147, DOI 10.1093/hmg/11.2.147; Fujimoto S, 1999, AM J MED GENET, V86, P427, DOI 10.1002/(SICI)1096-8628(19991029)86:5<427::AID-AJMG6>3.0.CO;2-I; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Hasegawa T, 1997, AM J MED GENET, V73, P416, DOI 10.1002/(SICI)1096-8628(19971231)73:4<416::AID-AJMG9>3.0.CO;2-L; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Louvet O, 1997, BIOTECHNIQUES, V23, P816, DOI 10.2144/97235bm11; Mehaffey MG, 2001, BLOOD, V98, P2681, DOI 10.1182/blood.V98.9.2681; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Muroya K, 2001, J MED GENET, V38, P374, DOI 10.1136/jmg.38.6.374; NEWTON CR, 1989, LANCET, V2, P1481; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; ORKIN SH, 1992, BLOOD, V80, P575; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; Oxburgh L, 2002, MECH DEVELOP, V112, P207, DOI 10.1016/S0925-4773(01)00648-7; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; Pehlivan T, 1999, AM J MED GENET, V83, P201, DOI 10.1002/(SICI)1096-8628(19990319)83:3<201::AID-AJMG11>3.0.CO;2-V; PERNG GS, 1988, ANAL BIOCHEM, V173, P387, DOI 10.1016/0003-2697(88)90204-7; Quadrini KJ, 2002, J BIOL CHEM, V277, P32243, DOI 10.1074/jbc.M205677200; ROYERPOKORA B, 1995, ONCOGENE, V10, P1353; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Takahashi S, 2000, BLOOD, V96, P910, DOI 10.1182/blood.V96.3.910.015k29_910_916; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; THAKKER RV, 1989, NEW ENGL J MED, V321, P218, DOI 10.1056/NEJM198907273210403; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; Tsai FY, 1998, DEV BIOL, V196, P218, DOI 10.1006/dbio.1997.8842; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Uchida S, 1997, BIOCHEM BIOPH RES CO, V232, P65, DOI 10.1006/bbrc.1997.6236; Van Esch H, 1999, CLIN GENET, V55, P269, DOI 10.1034/j.1399-0004.1999.550410.x; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; WEISS MJ, 1995, EXP HEMATOL, V23, P99; YANG HY, 1995, MOL CELL BIOL, V15, P1353; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201; Yu CN, 2002, BLOOD, V100, P2040, DOI 10.1182/blood-2002-02-0387	63	116	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22624	22634		10.1074/jbc.M401797200	http://dx.doi.org/10.1074/jbc.M401797200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14985365	hybrid			2022-12-27	WOS:000221417100114
J	Okeley, NM; Gelb, MH				Okeley, NM; Gelb, MH			A designed probe for acidic phospholipids reveals the unique enriched anionic character of the cytosolic face of the mammalian plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C2 DOMAIN; K-RAS; ELECTROSTATIC INTERACTION; NUCLEAR-ENVELOPE; BINDING DOMAIN; HIGH-AFFINITY; A(2); PROTEIN; CELLS; TRANSLOCATION	It is generally accepted that the cytosolic face of the plasma membrane of mammalian cells is enriched in acidic phospholipids due to an asymmetric distribution of neutral and anionic phospholipids in the two bilayer leaflets. However, the phospholipid asymmetry across intracellular membranes is not known. Two models have been proposed for the selective targeting of K- Ras4B, which contains a C- terminal farnesyl cysteine methyl ester adjacent to a polybasic peptide segment, to the cytosolic face of the plasma membrane. One involves electrostatic interaction of the lipidated polybasic domain with anionic phospholipids in the plasma membrane, and the other involves binding of K- Ras4B to a specific protein receptor. To address this issue, we prepared by semi- synthesis a green fluorescent protein variant that is linked to a farnesylated, polybasic peptide corresponding to the K- Ras4B C terminus as well as a variant that contains an all- D amino acid version of the K- Ras4B peptide. As expected based on electrostatics, both constructs showed preferential in vitro binding to anionic phospholipid vesicles versus those composed only of zwitterionic phospholipid. Both constructs fully targeted to the plasma membrane when microinjected into live Chinese hamster ovary and Madin- Darby canine kidney cells. Because the all- D amino acid peptide should be devoid of binding affinity to a putative highly specific K- Ras membrane receptor, these results support an electrostatic basis for the targeting of K- Ras4B to the plasma membrane, and they support an intracellular landscape of phospholipids in which the cytosolic face of the plasma membrane is the most enriched in acidic phospholipids.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.	gelb@chem.washington.edu		gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL50040, HL71405] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bruckheimer EM, 1996, J LEUKOCYTE BIOL, V59, P784, DOI 10.1002/jlb.59.6.784; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Chiang CF, 2001, ARCH BIOCHEM BIOPHYS, V394, P229, DOI 10.1006/abbi.2001.2537; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Diaz C, 1996, J MEMBRANE BIOL, V151, P1, DOI 10.1007/s002329900051; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ETEMADI AH, 1980, BIOCHIM BIOPHYS ACTA, V604, P423; Gerber SH, 2001, J BIOL CHEM, V276, P32288, DOI 10.1074/jbc.C100108200; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; GLOUSHANKOVA NA, 1994, P NATL ACAD SCI USA, V91, P8597, DOI 10.1073/pnas.91.18.8597; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Hofemeister H, 2000, MOL BIOL CELL, V11, P3233, DOI 10.1091/mbc.11.9.3233; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; Jansen B, 1999, P NATL ACAD SCI USA, V96, P14019, DOI 10.1073/pnas.96.24.14019; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PLETJUSHKINA OJ, 1994, EXP CELL RES, V212, P201, DOI 10.1006/excr.1994.1135; Pomorski T, 2001, SEMIN CELL DEV BIOL, V12, P139, DOI 10.1006/scdb.2000.0231; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; XUE CB, 1992, TETRAHEDRON LETT, V33, P1435, DOI 10.1016/S0040-4039(00)91640-X; Yakhnin AV, 1998, PROTEIN EXPRES PURIF, V14, P382, DOI 10.1006/prep.1998.0981; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	52	38	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21833	21840		10.1074/jbc.M313469200	http://dx.doi.org/10.1074/jbc.M313469200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007075	hybrid			2022-12-27	WOS:000221417100021
J	Filippova, N; Wotring, VE; Weiss, DS				Filippova, N; Wotring, VE; Weiss, DS			Evidence that the TM1-TM2 loop contributes to the rho 1 GABA receptor pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; SINGLE-CHANNEL CONDUCTANCE; MEMBRANE-SPANNING SEGMENT; CONSERVED M2 LEUCINE; GATED ION CHANNELS; GLYCINE RECEPTOR; NONCOMPETITIVE ANTAGONIST; CYSTEINE-SUBSTITUTION; FUNCTIONAL EXPRESSION; LINING RESIDUES	Considerable evidence indicates the second transmembrane domain (TM2) of the gamma-aminobutyric acid (GABA) receptor lines the integral ion pore. To further delineate the structures that constitute the ion pore and selectivity filter of the rho1 GABA receptor, we used the substituted cysteine accessibility method with charged reagents to identify anion- and cation-accessible surfaces. Twenty-one consecutive residues were mutated to cysteine, one at a time, in the presumed intracellular end of the first transmembrane domain (TM1; Ala(271)-Met(276)), the entire linker connecting TM1 to TM2 (Leu(277)- Arg(287)), and the presumed intracellular end of TM2 (Ala(288)-Ala(291)). Positively (MTSEA(+)) and negatively (pCMBS(-)) charged sulfhydryl reagents, as well as Cd2+, were added extracellularly to test accessibility of the engineered cysteines. Four of the mutants, all at the intracellular end of TM2 (R287C, V289C, P290C, A291C), were accessible to positively charged reagents, whereas seven mutants (A271C, T272C, L277C, W279C, V280C, P290C, A291C) were functionally modified by negatively charged pCMBS(-). These seven modified residues were at the intracellular end of TM2, in the TM1-TM2 linker, and at the intracellular end of TM1. In nearly all cases ( excluding P290C), the rate and the degree of modification were state-dependent, with greater accessibility in the presence of agonist. Select cysteine mutants were combined with a point mutation (A291E) that converted the pore from chloride- to non-selective. In this case, positively charged reagents could modify residues in the TM1-TM2 linker (Leu(277) and Val(280)), supporting the notion that the modifying reagents were reaching their target through the pore. Taken together, our results suggest that, up to its intracellular end, the TM2 domain is not charge selective. In addition, we propose that the TM1-TM2 linker and the intracellular end of TM1 are along the pathway of the permeating ion. These findings may lend new insights into the structure of the GABA receptor pore.	Univ Alabama, Sch Med, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Weiss, DS (corresponding author), Univ Alabama, Sch Med, Dept Neurobiol, 1719 6th Ave So CIRC410, Birmingham, AL 35294 USA.	dweiss@nrc.uab.edu		Filippova, Natalia/0000-0003-2128-5511; Wotring, Virginia/0000-0002-3391-3899				AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMIN J, 1994, MOL PHARMACOL, V45, P317; AMIN J, 1994, RECEPTOR CHANNEL, V2, P227; Bertaccini E, 2002, PROTEIN ENG, V15, P443, DOI 10.1093/protein/15.6.443; Chang YC, 1999, BIOPHYS J, V77, P2542, DOI 10.1016/S0006-3495(99)77089-X; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KAMMANN M, 1989, NUCLEIC ACIDS RES, V12, P4445; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; Leite JF, 2002, BIOCHEMISTRY-US, V41, P6140, DOI 10.1021/bi015895m; Leite JF, 2001, MOL CELL NEUROSCI, V17, P777, DOI 10.1006/mcne.2001.0984; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Wotring VE, 2003, J PHYSIOL-LONDON, V548, P527, DOI 10.1113/jphysiol.2002.032045; Wotring VE, 1999, J PHYSIOL-LONDON, V521, P327, DOI 10.1111/j.1469-7793.1999.00327.x; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195	38	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20906	20914		10.1074/jbc.M401012200	http://dx.doi.org/10.1074/jbc.M401012200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15007065	hybrid			2022-12-27	WOS:000221273800043
J	Narizhneva, NV; Byers-Ward, VJ; Quinn, MJ; Zidar, FJ; Plow, EF; Topol, EJ; Byzova, TV				Narizhneva, NV; Byers-Ward, VJ; Quinn, MJ; Zidar, FJ; Plow, EF; Topol, EJ; Byzova, TV			Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN E-DEFICIENT; HUMAN-PLATELETS; RECEPTOR; EXPRESSION; FIBRINOGEN; INHIBITION; THROMBIN; BINDING; GENE; GLYCOPROTEIN	A serine (Ser-700) amino acid rather than an asparagine (Asn-700) at residue 700 of thrombospondin-1 has been linked to an increased risk for development of premature, familial heart attacks. We now have identified both functional and structural differences between the Ser-700 and Asn-700 thrombospondin-1 variants. The Ser-700 variant increased the rate and extent of platelet aggregation and showed increased surface expression on platelets compared with the Asn-700 variant. These differences could be ascribed to an enhanced interaction of the Ser-700 variant with fibrinogen on the platelet surface and are consistent with a prothrombotic phenotype in Ser-700 individuals. The Ser-700 variant thrombospondin-1 was conformationally more labile than the Asn-700 variant as demonstrated by increased susceptibility to proteolytic digestion and enhanced susceptibility to unfolding by denaturants. These data suggest a potential molecular and cellular basis for a genetic risk factor associated with early onset myocardial infarction.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Topol, EJ (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	topole@ccf.org		Byzova, Tatiana/0000-0002-2615-875X; Topol, Eric/0000-0002-1478-4729	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071625] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071625, HL 071625] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 1997, INT J BIOCHEM CELL B, V29, P861, DOI 10.1016/S1357-2725(96)00171-9; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Adler A J, 1973, Methods Enzymol, V27, P675; AIKEN ML, 1987, BLOOD, V69, P58; AIKEN ML, 1987, SEMIN THROMB HEMOST, V13, P307, DOI 10.1055/s-2007-1003506; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Boekholdt SM, 2002, ARTERIOSCL THROM VAS, V22, pE24, DOI 10.1161/01.ATV.0000046235.22451.66; Bonnefoy A, 2001, J BIOL CHEM, V276, P5605, DOI 10.1074/jbc.M010091200; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Calara F, 2001, J PATHOL, V195, P257, DOI 10.1002/path.915; CASTELLINO FJ, 1993, METHOD ENZYMOL, V223, P168; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; HAGEN I, 1975, BIOCHIM BIOPHYS ACTA, V392, P242, DOI 10.1016/0304-4165(75)90006-9; Hang LW, 2003, J CLIN LAB ANAL, V17, P57, DOI 10.1002/jcla.10068; Hannah BLA, 2003, J BIOL CHEM, V278, P8929, DOI 10.1074/jbc.M211185200; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; LAWLER J, 1985, J BIOL CHEM, V260, P3762; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER JW, 1977, THROMB HAEMOSTASIS, V37, P355; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LEGRAND C, 1992, BLOOD, V79, P1995; LEGRAND C, 1994, ARTERIOSCLER THROMB, V14, P1784, DOI 10.1161/01.ATV.14.11.1784; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; MOSHER DF, 1990, ANNU REV MED, V41, P85; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Peyvandi F, 2003, BLOOD, V102, p801A; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; Riessen R, 1998, AM HEART J, V135, P357, DOI 10.1016/S0002-8703(98)70105-X; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; Takeoka S, 2001, J HUM GENET, V46, P57, DOI 10.1007/s100380170109; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; WOLFF R, 1986, J BIOL CHEM, V261, P6840; YAMADA Y, 2004, NEW ENGL J MED, V347, P1916	49	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21651	21657		10.1074/jbc.M311090200	http://dx.doi.org/10.1074/jbc.M311090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15007078	hybrid, Green Accepted			2022-12-27	WOS:000221273800132
J	Zhang, LZ; Insel, PA				Zhang, LZ; Insel, PA			The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; CYCLIC-AMP; DEPENDENT APOPTOSIS; MICROARRAY ANALYSIS; SIGNALING PATHWAY; BH3-ONLY PROTEIN; GENE-EXPRESSION; RELATIVE BIM; C-MYC; CAMP	The mechanisms by which cAMP mediates apoptosis are not well understood. In the current studies, we used wild-type (WT) S49 T-lymphoma cells and the kin(-) variant (which lacks protein kinase A (PKA)) to examine cAMP/PKA-mediated apoptosis. The cAMP analog, 8-CPT-cAMP, increased phosphorylation of the cAMP response element-binding protein ( CREB), activated caspase-3, and induced apoptosis in WT but not in kin(-) S49 cells. Using an array of 96 apoptosis-related genes, we found that treatment of WT cells with 8-CPT-cAMP for 24 h induced expression of mRNA for the pro-apoptotic gene, Bim. Real-time PCR analysis indicated that 8-CPT-cAMP increased Bim RNA in WT cells in < 2 h and maintained this increase for > 24 h. Bim protein expression increased in WT but not kin(-) cells treated with 8-CPT-cAMP or with the beta-adrenergic receptor agonist isoproterenol. Both apoptosis and Bim expression were reversible with removal of 8-CPT-cAMP after < 6 h. The glucocorticoid dexamethasone also promoted apoptosis and Bim expression in S49 cells. In contrast, both UV light and anti-mouse Fas monoclonal antibody promoted apoptosis in S49 cells but did not induce Bim expression. 8-CPT-cAMP also induced Bim expression and enhanced dexamethasone-promoted apoptosis in human T-cell leukemia CEM-C7-14 (glucocorticoid-sensitive) and CEM-C1-15 (glucocorticoid-resistant) cells; increased Bim expression in 8-CPT-cAMP-treated CEM-C1-15 cells correlated with conversion of the cells from resistance to sensitivity to glucocorticoid-promoted apoptosis. Induction of Bim appears to be a key event in cAMP-promoted apoptosis in both murine and human T-cell lymphoma and leukemia cells and thus appears to be a convergence point for the killing of such cells by glucocorticoids and agents that elevate cAMP.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pinsel@ucsd.edu			NIGMS NIH HHS [R01 GM 61774] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061774] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bouillet P, 2002, J CELL SCI, V115, P1567; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Chang HS, 2000, CELL IMMUNOL, V203, P29, DOI 10.1006/cimm.2000.1668; Coffino P, 1976, Recent Prog Horm Res, V32, P669; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; DOWD DR, 1992, MOL CELL BIOL, V12, P3600, DOI 10.1128/MCB.12.8.3600; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; FARRAR WL, 1987, J IMMUNOL, V139, P2075; GRUOL DJ, 1989, MOL ENDOCRINOL, V3, P2119, DOI 10.1210/mend-3-12-2119; Harris CA, 2001, J BIOL CHEM, V276, P37754; HUGHES FM, 1994, J STEROID BIOCHEM, V49, P303, DOI 10.1016/0960-0760(94)90272-0; INSEL PA, 1975, SCIENCE, V190, P896, DOI 10.1126/science.171770; Krett NL, 1997, CLIN CANCER RES, V3, P1781; Lamb D, 2002, J CELL PHYSIOL, V192, P216, DOI 10.1002/jcp.10131; Lerner A, 2000, LEUKEMIA LYMPHOMA, V37, P39, DOI 10.3109/10428190009057627; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Luo YQ, 2002, J NEUROCHEM, V83, P1481, DOI 10.1046/j.1471-4159.2002.01260.x; Matuszyk J, 2002, INT IMMUNOPHARMACOL, V2, P435, DOI 10.1016/S1567-5769(01)00167-9; MCCONKEY DJ, 1993, FASEB J, V7, P580, DOI 10.1096/fasebj.7.6.8386120; Medh RD, 1998, CANCER RES, V58, P3684; Nakazawa Y, 2003, J BIOL CHEM, V278, P27888, DOI 10.1074/jbc.M300510200; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ogawa R, 2002, BLOOD, V99, P3390, DOI 10.1182/blood.V99.9.3390; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163-7258(00)00051-6; Seward RJ, 2003, MOL IMMUNOL, V39, P983, DOI 10.1016/S0161-5890(03)00047-6; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; STEINBERG RA, 1977, CELL, V10, P381, DOI 10.1016/0092-8674(77)90025-3; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Thompson EB, 1999, J STEROID BIOCHEM, V69, P453, DOI 10.1016/S0960-0760(99)00063-1; Usher LR, 2002, J IMMUNOL, V168, P1861, DOI 10.4049/jimmunol.168.4.1861; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Yan LZ, 2000, AM J PHYSIOL-CELL PH, V279, pC1665, DOI 10.1152/ajpcell.2000.279.5.C1665; Zhang LZ, 2001, AM J PHYSIOL-CELL PH, V281, pC1642, DOI 10.1152/ajpcell.2001.281.5.C1642	44	117	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20858	20865		10.1074/jbc.M310643200	http://dx.doi.org/10.1074/jbc.M310643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14996839	hybrid			2022-12-27	WOS:000221273800037
J	Carrillo, CD; Taboada, E; Nash, JHE; Lanthier, P; Kelly, J; Lau, PC; Verhulp, R; Mykytczuk, O; Sy, J; Findlay, WA; Amoako, K; Gomis, S; Willson, P; Austin, JW; Potter, A; Babiuk, L; Allan, B; Szymanski, CM				Carrillo, CD; Taboada, E; Nash, JHE; Lanthier, P; Kelly, J; Lau, PC; Verhulp, R; Mykytczuk, O; Sy, J; Findlay, WA; Amoako, K; Gomis, S; Willson, P; Austin, JW; Potter, A; Babiuk, L; Allan, B; Szymanski, CM			Genome-wide expression analyses of Campylobacter jejuni NCTC11168 reveals coordinate regulation of motility and virulence by flhA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAGELLAR EXPORT APPARATUS; HELICOBACTER-PYLORI; POSTTRANSLATIONAL MODIFICATION; PSEUDOMONAS-AERUGINOSA; TRANSPOSON MUTAGENESIS; PROMOTER SEQUENCES; EPITHELIAL-CELLS; GENE; PROTEIN; IDENTIFICATION	We examined two variants of the genome-sequenced strain, Campylobacter jejuni NCTC11168, which show marked differences in their virulence properties including colonization of poultry, invasion of Caco-2 cells, and motility. Transcript profiles obtained from whole genome DNA microarrays and proteome analyses demonstrated that these differences are reflected in late flagellar structural components and in virulence factors including those involved in flagellar glycosylation and cytolethal distending toxin production. We identified putative sigma(28) and sigma(54) promoters for many of the affected genes and found that greater differences in expression were observed for sigma(28)-controlled genes. Inactivation of the gene encoding sigma(28), fliA, resulted in an unexpected increase in transcripts with sigma(54) promoters, as well as decreased transcription of sigma(28)-regulated genes. This was unlike the transcription profile observed for the attenuated C. jejuni variant, suggesting that the reduced virulence of this organism was not entirely due to impaired function of sigma(28). However, inactivation of flhA, an important component of the flagellar export apparatus, resulted in expression patterns similar to that of the attenuated variant. These findings indicate that the flagellar regulatory system plays an important role in campylobacter pathogenesis and that flhA is a key element involved in the coordinate regulation of late flagellar genes and of virulence factors in C. jejuni.	Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Saskatchewan, Western Coll Med, Dept Vet Pathol, Saskatoon, SK S7N 5B4, Canada; Hlth Canada, Bur Microbial Hazards, Ottawa, ON K1A 0L2, Canada	University of Saskatchewan; National Research Council Canada; University of Saskatchewan; Health Canada	Allan, B (corresponding author), Vaccine & Infect Dis Org, 120 Vet Rd, Saskatoon, SK S7N 5E3, Canada.	allanb@sask.usask.ca; christine.szymanski@nrc-cnrc.gc.ca	Nash, John HE/P-2384-2017; Taboada, Eduardo N/Y-4854-2018; Carrillo, Catherine/X-2714-2019	Nash, John HE/0000-0003-2925-8710; Taboada, Eduardo N/0000-0001-8373-3653; Carrillo, Catherine/0000-0002-2334-8718; Austin, John/0000-0001-8824-0495; Luu, Rachel/0000-0001-7041-9104				Ahmed IH, 2002, MICROBIOL-SGM, V148, P1203, DOI 10.1099/00221287-148-4-1203; Allos BM, 2001, CLIN INFECT DIS, V32, P1201, DOI 10.1086/319760; Arora SK, 1998, INFECT IMMUN, V66, P1000, DOI 10.1128/IAI.66.3.1000-1007.1998; Barrios H, 1999, NUCLEIC ACIDS RES, V27, P4305, DOI 10.1093/nar/27.22.4305; BLASER MJ, 1984, INFECT IMMUN, V44, P292, DOI 10.1128/IAI.44.2.292-298.1984; CHAN VL, 2003, INT J MED MICROBIOL, V291, P120; Colegio OR, 2001, J BACTERIOL, V183, P2384, DOI 10.1128/JB.183.7.2384-2388.2001; Colland F, 2001, MOL MICROBIOL, V41, P477, DOI 10.1046/j.1365-2958.2001.02537.x; Day WA, 2000, INFECT IMMUN, V68, P6337, DOI 10.1128/IAI.68.11.6337-6345.2000; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; Fleiszig SMJ, 2001, INFECT IMMUN, V69, P4931, DOI 10.1128/IAI.69.8.4931-4937.2001; Fraser GM, 2003, MOL MICROBIOL, V48, P1043, DOI 10.1046/j.1365-2958.2003.03487.x; Ghelardi E, 2002, J BACTERIOL, V184, P6424, DOI 10.1128/JB.184.23.6424-6433.2002; Golden NJ, 2002, INFECT IMMUN, V70, P1761, DOI 10.1128/IAI.70.4.1761-1771.2002; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; GUERRY P, 1991, J BACTERIOL, V173, P4757, DOI 10.1128/jb.173.15.4757-4764.1991; GUERRY P, 1990, J BACTERIOL, V172, P1853, DOI 10.1128/jb.172.4.1853-1860.1990; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; GUERRY P, 1994, METHOD ENZYMOL, V235, P474; GUERRY P, 2000, CAMPYLOBACTER, P405; Hendrixson DR, 2003, MOL MICROBIOL, V50, P687, DOI 10.1046/j.1365-2958.2003.03731.x; Hendrixson DR, 2001, MOL MICROBIOL, V40, P214, DOI 10.1046/j.1365-2958.2001.02376.x; Hickey TE, 2000, INFECT IMMUN, V68, P6535, DOI 10.1128/IAI.68.12.6535-6541.2000; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Jagannathan A, 2001, J BACTERIOL, V183, P2937, DOI 10.1128/JB.183.9.2937-2942.2001; JOHNSON WM, 1987, FEMS MICROBIOL LETT, V43, P19, DOI 10.1111/j.1574-6968.1987.tb02091.x; Josenhans C, 2002, MOL MICROBIOL, V43, P307, DOI 10.1046/j.1365-2958.2002.02765.x; Kim JS, 1999, J BACTERIOL, V181, P6969; Kinsella N, 1997, J BACTERIOL, V179, P4647, DOI 10.1128/jb.179.15.4647-4653.1997; LABIGNEROUSSEL A, 1988, J BACTERIOL, V170, P1704, DOI 10.1128/jb.170.4.1704-1708.1988; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; LEYING H, 1992, MOL MICROBIOL, V6, P2863, DOI 10.1111/j.1365-2958.1992.tb01466.x; Logan SM, 2002, MOL MICROBIOL, V46, P587, DOI 10.1046/j.1365-2958.2002.03185.x; LOGAN SM, 1989, J BACTERIOL, V171, P3031, DOI 10.1128/jb.171.6.3031-3038.1989; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; Mao XQ, 2002, CELL MICROBIOL, V4, P245, DOI 10.1046/j.1462-5822.2002.00186.x; Matz C, 2002, MICROBIOL-SGM, V148, P1679, DOI 10.1099/00221287-148-6-1679; McGee DJ, 2002, J MED MICROBIOL, V51, P958, DOI 10.1099/0022-1317-51-11-958; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; Minamino T, 2000, MOL MICROBIOL, V35, P1052, DOI 10.1046/j.1365-2958.2000.01771.x; NUIJTEN PJM, 1990, J BIOL CHEM, V265, P17798; OELSCHLAEGER TA, 1993, P NATL ACAD SCI USA, V90, P6884, DOI 10.1073/pnas.90.14.6884; On SLW, 1998, EPIDEMIOL INFECT, V120, P231, DOI 10.1017/S0950268898008668; Park SF, 2000, J BACTERIOL, V182, P207, DOI 10.1128/JB.182.1.207-210.2000; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; *PERK ELM APPL BIO, 1997, US B, V2; Petersen L, 2003, J MOL BIOL, V326, P1361, DOI 10.1016/S0022-2836(03)00034-2; Rabaan AA, 2001, INFECT IMMUN, V69, P4257, DOI 10.1128/IAI.69.7.4257-4267.2001; RAMAGLI LS, 1985, ELECTROPHORESIS, V6, P559, DOI 10.1002/elps.1150061109; Schmitz A, 1997, J BACTERIOL, V179, P987, DOI 10.1128/jb.179.4.987-997.1997; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Soutourina OA, 2003, FEMS MICROBIOL REV, V27, P505, DOI 10.1016/S0168-6445(03)00064-0; Spohn G, 1999, J BACTERIOL, V181, P593, DOI 10.1128/JB.181.2.593-599.1999; STERN NJ, 1988, AVIAN DIS, V32, P330, DOI 10.2307/1590822; Szymanski CM, 2003, TRENDS MICROBIOL, V11, P233, DOI 10.1016/S0966-842X(03)00079-9; Szymanski CM, 2002, INFECT IMMUN, V70, P2242, DOI 10.1128/IAI.70.4.2242-2244.2002; SZYMANSKI CM, 1995, INFECT IMMUN, V63, P4295, DOI 10.1128/IAI.63.11.4295-4300.1995; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; WASSENAAR TM, 1994, INFECT IMMUN, V62, P3901, DOI 10.1128/IAI.62.9.3901-3906.1994; Wosten MMSM, 1998, J BACTERIOL, V180, P594; Young GM, 1999, P NATL ACAD SCI USA, V96, P6456, DOI 10.1073/pnas.96.11.6456; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200; Zhu K, 2002, BIOCHEMISTRY-US, V41, P9516, DOI 10.1021/bi0203280	63	157	165	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20327	20338		10.1074/jbc.M401134200	http://dx.doi.org/10.1074/jbc.M401134200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985343	hybrid			2022-12-27	WOS:000221164500110
J	Chandrasekar, B; Vemula, K; Surabhi, RM; Li-Weber, M; Owen-Schaub, LB; Jensen, LE; Mummidi, S				Chandrasekar, B; Vemula, K; Surabhi, RM; Li-Weber, M; Owen-Schaub, LB; Jensen, LE; Mummidi, S			Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FAS-MEDIATED APOPTOSIS; PROINFLAMMATORY CYTOKINE; SMOOTH-MUSCLE; CYTOCHROME-C; NITRIC-OXIDE; TNF-ALPHA; RECEPTOR; IL-18	Endothelial cells are the primary targets of circulating immune and inflammatory mediators. We hypothesize that interleukin-18, a proinflammatory cytokine, induces endothelial cell apoptosis. Human cardiac microvascular endothelial cells (HCMEC) were treated with interleukin (IL) 18. mRNA expression was analyzed by ribonuclease protection assay, protein levels by immunoblotting, and cell death by enzyme-linked immunosorbent assay and fluorescence-activated cell sorter analysis. We also investigated the signal transduction pathways involved in IL18-mediated cell death. Treatment of HCMEC with IL-18 increases 1) NF-kappaB DNA binding activity; 2) induces kappaB-driven luciferase activity; 3) induces IL-1beta and TNF-alpha expression via NF-kappaB activation; 4) inhibits anti-apoptotic Bcl-2 and Bcl-X-L; 5) up-regulates proapoptotic Fas, Fas-L, and Bcl-X-S expression; 6) induces fas and Fas-L promoter activities via NF-kappaB activation; 7) activates caspases-8, -3, -9, and BID; 8) induces cytochrome c release into the cytoplasm; 9) inhibits FLIP; and 10) induces HCME cell death by apoptosis as seen by increased annexin V staining and increased levels of mono- and oligonucleosomal fragmented DNA. Whereas overexpression of Bcl-2 significantly attenuated IL-18-induced endothelial cell apoptosis, Bcl-2/Bcl-X-L chimeric phosphorothioated 2'-MOE-modified antisense oligonucleotides potentiated the proapoptotic effects of IL-18. Furthermore, caspase-8, IKK-alpha, and NF-kappaB p65 knockdown or dominant negative IkappaB-alpha and dominant negative IkappaB-beta or kinase dead IKK-beta significantly attenuated IL-18-induced HCME cell death. Effects of IL-18 on cell death are direct and are not mediated by intermediaries such as IL-1beta, tumor necrosis factor-alpha, or interferon-gamma. Taken together, our results indicate that IL-18 activates both intrinsic and extrinsic proapoptotic signaling pathways, induces endothelial cell death, and thereby may play a role in myocardial inflammation and injury.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA 15213 USA; German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany; Univ Calif Riverside, Dept Biomed Sci, Riverside, CA 92521 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Pharmacogenet, Philadelphia, PA 19104 USA; S Texas Vet Hlth Care Syst, Vet Affairs Ctr HIV & AIDS, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Helmholtz Association; German Cancer Research Center (DKFZ); University of California System; University of California Riverside; University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Chandrasekar, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	chandraseka@uthscsa.edu	Mummidi, Srinivas/C-1004-2008; Mummidi, Srinivas/H-3335-2017	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380; Jensen, Liselotte/0000-0002-0267-8312	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068020] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 68020] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akita K, 1997, J BIOL CHEM, V272, P26595, DOI 10.1074/jbc.272.42.26595; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cain BS, 1999, CRIT CARE MED, V27, P1309, DOI 10.1097/00003246-199907000-00018; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Chandrasekar B, 2003, BIOCHEM J, V373, P547, DOI 10.1042/BJ20030207; Chandrasekar B, 2003, BIOCHEM BIOPH RES CO, V303, P1152, DOI 10.1016/S0006-291X(03)00496-0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Dimmeler S, 1997, CIRC RES, V81, P970; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; Fridovich I, 1998, J EXP BIOL, V201, P1203; Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Guseva NV, 2002, PROSTATE, V51, P231, DOI 10.1002/pros.10095; Hermann C, 1997, ARTERIOSCL THROM VAS, V17, P3588, DOI 10.1161/01.ATV.17.12.3588; Hoshino K, 1999, J IMMUNOL, V162, P5041; Hu RH, 2000, INT J IMMUNOPHARMACO, V22, P445, DOI 10.1016/S0192-0561(00)00009-6; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jensen LE, 2001, J BIOL CHEM, V276, P29037, DOI 10.1074/jbc.M103815200; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kelly RA, 1997, CIRCULATION, V95, P778; Kimura-Shimmyo A, 2002, J IMMUNOTHER, V25, pS42, DOI 10.1097/00002371-200203001-00007; LE JM, 1987, LAB INVEST, V56, P234; Leite-De-Moraes MC, 2000, J IMMUNOL, V165, P4367, DOI 10.4049/jimmunol.165.8.4367; Leung BP, 2001, J IMMUNOL, V167, P2879, DOI 10.4049/jimmunol.167.5.2879; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; LopezCollazo E, 1997, FEBS LETT, V413, P124, DOI 10.1016/S0014-5793(97)00893-4; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Maekawa N, 2002, J AM COLL CARDIOL, V39, P1229, DOI 10.1016/S0735-1097(02)01738-2; Marino E, 2003, CYTOKINE, V22, P142, DOI 10.1016/S1043-4666(03)00150-9; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Matsumoto S, 1997, BIOCHEM BIOPH RES CO, V234, P454, DOI 10.1006/bbrc.1997.6665; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Morel JCM, 2001, LAB INVEST, V81, P1371, DOI 10.1038/labinvest.3780351; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Olee T, 1999, J IMMUNOL, V162, P1096; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Prabhu SD, 2003, J MOL CELL CARDIOL, V35, P483, DOI 10.1016/S0022-2828(03)00052-X; ROBAYE B, 1991, AM J PATHOL, V138, P447; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Wald D, 2001, EUR J IMMUNOL, V31, P3747, DOI 10.1002/1521-4141(200112)31:12<3747::AID-IMMU3747>3.0.CO;2-E; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wigginton JM, 2002, J IMMUNOL, V169, P4467, DOI 10.4049/jimmunol.169.8.4467; Williams FM, 1996, PHARMACOL THERAPEUT, V72, P1, DOI 10.1016/S0163-7258(96)00090-3; Wyman TH, 2002, J LEUKOCYTE BIOL, V72, P401; Youker KA, 1997, ANN NY ACAD SCI, V832, P243, DOI 10.1111/j.1749-6632.1997.tb46252.x; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	68	92	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20221	20233		10.1074/jbc.M313980200	http://dx.doi.org/10.1074/jbc.M313980200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14960579	hybrid			2022-12-27	WOS:000221164500099
J	Hendzel, MJ; Lever, MA; Crawford, E; Th'ng, JPH				Hendzel, MJ; Lever, MA; Crawford, E; Th'ng, JPH			The C-terminal domain is the primary determinant of histone H1 binding to chromatin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; LINKER HISTONES; CAENORHABDITIS-ELEGANS; GLOBULAR DOMAIN; MMTV PROMOTER; DNA; PHOSPHORYLATION; LOCATION; SUBTYPES; CELLS	We have used a combination of kinetic measurements and targeted mutations to show that the C-terminal domain is required for high-affinity binding of histone H1 to chromatin, and phosphorylations can disrupt binding by affecting the secondary structure of the C terminus. By measuring the fluorescence recovery after photo-bleaching profiles of green fluorescent protein-histone H1 proteins in living cells, we find that the deletion of the N terminus only modestly reduces binding affinity. Deletion of the C terminus, however, almost completely eliminates histone H1.1 binding. Specific mutations of the C-terminal domain identified Thr-152 and Ser-183 as novel regulatory switches that control the binding of histone H1.1 in vivo. It is remarkable that the single amino acid substitution of Thr-152 with glutamic acid was almost as effective as the truncation of the C terminus to amino acid 151 in destabilizing histone H1.1 binding in vivo. We found that modifications to the C terminus can affect histone H1 binding dramatically but have little or no influence on the charge distribution or the overall net charge of this domain. A comparison of individual point mutations and deletion mutants, when reviewed collectively, cannot be reconciled with simple charge-dependent mechanisms of C-terminal domain function of linker histones.	Univ Alberta, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; NW Ontario Reg Canc Ctr, Thunder Bay, ON P7B 6V4, Canada	University of Alberta; University of Alberta	Th'ng, JPH (corresponding author), 980 Oliver Rd, Thunder Bay, ON P7B 6V4, Canada.	thngj@tbh.net	Hendzel, Michael/C-3391-2009	Hendzel, Michael/0000-0002-9603-7945				Alami R, 2003, P NATL ACAD SCI USA, V100, P5920, DOI 10.1073/pnas.0736105100; ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; Bharath MMS, 2003, NUCLEIC ACIDS RES, V31, P4264, DOI 10.1093/nar/gkg481; Bharath MMS, 2002, BIOCHEMISTRY-US, V41, P7617, DOI 10.1021/bi025773+; Bharath MMS, 2002, PROTEINS, V49, P71, DOI 10.1002/prot.10204; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Contreras A, 2003, MOL CELL BIOL, V23, P8626, DOI 10.1128/MCB.23.23.8626-8636.2003; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; Dou YL, 2000, MOL CELL, V6, P225, DOI 10.1016/S1097-2765(00)00024-1; Dou YL, 2002, J CELL BIOL, V158, P1161, DOI 10.1083/jcb.200202131; Folco HD, 2003, EUKARYOT CELL, V2, P341, DOI 10.1128/EC.2.2.341-350.2003; Gabrilovich DI, 2002, J LEUKOCYTE BIOL, V72, P285; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; Jedrusik MA, 2003, MOL CELL BIOL, V23, P3681, DOI 10.1128/MCB.23.10.3681-3691.2003; Jedrusik MA, 2001, DEVELOPMENT, V128, P1069; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; Kasinsky HE, 2001, FASEB J, V15, P34, DOI 10.1096/fj.00-0237rev; Koop R, 2003, EMBO J, V22, P588, DOI 10.1093/emboj/cdg052; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Lu X, 2004, J BIOL CHEM, V279, P8701, DOI 10.1074/jbc.M311348200; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; Ponte I, 2003, MOL BIOL EVOL, V20, P371, DOI 10.1093/molbev/msg041; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; Takami Y, 2000, BIOCHEM BIOPH RES CO, V268, P501, DOI 10.1006/bbrc.2000.2172; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; Vignali M, 1998, NAT STRUCT BIOL, V5, P1025, DOI 10.1038/4133; Vila R, 2000, PROTEIN SCI, V9, P627; Vila R, 2002, PROTEIN SCI, V11, P214, DOI 10.1110/ps.29602; Vila R, 2001, J BIOL CHEM, V276, P46429, DOI 10.1074/jbc.M106952200; Vila R, 2001, J BIOL CHEM, V276, P30898, DOI 10.1074/jbc.M104189200	37	177	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20028	20034		10.1074/jbc.M400070200	http://dx.doi.org/10.1074/jbc.M400070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985337	hybrid			2022-12-27	WOS:000221164500078
J	Li, B; Zhuang, L; Trueb, B				Li, B; Zhuang, L; Trueb, B			Zyxin interacts with the SH3 domains of the cytoskeletal proteins LIM-nebulette and Lasp-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTININ; NEBULIN; BINDING; GENE; MUSCLE; IDENTIFICATION; LOCALIZATION; MYOPALLADIN; RECOGNITION; COMPLEXITY	Zyxin is a versatile component of focal adhesions in eukaryotic cells. Here we describe a novel binding partner of zyxin, which we have named LIM-nebulette. LIM-nebulette is an alternative splice variant of the sarcomeric protein nebulette, which, in contrast to nebulette, is expressed in non-muscle cells. It displays a modular structure with an N-terminal LIM domain, three nebulin-like repeats, and a C-terminal SH3 domain and shows high similarity to another cytoskeletal protein, Lasp-1 (LIM and SH3 protein-1). Co-precipitation studies and results obtained with the two-hybrid system demonstrate that LIM-nebulette and Lasp-1 interact specifically with zyxin. Moreover, the SH3 domain from LIM-nebulette is both necessary and sufficient for zyxin binding. The SH3 domains from Lasp-1 and nebulin can also interact with zyxin, but the SH3 domains from more distantly related proteins such as vinexin and sorting nexin 9 do not. On the other hand, the binding site in zyxin is situated at the extreme N terminus as shown by site-directed mutagenesis. LIM-nebulette and Lasp-1 use the same linear binding motif. This motif shows some similarity to a class II binding site but does not contain the classical PXXP sequence. LIM-nebulette reveals a subcellular distribution at focal adhesions similar to Lasp-1. Thus, LIM-nebulette, Lasp-1, and zyxin may play an important role in the organization of focal adhesions.	Univ Bern, ITI Res Inst, CH-3010 Bern, Switzerland	University of Bern	Trueb, B (corresponding author), Univ Bern, ITI Res Inst, POB 54, CH-3010 Bern, Switzerland.	beat.trueb@iti.unibe.ch	Trueb, Beat/AAL-9621-2020	Trueb, Beat/0000-0001-8684-6856				Arimura T, 2000, HUM GENET, V107, P440, DOI 10.1007/s004390000389; Bang ML, 2001, J CELL BIOL, V153, P413, DOI 10.1083/jcb.153.2.413; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Butt E, 2003, J BIOL CHEM, V278, P15601, DOI 10.1074/jbc.M209009200; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Chew CS, 2000, J CELL SCI, V113, P2035; Chew CS, 2002, J CELL SCI, V115, P4787, DOI 10.1242/jcs.00174; Costa G L, 1996, Methods Mol Biol, V57, P239; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hobert O, 1996, ONCOGENE, V12, P1577; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Katoh M, 2003, INT J MOL MED, V12, P405; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; Li B, 2003, J CELL SCI, V116, P1359, DOI 10.1242/jcs.00309; Li B, 2001, J BIOL CHEM, V276, P33328, DOI 10.1074/jbc.M100789200; Luo G, 1997, CELL MOTIL CYTOSKEL, V38, P75; Ma K, 2002, FEBS LETT, V532, P273, DOI 10.1016/S0014-5793(02)03655-4; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; Mayer BJ, 2001, J CELL SCI, V114, P1253; Millevoi S, 1998, J MOL BIOL, V282, P111, DOI 10.1006/jmbi.1998.1999; Moncman CL, 1999, CELL MOTIL CYTOSKEL, V44, P1, DOI 10.1002/(SICI)1097-0169(199909)44:1<1::AID-CM1>3.0.CO;2-8; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305; Politou AS, 2002, J MOL BIOL, V316, P305, DOI 10.1006/jmbi.2001.5312; Politou AS, 1998, J MOL BIOL, V276, P189, DOI 10.1006/jmbi.1997.1521; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Rottner K, 2001, MOL BIOL CELL, V12, P3103, DOI 10.1091/mbc.12.10.3103; Schmeichel KL, 1998, BIOCHEM J, V331, P885, DOI 10.1042/bj3310885; Schreiber V, 1998, GENE, V207, P171, DOI 10.1016/S0378-1119(97)00622-7; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200; Zamir E, 2001, J CELL SCI, V114, P3583; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x	39	87	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20401	20410		10.1074/jbc.M310304200	http://dx.doi.org/10.1074/jbc.M310304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004028	hybrid			2022-12-27	WOS:000221164500119
J	Moro, F; Fernandez-Saiz, V; Muga, A				Moro, F; Fernandez-Saiz, V; Muga, A			The lid subdomain of DnaK is required for the stabilization of the substrate-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE DNAK; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; INFRARED-SPECTROSCOPY; STRUCTURAL-ANALYSIS; HSP70; DOMAIN; MECHANISM; AFFINITY	We examined the effect of deletion of different segments in the helical subdomain ( the so-called "lid") of the DnaK peptide-binding domain on peptide binding and protein stability. At 25 degreesC, wt DnaK and the deletion mutant proteins are able to stably bind peptides with similar affinity. However, at physiological ( 37 degreesC) and stress ( 42 degreesC) temperatures, removal of the N-terminal half of alphaB and the rest of the lid drastically decreases the ability of the protein to bind substrates. Differential scanning calorimetry and infrared spectroscopy show that this behavior is accompanied by destabilization of the peptide-binding domain. Our data suggest that the reversible interaction between the lid and beta-sandwich subdomains of DnaK peptide-binding domain is required for the stabilization of the loops that form the peptide-binding site, which in turn modulates the protein affinity for peptide substrates. This interaction might have functional implications because it could prevent rebinding of the peptide substrate, which would be forced to fold.	Univ Basque Country, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Muga, A (corresponding author), Univ Basque Country, Unidad Biofis, E-48080 Bilbao, Spain.	gbpmuvia@lg.ehu.es	Muga, Arturo/N-1174-2014; Moro Pérez, Fernando/P-3891-2015; Fernandez, Vanesa/ABD-6688-2021	Muga, Arturo/0000-0003-0345-6882; Moro Pérez, Fernando/0000-0002-3568-3388; Fernandez-Saiz, Vanesa/0000-0002-7139-8680				Albeck S, 2000, J MOL BIOL, V298, P503, DOI 10.1006/jmbi.2000.3656; Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; BANECKI B, 1992, J BIOL CHEM, V267, P25051; Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815; Buczynski G, 2001, J BIOL CHEM, V276, P27231, DOI 10.1074/jbc.M100237200; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; FABIAN H, 1993, J MOL BIOL, V232, P967, DOI 10.1006/jmbi.1993.1442; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Galan A, 2001, J BIOL CHEM, V276, P957, DOI 10.1074/jbc.M006861200; Gisler SM, 1998, J MOL BIOL, V279, P833, DOI 10.1006/jmbi.1998.1815; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Moro F, 2003, FEBS LETT, V533, P119, DOI 10.1016/S0014-5793(02)03752-3; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Qian XG, 2002, BIOCHEM J, V361, P27, DOI 10.1042/0264-6021:3610027; Slepenkov SV, 2003, BIOCHEMISTRY-US, V42, P5867, DOI 10.1021/bi034126v; Slepenkov SV, 2002, BIOCHEMISTRY-US, V41, P12224, DOI 10.1021/bi0263208; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; Taneva SG, 1999, BIOCHEMISTRY-US, V38, P9640, DOI 10.1021/bi990376t; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	30	37	37	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19600	19606		10.1074/jbc.M400921200	http://dx.doi.org/10.1074/jbc.M400921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985342	hybrid			2022-12-27	WOS:000221164500028
J	Chen, WNU; Woodbury, RL; Kathmann, LE; Opresko, LK; Zangar, RC; Wiley, HS; Thrall, BD				Chen, WNU; Woodbury, RL; Kathmann, LE; Opresko, LK; Zangar, RC; Wiley, HS; Thrall, BD			Induced autocrine signaling through the epidermal growth factor receptor contributes to the response of mammary epithelial cells to tumor necrosis factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EGF RECEPTOR; KINASE PATHWAY; TGF-ALPHA; ACTIVATION; EXPRESSION; TRANSDUCTION; PROLIFERATION; MMP-9; METALLOPROTEINASE	In contrast to the well known cytotoxic effects of tumor necrosis factor (TNF) alpha in many mammary cancer cells, we have found that TNF stimulates the proliferation and motility of human mammary epithelial cells (HMECs). Since the response of HMECs to TNF is similar to effects mediated by epidermal growth factor receptor ( EGFR) activation, we explored the potential role of cross-talk through the EGFR signaling pathways in mediating cellular responses to TNF. Using a microarray enzyme-linked immunoassay, we found that exposure to TNF stimulated the dose-dependent shedding of the EGFR ligand transforming growth factor alpha (TGFalpha). Both proliferation and motility of HMECs induced by TNF was prevented either by inhibiting membrane protein shedding with a metalloprotease inhibitor, by blocking epidermal growth factor receptor ( EGFR) kinase activity, or by limiting ligand-receptor interactions with an antagonistic anti-EGFR antibody. EGFR activity was also necessary for TNF-induced release of matrix metalloprotease-9, thought to be an essential regulator of mammary cell migration. The cellular response to TNF was associated with a biphasic temporal pattern of extracellular signal-regulated kinase (ERK) phosphorylation, which was EGFR-dependent and modulated by inhibition of metalloprotease-mediated shedding. Significantly, the late phase of ERK phosphorylation, detectable within 4 h after exposure, was blocked by the metalloprotease inhibitor batimastat, indicating that autocrine signaling through ligand shedding was responsible for this secondary wave of ERK activity. Our results indicate a novel and important role for metalloprotease activation and EGFR transmodulation in mediating the cellular response to TNF.	Pacific NW Natl Lab, Div Biol Sci, Cell Biol Grp, Richland, WA 99352 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory	Thrall, BD (corresponding author), Pacific NW Natl Lab, Div Biol Sci, Cell Biol Grp, Box 999,Mail Stop P7-56, Richland, WA 99352 USA.	brian.thrall@pnl.gov		Wiley, Steven/0000-0003-0232-6867	NATIONAL CANCER INSTITUTE [R21CA093306] Funding Source: NIH RePORTER; NCI NIH HHS [CA93306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; DeWitt AE, 2001, J CELL SCI, V114, P2301; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; DOLLBAUM C, 1988, P NATL ACAD SCI USA, V85, P4740, DOI 10.1073/pnas.85.13.4740; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Fukagawa K, 1997, CORNEA, V16, P564; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Genersch E, 2000, J CELL SCI, V113, P4319; GILL GN, 1984, J BIOL CHEM, V259, P7755; Hambek M, 2001, CANCER RES, V61, P1045; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; IP MM, 1992, ENDOCRINOLOGY, V130, P2833, DOI 10.1210/en.130.5.2833; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lagow EL, 2002, J CELL BIOCHEM, V86, P759, DOI 10.1002/jcb.10261; Ledgerwood EC, 1999, LAB INVEST, V79, P1041; Lee PPH, 2000, ENDOCRINOLOGY, V141, P3764, DOI 10.1210/en.141.10.3764; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Maheshwari G, 2001, J CELL BIOL, V155, P1123, DOI 10.1083/jcb.200109060; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mounho BJ, 1999, TOXICOL APPL PHARM, V159, P125, DOI 10.1006/taap.1999.8740; Mueller H, 1996, EUR J CANCER, V32A, P2312, DOI 10.1016/S0959-8049(96)00273-0; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Perez M, 1996, J INTERF CYTOK RES, V16, P307, DOI 10.1089/jir.1996.16.307; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; Shvartsman SY, 2002, AM J PHYSIOL-CELL PH, V282, pC545, DOI 10.1152/ajpcell.00260.2001; SPRIGGS D, 1987, P NATL ACAD SCI USA, V84, P6563, DOI 10.1073/pnas.84.18.6563; STAMPFER MR, 1993, CANCER SURV, V18, P7; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stangle N. C., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P161; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Varela LM, 1996, ENDOCRINOLOGY, V137, P4915, DOI 10.1210/en.137.11.4915; Varela LM, 2001, J CELL PHYSIOL, V188, P120, DOI 10.1002/jcp.1103; Wiley HS, 1998, J CELL BIOL, V143, P1317, DOI 10.1083/jcb.143.5.1317; Woodbury RL, 2002, J PROTEOME RES, V1, P233, DOI 10.1021/pr025506q; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	50	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18488	18496		10.1074/jbc.M310874200	http://dx.doi.org/10.1074/jbc.M310874200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978035	hybrid			2022-12-27	WOS:000221041500049
J	Ikuta, T; Kobayashi, Y; Kawajiri, K				Ikuta, T; Kobayashi, Y; Kawajiri, K			Cell density regulates intracellular localization of aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; HEAT-SHOCK-PROTEIN; POLYPOSIS-COLI PROTEIN; C57BL/6N MOUSE EMBRYO; AH DIOXIN RECEPTOR; ESTROGEN-RECEPTOR; TRANSCRIPTION FACTOR; NUCLEOCYTOPLASMIC TRANSPORT; DEVELOPMENTAL EXPRESSION; SUBCELLULAR-LOCALIZATION	The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that plays a role as an intracellular mediator of the xenobiotic signaling pathway. AhR contains signals for both nuclear localization and nuclear export (NES). The objective of this study was to demonstrate how AhR intracellular distribution was regulated physiologically in cells. We found that cell density, but not the cell cycle, influenced the subcellular distribution of AhR in a keratinocyte cell line, HaCaT: AhR was predominantly nuclear at sparse cell densities, both nuclear and cytoplasmic at subconfluence, and predominantly cytoplasmic at confluence. Stable transfectants of HaCaT carrying a reporter gene fused with xenobiotic responsive element showed an association between xenobiotic responsive element-mediated transcription and AhR relocalization. Leptomycin B promoted nuclear accumulation of AhR irrespective of cell density, suggesting that this alteration may be because of a change of the regulation of the nuclear export of AhR. We found that Ser-68 in the NES of AhR was phosphorylated after nuclear accumulation of activated AhR and the nuclear export of a chimeric GST-AhR-GFP fusion protein was suppressed by substitution of a serine residue (Ser-68) to aspartic acid, which mimics the negative charge of phosphorylation. This novel cell density-dependent AhR relocalization was affected by exposure to SB203580, okadaic acid, and low Ca2+ concentrations. These findings strongly suggest that cell density regulates the intracellular localization and function of AhR, because of modulation of nuclear export activity. The p38 MAPK-mediated phosphorylation of the NES and its dephosphorylation, regulated by cell-cell contact signals, may have pivotal roles in the novel AhR relocalization.	Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan; Saitama Canc Ctr, Dept Pathol, Ina, Saitama 3620806, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol CREST, Saitama 3320012, Japan	Japan Science & Technology Agency (JST)	Kawajiri, K (corresponding author), Saitama Canc Ctr, Res Inst, 818 Komuro, Ina, Saitama 3620806, Japan.	kawajiri@cancer-c.pref.saitama.jp						ABBOTT BD, 1995, DEV DYNAM, V204, P144, DOI 10.1002/aja.1002040205; ABBOTT BD, 1995, DEV DYNAM, V204, P133, DOI 10.1002/aja.1002040204; Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Berg P, 2001, J BIOL CHEM, V276, P43231, DOI 10.1074/jbc.M105261200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Carver LA, 1997, J BIOL CHEM, V272, P11452; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Heid SE, 2000, MOL PHARMACOL, V57, P82; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Ikuta T, 2000, J BIOCHEM, V127, P503, DOI 10.1093/oxfordjournals.jbchem.a022633; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Klinge CM, 2000, ARCH BIOCHEM BIOPHYS, V373, P163, DOI 10.1006/abbi.1999.1552; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kwon YW, 2002, J BIOL CHEM, V277, P1837, DOI 10.1074/jbc.M105033200; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Leach C, 2002, J CELL SCI, V115, P3739, DOI 10.1242/jcs.00052; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lees MJ, 1999, MOL CELL BIOL, V19, P5811; Ma Q, 1997, J BIOL CHEM, V272, P8878; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; MOSES M, 1985, J AM ACAD DERMATOL, V12, P497, DOI 10.1016/S0190-9622(85)70070-9; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ogi T, 2001, GENES CELLS, V6, P943, DOI 10.1046/j.1365-2443.2001.00478.x; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Pennisi E, 1998, SCIENCE, V279, P1129, DOI 10.1126/science.279.5354.1129; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Robles R, 2000, ENDOCRINOLOGY, V141, P450, DOI 10.1210/en.141.1.450; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; SLADEK CM, 1994, J BIOL CHEM, V269, P16067; Song JS, 2002, P NATL ACAD SCI USA, V99, P14694, DOI 10.1073/pnas.232562899; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; WANNER R, 1995, BIOCHEM BIOPH RES CO, V209, P706, DOI 10.1006/bbrc.1995.1556; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	62	91	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19209	19216		10.1074/jbc.M310492200	http://dx.doi.org/10.1074/jbc.M310492200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985336	hybrid			2022-12-27	WOS:000221041500134
J	Salas, TR; Kim, J; Vakar-Lopez, F; Sabichi, AL; Troncoso, P; Jenster, G; Kikuchi, A; Chen, SY; Shemshedini, L; Suraokar, M; Logothetis, CJ; DiGiovanni, J; Lippman, SM; Menter, DG				Salas, TR; Kim, J; Vakar-Lopez, F; Sabichi, AL; Troncoso, P; Jenster, G; Kikuchi, A; Chen, SY; Shemshedini, L; Suraokar, M; Logothetis, CJ; DiGiovanni, J; Lippman, SM; Menter, DG			Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PROSTATE-CANCER; SUBSTRATE-SPECIFICITY; CELLS; AKT; IDENTIFICATION; ACTIVATION; EXPRESSION; PROTEIN; BINDING; GROWTH	Kinases can phosphorylate and regulate androgen receptor activity during prostate cancer progression. In particular, we showed that glycogen synthase kinase-3beta phosphorylates the androgen receptor, thereby inhibiting androgen receptor-driven transcription. Conversely, the glycogen synthase kinase-3beta inhibitor lithium chloride suppressed the glycogen synthase kinase-3beta-mediated phosphorylation of the androgen receptor, thereby enabling androgen receptor-driven transcription to occur. The androgen receptor hinge and ligand-binding domains were important for both the phosphorylation and the inhibition of transcriptional activity of the receptor by glycogen synthase kinase-3beta. Furthermore, androgen receptor phosphorylation was augmented by LY294002, an indirect inhibitor of protein kinase B/Akt that inhibits glycogen synthase kinase-3beta. We also showed that the mutation of various phosphorylation sites on glycogen synthase kinase-3beta affected the ability of these mutants to co-distribute with the androgen receptor in the cell nucleus, also that both glycogen synthase kinase-3beta and androgen receptor proteins can be found in cell nuclei of prostate cancer tissue samples. Because glycogen synthase kinase-3beta activity is suppressed after the enzyme is phosphorylated by protein kinase B/Akt and Akt activity frequently increases during the progression of prostate cancer, nullification of the glycogen synthase kinase-3beta-mediated suppression of androgen receptor activity by Akt likely contributes to prostate cancer progression.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Erasmus Med Ctr, Dept Urol, NL-3000 DR Rotterdam, Netherlands; Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Erasmus University Rotterdam; Erasmus MC; Hiroshima University; University System of Ohio; University of Toledo; University of Texas System; UTMD Anderson Cancer Center	Menter, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Box 236,1515 Holcombe Blvd, Houston, TX 77030 USA.	dmenter@mdanderson.org	CHEN, Shaoyong/ABF-3357-2021					Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 2002, CLIN CANCER RES, V8, P1904; DUBE JY, 1978, J CLIN ENDOCR METAB, V47, P41, DOI 10.1210/jcem-47-1-41; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; Jenster G, 1999, SEMIN ONCOL, V26, P407; Jenster G, 2000, J PATHOL, V191, P227; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; KAUFMAN M, 1983, J STEROID BIOCHEM, V18, P383, DOI 10.1016/0022-4731(83)90055-9; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; LOGOTHETIS CJ, 1994, SEMIN ONCOL, V21, P620; Malik SN, 2002, CLIN CANCER RES, V8, P1168; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; MURTHY LR, 1984, PROSTATE, V5, P567, DOI 10.1002/pros.2990050602; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; SCHILLING K, 1984, PROSTATE, V5, P581, DOI 10.1002/pros.2990050603; Subbarayan V, 2001, CANCER RES, V61, P2720; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; TRAISH AM, 1981, J BIOL CHEM, V256, P2028; Wen Y, 2000, CANCER RES, V60, P6841; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; Zhu ZX, 2001, BIOCHEM BIOPH RES CO, V284, P836, DOI 10.1006/bbrc.2001.5030	33	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19191	19200		10.1074/jbc.M309560200	http://dx.doi.org/10.1074/jbc.M309560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985354	hybrid			2022-12-27	WOS:000221041500132
J	Du, KL; Chen, M; Li, J; Lepore, JJ; Mericko, P; Parmacek, MS				Du, KL; Chen, M; Li, J; Lepore, JJ; Mericko, P; Parmacek, MS			Megakaryoblastic leukemia factor-1 transduces cytoskeletal signals and induces smooth muscle cell differentiation from undifferentiated embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; GENE-EXPRESSION; TRANSCRIPTIONAL COACTIVATOR; MYOCARDIN; ACTIVATION; BINDING; FAMILY; RHOA; REGULATOR; COFACTOR	The SAP domain transcription factor myocardin plays a critical role in the transcriptional program regulating smooth muscle cell differentiation. In this report, we describe the capacity of myocardin to physically associate with megakaryoblastic leukemia factor-1 (MKL1) and characterize the function of MKL1 in smooth muscle cells (SMCs). The MKL1 gene is expressed in most human tissues and myocardin and MKL are co-expressed in SMCs. MKL1 and myocardin physically associate via conserved leucine zipper domains. Overexpression of MKL1 transactivates serum response factor (SRF)-dependent SMC-restricted transcriptional regulatory elements including the SM22alpha promoter, smooth muscle myosin heavy chain promoter/enhancer, and SM-alpha-actin promoter/enhancer in non-SMCs. Moreover, forced expression of MKL1 and SRF in undifferentiated SRF-/- embryonic stem cells activates multiple endogenous SMC-restricted genes at levels equivalent to, or exceeding, myocardin. Forced expression of a dominant-negative MKL1 mutant reduces myocardin-induced activation of the SMC-specific SM22alpha promoter. In NIH3T3 fibroblasts MKL1 localizes to the cytoplasm and translocates to the nucleus in response to serum stimulation, actin treadmilling, and RhoA signaling. In contrast, in SMCs MKL1 is observed exclusively in the nucleus regardless of serum conditions or RhoA signaling. However, when actin polymerization is disrupted MKL1 translocates from the nucleus to the cytoplasm in SMCs. Together, these data were consistent with a model wherein MKL1 transduces signals from the cytoskeleton to the nucleus in SMCs and regulates SRF-dependent SMC differentiation autonomously or in concert with myocardin.	Univ Penn, Sch Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Parmacek, MS (corresponding author), Univ Penn, Sch Med, Div Cardiovasc Med, 3400 Spruce St,9123 Founders Pavil, Philadelphia, PA 19104 USA.	Michael.Parmacek@uphs.upenn.edu			PHS HHS [R01-56915] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2001, DEV BIOL, V240, P404, DOI 10.1006/dbio.2001.0403; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; Parmacek MS, 2001, CURR TOP DEV BIOL, V51, P69, DOI 10.1016/S0070-2153(01)51002-9; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; Sasazuki T, 2002, J BIOL CHEM, V277, P28853, DOI 10.1074/jbc.M203190200; Selvaraj A, 2003, J BIOL CHEM, V278, P41977, DOI 10.1074/jbc.M305679200; Small JV, 1998, ACTA PHYSIOL SCAND, V164, P341; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Strobeck M, 2001, J BIOL CHEM, V276, P16418, DOI 10.1074/jbc.M100631200; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhang JCL, 2002, MECH DEVELOP, V115, P161, DOI 10.1016/S0925-4773(02)00088-6	37	128	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17578	17586		10.1074/jbc.M400961200	http://dx.doi.org/10.1074/jbc.M400961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970199	hybrid			2022-12-27	WOS:000220870400086
J	McDonald, JF; Zheleznyak, A; Frazier, WA				McDonald, JF; Zheleznyak, A; Frazier, WA			Cholesterol-independent interactions with CD47 enhance alpha(v)beta(3) avidity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; CELL-ADHESION; LIPID RAFTS; EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; MEMBRANE; DOMAIN; ALPHA(IIB)BETA(3); ALPHA-V-BETA-3; INHIBITION	Expression in OV10 cells of either wild-type CD47 or its extracellular IgV domain linked to a glycosylphosphatidylinositol anchor- (IgV-GPI) enhanced ligand-induced alpha(v)beta(3) activation as detected by the binding of LIBS1 and LIBS6 mAbs. The amplitude of LIBS binding was greater with both CD47 and IgV-GPI expression, indicating an increase in the population of "activable" integrin molecules. Expression of either CD47 species also increased alpha(v)beta(3)-mediated adhesion to vitronectin, and to surfaces coated with the anti-beta(3) antibody AP3, because of enhanced clustering of alpha(v)beta(3) as confirmed by chemical cross-linking. Cholesterol depletion with methyl-beta-cyclodextrin did not prevent the increase in anti-LIBS binding, but reduced cell adhesion to vitronectin and AP3. However, cells expressing CD47 were partially insulated against this disruption, and IgV-GPI was even more effective. Both CD47 and IgV-GPI were found in cholesterol-rich rafts prepared in the absence of detergent, but only CD47 could recruit alpha(v)beta(3) and its associated signaling molecules to these domains. Thus CD47-alpha(v)beta(3) complexes in cholesterol-rich raft domains appear to engage in G(i)-dependent signaling whereas CD47-alpha(v)beta(3) interactions that lead to integrin clustering are also detergent resistant, but are insensitive to cholesterol depletion and do not require the transmembrane region of CD47.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Frazier, WA (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	frazier@biochem.wustl.edu			NHLBI NIH HHS [F32-HL10209, HL54390] Funding Source: Medline; NIGMS NIH HHS [GM57573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054390, F32HL010209, R56HL054390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barazi HO, 2002, J BIOL CHEM, V277, P42859, DOI 10.1074/jbc.M206849200; Braccia A, 2003, J BIOL CHEM, V278, P15679, DOI 10.1074/jbc.M211228200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown E, 2001, J CLIN INVEST, V107, P1499, DOI 10.1172/JCI13315; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; BROWN EJ, 1988, J EXP MED, V167, P777, DOI 10.1084/jem.167.3.777; Brown EJ, 2002, CURR OPIN CELL BIOL, V14, P603, DOI 10.1016/S0955-0674(02)00360-5; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Fujimoto TT, 2003, J BIOL CHEM, V278, P26655, DOI 10.1074/jbc.M302194200; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Gopalakrishna P, 2000, J CELL BIOCHEM, V77, P517, DOI 10.1002/(SICI)1097-4644(20000615)77:4<517::AID-JCB1>3.3.CO;2-Y; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Maile LA, 2002, J BIOL CHEM, V277, P1800, DOI 10.1074/jbc.M108380200; Manna PP, 2003, J IMMUNOL, V170, P3544, DOI 10.4049/jimmunol.170.7.3544; Marwali MR, 2003, BLOOD, V102, P215, DOI 10.1182/blood-2002-10-3195; McDonald JF, 2003, BIOCHEMISTRY-US, V42, P10001, DOI 10.1021/bi0341408; NEWMAN PJ, 1985, BLOOD, V65, P227; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Pierini LM, 2001, P NATL ACAD SCI USA, V98, P9471, DOI 10.1073/pnas.181353098; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Rebres RA, 2001, J BIOL CHEM, V276, P7672, DOI 10.1074/jbc.M008858200; REBRES RA, 2001, J BIOL CHEM, V276, P2001; REITVELD A, 1998, BIOCHIM BIOPHYS ACTA, V1376, P467; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tulasne D, 2001, BLOOD, V98, P3346, DOI 10.1182/blood.V98.12.3346; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; Weetall M, 2001, ANAL BIOCHEM, V293, P277, DOI 10.1006/abio.2001.5140; Wu AL, 1999, MOL CELL, V4, P619, DOI 10.1016/S1097-2765(00)80212-9; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	43	29	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17301	17311		10.1074/jbc.M312782200	http://dx.doi.org/10.1074/jbc.M312782200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966135	hybrid			2022-12-27	WOS:000220870400053
J	Sinnett-Smith, J; Zhukova, E; Hsieh, N; Jiang, XH; Rozengurt, E				Sinnett-Smith, J; Zhukova, E; Hsieh, N; Jiang, XH; Rozengurt, E			Protein kinase D potentiates DNA synthesis induced by G(q)-coupled receptors by increasing the duration of ERK signaling in swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ACTIVATION LOOP PHOSPHORYLATION; TERNARY COMPLEX-FORMATION; GROWTH-FACTOR BINDING; CYSTEINE-RICH MOTIFS; RIBOSOMAL S6 KINASE; D PKD ACTIVATION; 3T3 CELLS; TYROSINE PHOSPHORYLATION; PHORBOL ESTERS	Protein kinase D (PKD) potentiates cellular DNA synthesis in response to G protein-coupled receptor ( GPCR) agonists but the mechanism(s) involved has not been elucidated. Here, we examined whether PKD overexpression in Swiss 3T3 cells regulates the activation/inactivation kinetics of the extracellular-regulated protein kinase (ERK) in response to the mitogenic GPCR agonists bombesin and vasopressin. Addition of bombesin or vasopressin to Swiss 3T3 cells overexpressing PKD induced a striking increase in the duration of MEK/ ERK/RSK activation as compared with cultures of either control Swiss 3T3 cells or Swiss 3T3 cells expressing a kinase-inactive PKD mutant. In contrast, the duration of ERK activation in response to epidermal growth factor, which acts via protein kinase C/PKD-independent pathways, was not increased. Furthermore, bombesin or vasopressin promoted a striking increase in phosphorylation ( at Ser-374) and accumulation of c-Fos ( the c-fos proto-oncogene product) in Swiss 3T3 cells overexpressing wild-type ( but not kinase-inactive) PKD. Inhibition of the sustained phase of ERK/RSK activation abrogated the increase in c-Fos accumulation and DNA synthesis induced by bombesin or vasopressin in PKD-overexpressing cells. Our results demonstrate that PKD selectively potentiates mitogenesis induced by bombesin or vasopressin in Swiss 3T3 cells by increasing the duration of MEK/ ERK/RSK signaling.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 900 Vet Ave,Warren Hall,Room 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu	jiang, cynthia xiaohua/F-7580-2017	jiang, cynthia xiaohua/0000-0002-7372-4961	NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK056930] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA 90388] Funding Source: Medline; NIDDK NIH HHS [DK56930, P30 DK 41301, DK55003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi S, 2002, CELL IMMUNOL, V215, P45, DOI 10.1016/S0008-8749(02)00012-6; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Charlesworth A, 1996, ONCOGENE, V12, P1337; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1989, J CELL PHYSIOL, V141, P253, DOI 10.1002/jcp.1041410204; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Hunger-Glaser I, 2003, J BIOL CHEM, V278, P22631, DOI 10.1074/jbc.M210876200; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Leopoldt D, 2000, J CELL PHYSIOL, V183, P208, DOI 10.1002/(SICI)1097-4652(200005)183:2<208::AID-JCP7>3.0.CO;2-5; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; Mariathasan S, 2001, J IMMUNOL, V167, P4966, DOI 10.4049/jimmunol.167.9.4966; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Paolucci L, 1999, CANCER RES, V59, P572; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Rey O, 2003, J BIOL CHEM, V278, P23773, DOI 10.1074/jbc.M300226200; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rey O, 2003, BIOCHEM BIOPH RES CO, V302, P817, DOI 10.1016/S0006-291X(03)00269-9; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; ROZENGURT E, 1981, J BIOL CHEM, V256, P716; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Rozengurt E, 1998, AM J PHYSIOL-GASTR L, V275, pG177, DOI 10.1152/ajpgi.1998.275.2.G177; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Santiskulvong C, 2001, AM J PHYSIOL-CELL PH, V281, pC886, DOI 10.1152/ajpcell.2001.281.3.C886; Seckl MJ, 1996, J BIOL CHEM, V271, P29453, DOI 10.1074/jbc.271.46.29453; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Withers DJ, 1997, J BIOL CHEM, V272, P2509; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1987, J BIOL CHEM, V262, P3947; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	91	98	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16883	16893		10.1074/jbc.M313225200	http://dx.doi.org/10.1074/jbc.M313225200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14963034	hybrid			2022-12-27	WOS:000220747900141
J	Katsumi, A; Orr, AW; Tzima, E; Schwartz, MA				Katsumi, A; Orr, AW; Tzima, E; Schwartz, MA			Integrins in mechanotransduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FOCAL ADHESION KINASE; ENDOTHELIAL SURFACE-LAYER; CYCLIN-DEPENDENT KINASES; SIGNAL-REGULATED KINASE; SHEAR-STRESS ACTIVATION; SMOOTH-MUSCLE-CELLS; TYROSINE PHOSPHORYLATION; MECHANICAL STRETCH; CARDIAC MYOCYTES; RHO	Mechanical forces are crucial to the regulation of cell and tissue morphology and function. At the cellular level, forces influence cytoskeletal organization, gene expression, proliferation, and survival. Integrin-mediated adhesions are intrinsically mechanosensitive and a large body of data implicates integrins in sensing mechanical forces. We review the relationship between integrins and mechanical forces, the role of integrins in cellular responses to stretch and fluid flow, and propose that some of these events are mechanistically related.	Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Mellon Prostate Canc Inst, Charlottesville, VA 22908 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; Scripps Research Institute	Schwartz, MA (corresponding author), Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA.	maschwartz@virginia.edu	Orr, Anthony/P-8927-2015; Tzima, Ellie/L-9256-2017	Orr, Anthony/0000-0002-2377-213X; Tzima, Ellie/0000-0002-3437-0902; schwartz, martin/0000-0002-2071-1243	NHLBI NIH HHS [R01 HL 075092] Funding Source: Medline; NIGMS NIH HHS [R01 GM 47214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aikawa R, 2002, HYPERTENSION, V39, P233, DOI 10.1161/hy0202.102699; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; Dembo M, 1999, BIOPHYS J, V76, P2307, DOI 10.1016/S0006-3495(99)77386-8; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; Ernstrom GG, 2002, ANNU REV GENET, V36, P411, DOI 10.1146/annurev.genet.36.061802.101708; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V281, pL529, DOI 10.1152/ajplung.2001.281.3.L529; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Gloe T, 2002, J BIOL CHEM, V277, P23453, DOI 10.1074/jbc.M203889200; Grinnell F, 2003, TRENDS CELL BIOL, V13, P264, DOI 10.1016/S0962-8924(03)00057-6; HARRIS AK, 1980, SCIENCE, V208, P177, DOI 10.1126/science.6987736; Helmke BP, 2003, BIOPHYS J, V84, P2691, DOI 10.1016/S0006-3495(03)75074-7; Hove JR, 2003, NATURE, V421, P172, DOI 10.1038/nature01282; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Kudoh S, 1998, J BIOL CHEM, V273, P24037, DOI 10.1074/jbc.273.37.24037; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Lehoux S, 2003, J BIOMECH, V36, P631, DOI 10.1016/S0021-9290(02)00441-4; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Liu Y, 2002, ARTERIOSCL THROM VAS, V22, P76, DOI 10.1161/hq0102.101822; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Martinez-Lemus LA, 2003, J VASC RES, V40, P211, DOI 10.1159/000071886; MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Pelham RJ, 1999, MOL BIOL CELL, V10, P935, DOI 10.1091/mbc.10.4.935; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Putnam AJ, 2003, AM J PHYSIOL-CELL PH, V284, pC627, DOI 10.1152/ajpcell.00137.2002; Ren XD, 2000, J CELL SCI, V113, P3673; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sai XR, 1999, J CELL SCI, V112, P1365; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 2001, J CELL SCI, V114, P2553; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Shi Q, 2003, MOL BIOL CELL, V14, P4306, DOI 10.1091/mbc.E03-01-0046; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; Smith ML, 2003, BIOPHYS J, V85, P637, DOI 10.1016/S0006-3495(03)74507-X; THUBRIKAR MJ, 1995, ANN THORAC SURG, V59, P1594, DOI 10.1016/0003-4975(94)01037-D; Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688; Tzima E, 2003, J BIOL CHEM, V278, P31020, DOI 10.1074/jbc.M301179200; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Urbich C, 2000, CIRC RES, V87, P683, DOI 10.1161/01.RES.87.8.683; Vink H, 2000, AM J PHYSIOL-HEART C, V278, pH285, DOI 10.1152/ajpheart.2000.278.1.H285; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wang JG, 2001, BIOCHEM BIOPH RES CO, V288, P356, DOI 10.1006/bbrc.2001.5775; Wernig F, 2003, HYPERTENSION, V41, P903, DOI 10.1161/01.HYP.0000062882.42265.88; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yano Y, 1996, AM J PHYSIOL-CELL PH, V271, pC635, DOI 10.1152/ajpcell.1996.271.2.C635; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	69	505	522	1	68	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12001	12004		10.1074/jbc.R300038200	http://dx.doi.org/10.1074/jbc.R300038200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14960578	hybrid			2022-12-27	WOS:000220334900001
J	Bolam, DN; Xie, HF; Pell, G; Hogg, D; Galbraith, G; Henrissat, B; Gilbert, HJ				Bolam, DN; Xie, HF; Pell, G; Hogg, D; Galbraith, G; Henrissat, B; Gilbert, HJ			X4 modules represent a new family of carbohydrate-binding modules that display novel properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENS SUBSP CELLULOSA; LIGAND-BINDING; PSEUDOMONAS XYLANASE; CALCIUM-BINDING; DOMAIN; RECOGNITION; FIMI; MECHANISM; CONTAINS; COMPLEX	The hydrolysis of the plant cell wall by microbial glycoside hydrolases and esterases is the primary mechanism by which stored organic carbon is utilized in the biosphere, and thus these enzymes are of considerable biological and industrial importance. Plant cell wall-degrading enzymes in general display a modular architecture comprising catalytic and non-catalytic modules. The X4 modules in glycoside hydrolases represent a large family of non-catalytic modules whose function is unknown. Here we show that the X4 modules from a Cellvibrio japonicus mannanase (Man5C) and arabinofuranosidase (Abf62A) bind to polysaccharides, and thus these proteins comprise a new family of carbohydrate-binding modules (CBMs), designated CBM35. The Man5C-CBM35 binds to galactomannan, insoluble amorphous mannan, glucomannan, and manno-oligosaccharides but does not interact with crystalline mannan, cellulose, cello-oligosaccharides, or other polysaccharides derived from the plant cell wall. Man5C-CBM35 also potentiates mannanase activity against insoluble amorphous mannan. Abf62A-CBM35 interacts with unsubstituted oat-spelt xylan but not substituted forms of the hemicellulose or xylo-oligosaccharides, and requires calcium for binding. This is in sharp contrast to other xylan-binding CBMs, which interact in a calcium-independent manner with both xylo-oligosaccharides and decorated xylans.	Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France	Newcastle University - UK; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Gilbert, HJ (corresponding author), Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Agr Bldg, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk	Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588; Bolam, David/0000-0003-0314-3122				Abou-Hachem M, 2002, BIOCHEMISTRY-US, V41, P5720, DOI 10.1021/bi012094a; BLACK GW, 1995, BIOCHEM J, V307, P191, DOI 10.1042/bj3070191; Bolam DN, 2001, BIOCHEMISTRY-US, V40, P2468, DOI 10.1021/bi002564l; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2002, MOL MICROBIOL, V43, P187, DOI 10.1046/j.1365-2958.2002.02730.x; Boraston AB, 1999, ROY SOC CH, P202; Brett CT, 1996, PHYSL BIOCH PLANT CE; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Coutinho PM, 1999, ROY SOC CH, P3; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; FERREIRA LMA, 1993, BIOCHEM J, V294, P349, DOI 10.1042/bj2940349; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; GLAUDEMANS CPJ, 1958, J AM CHEM SOC, V43, P941; Halstead JR, 2000, FEMS MICROBIOL LETT, V192, P197, DOI 10.1016/S0378-1097(00)00432-8; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; Johnson PE, 1998, BIOCHEMISTRY-US, V37, P12772, DOI 10.1021/bi980978x; JOSELEAU JP, 1992, PROGR BIOTECHNOL, V7, P1; KELLETT LE, 1990, BIOCHEM J, V272, P369, DOI 10.1042/bj2720369; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Linder M, 1996, J BIOL CHEM, V271, P21268, DOI 10.1074/jbc.271.35.21268; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Notenboom V, 2001, BIOCHEMISTRY-US, V40, P6248, DOI 10.1021/bi0101704; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; TAKEO K, 1984, ELECTROPHORESIS, V5, P187, DOI 10.1002/elps.1150050402; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	36	64	65	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22953	22963		10.1074/jbc.M313317200	http://dx.doi.org/10.1074/jbc.M313317200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15004012	hybrid			2022-12-27	WOS:000221570900022
J	Vinogradova, MV; Reddy, VS; Reddy, ASN; Sablin, EP; Fletterick, RJ				Vinogradova, MV; Reddy, VS; Reddy, ASN; Sablin, EP; Fletterick, RJ			Crystal structure of kinesin regulated by Ca2+-calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; MOTOR DOMAIN; ANGSTROM RESOLUTION; MOLECULAR MOTORS; POWER STROKE; ARABIDOPSIS; NCD; MOTILITY; COMPLEX; CRYSTALLOGRAPHY	Kinesins orchestrate cell division by controlling placement of chromosomes. Kinesins must be precisely regulated or else cell division fails. Calcium, a universal second messenger in eukaryotes, and calmodulin regulate some kinesins by causing the motor to dissociate from its biological track, the microtubule. Our focus was the mechanism of calcium regulation of kinesin at atomic resolution. Here we report the crystal structure of kinesin-like calmodulin-binding protein ( KCBP) from potato, which was resolved to 2.3. The structure reveals three subdomains of the regulatory machinery located at the C terminus extension of the kinesin motor. Calmodulin that is activated by Ca2+ ions binds to an alpha-helix positioned on the microtubule-binding face of kinesin. A negatively charged segment following this helix competes with microtubules. A mimic of the conventional kinesin neck, connecting the calmodulin-binding helix to the KCBP motor core, links the regulatory machine to the kinesin catalytic cycle. Together with biochemical data, the crystal structure suggests that Ca2+-calmodulin inhibits the binding of KCBP to microtubules by blocking the microtubule-binding sites on KCBP.	Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA; Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA	University of California System; University of California San Francisco; Colorado State University; Colorado State University	Fletterick, RJ (corresponding author), Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA.	flett@msg.ucsf.edu			NIAMS NIH HHS [P01 AR42895] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bowser J, 1997, PLANT J, V12, P1429, DOI 10.1046/j.1365-313x.1997.12061429.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casey DM, 2003, MOL BIOL CELL, V14, P3650, DOI 10.1091/mbc.E03-01-0057; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Deavours BE, 1998, CELL MOTIL CYTOSKEL, V40, P408, DOI 10.1002/(SICI)1097-0169(1998)40:4<408::AID-CM8>3.0.CO;2-6; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Kao YL, 2000, BIOCHEM BIOPH RES CO, V267, P201, DOI 10.1006/bbrc.1999.1896; Kikkawa M, 2000, CELL, V100, P241, DOI 10.1016/S0092-8674(00)81562-7; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Naber N, 2003, SCIENCE, V300, P798, DOI 10.1126/science.1082374; Oppenheimer DG, 1997, P NATL ACAD SCI USA, V94, P6261, DOI 10.1073/pnas.94.12.6261; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reddy A S, 2001, BMC Genomics, V2, P2, DOI 10.1186/1471-2164-2-2; Reddy ASN, 1996, PLANT J, V10, P9, DOI 10.1046/j.1365-313X.1996.10010009.x; Reddy ASN, 2001, INT REV CYTOL, V204, P97, DOI 10.1016/S0074-7696(01)04004-9; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; Reddy VS, 2002, J BIOL CHEM, V277, P48058, DOI 10.1074/jbc.M205459200; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rogers GC, 1999, J MOL BIOL, V294, P1, DOI 10.1006/jmbi.1999.3249; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sablin EP, 2001, CURR OPIN STRUC BIOL, V11, P716, DOI 10.1016/S0959-440X(01)00265-2; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Vos JW, 2000, PLANT CELL, V12, P979, DOI 10.1105/tpc.12.6.979; Wendt TG, 2002, EMBO J, V21, P5969, DOI 10.1093/emboj/cdf622; Yun M, 2003, EMBO J, V22, P5382, DOI 10.1093/emboj/cdg531; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	37	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23504	23509		10.1074/jbc.M400741200	http://dx.doi.org/10.1074/jbc.M400741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	14988396	hybrid			2022-12-27	WOS:000221570900088
J	Fernandez, FJ; Vega, MC; Lehmann, F; Sandmeier, E; Gehring, H; Christen, P; Wilmanns, M				Fernandez, FJ; Vega, MC; Lehmann, F; Sandmeier, E; Gehring, H; Christen, P; Wilmanns, M			Structural studies of the catalytic reaction pathway of a hyperthermophilic histidinol-phosphate aminotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; DECARBOXYLASE COBD ENZYME; THERMUS-THERMOPHILUS HB8; ESCHERICHIA-COLI; THERMOTOGA-MARITIMA; ASPARTATE-AMINOTRANSFERASE; SALMONELLA-ENTERICA; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; PROTEIN STRUCTURES	In histidine biosynthesis, histidinol-phosphate aminotransferase catalyzes the transfer of the amino group from glutamate to imidazole acetol-phosphate producing 2-oxoglutarate and histidinol phosphate. In some organisms such as the hyperthermophile Thermotoga maritima, specific tyrosine and aromatic amino acid transaminases have not been identified to date, suggesting an additional role for histidinol-phosphate aminotransferase in other transamination reactions generating aromatic amino acids. To gain insight into the specific function of this transaminase, we have determined its crystal structure in the absence of any ligand except phosphate, in the presence of covalently bound pyridoxal 5'-phosphate, of the coenzyme histidinol phosphate adduct, and of pyridoxamine 5'-phosphate. The enzyme accepts histidinol phosphate, tyrosine, tryptophan, and phenylalanine, but not histidine, as substrates. The structures provide a model of how these different substrates could be accommodated by histidinol-phosphate aminotransferase. Some of the structural features of the enzyme are more preserved between the T. maritima enzyme and a related threonine-phosphate decarboxylase from S. typhimurium than with histidinol-phosphate aminotransferases from different organisms.	DESY, EMBL, D-22603 Hamburg, Germany; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Zurich	Wilmanns, M (corresponding author), DESY, EMBL, Notkestr 85,Bldg 25A, D-22603 Hamburg, Germany.	wilmanns@embl-hamburg.de	Vega, M. Cristina/C-3640-2011; Fernandez, Francisco J./C-3647-2011	Vega, M. Cristina/0000-0003-0628-8378; Wilmanns, Matthias/0000-0002-4643-5435; Fernandez, Francisco J./0000-0002-5015-1849				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Banfield MJ, 2001, ACTA CRYSTALLOGR D, V57, P1518, DOI 10.1107/S0907444901012604; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; BRAUNSTEIN AE, 1964, VITAM HORM, V22, P451, DOI 10.1016/S0083-6729(08)60348-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; Cheong CG, 2002, BIOCHEMISTRY-US, V41, P4798, DOI 10.1021/bi012111w; Cheong CG, 2002, BIOCHEMISTRY-US, V41, P9079, DOI 10.1021/bi020294w; Cho Y, 2003, J BIOL CHEM, V278, P8333, DOI 10.1074/jbc.M212124200; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Douangamath A, 2002, STRUCTURE, V10, P185, DOI 10.1016/S0969-2126(02)00702-5; Haruyama K, 2001, BIOCHEMISTRY-US, V40, P4633, DOI 10.1021/bi002769u; HAYASHI H, 1993, BIOCHEMISTRY-US, V32, P12229, DOI 10.1021/bi00096a036; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Jaenicke R, 1996, ADV PROTEIN CHEM, V48, P181; Jaenicke R, 2001, METHOD ENZYMOL, V334, P438; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; MALASHKEVICH VN, 1995, NAT STRUCT BIOL, V2, P548, DOI 10.1038/nsb0795-548; Matsui I, 2000, J BIOL CHEM, V275, P4871, DOI 10.1074/jbc.275.7.4871; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McClelland M, 2000, NUCLEIC ACIDS RES, V28, P4974, DOI 10.1093/nar/28.24.4974; METHA PK, 2000, ADV ENZYMOL RELAT AR, V74, P129; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; NESTER EW, 1976, J BACTERIOL, V126, P699, DOI 10.1128/JB.126.2.699-705.1976; NOVOGRODSKY A, 1963, J BIOL CHEM, V238, P1903; Okamoto A, 1996, J BIOCHEM-TOKYO, V119, P135; Omi R, 2002, J BIOCHEM, V132, P759, DOI 10.1093/oxfordjournals.jbchem.a003284; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oue S, 1997, J BIOCHEM-TOKYO, V121, P161; POWELL JT, 1978, EUR J BIOCHEM, V87, P391, DOI 10.1111/j.1432-1033.1978.tb12388.x; POWELL JT, 1978, J BACTERIOL, V136, P1; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SCHIRCH L, 1975, J BIOL CHEM, V250, P1939; Sivaraman J, 2001, J MOL BIOL, V311, P761, DOI 10.1006/jmbi.2001.4882; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; WEIGENT DA, 1976, J BIOL CHEM, V251, P6974; Westhead DR, 1999, PROTEIN SCI, V8, P897	48	13	19	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21478	21488		10.1074/jbc.M400291200	http://dx.doi.org/10.1074/jbc.M400291200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15007066	Green Published, hybrid			2022-12-27	WOS:000221273800113
J	Huang, JY; Sun, YT; Huang, XY				Huang, JY; Sun, YT; Huang, XY			Distinct roles for Src tyrosine kinase in beta(2)-adrenergic receptor signaling to MAPK and in receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BETA-ADRENERGIC-RECEPTOR; COUPLED RECEPTORS; FAMILY KINASES; C-SRC; MEDIATED ENDOCYTOSIS; DEPENDENT ACTIVATION; 3T3 CELLS; B-RAF; PATHWAY	G protein-coupled receptors form the largest family of membrane receptors and transmit diverse ligand signals to modulate various cellular responses. After activation by their ligands, some of these G protein-coupled receptors are desensitized, internalized (endocytosed), and down-regulated ( degraded). In HEK 293 cells, the G(s)-coupled beta(2)-adrenergic receptor was postulated to initiate a second wave of signaling, such as the activation of the mitogen-activated protein kinase ( MAPK) pathway after the receptor is internalized. The tyrosine kinase c-Src plays a critical role in these events. Here we used mouse embryonic fibroblast (MEF) cells deficient in Src family tyrosine kinases to examine the role of Src in beta(2)-adrenergic receptor signaling to the MAPK pathway and in receptor internalization. We found that in Src-deficient cells the beta(2)-adrenergic receptor could activate the MAPK pathway. However, the internalization of beta(2)-adrenergic receptors was blocked in Src-deficient MEF cells. Furthermore, we observed that in MEF cells deficient in beta-arrestin 2 the internalization of the beta(2)-adrenergic receptor was impaired, whereas the activation of the MAPK pathway by the beta(2)-adrenergic receptor was normal. Our data demonstrate that although Src and beta-arrestin 2 play essential roles in beta(2)-adrenergic receptor internalization, they are not required for the activation of the MAPK pathway by the beta(2)-adrenergic receptor. In other words, our finding suggests that receptor internalization is not required for beta(2)-adrenergic receptor signaling to the MAPK pathway in MEF cells.	Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA	Cornell University	Huang, XY (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA.	xyhuang@med.cornell.edu		Sun, Yutong/0000-0002-9368-2957				BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; FAURE M, 1994, J BIOL CHEM, V269, P7851; Friedman J, 2002, MOL PHARMACOL, V62, P1094, DOI 10.1124/mol.62.5.1094; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Jiang YW, 2001, P NATL ACAD SCI USA, V98, P10102, DOI 10.1073/pnas.131200398; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Ma YC, 2002, TRENDS CARDIOVAS MED, V12, P46, DOI 10.1016/S1050-1738(01)00138-4; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Schieffer B, 1997, AM J PHYSIOL-CELL PH, V272, pC2019, DOI 10.1152/ajpcell.1997.272.6.C2019; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328	59	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21637	21642		10.1074/jbc.M400956200	http://dx.doi.org/10.1074/jbc.M400956200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14990578	hybrid			2022-12-27	WOS:000221273800130
J	Bellingham, SA; Lahiri, DK; Maloney, B; La Fontaine, S; Multhaup, G; Camakaris, J				Bellingham, SA; Lahiri, DK; Maloney, B; La Fontaine, S; Multhaup, G; Camakaris, J			Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; TRANSCRIPTIONAL ACTIVITY; TRANSGENIC MICE; MENKES-DISEASE; PROMOTER; BINDING; REDUCTION; TRANSPORT; CELLS; BRAIN	Alzheimer's disease is characterized by the accumulation of amyloid-beta peptide, which is cleaved from the amyloid-beta precursor protein (APP). Reduction in levels of the potentially toxic amyloid-beta has emerged as one of the most important therapeutic goals in Alzheimer's disease. Key targets for this goal are factors that affect the regulation of the APP gene. Recent in vivo and in vitro studies have illustrated the importance of copper in Alzheimer's disease neuropathogenesis and suggested a role for APP and amyloid-beta in copper homeostasis. We hypothesized that metals and in particular copper might alter APP gene expression. To test the hypothesis, we utilized human fibroblasts overexpressing the Menkes protein (MNK), a major mammalian copper efflux protein. MNK deletion fibroblasts have high intracellular copper, whereas MNK overexpressing fibroblasts have severely depleted intracellular copper. We demonstrate that copper depletion significantly reduced APP protein levels and down-regulated APP gene expression. Furthermore, APP promoter deletion constructs identified the copper-regulatory region between -490 and +104 of the APP gene promoter in both basal MNK overexpressing cells and in copper-chelated MNK deletion cells. Overall these data support the hypothesis that copper can regulate APP expression and further support a role for APP to function in copper homeostasis. Copper-regulated APP expression may also provide a potential therapeutic target in Alzheimer's disease.	Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia; Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat,Lab Neurogenet, Indianapolis, IN 46202 USA; Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, Geelong, Vic 3125, Australia; Free Univ Berlin, Inst Biochem Chem, D-14195 Berlin, Germany	University of Melbourne; Indiana University System; Indiana University-Purdue University Indianapolis; Deakin University; Free University of Berlin	Camakaris, J (corresponding author), Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia.	j.camakaris@unimelb.edu.au	Lahiri, Debomoy/AAZ-3322-2020; La Fontaine, Sharon/G-7113-2018; Maloney, Bryan J/C-4924-2011; Bellingham, Shayne A/E-5665-2012	La Fontaine, Sharon/0000-0002-9948-074X; Maloney, Bryan J/0000-0003-2364-9649; 	NATIONAL INSTITUTE ON AGING [R01AG018884] Funding Source: NIH RePORTER; NIA NIH HHS [AG 18884, AG 18739] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ambrosini L, 1999, HUM MOL GENET, V8, P1547, DOI 10.1093/hmg/8.8.1547; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; Belandia B, 1998, J BIOL CHEM, V273, P30366, DOI 10.1074/jbc.273.46.30366; Bingham MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG1400, DOI 10.1152/ajpgi.1997.272.6.G1400; Borchardt T, 1999, BIOCHEM J, V344, P461, DOI 10.1042/0264-6021:3440461; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; CAMAKARIS J, 1980, BIOCHEM GENET, V18, P117, DOI 10.1007/BF00504364; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; HOLTZMAN DM, 1992, EMBO J, V11, P619, DOI 10.1002/j.1460-2075.1992.tb05094.x; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Koizumi S, 1999, EUR J BIOCHEM, V259, P635, DOI 10.1046/j.1432-1327.1999.00069.x; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lahiri DK, 2000, MOL BRAIN RES, V77, P185, DOI 10.1016/S0169-328X(00)00051-6; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Phinney AL, 2003, P NATL ACAD SCI USA, V100, P14193, DOI 10.1073/pnas.2332851100; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Ringheim GE, 1996, BIOCHEM BIOPH RES CO, V224, P246, DOI 10.1006/bbrc.1996.1015; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; SALBAUM JM, 1994, J EXP ZOOL, V269, P116, DOI 10.1002/jez.1402690205; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Sayre LM, 2000, CELL MOL BIOL, V46, P731; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; SCHUG J, 1997, COMPUTATIONAL BIOL I; Song WH, 1998, GENE, V217, P165, DOI 10.1016/S0378-1119(98)00340-0; Song WH, 1998, GENE, V217, P151, DOI 10.1016/S0378-1119(98)00337-0; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; Theuns J, 2000, HUM MOL GENET, V9, P2383, DOI 10.1093/hmg/9.16.2383; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; White AR, 1999, J NEUROSCI, V19, P9170; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2	45	140	145	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20378	20386		10.1074/jbc.M400805200	http://dx.doi.org/10.1074/jbc.M400805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985339	Green Submitted, hybrid			2022-12-27	WOS:000221164500116
J	Catalano, S; Mauro, L; Marsico, S; Giordano, C; Rizza, P; Rago, V; Montanaro, D; Maggiolini, M; Panno, ML; Ando, S				Catalano, S; Mauro, L; Marsico, S; Giordano, C; Rizza, P; Rago, V; Montanaro, D; Maggiolini, M; Panno, ML; Ando, S			Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; MAMMARY EPITHELIAL-CELLS; BREAST-CANCER RISK; GROWTH-FACTOR; PROLIFERATIVE RESPONSE; IN-VITRO; NUCLEAR TRANSLOCATION; PROTEIN-KINASE; ADIPOSE-TISSUE; PHOSPHORYLATION	Leptin is a hormone with multiple biological actions, produced predominantly by adipose tissue. In humans, plasma levels correlate with total body fat, and high concentrations occur in obese women. Among its functions, leptin is able to stimulate normal and tumor cell growth. We demonstrated that leptin induces aromatase activity in MCF-7 cells evidencing its important role in enhancing in situ estradiol production and promoting estrogen-dependent breast cancer progression. Estrogen receptor alpha (ERalpha), which plays an essential role in breast cancer development, can be transcriptionally activated in a ligand-independent manner. Taking into account that unliganded ERalpha is an effector of mitogen-activated protein kinase (MAPK) signal and that leptin is able, via Janus kinase, to activate the Ras-dependent MAPK pathway, in the present study we investigate the ability of leptin to transactivate ERalpha. We provided evidence that leptin is able to reproduce the classic features of ERalpha transactivation in a breast cancer cell line: nuclear localization, down-regulation of its mRNA and protein levels, and up-regulation of a classic estrogen-dependent gene such as pS2. Transactivation experiments with a transfected reporter gene for nuclear ER showed an activation of ERalpha either in MCF-7 or in HeLa cells. Using a dominant negative ERK2 or the MAPK inhibitor PD 98059, we showed that leptin activates the ERalpha through the MAPK pathway. The N-terminal transcriptional activation function 1 appears essential for the leptin response. Finally, it is worth noting that leptin exposure potentates also the estradiol-induced activation of ERalpha. Thus, we are able to demonstrate that the amplification of estrogen signal induced by leptin occurs through an enhancing in situ E-2 production as well as a direct functional activation of ERalpha.	Univ Calabria, Fac Pharm, Dept Cell Biol, I-87030 Cosenza, Italy; Univ Calabria, Fac Pharm, Dept Pharmacobiol, I-87030 Cosenza, Italy; Univ Calabria, Fac Pharm, Ctr Sanitario, I-87030 Cosenza, Italy	University of Calabria; University of Calabria; University of Calabria	Ando, S (corresponding author), Univ Calabria, Fac Pharm, Dept Cell Biol, I-87030 Cosenza, Italy.	sebastiano.ando@unical.it	MARSICO, Stefania/J-9938-2019; Rago, Vittoria/AAE-5924-2020; Maggiolini, Marcello/Z-4729-2019	MARSICO, Stefania/0000-0003-1598-0526; Rago, Vittoria/0000-0003-3971-7378; Maggiolini, Marcello/0000-0002-7485-854X; CATALANO, Stefania/0000-0002-6352-9628; RIZZA, Pietro/0000-0002-1267-3910; GIORDANO, Cinzia/0000-0003-4969-0607				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bray GA, 2002, J NUTR, V132, p3451S, DOI 10.1093/jn/132.11.3451S; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Casabiell X, 1998, J CLIN ENDOCR METAB, V83, P2149, DOI 10.1210/jc.83.6.2149; Catalano S, 2003, J BIOL CHEM, V278, P28668, DOI 10.1074/jbc.M301695200; Cenni B, 1999, TRENDS ENDOCRIN MET, V10, P41, DOI 10.1016/S1043-2760(98)00121-0; Chen SA, 1998, FRONT BIOSCI-LANDMRK, V3, P922; Dieudonne MN, 2002, BIOCHEM BIOPH RES CO, V293, P622, DOI 10.1016/S0006-291X(02)00205-X; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Hu X, 2002, J NATL CANCER I, V94, P1704, DOI 10.1093/jnci/94.22.1704; INE BA, 1994, MOL ENDOCRINOL, V8, P1397; Islam MS, 1997, BIOCHEM BIOPH RES CO, V238, P851, DOI 10.1006/bbrc.1997.7399; JENSEN EV, 1995, ANN NY ACAD SCI, V761, P1, DOI 10.1111/j.1749-6632.1995.tb31364.x; Karas RH, 1998, J CLIN INVEST, V101, P2851, DOI 10.1172/JCI1416; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Laud K, 1999, FEBS LETT, V463, P194, DOI 10.1016/S0014-5793(99)01616-6; Laud K, 2002, MOL CELL ENDOCRINOL, V188, P219, DOI 10.1016/S0303-7207(01)00678-5; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Lu Q, 2002, FEBS LETT, V516, P1, DOI 10.1016/S0014-5793(02)02432-8; Machinal-Quelin F, 2002, AM J PHYSIOL-CELL PH, V282, pC853, DOI 10.1152/ajpcell.00331.2001; Maehle BO, 1996, BREAST CANCER RES TR, V41, P123, DOI 10.1007/BF01807157; Maggiolini M, 1999, BIOL CHEM, V380, P695, DOI 10.1515/BC.1999.086; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; O'Brien SN, 1999, BIOCHEM BIOPH RES CO, V259, P695, DOI 10.1006/bbrc.1999.0843; Park HY, 2001, EXP MOL MED, V33, P95, DOI 10.1038/emm.2001.17; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Reed MJ, 2001, CLIN ENDOCRINOL, V54, P563, DOI 10.1046/j.1365-2265.2001.01276.x; Santagati S, 1997, MOL ENDOCRINOL, V11, P938, DOI 10.1210/me.11.7.938; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schneider R, 2001, HORM METAB RES, V33, P1, DOI 10.1055/s-2001-12617; Shimizu H, 1997, J ENDOCRINOL, V154, P285, DOI 10.1677/joe.0.1540285; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Smith-Kirwin SM, 1998, J CLIN ENDOCR METAB, V83, P1810, DOI 10.1210/jc.83.5.1810; Stallmeyer B, 2001, J INVEST DERMATOL, V117, P98, DOI 10.1046/j.0022-202x.2001.01387.x; Stoll BA, 1998, BREAST CANCER RES TR, V49, P187, DOI 10.1023/A:1006003110909; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; Tsuchiya T, 1999, EUR J PHARMACOL, V365, P273, DOI 10.1016/S0014-2999(98)00884-X; van den Brandt PA, 2000, AM J EPIDEMIOL, V152, P514, DOI 10.1093/aje/152.6.514; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; Zabeau L, 2003, FEBS LETT, V546, P45, DOI 10.1016/S0014-5793(03)00440-X; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	51	208	221	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19908	19915		10.1074/jbc.M313191200	http://dx.doi.org/10.1074/jbc.M313191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985328	hybrid			2022-12-27	WOS:000221164500065
J	De Taeye, B; Compernolle, G; Declerck, PJ				De Taeye, B; Compernolle, G; Declerck, PJ			Site-directed targeting of plasminogen activator inhibitor-1 as an example for a novel approach in rational drug design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; MONOCLONAL-ANTIBODIES; BETA-SHEET; PROTEINASE INHIBITION; SERPIN; SUBSTRATE; COMPLEX; INSERTION; EPITOPE; PAI-1	As plasminogen activator inhibitor-1 (PAI-1), the physiological inhibitor of tissue-type plasminogen activator, is considered to be an important risk factor in several (patho) physiological conditions, many research activities focus on attempts to inhibit this serpin. The approach illustrated in the current study focuses on elucidating important interaction sites allowing the inhibition of PAI-1. Since monoclonal antibodies are in most cases not ideal for therapeutic use, the question of whether smaller molecules exert comparable effects is a hot issue. To answer this question, Cys residues were introduced in PAI-1 at positions previously identified as determining the epitope of a PAI-1-inhibiting antibody, MA-8H9D4, resulting in PAI-1-R300C, PAI-1-Q303C, and PAI-1-D305C. Subsequently, low molecular mass sulfhydryl-specific reagents (i.e. BODIPY(R) 530/550 IA (molecular mass 626 Da) and BODIPY(R) FL C-1-IA (molecular mass 417 Da)) were allowed to react covalently with the cysteine. The functional distribution ( inhibitory versus substrate) toward tissue-type plasminogen activator was determined for the labeled and the unlabeled samples. Labeling at position 300 leads to a 1.7- and 2.2-fold increase in SI value for BODIPY(R) 530/550 IA and BODIPY(R) FL C-1-IA, respectively. Labeling at position 303 results in a 3.3- and 1.9-fold increase of the SI value for the large and the small label, respectively. At position 305, the SI values are 3.1-fold increased for both labels. The effect ( on SI and on serpin activity) of the manipulations at these positions is in good agreement with the effect exerted by MA-8H9D4. In conclusion, our study provides proof of concept for the proposed approach in evaluating whether targeting a functional epitope with a small synthetic compound may be a feasible strategy in rational drug design.	Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium	KU Leuven	Declerck, PJ (corresponding author), Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, E Van Evenstr 4, B-3000 Louvain, Belgium.	paul.declerck@pharm.kuleuven.ac.be	Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105				Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; Bijnens AP, 2001, J BIOL CHEM, V276, P44912, DOI 10.1074/jbc.M103077200; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; Charlton P, 1997, FIBRINOLYSIS PROTEOL, V11, P51, DOI 10.1016/S0268-9499(97)80009-4; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Debrock S, 1997, GENE, V189, P83, DOI 10.1016/S0378-1119(96)00838-4; Egelund R, 2001, J BIOL CHEM, V276, P13077, DOI 10.1074/jbc.M009024200; EITZMAN DT, 1995, J CLIN INVEST, V95, P2416, DOI 10.1172/JCI117937; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; Komissarov AA, 2002, J BIOL CHEM, V277, P43858, DOI 10.1074/jbc.M204110200; KRUITHOF EKO, 1984, BLOOD, V64, P907; KVASSMAN JO, 1995, J BIOL CHEM, V270, P27942, DOI 10.1074/jbc.270.46.27942; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; Naessens D, 2003, THROMB HAEMOSTASIS, V90, P52, DOI 10.1055/s-0037-1613598; Naessens D, 2003, J THROMB HAEMOST, V1, P1028, DOI 10.1046/j.1538-7836.2003.00206.x; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6284, DOI 10.1021/bi010100x; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P261; Verbeke K, 2003, THROMB HAEMOSTASIS, V89, P74; Vleugels N, 1998, FIBRINOLYSIS PROTEOL, V12, P277, DOI 10.1016/S0268-9499(98)80020-9; Wind T, 2001, EUR J BIOCHEM, V268, P1095, DOI 10.1046/j.1432-1327.2001.2680041095.x	28	6	6	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20447	20450		10.1074/jbc.M401971200	http://dx.doi.org/10.1074/jbc.M401971200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14988411	hybrid			2022-12-27	WOS:000221164500123
J	Han, NLR; Clements, JD; Lynch, JW				Han, NLR; Clements, JD; Lynch, JW			Comparison of taurine- and glycine-induced conformational changes in the M2-M3 domain of the glycine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; GABA(A) RECEPTOR; ALPHA-SUBUNITS; DISULFIDE LOOP; AGONIST ACTION; CHANNEL; ACTIVATION; IDENTIFICATION; ACCESSIBILITY; RESIDUES	In the ionotropic glutamate receptor, the global conformational changes induced by partial agonists are smaller than those induced by full agonists. However, in the pentameric ligand-gated ion channel receptor family, the structural basis of partial agonism is not understood. This study investigated whether full and partial agonists induce different conformation changes in the glycine receptor chloride channel ( GlyR). A substituted cysteine accessibility analysis demonstrated previously that glycine binding induced an increase in surface accessibility of all residues from Arg(271) to Lys(276) in the M2-M3 domain of the homomeric alpha1 GlyR. Here we compare the surface accessibility changes induced by the full agonist, glycine, and the partial agonist, taurine. In GlyRs incorporating the A272C, S273C, L274C, or P275C mutation, the reaction rate of the cysteine-specific compound, methanethiosulfonate ethyltrimethylammonium, depended on how strongly the receptors were activated but was agonist-independent. Reaction rates could not be compared in the R271C and K276C mutant GlyRs because methanethiosulfonate ethyltrimethylammonium did not modify the extremely small currents induced by saturating taurine or equivalent low glycine concentrations. The results indicate that bound taurine and glycine molecules impose identical conformational changes to the M2-M3 domain. We therefore conclude that the higher efficacy of glycine is due to an increased ability to stabilize a common activated configuration.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Neurosci, Canberra, ACT 0200, Australia	University of Queensland; Australian National University; John Curtin School of Medical Research	Lynch, JW (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	j.lynch@uq.edu.au	Lynch, Joseph/C-8636-2009					Absalom NL, 2003, J BIOL CHEM, V278, P50151, DOI 10.1074/jbc.M305357200; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Boileau AJ, 1999, J NEUROSCI, V19, P10213; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Fisher JL, 1998, J NEUROSCI, V18, P2944; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kash TL, 2004, J BIOL CHEM, V279, P4887, DOI 10.1074/jbc.M311441200; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Lewis TM, 2003, J PHYSIOL-LONDON, V549, P361, DOI 10.1113/jphysiol.2002.037796; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; O'Shea SM, 2000, J BIOL CHEM, V275, P22764, DOI 10.1074/jbc.M001299200; RAJENDRA S, 1995, EMBO J, V14, P2987, DOI 10.1002/j.1460-2075.1995.tb07301.x; Rovira JC, 1998, FEBS LETT, V433, P89, DOI 10.1016/S0014-5793(98)00889-8; Rovira JC, 1999, PFLUG ARCH EUR J PHY, V439, P86, DOI 10.1007/s004240051131; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SCHMIEDEN V, 1995, MOL PHARMACOL, V48, P919; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; Schofield CM, 2003, J BIOL CHEM, V278, P34079, DOI 10.1074/jbc.M302416200; Shan Q, 2003, J NEUROCHEM, V86, P498, DOI 10.1046/j.1471-4159.2003.01872.x; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1	36	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19559	19565		10.1074/jbc.M400548200	http://dx.doi.org/10.1074/jbc.M400548200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14981077	hybrid			2022-12-27	WOS:000221164500023
J	Choi, JY; Guengerich, FP				Choi, JY; Guengerich, FP			Analysis of the effect of bulk at N-2-alkylguanine DNA adducts on catalytic efficiency and fidelity of the processive DNA polymerases bacteriophage T7 exonuclease(-) and HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; DOUBLE-STRANDED DNA; STEADY-STATE; ESCHERICHIA-COLI; REPLICATION FIDELITY; NUCLEOTIDE INCORPORATION; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; BEARING ADDUCTS	The N-2 atom of guanine (G) is susceptible to modification by various carcinogens. Oligonucleotides with increasing bulk at this position were analyzed for fidelity and catalytic efficiency with the processive DNA polymerases human immunodeficiency virus, type 1, reverse transcriptase (RT), and bacteriophage T7 exonuclease (T7(-)). RT and T7(-) effectively bypassed N-2-methyl(Me) G and readily extended primers but were strongly blocked by N-2-ethyl(Et)G, N-2-isobutylG, N-2-benzylG, and N-2-methyl(9-anthracenyl)G. Steady-state kinetics of single nucleotide incorporation by RT and T7(-) showed a decrease of 103 in k(cat)/K-m for dCTP incorporation opposite N-2-MeG and a further large decrease opposite N-2-EtG. Misincorporation frequency was increased 10(2)-10(3)-fold by a Me group and another similar to10(3)-fold by an Et group. dATP was preferentially incorporated opposite bulky N-2-alkylG molecules. N-2-MeG attenuated the pre-steady-state kinetic bursts with RT and T7(-), and N-2-EtG eliminated the bursts. Large elemental effects with thio-dCTP(alphaS) were observed with N-2-EtG (6-and 72-fold decreases) but were much less with N-2-MeG, indicating that the N-2-Et group may affect the rate of the chemistry step (phosphodiester bond formation). Similar values of K-d(dCTP) and K-d(DNA) and k(off) rates of DNA substrates from RT and T7(-) indicate that ground-state binding and dissociation rates are not considerably affected by the bulk. We conclude that even a Me group at the guanine N-2 atom can cause a profound interfering effect on the fidelity and efficiency; an Et or larger group causes preferential misincorporation and strong blockage of replicative polymerases, probably at and before the chemistry step, demonstrating the role of bulk in DNA lesions.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NIEHS NIH HHS [R01 ES10375, P30 ES00267] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010375, P30ES000267] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BORER PN, 1975, HDB BIOCH MOL BIOL, P589; CASALE R, 1990, J AM CHEM SOC, V112, P5264, DOI 10.1021/ja00169a039; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; de los Santos C, 2001, J BIOL CHEM, V276, P9077, DOI 10.1074/jbc.M009028200; DeCorte BL, 1996, CHEM RES TOXICOL, V9, P630, DOI 10.1021/tx9501795; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; Fang JL, 1997, CARCINOGENESIS, V18, P627, DOI 10.1093/carcin/18.4.627; Fernandes A, 1998, BIOCHEMISTRY-US, V37, P10164, DOI 10.1021/bi980401f; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; Friedman CHG, 1995, NAT LANG ENG, V1, P83, DOI [10.1017/S1351324900000061, DOI 10.1017/S1351324900000061]; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Furge LL, 1999, BIOCHEMISTRY-US, V38, P4818, DOI 10.1021/bi982163u; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kim MS, 1998, CHEM RES TOXICOL, V11, P311, DOI 10.1021/tx970206m; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Langouet S, 1998, BIOCHEMISTRY-US, V37, P5184, DOI 10.1021/bi972327r; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; Liu J, 2001, BIOCHEMISTRY-US, V40, P9014, DOI 10.1021/bi010646j; LUNN CA, 1984, J BIOL CHEM, V259, P469; Matsuda T, 1999, BIOCHEMISTRY-US, V38, P929, DOI 10.1021/bi982134j; MEEHAN T, 1979, NATURE, V277, P410, DOI 10.1038/277410a0; MEYER RB, 1994, PROTOCOLS OLIGONUCLE, P73; Minko IG, 2003, J BIOL CHEM, V278, P784, DOI 10.1074/jbc.M207774200; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; Nechev LV, 2002, CHEM RES TOXICOL, V15, P607, DOI 10.1021/tx010181y; Nechev LV, 2001, CHEM RES TOXICOL, V14, P379, DOI 10.1021/tx000241k; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Perrino FW, 2003, CHEM RES TOXICOL, V16, P1616, DOI 10.1021/tx034164f; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Sako M, 1999, J ORG CHEM, V64, P5719, DOI 10.1021/jo990500e; Searle C. F., 1984, CHEM CARCINOGENS; Showalter AK, 2002, BIOCHEMISTRY-US, V41, P10571, DOI 10.1021/bi026021i; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1999, BIOCHEMISTRY-US, V38, P715, DOI 10.1021/bi981854n; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; TAN HB, 1994, BIOCHEMISTRY-US, V33, P5335, DOI 10.1021/bi00183a042; Terashima I, 2001, BIOCHEMISTRY-US, V40, P4106, DOI 10.1021/bi002719p; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1027, DOI 10.1021/bi011495n; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1039, DOI 10.1021/bi011496f; Yasui M, 2001, NUCLEIC ACIDS RES, V29, P1994, DOI 10.1093/nar/29.9.1994; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	60	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19217	19229		10.1074/jbc.M313759200	http://dx.doi.org/10.1074/jbc.M313759200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985330	hybrid			2022-12-27	WOS:000221041500135
J	Song, LP; Chaudhuri, M; Knopf, CW; Parris, DS				Song, LP; Chaudhuri, M; Knopf, CW; Parris, DS			Contribution of the 3 '- to 5 '-exonuclease activity of herpes simplex virus type 1 DNA polymerase to the fidelity of DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FIDELITY; EXONUCLEASE ACTIVITY; MISMATCH EXTENSION; PROTEIN; PROCESSIVITY; MUTATIONS; SPECTRA; MUTANT; DOMAIN; UL42	Nucleotide incorporation by the herpes simplex virus type 1 DNA polymerase catalytic subunit (pol) is less faithful than for most replicative DNA polymerases, despite the presence of an associated 3'- to 5'-exonuclease (exo) activity. To determine the aspects of fidelity affected by the exo activity, nucleotide incorporation and mismatch extension frequency for purified wild-type and an exo-deficient mutant (D368A) pol were compared using primer/templates that varied at only a single position. For both enzymes, nucleotide discrimination during incorporation occurred predominantly at the level of Km for nucleotide and was the major contributor to fidelity. The contribution of the exo activity to reducing the efficiency of formation of half of all possible mispairs was 6-fold or less, and 30-fold when averaged for the formation of all possible mispairs. In steady-state reactions, mismatches imposed a significant kinetic barrier to extension independent of exo activity. However, during processive DNA synthesis in the presence of only three nucleotides, misincorporation and mismatch extension were efficient for both exo-deficient and wildtype pol catalytic subunits, although slower kinetics of mismatch extension by the exo-deficient pol were observed. The UL42 processivity factor decreased the extent of misincorporation by both the wild-type and the exo-deficient pol to similar levels, but mismatch extension by the wild-type pol . UL42 complex was much less efficient than by the mutant pol . UL42. Thus, despite relatively frequent ( 1 in 300) misincorporation events catalyzed by wild-type herpes simplex virus pol . UL42 holoenzyme, mismatch extension occurs only rarely, prevented in part by the kinetic barrier to extending a mismatch. The kinetic barrier also increases the probability that a mismatched primer terminus will be transferred to the exo site where it can be excised by the associated exo activity and subsequently extended with correct nucleotide.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Deutsch Krebsforschungszentrum, Inst Appl Tumor Virol, D-69120 Heidelberg, Germany	University System of Ohio; Ohio State University; Helmholtz Association; German Cancer Research Center (DKFZ)	Parris, DS (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.	parris.1@osu.edu			NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034930] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058] Funding Source: Medline; NIGMS NIH HHS [GM34930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker RO, 1998, J BIOL CHEM, V273, P24075, DOI 10.1074/jbc.273.37.24075; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; Challberg M., 1996, DNA REPLICATION EUKA, P721; Chaudhuri M, 2003, J BIOL CHEM, V278, P8996, DOI 10.1074/jbc.M210023200; Chaudhuri M, 2002, J VIROL, V76, P10270, DOI 10.1128/JVI.76.20.10270-10281.2002; Creighton S, 1995, METHOD ENZYMOL, V262, P232; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; GALLO ML, 1989, J VIROL, V63, P5023, DOI 10.1128/JVI.63.12.5023-5029.1989; Goodman MF, 1998, GENETICS, V148, P1475; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HALL JD, 1995, J GEN VIROL, V76, P2999, DOI 10.1099/0022-1317-76-12-2999; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Hwang YT, 1999, J VIROL, V73, P5326, DOI 10.1128/JVI.73.7.5326-5332.1999; Hwang YT, 1997, J VIROL, V71, P7791, DOI 10.1128/JVI.71.10.7791-7798.1997; Hwang YT, 2003, J VIROL, V77, P2946, DOI 10.1128/JVI.77.5.2946-2955.2003; Knopf CW, 2000, ACTA VIROL, V44, P289; Knopf CW, 1998, VIRUS GENES, V16, P47, DOI 10.1023/A:1007997609122; KNOPF KW, 1979, EUR J BIOCHEM, V98, P231, DOI 10.1111/j.1432-1033.1979.tb13181.x; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; Kuhn FJP, 1996, J BIOL CHEM, V271, P29245; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUNKEL TA, 1984, J BIOL CHEM, V259, P1539; Lu QS, 2002, J VIROL, V76, P5822, DOI 10.1128/JVI.76.11.5822-5828.2002; MARCY AI, 1990, NUCLEIC ACIDS RES, V18, P1207, DOI 10.1093/nar/18.5.1207; Roizman B, 2001, FIELDS VIROL, P2381; Washington MT, 2001, J BIOL CHEM, V276, P2263, DOI 10.1074/jbc.M009049200; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; Zhu YL, 2003, J VIROL, V77, P10147, DOI 10.1128/JVI.77.18.10147-10153.2003	33	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18535	18543		10.1074/jbc.M309848200	http://dx.doi.org/10.1074/jbc.M309848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14982924	hybrid			2022-12-27	WOS:000221041500055
J	Garcia-Castellanos, R; Mallorqui-Fernandez, G; Marrero, A; Potempa, J; Coll, M; Gomis-Ruth, FX				Garcia-Castellanos, R; Mallorqui-Fernandez, G; Marrero, A; Potempa, J; Coll, M; Gomis-Ruth, FX			On the transcriptional regulation of methicillin resistance - MecI repressor in complex with its operator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAMASE SYNTHESIS; BACILLUS-LICHENIFORMIS; BINDING PROTEIN; PENICILLINASE REPRESSOR; ANTIBIOTIC-RESISTANCE; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; GENE; BLAI; REGION	Bacterial resistance to antibiotics poses a serious worldwide public health problem due to the high morbidity and mortality caused by infectious diseases. Most hospital-onset infections are associated with methicillin-resistant Staphylococcus aureus (MRSA) strains that have acquired multiple drug resistance to beta-lactam antibiotics. In a response to antimicrobial stress, nearly all clinical MRSA isolates produce beta-lactamase (BlaZ) and a penicillin-binding protein with low affinity for beta-lactam antibiotics (PBP2a, also known as PBP2' or MecA). Both effectors are regulated by homologous signal transduction systems consisting of a sensor/transducer and a transcriptional repressor. MecI (methicillin repressor) blocks mecA but also blaZ transcription and that of itself and the co-transcribed sensor/transducer. The structure of MecI in complex with a cognate operator double-stranded DNA reveals a homodimeric arrangement with a novel C-terminal spiral staircase dimerization domain responsible for dimer integrity. Each protomer interacts with the DNA major groove through a winged helix DNA-binding domain and specifically recognizes the nucleotide sequence 5'-Gua-Thy-Ade-X-Thy-3'. This results in an unusual convex bending of the DNA helix. The structure of this first molecular determinant of methicillin resistance in complex with its target DNA provides insights into its regulatory mechanism and paves the way for new antimicrobial strategies against MRSA.	CSIC, CID, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain; Jagiellonian Univ, Fac Biotechnol, Dept Microbiol, PL-30387 Krakow, Poland; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Jagiellonian University; University System of Georgia; University of Georgia	Gomis-Ruth, FX (corresponding author), CSIC, CID, Inst Biol Mol Barcelona, C Jordi Girona 18-26, ES-08034 Barcelona, Spain.	xgrcri@ibmb.csic.es	Coll, Miquel/L-5999-2014	Coll, Miquel/0000-0003-4471-8674; Garcia-Castellanos, Raquel/0000-0001-6225-5373; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berger-Bachi B, 2002, ARCH MICROBIOL, V178, P165, DOI 10.1007/s00203-002-0436-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Busenlehner LS, 2003, FEMS MICROBIOL REV, V27, P131, DOI 10.1016/S0168-6445(03)00054-8; Clarke SR, 2001, MICROBIOL-UK, V147, P803, DOI 10.1099/00221287-147-4-803; Clarke SR, 2001, J ANTIMICROB CHEMOTH, V47, P377, DOI 10.1093/jac/47.4.377; COHEN S, 1968, J BACTERIOL, V95, P1368, DOI 10.1128/JB.95.4.1368-1374.1968; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; Dickerson RE, 1997, BIOPOLYMERS, V44, P361, DOI 10.1002/(SICI)1097-0282(1997)44:4<361::AID-BIP4>3.0.CO;2-X; Diederichs K, 2003, ACTA CRYSTALLOGR D, V59, P903, DOI 10.1107/S0907444903006516; DUBNAU DA, 1965, J GEN MICROBIOL, V41, P7, DOI 10.1099/00221287-41-1-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Filee P, 2003, J BIOL CHEM, V278, P16482, DOI 10.1074/jbc.M210887200; Filee P, 2002, MOL MICROBIOL, V44, P685, DOI 10.1046/j.1365-2958.2002.02888.x; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; Garcia-Castellanos R, 2003, J BIOL CHEM, V278, P39897, DOI 10.1074/jbc.M307199200; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Gregory PD, 1997, MOL MICROBIOL, V24, P1025, DOI 10.1046/j.1365-2958.1997.4051770.x; GROSSMAN MJ, 1989, FEBS LETT, V246, P83, DOI 10.1016/0014-5793(89)80258-3; HACKBARTH CJ, 1993, ANTIMICROB AGENTS CH, V37, P1144, DOI 10.1128/AAC.37.5.1144; Hardt K, 1997, MOL MICROBIOL, V23, P935, DOI 10.1046/j.1365-2958.1997.2761642.x; HIMENO T, 1986, J BACTERIOL, V168, P1128, DOI 10.1128/jb.168.3.1128-1132.1986; Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3; HIRAMATSU K, 1992, FEBS LETT, V298, P133, DOI 10.1016/0014-5793(92)80039-J; JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Katayama Y, 2003, J BACTERIOL, V185, P5465, DOI 10.1128/JB.185.18.5465-5472.2003; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; Lewis RA, 2000, J ANTIMICROB CHEMOTH, V45, P139, DOI 10.1093/jac/45.2.139; Lewis RA, 1999, FEMS MICROBIOL LETT, V178, P271, DOI 10.1016/S0378-1097(99)00366-3; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; McKinney TK, 2001, J BACTERIOL, V183, P6862, DOI 10.1128/JB.183.23.6862-6868.2001; Moore HF, 1917, ARCH INTERN MED, V19, P611; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Pinho MG, 2001, P NATL ACAD SCI USA, V98, P10886, DOI 10.1073/pnas.191260798; Ray SS, 2003, PROTEINS, V50, P170, DOI 10.1002/prot.10272; RYFFEL C, 1992, ANTIMICROB AGENTS CH, V36, P25, DOI 10.1128/AAC.36.1.25; Sharma VK, 1998, J BACTERIOL, V180, P2160, DOI 10.1128/JB.180.8.2160-2166.1998; SHI WP, 1994, J BIOL CHEM, V269, P19826; Solioz M, 2003, FEMS MICROBIOL REV, V27, P183, DOI 10.1016/S0168-6445(03)00053-6; Van Melckebeke H, 2003, J MOL BIOL, V333, P711, DOI 10.1016/j/jmb.2003.09.005; Weller TMA, 1999, J ANTIMICROB CHEMOTH, V43, P15, DOI 10.1093/jac/43.1.15; WHO, 2001, WHOCDSCSRDRS20012; WITTMAN V, 1993, J BACTERIOL, V175, P7383, DOI 10.1128/JB.175.22.7383-7390.1993; Zhang HZ, 2001, SCIENCE, V291, P1962, DOI 10.1126/science.1055144	48	56	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17888	17896		10.1074/jbc.M313123200	http://dx.doi.org/10.1074/jbc.M313123200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960592	hybrid			2022-12-27	WOS:000220870400122
J	Lee, HJ; Lim, HM; Adhya, S				Lee, HJ; Lim, HM; Adhya, S			An unsubstituted C2 hydrogen of adenine is critical and sufficient at the-11 position of a promoter to signal base pair deformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE HOLOENZYME; OPEN COMPLEX-FORMATION; URACIL-DNA GLYCOSYLASE; AROMATIC-AMINO-ACIDS; TRANSCRIPTION INITIATION; CRYSTAL-STRUCTURE; SIGMA-FACTOR; CONSERVED REGION-2; GENETIC-EVIDENCE; STRUCTURAL BASIS	The conserved A: T base pair at the -11 position of the promoters in Escherichia coli is very sensitive to substitutions. In vitro transcription with the galP1 promoter having a natural or unnatural base in either strand at position -11 showed that only a purine base with no side group at C2 in the nontemplate strand is transcriptionally potent; neither a purine with an amino group at C2 nor a pyrimidine support transcription. The amino group at C6 in the omnipresent adenine at -11 does not play any role in promoting transcription. The nature of the base, complementary or noncomplementary, at -11 in the template strand also does not influence transcription. We propose that the adenine, by becoming extra-helical, interacts with an amino acid(s) of the 2.3-2.4 region of sigma for which an unsubstituted C2 hydrogen is critical.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Chungnam Natl Univ, Coll Nat Sci, Dept Biol, Taejon 305764, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Chungnam National University	Lim, HM (corresponding author), NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	hmlim@cnu.ac.kr; sadhya@helix.nih.gov		Lim, Heon/0000-0003-1711-2589	NATIONAL CANCER INSTITUTE [Z01BC008751, ZIABC008751] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARIK S, 1991, BIOTECHNIQUES, V10, P489; BOROWIEC JA, 1986, BIOCHEMISTRY-US, V25, P5051, DOI 10.1021/bi00366a012; BUSBY S, 1982, J MOL BIOL, V154, P211, DOI 10.1016/0022-2836(82)90061-4; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Campbell EA, 2002, CELL, V108, P795, DOI 10.1016/S0092-8674(02)00662-1; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHOY HE, 1993, P NATL ACAD SCI USA, V90, P472, DOI 10.1073/pnas.90.2.472; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; DICKERSON RE, 1982, SCIENCE, V216, P475, DOI 10.1126/science.7071593; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; JONES CH, 1992, P NATL ACAD SCI USA, V89, P1958, DOI 10.1073/pnas.89.5.1958; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Li XY, 1998, J BIOL CHEM, V273, P23558, DOI 10.1074/jbc.273.36.23558; Lim HM, 2001, P NATL ACAD SCI USA, V98, P14849, DOI 10.1073/pnas.261517398; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Panaghie G, 2000, J MOL BIOL, V299, P1217, DOI 10.1006/jmbi.2000.3808; PONNAMBALAM S, 1987, FEBS LETT, V219, P189, DOI 10.1016/0014-5793(87)81214-0; Pues H, 1999, BIOCHEMISTRY-US, V38, P1426, DOI 10.1021/bi9818016; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Roberts CW, 1996, CELL, V86, P495; Roy S, 2004, EMBO J, V23, P869, DOI 10.1038/sj.emboj.7600098; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; TATTI KM, 1991, J BACTERIOL, V173, P7828, DOI 10.1128/jb.173.24.7828-7833.1991; Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; Xiao GY, 1999, PROTEINS, V35, P13; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	43	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16899	16902		10.1074/jbc.C400054200	http://dx.doi.org/10.1074/jbc.C400054200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14990576	hybrid			2022-12-27	WOS:000220870400002
J	Miyazaki, T; Sagawa, R; Honma, T; Noguchi, S; Harada, T; Komatsuda, A; Ohtani, H; Wakui, H; Sawada, K; Otaka, M; Watanabe, S; Jikei, M; Ogawa, N; Hamada, F; Itoh, H				Miyazaki, T; Sagawa, R; Honma, T; Noguchi, S; Harada, T; Komatsuda, A; Ohtani, H; Wakui, H; Sawada, K; Otaka, M; Watanabe, S; Jikei, M; Ogawa, N; Hamada, F; Itoh, H			73-kDa molecular chaperone HSP73 is a direct target of antibiotic gentamicin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; HEAT-SHOCK; RAT KIDNEYS; BINDING; IDENTIFICATION; LOCALIZATION; HSC70; HSP90; NEPHROTOXICITY; MECHANISM	Although gentamicin (GM) has been used widely as an antibiotic, the specific binding protein of the drug has not yet been understood sufficiently. Here we show that GM specifically associates with the 73-kDa molecular chaperone HSP73 and reduces its chaperone activity in vitro. In the present study, we investigated GM-specific binding proteins using a GM-affinity column and porcine kidney cytosol. After washing the column, only the 73-kDa protein was eluted from the column by the addition of 10 mM GM. None of the other proteins were found in the eluant. Upon immunoblotting, the protein was identical to HSP73. Upon CD spectrum analysis, the binding of GM to HSP73 resulted in a conformational change in the protein. Although HSP73 prevents aggregation of unfolded rhodanese in vitro, the chaperone activity of HSP73 was suppressed in the presence of GM. Using limited proteolysis of HSP73 by TPCK-trypsin, the GM binding site is a COOH-terminal for one third of the protein known to be a peptide-binding domain. During immunohistochemistry, HSP73 and GM were co-localized in enlarged lysosomes of rat kidneys with GM-induced acute tubular injury in vivo. Our results suggest that the specific association between HSP73 and GM may reduce the chaperone activity of HSP73 in vitro and/or in vivo, and this may have an interaction with GM toxicity in kidneys with GM-induced acute tubular injury.	Akita Univ, Fac Engn & Resource Sci, Dept Mat Proc Engn & Appl Chem Environm, Akita 0108502, Japan; Akita Univ, Sch Med, Dept Internal Med 3, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Internal Med 1, Akita 0108543, Japan	Akita University; Akita University; Akita University	Itoh, H (corresponding author), Akita Univ, Fac Engn & Resource Sci, Dept Mat Proc Engn & Appl Chem Environm, 1-1 Tegata Gakuen Town, Akita 0108502, Japan.	itohh@ipc.akita-u.ac.jp						ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HOSTETLER KY, 1982, P NATL ACAD SCI-BIOL, V79, P1663, DOI 10.1073/pnas.79.5.1663; Itoh H, 1999, BIOCHEM J, V343, P697, DOI 10.1042/0264-6021:3430697; ITOH H, 1995, J BIOL CHEM, V270, P13429, DOI 10.1074/jbc.270.22.13429; Itoh H, 1999, J BIOL CHEM, V274, P35147, DOI 10.1074/jbc.274.49.35147; Itoh H, 1997, BIOCHEM J, V326, P567, DOI 10.1042/bj3260567; ITOH H, 1991, INT J BIOCHEM, V23, P1185; ITOH H, 1991, INT J BIOCHEM, V23, P69; KOMATSUDA A, 1993, LAB INVEST, V68, P687; Komatsuda A, 1997, NEPHROLOGY, V3, P413, DOI 10.1111/j.1440-1797.1997.tb00264.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST S, 1980, DEV BIOL, V77, P463, DOI 10.1016/0012-1606(80)90488-1; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MINGEOTLECLERCQ MP, 1989, BIOCHEM PHARMACOL, V38, P729, DOI 10.1016/0006-2952(89)90225-6; Molitoris BA, 1997, CURR OPIN NEPHROL HY, V6, P384; MORGHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Walker PD, 1999, RENAL FAILURE, V21, P433, DOI 10.3109/08860229909085109; WANG TF, 1993, J BIOL CHEM, V268, P26049; Wu SJ, 2001, BIOCHEM J, V359, P419, DOI 10.1042/0264-6021:3590419	31	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17295	17300		10.1074/jbc.M312217200	http://dx.doi.org/10.1074/jbc.M312217200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966137	hybrid			2022-12-27	WOS:000220870400052
J	Pullikotil, P; Vincent, M; Nichol, ST; Seidah, NG				Pullikotil, P; Vincent, M; Nichol, ST; Seidah, NG			Development of protein-based inhibitors of the proprotein of convertase SKI-1/S1P - Processing of SREBP-2, ATF6, and a viral glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIOMENINGITIS VIRUS GLYCOPROTEIN; TIGHT-BINDING INHIBITORS; ALPHA-1-ANTITRYPSIN PORTLAND; POTENT INHIBITORS; FURIN; CLEAVAGE; ALPHA(1)-ANTITRYPSIN; ENDOPROTEASE; SPECIFICITY; PROPEPTIDE	Processing of membrane-bound transcription factors such as sterol regulatory element-binding proteins (SREBPs) and the ER-stress response factor ATF6, and glycoproteins of some hemorrhagic fever viruses are initiated by the proprotein convertase SKI-1/S1P. So far, no cellular protein-based inhibitor of the hydrophobic-amino acid specific SKI-1 is known. The prosegment of the basic-amino acid specific convertases (e.g. furin and PC5) or alpha(1)-PDX, a variant of alpha(1)-antitrypsin (alpha(1)-AT) exhibiting an RIPR358 sequence at the reactive site loop, were shown to potently inhibit these secretory proteinases. Accordingly, we tested the SKI-1-inhibitory potential of various point mutants of either the 198 amino acid preprosegment of SKI-1-(1-198) or alpha(1)-AT. Transient transfections data showed that, out of numerous mutants studied, the R134E prosegment mutant or the alpha(1)-AT reactive site loop variants RRVL358, RRYL358 and RRIL358 are the best specific cellular inhibitors of SKI-1. The observed inhibition of the processing of endogenous SREBP-2, exogenous ATF6 and a PDGF-A (RRLL86) variant were >55% and reach similar to80% in stable transfectants. We also show that SKI-1 forms SDS-stable complexes with these alpha(1)-AT variants, but not with wild-type alpha(1)-AT or alpha(1)-PDX. Finally, these inhibitors were also shown to affect the processing and stability of the Crimean-Congo hemorrhagic fever virus glycoprotein.	Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Ctr Dis Control & Prevent, Special Pathogens Branch, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Centers for Disease Control & Prevention - USA	Seidah, NG (corresponding author), Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	seidahn@ircm.qc.ca	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; ANGLIKER H, 1995, J MED CHEM, V38, P4014, DOI 10.1021/jm00020a016; Basak A, 1999, BIOCHEM J, V338, P107, DOI 10.1042/0264-6021:3380107; BASAK A, 1995, INT J PEPT PROT RES, V46, P228; Basak A, 2002, FEBS LETT, V514, P333, DOI 10.1016/S0014-5793(02)02394-3; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Beyer WR, 2003, J VIROL, V77, P2866, DOI 10.1128/JVI.77.5.2866-2872.2003; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; CHRETIEN M, 1995, P ASSOC AM PHYSICIAN, V107, P47; Dahlen JR, 1998, J BIOL CHEM, V273, P1851, DOI 10.1074/jbc.273.4.1851; Dufour EK, 1998, FEBS LETT, V426, P41, DOI 10.1016/S0014-5793(98)00307-X; Dufour EK, 2001, J BIOL CHEM, V276, P38971, DOI 10.1074/jbc.M102959200; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Elagoz A, 2002, J BIOL CHEM, V277, P11265, DOI 10.1074/jbc.M109011200; ELAGOZ A, 2001, J BIOL CHEM; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Fu X, 2000, J BIOL CHEM, V275, P16871, DOI 10.1074/jbc.275.22.16871; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Komiyama T, 2003, P NATL ACAD SCI USA, V100, P8205, DOI 10.1073/pnas.1032865100; Komiyama T, 2000, BIOCHEMISTRY-US, V39, P15156, DOI 10.1021/bi001907c; Kunz S, 2003, VIROLOGY, V314, P168, DOI 10.1016/S0042-6822(03)00421-5; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; Lenz O, 2001, P NATL ACAD SCI USA, V98, P12701, DOI 10.1073/pnas.221447598; Lesage G, 2001, FEBS LETT, V508, P332, DOI 10.1016/S0014-5793(01)03096-4; LU WY, 1993, J BIOL CHEM, V268, P14583; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Naureckiene S, 2003, ARCH BIOCHEM BIOPHYS, V420, P55, DOI 10.1016/j.abb.2003.09.011; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Raggo C, 2002, MOL CELL BIOL, V22, P5639, DOI 10.1128/MCB.22.16.5639-5649.2002; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 2003, BIOCHEM SOC SYMP, V70, P221, DOI 10.1042/bss0700221; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; SCHLOMBS K, 2003, P NATL ACAD SCI US; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; SEIDAH NG, 2002, CO POST TRANSLATIONA, V22, P237; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Siegfried G, 2003, CANCER RES, V63, P1458; Toure BB, 2000, J BIOL CHEM, V275, P2349, DOI 10.1074/jbc.275.4.2349; Tsuji A, 2002, PROTEIN ENG, V15, P123, DOI 10.1093/protein/15.2.123; VanRompaey L, 1997, BIOCHEM J, V326, P507; Vincent MJ, 2003, J VIROL, V77, P8640, DOI 10.1128/JVI.77.16.8640-8649.2003; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	66	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17338	17347		10.1074/jbc.M313764200	http://dx.doi.org/10.1074/jbc.M313764200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970232	hybrid			2022-12-27	WOS:000220870400057
J	Sloane, V; Waldrop, GL				Sloane, V; Waldrop, GL			Kinetic characterization of mutations found in propionic acidemia and methylcrotonylglycinuria - Evidence for cooperativity in biotin carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; ESCHERICHIA-COLI; COA CARBOXYLASE; ATP BINDING; SUBUNIT; DEFICIENCY; ACTIVATION; MECHANISM; RESIDUES; ENZYME	Acetyl-CoA carboxylase catalyzes the committed step in fatty acid synthesis in all plants, animals, and bacteria. The Escherichia coli form is a multifunctional enzyme consisting of three separate proteins: biotin carboxylase, carboxyltransferase, and the biotin carboxyl carrier protein. The biotin carboxylase component, which catalyzes the ATP-dependent carboxylation of biotin using bicarbonate as the carboxylate source, has a homologous functionally identical subunit in the mammalian biotin-dependent enzymes propionyl-CoA carboxylase and 3-methylcrotonyl-CoA carboxylase. In humans, mutations in either of these enzymes result in the metabolic deficiency propionic acidemia or methylcrotonylglycinuria. The lack of a system for structure-function studies of these two biotin-dependent carboxylases has prevented a detailed analysis of the disease-causing mutations. However, structural data are available for E. coli biotin carboxylase as is a system for its overexpression and purification. Thus, we have constructed three site-directed mutants of biotin carboxylase that are homologous to three missense mutations found in propionic acidemia or methylcrotonylglycinuria patients. The mutants M169K, R338Q, and R338S of E. coli biotin carboxylase were selected for study to mimic the disease-causing mutations M204K and R374Q of propionyl-CoA carboxylase and R385S of 3-methylcrotonyl-CoA carboxylase. These three mutants were subjected to a rigorous kinetic analysis to determine the function of the residues in the catalytic mechanism of biotin carboxylase as well as to establish a molecular basis for the two diseases. The results of the kinetic studies have revealed the first evidence for negative cooperativity with respect to bicarbonate and suggest that Arg-338 serves to orient the carboxyphosphate intermediate for optimal carboxylation of biotin.	Louisiana State Univ, Dept Biol Sci, Div Biochem & Mol Biol, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Waldrop, GL (corresponding author), Louisiana State Univ, Dept Biol Sci, Div Biochem & Mol Biol, Rm 206,Life Sci Bldg, Baton Rouge, LA 70803 USA.	gwaldro@lsu.edu						BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Baumgartner MR, 2001, J CLIN INVEST, V107, P495, DOI 10.1172/JCI11948; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; Blanchard CZ, 1999, BIOCHEM BIOPH RES CO, V266, P466, DOI 10.1006/bbrc.1999.1844; BRANDT IK, 1974, PEDIATRICS, V53, P391; Campeau E, 1999, MOL GENET METAB, V67, P11, DOI 10.1006/mgme.1999.2850; Chloupkova M, 2002, HUM MUTAT, V19, P629, DOI 10.1002/humu.10085; Clavero S, 2002, BBA-MOL BASIS DIS, V1588, P119, DOI 10.1016/S0925-4439(02)00155-2; CLIMENT I, 1986, ARCH BIOCHEM BIOPHYS, V251, P465, DOI 10.1016/0003-9861(86)90353-X; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; Desviat LR, 2003, MOL GENET METAB, V80, P315, DOI 10.1016/S1096-7192(03)00130-6; EISENSTEIN E, 1990, BIOCHEMISTRY-US, V29, P3724, DOI 10.1021/bi00467a019; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; Hall PR, 2003, EMBO J, V22, P2334, DOI 10.1093/emboj/cdg244; Ikeda Y, 1997, J BIOL CHEM, V272, P20495, DOI 10.1074/jbc.272.33.20495; Janiyani K, 2001, J BIOL CHEM, V276, P29864, DOI 10.1074/jbc.M104102200; Kolodziej AF, 1996, BIOCHEMISTRY-US, V35, P14782, DOI 10.1021/bi961481v; Koshland DE, 2002, J BIOL CHEM, V277, P46841, DOI 10.1074/jbc.R200014200; Lazcano A, 1996, CELL, V85, P793, DOI 10.1016/S0092-8674(00)81263-5; Levert KL, 2000, BIOCHEMISTRY-US, V39, P4122, DOI 10.1021/bi992662a; Perutz M. F., 1990, MECH COOPERATIVITY A; Sloane V, 2001, J BIOL CHEM, V276, P24991, DOI 10.1074/jbc.M101472200; Steen C, 1999, EUR J PEDIATR, V158, P730, DOI 10.1007/s004310051189; TANABE T, 1975, EUR J BIOCHEM, V57, P15, DOI 10.1111/j.1432-1033.1975.tb02272.x; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; Ugarte M, 1999, HUM MUTAT, V14, P275, DOI 10.1002/(SICI)1098-1004(199910)14:4<275::AID-HUMU1>3.0.CO;2-N; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004	28	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15772	15778		10.1074/jbc.M311982200	http://dx.doi.org/10.1074/jbc.M311982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14960587	hybrid			2022-12-27	WOS:000220747900011
J	Assem, M; Schuetz, EG; Leggas, M; Sun, DX; Yasuda, K; Reid, G; Zelcer, N; Adachi, M; Strom, S; Evans, RM; Moore, DD; Borst, P; Schuetz, JD				Assem, M; Schuetz, EG; Leggas, M; Sun, DX; Yasuda, K; Reid, G; Zelcer, N; Adachi, M; Strom, S; Evans, RM; Moore, DD; Borst, P; Schuetz, JD			Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; NUCLEAR RECEPTOR; BILE-ACIDS; IN-VIVO; P-GLYCOPROTEIN; HYDROXYSTEROID SULFOTRANSFERASE; LITHOCHOLIC ACID; DRUG-METABOLISM; GENE-EXPRESSION; PROTEIN-3 MRP3	The ABC transporter, Mrp4, transports the sulfated steroid DHEA-s, and sulfated bile acids interact with Mrp4 with high affinity. Hepatic Mrp4 levels are low, but increase under cholestatic conditions. We therefore inferred that up-regulation of Mrp4 during cholestasis is a compensatory mechanism to protect the liver from accumulation of hydrophobic bile acids. We determined that the nuclear receptor CAR is required to coordinately up-regulate hepatic expression of Mrp4 and an enzyme known to sulfate hydroxy-bile acids and steroids, Sult2a1. CAR activators increased Mrp4 and Sult2a1 expression in primary human hepatocytes and HepG2, a human liver cell line. Sult2a1 was down-regulated in Mrp4-null mice, further indicating an inter-relation between Mrp4 and Sult2a1 gene expression. Based on the hydrophilic nature of sulfated bile acids and the Mrp4 capability to transport sulfated steroids, our findings suggest that Mrp4 and Sult2a1 participate in an integrated pathway mediating elimination of sulfated steroid and bile acid metabolites from the liver.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Netherlands Cancer Institute; Netherlands Cancer Institute; Baylor College of Medicine; Howard Hughes Medical Institute; Salk Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale Ave, Memphis, TN 38105 USA.	John.schuetz@stjude.org	Strom, Stephen C/A-6501-2008; Leggas, Markos/E-6618-2011; Schuetz, John D/N-2692-2018; Schuetz, Erin/N-8087-2018; Evans, Ronald/AAF-4001-2019; Zelcer, Noam/C-6393-2009	Leggas, Markos/0000-0003-4314-4533; Evans, Ronald/0000-0002-9986-5965; Reid, Glen/0000-0001-6465-5223; Strom, Stephen/0000-0002-2889-3387; Zelcer, Noam/0000-0001-6935-7532	NCI NIH HHS [P30 CA21745, CA77545] Funding Source: Medline; NIEHS NIH HHS [ES058571] Funding Source: Medline; NIGMS NIH HHS [GM60346, GM60904, U01-GM61393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM060904, R01GM060346, R01GM060904, U01GM061393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2002, J BIOL CHEM, V277, P38998, DOI 10.1074/jbc.M203262200; ANDERSON KE, 1986, CLIN PHARMACOL THER, V39, P510, DOI 10.1038/clpt.1986.88; Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; CAPRON JP, 1975, DIGESTION, V12, P43, DOI 10.1159/000197653; Cherrington NJ, 2003, DRUG METAB DISPOS, V31, P1315, DOI 10.1124/dmd.31.11.1315; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GADACZ TR, 1976, GASTROENTEROLOGY, V70, P1125; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; Handschin C, 2003, PHARMACOL REV, V55, P649, DOI 10.1124/pr.55.4.2; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; Imai Y, 2003, MOL PHARMACOL, V64, P610, DOI 10.1124/mol.64.3.610; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kitada H, 2003, J BIOL CHEM, V278, P17838, DOI 10.1074/jbc.M210634200; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Lamba JK, 2003, HUM MOL GENET, V12, P99, DOI 10.1093/hmg/ddg011; Lecureur V, 2000, MOL PHARMACOL, V57, P24; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; Ostrow J. Donald, 1993, P673; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PIPER WN, 1986, ARCH BIOCHEM BIOPHYS, V246, P143, DOI 10.1016/0003-9861(86)90457-1; Raftogianis RB, 1997, BIOCHEM BIOPH RES CO, V239, P298, DOI 10.1006/bbrc.1997.7466; Rius M, 2003, HEPATOLOGY, V38, P374, DOI 10.1053/jhep.2003.50331; Schuetz E, 2002, MOL PHARMACOL, V62, P439, DOI 10.1124/mol.62.3.439; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Shimizu C, 2003, ENDOCRINOLOGY, V144, P1186, DOI 10.1210/en.2002-221011; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Song CS, 1998, J BIOL CHEM, V273, P21856, DOI 10.1074/jbc.273.34.21856; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; St-Pierre MV, 2001, J EXP BIOL, V204, P1673; Staudinger JL, 2003, DRUG METAB DISPOS, V31, P523, DOI 10.1124/dmd.31.5.523; Stieger B, 2000, GASTROENTEROLOGY, V118, P422, DOI 10.1016/S0016-5085(00)70224-1; STRAUTNIEKS SS, 2003, J NAT GENET, V20, P233; Strott CA, 2002, ENDOCR REV, V23, P703, DOI 10.1210/er.2001-0040; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Wagner M, 2003, GASTROENTEROLOGY, V125, P825, DOI 10.1016/S0016-5085(03)01068-0; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang RX, 2003, HEPATOLOGY, V38, P1489, DOI 10.1016/j.hep.2003.09.037; Wang RX, 2001, P NATL ACAD SCI USA, V98, P2011, DOI 10.1073/pnas.031465498; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xiong H, 2002, DRUG METAB DISPOS, V30, P918, DOI 10.1124/dmd.30.8.918; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zelcer N, 2003, BIOCHEM J, V369, P23, DOI 10.1042/BJ20021081; ZELCER N, 2003, THESIS NETHERLANDS C; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999	50	198	208	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22250	22257		10.1074/jbc.M314111200	http://dx.doi.org/10.1074/jbc.M314111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004017	hybrid			2022-12-27	WOS:000221417100072
J	Lee, J; Rudd, JJ; Macioszek, VK; Scheel, D				Lee, J; Rudd, JJ; Macioszek, VK; Scheel, D			Dynamic changes in the localization of MAPK cascade components controlling pathogenesis-related (PR) gene expression during innate immunity in parsley	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; WRKY TRANSCRIPTION FACTORS; OLIGOPEPTIDE ELICITOR; NUCLEAR TRANSLOCATION; OXIDATIVE BURST; IN-VITRO; TOBACCO; DEFENSE; ARABIDOPSIS; STRESS	The activation of mitogen-activated protein kinase ( MAPK) cascades is an important mechanism for stress adaptation through the control of gene expression in mammals, yeast, and plants. MAPK activation has emerged as a common mechanism by which plants trigger pathogen defense responses following innate immune recognition of potential microbial pathogens. We are studying the non-host plant defense response of parsley to attempted infection by Phytophthora species using an experimental system of cultured parsley cells and the Phytophthora-derived Pep-13 peptide elicitor. Following receptor-mediated recognition of this peptide, parsley cells trigger a multifaceted innate immune response, involving the activation of three MAPKs that have been shown to function in the oxidative burst-independent activation of defense gene expression. Using this same experimental model we now report the identification of a MAPK kinase ( MAPKK) that functions upstream in this pathway. This kinase, referred to as PcMKK5 based on sequence similarity to Arabidopsis thaliana AtMKK5, is activated in parsley cells following Pep-13 treatment and functions as an in vivo activator of all three MAPKs previously shown to be involved in this response. Gain- and loss-of-function mutant versions of PcMKK5, when used in protoplast co-transfection assays, demonstrated that kinase activity of PcMKK5 is required for PR gene promoter activation following Pep-13 treatment. Furthermore, using specific antibodies and immunofluorescent labeling, we demonstrate that activation of MAPKs in parsley cells correlates with an increase in their nuclear localization, which is not detectable for activated PcMKK5. These results suggest that activation of gene expression through MAPK cascades during innate immune responses in plants involves dynamic changes in the localization of the proteins involved, which may reflect the distribution of key protein substrates for the activated MAPKs.	Inst Plant Biochem, Dept Stress & Dev Biol, D-06120 Halle An Der Saale, Germany		Scheel, D (corresponding author), Inst Plant Biochem, Dept Stress & Dev Biol, Weinberg 3, D-06120 Halle An Der Saale, Germany.	dscheel@ipb-halle.de	Macioszek, Violetta/AAD-2472-2019; Macioszek, Violetta/C-8251-2011; Lee, Justin/B-6096-2012	Macioszek, Violetta/0000-0002-5143-4226; Lee, Justin/0000-0001-8269-7494; Rudd, Jason/0000-0002-4743-1401				Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Benes C, 1998, J BIOL CHEM, V273, P15507, DOI 10.1074/jbc.273.25.15507; Blume B, 2000, PLANT CELL, V12, P1425, DOI 10.1105/tpc.12.8.1425; Bogre L, 1999, PLANT CELL, V11, P101, DOI 10.1105/tpc.11.1.101; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Brunner F, 2002, EMBO J, V21, P6681, DOI 10.1093/emboj/cdf667; Calderini O, 1998, J CELL SCI, V111, P3091; Cardinale F, 2000, J BIOL CHEM, V275, P36734, DOI 10.1074/jbc.M007418200; Cardinale F, 2002, PLANT CELL, V14, P703, DOI 10.1105/tpc.010256; Cazale AC, 1999, PLANT J, V19, P297, DOI 10.1046/j.1365-313X.1999.00528.x; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; Cormack RS, 2002, BBA-GENE STRUCT EXPR, V1576, P92, DOI 10.1016/S0167-4781(02)00298-1; Coronado MJ, 2002, J STRUCT BIOL, V140, P200, DOI 10.1016/S1047-8477(02)00542-7; Eulgem T, 1999, EMBO J, V18, P4689, DOI 10.1093/emboj/18.17.4689; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Furuno T, 2001, J IMMUNOL, V166, P4416, DOI 10.4049/jimmunol.166.7.4416; HACKETT RM, 1998, PLANT PHYSIOL, V117, P1526; HAHLBROCK K, 1995, P NATL ACAD SCI USA, V92, P4150, DOI 10.1073/pnas.92.10.4150; Huang YF, 2000, PLANT PHYSIOL, V122, P1301, DOI 10.1104/pp.122.4.1301; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Jabs T, 1997, P NATL ACAD SCI USA, V94, P4800, DOI 10.1073/pnas.94.9.4800; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim-Kaneyama JR, 2000, J BIOL CHEM, V275, P20685, DOI 10.1074/jbc.M908723199; Kroj T, 2003, J BIOL CHEM, V278, P2256, DOI 10.1074/jbc.M208200200; Lee J, 2001, PLANT CELL, V13, P1079, DOI 10.1105/tpc.13.5.1079; Lee J, 2001, P NATL ACAD SCI USA, V98, P289, DOI 10.1073/pnas.011265298; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Ligterink W, 1997, SCIENCE, V276, P2054, DOI 10.1126/science.276.5321.2054; Liu YH, 2000, MOL PLANT MICROBE IN, V13, P118, DOI 10.1094/MPMI.2000.13.1.118; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Meskiene I, 2003, J BIOL CHEM, V278, P18945, DOI 10.1074/jbc.M300878200; Mizoguchi T, 2000, RES PRO CEL, V27, P29; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; NURNBERGER T, 1995, P NATL ACAD SCI USA, V92, P2338, DOI 10.1073/pnas.92.6.2338; Nurnberger T, 2001, TRENDS PLANT SCI, V6, P372, DOI 10.1016/S1360-1385(01)02019-2; Nurnberger T, 2002, CURR OPIN PLANT BIOL, V5, P318, DOI 10.1016/S1369-5266(02)00265-0; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Ren DT, 2002, J BIOL CHEM, V277, P559, DOI 10.1074/jbc.M109495200; Rushton PJ, 1996, EMBO J, V15, P5690, DOI 10.1002/j.1460-2075.1996.tb00953.x; Samaj J, 2002, EMBO J, V21, P3296, DOI 10.1093/emboj/cdf349; Samuel MA, 2000, PLANT J, V22, P367, DOI 10.1046/j.1365-313x.2000.00741.x; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; SOMSSICH IE, 1988, MOL GEN GENET, V213, P93, DOI 10.1007/BF00333403; Testillano PS, 2000, J STRUCT BIOL, V129, P223, DOI 10.1006/jsbi.2000.4249; Xing T, 2001, PLANT MOL BIOL, V46, P109, DOI 10.1023/A:1010633215445; Yang KY, 2001, P NATL ACAD SCI USA, V98, P741, DOI 10.1073/pnas.98.2.741; Yoshioka H, 2003, PLANT CELL, V15, P706, DOI 10.1105/tpc.008680; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435; Zhang SQ, 2001, TRENDS PLANT SCI, V6, P520, DOI 10.1016/S1360-1385(01)02103-3; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zwerger K, 2001, BIOL CHEM, V382, P1123, DOI 10.1515/BC.2001.142; 2000, NATURE, V408, P977	55	99	111	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22440	22448		10.1074/jbc.M401099200	http://dx.doi.org/10.1074/jbc.M401099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15001572	hybrid			2022-12-27	WOS:000221417100093
J	Westin, MAK; Alexson, SEH; Hunt, MC				Westin, MAK; Alexson, SEH; Hunt, MC			Molecular cloning and characterization of two mouse peroxisome proliferator-activated receptor alpha (PPAR alpha)-regulated peroxisomal Acyl-CoA thioesterases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; FATTY-ACID OXIDATION; BETA-OXIDATION; ADAPTIVE RESPONSE; MESSENGER-RNA; EXPRESSION; METABOLISM; IDENTIFICATION; PURIFICATION; EICOSANOIDS	Peroxisomes are organelles that function in the beta-oxidation of long- and very long- chain acyl- CoAs, bile acid- CoA intermediates, prostaglandins, leukotrienes, thromboxanes, dicarboxylic fatty acids, pristanic acid, and xenobiotic carboxylic acids. The very long- and long- chain acyl- CoAs are mainly chain- shortened and then transported to mitochondria for further metabolism. We have now identified and characterized two peroxisomal acyl- CoA thioesterases, named PTE- Ia and PTE- Ic, that hydrolyze acyl- CoAs to the free fatty acid and coenzyme A. PTE- Ia and PTE- Ic show 82% sequence identity at the amino acid level, and a putative peroxisomal type 1 targeting signal of - AKL was identified at the carboxyl- terminal end of both proteins. Localization experiments using green fluorescent fusion protein showed PTE- Ia and PTE- Ic to be localized in peroxisomes. Despite their high level of sequence identity, we show that PTE- Ia is mainly active on long- chain acyl-CoAs, whereas PTE- Ic is mainly active on medium- chain acyl- CoAs. Lack of regulation of enzyme activity by free CoASH suggests that PTE- Ia and PTE- Ic regulate intra-peroxisomal levels of acyl- CoA, and they may have a function in termination of beta- oxidation of fatty acids of different chain lengths. Tissue expression studies revealed that PTE- Ia is highly expressed in kidney, whereas PTE- Ic is most highly expressed in spleen, brain, testis, and proximal and distal intestine. Both PTE- Ia and PTE- Ic were highly up- regulated in mouse liver by treatment with the peroxisome proliferator WY- 14,643 and by fasting in a peroxisome proliferator- activated receptor alpha- dependent manner. These data show that PTE- Ia and PTE- Ic have different functions based on different substrate specificities and tissue expression.	Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Hunt, MC (corresponding author), Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem, C1-74, SE-14186 Stockholm, Sweden.	mary.hunt@labmed.ki.se		Watter, Maria/0000-0001-9047-5517; Hunt, Mary/0000-0001-6415-2992				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DICZFALUSY U, 1991, J CLIN INVEST, V88, P978, DOI 10.1172/JCI115401; FALANY CN, 1994, J BIOL CHEM, V269, P19375; Falany CN, 1997, J LIPID RES, V38, P1139; Ferdinandusse S, 1999, BIOCHEM BIOPH RES CO, V263, P213, DOI 10.1006/bbrc.1999.1340; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FURUTANI M, 1995, BIOCHEM J, V311, P203, DOI 10.1042/bj3110203; Garcia-Blanco MA, 2003, J CLIN INVEST, V112, P474, DOI 10.1172/JCI200319462; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Hiltunen JK, 2000, BBA-MOL CELL BIOL L, V1484, P117, DOI 10.1016/S1388-1981(00)00013-5; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Hunt MC, 2000, J LIPID RES, V41, P814; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jones JM, 2000, BIOCHEM BIOPH RES CO, V275, P233, DOI 10.1006/bbrc.2000.3285; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Legakis JE, 2001, TRAFFIC, V2, P252, DOI 10.1034/j.1600-0854.2001.90165.x; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; NEMALI MR, 1988, CANCER RES, V48, P5316; Ofman R, 2002, BIOCHEM BIOPH RES CO, V290, P629, DOI 10.1006/bbrc.2001.6245; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Tilton GB, 2004, J BIOL CHEM, V279, P7487, DOI 10.1074/jbc.M309532200; van Roermund CWT, 2003, CELL MOL LIFE SCI, V60, P1838, DOI 10.1007/s00018-003-3076-x; van Roermund CWT, 2000, J CELL BIOL, V150, P489, DOI 10.1083/jcb.150.3.489; Van Veldhoven PP, 1999, ADV EXP MED BIOL, V466, P261; Wanders RJA, 2001, BIOCHEM SOC T, V29, P250, DOI 10.1042/0300-5127:0290250; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x	38	34	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21841	21848		10.1074/jbc.M313863200	http://dx.doi.org/10.1074/jbc.M313863200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007068	hybrid			2022-12-27	WOS:000221417100022
J	Chong, YP; Mulhern, TD; Zhu, HJ; Fujita, DJ; Bjorge, JD; Tantiongco, JP; Sotirellis, N; Lio, DSS; Scholz, G; Cheng, HC				Chong, YP; Mulhern, TD; Zhu, HJ; Fujita, DJ; Bjorge, JD; Tantiongco, JP; Sotirellis, N; Lio, DSS; Scholz, G; Cheng, HC			A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; DOMAIN ACCESSIBILITY; STRUCTURAL BASIS; BREAST-CANCER; CSK; PHOSPHORYLATION; AUTOPHOSPHORYLATION; HCK; EXPRESSION; ACTIVATION	Although C-terminal Src kinase (CSK)-homologous kinase (CHK) is generally believed to inactivate Src-family tyrosine kinases (SFKs) by phosphorylating their consensus C-terminal regulatory tyrosine (Tyr(T)), exactly how CHK inactivates SFKs is not fully understood. Herein, we report that in addition to phosphorylating Tyr(T), CHK can inhibit SFKs by a novel non-catalytic mechanism. First, CHK directly binds to the SFK members Hck, Lyn, and Src to form stable protein complexes. The complex formation is mediated by a non-catalytic Tyr(T)-independent mechanism because it occurs even in the absence of ATP or when Tyr(T) of Hck is replaced by phenylalanine. Second, the non-catalytic CHK-SFK interaction alone is sufficient to inactivate SFKs by inhibiting the catalytic activity of autophosphorylated SFKs. Third, CHK and Src co-localize to specific plasma membrane microdomains of rat brain cells, suggesting that CHK is in close proximity to Src such that it can effectively inactivate Src in vivo. Fourth, native CHK . Src complex exists in rat brain, and recombinant CHK . Hck complex exists in transfected HEK293T cells, implying that CHK forms stable complexes with SFKs in vivo. Taken together, our findings suggest that CHK inactivates SFKs (i) by phosphorylating their Tyr(T) and (ii) by this novel Tyr(T)-independent mechanism involving direct binding of CHK to SFKs. It has been documented that autophosphorylated SFKs can still be active, in some cases even when their Tyr(T) is phosphorylated. Thus, the ability of the Tyr(T)-independent mechanism to suppress the activity of both non-phosphorylated and autophosphorylated SFKs represents a fail-safe measure employed by CHK to down-regulate SFK signaling under all circumstances.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia; Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 2N1, Canada; Univ Melbourne, Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3052, Australia	University of Melbourne; University of Melbourne; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Melbourne	Cheng, HC (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.	h.cheng@biochemistry.unimelb.edu.au	Mulhern, Terrence/A-1206-2007	Zhu, Hong-Jian/0000-0002-1478-995X; Scholz, Glen/0000-0003-2722-6344; Cheng, Heung-Chin/0000-0002-4965-7148; Mulhern, Terrence/0000-0002-1609-7498; Chong, Yuh Ping/0000-0002-9596-3242; Lio, Sio/0000-0002-6642-9841				Allen G., 1981, SEQUENCING PROTEINS; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bougeret C, 2001, J BIOL CHEM, V276, P33711, DOI 10.1074/jbc.M104209200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantley LC, 1997, ADV SEC MESS PHOSPH, V31, P41; CHENG HC, 1991, J BIOL CHEM, V266, P17919; Cheng HC, 1996, BIOCHEMISTRY-US, V35, P11874, DOI 10.1021/bi9603940; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHOW LML, 1994, ONCOGENE, V9, P3437; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; Hamaguchi I, 1996, BIOCHEM BIOPH RES CO, V224, P172, DOI 10.1006/bbrc.1996.1003; HARLOW E, 1999, USING ANTIBODIES LAB, P323; Hirao A, 1998, J BIOL CHEM, V273, P10004, DOI 10.1074/jbc.273.16.10004; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Johnson TM, 2000, J BIOL CHEM, V275, P33353, DOI 10.1074/jbc.M002022200; Kim S, 2002, J BIOL CHEM, V277, P36465, DOI 10.1074/jbc.M206018200; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; Kuo SS, 1997, EUR J NEUROSCI, V9, P2383, DOI 10.1111/j.1460-9568.1997.tb01655.x; KUO SS, 1994, J NEUROSCI RES, V38, P705, DOI 10.1002/jnr.490380613; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; Lee S, 2003, P NATL ACAD SCI USA, V100, P14707, DOI 10.1073/pnas.2534493100; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MACAULEY A, 1993, ONCOGENE, V8, P117; OKADA M, 1991, J BIOL CHEM, V266, P24249; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sicilia RJ, 1998, J BIOL CHEM, V273, P16756, DOI 10.1074/jbc.273.27.16756; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	42	40	43	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20752	20766		10.1074/jbc.M309865200	http://dx.doi.org/10.1074/jbc.M309865200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985335	hybrid			2022-12-27	WOS:000221273800027
J	Kim, JS; Diebold, BA; Kim, JI; Kim, J; Lee, JY; Park, JB				Kim, JS; Diebold, BA; Kim, JI; Kim, J; Lee, JY; Park, JB			Rho is involved in superoxide formation during phagocytosis of opsonized zymosans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE ACTIVATION; GTP-BINDING PROTEIN; RECEPTOR-MEDIATED PHAGOCYTOSIS; ACTIN STRESS FIBERS; LIGHT-CHAIN KINASE; RESPIRATORY BURST; COMPONENT P47(PHOX); HUMAN NEUTROPHILS; PHOSPHOLIPASE-D; CR3 CD11B/CD18	Phagocytosis is accompanied by the production of superoxide by the NADPH oxidase complex, for which GTP-bound Rac is essential. We wanted to determine whether Rho is also involved in the production of superoxide during phagocytosis. Inhibition of Rho by Tat-C3 exoenzyme (Tat-C3) blocked superoxide formation and curtailed the phagocytosis of serum- (SOZ), C3bi- (COZ), and IgG-opsonized zymosan (IOZ) particles. Tat-C3 did not affect superoxide formation in response to phorbol myristate acetate (PMA), formyl Met-Leu-Phe ( fMLP), or macrophage colony-stimulating factor (M-CSF). Superoxide formation was also reduced in J774 cells transfected with a cDNA expressing dominant-negative form of RhoA ( N19RhoA). However, purified prenylated recombinant RhoA did not activate NADPH oxidase in vitro, suggesting that Rho does not interact directly with NADPH oxidase. Tat-C3 inhibited the activity of RhoA, but did not affect that of Rac in vitro or in vivo. It also inhibited the phosphorylation of p47(PHOX), one of the cytosolic components of NADPH oxidase. Taken together, these results suggest that Rho plays an important role in superoxide formation during phagocytosis of SOZ, COZ, and IOZ via phosphorylation of p47(PHOX).	Hallym Univ, Coll Med, Dept Biochem, Chunchon 200702, Kangwon Do, South Korea; Scripps Res Inst, Dept Immunol & Cell Biol, La Jolla, CA 92037 USA	Hallym University; Scripps Research Institute	Park, JB (corresponding author), Hallym Univ, Coll Med, Dept Biochem, Chunchon 200702, Kangwon Do, South Korea.	jbpark@hallym.ac.kr	KIM, JONG-IL/D-1019-2011; Kim, Jaebong/AAV-1986-2021	KIM, JONG-IL/0000-0002-7240-3744; Kim, Jaebong/0000-0003-1609-338X				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Allen WE, 1997, J CELL SCI, V110, P707; Astarie-Dequeker C, 1999, INFECT IMMUN, V67, P469, DOI 10.1128/IAI.67.2.469-477.1999; Azim AC, 2000, METHOD ENZYMOL, V325, P257; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; DeLeo FR, 1999, J IMMUNOL, V163, P6732; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Dewitt S, 2002, J CELL BIOL, V159, P181, DOI 10.1083/jcb.200206089; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ENTWISTLE A, 1992, J MICROSC-OXFORD, V165, P347, DOI 10.1111/j.1365-2818.1992.tb01492.x; FALLMAN M, 1993, J IMMUNOL, V151, P330; GELFAND JA, 1976, J IMMUNOL, V116, P595; GIAIMIS J, 1993, J LEUKOCYTE BIOL, V54, P564, DOI 10.1002/jlb.54.6.564; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955; HED J, 1982, IMMUNOLOGY, V45, P727; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1995, BIOCHEM J, V311, P81, DOI 10.1042/bj3110081; Hippenstiel S, 1998, BIOCHEM BIOPH RES CO, V245, P830, DOI 10.1006/bbrc.1998.8525; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; Kim JS, 2003, EXP MOL MED, V35, P211, DOI 10.1038/emm.2003.29; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Le Cabec V, 2000, INFECT IMMUN, V68, P4736, DOI 10.1128/IAI.68.8.4736-4745.2000; Lofgren R, 1999, BBA-MOL CELL RES, V1452, P46, DOI 10.1016/S0167-4889(99)00112-3; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; NEWMAN SL, 1985, J EXP MED, V161, P1414, DOI 10.1084/jem.161.6.1414; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Park J, 2003, MOL CELLS, V16, P216; Park JB, 2002, BIOCHEM J, V362, P651, DOI 10.1042/0264-6021:3620651; Park JW, 1997, BIOCHEMISTRY-US, V36, P7474, DOI 10.1021/bi9700936; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Regier DS, 2000, J BIOL CHEM, V275, P28406, DOI 10.1074/jbc.M004703200; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ross GD, 2000, CRIT REV IMMUNOL, V20, P197; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; Sauzeau V, 2001, CIRC RES, V88, P1102, DOI 10.1161/hh1101.092034; Serrander L, 1999, BBA-MOL CELL RES, V1452, P133, DOI 10.1016/S0167-4889(99)00123-8; Suzuki M, 2003, J ALLERGY CLIN IMMUN, V112, P126, DOI 10.1067/mai.2003.1515; van Wetering S, 2002, J CELL SCI, V115, P1837; Wientjes FB, 1996, BIOCHEM J, V317, P919, DOI 10.1042/bj3170919; Yamamori T, 2000, FEBS LETT, V467, P253, DOI 10.1016/S0014-5793(00)01167-4; Yamamori T, 2002, BIOCHEM BIOPH RES CO, V293, P1571, DOI 10.1016/S0006-291X(02)00418-7; Zhao XX, 2003, J BIOL CHEM, V278, P40788, DOI 10.1074/jbc.M302208200	67	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21589	21597		10.1074/jbc.M308386200	http://dx.doi.org/10.1074/jbc.M308386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14970220	hybrid			2022-12-27	WOS:000221273800125
J	Peterson, ME; Eisenthal, R; Danson, MJ; Spence, A; Daniel, RM				Peterson, ME; Eisenthal, R; Danson, MJ; Spence, A; Daniel, RM			A new intrinsic thermal parameter for enzymes reveals true temperature optima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Two established thermal properties of enzymes are the Arrhenius activation energy and thermal stability. Arising from anomalies found in the variation of enzyme activity with temperature, a comparison has been made of experimental data for the activity and stability properties of five different enzymes with theoretical models. The results provide evidence for a new and fundamental third thermal parameter of enzymes, T-eq, arising from a subsecond timescale-reversible temperature-dependent equilibrium between the active enzyme and an inactive (or less active) form. Thus, at temperatures above its optimum, the decrease in enzyme activity arising from the temperature-dependent shift in this equilibrium is up to two orders of magnitude greater than what occurs through thermal denaturation. This parameter has important implications for our understanding of the connection between catalytic activity and thermostability and of the effect of temperature on enzyme reactions within the cell. Unlike the Arrhenius activation energy, which is unaffected by the source ("evolved") temperature of the enzyme, and enzyme stability, which is not necessarily related to activity, T-eq is central to the physiological adaptation of an enzyme to its environmental temperature and links the molecular, physiological, and environmental aspects of the adaptation of life to temperature in a way that has not been described previously. We may therefore expect the effect of evolution on T-eq with respect to enzyme temperature/activity effects to be more important than on thermal stability. T-eq is also an important parameter to consider when engineering enzymes to modify their thermal properties by both rational design and by directed enzyme evolution.	Univ Waikato, Dept Biol Sci, Hamilton, New Zealand; Univ Bath, Dept Biol & Biochem, Ctr Extremophile Res, Bath BA2 7AY, Avon, England; Univ Bath, Dept Math Sci, Bath BA2 7AY, Avon, England	University of Waikato; University of Bath; University of Bath	Daniel, RM (corresponding author), Univ Waikato, Dept Biol Sci, Private Bag 3105, Hamilton, New Zealand.	r.daniel@waikato.ac.nz	Peterson, Michelle E/C-2455-2009	Peterson, Michelle E/0000-0002-6413-322X				[Anonymous], 1971, ENZYME; Arnott MA, 2000, J MOL BIOL, V304, P657, DOI 10.1006/jmbi.2000.4240; BROOKS CL, 1988, ADV CHEM PHYS, V71, P1; Buchanan CL, 1999, BIOCHEM J, V343, P563, DOI 10.1042/0264-6021:3430563; Cleveland WS., 1993, VISUALIZING DATA; Creighton T. E., 1993, PROTEINS STRUCTURES, P287; Daniel RM, 1996, BIOCHEM J, V317, P1, DOI 10.1042/bj3170001; Daniel RM, 2001, TRENDS BIOCHEM SCI, V26, P223, DOI 10.1016/S0968-0004(01)01803-5; Fernley H.N., 1971, ENZYMES, V4, P417; Gerike U, 1997, EUR J BIOCHEM, V248, P49, DOI 10.1111/j.1432-1033.1997.00049.x; HAMMOND PM, 1983, EUR J BIOCHEM, V132, P651, DOI 10.1111/j.1432-1033.1983.tb07413.x; Medina DC, 2001, ARCH BIOCHEM BIOPHYS, V393, P51, DOI 10.1006/abbi.2001.2490; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; PFROGNER N, 1967, ARCH BIOCHEM BIOPHYS, V119, P141, DOI 10.1016/0003-9861(67)90439-0; Scopes, 1994, PROTEIN PURIFICATION, P44; Svensson AKE, 2003, J MOL BIOL, V326, P569, DOI 10.1016/S0022-2836(02)01444-4; Thomas TM, 1998, BIOCHEM J, V330, P1087; Wintrode PL, 2003, J MOL BIOL, V327, P745, DOI 10.1016/S0022-2836(03)00147-5	18	74	77	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20717	20722		10.1074/jbc.M309143200	http://dx.doi.org/10.1074/jbc.M309143200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14973131	Green Accepted, hybrid			2022-12-27	WOS:000221273800023
J	Tulipano, G; Stumm, R; Pfeiffer, M; Kreienkamp, HJ; Hollt, V; Schulz, S				Tulipano, G; Stumm, R; Pfeiffer, M; Kreienkamp, HJ; Hollt, V; Schulz, S			Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; INTERNALIZATION; THERAPY; UBIQUITINATION; ENDOCYTOSIS; ANALOGS	The physiological responses of somatostatin are mediated by five different G protein-coupled receptors. Although agonist-induced endocytosis of the various somatostatin receptor subtypes (sst(1)-sst(5)) has been studied in detail, little is known about their postendocytic trafficking. Here we show that somatostatin receptors profoundly differ in patterns of beta-arrestin mobilization and endosomal sorting. The beta-arrestin-dependent trafficking of the sst(2A) somatostatin receptor resembled that of a class B receptor in that upon receptor activation, beta-arrestin and the receptor formed stable complexes and internalized together into the same endocytic vesicles. This pattern was dependent on GRK2 (G protein-coupled receptor kinase 2)-mediated phosphorylation of a cluster of phosphate acceptor sites within the cytoplasmic tail of the sst(2A) receptor. Unlike other class B receptors, however, the sst(2A) receptor was rapidly resensitized and recycled to the plasma membrane. The beta-arrestin mobilization of the sst(3) and the sst(5) somatostatin receptors resembled that of a class A receptor in that upon receptor activation, beta-arrestin and the receptor formed relatively unstable complexes that dissociated at or near the plasma membrane. Consequently, beta-arrestin was excluded from sst(3)-containing vesicles. Unlike other class A receptors, a large proportion of sst3 receptors was subject to ubiquitin-dependent lysosomal degradation and did not rapidly recycle to the plasma membrane. The sst(4) somatostatin receptor is unique in that it did not exhibit agonist-dependent receptor phosphorylation and beta-arrestin recruitment. Together, these findings may provide important clues about the regulation of receptor responsiveness during long-term administration of somatostatin analogs.	Otto Von Guericke Univ, Inst Pharmakol & Toxikol, D-39120 Magdeburg, Germany; Univ Hamburg, Univ Krankenhaus Hamburg Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	Otto von Guericke University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Schulz, S (corresponding author), Otto Von Guericke Univ, Inst Pharmakol & Toxikol, Leipziger Str 44, D-39120 Magdeburg, Germany.	Stefan.Schulz@Medizin.Uni-Magdeburg.de	Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885				Csaba Z, 2001, NEUROPEPTIDES, V35, P1, DOI 10.1054/npep.2001.0848; Culler MD, 2002, ANN ENDOCRINOL-PARIS, V63, pS5; Forster GJ, 2001, EUR J NUCL MED, V28, P1743, DOI 10.1007/s002590100628; Giustina A, 1996, PHARMACOL RES, V34, P247, DOI 10.1006/phrs.1996.0095; Hofland LJ, 2003, ENDOCR REV, V24, P28, DOI 10.1210/er.2000-0001; Hukovic N, 1999, J BIOL CHEM, V274, P24550, DOI 10.1074/jbc.274.35.24550; Kreienkamp HJ, 1998, DNA CELL BIOL, V17, P869, DOI 10.1089/dna.1998.17.869; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Roosterman D, 1997, J NEUROENDOCRINOL, V9, P741, DOI 10.1046/j.1365-2826.1997.00632.x; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; Schulz S, 2000, CLIN CANCER RES, V6, P1865; Schwartkop CP, 1999, J NEUROCHEM, V72, P1275, DOI 10.1046/j.1471-4159.1999.0721275.x; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shimon I, 1997, J CLIN INVEST, V100, P2386, DOI 10.1172/JCI119779; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vines CM, 2003, J BIOL CHEM, V278, P41581, DOI 10.1074/jbc.C300291200	25	142	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21374	21382		10.1074/jbc.M313522200	http://dx.doi.org/10.1074/jbc.M313522200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15001578	hybrid			2022-12-27	WOS:000221273800101
J	Bao, XY; Reuss, L; Altenberg, GA				Bao, XY; Reuss, L; Altenberg, GA			Regulation of purified and reconstituted connexin 43 hemichannels by protein kinase C-mediated phosphorylation of serine 368	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; CYCLIC ADP-RIBOSE; INTRACELLULAR CALCIUM; PH REGULATION; INHIBITION; ASTROCYTES; COMMUNICATION; TRANSPORT; BINDING; CELLS	Indirect evidence suggests that the permeability of connexin 43 (Cx43) gap-junctional channels (connexons) to small organic molecules (M-r < 1,000) is decreased by protein kinase C (PKC)-mediated phosphorylation of Ser-368. However, it is currently unknown whether this effect is produced directly by phosphorylation of this residue or whether cytoplasmic regulatory factors are required for the decrease in Cx43 gap-junctional channel permeability. Here we studied the effects of PKC-mediated phosphorylation on purified recombinant wild-type Cx43 and a PKC-unresponsive mutant (S368A). Our studies show that (a) PKC phosphorylates Ser-368, (b) the phosphorylation by PKC of purified and reconstituted connexons abolishes sucrose and Lucifer Yellow permeability, (c) the regulation of Cx43 by PKC is the direct result of phosphorylation of Ser-368 and does not involve intermediary regulatory factors, and (d) phosphorylation of Ser-368 produces a conformational change in purified Cx43 as demonstrated by changes in intrinsic Trp fluorescence and proteolytic digestion pattern. We conclude that phosphorylation of Ser-368 by PKC induces a conformational change of Cx43 that results in a decrease in connexon permeability.	Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Membrane Prot Lab, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Altenberg, GA (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA.	galtenbe@utmb.edu		Altenberg, Guillermo/0000-0002-8932-740X				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; Bao XY, 2004, AM J PHYSIOL-CELL PH, V286, pC647, DOI 10.1152/ajpcell.00295.2003; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799; Davey RA, 1997, J VIROL, V71, P8096, DOI 10.1128/JVI.71.11.8096-8102.1997; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; Eskandari S, 2002, J MEMBRANE BIOL, V185, P93, DOI 10.1007/s00232-001-0115-0; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; Han ES, 1996, AM J PHYSIOL-CELL PH, V270, pC1370, DOI 10.1152/ajpcell.1996.270.5.C1370; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Harris AL, 2001, METH MOL B, V154, P357; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Kim DY, 1999, J BIOL CHEM, V274, P5581, DOI 10.1074/jbc.274.9.5581; Kondo RP, 2000, J MOL CELL CARDIOL, V32, P1859, DOI 10.1006/jmcc.2000.1220; KWAK BR, 1995, EXP CELL RES, V220, P456, DOI 10.1006/excr.1995.1337; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lau AF, 2000, CURR TOP MEMBR, V49, P315; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; LITTLE TL, 1995, AM J PHYSIOL-HEART C, V268, pH729, DOI 10.1152/ajpheart.1995.268.2.H729; LIU SG, 1993, BIOPHYS J, V64, P1422, DOI 10.1016/S0006-3495(93)81508-X; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; MORENO AP, 1994, CIRC RES, V74, P1050, DOI 10.1161/01.RES.74.6.1050; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; Nicholson BJ, 1998, GAP JUNCTIONS, P3; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; SAEZ JC, 1990, EUR J BIOCHEM, V192, P263, DOI 10.1111/j.1432-1033.1990.tb19223.x; Saez JC, 1997, J MOL CELL CARDIOL, V29, P2131, DOI 10.1006/jmcc.1997.0447; SAINIO K, 1992, DEVELOPMENT, V115, P827; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Valiunas V, 2002, CIRC RES, V91, P104, DOI 10.1161/01.RES.0000025638.24255.AA; Venance L, 1998, J PHYSIOL-LONDON, V510, P429, DOI 10.1111/j.1469-7793.1998.429bk.x; Vergara L, 2003, J MEMBRANE BIOL, V196, P173, DOI 10.1007/s00232-003-0636-9; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033; ZIMMER DB, 1987, J BIOL CHEM, V262, P7751	45	121	131	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20058	20066		10.1074/jbc.M311137200	http://dx.doi.org/10.1074/jbc.M311137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14973142	hybrid			2022-12-27	WOS:000221164500082
J	Hwang, CK; Kim, CS; Choi, HS; McKercher, SR; Loh, HH				Hwang, CK; Kim, CS; Choi, HS; McKercher, SR; Loh, HH			Transcriptional regulation of mouse mu opioid receptor gene by PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; ENHANCES HIV-INFECTION; IFN-GAMMA; BINDING-SITES; UP-REGULATION; PROMOTER; KAPPA; MACROPHAGE; CELLS; SPI-1	We previously reported that the 34-bp cis-acting element of the mouse mu opioid receptor (MOR) gene represses transcription of the MOR gene from the distal promoter. Using a yeast one-hybrid screen to identify potential transcription factors of the MOR promoter, we have identified PU.1 as one of the candidate genes. PU.1 is a member of the ets family of transcription factors, expressed predominantly in hematopoietic cells and microglia of brain. PU.1 plays an essential role in the development of both lymphoid and myeloid lineages. Opioids exert neuromodulatory as well as immunomodulatory effects, which are transduced by MOR. Moreover, MOR-deficient mice exhibit increased proliferation of hematopoietic cells, suggesting a possible link between the opioid system and hematopoietic development. The PU.1 protein binds to the 34-bp element of the MOR gene in a sequence-specific manner confirmed by electrophoretic mobility shift assay and supershift assays. We have also determined endogenous PU.1 interactions with the 34-bp element of MOR promoter by chromatin immunoprecipitation assays. In co-transfection studies PU.1 represses MOR promoter reporter constructs through its PU.1 binding site. When the PU.1 gene is disrupted as in PU.1 knock-out mice and using small interfering RNA-based strategy in RAW264.7 cells, the transcription of the endogenous target MOR gene is increased significantly. This increase is probably mediated through modification of the chromatin structure, as suggested by the reversal of the PU.1-mediated repression of MOR promoter activity after trichostatin A treatment in neuroblastoma NMB cells. Our results suggest that PU.1 may be an important regulator of the MOR gene, particularly in brain and immune cells.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA; Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA	University of Minnesota System; University of Minnesota Twin Cities; Sanford Burnham Prebys Medical Discovery Institute	Hwang, CK (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	hwang025@umn.edu			NIDA NIH HHS [K05 DA 70554, DA 01583, DA 00564, DA 11806] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA001583, K05DA070554, R56DA000564, R01DA000564, P50DA011806, R01DA001583] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Azaryan AV, 1998, CAN J PHYSIOL PHARM, V76, P278, DOI 10.1139/cjpp-76-3-278; BELKOWSKI SM, 1995, J NEUROIMMUNOL, V62, P113, DOI 10.1016/0165-5728(95)00116-J; BIDLACK JM, 1992, EUR J PHARM-MOLEC PH, V227, P257, DOI 10.1016/0922-4106(92)90003-E; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Bohn LM, 2000, J NEUROCHEM, V74, P564, DOI 10.1046/j.1471-4159.2000.740564.x; Brand JM, 2001, J INTERF CYTOK RES, V21, P793, DOI 10.1089/107999001753238024; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; CARR DJJ, 1989, J ENDOCRINOL, V122, P161, DOI 10.1677/joe.0.1220161; Chai L, 1999, NEUROSCI LETT, V261, P45, DOI 10.1016/S0304-3940(98)01016-7; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chang SLL, 2001, ADV EXP MED BIOL, V493, P187; Chen HC, 2001, NEUROSCIENCE, V108, P7, DOI 10.1016/S0306-4522(01)00397-9; CHEN HM, 1995, ONCOGENE, V11, P1549; Choe CY, 1998, J BIOL CHEM, V273, P34926, DOI 10.1074/jbc.273.52.34926; CHUANG LF, 1994, BIOCHEM BIOPH RES CO, V202, P1291, DOI 10.1006/bbrc.1994.2071; CHUANG TK, 1995, BIOCHEM BIOPH RES CO, V216, P922, DOI 10.1006/bbrc.1995.2709; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DELFS JM, 1994, J NEUROCHEM, V63, P777; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; Elser B, 2002, IMMUNITY, V17, P703, DOI 10.1016/S1074-7613(02)00471-5; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; Gaveriaux-Ruff C, 1998, P NATL ACAD SCI USA, V95, P6326, DOI 10.1073/pnas.95.11.6326; Goenka S, 1999, J IMMUNOL, V163, P4663; Guo CJ, 2002, J INVEST MED, V50, P435, DOI 10.1136/jim-50-06-03; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HROMAS R, 1993, BLOOD, V82, P2998; Hwang CK, 2003, J BIOL CHEM, V278, P3742, DOI 10.1074/jbc.M208780200; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; Kraus J, 2001, J BIOL CHEM, V276, P43901, DOI 10.1074/jbc.M107543200; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuwata T, 2002, MOL CELL BIOL, V22, P7439, DOI 10.1128/MCB.22.21.7439-7448.2002; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; Li Y, 2003, PEDIATR RES, V54, P282, DOI 10.1203/01.PDR.0000074973.83826.4C; Liang YB, 1997, BRAIN RES, V769, P372, DOI 10.1016/S0006-8993(97)00854-8; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; LopezRodriguez C, 1997, EUR J IMMUNOL, V27, P1843, DOI 10.1002/eji.1830270804; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; Marecki S, 2002, J INTERF CYTOK RES, V22, P121, DOI 10.1089/107999002753452737; McCarthy L, 2001, DRUG ALCOHOL DEPEN, V62, P111, DOI 10.1016/S0376-8716(00)00181-2; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nyland SB, 1998, ADV EXP MED BIOL, V437, P91; Ohmori Y, 1997, J IMMUNOL, V159, P5474; PETERSON PK, 1987, J CLIN INVEST, V80, P824, DOI 10.1172/JCI113140; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Roy S, 2001, ADV EXP MED BIOL, V493, P117; Ruzicka BB, 1997, NEUROSCIENCE, V79, P517, DOI 10.1016/S0306-4522(96)00669-0; Satoh M, 1995, PHARMACOL THERAPEUT, V68, P343, DOI 10.1016/0163-7258(95)02011-X; Sawada K, 2000, J CELL SCI, V113, P2705; SCHUG J, 1998, CBILTR19971001V00 U; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEDQI M, 1995, BIOCHEM BIOPH RES CO, V209, P563, DOI 10.1006/bbrc.1995.1538; Sheng Wen S., 1997, Archivum Immunologiae et Therapiae Experimentalis, V45, P359; SIBINGA NES, 1988, ANNU REV IMMUNOL, V6, P219; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Suzuki S, 2000, BIOCHEM BIOPH RES CO, V279, P621, DOI 10.1006/bbrc.2000.4006; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; Tong Y, 2000, J CHEM NEUROANAT, V18, P209, DOI 10.1016/S0891-0618(00)00043-0; Walton MR, 2000, J NEUROIMMUNOL, V104, P109, DOI 10.1016/S0165-5728(99)00262-3; Wang JH, 2002, J LEUKOCYTE BIOL, V71, P782; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wei LN, 2002, CURR OPIN PHARMACOL, V2, P69, DOI 10.1016/S1471-4892(01)00123-0; Wick MJ, 1996, J NEUROIMMUNOL, V64, P29, DOI 10.1016/0165-5728(95)00144-1; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhu YX, 1998, J NEUROSCI, V18, P2538	83	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19764	19774		10.1074/jbc.M400755200	http://dx.doi.org/10.1074/jbc.M400755200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14998994	hybrid			2022-12-27	WOS:000221164500047
J	Koller, D; Ittner, LM; Muff, R; Husmann, K; Fischer, JA; Born, W				Koller, D; Ittner, LM; Muff, R; Husmann, K; Fischer, JA; Born, W			Selective inactivation of adrenomedullin over calcitonin gene-related peptide receptor function by the deletion of amino acids 14-20 of the mouse calcitonin-like receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-MODIFYING PROTEINS; AMINO-TERMINUS; COUPLED RECEPTORS; BINDING; HETERODIMERS	The receptors for the neuropeptide calcitonin (CT) gene-related peptide (CGRP) and the multifunctional peptide hormone adrenomedullin ( AM) are calcitonin-like receptor (CLR)/receptor-activity-modifying protein (RAMP) 1 and CLR/RAMP2 heterodimers, respectively. Here, the amino acid sequence TRNKIMT, corresponding to the residues 14-20 of the N terminus of the mouse (m) CLR, was found to be required for a functional mCLR/RAMP2 AM receptor. The deletion of amino acids 14-20 (Delta14-20) or their substitution by alanine (14-20A) did not affect the heterodimerization of the mCLR with mRAMP1 or mRAMP2, and the levels of expression at the surface of transiently transfected COS-7 cells were not altered. In mRAMP1/mCLR- or mRAMP1/mCLR-(Delta14-20)-expressing cells CGRP stimulated cAMP formation with EC50 values of 0.12 +/- 0.01 and 1.5 +/- 0.4 nM, respectively. In mRAMP2/mCLR-expressing cells the EC50 of AM was 0.8 +/- 0.2 nM. However, in cells expressing mRAMP2/mCLR-(Delta14-20) up to 10(-6) M AM failed to stimulate cAMP production. In mRAMP2/mCLR-(14-20A) expressing cells the cAMP response to AM was minimally restored, and the EC50 was >100 nM. In conclusion, the deletion of the amino acid sequence TRNKIMT of the extreme N terminus of the mCLR maintained CGRP receptor function of mRAMP1/receptor heterodimers, but AM no longer activated the mutant mCLR-(Delta14-20) in the presence of mRAMP2. The TRNKIMT sequence is required for normal mCLR/mRAMP2 association, and as a consequence, high affinity AM binding signaling the activation of adenylyl cyclase.	Univ Zurich, Klin Balgrist, Dept Orthopaed Surg, Res Lab Calcium Metab, CH-8008 Zurich, Switzerland; Univ Zurich, Klin Balgrist, Dept Med, Res Lab Calcium Metab, CH-8008 Zurich, Switzerland	University of Zurich; University of Zurich	Born, W (corresponding author), Univ Zurich, Klin Balgrist, Dept Orthopaed Surg, Res Lab Calcium Metab, Forchstr 340, CH-8008 Zurich, Switzerland.	wborn@balgrist.unizh.ch	Muff, Roman/A-4247-2009	Ittner, Lars/0000-0001-6738-3825				Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; Dong MQ, 2004, J BIOL CHEM, V279, P1167, DOI 10.1074/jbc.M305719200; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Gujer R, 2001, BIOCHEMISTRY-US, V40, P5392, DOI 10.1021/bi002497v; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; Koller D, 2002, FEBS LETT, V531, P464, DOI 10.1016/S0014-5793(02)03585-8; Leuthauser K, 2000, BIOCHEM J, V351, P347, DOI 10.1042/0264-6021:3510347; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Wimalawansa SJ, 1996, ENDOCR REV, V17, P533, DOI 10.1210/er.17.5.533	12	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20387	20391		10.1074/jbc.M313058200	http://dx.doi.org/10.1074/jbc.M313058200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15007076	hybrid			2022-12-27	WOS:000221164500117
J	Xie, XS; Padron, D; Liao, XB; Wang, J; Roth, MG; De Brabander, JK				Xie, XS; Padron, D; Liao, XB; Wang, J; Roth, MG; De Brabander, JK			Salicylihalamide A inhibits the V-0 sector of the V-ATPase through a mechanism distinct from bafilomycin A(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASES; PLASMA-MEMBRANE; SUBUNIT-C; WILD-TYPE; YEAST; RECONSTITUTION; HYDROLYSIS; PUMP; ACIDIFICATION	The newly identified specific V-ATPase inhibitor, salicylihalamide A, is distinct from any previously identified V-ATPase inhibitors in that it inhibits only mammalian V-ATPases, but not those from yeast or other fungi (Boyd, M. R., Farina, C., Belfiore, P., Gagliardi, S., Kim, J. W., Hayakawa, Y., Beutler, J. A., McKee, T. C., Bowman, B. J., and Bowman, E. J. ( 2001) J. Pharmacol. Exp. Ther. 297, 114 - 120). In addition, salicylihalamide A does not compete with concanamycin or bafilomycin for binding to V-ATPase, indicating that it has a different binding site from those classic V-ATPase inhibitors (Huss, M., Ingenhorst, G., Konig, S., Gassel, M., Drose, S., Zeeck, A., Altendorf, K., and Wieczorek, H. ( 2002) J. Biol. Chem. 277, 40544 - 40548). By using purified bovine brain V-pump and its dissociated V-1 and V-0 sectors, we identified the recognition and binding site for salicylihalamide to be within the V-0 domain. Salicylihalamide does not inhibit the ATP hydrolysis activity of the dissociated V-1-ATPase but inhibits the ATPase activity of the holoenzyme by inhibiting the V-0 domain. Salicylihalamide causes a dramatic redistribution of cytosolic V-1 from soluble to membrane-associated form, a change not observed in cells treated with either bafilomycin or NH4Cl. By synthesizing and characterizing a series of salicylihalamide derivatives, we investigated the structural determinants of salicylihalamide inhibition in terms of potency and reversibility, and used this information to suggest a possible binding mechanism.	Univ Texas, SW Med Ctr, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Xie, XS (corresponding author), Univ Texas, SW Med Ctr, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA.	Xiao-Song.Xie@UTSouthwestern.edu; jdebra@biochem.swmed.edu		Roth, Michael/0000-0002-9056-332X	NATIONAL CANCER INSTITUTE [P01CA095471, R01CA090349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA095471, P01 CA 95471, R01 CA 90349] Funding Source: Medline; NIDDK NIH HHS [R01 DK 33627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Boyd MR, 2001, J PHARMACOL EXP THER, V297, P114; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Crider BP, 2003, J BIOL CHEM, V278, P44281, DOI 10.1074/jbc.M307372200; Gentle CA, 1999, J CHEM SOC PERK T 1, P1279, DOI 10.1039/a901279f; GLUCK S, 1982, J BIOL CHEM, V257, P9230; GLUCK S, 1992, J EXP BIOL, V172, P29; Harvey WR, 1997, J EXP BIOL, V200, P203; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; KANE PM, 1995, J BIOL CHEM, V270, P17025; LOUDON GM, 1981, J AM CHEM SOC, V103, P4508, DOI 10.1021/ja00405a036; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; MacLeod KJ, 1999, J BIOL CHEM, V274, P32869, DOI 10.1074/jbc.274.46.32869; Nelson N, 1996, EXPERIENTIA, V52, P1101, DOI 10.1007/BF01952108; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Peng SB, 1996, J BIOL CHEM, V271, P3324, DOI 10.1074/jbc.271.6.3324; PENG SB, 1994, J BIOL CHEM, V269, P11356; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Shao E, 2003, J BIOL CHEM, V278, P12985, DOI 10.1074/jbc.M212096200; SPECKAMP WN, 1985, TETRAHEDRON, V41, P4367, DOI 10.1016/S0040-4020(01)82334-6; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; STONE DK, 1988, KIDNEY INT, V33, P767, DOI 10.1038/ki.1988.65; STONE DK, 1984, J BIOL CHEM, V259, P2701; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wu YS, 2002, J AM CHEM SOC, V124, P3245, DOI 10.1021/ja0177713; Wu YS, 2000, ORG LETT, V2, P4241, DOI 10.1021/ol0068086; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1994, J BIOL CHEM, V269, P25809; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; XIE XS, 1988, J BIOL CHEM, V263, P9859; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; ZHANG JM, 1994, J BIOL CHEM, V269, P23518	38	102	110	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19755	19763		10.1074/jbc.M313796200	http://dx.doi.org/10.1074/jbc.M313796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14998996	hybrid			2022-12-27	WOS:000221164500046
J	Zhang, LS; Lin, JQ; Ji, GY				Zhang, LS; Lin, JQ; Ji, GY			Membrane anchoring of the AgrD N-terminal amphipathic region is required for its processing to produce a quorum-sensing pheromone in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALPHA-HELIX; TRANSMEMBRANE TOPOLOGY; ENTEROCOCCUS-FAECALIS; SIGNAL-TRANSDUCTION; PROTEIN; PEPTIDE; IDENTIFICATION; VIRULENCE; BINDING	Quorum-sensing pheromones are signal molecules that are secreted from Gram-positive bacteria and utilized by these bacteria to communicate among individual cells to regulate their activities as a group through a cell density-sensing mechanism. Typically, these pheromones are processed from precursor polypeptides. The mechanisms of trafficking, processing, and modification of the precursor to generate a mature pheromone are unclear. In Staphylococcus aureus, AgrD is the propeptide for an autoinducing peptide (AIP) pheromone that triggers the Agr cell density-sensing system upon reaching a threshold and subsequently regulates expression of virulence factor genes. The transmembrane protein AgrB, encoded in the agr locus, is necessary for the processing of AgrD to produce mature AIP; however, it is not clear how AgrD interacts with AgrB and how this interaction results in the generation of mature AIP. In this study, we found that the AgrD propeptide was integrated into the cytoplasmic membrane by a conserved alpha-helical amphipathic motif in its N-terminal region. We demonstrated that membrane targeting of AgrD by this motif was required for the stabilization of AgrD and the production of mature AIP, although this region was not specifically involved in the interaction with AgrB. An artificial amphipathic peptide replacing the N-terminal amphipathic motif of AgrD directed the protein to the cytoplasmic membrane and enabled the production of AIP. Analysis of Bacillus ComX precursor protein sequences suggested that the amphipathic membrane-targeting motif might also exist in pheromone precursors of other Gram-positive bacteria.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Ji, GY (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gji@usuhs.mil			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046445] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 46445] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		An FY, 1999, J BACTERIOL, V181, P5915, DOI 10.1128/JB.181.19.5915-5921.1999; An FY, 2002, J BACTERIOL, V184, P1880, DOI 10.1128/JB.184.7.1880-1887.2002; Bassler BL, 2002, CELL, V109, P421, DOI 10.1016/S0092-8674(02)00749-3; Biggin PC, 1999, BIOPHYS CHEM, V76, P161, DOI 10.1016/S0301-4622(98)00233-6; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Dunny GM, 1999, CELL-CELL SIGNALING IN BACTERIA, P1; Eijsink VGH, 1996, J BACTERIOL, V178, P2232, DOI 10.1128/jb.178.8.2232-2237.1996; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Hauge HH, 1998, EUR J BIOCHEM, V251, P565, DOI 10.1046/j.1432-1327.1998.2510565.x; Hauge HH, 1998, BIOCHEMISTRY-US, V37, P16026, DOI 10.1021/bi981532j; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140; Hristova K, 1999, J MOL BIOL, V290, P99, DOI 10.1006/jmbi.1999.2840; Hu ZL, 2003, MOL MICROBIOL, V47, P345, DOI 10.1046/j.1365-2958.2003.03321.x; Jarraud S, 2000, J BACTERIOL, V182, P6517, DOI 10.1128/JB.182.22.6517-6522.2000; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; Lazazzera BA, 1997, CELL, V89, P917, DOI 10.1016/S0092-8674(00)80277-9; Lina G, 1998, MOL MICROBIOL, V28, P655, DOI 10.1046/j.1365-2958.1998.00830.x; Lyon GJ, 2002, J BIOL CHEM, V277, P6247, DOI 10.1074/jbc.M109989200; MARCH PE, 1985, J BIOL CHEM, V260, P7206; Mercier C, 1998, J CELL SCI, V111, P2171; Nes IF, 1999, CELL-CELL SIGNALING IN BACTERIA, P175; Nina M, 2000, EUR BIOPHYS J BIOPHY, V29, P439, DOI 10.1007/PL00006649; Novick RP, 1999, CELL-CELL SIGNALING IN BACTERIA, P129; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; NOVICK RP, 1995, MOL GEN GENET, V248, P446, DOI 10.1007/BF02191645; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; Osickova A, 1999, J BIOL CHEM, V274, P37644; SAMBROOK J, 2000, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWAB RB, 2001, CURRENT PROTOCOLS CE; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Szeto TH, 2002, P NATL ACAD SCI USA, V99, P15693, DOI 10.1073/pnas.232590599; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wieprecht T, 2002, BIOPHYS CHEM, V96, P191, DOI 10.1016/S0301-4622(02)00025-X; Wieprecht T, 1999, J MOL BIOL, V294, P785, DOI 10.1006/jmbi.1999.3268; Zhang LS, 2002, J BIOL CHEM, V277, P34736, DOI 10.1074/jbc.M205367200	44	54	57	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19448	19456		10.1074/jbc.M311349200	http://dx.doi.org/10.1074/jbc.M311349200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15001569	hybrid			2022-12-27	WOS:000221164500010
J	Bedirian, A; Baldwin, C; Abe, J; Takano, T; Lemay, S				Bedirian, A; Baldwin, C; Abe, J; Takano, T; Lemay, S			Pleckstrin homology and phosphotyrosine-binding domain-dependent membrane association and tyrosine phosphorylation of Dok-4, an inhibitory adapter molecule expressed in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; SRC FAMILY KINASES; DOCKING PROTEIN; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE BINDING; NEGATIVE REGULATION; ACTIVATING PROTEIN; PTB DOMAIN; P62(DOK)	Dok-like adapter molecules represent an expanding family of pleckstrin homology (PH) and phosphotyrosine-binding (PTB) domain-containing tyrosine kinase substrates with negative regulatory functions in hematopoietic cell signaling. In a search for nonhematopoietic counterparts to Dok molecules, we identified and characterized Dok-4, a recently cloned member of the family. dok-4 mRNA was strongly expressed in nonhematopoietic organs, particularly the intestine, kidney, and lung, whereas both mRNA and protein were expressed at high levels in cells of epithelial origin. In Caco-2 human colon cancer cells, endogenous Dok-4 underwent tyrosine phosphorylation in response to pervanadate stimulation. In transfected COS cells, Dok-4 was a substrate for the cytosolic tyrosine kinases Src and Fyn as well as for Jak2. Dok-4 could also be phosphorylated by the receptor tyrosine kinase Ret but not by platelet-derived growth factor receptor-beta or IGF-IR. In both mammalian cells and yeast, Dok-4 was constitutively localized at the membrane in a manner that required both its PH and PTB domains. The PH and PTB domains of Dok-4 were also required for tyrosine phosphorylation of Dok-4 by Fyn and Ret. Finally, wild type Dok-4 strongly inhibited activation of Elk-1 induced by either Ret or Fyn. The attenuation of this inhibitory effect by deletion of the PH domain and its restoration by the addition of a myristoylation signal suggested an important role for constitutive membrane localization of Dok-4. In summary, Dok-4 is a constitutively membrane-localized adapter molecule that may function as an inhibitor of tyrosine kinase signaling in epithelial cells.	McGill Univ, Ctr Hlth, Dept Med, Div Nephrol, Montreal, PQ H3A 2B4, Canada; Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Rochester, NY 14642 USA	McGill University; University of Rochester	Lemay, S (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Div Nephrol, Lyman Duff Bldg,Rm 228,3775 Univ St, Montreal, PQ H3A 2B4, Canada.	serge.lemay@mcgill.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066919] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL66919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cong F, 1999, MOL CELL BIOL, V19, P8314; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HEIDARAN MA, 1992, ONCOGENE, V7, P147; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Jacobs AR, 2001, J BIOL CHEM, V276, P40795, DOI 10.1074/jbc.M105194200; Jones N, 1999, CURR BIOL, V9, P1057, DOI 10.1016/S0960-9822(99)80458-8; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lemay S, 2000, TRANSPLANTATION, V69, P959; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Lemay S, 1996, KIDNEY INT, V50, P85, DOI 10.1038/ki.1996.290; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Liang XQ, 2002, J BIOL CHEM, V277, P13732, DOI 10.1074/jbc.M200277200; Lock P, 1999, J BIOL CHEM, V274, P22775, DOI 10.1074/jbc.274.32.22775; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Saxena A, 2002, J BIOL CHEM, V277, P49935, DOI 10.1074/jbc.M206497200; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Suzu S, 2000, EMBO J, V19, P5114, DOI 10.1093/emboj/19.19.5114; Takano T, 2000, AM J PATHOL, V156, P2091, DOI 10.1016/S0002-9440(10)65080-8; Takeuchi H, 1998, BIOCHEM J, V334, P211, DOI 10.1042/bj3340211; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; van Dijk TB, 2000, BLOOD, V96, P3406; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Whitehead JP, 2000, CURR OPIN CELL BIOL, V12, P222, DOI 10.1016/S0955-0674(99)00079-4; WILSON LK, 1995, J BIOL CHEM, V270, P25185, DOI 10.1074/jbc.270.42.25185; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yu CCK, 2001, CURR BIOL, V11, P34, DOI 10.1016/S0960-9822(00)00024-5; Zhao MM, 2001, J EXP MED, V194, P265, DOI 10.1084/jem.194.3.265	67	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19335	19349		10.1074/jbc.M310689200	http://dx.doi.org/10.1074/jbc.M310689200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14963042	hybrid			2022-12-27	WOS:000221041500147
J	Czirjak, B; Toth, ZE; Enyedi, P				Czirjak, B; Toth, ZE; Enyedi, P			The two-pore domain K+ channel, TRESK, is activated by the cytoplasmic calcium signal through calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; POLYUNSATURATED FATTY-ACIDS; ADRENAL GLOMERULOSA CELLS; POTASSIUM CHANNEL; PHOSPHATASE-ACTIVITY; ANGIOTENSIN-II; TASK-1; INHIBITION; RECEPTORS; SUBUNIT	Agonist-induced cytoplasmic calcium signals often have profound effects on the membrane potential during cellular activation. In the present study, we report that cytoplasmic calcium elevation can regulate the membrane potential by a novel mechanism. TRESK, a recently described member of the two-pore domain potassium (2PK(+)) channel family, was activated 5-15-fold after stimulation of various Ca2+-mobilizing receptors in Xenopus oocytes. Extracellular application of ionomycin, as well as the microinjection of inositol 1,4,5-trisphosphate or calcium, also evoked TRESK activation, whereas microinjection of EGTA or pretreatment of the oocytes with thapsigargin prevented the receptor-mediated effect. These data indicate that TRESK is activated by increased cytoplasmic calcium concentration. However, application of Ca2+ to inside-out membrane patches failed to influence TRESK single channel activity, suggesting that cytoplasmic factors are also required for the regulation. Cyclosporin A and FK506, specific inhibitors of the calcium/calmodulin-dependent protein phosphatase ( calcineurin), completely eliminated TRESK activation. Coexpression of a constitutively active form of calcineurin with TRESK increased the basal background K+ current and attenuated the response of the channel to the calcium signal, indicating that TRESK was activated by the permanent calcineurin activity. Serine 276 was identified as the major functional target of calcineurin in TRESK by alanine-scanning mutagenesis. This is the first example of calcineurin being involved in the regulation of a two-pore domain K+ channel, and thus, TRESK channels may regulate the excitability of neurons and other cell types in response to Ca2+-mobilizing hormones and neurotransmitters in a manner that is sensitive to immunosuppressive drugs.	Semmelweis Univ, Dept Physiol, H-1444 Budapest, Hungary; Semmelweis Univ, Neuromorphol Lab, H-1444 Budapest, Hungary	Semmelweis University; Semmelweis University	Enyedi, P (corresponding author), Semmelweis Univ, Dept Physiol, POB 259, H-1444 Budapest, Hungary.	enyedi@puskin.sote.hu	Toth, Zsuzsanna/U-2579-2019	Czirjak, Gabor/0000-0002-5485-2327				Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Bayliss DA, 2001, RESP PHYSIOL, V129, P159, DOI 10.1016/S0034-5687(01)00288-2; BONNER TI, 1989, TRENDS PHARMACOL SCI, P11; Boyd DF, 2000, J PHYSIOL-LONDON, V529, P321, DOI 10.1111/j.1469-7793.2000.00321.x; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chemin J, 2003, EMBO J, V22, P5403, DOI 10.1093/emboj/cdg528; Czirjak G, 2002, J BIOL CHEM, V277, P5426, DOI 10.1074/jbc.M107138200; Czirjak G, 2000, MOL ENDOCRINOL, V14, P863, DOI 10.1210/me.14.6.863; Czirjak G, 2002, MOL ENDOCRINOL, V16, P621, DOI 10.1210/me.16.3.621; Czirjak G, 2001, AM J PHYSIOL-CELL PH, V281, pC700, DOI 10.1152/ajpcell.2001.281.2.C700; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Han J, 2002, J PHYSIOL-LONDON, V542, P431, DOI 10.1113/jphysiol.2002.017590; Hartness ME, 2001, J BIOL CHEM, V276, P26499, DOI 10.1074/jbc.M010357200; HO S, 1996, CLIN IMMUNOL IMMUNOP, V80, P40; Honore E, 2002, EMBO J, V21, P2968, DOI 10.1093/emboj/cdf288; Horvath A, 1998, CELL CALCIUM, V23, P33, DOI 10.1016/S0143-4160(98)90072-0; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Lesage F, 2000, J BIOL CHEM, V275, P28398, DOI 10.1074/jbc.M002822200; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; O'Kelly I, 1999, AM J PHYSIOL-LUNG C, V276, pL96, DOI 10.1152/ajplung.1999.276.1.L96; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; Philipson KD, 2002, ANN NY ACAD SCI, V976, P1; Plant LD, 2002, STROKE, V33, P2324, DOI 10.1161/01.STR.0000027440.68031.B0; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; Sano Y, 2003, J BIOL CHEM, V278, P27406, DOI 10.1074/jbc.M206810200; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; Talley EM, 2002, J BIOL CHEM, V277, P17733, DOI 10.1074/jbc.M200502200; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wang Z, 2002, J BIOL CHEM, V277, P24022, DOI 10.1074/jbc.M201949200	45	111	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18550	18558		10.1074/jbc.M312229200	http://dx.doi.org/10.1074/jbc.M312229200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14981085	Green Published, hybrid			2022-12-27	WOS:000221041500057
J	El Fadili, A; Kundig, C; Roy, G; Ouellette, M				El Fadili, A; Kundig, C; Roy, G; Ouellette, M			Inactivation of the Leishmania tarentolae pterin transporter (BT1) and reductase (PTR1) genes leads to viable parasites with changes in folate metabolism and hypersensitivity to the antifolate methotrexate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN DEHYDROGENASE GENE; RESISTANT LEISHMANIA; THYMIDYLATE SYNTHASE; WILD-TYPE; AMPLIFICATION; DONOVANI; CELLS; BIOPTERIN; LOCUS; POLYGLUTAMYLATION	The protozoan parasite Leishmania is a folate and pterin auxotroph. The main biopterin transporter (BT1) and pterin reductase (PTR1) have already been characterized in Leishmania. In this study, we have succeeded in generating a BT1 and PTR1 null mutant in the same Leishmania tarentolae strain. These cells are viable with growth properties indistinguishable from wildtype cells. However, in response to the inactivation of BT1 and PTR1, at least one of the folate transporter genes was deleted, and the level of the folylpolyglutamate synthetase activity was increased, leading to increased polyglutamylation of both folate and methotrexate (MTX). Secondary events following gene inactivation should be considered when analyzing a phenotype in Leishmania. The BT1/PTR1 null mutant is hypersensitive to MTX, but in a step-by-step fashion, we could induce resistance to MTX in these cells. Several resistance mechanisms were found to co-exist including a reduced folate and MTX accumulation, demonstrating that cells with no measurable biopterin uptake but also greatly reduced folate uptake are viable, despite their auxotrophy for each of these substrates. The resistant cells have also amplified the gene coding for the MTX target dihydrofolate reductase. Finally, we found a marked reduction in MTX polyglutamylation in resistant cells. These studies further highlight the formidable ability of Leishmania cells to bypass the blockage of key metabolic pathways.	CHU Laval, Ctr Rech Infect, CHUQ, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Div Microbiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Ouellette, M (corresponding author), CHU Laval, Ctr Rech Infect, CHUQ, Pavillon CHUL,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	marc.ouellette@crchul.ulaval.ca	Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646				ARREBOLA R, 1994, J BIOL CHEM, V269, P10590; BECK JT, 1990, MOL BIOCHEM PARASIT, V43, P221, DOI 10.1016/0166-6851(90)90147-E; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BEVERLEY SM, 1990, MOL BIOCHEM PARASIT, V42, P133, DOI 10.1016/0166-6851(90)90121-2; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; BRUN R, 1979, ACTA TROP, V36, P289; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; Cotrim PC, 1999, J BIOL CHEM, V274, P37723, DOI 10.1074/jbc.274.53.37723; Cunningham ML, 2001, MOL BIOCHEM PARASIT, V113, P199, DOI 10.1016/S0166-6851(01)00213-4; Cunningham ML, 2001, SCIENCE, V292, P285, DOI 10.1126/science.1057740; Drummelsmith J, 2003, MOL CELL PROTEOMICS, V2, P146, DOI 10.1074/mcp.M200085-MCP200; El Fadili A, 2003, BIOCHEM PHARMACOL, V66, P999, DOI 10.1016/S0006-2952(03)00417-9; El Fadili A, 2002, MOL BIOCHEM PARASIT, V124, P63, DOI 10.1016/S0166-6851(02)00163-9; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15960; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P13501; Galivan J, 2000, PHARMACOL THERAPEUT, V85, P207, DOI 10.1016/S0163-7258(99)00063-7; Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X; Guimond C, 2003, NUCLEIC ACIDS RES, V31, P5886, DOI 10.1093/nar/gkg806; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; KAUR K, 1988, J BIOL CHEM, V263, P7020; KIDDER GW, 1958, J GEN MICROBIOL, V18, P621, DOI 10.1099/00221287-18-3-621; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; Kundig C, 1999, NUCLEIC ACIDS RES, V27, P3653, DOI 10.1093/nar/27.18.3653; Lemley C, 1999, MOL BIOCHEM PARASIT, V104, P93, DOI 10.1016/S0166-6851(99)00132-2; Moran RG, 1999, SEMIN ONCOL, V26, P24; Nare B, 1997, J BIOL CHEM, V272, P13883, DOI 10.1074/jbc.272.21.13883; Nare B, 1997, PARASITOLOGY, V114, pS101, DOI 10.1017/S0031182097001133; OE H, 1983, J NUTR SCI VITAMINOL, V29, P523; Ouellette M, 1998, METHOD ENZYMOL, V292, P182; Ouellette M, 2002, INT J PARASITOL, V32, P385, DOI 10.1016/S0020-7519(01)00346-0; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; Papadopoulou B, 2002, INFECT IMMUN, V70, P62, DOI 10.1128/IAI.70.1.62-68.2002; PAPADOPOULOU B, 1993, NUCLEIC ACIDS RES, V21, P4305, DOI 10.1093/nar/21.18.4305; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P7310; PEIXOTO MP, 1987, ANTIMICROB AGENTS CH, V31, P1575, DOI 10.1128/AAC.31.10.1575; Richard D, 2002, J BIOL CHEM, V277, P29460, DOI 10.1074/jbc.M204796200; Roy G, 2001, EXP PARASITOL, V97, P161, DOI 10.1006/expr.2001.4595; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTI DV, 1987, BIOCHEM BIOPH RES CO, V146, P1089, DOI 10.1016/0006-291X(87)90759-5; Saxena A, 2003, MOL BIOCHEM PARASIT, V129, P103, DOI 10.1016/S0166-6851(03)00100-2; Senkovich O, 2003, MOL BIOCHEM PARASIT, V127, P89, DOI 10.1016/S0166-6851(02)00309-2; SHANE B, 1989, VITAM HORM, V45, P263; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; TRAGER W, 1969, J PROTOZOOL, V16, P372, DOI 10.1111/j.1550-7408.1969.tb02284.x	45	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18575	18582		10.1074/jbc.M400652200	http://dx.doi.org/10.1074/jbc.M400652200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14981076	hybrid			2022-12-27	WOS:000221041500060
J	Hughey, RP; Bruns, JB; Kinlough, CL; Harkleroad, KL; Tong, QS; Carattino, MD; Johnson, JP; Stockand, JC; Kleyman, TR				Hughey, RP; Bruns, JB; Kinlough, CL; Harkleroad, KL; Tong, QS; Carattino, MD; Johnson, JP; Stockand, JC; Kleyman, TR			Epithelial sodium channels are activated by furin-dependent proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNELS; PROPROTEIN CONVERTASE; HISTIDINE-RESIDUES; SERINE PROTEASES; OPEN PROBABILITY; XENOPUS-OOCYTES; GAMMA-SUBUNIT; ALPHA-SUBUNIT; PORE REGION; CELL-LINE	Epithelial Na+ channels (ENaCs) are activated by extracellular trypsin or by co-expression with channel-activating proteases, although there is no direct evidence that these proteases activate ENaC by cleaving the channel. We previously demonstrated that the alpha and gamma subunits of ENaC are cleaved during maturation near consensus sites for furin cleavage. Using site-specific mutagenesis of channel subunits, ENaC expression in furin-deficient cells, and furin-specific inhibitors, we now report that ENaC cleavage correlates with channel activity. Channel activity in furin-deficient cells was rescued by expression of furin. Our data provide the first example of a vertebrate ion channel that is a substrate for furin and whose activity is dependent on its proteolysis.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Health San Antonio	Kleyman, TR (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu		Stockand, James/0000-0002-3817-4319	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054787, R01DK054354, R01DK059594, R56DK065161, R01DK065161] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54787, DK59594, DK54354, DK65161] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; Bruns JB, 2003, AM J PHYSIOL-RENAL, V285, pF600, DOI 10.1152/ajprenal.00095.2003; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; Guipponi M, 2002, HUM MOL GENET, V11, P2829, DOI 10.1093/hmg/11.23.2829; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Sheng SH, 2004, J BIOL CHEM, V279, P9743, DOI 10.1074/jbc.M311952200; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tsuji A, 2002, PROTEIN ENG, V15, P123, DOI 10.1093/protein/15.2.123; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	39	329	334	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18111	18114		10.1074/jbc.C400080200	http://dx.doi.org/10.1074/jbc.C400080200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	15007080	hybrid			2022-12-27	WOS:000221041500004
J	Jeong, YJ; Kim, DE; Patel, SS				Jeong, YJ; Kim, DE; Patel, SS			Nucleotide binding induces conformational changes in Escherichia coli transcription termination factor Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING; PROTEIN-RHO; HELICASE; ANALOGS; DOMAIN; IDENTIFICATION; RECOGNITION; MECHANISM; HEXAMER; ADENINE	The Escherichia coli Rho protein uses the energy of ATP binding and hydrolysis to translocate along RNA and cause transcription termination. Using fluorescence stopped-flow kinetic studies, we have discerned the conformational changes in the Rho protein that occur upon nucleotide and nucleic acid binding. We show that the 2',(3')-O-[N-methylanthraniloyl] derivative of ATP (mant-ATP) is a good fluorescent substrate of Rho and is hydrolyzed with a K-m comparable with that for ATP but a k(cat) five to six times slower than that for ATP. The kinetics of ATP and mant-ATP binding indicates that, in the absence of RNA, the Rho protein is structurally distinct from the Rho hexamer found when bound to RNA or DNA. In the absence of RNA, the nucleotide-binding rates are 50- to 70-fold slower, and the dissociation rates are 40- to 120-fold slower than the corresponding rates in the presence of RNA. We conclude that RNA or DNA binding to the primary nucleic acid binding sites causes conformational changes in the Rho hexamer that result in the opening of the subunit interfaces. Furthermore, the kinetic studies revealed a unique protein conformational change in the Rho.RNA complex upon ATP binding that is a result of RNA contacting the secondary nucleic acid binding sites in the central channel of the Rho ring. This conformational change seems to render the Rho ring competent in ATP hydrolysis and translocation.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Dong Eui Univ, Dept Biotechnol & Bioengn, Pusan 614714, South Korea	Rutgers State University New Brunswick; Rutgers State University Medical Center; Dong-Eui University	Patel, SS (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.	patelss@umdnj.edu	Kim, Dong-Eun/D-8304-2011	Kim, Dong-Eun/0000-0001-6545-8387	PHS HHS [55310] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; Burgess BR, 2001, J BIOL CHEM, V276, P4182, DOI 10.1074/jbc.M007066200; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; FINGER LR, 1981, BIOCHEMISTRY-US, V20, P1640, DOI 10.1021/bi00509a036; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; Johnson K. A., 1992, ENZYMES, P1; Kim DE, 2001, J BIOL CHEM, V276, P13902, DOI 10.1074/jbc.M011043200; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOWERY C, 1977, J BIOL CHEM, V252, P1381; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; PIPER JM, 1981, ANAL BIOCHEM, V117, P70, DOI 10.1016/0003-2697(81)90693-X; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 2003, CELL, V114, P157, DOI 10.1016/S0092-8674(03)00554-3; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Wei RR, 2001, J BIOL CHEM, V276, P28380, DOI 10.1074/jbc.M102444200; Yu X, 2000, J MOL BIOL, V299, P1279, DOI 10.1006/jmbi.2000.3810	29	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18370	18376		10.1074/jbc.M309162200	http://dx.doi.org/10.1074/jbc.M309162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970217	hybrid			2022-12-27	WOS:000221041500034
J	Krakowiak, A; Pace, HC; Blackburn, GM; Adams, M; Mekhalfia, A; Kaczmarek, R; Baraniak, J; Stec, WJ; Brenner, C				Krakowiak, A; Pace, HC; Blackburn, GM; Adams, M; Mekhalfia, A; Kaczmarek, R; Baraniak, J; Stec, WJ; Brenner, C			Biochemical, crystallographic, and mutagenic characterization of hint, the AMP-lysine hydrolase, with novel substrates and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE TRIAD PROTEINS; SEX DETERMINATION; SUPERFAMILY; ENCODES; ATAXIA; KIN28; FHIT; GENE; CDK7; GALT	Hint, histidine triad nucleotide-binding protein, is a universally conserved enzyme that hydrolyzes AMP linked to lysine and, in yeast, functions as a positive regulator of the RNA polymerase II C-terminal domain kinase, Kin28. To explore the biochemical and structural bases for the adenosine phosphoramidate hydrolase activity of rabbit Hint, we synthesized novel substrates linking a p-nitroaniline group to adenylate (AMP-pNA) and inhibitors that consist of an adenosine group and 5'-sulfamoyl (AdoOSO(2)NH(2)) or N-ethylsulfamoyl (AdoOSO(2)NHCH(2)CH(3)) group. AMP-pNA is a suitable substrate for Hint that allowed characterization of the inhibitors; titration of each inhibitor into AMP-pNA assays revealed their K-i values. The N-ethylsulfamoyl derivative has a 13-fold binding advantage over the sulfamoyl adenosine. The 1.8-Angstrom cocrystal structure of rabbit Hint with N-ethylsulfamoyl adenosine revealed a binding site for the ethyl group against Trp-123, a residue that reaches across the Hint dimer interface to interact with the alkyl portion of the inhibitor and, presumably, the alkyl portion of a lysyl substrate. Ser-107 is positioned to donate a hydrogen bond to the leaving group nitrogen. Consistent with a role in acid-base catalysis, the Hint S107A mutant protein displayed depressed catalytic activity.	Kimmel Canc Ctr, Struct Biol & Bioinformat Program, Philadelphia, PA 19107 USA; Polish Acad Sci, Ctr Mol & Macromol Studies, Dept Bioorgan Chem, PL-90363 Lodz, Poland; Univ Sheffield, Krebs Inst, Dept Chem, Sheffield S3 7HF, S Yorkshire, England; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Biochem, Lebanon, NH 03756 USA	Jefferson University; Polish Academy of Sciences; Centre of Molecular & Macromolecular Studies of the Polish Academy of Sciences; University of Sheffield; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Dartmouth College	Brenner, C (corresponding author), Kimmel Canc Ctr, Struct Biol & Bioinformat Program, Philadelphia, PA 19107 USA.	charles.brenner@dartmouth.edu	Krakowiak, Agnieszka/ABC-8848-2020; Brenner, Charles/D-6339-2014	Brenner, Charles/0000-0002-4955-3226; Krakowiak, Agnieszka/0000-0002-0273-2972	NCI NIH HHS [R01 CA075954-07, CA75954, R01 CA075954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Draganescu A, 2000, J BIOL CHEM, V275, P4555, DOI 10.1074/jbc.275.7.4555; Geeganage S, 2000, BIOCHEMISTRY-US, V39, P5397, DOI 10.1021/bi992594s; GRAF R, 1959, CHEM BER-RECL, V92, P509, DOI 10.1002/cber.19590920237; Guga P, 2002, TOP CURR CHEM, V220, P169; Hori T, 2000, MOL BIOL CELL, V11, P3645, DOI 10.1091/mbc.11.10.3645; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Korsisaari N, 2003, MOL CELL BIOL, V23, P3929, DOI 10.1128/MCB.23.11.3929-3935.2003; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Pace HC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r18; SHUMAN DA, 1969, J AM CHEM SOC, V91, P3391, DOI 10.1021/ja01040a062; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; WEISS G, 1969, LIEBIGS ANN CHEM, V729, P40	20	46	51	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18711	18716		10.1074/jbc.M314271200	http://dx.doi.org/10.1074/jbc.M314271200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14982931	Green Accepted, hybrid			2022-12-27	WOS:000221041500077
J	Kukkola, L; Koivunen, P; Pakkanen, O; Page, AP; Myllyharju, J				Kukkola, L; Koivunen, P; Pakkanen, O; Page, AP; Myllyharju, J			Collagen prolyl 4-hydroxylase tetramers and dimers show identical decreases in K-m values for peptide substrates with increasing chain length - Mutation of one of the two catalytic sites in the tetramer inactivates the enzyme by more than half	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-ISOMERASE SUBUNIT; CAENORHABDITIS-ELEGANS; BACULOVIRUS EXPRESSION; ALPHA-SUBUNIT; BINDING DOMAIN; CLONING; IDENTIFICATION; HYDROXYLATION; PROCOLLAGEN; ISOFORM	The collagen prolyl 4-hydroxylases ( collagen P4Hs, EC 1.14.11.2) play a key role in the synthesis of the extracellular matrix. The vertebrate enzymes are alpha(2)beta(2) tetramers, the beta subunit being identical to protein disulfide isomerase (PDI). The main Caenorhabditis elegans collagen P4H form is an unusual PHY-1/PHY-2/(PDI)(2) mixed tetramer consisting of two types of catalytic alpha subunit, but the PHY-1 and PHY-2 polypeptides also form active PHY/PDI dimers. The lengths of peptide substrates have a major effect on their interaction with the P4H tetramers, the K-m values decreasing markedly with increasing chain length. This phenomenon has been explained in terms of processive binding of the two catalytic subunits to long peptides. We determined here the K-m values of a collagen P4H having two catalytic sites, the C. elegans mixed tetramer, and a form having only one such site, the PHY-1/PDI dimer, for peptides of varying lengths. All the K-m values of the PHY-1/PDI dimer were found to be about 1.5-2.5 times those of the tetramer, but increasing peptide length led to identical decreases in the values of both enzyme forms. The K-m for a nonhydroxylated collagen fragment with 33-X-Y-Gly- triplets but only 11 -X-Pro-Gly-triplets was found to correspond to the number of the former rather than the latter. To study the individual roles of the two catalytic sites in a tetramer, we produced mutant PHY-1/PHY-2/(PDI)(2) tetramers in which binding of the Fe2+ ion or 2-oxoglutarate to one of the two catalytic sites was prevented. The activities of the mutant tetramers decreased to markedly less than 50% of that of the wild type, being about 5 - 10% and 20 - 30% with the enzymes having one of the two Fe2+-binding sites or 2-oxoglutarate-binding sites inactivated, respectively, while the K-m values for these cosubstrates or peptide substrates were not affected. Our data thus indicate that although collagen P4Hs do not act on peptide substrates by a processive mechanism, prevention of hydroxylation at one of the two catalytic sites in the tetramer impairs the function of the other catalytic site.	Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland	University of Oulu; University of Oulu; University of Glasgow	Myllyharju, J (corresponding author), Univ Oulu, Dept Med Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; DEJONG L, 1991, BIOCHIM BIOPHYS ACTA, V1079, P103, DOI 10.1016/0167-4838(91)90030-4; DEWAAL A, 1988, BIOCHEMISTRY-US, V27, P150, DOI 10.1021/bi00401a023; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Hieta R, 2002, J BIOL CHEM, V277, P23965, DOI 10.1074/jbc.M201865200; Hill KL, 2000, GENETICS, V155, P1139; Invitrogen &TRADE;, 2002, MAN METH EXPR REC PR; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myllyharju J, 2002, J BIOL CHEM, V277, P29187, DOI 10.1074/jbc.M203824200; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; Riihimaa P, 2002, J BIOL CHEM, V277, P18238, DOI 10.1074/jbc.M200895200; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000	34	11	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18656	18661		10.1074/jbc.M401514200	http://dx.doi.org/10.1074/jbc.M401514200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985345	hybrid			2022-12-27	WOS:000221041500070
J	Ludeman, MJ; Zheng, YW; Ishii, K; Coughlin, SR				Ludeman, MJ; Zheng, YW; Ishii, K; Coughlin, SR			Regulated shedding of PAR1 N-terminal exodomain from endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING-ENZYME; NECROSIS-FACTOR-ALPHA; PLATELET THROMBIN RECEPTOR; PROTEIN-COUPLED RECEPTORS; EGF RECEPTOR; PROSTACYCLIN PRODUCTION; ACTIVATION; CLEAVAGE; METALLOPROTEINASE; TACE	G protein-coupled receptors can trigger metalloproteinase-dependent shedding of proteins from the cell surface. We now report that G protein-coupled receptors can themselves undergo regulated metalloproteinase-dependent shedding. The N-terminal exodomain of protease-activated receptor-1 (PAR1), a G protein-coupled receptor for thrombin, displayed regulated shedding in endothelial cells, which normally express this receptor. Cleavage occurred at a site predicted to render the receptor unresponsive to thrombin. A chimeric protein in which the N-terminal exodomain of PAR1 was fused to an unrelated transmembrane segment was shed as efficiently as PAR1, shedding of both proteins was stimulated by phorbol ester and by a PAR1 agonist. TNFalpha protease inhibitor-2 (TAPI-2), phenanthroline, and tissue inhibitor of metalloproteinase-3 (TIMP-3) but not TIMP-1 or -2 inhibited such shedding. These and other data suggest that the information that specifies PAR1 shedding resides within its N-terminal exodomain rather than its heptahelical segment, that activation of protein kinase C or of PAR1 itself can stimulate PAR1 shedding in trans, and that ADAM17/TACE or a metalloproteinase with similar properties mediates PAR1 shedding. Regulated shedding reduced the amount of cell surface PAR1 available for productive cleavage by thrombin by half or more, but thus far we have been unable to demonstrate an effect of PAR1 shedding on cellular responsiveness to thrombin. Nonetheless, regulated shedding of G protein-coupled receptors represents a new mechanism by which signaling by this important class of receptors might be modulated.	Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kyoto University	Coughlin, SR (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, HSE-1300,513 Parnassus Ave, San Francisco, CA 94143 USA.	coughlin@cvrimail.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059202, R01HL044907, R01HL065590, R01HL065185] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907, HL65590, HL65185, HL59202] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; Boulday G, 2001, CIRC RES, V88, P430; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHEN J, 1994, J BIOL CHEM, V269, P16041; CHEN J, 1994, J BIOL CHEM, V269; Cunningham MA, 2000, J EXP MED, V191, P455, DOI 10.1084/jem.191.3.455; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; GARTON KJ, 2003, J BIOL CHEM, V23, P23; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P2486, DOI 10.1021/bi982527i; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; Imaizumi T, 2000, ARTERIOSCL THROM VAS, V20, P410, DOI 10.1161/01.ATV.20.2.410; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; Marin V, 2002, EUR J IMMUNOL, V32, P2965, DOI 10.1002/1521-4141(2002010)32:10<2965::AID-IMMU2965>3.0.CO;2-V; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Nath D, 2001, J CELL SCI, V114, P1213; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Schlondorff J, 1999, J CELL SCI, V112, P3603; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; Xu J, 2000, J BIOL CHEM, V275, P6038, DOI 10.1074/jbc.275.8.6038; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhao JS, 2001, DEV BIOL, V232, P204, DOI 10.1006/dbio.2001.0176	38	32	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18592	18599		10.1074/jbc.M310836200	http://dx.doi.org/10.1074/jbc.M310836200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14982936	hybrid			2022-12-27	WOS:000221041500062
J	Luo, Q; Ma, XJ; Wahl, SM; Bieker, JJ; Crossley, M; Montaner, LJ				Luo, Q; Ma, XJ; Wahl, SM; Bieker, JJ; Crossley, M; Montaner, LJ			Activation and repression of interleukin-12 p40 transcription by erythroid Kruppel-like factor in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BETA-GLOBIN PROMOTER; BOX-BINDING-PROTEIN; FACTOR EKLF; CACCC-BOX; GENE PROMOTER; FACTOR PU.1; PROTECTIVE IMMUNITY; INTERFERON-GAMMA; IL-12 PRODUCTION	Transcription of interleukin (IL)-12 p40 in myeloid cells is attributed to the recruitment of multiple activated transcription factors such as nuclear factor kappaB (NFkappaB), CCAAT enhancer-binding protein beta, ets-2, PU.1, and so forth. We now provide the first description of the human erythroid Kruppel-like factor ( EKLF) in human primary macrophages and identify the role of EKLF in IL-12 p40 expression. EKLF-specific binding to the CACCC element (-224 to -220) on the human IL-12 p40 promoter was observed in resting human primary macrophages. Functional analysis of the CACCC element revealed a dependent role for EKLF binding in activating IL-12 p40 transcription in resting RAW264.7 cells, whereas EKLF overexpression in the presence or absence of this element repressed IL-12 p40 transcription in interferon gamma/lipopolysaccharide-stimulated RAW264.7 cells. Murine endogenous IL-12 p40 mRNA was consistently induced by overexpressed EKLF in resting RAW264.7 cells, whereas EKLF suppressed IL-12 p40 expression in activated RAW264.7 cells. Modulation of nuclear binding activities at the IL-12 p40 NFkappaB half-site was induced by EKLF for down-regulation of IL-12 p40 transcription in activated RAW264.7 cells, but no effect of EKLF on NFkappaB activity was observed in resting RAW264.7 cells. Taken together, we identify EKLF as a transcription factor in macrophages able to regulate IL-12 p40 transcription depending on the cellular activation status. The bifunctional control of IL-12 p40 by EKLF and its modulation of NFkappaB support a potential function for this factor in orchestrating IL-12 p40 production in macrophages.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10012 USA; NIH, Cellular Immunol Sect, Bethesda, MD 20892 USA; Mt Sinai Sch Med, New York, NY 10029 USA; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	The Wistar Institute; Cornell University; National Institutes of Health (NIH) - USA; Icahn School of Medicine at Mount Sinai; University of Sydney	Montaner, LJ (corresponding author), Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.	montaner@wistar.upenn.edu	Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642	NATIONAL CANCER INSTITUTE [R01CA100223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054891, R01AI034412, R01AI051225, R01AI047760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000046] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100223, R01 CA100223-01A1] Funding Source: Medline; NIAID NIH HHS [R01 AI047760, AI47760, AI51225, R01 AI051225, AI54891, AI34412, R01 AI034412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Becker C, 2001, J IMMUNOL, V167, P2608, DOI 10.4049/jimmunol.167.5.2608; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bradley MN, 2003, MOL CELL BIOL, V23, P4841, DOI 10.1128/MCB.23.14.4841-4858.2003; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen XY, 2001, MOL CELL BIOL, V21, P3118, DOI 10.1128/MCB.21.9.3118-3125.2001; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Crossley M, 1996, MOL CELL BIOL, V16, P1695; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Goto M, 1999, CYTOKINE, V11, P16, DOI 10.1006/cyto.1998.0390; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kelly RW, 1997, BIOCHEM BIOPH RES CO, V239, P557, DOI 10.1006/bbrc.1997.7502; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Lankford CSR, 2003, J LEUKOCYTE BIOL, V73, P49, DOI 10.1189/jlb.0602326; Lee JS, 1999, P NATL ACAD SCI USA, V96, P10051, DOI 10.1073/pnas.96.18.10051; Lee JS, 2000, P NATL ACAD SCI USA, V97, P2468, DOI 10.1073/pnas.040476297; Ma XJ, 2000, J IMMUNOL, V164, P1722, DOI 10.4049/jimmunol.164.4.1722; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Maruyama S, 2003, J IMMUNOL, V170, P997, DOI 10.4049/jimmunol.170.2.997; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Paludan SR, 2001, J VIROL, V75, P8008, DOI 10.1128/JVI.75.17.8008-8015.2001; PERKINS AC, 1995, NATURE, V375, P318; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Southwood CM, 1996, DEV DYNAM, V206, P248, DOI 10.1002/(SICI)1097-0177(199607)206:3<248::AID-AJA3>3.0.CO;2-I; Su Z, 2002, J IMMUNOL, V168, P1348, DOI 10.4049/jimmunol.168.3.1348; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Ulgiati D, 2000, J IMMUNOL, V164, P300, DOI 10.4049/jimmunol.164.1.300; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Verhagen CE, 2000, J EXP MED, V192, P517, DOI 10.1084/jem.192.4.517; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200; Xu ZJ, 2001, J IMMUNOL, V167, P6975, DOI 10.4049/jimmunol.167.12.6975; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	55	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18451	18456		10.1074/jbc.M400320200	http://dx.doi.org/10.1074/jbc.M400320200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976188	Green Accepted, hybrid			2022-12-27	WOS:000221041500044
J	Liu, AG; Hoffman, PW; Lu, WW; Bai, G				Liu, AG; Hoffman, PW; Lu, WW; Bai, G			NF-kappa B site interacts with Sp factors and up-regulates the NR1 promoter during neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; DNA-BINDING; ENHANCER ACTIVATION; GLUTAMATE RECEPTORS; FUNCTIONAL-ANALYSIS; T-LYMPHOCYTES; RAT-BRAIN; IN-VITRO; GT-BOX	The NR1 gene undergoes induction in neurogenesis mainly via promoter de-repression, and up-regulation during neuronal differentiation by undefined mechanism(s). Here, we show that in the distal region the NR1 promoter has an active NF-kappaB site sharing the consensus with the immunoglobulin (Ig)/human immunodeficiency virus NF-kappaB site. Mutation of this site significantly reduced NR1 promoter up-regulation during neuronal differentiation of P19 cells. Electrophoretic mobility shift assays revealed that P19 nuclei constitutively contained p50 and that neuronal differentiation not only increased nuclear p50 but also induced p65 nuclear translocation. Responding to this change was an up-regulation of NF-kappaB-dependent promoter activity. However, inhibition of NF-kappaB nuclear translocation by an IkappaBalpha super-repressor or decoy DNA only moderately inhibited NR1 promoter up-regulation. Interestingly, the NR1 NF-kappaB site strongly interacted with Sp3/Sp1, instead of NF-kappaB factors, in P19 nuclear extracts. This interaction was reduced for Sp3 following neuronal differentiation, accompanied by dynamic expression of Sp factors. Cotransfection of Sp factors (Sp1, 3, or 4) up-regulated the NR1 NF-kappaB site dramatically in differentiated neurons, but only moderately in undifferentiated P19 cells. This up-regulation was strong for Sp1 in differentiated cells and for Sp3 in undifferentiated cells. Chromatin-immunoprecipitation assays further demonstrated that Sp1 and Sp3 interacted with the NR1 NF-kappaB site in situ, and Sp3 lost its interaction after neuronal differentiation. We conclude that the NF-kappaB site positively regulates the NR1 promoter during neuronal differentiation via interacting mainly with Sp factors and neuronal differentiation reduces the effect of Sp3 factor on this site.	Univ Maryland, Sch Dent, Dept Biomed Sci, Program Neurosci, Baltimore, MD 21201 USA; Univ Maryland, Program Mol & Cellular Biol, Baltimore, MD 21201 USA; Coll Notre Dame Maryland, Dept Biol, Baltimore, MD 21210 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Bai, G (corresponding author), Univ Maryland, Sch Dent, Dept Biomed Sci, Program Neurosci, 666 W Baltimore St, Baltimore, MD 21201 USA.	GNB001@dental.umaryland.edu			NINDS NIH HHS [NS38077] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038077] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Bai G, 2003, J NEUROCHEM, V86, P992, DOI 10.1046/j.1471-4159.2003.01922.x; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; BAKALKIN G, 1994, MOL BRAIN RES, V24, P301, DOI 10.1016/0169-328X(94)90143-0; BAKALKIN GY, 1993, MOL BRAIN RES, V20, P137, DOI 10.1016/0169-328X(93)90119-A; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Dingledine R, 1999, PHARMACOL REV, V51, P7; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hatzis P, 2001, MOL CELL BIOL, V21, P7320, DOI 10.1128/MCB.21.21.7320-7330.2001; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hernandez EM, 2002, J BIOCHEM MOL BIOL, V35, P273; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Liu A, 2001, J BIOL CHEM, V276, P45372, DOI 10.1074/jbc.M105399200; Liu AG, 2003, J BIOL CHEM, V278, P26423, DOI 10.1074/jbc.M211165200; Mao XR, 2002, J BIOL CHEM, V277, P44911, DOI 10.1074/jbc.M204292200; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Miyasaka N, 1999, MOL BRAIN RES, V69, P62, DOI 10.1016/S0169-328X(99)00107-2; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Okamoto S, 2002, MOL BRAIN RES, V107, P89, DOI 10.1016/S0169-328X(02)00440-0; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Qin ZH, 1996, BRAIN RES, V725, P166, DOI 10.1016/S0006-8993(96)00200-4; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Song J, 2003, INT J MOL MED, V11, P547; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; URBAN MB, 1991, NEW BIOL, V3, P279; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	51	68	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17449	17458		10.1074/jbc.M311267200	http://dx.doi.org/10.1074/jbc.M311267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970236	hybrid			2022-12-27	WOS:000220870400071
J	Seo, MR; Cho, CH; Lee, YI; Shin, EY; Park, D; Bae, CD; Lee, JW; Lee, ES; Juhnn, YS				Seo, MR; Cho, CH; Lee, YI; Shin, EY; Park, D; Bae, CD; Lee, JW; Lee, ES; Juhnn, YS			Cdc42-dependent mediation of UV-induced p38 activation by G protein beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; INFLAMMATORY CYTOKINES; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; KINASE ACTIVATION; GROWTH-FACTOR; RHO GTPASES; RAS; PATHWAY; PAK	The beta and gamma subunits of heterotrimeric GTP-binding proteins (Gbetagamma) were found to bi-directionally regulate the UV-induced activation of p38 and c-Jun NH2-terminal kinase, and the UV-induced activation of p38 was reported to enhance the resistance of normal keratinocytes to apoptosis. However, the signaling pathway downstream of Gbetagamma for this UV-induced p38 activation is not known. Thus, we examined the role of the Rho GTPase family in the regulation of UV-induced p38 activation by Gbetagamma. We found that overexpression of Gbetagamma increased the UV-induced activation of Cdc42 and that overexpression of constitutively active V12 Cdc42 increased the UV-induced p38 activation. Transfection of dominant negative N17 Cdc42 or small interfering RNA for Cdc42 blocked UV-induced p38 activation mediated by Gbetagamma in COS-1 and HaCaT cells. UV-induced p38 activation by Gbetagamma was blocked by overexpression of dominant negative p21-activated kinase (PAK)-interacting exchange factor beta (betaPix), and wild type betaPix stimulated the UV-induced p38 activation, which was blocked by N17 Cdc42. Gbetagamma increased the UV-induced activation of Ras, and the overexpression of V12 Ras increased UV-induced p38 activation, which was blocked by dominant negative betaPix. UV-induced p38 activation was inhibited by N17 Ras and a farnesyltransferase inhibitor, manumycin A. Gbetagamma also increased the UV-induced phosphorylation of the epidermal growth factor receptor ( EGFR), and the UV-induced p38 activation was blocked by an EGFR kinase inhibitor, AG1478. From these results, we conclude that Gbetagamma mediates UV-induced activation of p38 in a Cdc42-dependent way and that EGFR, Ras, and betaPix act sequentially upstream of Cdc42 in COS-1 and HaCaT cells.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Lab Mol Carcinogenesis & Expt Therapeut, Canc Res Inst, Seoul 110799, South Korea; Chungbuk Natl Univ, Coll Med, Dept Biochem, Cheongju 3617632, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Sungkyunkwan Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 440746, South Korea; Ajou Univ, Sch Med, Dept Dermatol, Suwon 442749, South Korea	Seoul National University (SNU); Seoul National University (SNU); Chungbuk National University; Seoul National University (SNU); Sungkyunkwan University (SKKU); Ajou University	Juhnn, YS (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, 28 Yongon Dong, Seoul 110799, South Korea.	juhnn@snu.ac.kr	Lee, Jung Weon/F-9149-2012; Juhnn, Yong-Sung/J-2790-2012; Lee, Jung Weon/AAC-1146-2020	Lee, Jung Weon/0000-0003-2722-8200; Lee, Eun-So/0000-0003-0232-7704				ARUFFO A, 1991, CURRENT PROTOCOLS MO; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Benard V, 2002, METHOD ENZYMOL, V345, P349; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chouinard N, 2002, BIOCHEM J, V365, P133, DOI 10.1042/BJ20020072; COFFER PJ, 1995, ONCOGENE, V11, P561; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; Eom YW, 2001, BIOCHEM BIOPH RES CO, V285, P825, DOI 10.1006/bbrc.2001.5233; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Gutkind J.S, 2000, SCI STKE; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; He H, 2001, CANCER J, V7, P191; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; Li, 2000, Arterioscler Thromb Vasc Biol, V20, pE1; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Seo M, 2002, J BIOL CHEM, V277, P24197, DOI 10.1074/jbc.M201717200; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yamauchi J, 2001, J BIOL CHEM, V276, P23362, DOI 10.1074/jbc.M011752200; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	44	33	34	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17366	17375		10.1074/jbc.M312442200	http://dx.doi.org/10.1074/jbc.M312442200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970210	hybrid			2022-12-27	WOS:000220870400060
J	Yamamoto, J; Ikeda, Y; Iguchi, H; Fujino, T; Tanaka, T; Asaba, H; Iwasaki, S; Ioka, RX; Kaneko, IW; Magoori, K; Takahashi, S; Mori, T; Sakaue, H; Kodama, T; Yanagisawa, M; Yamamoto, TT; Ito, S; Sakai, J				Yamamoto, J; Ikeda, Y; Iguchi, H; Fujino, T; Tanaka, T; Asaba, H; Iwasaki, S; Ioka, RX; Kaneko, IW; Magoori, K; Takahashi, S; Mori, T; Sakaue, H; Kodama, T; Yanagisawa, M; Yamamoto, TT; Ito, S; Sakai, J			A Kruppel-like factor KLF15 contributes fasting-induced transcriptional activation of mitochondrial acetyl-CoA synthetase gene AceCS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; MICE LACKING; EXPRESSION; INSULIN; IDENTIFICATION; PATTERNS; PROMOTER; MUTATION; LIVER	Acetyl-CoA synthetase 2 (AceCS2) produces acetylCoA for oxidation through the citric acid cycle in the mitochondrial matrix. AceCS2 is highly expressed in the skeletal muscle and is robustly induced by fasting. Quantification of AceCS2 transcripts both in C2C12 and human myotubes indicated that fasting-induced AceCS2 gene expression appears to be independent on insulin action. Characterization of 5'-flanking region of the mouse AceCS2 gene demonstrates that Kruppel-like factor 15 (KLF15) plays a key role in the trans-activation of the AceCS2 gene. Deletion and mutation analyses of AceCS2 promoter region revealed that the most proximal KLF site is a curtail site for the trans-activation of the AceCS2 gene by KLF15. Using Sp-null Drosophila SL2 cells, we showed that the combination of KLF15 and Sp1 resulted in a synergistic activation of the AceCS2 promoter. Mutation analyses of three GC-boxes in the AceCS2 promoter indicated that the GC-box, located 8 bases downstream of the most proximal KLF15 site, is the most important GC-box in the synergistic trans-activation of the AceCS2 gene by KLF15 and Sp1. GST pull-down assays showed that KLF15 interacts with Sp1 in vitro. Quantification of various KLF transcripts revealed that 48 h fasting robustly induced the KLF15 transcripts in the skeletal muscle. Together with the trans-activation of the AceCS2 promoter, it is suggested that fasting-induced AceCS2 expression is largely contributed by KLF15. Furthermore, KLF15 overexpression induced the levels of AceCS2 transcripts both in myoblasts and in myotubes, indicating that AceCS2 gene expression in vivo is indeed induced by KLF15.	Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo 1538904, Japan; Tohoku Univ, Grad Sch Med, Dept Med, Div Nephrol Endocrinol & Vasc Med, Sendai, Miyagi 9808574, Japan; Japan Sci & Technol Corp, Exploratory Res Adv Technol, Yanagisawa Orphan Receptor Project, Tokyo 1350064, Japan; Tohoku Univ, Ctr Gene Res, Sendai, Miyagi 9818555, Japan; Fukui Med Univ, Dept Internal Med 3, Fukui 9101193, Japan; Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis, Kobe, Hyogo 6500017, Japan; Univ Texas, SW Med Ctr, Dept Mol Genet, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Tokyo; Tohoku University; Japan Science & Technology Agency (JST); Tohoku University; University of Fukui; Kobe University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sakai, J (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo 1538904, Japan.	jmsakai-tky@umin.ac.jp	Sakaue, Hiroshi/ABE-2337-2021; Ito, Sadayoshi/A-3933-2015	Sakaue, Hiroshi/0000-0002-2468-2363; Ito, Sadayoshi/0000-0002-5092-3626; Sakai, Juro/0000-0003-4043-1035				*APPL BIOS, 2001, US B APPL BIOS, V2; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; Fukuoka M, 2003, INT J MOL MED, V12, P503; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Gray S, 2002, J BIOL CHEM, V277, P34322, DOI 10.1074/jbc.M201304200; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Hatta M, 2002, INT J MOL MED, V9, P147; Ikeda Y, 2001, J BIOL CHEM, V276, P34259, DOI 10.1074/jbc.M103848200; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kishida K, 2001, J BIOL CHEM, V276, P36251, DOI 10.1074/jbc.M106040200; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Minami T, 1998, EUR J BIOCHEM, V258, P879, DOI 10.1046/j.1432-1327.1998.2580879.x; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERKINS AC, 1995, NATURE, V375, P318; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Yamagata K, 1998, DIABETES, V47, P1231, DOI 10.2337/diabetes.47.8.1231; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999; Yoshiuchi I, 2002, DIABETOLOGIA, V45, P154; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598	30	69	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16954	16962		10.1074/jbc.M312079200	http://dx.doi.org/10.1074/jbc.M312079200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960588	hybrid			2022-12-27	WOS:000220870400010
J	Machida, N; Umikawa, M; Takei, K; Sakima, N; Myagmar, BE; Taira, K; Uezato, H; Ogawa, Y; Kariya, K				Machida, N; Umikawa, M; Takei, K; Sakima, N; Myagmar, BE; Taira, K; Uezato, H; Ogawa, Y; Kariya, K			Mitogen-activated protein kinase kinase kinase kinase 4 as a putative effector of Rap2 to activate the c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; SIGNALING PATHWAY; CELLS; HGK	Little is known about the specific signaling roles of Rap2, a Ras family small GTP-binding protein. In a search for novel Rap2-interacting proteins by the yeast two-hybrid system, we isolated isoform 3 of the human mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), a previously described but uncharacterized isoform. Other isoforms of MAP4K4 in humans and mice are known as hematopoietic progenitor kinase (HPK)/germinal center kinase (GCK)-like kinase and Nck-interacting kinase, respectively. MAP4K4 belongs to the STE20 group of protein kinases and regulates c-Jun N-terminal kinase (JNK). MAP4K4 interacted with Rap2 through its C-terminal citron homology domain but did not interact with Rap1 or Ras. Interaction with Rap2 required the intact effector region of Rap2. MAP4K4 interacted preferentially with GTP-bound Rap2 over GDP-bound Rap2 in vitro. In cultured cells, MAP4K4 co-localized with Rap2, while a mutant MAP4K4 lacking the citron homology domain failed to do so. Furthermore, Rap2 enhanced MAP4K4-induced activation of JNK. These results suggest that MAP4K4 is a putative effector of Rap2 mediating the activation of JNK by Rap2.	Univ Ryukyus, Grad Sch Med, Div Cell Biol, Nishihara, Okinawa 9030215, Japan; Univ Ryukyus, Fac Med, Dept Dermatol, Nishihara, Okinawa 9030215, Japan; Univ Ryukyus, Fac Med, Dept Urol, Nishihara, Okinawa 9030215, Japan	University of the Ryukyus; University of the Ryukyus; University of the Ryukyus	Kariya, K (corresponding author), Univ Ryukyus, Grad Sch Med, Div Cell Biol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.	kariya@med.u-ryukyu.ac.jp						Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Sendoh H, 2000, BIOCHEM BIOPH RES CO, V271, P596, DOI 10.1006/bbrc.2000.2674; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; Wright JH, 2003, MOL CELL BIOL, V23, P2068, DOI 10.1128/MCB.23.6.2068-2082.2003; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118	14	90	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15711	15714		10.1074/jbc.C300542200	http://dx.doi.org/10.1074/jbc.C300542200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14966141	hybrid			2022-12-27	WOS:000220747900002
J	Bax, DV; Messent, AJ; Tart, J; van Hoang, M; Kott, J; Maciewicz, RA; Humphries, MJ				Bax, DV; Messent, AJ; Tart, J; van Hoang, M; Kott, J; Maciewicz, RA; Humphries, MJ			Integrin alpha(5)beta(1) and ADAM-17 interact in vitro and co-localize in migrating HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CONVERTING-ENZYME; TNF-ALPHA; METALLOPROTEASE-DISINTEGRINS; INTERLEUKIN-6 RECEPTOR; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAIN; BINDING; PROTEINS; CLEAVAGE	Tumor necrosis factor (TNF) alpha-converting enzyme (TACE/ADAM-17) has diverse roles in the proteolytic processing of cell surface molecules and, due to its ability to process TNFalpha, is a validated therapeutic target for anti-inflammatory therapies. Unlike a number of other ADAM proteins, which interact with integrin receptors via their disintegrin domains, there is currently no evidence for an ADAM-17-integrin association. By analyzing the adhesion of a series of cell lines with recombinant fragments of the extracellular domain of ADAM-17, we now demonstrate a functional interaction between ADAM-17 and alpha(5)beta(1) integrin in a trans orientation. Because ADAM-17-mediated adhesion was sensitive to RGD peptides and EDTA, and the integrin-binding site within ADAM-17 was narrowed down to the disintegrin/cysteine-rich region, the two molecules appear to have a ligand-receptor relationship mediated by the alpha(5)beta(1) ligand binding pocket. Intriguingly, ADAM-17 and alpha(5)beta(1) were found to co-localize in both membrane ruffles and focal adhesions in HeLa cells. When confluent HeLa cell monolayers were wounded, ADAM-17 and alpha(5)beta(1) redistributed to the leading edge and co-localized, which is suggestive of a cis orientation. We postulate that the interaction of ADAM-17 with alpha(5)beta(1) may target or modulate its metalloproteolytic activity.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; AstraZeneca, Inflammat Res Dept, Macclesfield SK10 4TG, Cheshire, England	University of Manchester; AstraZeneca	Humphries, MJ (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	martin.humphries@man.ac.uk		Humphries, Martin/0000-0002-4331-6967				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Barlaam B, 1999, J MED CHEM, V42, P4890, DOI 10.1021/jm990377j; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Boissy P, 2003, FEBS LETT, V553, P257, DOI 10.1016/S0014-5793(03)01022-6; Bridges LC, 2002, J BIOL CHEM, V277, P3784, DOI 10.1074/jbc.M109538200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Cao Y, 2001, BIOCHEM J, V357, P353, DOI 10.1042/0264-6021:3570353; Colon AL, 2001, CYTOKINE, V16, P220, DOI 10.1006/cyto.2001.0969; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Duffy MJ, 2003, THROMB HAEMOSTASIS, V89, P622; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Eto K, 2002, J BIOL CHEM, V277, P17804, DOI 10.1074/jbc.M200086200; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gaultier A, 2002, J BIOL CHEM, V277, P23336, DOI 10.1074/jbc.M201792200; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Huang X, 2003, DEVELOPMENT, V130, P3147, DOI 10.1242/dev.00518; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; Patel IR, 1998, J IMMUNOL, V160, P4570; Peiretti F, 2003, J CELL SCI, V116, P1949, DOI 10.1242/jcs.00415; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; Takahashi Y, 2001, MOL BIOL CELL, V12, P809, DOI 10.1091/mbc.12.4.809; Tuckwell DS, 2000, BIOCHEM J, V350, P485, DOI 10.1042/0264-6021:3500485; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200; Zhu PC, 2003, BIOCHEM BIOPH RES CO, V301, P991, DOI 10.1016/S0006-291X(03)00056-1; Zigrino P, 2002, J BIOL CHEM, V277, P40528, DOI 10.1074/jbc.M202049200	53	67	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22377	22386		10.1074/jbc.M400180200	http://dx.doi.org/10.1074/jbc.M400180200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14970227	hybrid			2022-12-27	WOS:000221417100086
J	Degryse, B; Neels, JG; Czekay, RP; Aertgeerts, K; Kamikubo, Y; Loskutoff, DJ				Degryse, B; Neels, JG; Czekay, RP; Aertgeerts, K; Kamikubo, Y; Loskutoff, DJ			The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; SMOOTH-MUSCLE-CELLS; UROKINASE RECEPTOR; CYTOSKELETON REORGANIZATION; ENDOTHELIAL-CELLS; ALPHA(2)-MACROGLOBULIN RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; ENDOCYTIC RECEPTOR; INDUCE CHEMOTAXIS; LIGAND-BINDING	Although plasminogen activator inhibitor-1 (PAI-1) is known to stimulate cell migration, little is known about underlying mechanisms. We show that both active and inactive (e.g. cleaved) PAI-1 can activate the Jak/Stat signaling system and stimulate cell migration in chemotaxis, haptotaxis, chemokinesis, and wound healing assays. Moreover, antibodies to the LDL receptor-related protein (LRP) and an LRP antagonist ( RAP) blocked these motogenic effects of PAI-1, while a PAI-1 mutant that did not bind to LRP failed to activate the Jak/Stat signaling pathway or to stimulate cell migration. PAI-1 had no chemotactic effect on LRP-deficient cells. These results indicate that LRP is a signaling molecule, that it mediates the migration-promoting activity of PAI-1, and that this activity does not require intact, biologically active PAI-1. Activation of this LRP-dependent signaling pathway by PAI-1 may begin to explain how the inhibitor stimulates cell migration in a variety of normal and pathological processes.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Loskutoff, DJ (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, 10550 N Torrey Pines Rd,VB-3, La Jolla, CA 92037 USA.	loskutof@scripps.edu	Neels, Jaap G/F-5534-2010	Neels, Jaap G/0000-0002-5900-8395	NHLBI NIH HHS [HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Chapman HA, 2001, THROMB HAEMOSTASIS, V86, P124; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Degryse B, 2001, ONCOGENE, V20, P2032, DOI 10.1038/sj.onc.1204261; Degryse B, 2001, FEBS LETT, V505, P249, DOI 10.1016/S0014-5793(01)02797-1; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; Degryse Bernard, 2003, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V2, P237, DOI 10.2174/1568014033483734; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Horn IR, 1998, THROMB HAEMOSTASIS, V80, P822; JI ZS, 1993, J BIOL CHEM, V268, P10160; KIRCHHEIMER JC, 1990, J IMMUNOL, V145, P1518; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Neels JG, 2000, BLOOD, V96, P3459, DOI 10.1182/blood.V96.10.3459.h8003459_3459_3465; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Palmieri D, 2002, J BIOL CHEM, V277, P40950, DOI 10.1074/jbc.M202333200; PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Sarafanov AG, 2001, J BIOL CHEM, V276, P11970, DOI 10.1074/jbc.M008046200; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; SLIVKA SR, 1991, BLOOD, V77, P1013; Stahl A, 1997, INT J CANCER, V71, P116, DOI 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.3.CO;2-Z; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; vanLeeuwen RTJ, 1996, FIBRINOLYSIS, V10, P59, DOI 10.1016/S0268-9499(96)80081-6; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407	54	157	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22595	22604		10.1074/jbc.M313004200	http://dx.doi.org/10.1074/jbc.M313004200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15001579	hybrid			2022-12-27	WOS:000221417100111
J	Nishino, K; Hattori, N; Tanaka, S; Shiota, K				Nishino, K; Hattori, N; Tanaka, S; Shiota, K			DNA methylation-mediated control of Sry gene expression in mouse gonadal development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-DETERMINING GENE; SEX-DETERMINING GENE; CPG-BINDING-PROTEIN; MAMMALIAN DEVELOPMENT; CIRCULAR TRANSCRIPTS; DETERMINING REGION; IMPRINTED GENES; SOMATIC-CELLS; SERTOLI CELLS; Y-CHROMOSOME	DNA methylation at CpG sequences is involved in tissue-specific and developmentally regulated gene expression. The Sry (sex-determining region on the Y chromosome) gene encodes a master protein for initiating testis differentiation in mammals, and its expression is restricted to gonadal somatic cells at 10.5-12.5 days post-coitum (dpc) in the mouse. We found that in vitro methylation of the 5'-flanking region of the Sry gene caused suppression of reporter activity, implying that Sry gene expression could be regulated by DNA methylation-mediated gene silencing. Bisulfite restriction mapping and sodium bisulfite sequencing revealed that the 5'-flanking region of the Sry gene was hypermethylated in the 8.5-dpc embryos in which the Sry gene was not expressed. Importantly, this region was specifically hypomethylated in the gonad at 11.5 dpc, while the hypermethylated status was maintained in tissues that do not express the Sry gene. We concluded that expression of the Sry gene is under the control of an epigenetic mechanism mediated by DNA methylation.	Univ Tokyo, Dept Anim Resource Sci Vet Med Sci, Lab Cellular Biochem, Bunkyo Ku, Tokyo 1138657, Japan; Biooriented Technol Res Advancement Inst, Saitama 3318537, Japan; Natl Inst Genet, Div Appl Genet, Shizuoka 4118540, Japan	University of Tokyo; National Agriculture & Food Research Organization - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Shiota, K (corresponding author), Univ Tokyo, Dept Anim Resource Sci Vet Med Sci, Lab Cellular Biochem, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.	ashiota@mail.ecc.u-tokyo.ac.jp		Hattori, Naoko/0000-0002-0901-4869; Tanaka, Satoshi/0000-0002-4745-550X				BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; BURGOYNE PS, 1988, DEVELOPMENT, V102, P443; CAO QP, 1995, MOL REPROD DEV, V40, P196, DOI 10.1002/mrd.1080400208; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; Cho JH, 2001, ENDOCRINOLOGY, V142, P3389, DOI 10.1210/en.142.8.3389; Dasari VK, 2002, J UROLOGY, V167, P335, DOI 10.1016/S0022-5347(05)65464-X; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Dolci S, 1997, BIOL REPROD, V57, P1128, DOI 10.1095/biolreprod57.5.1128; Dragatsis I, 1998, DEVELOPMENT, V125, P1529; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; Imamura T, 2001, GENOMICS, V76, P117, DOI 10.1006/geno.2001.6607; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Lahr Georgia, 1995, Molecular Brain Research, V33, P179, DOI 10.1016/0169-328X(95)00136-G; Lee J, 2002, DEVELOPMENT, V129, P1807; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Margarit E, 1998, BIOCHEM BIOPH RES CO, V245, P370, DOI 10.1006/bbrc.1998.8441; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ohgane J, 2002, BIOCHEM BIOPH RES CO, V290, P701, DOI 10.1006/bbrc.2001.6258; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PALMER SJ, 1991, DEVELOPMENT, V112, P265; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; ROSSI P, 1993, MOL REPROD DEV, V34, P369, DOI 10.1002/mrd.1080340404; Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x; Shiota K, 2002, DIFFERENTIATION, V69, P162, DOI 10.1046/j.1432-0436.2002.690406.x; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Yono M, 2002, J PHARMACOL TOXICOL, V48, P87, DOI 10.1016/S1056-8719(03)00022-4	38	121	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22306	22313		10.1074/jbc.M309513200	http://dx.doi.org/10.1074/jbc.M309513200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14978045	hybrid			2022-12-27	WOS:000221417100078
J	Tay, HK; Melendez, AJ				Tay, HK; Melendez, AJ			Fc gamma RI-triggered generation of arachidonic acid and eicosanoids requires iPLA(2) but not cPLA(2) in human monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PHOSPHOLIPASE A(2); SMOOTH-MUSCLE-CELLS; MEDIATED PHAGOCYTOSIS; IMMUNOGLOBULIN-G; CALCIUM; ACTIVATION; INHIBITION; PROTEIN; RELEASE; MOBILIZATION	Aggregation of receptors for immunoglobulin G (FcgammaRs) on myeloid cells activates a series of events that are key in the inflammatory response and that can ultimately lead to targeted cell killing by antibody-directed cellular cytotoxicity. Generation of lipid-derived proinflammatory mediators is an important component of the integrated cellular response mediated by receptors for the constant region of immunoglobulins (Fc). We have demonstrated previously that, in interferon-gamma-primed U937 cells, the high affinity receptor for IgG, FcgammaRI, is coupled to a novel intracellular signaling pathway that involves the sequential activation of phospholipase D, sphingosine kinase, calcium transients, and protein kinase C isoforms, leading to the activation of the NADPH-oxidative burst. Here, we investigate the nature of the phospholipase that regulates arachidonic acid and eicosanoid production. Our data show that FcgammaRI couples to iPLA(2)beta for the release of arachidonic acid and the generation of leukotriene B-4 and prostaglandin E-2. Activation of iPLA(2)beta was protein kinase C-dependent; on the other hand, platelet-activating factor triggered cPLA(2)alpha by means of the mitogen-activated protein kinase pathway. These studies demonstrate that intracellular PLA(2)s can be selectively regulated by different stimuli and suggest a critical role for iPLA(2)beta in the intracellular signaling cascades initiated by FcgammaRI and its functional role in the generation of key inflammatory mediators.	Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117597, Singapore	National University of Singapore	Melendez, AJ (corresponding author), Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117597, Singapore.	phsmraj@nus.edu.sg						ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Burke JR, 1997, BBA-PROTEIN STRUCT M, V1341, P223, DOI 10.1016/S0167-4838(97)00085-X; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Ely P, 1996, BLOOD, V87, P3813, DOI 10.1182/blood.V87.9.3813.bloodjournal8793813; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; Fitzpatrick FA, 2001, J CLIN INVEST, V107, P1347, DOI 10.1172/JCI13241; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; Hsu FF, 2000, J BIOL CHEM, V275, P16579, DOI 10.1074/jbc.M908342199; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; Jenkins CM, 2001, J BIOL CHEM, V276, P7129, DOI 10.1074/jbc.M010439200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; KARIMI K, 1995, J IMMUNOL, V155, P5786; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; Lennartz MR, 1999, INT J BIOCHEM CELL B, V31, P415, DOI 10.1016/S1357-2725(98)00108-3; LENNARTZ MR, 1993, J LEUKOCYTE BIOL, V54, P389, DOI 10.1002/jlb.54.5.389; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Mancuso DJ, 2003, J BIOL CHEM, V278, P22231, DOI 10.1074/jbc.C300033200; MCCOLL SR, 1991, J IMMUNOL, V146, P1204; Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 1999, IMMUNOLOGY, V96, P457; Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421; Melendez AJ, 2001, CURR BIOL, V11, P869, DOI 10.1016/S0960-9822(01)00260-3; MUKRAKAMI M, 1999, J BIOL CHEM, V274, P3103; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; QUI ZH, 1998, J BIOL CHEM, V273, P8203; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; Seegers HC, 2002, J PHARMACOL EXP THER, V302, P918, DOI 10.1124/jpet.302.3.918; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Yang VW, 1996, GASTROENTEROL CLIN N, V25, P317, DOI 10.1016/S0889-8553(05)70249-1	42	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22505	22513		10.1074/jbc.M308788200	http://dx.doi.org/10.1074/jbc.M308788200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007079	hybrid			2022-12-27	WOS:000221417100101
J	Melo, FR; Pereira, MS; Foguel, D; Mourao, PAS				Melo, FR; Pereira, MS; Foguel, D; Mourao, PAS			Antithrombin-mediated anticoagulant activity of sulfated polysaccharides - Different mechanisms for heparin and sulfated galactans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY ABNORMAL ANTITHROMBIN; ANTI-THROMBIN-III; HIGH-AFFINITY; INDUCED THROMBOCYTOPENIA; DERMATAN SULFATE; COFACTOR-II; FACTOR-XA; BINDING; IDENTIFICATION; FUCOIDAN	We investigated the mechanisms of anticoagulant activity mediated by sulfated galactans. The anticoagulant activity of sulfated polysaccharides is achieved mainly through potentiation of plasma cofactors, which are the natural inhibitors of coagulation proteases. Our results indicated the following. 1) Structural requirements for the interaction of sulfated galactans with coagulation inhibitors and their target proteases are not merely a consequence of their charge density. 2) The structural basis of this interaction is complex because it involves naturally heterogeneous polysaccharides but depends on the distribution of sulfate groups and on monosaccharide composition. 3) Sulfated galactans require significantly longer chains than heparin to achieve anticoagulant activity. 4) Possibly, it is the bulk structure of the sulfated galactan, and not a specific minor component as in heparin, that determines its interaction with antithrombin. 5) Sulfated galactans of similar to 15 to similar to 45 kDa bind to antithrombin but are unable to link the plasma inhibitor and thrombin. This last effect requires a molecular size above 45 kDa. 6) Sulfated galactan and heparin bind to different sites on antithrombin. 7) Sulfated galactans are less effective than heparin at promoting antithrombin conformational activation. Overall, these observations indicate that a different mechanism predominates over the conformational activation of antithrombin in ensuring the antithrombin-mediated anticoagulant activity of the sulfated galactans. Possibly, sulfated galactan connects antithrombin and thrombin, holding the protease in an inactive form. The conformational activation of antithrombin and the consequent formation of a covalent complex with thrombin appear to be less important for the anticoagulant activity of sulfated galactan than for heparin. Our results demonstrate that the paradigm of heparin-antithrombin interaction cannot be extended to other sulfated polysaccharides. Each type of polysaccharide may form a particular complex with the plasma inhibitor and the target protease.	Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Lab Tecido Conjunt, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Mourao, PAS (corresponding author), Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Lab Tecido Conjunt, Caixa Postal 68041, BR-21941590 Rio De Janeiro, Brazil.	pmourao@hucff.ufrj.br	Melo, Fabio Rabelo/GQP-0844-2022; Mourao, Paulo/AAA-5386-2020; Pereira, Mariana/GSE-3546-2022; Sá Pereira, Mariana/C-2211-2015	Foguel, Debora/0000-0001-7312-7115				Alves AP, 1997, J BIOL CHEM, V272, P6965, DOI 10.1074/jbc.272.11.6965; Alves AP, 1998, GLYCOBIOLOGY, V8, P939, DOI 10.1093/glycob/8.9.939; ANDERSSON LO, 1976, THROMB RES, V9, P575, DOI 10.1016/0049-3848(76)90105-5; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; BEGUIN S, 1988, THROMB HAEMOSTASIS, V60, P457; BETHELL RC, 1995, BIOCHEM BIOPH RES CO, V206, P355, DOI 10.1006/bbrc.1995.1049; Cavalcante MCM, 2000, J BIOL CHEM, V275, P36189, DOI 10.1074/jbc.M005830200; CHANG JY, 1986, J BIOL CHEM, V261, P1174; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHURCH FC, 1989, J BIOL CHEM, V264, P3618; COLLIEC S, 1994, PHYTOCHEMISTRY, V35, P697, DOI 10.1016/S0031-9422(00)90590-9; DUBOIS M, 1956, ANAL CHEM, V28, P250; Fareed J, 2000, SEMIN THROMB HEMOST, V26, P87; Farias WRL, 2000, J BIOL CHEM, V275, P29299, DOI 10.1074/jbc.M002422200; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HOOK M, 1976, FEBS LETT, V66, P90, DOI 10.1016/0014-5793(76)80592-3; HORNER AA, 1982, J BIOL CHEM, V257, P8749; JORDAN R, 1979, J BIOL CHEM, V254, P2902; KAKKAR VV, 1989, HEPARIN CHEM BIOL PR, P455; KELTON JG, 1980, SEMIN HEMATOL, V17, P259; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; LIN PH, 2001, BIOCHIM BIOPHYS ACTA, V1562, P105; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; Mourao PAS, 1996, J BIOL CHEM, V271, P23973, DOI 10.1074/jbc.271.39.23973; Nishino T, 1999, THROMB RES, V96, P37, DOI 10.1016/S0049-3848(99)00060-2; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN MC, 1987, BLOOD, V69, P1275; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; Pavao MSG, 1998, J BIOL CHEM, V273, P27848, DOI 10.1074/jbc.273.43.27848; Pereira MS, 1999, J BIOL CHEM, V274, P7656, DOI 10.1074/jbc.274.12.7656; Pereira MS, 2002, GLYCOBIOLOGY, V12, P573, DOI 10.1093/glycob/cwf077; POTIN P, 1992, J APPL PHYCOL, V4, P119, DOI 10.1007/BF02442460; SANTOS JA, 1992, EUR J BIOCHEM, V204, P669, DOI 10.1111/j.1432-1033.1992.tb16680.x; SEM SR, 1994, INT J BIOL MACROMOL, V16, P279; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; THUMBERG L, 1982, CARBOHYD RES, V100, P393; Vilela-Silva ACES, 1999, GLYCOBIOLOGY, V9, P927, DOI 10.1093/glycob/9.9.927; Visentin GP, 1999, THROMB HAEMOSTASIS, V82, P448; Warkentin TE, 1999, THROMB HAEMOSTASIS, V82, P439	48	118	133	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20824	20835		10.1074/jbc.M308688200	http://dx.doi.org/10.1074/jbc.M308688200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14996843	hybrid			2022-12-27	WOS:000221273800034
J	Nie, J; Li, SSC; McGlade, CJ				Nie, J; Li, SSC; McGlade, CJ			A novel PTB-PDZ domain interaction mediates isoform-specific ubiquitylation of mammalian numb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; UBIQUITIN-PROTEIN LIGASES; FATE DETERMINANT NUMB; CELL FATE; ASYMMETRIC LOCALIZATION; IMMUNE RECEPTORS; PEPTIDE COMPLEX; RING-TYPE; IN-VIVO; DROSOPHILA	LNX was originally cloned as a Numb PTB-binding molecule, and it was subsequently found to act as a RING finger-type E3 ubiquitin ligase for the ubiquitylation and degradation of mNumb. Numb is a PTB domain-containing protein that functions as an intrinsic determinant of cell fate in asymmetric cell division. In mammals, four protein isoforms arise from alternative mRNA splicing. Here we report that while all four protein isoforms bind to LNX, only p72 and p66 Numb isoforms are ubiquitylated and degraded. The p72 and p66 Numb proteins differ from the other two isoforms by the presence of an 11-amino acid sequence insert in the PTB domain (PTBi). We demonstrate that the isoform-specific ubiquitylation of mNumb is due to a novel interaction between the first PDZ domain (PDZ1) of LNX and the PTBi variant. Deletion of LNX PDZ1 domain resulted in loss of ubiquitylation and subsequent degradation of the PTBi form of Numb. Interestingly efficient PTBi ubiquitylation not only depends on association with the LNX PDZ1 domain but also requires binding to the canonical PTB-binding motif NPAY in LNX. Thus two distinct modes of PTBi-mediated interaction with LNX work in concert to allow the effective and specific degradation of the p72 and p66 isoforms of mNumb.	Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X8, Canada; Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Western University (University of Western Ontario)	McGlade, CJ (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jmcglade@sickkids.on.ca						Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; BREWSTER R, 1995, DEVELOPMENT, V121, P2923; Chan B, 2003, NAT CELL BIOL, V5, P155, DOI 10.1038/ncb920; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gomez MR, 1997, DEVELOPMENT, V124, P4857; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Latour S, 2003, NAT CELL BIOL, V5, P149, DOI 10.1038/ncb919; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li CJ, 2003, J BIOL CHEM, V278, P3852, DOI 10.1074/jbc.M206649200; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Lu BW, 1999, MOL CELL, V4, P883, DOI 10.1016/S1097-2765(00)80218-X; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Park M, 1998, MECH DEVELOP, V75, P117, DOI 10.1016/S0925-4773(98)00098-7; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Rice DS, 2001, MOL CELL NEUROSCI, V18, P525, DOI 10.1006/mcne.2001.1024; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Shen Q, 2002, DEVELOPMENT, V129, P4843; Sollerbrant K, 2003, J BIOL CHEM, V278, P7439, DOI 10.1074/jbc.M205927200; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Varshavsky A, 2000, BIOL CHEM, V381, P779, DOI 10.1515/BC.2000.101; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wang P, 2000, EUR J BIOCHEM, V267, P3116, DOI 10.1046/j.1432-1327.2000.01318.x; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zwahlen C, 2000, EMBO J, V19, P1505, DOI 10.1093/emboj/19.7.1505	51	29	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20807	20815		10.1074/jbc.M311396200	http://dx.doi.org/10.1074/jbc.M311396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14990566	hybrid			2022-12-27	WOS:000221273800032
J	Raina, D; Kharbanda, S; Kufe, D				Raina, D; Kharbanda, S; Kufe, D			The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-x(L) pathways in rat 3Y1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; SYNTHASE KINASE 3-BETA; GROWTH-FACTOR RECEPTOR; CYTOCHROME-C RELEASE; CELL-DEATH RESPONSE; NF-KAPPA-B; BETA-CATENIN; OXIDATIVE STRESS; TYROSINE KINASE; MULTIDRUG-RESISTANCE	The MUC1 transmembrane glycoprotein is overexpressed by most human carcinomas. Overexpression of MUC1 confers transformation; however, the signaling pathways activated by this oncoprotein are largely unknown. The present studies demonstrated that MUC1-induced transformation of 3Y1 fibroblasts is associated with increased levels of phospho-Akt and phospho-Bad. The finding that LY294002 blocks MUC1-mediated increases in phospho-Akt and phospho-Bad supports the involvement of phosphoinositide 3-kinase (PI3K) as an upstream effector of this response. We also show that MUC1 increases the expression of the anti-apoptotic Bcl-x(L) protein (but not Bcl-2) by a PI3K-independent mechanism. In concert with these results, MUC1 attenuated (i) the loss of mitochondrial transmembrane potential, (ii) mitochondrial cytochrome c release, (iii) activation of caspase-9, and (iv) induction of apoptosis by the antimetabolite, 1-beta-D-arabinofuranosylcytosine. Similar results were obtained with the anti-cancer agent, gemcitabine. These findings indicate that expression of MUC1 in 3Y1 cells activates the anti-apoptotic PI3K/Akt and Bcl-x(L) pathways.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; ILEX Prod Inc, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA 97098, CA 29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431, R01CA097098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Huang L, 2003, CANCER BIOL THER, V2, P702; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kobayashi M, 2003, ONCOGENE, V22, P1294, DOI 10.1038/sj.onc.1206256; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Kumar S, 2003, MOL PHARMACOL, V63, P276, DOI 10.1124/mol.63.2.276; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG M, 1992, CANCER RES, V52, P223; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MERLO GR, 1989, CANCER RES, V49, P6966; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Parry S, 2001, BIOCHEM BIOPH RES CO, V283, P715, DOI 10.1006/bbrc.2001.4775; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang AS, 2003, CANCER RES, V63, P2150; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	51	137	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20607	20612		10.1074/jbc.M310538200	http://dx.doi.org/10.1074/jbc.M310538200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14999001	hybrid			2022-12-27	WOS:000221273800009
J	Caloca, MJ; Zugaza, JL; Vicente-Manzanares, M; Sanchez-Madrid, F; Bustelo, XR				Caloca, MJ; Zugaza, JL; Vicente-Manzanares, M; Sanchez-Madrid, F; Bustelo, XR			F-actin-dependent translocation of the Rap1 GDP/GTP exchange factor RasGRP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING PROTEIN; FILAMENT-BINDING PROTEIN; MEDIATED CELL-ADHESION; SMALL GTPASE RAP1; ADHERENS JUNCTION; PHORBOL ESTERS; VAV PROTEINS; R-RAS; ACTIVATION; FAMILY	RasGRPs constitute a new group of diacylglycerol-dependent GDP/GTP exchange factors that activate Ras subfamily GTPases. Despite a common structure, RasGRPs diverge in their GTPase specificity, subcellular distribution, and downstream biological effects. The more divergent family member is RasGRP2, a Rap1-specific exchange factor with low affinity toward diacylglycerol. The regulation of RasGRP2 during signal transduction has remained elusive up to now. In this report, we show that the subcellular localization of RasGRP2 is highly dependent on actin dynamics. Thus, the induction of F-actin by cytoskeletal regulators such as Vav, Vav2, Dbl, and Rac1 leads to the shift of RasGRP2 from the cytosol to membrane ruffles and its co-localization with F-actin. Treatment of cells with cytoskeletal disrupting drugs abolishes this effect, leading to an abnormal localization of RasGRP2 in cytoplasmic clusters of actin. The use of Rac1 effector mutants indicates that the RasGRP2 translocation is linked exclusively to actin polymerization and is independent of other pathways such as p21-activated kinase JNK, or superoxide production. Biochemical experiments demonstrate that the translocation of RasGRP2 to membrane ruffles is mediated by the direct association of this protein with F-actin, a property contained within its 150 first amino acids. Finally, we show that the RasGRP2/F-actin interaction promotes the regionalized activation of Rap1 in juxtamembrane areas of the cell. These results reveal a novel function of the actin cytoskeleton in mediating the spatial activation of Ras subfamily GTPases through the selective recruitment of GDP/GTP exchange factors.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain; Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Autonomous University of Madrid; Hospital de La Princesa	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Caloca, María-José/K-9357-2014; Sanchez-Madrid, Francisco/M-7889-2016; Bustelo, Xose R./A-9526-2010; Vicente-Manzanares, Miguel/H-1010-2018	Bustelo, Xose R./0000-0001-9398-6072; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Bustelo, Xose R./0000-0001-9398-6072; Vicente-Manzanares, Miguel/0000-0001-5943-3220; Caloca, Maria-Jose/0000-0002-1003-2685; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671	NCI NIH HHS [CA 73735-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Caloca MJ, 2003, J BIOL CHEM, V278, P33465, DOI 10.1074/jbc.M302807200; Caloca MJ, 2003, EMBO J, V22, P3326, DOI 10.1093/emboj/cdg316; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Jorge B, 2002, J BIOL CHEM, V277, P44171, DOI 10.1074/jbc.M204423200; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Li LX, 2002, MOL IMMUNOL, V38, P1283, DOI 10.1016/S0161-5890(02)00076-7; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Lorenzo PS, 2001, CANCER RES, V61, P943; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Ohtsuka T, 1998, J CELL BIOL, V143, P1227, DOI 10.1083/jcb.143.5.1227; Pierret P, 2002, NEUROSCIENCE, V111, P83, DOI 10.1016/S0306-4522(01)00597-8; Pierret P, 2001, NEUROSCIENCE, V108, P381, DOI 10.1016/S0306-4522(01)00429-8; Pierret P, 2000, J NEUROCYTOL, V29, P485, DOI 10.1023/A:1007245728751; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Reuther GW, 2002, J BIOL CHEM, V277, P30508, DOI 10.1074/jbc.M111330200; Rong SB, 2002, J MED CHEM, V45, P853, DOI 10.1021/jm010422z; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Scita G, 2001, J CELL BIOL, V154, P1031, DOI 10.1083/jcb.200103146; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Toki S, 2001, J COMP NEUROL, V437, P398, DOI 10.1002/cne.1291; TOKSOZ D, 1994, ONCOGENE, V9, P621; VAN AL, 1997, GENE DEV, V11, P2295; WHITE GC, 1993, ADV EXP MED BIOL, V344, P187; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	54	40	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20435	20446		10.1074/jbc.M313013200	http://dx.doi.org/10.1074/jbc.M313013200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14988412	hybrid			2022-12-27	WOS:000221164500122
J	Choi, WS; Eom, DS; Han, BS; Kim, WK; Han, BH; Choi, EJ; Oh, TH; Markelonis, GJ; Cho, JW; Oh, YJ				Choi, WS; Eom, DS; Han, BS; Kim, WK; Han, BH; Choi, EJ; Oh, TH; Markelonis, GJ; Cho, JW; Oh, YJ			Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8-and-9-mediated apoptotic pathways in dopaminergic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROBLASTOMA SH-SY5Y CELLS; OXIDE-INDUCED APOPTOSIS; PARKINSONS-DISEASE; PROTEIN-KINASE; SUPEROXIDE-DISMUTASE; NITRIC-OXIDE; C-JUN; DISTINCT MECHANISMS; CASPASE-8 ACTIVATION; ALZHEIMERS-DISEASE	We evaluated the contribution of p38 mitogen-activated protein kinase and the events upstream/downstream of p38 leading to dopaminergic neuronal death. We utilized MN9D cells and primary cultures of mesencephalic neurons treated with 6-hydroxydopamine. Phosphorylation of p38 preceded apoptosis and was sustained in 6-hydroxydopamine-treated MN9D cells. Co-treatment with PD169316 ( an inhibitor of p38) or expression of a dominant negative p38 was neuroprotective in death induced by 6-hydroxydopamine. The superoxide dismutase mimetic and the nitric oxide chelator blocked 6-hydroxydopamine-induced phosphorylation of p38, suggesting a role for superoxide anion and nitric oxide in eliciting a neurotoxic signal by activating p38. Following 6-hydroxydopamine treatment, inhibition of p38 prevented both caspase-8- and -9-mediated apoptotic pathways as well as generation of truncated Bid. Consequently, 6-hydroxydopamine-induced cell death was rescued by blockading activation of caspase-8 and -9. In primary cultures of mesencephalic neurons, the phosphorylation of p38 similarly appeared in tyrosine hydroxylasepositive, dopaminergic neurons after 6-hydroxydopamine treatment. This neurotoxin-induced phosphorylation of p38 was inhibited in the presence of superoxide dismutase mimetic or nitric oxide chelator. Co-treatment with PD169316 deterred 6-hydroxydopamine-induced loss of dopaminergic neurons and activation of caspase-3 in these neurons. Furthermore, inhibition of caspase-8 and -9 significantly rescued 6-hydroxydopamine-induced loss of dopaminergic neurons. Taken together, our data suggest that superoxide anion and nitric oxide induced by 6-hydroxydopamine initiate the p38 signal pathway leading to activation of both mitochondrial and extramitochondrial apoptotic pathways in our culture models of Parkinson's disease.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Coll Sci, Prot Network Res Ctr, Seoul 120749, South Korea; Ewha Womans Univ, Sch Med, Dept Pharmacol, Seoul 110783, South Korea; Seoul Natl Univ, Coll Pharm, Inst Nat Prod Res, Seoul 110460, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA	Yonsei University; Yonsei University; Ewha Womans University; Seoul National University (SNU); Korea University; University System of Maryland; University of Maryland Baltimore	Oh, YJ (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, 134 Shinchon Dong, Seoul 120749, South Korea.	yjoh@yonsei.ac.kr		Eom, Dae Seok/0000-0002-0617-8788				Asanuma M, 1998, NEUROSCIENCE, V85, P907, DOI 10.1016/S0306-4522(97)00665-9; Barkats M, 2002, J NEUROCHEM, V82, P101, DOI 10.1046/j.1471-4159.2002.00952.x; Barone FC, 2001, MED RES REV, V21, P129, DOI 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Cassarino DS, 2000, J NEUROCHEM, V74, P1384, DOI 10.1046/j.1471-4159.2000.0741384.x; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; CHOI HK, 1991, BRAIN RES, V552, P67, DOI 10.1016/0006-8993(91)90661-E; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Dalrymple SA, 2002, J MOL NEUROSCI, V19, P295, DOI 10.1385/JMN:19:3:295; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; De Girolamo LA, 2001, J NEUROCHEM, V76, P650, DOI 10.1046/j.1471-4159.2001.00066.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Ferrer I, 2001, J NEURAL TRANSM, V108, P1383, DOI 10.1007/s007020100015; Gearan T, 2001, PARKINSONISM RELAT D, V8, P19, DOI 10.1016/S1353-8020(00)00078-X; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gomez-Santos C, 2002, BRAIN RES, V935, P32, DOI 10.1016/S0006-8993(02)02422-8; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Ha KS, 2003, FASEB J, V17, P1036, DOI 10.1096/fj.02-0738com; Halvorsen EM, 2002, BRAIN RES, V952, P98, DOI 10.1016/S0006-8993(02)03216-X; Han BS, 2003, J NEUROSCI, V23, P5069; Han BS, 2003, NEUROSCI LETT, V341, P99, DOI 10.1016/S0304-3940(03)00173-3; Hartmann A, 2001, ADV NEUROL, V86, P143; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holtz WA, 2003, J BIOL CHEM, V278, P19367, DOI 10.1074/jbc.M211821200; Inman GJ, 2000, J IMMUNOL, V165, P2500, DOI 10.4049/jimmunol.165.5.2500; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Itoh Y, 2000, ANAL BIOCHEM, V287, P203, DOI 10.1006/abio.2000.4859; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jeohn GH, 2002, ANN NY ACAD SCI, V962, P332, DOI 10.1111/j.1749-6632.2002.tb04078.x; Junn E, 2001, J NEUROCHEM, V78, P374, DOI 10.1046/j.1471-4159.2001.00425.x; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kunikowska G, 2001, BRAIN RES, V922, P51, DOI 10.1016/S0006-8993(01)03149-3; Lotharius J, 1999, J NEUROSCI, V19, P1284; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Oh YJ, 1995, NEUROBIOL DIS, V2, P157, DOI 10.1006/nbdi.1995.0017; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; Sawada H, 2002, NEUROPHARMACOLOGY, V42, P1056, DOI 10.1016/S0028-3908(02)00049-7; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Shimoke K, 2002, DEV BRAIN RES, V133, P105, DOI 10.1016/S0165-3806(02)00276-6; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wilms H, 2003, FASEB J, V17, P500, DOI 10.1096/fj.02-0314fje; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Zawada WM, 2001, BRAIN RES, V891, P185; Zhu XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000067426	54	176	190	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20451	20460		10.1074/jbc.M311164200	http://dx.doi.org/10.1074/jbc.M311164200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14993216	hybrid			2022-12-27	WOS:000221164500124
J	Maglich, JM; Watson, J; McMillen, PJ; Goodwin, B; Willson, TM; Moore, JT				Maglich, JM; Watson, J; McMillen, PJ; Goodwin, B; Willson, TM; Moore, JT			The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE-ANDROSTANE RECEPTOR; MICROSOMAL-ENZYME INDUCERS; PREGNANE-X RECEPTOR; HUMAN CYP2B6 GENE; MOLECULAR-CLONING; LIVER; RATS; INDUCTION; SULFOTRANSFERASES; EXCRETION	The orphan nuclear receptor CAR (NR1I3) has been characterized as a central component in the coordinate response to xenobiotic and endobiotic stress. In this study, we demonstrate that CAR plays a pivotal function in energy homeostasis and establish an unanticipated metabolic role for this nuclear receptor. Wild-type mice treated with the synthetic CAR agonist 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) exhibited decreased serum concentration of the thyroid hormone (TH) thyroxine (T-4). However, treatment of Car(-/-) mice with TCPOBOP failed to elicit these changes. To examine whether CAR played a role in the regulation of TH levels under physiological conditions, wild-type and Car(-/-) mice were fasted for 24 h, a process known to alter TH metabolism in mammals. As expected, the serum triiodothyronine and T4 concentrations decreased in wild-type mice. However, triiodothyronine and T4 levels in fasted Car(-/-) mice remained significantly higher than those in fasted wild-type animals. Concomitant with the changes in serum TH levels, both CAR agonist treatment and fasting induced the expression of CAR target genes (notably, Cyp2b10, Ugt1a1, Sultn, Sult1a1, and Sult2a1) in a receptor-dependent manner. Importantly, the Ugt1a1, Sultn, Sult1a1, and Sult2a1 genes encode enzymes that are capable of metabolizing TH. An attenuated reduction in TH levels during fasting, as observed in Car(-/-) mice, would be predicted to increase weight loss during caloric restriction. Indeed, when Car(-/-) animals were placed on a 40% caloric restriction diet for 12 weeks, Car(-/-) animals lost over twice as much weight as their wild-type littermates. Thus, CAR participates in the molecular mechanisms contributing to homeostatic resistance to weight loss. These data imply that CAR represents a novel therapeutic target to uncouple metabolic rate from food intake and has implications in obesity and its associated disorders.	GlaxoSmithKline, High Throughput Biol, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Biosci Support, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Genet Res, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, High Throughput Chem, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Moore, JT (corresponding author), GlaxoSmithKline, High Throughput Biol, 5 Moore Dr,Venture 116-1B, Res Triangle Pk, NC 27709 USA.	John.T.Moore@gsk.com	feinstein, doug/M-9414-2019					Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Brown BL, 1995, TOXICOL LETT, V81, P39, DOI 10.1016/0378-4274(95)03407-2; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; Chopra M, 2002, B WORLD HEALTH ORGAN, V80, P952; Diwan BA, 1996, CARCINOGENESIS, V17, P37, DOI 10.1093/carcin/17.1.37; Findlay KAB, 2000, J CLIN ENDOCR METAB, V85, P2879, DOI 10.1210/jc.85.8.2879; Glatt H, 2000, TOXICOL LETT, V112, P341, DOI 10.1016/S0378-4274(99)00214-3; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Harvey CB, 2002, THYROID, V12, P441, DOI 10.1089/105072502760143791; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honma W, 2001, DRUG METAB DISPOS, V29, P274; Hood A, 2003, TOXICOL APPL PHARM, V188, P6, DOI 10.1016/S0041-008X(02)00071-6; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; HURD RE, 1993, ENDOCRINOLOGY, V133, P1951, DOI 10.1210/en.133.5.1951; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kester MHA, 1999, J CLIN ENDOCR METAB, V84, P1357, DOI 10.1210/jc.84.4.1357; KINLAW WB, 1985, J CLIN INVEST, V75, P1238, DOI 10.1172/JCI111821; KONG ANT, 1993, BIOCHIM BIOPHYS ACTA, V1171, P315, DOI 10.1016/0167-4781(93)90073-M; Krotkiewski M, 2000, INT J OBESITY, V24, pS116, DOI 10.1038/sj.ijo.0801294; Larson P. R., 1992, TXB ENDOCRINOLOGY, P357; Li X, 2001, J ENDOCRINOL, V171, P525, DOI 10.1677/joe.0.1710525; Li XY, 1999, BIOCHEM BIOPH RES CO, V263, P632, DOI 10.1006/bbrc.1999.1419; LIVOLSI VA, 1989, PATHOLOGY THYROID; Locker J, 2003, HEPATOLOGY, V38, P314, DOI 10.1053/jhep.2003.50299; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; MOL JA, 1985, ENDOCRINOLOGY, V117, P8, DOI 10.1210/endo-117-1-8; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; O'Connor JC, 2002, TOXICOL SCI, V69, P79, DOI 10.1093/toxsci/69.1.79; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Rosenbaum M, 2000, AM J CLIN NUTR, V71, P1421; RUTGERS M, 1989, ENDOCRINOLOGY, V125, P2175, DOI 10.1210/endo-125-4-2175; Sakakibara Y, 1995, J BIOL CHEM, V270, P30470, DOI 10.1074/jbc.270.51.30470; Shiraki T, 2003, J BIOL CHEM, V278, P11344, DOI 10.1074/jbc.M212859200; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Vansell NR, 2002, TOXICOL SCI, V65, P184, DOI 10.1093/toxsci/65.2.184; Vansell NR, 2002, DRUG METAB DISPOS, V30, P240, DOI 10.1124/dmd.30.3.240; Visser TJ, 1996, ACTA MED AUST, V23, P10; VISSER TJ, 1990, THYROID GLAND, P255; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; WU SY, 1990, ACTA ENDOCRINOL-COP, V122, P175, DOI 10.1530/acta.0.1220175; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	47	184	192	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19832	19838		10.1074/jbc.M313601200	http://dx.doi.org/10.1074/jbc.M313601200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004031	hybrid			2022-12-27	WOS:000221164500055
J	Wickstrom, SA; Alitalo, K; Keski-Oja, J				Wickstrom, SA; Alitalo, K; Keski-Oja, J			An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-GROWTH; INHIBITOR; ANGIOGENESIS; GENE; MECHANISMS; ADENOVIRUS; COLLAGEN; THERAPY; SULFATE; XVIII	Endostatin, the C-terminal fragment of collagen XVIII, is a potent inhibitor of angiogenesis and endothelial cell migration. To define its critical cell interaction domains we used endostatin-derived synthetic peptides containing surface-exposed sequences. We observed that, when immobilized, an arginine-rich peptide of 11 amino acids from its N terminus efficiently promoted endothelial cell adhesion through beta(1) integrin- and heparin-dependent mechanisms. In addition, the peptide induced the formation of membrane ruffles and focal contacts. In the soluble form, the peptide inhibited basic fibroblast growth factor-induced directional migration and tubular morphogenesis of microvascular endothelial cells. Accordingly, the peptide induced the loss of focal adhesions and actin stress fibers in these cells. Substitution of the arginine residues with alanines resulted in the loss of these properties. In the current study we describe a putative integrin- binding sequence with anti-migratory activity within endostatin.	Univ Helsinki, Biomedicum Helsinki, Haartman Inst, Dept Pathol,Cell Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland; Univ Helsinki Hosp, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Keski-Oja, J (corresponding author), Univ Helsinki, Biomedicum Helsinki, Haartman Inst, Dept Pathol,Cell Biol Lab, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	jorma.keski-oja@helsinki.fi	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Wickstrom, Sara/0000-0001-6383-6292				BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Chang Z, 1999, AM J PATHOL, V155, P71, DOI 10.1016/S0002-9440(10)65101-2; Chillemi F, 2003, J MED CHEM, V46, P4165, DOI 10.1021/jm0308287; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dixelius J, 2002, CANCER RES, V62, P1944; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Eriksson K, 2003, FEBS LETT, V536, P19, DOI 10.1016/S0014-5793(03)00003-6; Feldman AL, 2000, CANCER RES, V60, P1503; Floquet N, 2004, J BIOL CHEM, V279, P2091, DOI 10.1074/jbc.M307736200; Hagedorn M, 2000, CRIT REV ONCOL HEMAT, V34, P89, DOI 10.1016/S1040-8428(00)00056-1; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Schwarzbauer JE, 1997, CURR BIOL, V7, pR292, DOI 10.1016/S0960-9822(06)00140-0; Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100; Wickstrom SA, 2003, J BIOL CHEM, V278, P37895, DOI 10.1074/jbc.M303569200; Wickstrom SA, 2001, CANCER RES, V61, P6511; Wickstrom SA, 2002, CANCER RES, V62, P5580; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yoon SS, 1999, CANCER RES, V59, P6251	39	98	107	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20178	20185		10.1074/jbc.M312921200	http://dx.doi.org/10.1074/jbc.M312921200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14973128	hybrid			2022-12-27	WOS:000221164500094
J	Shnaper, S; Sackett, K; Gallo, SA; Blumenthal, R; Shai, Y				Shnaper, S; Sackett, K; Gallo, SA; Blumenthal, R; Shai, Y			The C- and the N-terminal regions of glycoprotein 41 ectodomain fuse membranes enriched and not enriched with cholesterol, respectively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TRANSMEMBRANE GLYCOPROTEIN; TYPE-1 ENVELOPE PROTEIN; SYNTHETIC PEPTIDE; VIRAL FUSION; SECONDARY STRUCTURE; ATOMIC-STRUCTURE; PLASMA-MEMBRANE; MEDIATED FUSION; ENERGY-TRANSFER; GP41	To infect target cells, HIV-1 employs a virally encoded transmembrane protein (gp41) to fuse its viral envelope with the target cell plasma membrane. We describe the gp41 ectodomain as comprised of N- and C-terminal subdomains, each containing a heptad repeat as well as a fusogenic region, whose organization is mirrored by the intervening loop region. Recent evidence indicates that the gp41 directed fusion reaction proceeds to initial pore formation prior to gp41 folding into its low energy hairpin conformation. This implies that exposed regions of the gp41 ectodomain are responsible for the bulk of the fusion work, probably through direct protein-membrane interactions. Prevalent fusion models contend that the gp41 ectodomain initially interacts with the target cell surface through its highly hydrophobic N terminus, which is believed to insert into the target membrane, thereby linking the virus to the target cell. This arrangement allows the N- terminal subdomain to interact with the target cell surface, whereas the C-terminal subdomain remains proximal to the virion, allowing interaction with the viral envelope. The composition of the viral envelope and the target cell surface differ due to the virus budding from raft microdomains. We show here that constructs corresponding to the C-terminal subdomain specifically destabilize ordered and cholesterol rich membranes ( 33 molar %), whereas the N- terminal subdomain is more effective in fusing both unordered cholesterol-free membranes and those containing lower amounts of cholesterol ( 10 molar %). Moreover we show that, in the context of the C-terminal subdomain, the heptad repeat contributes helical structure, which may describe the enhanced inhibitory effect of the C-terminal subdomain relative to the C-terminal heptad repeat (C34) alone. Our results are discussed in light of recent findings that showcase the role of exposed gp41 regions in effecting membrane fusion.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; NCI, Lab Expt & Computat Biol, NIH, Frederick, MD 21702 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il		Gallo, Stephen/0000-0001-6043-2153	NATIONAL CANCER INSTITUTE [Z01BC008303, ZIABC008303] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; Campbell SM, 2002, AIDS, V16, P2253, DOI 10.1097/00002030-200211220-00004; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/0022-1317-83-8-1809; DEVAUX PF, 1994, CHEM PHYS LIPIDS, V73, P107, DOI 10.1016/0009-3084(94)90177-5; Durell SR, 1997, MOL MEMBR BIOL, V14, P97, DOI 10.3109/09687689709048170; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gazit E, 1996, J MOL BIOL, V258, P860, DOI 10.1006/jmbi.1996.0293; Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; Ishiguro R, 1996, BIOCHEMISTRY-US, V35, P4976, DOI 10.1021/bi952547+; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; Koshiba T, 2003, J BIOL CHEM, V278, P7573, DOI 10.1074/jbc.M211154200; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573; MARTIN I, 1993, BIOCHIM BIOPHYS ACTA, V1145, P124, DOI 10.1016/0005-2736(93)90389-H; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Otaka A, 2002, ANGEW CHEM INT EDIT, V41, P2938, DOI 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; Peisajovich SG, 2000, BIOCHEMISTRY-US, V39, P1826, DOI 10.1021/bi991887i; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; Sackett K, 2002, BIOCHEMISTRY-US, V41, P4678, DOI 10.1021/bi0255322; Saez-Cirion A, 2002, J BIOL CHEM, V277, P21776, DOI 10.1074/jbc.M202255200; Salzwedel K, 2000, P NATL ACAD SCI USA, V97, P12794, DOI 10.1073/pnas.230438497; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; Silvius JR, 2003, BIOPHYS J, V85, P1034, DOI 10.1016/S0006-3495(03)74542-1; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEIN BS, 1990, J BIOL CHEM, V265, P2640; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Suarez T, 2000, FEBS LETT, V477, P145, DOI 10.1016/S0014-5793(00)01785-3; Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Tatulian SA, 2000, BIOCHEMISTRY-US, V39, P496, DOI 10.1021/bi991594p; Viard M, 2002, J VIROL, V76, P11584, DOI 10.1128/JVI.76.22.11584-11595.2002; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	54	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18526	18534		10.1074/jbc.M304950200	http://dx.doi.org/10.1074/jbc.M304950200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14981088	hybrid			2022-12-27	WOS:000221041500054
J	Vitikainen, M; Lappalainen, I; Seppala, R; Antelmann, H; Boer, H; Taira, S; Savilahti, H; Hecker, M; Vihinen, M; Sarvas, M; Kontinen, VP				Vitikainen, M; Lappalainen, I; Seppala, R; Antelmann, H; Boer, H; Taira, S; Savilahti, H; Hecker, M; Vihinen, M; Sarvas, M; Kontinen, VP			Structure-function analysis of PrsA reveals roles for the parvulin-like and flanking N- and C-terminal domains in protein folding and secretion in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL CIS/TRANS ISOMERASE; CIS-TRANS ISOMERASE; TRIGGER FACTOR; IN-VIVO; CHAPERONE; BINDING; GENE; DNAK; SEQUENCE; ENZYMES	The PrsA protein of Bacillus subtilis is an essential membrane-bound lipoprotein that is assumed to assist post-translocational folding of exported proteins and stabilize them in the compartment between the cytoplasmic membrane and cell wall. This folding activity is consistent with the homology of a segment of PrsA with parvulin-type peptidyl-prolyl cis/trans isomerases (PPIase). In this study, molecular modeling showed that the parvulin-like region can adopt a parvulin-type fold with structurally conserved active site residues. PrsA exhibits PPIase activity in a manner dependent on the parvulin-like domain. We constructed deletion, peptide insertion, and amino acid substitution mutations and demonstrated that the parvulin-like domain as well as flanking N- and C-terminal domains are essential for in vivo PrsA function in protein secretion and growth. Surprisingly, none of the predicted active site residues of the parvulin-like domain was essential for growth and protein secretion, although several active site mutations reduced or abolished the PPIase activity or the ability of PrsA to catalyze proline-limited protein folding in vitro. Our results indicate that PrsA is a PPIase, but the essential role in vivo seems to depend on some non-PPIase activity of both the parvulin-like and flanking domains.	Natl Publ Hlth Inst, Vaccine Dev Lab, FIN-00300 Helsinki, Finland; Univ Helsinki, Fac Biosci, Dept Biol & Environm Sci, Div Biochem, FIN-00014 Helsinki, Finland; Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland; Ernst Moritz Arndt Univ Greifswald, Inst Mikrobiol & Mol Biol, D-17487 Greifswald, Germany; VTT Biotechnol, FIN-02044 Espoo, Finland; Univ Helsinki, Viikki Bioctr, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland; Tampere Univ Hosp, Res Unit, FIN-30520 Tampere, Finland	Finland National Institute for Health & Welfare; University of Helsinki; Tampere University; Ernst Moritz Arndt Universitat Greifswald; VTT Technical Research Center Finland; University of Helsinki; Tampere University; Tampere University Hospital	Kontinen, VP (corresponding author), Natl Publ Hlth Inst, Vaccine Dev Lab, Mannerheimintie 166, FIN-00300 Helsinki, Finland.	Vesa.Kontinen@ktl.fi	Antelmann, Haike/I-3129-2019; Vihinen, Mauno/A-8452-2012; Kontinen, Vesa P/A-2260-2012	Antelmann, Haike/0000-0002-1766-4386; Vihinen, Mauno/0000-0002-9614-7976; Lappalainen, Ilkka/0000-0001-5762-893X; Savilahti, Harri/0000-0002-6246-2572; Boer, Harry/0000-0002-1685-2270				Antelmann H, 2001, GENOME RES, V11, P1484, DOI 10.1101/gr.182801; Behrens S, 2001, EMBO J, V20, P285, DOI 10.1093/emboj/20.1.285; Bitto E, 2002, STRUCTURE, V10, P1489, DOI 10.1016/S0969-2126(02)00877-8; Dartigalongue C, 1998, EMBO J, V17, P3968, DOI 10.1093/emboj/17.14.3968; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Drouault S, 2002, APPL ENVIRON MICROB, V68, P3932, DOI 10.1128/AEM.68.8.3932-3942.2002; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1992, MOL MICROBIOL, V6, P1375, DOI 10.1111/j.1365-2958.1992.tb00858.x; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Hennig L, 1998, BIOCHEMISTRY-US, V37, P5953, DOI 10.1021/bi973162p; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Horowitz P M, 1995, Methods Mol Biol, V40, P361; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hyyrylainen HL, 2001, MOL MICROBIOL, V41, P1159, DOI 10.1046/j.1365-2958.2001.02576.x; Hyyrylainen HL, 2000, J BIOL CHEM, V275, P26696; Ideno A, 2000, EUR J BIOCHEM, V267, P3139, DOI 10.1046/j.1432-1327.2000.01332.x; JACOBS M, 1993, MOL MICROBIOL, V8, P957, DOI 10.1111/j.1365-2958.1993.tb01640.x; KIEWIET R, 1993, APPL ENVIRON MICROB, V59, P358, DOI 10.1128/AEM.59.2.358-364.1993; KOSKI P, 2001, FUNCTIONAL ANAL BACT, pA15; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu KP, 1996, NATURE, V380, P544; POUSSU E, 2004, IN PRESS PROTEINS ST; Pummi T, 2002, J BACTERIOL, V184, P1010, DOI 10.1128/jb.184.4.1010-1018.2002; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Ramm K, 2001, J MOL BIOL, V310, P485, DOI 10.1006/jmbi.2001.4747; Ramm K, 2000, J BIOL CHEM, V275, P17106, DOI 10.1074/jbc.M910234199; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Riboldi-Tunnicliffe A, 2001, NAT STRUCT BIOL, V8, P779, DOI 10.1038/nsb0901-779; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Schiene-Fischer C, 2002, NAT STRUCT BIOL, V9, P419, DOI 10.1038/nsb804; Schmid FX, 1996, BIOL CHEM, V377, P417; Schmid FX, 2002, ADV PROTEIN CHEM, V59, P243; Scholz C, 1997, J MOL BIOL, V273, P752, DOI 10.1006/jmbi.1997.1301; Sekerina E, 2000, J MOL BIOL, V301, P1003, DOI 10.1006/jmbi.2000.4013; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Stoller G, 1996, FEBS LETT, V384, P117, DOI 10.1016/0014-5793(96)00282-7; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; Terada T, 2001, J MOL BIOL, V305, P917, DOI 10.1006/jmbi.2000.4293; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Vitikainen M, 2001, J BACTERIOL, V183, P1881, DOI 10.1128/JB.183.6.1881-1890.2001; WU XC, 1991, J BACTERIOL, V173, P4952, DOI 10.1128/jb.173.16.4952-4958.1991; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957	48	90	94	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19302	19314		10.1074/jbc.M400861200	http://dx.doi.org/10.1074/jbc.M400861200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976191	hybrid			2022-12-27	WOS:000221041500144
J	Wang, ZQ; Wei, CC; Sharma, M; Pant, K; Crane, BR; Stuehr, DJ				Wang, ZQ; Wei, CC; Sharma, M; Pant, K; Crane, BR; Stuehr, DJ			A conserved Val to Ile switch near the heme pocket of animal and bacterial nitric-oxide synthases helps determine their distinct catalytic profiles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; SPECTRAL CHARACTERIZATION; BACILLUS-SUBTILIS; ELECTRON-TRANSFER; OXYGENASE DIMER; DIOXY REDUCTION; SINGLE-TURNOVER; LIGAND-BINDING; TETRAHYDROBIOPTERIN; NO	Nitric oxide (NO) release from nitric oxide synthases (NOSs) is largely dependent on the dissociation of an enzyme ferric heme-NO product complex ((FeNO)-N-III). Although the NOS-like protein from Bacillus subtilis (bs-NOS) generates (FeNO)-N-III from the reaction intermediate N-hydroxy-L-arginine (NOHA), its NO dissociation is about 20-fold slower than in mammalian NOSs. Crystal structures suggest that a conserved Val to Ile switch near the heme pocket of bsNOS might determine its kinetic profile. To test this we generated complementary mutations in the mouse inducible NOS oxygenase domain (iNOSoxy, V346I) and in bsNOS (I224V) and characterized the kinetics and extent of their NO synthesis from NOHA and their NO-binding kinetics. The mutations did not greatly alter binding of Arg, (6R)-tetrahydrobiopterin, or alter the electronic properties of the heme or various heme-ligand complexes. Stopped-flow spectroscopy was used to study heme transitions during single turnover NOHA reactions. I224V bsNOS displayed three heme transitions involving four species as typically occurs in wildtype NOS, the beginning ferrous enzyme, a ferrous-dioxy ((FeO2)-O-II) intermediate, (FeNO)-N-III, and an ending ferric enzyme. The rate of each transition was increased relative to wild-type bsNOS, with (FeNO)-N-III dissociation being 3.6 times faster. In V346I iNOSoxy we consecutively observed the beginning ferrous, (FeO2)-O-II, a mixture of (FeNO)-N-III and ferric heme species, and ending ferric enzyme. The rate of each transition was decreased relative to wild-type iNOSoxy, with the (FeNO)-N-III dissociation being 3 times slower. An independent measure of NO binding kinetics confirmed that V346I iNOSoxy has slower NO binding and dissociation than wild-type. Citrulline production by both mutants was only slightly lower than wild-type enzymes, indicating good coupling. Our data suggest that a greater shielding of the heme pocket caused by the Val/Ile switch slows down NO synthesis and NO release in NOS, and thus identifies a structural basis for regulating these kinetic variables.	Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cornell University	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Dept Immunol, NB-3,9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org		Wei, Chin-Chuan/0000-0001-6453-9409	NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Andersen JF, 2000, BIOCHEMISTRY-US, V39, P10118, DOI 10.1021/bi000766b; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; Couture M, 2001, J BIOL CHEM, V276, P38280; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Ford PC, 2002, CHEM REV, V102, P993, DOI 10.1021/cr0000271; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Lewis DFV, 2003, PHARMACOGENOMICS, V4, P387, DOI 10.1517/phgs.4.4.387.22752; Makris TM, 2002, DRUG METAB REV, V34, P691, DOI 10.1081/DMR-120015691; Munro AW, 1996, EUR J BIOCHEM, V239, P403, DOI 10.1111/j.1432-1033.1996.0403u.x; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; Schelvis JPM, 2002, BIOCHEMISTRY-US, V41, P5695, DOI 10.1021/bi0118456; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Takahashi H, 2003, CHEM LETT, V32, P998, DOI 10.1246/cl.2003.998; TSAI AL, 1994, ARCH BIOCHEM BIOPHYS, V313, P367, DOI 10.1006/abbi.1994.1400; Wang JL, 2003, J BIOL CHEM, V278, P2341, DOI 10.1074/jbc.M211131200; Wang ZQ, 2002, J BIOL CHEM, V277, P12830, DOI 10.1074/jbc.M111967200; Wang ZQ, 2001, BIOCHEMISTRY-US, V40, P12819, DOI 10.1021/bi011182s; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200	40	57	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19018	19025		10.1074/jbc.M311663200	http://dx.doi.org/10.1074/jbc.M311663200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976216	hybrid			2022-12-27	WOS:000221041500114
J	Auesukaree, C; Homma, T; Tochio, H; Shirakawa, M; Kaneko, Y; Harashima, S				Auesukaree, C; Homma, T; Tochio, H; Shirakawa, M; Kaneko, Y; Harashima, S			Intracellular phosphate serves as a signal for the regulation of the PHO pathway in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PHO4; TRANSDUCTION PATHWAY; FUNCTIONAL DOMAINS; INHIBITOR PHO81; YEAST; EXPRESSION; GENE; TRANSPORTERS; METABOLISM; PROTEIN	In Saccharomyces cerevisiae, the phosphate signal transduction pathway (PHO pathway) is known to regulate the expression of several phosphate-responsive genes, such as PHO5 and PHO84. However, the fundamental issue of whether cells sense intracellular or extracellular phosphate remains unresolved. To address this issue, we have directly measured intracellular phosphate concentrations by P-31 NMR spectroscopy. We find that PHO5 expression is strongly correlated with the levels of both intracellular orthophosphate and intracellular polyphosphate and that the signaling defect in the Deltapho84 strain is likely to result from insufficient intracellular phosphate caused by a defect in phosphate uptake. Furthermore, the Deltaphm1Deltaphm2, Deltaphm3, and Deltaphm4 strains, which lack intracellular polyphosphate, have higher intracellular orthophosphate levels and lower expression of PHO5 than the wild-type strain. By contrast, the Deltaphm5 strain, which has lower intracellular orthophosphate and higher polyphosphate levels than the wild-type strain, shows repressed expression of PHO5, similar to the wildtype strain. These observations suggest that PHO5 expression is under the regulation of intracellular orthophosphate, although orthophosphate is not the sole signaling molecule. Moreover, the disruption of PHM3, PHM4, or of both PHM1 and PHM2 in the Deltapho84 strain suppresses, although not completely, the PHO5 constitutive phenotype by increasing intracellular orthophosphate, suggesting that Pho84p affects phosphate signaling largely by functioning as a transporter.	Osaka Univ, Grad Sch Engn, Dept Biotechnol, Osaka 5650871, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Yokohama, Kanagawa 2310045, Japan	Osaka University; Yokohama City University	Harashima, S (corresponding author), Osaka Univ, Grad Sch Engn, Dept Biotechnol, 2-1 Yamadaoka, Osaka 5650871, Japan.	harashima@bio.eng.osaka-u.ac.jp	Tochio, Hidehito/F-6109-2011; Auesukaree, Choowong/AAE-8614-2022; Auesukaree, Choowong/V-8254-2019; Auesukaree, Choowong/J-3484-2016	Auesukaree, Choowong/0000-0002-5655-0058; Auesukaree, Choowong/0000-0002-5655-0058; Tochio, Hidehito/0000-0003-3843-3330				BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; Burke D., 2000, METHODS YEAST GENETI; CAMPBELLBURK SL, 1987, ANNU REV MICROBIOL, V41, P595; Cohen A, 1999, J BIOL CHEM, V274, P26885, DOI 10.1074/jbc.274.38.26885; Coons DM, 1997, YEAST, V13, P9, DOI 10.1002/(SICI)1097-0061(199701)13:1<9::AID-YEA51>3.0.CO;2-U; GILLIES RJ, 1981, P NATL ACAD SCI-BIOL, V78, P2125, DOI 10.1073/pnas.78.4.2125; Huang SD, 2001, MOL CELL BIOL, V21, P6695, DOI 10.1128/MCB.21.19.6695-6705.2001; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Kulaev IS, 1979, BIOCH INORGANIC POLY; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Liang H, 1996, MOL BIOL CELL, V7, P1953, DOI 10.1091/mbc.7.12.1953; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; NAVON G, 1979, BIOCHEMISTRY-US, V18, P4487, DOI 10.1021/bi00588a006; NICOLAY K, 1983, ARCH MICROBIOL, V134, P270, DOI 10.1007/BF00407801; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; OGAWA N, 1995, MOL CELL BIOL, V15, P997; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; Persson BL, 2003, CURR GENET, V43, P225, DOI 10.1007/s00294-003-0400-9; Sakumoto NM, 1999, YEAST, V15, P1669, DOI 10.1002/(SICI)1097-0061(199911)15:15<1669::AID-YEA480>3.0.CO;2-6; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; Sethuraman A, 2001, P NATL ACAD SCI USA, V98, P8542, DOI 10.1073/pnas.151269398; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; TORRIANIGORINI A, 1994, PHOSPHATE MICROORGAN; Van Belle D, 2001, CURR OPIN CELL BIOL, V13, P389, DOI 10.1016/S0955-0674(00)00226-X; Wykoff DD, 2001, GENETICS, V159, P1491; YOSHIDA K, 1989, MOL GEN GENET, V217, P31, DOI 10.1007/BF00330939	34	99	101	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17289	17294		10.1074/jbc.M312202200	http://dx.doi.org/10.1074/jbc.M312202200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966138	hybrid			2022-12-27	WOS:000220870400051
J	Batandier, C; Leverve, X; Fontaine, E				Batandier, C; Leverve, X; Fontaine, E			Opening of the mitochondrial permeability transition pore induces reactive oxygen species production at the level of the respiratory chain complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE GENERATION; NADH-UBIQUINONE REDUCTASE; CYTOCHROME-C; CELL-DEATH; HEART-MITOCHONDRIA; INDUCED APOPTOSIS; BRAIN MITOCHONDRIA; RELEASE; ROS; HEPATOCYTES	We have investigated the consequences of permeability transition pore (PTP) opening on the rate of production of reactive oxygen species in isolated rat liver mitochondria. We found that PTP opening fully inhibited H2O2 production when mitochondria were energized both with complex I or II substrates. Because PTP opening led to mitochondrial pyridine nucleotide depletion, H2O2 production was measured again in the presence of various amounts of NADH. PTP opening-induced H2O2 production began when NADH concentration was higher than 50 muM and reached a maximum at over 300 muM. At such concentrations of NADH, the maximal H2O2 production was 4-fold higher than that observed when mitochondria were permeabilized with the channel-forming antibiotic alamethicin, indicating that the PTP opening-induced H2O2 production was not due to antioxidant depletion. Moreover, PTP opening decreased rotenone-sensitive NADH ubiquinone reductase activity, whereas it did not affect the NADH FeCN reductase activity. We conclude that PTP opening induces a specific conformational change of complex I that (i) dramatically increases H2O2 production so long as electrons are provided to complex I, and (ii) inhibits the physiological pathway of electrons inside complex I. These data allowed the identification of a novel consequence of permeability transition that may partly account for the mechanism by which PTP opening induces cell death.	Univ Grenoble 1, INSERM, E0221, F-38041 Grenoble 09, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Fontaine, E (corresponding author), Univ Grenoble 1, INSERM, E0221, BP 53X, F-38041 Grenoble 09, France.	eric.fontaine@ujf-grenoble.fr	Fontaine, Eric/ABA-8853-2020	Fontaine, Eric/0000-0002-5204-9477; Batandier, Cecile/0000-0003-1173-458X				Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DIVIRGILIO F, 1982, J BIOL CHEM, V257, P4106; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Gastman BR, 2000, CANCER RES, V60, P6811; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; He K, 1996, BIOPHYS J, V70, P2659, DOI 10.1016/S0006-3495(96)79835-1; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; KORETSKY AP, 1987, BIOCHIM BIOPHYS ACTA, V893, P398, DOI 10.1016/0005-2728(87)90092-2; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; LAWFORD HG, 1972, BIOCHEM J, V130, P1029, DOI 10.1042/bj1301029; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1999, BIOPHYS J, V77, P1747, DOI 10.1016/S0006-3495(99)77020-7; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pastorino JG, 2000, HEPATOLOGY, V31, P1141, DOI 10.1053/he.2000.7013; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TAKEYAMA N, 1993, BIOCHEM J, V294, P719, DOI 10.1042/bj2940719; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	54	198	208	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17197	17204		10.1074/jbc.M310329200	http://dx.doi.org/10.1074/jbc.M310329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963044	hybrid			2022-12-27	WOS:000220870400040
J	Kunkel, TA				Kunkel, TA			DNA replication fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SYN THYMINE DIMER; POLYMERASE-ETA; ERROR-PRONE; STRUCTURAL INSIGHTS; NUCLEOTIDE INCORPORATION; ACTIVE-SITE; INDUCED-FIT; BYPASS; MECHANISM; BETA		NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Johnson, Arthur E/G-3457-2012; Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065070, Z01ES065070, Z01ES065046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arndt JW, 2001, BIOCHEMISTRY-US, V40, P5368, DOI 10.1021/bi002176j; Beard WA, 2002, J BIOL CHEM, V277, P47393, DOI 10.1074/jbc.M210036200; Beard WA, 2003, STRUCTURE, V11, P489, DOI 10.1016/S0969-2126(03)00051-0; Beard WA, 2001, STRUCTURE, V9, P759, DOI 10.1016/S0969-2126(01)00646-3; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Bebenek A, 2002, GENETICS, V162, P1003; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; Bebenek K, 2001, J BIOL CHEM, V276, P2317, DOI 10.1074/jbc.C000690200; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; Boudsocq F, 2002, DNA REPAIR, V1, P343, DOI 10.1016/S1568-7864(02)00019-8; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Fowler RG, 1997, FEMS MICROBIOL REV, V21, P43, DOI 10.1111/j.1574-6976.1997.tb00344.x; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; Krahn JM, 2003, STRUCTURE, V11, P121, DOI 10.1016/S0969-2126(02)00930-9; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Kunkel TA, 2003, DNA REPAIR, V2, P135, DOI 10.1016/S1568-7864(02)00224-0; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; LOEB LA, 2003, CANCER RES, V51, P3075; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Matsuda T, 2003, J BIOL CHEM, V278, P25947, DOI 10.1074/jbc.C300170200; McCulloch SD, 2004, NATURE, V428, P97, DOI 10.1038/nature02352; Minnick DT, 2002, P NATL ACAD SCI USA, V99, P1194, DOI 10.1073/pnas.032457899; Pages V, 2003, SCIENCE, V300, P1300, DOI 10.1126/science.1083964; PERRINO FW, 1990, BIOCHEMISTRY-US, V29, P5226, DOI 10.1021/bi00474a002; Perrino FW, 2003, CHEM RES TOXICOL, V16, P1616, DOI 10.1021/tx034164f; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; Post CB, 1995, BIOCHEMISTRY-US, V34, P15881, DOI 10.1021/bi00049a001; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; Purohit V, 2003, BIOCHEMISTRY-US, V42, P10200, DOI 10.1021/bi0341206; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; SHCHERBAKOVA PV, 2003, SCI AGING KNOWL ENV; Showalter AK, 2002, BIOCHEMISTRY-US, V41, P10571, DOI 10.1021/bi026021i; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Tissier A, 2000, GENE DEV, V14, P1642; Washington MT, 2003, MOL CELL BIOL, V23, P5107, DOI 10.1128/MCB.23.14.5107-5112.2003; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Yang IY, 2003, J BIOL CHEM, V278, P13989, DOI 10.1074/jbc.M212535200; Yang LJ, 2002, J MOL BIOL, V317, P651, DOI 10.1006/jmbi.2002.5450; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000	60	473	480	2	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16895	16898		10.1074/jbc.R400006200	http://dx.doi.org/10.1074/jbc.R400006200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14988392	hybrid			2022-12-27	WOS:000220870400001
J	Martin-Ruiz, C; Saretzki, G; Petrie, J; Ladhoff, J; Jeyapalan, J; Wei, WY; Sedivy, J; von Zglinicki, T				Martin-Ruiz, C; Saretzki, G; Petrie, J; Ladhoff, J; Jeyapalan, J; Wei, WY; Sedivy, J; von Zglinicki, T			Stochastic variation in telomere shortening rate causes heterogeneity of human fibroblast replicative life span	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR SENESCENCE; OXIDATIVE STRESS; IN-VITRO; P16; ACCUMULATION; HTERT; CELLS; GENE; ANTIOXIDANT; EXPRESSION	The replicative life span of human fibroblasts is heterogeneous, with a fraction of cells senescing at every population doubling. To find out whether this heterogeneity is due to premature senescence, i.e. driven by a nontelomeric mechanism, fibroblasts with a senescent phenotype were isolated from growing cultures and clones by flow cytometry. These senescent cells had shorter telomeres than their cycling counterparts at all population doubling levels and both in mass cultures and in individual subclones, indicating heterogeneity in the rate of telomere shortening. Ectopic expression of telomerase stabilized telomere length in the majority of cells and rescued them from early senescence, suggesting a causal role of telomere shortening. Under standard cell culture conditions, there was a minor fraction of cells that showed a senescent phenotype and short telomeres despite active telomerase. This fraction increased under chronic mild oxidative stress, which is known to accelerate telomere shortening. It is possible that even high telomerase activity cannot fully compensate for telomere shortening in all cells. The data show that heterogeneity of the human fibroblast replicative life span can be caused by significant stochastic cell-to-cell variation in telomere shortening.	Newcastle Univ, Gen Hosp, Sch Clin Med Sci, Henry Wellcome Biogerontol Lab, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Brown Univ, Dept Mol Biol Cell Biol & Biochem, Div Biol & Med, Providence, RI 02912 USA	Newcastle University - UK; Brown University	von Zglinicki, T (corresponding author), Newcastle Univ, Gen Hosp, Sch Clin Med Sci, Henry Wellcome Biogerontol Lab, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	t.vonzglinicki@ncl.ac.uk	Saretzki, Gabriele Christine/I-7175-2019	Saretzki, Gabriele Christine/0000-0003-2100-8223; Martin-Ruiz, Carmen/0000-0002-3361-6974; von Zglinicki, Thomas/0000-0002-5939-0248				Baerlocher GM, 2002, CYTOMETRY, V47, P89, DOI 10.1002/cyto.10053; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 2003, EXP GERONTOL, V38, P5, DOI 10.1016/S0531-5565(02)00152-3; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; COLLINS VP, 1983, MECH AGEING DEV, V23, P199; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Forsyth NR, 2003, AGING CELL, V2, P235, DOI 10.1046/j.1474-9728.2003.00057.x; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Gorbunova V, 2003, J BIOL CHEM, V278, P7692, DOI 10.1074/jbc.M212944200; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hemmer Ruth, 2003, Methods Mol Biol, V223, P187; Herbig U, 2003, AGING CELL, V2, P295, DOI 10.1046/j.1474-9728.2003.00067.x; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; KILL IR, 1994, J CELL SCI, V107, P571; Kirkwood TBL, 2002, NATURE, V419, P794, DOI 10.1038/419794a; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; Liu L, 2002, AGING CELL, V1, P40, DOI 10.1046/j.1474-9728.2002.00004.x; Lorenz M, 2001, FREE RADICAL BIO MED, V31, P824, DOI 10.1016/S0891-5849(01)00664-5; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Nagele RG, 2001, J CELL SCI, V114, P377; Naka K, 2004, J BIOL CHEM, V279, P2030, DOI 10.1074/jbc.M309457200; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; Saretzki G, 2002, CANCER LETT, V176, P81, DOI 10.1016/S0304-3835(01)00644-9; Saretzki G, 2003, AGING CELL, V2, P141, DOI 10.1046/j.1474-9728.2003.00040.x; Serra V, 2003, J BIOL CHEM, V278, P6824, DOI 10.1074/jbc.M207939200; Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490; Sitte N, 2001, EXP GERONTOL, V36, P475, DOI 10.1016/S0531-5565(00)00253-9; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; SMITH JR, 1980, SCIENCE, V207, P82; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Terman A, 1998, MECH AGEING DEV, V104, P277, DOI 10.1016/S0047-6374(98)00073-6; von Zglinicki T, 2000, LAB INVEST, V80, P1739, DOI 10.1038/labinvest.3780184; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; von Zglinicki T, 2003, NAT BIOTECHNOL, V21, P229, DOI 10.1038/nbt0303-229b; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Wei WY, 2003, EMBO REP, V4, P1061, DOI 10.1038/sj.embor7400001; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682	49	107	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17826	17833		10.1074/jbc.M311980200	http://dx.doi.org/10.1074/jbc.M311980200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963037	hybrid			2022-12-27	WOS:000220870400115
J	Dooley, CT; Dore, TM; Hanson, GT; Jackson, WC; Remington, SJ; Tsien, RY				Dooley, CT; Dore, TM; Hanson, GT; Jackson, WC; Remington, SJ; Tsien, RY			Imaging dynamic redox changes in mammalian cells with green fluorescent protein indicators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; OXIDATIVE STRESS; AQUEOUS-SOLUTION; GLUTATHIONE; INHIBITION; DISULFIDES; MENADIONE; REDUCTION; STATE; DIFFERENTIATION	Changes in the redox equilibrium of cells influence a host of cell functions. Alterations in the redox equilibrium are precipitated by changing either the glutathione/glutathione-disulfide ratio (GSH/GSSG) and/or the reduced/oxidized thioredoxin ratio. Redox-sensitive green fluorescent proteins (GFP) allow real time visualization of the oxidation state of the indicator. Ratios of fluorescence from excitation at 400 and 490 nm indicate the extent of oxidation and thus the redox potential while canceling out the amount of indicator and the absolute optical sensitivity. Because the indicator is genetically encoded, it can be targeted to specific proteins or organelles of interest and expressed in a wide variety of cells and organisms. We evaluated roGFP1 ( GFP with mutations C48S, S147C, and Q204C) and roGFP2 ( the same plus S65T) with physiologically or toxicologically relevant oxidants both in vitro and in living mammalian cells. Furthermore, we investigated the response of the redox probes under physiological redox changes during superoxide bursts in macrophage cells, hyperoxic and hypoxic conditions, and in responses to H2O2-stimulating agents, e.g. epidermal growth factor and lysophosphatidic acid.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Oregon	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	rtsien@ucsd.edu	Dore, Timothy/AAV-1496-2021; Dore, Timothy/GQP-2490-2022	Dore, Timothy/0000-0002-3876-5012	NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER; NCI NIH HHS [2P30CA23100-018] Funding Source: Medline; NIEHS NIH HHS [ES10337] Funding Source: Medline; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arner ESJ, 2001, FREE RADICAL BIO MED, V31, P1170, DOI 10.1016/S0891-5849(01)00698-0; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; COLLINS SJ, 1987, BLOOD, V70, P1233; De Bleser PJ, 1999, J BIOL CHEM, V274, P33881, DOI 10.1074/jbc.274.48.33881; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P334, DOI 10.1016/0003-9861(84)90206-6; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X; GOODROW MH, 1981, SYNTHESIS-STUTTGART, P457; HAMPTON MB, 1995, FREE RADICAL BIO MED, V18, P633, DOI 10.1016/0891-5849(94)00181-I; Hanson GT, 2004, J BIOL CHEM, V279, P13044, DOI 10.1074/jbc.M312846200; Haramaki N, 1997, FREE RADICAL BIO MED, V22, P535, DOI 10.1016/S0891-5849(96)00400-5; HWANG C, 1995, METHOD ENZYMOL, V251, P212, DOI 10.1016/0076-6879(95)51123-7; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Karin M, 2001, IUBMB LIFE, V52, P17; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; KRAUTHSIEGEL RL, 1989, BIOCHEM SOC T, V17, P315, DOI 10.1042/bst0170315; LAMOUREUX GV, 1993, J ORG CHEM, V58, P633, DOI 10.1021/jo00055a015; LEES WJ, 1991, J ORG CHEM, V56, P7328, DOI 10.1021/jo00026a026; Liochev SI, 1998, FREE RADICAL BIO MED, V25, P926, DOI 10.1016/S0891-5849(98)00121-X; Liu SQ, 1996, CURR EYE RES, V15, P726; MIRABELLI F, 1988, BIOCHEM PHARMACOL, V37, P3423, DOI 10.1016/0006-2952(88)90691-0; OLSON JS, 1974, J BIOL CHEM, V249, P4363; Ostergaard H, 2001, EMBO J, V20, P5853, DOI 10.1093/emboj/20.21.5853; Rojkind M, 2002, CELL MOL LIFE SCI, V59, P1872, DOI 10.1007/PL00012511; ROSS D, 1985, CHEM-BIOL INTERACT, V55, P177, DOI 10.1016/S0009-2797(85)80126-5; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sekharam M, 2000, BIOCHEM J, V346, P751, DOI 10.1042/0264-6021:3460751; Van den Worm E, 2001, EUR J PHARMACOL, V433, P225, DOI 10.1016/S0014-2999(01)01516-3; YANPING L, 2002, CLIN EXP PHARM PHYSL, V29, P305	36	577	607	3	87	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22284	22293		10.1074/jbc.M312847200	http://dx.doi.org/10.1074/jbc.M312847200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14985369	hybrid			2022-12-27	WOS:000221417100076
J	Harreman, MT; Kline, TM; Milford, HG; Harben, MB; Hodel, AE; Corbett, AH				Harreman, MT; Kline, TM; Milford, HG; Harben, MB; Hodel, AE; Corbett, AH			Regulation of nuclear import by phosphorylation adjacent to nuclear localization signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST-CELL CYCLE; TRANSCRIPTION FACTOR; NUCLEOCYTOPLASMIC TRANSPORT; CRYSTALLOGRAPHIC ANALYSIS; KARYOPHERIN-ALPHA; PROTEIN-KINASE; PORE COMPLEX; RECOGNITION; IDENTIFICATION; ACTIVATION	Many important regulatory proteins, including cell cycle regulators and transcription factors, contain a phosphorylation site within or adjacent to a classic nuclear localization signal (NLS) sequence. Previous studies show that the nuclear localization of these cargoes can be regulated by phosphorylation at these sites. It was hypothesized that this phosphorylation regulates the nuclear import of NLS cargo proteins by modulating the interaction of the cargo with the classic nuclear transport receptor, importin alpha. In this study, we utilize in vitro solution binding assays and in vivo analyses to directly test this model. We demonstrate that mimicking phosphorylation at a site adjacent to an NLS decreases the binding affinity of the NLS for importin alpha. This decrease in cargo affinity for importin alpha correlates with a decrease in nuclear accumulation in vivo. Through these analyses, we show that the cell cycle-dependent nuclear import of the Saccharomyces cerevisiae transcription factor Swi6p correlates with a phosphorylation-dependent change in affinity for importin alpha. Furthermore, we present data using the SV40 NLS to suggest that this form of regulation can be utilized to artificially modulate the nuclear import of a cargo, which is usually constitutively targeted to the nucleus. This work defines one molecular mechanism for regulating nuclear import by the classic NLS-mediated transport pathway.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Corbett, AH (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.	acorbe2@emory.edu	Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; ANDREWS BJ, 1992, P NATL ACAD SCI USA, V89, P11852, DOI 10.1073/pnas.89.24.11852; Berland KM, 1997, BIOPHYS J, V72, P1487, DOI 10.1016/S0006-3495(97)78796-4; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Fontes MRM, 2003, BIOCHEM J, V375, P339, DOI 10.1042/BJ20030510; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Foord R, 1999, NAT STRUCT BIOL, V6, P157; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Leung SW, 2003, J BIOL CHEM, V278, P41947, DOI 10.1074/jbc.M307162200; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Partridge JF, 1997, J BIOL CHEM, V272, P9071; Queralt E, 2003, MOL CELL BIOL, V23, P3126, DOI 10.1128/MCB.23.9.3126-3140.2003; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Sambrook J., 2001, MOL CLONING LAB MANU; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; Siegmund RF, 1996, MOL CELL BIOL, V16, P2647; SIKORSKI RS, 1989, GENETICS, V122, P19; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597	52	108	110	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20613	20621		10.1074/jbc.M401720200	http://dx.doi.org/10.1074/jbc.M401720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14998990	hybrid			2022-12-27	WOS:000221273800010
J	Volpon, L; Lamthanh, H; Barbier, J; Gilles, N; Molgo, J; Menez, A; Lancelin, JM				Volpon, L; Lamthanh, H; Barbier, J; Gilles, N; Molgo, J; Menez, A; Lancelin, JM			NMR solution structures of delta-conotoxin EVIA from Conus ermineus that selectively acts on vertebrate neuronal Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	26th European Peptide Symposium	SEP 10-15, 2000	MONTPELLIER, FRANCE				NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL SOLUTION STRUCTURE; SPIDER SELENOCOSMIA-HUWENA; RELAXATION MATRIX ANALYSIS; AMINO-ACID-SEQUENCE; FUNNEL-WEB SPIDER; CIS PEPTIDE-BONDS; OMEGA-CONOTOXIN; SODIUM-CHANNEL; PROTEIN STRUCTURES	delta-Conotoxin EVIA, from Conus ermineus, is a 32-residue polypeptide cross-linked by three disulfide bonds forming a four-loop framework. delta-Conotoxin EVIA is the first conotoxin known to inhibit sodium channel inactivation in neuronal membranes from amphibians and mammals (subtypes rNa(v)1.2a, rNa(v)1.3, and rNa(v)1.6), without affecting rat skeletal muscle (subtype rNa(v)1.4) and human cardiac muscle (subtype hNa(v)1.5) sodium channel (Barbier, J., Lamthanh, H., Le Gall, F., Favreau, P., Benoit, E., Chen, H., Gilles, N., Ilan, N., Heinemann, S. F., Gordon, D., Menez, A., and Molgo, J. (2004) J. Biol. Chem. 279, 4680-4685). Its structure was solved by NMR and is characterized by a 1:1 cis/trans isomerism of the Leu(12)-Pro(13) peptide bond in slow exchange on the NMR time scale. The structure of both cis and trans isomers could be calculated separately. The isomerism occurs within a specific long disordered loop 2, including residues 11-19. These contribute to an important hydrophobic patch on the surface of the toxin. The rest of the structure matches the "inhibitor cystine-knot motif" of conotoxins from the "O superfamily" with a high structural order. To probe a possible functional role of the Leu(12)-Pro(13) cis/trans isomerism, a Pro(13)-->Ala delta-conotoxin EVIA was synthesized and shown to exist only as a trans isomer. P13A delta-conotoxin EVIA was estimated only two times less active than the wild-type EVIA in binding competition to rat brain synaptosomes and when injected intracerebroventricularly into mice.	Univ Lyon 1, ESCPE Lyon, CNRS, Umr 5180,Lab RMN Biomol, F-69622 Villeurbanne, France; CEA, Ctr Etud Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; CNRS, UPR 9040, Neurobiol Cellulaire & Mol Lab, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lancelin, JM (corresponding author), Univ Lyon 1, ESCPE Lyon, CNRS, Umr 5180,Lab RMN Biomol, Domaine Sci La Doua, F-69622 Villeurbanne, France.	lancelin@hikari.cpe.fr	Lancelin, Jean-marc/AAC-5686-2019	barbier, julien/0000-0003-2187-4973				Adjadj E, 1997, EUR J BIOCHEM, V246, P218, DOI 10.1111/j.1432-1033.1997.00218.x; Atkinson RA, 2000, BIOCHEMISTRY-US, V39, P3908, DOI 10.1021/bi992651h; Barbier J, 2004, J BIOL CHEM, V279, P4680, DOI 10.1074/jbc.M309576200; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN MR, 1988, BIOCHEM J, V250, P401, DOI 10.1042/bj2500401; BRUNGER AT, 1991, ACCOUNTS CHEM RES, V24, P54; BRUNGER AT, 1996, XPLOR VERSION 3 851; Bulaj G, 2001, BIOCHEMISTRY-US, V40, P13201, DOI 10.1021/bi010683a; CARPINO LA, 1994, J CHEM SOC CHEM COMM, P201, DOI 10.1039/c39940000201; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chi YH, 2000, J BIOL CHEM, V275, P39444, DOI 10.1074/jbc.M007205200; Civera C, 1999, BIOCHEM BIOPH RES CO, V254, P32, DOI 10.1006/bbrc.1998.9878; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DAVIS JH, 1993, BIOCHEMISTRY-US, V32, P7396, DOI 10.1021/bi00080a009; DeLa Cruz R, 2003, J PEPT RES, V61, P202, DOI 10.1034/j.1399-3011.2003.t01-1-00048.x; Eyles SJ, 2000, J MOL BIOL, V301, P737, DOI 10.1006/jmbi.2000.4002; FAINZILBER M, 1995, J BIOL CHEM, V270, P1123, DOI 10.1074/jbc.270.3.1123; FAINZILBER M, 1995, BIOCHEMISTRY-US, V34, P5364, DOI 10.1021/bi00016a007; FARRJONES S, 1995, J MOL BIOL, V248, P106, DOI 10.1006/jmbi.1995.0205; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; Favreau P, 2001, BIOCHEMISTRY-US, V40, P14567, DOI 10.1021/bi002871r; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FESIK SW, 1990, SCIENCE, V250, P1406, DOI 10.1126/science.2255910; Fletcher JI, 1997, STRUCTURE, V5, P1525, DOI 10.1016/S0969-2126(97)00301-8; FRAENKEL Y, 1994, BIOCHEMISTRY-US, V33, P644, DOI 10.1021/bi00169a004; Francart C, 1996, J AM CHEM SOC, V118, P7019, DOI 10.1021/ja960257q; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Han KH, 1997, BIOCHEMISTRY-US, V36, P1669, DOI 10.1021/bi962301k; HASSON A, 1993, EUR J NEUROSCI, V5, P56, DOI 10.1111/j.1460-9568.1993.tb00205.x; Hattori N, 2003, BRAIN, V126, P134, DOI 10.1093/brain/awg012; Hill JM, 1997, STRUCTURE, V5, P571, DOI 10.1016/S0969-2126(97)00212-8; Hill JM, 2000, EUR J BIOCHEM, V267, P4649, DOI 10.1046/j.1432-1327.2000.01507.x; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; HYBERTS SG, 1987, EUR J BIOCHEM, V164, P625, DOI 10.1111/j.1432-1033.1987.tb11173.x; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kaji R, 2003, MUSCLE NERVE, V27, P285, DOI 10.1002/mus.10273; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; Kohno T, 2002, J BIOL CHEM, V277, P36387, DOI 10.1074/jbc.M206833200; KOHNO T, 1995, BIOCHEMISTRY-US, V34, P10256, DOI 10.1021/bi00032a020; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LAPLANCHE LA, 1964, J AM CHEM SOC, V86, P337, DOI 10.1021/ja01057a007; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEVRAM V, 1994, BRAIN RES, V640, P48, DOI 10.1016/0006-8993(94)91856-2; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; Lewis RJ, 2000, J BIOL CHEM, V275, P35335, DOI 10.1074/jbc.M002252200; LIANG SP, 1993, TOXICON, V31, P969, DOI 10.1016/0041-0101(93)90256-I; LIPPENS G, 1995, BIOCHEMISTRY-US, V34, P13, DOI 10.1021/bi00001a003; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MONJE VD, 1993, NEUROPHARMACOLOGY, V32, P1141, DOI 10.1016/0028-3908(93)90008-Q; Nielsen KJ, 1996, J MOL BIOL, V263, P297, DOI 10.1006/jmbi.1996.0576; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; Omecinsky DO, 1996, BIOCHEMISTRY-US, V35, P2836, DOI 10.1021/bi952605r; Pal D, 1999, J MOL BIOL, V294, P271, DOI 10.1006/jmbi.1999.3217; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; PERRICAUDET M, 1973, INT J PEPT PROT RES, V5, P99; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Qu YX, 1997, J PROTEIN CHEM, V16, P565, DOI 10.1023/A:1026314722607; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; SCHNUR DM, 1989, J ORG CHEM, V54, P3779, DOI 10.1021/jo00277a008; SHON KJ, 1995, BIOCHEMISTRY-US, V34, P4913, DOI 10.1021/bi00015a002; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; VANBETSBRUGGE J, 1996, PEPTIDES ELMSFORD, V371, P859; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; WUTHRICH K, 1991, SCIENCE, V254, P953, DOI 10.1126/science.1948082; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANAGAWA Y, 1988, BIOCHEMISTRY-US, V27, P6256, DOI 10.1021/bi00417a009; Yuan P, 1999, J BIOMOL NMR, V15, P55, DOI 10.1023/A:1008398807718	88	28	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21356	21366		10.1074/jbc.M309594200	http://dx.doi.org/10.1074/jbc.M309594200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	818VY	14976206	hybrid			2022-12-27	WOS:000221273800099
J	Kravets, A; Hu, ZB; Miralem, T; Torno, MD; Maines, MD				Kravets, A; Hu, ZB; Miralem, T; Torno, MD; Maines, MD			Biliverdin reductase, a novel regulator for induction of activating transcription factor-2 and heme oxygenase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; IX-ALPHA REDUCTASE; C-JUN PROMOTER; GENE-EXPRESSION; CARBON-MONOXIDE; RAT-KIDNEY; NUCLEOTIDE-SEQUENCE; ENDOTHELIAL-CELLS; RESPONSE ELEMENTS; CRYSTAL-STRUCTURE	Biliverdin IXalpha reductase (BVR) catalyzes reduction of the HO activity product, biliverdin, to bilirubin. hBVR is a serine/threonine kinase that contains a bZip domain. Presently, regulation of gene expression by hBVR was examined. 293A cells were infected with adenovirus-doxycycline (Ad-Dox)-inducible hBVR cDNA. High level expression of hBVR was determined at mRNA, protein, and activity levels 8 h after induction. Cell signal transduction microarray analysis of cells infected with expression or with the control Ad-inverted (INV)-hBVR vector identified ATF-2 among several up-regulated genes. ATF-2 is a bZip transcription factor for activation of cAMP response element (CRE) and a dimeric partner to c-jun in MAPK pathway that regulates the stress protein, HO-1, expression. Northern and Western blot analyses showed increases of similar to10-fold in ATF-2 mRNA and protein at 16 and 24 h after Dox addition. Ad-INV-hBVR did not effect ATF-2 expression. In hBVR-infected cells, levels of HO-1 mRNA and protein were increased. In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling. We propose that increased expression of the protein can be used to alter the gene expression profile in the cell.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Maines, MD (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	mahin_maines@urmc.rochester.edu	Miralem, Tihomir/F-7576-2013	Miralem, Tihomir/0000-0001-7705-0442	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004066, R01ES012187] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES 12187 A, R01 ES 04066] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal A, 1996, AM J PHYSIOL-RENAL, V271, pF814, DOI 10.1152/ajprenal.1996.271.4.F814; Ahmad Z, 2002, J BIOL CHEM, V277, P9226, DOI 10.1074/jbc.M108239200; ALAM J, 1992, J BIOL CHEM, V267, P21894; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Chen YH, 2003, EXP BIOL MED, V228, P447, DOI 10.1177/15353702-0322805-03; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Durante W, 1997, AM J PHYSIOL-HEART C, V273, pH317, DOI 10.1152/ajpheart.1997.273.1.H317; Ennis O, 1997, BIOCHEM J, V328, P33, DOI 10.1042/bj3280033; FAKHRAI H, 1992, J BIOL CHEM, V267, P4023; Falchuk KH, 2002, P NATL ACAD SCI USA, V99, P251, DOI 10.1073/pnas.012616099; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; Gong PF, 2002, ANTIOXID REDOX SIGN, V4, P249, DOI 10.1089/152308602753666307; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; KAWASAKI H, 2000, NUCL ACIDS S SER, V44, P259; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kikuchi A, 2001, NAT STRUCT BIOL, V8, P221, DOI 10.1038/84955; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; Lee MY, 2002, DIABETES, V51, P3400; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; Maines MD, 2003, TOXICOL SCI, V71, P9, DOI 10.1093/toxsci/71.1.9; Maines MD, 2001, J PHARMACOL EXP THER, V296, P1091; MAINES MD, 1992, HEME OXYGENASE CLIN, P1; McDonagh AF, 2001, NAT STRUCT BIOL, V8, P198, DOI 10.1038/84915; Miralem T, 2003, MOL CELL BIOL, V23, P579, DOI 10.1128/MCB.23.2.579-593.2003; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; Morse D, 2002, CRIT CARE MED, V30, pS12, DOI 10.1097/00003246-200201001-00002; Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; Naiki T, 2002, J BIOL CHEM, V277, P14011, DOI 10.1074/jbc.M105403200; NAKAGAWA J, 1988, J BIOL CHEM, V263, P2460; OCARRA P, 1970, J CHROMATOGR, V50, P458, DOI 10.1016/S0021-9673(00)97973-1; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Patel VA, 2002, J BIOL CHEM, V277, P38915, DOI 10.1074/jbc.M206855200; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PIZURKI L, 1994, J CELL PHYSIOL, V161, P169, DOI 10.1002/jcp.1041610120; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Sax JK, 2003, J BIOL CHEM, V278, P36435, DOI 10.1074/jbc.M303191200; Schluchter WM, 1997, J BIOL CHEM, V272, P13562, DOI 10.1074/jbc.272.21.13562; Shibahara S, 2003, EXP BIOL MED, V228, P472, DOI 10.1177/15353702-0322805-08; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SINGLETON JW, 1965, J BIOL CHEM, V240, P4780; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Whitby FG, 2002, J MOL BIOL, V319, P1199, DOI 10.1016/S0022-2836(02)00383-2; Wilks A, 1996, BIOCHEMISTRY-US, V35, P930, DOI 10.1021/bi952405f; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200	63	97	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19916	19923		10.1074/jbc.M314251200	http://dx.doi.org/10.1074/jbc.M314251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14988408	hybrid			2022-12-27	WOS:000221164500066
J	Ouchi, M; Fujiuchi, N; Sasai, K; Katayama, H; Minamishima, YA; Ongusaha, PP; Deng, CX; Sen, S; Lee, SW; Ouchi, T				Ouchi, M; Fujiuchi, N; Sasai, K; Katayama, H; Minamishima, YA; Ongusaha, PP; Deng, CX; Sen, S; Lee, SW; Ouchi, T			BRCA1 phosphorylation by Aurora-A in the regulation of G(2) to M transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER SUSCEPTIBILITY GENE; DNA-DAMAGE RESPONSE; BREAST-CANCER; CELL-CYCLE; SUBCELLULAR-LOCALIZATION; CENTROSOME AMPLIFICATION; TRANSCRIPTIONAL ACTIVATION; IONIZING IRRADIATION; S-PHASE; KINASE	Aurora-A/BTAK/STK15 localizes to the centrosome in the G(2)-M phase, and its kinase activity regulates the G(2) to M transition of the cell cycle. Previous studies have shown that the BRCA1 breast cancer tumor suppressor also localizes to the centrosome and that BRCA1 inactivation results in loss of the G(2)-M checkpoint. We demonstrate here that Aurora-A physically binds to and phosphorylates BRCA1. Biochemical analysis showed that BRCA1 amino acids 1314 - 1863 binds to Aurora-A. Site-directed mutagenesis indicated that Ser(308) of BRCA1 is phosphorylated by Aurora-A in vitro. Anti-phospho-specific antibodies against Ser(308) of BRCA1 demonstrated that Ser(308) is phosphorylated in vivo. Phosphorylation of Ser(308) increased in the early M phase when Aurora-A activity also increases; these effects could be abolished by ionizing radiation. Consistent with these observations, acute loss of Aurora-A by small interfering RNA resulted in reduced phosphorylation of BRCA1 Ser(308), and transient infection of adenovirus Aurora-A increased Ser(308) phosphorylation. Mutation of a single phosphorylation site of BRCA1 (S308N), when expressed in BRCA1-deficient mouse embryo fibroblasts, decreased the number of cells in the M phase to a degree similar to that with wild type BRCA1-mediated G(2) arrest induced by DNA damage. We propose that BRCA1 phosphorylation by Aurora-A plays a role in G(2) to M transition of cell cycle.	NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA; NIH, Genet Dev & Dis Branch, Bethesda, MD 20892 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Icahn School of Medicine at Mount Sinai; New York University; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Ouchi, T (corresponding author), NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	Toru.Ouchi@mssm.edu	deng, chuxia/N-6713-2016		NCI NIH HHS [CA 79892, CA 90631] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA090631, R01CA079892, R01CA090631] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Alberg Anthony J., 1999, Current Opinion in Oncology, V11, P435, DOI 10.1097/00001622-199911000-00003; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hsu LC, 2001, CANCER RES, V61, P7713; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Juan G, 1998, CYTOMETRY, V32, P71, DOI 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Roghi C, 1998, J CELL SCI, V111, P557; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Spector D. L., 1998, CELLS LAB MANUAL; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	55	177	189	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19643	19648		10.1074/jbc.M311780200	http://dx.doi.org/10.1074/jbc.M311780200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14990569	hybrid			2022-12-27	WOS:000221164500033
J	Boczan, J; Leenders, AGM; Sheng, ZH				Boczan, J; Leenders, AGM; Sheng, ZH			Phosphorylation of syntaphilin by cAMP-dependent protein kinase modulates its interaction with syntaxin-1 and annuls its inhibitory effect on vesicle exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE STRING PROTEIN; LONG-TERM POTENTIATION; CYCLIC-AMP; SYNAPTIC VESICLES; DIFFERENTIAL PHOSPHORYLATION; SECRETORY MACHINERY; ADENYLATE-CYCLASE; NERVE-TERMINALS; SNARE COMPLEX; PC12 CELLS	cAMP-dependent protein kinase (PKA) can modulate synaptic transmission by acting directly on the neurotransmitter secretory machinery. Here, we identify one possible target: syntaphilin, which was identified as a molecular clamp that controls free syntaxin-1 and dynamin-1 availability and thereby regulates synaptic vesicle exocytosis and endocytosis. Deletion mutation and site-directed mutagenesis experiments pinpoint dominant PKA phosphorylation sites to serines 43 and 56. PKA phosphorylation of syntaphilin significantly decreases its binding to syntaxin-1A in vitro. A syntaphilin mutation of serine 43 to aspartic acid (S43D) shows similar effects on binding. To characterize in vivo phosphorylation events, we generated antisera against a peptide of syntaphilin containing a phosphorylated serine 43. Treatment of rat brain synaptosomes or syntaphilin-transfected HEK 293 cells with the cAMP analogue BIMPS induces in vivo phosphorylation of syntaphilin and inhibits its interaction with syntaxin-1 in neurons. To determine whether PKA phosphorylation of syntaphilin is involved in the regulation of Ca2+-dependent exocytosis, we investigated the effect of overexpression of syntaphilin and its S43D mutant on the regulated secretion of human growth hormone from PC12 cells. Although expression of wild type syntaphilin in PC12 cells exhibits significant reduction in high K+-induced human growth hormone release, the S43D mutant fails to inhibit exocytosis. Our data predict that syntaphilin could be a highly regulated molecule and that PKA phosphorylation could act as an "off" switch for syntaphilin, thus blocking its inhibitory function via the cAMP-dependent signal transduction pathway.	NINDS, Synaptic Funct Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Sheng, ZH (corresponding author), NINDS, Synaptic Funct Unit, NIH, Bldg 36,Rm 5A23,36 Convent Dr, Bethesda, MD 20892 USA.	shengz@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002946, ZIANS002946] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bouron A, 1999, EUR J NEUROSCI, V11, P4446, DOI 10.1046/j.1460-9568.1999.00869.x; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; Chavis P, 1998, NEURON, V20, P773, DOI 10.1016/S0896-6273(00)81015-6; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Chi P, 2001, NAT NEUROSCI, V4, P1187, DOI 10.1038/nn756; Das S, 2003, J BIOL CHEM, V278, P41221, DOI 10.1074/jbc.M304851200; Das S, 2003, MOL BRAIN RES, V116, P38, DOI 10.1016/S0169-328X(03)00212-2; DIXON D, 1989, J NEUROSCI, V9, P4246; Evans GJO, 2002, BIOCHEM J, V364, P343, DOI 10.1042/BJ20020123; Evans GJO, 2001, J BIOL CHEM, V276, P47877, DOI 10.1074/jbc.M108186200; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; Hepp R, 2002, FEBS LETT, V532, P52, DOI 10.1016/S0014-5793(02)03629-3; Hilfiker S, 1999, NAT NEUROSCI, V2, P104, DOI 10.1038/5659; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KLEIN M, 1994, NEURON, V13, P159, DOI 10.1016/0896-6273(94)90466-9; Kohara K, 2001, NEUROSCI RES, V41, P79, DOI 10.1016/S0168-0102(01)00267-X; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; Lonart G, 2003, CELL, V115, P49, DOI 10.1016/S0092-8674(03)00727-X; Lonart G, 1998, J NEUROSCI, V18, P634; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; Ma L, 1999, NAT NEUROSCI, V2, P24, DOI 10.1038/4525; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Trudeau LE, 1996, NEURON, V17, P789, DOI 10.1016/S0896-6273(00)80210-X; Trudeau LE, 1998, P NATL ACAD SCI USA, V95, P7163, DOI 10.1073/pnas.95.12.7163; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WICK PF, 1993, J BIOL CHEM, V268, P10983; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yasuda H, 2003, NAT NEUROSCI, V6, P15, DOI 10.1038/nn985; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	51	22	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18911	18919		10.1074/jbc.M400496200	http://dx.doi.org/10.1074/jbc.M400496200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985338	Green Published, hybrid			2022-12-27	WOS:000221041500101
J	Lu, H; Golovanov, AP; Alcock, F; Grossmann, JG; Allen, S; Lian, LY; Tokatlidis, K				Lu, H; Golovanov, AP; Alcock, F; Grossmann, JG; Allen, S; Lian, LY; Tokatlidis, K			The structural basis of the TIM10 chaperone assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INTERMEMBRANE SPACE; INNER MEMBRANE-PROTEINS; ADP/ATP CARRIER; PRECURSOR PROTEINS; MOLTEN GLOBULE; OUTER-MEMBRANE; TOM COMPLEX; IMPORT PORE; TRANSLOCASE; DOMAINS	Tim9 and Tim10 are essential components of the "small Tim" family of proteins that facilitate insertion of polytopic proteins at the inner mitochondrial membrane. The small Tims are themselves imported from the cytosol and are organized in specific translocation assemblies in the intermembrane space. Their conformational properties and how these influence the mechanism of assembly remain poorly understood. Moreover, the three-dimensional structure of the TIM10 complex is unknown. We have characterized the structural properties of these proteins in their free and assembled states using NMR, circular dichroism, and small angle x-ray scattering. We show that the free proteins are largely unfolded in their reduced assembly-incompetent state and molten globules in their oxidized assembly-competent state. Tim10 appears less structured than Tim9 in their respective free oxidized forms and undergoes a larger structural change than Tim9 upon complexation. The NMR data here demonstrates unequivocally that only the oxidized states of the Tim9 and Tim10 proteins are capable of forming a complex. Zinc binding stabilizes the reduced state against proteolysis without significantly affecting the secondary structure. Solution x-ray scattering was used to obtain a molecular envelope for the subunits individually and for their fully functional TIM10 complex. Ab initio shape reconstructions based on the scattering data has allowed us to obtain the first low resolution three-dimensional structure of the TIM10 complex. This is a novel structure that displays extensive surface hydrophobicity. The structure also provides an explanation for the escorting function of this non-ATP-powered chaperone particle.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; SERC, Daresbury Lab, Synchrotron Radiat Dept, Res Councils,Council Cent Lab, Warrington WA4 4AD, Cheshire, England; Univ Crete, Dept Chem, Iraklion 71409, Greece; FORTH, IMBB, Iraklion 71110, Greece	University of Manchester; University of Manchester; STFC Daresbury Laboratory; University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Tokatlidis, K (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.	tokatlid@imbb.forth.gr	Alcock, Felicity/T-4073-2019; Golovanov, Alexander P./ABN-0572-2022; Lu, Hui/AAB-5476-2021	Alcock, Felicity/0000-0002-3983-6097; Golovanov, Alexander P./0000-0002-8592-3984; Tokatlidis, Kostas/0000-0001-6295-8183; Lu, Hui/0000-0002-7029-2681; Allen, Scott/0000-0003-4418-7375	MRC [G0000153] Funding Source: UKRI; Medical Research Council [G0000153] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Allen S, 2003, J BIOL CHEM, V278, P38505, DOI 10.1074/jbc.M306027200; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Chacinska A, 2002, TRENDS CELL BIOL, V12, P299, DOI 10.1016/S0962-8924(02)02310-3; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Dunker AK, 2001, NAT BIOTECHNOL, V19, P805, DOI 10.1038/nbt0901-805; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; Golovanov AP, 2001, J MOL BIOL, V305, P121, DOI 10.1006/jmbi.2000.4262; Grossmann JG, 2001, BIOCHEMISTRY-US, V40, P6267, DOI 10.1021/bi0028946; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200; Huang SH, 1999, NAT STRUCT BIOL, V6, P1132; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Lu H, 2004, J BIOL CHEM, V279, P18952, DOI 10.1074/jbc.M313045200; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Lutz T, 2003, EMBO J, V22, P4400, DOI 10.1093/emboj/cdg421; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; Schwartz MP, 1999, P NATL ACAD SCI USA, V96, P13086, DOI 10.1073/pnas.96.23.13086; Schwartz MP, 1999, J BIOL CHEM, V274, P12759, DOI 10.1074/jbc.274.18.12759; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Uversky VN, 1996, BIOPHYS CHEM, V60, P79, DOI 10.1016/0301-4622(96)00009-9; Van Der Goot Francoise G., 1992, Trends in Cell Biology, V2, P343; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200; Witty M, 2002, EMBO J, V21, P4207, DOI 10.1093/emboj/cdf417; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	44	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18959	18966		10.1074/jbc.M313046200	http://dx.doi.org/10.1074/jbc.M313046200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14973126	hybrid			2022-12-27	WOS:000221041500107
J	Shi, WX; Ting, LM; Kicska, GA; Lewandowicz, A; Tyler, PC; Evans, GB; Furneaux, RH; Kim, K; Almo, SC; Schramm, VL				Shi, WX; Ting, LM; Kicska, GA; Lewandowicz, A; Tyler, PC; Evans, GB; Furneaux, RH; Kim, K; Almo, SC; Schramm, VL			Plasmodium falciparum purine nucleoside phosphorylase - Crystal structures, immucillin inhibitors, and dual catalytic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG	Purine nucleoside phosphorylase from Plasmodium falciparum (PfPNP) is an anti-malarial target based on the activity of Immucillins. The crystal structure of PfPNP . Immucillin-H (ImmH) . SO4 reveals a homohexamer with ImmH and SO4 bound at each catalytic site. A solvent-filled cavity close to the 5'-hydroxyl group of ImmH suggested that PfPNP can accept additional functional groups at the 5'-carbon. Assays established 5'-methylthioinosine (MTI) as a substrate for PfPNP. MTI is not found in human metabolism. These properties of PfPNP suggest unusual purine pathways in P. falciparum and provide structural and mechanistic foundations for the design of malaria-specific transition state analogue inhibitors. 5'-Methylthio-Immucillin-H (MT-ImmH) was designed to resemble the transition state of PfPNP and binds to PfPNP and human-PNP with K-d values of 2.7 and 303 nM, respectively, to give a discrimination factor of 112. MT-ImmH is the first inhibitor that favors PfPNP inhibition. The structure of PfPNP . MT-ImmH . SO4 shows that the hydrophobic methylthio group inserts into a hydrophobic region adjacent to the more hydrophilic 5'-hydroxyl binding site of ImmH. The catalytic features of PfPNP indicate a dual cellular function in purine salvage and polyamine metabolism. Combined metabolic functions in a single enzyme strengthen the rationale for targeting PfPNP in anti-malarial action.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Ind Res Ltd, Carbohydrate Chem Team, Lower Hutt 6009, New Zealand	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Callaghan Innovation	Schramm, VL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	vern@aecom.yu.edu	Evans, Gary/B-8343-2011; Evans, Gary/I-4123-2019; Furneaux, Richard Hubert/B-4157-2015	Evans, Gary/0000-0002-6973-2002; Evans, Gary/0000-0002-6973-2002; Furneaux, Richard Hubert/0000-0003-0973-2606; Lewandowicz, Andrzej/0000-0002-4207-9023; Kim, Kami/0000-0003-3384-152X				Asahi H, 1996, PARASITOLOGY, V113, P19, DOI 10.1017/S0031182000066233; Bennett EM, 2003, J BIOL CHEM, V278, P47110, DOI 10.1074/jbc.M304622200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bzowska A, 2000, PHARMACOL THERAPEUT, V88, P349, DOI 10.1016/S0163-7258(00)00097-8; Evans GB, 2001, J ORG CHEM, V66, P5723, DOI 10.1021/jo0155613; Evans GB, 2000, TETRAHEDRON, V56, P3053, DOI 10.1016/S0040-4020(00)00194-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; Kicska GA, 2002, J BIOL CHEM, V277, P3219, DOI 10.1074/jbc.M105905200; KIKAGAWA K, 1972, J MED CHEM, V15, P387; Lewandowicz A, 2004, BIOCHEMISTRY-US, V43, P1458, DOI 10.1021/bi0359123; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REYES P, 1982, MOL BIOCHEM PARASIT, V5, P275, DOI 10.1016/0166-6851(82)90035-4	18	105	122	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18103	18106		10.1074/jbc.C400068200	http://dx.doi.org/10.1074/jbc.C400068200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14982926	hybrid			2022-12-27	WOS:000221041500002
J	Guo, Y; Smith, K; Lee, J; Thiele, DJ; Petris, MJ				Guo, Y; Smith, K; Lee, J; Thiele, DJ; Petris, MJ			Identification of methionine-rich clusters that regulate copper-stimulated endocytosis of the human Ctr1 copper transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; BIOCHEMICAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHARACTERIZATION; PLASMA-MEMBRANE; DISEASE PROTEIN; BINDING SITES; TRAFFICKING; HCTR1; YEAST	Copper uptake and subsequent delivery to copper-dependent enzymes are essential for many cellular processes. However, the intracellular levels of this nutrient must be controlled because of its potential toxicity. The hCtr1 protein functions in high affinity copper uptake at the plasma membrane of human cells. Recent studies have shown that elevated copper stimulates the endocytosis and degradation of the hCtr1 protein, and this response is likely an important homeostatic mechanism that prevents the overaccumulation of copper. The domains of hCtr1 involved in copper-stimulated endocytosis and degradation are unknown. In this study we examined the importance of potential copper-binding sequences in the extracellular domain and a conserved transmembrane (MXXXM154)-M-150 motif for copper-stimulated endocytosis and degradation of hCtr1. The endocytic response of hCtr1 to low copper concentrations required an amino-terminal methionine cluster ((MMMMPM45)-M-40) closest to the transmembrane region. However, this cluster was not required for the endocytic response to higher copper levels, suggesting this motif may function as a high affinity copper-sensing domain. Moreover, the transmembrane (MXXXM154)-M-150 motif was absolutely required for copper-stimulated endocytosis and degradation of hCtr1 even under high copper concentrations. Together with previous studies demonstrating a role for these motifs in high affinity copper transport activity, our findings suggest common biochemical mechanisms regulate both transport and trafficking functions of hCtr1.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68588 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Sarah W Steadman Nutr & Metab Ctr, Durham, NC 27710 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Duke University; Duke University	Petris, MJ (corresponding author), Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA.	petrism@missouri.edu		Fulcher, Yan/0000-0002-7060-3523	NIDDK NIH HHS [DK66333, DK59893] Funding Source: Medline; NIGMS NIH HHS [GM62555] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066333, R01DK059893, R56DK066333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062555] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; Forbes JR, 2000, HUM MOL GENET, V9, P1927, DOI 10.1093/hmg/9.13.1927; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Kim BE, 2003, J MED GENET, V40, P290, DOI 10.1136/jmg.40.4.290; Klomp AEM, 2003, BIOCHEM J, V370, P881, DOI 10.1042/BJ20021128; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030	23	144	148	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17428	17433		10.1074/jbc.M401493200	http://dx.doi.org/10.1074/jbc.M401493200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14976198	Green Published, hybrid			2022-12-27	WOS:000220870400068
J	Roy, M; Li, ZG; Sacks, DB				Roy, M; Li, ZG; Sacks, DB			IQGAP1 binds ERK2 and modulates its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; SIGNAL-TRANSDUCTION; RNA INTERFERENCE; CELL-ADHESION; MAP KINASES; CDC42; CALMODULIN; CYTOSKELETON; CALCIUM	IQGAP1 binds several proteins including actin, calmodulin, E-cadherin, beta-catenin, Cdc42, Rac1, and CLIP-170. The interaction with these targets enables IQGAP1 to participate in many cellular functions varying from regulation of the cytoskeleton to gene transcription. Here we show that extracellular signal-regulated kinase (ERK) 2 binds to IQGAP1. In vitro analysis with purified proteins demonstrated a direct interaction between ERK2 and IQGAP1. Moreover, binding occurred in cells as endogenous ERK2 co-immunoprecipitated with IQGAP1 from human breast epithelial cell lysates. The association between ERK2 and IQGAP1 was independent of epidermal growth factor. The in vivo interaction has functional significance. Manipulation of intracellular IQGAP1 levels significantly reduced growth factor-stimulated ERK1 and ERK2 activity. Similarly, stimulation of ERK1 and ERK2 activity by insulin-like growth factor I was reduced when IQGAP1 levels were changed. In contrast, overexpression of an IQGAP1 construct lacking the ERK2 binding region did not interfere with activation of ERK1 and ERK2 by epidermal growth factor. Our data disclose a previously unidentified communication between IQGAP1 and the ERK pathway and imply that IQGAP1 modulates the Ras/mitogen-activated protein kinase signaling cascade.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735				AHN NG, 1991, J BIOL CHEM, V266, P4220; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Janssen RAJ, 2003, MOL CELL BIOL, V23, P1786, DOI 10.1128/MCB.23.5.1786-1797.2003; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mateer SC, 2003, CELL MOTIL CYTOSKEL, V55, P147, DOI 10.1002/cm.10118; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; Mbele GO, 2002, J BIOL CHEM, V277, P49998, DOI 10.1074/jbc.M205363200; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Raman M, 2003, CURR BIOL, V13, pR886, DOI 10.1016/j.cub.2003.10.053; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Sokol SY, 2001, J BIOL CHEM, V276, P48425, DOI 10.1074/jbc.M107975200; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	39	169	176	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17329	17337		10.1074/jbc.M308405200	http://dx.doi.org/10.1074/jbc.M308405200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970219	hybrid			2022-12-27	WOS:000220870400056
J	Karai, LJ; Russell, JT; Iadarola, MJ; Olah, Z				Karai, LJ; Russell, JT; Iadarola, MJ; Olah, Z			Vanilloid receptor 1 regulates multiple calcium compartments and contributes to Ca2+-induced Ca2+ release in sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-ROOT GANGLION; PROTEIN-KINASE-C; CAPSAICIN-INDUCED DESENSITIZATION; ENDOPLASMIC-RETICULUM; RUTHENIUM RED; DIRECT PHOSPHORYLATION; INTRACELLULAR CALCIUM; SYMPATHETIC NEURONS; CHANNEL ACTIVITY; NERVE-FIBERS	Vanilloid receptor 1 belongs to the transient receptor potential ion channel family and transduces sensations of noxious heat and inflammatory hyperalgesia in nociceptive neurons. These neurons contain two vanilloid receptor pools, one in the plasma membrane and the other in the endoplasmic reticulum. The present experiments characterize these two pools and their functional significance using calcium imaging and Ca-45 uptake in stably transfected cells or dorsal root ganglion neurons. The plasma membrane localized receptor is directly activated by vanilloids. The endoplasmic reticulum pool was demonstrated to be independently activated with 20 muM capsaicin or 1.6 muM resiniferatoxin using a bathing solution containing 10 muM Ruthenium Red (to selectively block plasma membrane-localized receptors) and 100 muM EGTA. We also demonstrate an overlap between the endoplasmic reticulum-localized vanilloid receptor regulated stores and thapsigargin-sensitive stores. Direct depletion of calcium via activation of endoplasmic reticulum-localized vanilloid receptor 1 triggered store operated calcium entry. Furthermore, we found that, in the presence of low extracellular calcium (10(-5) M), either 2 muM capsaicin or 0.1 nM- 1.6 muM resiniferatoxin caused a pronounced calcium-induced calcium release in either vanilloid receptor-expressing neurons or heterologous expression systems. This phenomenon may allow new insight into how nociceptive neuron function in response to a variety of nociceptive stimuli both acutely and during prolonged nociceptive signaling.	NIDCR, Neuronal Gene Express Unit, Pain & Neurosurg Mech Branch, NIH, Bethesda, MD 20892 USA; NICHD, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Olah, Z (corresponding author), NIDCR, Neuronal Gene Express Unit, Pain & Neurosurg Mech Branch, NIH, Bldg 49,Rm 1A19,49 Convent Dr,MSC-4410, Bethesda, MD 20892 USA.	zoltan.olah@nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD001206, Z01HD001206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000688] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Acs G, 1996, MOL BRAIN RES, V35, P173, DOI 10.1016/0169-328X(95)00204-6; Aihara Y, 2001, J NEUROSCI RES, V65, P236, DOI 10.1002/jnr.1147; AMANN R, 1990, EUR J PHARMACOL, V186, P169, DOI 10.1016/0014-2999(90)90430-E; Amaya F, 2003, BRAIN RES, V963, P190, DOI 10.1016/S0006-8993(02)03972-0; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; Cain DM, 2001, J NEUROSCI, V21, P9367, DOI 10.1523/JNEUROSCI.21-23-09367.2001; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOLEWINSKI A, 1993, NEUROSCIENCE, V55, P1015, DOI 10.1016/0306-4522(93)90315-7; Dedov VN, 2000, NEUROSCIENCE, V95, P183; Dove LS, 2000, J NEUROPHYSIOL, V84, P513, DOI 10.1152/jn.2000.84.1.513; DRAY A, 1990, BRIT J PHARMACOL, V101, P727, DOI 10.1111/j.1476-5381.1990.tb14148.x; Dux M, 1999, CELL TISSUE RES, V296, P471, DOI 10.1007/s004410051307; Eun SY, 2001, BIOCHEM BIOPH RES CO, V285, P1114, DOI 10.1006/bbrc.2001.5272; Fields RD, 1997, J NEUROSCI, V17, P7252; Fink CC, 2000, BIOPHYS J, V79, P163, DOI 10.1016/S0006-3495(00)76281-3; FRIEL DD, 1994, J NEUROSCI, V14, P4007; Glaser ST, 2003, P NATL ACAD SCI USA, V100, P4269, DOI 10.1073/pnas.0730816100; Grant ER, 2002, J PHARMACOL EXP THER, V300, P9, DOI 10.1124/jpet.300.1.9; Herbert MK, 2002, ANASTH INTENSIV NOTF, V37, P314, DOI 10.1055/s-2002-32233; HOLZER P, 1991, PHARMACOL REV, V43, P143; Hu HJ, 2002, J NEUROSCI, V22, P7444; Hudson LJ, 2001, EUR J NEUROSCI, V13, P2105, DOI 10.1046/j.0953-816x.2001.01591.x; JANCSO G, 1981, BRAIN RES, V210, P83, DOI 10.1016/0006-8993(81)90886-6; JEFTINIJA S, 1992, REGUL PEPTIDES, V39, P123, DOI 10.1016/0167-0115(92)90534-2; Jung YS, 1998, EUR J PHARMACOL, V362, P193, DOI 10.1016/S0014-2999(98)00786-9; Kennedy HJ, 2002, J PHYSIOL-LONDON, V539, P15, DOI 10.1113/jphysiol.2001.013171; LAMOTTE RH, 1992, J PHYSIOL-LONDON, V448, P749, DOI 10.1113/jphysiol.1992.sp019068; Langford GM, 1999, FASEB J, V13, pS248, DOI 10.1096/fasebj.13.9002.S248; LEIN PJ, 1989, DEV BIOL, V136, P330, DOI 10.1016/0012-1606(89)90260-1; Liu M, 2003, J BIOL CHEM, V278, P5462, DOI 10.1074/jbc.M209111200; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; MARSH SJ, 1987, NEUROSCIENCE, V23, P275, DOI 10.1016/0306-4522(87)90289-2; Marshall ICB, 2003, BRIT J PHARMACOL, V138, P172, DOI 10.1038/sj.bjp.0705003; Messutat S, 2001, CELL CALCIUM, V30, P199, DOI 10.1054/ceca.2001.0227; Neubert JK, 2003, PAIN, V104, P219, DOI 10.1016/S0304-3959(03)00009-5; Nolano M, 1999, PAIN, V81, P135, DOI 10.1016/S0304-3959(99)00007-X; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Olah Z, 2002, J BIOL CHEM, V277, P35752, DOI 10.1074/jbc.M201551200; Olah Z, 2001, J BIOL CHEM, V276, P31163, DOI 10.1074/jbc.M101607200; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Purkiss J, 2000, BIOCHEM PHARMACOL, V59, P1403, DOI 10.1016/S0006-2952(00)00260-4; Rosenbaum T, 2004, J GEN PHYSIOL, V123, P53, DOI 10.1085/jgp.200308906; Sakurada T, 2003, PHARMACOL BIOCHEM BE, V75, P115, DOI 10.1016/S0091-3057(03)00066-2; Spitzer NC, 2002, J PHYSIOLOGY-PARIS, V96, P73, DOI 10.1016/S0928-4257(01)00082-1; Subramanian K, 1997, CELL, V89, P963, DOI 10.1016/S0092-8674(00)80281-0; SZALLASI A, 1989, NEUROSCIENCE, V30, P515, DOI 10.1016/0306-4522(89)90269-8; Szoke E, 2002, NEUROSCIENCE, V115, P805, DOI 10.1016/S0306-4522(02)00420-7; TAKEI K, 1992, J NEUROSCI, V12, P489; Tang FJ, 2003, J NEUROSCI, V23, P927; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Turner H, 2003, BIOCHEM J, V371, P341, DOI 10.1042/BJ20021381; Usachev YM, 1999, BIOESSAYS, V21, P743, DOI 10.1002/(SICI)1521-1878(199909)21:9<743::AID-BIES5>3.0.CO;2-M; Usachev YM, 1999, J PHYSIOL-LONDON, V519, P115, DOI 10.1111/j.1469-7793.1999.0115o.x; Wisnoskey BJ, 2003, BIOCHEM J, V372, P517, DOI 10.1042/BJ20021574; Wu Z, 2002, HISTOCHEM CELL BIOL, V118, P213, DOI 10.1007/s00418-002-0443-x; Yamamoto K, 2002, NEUROSCIENCE, V109, P665, DOI 10.1016/S0306-4522(01)00486-9; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang HW, 2003, J PHARMACOL SCI, V91, P167; Zhou Y, 2003, J NEUROCHEM, V85, P571, DOI 10.1046/j.1471-4159.2003.01675.x	67	108	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16377	16387		10.1074/jbc.M310891200	http://dx.doi.org/10.1074/jbc.M310891200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14963041	hybrid			2022-12-27	WOS:000220747900084
J	Wiedemann, N; Frazier, AE; Pfanner, N				Wiedemann, N; Frazier, AE; Pfanner, N			The protein import machinery of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TIM23 PREPROTEIN TRANSLOCASE; INNER MEMBRANE; OUTER-MEMBRANE; INTERMEMBRANE SPACE; ADP/ATP CARRIER; PRESEQUENCE TRANSLOCASE; MOLECULAR CHAPERONES; RECEPTORS TOM20; CHANNEL; COMPLEX		Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Freiburg	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	Nikolaus.Pfanner@biochemie.uni-freiburg.de	Pfanner, Nikolaus/AAV-7878-2021	Frazier, Ann/0000-0002-6491-3437; Wiedemann, Nils/0000-0001-8305-6728				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; D'Silva PD, 2003, P NATL ACAD SCI USA, V100, P13839, DOI 10.1073/pnas.1936150100; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Frazier AE, 2004, NAT STRUCT MOL BIOL, V11, P226, DOI 10.1038/nsmb735; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Herrmann JM, 2003, IUBMB LIFE, V55, P219, DOI 10.1080/1521654031000123349; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; Huang SH, 2002, NAT STRUCT BIOL, V9, P301, DOI 10.1038/nsb772; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; Kozany C, 2004, NAT STRUCT MOL BIOL, V11, P234, DOI 10.1038/nsmb734; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Liu QL, 2003, SCIENCE, V300, P139, DOI 10.1126/science.1083379; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Stuart RA, 2002, BBA-MOL CELL RES, V1592, P79, DOI 10.1016/S0167-4889(02)00266-5; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; WIEDEMANN N, 2004, J BIOL CHEM     0220; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X; Yano M, 2003, J CELL BIOL, V163, P45, DOI 10.1083/jcb.200305051; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	64	250	258	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14473	14476		10.1074/jbc.R400003200	http://dx.doi.org/10.1074/jbc.R400003200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14973134	hybrid			2022-12-27	WOS:000220594700001
J	Wen, Y; Yang, SH; Liu, R; Brun-Zinkernagel, AM; Koulen, P; Simpkins, JW				Wen, Y; Yang, SH; Liu, R; Brun-Zinkernagel, AM; Koulen, P; Simpkins, JW			Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer's disease-like tauopathy in female rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PAIRED HELICAL FILAMENTS; TRANSGENIC MICE; TAU-PROTEIN; NEURODEGENERATIVE DISEASES; ARTERY OCCLUSION; MONOCLONAL-ANTIBODIES; SYMPATHETIC NEURONS; HOSPITALIZED COHORT; INDUCED APOPTOSIS	Aberrant mitosis occurs in many tauopathy-related neurodegenerative diseases and is believed to precede the formation of neurofibrillary tangles. In this study, we report for the first time that transient cerebral ischemia induces aberrant mitotic proteins and hyperphosphorylation of tau protein with neurofibrillary tangle-like conformational epitopes in adult female rat cortex. Following transient cerebral ischemia in rats, initiation of apoptosis precedes and is potentially integrated with subsequent aberrant mitosis and tau hyperphosphorylation. Furthermore, inhibition of mitosis-related cyclin-dependent kinases (Cdks) by roscovitine significantly reduced the hyperphosphorylation of tau. Administration of the female sex steroid and potent neuroprotective agent, 17beta-estradiol, reduced ischemia-reperfusion-induced cerebral damage and the subsequent aberrant mitosis and tauopathies. These results provide a neuropathological basis for the higher prevalence of dementia in stroke patients and support the hypothesis that apoptosis and aberrant mitosis are integrated pathological events in neurons that may play a critical role in the development of Alzheimer's disease and other tauopathy-related neuropathology.	Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA; Univ N Texas, Hlth Sci Ctr, Dept Cell Biol & Genet, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Simpkins, JW (corresponding author), 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	JSIMPKIN@hsc.unt.edu	Yang, Shaohua/D-1738-2013	Liu, Ran/0000-0002-3882-0616	NATIONAL INSTITUTE ON AGING [P01AG022550, P01AG010485] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG022550, AG 22550, AG10485, P01 AG010485] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Behl C, 2002, PROG BRAIN RES, V138, P135, DOI 10.1016/S0079-6123(02)38075-0; Campagne MV, 1998, J NEUROSCI RES, V53, P279; Contois JH, 1996, CLIN LAB MED, V16, P105, DOI 10.1016/S0272-2712(18)30290-7; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dranovsky A, 2001, NEUROBIOL AGING, V22, P517, DOI 10.1016/S0197-4580(00)00248-7; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Husseman JW, 2000, NEUROBIOL AGING, V21, P815, DOI 10.1016/S0197-4580(00)00221-9; Ikeda K, 2000, NEUROSCI LETT, V284, P187, DOI 10.1016/S0304-3940(00)01009-0; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; Katsuse O, 2001, NEUROPATHOLOGY, V21, P272, DOI 10.1046/j.1440-1789.2001.00411.x; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; Lin SH, 2001, NEUROSCI LETT, V310, P173, DOI 10.1016/S0304-3940(01)02118-8; LOEB C, 1992, STROKE, V23, P1225, DOI 10.1161/01.STR.23.9.1225; Lu PJ, 1999, NATURE, V399, P784; Marx J, 2001, SCIENCE, V293, P2192, DOI 10.1126/science.293.5538.2192; McPhie DL, 2003, J NEUROSCI, V23, P6914; Nuydens R, 1998, J NEUROCHEM, V70, P1124; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Pasquier F, 1997, J NEUROL, V244, P135, DOI 10.1007/s004150050064; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3; PELECH SL, 1995, NEUROBIOL AGING, V16, P247, DOI 10.1016/0197-4580(94)00187-6; Raina A K, 2000, Prog Cell Cycle Res, V4, P235; Sakai K, 1999, J NEUROSCI RES, V58, P396, DOI 10.1002/(SICI)1097-4547(19991101)58:3<396::AID-JNR5>3.3.CO;2-B; Sanchez MP, 2001, REV NEUROLOGIA, V33, P169, DOI 10.33588/rn.3302.2001187; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shi J, 2000, BRAIN RES, V853, P1, DOI 10.1016/S0006-8993(99)02113-7; Shirvan A, 1997, J NEURAL TRANSM-SUPP, P67; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; TATEMICHI TK, 1992, NEUROLOGY, V42, P1185, DOI 10.1212/WNL.42.6.1185; Tomasevic G, 1998, MOL BRAIN RES, V60, P168, DOI 10.1016/S0169-328X(98)00173-9; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1998, NEUROBIOL AGING, V19, P287, DOI 10.1016/S0197-4580(98)00071-2; Vincent I, 1997, J NEUROSCI, V17, P3588; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001; YEN SH, 1995, NEUROBIOL AGING, V16, P381, DOI 10.1016/0197-4580(95)00022-7	57	117	125	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22684	22692		10.1074/jbc.M311768200	http://dx.doi.org/10.1074/jbc.M311768200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14982935	hybrid			2022-12-27	WOS:000221417100120
J	Gong, CL; Martins, A; Bongiorno, P; Glickman, M; Shuman, S				Gong, CL; Martins, A; Bongiorno, P; Glickman, M; Shuman, S			Biochemical and genetic analysis of the four DNA ligases of mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MUTATIONAL ANALYSIS; MYCOLIC ACID; VIRUS; TUBERCULOSIS; DOMAIN; IDENTIFICATION; MUTAGENESIS	Mycobacterium tuberculosis encodes an NAD(+)-dependent DNA ligase (LigA) plus three distinct ATP-dependent ligase homologs (LigB, LigC, and LigD). Here we purify and characterize the multiple DNA ligase enzymes of mycobacteria and probe genetically whether the ATP-dependent ligases are required for growth of M. tuberculosis. We find significant differences in the reactivity of mycobacterial ligases with a nicked DNA substrate, whereby LigA and LigB display vigorous nick sealing activity in the presence of NAD(+) and ATP, respectively, whereas LigC and LigD, which have ATP-specific adenylyltransferase activity, display weak nick joining activity and generate high levels of the DNA-adenylate intermediate. All four of the mycobacterial ligases are monomeric enzymes. LigA has a low K-m for NAD(+) (1 muM) and is sensitive to a recently described pyridochromanone inhibitor of NAD(+)-dependent ligases. LigA is able to sustain growth of Saccharomyces cerevisiae in lieu of the essential yeast ligase Cdc9, but LigB, LigC, and LigD are not. LigB is distinguished by its relatively high K-m for ATP (0.34 mM) and its dependence on a distinctive N-terminal domain for nick joining. None of the three ATP-dependent ligases are essential for mycobacterial growth. M. tuberculosis ligDDelta cells are defective in nonhomologous DNA end joining.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Sloan Kettering Inst, Program Immunol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Div Infect Dis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Glickman, M (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	glickmam@MSKCC.ORG; s-shuman@ski.mskcc.org	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497; Glickman, Michael S/0000-0001-7918-5164				Aravind L, 2001, GENOME RES, V11, P1365, DOI 10.1101/gr.181001; Brotz-Oesterhelt H, 2003, J BIOL CHEM, V278, P39435, DOI 10.1074/jbc.M306479200; Cheng CH, 1997, NUCLEIC ACIDS RES, V25, P1369, DOI 10.1093/nar/25.7.1369; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Glickman MS, 2003, J BIOL CHEM, V278, P7844, DOI 10.1074/jbc.M212458200; Glickman MS, 2001, J BIOL CHEM, V276, P2228, DOI 10.1074/jbc.C000652200; GOTTESMAN MM, 1973, J MOL BIOL, V77, P531, DOI 10.1016/0022-2836(73)90221-0; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; Kaczmarek FS, 2001, J BACTERIOL, V183, P3016, DOI 10.1128/JB.183.10.3016-3024.2001; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; KONRAD EB, 1973, J MOL BIOL, V77, P519, DOI 10.1016/0022-2836(73)90220-9; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; Magnet S, 2004, BIOCHEMISTRY-US, V43, P710, DOI 10.1021/bi0355387; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Odell M, 1996, VIROLOGY, V221, P120, DOI 10.1006/viro.1996.0358; Odell M, 2003, NUCLEIC ACIDS RES, V31, P5090, DOI 10.1093/nar/gkg665; PARK UE, 1989, J BACTERIOL, V171, P2173, DOI 10.1128/jb.171.4.2173-2180.1989; Petit MA, 2000, NUCLEIC ACIDS RES, V28, P4642, DOI 10.1093/nar/28.23.4642; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P727, DOI 10.1093/nar/25.4.727; Shuman S, 1995, BIOCHEMISTRY-US, V34, P16138, DOI 10.1021/bi00049a029; SHUMAN S, 1995, VIROLOGY, V211, P73, DOI 10.1006/viro.1995.1380; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2000, NUCLEIC ACIDS RES, V28, P2221, DOI 10.1093/nar/28.11.2221; Sriskanda V, 2001, NUCLEIC ACIDS RES, V29, P4930, DOI 10.1093/nar/29.24.4930; Sriskanda V, 2001, J BIOL CHEM, V276, P36100, DOI 10.1074/jbc.M105643200; SRISKANDA V, 2002, J BIOL CHEM, V277, P9685; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Weller GR, 2001, FEBS LETT, V505, P340, DOI 10.1016/S0014-5793(01)02831-9; Wilkinson A, 2003, PROTEINS, V51, P321, DOI 10.1002/prot.10361; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365	41	113	124	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20594	20606		10.1074/jbc.M401841200	http://dx.doi.org/10.1074/jbc.M401841200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985346	hybrid			2022-12-27	WOS:000221273800008
J	Guffanti, E; Corradini, R; Ottonello, S; Dieci, G				Guffanti, E; Corradini, R; Ottonello, S; Dieci, G			Functional dissection of RNA polymerase III termination using a peptide nucleic acid as a transcriptional roadblock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; CHAIN ELONGATION; ESCHERICHIA-COLI; MECHANISM; RELEASE; RECOGNITION; COMPLEXES; SUBUNIT; MODEL; GENES	We have shown previously that a T-10 peptide nucleic acid (PNA) bound to the transcriptional terminator of a Saccharomyces cerevisiae tDNA(IIe)(TAT) gene arrests elongating yeast RNA polymerase (pol) III at a position that precedes by 20 bp the upstream end of the PNA roadblock (Dieci, G., Corradini, R., Sforza, S., Marchelli, R., and Ottonello, S. (2001) J. Biol. Chem. 276, 5720-5725). Here, a PNA-binding cassette was placed at various distances downstream of a functional tDNA(IIe) transcriptional terminator (T-6) that is not bound by the T-10 PNA, and the effect of the PNA roadblock on RNA 3'-end formation, transcript release, and transcription reinitiation was examined. With a PNA roadblock placed as close as 5 bp downstream of the T-6 terminator, pol III could still reach the termination site and complete pretRNA synthesis, implying that the catalytic site-to-front edge (C-F) distance of the polymerase can shorten by > 10 bp upon recognition of the terminator element. In addition, transcripts synthesized by a PNA-roadblocked terminating pol III were found to be released from transcription complexes. Interestingly, however, the same roadblock dramatically reduced the rate of transcription reinitiation. Also, when placed 5 bp downstream of a mutationally inactivated terminator element (T(3)GT(2)), the PNA roadblock restored transcription termination, thus indicating that the inactivated terminator is compromised in its ability to cause pol III pausing, but can still induce C-F distance shortening and transcript release. The latter two activities were found to be further impaired in variants of the inactivated terminator bearing fewer than three consecutive T residues (T(2)G(2)T(2) and TG(2)TGT). The data indicate that RNA polymerase pausing, C-F distance shortening, and transcript release are functionally distinguishable features of the termination process and point to the RNA release propensity of pol III as a major determinant of its remarkably high termination efficiency.	Univ Parma, Dipartmento Biochim & Biol Mol, I-43100 Parma, Italy; Univ Parma, Dipartimento Chim Organ & Ind, I-43100 Parma, Italy	University of Parma; University of Parma	Dieci, G (corresponding author), Univ Parma, Dipartmento Biochim & Biol Mol, I-43100 Parma, Italy.	giorgio.dieci@unipr.it	Corradini, Roberto/K-4791-2015; Dieci, Giorgio/B-3434-2012	Corradini, Roberto/0000-0002-8026-0923; Dieci, Giorgio/0000-0002-8792-3961				Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; Bobkova EV, 1997, J BIOL CHEM, V272, P22832, DOI 10.1074/jbc.272.36.22832; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; Dieci G, 2003, TRENDS BIOCHEM SCI, V28, P202, DOI 10.1016/S0968-0004(03)00054-9; Dieci G, 2001, J BIOL CHEM, V276, P5720, DOI 10.1074/jbc.M009367200; Epshtein V, 2003, EMBO J, V22, P4719, DOI 10.1093/emboj/cdg452; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; Gottesfeld JM, 2002, J MOL BIOL, V321, P249, DOI 10.1016/S0022-2836(02)00598-3; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; JEONG SW, 1995, MOL CELL BIOL, V15, P5929; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; Komissarova N, 2002, MOL CELL, V10, P1151, DOI 10.1016/S1097-2765(02)00738-4; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LANG WH, 1994, CELL, V79, P527, DOI 10.1016/0092-8674(94)90261-5; Mason SW, 1997, EMBO J, V16, P163, DOI 10.1093/emboj/16.1.163; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; NIELSEN PE, 1994, GENE, V149, P139, DOI 10.1016/0378-1119(94)90422-7; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Reeder RH, 1997, TRENDS BIOCHEM SCI, V22, P473, DOI 10.1016/S0968-0004(97)01133-X; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; SYROID DE, 1994, J MOL BIOL, V244, P482, DOI 10.1006/jmbi.1994.1747; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; von Hippel PH, 2002, BIOPHYS CHEM, V101, P401, DOI 10.1016/S0301-4622(02)00160-6; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611	39	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20708	20716		10.1074/jbc.M311295200	http://dx.doi.org/10.1074/jbc.M311295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14970213	hybrid			2022-12-27	WOS:000221273800022
J	Kamada, A; Nagaya, H; Tamura, T; Kinjo, M; Jin, HY; Yamashita, T; Jimbow, K; Kanoh, H; Wada, I				Kamada, A; Nagaya, H; Tamura, T; Kinjo, M; Jin, HY; Yamashita, T; Jimbow, K; Kanoh, H; Wada, I			Regulation of immature protein dynamics in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; STOMATITIS-VIRUS-G; INTRACELLULAR-TRANSPORT; SECRETORY PATHWAY; DI-LEUCINE; PHOTOBLEACHING RECOVERY; HUMAN TYROSINASE; MELANOMA-CELLS; IN-VIVO; ER	The quality of nascent protein folding in vivo is influenced by the microdynamics of the proteins. Excessive collisions between proteins may lead to terminal misfolding, and the frequency of protein interactions with molecular chaperones determines their folding rates. However, it is unclear how immature protein dynamics are regulated. In this study, we analyzed the diffusion of immature tyrosinase in the endoplasmic reticulum (ER) of non-pigmented cells by taking advantage of the thermal sensitivity of the tyrosinase. The diffusion of tyrosinase tagged with yellow fluorescence protein (YFP) in living cells was directly measured using fluorescent correlation spectroscopy. The diffusion of folded tyrosinase in the ER of cells treated with brefeldin A, as measured by fluorescent correlation spectroscopy, was critically affected by the expression level of tyrosinase-YFP. Under defined conditions in which random diffusional motion of folded protein was allowed, we found that the millisecond-order diffusion rate observed for folded tyrosinase almost disappeared for the misfolded molecules synthesized at a nonpermissive high temperature. This was not because of enhanced aggregation at the high temperature, as terminally misfolded tyrosinase synthesized in the absence of calnexin interactions showed comparable, albeit slightly slower, diffusion. Yet, the thermally misfolded tyrosinase was not immobilized when measured by fluorescence recovery after photobleaching. In contrast, terminally misfolded tyrosinase synthesized in cells in which alpha-glucosidases were inhibited showed extensive immobilization. Hence, we suggest that the ER represses random fluctuations of immature tyrosinase molecules while preventing their immobilization.	Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan; Hokkaido Univ, Res Inst Elect Sci, Sapporo, Hokkaido, Japan; JST, Core Res Evolut Sci & Technol, Osaka, Japan; Sapporo Med Univ, Sch Med, Dept Dermatol, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 0608556, Japan	Fukushima Medical University; Hokkaido University; Japan Science & Technology Agency (JST); Sapporo Medical University; Sapporo Medical University	Wada, I (corresponding author), Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan.	iwada@fmu.ac.jp	Kinjo, Masataka/F-5267-2011	Kinjo, Masataka/0000-0001-8889-8369; Tamura, Taku/0000-0001-6074-9273; Wada, Ikuo/0000-0001-5668-6994				Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Benham AM, 2000, CRIT REV BIOCHEM MOL, V35, P433, DOI 10.1080/10409230091169258; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; BOSE S, 1994, BIOCHEM J, V300, P865, DOI 10.1042/bj3000865; Braakman I, 2001, EMBO REP, V2, P666, DOI 10.1093/embo-reports/kve162; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Calvo PA, 1999, J BIOL CHEM, V274, P12780, DOI 10.1074/jbc.274.18.12780; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; Elson EL, 2001, TRAFFIC, V2, P789, DOI 10.1034/j.1600-0854.2001.21107.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Foldes-Papp Z, 2001, P NATL ACAD SCI USA, V98, P11509, DOI 10.1073/pnas.181337998; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; Hendershot LM, 2000, NAT CELL BIOL, V2, pE105, DOI 10.1038/35014100; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; Hirosaki K, 2002, J INVEST DERMATOL, V119, P475, DOI 10.1046/j.1523-1747.2002.01832.x; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Jarosch E, 2002, TRAFFIC, V3, P530, DOI 10.1034/j.1600-0854.2002.30803.x; Jimbow K, 2000, PIGM CELL RES, V13, P222, DOI 10.1034/j.1600-0749.2000.130403.x; Kohler RH, 2000, J CELL SCI, V113, P3921; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Larson DR, 2003, J CELL BIOL, V162, P1233, DOI 10.1083/jcb.200303200; Lord JM, 2002, CURR BIOL, V12, pR182, DOI 10.1016/S0960-9822(02)00738-8; Lukacs GL, 2000, J BIOL CHEM, V275, P1625, DOI 10.1074/jbc.275.3.1625; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Misteli T, 2001, J CELL BIOL, V155, P181, DOI 10.1083/jcb.200108110; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Mori K, 2003, TRAFFIC, V4, P519, DOI 10.1034/j.1600-0854.2003.00112.x; Nagaya H, 2002, MOL BIOL CELL, V13, P302, DOI 10.1091/mbc.01-05-0255; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Phair RD, 2001, NAT REV MOL CELL BIO, V2, P898, DOI 10.1038/35103000; Rigler R., 2001, FLUORESCENCE CORRELA; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; Simmen T, 1999, J CELL SCI, V112, P45; Spector DL., 1997, CELLS LAB MANUAL, V2; SPRITZ RA, 1994, ADV HUM GENET, V22, P1; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Terada S, 2000, CELL, V103, P141, DOI 10.1016/S0092-8674(00)00094-5; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Toyofuku K, 2001, BIOCHEM J, V355, P259, DOI 10.1042/0264-6021:3550259; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193; Widengren J, 1998, CELL MOL BIOL, V44, P857	60	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21533	21542		10.1074/jbc.M401403200	http://dx.doi.org/10.1074/jbc.M401403200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14976197	hybrid			2022-12-27	WOS:000221273800119
J	McConkey, M; Gillin, H; Webster, CRL; Anwer, MS				McConkey, M; Gillin, H; Webster, CRL; Anwer, MS			Cross-talk between protein kinases C zeta and B in cyclic AMP-mediated sodium taurocholate co-transporting polypeptide translocation in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; 3-KINASE LIPID PRODUCTS; BILE-ACID UPTAKE; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; NA+/TAUROCHOLATE COTRANSPORT; GLUT4 TRANSLOCATION; SIGNALING PATHWAY	Cyclic AMP stimulates taurocholate (TC) uptake and sodium taurocholate co-transporting polypeptide (Ntcp) translocation in hepatocytes via the phosphoinositide-3 kinase (PI3K) signaling pathway. The aim of the present study was to determine whether protein kinase (PK) Czeta, one of the downstream mediators of the PI3K signaling pathway, is involved in cAMP-mediated stimulation of TC uptake. Studies were conducted in isolated rat hepatocytes and in HuH-7 cells stably transfected with rat liver Ntcp (HuH-Ntcp cells). Studies in hepatocytes showed that cAMP activates PKCzeta in a PI3K-dependent manner without inducing translocation of PKCzeta to the plasma membrane. Inhibition of cAMP-induced PKCzeta activity by myristoylated PKC (zeta/lambda) pseudosubstrate, a specific inhibitor of PKCzeta, and Go6850, a PKC inhibitor, resulted in inhibition of cAMP-induced increases in TC uptake and Ntcp translocation. Studies in HuH-Ntcp cells showed that inhibition of cAMP-induced PKCzeta activation by dominant-negative (DN) PKCzeta resulted in inhibition of cAMP-induced increases in TC uptake and Ntcp translocation. DN PKCzeta also inhibited wild-type PKCzeta-induced increases in PKCzeta activity, TC uptake, and Ntcp translocation. Myristoylated PKC (zeta/lambda) pseudosubstrate and DN PKCzeta also inhibited cAMP-induced activation of PKB in hepatocytes and HuH-Ntcp cells, respectively. Neither DN PKB nor constitutively active PKB affected cAMP-induced activation of PKCzeta, and wild-type PKCzeta did not activate PKB. Taken together, these results suggest that cAMP-induced activation of PKB is dependent on cAMP-induced stimulation of PKCzeta. It is proposed that cAMP-induced Ntcp translocation involves the activation of the PI3K/PKCzeta signaling pathway followed by the activation of the PI3K/PKB signaling pathway.	Tufts Univ, Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01536 USA; Tufts Univ, Sch Vet Med, Dept Clin Sci, North Grafton, MA 01536 USA	Tufts University; Tufts University	Anwer, MS (corresponding author), 200 Westboro Rd, North Grafton, MA 01536 USA.	sawkat.anwer@tufts.edu			NIDDK NIH HHS [DK 33436, DK 02721] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002721, R01DK033436] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; Anwer MS, 1998, CURR OPIN GASTROEN, V14, P182, DOI 10.1097/00001574-199805000-00002; ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; Beuers U, 2003, J BIOL CHEM, V278, P17810, DOI 10.1074/jbc.M209898200; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calcerrada MC, 2002, FEBS LETT, V514, P361, DOI 10.1016/S0014-5793(02)02401-8; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Dranoff JA, 1999, HEPATOLOGY, V30, P223, DOI 10.1002/hep.510300136; Elmendorf JS, 2002, J MEMBRANE BIOL, V190, P167, DOI 10.1007/s00232-002-1035-3; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Feranchak AP, 1999, J BIOL CHEM, V274, P30979, DOI 10.1074/jbc.274.43.30979; HAYAKAWA T, 1990, AM J PHYSIOL, V259, pG727, DOI 10.1152/ajpgi.1990.259.5.G727; Hernandez R, 2001, FEBS LETT, V494, P225, DOI 10.1016/S0014-5793(01)02353-5; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P10351, DOI 10.1021/bi026065r; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mao ML, 2000, BIOCHEM J, V352, P475, DOI 10.1042/0264-6021:3520475; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meier PJ, 2000, NEWS PHYSIOL SCI, V15, P89; Miguel BG, 2000, BIOCHEM BIOPH RES CO, V274, P596, DOI 10.1006/bbrc.2000.3194; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; Mukhopadhayay S, 1997, AM J PHYSIOL-GASTR L, V273, pG842, DOI 10.1152/ajpgi.1997.273.4.G842; Mukhopadhyay S, 1998, HEPATOLOGY, V28, P1629, DOI 10.1002/hep.510280624; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sauvage M, 2000, EUR J BIOCHEM, V267, P955, DOI 10.1046/j.1432-1327.2000.01084.x; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Trauner M, 1999, J HEPATOL, V31, P165, DOI 10.1016/S0168-8278(99)80179-2; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Webster CRL, 1999, AM J PHYSIOL-GASTR L, V277, pG1165, DOI 10.1152/ajpgi.1999.277.6.G1165; Webster CRL, 2002, J BIOL CHEM, V277, P28578, DOI 10.1074/jbc.M201937200; Webster CRL, 2002, AM J PHYSIOL-GASTR L, V283, pG727, DOI 10.1152/ajpgi.00410.2001; Webster CRL, 2000, J BIOL CHEM, V275, P29754, DOI 10.1074/jbc.M002831200	51	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20882	20888		10.1074/jbc.M309988200	http://dx.doi.org/10.1074/jbc.M309988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15007074	hybrid			2022-12-27	WOS:000221273800040
J	Pires, VMR; Henshaw, JL; Prates, JAM; Bolam, DN; Ferreira, LMA; Fontes, CMGA; Henrissat, B; Planas, A; Gilbert, HJ; Czjzek, M				Pires, VMR; Henshaw, JL; Prates, JAM; Bolam, DN; Ferreira, LMA; Fontes, CMGA; Henrissat, B; Planas, A; Gilbert, HJ; Czjzek, M			The crystal structure of the family 6 carbohydrate binding module from Cellvibrio mixtus endoglucanase 5A in complex with oligosaccharides reveals two distinct binding sites with different ligand Specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAN-BINDING; DOMAINS; RECOGNITION; XYLANASE; CENC	Glycoside hydrolases that release fixed carbon from the plant cell wall are of considerable biological and industrial importance. These hydrolases contain noncatalytic carbohydrate binding modules (CBMs) that, by bringing the appended catalytic domain into intimate association with its insoluble substrate, greatly potentiate catalysis. Family 6 CBMs (CBM6) are highly unusual because they contain two distinct clefts ( cleft A and cleft B) that potentially can function as binding sites. Henshaw et al. ( Henshaw, J., Bolam, D. N., Pires, V. M. R., Czjzek, M., Henrissat, B., Ferreira, L. M. A., Fontes, C. M. G. A., and Gilbert, H. J. (2003) J. Biol. Chem. 279, 21552 - 21559) show that CmCBM6 contains two binding sites that display both similarities and differences in their ligand specificity. Here we report the crystal structure of CmCBM6 in complex with a variety of ligands that reveals the structural basis for the ligand specificity displayed by this protein. In cleft A the two faces of the terminal sugars of beta-linked oligosaccharides stack against Trp-92 and Tyr-33, whereas the rest of the binding cleft is blocked by Glu-20 and Thr-23, residues that are not present in CBM6 proteins that bind to the internal regions of polysaccharides in cleft A. Cleft B is solvent-exposed and, therefore, able to bind ligands because the loop, which occludes this region in other CBM6 proteins, is much shorter and flexible ( lacks a conserved proline) in CmCBM6. Subsites 2 and 3 of cleft B accommodate cellobiose (Glc-beta-1,4-Glc), subsite 4 will bind only to a beta-1,3-linked glucose, whereas subsite 1 can interact with either a beta-1,3- or beta-1,4-linked glucose. These different specificities of the subsites explain how cleft B can accommodate beta-1,4-beta- 1,3- or beta-1,3-beta-1,4-linked gluco-configured ligands.	CNRS, Unite Mixte Rech 6098, Lab Architecture & Fonct Macromol Biol, F-13402 Marseille 20, France; Fac Med Vet, CIISA, P-1300477 Lisbon, Portugal; Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; Univ Ramon Llull, Inst Quim Sarria, Biochem Lab, Barcelona 08017, Spain	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Universidade de Lisboa; Newcastle University - UK; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Universitat Ramon Llull; Institut Quimic de Sarria	Czjzek, M (corresponding author), CNRS, Unite Mixte Rech 6098, Lab Architecture & Fonct Macromol Biol, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	czjzek@afmb.cnrs-mrs.fr	Pires, Virginia/J-4799-2013; Henrissat, Bernard/J-2475-2012; Prates, José A M/K-9934-2013; PLANAS, ANTONI/I-4803-2015	Pires, Virginia/0000-0003-1307-3797; Henrissat, Bernard/0000-0002-3434-8588; Prates, José A M/0000-0003-1032-5987; PLANAS, ANTONI/0000-0001-7073-3320; Fontes, Carlos/0000-0002-1219-9753; Ferreira, Luis/0000-0002-3543-9166; Bolam, David/0000-0003-0314-3122				Abou Hachem M, 2000, BIOCHEM J, V345, P53, DOI 10.1042/0264-6021:3450053; ATKINS EDT, 1992, PROGR BIOTECHNOL, V7, P39; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boraston AB, 2003, J MOL BIOL, V327, P659, DOI 10.1016/S0022-2836(03)00152-9; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P14679, DOI 10.1021/bi015760g; Brett CT, 1996, PHYSL BIOCH PLANT CE; Brun E, 2000, BIOCHEMISTRY-US, V39, P2445, DOI 10.1021/bi992079u; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; GILBERT HJ, 2001, CARBOHYDRATE BIOENGI; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Henrissat B, 2000, PLANT PHYSIOL, V124, P1515, DOI 10.1104/pp.124.4.1515; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; Johnson PE, 1999, J MOL BIOL, V287, P609, DOI 10.1006/jmbi.1999.2627; Lehtio J, 2003, P NATL ACAD SCI USA, V100, P484, DOI 10.1073/pnas.212651999; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Pell G, 2004, J BIOL CHEM, V279, P11777, DOI 10.1074/jbc.M311947200; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; ROUSSEL A, 1991, SILICON GRAPHICS GEO, V88; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; Tomme P, 1996, BIOCHEMISTRY-US, V35, P13885, DOI 10.1021/bi961185i; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Zverlov VV, 2001, MICROBIOL-SGM, V147, P621, DOI 10.1099/00221287-147-3-621	29	61	63	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21560	21568		10.1074/jbc.M401599200	http://dx.doi.org/10.1074/jbc.M401599200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010454	hybrid			2022-12-27	WOS:000221273800122
J	Wallis, TP; Huang, CY; Nimkar, SB; Young, PR; Gorman, JJ				Wallis, TP; Huang, CY; Nimkar, SB; Young, PR; Gorman, JJ			Determination of the disulfide bond arrangement of dengue virus NS1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL GLYCOPROTEIN NS1; ASSISTED LASER-DESORPTION; IONIZATION MASS-SPECTROMETRY; TICK-BORNE ENCEPHALITIS; GLYCOSYLATION SITES; NUCLEOTIDE-SEQUENCE; PEPTIDE-FRAGMENTS; MOLECULAR-BIOLOGY; LINKED PEPTIDES; RNA REPLICATION	The 12 half-cystines of NS1 proteins are absolutely conserved among flaviviruses, suggesting their importance to the structure and function of these proteins. In the present study, peptides from recombinant Dengue-2 virus NS1 were produced by tryptic digestion in 100% (H2O)-O-16, peptic digestion in 50% (H2O)-O-18, thermolytic digestion in 50% (H2O)-O-18, or combinations of these digestion conditions. Peptides were separated by size exclusion and/or reverse phase high performance liquid chromatography and examined by matrix-assisted laser desorption ionization-time of flight mass spectrometry, matrix-assisted laser desorption ionization post-source decay, and matrix-assisted laser desorption ionization tandem mass spectrometry. Where digests were performed in 50% (H2O)-O-18, isotope profiles of peptide ions aided in the identification and characterization of disulfide-linked peptides. It was possible to produce two-chain peptides containing C1/C2, C3/C4, C5/C6, and C7/C12 linkages as revealed by comparison of the peptide masses before and after reduction and by post-source decay analysis. However, the remaining four half-cystines (C8, C9, C10, and C11) were located in a three-chain peptide of which one chain contained adjacent half-cystines (C9 and C10). The linkages of C8/C10 and C9/C11 were determined by tandem mass spectrometry of an in-source decay fragment ion containing C9, C10, and C11. This disulfide bond arrangement provides the basis for further refinement of flavivirus NS1 protein structural models.	Univ Queensland, Inst Mol Biosci, Mol & Cellular Proteom Lab, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Microbiol & Parasitol, St Lucia, Qld 4072, Australia; Appl Biosyst Inc, Foster City, CA 94404 USA	University of Queensland; University of Queensland; Thermo Fisher Scientific; Applied Biosystems	Gorman, JJ (corresponding author), Univ Queensland, Inst Mol Biosci, Mol & Cellular Proteom Lab, St Lucia, Qld 4072, Australia.	j.gorman@imb.uq.edu.au	Young, Paul R/A-6176-2010	Young, Paul R/0000-0002-2040-5190				BEAN MF, 1992, ANAL BIOCHEM, V201, P216, DOI 10.1016/0003-2697(92)90331-Z; Blitvich BJ, 2001, J GEN VIROL, V82, P2251, DOI 10.1099/0022-1317-82-9-2251; CAUCHI MR, 1991, VIROLOGY, V180, P659, DOI 10.1016/0042-6822(91)90079-Q; Clarke T, 2002, NATURE, V416, P672, DOI 10.1038/416672a; CRIMMINS DL, 1995, ANAL BIOCHEM, V226, P355, DOI 10.1006/abio.1995.1236; CROOKS AJ, 1994, J GEN VIROL, V75, P3453, DOI 10.1099/0022-1317-75-12-3453; DEUBEL V, 1988, VIROLOGY, V165, P234, DOI 10.1016/0042-6822(88)90677-0; FALCONAR AKI, 1991, J GEN VIROL, V72, P961, DOI 10.1099/0022-1317-72-4-961; Flamand M, 1999, J VIROL, V73, P6104, DOI 10.1128/JVI.73.7.6104-6110.1999; GIBSON CA, 1988, VACCINE, V6, P7, DOI 10.1016/0264-410X(88)90004-7; Gorman JJ, 1996, RAPID COMMUN MASS SP, V10, P529, DOI 10.1002/(SICI)1097-0231(19960331)10:5<529::AID-RCM522>3.0.CO;2-9; Gorman JJ, 2002, MASS SPECTROM REV, V21, P183, DOI 10.1002/mas.10025; Gorman JJ, 1997, PROTEIN SCI, V6, P1308, DOI 10.1002/pro.5560060619; Gubler DJ, 1999, ENCY VIROLOGY, P375; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; HALL RA, 1995, J VIROL METHODS, V51, P201, DOI 10.1016/0166-0934(94)00105-P; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HANIU M, 1994, INT J PEPT PROT RES, V43, P81; Jacobs MG, 2000, FASEB J, V14, P1603, DOI 10.1096/fj.14.11.1603; Jacobs MG, 1998, CURR OPIN INFECT DIS, V11, P319, DOI 10.1097/00001432-199806000-00009; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Lindenbach BD, 1999, J VIROL, V73, P4611, DOI 10.1128/JVI.73.6.4611-4621.1999; Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997; Lopaticki S, 1998, J MASS SPECTROM, V33, P950, DOI 10.1002/(SICI)1096-9888(199810)33:10<950::AID-JMS704>3.3.CO;2-1; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; MACKOW E, 1987, VIROLOGY, V159, P217, DOI 10.1016/0042-6822(87)90458-2; MORRIS HR, 1985, BIOCHEM BIOPH RES CO, V126, P1122, DOI 10.1016/0006-291X(85)90302-X; Muylaert IR, 1997, J VIROL, V71, P291, DOI 10.1128/JVI.71.1.291-298.1997; Muylaert IR, 1996, VIROLOGY, V222, P159, DOI 10.1006/viro.1996.0406; PARRISH CR, 1991, ARCH VIROL, V117, P279, DOI 10.1007/BF01310771; PATTERSON SD, 1994, ANAL CHEM, V66, P3727, DOI 10.1021/ac00093a030; Pitt JJ, 2000, J BIOL CHEM, V275, P6469, DOI 10.1074/jbc.275.9.6469; PLETNEV AG, 1993, J VIROL, V67, P4956, DOI 10.1128/JVI.67.8.4956-4963.1993; Pryor MJ, 1998, J GEN VIROL, V79, P2631, DOI 10.1099/0022-1317-79-11-2631; PRYOR MJ, 1994, J GEN VIROL, V75, P1183, DOI 10.1099/0022-1317-75-5-1183; PRYOR MJ, 1993, VIROLOGY, V194, P769, DOI 10.1006/viro.1993.1318; RICE CM, 1996, FIELDS VIROLOGY, P931; Rudd PM, 2000, BIOCHEMISTRY-US, V39, P1596, DOI 10.1021/bi9918285; Ruggli N, 1999, ADV VIRUS RES, V53, P183, DOI 10.1016/S0065-3527(08)60348-6; RYLE AP, 1955, BIOCHEM J, V60, P535, DOI 10.1042/bj0600535; SCHLESINGER JJ, 1990, J GEN VIROL, V71, P593, DOI 10.1099/0022-1317-71-3-593; SCHLESINGER S, 1990, P697; Schnaible V, 2002, ANAL CHEM, V74, P4980, DOI 10.1021/ac025807j; Schnolzer M, 1996, ELECTROPHORESIS, V17, P945, DOI 10.1002/elps.1150170517; SPEIGHT G, 1988, J GEN VIROL, V69, P23, DOI 10.1099/0022-1317-69-1-23; Wallis TP, 2001, PROTEIN SCI, V10, P2251, DOI 10.1110/ps.15401; WANG P, 2001, J BIOCHEM MOL BIOL, V17, P148; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; WINKLER G, 1988, VIROLOGY, V162, P187, DOI 10.1016/0042-6822(88)90408-4; WINKLER G, 1989, VIROLOGY, V171, P302, DOI 10.1016/0042-6822(89)90544-8; WRIGHT PJ, 1989, VIROLOGY, V171, P61, DOI 10.1016/0042-6822(89)90510-2; Yang Y, 1998, J AM CHEM SOC, V120, P5834, DOI 10.1021/ja9736018; YAZDANPARAST R, 1987, J BIOL CHEM, V262, P2507; YAZDANPARAST R, 1986, ANAL BIOCHEM, V153, P348, DOI 10.1016/0003-2697(86)90102-8; ZHOU J, 1993, INT J MASS SPECTROM, V126, P115, DOI 10.1016/0168-1176(93)80076-Q	56	52	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20729	20741		10.1074/jbc.M312907200	http://dx.doi.org/10.1074/jbc.M312907200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14981082	hybrid			2022-12-27	WOS:000221273800025
J	Drew, DR; O'Donnell, RA; Smith, BJ; Crabb, BS				Drew, DR; O'Donnell, RA; Smith, BJ; Crabb, BS			A common cross-species function for the double epidermal growth factor-like modules of the highly divergent Plasmodium surface proteins MSP-1 and MSP-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL FRAGMENT; MALARIA VACCINE CANDIDATE; FACTOR-LIKE DOMAINS; FALCIPARUM MALARIA; HUMAN ERYTHROCYTES; CRYSTAL-STRUCTURE; RODENT MALARIA; INVASION; ANTIBODIES; ANTIGEN	An understanding of structural and functional constraints on the C-terminal double epidermal growth factor (EGF)-like modules of merozoite surface protein (MSP)-1 and related proteins is of importance to the development of these molecules as malaria vaccines and drug targets. Using allelic replacement, we show that Plasmodium falciparum parasites can invade erythrocytes and grow efficiently in the absence of an MSP-1 protein with authentic MSP-1 EGF domains. In this mutant parasite line, the MSP-1 EGFs were replaced by the corresponding double EGF module from P. berghei MSP-8, the sequence of which shares only low identity with its MSP-1 counterpart. Hence, the C-terminal EGF domains of at least some Plasmodium surface proteins appear to perform the same function in asexual blood-stage development. Mapping the surface location of the few residues that are common to these functionally complementary EGF modules revealed the presence of a highly conserved pocket of potential functional significance. In contrast to MSP-8, an even more divergent double EGF module, that from the sexual stage protein PbS25, was not capable of complementing MSP-1 EGF function. More surprisingly, two chimeric double EGF modules comprising hybrids of the EGF domains from P. falciparum and P. chabaudi MSP-1 were also not capable of replacing the P. falciparum MSP-1 EGF module. Together, these data suggest that although the MSP-1 EGFs can accommodate extensive sequence diversity, there appear to be constraints that may restrict the simple accumulation of point mutations in the face of immune pressure in the field.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Crabb, BS (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	crabb@wehi.edu.au	Smith, Brian J/F-8282-2011; Crabb, Brendan/F-5287-2013	Smith, Brian J/0000-0003-0498-1910; 				Ayala FJ, 2000, GENE, V261, P161, DOI 10.1016/S0378-1119(00)00478-9; Baldi DL, 2000, EMBO J, V19, P2435, DOI 10.1093/emboj/19.11.2435; Black CG, 2001, MOL BIOCHEM PARASIT, V114, P217, DOI 10.1016/S0166-6851(01)00265-1; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P35, DOI 10.1016/0166-6851(91)90128-S; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; Burns JM, 2000, INFECT IMMUN, V68, P6189, DOI 10.1128/IAI.68.11.6189-6195.2000; Chitarra V, 1999, MOL CELL, V3, P457, DOI 10.1016/S1097-2765(00)80473-6; COOPER JA, 1992, MOL BIOCHEM PARASIT, V51, P301, DOI 10.1016/0166-6851(92)90080-4; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; DALY TM, 1995, J IMMUNOL, V155, P236; de Koning-Ward TF, 2003, J EXP MED, V198, P869, DOI 10.1084/jem.20030085; DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753; DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1; Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096; Egan AF, 1996, J INFECT DIS, V173, P765, DOI 10.1093/infdis/173.3.765; Egan AF, 1999, PARASITE IMMUNOL, V21, P133, DOI 10.1046/j.1365-3024.1999.00209.x; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Garman SC, 2003, J BIOL CHEM, V278, P7264, DOI 10.1074/jbc.M210716200; Goel VK, 2003, P NATL ACAD SCI USA, V100, P5164, DOI 10.1073/pnas.0834959100; Hirunpetcharat C, 1999, J IMMUNOL, V162, P7309; Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400; KANG Y, 1995, MOL BIOCHEM PARASIT, V73, P103, DOI 10.1016/0166-6851(95)00102-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LUETHY R, 1992, Nature (London), V356, P83; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; O'Donnell RA, 2001, NUCLEIC ACIDS RES, V29, P716, DOI 10.1093/nar/29.3.716; Pizarro JC, 2003, J MOL BIOL, V328, P1091, DOI 10.1016/S0022-2836(03)00376-0; Qari SH, 1998, MOL BIOCHEM PARASIT, V92, P241, DOI 10.1016/S0166-6851(98)00010-3; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509; Rich SM, 2000, P NATL ACAD SCI USA, V97, P6994, DOI 10.1073/pnas.97.13.6994; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saul A, 2001, J EXP MED, V193, pF51, DOI 10.1084/jem.193.12.F51; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stowers AW, 2001, INFECT IMMUN, V69, P1536, DOI 10.1128/IAI.69.3.1536-1546.2001; Tomas AM, 2001, EMBO J, V20, P3975, DOI 10.1093/emboj/20.15.3975; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Williamson DH, 2002, NUCLEIC ACIDS RES, V30, P726, DOI 10.1093/nar/30.3.726	44	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20147	20153		10.1074/jbc.M401114200	http://dx.doi.org/10.1074/jbc.M401114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14976193	hybrid			2022-12-27	WOS:000221164500091
J	Isaji, T; Gu, JG; Nishiuchi, R; Zhao, YY; Takahashi, M; Miyoshi, E; Honke, K; Sekiguchi, K; Taniguchi, N				Isaji, T; Gu, JG; Nishiuchi, R; Zhao, YY; Takahashi, M; Miyoshi, E; Honke, K; Sekiguchi, K; Taniguchi, N			Introduction of bisecting GlcNAc into integrin alpha(5)beta(1) reduces ligand binding and down-regulates cell adhesion and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; EPIDERMAL-GROWTH-FACTOR; BETA-1-6 BRANCHED OLIGOSACCHARIDES; III GNT-III; TYROSINE PHOSPHORYLATION; GENE TRANSFECTION; LUNG METASTASIS; CDNA CLONING; PC12 CELLS; FIBRONECTIN	The enzyme beta1,4-N-acetylglucosaminyltransferase III (GnT-III) catalyzes the addition of a bisecting GlcNAc residue to glycoproteins, resulting in a modulation in biological function. Our previous studies showed that the transfection of the GnT-III gene into B16 melanoma cells results in a suppression of invasive ability and lung colonization. The suppression has been postulated to be due to an increased level of E-cadherin expression on the cell surface, which in turn leads to the up-regulation of cell-cell adhesion. In this study, we report on the effects of overexpression of GnT-III on cell-matrix adhesion. The overexpression of GnT-III, but not that of an enzymatic inactive GnT-III (D323A), inhibits cell spreading and migration on fibronectin, a specific ligand for integrin alpha(5)beta(1), and the focal adhesion kinase phosphorylation. E-4-PHA lectin blot analyses showed that the levels of bisecting GlcNAc structures on the integrin alpha(5) subunit as well as alpha(2) and alpha(3) subunits immunoprecipitated from GnT-III transfectants were substantially increased. In addition, the affinity of the binding of integrin alpha(5)beta(1) to fibronectin was significantly reduced by the introduction of the bisecting GlcNAc, to the alpha(5) subunit. These findings suggest that the modification of N-glycan of integrin by GnT-III inhibits its ligand binding ability, subsequently leading to the down-regulation of integrin-mediated signaling.	Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Div Prot Chem, Suita, Osaka 5650871, Japan; Kochi Univ, Sch Med, Dept Mol Genet, Nanko Ku, Kochi 7838505, Japan	Osaka University; Osaka University; Kochi University	Gu, JG (corresponding author), Osaka Univ, Grad Sch Med, Dept Biochem, B1,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	jgu@biochem.med.osaka-u.ac.jp	Gu, Jianguo/ABC-9257-2020; Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016; Isaji, Tomoya/ABC-9285-2021; Takahashi, Motoko/I-3154-2013	Taniguchi, Naoyuki/0000-0001-5889-5968; Takahashi, Motoko/0000-0002-2112-6142				AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; Dennis JW, 2002, BBA-GEN SUBJECTS, V1573, P414, DOI 10.1016/S0304-4165(02)00411-7; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DUNLEVY JR, 1993, J CELL SCI, V105, P489; FERNANDES B, 1991, CANCER RES, V51, P718; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; Gu JG, 2004, GLYCOBIOLOGY, V14, P177, DOI 10.1093/glycob/cwh016; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; Gu JG, 2002, J BIOL CHEM, V277, P19922, DOI 10.1074/jbc.M200383200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Guo HB, 2002, CANCER RES, V62, P6837; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ihara H, 2002, EUR J BIOCHEM, V269, P193, DOI 10.1046/j.0014-2956.2001.02640.x; Ihara S, 2002, J BIOL CHEM, V277, P16960, DOI 10.1074/jbc.M200673200; Ihara Y, 1997, J BIOL CHEM, V272, P9629; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kitada T, 2001, J BIOL CHEM, V276, P475, DOI 10.1074/jbc.M006689200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LU Y, 1994, CLIN EXP METASTAS, V12, P47, DOI 10.1007/BF01784333; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; Murata K, 2000, CLIN CANCER RES, V6, P1772; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; Nishiuchi R, 2003, J BIOCHEM, V134, P497, DOI 10.1093/jb/mvg185; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sasai K, 2002, FEBS LETT, V522, P151, DOI 10.1016/S0014-5793(02)02916-2; Sato Y, 2001, J BIOL CHEM, V276, P11956, DOI 10.1074/jbc.M008551200; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seelentag WKF, 1998, CANCER RES, V58, P5559; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	41	141	145	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19747	19754		10.1074/jbc.M311627200	http://dx.doi.org/10.1074/jbc.M311627200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14998999	hybrid, Green Published			2022-12-27	WOS:000221164500045
J	Jiang, BB; Xu, SQ; Hou, XY; Pimentel, DR; Cohen, RA				Jiang, BB; Xu, SQ; Hou, XY; Pimentel, DR; Cohen, RA			Angiotensin II differentially regulates interleukin-1-beta-inducible NO synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) expression - Role of p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; FACTOR-KAPPA-B; ACTIVATED PROTEIN-KINASE; CONVERTING ENZYME; GENE-EXPRESSION; PERSISTENT ACTIVATION; TRANSCRIPTION FACTOR; AT(1) RECEPTOR; ATHEROSCLEROSIS	Angiotensin II is implicated in pathophysiological processes associated with vascular injury and repair, which include regulating the expression of numerous NF-kappaB-dependent genes. The present study examined the effect of angiotensin II on interleukin-1beta-induced NF-kappaB activation and the subsequent expression of inducible NO synthase ( iNOS) and vascular cell adhesion molecule-1 (VCAM-1) in cultured rat vascular smooth muscle cells. Neither NF-kappaB activation nor iNOS or VCAM-1 expression was induced in cells treated with angiotensin II alone. However, when added together with interleukin-1beta, angiotensin II, through activation of the AT(1) receptor, inhibited iNOS expression and enhanced VCAM-1 expression induced by the cytokine. The inhibitory effect of angiotensin II on iNOS expression was associated with a down-regulation of the sustained activation of extracellular signal-regulated kinase (ERK) and NF-kappaB by interleukin-1beta, whereas the effect on VCAM-1 was independent of ERK activation. The effect of angiotensin II on iNOS was abolished by inhibition of p38 mitogen-activated protein kinase ( MAPK) with SB203580, but not by inhibition of PI3 kinase with wortmannin or stress-activated protein kinase/c-Jun NH2-terminal kinase (JNK) with JNK inhibitor II. Thus, angiotensin II, by a mechanism that requires the participation of p38 MAPK, differentially regulates the expression of NF-kappaB-dependent genes in response to interleukin-1beta stimulation by controlling the duration of activation of ERK and NF-kappaB.	Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst,Vasc Biol Unit, Boston, MA 02118 USA	Boston University	Jiang, BB (corresponding author), Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst,Vasc Biol Unit, Boston, MA 02118 USA.	bjiang@bu.edu		/0000-0002-1070-6408; Pimentel, David/0000-0002-0537-7195	NHLBI NIH HHS [HL 55620] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055620] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Badger AM, 1998, J IMMUNOL, V161, P467; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Brasier AR, 2002, ARTERIOSCL THROM VAS, V22, P1257, DOI 10.1161/01.ATV.0000021412.56621.A2; Candido R, 2002, CIRCULATION, V106, P246, DOI 10.1161/01.CIR.0000021122.63813.32; Chen CC, 1999, MOL PHARMACOL, V55, P481; Chen F, 1999, CLIN CHEM, V45, P7; Chen XL, 1998, CIRC RES, V83, P952; Cruzado M, 2002, BIOCELL, V26, P61; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Dzau VJ, 2001, AM J CARDIOL, V88, p1L; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Hu ZW, 2002, J PHARMACOL EXP THER, V303, P563, DOI 10.1124/jpet.102.037705; Huleihel M, 1997, EUR CYTOKINE NETW, V8, P179; Jiang BB, 1999, HYPERTENSION, V34, P574, DOI 10.1161/01.HYP.34.4.574; Jiang BB, 2000, HYPERTENSION, V35, P914, DOI 10.1161/01.HYP.35.4.914; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Jiang BB, 2002, ARTERIOSCL THROM VAS, V22, P1811, DOI 10.1161/01.ATV.0000037679.60584.3F; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; Jin L, 1997, CANCER-AM CANCER SOC, V80, P421, DOI 10.1002/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z; Kim S, 2000, PHARMACOL REV, V52, P11; Kim S, 2002, ARTERIOSCL THROM VAS, V22, P1299, DOI 10.1161/01.ATV.0000026298.00663.58; Kopnisky KL, 2000, J NEUROCHEM, V74, P613, DOI 10.1046/j.1471-4159.2000.740613.x; Kranzhofer R, 1999, ARTERIOSCL THROM VAS, V19, P1623, DOI 10.1161/01.ATV.19.7.1623; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Lonn EM, 2001, CIRCULATION, V103, P919; Lui P, 2004, AM J PHYSIOL-CELL PH, V286, pC145, DOI 10.1152/ajpcell.00233.2003; NAKAYAMA I, 1994, J BIOL CHEM, V269, P11628; Ruiz-Ortega M, 2000, CIRC RES, V86, P1266, DOI 10.1161/01.RES.86.12.1266; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sasaki A, 1998, J NEUROPATH EXP NEUR, V57, P653, DOI 10.1097/00005072-199807000-00002; Schieffer B, 1996, J MOL MED-JMM, V74, P85, DOI 10.1007/BF00196783; SILVA JD, 1997, J BIOL CHEM, V272, P28373; Tummala PE, 1999, CIRCULATION, V100, P1223, DOI 10.1161/01.CIR.100.11.1223; Zhuo JL, 2002, HYPERTENSION, V39, P634, DOI 10.1161/hy0202.103417	35	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20363	20368		10.1074/jbc.M314172200	http://dx.doi.org/10.1074/jbc.M314172200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15001568	hybrid			2022-12-27	WOS:000221164500114
J	Rubio, LM; Singer, SW; Ludden, PW				Rubio, LM; Singer, SW; Ludden, PW			Purification and characterization of NafY (Apodinitrogenase gamma subunit) from Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; APO-MOFE PROTEIN; CRYSTALLOGRAPHIC STRUCTURE; DINITROGENASE REDUCTASE; KLEBSIELLA-PNEUMONIAE; FEMO-COFACTOR; NIFB COFACTOR; NITROGENASE; BIOSYNTHESIS; MATURATION	The formation of an active dinitrogenase requires the synthesis and the insertion of the iron-molybdenum cofactor (FeMo-co) into a presynthesized apodinitrogenase. In Azotobacter vinelandii, NafY ( also known as gamma protein) has been proposed to be a FeMo-co insertase because of its ability to bind FeMo-co and apodinitrogenase. Here we report the purification and biochemical characterization of NafY and reach the following conclusions. First, NafY is a 26-kDa monomeric protein that binds one molecule of FeMo-co with very high affinity (K-d approximate to 60 nM); second, the NafY-FeMo-co complex exhibits a S = 3/2 EPR signal with features similar to the signals for extracted FeMo-co and the M center of dinitrogenase; third, site-directed mutagenesis of nafY indicates that the His(121) residue of NafY is involved in cofactor binding; and fourth, NafY binding to apodinitrogenase or to FeMo-co does not require the presence of any additional protein. In addition, we have obtained evidence that suggests the ability of NafY to bind NifB-co, an FeS cluster of unknown structure that is a biosynthetic precursor to FeMo-co.	Univ Calif Berkeley, Coll Nat Resources, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Ludden, PW (corresponding author), Univ Calif Berkeley, Coll Nat Resources, Dept Plant & Microbial Biol, 111 Koshland Hall, Berkeley, CA 94720 USA.	pludden@nature.berkeley.edu	Rubio, Luis M./B-5827-2009; Singer, STeven W/I-1851-2014	Rubio, Luis M./0000-0003-1596-2475; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035332, R37GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35332, R37 GM035332-18] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; Allen RM, 1999, J BIOL CHEM, V274, P15869, DOI 10.1074/jbc.274.22.15869; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; Allen RM, 1996, J BIOL CHEM, V271, P4256; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; Dyer DH, 2003, J BIOL CHEM, V278, P39085, DOI 10.1074/jbc.M306214200; George GN, 1996, INORG CHEM, V35, P434, DOI 10.1021/ic950740m; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Magnuson JK, 1997, TETRAHEDRON, V53, P11971, DOI 10.1016/S0040-4020(97)00710-2; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; Rangaraj P, 2001, J BIOL CHEM, V276, P15968, DOI 10.1074/jbc.M100907200; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; Rubio LM, 2002, J BIOL CHEM, V277, P14299, DOI 10.1074/jbc.M107289200; Ruttimann-Johnson C, 1999, J BIOL CHEM, V274, P18087, DOI 10.1074/jbc.274.25.18087; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; Siemann S, 2001, EUR J BIOCHEM, V268, P1940, DOI 10.1046/j.1432-1327.2001.02063.x; Smith J.A., 2000, CURRENT PROTOCOLS MO; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WHITE TC, 1992, J BIOL CHEM, V267, P24007	37	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19739	19746		10.1074/jbc.M400965200	http://dx.doi.org/10.1074/jbc.M400965200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996831	hybrid, Green Accepted			2022-12-27	WOS:000221164500044
J	Stokes, L; Gordon, J; Grafton, G				Stokes, L; Gordon, J; Grafton, G			Non-voltage-gated L-type Ca2+ channels in human T cells - Pharmacology and molecular characterization of the major alpha pore-forming and auxiliary beta-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM-CHANNELS; SKELETAL-MUSCLE; SUBCELLULAR-LOCALIZATION; HUMAN-LYMPHOCYTES; PLASMA-MEMBRANE; CLASS-C; RECEPTOR; INFLUX; IDENTIFICATION; GENE	In T lymphocytes, engagement of the antigen receptor leads to a biphasic Ca2+ flux consisting of a mobilization of Ca2+ from intracellular stores followed by a lower but sustained elevation that is dependent on extracellular Ca2+. The prolonged Ca2+ flux is required for activation of transcription factors and for subsequent activation of the T cell. Ca2+ influx requires as yet unidentified Ca2+ channels, which potentially play a role in T cell activation. Here we present evidence that human T cells express a non-voltage-gated Ca2+ channel related to L-type voltage-gated Ca2+ channels. Drugs that block classical L-type channels inhibited the initial phase of the antigen receptor-induced Ca2+ flux and could also inhibit the sustained phase of the Ca2(+) signal suggesting a role for the L-type Ca2+ channel in antigen receptor signaling. T cells expressed transcripts for the alpha(1)1.2 and alpha(1)1.3 pore-forming subunits of L-type voltage-gated Ca2+ channels and transcripts for all four known beta-subunits including several potential new splice variants. Jurkat T leukemia cells expressed a small amount of full-length alpha(1)1.2 protein but the dominant form was a truncated protein identical in size to a truncated alpha(1)1.2 protein known to be expressed in B lymphocytes. They further expressed a truncated form of the alpha(1)1.3 subunit and auxiliary beta1- and beta3-subunit proteins. Our data strongly suggest that functional but non-voltage-gated L-type Ca2+ channels are expressed at the plasma membrane in T cells and play a role in the antigen receptor-mediated Ca2+ flux in these cells.	Univ Birmingham, Sch Med, Inst Biomed Res, MRC,Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Grafton, G (corresponding author), Univ Birmingham, Sch Med, Inst Biomed Res, MRC,Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England.	g.grafton@bham.ac.uk	Stokes, Leanne/B-9580-2008	Stokes, Leanne/0000-0003-4013-6781; Grafton, Gillian/0000-0002-6752-7742				Akha AAS, 1996, J BIOL CHEM, V271, P7297, DOI 10.1074/jbc.271.13.7297; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BIRX DL, 1984, J IMMUNOL, V133, P2904; Brereton HM, 1997, CELL CALCIUM, V22, P39, DOI 10.1016/S0143-4160(97)90088-9; Catterall WA, 2003, PHARMACOL REV, V55, P579, DOI 10.1124/pr.55.4.8; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CHANG FC, 1988, J BIOL CHEM, V263, P18929; Cui J, 2002, J BIOL CHEM, V277, P47175, DOI 10.1074/jbc.M205870200; DUGAS B, 1986, EUR J IMMUNOL, V16, P162, DOI 10.1002/eji.1830160210; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; Gao TY, 2001, J BIOL CHEM, V276, P21089, DOI 10.1074/jbc.M008000200; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Grafton G, 1997, CELL IMMUNOL, V182, P45, DOI 10.1006/cimm.1997.1205; Grafton G, 2003, BIOCHEM PHARMACOL, V66, P2001, DOI 10.1016/j.bcp.2003.07.005; Grafton G, 2001, IMMUNOLOGY, V104, P119, DOI 10.1046/j.0019-2805.2001.01321.x; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Harper JL, 2003, BIOCHEM PHARMACOL, V65, P329, DOI 10.1016/S0006-2952(02)01488-0; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Helton TD, 2002, J NEUROSCI, V22, P1573, DOI 10.1523/JNEUROSCI.22-05-01573.2002; Hogan K, 1999, NEUROSCI LETT, V277, P111, DOI 10.1016/S0304-3940(99)00851-4; KAJI DM, 1990, AM J PHYSIOL-CELL PH, V259, pC322; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; Kotturi MF, 2003, J BIOL CHEM, V278, P46949, DOI 10.1074/jbc.M309268200; Krajewski S, 1996, ANAL BIOCHEM, V236, P221, DOI 10.1006/abio.1996.0160; Li SW, 2002, TRENDS PHARMACOL SCI, V23, P63, DOI 10.1016/S0165-6147(00)01897-6; Manzotti CN, 2002, EUR J IMMUNOL, V32, P2888, DOI 10.1002/1521-4141(2002010)32:10<2888::AID-IMMU2888>3.0.CO;2-F; MORGANO A, 1990, EUR J CLIN PHARMACOL, V39, P545, DOI 10.1007/BF00316092; Nofer JR, 2000, CELL SIGNAL, V12, P289, DOI 10.1016/S0898-6568(00)00068-1; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; Philipp S, 2003, J BIOL CHEM, V278, P26629, DOI 10.1074/jbc.M304044200; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; POWERS PA, 1992, J BIOL CHEM, V267, P22967; Ricci A, 1996, EUR J PHARMACOL, V301, P189, DOI 10.1016/0014-2999(96)00016-7; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Savignac M, 2001, FASEB J, V15, P1577, DOI 10.1096/fj.00-0733fje; Schwarzmann N, 2002, J BIOL CHEM, V277, P50636, DOI 10.1074/jbc.M209061200; Su ZC, 2001, AM J PHYSIOL-CELL PH, V280, pC1284, DOI 10.1152/ajpcell.2001.280.5.C1284; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Tanimura A, 2000, J BIOL CHEM, V275, P27488; TSURUO T, 1983, CANCER RES, V43, P2905; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhang X, 1997, J PHARMACOL EXP THER, V281, P1247; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	49	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19566	19573		10.1074/jbc.M401481200	http://dx.doi.org/10.1074/jbc.M401481200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14981074	hybrid			2022-12-27	WOS:000221164500024
J	Wang, P; Wang, X; Pei, DQ				Wang, P; Wang, X; Pei, DQ			Mint-3 regulates the retrieval of the internalized membrane-type matrix metalloproteinase, MT5-MMP, to the plasma membrane by binding to its carboxyl end motif EWV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MT1-MMP; PROTEIN; IDENTIFICATION; ACTIVATION; DOMAINS; MT3-MMP; SURFACE; CELLS	Membrane type matrix metalloproteinases (MT-MMPs) play a critical role in promoting cell growth and migration within the extracellular matrix by trafficking to specialized areas. Here we show that the carboxyl EWV motif of MT5-MMP serves as a retrieval signal for internalized MT5-MMP by interacting with Mint-3, a protein with two type III PDZ domains. Deletion of the EWV signal impairs the recycling of MT5-MMP without affecting its internalization, leading to decreased activity on the cell surface. A yeast two-hybrid screening identified Mint-3 as the EWV-binding protein. Mint-3 stimulates MT5-MMP activity when expressed at low levels in an EWV-dependent fashion, but inhibits its activity at higher levels independent of the EWV motif. siRNA-mediated knockdown of endogenous Mint-3 decreased MT5-MMP activity. Furthermore, Mint-3 significantly increased the level of MT5-MMP on the cell surface without affecting its synthesis and internalization. Therefore, Mints may be the adaptor proteins that regulate the trafficking of MT-MMPs.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	peixx003@umn.edu	Wang, Xing/G-2917-2015		NATIONAL CANCER INSTITUTE [R29CA076308, R01CA076308] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Hayashita-Kinoh H, 2001, CELL GROWTH DIFFER, V12, P573; Ho A, 2003, P NATL ACAD SCI USA, V100, P1409, DOI 10.1073/pnas.252774899; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2001, J BIOL CHEM, V276, P21960, DOI 10.1074/jbc.M007997200; Llano E, 1999, CANCER RES, V59, P2570; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Okamoto M, 2001, NEUROSCIENCE, V104, P653, DOI 10.1016/S0306-4522(01)00124-5; Okamoto M, 1998, EUR J CELL BIOL, V77, P161, DOI 10.1016/S0171-9335(98)80103-9; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2002, FEBS LETT, V527, P51, DOI 10.1016/S0014-5793(02)03153-8; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Yamada KM, 2003, NATURE, V424, P889, DOI 10.1038/424889a; Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	25	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20461	20470		10.1074/jbc.M400264200	http://dx.doi.org/10.1074/jbc.M400264200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14990567	hybrid			2022-12-27	WOS:000221164500125
J	Miyazaki, W; Iwasaki, T; Takeshita, A; Kuroda, Y; Koibuchi, N				Miyazaki, W; Iwasaki, T; Takeshita, A; Kuroda, Y; Koibuchi, N			Polychlorinated biphenyls suppress thyroid hormone receptor-mediated transcription through a novel mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN-DEVELOPMENT; RISK-ASSESSMENT; MOLECULAR-BASIS; DIOXIN-LIKE; PCBS; EXPOSURE; BINDING; TRANSTHYRETIN; GENE; TRANSACTIVATION	Polychlorinated biphenyls (PCBs) are environmental compounds that disrupt the endocrine system, and exposure to low doses causes abnormalities, particularly in the developing central nervous system. Because they are structurally similar to thyroid hormone (TH), PCBs might affect systems involving this hormone. We previously found, using reporter assays, that hydroxylated-PCB at doses as low as 10(-10) M suppress TH-induced transcriptional activation of TH receptor (TR). To understand the molecular mechanisms of this process, we examined whether PCBs alter coactivator or corepressor interaction with TR. Polychlorinated biphenyls suppressed steroid receptor coactivator-1 enhanced TR-mediated transcription, but did not reduce TR/steroid receptor coactivator-1 interaction in mammalian two-hybrid and glutathione S-transferase pull-down studies. Thus, the suppression was probably not caused by coactivator dissociation. Nuclear receptor co-repressor was not recruited to TR by PCBs either in vivo or in vitro, indicating that TR corepressor binding did not induce the suppression. We then examined whether PCB influences TR binding to the thyroid hormone-response element (TRE). Electrophoretic mobility shift assays revealed that the TR/retinoid X receptor heterodimer complex was partially dissociated from TRE in the presence of PCB. These results indicate that partial dissociation of TR/retinoid X receptor heterodimer complex from the TRE is involved in the suppression of transcription induced by PCB.	Gunma Univ, Grad Sch Med, Div Biol Regualt, Dept Integrat Physiol, Gunma 3718511, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cellular Biol,Div Immunol, Tottori 6838503, Japan; Toranomon Gen Hosp, Okinaka Mem Inst Med Res, Div Endocrinol & Metab, Tokyo 1058470, Japan; Tokyo Metropolitan Inst Neurosci, Dept Mol & Cellular Neurobiol, Tokyo 1838526, Japan	Gunma University; Japan Science & Technology Agency (JST); Tottori University; Toranomon Hospital; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Iwasaki, T (corresponding author), Gunma Univ, Grad Sch Med, Div Biol Regualt, Dept Integrat Physiol, Gunma 3718511, Japan.	tiwasaki@med.gunma-u.ac.jp		Koibuchi, Noriyuki/0000-0002-2247-9740				Abnet CC, 1999, TOXICOL APPL PHARM, V159, P41, DOI 10.1006/taap.1999.8719; Ayotte P, 1997, CHEMOSPHERE, V34, P1459, DOI 10.1016/S0045-6535(97)00442-6; BROUWER A, 1986, TOXICOL APPL PHARM, V85, P301, DOI 10.1016/0041-008X(86)90337-6; Brouwer A, 1998, TOXICOL IND HEALTH, V14, P59, DOI 10.1177/074823379801400107; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Cheek AO, 1999, ENVIRON HEALTH PERSP, V107, P273, DOI 10.2307/3434593; CHEN YCJ, 1992, JAMA-J AM MED ASSOC, V268, P3213, DOI 10.1001/jama.268.22.3213; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Darnerud PO, 1996, TOXICOLOGY, V106, P105, DOI 10.1016/0300-483X(95)03169-G; DEWAILLY E, 1994, ENVIRON HEALTH PERSP, V102, P205, DOI 10.1289/ehp.94102s1205; Giesy JP, 1998, CRIT REV TOXICOL, V28, P511, DOI 10.1080/10408449891344263; GLADEN BC, 1991, J PEDIATR-US, V119, P58, DOI 10.1016/S0022-3476(05)81039-X; Hauser P, 1998, TOXICOL IND HEALTH, V14, P85, DOI 10.1177/074823379801400108; Iwasaki T, 2002, BIOCHEM BIOPH RES CO, V299, P384, DOI 10.1016/S0006-291X(02)02659-1; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; Jacobson JL, 1997, NEUROTOXICOLOGY, V18, P415; JACOBSON JL, 1990, NEUROTOXICOL TERATOL, V12, P319, DOI 10.1016/0892-0362(90)90050-M; Jacobson JL, 1996, TOXICOL IND HEALTH, V12, P435, DOI 10.1177/074823379601200315; JACOBSON SW, 1985, CHILD DEV, V56, P853, DOI 10.2307/1130097; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Kimura-Kuroda J, 2002, DEV BRAIN RES, V137, P55, DOI 10.1016/S0165-3806(02)00408-X; Koibuchi N, 1999, ENDOCRINOLOGY, V140, P1356, DOI 10.1210/en.140.3.1356; Koibuchi N, 2000, TRENDS ENDOCRIN MET, V11, P123, DOI 10.1016/S1043-2760(00)00238-1; Kuroda Y, 2003, ENV SCI, V10, P23; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; MCKINNEY JD, 1994, ENVIRON HEALTH PERSP, V102, P290, DOI 10.1289/ehp.94102290; MCKINNEY JD, 1989, ENVIRON HEALTH PERSP, V82, P323, DOI 10.2307/3430790; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Mormede S, 2003, CHEMOSPHERE, V50, P563, DOI 10.1016/S0045-6535(02)00493-9; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; Porterfield SP, 1998, TOXICOL IND HEALTH, V14, P103, DOI 10.1177/074823379801400109; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; RABIE A, 1973, BRAIN RES, V61, P267, DOI 10.1016/0006-8993(73)90532-5; RABIE A, 1977, BRAIN RES, V120, P521, DOI 10.1016/0006-8993(77)90405-X; RON D, 1992, BIOTECHNIQUES, V13, P866; SAFE SH, 1994, CRIT REV TOXICOL, V24, P87, DOI 10.3109/10408449409049308; Sandau CD, 2000, ENVIRON HEALTH PERSP, V108, P611, DOI 10.2307/3434880; Sandau CD, 2002, ENVIRON HEALTH PERSP, V110, P411, DOI 10.1289/ehp.02110411; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; Shimada T, 2003, TOXICOL APPL PHARM, V187, P1, DOI 10.1016/S0041-008X(02)00035-2; Smith JW, 2002, NEUROSCI BIOBEHAV R, V26, P45, DOI 10.1016/S0149-7634(01)00037-9; Takeshita A, 1998, J BIOL CHEM, V273, P21554, DOI 10.1074/jbc.273.34.21554; Takeshita A, 2002, J BIOL CHEM, V277, P32453, DOI 10.1074/jbc.M111245200; Tilson HA, 1997, NEUROTOXICOLOGY, V18, P727; TILSON HA, 1990, NEUROTOXICOL TERATOL, V12, P239, DOI 10.1016/0892-0362(90)90095-T; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	48	112	117	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18195	18202		10.1074/jbc.M310531200	http://dx.doi.org/10.1074/jbc.M310531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985366	hybrid			2022-12-27	WOS:000221041500014
J	Hermoso, M; Olivero, P; Torres, R; Riveros, A; Quest, AFG; Stutzin, A				Hermoso, M; Olivero, P; Torres, R; Riveros, A; Quest, AFG; Stutzin, A			Cell volume regulation in response to hypotonicity is impaired in HeLa cells expressing a protein kinase C alpha mutant lacking kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNELS; TAURINE EFFLUX; ANION CHANNEL; ACTIVATION; CALCIUM; DECREASE; CHELERYTHRINE; INHIBITION; ISOZYMES; SIGNAL	The chloride conductance (GC(l,swell)) that participates in the regulatory volume decrease process triggered by osmotic swelling in HeLa cells was impaired by removal of extracellular Ca2+, depletion of intracellular Ca2+ stores with thapsigargin, or by preloading the cells with BAPTA-AM (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid). Furthermore, overnight exposure to the phorbol ester tetradecanoyl phorbol acetate and acute incubation with inhibitors of the conventional protein kinase C (PKC) isoforms bisindolylmaleimide I and Go6976 inhibited G(Cl,swell). Treatment of HeLa cells with U73122, a phospholipase C inhibitor, also prevented G(Cl,swell). Hypotonicity induced selective PKCalpha accumulation in the membrane/cytoskeleton fraction in fractionation experiments and translocation of a green fluorescent protein-PKCalpha fusion protein to the plasma membrane of transiently transfected HeLa cells. To further explore the role of PKCs in hypotonicity-induced G(Cl,swell), HeLa clones stably expressing either a kinase-dead dominant negative variant of the Ca2+-dependent PKC isoform alpha (PKCalpha K386R) or of the atypical PKC isoform zeta (PKCzeta K275W) were generated. G(Cl,swell) was significantly reduced in HeLa cells expressing the dominant negative PKCalpha mutant but remained unaltered in cells expressing dominant negative PKCzeta. These findings strongly implicate PKCalpha as a critical regulatory element that is required for efficient regulatory volume decrease in HeLa cells.	Univ Chile, Fac Med, Inst Ciencias Biomed, Santiago 6530499, Chile; Univ Chile, Fac Med, Ctr Estudios Mol Celula, Santiago 6530499, Chile; Univ Valparaiso, Escuela Med, Valparaiso 2340276, Chile	Universidad de Chile; Universidad de Chile; Universidad de Valparaiso	Stutzin, A (corresponding author), Univ Chile, Fac Med, Inst Ciencias Biomed, Santiago 6530499, Chile.	astutzin@bitmed.med.uchile.cl	Olivero, Pablo/AAS-5076-2021; Hermoso, Marcela A./AAF-6893-2021; Hermoso, Marcela/L-1500-2014; riveros, ana/AAD-2134-2020; Stutzin, Andrés/I-7605-2013	Olivero, Pablo/0000-0001-8886-7706; Hermoso, Marcela A./0000-0002-7936-7571; Stutzin, Andrés/0000-0002-7264-066X				ADORANTE JS, 1995, AM J PHYSIOL-CELL PH, V268, pC89, DOI 10.1152/ajpcell.1995.268.1.C89; ALVAREZLEEFMANS FJ, 1995, METH NEUROSCI, V27, P361; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan SL, 2003, J BIOL CHEM, V278, P20453, DOI 10.1074/jbc.C300138200; Chou CY, 1998, J PHYSIOL-LONDON, V512, P435, DOI 10.1111/j.1469-7793.1998.435be.x; COLCLASURE GC, 1992, J GEN PHYSIOL, V100, P1, DOI 10.1085/jgp.100.1.1; DIAZ M, 1993, PFLUG ARCH EUR J PHY, V422, P347, DOI 10.1007/BF00374290; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; FULLER CM, 1994, J BIOL CHEM, V269, P26642; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; HALLBRUCKER C, 1994, PFLUG ARCH EUR J PHY, V428, P552, DOI 10.1007/BF00374577; Hamill OP, 1996, PHARMACOL REV, V48, P231; Hoffmann EK, 2000, CELL PHYSIOL BIOCHEM, V10, P273, DOI 10.1159/000016356; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Hougaard C, 2000, PFLUG ARCH EUR J PHY, V440, P283, DOI 10.1007/s004240051050; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; KIRK J, 1994, J BIOL CHEM, V269, P29389; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LARSEN AK, 1994, BBA-MOL CELL RES, V1222, P477, DOI 10.1016/0167-4889(94)90057-4; Le Corvoisier P, 2002, FUND CLIN PHARMACOL, V16, P31, DOI 10.1046/j.1472-8206.2002.00069.x; Lee SK, 1998, J BIOL CHEM, V273, P19829, DOI 10.1074/jbc.273.31.19829; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Miley HE, 1999, J PHYSIOL-LONDON, V515, P413, DOI 10.1111/j.1469-7793.1999.413ac.x; MINTA A, 1989, J BIOL CHEM, V264, P8171; Mongin AA, 1999, AM J PHYSIOL-CELL PH, V276, pC1226, DOI 10.1152/ajpcell.1999.276.5.C1226; Moore AL, 2002, J BIOL CHEM, V277, P34030, DOI 10.1074/jbc.M205945200; Nilius B, 1999, J PHYSIOL-LONDON, V516, P67, DOI 10.1111/j.1469-7793.1999.067aa.x; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; OKADA Y, 1990, NEUROSCI RES       S, V12, P5; Olivero P, 2004, NEUROCHEM RES, V29, P169, DOI 10.1023/B:NERE.0000010446.50158.8d; Pasantes-Morales H, 2000, NEPHRON, V86, P414, DOI 10.1159/000045829; Quesada O, 1999, J NEUROSCI RES, V57, P350; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Roman RM, 1998, HEPATOLOGY, V28, P1073, DOI 10.1002/hep.510280423; Sadoshima J, 1996, EMBO J, V15, P5535, DOI 10.1002/j.1460-2075.1996.tb00938.x; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Stutzin A, 1999, AM J PHYSIOL-CELL PH, V277, pC392, DOI 10.1152/ajpcell.1999.277.3.C392; Stutzin A, 1997, AM J PHYSIOL-CELL PH, V273, pC999, DOI 10.1152/ajpcell.1997.273.3.C999; Tilly BC, 1996, FEBS LETT, V395, P133, DOI 10.1016/0014-5793(96)01028-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Urbach V, 1999, J MEMBRANE BIOL, V168, P29, DOI 10.1007/s002329900495; VANDERMEULEN JA, 1987, LANCET, V2, P306; Voets T, 1999, P NATL ACAD SCI USA, V96, P5298, DOI 10.1073/pnas.96.9.5298	52	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17681	17689		10.1074/jbc.M304506200	http://dx.doi.org/10.1074/jbc.M304506200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960580	hybrid			2022-12-27	WOS:000220870400098
J	Sandgren, S; Wittrup, A; Cheng, F; Jonsson, M; Eklund, E; Busch, S; Belting, M				Sandgren, S; Wittrup, A; Cheng, F; Jonsson, M; Eklund, E; Busch, S; Belting, M			The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; HEPARAN-SULFATE; HOST-DEFENSE; INNATE IMMUNITY; HUMAN LUNG; ANTIBIOTICS; PROTEIN; SURFACE; GLYCOSAMINOGLYCANS; CATHELICIDINS	Antimicrobial peptides, such as LL-37, are found both in nonvertebrates and vertebrates, where they represent important components of innate immunity. Bacterial infections at epithelial surfaces are associated with substantial induction of LL-37 expression, which allows efficient lysis of the invading microbes. Peptide-mediated lysis results in the release of bacterial nucleic acids with potential pathobiological activity in the host. Here, we demonstrate that LL-37 targets extracellular DNA plasmid to the nuclear compartment of mammalian cells, where it is expressed. DNA transfer occurred at physiological LL-37 concentrations that killed bacterial cells, whereas virtually no cytotoxic or growth-inhibitory effects were observed in mammalian cells. Furthermore, LL-37 protected DNA from serum nuclease degradation. LL-37.DNA complex uptake was a saturable time- and temperature-dependent process and was sensitive to cholesterol-depleting agents that are known to disrupt lipid rafts and caveolae, as shown by flow cytometry. Confocal fluorescence microscopy studies showed localization of internalized DNA to compartments stained by cholera toxin B, a marker of lipid rafts, but failed to demonstrate any co-localization of internalized DNA with caveolin-positive endocytotic vesicles. Moreover, LL-37-mediated plasmid uptake and reporter gene expression were strictly dependent on cell surface proteoglycans. We conclude that the human antimicrobial peptide LL-37 binds to, protects, and efficiently targets DNA plasmid to the nuclei of mammalian cells through caveolae-independent membrane raft endocytosis and cell surface proteoglycans.	Lund Univ, Biomed Ctr C13, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, SE-22184 Lund, Sweden	Lund University	Belting, M (corresponding author), Scripps Res Inst, Dept Immunol, C-204,105 50 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belting@scripps.edu		Wittrup, Anders/0000-0003-4918-0500; Belting, Mattias/0000-0003-1585-5434				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Bals R, 1999, J CLIN INVEST, V103, P1113, DOI 10.1172/JCI6570; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; Cheng F, 2001, J CELL BIOCHEM, V83, P597, DOI 10.1002/jcb.1254; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; Davidson DJ, 2004, J IMMUNOL, V172, P1146, DOI 10.4049/jimmunol.172.2.1146; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Ganz T, 2002, J CLIN INVEST, V109, P693, DOI 10.1172/JCI200215218; Gudmundsson GH, 1999, J IMMUNOL METHODS, V232, P45, DOI 10.1016/S0022-1759(99)00152-0; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Islam D, 2001, NAT MED, V7, P180, DOI 10.1038/84627; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Malm J, 2000, INFECT IMMUN, V68, P4297, DOI 10.1128/IAI.68.7.4297-4302.2000; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nichols BJ, 2003, CURR BIOL, V13, P686, DOI 10.1016/S0960-9822(03)00209-4; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Nilsson MF, 1999, INFECT IMMUN, V67, P2561, DOI 10.1128/IAI.67.5.2561-2566.1999; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Ponting CP, 2001, TRENDS GENET, V17, P235, DOI 10.1016/S0168-9525(01)02282-X; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; Salzberg SL, 2001, SCIENCE, V292, P1903, DOI 10.1126/science.1061036; Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200; Stanhope MJ, 2001, NATURE, V411, P940, DOI 10.1038/35082058; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; ZANETTI M, 1993, J BIOL CHEM, V268, P522; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	46	171	178	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17951	17956		10.1074/jbc.M311440200	http://dx.doi.org/10.1074/jbc.M311440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963039	hybrid			2022-12-27	WOS:000220870400129
J	Sablin, EP; Fletterick, RJ				Sablin, EP; Fletterick, RJ			Coordination between motor domains in processive kinesins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MICROTUBULE-BASED MOTILITY; HAND-OVER-HAND; CRYSTAL-STRUCTURE; MOLECULAR MOTOR; DIMERIC KINESIN; ATP HYDROLYSIS; NECK-REGION; CATALYTIC CORE; POWER STROKE; 8-NM STEP		Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Fletterick, RJ (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 600 16th St, San Francisco, CA 94107 USA.	flett@msg.ucsf.edu						Arnal I, 1998, STRUCTURE, V6, P33, DOI 10.1016/S0969-2126(98)00005-7; Asbury CL, 2003, SCIENCE, V302, P2130, DOI 10.1126/science.1092985; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Coy DL, 1999, J BIOL CHEM, V274, P3667, DOI 10.1074/jbc.274.6.3667; Crevel I, 1999, EMBO J, V18, P5863, DOI 10.1093/emboj/18.21.5863; deCastro MJ, 2000, NAT CELL BIOL, V2, P724, DOI 10.1038/35036357; Endow SA, 2003, ANNU REV PHYSIOL, V65, P161, DOI 10.1146/annurev.physiol.65.092101.142550; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; Hancock WO, 1999, P NATL ACAD SCI USA, V96, P13147, DOI 10.1073/pnas.96.23.13147; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Kawaguchi K, 2001, SCIENCE, V291, P667, DOI 10.1126/science.291.5504.667; Kikkawa M, 2000, CELL, V100, P241, DOI 10.1016/S0092-8674(00)81562-7; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kozielski F, 1999, STRUCTURE, V7, P1407, DOI 10.1016/S0969-2126(00)80030-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Mandelkow E, 1999, CURR OPIN CELL BIOL, V11, P34, DOI 10.1016/S0955-0674(99)80005-2; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rice S, 2003, BIOPHYS J, V84, P1844, DOI 10.1016/S0006-3495(03)74992-3; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; Rosenfeld SS, 2003, J BIOL CHEM, V278, P18550, DOI 10.1074/jbc.M300849200; Rosenfeld SS, 2002, J BIOL CHEM, V277, P36731, DOI 10.1074/jbc.M205261200; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sablin EP, 2001, CURR OPIN STRUC BIOL, V11, P716, DOI 10.1016/S0959-440X(01)00265-2; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; Skiniotis G, 2003, EMBO J, V22, P1518, DOI 10.1093/emboj/cdg164; Song YH, 2001, EMBO J, V20, P6213, DOI 10.1093/emboj/20.22.6213; Tomishige M, 2000, J CELL BIOL, V151, P1081, DOI 10.1083/jcb.151.5.1081; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Vale RD, 2000, PHILOS T ROY SOC B, V355, P449, DOI 10.1098/rstb.2000.0586; Wendt TG, 2002, EMBO J, V21, P5969, DOI 10.1093/emboj/cdf622; Woehlke G, 2000, NAT REV MOL CELL BIO, V1, P50, DOI 10.1038/35036069; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753; Young EC, 1998, BIOCHEMISTRY-US, V37, P3467, DOI 10.1021/bi972172n; Yun M, 2003, EMBO J, V22, P5382, DOI 10.1093/emboj/cdg531	46	27	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15707	15710		10.1074/jbc.R300036200	http://dx.doi.org/10.1074/jbc.R300036200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14973135	hybrid			2022-12-27	WOS:000220747900001
J	Muraki, M; Ohkawara, B; Hosoya, T; Onogi, H; Koizumi, J; Koizumi, T; Sumi, K; Jun-ichiro, Y; Murray, MV; Kimura, H; Furuichi, K; Shibuya, H; Krainer, AR; Suzuki, M; Hagiwara, M				Muraki, M; Ohkawara, B; Hosoya, T; Onogi, H; Koizumi, J; Koizumi, T; Sumi, K; Jun-ichiro, Y; Murray, MV; Kimura, H; Furuichi, K; Shibuya, H; Krainer, AR; Suzuki, M; Hagiwara, M			Manipulation of alternative splicing by a newly developed inhibitor of Clks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; SPINAL MUSCULAR-ATROPHY; PROTEIN-KINASE; SR PROTEINS; SERINE-RICH; IN-VIVO; DROSOPHILA-MELANOGASTER; NUCLEAR SPECKLES; HUMAN-DISEASE; CELL-CYCLE	The regulation of splice site usage provides a versatile mechanism for controlling gene expression and for the generation of proteome diversity, playing an essential role in many biological processes. The importance of alternative splicing is further illustrated by the increasing number of human diseases that have been attributed to mis-splicing events. Appropriate spatial and temporal generation of splicing variants demands that alternative splicing be subjected to extensive regulation, similar to transcriptional control. The Clk (Cdc2-like kinase) family has been implicated in splicing control and consists of at least four members. Through extensive screening of a chemical library, we found that a benzothiazole compound, TG003, had a potent inhibitory effect on the activity of Clk1/Sty. TG003 inhibited SF2/ASF-dependent splicing of beta-globin pre-mRNA in vitro by suppression of Clk-mediated phosphorylation. This drug also suppressed serine/arginine-rich protein phosphorylation, dissociation of nuclear speckles, and Clk1/Sty-dependent alternative splicing in mammalian cells. Consistently, administration of TG003 rescued the embryonic defects induced by excessive Clk activity in Xenopus. Thus, TG003, a novel inhibitor of Clk family will be a valuable tool to dissect the regulatory mechanisms involving serine/arginine-rich protein phosphorylation signaling pathways in vivo, and may be applicable for the therapeutic manipulation of abnormal splicing.	Tokyo Med & Dent Univ, Sch Biomed Sci, Gene Express Lab, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Tokyo, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol & Cellular Biol, Tokyo, Japan; Gifu Univ, Grad Sch Med, Div Regenerat & Adv Med Sci, Gifu 5011193, Japan; Yamanouchi Pharmaceut Co Ltd, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Kyoto Univ, Grad Sch Med, Horizontal Med Res Org, Nucl Funct & Dynam Unit, Kyoto 6068501, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Gifu University; Astellas Pharmaceuticals; Cold Spring Harbor Laboratory; Kyoto University	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Sch Biomed Sci, Gene Express Lab, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	m.hagiwara.end@mri.tmd.ac.jp	Kimura, Hiroshi/B-9524-2015; Hosoya, Takamitsu/N-7762-2015	Kimura, Hiroshi/0000-0003-0854-083X; Hosoya, Takamitsu/0000-0002-7270-351X; Krainer, Adrian/0000-0001-9024-9501; Ohkawara, Bisei/0000-0002-1987-458X				Andreassi C, 2001, HUM MOL GENET, V10, P2841, DOI 10.1093/hmg/10.24.2841; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Cao WH, 1997, RNA, V3, P1456; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Celotto AM, 2002, RNA, V8, P718, DOI 10.1017/S1355838202021064; Chang JG, 2001, P NATL ACAD SCI USA, V98, P9808, DOI 10.1073/pnas.171105098; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; Epstein PM, 1998, METHODS, V14, P21, DOI 10.1006/meth.1997.0562; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; GUPTA AK, 1995, CAN J CHEM, V73, P1278, DOI 10.1139/v95-157; HAGIWARA M, 1987, MOL PHARMACOL, V31, P523; Hanamura A, 1998, RNA, V4, P430; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; Katsu R, 2002, J BIOL CHEM, V277, P44220, DOI 10.1074/jbc.M206504200; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kojima T, 2001, J BIOL CHEM, V276, P32247, DOI 10.1074/jbc.M103790200; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAWCZAK M, 1992, HUM GENET, V90, P41; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; Lai MC, 2003, BIOCHEM J, V371, P937, DOI 10.1042/BJ20021827; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lee K, 1996, J BIOL CHEM, V271, P27299, DOI 10.1074/jbc.271.44.27299; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; Mayeda A, 1999, METH MOL B, V118, P309; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Nayler O, 1998, J BIOL CHEM, V273, P34341, DOI 10.1074/jbc.273.51.34341; Nayler O, 1997, BIOCHEM J, V326, P693, DOI 10.1042/bj3260693; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Philips AV, 2000, CELL MOL LIFE SCI, V57, P235, DOI 10.1007/PL00000687; Pilch B, 2001, CANCER RES, V61, P6876; RABINOW L, 1993, GENETICS, V134, P1175; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; ROTH MB, 1991, J CELL BIOL, V115, P5877; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547; Soret J, 2003, CANCER RES, V63, P8203; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; STOSS O, 2000, GENE THER MOL BIOL, V5, P9; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	59	212	228	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24246	24254		10.1074/jbc.M314298200	http://dx.doi.org/10.1074/jbc.M314298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15010457	hybrid			2022-12-27	WOS:000221702500049
J	Anderluh, G; Gokce, I; Lakey, JH				Anderluh, G; Gokce, I; Lakey, JH			A natively unfolded toxin domain uses its receptor as a folding template	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; FILAMENTOUS PHAGE INFECTION; GROUP-A COLICINS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CIRCULAR-DICHROISM; ENDONUCLEASE COLICINS; IMMUNITY PROTEIN; RECOGNITION SITE; TOLA	Natively unfolded proteins range from molten globules to disordered coils. They are abundant in eukaryotic genomes and commonly involved in molecular interactions. The essential N-terminal translocation domains of colicin toxins from Escherichia coli are disordered bacterial proteins that bind at least one protein of the Tol or Ton family. The colicin N translocation domain (ColN-(1-90)), which binds to the C-terminal domain of TolA (TolA-(296-421)), shows a disordered far-UV CD spectrum, no near-UV CD signal, and non-cooperative thermal unfolding. As expected, TolA-(296-421) displays both secondary structure in far-UV CD and tertiary structure in near-UV CD. Furthermore it shows a cooperative unfolding transition at 65 degreesC. CD spectra of the 1:1 complex show both increased secondary structure and colicin N-specific near-UV CD signals. A new cooperative thermal transition at 35 degreesC is followed by the unchanged unfolding behavior of TolA-(296-421). Fluorescence and surface plasmon resonance confirm that the new unfolding transition accompanies dissociation of ColN-(1-90). Hence upon binding the disordered structure of ColN-(1-90) converts to a cooperatively folded domain without altering the TolA-(296-421) structure.	Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Ljubljana, Biotech Fac, Dept Biol, Ljubljana 1000, Slovenia; Gaziosmanpasa Univ, Dept Chem, TR-60240 Tokat, Turkey	Newcastle University - UK; University of Ljubljana; Gaziosmanpasa University	Lakey, JH (corresponding author), Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.h.lakey@ncl.ac.uk	Anderluh, Gregor/C-6905-2014	Anderluh, Gregor/0000-0002-9916-8465				Anderluh G, 2003, J BIOL CHEM, V278, P21860, DOI 10.1074/jbc.M300411200; Anderluh G, 2003, PROTEIN EXPRES PURIF, V28, P173, DOI 10.1016/S1046-5928(02)00681-2; Bienkiewicz EA, 2000, J MOL BIOL, V297, P119, DOI 10.1006/jmbi.2000.3545; Braun V, 2002, BIOCHIMIE, V84, P365, DOI 10.1016/S0300-9084(02)01427-X; COLLINS ES, 2002, J MOL BIOL, V122, P145; CRAIG S, 1989, INT J PEPT PROT RES, V33, P256; Deprez C, 2002, BIOCHEMISTRY-US, V41, P2589, DOI 10.1021/bi0157262; Derouiche R, 1996, EMBO J, V15, P6408, DOI 10.1002/j.1460-2075.1996.tb01032.x; Dover LG, 2000, BIOCHEMISTRY-US, V39, P8632, DOI 10.1021/bi000160n; Dubuisson JF, 2002, J BACTERIOL, V184, P4620, DOI 10.1128/JB.184.16.4620-4625.2002; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Eker F, 2003, J AM CHEM SOC, V125, P8178, DOI 10.1021/ja034625j; ELKOUHEN R, 1993, EUR J BIOCHEM, V214, P635; Evans LJA, 1996, BIOCHEMISTRY-US, V35, P13180, DOI 10.1021/bi960990u; Evans LJA, 1996, BIOCHEMISTRY-US, V35, P15143, DOI 10.1021/bi9615497; Evans LJA, 1996, J MOL BIOL, V255, P559, DOI 10.1006/jmbi.1996.0047; Fasman G.D., 1996, CIRCULAR DICHROISM C; GELI V, 1986, MOL GEN GENET, V202, P455, DOI 10.1007/BF00333276; Gokce I, 2000, J MOL BIOL, V304, P621, DOI 10.1006/jmbi.2000.4232; James R, 2002, BIOCHIMIE, V84, P381, DOI 10.1016/S0300-9084(02)01450-5; JAMES R, 1988, J GEN MICROBIOL, V134, P2525; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; Kerr B, 2002, NATURE, V418, P171, DOI 10.1038/nature00823; Kleanthous C, 1999, NAT STRUCT BIOL, V6, P243, DOI 10.1038/6683; Kleanthous C, 1998, MOL MICROBIOL, V28, P227, DOI 10.1046/j.1365-2958.1998.00811.x; Kurisu G, 2003, NAT STRUCT BIOL, V10, P948, DOI 10.1038/nsb997; Lakey JH, 2001, CURR TOP MICROBIOL, V257, P131; Lazzaroni JC, 2002, BIOCHIMIE, V84, P391, DOI 10.1016/S0300-9084(02)01419-0; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Lubkowski J, 1999, STRUCTURE, V7, P711, DOI 10.1016/S0969-2126(99)80092-6; Mosbahi K, 2002, NAT STRUCT BIOL, V9, P476, DOI 10.1038/nsb797; Pappu RV, 2002, PROTEIN SCI, V11, P2437, DOI 10.1110/ps.0217402; Park SH, 1997, PROTEIN SCI, V6, P1694, DOI 10.1002/pro.5560060809; Pilpel Y, 2003, BIOCHEMISTRY-US, V42, P3519, DOI 10.1021/bi0266176; PILSL H, 1995, J BACTERIOL, V177, P6966, DOI 10.1128/jb.177.23.6966-6972.1995; POLITOU AS, 1994, BIOCHEMISTRY-US, V33, P4730, DOI 10.1021/bi00181a604; PUGSLEY AP, 1984, MICROBIOL SCI, V1, P168; PUGSLEY AP, 1987, MOL MICROBIOL, V1, P317, DOI 10.1111/j.1365-2958.1987.tb01938.x; Raggett EM, 1998, MOL MICROBIOL, V28, P1335, DOI 10.1046/j.1365-2958.1998.00899.x; Rakin A, 1996, MICROBIOL-UK, V142, P3415, DOI 10.1099/13500872-142-12-3415; Riechmann L, 1997, CELL, V90, P351, DOI 10.1016/S0092-8674(00)80342-6; Schendel SL, 1997, J BACTERIOL, V179, P3683, DOI 10.1128/jb.179.11.3683-3690.1997; Soelaiman S, 2001, MOL CELL, V8, P1053, DOI 10.1016/S1097-2765(01)00396-3; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Vetter IR, 1998, STRUCTURE, V6, P863, DOI 10.1016/S0969-2126(98)00088-4; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; WILMSEN HU, 1990, EUR BIOPHYS J, V18, P149, DOI 10.1007/BF02427374; Zakharov SD, 2002, BBA-BIOMEMBRANES, V1565, P333, DOI 10.1016/S0005-2736(02)00579-5	50	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22002	22009		10.1074/jbc.M313603200	http://dx.doi.org/10.1074/jbc.M313603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004032	hybrid			2022-12-27	WOS:000221417100041
J	Dinescu, A; Cundari, TR; Bhansali, VS; Luo, JL; Anderson, ME				Dinescu, A; Cundari, TR; Bhansali, VS; Luo, JL; Anderson, ME			Function of conserved residues of human glutathione synthetase - Implications for the Atp-grasp enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-B; SITE-DIRECTED MUTAGENESIS; GAMMA-GLUTAMYL SUBSTRATE; RIBONUCLEOTIDE SYNTHETASE; 3-DIMENSIONAL STRUCTURE; COOPERATIVE BINDING; MISSENSE MUTATIONS; FLEXIBLE LOOP; LARGE SUBUNIT; RAT-KIDNEY	Glutathione synthetase is an enzyme that belongs to the glutathione synthetase ATP-binding domain-like superfamily. It catalyzes the second step in the biosynthesis of glutathione from gamma-glutamylcysteine and glycine in an ATP-dependent manner. Glutathione synthetase has been purified and sequenced from a variety of biological sources; still, its exact mechanism is not fully understood. A variety of structural alignment methods were applied and four highly conserved residues of human glutathione synthetase (Glu-144, Asn-146, Lys-305, and Lys-364) were identified in the binding site. The function of these was studied by experimental and computational site-directed mutagenesis. The three-dimensional coordinates for several human glutathione synthetase mutant enzymes were obtained using molecular mechanics and molecular dynamics simulation techniques, starting from the reported crystal structure of human glutathione synthetase. Consistent with circular dichroism spectroscopy, our results showed no major changes to overall enzyme structure upon residue mutation. However, semiempirical calculations revealed that ligand binding is affected by these mutations. The key interactions between conserved residues and ligands were detected and found to be essential for enzymatic activity. Particularly, the negatively charged Glu-144 residue plays a major role in catalysis.	Texas Womans Univ, Dept Chem & Phys, Denton, TX 76204 USA; Univ N Texas, Dept Chem, Denton, TX 76203 USA; Univ N Texas, Dept Biol, Denton, TX 76203 USA; Hisun Pharmaceut Co Ltd, Zhejiang 318000, Peoples R China	Texas Womans University; University of North Texas System; University of North Texas Denton; University of North Texas System; University of North Texas Denton	Anderson, ME (corresponding author), Texas Womans Univ, Dept Chem & Phys, POB 425859, Denton, TX 76204 USA.	Manderson3@mail.twu.edu						ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Dahl N, 1997, HUM MOL GENET, V6, P1147, DOI 10.1093/hmg/6.7.1147; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; Fan C, 1997, BIOCHEMISTRY-US, V36, P2531, DOI 10.1021/bi962431t; GALI RR, 1995, BIOCHEM J, V310, P353, DOI 10.1042/bj3100353; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gogos A, 2002, STRUCTURE, V10, P1669, DOI 10.1016/S0969-2126(02)00906-1; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUSHIMA H, 1984, NUCLEIC ACIDS RES, V12, P9299, DOI 10.1093/nar/12.24.9299; Gushima H, 1983, J Appl Biochem, V5, P210; HABENICHT A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P295, DOI 10.1016/0167-4781(93)90202-O; HARA T, 1995, PROTEIN ENG, V8, P711, DOI 10.1093/protein/8.7.711; Hara T, 1996, BIOCHEMISTRY-US, V35, P11967, DOI 10.1021/bi9605245; HIBI T, 1993, BIOCHEMISTRY-US, V32, P1548, DOI 10.1021/bi00057a020; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HUANG CS, 1995, P NATL ACAD SCI USA, V92, P1232, DOI 10.1073/pnas.92.4.1232; Inoue Y, 1998, BBA-GENE STRUCT EXPR, V1395, P315, DOI 10.1016/S0167-4781(97)00199-1; KATO H, 1989, J MOL BIOL, V209, P503, DOI 10.1016/0022-2836(89)90015-6; KATO H, 1988, J BIOL CHEM, V263, P11646; KATO H, 1994, BIOCHEMISTRY-US, V33, P4995, DOI 10.1021/bi00183a001; LARSSON A, 1976, CLIN CHIM ACTA, V67, P245, DOI 10.1016/0009-8981(76)90332-6; LARSSON A, 2001, METABOLIC MOL BASES, P2205; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo JL, 2000, BIOCHEM BIOPH RES CO, V275, P577, DOI 10.1006/bbrc.2000.3337; Meierjohann S, 2002, BIOCHEM J, V363, P833, DOI 10.1042/0264-6021:3630833; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1983, GLUTATHIONE CHEM BIO, P367; MOOZ ED, 1967, BIOCHEMISTRY-US, V6, P1722, DOI 10.1021/bi00858a022; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; MUTOH N, 1991, BIOCHEM BIOPH RES CO, V181, P430, DOI 10.1016/S0006-291X(05)81437-8; Njalsson R, 2000, BIOCHEM J, V349, P275, DOI 10.1042/0264-6021:3490275; Njalsson R, 2001, BIOCHEM BIOPH RES CO, V289, P80, DOI 10.1006/bbrc.2001.5961; OPPENHEIMER L, 1979, J BIOL CHEM, V254, P5184; PETERS JM, 1992, BIOCHEM BIOPH RES CO, V182, P1040, DOI 10.1016/0006-291X(92)91836-F; Polekhina G, 1999, EMBO J, V18, P3204, DOI 10.1093/emboj/18.12.3204; RACKER E, 1951, J BIOL CHEM, V190, P685; RAWLINS MR, 1995, FEBS LETT, V376, P81, DOI 10.1016/0014-5793(95)01253-1; Ristoff E, 2002, J INHERIT METAB DIS, V25, P577, DOI 10.1023/A:1022095324407; Ristoff E, 2001, J PEDIATR-US, V139, P79, DOI 10.1067/mpd.2001.114480; Shi ZZ, 1996, NAT GENET, V14, P361, DOI 10.1038/ng1196-361; Sloane V, 2001, J BIOL CHEM, V276, P24991, DOI 10.1074/jbc.M101472200; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; STEWART JJP, 1989, J COMPUT CHEM, V10, P221, DOI 10.1002/jcc.540100209; Szustakowski JD, 2000, PROTEINS, V38, P428, DOI 10.1002/(SICI)1097-0134(20000301)38:4<428::AID-PROT8>3.0.CO;2-N; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; TANAKA T, 1993, BIOCHEMISTRY-US, V32, P12398, DOI 10.1021/bi00097a018; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P8791, DOI 10.1021/bi000926j; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P15480, DOI 10.1021/bi991618s; UOTILA L, 1974, J BIOL CHEM, V249, P7664; Wang WR, 1998, BIOCHEMISTRY-US, V37, P15647, DOI 10.1021/bi981405n; WELLNER VP, 1974, P NATL ACAD SCI USA, V71, P2505, DOI 10.1073/pnas.71.6.2505; Whitbread L, 1998, CHEM-BIOL INTERACT, V112, P35, DOI 10.1016/S0009-2797(97)00149-X; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106	58	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22412	22421		10.1074/jbc.M401334200	http://dx.doi.org/10.1074/jbc.M401334200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14990577	Green Published, hybrid			2022-12-27	WOS:000221417100090
J	Galigniana, MD; Harrell, JM; O'Hagen, HM; Ljungman, M; Pratt, WB				Galigniana, MD; Harrell, JM; O'Hagen, HM; Ljungman, M; Pratt, WB			Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; TETRATRICOPEPTIDE REPEAT DOMAIN; PEPTIDYLPROLYL ISOMERASE DOMAIN; WILD-TYPE P53; GLUCOCORTICOID-RECEPTOR; MUTANT P53; IN-VIVO; CYTOPLASMIC DYNEIN; INTRACELLULAR-LOCALIZATION; CHAPERONE MACHINERY	The tumor suppressor protein p53 is known to be transported to the nucleus along microtubular tracks by cytoplasmic dynein. However, the connection between p53 and the dynein motor protein complex has not been established. Here, we show that hsp90.binding immunophilins link p53.hsp90 complexes to dynein and that prevention of that linkage in vivo inhibits the nuclear movement of p53. First, we show that p53.hsp90 hetero-complexes from DLD-1 human colon cancer cells contain an immunophilin (FKBP52, CyP-40, or PP5) as well as dynein. p53.hsp90.immunophilin.dynein complexes can be formed by incubating immunopurified p53 with rabbit reticulocyte lysate, and we show by peptide competition that the immunophilins link via their tetratricopeptide repeat domains to p53-bound hsp90 and by means of their PPIase domains to the dynein complex. The linkage of immunophilins to the dynein motor is indirect by means of the dynamitin component of the dynein-associated dynactin complex, and we show that purified FKBP52 binds directly by means of its PPIase domain to purified dynamitin. By using a temperature-sensitive mutant of p53 where cytoplasmic-nuclear movement occurs by shift to permissive temperature, we show that p53 movement is impeded when p53 binding to hsp90 is inhibited by the hsp90 inhibitor radicicol. Also, nuclear movement of p53 is inhibited when immunophilin binding to dynein is competed for by expression of a PPIase domain fragment in the same manner as when dynein linkage to cargo is dissociated by expression of dynamitin. This is the first demonstration of the linkage between an hsp90-chaperoned transcription factor and the system for its retrograde movement to the nucleus both in vitro and in vivo.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Buenos Aires, Programa Regulac Hormonal & Metab, Consejo Nacl Invest Cient & Tecn, Fac Ciencias Exactas & Nat,Dept Quim Biol, Buenos Aires, DF, Argentina	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	mgali@umich.edu		O'Hagan, Heather/0000-0001-9750-5088; GALIGNIANA, MARIO/0000-0002-9130-8574	NCI NIH HHS [CA82376, CA28010] Funding Source: Medline; NIDDK NIH HHS [P60DK20572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082376, R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; GANNON JV, 1991, NATURE, V349, P802; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Harrell JM, 2002, BIOCHEMISTRY-US, V41, P5581, DOI 10.1021/bi020073q; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Komarova EA, 1997, CANCER RES, V57, P5217; LEBIHAN S, 1993, BIOCHEM BIOPH RES CO, V195, P600, DOI 10.1006/bbrc.1993.2088; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; Merchant AK, 1996, ONCOGENE, V13, P2631; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; OwensGrillo JK, 1996, BIOCHEMISTRY-US, V35, P15249, DOI 10.1021/bi9615349; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pirkl F, 2001, J MOL BIOL, V308, P795, DOI 10.1006/jmbi.2001.4595; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Uberti D, 1999, MOL BRAIN RES, V65, P167, DOI 10.1016/S0169-328X(98)00339-8; Vallee RB, 1998, TRENDS CELL BIOL, V8, P490, DOI 10.1016/S0962-8924(98)01379-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	52	119	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22483	22489		10.1074/jbc.M402223200	http://dx.doi.org/10.1074/jbc.M402223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004035	Green Published, hybrid			2022-12-27	WOS:000221417100098
J	Domenech, P; Reed, MB; Dowd, CS; Manca, C; Kaplan, G; Barry, CE				Domenech, P; Reed, MB; Dowd, CS; Manca, C; Kaplan, G; Barry, CE			The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLIPID-I; TRANSPOSON MUTAGENESIS; LIPIDS; MICE; GENE; DIFFERENTIATION; PURIFICATION; BIOSYNTHESIS; INHIBITION; COMPLEX	To study the role of MmpL8-mediated lipid transport in sulfatide biogenesis, we insertionally inactivated the mmpL8 gene in Mycobacterium tuberculosis. Characterization of this strain showed that the synthesis of mature sulfolipid SL-1 was interrupted and that a more polar sulfated molecule, termed SL-N, accumulated within the cell. Purification of SL-N and structural analysis identified this molecule as a family of 2,3-diacyl-alpha,alpha'-D-trehalose-2'-sulfates. This structure suggests that transport and biogenesis of SL-1 are coupled and that the final step in sulfatide biosynthesis may be the extracellular esterification of two trehalose 6-positions with hydroxyphthioceranic acids. To assess the effect of the loss of this anionic surface lipid on virulence, we infected mice via aerosol with the MmpL8 mutant and found that, although initial replication rates and containment levels were identical, compared with the wild type, a significant attenuation of the MmpL8 mutant strain in time-to-death was observed. Early in infection, differential expression of cytokines and cytokine receptors revealed that the mutant strain less efficiently suppresses key indicators of a Th1-type immune response, suggesting an immunomodulatory role for sulfatides in the pathogenesis of tuberculosis.	NIAID, TB Res Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Publ Hlth Res Inst, Newark, NJ 07103 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Barry, CE (corresponding author), NIAID, TB Res Sect, Immunogenet Lab, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.	cbarry@niaid.nih.gov	Barry, Clifton E/ABE-7992-2020; Barry, III, Clifton/H-3839-2012	Barry, Clifton E/0000-0002-2927-270X; Barry, III, Clifton/0000-0002-2927-270X	Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; NIAID NIH HHS [AI 54361, AI 22616] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI022616, R01AI054361, Z01AI000783, R01AI022616] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALUGUPALLI S, 1995, J BACTERIOL, V177, P4566, DOI 10.1128/jb.177.15.4566-4570.1995; BAER HH, 1993, CARBOHYD RES, V240, P1, DOI 10.1016/0008-6215(93)84167-5; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; BROZNA JP, 1991, INFECT IMMUN, V59, P2542, DOI 10.1128/IAI.59.8.2542-2548.1991; Bystrykh LV, 1996, J BACTERIOL, V178, P2238, DOI 10.1128/jb.178.8.2238-2244.1996; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Converse SE, 2003, P NATL ACAD SCI USA, V100, P6121, DOI 10.1073/pnas.1030024100; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; DOMENECH P, 1994, FEMS MICROBIOL LETT, V116, P19, DOI 10.1016/0378-1097(94)90101-5; FOLCH J, 1957, J BIOL CHEM, V226, P497; GANGADHARAM P R, 1963, Tubercle, V44, P452, DOI 10.1016/S0041-3879(63)80087-2; GOREN MB, 1976, P NATL ACAD SCI USA, V73, P2510, DOI 10.1073/pnas.73.7.2510; GOREN MB, 1970, BIOCHIM BIOPHYS ACTA, V210, P116, DOI 10.1016/0005-2760(70)90067-6; GOREN MB, 1974, INFECT IMMUN, V9, P142, DOI 10.1128/IAI.9.1.142-149.1974; GOREN MB, 1976, BIOCHEMISTRY-US, V15, P2728, DOI 10.1021/bi00658a003; GOREN MB, 1971, BIOCHEMISTRY-US, V10, P72, DOI 10.1021/bi00777a012; HUGHES DE, 1954, AM J CLIN PATHOL, V24, P621, DOI 10.1093/ajcp/24.5_ts.621; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATO M, 1974, INFECT IMMUN, V10, P733, DOI 10.1128/IAI.10.4.733-741.1974; Manca C, 1999, J IMMUNOL, V162, P6740; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; MIDDLEBROOK G, 1959, P NATL ACAD SCI USA, V45, P1801, DOI 10.1073/pnas.45.12.1801; Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4; MORSE WC, 1953, AM J PUBLIC HEALTH, V43, P36, DOI 10.2105/AJPH.43.1.36; Mougous JD, 2002, P NATL ACAD SCI USA, V99, P17037, DOI 10.1073/pnas.252514899; PABST MJ, 1988, J IMMUNOL, V140, P634; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; Rousseau C, 2003, INFECT IMMUN, V71, P4684, DOI 10.1128/IAI.71.8.4684-4690.2003; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Slayden R A, 2001, Methods Mol Med, V54, P229, DOI 10.1385/1-59259-147-7:229; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Soto CY, 2002, J CLIN MICROBIOL, V40, P3021, DOI 10.1128/JCM.40.8.3021-3024.2002; Tekaia F., 1999, Tubercle and Lung Disease, V79, P329, DOI 10.1054/tuld.1999.0220; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; ZHANG L, 1991, J IMMUNOL, V146, P2730; ZHANG L, 1988, INFECT IMMUN, V56, P2876, DOI 10.1128/IAI.56.11.2876-2883.1988; Zhang Liang, 1994, Journal of Biomedical Science, V1, P253, DOI 10.1007/BF02253310	42	128	135	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21257	21265		10.1074/jbc.M400324200	http://dx.doi.org/10.1074/jbc.M400324200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15001577	hybrid			2022-12-27	WOS:000221273800086
J	Ji, GJ; Feldman, ME; Deng, KY; Greene, KS; Wilson, J; Lee, JC; Johnston, RC; Rishniw, M; Tallini, Y; Zhang, J; Wier, WG; Blaustein, MP; Xin, HB; Nakai, J; Kotlikoff, MI				Ji, GJ; Feldman, ME; Deng, KY; Greene, KS; Wilson, J; Lee, JC; Johnston, RC; Rishniw, M; Tallini, Y; Zhang, J; Wier, WG; Blaustein, MP; Xin, HB; Nakai, J; Kotlikoff, MI			Ca2+-sensing transgenic mice - Postsynaptic signaling in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEINS; INDUCED CALCIUM-RELEASE; PIG URINARY-BLADDER; ALPHA,BETA-METHYLENE ATP; CA2+ TRANSIENTS; CRE RECOMBINASE; CELLS; INDICATORS; EXPRESSION; RESPONSES	Genetically encoded signaling proteins provide remarkable opportunities to design and target the expression of molecules that can be used to report critical cellular events in vivo, thereby markedly extending the scope and physiological relevance of studies of cell function. Here we report the development of a transgenic mouse expressing such a reporter and its use to examine postsynaptic signaling in smooth muscle. The circularly permutated, Ca2+-sensing molecule G-CaMP (Nakai, J., Ohkura, M., and Imoto, K. (2001) Nat. Biotechnol. 19, 137-141) was expressed in vascular and non-vascular smooth muscle and functioned as a lineage-specific intracellular Ca2+ reporter. Detrusor tissue from these mice was used to identify two separate types of postsynaptic Ca2+ signals, mediated by distinct neurotransmitters. Intrinsic nerve stimulation evoked rapid, whole-cell Ca2+ transients, or "Ca2+ flashes," and slowly propagating Ca2+ waves. We show that Ca2+ flashes occur through P2X receptor stimulation and ryanodine receptor-mediated Ca2+ release, whereas Ca2+ waves arise from muscarinic receptor stimulation and inositol trisphosphate-mediated Ca2+ release. The distinct ionotropic and metabotropic postsynaptic Ca2+ signals are related at the level of Ca2+ release. Importantly, individual myocytes are capable of both postsynaptic responses, and a transition between Ca2+-induced Ca2+ release and inositol trisphosphate waves occurs at higher synaptic inputs. Ca2+ signaling mice should provide significant advantages in the study of processive biological signaling.	Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dynam, Wako, Saitama 3510198, Japan	Cornell University; University System of Maryland; University of Maryland Baltimore; RIKEN	Kotlikoff, MI (corresponding author), Cornell Univ, Coll Vet Med, Dept Biomed Sci, T4018 VRT,Box 11, Ithaca, NY 14853 USA.	mik7@cornell.edu	Wier, Withrow/AAE-2451-2020; Nakai, Junichi/GQZ-6415-2022		NHLBI NIH HHS [HL 64708, HL 45215, HL 045239] Funding Source: Medline; NIDDK NIH HHS [DK 065992] Funding Source: Medline; PHS HHS [D 58795] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045239, R01HL045215, R01HL064708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065992] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asada Y, 1999, J PHYSIOL-LONDON, V521, P497, DOI 10.1111/j.1469-7793.1999.00497.x; BASSANI JWM, 1995, BIOPHYS J, V68, P1453, DOI 10.1016/S0006-3495(95)80318-8; Baylor SM, 2000, NEWS PHYSIOL SCI, V15, P19; Bergner A, 2002, J GEN PHYSIOL, V119, P187, DOI 10.1085/jgp.119.2.187; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BRADING AF, 1990, BRIT J PHARMACOL, V99, P493, DOI 10.1111/j.1476-5381.1990.tb12956.x; Brain KL, 2002, J PHYSIOL-LONDON, V541, P849, DOI 10.1113/jphysiol.2002.019612; BURNSTOCK G, 1972, BRIT J PHARMACOL, V44, P451, DOI 10.1111/j.1476-5381.1972.tb07283.x; BURNSTOCK G, 1986, PROG BRAIN RES, V68, P193, DOI 10.1016/S0079-6123(08)60239-3; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Collier ML, 2000, J GEN PHYSIOL, V115, P653, DOI 10.1085/jgp.115.5.653; Fiala A., 2003, SCI STKE, V6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heppner TJ, 2002, AM J PHYSIOL-HEART C, V283, pH2169, DOI 10.1152/ajpheart.00603.2002; HIGASHIJIMA SI, 2003, J NEUROPHYSIOL; HOYLE CHV, 1985, EUR J PHARMACOL, V114, P239, DOI 10.1016/0014-2999(85)90635-1; HOYLE CHV, 1990, BRIT J PHARMACOL, V99, P617, DOI 10.1111/j.1476-5381.1990.tb12979.x; IINO M, 1994, EMBO J, V13, P5026, DOI 10.1002/j.1460-2075.1994.tb06831.x; Ji GJ, 2002, J GEN PHYSIOL, V119, P533, DOI 10.1085/jgp.20028514; KUREBAYASHI N, 1993, BIOPHYS J, V64, P1934, DOI 10.1016/S0006-3495(93)81564-9; Lamont C, 2003, J PHYSIOL-LONDON, V549, P801, DOI 10.1113/jphysiol.2003.043380; Liu L, 2003, NAT NEUROSCI, V6, P267, DOI 10.1038/nn1009; Madsen CS, 1998, CIRC RES, V82, P908; MINTA A, 1989, J BIOL CHEM, V264, P8171; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Nakai J, 2001, NAT BIOTECHNOL, V19, P137, DOI 10.1038/84397; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; Regan CP, 2000, CIRC RES, V87, P363; Stevens RJ, 1999, NATURE, V399, P62, DOI 10.1038/19973; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vial C, 2000, BRIT J PHARMACOL, V131, P1489, DOI 10.1038/sj.bjp.0703720; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Xin HB, 2002, PHYSIOL GENOMICS, V10, P211, DOI 10.1152/physiolgenomics.00054.2002; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	36	55	58	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21461	21468		10.1074/jbc.M401084200	http://dx.doi.org/10.1074/jbc.M401084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14990564	hybrid			2022-12-27	WOS:000221273800111
J	Minsavage, GD; Park, SK; Gasiewicz, TA				Minsavage, GD; Park, SK; Gasiewicz, TA			The aryl hydrocarbon receptor (AhR) tyrosine 9, a residue that is essential for AhR DNA binding activity, is not a phosphoresidue but augments AhR phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MEDIATED SIGNAL-TRANSDUCTION; LOOP-HELIX PROTEIN; NUCLEAR TRANSLOCATOR; DIOXIN RECEPTOR; CYP1A1 GENE; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; TRANSACTIVATION DOMAINS; RESPONSE ELEMENT; IN-VIVO	We delineate a mechanism by which dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin or TCDD)-mediated formation of the aryl hydrocarbon receptor (AhR) DNA binding complex is disrupted by a single mutation at the conserved AhR tyrosine 9. Replacement of tyrosine 9 with the structurally conservative phenylalanine (AhRY9F) abolished binding to dioxin response element (DRE) D, E, and A and abrogated DRE-driven gene induction mediated by the AhR with no effect on TCDD binding, TCDD-induced nuclear localization, or ARNT heterodimerization. The speculated role for phosphorylation at tyrosine 9 was also examined. Anti-phosphotyrosine immunoblotting could not detect a major difference between the AhRY9F mutant and wild-type AhR, but a basic isoelectric point shift was detected by two-dimensional gel electrophoresis of AhRY9F. However, an antibody raised to recognize only phosphorylated tyrosine 9 (anti-AhRpY9) confirmed that AhR tyrosine 9 is not a phosphorylated residue required for DRE binding. Kinase assays using synthetic peptides corresponding to the wild-type and mutant AhR residues 1-23 demonstrated that a tyrosine at position 9 is important for substrate recognition at serine(s)/threonine(s) within this sequence by purified protein kinase C (PKC). Also, compared with AhRY9F, immunopurified full-length wild-type receptor was more rapidly phosphorylated by PKC. Furthermore, co-treatment of AhR-deficient cells that expressed AhRY9F and a DRE-driven luciferase construct with phorbol 12-myristate 13-acetate and TCDD resulted in a 30% increase in luciferase activity compared with AhRY9F treated with TCDD alone. Overall, AhR tyrosine 9, which is not a phosphorylated residue itself but is required for DNA binding, appears to play a crucial role in AhR activity by permitting proper phosphorylation of the AhR.	Univ Rochester, Med Ctr, Dept Environm Med, Sch Med, Rochester, NY 14642 USA	University of Rochester	Gasiewicz, TA (corresponding author), Univ Rochester, Med Ctr, Dept Environm Med, Sch Med, Box EHSC,575 Elmwood Ave, Rochester, NY 14642 USA.	Tom_Gasiewicz@urmc.rochester.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002515, P30ES001247] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 02515, ES 01247, ES 07026] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; Bernard A, 1999, EXP CELL RES, V253, P704, DOI 10.1006/excr.1999.4715; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; CARRIER F, 1994, BIOCHEM PHARMACOL, V48, P1767, DOI 10.1016/0006-2952(94)90463-4; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; DEPETRILLO PB, 1993, TOXICOL LETT, V69, P31, DOI 10.1016/0378-4274(93)90142-K; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; GASIEWICZ TA, 1982, ANAL BIOCHEM, V124, P1, DOI 10.1016/0003-2697(82)90212-3; Henry EC, 1997, ARCH BIOCHEM BIOPHYS, V339, P305, DOI 10.1006/abbi.1996.9873; Henry EC, 1999, MOL PHARMACOL, V55, P716; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Ikuta T, 2004, J BIOL CHEM, V279, P19209, DOI 10.1074/jbc.M310492200; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Kikuchi Y, 2003, J BIOCHEM, V134, P83, DOI 10.1093/jb/mvg115; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Long WP, 1999, ARCH BIOCHEM BIOPHYS, V371, P246, DOI 10.1006/abbi.1999.1452; Long WP, 1998, MOL PHARMACOL, V53, P691, DOI 10.1124/mol.53.4.691; Long WP, 1999, J BIOL CHEM, V274, P12391, DOI 10.1074/jbc.274.18.12391; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Minsavage GD, 2003, ARCH BIOCHEM BIOPHYS, V412, P95, DOI 10.1016/S0003-9861(03)00033-X; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Park SK, 2000, ARCH BIOCHEM BIOPHYS, V381, P302, DOI 10.1006/abbi.2000.1999; PERDEW GH, 1990, BIOCHEMISTRY-US, V29, P6210, DOI 10.1021/bi00478a014; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; PIMENTAL RA, 1993, MOL CELL BIOL, V13, P4365, DOI 10.1128/MCB.13.7.4365; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; SCHAFER MW, 1993, ARCH BIOCHEM BIOPHYS, V307, P267, DOI 10.1006/abbi.1993.1589; Swanson HI, 1996, J BIOL CHEM, V271, P31657, DOI 10.1074/jbc.271.49.31657; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang Z, 2002, J BIOL CHEM, V277, P24022, DOI 10.1074/jbc.M201949200; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103	38	23	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20582	20593		10.1074/jbc.M312977200	http://dx.doi.org/10.1074/jbc.M312977200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14978034	hybrid			2022-12-27	WOS:000221273800007
J	Alam, H; Maizels, ET; Park, Y; Ghaey, S; Feiger, ZJ; Chandel, NS; Hunzicker-Dunn, M				Alam, H; Maizels, ET; Park, Y; Ghaey, S; Feiger, ZJ; Chandel, NS; Hunzicker-Dunn, M			Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; P70 S6 KINASE; TUBEROUS SCLEROSIS COMPLEX-1; HISTONE H3 PHOSPHORYLATION; LUTEINIZING-HORMONE; TUMOR-SUPPRESSOR; FACTOR 1-ALPHA; GENE-PRODUCTS; TRANSCRIPTION FACTOR; REGULATORY SUBUNIT	We sought to elucidate the role of AKT in follicle-stimulating hormone (FSH)-mediated granulosa cell (GC) differentiation. Our results define a signaling pathway in GCs whereby the inactivating phosphorylation of tuberin downstream of phosphatidylinositol (PI)3-kinase/AKT activity leads to Rheb (Ras homolog enriched in brain) and subsequent mTOR (mammalian target of rapamycin) activation. mTOR then stimulates translation by phosphorylating p70 S6 kinase and, consequently, the 40 S ribosomal protein S6. Activation of this pathway is required for FSH-mediated induction of several follicular differentiation markers, including luteinizing-hormone receptor (LHR), inhibin-alpha, microtubule-associated protein 2D, and the PKA type IIbeta regulatory subunit. FSH also promotes activation of the transcription factor hypoxia-inducible factor-1 (HIF-1). FSH-stimulated HIF-1 activity is inhibited by the PI 3-kinase inhibitor LY294002, the Rheb inhibitor FTI-277 ((f) under bar arnesyl (t) under bar ransferase (i) under bar nhibitor-277), and the mTOR inhibitor rapamycin. Finally, we find that the FSH-mediated up-regulation of reporter activities for LHR, inhibin-alpha, and vascular endothelial growth factor is dependent upon HIF-1 activity, because a dominant negative form of HIF-1alpha interferes with the up-regulation of these genes. These results show that FSH enhances HIF-1 activity downstream of the PI 3-kinase/AKT/Rheb/mTOR pathway in GCs and that HIF-1 activity is necessary for FSH to induce multiple follicular differentiation markers.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Hunzicker-Dunn, M (corresponding author), 303 E Chicago Ave, Chicago, IL 60611 USA.	mhd@northwestern.edu		Maizels, Evelyn/0000-0001-9072-1095	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071643] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060472] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 071643, P01 HL071643] Funding Source: Medline; NICHD NIH HHS [P01 HD021921, T32 HD 07086, P01 HD 21921] Funding Source: Medline; NIGMS NIH HHS [R01 GM060472, GM 60472-05] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel MH, 2000, ENDOCRINOLOGY, V141, P1795, DOI 10.1210/en.141.5.1795; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Burns KH, 2001, ENDOCRINOLOGY, V142, P2742, DOI 10.1210/en.142.7.2742; Carr DW, 1999, BIOCHEM J, V344, P613, DOI 10.1042/0264-6021:3440613; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Cottom J, 2003, J BIOL CHEM, V278, P7167, DOI 10.1074/jbc.M203901200; CREWS TS, 1998, GENE DEV, V12, P620; Cunningham MA, 2003, ENDOCRINOLOGY, V144, P5585, DOI 10.1210/en.2003-0678; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DeManno DA, 1999, MOL ENDOCRINOL, V13, P91, DOI 10.1210/me.13.1.91; Desclozeaux M, 2002, MOL CELL BIOL, V22, P7193, DOI 10.1128/MCB.22.20.7193-7203.2002; Duan WR, 2002, MOL ENDOCRINOL, V16, P221, DOI 10.1210/me.16.2.221; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; DYKEMA JC, 1994, ENDOCRINOLOGY, V135, P702, DOI 10.1210/en.135.2.702; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eimerl S, 2002, BIOL REPROD, V67, P900, DOI 10.1095/biolreprod.101.002170; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gao N, 2002, J BIOL CHEM, V277, P31963, DOI 10.1074/jbc.M200082200; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HILLIER SG, 1985, OXFORD REV REPROD B, V7, P168; Hillier SG, 2001, MOL CELL ENDOCRINOL, V179, P39, DOI 10.1016/S0303-7207(01)00469-5; Hirakawa T, 1999, ENDOCRINOLOGY, V140, P4965, DOI 10.1210/en.140.11.4965; HSUEH AJW, 1989, RECENT PROG HORM RES, V45, P209; HUHTANIEMI IT, 1992, MOL CELL ENDOCRINOL, V88, P55, DOI 10.1016/0303-7207(92)90009-U; HUNZICKERDUNN M, 1981, J BIOL CHEM, V256, P2185; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Ito M, 2000, MOL ENDOCRINOL, V14, P66, DOI 10.1210/me.14.1.66; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Khan SA, 2002, ENDOCRINOLOGY, V143, P2259, DOI 10.1210/en.143.6.2259; Kietzmann T, 2003, BLOOD, V101, P907, DOI 10.1182/blood-2002-06-1693; KRAMER A, 1984, STAT METHODS FOOD AG; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Le Provost F, 2002, GENESIS, V32, P231, DOI 10.1002/gene.10037; Li DM, 1998, BIOL REPROD, V58, P219, DOI 10.1095/biolreprod58.1.219; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Long X, 2003, CURR TOP MICROBIOL, V279, P115; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maizels ET, 2001, MOL ENDOCRINOL, V15, P716, DOI 10.1210/me.15.5.716; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meeks JJ, 2003, BIOL REPROD, V69, P154, DOI 10.1095/biolreprod.102.011429; Meroni SB, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740195; Miki N, 2004, J BIOL CHEM, V279, P15025, DOI 10.1074/jbc.M313186200; Mole DR, 2001, IUBMB LIFE, V52, P43; Mukherjee A, 1996, ENDOCRINOLOGY, V137, P3234, DOI 10.1210/en.137.8.3234; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; PIQUETTE GN, 1991, ENDOCRINOLOGY, V128, P2449, DOI 10.1210/endo-128-5-2449; RATOOSH SL, 1987, J BIOL CHEM, V262, P7306; RICHARDS J S, 1987, Steroids, V50, P393, DOI 10.1016/0039-128X(87)90027-4; Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Sasson R, 2003, FASEB J, V17, P1256, DOI 10.1096/fj.02-0740com; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Schroedl C, 2002, AM J PHYSIOL-LUNG C, V283, pL922, DOI 10.1152/ajplung.00014.2002; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SINGH IS, 1994, MOL ENDOCRINOL, V8, P1163, DOI 10.1210/me.8.9.1163; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Sun GW, 2003, ENDOCRINOLOGY, V144, P793, DOI 10.1210/en.2002-220900; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WOODRUFF TK, 1987, MOL ENDOCRINOL, V1, P561, DOI 10.1210/mend-1-8-561; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Zeleznik AJ, 2003, ENDOCRINOLOGY, V144, P3985, DOI 10.1210/en.2003-0293; Zhang Y, 2003, J STEROID BIOCHEM, V85, P401, DOI 10.1016/S0960-0760(03)00230-9; Zhong H, 2000, CANCER RES, V60, P1541; Zimmermann RC, 2003, J CLIN INVEST, V112, P659, DOI 10.1172/JCI200318740	86	191	202	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19431	19440		10.1074/jbc.M401235200	http://dx.doi.org/10.1074/jbc.M401235200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14982927	hybrid, Green Accepted			2022-12-27	WOS:000221164500008
J	Pittler, SJ; Zhang, YW; Chen, SM; Mears, AJ; Zack, DJ; Ren, ZY; Swain, PK; Yao, SX; Swaroop, A; White, JB				Pittler, SJ; Zhang, YW; Chen, SM; Mears, AJ; Zack, DJ; Ren, ZY; Swain, PK; Yao, SX; Swaroop, A; White, JB			Functional analysis of the rod photoreceptor cGMP phosphodiesterase alpha-subunit gene promoter - Nrl and Crx are required for full transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; RETINOBLASTOMA CELLS; RHODOPSIN GENE; LEUCINE-ZIPPER; HOMEOBOX GENE; EXPRESSION; MOUSE; PROTEINS; MUTATION; UPSTREAM	To understand the factors controlling expression of the cGMP phosphodiesterase type 6 (PDE6) genes, we have characterized the promoter of the human PDE6A gene that encodes the catalytic alpha-subunit. In vivo DNase I hypersensitivity assays revealed two sites immediately upstream of the PDE6A core promoter region. Transient transfection assay in Y79 cells of constructs containing varying lengths of the promoter region showed a decrease in promoter activity with increasing length. The most active segment contained a 177-bp upstream sequence including apparent Crx and Nrl transcription factor binding sites. Both Crx and Nrl transactivated the PDE6A promoter in HEK293 cells and showed a > 100-fold increase when coexpressed. Coexpression of a dominant negative inhibitor of Nrl abolished Nrl transactivation but had no effect on Crx. DNase I footprinting assays identified three potential Crx binding sites within a 55-bp segment beginning 29 bp upstream of the transcription start point. Mutation of two of these sites reduced reporter gene activity by as much as 69%. Gel shifts showed that all three Crx sites required a TAAT sequence for efficient binding. Consistent with a requirement for Crx and Nrl in Pde6a promoter activity, Pde6a mRNA is reduced by 87% in the retina of Crx(-/-) mice and is undetectable in Nrl(-/-) mice at postnatal day 10. These results establish that both Nrl and Crx are required for full transcriptional activity of the PDE6A gene.	Univ Alabama Birmingham, Sch Optometry, Vis Sci Res Ctr, Dept Physiol Opt, Birmingham, AL 35294 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA; Univ Michigan, Kellogg Eye Ctr, Dept Human Genet, Ann Arbor, MI 48105 USA; Johns Hopkins Med Sch, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Med Sch, Dept Mol Biol & Genet, Baltimore, MD 21287 USA; Johns Hopkins Med Sch, Dept Neurosci, Baltimore, MD 21287 USA	University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Pittler, SJ (corresponding author), Univ Alabama Birmingham, Sch Optometry, Vis Sci Res Ctr, Dept Physiol Opt, 924 18th St S, Birmingham, AL 35294 USA.	pittler@uab.edu	Pittler, Steven/J-7091-2013	Pittler, Steven/0000-0002-8464-9303; Zack, Don/0000-0002-7966-1973; Swaroop, Anand/0000-0002-1975-1141	NATIONAL EYE INSTITUTE [R01EY009924, P30EY001765, R01EY011115, R01EY006109, R01EY012543, P30EY003039, R01EY009769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054781] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY009769, EY 09924, P30 EY001765, EY 06109, EY 11115, P30 EY 03039, EY 09769, R01 EY012543, EY 12543] Funding Source: Medline; NIDDK NIH HHS [T30 DK 54781] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad I, 1995, Brain Res Dev Brain Res, V90, P184; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; Boatright J H, 1997, Mol Vis, V3, P15; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; DiPolo A, 1997, NUCLEIC ACIDS RES, V25, P3863, DOI 10.1093/nar/25.19.3863; DIPOLO A, 1995, P NATL ACAD SCI USA, V92, P4016, DOI 10.1073/pnas.92.9.4016; Furukawa A, 2002, J NEUROSCI, V22, P1640, DOI 10.1523/JNEUROSCI.22-05-01640.2002; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; HUANG SH, 1995, NAT GENET, V11, P468, DOI 10.1038/ng1295-468; KOUTALOS Y, 1995, J GEN PHYSIOL, V106, P891, DOI 10.1085/jgp.106.5.891; Lerner LE, 2003, INVEST OPHTH VIS SCI, V44, pU271; Lerner LE, 2002, J BIOL CHEM, V277, P25877, DOI 10.1074/jbc.M201407200; Lerner LE, 2001, J BIOL CHEM, V276, P34999, DOI 10.1074/jbc.M103301200; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Mohamed MK, 1998, J MOL NEUROSCI, V10, P235, DOI 10.1007/BF02761777; MONTECINO M, 1994, BIOCHEMISTRY-US, V33, P348, DOI 10.1021/bi00167a045; Nakatani K, 2002, ADV EXP MED BIOL, V514, P1; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; Piri N, 2003, J BIOL CHEM, V278, P36999, DOI 10.1074/jbc.M303710200; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Tan E, 2001, INVEST OPHTH VIS SCI, V42, P589; Taylor RE, 2001, BIOCHEM BIOPH RES CO, V282, P543, DOI 10.1006/bbrc.2001.4605; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; White JB, 2001, J NEUROSCI METH, V106, P1, DOI 10.1016/S0165-0270(00)00368-X; YU J, GENOME BIOL	33	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19800	19807		10.1074/jbc.M401864200	http://dx.doi.org/10.1074/jbc.M401864200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15001570	hybrid			2022-12-27	WOS:000221164500051
J	Duncan, MJ; Li, GJ; Shin, JS; Carson, JL; Abraham, SN				Duncan, MJ; Li, GJ; Shin, JS; Carson, JL; Abraham, SN			Bacterial penetration of bladder epithelium through lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY-TRACT INFECTION; UROPATHOGENIC ESCHERICHIA-COLI; MEMBRANE DOMAINS; PLASMA-MEMBRANE; CELL BIOLOGY; CAVEOLAE; CHOLESTEROL; EXPRESSION; INVASION; ENTRY	Type 1 fimbriated Escherichia coli represents the most common human uropathogen, owing much of its virulence to invasion of the uroepithelium, which is highly impermeable due to the preponderance of uroplakins and highly ordered lipid components. We sought to elucidate the molecular basis for E. coli invasion of the bladder epithelium by employing human 5637 bladder epithelial cells, and we found the following: ( i) intracellular E. coli associated with caveolae and lipid raft components; (ii) RNAi reduction of caveolin-1 expression inhibited bacterial invasion; (iii) a signaling molecule required for E. coli invasion was located in lipid rafts and physically associated with caveolin-1; (iv) bacterial invasion was inhibited by lipid raft disrupting/ usurping agents. In the mouse bladder, the E. coli type 1 fimbrial receptor, uroplakin Ia, was located in lipid rafts, and lipid raft disruptors inhibited E. coli invasion. Cumulatively, E. coli uroepithelial invasion occurs through lipid rafts, which, paradoxically, contribute to bladder impermeability.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Duke University	Abraham, SN (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	soman.abraham@duke.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050814] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI50021] Funding Source: Medline; NIDDK NIH HHS [R37-DK50814] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; Barnett BJ, 1997, AM J MED SCI, V314, P245, DOI 10.1097/00000441-199710000-00007; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Duncan MJ, 2002, CELL MICROBIOL, V4, P783, DOI 10.1046/j.1462-5822.2002.00230.x; FOXMAN B, 1990, AM J PUBLIC HEALTH, V80, P331, DOI 10.2105/AJPH.80.3.331; Gulati S, 1996, PEDIATR INFECT DIS J, V15, P237, DOI 10.1097/00006454-199603000-00012; Hooton TM, 2001, INT J ANTIMICROB AG, V17, P259, DOI 10.1016/S0924-8579(00)00350-2; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Hu P, 2002, AM J PHYSIOL-RENAL, V283, pF1200, DOI 10.1152/ajprenal.00043.2002; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; KETTERER B, 1973, BIOCHIM BIOPHYS ACTA, V311, P180, DOI 10.1016/0005-2736(73)90265-4; Krylov AV, 2001, J GEN PHYSIOL, V118, P333, DOI 10.1085/jgp.118.4.333; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; LEWIS SA, 1976, J MEMBRANE BIOL, V28, P1, DOI 10.1007/BF01869689; LEWIS SA, 1982, NATURE, V297, P685, DOI 10.1038/297685a0; Lewis SA, 2000, AM J PHYSIOL-RENAL, V278, pF867; Marjomaki V, 2002, J VIROL, V76, P1856, DOI 10.1128/JVI.76.4.1856-1865.2002; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; Martinez JJ, 2002, CELL MICROBIOL, V4, P19, DOI 10.1046/j.1462-5822.2002.00166.x; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Mulvey MA, 2001, INFECT IMMUN, V69, P4572, DOI 10.1128/IAI.69.7.4572-4579.2001; Naroeni A, 2002, INFECT IMMUN, V70, P1640, DOI 10.1128/IAI.70.3.1640-1644.2002; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; Razani B, 2001, J BIOL CHEM, V276, P38121; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Schilling JD, 2003, INFECT IMMUN, V71, P1470, DOI 10.1128/IAI.71.3.1470-1480.2003; Schilling JD, 2002, INFECT IMMUN, V70, P7042, DOI 10.1128/IAI.70.12.7042-7049.2002; Schilling JD, 2001, J IMMUNOL, V166, P1148, DOI 10.4049/jimmunol.166.2.1148; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Shin JS, 2001, SCIENCE, V293, P1447, DOI 10.1126/science.1061079; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stapleton A, 1999, ADV EXP MED BIOL, V462, P351; Svanborg C, 1997, INFECT DIS CLIN N AM, V11, P513, DOI 10.1016/S0891-5520(05)70371-8; Svanborg Eden C, 1983, Prog Food Nutr Sci, V7, P75; Toyoda K, 1997, FOOD CHEM TOXICOL, V35, P331, DOI 10.1016/S0278-6915(97)00128-2; Truschel ST, 2002, MOL BIOL CELL, V13, P830, DOI 10.1091/mbc.01-09-0435; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; VERGARA J, 1974, J CELL BIOL, V61, P83, DOI 10.1083/jcb.61.1.83; Vogel U, 1998, J CELL SCI, V111, P825; WU XR, 1995, J BIOL CHEM, V270, P29752; WU XR, 1990, J BIOL CHEM, V265, P19170; Zhou G, 2001, J CELL SCI, V114, P4095	50	139	141	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18944	18951		10.1074/jbc.M400769200	http://dx.doi.org/10.1074/jbc.M400769200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976212	hybrid, Green Published			2022-12-27	WOS:000221041500105
J	Iizuka, R; So, S; Inobe, T; Yoshida, T; Zako, T; Kuwajima, K; Yohda, M				Iizuka, R; So, S; Inobe, T; Yoshida, T; Zako, T; Kuwajima, K; Yohda, M			Role of the helical protrusion in the conformational change and molecular chaperone activity of the archaeal group II chaperonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOCOCCUS STRAIN KS-1; CRYSTAL-STRUCTURE; HYPERTHERMOPHILIC ARCHAEUM; SUBSTRATE-BINDING; GENE DUPLICATION; ATP HYDROLYSIS; PROTEIN; THERMOSOME; GROEL; CCT	To elucidate the exact role of the helical protrusion of a group II chaperonin in its molecular chaperone function, three deletion mutants of the chaperonin from a hyperthermophilic archaeum (Thermococcus sp. strain KS-1) lacking one-third, two-thirds, and the whole of the helical protrusion were constructed. The helical protrusion is thought to be substituted for the co-chaperonin GroES of a group I chaperonin and to be important for binding to unfolded proteins. Protease sensitivity assays and small angle x-ray scattering experiments were performed to demonstrate the conformation change of the wild type protein and the deletion mutants by adenine nucleotides. Whereas the binding of ATP to the wild type protein induced a structural transition corresponding to the closure of the built-in lid, it did not cause significant structural changes in deletion mutants. Although the mutants effectively protected proteins from thermal aggregation, ATP-dependent protein folding ability was remarkably diminished. We conclude that the helical protrusion is not necessarily important for binding to unfolded proteins, but its ATP-dependent conformational change mediates folding of captured unfolded proteins.	Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan; Univ Tokyo, Grad Sch Sci, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan	Tokyo University of Agriculture & Technology; University of Tokyo	Yohda, M (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, 2-24-16 Naka Cho, Tokyo 1848588, Japan.	yohda@cc.tuat.ac.jp	Zako, Tamotsu/C-3004-2012; Yohda, Masafumi/A-5149-2013	Yohda, Masafumi/0000-0001-8307-9671; Inobe, Tomonao/0000-0002-5864-6889; Iizuka, Ryo/0000-0002-9328-5628				AMEMIYA Y, 1995, REV SCI INSTRUM, V66, P2290, DOI 10.1063/1.1145667; Arai M, 2002, J MOL BIOL, V321, P121, DOI 10.1016/S0022-2836(02)00566-1; Archibald JM, 2002, J MOL BIOL, V316, P1041, DOI 10.1006/jmbi.2002.5409; Archibald JM, 2001, J STRUCT BIOL, V135, P157, DOI 10.1006/jsbi.2001.4353; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Furutani M, 1998, J BIOL CHEM, V273, P28399, DOI 10.1074/jbc.273.43.28399; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Gutsche I, 2001, J STRUCT BIOL, V135, P139, DOI 10.1006/jsbi.2001.4373; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Horst M, 1996, PROTEIN SCI, V5, P759; Iizuka R, 2003, J BIOL CHEM, V278, P44959, DOI 10.1074/jbc.M305484200; Iizuka R, 2001, BIOCHEM BIOPH RES CO, V289, P1118, DOI 10.1006/bbrc.2001.6139; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Llorca O, 2000, EMBO J, V19, P5971, DOI 10.1093/emboj/19.22.5971; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; Motojima F, 2003, J BIOL CHEM, V278, P26648, DOI 10.1074/jbc.M300806200; Nitsch M, 1998, NAT STRUCT BIOL, V5, P855, DOI 10.1038/2296; Pappenberger G, 2002, J MOL BIOL, V318, P1367, DOI 10.1016/S0022-2836(02)00190-0; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Shomura Y, 2004, J MOL BIOL, V335, P1265, DOI 10.1016/j.jmb.2003.11.028; Yoshida T, 2002, J MOL BIOL, V315, P73, DOI 10.1006/jmbi.2001.5220; Yoshida T, 1997, J MOL BIOL, V273, P635, DOI 10.1006/jmbi.1997.1337; Yoshida T, 2001, MOL MICROBIOL, V39, P1406, DOI 10.1046/j.1365-2958.2001.02334.x	29	32	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18834	18839		10.1074/jbc.M400839200	http://dx.doi.org/10.1074/jbc.M400839200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978026	hybrid			2022-12-27	WOS:000221041500092
J	Matsui, J; Wakabayashi, T; Asada, M; Yoshimatsu, K; Okada, M				Matsui, J; Wakabayashi, T; Asada, M; Yoshimatsu, K; Okada, M			Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; C-KIT; GROWTH-FACTOR; PROGENITOR CELLS; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC PROGENITOR; TUMOR ANGIOGENESIS; MESSENGER-RNA; MAST-CELLS	kit receptor tyrosine kinase is a marker of progenitor cells, which differentiate into blood and/or vascular endothelial cells, and has an important role in the amplification/ mobilization of progenitor cells. c-kit is expressed in mature endothelial cells, but its role there is unclear. Stem cell factor, a c-kit ligand, dose-dependently promoted survival, migration, and capillary tube formation of human umbilical vein endothelial cells. These effects mimicked those of vascular endothelial growth factor, except that stem cell factor did not sufficiently support proliferation of these cells. After exposing cells to this factor, Akt, Erk1/2, and c-kit were immediately (less than or equal to 5 min) and dose-dependently tyrosine-phosphorylated. STI-571, a c-kit inhibitor, dose-dependently attenuated these phosphorylations and inhibited stem cell factor-promoted survival and capillary tube formation over the same dose range. Wortmannin and LY294002, inhibitors of phosphoinositide 3-kinase, and PD98059, an inhibitor of MEK, abrogated survival and capillary tube formation, indicating that Akt and Erk1/2 should promote survival and capillary tube formation of these endothelial cells at a locus downstream to stem cell factor/c-kit signaling. Akt was more strongly phosphorylated, whereas Erk1/2 and p38 were more weakly phosphorylated with stem cell factor than with vascular endothelial growth factor. Phospholipase Cgamma was phosphorylated only with the latter, indicating that stem cell factor/c-kit signaling is somewhat different.	Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3002635, Japan	Eisai Co Ltd	Okada, M (corresponding author), Eisai & Co Ltd, Tsukuba Res Labs, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan.	m3-okada@hhc.eisai.co.jp						Abrams TJ, 2003, MOL CANCER THER, V2, P1011; Attoub S, 2002, CANCER RES, V62, P4879; AYE MT, 1992, EXP HEMATOL, V20, P523; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Carmeliet P, 2001, THROMB HAEMOSTASIS, V86, P289; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Davidoff AM, 2001, CLIN CANCER RES, V7, P2870; Deroanne CF, 1996, EXP CELL RES, V224, P215, DOI 10.1006/excr.1996.0131; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GALLI SJ, 1993, AM J PATHOL, V142, P965; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gill M, 2001, CIRC RES, V88, P167; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Kanda S, 2003, J BIOL CHEM, V278, P257, DOI 10.1074/jbc.M204771200; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kapur R, 2002, BLOOD, V100, P1287, DOI 10.1182/blood.V100.4.1287.h81602001287_1287_1293; Kijima T, 2002, CANCER RES, V62, P6304; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; KOENIG A, 1994, BLOOD, V83, P2836, DOI 10.1182/blood.V83.10.2836.2836; Konig A, 1997, BLOOD, V90, P148; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Krystal GW, 1998, CANCER RES, V58, P4660; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; MEININGER CJ, 1992, BLOOD, V79, P958; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117; Qi J H, 1999, Angiogenesis, V3, P371, DOI 10.1023/A:1026565908445; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sui XW, 2000, BRIT J HAEMATOL, V110, P63, DOI 10.1046/j.1365-2141.2000.02145.x; Sundstrom M, 2001, EXP CELL RES, V267, P144, DOI 10.1006/excr.2001.5239; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; TURNER AM, 1992, BLOOD, V80, P374; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Yamaguchi H, 1996, BRIT J HAEMATOL, V94, P606, DOI 10.1046/j.1365-2141.1996.d01-1855.x; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Zhang W, 2000, CANCER RES, V60, P6757	61	154	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18600	18607		10.1074/jbc.M311643200	http://dx.doi.org/10.1074/jbc.M311643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985355	hybrid			2022-12-27	WOS:000221041500063
J	Valdez, PA; Wang, H; Seshasayee, D; Campagne, MV; Gurney, A; Lee, WP; Grewal, IS				Valdez, PA; Wang, H; Seshasayee, D; Campagne, MV; Gurney, A; Lee, WP; Grewal, IS			NTB-A, a new activating receptor in T cells that regulates autoimmune disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED LYMPHOPROLIFERATIVE-DISEASE; NATURAL-KILLER-CELLS; GENE-PRODUCT SAP; MOLECULE SLAM; SIGNAL-TRANSDUCTION; SURFACE-MOLECULE; CD2; ICOS; COSTIMULATION; RESPONSES	The CD28 co-stimulatory pathway is well established for T cell activation; however, results from CD28 -/- mice suggest the existence of additional co-stimulatory pathways. Here we report the further characterization of a new member of the CD2 superfamily, NTB-A, important in T cell co-stimulation. NTB-A is expressed on T cells, and its expression is up-regulated on activated cells. Triggering of NTB-A with monoclonal antibodies in the absence of CD28 signals leads to T cell proliferation and interferon-gamma secretion but not interleukin-4. Cross-linking of NTB-A also induces phosphorylation of NTB-A and the association of SAP (SLAM-associated protein), the protein absent in X-linked lymphoproliferative disease. T helper cells differentiated by crosslinking NTB-A and CD3 developed predominantly into Th1 cells not Th2 cells. In vivo blocking of NTB-A interactions with its ligands by using soluble NTB-A-Fc fusion protein inhibits B cell isotype switching to IgG2a and IgG3, commonly induced by Th1-type cytokines. Most important, treatment of mice with NTB-A-Fc delays the onset of antigen-induced experimental allergic encephalomyelitis in myelin basic protein-T cell receptor transgenic mice, suggesting a role in T cell-mediated autoimmune disease. Regulation of interferon-gamma secretion, and not interleukin-4 in vitro, as well as inhibition of Th1 cell-induced isotype switching and attenuation of experimental allergic encephalomyelitis indicate that NTB-A is important for Th1 responses. The observation that cross-linking of NTB-A induces T cell activation, expansion, and Th1-type cytokine production suggests NTB-A is a novel co-stimulatory receptor. The identification of NTB-A as a regulator of T cell response paves the way to provide novel therapeutic approaches for modulation of the immune response.	Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Grewal, IS (corresponding author), Genentech Inc, Dept Immunol, 1 DNA Way, San Francisco, CA 94080 USA.	iqbal@gene.com		Grewal, Iqbal S/0000-0002-4775-055X				Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Aversa G, 1997, J IMMUNOL, V158, P4036; Bottino C, 2001, J EXP MED, V194, P235, DOI 10.1084/jem.194.3.235; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; Castro AG, 1999, J IMMUNOL, V163, P5860; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; delaFuente MA, 1997, BLOOD, V90, P2398; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Fraser CC, 2002, IMMUNOGENETICS, V53, P843, DOI 10.1007/s00251-001-0415-7; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Green JM, 2000, J IMMUNOL, V164, P3591, DOI 10.4049/jimmunol.164.7.3591; Howie D, 2002, BLOOD, V99, P957, DOI 10.1182/blood.V99.3.957; KILLEEN N, 1992, EMBO J, V11, P4329, DOI 10.1002/j.1460-2075.1992.tb05532.x; Latour S, 2001, NAT IMMUNOL, V2, P681, DOI 10.1038/90615; Lewis J, 2001, CLIN IMMUNOL, V100, P15, DOI 10.1006/clim.2001.5035; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; LUCAS PJ, 1995, J IMMUNOL, V154, P5757; Martin M, 2001, J IMMUNOL, V167, P3668, DOI 10.4049/jimmunol.167.7.3668; MATHEW PA, 1993, J IMMUNOL, V151, P5328; Mavaddat N, 2000, J BIOL CHEM, V275, P28100; Morra M, 2001, ANNU REV IMMUNOL, V19, P657, DOI 10.1146/annurev.immunol.19.1.657; Nichols KE, 2001, NAT IMMUNOL, V2, P665, DOI 10.1038/90595; Ozkaynak E, 2001, NAT IMMUNOL, V2, P591, DOI 10.1038/89731; Peck SR, 2000, IMMUNOGENETICS, V52, P63, DOI 10.1007/s002510000252; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; Rottman JB, 2001, NAT IMMUNOL, V2, P605, DOI 10.1038/89750; SANDRIN MS, 1992, J IMMUNOL, V149, P1636; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Shlapatska LM, 2001, J IMMUNOL, V166, P5480, DOI 10.4049/jimmunol.166.9.5480; Sperling AI, 2001, NAT IMMUNOL, V2, P573, DOI 10.1038/89709; STAUNTON DE, 1987, EMBO J, V6, P3695, DOI 10.1002/j.1460-2075.1987.tb02703.x; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; VALIANTE NM, 1993, J EXP MED, V178, P1397, DOI 10.1084/jem.178.4.1397; VEILLETTE A, 2002, SCI STKE	39	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18662	18669		10.1074/jbc.M312313200	http://dx.doi.org/10.1074/jbc.M312313200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14988414	hybrid			2022-12-27	WOS:000221041500071
J	Zenke, FT; Krendel, M; DerMardirossian, C; King, CC; Bohl, BP; Bokoch, GM				Zenke, FT; Krendel, M; DerMardirossian, C; King, CC; Bohl, BP; Bokoch, GM			p21-activated kinase 1 phosphorylates and regulates 14-3-3 binding to GEF-H1, a microtubule-localized Rho exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE; ACTIN CYTOSKELETON; FOCAL ADHESIONS; KINASE-ACTIVITY; STRESS FIBERS; GTPASES; IDENTIFICATION; CELLS; DYNAMICS; MOTILITY	GEF-H1 is a guanine nucleotide exchange factor for Rho whose activity is regulated through a cycle of microtubule binding and release. Here we identify a region in the carboxyl terminus of GEF-H1 that is important for suppression of its guanine nucleotide exchange activity by microtubules. This portion of the protein includes a coiled-coil motif, a proline-rich motif that may interact with Src homology 3 domain-containing proteins, and a potential binding site for 14-3-3 proteins. We identify GEF-H1 as a binding target and substrate for p21-activated kinase 1 (PAK1), an effector of Rac and Cdc42 GTPases, using an affinity-based screen and localize a PAK1 phosphorylation site to the inhibitory carboxyl-terminal region of GEF-H1. We show that phosphorylation of GEF-H1 at Ser(885) by PAK1 induces 14-3-3 binding to the exchange factor and relocation of 14-3-3 to microtubules. Phosphorylation of GEF-H1 by PAK may be involved in regulation of GEF-H1 activity and may serve to coordinate Rho-, Rac-, and Cdc42-mediated signaling pathways.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, IMM14,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bokoch@scripps.edu	DerMardirossian, Celine/P-1020-2015	Krendel, Mira/0000-0002-7008-9069; Zenke, Frank/0000-0002-2226-3755				Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; FERRALLI J, 1994, J CELL SCI, V107, P3115; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; LIAO GJ, 1995, J CELL SCI, V108, P3473; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Ozer RS, 2000, MOL BIOL CELL, V11, P3573, DOI 10.1091/mbc.11.10.3573; Qyang YB, 2002, MOL MICROBIOL, V44, P325, DOI 10.1046/j.1365-2958.2002.02882.x; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Wittmann T, 2001, J CELL SCI, V114, P3795; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhai JB, 2001, J BIOL CHEM, V276, P41318, DOI 10.1074/jbc.M107709200; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	32	121	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18392	18400		10.1074/jbc.M400084200	http://dx.doi.org/10.1074/jbc.M400084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970201	hybrid			2022-12-27	WOS:000221041500037
J	Miao, F; Gonzalo, IG; Lanting, L; Natarajan, R				Miao, F; Gonzalo, IG; Lanting, L; Natarajan, R			In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; KAPPA-B; HISTONE DEACETYLASES; OXIDANT STRESS; GLUCOSE; ACETYLATION; EXPRESSION; COMPLICATIONS; COREPRESSORS; PATHOGENESIS	The transcription factor NF-kappaB ( NF-kappaB) plays a pivotal role in regulating inflammatory gene expression. Its effects are optimized by various coactivators including histone acetyltransferases (HAT) such as CBP/p300 and p/CAF. Evidence shows that high glucose (HG) conditions mimicking diabetes can activate the transcription of NF-kappaB-regulated inflammatory genes. However, the underlying in vivo transcription and nuclear chromatin remodeling events are unknown. We therefore carried out chromatin immunoprecipitation (ChIP) assays in monocytes to identify 1) chromatin factors bound to the promoters of tumor necrosis factor-alpha (TNF-alpha) and related NF-kappaB-regulated genes under HG or diabetic conditions, 2) specific lysine (Lys ( K)) residues on histone H3 (HH3) and HH4 acetylated in this process. HG treatment of THP-1 monocytes increased the transcriptional activity of NF-kappaB p65, which was augmented by CBP/ p300 and p/CAF. ChIP assays showed that HG increased the recruitment of NF-kappaB p65, CPB, and p/CAF to the TNF-alpha and COX-2 promoters. Interestingly, ChIP assays also demonstrated concomitant acetylation of HH3 at Lys(9) and Lys(14), and HH4 at Lys(5), Lys(8), and Lys(12) at the TNF-alpha and COX-2 promoters. Overexpression of histone deacetylase (HDAC) isoforms inhibited p65-mediated TNF-alpha transcription. In contrast, a HDAC inhibitor stimulated gene transcription and histone acetylation. Finally, we demonstrated increased HH3 acetylation at TNF-alpha and COX-2 promoters in human blood monocytes from type 1 and type 2 diabetic subjects relative to nondiabetic. These results show for the first time that diabetic conditions can increase in vivo recruitment of NF-kappaB and HATs, as well as histone acetylation at the promoters of inflammatory genes, leading to chromatin remodeling and transcription.	City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet Ctr, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Natarajan, R (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.	rnatarajan@coh.org			NCRR NIH HHS [M01RR000043] Funding Source: Medline; NHLBI NIH HHS [P01 HL55798] Funding Source: Medline; NIDDK NIH HHS [R01 DK065073] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065073] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barrera-Hernandez G, 2000, MOL CELL BIOL, V20, P4253, DOI 10.1128/MCB.20.12.4253-4264.2000; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Guha M, 2000, J BIOL CHEM, V275, P17728, DOI 10.1074/jbc.275.23.17728; Hofmann MA, 1998, DIABETES CARE, V21, P1310, DOI 10.2337/diacare.21.8.1310; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Ido Y, 1997, DIABETOLOGIA, V40, pS115, DOI 10.1007/s001250051422; Ishii H, 1998, J MOL MED, V76, P21, DOI 10.1007/s109-1998-8101-y; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Leonardo MJ, 1998, CELL, V58, P227; MOROHOSHI M, 1995, ANN NY ACAD SCI, V748, P562; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; PUGLIESE G, 1991, DIABETES METAB REV, V7, P35, DOI 10.1002/dmr.5610070106; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; Shanmugam N, 2003, J BIOL CHEM, V278, P34834, DOI 10.1074/jbc.M302828200; Shanmugam N, 2003, DIABETES, V52, P1256, DOI 10.2337/diabetes.52.5.1256; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	39	267	287	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					18091	18097		10.1074/jbc.M311786200	http://dx.doi.org/10.1074/jbc.M311786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14976218	hybrid			2022-12-27	WOS:000220870400145
J	Ge, YZ; Pu, MT; Gowher, H; Wu, HP; Ding, JP; Jeltsch, A; Xu, GL				Ge, YZ; Pu, MT; Gowher, H; Wu, HP; Ding, JP; Jeltsch, A; Xu, GL			Chromatin targeting of de novo DNA methyltransferases by the PWWP domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 METHYLTRANSFERASE; ACUTE MYELOID-LEUKEMIA; IMMUNODEFICIENCY SYNDROME; MAMMALIAN DEVELOPMENT; METHYLATION PATTERNS; NEUROSPORA-CRASSA; COACTIVATORS P52; ICF SYNDROME; IN-VIVO; DNMT3B	DNA methylation patterns of mammalian genomes are generated in gametogenesis and early embryonic development. Two de novo DNA methyltransferases, Dnmt3a and Dnmt3b, are responsible for the process. Both enzymes contain a long N-terminal regulatory region linked to a conserved C-terminal domain responsible for the catalytic activity. Although a PWWP domain in the N-terminal region has been shown to bind DNA in vitro, it is unclear how the DNA methyltransferases access their substrate in chromatin in vivo. We show here that the two proteins are associated with chromatin including mitotic chromosomes in mammalian cells, and the PWWP domain is essential for the chromatin targeting of the enzymes. The functional significance of PWWP-mediated chromatin targeting is suggested by the fact that a missense mutation in this domain of human DNMT3B causes immunodeficiency, centromeric heterochromatin instability, facial anomalies (ICF) syndrome, which is characterized by loss of methylation in satellite DNA, pericentromeric instability, and immunodeficiency. We demonstrate that the mutant protein completely loses its chromatin targeting capacity. Our data establish the PWWP domain as a novel chromatin/chromosome-targeting module and suggest that the PWWP-mediated chromatin association is essential for the function of the de novo methyltransferases during development.	Chinese Acad Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China; Univ Giessen, Inst Biochem, Fachbereich 8, D-35392 Giessen, Germany; Int Jacobs Univ Bremen, Sch Sci & Engn, D-28759 Bremen, Germany	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Justus Liebig University Giessen	Xu, GL (corresponding author), Chinese Acad Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	glxu@sibs.ac.cn	Pu, Mintie/R-7757-2016; Gowher, Humaira/AAG-7112-2019; Jeltsch, Albert/O-7404-2014	Pu, Mintie/0000-0001-9654-8633; Jeltsch, Albert/0000-0001-6113-9290				Ahuja HG, 2000, CANCER RES, V60, P6227; Alvarez-Venegas R, 2001, GENE, V271, P215, DOI 10.1016/S0378-1119(01)00524-8; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Costello JF, 2002, NAT GENET, V31, P123, DOI 10.1038/ng0602-123; Fukagawa T, 1999, EMBO J, V18, P4196, DOI 10.1093/emboj/18.15.4196; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Garcia V, 2003, PLANT CELL, V15, P119, DOI 10.1105/tpc.006577; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Gowher H, 2002, J BIOL CHEM, V277, P20409, DOI 10.1074/jbc.M202148200; Gowher H, 2001, J MOL BIOL, V309, P1201, DOI 10.1006/jmbi.2001.4710; GU J, 1994, BIOTECHNIQUES, V17, P257; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hata K, 2002, DEVELOPMENT, V129, P1983; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Hussey DJ, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-20; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jaju RJ, 2001, BLOOD, V98, P1264, DOI 10.1182/blood.V98.4.1264; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Kang ES, 2001, BIOCHEM BIOPH RES CO, V289, P862, DOI 10.1006/bbrc.2001.6057; Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333; Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759; Reik W, 1999, NAT GENET, V23, P380, DOI 10.1038/70476; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Scholzen T, 2002, J PATHOL, V196, P135, DOI 10.1002/path.1016; Shirohzu H, 2002, AM J MED GENET, V112, P31, DOI 10.1002/ajmg.10658; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Thurston VC, 1996, CHROMOSOMA, V105, P20, DOI 10.1007/BF02510035; Weisenberger DJ, 2002, GENE, V298, P91, DOI 10.1016/S0378-1119(02)00976-9; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	51	150	155	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25447	25454		10.1074/jbc.M312296200	http://dx.doi.org/10.1074/jbc.M312296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	14998998	hybrid			2022-12-27	WOS:000221827900068
J	Gorski, JP; Wang, AM; Lovitch, D; Law, D; Powell, K; Midura, RJ				Gorski, JP; Wang, AM; Lovitch, D; Law, D; Powell, K; Midura, RJ			Extracellular bone acidic glycoprotein-75 defines condensed mesenchyme regions to be mineralized and localizes with bone sialoprotein during intramembranous bone formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIBIAL MARROW ABLATION; MATRIX VESICLES; COLLAGEN FIBRILS; IN-VITRO; GENE-EXPRESSION; MESSENGER-RNA; TENASCIN-C; RAT BONE; N-RAP; PROTEIN	Bone acidic glycoprotein-75 is expressed very early during in vivo models of intramembranous bone formation, highly enriched in condensing osteogenic mesenchyme after marrow ablation and the osteoprogenitor layer of tibial periosteum. Bone sialoprotein accumulates within bone acidic glycoprotein-75-enriched matrix areas at a later stage in both models. Decalcification of initial sites of mineralization consistently revealed focal immunostaining for bone acidic glycoprotein-75 underneath these sites suggesting that mineralization occurs within bone acidic glycoprotein-75-enriched matrix areas. Ultrastructural immunolocalization of bone acidic glycoprotein-75 does not support a direct association with banded collagen fibrils, but rather suggests it is a component of a separate, amorphous scaffold occupying interfibrillar spaces. Double immunogold labeling demonstrated that a sizeable proportion of bone sialoprotein particles were located within a 50-nm radius of bone acidic glycoprotein-75. These results define bone acidic glycoprotein-75 as the earliest bone-restricted, extracellular marker of osteogenic mesenchyme. Based on this early bone-restricted expression pattern and a previously documented propensity of bone acidic glycoprotein-75 to form supramolecular complexes through self-association, bone acidic glycoprotein-75 may serve a key structural role in setting boundary limits of condensing osteogenic mesenchyme.	Univ Missouri, Sch Dent, Dept Oral Biol, Bone Biol Res Program, Kansas City, MO 64108 USA; Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64108 USA; Cleveland Clin & Fdn, Orthopaed Res Ctr, Cleveland, OH 44195 USA; Cleveland Clin & Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Missouri System; University of Missouri Kansas City	Gorski, JP (corresponding author), Univ Missouri, Sch Dent, Dept Oral Biol, Bone Biol Res Program, 650 E 25th St, Kansas City, MO 64108 USA.	Gorskij@umkc.edu			NIAMS NIH HHS [AR-45171] Funding Source: Medline; NIDCR NIH HHS [DE-11197, DE-14619] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE014619, R03DE011197] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; BHARGAVA U, 1988, BONE, V9, P155, DOI 10.1016/8756-3282(88)90005-1; BIANCO P, 1993, J HISTOCHEM CYTOCHEM, V41, P193, DOI 10.1177/41.2.8419459; BONNUCI E, 1989, CONNECT TISSUE RES, V22, P43; BONUCCI E, 1992, BONE MINER, V17, P219, DOI 10.1016/0169-6009(92)90740-5; Bonucci E, 1995, Connect Tissue Res, V33, P157, DOI 10.3109/03008209509016996; BONUCCI E, 1978, CALC TISS RES, V25, P179, DOI 10.1007/BF02010766; BONUCCI E, 1988, CLIN ORTHOP RELAT R, P243; Bonucci E., 1992, CALCIFICATION BIOL S, P19; BOSKEY AL, 1995, ANN NY ACAD SCI, V760, P249, DOI 10.1111/j.1749-6632.1995.tb44635.x; BOSKEY AL, 1992, CLIN ORTHOP RELAT R, P244; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHEN Y, 1992, J BIOL CHEM, V267, P24871; Deak F, 1997, J BIOL CHEM, V272, P9268; Fell HB, 1925, J MORPHOL PHYSIOL, V40, P417, DOI 10.1002/jmor.1050400302; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; Gorski JP, 2003, J BONE MINER RES, V18, pS196; Gorski JP, 1996, CONNECT TISSUE RES, V35, P137, DOI 10.3109/03008209609029184; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; Gorski JP, 1997, J CELL BIOCHEM, V64, P547; Gorski JP, 1998, CRIT REV ORAL BIOL M, V9, P201, DOI 10.1177/10454411980090020401; Gorski JP, 2000, BONE, V27, P103, DOI 10.1016/S8756-3282(00)00295-7; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; Herrera AH, 2000, CELL MOTIL CYTOSKEL, V45, P211, DOI 10.1002/(SICI)1097-0169(200003)45:3<211::AID-CM4>3.3.CO;2-P; HIRAKAWA K, 1994, J BONE MINER RES, V9, P1551; Hoshi K, 1999, J BONE MINER RES, V14, P273, DOI 10.1359/jbmr.1999.14.2.273; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; Irie K, 1998, ANAT RECORD, V252, P554; Jee W., 1983, HISTOLOGY CELL TISSU, V5, P200; JEE WSS, 1988, BONE, V9, P381, DOI 10.1016/8756-3282(88)90120-2; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; KASUGAI S, 1992, J CELL PHYSIOL, V152, P467, DOI 10.1002/jcp.1041520305; Koyama E, 1996, J ORTHOPAED RES, V14, P403, DOI 10.1002/jor.1100140310; KOYAMA E, 1995, DEV DYNAM, V203, P152, DOI 10.1002/aja.1002030204; LAW DJ, 1993, AM J PATHOL, V142, P1513; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Magnuson SK, 1997, J BONE MINER RES, V12, P200, DOI 10.1359/jbmr.1997.12.2.200; MAJESKA RJ, 1975, BIOCHIM BIOPHYS ACTA, V391, P51, DOI 10.1016/0005-2744(75)90151-5; MCCULLOCH CAG, 1989, ANAT REC, V223, P27, DOI 10.1002/ar.1092230105; MCQUILLAN DJ, 1995, BONE, V16, P415; Midura RJ, 2004, J BIOL CHEM, V279, P25464, DOI 10.1074/jbc.M312409200; Midura RJ, 2003, J BIOL CHEM, V278, P51462, DOI 10.1074/jbc.M307567200; Nefussi JR, 1997, J HISTOCHEM CYTOCHEM, V45, P493, DOI 10.1177/002215549704500402; Piecha D, 2002, BIOCHEM J, V367, P715, DOI 10.1042/BJ20021069; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; Riminucci M, 1998, J BONE MINER RES, V13, P1852, DOI 10.1359/jbmr.1998.13.12.1852; RIMINUCCI M, 1995, CALCIFIED TISSUE INT, V57, P277, DOI 10.1007/BF00298883; SATO M, 1992, FASEB J, V6, P2966, DOI 10.1096/fasebj.6.11.1644260; SATOMURA K, 1991, ACTA ANAT, V142, P97; SAUREN YMHF, 1989, BONE, V10, P287, DOI 10.1016/8756-3282(89)90066-5; Schinke T, 1999, NAT GENET, V21, P150, DOI 10.1038/5928; SCHWARTZ Z, 1989, BONE, V10, P53, DOI 10.1016/8756-3282(89)90147-6; STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420; SUVA LJ, 1993, J BONE MINER RES, V8, P379; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; WANG A, 1999, T 45 ANN M ORTH RES, P209; Wang AM, 2000, J BIOL CHEM, V275, P11082, DOI 10.1074/jbc.275.15.11082; WUTHIER RE, 1989, CONNECT TISSUE RES, V22, P653, DOI 10.3109/03008208909114117; Zhang RQ, 2001, BIOCHEMISTRY-US, V40, P14898, DOI 10.1021/bi0107445; Zhu JX, 2001, HISTOCHEM J, V33, P25, DOI 10.1023/A:1017587712914; ZIMMERMANN B, 1984, HISTOCHEMISTRY, V81, P353, DOI 10.1007/BF00514329	64	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25455	25463		10.1074/jbc.M312408200	http://dx.doi.org/10.1074/jbc.M312408200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15004029	hybrid			2022-12-27	WOS:000221827900069
J	Ahn, JH; Kim, JS; Yu, HK; Lee, HJ; Yoon, Y				Ahn, JH; Kim, JS; Yu, HK; Lee, HJ; Yoon, Y			A truncated kringle domain of human apolipoprotein(a) inhibits the activation of extracellular signal-regulated kinase 1 and 2 through a tyrosine phosphatase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; MAP-KINASE; PROTEIN PHOSPHATASES; CELL MIGRATION; ANGIOGENESIS; PHOSPHORYLATION; ANGIOSTATIN; VEGF; PLASMINOGEN; MECHANISM	Most proangiogenic factors exert their biological effects primarily by activating extracellular signal- regulated kinase ( ERK) and phosphoinositide 3- kinase ( PI3K)/ Akt signaling pathways. These pathways appear to play a critical role in endothelial cell migration, because selective inhibition of either ERK or PI3- K/ Akt signaling almost completely prevented endothelial cell migration. Recently, we demonstrated that a truncated kringle domain of human apolipoprotein( a), termed rhLK68, inhibits endothelial cell migration in vitro. However, its mechanism of action was not well defined. In this study, we determined the effects of rhLK68 on ERK1/ 2 and PI3- K/ Akt signaling pathways to explore the molecular mechanism of rhLK68- mediated inhibition of endothelial cell migration. Treatment with rhLK68 inhibited ERK1/ 2 phosphorylation but did not influence Akt activation. Interestingly, an inhibitor of protein- tyrosine phosphatase, sodium orthovanadate, dose- dependently reversed both rhLK68- induced dephosphorylation of ERK1/ 2 and decreased migration of endothelial cells, whereas rhLK68 showed no significant effects on MEKs phosphorylation. In conclusion, these results indicate that inhibition of endothelial cell migration by rhLK68 may be achieved by interfering with ERK1/ 2 activation via a protein- tyrosine phosphatase- dependent pathway.	Mogam Biotechnol Res Inst, Yongin 449910, Kyonggi Do, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Yoon, Y (corresponding author), Mogam Biotechnol Res Inst, Yongin 449910, Kyonggi Do, South Korea.	yy@greencross.com						ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cao Yihai, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P667, DOI 10.2174/1568011023353705; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Eriksson K, 2003, FEBS LETT, V536, P19, DOI 10.1016/S0014-5793(03)00003-6; Folkman J, 2002, CANCER CELL, V1, P113, DOI 10.1016/S1535-6108(02)00038-7; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; Gabel S, 1999, OTOLARYNG HEAD NECK, V121, P463, DOI 10.1016/S0194-5998(99)70238-X; Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200; GUEVARA J, 1992, PROTEINS, V12, P188, DOI 10.1002/prot.340120212; Hagedorn M, 2001, FASEB J, V15, P550; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Jackson Jodi, 1997, Invasion and Metastasis, V17, P199; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Kim JS, 2003, J BIOL CHEM, V278, P29000, DOI 10.1074/jbc.M301042200; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; Pettiford SM, 2000, ONCOGENE, V19, P858, DOI 10.1038/sj.onc.1203408; Pintucci G, 1999, SURGERY, V126, P422, DOI 10.1067/msy.1999.99169; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Redlitz A, 1999, J VASC RES, V36, P28, DOI 10.1159/000025623; Schulter V, 2001, ARTERIOSCL THROM VAS, V21, P433, DOI 10.1161/01.ATV.21.3.433; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tarrega C, 2002, J BIOL CHEM, V277, P2629, DOI 10.1074/jbc.M108874200; Trieu VN, 1999, BIOCHEM BIOPH RES CO, V257, P714, DOI 10.1006/bbrc.1999.0519; Urbich C, 2002, FASEB J, V16, P706, DOI 10.1096/fj.01-0637fje; Wajih N, 2003, BLOOD, V101, P1857, DOI 10.1182/blood-2002-02-0582; Wickstrom SA, 2002, CANCER RES, V62, P5580; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200	36	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21808	21814		10.1074/jbc.M313633200	http://dx.doi.org/10.1074/jbc.M313633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14996836	hybrid			2022-12-27	WOS:000221417100018
J	Chung, MK; Lee, H; Mizuno, A; Suzuki, M; Caterina, MJ				Chung, MK; Lee, H; Mizuno, A; Suzuki, M; Caterina, MJ			TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; VANILLOID RECEPTOR; EPOXYEICOSATRIENOIC ACIDS; CAPSAICIN-RECEPTOR; ACTIVATE TRPV4; ION-CHANNEL; EXPRESSION; HEAT; PROTEIN; PAIN	Recently, a family of temperature-activated ion channels has been identified in mammalian and nonmammalian species that appear to contribute to thermosensation. Two of these proteins, TRPV3 and TRPV4, are ion channels activated by modest increases in ambient temperature. Localization studies have indicated that both proteins, in addition to being expressed in sensory neurons, are also expressed in skin keratinocytes. These and other findings have suggested that keratinocytes might act in concert with sensory neurons to perceive our thermal environment. In this study, we demonstrate that primary keratinocytes isolated from mouse skin exhibit two distinct heat-evoked current responses to mild increases in ambient temperature. The more common of these response types bears considerable similarity to responses mediated by recombinant TRPV4, is absent in mice lacking this ion channel, and is restored upon TRPV4 reintroduction. The second, rarer response strongly resembles those mediated by recombinant TRPV3. Together, these findings demonstrate that keratinocytes can indeed act as thermosensory cells and that they do so via at least two distinct transduction mechanisms.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi 3290498, Japan	Johns Hopkins University; Johns Hopkins University; Jichi Medical University	Caterina, MJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 408 Biophys Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	caterina@jhmi.edu	Chung, Man-Kyo/S-7433-2019	Chung, Man-Kyo/0000-0001-7637-1148; , Hyosang/0000-0002-3200-8678				Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; Denda M, 2002, J INVEST DERMATOL, V119, P1034, DOI 10.1046/j.1523-1747.2002.19505.x; Denda M, 2001, BIOCHEM BIOPH RES CO, V285, P1250, DOI 10.1006/bbrc.2001.5299; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; Guler AD, 2002, J NEUROSCI, V22, P6408; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENSEL H, 1960, J PHYSIOL-LONDON, V153, P113, DOI 10.1113/jphysiol.1960.sp006522; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; Inoue K, 2002, BIOCHEM BIOPH RES CO, V291, P124, DOI 10.1006/bbrc.2002.6393; Khodorova A, 2003, NAT MED, V9, P1055, DOI 10.1038/nm885; Komuves L, 2002, J CELL PHYSIOL, V192, P45, DOI 10.1002/jcp.10107; Ladd PA, 2003, J BIOL CHEM, V278, P35184, DOI 10.1074/jbc.M301666200; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Paladini RD, 1998, J CELL BIOL, V142, P1035, DOI 10.1083/jcb.142.4.1035; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Souslova V, 2000, NATURE, V407, P1015, DOI 10.1038/35039526; Southall MD, 2003, J PHARMACOL EXP THER, V304, P217, DOI 10.1124/jpet.102.040675; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Strotmann R, 2003, J BIOL CHEM, V278, P26541, DOI 10.1074/jbc.M302590200; Suzuki M, 2003, J BIOL CHEM, V278, P51448, DOI 10.1074/jbc.M308212200; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; TRON VA, 1990, J CLIN INVEST, V85, P1085, DOI 10.1172/JCI114539; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; WATT FM, 1984, J CELL BIOL, V99, P2211, DOI 10.1083/jcb.99.6.2211; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882	40	212	227	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21569	21575		10.1074/jbc.M401872200	http://dx.doi.org/10.1074/jbc.M401872200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004014	hybrid			2022-12-27	WOS:000221273800123
J	Hedengren-Olcott, M; Olcott, MC; Mooney, DT; Ekengren, S; Geller, BL; Taylor, BJ				Hedengren-Olcott, M; Olcott, MC; Mooney, DT; Ekengren, S; Geller, BL; Taylor, BJ			Differential activation of the NF-kappa B-like factors relish and Dif in Drosophila melanogaster by fungi and Gram-positive bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDOGLYCAN-RECOGNITION PROTEIN; INSECT IMMUNITY; INNATE IMMUNITY; ANTIBACTERIAL DEFENSE; NEGATIVE BACTERIA; TEICHURONIC ACID; GENE-CLUSTER; CELL-WALLS; TOLL; RECEPTOR	The current model of immune activation in Drosophila melanogaster suggests that fungi and Gram-positive (G(+)) bacteria activate the Toll/Dif pathway and that Gram-negative (G(-)) bacteria activate the Imd/Relish pathway. To test this model, we examined the response of Relish and Dif (Dorsal-related immunity factor) mutants to challenge by various fungi and G(+) and G(-) bacteria. In Relish mutants, the Cecropin A gene was induced by the G(+) bacteria Micrococcus luteus and Staphylococcus aureus, but not by other G(+) or G(-) bacteria. This Relish-independent Cecropin A induction was blocked in Dif/Relish double mutant flies. Induction of the Cecropin A1 gene by M. luteus required Relish, whereas induction of the Cecropin A2 gene required Dif. Intact peptidoglycan (PG) was necessary for this differential induction of Cecropin A. PG extracted from M. luteus induced Cecropin A in Relish mutants, whereas PGs from the G(+) bacteria Bacillus megaterium and Bacillus subtilis did not, suggesting that the Drosophila immune system can distinguish PGs from various G(+) bacteria. Various fungi stimulated antimicrobial peptides through at least two different pathways requiring Relish and/or Dif. Induction of Attacin A by Geotrichum candidum required Relish, whereas activation by Beauvaria bassiana required Dif, suggesting that the Drosophila immune system can distinguish between at least these two fungi. We conclude that the Drosophila immune system is more complex than the current model. We propose a new model to account for this immune system complexity, incorporating distinct pattern recognition receptors of the Drosophila immune system, which can distinguish between various fungi and G(+) bacteria, thereby leading to selective induction of antimicrobial peptides via differential activation of Relish and Dif.	Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ Stockholm, Wenner Gren Inst, S-10691 Stockholm, Sweden; Umea Univ, Umea Ctr Mol Pathogenesis, S-90187 Umea, Sweden	Oregon State University; Oregon State University; Oregon State University; Stockholm University; Umea University	Hedengren-Olcott, M (corresponding author), Oregon State Univ, Dept Microbiol, 220 Nash Hall, Corvallis, OR 97331 USA.	hedengrm@science.oregonstate.edu						Akira S, 2001, ADV IMMUNOL, V78, P1, DOI 10.1016/S0065-2776(01)78001-7; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; ASLING B, 1995, INSECT BIOCHEM MOLEC, V25, P511, DOI 10.1016/0965-1748(94)00091-C; Battey, 1986, BASIC METHODS MOL BI; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; BOMAN HG, 1974, INFECT IMMUN, V10, P136, DOI 10.1128/IAI.10.1.136-145.1974; BOMAN HG, 1968, GENET RES, V12, P169, DOI 10.1017/S0016672300011782; Cebo C, 2002, BBA-GEN SUBJECTS, V1572, P422, DOI 10.1016/S0304-4165(02)00323-9; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; DENOBEL H, 2001, MYCOTA BIOL FUNGAL C, V7; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; EDLUND T, 1976, INFECT IMMUN, V14, P934, DOI 10.1128/IAI.14.4.934-941.1976; ENGSTROM Y, 1992, ROUX ARCH DEV BIOL, V201, P65, DOI 10.1007/BF00420417; FAYE I, 1975, INFECT IMMUN, V12, P1426, DOI 10.1128/IAI.12.6.1426-1438.1975; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FLAMM RK, 1984, INFECT IMMUN, V44, P157, DOI 10.1128/IAI.44.1.157-161.1984; GELLER BL, 1993, J BACTERIOL, V175, P5510, DOI 10.1128/JB.175.17.5510-5519.1993; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; HANCOCK IC, 1988, BACTERIAL CELL SURFA; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; Hedengren M, 2000, BIOCHEM BIOPH RES CO, V279, P574, DOI 10.1006/bbrc.2000.3988; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; HULTMARK D, 1982, EUR J BIOCHEM, V127, P207, DOI 10.1111/j.1432-1033.1982.tb06857.x; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JOHNSON SD, 1981, BIOCHEMISTRY-US, V20, P4781, DOI 10.1021/bi00519a039; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; Labischinski H., 1994, BACTERIAL CELL WALL; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; MORISHIMA I, 1998, TECHNIQUES INSECT IM, P59; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PEBERDY JF, 1990, BIOCH CELL WALLS MEM; Poget SF, 2001, BIOCHEMISTRY-US, V40, P10966, DOI 10.1021/bi002698z; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; RASMUSON T, 1977, DEV IMMUNOBIOLOGY; Rehman A, 2001, CYTOKINE, V13, P8, DOI 10.1006/cyto.2000.0800; Roos E, 1998, INSECT MOL BIOL, V7, P51, DOI 10.1046/j.1365-2583.1998.71050.x; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tzou P, 2002, CURR OPIN MICROBIOL, V5, P102, DOI 10.1016/S1369-5274(02)00294-1; Uv AE, 2000, GENE DEV, V14, P1945; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Werner T, 2003, J BIOL CHEM, V278, P26319, DOI 10.1074/jbc.C300184200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; WICKER C, 1990, J BIOL CHEM, V265, P22493; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; YAMADA M, 1975, J BACTERIOL, V123, P678, DOI 10.1128/JB.123.2.678-686.1975; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	63	77	80	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21121	21127		10.1074/jbc.M313856200	http://dx.doi.org/10.1074/jbc.M313856200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985331	hybrid			2022-12-27	WOS:000221273800069
J	Yahagi, N; Shimano, H; Matsuzaka, T; Sekiya, M; Najima, Y; Okazaki, S; Okazaki, H; Tamura, Y; Iizuka, Y; Inoue, N; Nakagawa, Y; Takeuchi, Y; Ohashi, K; Harada, K; Gotoda, T; Nagai, R; Kadowaki, T; Ishibashi, S; Osuga, J; Yamada, N				Yahagi, N; Shimano, H; Matsuzaka, T; Sekiya, M; Najima, Y; Okazaki, S; Okazaki, H; Tamura, Y; Iizuka, Y; Inoue, N; Nakagawa, Y; Takeuchi, Y; Ohashi, K; Harada, K; Gotoda, T; Nagai, R; Kadowaki, T; Ishibashi, S; Osuga, J; Yamada, N			P53 involvement in the pathogenesis of fatty liver disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; NECROSIS-FACTOR-ALPHA; NONALCOHOLIC STEATOHEPATITIS; OBESE MICE; GENE; EXPRESSION; APOPTOSIS; CHOLESTEROL; REGULATORS; INDUCTION	Obesity is a major health problem in industrialized societies, and fatty liver disease (hepatic steatosis) is common in obese individuals. Oxidative stress originating from increased intracellular levels of fatty acids has been implicated as a cause of hepatocellular injury in steatosis, although the precise mechanisms remain to be elucidated. p53, widely known as a tumor suppressor, has been shown often to be activated in stressed cells, inducing cell cycle arrest or death. Here we demonstrate that p53 is involved in the molecular mechanisms of hepatocellular injury associated with steatosis. We found that p53 in the nucleus is induced in the liver from two mouse models of fatty liver disease, ob/ob and a transgenic mouse model that overexpresses an active form of sterol regulatory element-binding protein-1 in the liver (TgSREBP-1), the one with obesity and the other without obesity. This activation of the p53 pathway leads to the elevation of p21 mRNA expression, which can be considered an indicator of p53 activity, because ob/ob mice lacking p53 generated by targeting gene disruption exhibited the complete restoration of the p21 elevation to wild type levels. Consistent with these results, the amelioration of hepatic steatosis caused by Srebp-1 gene disruption in ob/ob mice lowered the p21 expression in a triglyceride content-dependent manner. Moreover, p53 deficiency in ob/ob mice resulted in a marked improvement of plasma alanine aminotransferase levels, demonstrating that p53 is involved in the mechanisms of hepatocellular injury. In conclusion, we revealed that p53 plays an important role in the pathogenesis of fatty liver disease.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan	University of Tsukuba; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Shimano, Hitoshi/AAI-5648-2020; Yahagi, Naoya/D-2360-2014; Najima, Yuho/W-3858-2019; Harada, Kenji/J-2230-2016; Shimano, Hitoshi/V-1761-2019	Yahagi, Naoya/0000-0002-1823-1865; Najima, Yuho/0000-0001-8910-0021; Shimano, Hitoshi/0000-0002-5562-5572				Akyol G, 1999, PATHOL INT, V49, P214, DOI 10.1046/j.1440-1827.1999.00849.x; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; [Anonymous], 1985, Ann Intern Med, V103, P147; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Crespo J, 2001, HEPATOLOGY, V34, P1158, DOI 10.1053/jhep.2001.29628; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; Fei PW, 2002, CANCER RES, V62, P7316; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAYER J, 1951, SCIENCE, V113, P746, DOI 10.1126/science.113.2948.746; MIYASHITA T, 1995, CELL, V80, P293; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Rashid A, 1999, HEPATOLOGY, V29, P1131, DOI 10.1002/hep.510290428; Schafer T, 2003, FASEB J, V17, P660, DOI 10.1096/fj.02-0774com; Sekiya M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/j.hep.2003.09.028; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Sola S, 2003, J BIOL CHEM, V278, P48831, DOI 10.1074/jbc.M300468200; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	37	94	96	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20571	20575		10.1074/jbc.M400884200	http://dx.doi.org/10.1074/jbc.M400884200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985341	hybrid			2022-12-27	WOS:000221273800005
J	An, J; Chen, YM; Huang, ZW				An, J; Chen, YM; Huang, ZW			Critical upstream signals of cytochrome c release induced by a novel Bcl-2 inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; MITOCHONDRIAL-MEMBRANE; INDUCED APOPTOSIS; OXIDATIVE STRESS; FAMILY PROTEINS; TUMOR-CELLS; WILD-TYPE; BAX	Cytochrome c release is a central step in the apoptosis induced by many death stimuli. Bcl-2 plays a critical role in controlling this step. In this study, we investigated the upstream mechanism of cytochrome c release induced by ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2- oxoethyl)-4H-chromene-3-carboxylate (HA14-1), a recently discovered small molecule inhibitor of Bcl-2. HA14-1 was found to induce cytochrome c release from the mitochondria of intact cells but not from isolated mitochondria. Cytochrome c release from isolated mitochondria requires the presence of both HA14-1 and exogenous Ca2+. This suggests that both mitochondrial and extramitochondrial signals are important. In intact cells, treatment with HA14-1 caused Ca2+ spike, change in mitochondrial membrane potential (DeltaPsi(m)) transition, Bax translocation, and reactive oxygen species (ROS) generation prior to cytochrome c release. Pretreatment with either EGTA acetoxymethyl ester or vitamin E resulted in a significant decrease in cytochrome c release and cell death induced by HA14-1. Furthermore pretreatment with RU-360, an inhibitor of the mitochondrial Ca2+ uniporter, or with EGTA acetoxymethyl ester, but not with vitamin E, prevented the HA14-1-induced DeltaPsi(m) transition and Bax translocation. This suggests that ROS generation is an event that occurs after the DeltaPsi(m) transition and Bax translocation. Together these data demonstrate that the Ca2+ spike, mitochondrial Bcl-2 presensitization, and subsequent DeltaPsi(m) transition, Bax translocation, and ROS generation are important upstream signals for cytochrome c release upon HA14-1 stimulation. The involvement of endoplasmic reticulum and mitochondrial signals suggests both organelles are crucial for HA14-1-induced apoptosis.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	An, J (corresponding author), Univ Illinois, Dept Biochem, 302 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	jingan@life.uiuc.edu						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Borner MM, 1999, BRIT J CANCER, V79, P952, DOI 10.1038/sj.bjc.6690152; Brubacher JL, 2001, J IMMUNOL METHODS, V251, P81, DOI 10.1016/S0022-1759(01)00308-8; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Huang ZW, 2002, CHEM BIOL, V9, P1059, DOI 10.1016/S1074-5521(02)00247-8; Inoue S, 2001, Hum Cell, V14, P211; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Krajewska M, 1996, AM J PATHOL, V148, P1567; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Lickliter JD, 2003, LEUKEMIA, V17, P2074, DOI 10.1038/sj.leu.2403102; Lipton SA, 1998, CELL CALCIUM, V23, P165, DOI 10.1016/S0143-4160(98)90115-4; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Milella M, 2002, BLOOD, V99, P3461, DOI 10.1182/blood.V99.9.3461; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; ORRENIUS S, 1992, TOXICOL LETT, V64-5, P357, DOI 10.1016/0378-4274(92)90208-2; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Pei XY, 2003, LEUKEMIA, V17, P2036, DOI 10.1038/sj.leu.2403109; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 2002, BIOCHIMIE, V84, P195, DOI 10.1016/S0300-9084(02)01373-1; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Reed J C, 1996, Cancer Treat Res, V84, P31; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Szewczyk A, 2002, PHARMACOL REV, V54, P101, DOI 10.1124/pr.54.1.101; Tothova E, 2002, NEOPLASMA, V49, P141; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Villar E, 2001, TUMOR BIOL, V22, P137, DOI 10.1159/000050608; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Yamaguchi H, 2002, CANCER RES, V62, P466; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yu NF, 2000, TETRAHEDRON LETT, V41, P6993, DOI 10.1016/S0040-4039(00)01195-3	68	86	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19133	19140		10.1074/jbc.M400295200	http://dx.doi.org/10.1074/jbc.M400295200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966123	hybrid			2022-12-27	WOS:000221041500126
J	Banfi, B; Tirone, F; Durussel, I; Knisz, J; Moskwa, P; Molnar, GZ; Krause, KH; Cox, JA				Banfi, B; Tirone, F; Durussel, I; Knisz, J; Moskwa, P; Molnar, GZ; Krause, KH; Cox, JA			Mechanism of Ca2+ activation of the NADPH oxidase 5 (NOX5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BINDING PROPERTIES; RESPIRATORY BURST OXIDASE; COLON EPITHELIAL-CELLS; EF-HAND; NAD(P)H OXIDASE; CRYSTAL-STRUCTURE; PHOSPHATIDIC-ACID; CYTOCHROME B(558); CATION-BINDING; PROTEIN	NADPH oxidase 5 (NOX5) is a homologue of the gp91(phox) subunit of the phagocyte NADPH oxidase. NOX5 is expressed in lymphoid organs and testis and distinguished from the other NADPH oxidases by its unique N terminus, which contains three canonical EF-hands, Ca2+-binding domains. Upon heterologous expression, NOX5 was shown to generate superoxide in response to intracellular Ca2+ elevations. In this study, we have analyzed the mechanism of Ca2+ activation of NOX5. In a cell-free system, Ca2+ elevations triggered superoxide production by NOX5 (K-m = 1.06 muM) in an NADPH- and FAD-dependent but cytosol-independent manner. That result indicated a role for the N-terminal EF-hands in NOX5 activation. Therefore, we generated recombinant proteins of NOX5 N terminus and investigated their interactions with Ca2+. Flow dialysis experiments showed that NOX5 N terminus contained four Ca2+-binding sites and allowed us to define the hitherto unidentified fourth, non-canonical EF-hand. The EF-hands of NOX5 formed two pairs: the very N-terminal pair had relatively low affinity for Ca2+, whereas the more C-terminal pair bound Ca2+ with high affinity. Ca2+-binding caused a marked conformation change in the N terminus, which exposed its hydrophobic core, and became able to bind melittin, a model peptide for calmodulin targets. Using a pull-down assay, we demonstrate that the regulatory N terminus and the catalytic C terminus of NOX5 interact in a Ca2+-dependent way. Our results indicate that the Ca2+-induced conformation change of NOX5 N terminus led to enzyme activation through an intra-molecular interaction. That represents a novel mechanism of activation among NAD(P) H oxidases and Ca2+-activated enzymes.	Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Dept Geriatr, CH-1225 Geneva, Switzerland; Semmelweis Hosp, Dept Physiol, H-1088 Budapest, Hungary; Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Inflammat Program, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Gene Therapy Ctr Cyst Fibrosis & Other Genet Dis, Dept Anat & Cell Biol, Iowa City, IA 52242 USA	University of Geneva; University of Geneva; Semmelweis University; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa	Cox, JA (corresponding author), Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland.	jos.cox@biochem.unige.ch	Krause, Karl-Heinz/E-8030-2011; Knisz, Judit/HDN-2414-2022	Krause, Karl-Heinz/0000-0002-9033-6768; Banfi, Botond/0000-0001-9273-1318	NIAID NIH HHS [AI20866, R01 AI020866] Funding Source: Medline; NIA NIH HHS [AG19519, R01 AG019519] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020866, R37AI020866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Atkinson RA, 2001, NAT STRUCT BIOL, V8, P853, DOI 10.1038/nsb1001-853; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; COMTE M, 1983, BIOCHEM J, V209, P269, DOI 10.1042/bj2090269; Cox J.A., 1996, GUIDEBOOK CALCIUM BI, P1; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DINAUER MC, 1992, ANNU REV MED, V43, P117, DOI 10.1146/annurev.med.43.1.117; Durussel I, 2000, FEBS LETT, V472, P208, DOI 10.1016/S0014-5793(00)01452-6; Durussel I, 2002, BIOCHEMISTRY-US, V41, P5439, DOI 10.1021/bi016062z; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P2394, DOI 10.1021/bi00060a034; Ebert BL, 1999, BLOOD, V94, P1864; Esser MT, 1998, J EXP MED, V187, P1057, DOI 10.1084/jem.187.7.1057; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Hanna IR, 2002, ANTIOXID REDOX SIGN, V4, P899, DOI 10.1089/152308602762197443; HERMANN A, 1995, COMP BIOCHEM PHYS B, V111, P337, DOI 10.1016/0305-0491(94)00218-J; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Ilari A, 2002, J MOL BIOL, V317, P447, DOI 10.1006/jmbi.2002.5417; Jia J, 2000, J MOL BIOL, V300, P1271, DOI 10.1006/jmbi.2000.3925; Jia J, 2001, STRUCTURE, V9, P267, DOI 10.1016/S0969-2126(01)00585-8; Kikuchi H, 2000, GENE, V254, P237, DOI 10.1016/S0378-1119(00)00258-4; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lee JR, 1998, EUR J IMMUNOL, V28, P4188, DOI 10.1002/(SICI)1521-4141(199812)28:12<4188::AID-IMMU4188>3.0.CO;2-B; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; Morales P, 2002, ANDROLOGIA, V34, P301; Munzel T, 1999, ANN NY ACAD SCI, V874, P386, DOI 10.1111/j.1749-6632.1999.tb09253.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palicz A, 2001, J BIOL CHEM, V276, P3090, DOI 10.1074/jbc.M007759200; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Shatwell KP, 1996, INT J BIOCHEM CELL B, V28, P1191, DOI 10.1016/S1357-2725(96)00084-2; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Torres MA, 1998, PLANT J, V14, P365, DOI 10.1046/j.1365-313X.1998.00136.x; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	51	288	297	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18583	18591		10.1074/jbc.M310268200	http://dx.doi.org/10.1074/jbc.M310268200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14982937	hybrid			2022-12-27	WOS:000221041500061
J	Dupuis, M; Levy, A; Mhaouty-Kodja, S				Dupuis, M; Levy, A; Mhaouty-Kodja, S			Functional coupling of rat myometrial alpha 1-adrenergic receptors to Gh alpha/tissue transglutaminase 2 during pregnancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; TISSUE TRANSGLUTAMINASE; RETINOIC ACID; PHOSPHOLIPASE C-DELTA-1; SIGNAL-TRANSDUCTION; CYCLASE ACTIVITY; PROGESTERONE; EXPRESSION; G-ALPHA(H); UTERUS	Ghalpha protein, which exhibits both transglutaminase and GTPase activities, represents a new class of GTP-binding proteins. In the present study, we characterized Ghalpha in rat uterine smooth muscle (myometrium) and followed its expression during pregnancy by reverse transcription-PCR and Western blot. We also measured transglutaminase and GTP binding functions and used a smooth muscle cell line to evaluate the role of Ghalpha in cell proliferation. The results show that pregnancy is associated with an up-regulation of Ghalpha expression at both the mRNA and protein level. Ghalpha induced during pregnancy is preferentially localized to the plasma membrane. This was found associated with an increased ability of plasma membrane preparations to catalyze Ca2+-dependent incorporation of [H-3]putrescine into casein in vitro. In the cytosol, significant changes in the level of immunodetected Ghalpha and transglutaminase activity were seen only at term. Activation of alpha1-adrenergic receptors (alpha1-AR) enhanced photoaffinity labeling of plasma membrane Ghalpha. Moreover, the level of alpha1-AR-coupled Ghalpha increased progressively with pregnancy, which parallels the active period of myometrial cell proliferation. Overexpression of wild type Ghalpha in smooth muscle cell line DDT1-MF2 increased alpha1-AR-induced [ 3H] thymidine incorporation. A similar response was obtained in cells expressing the transglutaminase inactive mutant (C277S) of Ghalpha. Together, these findings underscore the role of Ghalpha as signal transducer of alpha1-AR-induced smooth muscle cell proliferation. In this context, pregnant rat myometrium provides an interesting physiological model to study the mechanisms underlying the regulation of the GTPase function of Ghalpha.	CNRS, UMR 7079, Lab Physiol & Physiopathol, Paris 05, France	Centre National de la Recherche Scientifique (CNRS)	Mhaouty-Kodja, S (corresponding author), Inst Pasteur, Dept Dev Biol, Batiment Jacques Monod,25 Rue Docteur Roux, F-75724 Paris 15, France.	smhaouty@pasteur.fr		Mhaouty-Kodja, Sakina/0000-0001-9743-5243				ALEXANDROVA M, 1980, ENDOCRINOLOGY, V106, P730, DOI 10.1210/endo-106-3-730; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Baek KJ, 1996, BIOCHEM J, V315, P739; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breuiller-Fouche M, 1998, MOL HUM REPROD, V4, P33, DOI 10.1093/molehr/4.1.33; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chowdhury ZA, 1997, EXP CELL RES, V231, P38, DOI 10.1006/excr.1996.3448; COHEN-TANNOUDJI J, 1995, BIOL REPROD, V53, P55, DOI 10.1095/biolreprod53.1.55; COHEN-TANNOUDJI J, 1991, J MOL ENDOCRINOL, V6, P137, DOI 10.1677/jme.0.0060137; ELWARDYMEREZAK J, 1994, J MOL ENDOCRINOL, V13, P23, DOI 10.1677/jme.0.0130023; Engstrom T, 1997, J ENDOCRINOL, V153, P393, DOI 10.1677/joe.0.1530393; Feng JF, 1999, BIOCHEMISTRY-US, V38, P10743, DOI 10.1021/bi9905009; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Gill LS, 1998, BRAIN RES, V788, P95, DOI 10.1016/S0006-8993(97)01526-6; Hitomi K, 2000, BIOSCI BIOTECH BIOCH, V64, P657, DOI 10.1271/bbb.64.657; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; Kang SK, 2002, BIOCHEM BIOPH RES CO, V293, P383, DOI 10.1016/S0006-291X(02)00197-3; KORNER G, 1987, J CELL PHYSIOL, V130, P44, DOI 10.1002/jcp.1041300108; LARCHER A, 1995, MOL CELL ENDOCRINOL, V114, P69, DOI 10.1016/0303-7207(95)03643-L; Lee KH, 2003, J STEROID BIOCHEM, V84, P101, DOI 10.1016/S0960-0760(03)00006-2; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LEGRAND C, 1986, J REPROD FERTIL, V76, P415, DOI 10.1530/jrf.0.0760415; Limon-Boulez I, 2001, MOL PHARMACOL, V59, P331, DOI 10.1124/mol.59.2.331; LimonBoulez I, 1997, BIOL REPROD, V57, P1175, DOI 10.1095/biolreprod57.5.1175; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Marjamaki A, 1997, J BIOL CHEM, V272, P16466, DOI 10.1074/jbc.272.26.16466; MHAOUTY S, 1995, J BIOL CHEM, V270, P11012, DOI 10.1074/jbc.270.18.11012; Mhaouty-Kodja S, 2004, BIOL REPROD, V70, P570, DOI 10.1095/biolreprod.103.021535; Mhaouty-Kodja S, 1997, J BIOL CHEM, V272, P31100, DOI 10.1074/jbc.272.49.31100; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Park ES, 1998, BIOCHEM J, V331, P283, DOI 10.1042/bj3310283; Park H, 2001, BIOCHEM BIOPH RES CO, V284, P496, DOI 10.1006/bbrc.2001.4997; Schweigert FJ, 1999, BIOL REPROD, V61, P906, DOI 10.1095/biolreprod61.4.906; Simon V, 2001, ENDOCRINOLOGY, V142, P1899, DOI 10.1210/en.142.5.1899; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Szondy Z, 2003, P NATL ACAD SCI USA, V100, P7812, DOI 10.1073/pnas.0832466100; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Vezza R, 1999, J BIOL CHEM, V274, P12774, DOI 10.1074/jbc.274.18.12774; VIVAT V, 1992, J BIOL CHEM, V267, P7975; WRAY S, 1993, AM J PHYSIOL, V264, pC1, DOI 10.1152/ajpcell.1993.264.1.C1; Wu J, 2000, J BIOL CHEM, V275, P22213, DOI 10.1074/jbc.M000091200; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zheng WL, 1998, BIOL REPROD, V58, P963, DOI 10.1095/biolreprod58.4.963; Zhong HY, 1999, EUR J PHARMACOL, V375, P261, DOI 10.1016/S0014-2999(99)00222-8	51	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19257	19263		10.1074/jbc.M314299200	http://dx.doi.org/10.1074/jbc.M314299200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970202	hybrid			2022-12-27	WOS:000221041500139
J	Goodwin, BL; Solomonson, LP; Eichler, DC				Goodwin, BL; Solomonson, LP; Eichler, DC			Argininosuccinate synthase expression is required to maintain nitric oxide production and cell viability in aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ORAL L-ARGININE; L-CITRULLINE; DEPENDENT VASODILATION; MESSENGER-RNA; NO PRODUCTION; SHEAR-STRESS; INHIBITS APOPTOSIS; RELAXING FACTOR; IN-VIVO	Although cellular levels of arginine greatly exceed the apparent K-m for endothelial nitric-oxide synthase, current evidence suggests that the bulk of this arginine may not be available for nitric oxide ( NO) production. We propose that arginine regeneration, that is the recycling of citrulline back to arginine, defines the essential source of arginine for NO production. To support this proposal, RNA interference analysis was used to selectively reduce the expression of argininosuccinate synthase ( AS), because the only known metabolic role for AS in endothelial cells is in the regeneration of L-arginine from L-citrulline. Western blot analysis demonstrated a significant and dose-dependent reduction of AS protein as a result of AS small interfering RNA treatment with a corresponding diminished capacity to produce basal or stimulated levels of NO, despite saturating levels of arginine in the medium. Unanticipated, however, was the finding that the viability of AS small interfering RNA-treated endothelial cells was significantly decreased when compared with control cells. Trypan blue exclusion analysis suggested that the loss of viability was not because of necrosis. Two indicators, reduced expression of Bcl-2 and an increase in caspase activity, which correlated directly with reduced expression of AS, suggested that the loss of viability was because of apoptosis. The exposure of cells to an NO donor prevented apoptosis associated with reduced AS expression. Overall, these results demonstrate the essential role of AS for endothelial NO production and cell viability.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33647 USA	State University System of Florida; University of South Florida	Eichler, DC (corresponding author), Univ S Florida, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd,MDC7, Tampa, FL 33612 USA.	deichler@hsc.usf.edu	Eichler, Duane/A-1906-2012					BodeBoger SM, 1996, CIRCULATION, V93, P85, DOI 10.1161/01.CIR.93.1.85; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Candipan RC, 1996, ARTERIOSCL THROM VAS, V16, P44, DOI 10.1161/01.ATV.16.1.44; CAPLAN BA, 1973, ATHEROSCLEROSIS, V17, P401, DOI 10.1016/0021-9150(73)90031-2; Clarkson P, 1996, J CLIN INVEST, V97, P1989, DOI 10.1172/JCI118632; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; Daniel EE, 2000, NEUROGASTROENT MOTIL, V12, P317; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656; Dimmeler S, 1998, EUR CYTOKINE NETW, V9, P697; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; ESTRADA C, 1992, BIOCHEM BIOPH RES CO, V186, P475, DOI 10.1016/S0006-291X(05)80832-0; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Flam BR, 2001, NITRIC OXIDE-BIOL CH, V5, P187, DOI 10.1006/niox.2001.0340; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Gow AJ, 2001, J CELL PHYSIOL, V187, P277, DOI 10.1002/jcp.1085; Haendeler J, 1999, VITAM HORM, V57, P49; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; Hellermann GR, 2000, ARTERIOSCL THROM VAS, V20, P2045, DOI 10.1161/01.ATV.20.9.2045; Hermann C, 1997, ARTERIOSCL THROM VAS, V17, P3588, DOI 10.1161/01.ATV.17.12.3588; Kawahara K, 2001, MOL BRAIN RES, V90, P165, DOI 10.1016/S0169-328X(01)00100-0; Koga T, 2003, EXP EYE RES, V76, P15, DOI 10.1016/S0014-4835(02)00274-9; KORZENIEWSKI C, 1983, J IMMUNOL METHODS, V64, P313, DOI 10.1016/0022-1759(83)90438-6; Kotamraju S, 2001, J BIOL CHEM, V276, P17316, DOI 10.1074/jbc.M011731200; Krummrei U, 2003, P NATL ACAD SCI USA, V100, P2444, DOI 10.1073/pnas.0438007100; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Loscalzo J, 2003, ARTERIOSCL THROM VAS, V23, P3, DOI 10.1161/01.ATV.0000040860.71626.9D; MARTIN A, 1993, CYTOTECHNOLOGY, V11, P49, DOI 10.1007/BF00749057; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; Melino G, 2000, CELL MOL LIFE SCI, V57, P612, DOI 10.1007/PL00000723; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Nagasaki A, 1996, J BIOL CHEM, V271, P2658, DOI 10.1074/jbc.271.5.2658; NORIS M, 1995, CIRC RES, V76, P536, DOI 10.1161/01.RES.76.4.536; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; OBRIEN WE, 1979, BIOCHEMISTRY-US, V18, P5353, DOI 10.1021/bi00591a015; Oomen CM, 2000, ARTERIOSCL THROM VAS, V20, P2134, DOI 10.1161/01.ATV.20.9.2134; Pendleton LC, 2002, J BIOL CHEM, V277, P25363, DOI 10.1074/jbc.M111677200; POU S, 1992, J BIOL CHEM, V267, P24173; Rossig L, 2000, J BIOL CHEM, V275, P25502, DOI 10.1074/jbc.M002283200; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; SESSA WC, 1990, P NATL ACAD SCI USA, V87, P8607, DOI 10.1073/pnas.87.21.8607; Shen YH, 1998, FEBS LETT, V433, P125, DOI 10.1016/S0014-5793(98)00844-8; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; SHUTTLEWORTH CWR, 1995, NEUROSCIENCE, V68, P1295, DOI 10.1016/0306-4522(95)00193-M; Solomonson LP, 2003, J EXP BIOL, V206, P2083, DOI 10.1242/jeb.00361; SU YC, 1995, AM J PHYSIOL-LUNG C, V269, pL581, DOI 10.1152/ajplung.1995.269.5.L581; Vallance P, 2001, HEART, V85, P342, DOI 10.1136/heart.85.3.342; Van Geldre LA, 2002, EUR J PHARMACOL, V455, P149, DOI 10.1016/S0014-2999(02)02584-0; Walker HA, 2001, J AM COLL CARDIOL, V38, P499, DOI 10.1016/S0735-1097(01)01380-8; Wu G, 2000, Curr Opin Clin Nutr Metab Care, V3, P59, DOI 10.1097/00075197-200001000-00010; Xie LJ, 1997, J BIOL CHEM, V272, P16624, DOI 10.1074/jbc.272.26.16624; Xie LJ, 2000, SEMIN PERINATOL, V24, P42, DOI 10.1016/S0146-0005(00)80054-3; Zhang WG, 2003, BIOCHEM BIOPH RES CO, V301, P147, DOI 10.1016/S0006-291X(02)02981-9	62	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18353	18360		10.1074/jbc.M308160200	http://dx.doi.org/10.1074/jbc.M308160200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970240	hybrid			2022-12-27	WOS:000221041500032
J	Liu, YM; Borchert, GL; Phang, JM				Liu, YM; Borchert, GL; Phang, JM			Polyoma enhancer activator 3, an Ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; COLON CARCINOGENESIS; EPITHELIAL-CELLS; PEA3 SUBFAMILY; EWING SARCOMA; BETA-CATENIN; EXPRESSION; PROTEIN; BINDING; AP-1	Abundant evidence supports the role of cyclooxygenase-2 (COX-2) in colorectal cancer. Nitric oxide ( NO), a pro-inflammatory signaling factor, may regulate COX-2 expression and activity thereby linking hyper-inflammatory states to cancer susceptibility. Previously we showed that NO induced COX-2 expression. Although NO also activated the beta-catenin . T-cell factor/lymphocyte enhancing factor transcriptional pathway, a direct causal link between this pathway and COX-2 expression was not demonstrated. In this current study, we focused on NO-induced transcriptional activity and elucidated its role in COX-2 expression. NO donors stimulated the expression of peroxisome proliferator-activated receptor-delta and c-myc, both downstream genes of beta-catenin. They also induced the expression of polyoma enhancer activator 3 (PEA3) and increased its DNA-binding activity. To establish a role for PEA3 to beta-catenin-induced COX-2, we transfected RKO cells with beta-catenin and found that beta-catenin increased PEA3 expression. Also, there was higher PEA3 in immortal mouse colon epithelium cells (Apc(Min/+)) compared with young adult mouse colon cells (Apc(+/+)). Luciferase reporter assays revealed that, although several transcription factors/coactivator, acting alone or in synergistic combination, induced COX-2 promoter activity, PEA3 was one of the most potent. Interestingly, NO from NO donors or generated endogenously from transfected inducible nitric-oxide synthase, increased PEA3/p300-induced COX-2 promoter activity. We also found that an ETS site (-75/ - 72) and the NF-IL6 site were responsible for COX-2 activity induced by PEA3, PEA3/p300, and NO. Taken together, our results demonstrated that NO through beta-catenin signaling stimulated PEA3 to increase COX-2 activity. In addition, NO augmented the synergistic interaction between PEA3 and CBP/p300.	NCI, Metab & Canc Susceptibil Sect, Comparat Carcinogenesis Lab, Ctr Canc Res,NIH, Frederick, MD 21702 USA; Sci Applicat Int Corp Frederick Inc, Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Phang, JM (corresponding author), NCI, Metab & Canc Susceptibil Sect, Comparat Carcinogenesis Lab, Ctr Canc Res,NIH, Bldg 538,Rm 144, Frederick, MD 21702 USA.	phang@ncifcrf.gov			DIVISION OF BASIC SCIENCES - NCI [Z01BC010005] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359-6101(00)00011-3; Ambs S, 1998, CANCER RES, V58, P334; Araki Y, 2003, CANCER RES, V63, P728; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Davidson B, 2003, CLIN CANCER RES, V9, P1412; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Denhardt DT, 1996, CRIT REV ONCOGENESIS, V7, P261, DOI 10.1615/CritRevOncog.v7.i3-4.70; Drevet JR, 1998, MOL REPROD DEV, V49, P131, DOI 10.1002/(SICI)1098-2795(199802)49:2<131::AID-MRD4>3.0.CO;2-Q; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Howe LR, 1999, CANCER RES, V59, P1572; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaneko Y, 1997, GENE CHROMOSOME CANC, V18, P228, DOI 10.1002/(SICI)1098-2264(199703)18:3<228::AID-GCC9>3.0.CO;2-3; Kaya M, 1996, ONCOGENE, V12, P221; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Mei JM, 2000, FASEB J, V14, P1188, DOI 10.1096/fasebj.14.9.1188; Mei JM, 2002, CARCINOGENESIS, V23, P2119, DOI 10.1093/carcin/23.12.2119; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Perez-Sala D, 2001, ANTIOXID REDOX SIGN, V3, P231, DOI 10.1089/152308601300185197; Polakis P, 2000, GENE DEV, V14, P1837; Rao CV, 1999, CARCINOGENESIS, V20, P641, DOI 10.1093/carcin/20.4.641; Rao CV, 2002, CANCER RES, V62, P165; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 2002, CANCER RES, V62, P2522; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Takahashi M, 2000, CARCINOGENESIS, V21, P1319, DOI 10.1093/carcin/21.7.1319; Takahashi M, 1997, CANCER RES, V57, P1233; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; WHITEHEAD RH, 1994, EPITHELIAL CELL BIOL, V3, P119; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133	43	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18694	18700		10.1074/jbc.M308136200	http://dx.doi.org/10.1074/jbc.M308136200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976201	hybrid			2022-12-27	WOS:000221041500075
J	Lu, H; Allen, S; Wardleworth, L; Savory, P; Tokatlidis, K				Lu, H; Allen, S; Wardleworth, L; Savory, P; Tokatlidis, K			Functional TIM10 chaperone assembly is redox-regulated in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INTERMEMBRANE SPACE; PROTEIN DISULFIDE-ISOMERASE; INNER MEMBRANE-PROTEINS; ADP/ATP CARRIER; IMPORT PATHWAY; BOND FORMATION; COMPLEX; TRANSLOCASE; BIOGENESIS; SWITCH	The TIM10 chaperone facilitates the insertion of hydrophobic proteins at the mitochondrial inner membrane. Here we report the novel molecular mechanism of TIM10 assembly. This process crucially depends on oxidative folding in mitochondria and involves: (i) import of the subunits in a Cys-reduced and unfolded state; (ii) folding to an assembly-competent structure maintained by intramolecular disulfide bonding of their four conserved cysteines; and (iii) assembly of the oxidized zinc-devoid subunits to the functional complex. We show that intramolecular disulfide bonding occurs in vivo, whereas intermolecular disulfides observed in vitro are abortive intermediates in the assembly pathway. This novel mechanism of compartment-specific redox-regulated assembly is crucial for the formation of a functional TIM10 chaperone.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Crete, Dept Chem, Iraklion 71409, Greece; FORTH, IMBB, Iraklion 71110, Greece	University of Manchester; University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Tokatlidis, K (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.	tokatlid@imbb.forth.gr	Lu, Hui/AAB-5476-2021	Lu, Hui/0000-0002-7029-2681; Tokatlidis, Kostas/0000-0001-6295-8183; Allen, Scott/0000-0003-4418-7375	MRC [G0000153] Funding Source: UKRI; Medical Research Council [G0000153] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Allen S, 2003, J BIOL CHEM, V278, P38505, DOI 10.1074/jbc.M306027200; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Blackstone C, 2003, BIOCHEM BIOPH RES CO, V305, P345, DOI 10.1016/S0006-291X(03)00767-8; Chacinska A, 2002, TRENDS CELL BIOL, V12, P299, DOI 10.1016/S0962-8924(02)02310-3; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Curran SP, 2002, J CELL BIOL, V158, P1017, DOI 10.1083/jcb.200205124; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Da Silva J. F., 2001, BIOL CHEM ELEMENTS I; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P72; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; Lee JE, 2000, FEBS LETT, V477, P62, DOI 10.1016/S0014-5793(00)01767-1; Lu H, 2004, J BIOL CHEM, V279, P18959, DOI 10.1074/jbc.M313046200; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Lutz T, 2003, EMBO J, V22, P4400, DOI 10.1093/emboj/cdg421; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Rigobello MP, 2001, BIOCHEM J, V356, P567, DOI 10.1042/0264-6021:3560567; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Schwartz MP, 1999, J BIOL CHEM, V274, P12759, DOI 10.1074/jbc.274.18.12759; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; Tokatlidis K, 2000, METHOD ENZYMOL, V327, P305, DOI 10.1016/S0076-6879(00)27286-8; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200	33	105	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18952	18958		10.1074/jbc.M313045200	http://dx.doi.org/10.1074/jbc.M313045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14973127	hybrid			2022-12-27	WOS:000221041500106
J	Otzen, M; Perband, U; Wang, DY; Baerends, RJS; Kunau, WH; Veenhuis, M; Van der Klei, IJ				Otzen, M; Perband, U; Wang, DY; Baerends, RJS; Kunau, WH; Veenhuis, M; Van der Klei, IJ			Hansenula polymorpha Pex19p is essential for the formation of functional peroxisomal membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; GLYOXYSOMAL MALATE-DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; FARNESYLATED PROTEIN; DEFICIENT MUTANTS; PICHIA-PASTORIS; YEAST; PEX3P; BIOGENESIS	We have cloned and characterized the Hansenula polymorpha PEX19 gene. In cells of a pex19 disruption strain (Hppex19), induced on methanol, peroxisome structures were not detectable; peroxisomal matrix proteins accumulated in the cytosol, whereas peroxisomal membrane proteins (PMPs) were mislocalized to the cytosol (Pex3p) and mitochondria (Pex14p) or strongly reduced to undetectable levels (Pex10p). The defect in peroxisome formation in Hppex19 cells was largely suppressed upon overproduction of HpPex3p or a fusion protein that consisted of the first 50 N-terminal amino acids of Pex3p and GFP. In these cells PMPs were again correctly sorted to peroxisomal structures, which also harbored peroxisomal matrix proteins. In Saccharomyces cerevisiae pex19 cells overproduction of ScP ex3p led to the formation of numerous vesicles that contained PMPs but lacked the major matrix protein thiolase. Taken together, our data are consistent with a function of Pex19p in membrane protein assembly and function.	Univ Groningen, Inst Biotechnol, NL-9750 AA Haren, Netherlands; Ruhr Univ Bochum, Fak Med, Abt Zellbiochem, D-44780 Bochum, Germany	University of Groningen; Ruhr University Bochum	Van der Klei, IJ (corresponding author), Univ Groningen, Inst Biotechnol, POB 14, NL-9750 AA Haren, Netherlands.	I.J.van.der.Klei@biol.rug.nl	van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Bascom RA, 2003, MOL BIOL CELL, V14, P939, DOI 10.1091/mbc.E02-10-0633; Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; CREGG JM, 1990, YEAST, V6, P87, DOI 10.1002/yea.320060202; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FABER KN, 1992, J GEN MICROBIOL, V138, P2405, DOI 10.1099/00221287-138-11-2405; Faber KN, 2002, J BIOL CHEM, V277, P11026, DOI 10.1074/jbc.M112347200; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Geuze HJ, 2003, MOL BIOL CELL, V14, P2900, DOI 10.1091/mbc.E02-11-0734; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; GOODMAN JM, 1986, J BIOL CHEM, V261, P3464; Gotte K, 1998, MOL CELL BIOL, V18, P616; Haan GJ, 2002, J BIOL CHEM, V277, P26609, DOI 10.1074/jbc.M108569200; Hazra PP, 2002, TRAFFIC, V3, P560, DOI 10.1034/j.1600-0854.2002.30806.x; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HOCK B, 1982, ANN NY ACAD SCI, V386, P350, DOI 10.1111/j.1749-6632.1982.tb21427.x; Ito M, 2004, BIOCHEM J, V377, P607, DOI 10.1042/BJ20031223; Kiel JAKW, 1995, FEBS LETT, V377, P434, DOI 10.1016/0014-5793(95)01385-7; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambkin GR, 2001, MOL BIOL CELL, V12, P3353, DOI 10.1091/mbc.12.11.3353; Leao-Helder AN, 2003, J BIOL CHEM, V278, P40749, DOI 10.1074/jbc.M304029200; MERCKELBACH A, 1993, APPL MICROBIOL BIOT, V40, P361, DOI 10.1007/BF00170393; Muntau AC, 2003, EUR J CELL BIOL, V82, P333, DOI 10.1078/0171-9335-00325; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shen SG, 1998, GENE, V216, P93, DOI 10.1016/S0378-1119(98)00315-1; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; van der Klei IJ, 1998, CURR GENET, V34, P1, DOI 10.1007/s002940050360; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; VERDUYN C, 1984, J MICROBIOL METH, V2, P15, DOI 10.1016/0167-7012(84)90027-7; Wang DY, 2003, J BIOL CHEM, V278, P43340, DOI 10.1074/jbc.M307789200; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; WIDENGREN J, 1995, J PHYS CHEM-US, V99, P13368, DOI 10.1021/j100036a009; ZWART KB, 1983, A VAN LEEUW J MICROB, V49, P369	46	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19181	19190		10.1074/jbc.M314275200	http://dx.doi.org/10.1074/jbc.M314275200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14981078	Green Published, hybrid			2022-12-27	WOS:000221041500131
J	Tardif, KD; Mori, K; Kaufman, RJ; Siddiqui, A				Tardif, KD; Mori, K; Kaufman, RJ; Siddiqui, A			Hepatitis C virus suppresses the IRE1-XBP1 pathway of the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; MESSENGER-RNA; CELL-LINES; TRANSCRIPTION; ATF6; ACTIVATION; KINASE; TRANSLATION; INTERFERON	Hepatitis C virus (HCV) gene expression disrupts normal endoplasmic reticulum ( ER) functions and induces ER stress. ER stress results from the accumulation of unfolded or misfolded proteins in the ER; cells can alleviate this stress by degrading or refolding these proteins. The IRE1-XBP1 pathway directs both protein refolding and degradation in response to ER stress. Like IRE1-XBP1, other branches of the ER stress response mediate protein refolding. However, IRE1-XBP1 can also specifically activate protein degradation. We show here that XBP1 expression is elevated in cells carrying HCV subgenomic replicons, but XBP1 trans-activating activity is repressed. This prevents the IRE1-XBP1 transcriptional induction of EDEM ( ER degradation-enhancing alpha-mannosidase-like protein). The mRNA expression of EDEM is required for the degradation of misfolded proteins. Consequently, misfolded proteins are stable in cells expressing HCV replicons. HCV may suppress the IRE1-XBP1 pathway to stimulate the synthesis of its viral proteins. IRE1alpha-null MEFs, a cell line with a defective IRE1-XBP1 pathway, show elevated levels of HCV IRES-mediated translation. Therefore, HCV may suppress the IRE1-XBP1 pathway to not only promote HCV expression but also to contribute to the persistence of the virus in infected hepatocytes.	Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Kyoto University; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Siddiqui, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Campus Box B-172,4200 E 9th Ave, Denver, CO 80262 USA.	Aleem.Siddiqui@UCHSC.edu	Mori, Kazutoshi/AAW-5449-2020; Mori, Kazutoshi/K-6106-2015; Longo, Kenneth A/A-5631-2010		NIDDK NIH HHS [T3-DK07038, DK061566] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007038, R01DK061566] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; GONG G, 2001, P NATL ACAD SCI US; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Liberman E, 1999, J VIROL, V73, P3718, DOI 10.1128/JVI.73.5.3718-3722.1999; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; Parham P, 1996, TRENDS BIOCHEM SCI, V21, P427, DOI 10.1016/S0968-0004(96)10053-0; Pavio N, 2003, J VIROL, V77, P3578, DOI 10.1128/JVI.77.6.3578-3585.2003; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; RIJIBRAND R, 1999, CURR TOP MICROBIOL I, V242, P86; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Tardif KD, 2003, J VIROL, V77, P11644, DOI 10.1128/JVI.77.21.11644-11650.2003; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	40	174	182	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17158	17164		10.1074/jbc.M312144200	http://dx.doi.org/10.1074/jbc.M312144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960590	hybrid			2022-12-27	WOS:000220870400035
J	Wang, HJ; Haas, M; Liang, M; Cai, T; Tian, J; Li, SW; Xie, ZJ				Wang, HJ; Haas, M; Liang, M; Cai, T; Tian, J; Li, SW; Xie, ZJ			Ouabain assembles signaling cascades through the caveolar Na+/K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; GROWTH-FACTOR RECEPTOR; SRC TYROSINE KINASES; CARDIAC MYOCYTES; TRANSDUCING FUNCTION; CHOLESTEROL DEPLETION; MEMBRANE CHOLESTEROL; MAMMALIAN-CELLS; PROSTATE-CANCER; IN-VIVO	Based on the observation that the Na+/K+-ATPase alpha subunit contains two conserved caveolin-binding motifs, we hypothesized that clustering of the Na+/K+-ATPase and its partners in caveolae facilitates ouabain-activated signal transduction. Glutathione S-transferase pull-down assay showed that the Na+/K+-ATPase bound to the N terminus of caveolin-1. Significantly, ouabain regulated the interaction in a time- and dose-dependent manner and stimulated tyrosine phosphorylation of caveolin-1 in LLC-PK1 cells. When added to the isolated membrane fractions, ouabain increased tyrosine phosphorylation of proteins from the isolated caveolae but not other membrane fractions. Consistently, ouabain induced the formation of a Na+/K+-ATPase- Src-caveolin complex in the isolated caveolae preparations as it did in live cells. Finally, depletion of either cholesterol by methyl beta-cyclodextrin or caveolin-1 by siRNA significantly reduced the caveolar Na+/K+- ATPase and Src. Concomitantly, cholesterol depletion abolished ouabain-induced recruitment of Src to the Na+/K+-ATPase signaling complex. Like depletion of caveolin-1, it also blocked the effect of ouabain on ERKs, which was restored after cholesterol repletion. Clearly, the caveolar Na+/K+-ATPase represents the signaling pool of the pump that interacts with Src and transmits the ouabain signals.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA; Med Coll Ohio, Dept Med, Toledo, OH 43614 USA; Allergan Inc Pharmaceut R&D, Irvine, CA 92623 USA		Xie, ZJ (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	zxie@mco.edu	Li, Shengwen Calvin/H-1725-2012	Li, Shengwen Calvin/0000-0002-9699-9204	NCI NIH HHS [F32 CA071326] Funding Source: Medline; NHLBI NIH HHS [HL-36573, HL-67963, HL62338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067963, R01HL062338, P01HL036573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Caselli A, 2001, J BIOL CHEM, V276, P18849, DOI 10.1074/jbc.M100705200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Haas M, 2000, J BIOL CHEM, V275, P27832; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; JORDAN C, 1995, J BIOL CHEM, V270, P29971; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li SN, 1998, TOXICOL APPL PHARM, V151, P377, DOI 10.1006/taap.1998.8471; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 2000, J BIOL CHEM, V275, P27838; Liu LJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1550, DOI 10.1152/ajpcell.00555.2002; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Mohammadi K, 2003, J CARDIOVASC PHARM, V41, P609, DOI 10.1097/00005344-200304000-00014; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Scanlon SM, 2001, BIOCHEMISTRY-US, V40, P10507, DOI 10.1021/bi010730z; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; SKOU JC, 1957, BIOCHIM BIOPHYS ACTA, V23, P394, DOI 10.1016/0006-3002(57)90343-8; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Tahir SA, 2001, CANCER RES, V61, P3882; Tian J, 2001, AM J PHYSIOL-HEART C, V281, pH1899, DOI 10.1152/ajpheart.2001.281.5.H1899; Torihashi S, 2002, J BIOL CHEM, V277, P19191, DOI 10.1074/jbc.M201728200; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wu DQ, 2002, J BIOL CHEM, V277, P40449, DOI 10.1074/jbc.M206270200; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Xie ZJ, 2001, CELL MOL BIOL, V47, P383; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; Zager RA, 2002, KIDNEY INT, V61, P1674, DOI 10.1046/j.1523-1755.2002.00316.x	50	212	229	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17250	17259		10.1074/jbc.M313239200	http://dx.doi.org/10.1074/jbc.M313239200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963033	hybrid			2022-12-27	WOS:000220870400046
J	Warnakulasuriyarachchi, D; Cerquozzi, S; Cheung, HH; Holcik, M				Warnakulasuriyarachchi, D; Cerquozzi, S; Cheung, HH; Holcik, M			Translational induction of the inhibitor of apoptosis protein HIAP2 during endoplasmic reticulum stress attenuates cell death and is mediated via an inducible internal ribosome entry site element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; INITIATION; XIAP; ACTIVATION; PHOSPHORYLATION; CASPASE-12; RESISTANCE; CLEAVAGE; FAMILY	Prolonged endoplasmic reticulum ( ER) stress leads to activation of caspases and cell death. The inhibitor of apoptosis (IAP) proteins are intrinsic inhibitors of apoptosis by virtue of inhibiting distinct caspases and are, therefore, critical regulators of cell death. Here we demonstrate that the expression of one member of the IAP family, HIAP2, is induced in response to ER stress and attenuates ER stress-induced cell death. The induction of HIAP2 is executed at the level of protein synthesis and is mediated by an inducible internal ribosome entry site (IRES) element. The triggering of ER stress results in caspase-mediated proteolytic processing of eukaryotic initiation factor p97/DAP5/NAT1, producing a fragment that specifically activates HIAP2 IRES. These data suggest an existence of a novel mechanism that regulates apoptotic response in ER stress.	Univ Western Ontario, Childrens Hosp Eastern Ontario, Res Inst,Apoptosis Res Ctr, Dept Pediat, Ottawa, ON K1H 8L1, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; Western University (University of Western Ontario)	Holcik, M (corresponding author), Univ Western Ontario, Childrens Hosp Eastern Ontario, Res Inst,Apoptosis Res Ctr, Dept Pediat, Rm R310,401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	martin@mgcheo.med.uottawa.ca	Holcik, Martin/AAC-6660-2019; Holcik, Martin/A-9768-2008; Holcik, Martin/E-5372-2011	Holcik, Martin/0000-0002-1922-5299; 				Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Gerlitz G, 2002, EUR J BIOCHEM, V269, P2810, DOI 10.1046/j.1432-1033.2002.02974.x; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nevins TA, 2003, J BIOL CHEM, V278, P3572, DOI 10.1074/jbc.M206781200; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Warnakulasuriyarachchi D, 2003, CELL DEATH DIFFER, V10, P899, DOI 10.1038/sj.cdd.4401256	33	111	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17148	17157		10.1074/jbc.M308737200	http://dx.doi.org/10.1074/jbc.M308737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960583	hybrid			2022-12-27	WOS:000220870400034
J	Wan, M; Tang, Y; Tytler, EM; Lu, CY; Jin, BW; Vickers, SM; Yang, L; Shi, XM; Cao, X				Wan, M; Tang, Y; Tytler, EM; Lu, CY; Jin, BW; Vickers, SM; Yang, L; Shi, XM; Cao, X			Smad4 protein stability is regulated by ubiquitin ligase SCF beta-TrCP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; BETA-TRCP; COP9 SIGNALOSOME; DEPENDENT DEGRADATION; PHOSPHORYLATION; SCF; COMPLEX; TARGETS; SMURF2; JAB1	Smad4 is a key intracellular mediator for the transforming growth factor-beta (TGF-beta) superfamily of growth factors and is also an important tumor suppressor. The receptor-regulated Smad (R-Smad) proteins are regulated by ubiquitin-mediated degradation, yet the precise control of Smad4 protein stability is unclear. We have identified SCFbeta-TrCP1, a ubiquitin (E3) ligase, as a critical determinant for the protein degradation of Smad4 protein. F-box protein beta-TrCP1 in this E3 ligase interacts with Smad4 both in yeast and in mammalian cells, but has no interaction with Smad2 and has weak interaction with Smad3. The beta-TrCP1/Smad3 interaction was abolished by Smad4 gene silencing, indicating the interaction is indirect and is through Smad4. Ec-topic expression of SCF complex containing beta-TrCP1 is sufficient to induce the ubiquitination and degradation of Smad4. Furthermore, small interfering RNA-triggered endogenous beta-TrCP1 suppression increases the expression of Smad4 protein. Consistent with these results, cells that overexpress the SCF complex display an inhibited TGF-beta-dependent transcriptional activity and an impaired cell cycle arrest function. Thus, SCFbeta-TrCP1 abrogates TGF-beta function in vivo by decreasing Smad4 stability.	Univ Alabama, Sch Med, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Sch Med, Dept Surg, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Cao, X (corresponding author), Univ Alabama, Sch Med, Dept Pathol, Birmingham, AL 35294 USA.	cao@path.uab.edu		Tytler, Ewan/0000-0002-4552-8170	NCI NIH HHS [CA101955-01] Funding Source: Medline; NIDDK NIH HHS [DK57501, DK53757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA101955, P50CA101955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	17	81	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14484	14487		10.1074/jbc.C400005200	http://dx.doi.org/10.1074/jbc.C400005200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14988407	hybrid			2022-12-27	WOS:000220594700004
J	Jha, BK; Mitra, N; Rana, R; Surolia, A; Salunke, DM; Datta, K				Jha, BK; Mitra, N; Rana, R; Surolia, A; Salunke, DM; Datta, K			pH and cation-induced thermodynamic stability of human hyaluronan binding protein 1 regulates its hyaluronan affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTOR SF2; UNSTRUCTURED PROTEINS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; P-32 PROTEIN; CELL-SURFACE; LOCALIZATION; CARTILAGE; CLONING; GC1Q-R	Hyaluronan-binding protein 1 (HABP1) is a trimeric protein with high negative charges distributed asymmetrically along the faces of the molecule. Recently, we have reported that HABP1 exhibits a high degree of structural flexibility, which can be perturbed by ions under in vitro conditions near physiological pH (Jha, B. K., Salunke, D. M., and Datta, K. ( 2003) J. Biol. Chem. 278, 27464 - 27472). Here, we report the effect of ionic strength and pH on thermodynamic stability of HABP1. Trimeric HABP1 was shown to unfold reversibly upon dissociation ruling out the possibility of existence of folded monomer. An increase in ionic concentration (0.05 - 1 M) or decrease in pH ( pH 8.0 - pH 5.0) induced an unusually high thermodynamic stability of HABP1 as reflected in the gradual increase in transition midpoint temperature, enthalpy of transition, and conformational entropy. Our studies suggest that the presence of counter ions in the molecular environment of HABP1 leads to dramatic reduction of the intramolecular electrostatic repulsion either by de-ionizing the charged amino acid residues or by direct binding leading to a more stable conformation. A regulation on cellular HA-HABP1 interaction by changes in pH and ionic strength may exist, because the more stable conformation attained at higher ionic strength or at acidic pH showed maximum affinity toward HA as probed either in solid phase binding assay on HA-immobilized plates or an in-solution binding assay using intrinsic fluorescence of HABP1.	Jawaharlal Nehru Univ, SES, Biochem Lab 103, New Delhi 110067, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Natl Inst Immunol, Struct Biol Unit, New Delhi 110067, India; Jawaharlal Nehru Univ, Special Ctr Mol Med, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi; Indian Institute of Science (IISC) - Bangalore; Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Jawaharlal Nehru University, New Delhi	Datta, K (corresponding author), Jawaharlal Nehru Univ, SES, Biochem Lab 103, New Delhi 110067, India.	kdatta@mail.jnu.ac.in	jha, babal k/B-1803-2010; SUROLIA, AVADESHA/C-5442-2009	jha, babal k/0000-0002-7660-5255; Mitra, Nivedita/0000-0003-3799-5681				Apetri AC, 2003, J BIOL CHEM, V278, P22187, DOI 10.1074/jbc.M302130200; Backmann J, 1998, J MOL BIOL, V284, P817, DOI 10.1006/jmbi.1998.2216; BAGSHAW CR, 1988, SPECTROPHOTOMETRY SP, P91; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; DSOUZA M, 1985, BIOCHEM INT, V10, P43; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; FRASER JRE, 1996, EXTRACELLULAR MATRIX, V2, P141; FREIRE E, 1978, BIOPOLYMERS, V17, P1257, DOI 10.1002/bip.1978.360170512; Fukuda K, 1996, J PHARMACOL EXP THER, V277, P1672; Ghebrehiwet B, 2002, IMMUNOBIOLOGY, V205, P421, DOI 10.1078/0171-2985-00143; Ghebrehiwet B, 2001, IMMUNOL REV, V180, P65, DOI 10.1034/j.1600-065X.2001.1800106.x; Ghebrehiwet B, 1998, IMMUNOBIOLOGY, V199, P225, DOI 10.1016/S0171-2985(98)80029-6; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GUPTA S, 1991, EUR J CELL BIOL, V56, P58; GUPTA S, 1991, EXP CELL RES, V195, P386, DOI 10.1016/0014-4827(91)90388-B; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; Jekow P, 1999, EUR J BIOCHEM, V264, P724, DOI 10.1046/j.1432-1327.1999.00601.x; Jha BK, 2003, J BIOL CHEM, V278, P27464, DOI 10.1074/jbc.M206696200; Jha BK, 2002, EUR J BIOCHEM, V269, P298, DOI 10.1046/j.0014-2956.2001.02654.x; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Li X, 2000, Genome Inform Ser Workshop Genome Inform, V11, P172; Lommer BS, 2002, J BIOL CHEM, V277, P7108, DOI 10.1074/jbc.M109045200; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; McCrary BS, 1996, J MOL BIOL, V264, P784, DOI 10.1006/jmbi.1996.0677; Nishimura C, 2001, BIOCHEMISTRY-US, V40, P2113, DOI 10.1021/bi000861k; Pace CN, 1995, METHOD ENZYMOL, V259, P538; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; RANGANATHAN S, 1994, MOL REPROD DEV, V38, P69, DOI 10.1002/mrd.1080380112; Ranganathan S, 1995, CELL MOL BIOL RES, V41, P467; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Salminen T, 1996, PROTEIN SCI, V5, P1014; Saunders AJ, 2000, BIOPOLYMERS, V53, P293, DOI 10.1002/(SICI)1097-0282(20000405)53:4<293::AID-BIP2>3.3.CO;2-K; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Srinivas VR, 2001, BBA-GEN SUBJECTS, V1527, P102, DOI 10.1016/S0304-4165(01)00153-2; STURTEVANT JM, 1981, BIOCHEMISTRY-US, V20, P3792, DOI 10.1021/bi00516a019; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; XIE D, 1993, J MOL BIOL, V232, P5, DOI 10.1006/jmbi.1993.1364	51	8	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23061	23072		10.1074/jbc.M310676200	http://dx.doi.org/10.1074/jbc.M310676200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15004022	hybrid			2022-12-27	WOS:000221570900035
J	Bekesi, A; Zagyva, I; Hunyadi-Gulyas, E; Pongracz, V; Kovari, J; Nagy, AO; Erdei, A; Medzihradszky, KF; Vertessy, BG				Bekesi, A; Zagyva, I; Hunyadi-Gulyas, E; Pongracz, V; Kovari, J; Nagy, AO; Erdei, A; Medzihradszky, KF; Vertessy, BG			Developmental regulation of dUTPase in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-DNA REPAIR; BASE EXCISION-REPAIR; THYMIDYLATE SYNTHASE; DEOXYURIDINE TRIPHOSPHATASE; TRANSLATIONAL REGULATION; DIHYDROFOLATE-REDUCTASE; CELL-DEATH; NUCLEAR; EXPRESSION; LOCALIZATION	dUTPase prevents uracil incorporation into DNA by strict regulation of the cellular dUTP: dTTP ratio. Lack of the enzyme initiates thymineless cell death, prompting studies on enzyme regulation. We investigated expression pattern and localization of Drosophila dUTPase. Similarly to human, two isoforms of the fly enzyme were identified at both mRNA and protein levels. During larval stages, a drastic decrease of dUTPase expression was demonstrated at the protein level. In contrast, dUTPase mRNAs display constitutive character throughout development. A putative nuclear localization signal was identified in one of the two isoforms. However, immunohistochemistry of ovaries and embryos did not show a clear correlation between the presence of this signal and subcellular localization of the protein, suggesting that the latter may be perturbed by additional factors. Results are in agreement with a multilevel regulation of dUTPase in the Drosophila proteome, possibly involving several interacting protein partners of the enzyme. Using independent approaches, the existence of such macromolecular partners was verified.	Hungarian Acad Sci, BRC, Inst Enzymol, H-1518 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Mass Spectrometry Facil, H-6701 Szeged, Hungary; Eotvos Lorand Univ Sci, Dept Immunol, H-1518 Budapest, Hungary; Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Hungarian Academy of Sciences; Hungarian Biological Research Center; Eotvos Lorand University; University of California System; University of California San Francisco	Vertessy, BG (corresponding author), Hungarian Acad Sci, BRC, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	vertessy@enzim.hu	Vertessy, Beata G/H-6202-2012; Erdei, Anna/AAN-5988-2020	Erdei, Anna/0000-0002-3622-6680; Hunyadi-Gulyas, Eva/0000-0003-2089-1499; Vertessy, Beata G./0000-0002-1288-2982				Ashburner M., 1989, DROSOPHILA LAB HDB; Balajee AS, 1998, MUTAT RES-DNA REPAIR, V409, P135, DOI 10.1016/S0921-8777(98)00051-2; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Barabas O, 2003, J BIOL CHEM, V278, P38803, DOI 10.1074/jbc.M306967200; BERGMAN AC, 1994, VIROLOGY, V204, P420, DOI 10.1006/viro.1994.1547; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; BONIFACINO JS, 2003, CURRENT PROTOCOLS MO; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; CANMAN CE, 1994, CANCER RES, V54, P2296; Caradonna S, 2001, CURR PROTEIN PEPT SC, V2, P335, DOI 10.2174/1389203013381044; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; CHU E, 1994, MOL CELL BIOL, V14, P207, DOI 10.1128/MCB.14.1.207; Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; Deutsch W. A., 1995, Insect Molecular Biology, V4, P1, DOI 10.1111/j.1365-2583.1995.tb00001.x; DEUTSCH WA, 1982, J BIOL CHEM, V257, P3366; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; Fiser A, 2000, BIOCHEM BIOPH RES CO, V279, P534, DOI 10.1006/bbrc.2000.3994; FOE VE, 1993, MITOSIS MORPHOGENESI, P154; GIROIR IE, 1987, J BIOL CHEM, V262, P130; Hardeland U, 2003, NUCLEIC ACIDS RES, V31, P2261, DOI 10.1093/nar/gkg344; HIROSE F, 1993, J BIOL CHEM, V268, P2092; Hokari S, 1995, BIOCHEM MOL BIOL INT, V37, P583; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Kovari J, 2004, J BIOL CHEM, V279, P17932, DOI 10.1074/jbc.M313643200; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; Ladner RD, 1996, J BIOL CHEM, V271, P7745, DOI 10.1074/jbc.271.13.7745; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8; Matsukage A, 1995, GENE, V166, P233, DOI 10.1016/0378-1119(95)00586-2; MCINTOSH EM, 1994, CURR GENET, V26, P415, DOI 10.1007/BF00309928; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; Munoz-Pinedo C, 2001, BIOCHEM J, V353, P101, DOI 10.1042/bj3530101; NATION MD, 1989, BIOCHEM J, V259, P593, DOI 10.1042/bj2590593; Pinz KG, 1998, MOL CELL BIOL, V18, P1257, DOI 10.1128/MCB.18.3.1257; PIRROTTA V, 1988, GENE DEV, V2, P1839, DOI 10.1101/gad.2.12b.1839; PRICE AR, 1975, J BIOL CHEM, V250, P8804; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; Rothwell W.F., 2000, DROSOPHILA PROTOCOLS, P141; Schmitz JC, 2001, CANCER METAST REV, V20, P33, DOI 10.1023/A:1013100306315; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; STRAHLER JR, 1993, P NATL ACAD SCI USA, V90, P4991, DOI 10.1073/pnas.90.11.4991; STRASSER A, 1995, CURR OPIN IMMUNOL, V7, P228, DOI 10.1016/0952-7915(95)80007-7; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tinkelenberg BA, 2003, EXP CELL RES, V287, P39, DOI 10.1016/S0014-4827(03)00048-X; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Welch K, 1999, MOL CELL BIOL, V19, P8400; Zhang K, 2002, SCIENCE, V296, P545, DOI 10.1126/science.1068274	55	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22362	22370		10.1074/jbc.M313647200	http://dx.doi.org/10.1074/jbc.M313647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14996835	hybrid			2022-12-27	WOS:000221417100084
J	Grassilli, E; Ballabeni, A; Maellaro, E; Del Bello, B; Helin, K				Grassilli, E; Ballabeni, A; Maellaro, E; Del Bello, B; Helin, K			Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; FAS-LIGAND; CELL-DEATH; CYTOCHROME-C; EXPRESSION; FIBROBLASTS; INHIBITION; TARGET; ROLES; HTRA2	c-Myc plays an essential role in proliferation, differentiation, and apoptosis. Because of its relevance to cancer, most studies have focused on the cellular consequences of c-Myc overexpression. Here, we address the role of physiological levels of c-Myc in drug-induced apoptosis. By using c-MYC null cells we confirm and extend recent reports showing a c-Myc requirement for the induction of apoptosis by a number of anticancer agents. In particular, we show that c-Myc is required for the induction of apoptosis by doxorubicin and etoposide, whereas it is not required for camptothecin-induced cell death. We have investigated the molecular mechanisms involved in executing doxorubicin-induced apoptosis and show caspase-3 activation by both mitochondria-dependent and -independent pathways. Moreover, serine proteases participate in doxorubicin-induced apoptosis partly by contributing to caspase-3 activation. Finally, a complete rescue from doxorubicin-induced apoptosis is obtained only when serine proteases, caspase-3, and mitochondrial activation are inhibited simultaneously. Interestingly, doxorubicin requires c-Myc for the activation of all of these pathways. Our findings therefore support a model in which doxorubicin simultaneously triggers multiple c-Myc-dependent apoptosis pathways.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Siena, Dept Pathophysiol & Expt Med, I-53100 Siena, Italy; Biotech Res & Innovat Ctr, DK-2100 Copenhagen, Denmark	IRCCS European Institute of Oncology (IEO); University of Siena	Helin, K (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	khelin@ieo.it	Grassilli, Emanuela/L-7296-2013; Helin, Kristian/HDM-8306-2022; grassilli, emanuela/ABB-7845-2020; Helin, Kristian/K-2526-2019	Grassilli, Emanuela/0000-0001-5387-5925; Helin, Kristian/0000-0003-1975-6097; grassilli, emanuela/0000-0001-5387-5925; 				Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Arango D, 2001, CANCER RES, V61, P4910; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bratton SB, 2002, CELL DEATH DIFFER, V9, P881, DOI 10.1038/sj.cdd.4401069; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Chang EH, 2000, MOL MED TODAY, V6, P358, DOI 10.1016/S1357-4310(00)01767-6; Chen L, 2003, EUR J IMMUNOL, V33, P769, DOI 10.1002/eji.200323783; Dang CV, 1999, MOL CELL BIOL, V19, P1; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Del Bello B, 2001, ONCOGENE, V20, P4591, DOI 10.1038/sj.onc.1204618; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GRIGNANI F, CANC RES, V58, P14; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hishita T, 2001, CANCER RES, V61, P2878; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; JUIN P, GENES DEV, V13, P1367; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; Kilic M, 2002, CELL DEATH DIFFER, V9, P125, DOI 10.1038/sj/cdd/4400968; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Komiyama T, 1996, ADV EXP MED BIOL, V389, P173; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Oubrahim H, 2001, P NATL ACAD SCI USA, V98, P9505, DOI 10.1073/pnas.181319898; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vigo E, 1999, MOL CELL BIOL, V19, P6379	43	34	34	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21318	21326		10.1074/jbc.M313532200	http://dx.doi.org/10.1074/jbc.M313532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14990581	hybrid			2022-12-27	WOS:000221273800094
J	Clark, KL; Oelke, A; Johnson, ME; Eilert, KD; Simpson, PC; Todd, SC				Clark, KL; Oelke, A; Johnson, ME; Eilert, KD; Simpson, PC; Todd, SC			CD81 associates with 14-3-3 in a redox-regulated palmitoylation-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; ENVELOPE PROTEIN E2; TRANSMEMBRANE-4 SUPERFAMILY; CELL-ADHESION; T-CELLS; SIGNAL-TRANSDUCTION; CD81-DEFICIENT MICE; SYNCYTIUM FORMATION; IMMUNE-RESPONSE; B-LYMPHOCYTES	As a member of the tetraspanin superfamily of proteins, CD81 has been linked to a number of biologic functions including cellular proliferation, differentiation, activation, and degranulation. As a co-receptor for hepatitis C virus, and a requirement for hepatocytes for infectivity of human Plasmodium falciparum and rodent P. yoelii sporozoite infectivity, CD81 may also play a vital role in pathology. Despite the importance of CD81 in multiple cellular functions, the molecular mechanism of action of CD81 in these processes has remained elusive. Here we report an association between CD81 and the epsilon isoform of 14-3-3, a serine/threonine-binding intracellular signaling protein. Furthermore, we provide evidence that in human, this association is influenced by the palmitoylation state of the CD81 cytoplasmic tails. We have generated a series of CD81 cysteine mutants to identify palmitoylated intracellular motifs of CD81, and reveal palmitoylation on the N- and C-terminal tails as well as the intracellular loop between transmembrane domains 2 and 3. One of these mutants lacks all five of its intracellular cysteines and therefore cannot be palmitoylated. This unpalmitoylated version of CD81 shows constitutive association with 14-3-3. Interestingly, we find that under oxidative conditions, CD81 palmitoylation is inhibited and that condition correlates with the association of CD81 and 14-3-3. These finding suggest that CD81 signaling events could be mediated by 14-3-3 adapter proteins, and these signals may be dependent on cellular redox.	Kansas State Univ, Div Biol, Program Mol Cellular & Dev Biol, Manhattan, KS 66506 USA	Kansas State University	Clark, KL (corresponding author), Kansas State Univ, Div Biol, Program Mol Cellular & Dev Biol, 239C Chalmers Hall, Manhattan, KS 66506 USA.	c6vl@hotmail.com			NCRR NIH HHS [RR 16475] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016475] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; Berditchevski F, 2001, J BIOL CHEM, V276, P41165, DOI 10.1074/jbc.M104041200; Boismenu R, 1996, SCIENCE, V271, P198, DOI 10.1126/science.271.5246.198; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Clark KL, 2001, J IMMUNOL, V167, P5115, DOI 10.4049/jimmunol.167.9.5115; CLASSON BJ, 1990, J EXP MED, V172, P1007, DOI 10.1084/jem.172.3.1007; Crotta S, 2002, J EXP MED, V195, P35, DOI 10.1084/jem.20011124; Deng J, 2000, J IMMUNOL, V165, P5054, DOI 10.4049/jimmunol.165.9.5054; Drummer HE, 2002, J VIROL, V76, P11143, DOI 10.1128/JVI.76.21.11143-11147.2002; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Feigelson SW, 2003, J BIOL CHEM, V278, P51203, DOI 10.1074/jbc.M303601200; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000; HOTTA H, 1988, CANCER RES, V48, P2955; IMAI T, 1992, J IMMUNOL, V149, P2879; IMAI T, 1993, J IMMUNOL, V151, P6470; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; Miyazaki T, 1997, EMBO J, V16, P4217, DOI 10.1093/emboj/16.14.4217; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Parat MO, 2002, BIOCHEM J, V361, P681, DOI 10.1042/0264-6021:3610681; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; SCHICK MR, 1993, J IMMUNOL, V151, P4090; SCHICK MR, 1993, J IMMUNOL, V151, P1918; SEEHAFER JG, 1988, BIOCHIM BIOPHYS ACTA, V952, P92, DOI 10.1016/0167-4838(88)90105-7; SEEHAFER JG, 1988, BIOCHIM BIOPHYS ACTA, V957, P399, DOI 10.1016/0167-4838(88)90231-2; Silvie O, 2003, NAT MED, V9, P93, DOI 10.1038/nm808; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; TAKAHASHI K, 1990, J IMMUNOL, V145, P4371; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; Todd SC, 1998, BBA-GENE STRUCT EXPR, V1399, P101, DOI 10.1016/S0167-4781(98)00087-6; Todd SC, 1996, J EXP MED, V184, P2055, DOI 10.1084/jem.184.5.2055; Tseng CTK, 2002, J EXP MED, V195, P43, DOI 10.1084/jem.20011145; Tsitsikov EN, 1997, P NATL ACAD SCI USA, V94, P10844, DOI 10.1073/pnas.94.20.10844; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; VanCompernolle SE, 2003, VIROLOGY, V314, P371, DOI 10.1016/S0042-6822(03)00406-9; VanCompernolle SE, 2001, EUR J IMMUNOL, V31, P823, DOI 10.1002/1521-4141(200103)31:3<823::AID-IMMU823>3.3.CO;2-4; Wack A, 2001, EUR J IMMUNOL, V31, P166, DOI 10.1002/1521-4141(200101)31:1<166::AID-IMMU166>3.0.CO;2-L; WRIGHT MD, 1990, J IMMUNOL, V144, P3195; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	47	56	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19401	19406		10.1074/jbc.M312626200	http://dx.doi.org/10.1074/jbc.M312626200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14966136	hybrid			2022-12-27	WOS:000221164500005
J	Dressel, R; Raja, SM; Honing, S; Seidler, T; Froelich, CJ; von Figura, K; Gunther, E				Dressel, R; Raja, SM; Honing, S; Seidler, T; Froelich, CJ; von Figura, K; Gunther, E			Granzyme-mediated cytotoxicity does not involve the mannose 6-phosphate receptors on target cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-6-PHOSPHATE RECEPTOR; CYTOSOLIC DELIVERY; INDUCED APOPTOSIS; PORE FORMATION; T-LYMPHOCYTES; PERFORIN; DEATH; SERGLYCIN; CTL; HEAT-SHOCK-PROTEIN-70	Cytotoxic T lymphocytes (CTL) and natural killer cells secrete granzymes to kill infected or transformed cells. The mannose 6-phosphate receptor (Mpr) 300 on target cells has been reported to function as receptor for secreted granzyme B. Using lymphoblasts and mouse embryonal fibroblast lines from Mpr300 and Mpr46 knockout mice, we show here that both receptors are not essential for CTL-induced apoptosis. Similarly, cells exposed to either monomeric granzyme B or granzyme B-serglycin complexes readily internalize the granzyme and undergo apoptosis in the absence of Mpr300 and Mpr46. Further, no colocalization of granzyme B and Mpr300 could be observed in target cells after internalization. In conclusion, these results strongly argue against an Mpr300- or Mpr46-dependent pathway of granzyme-mediated killing and provide new insight in the internalization of monomeric and complexed granzyme B.	Univ Gottingen, Div Immunogenet, D-37073 Gottingen, Germany; Northwestern Univ, Feinberg Sch Med, Evanston Healthcare Res Inst, Evanston, IL 60201 USA; Univ Gottingen, Div Biochem 2, D-37073 Gottingen, Germany; Univ Gottingen, Div Cardiol & Pneumol, D-37075 Gottingen, Germany	University of Gottingen; Northwestern University; Feinberg School of Medicine; University of Gottingen; University of Gottingen	Dressel, R (corresponding author), Univ Gottingen, Div Immunogenet, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	rdresse@gwdg.de	Seidler, Tim/B-3929-2014; Seidler, Tim/ABH-8333-2020; Dressel, Ralf/R-7065-2016	Seidler, Tim/0000-0002-6158-5087; Dressel, Ralf/0000-0002-1651-1214				Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Browne KA, 1999, MOL CELL BIOL, V19, P8604; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; Dittmer F, 1998, TRANSGENIC RES, V7, P473, DOI 10.1023/A:1008823315416; Dressel R, 1999, EUR J IMMUNOL, V29, P3925, DOI 10.1002/(SICI)1521-4141(199912)29:12<3925::AID-IMMU3925>3.0.CO;2-S; Dressel R, 2000, J IMMUNOL, V164, P2362, DOI 10.4049/jimmunol.164.5.2362; Ewen C, 2003, J IMMUNOL METHODS, V276, P89, DOI 10.1016/S0022-1759(03)00073-5; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V229, P44, DOI 10.1006/bbrc.1996.1755; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GARNER R, 1994, J IMMUNOL, V153, P5413; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; Gross C, 2003, J BIOL CHEM, V278, P41173, DOI 10.1074/jbc.M302644200; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Lowin B, 1995, Curr Top Microbiol Immunol, V198, P1; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Metkar SS, 2002, IMMUNITY, V16, P417, DOI 10.1016/S1074-7613(02)00286-8; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Nyberg-Hoffman C, 1999, NAT MED, V5, P955, DOI 10.1038/11400; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; Raja SM, 2003, CURR OPIN IMMUNOL, V15, P528, DOI 10.1016/S0952-7915(03)00111-0; Raja SM, 2002, J BIOL CHEM, V277, P49523, DOI 10.1074/jbc.M209607200; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Trapani JA, 2003, J CELL BIOL, V160, P223, DOI 10.1083/jcb.200210150; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; YOUNG JDE, 1986, CELL, V44, P849, DOI 10.1016/0092-8674(86)90007-3	34	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20200	20210		10.1074/jbc.M313108200	http://dx.doi.org/10.1074/jbc.M313108200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985351	hybrid			2022-12-27	WOS:000221164500097
J	Harris, RH; Wilk, D; Bevins, CL; Munson, RS; Bakaletz, LO				Harris, RH; Wilk, D; Bevins, CL; Munson, RS; Bakaletz, LO			Identification and characterization of a mucosal antimicrobial peptide expressed by the chinchilla (Chinchilla lanigera) airway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-DEFENSIN 2; OTITIS-MEDIA; NASOPHARYNGEAL FLORA; MOLECULAR-CLONING; PLANT DEFENSIN; GENE; SEQUENCE; BACTERIA	Cationic antimicrobial peptides (APs) are produced at mucosal surfaces and play a key role as a first line of defense against infection. To understand how APs might impact disease progression in otitis media (OM), our goal was to identify and characterize APs expressed by the epithelium lining the uppermost airway of the chinchilla, the established rodent host for the study of the bacterial-viral pathogenesis in OM. Using a molecular approach, we cloned a cDNA encoding a homolog of human beta-defensin 3, designated chinchilla beta-defensin-1 (cBD-1), and found by Northern analysis expression of the corresponding mRNA in nasopharyngeal and tongue mucosae as well as skin. By reverse transcription-PCR, cBD-1 mRNA was also detected in RNA isolated from trachea, lung, and Eustachian tube tissues. The predicted mature form of cBD-1, expressed as a recombinant peptide in Escherichia coli, demonstrated bactericidal activity against the three primary opportunistic pathogens of OM as well as Candida albicans. Continued study of this and other APs will allow us to determine their role in bacterial colonization of the upper airway as well as how viruses might contribute to the pathogenesis of OM by modulating AP expression.	Ohio State Univ, Coll Med & Publ Hlth, Columbus Childrens Res Inst, Dept Pediat,Ctr Microbial Pathogenesis, Columbus, OH 43205 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Cleveland Clinic Foundation	Bakaletz, LO (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Columbus Childrens Res Inst, Dept Pediat,Ctr Microbial Pathogenesis, 700 Childrens Dr,Rm W591, Columbus, OH 43205 USA.	BakaletL@pediatrics.ohio-state.edu	Bevins, Charles L/P-4438-2015; Bakaletz, Lauren/GMW-8490-2022; Munson, Jr, Robert/E-3710-2011	Bevins, Charles L/0000-0003-2725-2622; Munson, Jr, Robert/0000-0002-3204-3019	NICHD NIH HHS [HD 34615] Funding Source: Medline; NIDCD NIH HHS [R01 DC 05847] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD034615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005847] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bakaletz LO, 2002, POLYMICROBIAL DISEASES, P259; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Bauer F, 2001, PROTEIN SCI, V10, P2470, DOI 10.1110/ps.ps.24401; Chen KC, 2002, J AGR FOOD CHEM, V50, P7258, DOI 10.1021/jf020527q; Cole AM, 1999, INFECT IMMUN, V67, P3267, DOI 10.1128/IAI.67.7.3267-3275.1999; FADEN H, 1990, PEDIATR INFECT DIS J, V9, P623; FADEN H, 1991, ANN OTO RHINOL LARYN, V100, P612, DOI 10.1177/000348949110000802; Faden H, 2001, EUR J PEDIATR, V160, P407, DOI 10.1007/s004310100754; Gennaro R, 2000, BIOPOLYMERS, V55, P31, DOI 10.1002/1097-0282(2000)55:1<31::AID-BIP40>3.3.CO;2-0; Giebink GS, 1999, MICROB DRUG RESIST, V5, P57, DOI 10.1089/mdr.1999.5.57; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Jia HP, 1999, INFECT IMMUN, V67, P4827, DOI 10.1128/IAI.67.9.4827-4833.1999; Jia HP, 2000, J BIOL CHEM, V275, P33314, DOI 10.1074/jbc.M006603200; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Koike M, 2002, BIOCHEM BIOPH RES CO, V298, P46, DOI 10.1016/S0006-291X(02)02391-4; Krisanaprakornkit S, 2000, INFECT IMMUN, V68, P2907, DOI 10.1128/IAI.68.5.2907-2915.2000; LEE HY, 2002, 25 ANN MIDW RES M AS, P223; Lee SH, 2002, ANN OTO RHINOL LARYN, V111, P135, DOI 10.1177/000348940211100205; Lim DJ, 2000, VACCINE, V19, pS17, DOI 10.1016/S0264-410X(00)00273-5; Lysenko ES, 2000, INFECT IMMUN, V68, P1664, DOI 10.1128/IAI.68.3.1664-1671.2000; Mathews M, 1999, INFECT IMMUN, V67, P2740, DOI 10.1128/IAI.67.6.2740-2745.1999; Moon SK, 2002, BBA-MOL CELL RES, V1590, P41, DOI 10.1016/S0167-4889(02)00196-9; Ouellette AJ, 2000, J BIOL CHEM, V275, P33969, DOI 10.1074/jbc.M004062200; Park HC, 2002, PLANT MOL BIOL, V50, P59; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Shirafuji Y, 2003, J BIOL CHEM, V278, P7910, DOI 10.1074/jbc.M210600200; Simmaco M, 1998, SCAND J IMMUNOL, V48, P357; Singh PK, 2000, AM J PHYSIOL-LUNG C, V279, pL799, DOI 10.1152/ajplung.2000.279.5.L799; Smith TPL, 2001, GENOME RES, V11, P626, DOI 10.1101/gr.170101; Stenberg B, 1999, ACTA AGR SCAND B-S P, V49, P1, DOI 10.1080/09064719950135669; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Tarver AP, 1998, INFECT IMMUN, V66, P1045, DOI 10.1128/IAI.66.3.1045-1056.1998; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	36	23	24	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20250	20256		10.1074/jbc.M400499200	http://dx.doi.org/10.1074/jbc.M400499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996845	hybrid			2022-12-27	WOS:000221164500102
J	Inbe, H; Watanabe, S; Miyawaki, M; Tanabe, E; Encinas, JA				Inbe, H; Watanabe, S; Miyawaki, M; Tanabe, E; Encinas, JA			Identification and characterization of a cell-surface receptor, P2Y15, for AMP and adenosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; RAT-LIVER; 5'-ADENOSINE MONOPHOSPHATE; NUCLEOTIDE RECEPTORS; CHLORIDE SECRETION; PLASMA-MEMBRANES; P2Y(2) RECEPTORS; A(2B) ADENOSINE; GENE-EXPRESSION; MAST-CELLS	AMP and adenosine are found in all cell types and can be released by cells or created extracellularly from the breakdown of ATP and ADP. We have identified an orphan G protein-coupled receptor with homology to the P2Y family of nucleotide receptors that can respond to both AMP and adenosine. Based on its ability to functionally bind the nucleotide AMP, we have named it P2Y15. Upon stimulation, P2Y15 induces both Ca2+ mobilization and cyclic AMP generation, suggesting coupling to at least two different G proteins. It is highly expressed in mast cells and is found predominantly in the tissues of the respiratory tract and kidneys, which are known to be affected by AMP, adenosine, and adenosine antagonists. Until now, the effects of AMP have been thought to depend on its dephosphorylation to adenosine but we demonstrate here that P2Y15 is a bona fide AMP receptor by showing that it binds [P-32] AMP. Because AMP and adenosine have bronchoconstrictive effects that can be inhibited by theophylline, we tested whether theophylline and other adenosine receptor antagonists can block P2Y15. We found inhibition at a theophylline concentration well within the therapeutic dose range, indicating that P2Y15 may be a clinically important target of this drug.	Bayer Yakuhin Ltd, Res Ctr Kyoto, Kizu, Kyoto 6190216, Japan	Bayer AG	Encinas, JA (corresponding author), Bayer Yakuhin Ltd, Res Ctr Kyoto, 6-5-1-3 Kunimidai, Kizu, Kyoto 6190216, Japan.	jencinas@post.harvard.edu						Abbracchio MP, 2003, TRENDS PHARMACOL SCI, V24, P52, DOI 10.1016/S0165-6147(02)00038-X; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Decking UKM, 1997, CIRC RES, V81, P154, DOI 10.1161/01.RES.81.2.154; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gao ZH, 1999, J BIOL CHEM, V274, P5972, DOI 10.1074/jbc.274.9.5972; Hannon JP, 2002, BRIT J PHARMACOL, V135, P685, DOI 10.1038/sj.bjp.0704516; HENDERSON JC, 1993, THORAX, V48, P824, DOI 10.1136/thx.48.8.824; Hofmann K, 1993, TMPRED PREDICTION TR; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; HOWELL RE, 1990, J PHARMACOL EXP THER, V255, P1008; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Jarvis GE, 1996, EUR J PHARMACOL, V315, P203, DOI 10.1016/S0014-2999(96)00637-1; JOAD JP, 1990, AM J RESP CELL MOL, V2, P193, DOI 10.1165/ajrcmb/2.2.193; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Lee DK, 2001, GENE, V275, P83, DOI 10.1016/S0378-1119(01)00651-5; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Lewis MD, 1996, J CLIN ENDOCR METAB, V81, P1296, DOI 10.1210/jc.81.3.1296; Linden J, 1999, MOL PHARMACOL, V56, P705; MADARA JL, 1993, J CLIN INVEST, V91, P2320, DOI 10.1172/JCI116462; MARQUARDT DL, 1984, P NATL ACAD SCI-BIOL, V81, P6192, DOI 10.1073/pnas.81.19.6192; MARQUARDT DL, 1997, ASTHMA, P585; Melamed J, 1995, ANN ALLERG ASTHMA IM, V75, P516; Merten MD, 1998, EUR J BIOCHEM, V251, P19, DOI 10.1046/j.1432-1327.1998.2510019.x; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; Morin D, 2000, PHARMACOL RES, V41, P435, DOI 10.1006/phrs.1999.0609; Moro S, 1999, BIOCHEMISTRY-US, V38, P3498, DOI 10.1021/bi982369v; Polosa R, 1997, THORAX, V52, P919, DOI 10.1136/thx.52.10.919; RESNICK MB, 1993, J IMMUNOL, V151, P5716; Saito H, 1996, J IMMUNOL, V157, P343; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tullin S, 2000, ENDOCRINOLOGY, V141, P3397, DOI 10.1210/en.141.9.3397; van den Berge M, 2002, CLIN EXP ALLERGY, V32, P824, DOI 10.1046/j.1365-2222.2002.01385.x; WEAVER DR, 1992, AM J PHYSIOL, V263, pF991, DOI 10.1152/ajprenal.1992.263.6.F991; Weinberger M, 1996, NEW ENGL J MED, V334, P1380, DOI 10.1056/NEJM199605233342107; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; Wittenberger T, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-17; WU SN, 1992, JPN J PHYSIOL, V42, P35, DOI 10.2170/jjphysiol.42.35; Yegutkin GG, 1999, J RECEPT SIGNAL TR R, V19, P437, DOI 10.3109/10799899909036663; Yegutkin GG, 2000, BBA-BIOMEMBRANES, V1466, P234, DOI 10.1016/S0005-2736(00)00165-6	42	66	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19790	19799		10.1074/jbc.M400360200	http://dx.doi.org/10.1074/jbc.M400360200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15001573	hybrid			2022-12-27	WOS:000221164500050
J	Roberts, DE; McNicol, A; Bose, R				Roberts, DE; McNicol, A; Bose, R			Mechanism of collagen activation in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; IONIZED CALCIUM; NA+/CA2+ EXCHANGE; EXTRAPLATELET NA+; CYTOSOLIC CALCIUM; CA-2+ HOMEOSTASIS; ARACHIDONIC-ACID; REVERSE MODE; THROMBIN; ADHESION	The mechanism of collagen-induced human platelet activation was examined using Ca2+, Na+, and the pH-sensitive fluorescent dyes calcium green/fura red, sodium-binding benzofuran isophthalate, and 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein. Administration of a moderate dose of collagen (10 mug/ml) to human platelets resulted in an increase in [Ca2+](i) and platelet aggregation. The majority of this increase in [Ca2+](i) resulted from the influx of calcium from the extracellular milieu via the Na+/Ca2+ exchanger (NCX) functioning in the reverse mode and was reduced in a dose-dependent manner by the NCX inhibitors 5-(4-chlorobenzyl)-2', 4'-dimethylbenzamil (KD50=4.7+/-1.1 muM) and KB-R7943 (KD50=35.1+/-4.8 muM). Collagen-induced platelet aggregation was dependent on an increase in [Ca2+](i) and could be inhibited by chelation of intra- and extracellular calcium through the administration of 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-AM) and EGTA, respectively, or via the administration of BAPTA-AM to platelets suspended in no-Na+/HEPES buffer. Collagen induced an increase in [Na+](i) (23.2+/-7.6 mM) via the actions of thromboxane A(2) and, to a lesser extent, of the Na+/H+ exchanger. This study demonstrates that the collagen-induced increase in [Ca2+](i) is dependent on the concentration of Na+ in the extracellular milieu, indicating that the collagen-induced increase in [Na+](i) causes the reversal of the NCX, ultimately resulting in an increase in [Ca2+](i) and platelet aggregation.	Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Oral Biol, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba	Bose, R (corresponding author), Univ Manitoba, Dept Pharmacol & Therapeut, A311,753 McDermot Ave, Winnipeg, MB R3E 0W3, Canada.	rbose@ms.umanitoba.ca						ARDLIE NG, 1986, THROMB RES, V42, P115, DOI 10.1016/0049-3848(86)90288-4; AUTHI KS, 1985, BIOCHEM J, V230, P247, DOI 10.1042/bj2300247; BAUMGARTNER HR, 1972, ANN NY ACAD SCI, V201, P22, DOI 10.1111/j.1749-6632.1972.tb16285.x; BRASS LF, 1984, J BIOL CHEM, V259, P2571; BRASS LF, 1985, J BIOL CHEM, V260, P5172; CONNOLLY TM, 1983, J BIOL CHEM, V258, P3907; CONNOLLY TM, 1983, P NATL ACAD SCI-BIOL, V80, P5320, DOI 10.1073/pnas.80.17.5320; COWAN DH, 1981, BRIT J HAEMATOL, V47, P257, DOI 10.1111/j.1365-2141.1981.tb02787.x; DOYLE VM, 1985, BIOCHEM BIOPH RES CO, V127, P161, DOI 10.1016/S0006-291X(85)80139-X; Feijge MAH, 1998, BRIT J HAEMATOL, V102, P850, DOI 10.1046/j.1365-2141.1998.00844.x; FEINBERG H, 1977, BIOCHIM BIOPHYS ACTA, V470, P317, DOI 10.1016/0005-2736(77)90109-2; GREENBERGSEPERSKY SM, 1984, J BIOL CHEM, V259, P1502; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IMAI S, 1967, J PHYSIOL-LONDON, V190, P155, DOI 10.1113/jphysiol.1967.sp008199; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; JOHNSON PC, 1985, J BIOL CHEM, V260, P2069; KRAUT RP, 1993, ANAL BIOCHEM, V214, P413, DOI 10.1006/abio.1993.1516; Kuwahara M, 1999, BLOOD, V94, P1149, DOI 10.1182/blood.V94.4.1149.416k18_1149_1155; Li Y, 2001, AM J PHYSIOL-HEART C, V280, pH1480, DOI 10.1152/ajpheart.2001.280.4.H1480; MACINTYRE DE, 1982, THROMB HAEMOSTASIS, V47, P22; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MATSUOKA S, 1992, J GEN PHYSIOL, V100, P963, DOI 10.1085/jgp.100.6.963; McNicol A, 1995, BIOCHEM PHARMACOL, V50, P1795, DOI 10.1016/0006-2952(95)02048-9; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; MOTULSKY HJ, 1983, CIRC RES, V52, P226, DOI 10.1161/01.RES.52.2.226; NAKANO T, 1986, J BIOCHEM-TOKYO, V99, P1285, DOI 10.1093/oxfordjournals.jbchem.a135594; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAPP B, 1991, J BIOL CHEM, V266, P14593; PATEL P, 1991, J VASC MED BIOL, V3, P314; PIPILI E, 1985, THROMB HAEMOSTASIS, V54, P645; POLLOCK WK, 1986, BIOCHEM J, V235, P869, DOI 10.1042/bj2350869; POOLE AW, 1995, BRIT J PHARMACOL, V115, P101, DOI 10.1111/j.1476-5381.1995.tb16326.x; PURDON AD, 1984, BIOCHIM BIOPHYS ACTA, V800, P178; RENGASAMY A, 1987, THROMB HAEMOSTASIS, V57, P337; RINK TJ, 1982, FEBS LETT, V148, P21, DOI 10.1016/0014-5793(82)81234-9; RITTENHOUSE SE, 1982, J CLIN INVEST, V70, P1216, DOI 10.1172/JCI110720; Roberts DE, 2002, ANN NY ACAD SCI, V976, P345; SAGE SO, 1986, BIOCHEM BIOPH RES CO, V136, P1124, DOI 10.1016/0006-291X(86)90450-X; SANDLER WC, 1980, BIOCHIM BIOPHYS ACTA, V600, P448, DOI 10.1016/0005-2736(80)90447-2; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SCHAEFFER J, 1989, CELL CALCIUM, V10, P101, DOI 10.1016/0143-4160(89)90050-X; Shiraishi M, 2000, CELL CALCIUM, V27, P53, DOI 10.1054/ceca.1999.0089; SIFFERT W, 1988, TRENDS BIOCHEM SCI, V13, P148, DOI 10.1016/0968-0004(88)90074-6; TAKAMURA H, 1987, J BIOL CHEM, V262, P2262; VALANT PA, 1992, J MEMBRANE BIOL, V130, P63; WARE JA, 1986, J CLIN INVEST, V77, P878, DOI 10.1172/JCI112385; WATSON SP, 1985, BIOCHEM J, V226, P831, DOI 10.1042/bj2260831; WUYTACK F, 1994, J BIOL CHEM, V269, P1410	48	100	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19421	19430		10.1074/jbc.M308864200	http://dx.doi.org/10.1074/jbc.M308864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14981087	hybrid			2022-12-27	WOS:000221164500007
J	Tzagoloff, A; Barrientos, A; Neupert, W; Herrmann, JM				Tzagoloff, A; Barrientos, A; Neupert, W; Herrmann, JM			Atp10p assists assembly of atp6p into the F-0 unit of the yeast mitochondrial ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONE; CROSS-LINKING; SYNTHASE; PROTEIN; IDENTIFICATION; MEMBRANE; COMPLEX; DNA; F-1-ATPASE	The F0F1-ATPase complex of yeast mitochondria contains three mitochondrial and at least 17 nuclear gene products. The coordinate assembly of mitochondrial and cytosolic translation products relies on chaperones and specific factors that stabilize the pools of some unassembled subunits. Atp10p was identified as a mitochondrial inner membrane component necessary for the biogenesis of the hydrophobic F-0 sector of the ATPase. Here we show that, following its synthesis on mitochondrial ribosomes, subunit 6 of the ATPase (Atp6p) can be cross-linked to Atp10p. This interaction is required for the integration of Atp6p into a partially assembled subcomplex of the ATPase. Pulse labeling and chase of mitochondrial translation products in vivo indicate that Atp6p is less stable and more rapidly degraded in an atp10 null mutant than in wild type. Based on these observations, we propose Atp10p to be an Atp6p-specific chaperone that facilitates the incorporation of Atp6p into an intermediate subcomplex of ATPase subunits.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Munich; Columbia University	Herrmann, JM (corresponding author), Univ Munich, Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	hannes.herrmann@bio.med.uni-muenchen.de			NHLBI NIH HHS [HL 2274, R01 HL022174] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Ackerman SH, 2002, BBA-BIOENERGETICS, V1555, P101, DOI 10.1016/S0005-2728(02)00262-1; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Garcia JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075; GRAY RE, 1990, FEBS LETT, V268, P265, DOI 10.1016/0014-5793(90)81024-I; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Herrmann JM, 2001, METHOD CELL BIOL, V65, P217, DOI 10.1016/S0091-679X(01)65013-1; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; Mueller DM, 2000, J BIOENERG BIOMEMBR, V32, P391, DOI 10.1023/A:1005532104617; ORIAN JM, 1984, J BIOENERG BIOMEMBR, V16, P561, DOI 10.1007/BF00743246; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paul MF, 2000, J BIOL CHEM, V275, P29238, DOI 10.1074/jbc.M004546200; Preuss M, 2001, J CELL BIOL, V153, P1085, DOI 10.1083/jcb.153.5.1085; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; SCHATZ G, 1968, J BIOL CHEM, V243, P2192; Sheluho D, 2001, J BIOL CHEM, V276, P39945, DOI 10.1074/jbc.M107252200; Stephens AN, 2003, J BIOL CHEM, V278, P17867, DOI 10.1074/jbc.M300967200; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Velours J, 2000, BBA-BIOENERGETICS, V1458, P443, DOI 10.1016/S0005-2728(00)00093-1; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; Westermann B, 2001, METHOD CELL BIOL, V65, P429, DOI 10.1016/S0091-679X(01)65025-8	27	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19775	19780		10.1074/jbc.M401506200	http://dx.doi.org/10.1074/jbc.M401506200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14998992	hybrid			2022-12-27	WOS:000221164500048
J	Zhang, DL; Bar-Eli, M; Meloche, S; Brodt, P				Zhang, DL; Bar-Eli, M; Meloche, S; Brodt, P			Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor - The phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; BREAST-CANCER CELLS; PROTEIN-KINASE-B; FACTOR-I; MATRIX-METALLOPROTEINASE; GENE-EXPRESSION; HUMAN-MELANOMA; TRANSDUCTION PATHWAYS; EXTRACELLULAR-MATRIX; MESANGIAL CELLS	The matrix metalloproteinase (MMP)-2 has been recognized as a major mediator of basement membrane degradation, angiogenesis, tumor invasion, and metastasis. The factors that regulate its expression have not, however, been fully elucidated. We previously identified the type I insulin-like growth factor (IGF-I) receptor as a regulator of MMP-2 synthesis. The objective of the present study was to investigate the signal transduction pathway(s) mediating this regulation. We show here that in Lewis lung carcinoma subline H-59 cells treated with IGF-I ( 10 ng/ml), the PI 3-kinase ( phosphatidylinositol 3'-kinase) /protein kinase B (Akt) and C-Raf/ERK pathways were activated, and MMP-2 promoter activity, mRNA, and protein synthesis were induced. MMP-2 induction was blocked by the PI 3-kinase inhibitors LY294002 and wortmannin, by overexpression of a dominant-negative Akt or wild-type PTEN ( phosphatase and tensin homologue deleted on chromosome 10), and by rapamycin. In contrast, a MEK inhibitor PD98059 failed to reduce MMP-2 promoter activation and actually increased MMP-2 mRNA and protein synthesis by up to 30%. Interestingly, suppression of PI 3-kinase signaling by a dominant-negative Akt enhanced ERK activity in cells stimulated with 10 ng/ml but not with 100 ng/ml IGF-I. Furthermore, at the higher ( 100 ng/ml) IGF-I concentration, C-Raf and ERK, but not PI 3-kinase activation, was enhanced, and this resulted in down-regulation of MMP-2 synthesis. This effect was reversed in cells expressing a dominant-negative ERK mutant. The results suggest that IGF-I can up-regulate MMP-2 synthesis via PI 3-kinase/Akt/mTOR ( the mammalian target of rapamycin) signaling while concomitantly transmitting a negative regulatory signal via the Raf/ERK pathway. The outcome of IGF-IR ( the receptor for IGF-I) activation may ultimately depend on factors, such as ligand bioavailability, that can shift the balance preferentially toward one pathway or the other.	Royal Victoria Hosp, Div Surg Res, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Surg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; Univ Montreal, Dept Pharmacol, Inst Rech Immunovirol & Cancerol, Montreal, PQ H3A 1A1, Canada; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77054 USA	McGill University; Royal Victoria Hospital; McGill University; McGill University; Universite de Montreal; University of Texas System; UTMD Anderson Cancer Center	Brodt, P (corresponding author), Royal Victoria Hosp, Div Surg Res, Room H6-25,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	pnina.brodt@muhc.mcgill.ca						Allgayer H, 1998, ONCOLOGY-BASEL, V55, P152, DOI 10.1159/000011850; Bar-Eli M, 1999, PATHOBIOLOGY, V67, P12, DOI 10.1159/000028045; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; BRODT P, 1986, CANCER RES, V46, P2442; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.3.CO;2-F; Foulstone EJ, 2003, HORM METAB RES, V35, P667; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM CH, 1994, EXP CELL RES, V214, P93, DOI 10.1006/excr.1994.1237; Guan KL, 2000, J BIOL CHEM, V275, P27354; Haas TL, 1999, TRENDS CARDIOVAS MED, V9, P70, DOI 10.1016/S1050-1738(99)00014-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanemaaijer R, 2000, INT J CANCER, V86, P204, DOI 10.1002/(SICI)1097-0215(20000415)86:2<204::AID-IJC9>3.0.CO;2-6; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Iwata Y, 1997, ARTHRITIS RHEUM, V40, P499, DOI 10.1002/art.1780400316; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Kanayama Hiro-omi, 2001, Journal of Medical Investigation, V48, P31; Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000; Krassas GE, 2003, J CLIN ENDOCR METAB, V88, P132, DOI 10.1210/jc.2002-021349; Lavandero S, 1998, FEBS LETT, V422, P193, DOI 10.1016/S0014-5793(98)00008-8; Lehman JA, 2002, BIOCHEM BIOPH RES CO, V293, P463, DOI 10.1016/S0006-291X(02)00238-3; Long L, 1998, CANCER RES, V58, P3243; Luca M, 1997, AM J PATHOL, V151, P1105; Lupia E, 1999, DIABETES, V48, P1638, DOI 10.2337/diabetes.48.8.1638; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; OHagan RC, 1996, ONCOGENE, V13, P1323; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Quevedo C, 2000, J BIOL CHEM, V275, P19192, DOI 10.1074/jbc.M000238200; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Samani A A, 2001, Surg Oncol Clin N Am, V10, P289; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; Skrtic S, 1999, ENDOCRINOLOGY, V140, P5729, DOI 10.1210/en.140.12.5729; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; Sugiyama H, 1998, KIDNEY INT, V54, P1188, DOI 10.1046/j.1523-1755.1998.00116.x; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Urban RJ, 1996, J BIOL CHEM, V271, P31695, DOI 10.1074/jbc.271.49.31695; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yoon A, 2001, MOL CELL BIOCHEM, V223, P1, DOI 10.1023/A:1017549222677; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	62	143	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19683	19690		10.1074/jbc.M313145200	http://dx.doi.org/10.1074/jbc.M313145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14993222	hybrid			2022-12-27	WOS:000221164500037
J	Alfthan, K; Heiska, L; Gronholm, M; Renkema, GH; Carpen, O				Alfthan, K; Heiska, L; Gronholm, M; Renkema, GH; Carpen, O			Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; ERM PROTEINS; BINDING-SITE; CAMP; GROWTH; CYTOSKELETON; INHIBITION; CELLS	Mutations in the NF2 tumor suppressor gene encoding merlin induce the development of tumors of the nervous system. Merlin is highly homologous to the ERM (ezrin-radixin-moesin) family of membrane/ cytoskeleton linker proteins. However, the mechanism for the tumor suppressing activity of merlin is not well understood. Previously, we characterized a novel role for merlin as a protein kinase A (PKA)-anchoring protein, which links merlin to the cAMP/PKA signaling pathway. In this study we show that merlin is also a target for PKA-induced phosphorylation. In vitro [gamma-P-33] ATP labeling revealed that both the merlin N and C termini are phosphorylated by PKA. Furthermore, both in vitro and in vivo phosphorylation studies of the wild-type and mutated C termini demonstrated that PKA can phosphorylate merlin at serine 518, a site that is phosphorylated also by p21-activated kinases (PAKs). Merlin was phosphorylated by PKA in cells in which PAK activity was suppressed, indicating that the two kinases function independently. Both in vitro and in vivo interaction studies indicated that phosphorylation of serine 518 promotes heterodimerization between merlin and ezrin, an event suggested to convert merlin from a growth-suppressive to a growth-permissive state. This study provides further evidence on the connection between merlin and cAMP/PKA signaling and suggests a role for merlin in the cAMP/PKA transduction pathway.	Univ Helsinki, Biomedicum Helsinki, Dept Anat & Pathol, Neurosci Program, FIN-00014 Helsinki, Finland; Univ Helsinki Hosp, FIN-00014 Helsinki, Finland; Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, FIN-33014 Tampere, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University; Tampere University Hospital	Carpen, O (corresponding author), Univ Helsinki, Biomedicum Helsinki, Dept Anat & Pathol, Neurosci Program, Rm C524,POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	olli.carpen@helsinki.fi	Renkema, Herma/L-1489-2015; Gronholm, Mikaela/B-4225-2010	Renkema, Herma/0000-0002-8174-6538; Gronholm, Mikaela/0000-0002-2378-8924				Albright TD, 2000, CURR OPIN NEUROBIOL, V10, P612, DOI 10.1016/S0959-4388(00)00132-X; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Bohling T, 1996, AM J PATHOL, V148, P367; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Gronholm M, 2003, J BIOL CHEM, V278, P41167, DOI 10.1074/jbc.M306149200; Gronholm M, 1999, J CELL SCI, V112, P895; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Howe DG, 2000, J NEUROSCI, V20, P3513, DOI 10.1523/JNEUROSCI.20-10-03513.2000; Kim HA, 1997, J NEUROSCI RES, V49, P236; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Ozer RS, 2000, MOL BIOL CELL, V11, P3573, DOI 10.1091/mbc.11.10.3573; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; Sainio M, 1997, J CELL SCI, V110, P2249; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; TASKEN K, 1994, ENDOCRINOLOGY, V135, P2109, DOI 10.1210/en.135.5.2109; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tu YP, 2003, J BIOL CHEM, V278, P52273, DOI 10.1074/jbc.M309626200; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhou RH, 2003, J BIOL CHEM, V278, P35651, DOI 10.1074/jbc.M303416200	46	102	104	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18559	18566		10.1074/jbc.M313916200	http://dx.doi.org/10.1074/jbc.M313916200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14981079	hybrid			2022-12-27	WOS:000221041500058
J	Campanella, M; de Jong, AS; Lanke, KWH; Melchers, WJG; Willems, PHGM; Pinton, P; Rizzuto, R; van Kuppeveld, FJM				Campanella, M; de Jong, AS; Lanke, KWH; Melchers, WJG; Willems, PHGM; Pinton, P; Rizzuto, R; van Kuppeveld, FJM			The coxsackievirus 2B protein suppresses apoptotic host cell responses by manipulating intracellular Ca2+ homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLIOVIRUS-INFECTED CELLS; GREEN FLUORESCENT PROTEIN; ENDOPLASMIC-RETICULUM; MEMBRANE PERMEABILIZATION; AMPHIPATHIC HELIX; VIRUS RELEASE; LIVING CELLS; CYTOCHROME-C; BCL-2; CALCIUM	Enteroviruses, small cytolytic RNA viruses, confer an antiapoptotic state to infected cells in order to suppress infection-limiting apoptotic host cell responses. This antiapoptotic state also lends protection against cell death induced by metabolic inhibitors like actinomycin D and cycloheximide. The identity of the viral antiapoptotic protein and the underlying mechanism are unknown. Here, we provide evidence that the coxsackievirus 2B protein modulates apoptosis by manipulating intracellular Ca2+ homeostasis. Using fluorescent Ca2+ indicators and organelle-targeted aequorins, we demonstrate that ectopic expression of 2B in HeLa cells decreases the Ca2+ content of both the endoplasmic reticulum and the Golgi, resulting in down-regulation of Ca2+ signaling between these stores and the mitochondria, and increases the influx of extracellular Ca2+. In our studies of the physiological importance of the 2B-induced alterations in Ca2+ signaling, we found that the expression of 2B suppressed caspase activation and apoptotic cell death induced by various stimuli, including actinomycin D and cycloheximide. Mutants of 2B that were defective in reducing the Ca2+ content of the stores failed to suppress apoptosis. These data implicate a functional role of the perturbation of intracellular Ca2+ compartmentalization in the enteroviral strategy to suppress intrinsic apoptotic host cell responses. The putative down-regulation of an endoplasmic reticulum-dependent apoptotic pathway is discussed.	Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Ctr Study Inflammatory Dis, I-44100 Ferrara, Italy; Univ Med Ctr Nijmegen, Ctr Mol Life Sci, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	van Kuppeveld, FJM (corresponding author), Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy.	f.vankuppeveld@ncmls.kun.nl	Pinton, Paolo/J-8025-2012; Jong, A.S./L-4416-2015; Melchers, Willem/C-8819-2015; Rizzuto, Rosario/B-6312-2008; Willems, P.H.G.M./L-4759-2015; Campanella, Michelangelo/K-8172-2016	Pinton, Paolo/0000-0001-7108-6508; Melchers, Willem/0000-0002-5446-2230; Willems, P.H.G.M./0000-0002-0915-1599; van Kuppeveld, Frank/0000-0001-5800-749X; Campanella, Michelangelo/0000-0002-6948-4184; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [GTF02013] Funding Source: Medline	Telethon(Fondazione Telethon)		Agirre A, 2002, J BIOL CHEM, V277, P40434, DOI 10.1074/jbc.M205393200; Agol VI, 2000, J VIROL, V74, P5534, DOI 10.1128/JVI.74.12.5534-5541.2000; Agol VI, 1998, VIROLOGY, V252, P343, DOI 10.1006/viro.1998.9438; Aldabe R, 1997, J VIROL, V71, P6214, DOI 10.1128/JVI.71.8.6214-6217.1997; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Barco A, 2000, VIROLOGY, V266, P352, DOI 10.1006/viro.1999.0043; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Belov GA, 2003, J VIROL, V77, P45, DOI 10.1128/JVI.77.1.45-56.2003; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BIENZ K, 1994, ARCH VIROL, P147; Bolsover S, 2001, BIOCHEM J, V356, P345, DOI 10.1042/0264-6021:3560345; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Carthy CM, 2003, VIROLOGY, V313, P147, DOI 10.1016/S0042-6822(03)00242-3; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Cuconati A, 1998, J VIROL, V72, P1297, DOI 10.1128/JVI.72.2.1297-1307.1998; de Jong AS, 2003, J BIOL CHEM, V278, P1012, DOI 10.1074/jbc.M207745200; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Goldstaub D, 2000, MOL CELL BIOL, V20, P1271, DOI 10.1128/MCB.20.4.1271-1277.2000; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hay S, 2002, J GEN VIROL, V83, P1547, DOI 10.1099/0022-1317-83-7-1547; IRURZUN A, 1995, J VIROL, V69, P5142, DOI 10.1128/JVI.69.8.5142-5146.1995; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; MCCARTHY CM, 1998, J VIROL, V72, P7669; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; TOLSKAYA EA, 1995, J VIROL, V69, P1181, DOI 10.1128/JVI.69.2.1181-1189.1995; van Kuppeveld FJM, 2002, J VIROL, V76, P9446, DOI 10.1128/JVI.76.18.9446-9456.2002; Vanden Abeele F, 2002, CANCER CELL, V1, P169; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; VANKUPPEVELD FJM, 1995, J VIROL, V69, P7782, DOI 10.1128/JVI.69.12.7782-7790.1995; vanKuppeveld FJM, 1996, J VIROL, V70, P3876, DOI 10.1128/JVI.70.6.3876-3886.1996	52	98	106	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18440	18450		10.1074/jbc.M309494200	http://dx.doi.org/10.1074/jbc.M309494200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976205	Green Published, hybrid			2022-12-27	WOS:000221041500043
J	Esumi, N; Oshima, Y; Li, YY; Campochiaro, PA; Zack, DJ				Esumi, N; Oshima, Y; Li, YY; Campochiaro, PA; Zack, DJ			Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-PIGMENT EPITHELIUM; TRANSCRIPTION FACTOR; MACULAR DYSTROPHY; TRANSGENIC MICE; MICROPHTHALMIA LOCUS; RETINITIS-PIGMENTOSA; SKELETAL-MUSCLE; TYROSINASE GENE; BESTS-DISEASE; SUBUNIT GENE	The retinal pigment epithelium (RPE) is crucial for the normal development and function of retinal photoreceptors, and mutations in several genes that are preferentially expressed in the RPE have been shown to cause retinal degeneration. We analyzed the 5'-upstream region of human VMD2, a gene that is preferentially expressed in the RPE and, when mutated, causes Best macular dystrophy. Transgenic mouse studies with VMD2 promoter/lacZ constructs demonstrated that a -253 to -38 bp fragment is sufficient to direct RPE-specific expression in the eye. Transient transfection assays using the D407 human RPE cell line with VMD2 promoter/luciferase reporter constructs identified two positive regulatory regions, -585 to -541 bp for high level expression and -56 to -42 bp for low level expression. Mutation of a canonical E-box located in the -56 to -42 bp region greatly diminished luciferase expression in D407 cells and abolished the bands shifted with bovine RPE nuclear extract in electrophoretic mobility shift assays. Independently a candidate approach was used to select microphthalmia-associated transcription factor (MITF) for testing because it is expressed in the RPE and associated with RPE abnormalities when mutated. MITF-M significantly increased luciferase expression in D407 cells in an E-box-dependent manner. These studies define the VMD2 promoter region sufficient to drive RPE-specific expression in the eye, identify positive regulatory regions in vitro, and suggest that MITF as well as other E-box binding factors may act as positive regulators of VMD2 expression.	Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Guerrieri Ctr Genet Engn & Mol Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Esumi, N (corresponding author), Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Guerrieri Ctr Genet Engn & Mol Ophthalmol, 832 Maumenee Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.	nesumi@jhmi.edu		Zack, Don/0000-0002-7966-1973				Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225; Amae S, 1998, BIOCHEM BIOPH RES CO, V247, P710, DOI 10.1006/bbrc.1998.8838; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BEERMANN F, 1992, P NATL ACAD SCI USA, V89, P2809, DOI 10.1073/pnas.89.7.2809; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BLAU HM, 1992, NATURE, V358, P284, DOI 10.1038/358284a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOK D, 1993, J CELL SCI, P189; Boulanger A, 2000, J BIOL CHEM, V275, P31274, DOI 10.1074/jbc.M003441200; Boulanger A, 2002, CURR EYE RES, V24, P368, DOI 10.1076/ceyr.24.5.368.8523; Burstedt MSI, 1999, INVEST OPHTH VIS SCI, V40, P995; CAMPOCHIARO PA, 1993, EXP EYE RES, V57, P539, DOI 10.1006/exer.1993.1158; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DONOGHUE MJ, 1992, DEVELOPMENT, V116, P1101; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; Felbor U, 1997, AM J HUM GENET, V60, P57; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1115; Fuse N, 1999, J BIOCHEM-TOKYO, V126, P1043, DOI 10.1093/oxfordjournals.jbchem.a022548; Goding CR, 2000, GENE DEV, V14, P1712; GRIESHAMMER U, 1992, CELL, V69, P79, DOI 10.1016/0092-8674(92)90120-2; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HERO I, 1991, INVEST OPHTH VIS SCI, V32, P2622; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; Kennedy BN, 1998, J BIOL CHEM, V273, P5591, DOI 10.1074/jbc.273.10.5591; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Li SM, 1998, J BIOL CHEM, V273, P31191, DOI 10.1074/jbc.273.47.31191; Mahony D, 2000, J INVEST DERMATOL, V115, P795, DOI 10.1046/j.1523-1747.2000.00132.x; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517; Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; Morimura H, 1999, NAT GENET, V23, P393, DOI 10.1038/70496; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; Nicoletti A, 1998, INVEST OPHTH VIS SCI, V39, P637; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; Nobukuni Y, 1996, AM J HUM GENET, V59, P76; Oboki K, 2002, BIOCHEM BIOPH RES CO, V290, P1250, DOI 10.1006/bbrc.2002.6332; PACKER SO, 1967, J EXP ZOOL, V165, P21, DOI 10.1002/jez.1401650103; Perron M, 2003, DEVELOPMENT, V130, P1565, DOI 10.1242/dev.00391; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Smith SD, 2000, J MED GENET, V37, P446, DOI 10.1136/jmg.37.6.446; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Takeda K, 2002, BBA-GENE STRUCT EXPR, V1574, P15, DOI 10.1016/S0167-4781(01)00339-6; Takemoto CM, 2002, J BIOL CHEM, V277, P30244, DOI 10.1074/jbc.M201441200; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Tsunenari T, 2003, J BIOL CHEM, V278, P41114, DOI 10.1074/jbc.M306150200; Udono T, 2000, BBA-GENE STRUCT EXPR, V1491, P205, DOI 10.1016/S0167-4781(00)00051-8; Villavicencio EH, 2002, GENESIS, V32, P247, DOI 10.1002/gene.10078; WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Yajima I, 1999, HUM MOL GENET, V8, P1431, DOI 10.1093/hmg/8.8.1431; Yasumoto K, 1997, J BIOL CHEM, V272, P503; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; ZINGG JM, 1994, NUCLEIC ACIDS RES, V22, P2234, DOI 10.1093/nar/22.12.2234; Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604	77	76	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19064	19073		10.1074/jbc.M309881200	http://dx.doi.org/10.1074/jbc.M309881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14982938	hybrid			2022-12-27	WOS:000221041500119
J	Ferguson, PL; Shaw, GS				Ferguson, PL; Shaw, GS			Human S100B protein interacts with the Escherichia coli division protein FtsZ in a calcium-sensitive manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CAPPING PROTEIN; CELL-DIVISION; CRYSTAL-STRUCTURE; MITOCHONDRIAL FTSZ; GTP HYDROLYSIS; SEPTAL RING; BINDING; ZIPA; IDENTIFICATION; TUBULIN	S100B is a small, dimeric EF-hand calcium-binding protein abundant in vertebrates. Upon calcium binding, S100B undergoes a conformational change allowing it to interact with a variety of target proteins, including the cytoskeletal proteins tubulin and glial fibrillary acidic protein. In both cases, S100B promotes the in vitro disassembly of these proteins in a calcium-sensitive manner. Despite this, there is little in vivo evidence for the interaction of proteins such as tubulin with S100B. To probe these interactions, we studied the expression of human S100B in Escherichia coli and its interaction with the prokaryotic ancestor of tubulin, FtsZ, the major protein involved in bacterial division. Expression of S100B protein in E. coli results in little change in FtsZ protein levels, causes a filamenting bacterial phenotype characteristic of FtsZ inhibition, and leads to missed rounds of cell division. Further, S100B localizes to positions similar to those of FtsZ in bacterial filaments: the small foci at the poles, the mid-cell positions, and between the nucleoids at regular intervals. Calcium-dependent physical interaction between S100B and FtsZ was demonstrated in vitro by affinity chromatography, and this interaction was severely inhibited by the competitor peptide TRTK-12. Together these results indicate that S100B interacts with the tubulin homologue FtsZ in vivo, modulating its activity in bacterial cell division. This approach will present an important step for the study of S100 protein interactions in vivo.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Shaw, GS (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	gshaw1@uwo.ca	Shaw, Gary S./C-7656-2009	Shaw, Gary S./0000-0002-4685-9625				Addinall SG, 1997, J BACTERIOL, V179, P4277, DOI 10.1128/jb.179.13.4277-4284.1997; Addinall SG, 1996, MOL MICROBIOL, V22, P231, DOI 10.1046/j.1365-2958.1996.00100.x; Addinall SG, 2002, J MOL BIOL, V318, P219, DOI 10.1016/S0022-2836(02)00024-4; ALDEA M, 1990, EMBO J, V9, P3787, DOI 10.1002/j.1460-2075.1990.tb07592.x; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; Beech PL, 2000, SCIENCE, V287, P1276, DOI 10.1126/science.287.5456.1276; BEGG KJ, 1985, J BACTERIOL, V163, P615, DOI 10.1128/JB.163.2.615-622.1985; Ben-Yehuda S, 2002, CELL, V109, P257, DOI 10.1016/S0092-8674(02)00698-0; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOWDEN GA, 1991, BIO-TECHNOL, V9, P725, DOI 10.1038/nbt0891-725; Buddelmeijer N, 2002, P NATL ACAD SCI USA, V99, P6316, DOI 10.1073/pnas.092128499; Chen JC, 2001, MOL MICROBIOL, V42, P395, DOI 10.1046/j.1365-2958.2001.02640.x; DAI K, 1991, J BACTERIOL, V173, P3500, DOI 10.1128/jb.173.11.3500-3506.1991; DAVIS GD, 2003, E COLI GENE EXPRESSI, V205, P141; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; Deloulme JC, 2003, MICROSC RES TECHNIQ, V60, P560, DOI 10.1002/jemt.10298; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Erickson HP, 2000, J CELL BIOL, V148, P1103, DOI 10.1083/jcb.148.6.1103; ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7; Erickson HP, 2001, CURR OPIN CELL BIOL, V13, P55, DOI 10.1016/S0955-0674(00)00174-5; Ferguson PL, 2002, BIOCHEMISTRY-US, V41, P3637, DOI 10.1021/bi0118052; Ferguson PL, 1997, ELECTROPHORESIS, V18, P2880, DOI 10.1002/elps.1150181528; FUJI T, 1990, J BIOCHEM-TOKYO, V107, P133, DOI 10.1093/oxfordjournals.jbchem.a122996; FUJII T, 1994, J BIOCHEM-TOKYO, V116, P121, DOI 10.1093/oxfordjournals.jbchem.a124484; Gangola P, 1988, Prog Clin Biol Res, V252, P215; Garbuglia M, 1998, CELL CALCIUM, V24, P177, DOI 10.1016/S0143-4160(98)90127-0; Garbuglia M, 2000, BBA-MOL CELL RES, V1498, P192, DOI 10.1016/S0167-4889(00)00096-3; GARRIDO T, 1993, EMBO J, V12, P3957, DOI 10.1002/j.1460-2075.1993.tb06073.x; Hale CA, 2000, J BACTERIOL, V182, P5153, DOI 10.1128/JB.182.18.5153-5166.2000; Hale CA, 2002, J BACTERIOL, V184, P2552, DOI 10.1128/JB.184.9.2552-2556.2002; Holland IB, 1999, BIOCHIMIE, V81, P901, DOI 10.1016/S0300-9084(99)00205-9; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; Jeong KJ, 2003, APPL ENVIRON MICROB, V69, P1295, DOI 10.1128/AEM.69.2.1295-1298.2003; Kiessling J, 2000, J CELL BIOL, V151, P945, DOI 10.1083/jcb.151.4.945; Kilby PM, 1997, PROTEIN SCI, V6, P2494; Koltzscher M, 2000, BIOCHEMISTRY-US, V39, P9533, DOI 10.1021/bi000257+; Levin PA, 2001, J BACTERIOL, V183, P5449, DOI 10.1128/JB.183.18.5449-5452.2001; Llorca O, 2001, J STRUCT BIOL, V135, P205, DOI 10.1006/jsbi.2001.4359; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lowe J, 2000, BIOL CHEM, V381, P993, DOI 10.1515/BC.2000.122; Lowe J, 1998, J STRUCT BIOL, V124, P235, DOI 10.1006/jsbi.1998.4041; Lu CL, 1998, CELL MOTIL CYTOSKEL, V40, P71, DOI 10.1002/(SICI)1097-0169(1998)40:1<71::AID-CM7>3.3.CO;2-Z; Lu CL, 1998, METHOD ENZYMOL, V298, P305, DOI 10.1016/S0076-6879(98)98027-2; Lu CL, 2000, J BACTERIOL, V182, P164, DOI 10.1128/JB.182.1.164-170.2000; Lutkenhaus J, 1998, CURR BIOL, V8, pR619, DOI 10.1016/S0960-9822(98)70391-4; Ma XL, 1996, P NATL ACAD SCI USA, V93, P12998, DOI 10.1073/pnas.93.23.12998; Margolin W, 2000, CURR BIOL, V10, pR328, DOI 10.1016/S0960-9822(00)00458-9; Margolin W, 1996, J BACTERIOL, V178, P1320, DOI 10.1128/jb.178.5.1320-1327.1996; Martin W, 2000, SCIENCE, V287, P1219, DOI 10.1126/science.287.5456.1219; McClintock KA, 2000, PROTEIN SCI, V9, P2043, DOI 10.1110/ps.9.10.2043; McClintock KA, 2002, BIOCHEMISTRY-US, V41, P5421, DOI 10.1021/bi011732m; Michiels J, 2002, TRENDS MICROBIOL, V10, P87, DOI 10.1016/S0966-842X(01)02284-3; Mileykovskaya E, 1998, J BACTERIOL, V180, P4252, DOI 10.1128/JB.180.16.4252-4257.1998; MIZUSAWA H, 1981, MUTAT RES, V82, P47, DOI 10.1016/0027-5107(81)90137-8; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; Mukherjee A, 1998, METHOD ENZYMOL, V298, P296, DOI 10.1016/S0076-6879(98)98026-0; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; NORRIS V, 1988, J THEOR BIOL, V134, P341, DOI 10.1016/S0022-5193(88)80065-1; NORRIS V, 1989, CELL CALCIUM, V10, P511, DOI 10.1016/0143-4160(89)90012-2; Palacios P, 1996, MOL MICROBIOL, V20, P1093, DOI 10.1111/j.1365-2958.1996.tb02549.x; Pichoff S, 2002, EMBO J, V21, P685, DOI 10.1093/emboj/21.4.685; PLA J, 1991, MOL MICROBIOL, V5, P1681, DOI 10.1111/j.1365-2958.1991.tb01915.x; RayChaudhuri D, 1999, EMBO J, V18, P2372, DOI 10.1093/emboj/18.9.2372; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Scheffers DJ, 2002, BIOCHEMISTRY-US, V41, P521, DOI 10.1021/bi011370i; Smith SP, 1996, BIOCHEMISTRY-US, V35, P8805, DOI 10.1021/bi952698c; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Sorci G, 1998, BBA-MOL CELL RES, V1448, P277, DOI 10.1016/S0167-4889(98)00134-7; Sorci G, 2000, NEUROSCIENCE, V99, P773, DOI 10.1016/S0306-4522(00)00238-4; Sossong TM, 1999, BIOCHEMISTRY-US, V38, P14843, DOI 10.1021/bi990917e; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; Stricker J, 2003, J BACTERIOL, V185, P4796, DOI 10.1128/JB.185.16.4796-4805.2003; Sun Q, 1998, J BACTERIOL, V180, P2050, DOI 10.1128/JB.180.8.2050-2056.1998; Sun Q, 2001, J BACTERIOL, V183, P1413, DOI 10.1128/JB.183.4.1413-1422.2001; Takahara M, 2000, MOL GEN GENET, V264, P452, DOI 10.1007/s004380000307; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; van den Ent F, 2000, EMBO J, V19, P5300, DOI 10.1093/emboj/19.20.5300; Vitha S, 2001, J CELL BIOL, V153, P111, DOI 10.1083/jcb.153.1.111; WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455; Ziegler DR, 1998, NEUROCHEM RES, V23, P1259, DOI 10.1023/A:1020740115790	87	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18806	18813		10.1074/jbc.M313948200	http://dx.doi.org/10.1074/jbc.M313948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14967825	hybrid			2022-12-27	WOS:000221041500089
J	Selvamurugan, N; Kwok, S; Alliston, T; Reiss, M; Partridge, NC				Selvamurugan, N; Kwok, S; Alliston, T; Reiss, M; Partridge, NC			Transforming growth factor-beta 1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the smad and MAPK signaling pathways and their components, Smad2 and Runx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; LATENT TGF-BETA; TRANSCRIPTIONAL ACTIVATION; PARATHYROID-HORMONE; INTERSTITIAL COLLAGENASE; CLEIDOCRANIAL DYSPLASIA; FUNCTIONAL COOPERATION; PROMOTER ACTIVITY; TUMOR-SUPPRESSOR	Transforming growth factor-beta (TGF-beta) plays a key role in osteoblast differentiation and bone development and remodeling. Collagenase-3 (matrix metalloproteinase-13) is expressed by osteoblasts and seems to be involved in osteoclastic bone resorption. Here, we show that TGF-beta1 stimulates collagenase-3 expression in the rat osteoblastic cell line UMR 106-01 and requires de novo protein synthesis. Dominant-negative Smad2/3 constructs indicated that Smad signaling is essential for TGF-beta1-stimulated collagenase-3 promoter activity. Inhibitors of the ERK1/2 and p38 MAPK pathways, but not the JNK pathway, reduced TGF-beta1-stimulated collagenase-3 expression, indicating that the p38 MAPK and ERK1/2 pathways are also required for TGF-beta1-stimulated collagenase-3 expression in UMR 106-01 cells. These inhibitors did not prevent nuclear localization of Smad proteins, but they inhibited Smad-mediated transcriptional activation. We have shown for the first time that Runx2 (a bone transcription factor and a potential substrate for the MAPK pathway) is phosphorylated in response to TGF-beta1 treatment in osteoblastic cells. Co-transfection of Smad2 and Runx2 constructs had a cooperative effect on TGF-beta1-stimulated collagenase-3 promoter activity in these cells. We further identified ligand-independent physical interaction between Smad2 and Runx2. Taken together, our results provide an important role for cross-talk between the Smad and MAPK pathways and their components in expression of collagenase-3 following TGF-beta1 treatment in UMR 106-01 cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Canc Inst New Jersey, Dept Med, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Selvamurugan, N (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	selvamn2@umdnj.edu	Selvamurugan, Nagarajan/P-7894-2016; Reiss, Michael/A-8314-2009	Selvamurugan, Nagarajan/0000-0003-3713-1920; Alliston, Tamara/0000-0001-9992-2897; Reiss, Michael/0000-0001-8543-8092; Partridge, Nicola/0000-0002-5406-4814	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047420, R01DK047420] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK047420, DK47420] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312; BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; CENTRELLA M, 1985, P NATL ACAD SCI USA, V82, P7335, DOI 10.1073/pnas.82.21.7335; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004-1013.2003; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Davis BA, 1998, CALCIFIED TISSUE INT, V63, P416, DOI 10.1007/s002239900550; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Horner A, 1998, BONE, V23, P95, DOI 10.1016/S8756-3282(98)00080-5; Johansson N, 2000, J CELL SCI, V113, P227; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Rydziel S, 2004, J BIOL CHEM, V279, P5397, DOI 10.1074/jbc.M311984200; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; Selvamurugan N, 2002, FEBS LETT, V532, P31, DOI 10.1016/S0014-5793(02)03620-7; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Tardif G, 2001, J RHEUMATOL, V28, P1631; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Uchiyama-Tanaka Y, 2002, KIDNEY INT, V62, P799, DOI 10.1046/j.1523-1755.2002.00537.x; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Varghese S, 1996, ENDOCRINOLOGY, V137, P431, DOI 10.1210/en.137.2.431; VARGHESE S, 1995, ENDOCRINOLOGY, V136, P2156, DOI 10.1210/en.136.5.2156; Varghese S, 2000, ENDOCRINOLOGY, V141, P2185, DOI 10.1210/en.141.6.2185; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481; Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158	58	110	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19327	19334		10.1074/jbc.M314048200	http://dx.doi.org/10.1074/jbc.M314048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14982932	hybrid			2022-12-27	WOS:000221041500146
J	Takano, Y; Adachi, S; Okuno, M; Muto, Y; Yoshioka, T; Matsushima-Nishiwaki, R; Tsurumi, H; Ito, K; Friedman, SL; Moriwaki, H; Kojima, S; Okano, Y				Takano, Y; Adachi, S; Okuno, M; Muto, Y; Yoshioka, T; Matsushima-Nishiwaki, R; Tsurumi, H; Ito, K; Friedman, SL; Moriwaki, H; Kojima, S; Okano, Y			The RING finger protein, RNF8, interacts with retinoid X receptor alpha and enhances its transcription-stimulating activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; UP-REGULATION; BETA; GENE; EXPRESSION; SUPPRESSION; CELLS; PHOSPHORYLATION; DIFFERENTIATION; UBIQUITINATION	Retinoid X receptor alpha (RXRalpha) is a member of the steroid hormone receptor superfamily. Using yeast two-hybrid screening, beta-galactosidase assays, and pull-down assays, we show that RNF8, a RING finger protein recently isolated as a protein binding to a ubiquitin-conjugating enzyme, binds to RXRalpha through the N-terminal regions of both proteins. In COS7 cells, overexpressed RNF8 colocalized and interacted with RXRalpha in the nucleus, as shown by fluorescence resonance energy transfer. A point mutation of RNF8, Cys-403 to Ser (C403S), which disrupts the RING finger structure, or deletion of the N-terminal region (DeltaN) of RNF8 prevented localization of RNF8 to the nucleus without affecting nuclear localization of RXRalpha. Although transient overexpression of RNF8 had little effect on RXRalpha ubiquitination, RNF8 dose-dependently enhanced RXRalpha-mediated transactivation of the RXR-responsive element (RXRE)bearing gene promoter without the addition of its ligand, 9-cis-retinoic acid (RA), and up-regulated the expression of the genes downstream of RXRE as well as an RA-response element. This transactivation-enhancing activity was not seen with either the C403S point mutant or the DeltaN deletion mutant of RNF8. These results suggest a novel function of RNF8 as a regulator of RXRalpha-mediated transcriptional activity through interaction between their respective N-terminal regions.	Gifu Univ, Sch Med, Dept Mol Pathobiochem, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Internal Med 1, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Basic Hlth Sci & Fundamental Nursing, Gifu 5008705, Japan; Ichimaru Pharcos Co Ltd, Gifu 5010475, Japan; CUNY, Mt Sinai Med Ctr, Div Liver Dis, New York, NY 10029 USA; RIKEN, Mol Cellular Pathol Res Unit, Wako, Saitama 3510198, Japan	Gifu University; Gifu University; Gifu University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; RIKEN	Okano, Y (corresponding author), Gifu Univ, Sch Med, Dept Mol Pathobiochem, Gifu 5008705, Japan.	bunbyo@cc.gifu-u.ac.jp	Kojima, Soichi/N-7104-2015	Kojima, Soichi/0000-0002-5252-1612	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37340] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi S, 2002, HEPATOLOGY, V35, P332, DOI 10.1053/jhep.2002.31164; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Benoit GR, 2001, MOL ENDOCRINOL, V15, P1154, DOI 10.1210/me.15.7.1154; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chiba H, 1997, J CELL BIOL, V139, P735, DOI 10.1083/jcb.139.3.735; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; DE LUCA LM, 1991, FASEB J, V5, P2924; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Fuse H, 2000, MOL ENDOCRINOL, V14, P889, DOI 10.1210/me.14.6.889; Geisen C, 1997, CANCER RES, V57, P1460; Gudas Lorraine J., 1994, P443; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Ito K, 2001, EUR J BIOCHEM, V268, P2725, DOI 10.1046/j.1432-1327.2001.02169.x; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kumar R, 2001, J BIOL CHEM, V276, P18146, DOI 10.1074/jbc.M100825200; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEVIN MS, 1993, J BIOL CHEM, V268, P8267; Li J, 2000, J CELL SCI, V113, P4143; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANO H, 1993, BIOCHEM BIOPH RES CO, V191, P943, DOI 10.1006/bbrc.1993.1308; Matsushima-Nishiwaki R, 2003, CARCINOGENESIS, V24, P1353, DOI 10.1093/carcin/bgg090; Matsushima-Nishiwaki R, 2001, CANCER RES, V61, P7675; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Parrado A, 2001, NUCLEIC ACIDS RES, V29, P4901, DOI 10.1093/nar/29.24.4901; Prufer K, 2000, J BIOL CHEM, V275, P41114, DOI 10.1074/jbc.M003791200; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; Seki N, 1998, J HUM GENET, V43, P272, DOI 10.1007/s100380050088; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Xu XC, 1999, CANCER RES, V59, P2477; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992	45	34	40	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18926	18934		10.1074/jbc.M309148200	http://dx.doi.org/10.1074/jbc.M309148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14981089	hybrid			2022-12-27	WOS:000221041500103
J	Wiedemann, N; Truscott, KN; Pfannschmidt, S; Guiard, B; Meisinger, C; Pfanner, N				Wiedemann, N; Truscott, KN; Pfannschmidt, S; Guiard, B; Meisinger, C; Pfanner, N			Biogenesis of the protein import channel Tom40 of the mitochondrial outer membrane - Intermembrane space components are involved in an early stage of the assembly pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROTEIN TRANSLOCASE; ADP/ATP CARRIER; INNER MEMBRANE; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; TIM COMPLEXES; RECEPTORS; PORE; MACHINERY; BETA	Tom40 forms the central channel of the preprotein translocase of the mitochondrial outer membrane ( TOM complex). The precursor of Tom40 is encoded in the nucleus, synthesized in the cytosol, and imported into mitochondria via a multi-step assembly pathway that involves the mature TOM complex and the sorting and assembly machinery of the outer membrane (SAM complex). We report that opening of the mitochondrial intermembrane space by swelling blocks the assembly pathway of the beta-barrel protein Tom40. Mitochondria with defects in small Tim proteins of the intermembrane space are impaired in the Tom40 assembly pathway. Swelling as well as defects in the small Tim proteins inhibit an early stage of the Tom40 import pathway that is needed for formation of a Tom40-SAM intermediate. We propose that the biogenesis pathway of beta-barrel proteins of the outer mitochondrial membrane not only requires TOM and SAM components, but also involves components of the intermembrane space.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Univ Paris 06, CNRS, Lab Propre, Ctr Mol Genet, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Freiburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	Nikolaus.Pfanner@biochemie.uni-freiburg.de	Meisinger, Chris/J-1110-2014; Truscott, Kaye/D-3362-2012; Pfanner, Nikolaus/AAV-7878-2021	Meisinger, Chris/0000-0002-8326-3548; Truscott, Kaye/0000-0002-5352-9835; Wiedemann, Nils/0000-0001-8305-6728				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; Curran SP, 2002, J CELL BIOL, V158, P1017, DOI 10.1083/jcb.200205124; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; DAUM G, 1982, J BIOL CHEM, V257, P3028; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dembowski M, 2001, J BIOL CHEM, V276, P17679, DOI 10.1074/jbc.M009653200; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8; Frazier AE, 2003, MOL CELL BIOL, V23, P7818, DOI 10.1128/MCB.23.21.7818-7828.2003; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Johnston AJ, 2002, J BIOL CHEM, V277, P42197, DOI 10.1074/jbc.M205613200; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; KEIL P, 1993, J BIOL CHEM, V268, P19177; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; Matouschek A, 2001, NAT STRUCT BIOL, V8, P284, DOI 10.1038/86140; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Mihara K, 2003, NATURE, V424, P505, DOI 10.1038/424505a; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Pfanner N, 2002, BBA-MOL CELL RES, V1592, P15, DOI 10.1016/S0167-4889(02)00260-4; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 2002, TRENDS BIOCHEM SCI, V27, P191, DOI 10.1016/S0968-0004(02)02065-0; Rothbauer U, 2001, J BIOL CHEM, V276, P37327, DOI 10.1074/jbc.M105313200; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; SIKORSKI RS, 1989, GENETICS, V122, P19; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; SMITH M, 1994, J BIOL CHEM, V269, P28460; SOGO LF, 1994, J CELL BIOL, V126, P1361, DOI 10.1083/jcb.126.6.1361; Stan T, 2000, EMBO J, V19, P4895, DOI 10.1093/emboj/19.18.4895; Taylor RD, 2003, J BIOL CHEM, V278, P765, DOI 10.1074/jbc.M208083200; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Westermann B, 2003, NAT BIOTECHNOL, V21, P239, DOI 10.1038/nbt0303-239; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Yano M, 2000, MOL CELL BIOL, V20, P7205, DOI 10.1128/MCB.20.19.7205-7213.2000	68	145	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18188	18194		10.1074/jbc.M400050200	http://dx.doi.org/10.1074/jbc.M400050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978039	hybrid			2022-12-27	WOS:000221041500013
J	Kallin, A; Demoulin, JB; Nishida, K; Hirano, T; Ronnstrand, L; Heldin, CH				Kallin, A; Demoulin, JB; Nishida, K; Hirano, T; Ronnstrand, L; Heldin, CH			Gab1 contributes to cytoskeletal reorganization and chemotaxis in response to platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASE; SIGNAL-REGULATED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; EPIDERMAL-GROWTH; GRB2-ASSOCIATED BINDER-1; CELL-SURVIVAL; BETA-RECEPTOR; IN-VIVO; PATHWAY	Gab1 is a scaffolding/docking protein that has been suggested to play a role in signal transduction downstream of certain plasma membrane receptors, including platelet-derived growth factor (PDGF) receptors. We found that PDGF induced a rapid Gab1 phosphorylation, which depended on the recruitment of Grb2, indicating that Grb2 acts as a bridge between Gab1 and the PDGF beta-receptor. PDGF also enhanced the binding of Gab1 to the phosphatase SHP-2, but not to p85. To further study the role of Gab1 in PDGF signaling, we transfected porcine aortic endothelial cells with a doxycycline-inducible Gab1 construct. Increased Gab1 expression enhanced the recruitment and activation of SHP-2, as well as the phosphorylation of the mitogen-activated protein kinases Erk and p38 by PDGF. Gab1 expression also enhanced the formation of lamellipodia and cellular protrusions. In Gab1-deficient mouse embryonic fibroblasts, the same phenotype was induced by restoring the expression of wild-type Gab1, but not a mutant Gab1 that was unable to associate with SHP-2. These effects of PDGF on the actin cytoskeleton were not altered by the inhibition of p38 or Erk, but could be blocked by a dominant-negative form of Rac (Asn(17)). Finally, Gab1-deficient fibroblasts showed a decreased chemotactic response toward gradients of PDGF as compared with wild-type cells. In conclusion, Gab1 plays a selective role in the regulation of the mitogen-activated protein kinases Erk and p38 downstream of the PDGF beta-receptor, and contributes to cytoskeletal reorganization and chemotaxis in response to PDGF.	Ludwig Inst Canc Res, Ctr Biomed, SE-75124 Uppsala, Sweden; Osaka Univ, Grad Sch Med, Dept Mol Oncol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Lab Dev Immunol, Suita, Osaka 5650871, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Cytokine Signaling, Kanagawa 2300045, Japan	Ludwig Institute for Cancer Research; Osaka University; Osaka University; RIKEN	Heldin, CH (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, SE-75124 Uppsala, Sweden.	C-H.Heldin@LICR.uu.se	Hirano, Toshio/C-8194-2009; Ronnstrand, Lars/A-2429-2011; Demoulin, Jean-Baptiste/E-5847-2010	Ronnstrand, Lars/0000-0003-1275-5809; Demoulin, Jean-Baptiste/0000-0002-8016-6689				Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Chen Y, 2003, J BIOL CHEM, V278, P16520, DOI 10.1074/jbc.M210572200; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2002, J BIOL CHEM, V277, P9498, DOI 10.1074/jbc.M110547200; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Demoulin JB, 2003, BIOCHEM J, V376, P505, DOI 10.1042/BJ20030385; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Guy GR, 2002, CELL SIGNAL, V14, P11, DOI 10.1016/S0898-6568(01)00227-3; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nishida K, 2003, CANCER SCI, V94, P1029, DOI 10.1111/j.1349-7006.2003.tb01396.x; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002	29	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17897	17904		10.1074/jbc.M312996200	http://dx.doi.org/10.1074/jbc.M312996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14973141	hybrid, Green Published			2022-12-27	WOS:000220870400123
J	Cheng, SWY; Fryer, LGD; Carling, D; Shepherd, PR				Cheng, SWY; Fryer, LGD; Carling, D; Shepherd, PR			Thr(2446) is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P70 S6 KINASE; GLYCOGEN-SYNTHASE KINASE-3; HORMONE-SENSITIVE LIPASE; EPIDIDYMAL FAT-CELLS; RAT SKELETAL-MUSCLE; AMINO-ACID; SIGNALING PATHWAY; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; EIF-4E BP1	The mammalian target of rapamycin (mTOR) is a key regulator of protein translation. Signaling via mTOR is increased by growth factors but decreased during nutrient deprivation. Previous studies have identified Ser(2448) as a nutrient-regulated phosphorylation site located in the mTOR catalytic domain, insulin stimulates Ser(2448) phosphorylation via protein kinase B (PKB), while Ser(2448) phosphorylation is attenuated with amino acid starvation. Here we have identified Thr(2446) as a novel nutrient-regulated phosphorylation site on mTOR. Thr(2446) becomes phosphorylated when CHO-IR cells are nutrient-deprived, but phosphorylation is reduced by insulin stimulation. Nutrient deprivation activates AMP-activated protein kinase (AMPK). To test whether this could be involved in regulating phoshorylation of mTOR, we treated cultured murine myotubes with 5'-aminoimidazole-4-carboxamide ribonucleoside (AICAR) or dinitrophenol (DNP). Both treatments activated AMPK and also caused a concomitant increase in phosphorylation of Thr(2446) and a parallel decrease in insulin's ability to phosphorylate p70 S6 kinase. In vitro kinase assays using peptides based on the sequence in amino acids 2440-2551 of mTOR found that PKB and AMPK are capable of phosphorylating sites in this region. However, phosphorylation by PKB is restricted when Thr(2446) is mutated to an acidic residue mimicking phosphorylation. Conversely, AMP-kinase-induced phosphorylation is reduced when Ser(2448) is phosphorylated. These data suggest differential phosphorylation Thr(2446) and Ser(2448) could act as a switch mechanism to integrate signals from nutrient status and growth factors to control the regulation of protein translation.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Cellular Stress Grp, London W12 0NN, England	University of London; University College London; Imperial College London	Shepherd, PR (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	shepherd@biochem.ucl.ac.uk	Carling, David/F-1943-2014	Carling, David/0000-0002-2316-1830	Medical Research Council [MC_U120027537] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Beugnet A, 2003, BIOCHEM J, V372, P555, DOI 10.1042/BJ20021266; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; GARTON AJ, 1990, EUR J BIOCHEM, V191, P245, DOI 10.1111/j.1432-1033.1990.tb19116.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Munday MR, 2002, BIOCHEM SOC T, V30, P1059, DOI 10.1042/bst0301059; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Peyrollier K, 2000, BIOCHEM J, V350, P361, DOI 10.1042/0264-6021:3500361; Proud CG, 1997, BIOCHEM J, V328, P329; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Withers DJ, 1997, J BIOL CHEM, V272, P2509; Withers DJ, 1997, BIOCHEM BIOPH RES CO, V241, P704, DOI 10.1006/bbrc.1997.7878; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	46	248	268	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15719	15722		10.1074/jbc.C300534200	http://dx.doi.org/10.1074/jbc.C300534200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14970221	hybrid			2022-12-27	WOS:000220747900004
J	Kalechman, Y; Gafter, U; Weinstein, T; Chagnac, A; Freidkin, I; Tobar, A; Albeck, M; Sredni, B				Kalechman, Y; Gafter, U; Weinstein, T; Chagnac, A; Freidkin, I; Tobar, A; Albeck, M; Sredni, B			Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis - Association with dephosphorylation of STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MAMMARY ADENOCARCINOMA; B16 MELANOMA; TNF-ALPHA; IL-10; MICE; MECHANISMS; EXPRESSION; INDUCTION; CYTOKINES	Mesangial cell ( MC) proliferation is essential for the pathogenesis and progression of glomerular disease. Using an acute model of mesangial proliferative glomerulonephritis (Thy1 GN), we show that neutralization of interleukin (IL)-10 greatly ameliorated the disease as expressed by both decreased MC expansion and proteinuria. Treatment with the tellurium compound AS101 (ammonium trichloro(dioxoethylene-o,o') tellurate) resulted in favorable effects provided that the compound was administered 24 h before insult, whereas partial effects were obtained when administered after insult. We identified STAT3 as playing a pivotal role in IL-10-induced MC proliferation in vitro and in vivo. IL-10 activates MC STAT3 in vitro as expressed by its phosphorylation and nuclear translocation. The role of STAT3 in MC proliferation induced by IL-10 was deduced from results showing that IL-10-induced proliferation was abrogated if MC transfected with STAT3 antisense oligonucleotides were used or if cells were incubated with inhibitors of STAT3. AS101 deactivates STAT3 in control but not in MC transfected with IL-10 antisense oligonucleotides. Inactivation of STAT3 prevents reduction of MC proliferation by AS101. We further demonstrate the role of STAT3 in the regulation of cell cycle and survival regulatory proteins by AS101 in MC via inhibition of IL-10. IL-10 increased MC expression of Bcl-2 and Bcl-X1 and simultaneously decreased the levels of p27kip1. These survival factors were decreased by AS101 in a STAT3- and IL-10-dependent manner, whereas p27kip1 was similarly increased. In Thy1 GN, phosphorylated STAT3 in glomerular MC peaked at day 6 and correlated with MC expansion. Neutralization of IL-10 or its inhibition by AS101 abolished phosphorylation of STAT3. This effect positively correlated with amelioration of the disease. These in vitro and in vivo studies indicate that the autocrine MC growth factor IL-10 induces MC proliferation via STAT3. We suggest that IL-10 or its downstream target STAT3 might be therapeutic targets for kidney diseases induced by mesangial proliferation.	Bar Ilan Univ, Fac Life Sci, Canc AIDS & Immunol Res Inst, IL-52900 Ramat Gan, Israel; Rabin Med Ctr, Dept Nephrol, IL-49372 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Pathol, IL-49372 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Bar Ilan University; Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Sredni, B (corresponding author), Bar Ilan Univ, Fac Life Sci, Canc AIDS & Immunol Res Inst, IL-52900 Ramat Gan, Israel.	srednib@mail.biu.ac.il						ABBOUD HE, 1993, KIDNEY INT, V43, P252, DOI 10.1038/ki.1993.39; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; Chadban SJ, 1997, LAB INVEST, V76, P619; COUSER WG, 1994, AM J KIDNEY DIS, V23, P193, DOI 10.1016/S0272-6386(12)80971-1; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FLOEGE J, 1993, J CLIN INVEST, V92, P2952, DOI 10.1172/JCI116918; FU YX, 1991, J IMMUNOL, V146, P783; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Gerard CM, 1996, HUM GENE THER, V7, P23, DOI 10.1089/hum.1996.7.1-23; GIOVARELLI M, 1995, J IMMUNOL, V155, P3112; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; IOANNIDES CG, 1993, CLIN IMMUNOL IMMUNOP, V66, P91, DOI 10.1006/clin.1993.1012; Kalechman Y, 1997, J IMMUNOL, V159, P2658; KALECHMAN Y, 1995, BLOOD, V85, P1555, DOI 10.1182/blood.V85.6.1555.bloodjournal8561555; Kalechman Y, 2000, INT J CANCER, V86, P281, DOI 10.1002/(SICI)1097-0215(20000415)86:2<281::AID-IJC20>3.0.CO;2-X; Kalechman Y, 2003, J AM SOC NEPHROL, V14, P620, DOI 10.1097/01.ASN.0000053415.29636.4F; Kalechman Y, 2002, J IMMUNOL, V169, P384, DOI 10.4049/jimmunol.169.1.384; Kitching AR, 2002, CLIN EXP IMMUNOL, V128, P36, DOI 10.1046/j.1365-2249.2002.01793.x; Kriz W, 2003, J AM SOC NEPHROL, V14, P1904, DOI 10.1097/01.ASN.0000070073.79690.57; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Niemir ZI, 1998, AM J KIDNEY DIS, V32, P80, DOI 10.1053/ajkd.1998.v32.pm9669428; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Rosenblatt-Bin H, 1998, CELL IMMUNOL, V184, P12, DOI 10.1006/cimm.1998.1251; RUEL CM, 1990, KIDNEY INT, V38, P249; Schrantz N, 2000, J IMMUNOL, V165, P4346, DOI 10.4049/jimmunol.165.8.4346; Shankland SJ, 1997, KIDNEY INT, V51, P1088, DOI 10.1038/ki.1997.151; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SILVER BJ, 1989, P NATL ACAD SCI USA, V86, P1056, DOI 10.1073/pnas.86.3.1056; SREDNI B, 1987, NATURE, V330, P173, DOI 10.1038/330173a0; Sredni B, 1996, J NATL CANCER I, V88, P1276, DOI 10.1093/jnci/88.18.1276; SREDNI B, 1995, J CLIN ONCOL, V13, P2342, DOI 10.1200/JCO.1995.13.9.2342; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Strassmann G, 1997, CELL IMMUNOL, V176, P180, DOI 10.1006/cimm.1997.1087; STRIKER LJ, 1989, SEMIN NEPHROL, V9, P318; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; TAKEYAMA H, 1991, CANCER RES, V51, P4476; Wapstra FH, 2001, EXP NEPHROL, V9, P21; Yanagita M, 2001, J BIOL CHEM, V276, P42364, DOI 10.1074/jbc.M107488200	44	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24724	24732		10.1074/jbc.M312006200	http://dx.doi.org/10.1074/jbc.M312006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15001575	hybrid			2022-12-27	WOS:000221702500103
J	Hori, T; Yokomizo, T; Ago, H; Sugahara, M; Ueno, G; Yamamoto, M; Kumasaka, T; Shimizu, T; Miyano, M				Hori, T; Yokomizo, T; Ago, H; Sugahara, M; Ueno, G; Yamamoto, M; Kumasaka, T; Shimizu, T; Miyano, M			Structural basis of leukotriene B-4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; QUINONE OXIDOREDUCTASE; CRYSTAL-STRUCTURE; CDNA CLONING; LIPOXIN A(4); PROTEIN; IDENTIFICATION; INACTIVATION; PURIFICATION; CYCLOOXYGENASE	The bifunctional leukotriene B-4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase (LTB412-HD/PGR) is an essential enzyme for eicosanoid inactivation. It is involved in the metabolism of the E and F series of 15-oxo-prostaglandins (15-oxo-PGs), leukotriene B-4 (LTB4), and 15-oxo-lipoxin A4 (15-oxo-LXA4). Some nonsteroidal anti-inflammatory drugs (NSAIDs), which primarily act as cyclooxygenase inhibitors also inhibit LTB4 12-HD/PGR activity. Here we report the crystal structure of the LTB4 12-HD/PGR, the binary complex structure with NADP(+), and the ternary complex structure with NADP(+) and 15-oxo-PGE(2). In the ternary complex, both in the crystalline form and in solution, the enolate anion intermediate accumulates as a brown chromophore. PGE(2) contains two chains, but only the omega-chain of 15-oxo-PGE(2) was defined in the electron density map in the ternary complex structure. The omega-chain was identified at the hydrophobic pore on the dimer interface. The structure showed that the 15-oxo group forms hydrogen bonds with the 2'-hydroxyl group of nicotine amide ribose of NADP(+) and a bound water molecule to stabilize the enolate intermediate during the reductase reaction. The electron-deficient C13 atom of the conjugated enolate may be directly attacked by a hydride from the NADPH nicotine amide in a stereospecific manner. The moderate recognition of 15-oxo-PGE(2) is consistent with a broad substrate specificity of LTB4 12-HD/PGR. The structure also implies that a Src homology domain 3 may interact with the left-handed proline-rich helix at the dimer interface and regulate LTB4 12HD/PGR activity by disruption of the substrate binding pore to accommodate the omega-chain.	SPring8, RIKEN Harima Inst, Struct Biophys Inst, Mikazuki, Hyogo 6795148, Japan; SPring8, RIKEN Harima Inst, Highthroughput Factory, Mikazuki, Hyogo 6795148, Japan; SPring8, RIKEN Harima Inst, Coherent Xray Opt Lab, Mikazuki, Hyogo 6795148, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Bunkyo Ku, Tokyo 1130033, Japan	Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Miyano, M (corresponding author), SPring8, RIKEN Harima Inst, Struct Biophys Inst, 1-1-1 Kouto, Mikazuki, Hyogo 6795148, Japan.	miyano@spring8.or.jp	Shimizu, Takao/AAV-7052-2021; Miyano, Masashi/R-2785-2016; Kumasaka, Takashi/D-7428-2018; Yamamoto, Masaki/B-7844-2015; Yokomizo, Takehiko/P-5673-2016	Miyano, Masashi/0000-0003-2253-6175; Kumasaka, Takashi/0000-0001-9289-1557; Yamamoto, Masaki/0000-0002-1311-1768; Yokomizo, Takehiko/0000-0002-5219-1553; Ago, Hideo/0000-0002-9040-488X				Airenne TT, 2003, J MOL BIOL, V327, P47, DOI 10.1016/S0022-2836(03)00038-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; BOLL W, 1993, J BIOL CHEM, V268, P12901; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clarke A. R., 1998, COMPREHENSIVE BIOL C, VIII, P1; Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200; Clish CB, 2001, BIOCHEM BIOPH RES CO, V288, P868, DOI 10.1006/bbrc.2001.5841; Dick RA, 2001, J BIOL CHEM, V276, P40803, DOI 10.1074/jbc.M105487200; EKLUND H, 1979, J BIOL CHEM, V254, P3458; ENSOR CM, 1995, J LIPID MEDIAT CELL, V12, P313, DOI 10.1016/0929-7855(95)00040-W; Ensor CM, 1998, BIOCHEM J, V330, P103, DOI 10.1042/bj3300103; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HANSEN HS, 1979, BIOCHIM BIOPHYS ACTA, V574, P136, DOI 10.1016/0005-2760(79)90092-4; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hoozemans JJM, 2003, CURR DRUG TARGETS, V4, P461, DOI 10.2174/1389450033490902; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLER TA, 1983, AM J PHYSIOL, V245, pG601, DOI 10.1152/ajpgi.1983.245.5.G601; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Nordling E, 2002, EUR J BIOCHEM, V269, P4267, DOI 10.1046/j.1432-1033.2002.03114.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parnova R G, 2000, Membr Cell Biol, V13, P287; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; Primiano T, 1998, CARCINOGENESIS, V19, P999, DOI 10.1093/carcin/19.6.999; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Ricchi P, 2003, BRIT J CANCER, V88, P803, DOI 10.1038/sj.bjc.6600829; Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Shimomura Y, 2003, J BACTERIOL, V185, P4211, DOI 10.1128/JB.185.14.4211-4218.2003; Sugahara Mitsuaki, 2002, Tanpakushitsu Kakusan Koso, V47, P1026; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THORN JM, 1995, J MOL BIOL, V249, P785, DOI 10.1006/jmbi.1995.0337; Yamamoto T, 2001, EUR J BIOCHEM, V268, P6105, DOI 10.1046/j.0014-2956.2001.02462.x; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	49	49	53	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22615	22623		10.1074/jbc.M312655200	http://dx.doi.org/10.1074/jbc.M312655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007077	hybrid			2022-12-27	WOS:000221417100113
J	Kakuda, S; Shiba, T; Ishiguro, M; Tagawa, H; Oka, S; Kajihara, Y; Kawasaki, T; Wakatsuki, S; Kato, R				Kakuda, S; Shiba, T; Ishiguro, M; Tagawa, H; Oka, S; Kajihara, Y; Kawasaki, T; Wakatsuki, S; Kato, R			Structural basis for acceptor substrate recognition of a human glucuronyltransferase, GlcAT-P, an enzyme critical in the biosynthesis of the carbohydrate epitope HNK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; MONOCLONAL-ANTIBODY HNK-1; SULFATED GLUCURONIC-ACID; PROTEIN LINKAGE REGION; NEURAL CREST MIGRATION; NERVOUS-SYSTEM; RAT-BRAIN; NEOLACTOTETRAOSYLCERAMIDE GLUCURONOSYLTRANSFERASE; ADHESION MOLECULES; GENOMIC STRUCTURE	The HNK-1 carbohydrate epitope is found on many neural cell adhesion molecules. Its structure is characterized by a terminal sulfated glucuronyl acid. The glucuronyltransferases, GlcAT-P and GlcAT-S, are involved in the biosynthesis of the HNK-1 epitope, GlcAT-P as the major enzyme. We overexpressed and purified the recombinant human GlcAT-P from Escherichia coli. Analysis of its enzymatic activity showed that it catalyzed the transfer reaction for N-acetyllactosamine (Galbeta1-4GlcNAc) but not lacto-N-biose (Galbeta1-3GlcNAc) as an acceptor substrate. Subsequently, we determined the first x-ray crystal structures of human GlcAT-P, in the absence and presence of a donor substrate product UDP, catalytic Mn2+, and an acceptor substrate analogue N-acetyllactosamine (Galbeta1-4GlcNAc) or an asparagine-linked biantennary nonasaccharide. The asymmetric unit contains two independent molecules. Each molecule is an alpha/beta protein with two regions that constitute the donor and acceptor substrate binding sites. The UDP moiety of donor nucleotide sugar is recognized by conserved amino acid residues including a DXD motif (Asp(195)-Asp(196)-Asp(197)). Other conserved amino acid residues interact with the terminal galactose moiety of the acceptor substrate. In addition, Val(320) and Asn(321), which are located on the C-terminal long loop from a neighboring molecule, and Phe(245) contribute to the interaction with GlcNAc moiety. These three residues play a key role in establishing the acceptor substrate specificity.	High Energy Accelerat Res Org, Inst Mat Struct Sci, Photon Factory, Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Kyoto 6068501, Japan; Suntory Inst Bioorgan Res, Osaka 6180024, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Yokohama, Kanagawa 2360027, Japan	High Energy Accelerator Research Organization (KEK); Kyoto University; Suntory Holdings Ltd; Yokohama City University	Kato, R (corresponding author), High Energy Accelerat Res Org, Inst Mat Struct Sci, Photon Factory, Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan.	ryuichi.kato@kek.jp		Wakatsuki, Soichi/0000-0001-5896-7968; Kato, Ryuichi/0000-0003-2087-2896				ARIGA T, 1987, J BIOL CHEM, V262, P848; BOLLENSEN E, 1987, NEUROSCI LETT, V82, P77, DOI 10.1016/0304-3940(87)90174-1; BRONNERFRASER M, 1987, DEV BIOL, V123, P321, DOI 10.1016/0012-1606(87)90390-3; BRONNERFRASER M, 1986, DEV BIOL, V115, P44, DOI 10.1016/0012-1606(86)90226-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; DAS KK, 1991, J BIOL CHEM, V266, P5238; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; ILYAS AA, 1990, J NEUROCHEM, V55, P594, DOI 10.1111/j.1471-4159.1990.tb04175.x; Imiya K, 2002, GENE, V296, P29, DOI 10.1016/S0378-1119(02)00840-5; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; Kajihara Y, 2003, METHOD ENZYMOL, V362, P44; KAWASHIMA C, 1992, GLYCOCONJUGATE J, V9, P307, DOI 10.1007/BF00731091; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2001, BIOCHEM J, V358, P539, DOI 10.1042/0264-6021:3580539; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Marcos I, 2002, J HUM GENET, V47, P677, DOI 10.1007/s100380200103; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitsumoto Y, 2000, GENOMICS, V65, P166, DOI 10.1006/geno.2000.6152; Negishi M, 2003, BIOCHEM BIOPH RES CO, V303, P393, DOI 10.1016/S0006-291X(03)00356-5; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohtsubo K, 2000, J BIOCHEM-TOKYO, V128, P283, DOI 10.1093/oxfordjournals.jbchem.a022751; OKA S, 1992, J BIOL CHEM, V267, P22711; Oka S, 2000, GLYCOCONJUGATE J, V17, P877, DOI 10.1023/A:1010973330152; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Terayama K, 1998, J BIOL CHEM, V273, P30295, DOI 10.1074/jbc.273.46.30295; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Yamamoto S, 2002, J BIOL CHEM, V277, P27227, DOI 10.1074/jbc.C200296200; YOSHIHARA Y, 1991, J CELL BIOL, V115, P731, DOI 10.1083/jcb.115.3.731	45	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22693	22703		10.1074/jbc.M400622200	http://dx.doi.org/10.1074/jbc.M400622200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14993226	hybrid			2022-12-27	WOS:000221417100121
J	Carvalho, E; Schellhorn, SE; Zabolotny, JM; Martin, S; Tozzo, E; Peroni, OD; Houseknecht, KL; Mundt, A; James, DE; Kahn, BB				Carvalho, E; Schellhorn, SE; Zabolotny, JM; Martin, S; Tozzo, E; Peroni, OD; Houseknecht, KL; Mundt, A; James, DE; Kahn, BB			GLUT4 overexpression or deficiency in adipocytes of transgenic mice alters the composition of GLUT4 vesicles and the subcellular localization of GLUT4 and insulin-responsive aminopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; REGULATED MEMBRANE AMINOPEPTIDASE; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; STIMULATED TRANSLOCATION; TISSUE DISTRIBUTION; STORAGE-VESICLES; PLASMA-MEMBRANE; PROTEIN	The majority of GLUT4 is sequestered in unique intracellular vesicles in the absence of insulin. Upon insulin stimulation GLUT4 vesicles translocate to, and fuse with, the plasma membrane. To determine the effect of GLUT4 content on the distribution and subcellular trafficking of GLUT4 and other vesicle proteins, adipocytes of adipose-specific, GLUT4-deficient (aP2-GLUT4-/-) mice and adipose-specific, GLUT4-overexpressing (aP2GLUT4- Tg) mice were studied. GLUT4 amount was reduced by 80 - 95% in aP2-GLUT4-/- adipocytes and increased similar to10-fold in aP2-GLUT4-Tg adipocytes compared with controls. Insulin-responsive aminopeptidase ( IRAP) protein amount was decreased 35% in aP2-GLUT4-/- adipocytes and increased 45% in aP2-GLUT4-Tg adipocytes. VAMP2 protein was also decreased by 60% in aP2-GLUT4-/- adipocytes and increased 2-fold in aP2GLUT4- Tg adipocytes. IRAP and VAMP2 mRNA levels were unaffected in aP2-GLUT4-Tg, suggesting that overexpression of GLUT4 affects IRAP and VAMP2 protein stability. The amount and subcellular distribution of syntaxin4, SNAP23, Munc-18c, and GLUT1 were unchanged in either aP2-GLUT4-/- or aP2-GLUT4-Tg adipocytes, but transferrin receptor was partially redistributed to the plasma membrane in aP2-GLUT4-Tg adipocytes. Immunogold electron microscopy revealed that overexpression of GLUT4 in adipocytes increased the number of GLUT4 molecules per vesicle nearly 2-fold and the number of GLUT4 and IRAP-containing vesicles per cell 3-fold. In addition, the proportion of cellular GLUT4 and IRAP at the plasma membrane in unstimulated aP2-GLUT4-Tg adipocytes was increased 4- and 2-fold, respectively, suggesting that sequestration of GLUT4 and IRAP is saturable. Our results show that GLUT4 overexpression or deficiency affects the amount of other GLUT4-vesicle proteins including IRAP and VAMP2 and that GLUT4 sequestration is saturable.	Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Endocrine Div Res N 325E, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Queensland; University of Queensland; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Endocrine Div Res N 325E, 99 Brookline Ave, Boston, MA 02215 USA.	bkahn@bidmc.harvard.edu	Carvalho, Eugenia/AAV-6868-2021; Mundt, Adrian/AAN-4641-2020; Martin, Sally/A-7150-2010	Carvalho, Eugenia/0000-0001-6264-3632; Mundt, Adrian/0000-0001-8763-4601; Martin, Sally/0000-0001-9294-5404; James, David/0000-0001-5946-5257	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK062212, F32DK009903, R37DK043051, R01DK043051] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK043051, DK 09903, DK 43051, K01 DK 62212] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Al-Hasani H, 1999, FEBS LETT, V460, P338, DOI 10.1016/S0014-5793(99)01369-1; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Brozinick JT, 1996, BIOCHEM J, V313, P133, DOI 10.1042/bj3130133; Brozinick JT, 1997, BIOCHEM J, V321, P75, DOI 10.1042/bj3210075; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CUSHMAN SW, 1978, J LIPID RES, V19, P269; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HUDSON AW, 1993, J CELL BIOL, V122, P579, DOI 10.1083/jcb.122.3.579; Inoue T, 1998, AM J PHYSIOL-RENAL, V275, pF752, DOI 10.1152/ajprenal.1998.275.5.F752; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Jiang H, 2001, BIOCHEM BIOPH RES CO, V284, P519, DOI 10.1006/bbrc.2001.4994; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAHN BB, 1988, J CLIN INVEST, V82, P691, DOI 10.1172/JCI113649; KANDROR K, 1994, J BIOL CHEM, V269, P138; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kawanishi M, 2000, J BIOL CHEM, V275, P8240, DOI 10.1074/jbc.275.11.8240; Keller SR, 2003, FRONT BIOSCI-LANDMRK, V8, pS410, DOI 10.2741/1078; Keller SR, 2002, J BIOL CHEM, V277, P17677, DOI 10.1074/jbc.M202037200; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; Leloup C, 1996, MOL BRAIN RES, V38, P45, DOI 10.1016/0169-328X(95)00306-D; Lim SN, 2001, MOL BIOL CELL, V12, P981, DOI 10.1091/mbc.12.4.981; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Mastick CC, 1997, ENDOCRINOLOGY, V138, P2391, DOI 10.1210/en.138.6.2391; MATSUOKA I, 1990, BIOCHIM BIOPHYS ACTA, V1026, P99, DOI 10.1016/0005-2736(90)90338-O; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Ramlal T, 1996, DIABETES, V45, P1516, DOI 10.2337/diabetes.45.11.1516; Ross SA, 1997, BIOCHEM BIOPH RES CO, V239, P247, DOI 10.1006/bbrc.1997.7459; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SHEPHERD PR, 2000, DIABETES MELLITUS FU, P627; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Thurmond DC, 2000, MOL CELL BIOL, V20, P379, DOI 10.1128/MCB.20.1.379-388.2000; TOZZO E, 1995, AM J PHYSIOL-ENDOC M, V268, pE956, DOI 10.1152/ajpendo.1995.268.5.E956; Tozzo E, 1996, J BIOL CHEM, V271, P10490, DOI 10.1074/jbc.271.18.10490; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Wang GY, 1997, J CELL SCI, V110, P505; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; Watson RT, 2001, EXP CELL RES, V271, P75, DOI 10.1006/excr.2001.5375; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V278, pE1019, DOI 10.1152/ajpendo.2000.278.6.E1019	51	47	49	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21598	21605		10.1074/jbc.M312269200	http://dx.doi.org/10.1074/jbc.M312269200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985357	hybrid			2022-12-27	WOS:000221273800126
J	Chen, BC; Chang, YS; Kang, JC; Hsu, MJ; Sheu, JR; Chen, TL; Teng, CM; Lin, CH				Chen, BC; Chang, YS; Kang, JC; Hsu, MJ; Sheu, JR; Chen, TL; Teng, CM; Lin, CH			Peptidoglycan induces nuclear factor-kappa B activation and cyclooxygenase-2 expression via Ras, Raf-1, and ERK in RAW 264.7 macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; TRANSCRIPTIONAL REGULATION; LIPOTEICHOIC ACID; PROINFLAMMATORY MEDIATORS; BACTERIAL PEPTIDOGLYCAN; PROSTAGLANDIN SYNTHASE; STAPHYLOCOCCUS-AUREUS; SIGNAL-TRANSDUCTION	In this study, we investigated the signaling pathway involved in cyclooxygenase-2 (COX-2) expression caused by peptidoglycan (PGN), a cell wall component of the Gram-positive bacterium Staphylococcus aureus, in RAW 264.7 macrophages. PGN caused dose- and time-dependent increases in COX-2 expression, which was attenuated by a Ras inhibitor ( manumycin A), a Raf-1 inhibitor (GW 5074), and an MEK inhibitor (PD 098059). Treatment of RAW 264.7 macrophages with PGN caused time-dependent activations of Ras, Raf-1, and ERK. The PGN-induced increase in Ras activity was inhibited by manumycin A. Raf-1 phosphorylation at Ser-338 by PGN was inhibited by manumycin A and GW 5074. The PGN-induced increase in ERK activity was inhibited by manumycin A, GW 5074, and PD 098059. Stimulation of cells with PGN activated IkappaB kinase alpha/beta (IKalpha/beta), IkappaBalpha phosphorylation, IkappaBalpha degradation, and kappaB-luciferase activity. Treatment of macrophages with an NF-kappaB inhibitor (pyrrolidine dithiocarbamate), an IkappaBalpha phosphorylation inhibitor (Bay 117082), and IkappaB protease inhibitors (L-1-tosylamido-2-phenylethyl chloromethyl ketone and calpain inhibitor I) all inhibited PGN-induced COX-2 expression. The PGN-mediated increase in the activities of IKKalpha/beta and kappaB-luciferase were also inhibited by the Ras dominant negative mutant (RasN17), manumycin A, GW 5074, and PD 098059. Further studies revealed that PGN induced the recruitment of p85alpha and Ras to Toll-like receptor 2 in a time-dependent manner. Our data demonstrate for the first time that PGN activates the Ras/Raf-1/ERK pathway, which in turn initiates IKKalpha/beta and NF-kappaB activation, and ultimately induces COX-2 expression in RAW 264.7 macrophages.	Taipei Med Univ, Sch Resp Therapy, Taipei 110, Taiwan; Taipei Med Univ, Grad Inst Biomed Technol, Taipei 110, Taiwan; Taipei Med Univ, Sch Med, Dept Pharmacol, Taipei 110, Taiwan; Taipei Med Univ, Wan Fang Hosp, Dept Anesthesiol, Taipei 110, Taiwan; Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei 110, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; National Taiwan University	Lin, CH (corresponding author), Taipei Med Univ, Sch Resp Therapy, 250 Wu Hsing St, Taipei 110, Taiwan.	chlin@tmu.edu.tw		Lin, Chien-Huang/0000-0002-0916-8737; TENG, CHE-MING/0000-0002-9719-7334; Hsu, Ming-Jen/0000-0001-9688-8494				Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BHAKDI S, 1991, INFECT IMMUN, V59, P4614, DOI 10.1128/IAI.59.12.4614-4620.1991; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; BONE RC, 1994, ARCH INTERN MED, V154, P26, DOI 10.1001/archinte.154.1.26; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen BC, 1998, J BIOL CHEM, V273, P29754, DOI 10.1074/jbc.273.45.29754; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chiang LL, 2003, J PHARM PHARMACOL, V55, P115, DOI 10.1111/j.2042-7158.2003.tb02441.x; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Elgavish A, 2000, J CELL PHYSIOL, V182, P232, DOI 10.1002/(SICI)1097-4652(200002)182:2<232::AID-JCP12>3.3.CO;2-X; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; GEPPERT TD, 1994, MOL MED, V1, P93; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Hinz B, 2002, J PHARMACOL EXP THER, V300, P367, DOI 10.1124/jpet.300.2.367; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Lin CH, 2002, EUR J PHARMACOL, V450, P1, DOI 10.1016/S0014-2999(02)02002-2; Lin CH, 2001, BRIT J PHARMACOL, V134, P543, DOI 10.1038/sj.bjp.0704290; Lin CH, 2000, MOL PHARMACOL, V57, P36; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MATTSSON E, 1993, FEMS IMMUNOL MED MIC, V7, P281, DOI 10.1016/0928-8244(93)90023-W; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; MITCHELL JA, 1995, BIOCHEM PHARMACOL, V50, P1535, DOI 10.1016/0006-2952(95)00212-X; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Musial A, 2001, J BIOL CHEM, V276, P24268, DOI 10.1074/jbc.M100725200; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Paul A, 1999, CELL SIGNAL, V11, P491, DOI 10.1016/S0898-6568(99)00018-2; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Sheng HM, 2001, CANCER RES, V61, P2670; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Varga EV, 2002, EUR J PHARMACOL, V451, P101, DOI 10.1016/S0014-2999(02)02220-3; Vasselon T, 2002, INFECT IMMUN, V70, P1033, DOI 10.1128/IAI.70.3.1033-1041.2002; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wang QL, 2001, INFECT IMMUN, V69, P2270, DOI 10.1128/IAI.69.4.2270-2276.2001; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Xu ZJ, 2001, J IMMUNOL, V167, P6975, DOI 10.4049/jimmunol.167.12.6975; Yadav PN, 2003, J PHARMACOL EXP THER, V305, P925, DOI 10.1124/jpet.103.049171; Yeo SJ, 2003, J BIOL CHEM, V278, P40590, DOI 10.1074/jbc.M306280200; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	66	80	82	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20889	20897		10.1074/jbc.M311279200	http://dx.doi.org/10.1074/jbc.M311279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15007072	hybrid			2022-12-27	WOS:000221273800041
J	Fadhil, I; Schmidt, R; Walpole, C; Carpenter, KA				Fadhil, I; Schmidt, R; Walpole, C; Carpenter, KA			Exploring deltorphin II binding to the third extracellular loop of the delta-opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; SIDE-CHAINS; PEPTIDES; ANALOGS; CLONING; DOMAIN; CONFORMATIONS; RESIDUE; CDNA; ACID	The third extracellular loop of the human delta-opioid receptor (hDOR) is known to play an important role in the binding of delta-selective ligands. In particular, mutation of three amino acids (Trp(284), Val(296), and Val(297)) to alanine significantly diminished delta-opioid receptor affinity for delta-selective ligands. To assess the changes in conformation accompanying binding of the endogenous opioid peptide deltorphin II to the delta-opioid receptor at both the receptor and ligand levels as well as to determine points of contact between the two, an in-depth spectroscopic study that addressed these points was initiated. Fragments of the delta-opioid receptor of variable length and containing residues in the third extracellular loop were synthesized and studied by NMR and CD spectroscopy in a membrane-mimetic milieu. The receptor peptides examined included hDOR-(279-299), hDOR-( 283-299), hDOR-(281-297), and hDOR-(283-297). A helical conformation was observed for the longest receptor fragment between Val(283) and Arg(291), whereas a nascent helix occurred in a similar region for hDOR-(281-297). Further removal of N-terminal residues Val(281) and Ile(282) abolished helical conformation completely. Binding of the delta-selective ligand deltorphin II to hDOR-(279-299) destabilized the helix at the receptor peptide N terminus. Dramatic changes in the alpha-proton chemical shifts for Trp(284) and Leu(286) in hDOR-(279-299) also accompanied this loss of helical conformation. Large upfield displacement of alpha-proton chemical shifts was observed for Leu(295), Val(296), and Val(297) in hDOR-(279-299) following its interaction with deltorphin II, thus identifying a gain in beta-conformation at the receptor peptide C terminus. Similar changes did not occur for the shorter peptide hDOR(281-297). A hypothesis describing the conformational events accompanying selective deltorphin II binding to the delta-opioid receptor is presented.	AstraZeneca R&D, Montreal, PQ H4S 1Z9, Canada	AstraZeneca	Carpenter, KA (corresponding author), AstraZeneca R&D, 7171 Frederick Banting, Montreal, PQ H4S 1Z9, Canada.	Katharine.carpenter@astrazeneca.com						Befort K, 1996, MOL PHARMACOL, V49, P216; Breveglieri A, 1996, J MED CHEM, V39, P773, DOI 10.1021/jm950490j; Bryant SD, 1997, J MED CHEM, V40, P2579, DOI 10.1021/jm9700530; BRYANT SD, 1993, J AM CHEM SOC, V115, P8503, DOI 10.1021/ja00071a092; BRYANT SD, 1994, PEPTIDE RES, V7, P175; COWAN A, 1988, J PHARMACOL EXP THER, V246, P950; Crescenzi O, 1996, J PEPT SCI, V2, P290, DOI 10.1002/psc.56; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Gordon LM, 2002, BBA-BIOMEMBRANES, V1559, P96, DOI 10.1016/S0005-2736(01)00443-6; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Haack T, 1997, J PEPT SCI, V3, P299, DOI 10.1002/(SICI)1099-1387(199707)3:4<299::AID-PSC121>3.3.CO;2-2; HEYMAN JS, 1987, BRAIN RES, V420, P100, DOI 10.1016/0006-8993(87)90244-7; HEYMAN JS, 1988, TRENDS PHARMACOL SCI, V9, P134, DOI 10.1016/0165-6147(88)90195-2; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KONG HY, 1993, J BIOL CHEM, V268, P23055; LAZARUS LH, 1991, J MED CHEM, V34, P1350, DOI 10.1021/jm00108a017; Lazarus LH, 1999, PROG NEUROBIOL, V57, P377, DOI 10.1016/S0301-0082(98)00050-1; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MISICKA A, 1992, PEPTIDES CHEM BIOL; MULLER G, 1993, PROTEINS, V15, P235, DOI 10.1002/prot.340150303; OHNO Y, 1993, EUR J BIOCHEM, V212, P185, DOI 10.1111/j.1432-1033.1993.tb17649.x; Pepin MC, 1997, J BIOL CHEM, V272, P9260; SASAKI Y, 1991, BIOCHEM BIOPH RES CO, V180, P822, DOI 10.1016/S0006-291X(05)81138-6; Schmidt R, 1997, PEPTIDES, V18, P1615, DOI 10.1016/S0196-9781(97)00235-0; Schullery SE, 1997, BIOORGAN MED CHEM, V5, P2221, DOI 10.1016/S0968-0896(97)00163-6; SEGAWA M, 1994, INT J PEPT PROT RES, V44, P295; SIMONIN F, 1995, P NATL ACAD SCI USA, V92, P7006, DOI 10.1073/pnas.92.15.7006; Toth G, 1997, J MED CHEM, V40, P990, DOI 10.1021/jm9602726; Tourwe D, 1996, BIOPOLYMERS, V38, P1, DOI 10.1002/(SICI)1097-0282(199601)38:1<1::AID-BIP1>3.0.CO;2-#; Valiquette M, 1996, J BIOL CHEM, V271, P18789, DOI 10.1074/jbc.271.31.18789; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; Waring AJ, 1998, PROTEINS, P38; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010	35	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21069	21077		10.1074/jbc.M311468200	http://dx.doi.org/10.1074/jbc.M311468200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14999000	hybrid			2022-12-27	WOS:000221273800064
J	Stephan, S; Sherratt, MJ; Hodson, N; Shuttleworth, CA; Kielty, CM				Stephan, S; Sherratt, MJ; Hodson, N; Shuttleworth, CA; Kielty, CM			Expression and supramolecular assembly of recombinant alpha 1(VIII) and alpha 2(VIII) collagen homotrimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELL-MIGRATION; SHORT-CHAIN COLLAGEN; VIII COLLAGEN; X COLLAGEN; METAPHYSEAL CHONDRODYSPLASIA; DESCEMETS-MEMBRANE; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; IN-VITRO; DOMAIN	Collagen VIII is an extracellular matrix macromolecule comprising two polypeptide chains, alpha1(VIII) and alpha2(VIII), that can form homotrimers in vitro and in vivo. Here, recombinant collagen VIII was expressed to study its supramolecular assembly following secretion. Cells transfected with alpha1(VIII) or alpha2(VIII) assembled and secreted homotrimers that were stable in denaturing conditions and had a molecular mass of similar to180 kDa on SDS-PAGE gels. Co-transfection with prolyl 4-hydroxylase generated homotrimers with stable pepsin-resistant triple-helical domains. Size fractionation of native recombinant collagen VIII molecules expressed with or without prolyl 4-hydroxylase identified urea-sensitive high molecular mass assemblies eluting in the void volume of a Superose 6HR 10/30 column and urea-resistant assemblies of similar to700 kDa, all of which were composed of homotrimers. Immunofluorescence analysis highlighted the extracellular deposition of recombinant alpha1(VIII)(3), alpha2(VIII)(3), and co-expressed alpha1(VIII)(3)/alpha2(VIII)(3). Microscopy analysis of recombinant collagen VIII identified rod-like molecules of 134 nm in length that assembled into angular arrays with branching angles of similar to114degrees and extensive networks. Based on these data, we propose a model of collagen VIII assembly in which four homotrimers form a tetrahedron stabilized by central interacting C-terminal NC1 trimers. Tetrahedrons may then act as building blocks of three-dimensional hexagonal lattices generated by secondary interactions involving terminal and helical sequences.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester	Kielty, CM (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd,2 205 Stopford Bldg, Manchester M13 9PT, Lancs, England.	cay.kielty@man.ac.uk	Sherratt, Michael J/A-1175-2015	Sherratt, Michael J/0000-0003-4759-6617; Hodson, Nigel/0000-0002-7486-1976	Biotechnology and Biological Sciences Research Council [BBS/B/02428] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BENYA P D, 1980, Renal Physiology, V3, P30; BENYA PD, 1986, J BIOL CHEM, V261, P4160; Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; Greenhill NS, 2000, MATRIX BIOL, V19, P19, DOI 10.1016/S0945-053X(99)00053-0; Hou GP, 2000, AM J PATHOL, V156, P467, DOI 10.1016/S0002-9440(10)64751-7; Illidge C, 2001, INT J BIOCHEM CELL B, V33, P521, DOI 10.1016/S1357-2725(01)00013-9; Illidge C, 1998, J BIOL CHEM, V273, P22091, DOI 10.1074/jbc.273.34.22091; KAPOOR R, 1986, BIOCHEMISTRY-US, V25, P3930, DOI 10.1021/bi00361a029; Kvansakul M, 2003, MATRIX BIOL, V22, P145, DOI 10.1016/S0945-053X(02)00119-1; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; MacBeath JRE, 1996, BIOCHEM J, V319, P993, DOI 10.1042/bj3190993; MANN K, 1990, FEBS LETT, V273, P168, DOI 10.1016/0014-5793(90)81076-Z; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; Rosenblum ND, 1996, BIOCHEM BIOPH RES CO, V227, P205, DOI 10.1006/bbrc.1996.1490; RUGER B, 1994, INT J EXP PATHOL, V75, P397; SAGE H, 1980, BIOCHEMISTRY-US, V19, P5747, DOI 10.1021/bi00566a013; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SAWADA H, 1991, CELL STRUCT FUNCT, V16, P455, DOI 10.1247/csf.16.455; Sherratt MJ, 2000, METH MOL B, V139, P119; Shuttleworth CA, 1997, INT J BIOCHEM CELL B, V29, P1145, DOI 10.1016/S1357-2725(97)00033-2; Sibinga NES, 1997, CIRC RES, V80, P532, DOI 10.1161/01.RES.80.4.532; Sinha S, 2001, INT J EXP PATHOL, V82, P295, DOI 10.1046/j.1365-2613.2001.00201.x; Weitkamp B, 1999, FASEB J, V13, P1445, DOI 10.1096/fasebj.13.11.1445; Wilson R, 2002, J BIOL CHEM, V277, P12516, DOI 10.1074/jbc.M112044200; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P16022; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409	29	46	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21469	21477		10.1074/jbc.M305805200	http://dx.doi.org/10.1074/jbc.M305805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14990571	hybrid, Green Published			2022-12-27	WOS:000221273800112
J	Yang, N; Huang, Y; Jiang, J; Frank, SJ				Yang, N; Huang, Y; Jiang, J; Frank, SJ			Caveolar and lipid raft localization of the growth hormone receptor and its signaling elements - Impact on growth hormone signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PLASMA-MEMBRANE CHOLESTEROL; JAK2 TYROSINE KINASE; GH RECEPTOR; INSULIN-RECEPTOR; IM-9 CELLS; FACTOR-I; INTERLEUKIN-2 RECEPTOR; NUCLEAR TRANSLOCATION; CYTOPLASMIC DOMAIN	The growth hormone receptor (GHR) is a cell surface receptor that mediates the somatogenic and metabolic effects of the growth hormone (GH). GHR signaling is transduced via the receptor-associated cytoplasmic tyrosine kinase called Janus protein kinase 2 (JAK2). The major intracellular signaling systems activated by JAK2 in response to GH include the signal transducer and activator of transcription ( STAT) 5 and extracellular signal-regulated kinase (ERK)-1 and -2 pathways. In this report, we investigate the role of cholesterol-rich plasma membrane microdomains (caveolae and lipid rafts) in GH signaling. By subcellular fractionation of the GH-responsive 3T3-F442A murine preadipocyte, we found dramatic enrichment (6.7-fold) of plasma membrane GHR in the caveolae membranes ( CM). JAK2 was also represented in the CM fraction, but was less enriched (2.5-fold) than GHR. ERK1/2 and the important ERK pathway upstream small adaptor protein, Grb2 (growth factor receptor-bound protein 2), were also enriched in caveolae (2.3- and 8.3-fold, respectively), but STAT5 was barely detected in the same fraction. Correspondingly, GH-induced tyrosine-phosphorylated GHR, JAK2, and ERK1/2 were highly represented in the CM fraction, whereas tyrosine-phosphorylated STAT5 was enriched in the non-membranous fraction of the post-nuclear supernatant. Additionally, GH induced further accumulation of GHR, Grb2, and SHC proteins in the CM fraction. Interestingly, treatment of the cells with the caveolae-disrupting agent, methyl-beta-cyclodextrin (mbetaCD), selectively inhibited GH-induced ERK1/2 activation but not STAT5 phosphorylation; repletion of cholesterol in mbetaCD-treated cells restored GH-induced ERK activation. Comparison of 3T3-F442A cells with the GHR-expressing human IM-9 lymphoblasts revealed similar enrichment of GHR in the lipid raft fraction of IM-9 as in the CM fraction of 3T3-F442A, but there were dramatic differences in the ERKs and Grb2. The IM-9 cell, in which ERKs are not activated by GH, displayed no enrichment of ERKs and Grb2 in the lipid raft fraction. Our results suggest that localization of GHRs in the CM fraction of the plasma membrane plays important roles in signaling.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Med Serv, Endocrinol Sect, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Frank, SJ (corresponding author), Univ Alabama, Dept Cell Biol, 1530 3rd Ave S,BDB 861, Birmingham, AL 35294 USA.	sjfrank@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R01DK058259, R29DK046395, R56DK058259, R01DK046395] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58259, DK 46395] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASAKAWA K, 1986, BIOCHEM J, V238, P379, DOI 10.1042/bj2380379; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Biedi C, 2003, ENDOCRINOLOGY, V144, P5497, DOI 10.1210/en.2003-0417; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Frank SJ, 2002, CYTOKINE REFERENCE O, P1; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Goebel J, 2002, J LEUKOCYTE BIOL, V72, P199; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Guan R, 2001, ENDOCRINOLOGY, V142, P1137, DOI 10.1210/en.142.3.1137; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; He K, 2003, MOL ENDOCRINOL, V17, P2211, DOI 10.1210/me.2003-0256; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200; Huo HR, 2003, J BIOL CHEM, V278, P11561, DOI 10.1074/jbc.M211785200; Ikonen E, 2000, TRAFFIC, V1, P212, DOI 10.1034/j.1600-0854.2000.010303.x; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Kim YN, 2002, ENDOCRINOLOGY, V143, P1726, DOI 10.1210/en.143.5.1726; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; LESNIAK MA, 1974, J BIOL CHEM, V249, P1661; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liang L, 2000, ENDOCRINOLOGY, V141, P3328, DOI 10.1210/en.141.9.3328; Liu LJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1550, DOI 10.1152/ajpcell.00555.2002; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Lobie PE, 1999, EXP CELL RES, V246, P47, DOI 10.1006/excr.1998.4288; Love DW, 1998, ENDOCRINOLOGY, V139, P1965, DOI 10.1210/en.139.4.1965; Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489; Matko J, 2002, EUR J BIOCHEM, V269, P1199, DOI 10.1046/j.0014-2956.2002.02759.x; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x; Shah BH, 2002, TRENDS ENDOCRIN MET, V13, P1, DOI 10.1016/S1043-2760(01)00539-2; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 2002, METHOD ENZYMOL, V353, P131; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; SOTIROPOULOS A, 1995, FEBS LETT, V369, P169, DOI 10.1016/0014-5793(95)00734-Q; Subramaniam PS, 2002, J IMMUNOL, V169, P1959, DOI 10.4049/jimmunol.169.4.1959; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Yoon M, 2003, BIOCHEM BIOPH RES CO, V308, P101, DOI 10.1016/S0006-291X(03)01341-X; Zhang Y, 2001, J BIOL CHEM, V276, P24565, DOI 10.1074/jbc.M101281200; Zhang Y, 1999, J BIOL CHEM, V274, P33072, DOI 10.1074/jbc.274.46.33072	78	53	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20898	20905		10.1074/jbc.M400625200	http://dx.doi.org/10.1074/jbc.M400625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010456	hybrid			2022-12-27	WOS:000221273800042
J	Bentin, T; Hamzavi, R; Salomonsson, J; Roy, H; Ibba, M; Nielsen, PE				Bentin, T; Hamzavi, R; Salomonsson, J; Roy, H; Ibba, M; Nielsen, PE			Photoreactive bicyclic amino acids as substrates for mutant Escherichia coli phenylalanyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO INCORPORATION; GENETIC-CODE; PROTEINS; ANALOGS; FUNCTIONALITY; SPECIFICITY	Unnatural amino acids carrying reactive groups that can be selectively activated under non-invasive biologically benign conditions are of interest in protein engineering as biological tools for the analysis of protein-protein and protein-nucleic acids interactions. The double ring system phenylalanine analogues benzofuranylalanine and benzotriazolylalanine were synthesized, and their photolability was tested by UV irradiation at 254, 320, and 365 nm. Although both showed photo reactivity, benzofuranylalanine appeared as the most promising compound because this amino acid was activated by UVA (long wavelength) irradiation. These amino acids were also tested for in vitro charging of tRNAPhe and for protein mutagenesis via the phenylalanyl-tRNA synthetase variant alphaA294G that is able to facilitate in vivo protein synthesis using a range of para-substituted phenylalanine analogues. The results demonstrate that benzofuranylalanine, but not benzotriazolylalanine, is a substrate for phenylalanine tRNA synthetase alphaA294G, and matrix-assisted laser desorption ionization time-of-flight analysis showed it to be incorporated into a model protein with high efficiency. The in vivo incorporation into a target protein of a bicyclic phenylalanine analogue, as described here, demonstrates the applicability of phenylalanine tRNA synthetase variants in expanding the scope of protein engineering.	Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, DK-2200 Copenhagen N, Denmark; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	University of Copenhagen; University System of Ohio; Ohio State University	Nielsen, PE (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Blegdamsvej 3C, DK-2200 Copenhagen N, Denmark.	pen@imbg.ku.dk	Roy, Hemant/AAC-9096-2020	/0000-0001-8771-330X				Behrens C, 2000, TETRAHEDRON, V56, P9443, DOI 10.1016/S0040-4020(00)00828-0; Chin JW, 2003, SCIENCE, V301, P964, DOI 10.1126/science.1084772; Datta D, 2002, J AM CHEM SOC, V124, P5652, DOI 10.1021/ja0177096; Furter R, 1998, PROTEIN SCI, V7, P419; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; IBBA M, 1994, BIOCHEMISTRY-US, V33, P7107, DOI 10.1021/bi00189a013; IBBA M, 1995, FEBS LETT, V364, P272, DOI 10.1016/0014-5793(95)00408-2; KATRITZKY AR, 1993, SYNTHETIC COMMUN, V23, P2019, DOI 10.1080/00397919308009862; Kirshenbaum K, 2002, CHEMBIOCHEM, V3, P235, DOI 10.1002/1439-7633(20020301)3:2/3<235::AID-CBIC235>3.0.CO;2-7; Kohrer C, 2001, P NATL ACAD SCI USA, V98, P14310, DOI 10.1073/pnas.251438898; Kowal AK, 2001, P NATL ACAD SCI USA, V98, P2268, DOI 10.1073/pnas.031488298; Kwon I, 2003, J AM CHEM SOC, V125, P7512, DOI 10.1021/ja0350076; MAGLIERY TJ, 2003, TRANSLATIONAL MECH; RAMABHADRAN TV, 1976, P NATL ACAD SCI USA, V73, P59, DOI 10.1073/pnas.73.1.59; Sakamoto M, 2000, CHEM COMMUN, P1201, DOI 10.1039/b002396p; Sharma N, 2000, FEBS LETT, V467, P37, DOI 10.1016/S0014-5793(00)01120-0; Wang H, 2000, J AM CHEM SOC, V122, P5849, DOI 10.1021/ja994464c; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799; YANIV M, 1969, NATURE, V223, P1331, DOI 10.1038/2231331a0; Zhang ZW, 2004, SCIENCE, V303, P371, DOI 10.1126/science.1089509	22	21	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19839	19845		10.1074/jbc.M401278200	http://dx.doi.org/10.1074/jbc.M401278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004015	Green Published, hybrid			2022-12-27	WOS:000221164500056
J	Cullinan, SB; Diehl, JA				Cullinan, SB; Diehl, JA			PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; TRANSCRIPTION FACTOR NRF2; INDUCED GENE-EXPRESSION; HEME OXYGENASE-1 GENE; OXIDATIVE STRESS; TRANSLATION INITIATION; MAMMALIAN-CELLS; INDUCTION; ELEMENT; KINASE	The accumulation of unfolded proteins elicits a cellular response that triggers both pro-survival and pro-apoptotic signaling events. PERK-dependent activation of NF-E2-related factor-2 (Nrf2) is critical for survival signaling during this response; however, the mechanism whereby Nrf2 confers a protective advantage to stressed cells remains to be defined. We now demonstrate that Nrf2 activation contributes to the maintenance of glutathione levels, which in turn functions as a buffer for the accumulation of reactive oxygen species during the unfolded protein response. The deleterious effects of Nrf2 or PERK deficiencies could be attenuated by the restoration of cellular glutathione levels or Nrf2 activity. In addition, the inhibition of reactive oxygen species production attenuated apoptotic induction following endoplasmic reticulum stress. Our data suggest that perturbations in cellular redox status sensitize cells to the harmful effects of endoplasmic reticulum stress, but that other factors are essential for apoptotic commitment.	Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Diehl, JA (corresponding author), Abramson Family Canc Res Inst, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu						Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; CAI JW, 1993, J CELL PHYSIOL, V154, P229, DOI 10.1002/jcp.1041540204; CARLBERG M, 1993, ANTICANCER RES, V13, P167; Chan D, 2000, AUSTRALAS J AGEING, V19, P26; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Izuishi K, 2000, CANCER RES, V60, P6201; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Walenta S, 2000, J HISTOCHEM CYTOCHEM, V48, P509, DOI 10.1177/002215540004800409; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	55	527	548	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20108	20117		10.1074/jbc.M314219200	http://dx.doi.org/10.1074/jbc.M314219200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14978030	hybrid			2022-12-27	WOS:000221164500087
J	Dalle, S; Longuet, C; Costes, S; Broca, C; Faruque, O; Fontes, G; Hani, EH; Bataille, D				Dalle, S; Longuet, C; Costes, S; Broca, C; Faruque, O; Fontes, G; Hani, EH; Bataille, D			Glucagon promotes cAMP-response element-binding protein phosphorylation via activation of ERK1/2 in MIN6 cell line and isolated islets of Langerhans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; NUCLEAR TRANSLOCATION; REGULATED KINASE; GENE-EXPRESSION; GLUCOSE; RECEPTOR; CREB; PATHWAY; CONTRIBUTE; HORMONE	By using the MIN6 cell line and pancreatic islets, we show that in the presence of a low glucose concentration, corresponding to physiological glucagon release from alpha cells, glucagon treatment of the beta cell caused a rapid, time-dependent phosphorylation and activation of p44/p42 mitogen-activated protein kinase (ERK1/2) independently from extracellular calcium influx. Inhibition of either cAMP-dependent protein kinase (PKA) or MEK completely blocked ERK1/2 activation by glucagon. However, no significant activation of several upstream activators of MEK, including Shc-p21(Ras) and phosphatidylinositol 3-kinase, was observed in response to glucagon treatment. Chelation of intracellular calcium (intracellular [Ca2+]) reduced glucagon-mediated ERK1/2 activation. In addition, internalization of glucagon receptors through clathrin-coated pits formation is required for ERK1/2 activation. Remarkably, glucagon promotes the nuclear translocation of ERK1/2 and induces the phosphorylation of cAMP-response element-binding protein (CREB). Miniglucagon, produced from glucagon and released together with the mother hormone from the alpha cells in low glucose situations, blocks the insulinotropic effect of glucagon, whereas it does not inhibit the glucagon-induced PKA/ERK1/2/CREB pathway. We conclude that glucagon-induced ERK1/2 activation is mediated by PKA and that an increase in [Ca2+](i) is required for maximal ERK activation. Our results uncover a novel mechanism by which the PKA/ERK1/2 signaling network engaged by glucagon, in situation of low glucose concentration, regulates phosphorylation of CREB, a transcription factor crucial for normal beta cell function and survival.	CHU Arnaud de Villeneuve, INSERM, U376, F-34295 Montpellier 5, France; Fac Med Montpellier, Inst Biol, CNRS, UMR 5160, F-34060 Montpellier 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Centre National de la Recherche Scientifique (CNRS)	Bataille, D (corresponding author), CHU Arnaud de Villeneuve, INSERM, U376, 371 Rue Doyen Gaston Giraud, F-34295 Montpellier 5, France.	bataille@montp.inserm.fr	Longuet, Christine/ABC-2556-2020; , Costes/AAC-2820-2020	, Costes/0000-0001-8323-1207				Arnette D, 2003, J BIOL CHEM, V278, P32517, DOI 10.1074/jbc.M301174200; Benes C, 1998, J BIOL CHEM, V273, P15507, DOI 10.1074/jbc.273.25.15507; BIRNBAUMER L, 1995, J RECEPT SIGNAL TR R, V15, P213; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Cryer PE, 1996, HORM RES, V46, P192, DOI 10.1159/000185022; Cypess AM, 1999, J BIOL CHEM, V274, P19455, DOI 10.1074/jbc.274.27.19455; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Dalle S, 1999, J BIOL CHEM, V274, P10869, DOI 10.1074/jbc.274.16.10869; Dalle S, 2002, DIABETES, V51, P406, DOI 10.2337/diabetes.51.2.406; Ehses JA, 2002, J BIOL CHEM, V277, P37088, DOI 10.1074/jbc.M205055200; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; HABENER JF, 1989, HORM RES, V32, P61, DOI 10.1159/000181246; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Huypens P, 2000, DIABETOLOGIA, V43, P1012, DOI 10.1007/s001250051484; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Jiang YW, 2001, P NATL ACAD SCI USA, V98, P10102, DOI 10.1073/pnas.131200398; KAWAI K, 1995, DIABETOLOGIA, V38, P274, DOI 10.1007/BF00400630; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Kieffer TJ, 1996, ENDOCRINOLOGY, V137, P5119, DOI 10.1210/en.137.11.5119; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Moens K, 2002, DIABETES, V51, P669, DOI 10.2337/diabetes.51.3.669; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Prasadan K, 2002, DIABETES, V51, P3229, DOI 10.2337/diabetes.51.11.3229; Sharp GWG, 1996, AM J PHYSIOL-CELL PH, V271, pC1781, DOI 10.1152/ajpcell.1996.271.6.C1781; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; UNGER RH, 1997, ELLENBERG RIFKINS DI, P115; UNGER RH, 1995, ENDOCRINOLOGY, P1337; Vilsboll T, 2003, REGUL PEPTIDES, V114, P115, DOI 10.1016/S0167-0115(03)00111-3; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1431, DOI 10.1210/mend-5-10-1431; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	44	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20345	20355		10.1074/jbc.M312483200	http://dx.doi.org/10.1074/jbc.M312483200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14988413	hybrid			2022-12-27	WOS:000221164500112
J	Kamm, C; Boston, H; Hewett, J; Wilbur, J; Corey, DP; Hanson, PI; Ramesh, V; Breakefield, XO				Kamm, C; Boston, H; Hewett, J; Wilbur, J; Corey, DP; Hanson, PI; Ramesh, V; Breakefield, XO			The early onset dystonia protein torsinA interacts with kinesin light chain 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOR1A DYT1 GENE; AXONAL-TRANSPORT; CAENORHABDITIS-ELEGANS; HEAVY-CHAIN; HUMAN BRAIN; POSTNATAL-DEVELOPMENT; ASHKENAZI JEWS; PC12 CELLS; MUTATION; MEMBRANE	Early onset dystonia is a movement disorder caused by loss of a glutamic acid residue (Glu(302/303)) in the carboxyl-terminal portion of the AAA(+) protein, torsinA. We identified the light chain subunit (KLC1) of kinesin-I as an interacting partner for torsinA, with binding occurring between the tetratricopeptide repeat domain of KLC1 and the carboxyl-terminal region of torsinA. Coimmunoprecipitation analysis demonstrated that wildtype torsinA and kinesin-I form a complex in vivo. In cultured cortical neurons, both proteins co-localized along processes with enrichment at growth cones. Wildtype torsinA expressed in CAD cells co-localized with endogenous KLC1 at the distal end of processes, whereas mutant torsinA remained confined to the cell body. Subcellular fractionation of adult rat brain revealed torsinA and KLC associated with cofractionating membranes, and both proteins were co-immunoprecipitated after cross-linking cytoplasmically oriented proteins on isolated rat brain membranes. These studies suggest that wild-type torsinA undergoes anterograde transport along microtubules mediated by kinesin and may act as a molecular chaperone regulating kinesin activity and/or cargo binding.	Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Mol Neurogenet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02114 USA; Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Washington University (WUSTL)	Breakefield, XO (corresponding author), Massachusetts Gen Hosp, Bldg 149,13th St,Rm 6101, Charlestown, MA 02129 USA.	breakefield@hms.harvard.edu	Hanson, Phyllis/E-9420-2012	Corey, David/0000-0003-4497-6016	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028384, P50NS037409, P01NS037409] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 37409, NS28384] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; Augood SJ, 1999, ANN NEUROL, V46, P761, DOI 10.1002/1531-8249(199911)46:5<761::AID-ANA12>3.3.CO;2-Q; Augood SJ, 2003, BRAIN RES, V986, P12, DOI 10.1016/S0006-8993(03)03164-0; Basham SE, 1999, DEV BIOL, V215, P253, DOI 10.1006/dbio.1999.9447; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; BRAGG DC, 2004, IN PRESS NEUROSCIENC; Breakefield XO, 2001, NEURON, V31, P9, DOI 10.1016/S0896-6273(01)00350-6; Brent R, 1997, ANNU REV GENET, V31, P663, DOI 10.1146/annurev.genet.31.1.663; Bressman SB, 2000, NEUROLOGY, V54, P1746, DOI 10.1212/WNL.54.9.1746; BRESSMAN SB, 1989, ANN NEUROL, V26, P612, DOI 10.1002/ana.410260505; BRESSMAN SB, 1994, ANN NEUROL, V36, P771, DOI 10.1002/ana.410360514; Caldwell GA, 2003, HUM MOL GENET, V12, P307, DOI 10.1093/hmg/ddg027; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DIFIGLIA M, 1980, J COMP NEUROL, V190, P303, DOI 10.1002/cne.901900207; Dron M, 2002, GENOMICS, V79, P315, DOI 10.1006/geno.2002.6709; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; Goodchild RE, 2004, P NATL ACAD SCI USA, V101, P847, DOI 10.1073/pnas.0304375101; GREENE P, 1995, MOVEMENT DISORD, V10, P143, DOI 10.1002/mds.870100204; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hedreen J C, 1988, Adv Neurol, V50, P123; Hewett J, 2000, HUM MOL GENET, V9, P1403, DOI 10.1093/hmg/9.9.1403; Hewett J, 2003, J NEUROSCI RES, V72, P158, DOI 10.1002/jnr.10567; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2002, CURR OPIN CELL BIOL, V14, P63, DOI 10.1016/S0955-0674(01)00295-2; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Klein C, 2002, CURR OPIN NEUROL, V15, P491, DOI 10.1097/00019052-200208000-00014; Konakova M, 2001, ARCH NEUROL-CHICAGO, V58, P921, DOI 10.1001/archneur.58.6.921; Konakova M, 2001, BRAIN RES, V922, P1, DOI 10.1016/S0006-8993(01)03014-1; Kustedjo K, 2000, J BIOL CHEM, V275, P27933; Kustedjo K, 2003, BIOCHEMISTRY-US, V42, P15333, DOI 10.1021/bi0349569; Leung JC, 2001, NEUROGENETICS, V3, P133, DOI 10.1007/s100480100111; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Liu ZH, 2003, BIOCHEM J, V374, P117, DOI 10.1042/BJ20030258; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; McCart AE, 2003, TRAFFIC, V4, P576, DOI 10.1034/j.1600-0854.2003.00113.x; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; Meiri KF, 1998, J NEUROSCI, V18, P10429; Miller J.H., 1992, SHORT COURSE BACTERI, P74; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; Morfini G, 2001, METH MOL B, V164, P147; Morfini G, 2001, DEV NEUROSCI-BASEL, V23, P364, DOI 10.1159/000048720; Murthy V, 2004, J BIOL CHEM, V279, P1351, DOI 10.1074/jbc.M310208200; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ozelius LJ, 1999, GENOMICS, V62, P377, DOI 10.1006/geno.1999.6039; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; Qi YP, 1997, J NEUROSCI, V17, P1217; Reid E, 2002, AM J HUM GENET, V71, P1189, DOI 10.1086/344210; REYNOLDS A, 1994, CURRENT PROTOCOLS MO; Rostasy K, 2003, NEUROBIOL DIS, V12, P11, DOI 10.1016/S0969-9961(02)00010-4; SADEE W, 1987, CANCER RES, V47, P5207; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Seiler S, 2000, NAT CELL BIOL, V2, P333, DOI 10.1038/35014022; SHORT MP, 1990, DEV NEUROSCI-BASEL, V12, P34, DOI 10.1159/000111833; Siddiqui SS, 2002, TRAFFIC, V3, P20, DOI 10.1034/j.1600-0854.2002.30104.x; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; TEPPER JM, 1993, PROG BRAIN RES, V99, P35; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; Tsai MY, 2000, MOL BIOL CELL, V11, P2161, DOI 10.1091/mbc.11.6.2161; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Vignali G, 1997, J NEUROCHEM, V69, P1840; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xu L, 1998, EXP CELL RES, V238, P231, DOI 10.1006/excr.1997.3843; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4	74	64	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19882	19892		10.1074/jbc.M401332200	http://dx.doi.org/10.1074/jbc.M401332200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14970196	hybrid			2022-12-27	WOS:000221164500062
J	Marchal, S; Gorren, ACF; Sorlie, M; Andersson, KK; Mayer, B; Lange, R				Marchal, S; Gorren, ACF; Sorlie, M; Andersson, KK; Mayer, B; Lange, R			Evidence of two distinct oxygen complexes of reduced endothelial nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; LOW-TEMPERATURE; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; OXYFERRO COMPLEX; DIOXYGEN COMPLEX; SINGLE-TURNOVER; REDOX ROLE; TETRAHYDROBIOPTERIN; HEME	Oxygen binding to the oxygenase domain of reduced endothelial nitric oxide synthase (eNOS) results in two distinct species differing in their Soret and visible absorbance maxima and in their capacity to exchange oxygen by CO. At 7degreesC, heme-oxy I (with maxima at 420 and 560 nm) is formed very rapidly (k(on) approximate to 2.5.10(6) M-1.s(-1)) in the absence of substrate but in the presence of pterin cofactor. It is capable of exchanging oxygen with CO at -30degreesC. Heme-oxy II is formed more slowly (k(on) approximate to 3.10(5) M-1.s(-1)) in the presence of substrate, regardless of the presence of pterin. It is also formed in the absence of both substrate and pterin. In contrast to heme-oxy I, it cannot exchange oxygen with CO at cryogenic temperature. In the presence of arginine, heme-oxy II is characterized by absorbance maxima near 432, 564, and 597 nm. When arginine is replaced by N-hydroxyarginine, and also in the absence of both substrate and pterin, its absorbance maxima are blue-shifted to 428, 560, and 593 nm. Heme-oxy I seems to resemble the ferrous dioxygen complex observed in many hemoproteins, including cytochrome P450. Heme-oxy II, which is the oxygen complex competent for product formation, appears to represent a distinct conformation in which the electronic configuration is essentially locked in the ferric superoxide complex.	Univ Montpellier 2, INSERM, U431, Dept Biol Sante, F-34095 Montpellier, France; Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria; Agr Univ Norway, Dept Chem & Biotechnol, N-1432 As, Norway; Univ Oslo, Dept Biochem, N-0316 Oslo, Norway	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Graz; Norwegian University of Life Sciences; University of Oslo	Lange, R (corresponding author), Univ Montpellier 2, INSERM, U431, Dept Biol Sante, Pl Eugene Bataillon, F-34095 Montpellier 5, France.	lange@montp.inserm.fr	MARCHAL, stéphane/M-4324-2017; Mayer, Bernd/B-9391-2008; Andersson, K Kristoffer/F-9624-2010	MARCHAL, stéphane/0000-0002-1101-7890; Mayer, Bernd/0000-0002-2921-3494; Gorren, Antonius Cornelis Franciscus/0000-0003-3476-6162				Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Bec N, 2000, J INORG BIOCHEM, V81, P207, DOI 10.1016/S0162-0134(00)00104-5; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Gorren ACF, 2002, METHOD ENZYMOL, V353, P114; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; Gorren ACF, 2001, NITRIC OXIDE-BIOL CH, V5, P176, DOI 10.1006/niox.2001.0332; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Groves JT, 2000, CURR OPIN CHEM BIOL, V4, P687, DOI 10.1016/S1367-5931(00)00146-0; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; Hagedoorn PL, 2001, J BIOL CHEM, V276, P22850, DOI 10.1074/jbc.M009458200; Hemmens B, 1998, METH MOL B, V100, P1; Hurshman AR, 2003, BIOCHEMISTRY-US, V42, P13287, DOI 10.1021/bi035491p; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KORTH HG, 1994, J BIOL CHEM, V269, P17776; Lange R, 2001, J INORG BIOCHEM, V87, P191, DOI 10.1016/S0162-0134(01)00330-0; LARROQUE C, 1980, FEBS LETT, V115, P175, DOI 10.1016/0014-5793(80)81161-6; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Raman CS, 2001, BIOCHEMISTRY-US, V40, P13448, DOI 10.1021/bi010957u; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; SHARROCK M, 1976, BIOCHIM BIOPHYS ACTA, V420, P8, DOI 10.1016/0005-2795(76)90340-8; SONO M, 1985, J BIOL CHEM, V260, P5530; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; TUCKEY RC, 1982, J BIOL CHEM, V257, P9309; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wang ZQ, 2002, J BIOL CHEM, V277, P12830, DOI 10.1074/jbc.M111967200; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200	43	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19824	19831		10.1074/jbc.M313587200	http://dx.doi.org/10.1074/jbc.M313587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004019	hybrid			2022-12-27	WOS:000221164500054
J	Balasubramanian, S; Teissere, JA; Raju, DV; Hall, RA				Balasubramanian, S; Teissere, JA; Raju, DV; Hall, RA			Hetero-oligomerization between GABA(A) and GABA(B) receptors regulates GABA(B) receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; METABOTROPIC GLUTAMATE RECEPTORS; PROTEIN-COUPLED RECEPTORS; B-RECEPTOR; RAT-BRAIN; SUBCELLULAR-LOCALIZATION; SPLICE VARIANTS; MESSENGER-RNAS; A RECEPTORS; SUBUNITS	The neurotransmitter gamma-aminobutyric acid (GABA) mediates inhibitory signaling in the brain via stimulation of both GABA(A) receptors (GABA(A)R), which are chloride-permeant ion channels, and GABA(B) receptors (GABA(B)R), which signal through coupling to G proteins. Here we report physical interactions between these two different classes of GABA receptor. Association of the GABA(B) receptor 1 (GABA(B)R1) with the GABA(A) receptor gamma2S subunit robustly promotes cell surface expression of GABA(B)R1 in the absence of GABA(B)R2, a closely related GABA(B) receptor that is usually required for efficient trafficking of GABA(B)R1 to the cell surface. The GABA(B)R1/gamma2S complex is not detectably functional when expressed alone, as assessed in both ERK activation assays and physiological analyses in oocytes. However, the gamma2S subunit associates not only with GABABR1 alone but also with the functional GABA(B)R1/GABA(B)R2 heterodimer to markedly enhance GABA(B) receptor internalization in response to agonist stimulation. These findings reveal that the GABA(B)R1/gamma2S interaction results in the regulation of multiple aspects of GABA(B) receptor trafficking, allowing for cross-talk between these two distinct classes of GABA receptor.	Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Emory University; Emory University	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rhall@pharm.emory.edu		Hall, Randy/0000-0002-8318-8728	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045644] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS45644] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Barila B, 1999, NEUROSCIENCE, V93, P1077, DOI 10.1016/S0306-4522(99)00257-2; Belley M, 1999, BIOORGAN MED CHEM, V7, P2697, DOI 10.1016/S0968-0896(99)00214-X; Bianchi M, 2001, NEUROPHARMACOLOGY, V40, P185, DOI 10.1016/S0028-3908(00)00146-5; BOWERY NG, 1990, ADV BIOCHEM PSYCHOPH, V46, P127; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; Calver AR, 2001, J NEUROSCI, V21, P1203; Castelli MP, 1999, LIFE SCI, V64, P1321, DOI 10.1016/S0024-3205(99)00067-3; Connolly CN, 1999, MOL CELL NEUROSCI, V13, P259, DOI 10.1006/mcne.1999.0746; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Enna S J, 2001, Mol Interv, V1, P208; Fiorentini C, 2003, J BIOL CHEM, V278, P20196, DOI 10.1074/jbc.M213140200; Fritschy JM, 1999, EUR J NEUROSCI, V11, P761, DOI 10.1046/j.1460-9568.1999.00481.x; Fujiyama F, 2000, J COMP NEUROL, V416, P158; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Green A, 2000, BRIT J PHARMACOL, V131, P1766, DOI 10.1038/sj.bjp.0703755; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Herring D, 2003, J BIOL CHEM, V278, P24046, DOI 10.1074/jbc.M301420200; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; KARDOS J, 1994, J NEUROSCI RES, V39, P646, DOI 10.1002/jnr.490390604; KARDOS J, 1991, NEUROREPORT, V2, P541, DOI 10.1097/00001756-199109000-00011; Kardos J, 1999, NEUROCHEM INT, V34, P353, DOI 10.1016/S0197-0186(99)00036-4; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kittler JT, 2000, J NEUROSCI, V20, P7972; Kulik A, 2003, J NEUROSCI, V23, P11026; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Obrietan K, 1998, J NEUROPHYSIOL, V79, P1360, DOI 10.1152/jn.1998.79.3.1360; Pagano A, 2001, J NEUROSCI, V21, P1189; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; RAITERI M, 1992, ADV BIOCHEM PSYCHOPH, V47, P205; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Rudolph U, 2001, TRENDS PHARMACOL SCI, V22, P188, DOI 10.1016/S0165-6147(00)01646-1; Sassoe-Pognetto M, 2000, EUR J NEUROSCI, V12, P2205, DOI 10.1046/j.1460-9568.2000.00106.x; Scotti AL, 2001, P NATL ACAD SCI USA, V98, P3489, DOI 10.1073/pnas.061028798; Shibuya I, 1997, EUR J PHARMACOL, V321, P241, DOI 10.1016/S0014-2999(96)00936-3; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; Smith Y, 2000, J ANAT, V196, P555, DOI 10.1046/j.1469-7580.2000.19640555.x; Sullivan R, 2000, J PHARMACOL EXP THER, V293, P460; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WATANABE W, 2000, INT REV CYTOL, V213, P1; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wisden W, 1996, NEUROPHARMACOLOGY, V35, P1139, DOI 10.1016/S0028-3908(96)00076-7; WISDEN W, 1992, J NEUROSCI, V12, P1040; Yamauchi T, 2000, EUR J NEUROSCI, V12, P3433, DOI 10.1046/j.1460-9568.2000.00248.x	54	91	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18840	18850		10.1074/jbc.M313470200	http://dx.doi.org/10.1074/jbc.M313470200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966130	hybrid			2022-12-27	WOS:000221041500093
J	Schlatterer, C; Happle, K; Lusche, DF; Sonnemann, J				Schlatterer, C; Happle, K; Lusche, DF; Sonnemann, J			Cytosolic [Ca2+] transients in Dictyostelium discoideum depend on the filling state of internal stores and on an active sarco/endoplasmic reticulum calcium ATPase (SERCA) Ca2+ pump10.1074/jbc.M307096200	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; INTRACELLULAR CALCIUM; CYCLIC-AMP; ENTRY; CELLS; INFLUX; OSCILLATIONS; CHEMOTAXIS; SIGNALS; PUMP	Stimulation of Dictyostelium discoideum with cAMP evokes a change of the cytosolic free Ca2+ concentration ([Ca2+](i)). We analyzed the role of the filling state of Ca2+ stores for the [Ca2+](i) transient. Parameters tested were the height of the [Ca2+](i) elevation and the percentage of responding amoebae. After loading stores with Ca2+, cAMP induced a [Ca2+](i) transient in many cells. Without prior loading, cAMP evoked a [Ca2+](i) change in a few cells only. This indicates that the [Ca2+](i) elevation is not mediated exclusively by Ca2+ influx but also by Ca2+ release from stores. Reducing the Ca2+ content of the stores by EGTA preincubation led to a cAMP-activated [Ca2+](i) increase even at low extracellular [Ca2+]. Moreover, the addition of Ca2+ itself elicited a capacitative [Ca2+](i) elevation. This effect was not observed when stores were emptied by the standard technique of inhibiting internal Ca2+ pumps with 2,5-di-(t-butyl)-1,4-hydroquinone. Therefore, in Dictyostelium, an active internal Ca2+-ATPase is absolutely required to allow for Ca2+ entry. No influence of the filling state of stores on Ca2+ influx characteristics was found by the Mn2+-quenching technique, which monitors the rate of Ca2+ entry. Both basal and cAMP-activated Mn2+ influx rates were similar in control cells and cells with empty stores. By contrast, determination of extracellular free Ca2+ concentration ([Ca2+](e)) changes, which represent the sum of Ca2+ influx and efflux, revealed a higher rate of [Ca2+](e) decrease in EGTA-treated than in control amoebae. We conclude that emptying of Ca2+ stores does not change the rate of Ca2+ entry but results in inhibition of the plasma membrane Ca2+-ATPase. Furthermore, the activities of the Ca2+ transport ATPases of the stores are of crucial importance for the regulation of [Ca2+](i) changes.	Univ Konstanz, Fac Biol, D-78457 Constance, Germany; Univ Greifswald, Inst Pharmacol Pediat Oncol & Hematol, D-17487 Greifswald, Germany	University of Konstanz; Ernst Moritz Arndt Universitat Greifswald	Schlatterer, C (corresponding author), Univ Konstanz, Fac Biol, D-78457 Constance, Germany.	Christina.Schlatterer@uni-konstanz.de	Sonnemann, Jürgen/H-9116-2019	Sonnemann, Jürgen/0000-0003-2993-9161; Lusche, Daniel Felix/0000-0002-8848-4198				Bauer PJ, 2002, ADV EXP MED BIOL, V514, P253; Bautista DM, 2002, J PHYSIOL-LONDON, V541, P877, DOI 10.1113/jphysiol.2001.016154; BOHME R, 1987, BIOCHIM BIOPHYS ACTA, V904, P125, DOI 10.1016/0005-2736(87)90093-9; Broad LM, 1996, BIOCHEM J, V316, P759, DOI 10.1042/bj3160759; BUMANN J, 1986, DIFFERENTIATION, V31, P85, DOI 10.1111/j.1432-0436.1986.tb00387.x; BUMANN J, 1984, J CELL BIOL, V98, P173, DOI 10.1083/jcb.98.1.173; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; FLAADT H, 1993, J CELL SCI, V105, P1131; Fusi F, 2001, BRIT J PHARMACOL, V133, P988, DOI 10.1038/sj.bjp.0704183; GROHOVAZ F, 1991, J CELL BIOL, V113, P1341, DOI 10.1083/jcb.113.6.1341; Groner M, 1996, CELL CALCIUM, V19, P105, DOI 10.1016/S0143-4160(96)90079-2; Madge L, 1997, J PHYSIOL-LONDON, V498, P351, DOI 10.1113/jphysiol.1997.sp021863; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MILNE JL, 1989, EXP CELL RES, V185, P21, DOI 10.1016/0014-4827(89)90033-5; MILNE JL, 1988, BIOCHEM J, V249, P223, DOI 10.1042/bj2490223; MONIAKIS J, 1995, J BIOL CHEM, V270, P28276; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; Nebl T, 1997, J CELL SCI, V110, P2845; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney JW, 2001, J CELL SCI, V114, P2223; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROONEY EK, 1992, P NATL ACAD SCI USA, V89, P8025, DOI 10.1073/pnas.89.17.8025; Schaloske R, 2000, J BIOL CHEM, V275, P8404, DOI 10.1074/jbc.275.12.8404; Schaloske R, 1997, BIOCHEM J, V327, P233, DOI 10.1042/bj3270233; Schaloske R, 1998, BIOCHEM J, V332, P541, DOI 10.1042/bj3320541; Schlatterer C, 1996, BIOCHEM J, V313, P661, DOI 10.1042/bj3130661; SCHLATTERER C, 1992, EUR J CELL BIOL, V58, P172; SCHLATTERER C, 1994, CELL CALCIUM, V16, P101, DOI 10.1016/0143-4160(94)90005-1; Schlatterer C, 2001, CELL CALCIUM, V29, P171, DOI 10.1054/ceca.2000.0181; SCHLATTERER C, 1994, J CELL SCI, V107, P2107; Shuttleworth TJ, 1999, CELL CALCIUM, V25, P237, DOI 10.1054/ceca.1999.0022; Snitsarev VA, 1999, CELL CALCIUM, V25, P409, DOI 10.1054/ceca.1999.0041; Sonnemann J, 1998, FEBS LETT, V436, P271, DOI 10.1016/S0014-5793(98)01139-9; Sonnemann J, 1997, CELL CALCIUM, V22, P65, DOI 10.1016/S0143-4160(97)90090-7; Szerencsei RT, 2002, ANN NY ACAD SCI, V976, P41; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Yumura S, 1996, J CELL SCI, V109, P2673	37	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18407	18414		10.1074/jbc.M307096200	http://dx.doi.org/10.1074/jbc.M307096200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14973132	hybrid			2022-12-27	WOS:000221041500039
J	Davis, JP; Rall, JA; Alionte, C; Tikunova, SB				Davis, JP; Rall, JA; Alionte, C; Tikunova, SB			Mutations of hydrophobic residues in the n-terminal domain of troponin C affect calcium binding and exchange with the troponin C-troponin I96-148 complex and muscle force production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; THIN FILAMENT; BIOLOGICAL-ACTIVITY; INHIBITORY REGION; CA2+ BINDING; MAGNESIUM BINDING; EF-HAND; FIBERS; RABBIT; MUTANTS	Interactions between troponin C and troponin I play a critical role in the regulation of skeletal muscle contraction and relaxation. We individually substituted 27 hydrophobic Phe, Ile, Leu, Val, and Met residues in the regulatory domain of the fluorescent troponin C-F29W with polar Gln to examine the effects of these mutations on: (a) the calcium binding and dynamics of troponin CF29W complexed with the regulatory fragment of troponin I (troponin I96-148) and (b) the calcium sensitivity of force production. Troponin I96-148 was an accurate mimic of intact troponin I for measuring the calcium dynamics of the troponin C-F29W-troponin I complexes. The calcium affinities of the troponin C-F29W-troponin I96-148 complexes varied similar to243-fold, whereas the calcium association and dissociation rates varied similar to38- and similar to33-fold, respectively. Interestingly, the effect of the mutations on the calcium sensitivity of force development could be better predicted from the calcium affinities of the troponin C-F29W-troponin I96-148 complexes than from that of the isolated troponin C-F29W mutants. Most of the mutations did not dramatically affect the affinity of calcium-saturated troponin C-F29W for troponin I96-148. However, the Phe(26) to Gln and Ile(62) to Gln mutations led to > 10-fold lower affinity of calcium-saturated troponin C-F29W for troponin I96-148, causing a drastic reduction in force recovery, even though these troponin C-F29W mutants still bound to the thin filaments. In conclusion, elucidating the determinants of calcium binding and exchange with troponin C in the presence of troponin I provides a deeper understanding of how troponin C controls signal transduction.	Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Davis, JP (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, 209 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	davis.812@osu.edu			NHLBI NIH HHS [HL073600] Funding Source: Medline; NIAMS NIH HHS [AR20792] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020792] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHANDRA M, 1994, J BIOL CHEM, V269, P14988; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; Davis JP, 2002, J BIOL CHEM, V277, P49716, DOI 10.1074/jbc.M208488200; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; JOHNSON JD, 1994, J BIOL CHEM, V269, P8919; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; Kobayashi T, 1999, BIOCHEMISTRY-US, V38, P5386, DOI 10.1021/bi981320m; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; Luo Y, 2002, J PHYSIOL-LONDON, V545, P887, DOI 10.1113/jphysiol.2002.031757; Luo Y, 2002, BIOCHEMISTRY-US, V41, P12891, DOI 10.1021/bi020396m; MAK AS, 1983, J BIOL CHEM, V258, P4330; McKay RT, 1999, BIOCHEMISTRY-US, V38, P5478; Mercier P, 2003, BIOCHEMISTRY-US, V42, P4333, DOI 10.1021/bi027041n; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MOSS RL, 1979, J PHYSIOL-LONDON, V292, P177, DOI 10.1113/jphysiol.1979.sp012845; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; NISHIO T, 1983, J BIOCHEM-TOKYO, V94, P745, DOI 10.1093/oxfordjournals.jbchem.a134415; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1982, CALCIUM CELL FUNCTIO, V2, P145; Ramakrishnan S, 1996, BIOCHEMISTRY-US, V35, P15515, DOI 10.1021/bi961788u; Ramos CHI, 1999, J BIOL CHEM, V274, P18189, DOI 10.1074/jbc.274.26.18189; Regnier M, 1999, BIOPHYS J, V76, P2664, DOI 10.1016/S0006-3495(99)77418-7; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; Swartz DR, 1997, BIOPHYS J, V73, P293, DOI 10.1016/S0006-3495(97)78070-6; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; Tikunova SB, 2002, BIOCHEMISTRY-US, V41, P6697, DOI 10.1021/bi011763h; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Tung CS, 2000, PROTEIN SCI, V9, P1312; VanEyk JE, 1997, J BIOL CHEM, V272, P10529; Zhang DH, 2000, BIOPHYS J, V78, P3103, DOI 10.1016/S0006-3495(00)76847-0	44	31	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17348	17360		10.1074/jbc.M314095200	http://dx.doi.org/10.1074/jbc.M314095200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970231	hybrid			2022-12-27	WOS:000220870400058
J	Lu, G; Broze, GJ; Krishnaswamy, S				Lu, G; Broze, GJ; Krishnaswamy, S			Formation of factors IXa and Xa by the extrinsic pathway - Differential regulation by tissue factor pathway inhibitor and antithrombin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK ANTICOAGULANT PEPTIDE; FACTOR-FACTOR VIIA; BLOOD-COAGULATION; EXTINCTION COEFFICIENTS; HUMAN-PROTHROMBIN; HEMOPHILIA-A; ACTIVATION; COMPLEX; HEPARIN; INITIATION	The activation of factor X by VIIa/TF and the Xa-dependent inhibition of the enzyme complex by tissue factor pathway inhibitor ( TFPI) are considered primary steps in the initiation of coagulation. IX activation by VIIa/TF is considered to contribute catalyst necessary for further Xa production in the ensuing amplification phase. We have investigated Xa and IXabeta production by VIIa-TF in a system reconstituted with both X and IX and the principal physiologic inhibitors of this pathway TFPI and antithrombin III (AT). Kinetic studies without inhibitors established that IX and X functioned as competitive alternate substrates for VIIa/TF with similar kinetic constants. When both IX and X were present, TFPI significantly inhibited the extent of formation of either IXabeta or Xa. In contrast, AT rapidly depleted active Xa with a small effect on IXabeta formation. When both AT and TFPI were present, active IXabeta formation significantly exceeded the formation of active Xa regardless of the VIIa/TF concentration. These findings could be quantitatively accounted for by a model encompassing the kinetics of the individual activation and inhibition steps. Active Xa formation by this pathway is regulated in a principal way by its rapid inactivation by AT. In contrast, the Xa-dependent inhibitory reactions of TFPI play a primary role in limiting zymogen consumption and the formation of active IXabeta. These regulatory phenomena yield active IXabeta as a major rather than secondary product of VIIa/TF. Our findings raise the possibility that IXabeta produced by the extrinsic pathway, and its ability to function within the intrinsic Xase complex to activate X may play a significant role in producing Xa necessary for both the initiation and sustained phases of the procoagulant response following vascular damage.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Washington Univ, Jewish Hosp, Div Hematol, St Louis, MO 63110 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Barnes-Jewish Hospital; Washington University (WUSTL)	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310A Abramson,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Krishnaswamy, Sriram/Z-4380-2019		NHLBI NIH HHS [HL-47465, HL-62523, HL-34462] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034462, R01HL062523, R01HL047465] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin AJ, 1998, PROTEIN EXPRES PURIF, V13, P136, DOI 10.1006/prep.1998.0877; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJAJ SP, 1983, BIOCHEMISTRY-US, V22, P4047, DOI 10.1021/bi00286a009; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Bedsted T, 2003, BIOCHEMISTRY-US, V42, P8143, DOI 10.1021/bi034363y; Bevington P. R., 1992, DATA REDUCTION ERROR, P141; Bjork I, 1997, ADV EXP MED BIOL, V425, P17; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; BROZE GJ, 1995, BLOOD COAGUL FIBRIN, V6, P7; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; Edgington TS, 1997, THROMB HAEMOSTASIS, V78, P401; ERHARDTSEN E, 1995, BLOOD COAGUL FIBRIN, V6, P388, DOI 10.1097/00001721-199507000-00004; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HOFFMAN M, 1995, BLOOD, V86, P1794, DOI 10.1182/blood.V86.5.1794.bloodjournal8651794; Huang ZF, 1997, BLOOD, V90, P944, DOI 10.1182/blood.V90.3.944.944_944_951; JESTY J, 1994, BIOCHEMISTRY-US, V33, P12686, DOI 10.1021/bi00208a020; JORDAN SP, 1992, BIOCHEMISTRY-US, V31, P5374, DOI 10.1021/bi00138a019; KIM DJ, 1994, BIOTECHNOL LETT, V16, P549, DOI 10.1007/BF00128598; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LINDHOUT T, 1995, THROMB HAEMOSTASIS, V74, P910; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; Mast AE, 2000, J BIOL CHEM, V275, P31715, DOI 10.1074/jbc.M006595200; Mast AE, 2002, ARTERIOSCL THROM VAS, V22, P2099, DOI 10.1161/01.ATV.0000042456.84190.F0; Nemerson Y, 1995, ADV EXP MED BIOL, V386, P157; NEMERSON Y, 1992, SEMIN HEMATOL, V29, P170; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NORDFANG O, 1991, THROMB HAEMOSTASIS, V66, P464; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; REPKE D, 1990, P NATL ACAD SCI USA, V87, P7623, DOI 10.1073/pnas.87.19.7623; RICK ME, 1982, BLOOD, V60, P744; Roberts HR, 1998, HAEMOPHILIA, V4, P331, DOI 10.1046/j.1365-2516.1998.440331.x; ROBERTS HR, 1998, THROMBOSIS HEMORRHAG, P773; RUF W, 1991, J BIOL CHEM, V266, P16256; Schmidt AE, 2003, TRENDS CARDIOVAS MED, V13, P39, DOI 10.1016/S1050-1738(02)00210-4; SEGEL IH, 1975, ENZYME KINETICS, P18; ZUR M, 1980, J BIOL CHEM, V255, P5703	58	62	63	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17241	17249		10.1074/jbc.M312827200	http://dx.doi.org/10.1074/jbc.M312827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963035	hybrid			2022-12-27	WOS:000220870400045
J	Papini, N; Anastasia, L; Tringali, C; Croci, G; Bresciani, R; Yamaguchi, K; Miyagi, T; Preti, A; Prinetti, A; Prioni, S; Sonnino, S; Tettamanti, G; Venerando, B; Monti, E				Papini, N; Anastasia, L; Tringali, C; Croci, G; Bresciani, R; Yamaguchi, K; Miyagi, T; Preti, A; Prinetti, A; Prioni, S; Sonnino, S; Tettamanti, G; Venerando, B; Monti, E			The plasma membrane-associated sialidase MmNEU3 modifies the ganglioside pattern of adjacent cells supporting its involvement in cell-to-cell interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; CARBOHYDRATE-CARBOHYDRATE INTERACTION; REACTIVE PROTEINS GLYCOSIDASES; SIGNAL-TRANSDUCTION; BOUND SIALIDASE; GROWTH-CONTROL; ADHESION; SURFACE; BRAIN; GLYCOSPHINGOLIPIDS	We describe herein the enzyme behavior of MmNEU3, the plasma membrane-associated sialidase from mouse (Mus musculus). MmNEU3 is localized at the plasma membrane as demonstrated directly by confocal microscopy analysis. In addition, administration of the radio-labeled ganglioside GD1a to MmNEU3-transfected cells, under conditions that prevent lysosomal activity, led to its hydrolysis into ganglioside GM1, further indicating the plasma membrane topology of MmNEU3. Metabolic labeling with [1-H-3] sphingosine allowed the characterization of the ganglioside patterns of COS-7 cells. MmNEU3 expression in COS-7 cells led to an extensive modification of the cell ganglioside pattern, i.e. GM3 and GD1a content was decreased to about one-third compared with mock-transfected cells. At the same time, a 35% increase in ganglioside GM1 content was observed. Mixed culture of MmNEU3-transfected cells with [1-H-3]sphingosine-labeled cells demonstrates that the enzyme present at the cell surface is able to recognize gangliosides exposed on the membrane of nearby cells. Under these experimental conditions, the extent of ganglioside pattern changes was a function of MmNEU3 transient expression. Overall, the variations in GM3, GD1a, and GM1 content were very similar to those observed in the case of [1-H-3]sphingosine-labeled MmNEU3-transfected cells, indicating that the enzyme mainly exerted its activity toward ganglioside substrates present at the surface of neighboring cells. These results indicate that the plasma membrane-associated sialidase MmNEU3 is able to hydrolyze ganglioside substrates in intact living cells at a neutral pH, mainly through cell-to-cell interactions.	Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Univ Milan, Sch Med, Ctr Excellence Neurodgenerat Dis, Dept Med Chem, I-20090 Segrate, Italy; Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan	University of Brescia; University of Milan	Monti, E (corresponding author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Viale Europa 11, I-25123 Brescia, Italy.	monti@med.unibs.it	Sonnino, Sandro/R-4154-2017; papini, nadia/M-2425-2017; Tringali, Cristina Alessandra/Q-7259-2017; Anastasia, Luigi/AAN-1964-2020; Bresciani, Roberto/AAA-9728-2020; Prinetti, Alessandro/R-4206-2017	Sonnino, Sandro/0000-0001-8180-5908; papini, nadia/0000-0003-4066-4955; Tringali, Cristina Alessandra/0000-0002-0632-6197; Anastasia, Luigi/0000-0002-0712-2161; Bresciani, Roberto/0000-0002-7881-7550; MONTI, Eugenio/0000-0002-4742-7445; Prinetti, Alessandro/0000-0003-0252-2593				Achyuthan KE, 2001, COMP BIOCHEM PHYS B, V129, P29, DOI 10.1016/S1096-4959(01)00372-4; Borgese N, 2003, J CELL BIOL, V161, P1013, DOI 10.1083/jcb.200303069; Brocca P, 1997, TRENDS GLYCOSCI GLYC, V9, P433, DOI 10.4052/tigg.9.433; CARTER HE, 1961, J LIPID RES, V228; CARTER WG, 1981, J CELL BIOL, V88, P138, DOI 10.1083/jcb.88.1.138; CHIARINI A, 1990, J NEUROCHEM, V55, P1576, DOI 10.1111/j.1471-4159.1990.tb04941.x; CHIARINI A, 1993, GLYCOCONJUGATE J, V10, P64, DOI 10.1007/BF00731189; Chigorno V, 1997, EUR J BIOCHEM, V250, P661, DOI 10.1111/j.1432-1033.1997.00661.x; Fantini J, 2000, GLYCOCONJUGATE J, V17, P173, DOI 10.1023/A:1026580905156; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P143, DOI 10.1023/A:1026524820177; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hasegawa T, 2000, J BIOL CHEM, V275, P14778; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kalka D, 2001, BIOCHEM BIOPH RES CO, V283, P989, DOI 10.1006/bbrc.2001.4864; Kopitz J, 1997, EUR J BIOCHEM, V248, P527, DOI 10.1111/j.1432-1033.1997.00527.x; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; Kopitz J, 2001, FEBS LETT, V491, P233, DOI 10.1016/S0014-5793(01)02207-4; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; Lukong KE, 2001, J BIOL CHEM, V276, P17286, DOI 10.1074/jbc.M100460200; MEIER EM, 1991, J BIOL CHEM, V266, P1879; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P787, DOI 10.1093/oxfordjournals.jbchem.a123126; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Monti E, 1999, GENOMICS, V57, P137, DOI 10.1006/geno.1999.5749; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; NYHOLM PG, 1993, BIOCHEMISTRY-US, V32, P1225, DOI 10.1021/bi00056a005; NYHOLM PG, 1990, CHEM PHYS LIPIDS, V52, P1, DOI 10.1016/0009-3084(90)90002-9; OHMAN R, 1970, BIOCHEMISTRY-US, V9, P3774, DOI 10.1021/bi00821a017; Olshefski R, 1996, FEBS LETT, V386, P11, DOI 10.1016/0014-5793(96)00392-4; PITTO M, 1992, NEUROCHEM INT, V21, P367, DOI 10.1016/0197-0186(92)90187-V; Prinetti A, 2001, J BIOL CHEM, V276, P21136, DOI 10.1074/jbc.M010666200; Prinetti A, 2000, J BIOL CHEM, V275, P11658, DOI 10.1074/jbc.275.16.11658; Proshin S, 2002, NEUROCHEM RES, V27, P841, DOI 10.1023/A:1020269326825; RAUVALA H, 1981, J CELL BIOL, V88, P127, DOI 10.1083/jcb.88.1.127; RIBONI L, 1992, FEBS LETT, V300, P188, DOI 10.1016/0014-5793(92)80193-K; RIBONI L, 1991, FEBS LETT, V287, P42, DOI 10.1016/0014-5793(91)80012-R; Rodriguez JA, 2001, J NEUROSCI, V21, P8387, DOI 10.1523/JNEUROSCI.21-21-08387.2001; Saito M, 1996, J NEUROCHEM, V66, P2205; Saito M, 1995, BIOL SIALIC ACIDS, P261, DOI [10.1007/978-1-4757-9504-2_8, DOI 10.1007/978-1-4757-9504-2_8]; Sambrook J., 2001, MOL CLONING LAB MANU; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song Y, 1998, J BIOL CHEM, V273, P2517, DOI 10.1074/jbc.273.5.2517; SONNINO S, 1994, CHEM PHYS LIPIDS, V71, P21, DOI 10.1016/0009-3084(94)02304-2; Sonnino S, 1996, GLYCOBIOLOGY, V6, P479, DOI 10.1093/glycob/6.5.479-e; SONNINO S, 1984, J LIPID RES, V25, P620; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; TOYOKUNI T, 1991, J LABELLED COMPD RAD, V29, P567, DOI 10.1002/jlcr.2580290508; Tringali C, 2004, J BIOL CHEM, V279, P3169, DOI 10.1074/jbc.M308381200; von Reitzenstein C, 2001, EUR J BIOCHEM, V268, P326, DOI 10.1046/j.1432-1327.2001.01883.x; Vyas AA, 2001, BIOCHIMIE, V83, P677, DOI 10.1016/S0300-9084(01)01308-6; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; Zhu JH, 1999, GLYCOBIOLOGY, V9, P985, DOI 10.1093/glycob/9.10.985	61	123	127	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16989	16995		10.1074/jbc.M400881200	http://dx.doi.org/10.1074/jbc.M400881200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970224	Green Published, hybrid			2022-12-27	WOS:000220870400014
J	Zuccato, E; Buratti, E; Stuani, C; Baralle, FE; Pagani, F				Zuccato, E; Buratti, E; Stuani, C; Baralle, FE; Pagani, F			An intronic polypyrimidine-rich element downstream of the donor site modulates cystic fibrosis transmembrane conductance regulator exon 9 alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT BINDING-PROTEIN; MESSENGER-RNA; VAS-DEFERENS; U1 SNRNP; CONGENITAL ABSENCE; 5'-SPLICE SITES; CFTR EXON-9; TIA-1; MUTATIONS; GENE	Two intronic elements, a polymorphic TGmTn locus at the end of intron 8 and an intronic splicing silencer in intron 9, regulate aberrant splicing of human cystic fibrosis transmembrane conductance regulator (CFTR) exon 9. Previous studies (Pagani, F., Buratti, E., Stuani, C., Romano, M., Zuccato, E., Niksic, M., Giglio, L., Faraguna, D., and Baralle, F. E. (2000) J. Biol. Chem. 275, 21041-21047 and Buratti, E., Dork, T., Zuccato, E., Pagani, F., Romano, M., and Baralle, F. E. (2001) Embo J. 20, 1774-1784) have demonstrated that trans-acting factors that bind to these sequences, TDP43 and Ser/Arg-rich proteins, respectively, mediate splicing inhibition. Here, we report the identification of two polypyrimidine-binding proteins, TIA-1 and polypyrimidine tract-binding protein (PTB), as novel players in the regulation of CFTR exon 9 splicing. In hybrid minigene experiments, TIA-1 induced exon inclusion, whereas PTB induced exon skipping. TIA-1 bound specifically to a polypyrimidine-rich controlling element (PCE) located between the weak 5'-splice site (ss) and the intronic splicing silencer. Mutants of the PCE polypyrimidine motifs did not bind TIA-1 and, in a splicing assay, did not respond to TIA-1 splicing enhancement. PTB antagonized in vitro TIA-1 binding to the PCE, but its splicing inhibition was independent of its binding to the PCE. Recruitment of U1 small nuclear RNA to the weak 5'-ss by complementarity also induced exon 9 inclusion, consistent with the facilitating role of TIA-1 in weak 5'-ss recognition by U1 small nuclear ribonucleoprotein. Interestingly, in the presence of a high number of TG repeats and a low number of T repeats in the TGmTn locus, TIA-1 activated a cryptic exonic 3'-ss. This effect was independent of both TIA-1 binding to the PCE and U1 small nuclear RNA recruitment to the 5'-ss. Moreover, it was abolished by deletion of either the TG or T sequence. These data indicate that, in CFTR exon 9, TIA-1 binding to the PCE recruits U1 small nuclear ribonucleoprotein to the weak 5'-ss and induces exon inclusion. The TIA-1-mediated alternative usage of the 3'-splice sites, which depends on the composition of the unusual TGmTn element, represents a new mechanism of splicing regulation by TIA-1.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Pagani, F (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	pagani@icgeb.org	Buratti, Emanuele/K-4691-2016	Buratti, Emanuele/0000-0002-1356-9074; Pagani, Franco/0000-0002-2678-3459	Telethon [GGP02453] Funding Source: Medline	Telethon(Fondazione Telethon)		Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; COHEN JB, 1994, P NATL ACAD SCI USA, V91, P10470, DOI 10.1073/pnas.91.22.10470; Cohn JA, 1998, NEW ENGL J MED, V339, P653, DOI 10.1056/NEJM199809033391002; Cuppens H, 1998, J CLIN INVEST, V101, P487, DOI 10.1172/JCI639; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Forch P, 2002, EMBO J, V21, P6882, DOI 10.1093/emboj/cdf668; Forch P, 2001, RNA, V7, P1185, DOI 10.1017/S1355838201010536; Gooding C, 1998, RNA, V4, P85; Gottschalk A, 1998, RNA, V4, P374; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; KAWAKAMI A, 1994, J IMMUNOL, V152, P4937; KAWAKAMI A, 1992, P NATL ACAD SCI USA, V89, P8681, DOI 10.1073/pnas.89.18.8681; Larriba S, 1998, HUM MOL GENET, V7, P1739, DOI 10.1093/hmg/7.11.1739; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; Mak V, 1997, HUM MOL GENET, V6, P2099, DOI 10.1093/hmg/6.12.2099; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; Niksic M, 1999, HUM MOL GENET, V8, P2339, DOI 10.1093/hmg/8.13.2339; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; Pagani F, 2000, J BIOL CHEM, V275, P21041, DOI 10.1074/jbc.M910165199; Pagani F, 2003, J BIOL CHEM, V278, P26580, DOI 10.1074/jbc.M212813200; Pagani F, 2002, NAT GENET, V30, P426, DOI 10.1038/ng858; Puig O, 1999, GENE DEV, V13, P569, DOI 10.1101/gad.13.5.569; Southby J, 1999, MOL CELL BIOL, V19, P2699; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799	35	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16980	16988		10.1074/jbc.M313439200	http://dx.doi.org/10.1074/jbc.M313439200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966131	hybrid			2022-12-27	WOS:000220870400013
J	Fornes, A; Nunez, E; Aragon, C; Lopez-Corcuera, B				Fornes, A; Nunez, E; Aragon, C; Lopez-Corcuera, B			The second intracellular loop of the glycine transporter 2 contains crucial residues for glycine transport and phorbol ester-induced regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE TRANSPORTER; PROTEIN-KINASE-C; TRANSMEMBRANE DOMAIN-I; SEROTONIN TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; GABA TRANSPORTER; CONFORMATIONAL EQUILIBRIUM; RECOMBINANT GLYT1; COCAINE BINDING; SYNTAXIN 1A	Na+ and Cl--coupled glycine transporters control the availability of glycine neurotransmitter in the synaptic cleft of inhibitory glycinergic pathways. In this report, we have investigated the involvement of the second intracellular loop of the neuronal glycine transporter 2 (GLYT2) on the protein conformational equilibrium and the regulation by 4alpha-phorbol 12 myristate 13-acetate (PMA). By substituting several charged (Lys-415, Lys-418, and Lys-422) and polar (Thr-419 and Ser-420) residues for different amino acids and monitoring plasma membrane expression and kinetic behavior, we found that residue Lys-422 is crucial for glycine transport. The introduction of a negative charge in 422, and to a lower extent in neighboring N-terminal residues, dramatically increases transporter voltage dependence as assessed by response to high potassium depolarizing conditions. In addition, [2-(trimethylammonium) ethyl] methanethiosulfonate accessibility revealed a conformational connection between Lys-422 and the glycine binding/permeation site. Finally, we show that the mutation of positions Thr-419, Ser-420, and mainly Lys-422 to acidic residues abolishes the PMA-induced inhibition of transport activity and the plasma membrane transporter internalization. Our results establish a new structural basis for the action of PMA on GLYT2 and suggest a complex nature of the PMA action on this glycine transporter.	Univ Autonoma Madrid, Ctr Biol Mol SeveroOchoa, Fac Ciencias, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Lopez-Corcuera, B (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol SeveroOchoa, Fac Ciencias, CSIC, E-28049 Madrid, Spain.	blopez@cbm.uam.es	Corcuera, Beatriz López/D-5188-2009; Aragon, Carmen/K-9783-2014	Corcuera, Beatriz López/0000-0002-0383-4241; Aragon, Carmen/0000-0001-8287-9386				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; Aragon C, 2003, EUR J PHARMACOL, V479, P249, DOI 10.1016/j.ejphar.2003.08.074; Barker EL, 1999, J NEUROSCI, V19, P4705; Beckman ML, 1998, J NEUROSCI, V18, P6103; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Chen NH, 2004, J BIOL CHEM, V279, P5508, DOI 10.1074/jbc.M306294200; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Geerlings A, 2000, FEBS LETT, V470, P51, DOI 10.1016/S0014-5793(00)01297-7; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; Gomeza J, 2003, NEURON, V40, P785, DOI 10.1016/S0896-6273(03)00672-X; Gomeza J, 2003, NEURON, V40, P797, DOI 10.1016/S0896-6273(03)00673-1; GONOVALEWSKY V, 1999, J BIOL CHEM, V274, P23020; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; Loland CJ, 2004, J BIOL CHEM, V279, P3228, DOI 10.1074/jbc.M304755200; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Lopez-Corcuera B, 2001, MOL MEMBR BIOL, V18, P13, DOI 10.1080/09687680120521; Lopez-Corcuera B, 2001, J BIOL CHEM, V276, P43463, DOI 10.1074/jbc.M107438200; Lopez-Corcuera B, 1998, J NEUROCHEM, V71, P2211; MacAulay N, 2003, J BIOL CHEM, V278, P28771, DOI 10.1074/jbc.M213023200; Martinez-Maza R, 2001, J BIOL CHEM, V276, P2168, DOI 10.1074/jbc.M006774200; Melikian HE, 1999, J NEUROSCI, V19, P7699; Nelson N, 1998, J NEUROCHEM, V71, P1785; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Nunez E, 2000, BRIT J PHARMACOL, V129, P200, DOI 10.1038/sj.bjp.0703049; Nunez E, 2000, BRIT J PHARMACOL, V129, P802, DOI 10.1038/sj.bjp.0703100; Ponce J, 2000, J BIOL CHEM, V275, P13856, DOI 10.1074/jbc.275.18.13856; QUIAN Y, 1997, J NEUROSCI, V17, P45; Quick MW, 1997, J NEUROSCI, V17, P2967; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; Roux MJ, 2000, NEURON, V25, P373, DOI 10.1016/S0896-6273(00)80901-0; Roux MJ, 2001, J BIOL CHEM, V276, P17699, DOI 10.1074/jbc.M009196200; Sakai N, 2000, NEUROCHEM INT, V36, P567, DOI 10.1016/S0197-0186(99)00160-6; SATO K, 1995, J NEUROCHEM, V65, P1967; SZATKOWSKI MS, 1989, J PHYSIOL-LONDON, V409, P103, DOI 10.1113/jphysiol.1989.sp017487; Willoughby D, 1999, PFLUG ARCH EUR J PHY, V438, P741, DOI 10.1007/s004240051101; ZAFRA F, 1995, J NEUROSCI, V15, P3952; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	48	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22934	22943		10.1074/jbc.M401337200	http://dx.doi.org/10.1074/jbc.M401337200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15010455	hybrid			2022-12-27	WOS:000221570900020
J	Deville, MA; Ouazana, R; Morle, F; Bernet, A				Deville, MA; Ouazana, R; Morle, F; Bernet, A			Disruption of the mechanism of long range activation within the human alpha-globin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY ELEMENT HS-40; TRANSGENIC MICE; ZETA-GLOBIN; GENE LOCUS; IN-VIVO; ENHANCER; UPSTREAM; EXPRESSION; SEQUENCE; PROMOTER	The human alpha- globin complex lies at the tip of the short arm of chromosome 16. It comprises three functional globin genes ( 5'-zeta2-alpha2-alpha1-3'), the expression of which is strictly dependent on a positive regulatory element located 40- kb upstream, HS- 40. This DNase I- hypersensitive site is the only known regulatory element displaying strong erythroid- specific enhancer activity within the human alpha- globin complex. How this enhancer activity is shared among different erythroid genes present in the same cluster without affecting the ubiquitous genes present within and around the complex is poorly understood. To address this issue, we used hybrid murine erythroleukemia cells containing a single copy of human chromosome 16 and targeted the insertion of different sequences downstream of HS- 40 by recombinase-mediated cassette exchange. We thus demonstrate that ( i) HS- 40- mediated erythroid- specific activation of the alpha- globin genes is impaired solely by the insertion of a promoter sequence and not a coding sequence, unless it is methylated, and that ( ii) the degree of transcriptional repression observed seems to be related directly to the transcriptional rate of the inserted promoter. Taken together, these results emphasize the importance of promoter sequences as the main targets for the activation mechanism of the human alpha- globin genes by HS- 40.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford OX3 9DS, England; CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France	University of Oxford; Centre National de la Recherche Scientifique (CNRS)	Deville, MA (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford OX3 9DS, England.	marie-alice.deville@imm.ox.ac.uk						Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; BERNET A, 1995, BLOOD, V86, P1202; BERNETGRANDAUDI A, 1994, CR ACAD SCI III-VIE, V314, P1; BRICKNER HE, 1991, J BIOL CHEM, V266, P15363; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; CRADDOCK CF, 1995, EMBO J, V14, P1718, DOI 10.1002/j.1460-2075.1995.tb07161.x; Esperet C, 2000, J BIOL CHEM, V275, P25831, DOI 10.1074/jbc.M001757200; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P9215, DOI 10.1093/nar/15.22.9215; GOURDON G, 1994, NUCLEIC ACIDS RES, V22, P4139, DOI 10.1093/nar/22.20.4139; HIGGS DR, 1993, BAILLIERE CLIN HAEM, V6, P117, DOI 10.1016/S0950-3536(05)80068-X; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; Huang BL, 1998, P NATL ACAD SCI USA, V95, P14669, DOI 10.1073/pnas.95.25.14669; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; Ohtsuki S, 1998, GENE DEV, V12, P547, DOI 10.1101/gad.12.4.547; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237, DOI 10.1093/nar/20.2.237; REN SC, 1993, BLOOD, V81, P1058; ROMBEL I, 1995, P NATL ACAD SCI USA, V92, P6454, DOI 10.1073/pnas.92.14.6454; SHARPE JA, 1992, EMBO J, V11, P4565, DOI 10.1002/j.1460-2075.1992.tb05558.x; Smith ZE, 1999, HUM MOL GENET, V8, P1373, DOI 10.1093/hmg/8.8.1373; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; VYAS P, 1995, GENOMICS, V29, P679, DOI 10.1006/geno.1995.9951; ZHANG QY, 1995, J BIOL CHEM, V270, P8501, DOI 10.1074/jbc.270.15.8501	23	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21793	21801		10.1074/jbc.M312298200	http://dx.doi.org/10.1074/jbc.M312298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14970235	hybrid			2022-12-27	WOS:000221417100016
J	Pereira, LA; Klejman, MP; Ruhlmann, C; Kavelaars, F; Oulad-Abdelghani, M; Timmers, HTM; Schultz, P				Pereira, LA; Klejman, MP; Ruhlmann, C; Kavelaars, F; Oulad-Abdelghani, M; Timmers, HTM; Schultz, P			Molecular architecture of the basal transcription factor B-TFIID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; YEAST SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; DNA-BINDING; CONFORMATIONAL CHANGE; FAMILY-MEMBER; TBP BINDING; MOT1; ATP	BTAF1 ( formerly named TAF(II)170/ TAF- 172) is an essential, evolutionarily conserved member of the SNF2-like family of ATPase proteins and together with TATA-binding protein ( TBP) forms the B- TFIID complex. BTAF1 has been proposed to play a key role in the dynamic regulation of TBP function in RNA polymerase II transcription. We have determined the structure of native B- TFIID purified from human cells by electron microscopy and by image analysis of single particles at a resolution of 28 Angstrom. B- TFIID is 15 x 9 nm in size and is organized into a large domain of about 170 kDa, which can be subdivided into two domains. Extending from this domain is a long thumb, which in turn is divided into subdomains of about 25, 15, and 35 kDa, the largest of which is located at the end of the thumb. Immunolabeling experiments localize the extreme carboxyl terminus of BTAF1 within the 170- kDa domain, whereas the amino terminus and TBP co- localize to the end of the protruding thumb. The central portion of BTAF1 localizes to the base of the thumb. Comparison of the native B- TFIID with its recombinant form shows that both share a similar domain organization. Collectively, these data provide the first structural model of the B- TFIID complex and map its key functional domains.	Univ Med Ctr Utrecht, Dept Physiol Chem, Div Biomed Genet, NL-3584 CG Utrecht, Netherlands; Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; Ecole Super Biotechnol Strasbourg, Pole API, F-67400 Illkirch Graffenstaden, France	Utrecht University; Utrecht University Medical Center; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Timmers, HTM (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Div Biomed Genet, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	h.t.m.timmers@med.uu.nl	abdelghani, mustapha oulad/A-5986-2017	abdelghani, mustapha oulad/0000-0002-8381-4397; schultz, patrick/0000-0002-7310-6186				Adamkewicz JI, 2000, J BIOL CHEM, V275, P21158, DOI 10.1074/jbc.M002639200; Adamkewicz JI, 2001, J BIOL CHEM, V276, P11883, DOI 10.1074/jbc.M010665200; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Andel F, 1999, SCIENCE, V286, P2153, DOI 10.1126/science.286.5447.2153; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Andrau JC, 2002, EMBO J, V21, P5173, DOI 10.1093/emboj/cdf485; Auble DT, 1999, MOL CELL BIOL, V19, P412; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; Darst RP, 2003, J BIOL CHEM, V278, P13216, DOI 10.1074/jbc.M211445200; Darst RP, 2001, EMBO J, V20, P2028, DOI 10.1093/emboj/20.8.2028; Dasgupta A, 2002, P NATL ACAD SCI USA, V99, P2666, DOI 10.1073/pnas.052397899; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; Geisberg JV, 2002, MOL CELL BIOL, V22, P8122, DOI 10.1128/MCB.22.23.8122-8134.2002; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Gumbs OH, 2003, EMBO J, V22, P3131, DOI 10.1093/emboj/cdg304; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Muldrow TA, 1999, MOL CELL BIOL, V19, P2835; Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; Pereira LA, 2003, GENE, V315, P1, DOI 10.1016/S0378-1119(03)00714-5; Pereira LA, 2001, MOL CELL BIOL, V21, P7523, DOI 10.1128/MCB.21.21.7523-7534.2001; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1994, J BIOL CHEM, V269, P23135; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Ranson NA, 2001, CELL, V107, P869, DOI 10.1016/S0092-8674(01)00617-1; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; vanderKnaap JA, 1997, P NATL ACAD SCI USA, V94, P11827, DOI 10.1073/pnas.94.22.11827; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Walhout AJM, 1997, NUCLEIC ACIDS RES, V25, P1493, DOI 10.1093/nar/25.8.1493	43	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21802	21807		10.1074/jbc.M313519200	http://dx.doi.org/10.1074/jbc.M313519200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14988402	hybrid			2022-12-27	WOS:000221417100017
J	Zdebik, AA; Cuffe, JE; Bertog, M; Korbmacher, C; Jentsch, TJ				Zdebik, AA; Cuffe, JE; Bertog, M; Korbmacher, C; Jentsch, TJ			Additional disruption of the ClC-2Cl(-) channel does not exacerbate the cystic fibrosis phenotype of cystic fibrosis transmembrane conductance regulator mouse models	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CHLORIDE CHANNEL; FETAL LUNG; EPITHELIAL-CELLS; DISEASE SEVERITY; CL-CONDUCTANCE; EXPRESSION; MICE; SECRETION; CFTR; GENE	Cystic fibrosis is a fatal inherited disease that is caused by mutations in the gene encoding a cAMP-activated chloride channel, the cystic fibrosis transmembrane conductance regulator (CFTR). It has been suggested that the cystic fibrosis phenotype might be modulated by the presence of other Cl- channels that are co-expressed with CFTR in some epithelial cells. Because the broadly expressed plasma membrane Cl- channel, ClC-2, is present in the tissues whose function is compromised in cystic fibrosis, we generated mice with a disruption of both Cl- channel genes. No morphological changes in their intestine, lung, or pancreas, tissues affected by cystic fibrosis, were observed in these mice. The mortality was not increased over that observed with a complete lack of functional CFTR. Surprisingly, mice expressing mutant CFTR ( deletion of phenylalanine 508), survived longer when ClC-2 was disrupted additionally. Currents across colonic epithelia were investigated in Ussing chamber experiments. The disruption of ClC-2, in addition to CFTR, did not decrease Cl- secretion. Colon expressing wild-type CFTR even secreted more Cl- when ClC-2 was disrupted, although CFTR transcript levels were unchanged. It is concluded that ClC-2 is unlikely to be a candidate rescue channel in cystic fibrosis. Our data are consistent with a model in which ClC-2 is located in the basolateral membrane.	ZMNH, D-20246 Hamburg, Germany; Univ Oxford, Univ Lab Physiol, Oxford OX1 3PT, England	University of Oxford	Jentsch, TJ (corresponding author), ZMNH, Falkenried 94, D-20246 Hamburg, Germany.	Jentsch@zmnh.uni-hamburg.de		Jentsch, Thomas/0000-0002-3509-2553; Bertog, Marko/0000-0002-1504-9582				Blaisdell CJ, 2004, AM J PHYSIOL-LUNG C, V286, pL420, DOI 10.1152/ajplung.00113.2003; Blaisdell CJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1248, DOI 10.1152/ajplung.2000.278.6.L1248; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; Catalan M, 2002, AM J PHYSIOL-GASTR L, V283, pG1004, DOI 10.1152/ajpgi.00158.2002; Chu SJ, 1999, AM J PHYSIOL-LUNG C, V276, pL614, DOI 10.1152/ajplung.1999.276.4.L614; Cuffe JE, 2002, J PHYSIOL-LONDON, V539, P209, DOI 10.1113/jphysiol.2001.013159; Duan D, 2000, CIRC RES, V86, pE63, DOI 10.1161/01.RES.86.4.e63; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; Grubb Barbara R., 1999, Physiological Reviews, V79, pS193; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; Gyomorey K, 2000, AM J PHYSIOL-CELL PH, V279, pC1787, DOI 10.1152/ajpcell.2000.279.6.C1787; Gyomorey K, 2000, PEDIATR RES, V48, P731; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Kajita H, 2000, J PHYSIOL-LONDON, V523, P313, DOI 10.1111/j.1469-7793.2000.t01-1-00313.x; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Kunzelmann E, 1997, PFLUG ARCH EUR J PHY, V435, P178, DOI 10.1007/s004240050498; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; LEVESQUE PC, 1992, CIRC RES, V71, P1002, DOI 10.1161/01.RES.71.4.1002; Lipecka J, 2002, AM J PHYSIOL-CELL PH, V282, pC805, DOI 10.1152/ajpcell.00291.2001; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Murray CB, 1996, AM J PHYSIOL-LUNG C, V271, pL829, DOI 10.1152/ajplung.1996.271.5.L829; MURRAY CB, 1995, AM J RESP CELL MOL, V12, P597, DOI 10.1165/ajrcmb.12.6.7766424; Nehrke K, 2002, J BIOL CHEM, V277, P23604, DOI 10.1074/jbc.M202900200; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P3879, DOI 10.1073/pnas.95.7.3879; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Speake T, 2002, J PHYSIOL-LONDON, V539, P385, DOI 10.1113/jphysiol.2001.014548; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Verkman AS, 2003, AM J PHYSIOL-CELL PH, V284, pC2, DOI 10.1152/ajpcell.00417.2002; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253	43	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22276	22283		10.1074/jbc.M309899200	http://dx.doi.org/10.1074/jbc.M309899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007059	hybrid			2022-12-27	WOS:000221417100075
J	Bahatyrova, S; Frese, RN; van der Werf, KO; Otto, C; Hunter, CN; Olsen, JD				Bahatyrova, S; Frese, RN; van der Werf, KO; Otto, C; Hunter, CN; Olsen, JD			Flexibility and size heterogeneity of the LH1 light harvesting complex revealed by atomic force microscopy - Functional significance for bacterial photosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-SPHAEROIDES; CORE COMPLEX; PUFX PROTEIN; RHODOSPIRILLUM-RUBRUM; LIGHT-HARVESTING-1 COMPLEXES; SPECTRAL HETEROGENEITY; CRYSTAL-STRUCTURE; DELETION MUTANT; ANTENNA COMPLEX; CAPSULATUS	Previous electron microscopic studies of bacterial RC-LH1 complexes demonstrated both circular and elliptical conformations of the LH1 ring, and this implied flexibility has been suggested to allow passage of quinol from the Q(B) site of the RC to the quinone pool prior to reduction of the cytochrome bc(1) complex. We have used atomic force microscopy to demonstrate that these are just two of many conformations for the LH1 ring, which displays large molecule-to-molecule variations, in terms of both shape and size. This atomic force microscope study has used a mutant lacking the reaction center complex, which normally sits within the LH1 ring providing a barrier to substantial changes in shape. This approach has revealed the inherent flexibility and lack of structural coherence of this complex in a reconstituted lipid bilayer at room temperature. Circular, elliptical, and even polygonal ring shapes as well as arcs and open rings have been observed for LH1; in contrast, no such variations in structure were observed for the LH2 complex under the same conditions. The basis for these differences between LH1 and LH2 is suggested to be the H-bonding patterns that stabilize binding of the bacteriochlorophylls to the LH polypeptides. The existence of open rings and arcs provides a direct visualization of the consequences of the relatively weak associations that govern the aggregation of the protomers (alpha(1)beta(1)Bchl(2)) comprising the LH1 complex. The demonstration that the linkage between adjacent protomer units is flexible and can even be uncoupled at room temperature in a detergent-free membrane bilayer provides a rationale for the dynamic separation of individual protomers, and we may now envisage experiments that seek to prove this active opening process.	Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomolec Res, Robert Hill Inst Photosynth Res, Sheffield S10 2TN, S Yorkshire, England; Univ Twente, Dept Sci & Technol, Biophys Tech Grp, NL-7500 AE Enschede, Netherlands	University of Sheffield; University of Twente	Olsen, JD (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomolec Res, Robert Hill Inst Photosynth Res, Sheffield S10 2TN, S Yorkshire, England.	j.olsen@sheffield.ac.uk	Otto, Cees/H-8421-2019	frese, raoul/0000-0001-8243-9954				APIZ M, 2003, J MOL BIOL, V326, P1523; BARZ WP, 1995, BIOCHEMISTRY-US, V34, P15248, DOI 10.1021/bi00046a033; Blankenship R. E, 2002, MOL MECH PHOTOSYNTHE, P61; CHANG MC, 1990, PHOTOCHEM PHOTOBIOL, V52, P873, DOI 10.1111/j.1751-1097.1990.tb08696.x; Cogdell RJ, 1996, PHOTOSYNTH RES, V48, P55, DOI 10.1007/BF00040996; Davis CM, 1997, BIOCHEMISTRY-US, V36, P3671, DOI 10.1021/bi962386p; FARCHAUS JW, 1989, EMBO J, V8, P47, DOI 10.1002/j.1460-2075.1989.tb03347.x; FARCHAUS JW, 1992, EMBO J, V11, P2779, DOI 10.1002/j.1460-2075.1992.tb05345.x; Fotiadis D, 2004, J BIOL CHEM, V279, P2063, DOI 10.1074/jbc.M310382200; Francia F, 1999, BIOCHEMISTRY-US, V38, P6834, DOI 10.1021/bi982891h; Frese RN, 2000, P NATL ACAD SCI USA, V97, P5197, DOI 10.1073/pnas.090083797; GERMEROTH L, 1993, BIOCHEMISTRY-US, V32, P5615, DOI 10.1021/bi00072a017; Jamieson SJ, 2002, EMBO J, V21, P3927, DOI 10.1093/emboj/cdf410; JONES MR, 1992, MOL MICROBIOL, V6, P1173, DOI 10.1111/j.1365-2958.1992.tb01556.x; Ketelaars M, 2002, BIOPHYS J, V83, P1701, DOI 10.1016/S0006-3495(02)73938-6; LILBURN TG, 1992, FEMS MICROBIOL LETT, V100, P155, DOI 10.1111/j.1574-6968.1992.tb05697.x; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MCGLYNN P, 1994, FEBS LETT, V349, P349, DOI 10.1016/0014-5793(94)00701-2; MILLER JF, 1987, BIOCHEMISTRY-US, V26, P5055, DOI 10.1021/bi00390a026; Moller C, 1999, BIOPHYS J, V77, P1150, DOI 10.1016/S0006-3495(99)76966-3; OLSEN JD, 1994, P NATL ACAD SCI USA, V91, P7124, DOI 10.1073/pnas.91.15.7124; Olsen JD, 1997, BIOCHEMISTRY-US, V36, P12625, DOI 10.1021/bi9710481; Ostafin AE, 2003, PHOTOSYNTH RES, V77, P53, DOI 10.1023/A:1024921115267; Pugh RJ, 1998, BBA-BIOENERGETICS, V1366, P301, DOI 10.1016/S0005-2728(98)00131-5; Recchia PA, 1998, BIOCHEMISTRY-US, V37, P11055, DOI 10.1021/bi980657l; Roszak AW, 2003, SCIENCE, V302, P1969, DOI 10.1126/science.1088892; Scheuring S, 2004, J BIOL CHEM, V279, P3620, DOI 10.1074/jbc.M310050200; Scheuring S, 2003, P NATL ACAD SCI USA, V100, P1690, DOI 10.1073/pnas.0437992100; Scheuring S, 2003, J MOL BIOL, V325, P569, DOI 10.1016/S0022-2836(02)01241-X; Scheuring S, 2001, EMBO J, V20, P3029, DOI 10.1093/emboj/20.12.3029; Siebert CA, 2004, EMBO J, V23, P690, DOI 10.1038/sj.emboj.7600092; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Stamouli A, 2003, BIOPHYS J, V84, P2483, DOI 10.1016/S0006-3495(03)75053-X; Sturgis JN, 1997, BIOCHEMISTRY-US, V36, P2772, DOI 10.1021/bi962524a; Todd JB, 1998, BIOCHEMISTRY-US, V37, P17458, DOI 10.1021/bi981114e; VANDERWERF KO, 1993, REV SCI INSTRUM, V64, P2892, DOI 10.1063/1.1144378; Walz T, 1998, J MOL BIOL, V282, P833, DOI 10.1006/jmbi.1998.2050; Westerhuis WHJ, 1999, J PHYS CHEM B, V103, P7733, DOI 10.1021/jp991816t; Westerhuis WHJ, 2002, BIOCHEMISTRY-US, V41, P8698, DOI 10.1021/bi011663b; Young CS, 1998, J BACTERIOL, V180, P4742, DOI 10.1128/JB.180.17.4742-4745.1998; Young CS, 1998, J BACTERIOL, V180, P1759, DOI 10.1128/JB.180.7.1759-1765.1998	41	94	102	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21327	21333		10.1074/jbc.M313039200	http://dx.doi.org/10.1074/jbc.M313039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14993213	Green Published, hybrid			2022-12-27	WOS:000221273800095
J	Henshaw, JL; Bolam, DN; Pires, VMR; Czjzek, M; Henrissat, B; Ferreira, LMA; Fontes, CMGA; Gilbert, HJ				Henshaw, JL; Bolam, DN; Pires, VMR; Czjzek, M; Henrissat, B; Ferreira, LMA; Fontes, CMGA; Gilbert, HJ			The family 6 carbohydrate binding module CmCBM6-2 contains two ligand-binding sites with distinct specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVIDANS XYLANASE 10A; CRYSTAL-STRUCTURE; CATALYTIC-ACTIVITY; GLUCAN-BINDING; DOMAIN; COMPLEX; RECOGNITION; REVEALS; OLIGOSACCHARIDE; MECHANISM	The microbial degradation of the plant cell wall is an important biological process, representing a major component of the carbon cycle. Enzymes that mediate the hydrolysis of this composite structure are modular proteins that contain non-catalytic carbohydrate binding modules (CBMs) that enhance catalytic activity. CBMs are grouped into sequence-based families, and in a previous study we showed that a family 6 CBM (CBM6) that interacts with xylan contains two potential ligand binding clefts, designated cleft A and cleft B. Mutagenesis and NMR studies showed that only cleft A in this protein binds to xylan. Family 6 CBMs bind to a range of polysaccharides, and it was proposed that the variation in ligand specificity observed in these proteins reflects the specific cleft that interacts with the target carbohydrate. Here the biochemical properties of the C-terminal cellulose binding CBM6 (CmCBM6-2) from Cellvibrio mixtus endoglucanase 5A were investigated. The CBM binds to the beta1,4-beta1,3-mixed linked glucans lichenan and barley beta-glucan, cello-oligosaccharides, insoluble forms of cellulose, the beta1,3-glucan laminarin, and xylooligosaccharides. Mutagenesis studies, informed by the crystal structure of the protein ( presented in the accompanying paper, Pires, V. M. R., Henshaw, J. L., Prates, J. A. M., Bolam, D., Ferreira, L. M. A. Fontes, C. M. G. A., Henrissat, B., Planas, A., Gilbert, H. J., Czjzek, M. ( 2004) J. Biol. Chem. 279, 21560 - 21568), show that both cleft A and B can accommodate cello-oligosaccharides and laminarin displays a preference for cleft A, whereas xylooligosaccharides exhibit absolute specificity for this site, and the beta1,4,-beta1,3-mixed linked glucans interact only with cleft B. The binding of CmCBM6-2 to insoluble cellulose involves synergistic interactions between cleft A and cleft B. These data show that CmCBM6-2 contains two binding sites that display differences in ligand specificity, supporting the view that distinct binding clefts with different specificities can contribute to the variation in ligand recognition displayed by family 6 CBMs. This is in sharp contrast to other CBM families, where variation in ligand binding is a result of changes in the topology of a single carbohydrate-binding site.	Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; CIISA, Fac Med Vet, P-1199 Lisbon, Portugal; CNRS, UMR6098, F-13402 Marseille, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France	Newcastle University - UK; Universidade de Lisboa; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Gilbert, HJ (corresponding author), Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk	Pires, Virginia/J-4799-2013; Henrissat, Bernard/J-2475-2012	Pires, Virginia/0000-0003-1307-3797; Henrissat, Bernard/0000-0002-3434-8588; Bolam, David/0000-0003-0314-3122; Ferreira, Luis/0000-0002-3543-9166; Fontes, Carlos/0000-0002-1219-9753				Abou Hachem M, 2000, BIOCHEM J, V345, P53, DOI 10.1042/0264-6021:3450053; Allouch J, 2003, J BIOL CHEM, V278, P47171, DOI 10.1074/jbc.M308313200; BLACK GW, 1995, BIOCHEM J, V307, P191, DOI 10.1042/bj3070191; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2003, J MOL BIOL, V327, P659, DOI 10.1016/S0022-2836(03)00152-9; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P14679, DOI 10.1021/bi015760g; Boraston AB, 2000, BIOCHEM J, V350, P933, DOI 10.1042/0264-6021:3500933; Boraston AB, 1999, ROY SOC CH, P202; BRETT CT, 1996, TOPICS PLANT FUNCTIO, V1; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Coutinho PM, 1999, ROY SOC CH, P3; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; FERREIRA LMA, 1990, BIOCHEM J, V269, P261, DOI 10.1042/bj2690261; Fontes CMGA, 1998, APPL MICROBIOL BIOT, V49, P552, DOI 10.1007/s002530051212; Freelove ACJ, 2001, J BIOL CHEM, V276, P43010, DOI 10.1074/jbc.M107143200; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Notenboom V, 2002, BIOCHEMISTRY-US, V41, P4246, DOI 10.1021/bi015865j; Pell G, 2003, BIOCHEMISTRY-US, V42, P9316, DOI 10.1021/bi0347510; Pires VMR, 2004, J BIOL CHEM, V279, P21560, DOI 10.1074/jbc.M401599200; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; Robert X, 2003, STRUCTURE, V11, P973, DOI 10.1016/S0969-2126(03)00151-5; Scharpf M, 2002, BIOCHEMISTRY-US, V41, P4255, DOI 10.1021/bi015866b; Simpson PJ, 1999, STRUCTURE, V7, P853, DOI 10.1016/S0969-2126(99)80108-7; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Skov LK, 2002, J BIOL CHEM, V277, P47741, DOI 10.1074/jbc.M207860200; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Williamson MP, 1997, BIOCHEMISTRY-US, V36, P7535, DOI 10.1021/bi9702896; WOOD TM, 1988, METHOD ENZYMOL, V160, P19; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011; Zverlov VV, 2001, MICROBIOL-SGM, V147, P621, DOI 10.1099/00221287-147-3-621	43	82	84	1	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21552	21559		10.1074/jbc.M401620200	http://dx.doi.org/10.1074/jbc.M401620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004011	hybrid			2022-12-27	WOS:000221273800121
J	Taru, H; Suzuki, T				Taru, H; Suzuki, T			Facilitation of stress-induced phosphorylation of beta-amyloid precursor protein family members by X11-like/Mint2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; C-JUN ACTIVATION; ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; SCAFFOLD PROTEINS; DEPENDENT REGULATION; JNK; METABOLISM; FE65; APP	beta-Amyloid precursor protein (APP) is the precursor of beta-amyloid (Abeta), which is implicated in Alzheimer's disease pathogenesis. APP complements amyloid precursor-like protein 2 (APLP2), and together they play essential physiological roles. Phosphorylation at the Thr(668) residue of APP ( with respect to the numbering conversion for the APP 695 isoform) and the Thr(736) residue of APLP2 ( with respect to the numbering conversion for the APLP2 763 isoform) in their cytoplasmic domains acts as a molecular switch for their protein-protein interaction and is implicated in neural function(s) and/or Alzheimer's disease pathogenesis. Here we demonstrate that both APP and APLP2 can be phosphorylated by JNK at the Thr(668) and Thr(736) residues, respectively, in response to cellular stress. X11-like (X11L, also referred to as X11beta and Mint2), which is a member of the mammalian LIN-10 protein family and a possible regulator of Abeta production, elevated APP and APLP2 phosphorylation probably by facilitating JNK-mediated phosphorylation, whereas other members of the family, X11 and X11L2, did not. These observations revealed an involvement of X11L in the phosphorylation of APP family proteins in cellular stress and suggest that X11L protein may be important in the physiology of APP family proteins as well as in the regulation of Abeta production.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Suzuki, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tsuzuki@pharm.hokudai.ac.jp	Suzuki, Toshiharu/B-5342-2013; Taru, Hidenori/B-7059-2009					Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Ando K, 1999, J NEUROSCI, V19, P4421; Aplin AE, 1996, J NEUROCHEM, V67, P699; Araki Y, 2003, J BIOL CHEM, V278, P49448, DOI 10.1074/jbc.M306024200; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heber S, 2000, J NEUROSCI, V20, P7951; Ho CS, 2002, J BIOL CHEM, V277, P27021, DOI 10.1074/jbc.M201823200; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Lee DS, 2000, J BIOL CHEM, V275, P23134, DOI 10.1074/jbc.C000302200; Lee MS, 2003, J CELL BIOL, V163, P83, DOI 10.1083/jcb.200301115; Matsuda S, 2001, J NEUROSCI, V21, P6597; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Savage MJ, 2002, J NEUROSCI, V22, P3376; Scheinfeld MH, 2003, J BIOL CHEM, V278, P42058, DOI 10.1074/jbc.M304853200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sisodia SS, 2002, SCIENCE, V295, P805, DOI 10.1126/science.1069661; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; Sumioka A, 2003, BIOCHEM J, V374, P261, DOI 10.1042/BJ20030489; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Suzuki T, 1997, BIOCHEMISTRY-US, V36, P4643, DOI 10.1021/bi962618k; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zhu XW, 2001, MECH AGEING DEV, V123, P39, DOI 10.1016/S0047-6374(01)00342-6	50	40	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21628	21636		10.1074/jbc.M312007200	http://dx.doi.org/10.1074/jbc.M312007200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14970211	hybrid			2022-12-27	WOS:000221273800129
J	Beuret, N; Stettler, H; Renold, A; Rutishauser, J; Spiess, M				Beuret, N; Stettler, H; Renold, A; Rutishauser, J; Spiess, M			Expression of regulated secretory proteins is sufficient to generate granule-like structures in constitutively secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; DISULFIDE-BONDED LOOP; B SECRETOGRANIN-I; CHROMOGRANIN-B; ASIALOGLYCOPROTEIN RECEPTOR; CARBOXYPEPTIDASE E; MEMBRANE-PROTEINS; ON/OFF SWITCH; PC12 CELLS; PATHWAY	The formation of secretory granules and regulated secretion are generally assumed to occur only in specialized endocrine, neuronal, or exocrine cells. We discovered that regulated secretory proteins such as the hormone precursors pro-vasopressin, pro-oxytocin, and pro-opiomelanocortin, as well as the granins secretogranin II and chromogranin B but not the constitutive secretory protein alpha(1)-protease inhibitor, accumulate in granular structures at the Golgi and in the cell periphery in transfected COS-1 fibroblast cells. The accumulations were observed in 30-70% of the transfected cells expressing the pro-hormones and for virtually all of the cells expressing the granins. Similar structures were also generated in other cell lines believed to be lacking a regulated secretory pathway. The accumulations resembled secretory granules morphologically in immunofluorescence and electron microscopy. They were devoid of markers of the endoplasmic reticulum, endosomes, and lysosomes but in part stained positive for the trans-Golgi network marker TGN46, consistent with their formation at the trans-Golgi network. When different regulated proteins were coexpressed, they were frequently found in the same granules, whereas alpha(1)-protease inhibitor could not be detected in accumulations formed by secretogranin II, demonstrating segregation of regulated from constitutive secretory proteins. In pulse-chase experiments, significant intracellular storage of secretogranin II and chromogranin B was observed and secretion of retained secretogranin II was stimulated with the calcium ionophore A23187. The results suggest that expression of regulated cargo proteins is sufficient to generate structures that resemble secretory granules in the background of constitutively secreting cells, supporting earlier proposals on the mechanism of granule formation.	Univ Basel, Bioctr, CH-4056 Basel, Switzerland; Univ Basel Hosp, CH-4031 Basel, Switzerland	University of Basel; University of Basel	Spiess, M (corresponding author), Univ Basel, Bioctr, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Martin.Spiess@unibas.ch		Spiess, Martin/0000-0001-7139-0550				Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Beuret N, 1999, J BIOL CHEM, V274, P18965, DOI 10.1074/jbc.274.27.18965; Borgonovo B, 2002, NAT CELL BIOL, V4, P955, DOI 10.1038/ncb888; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Chavez RA, 1996, J CELL BIOL, V133, P1177, DOI 10.1083/jcb.133.6.1177; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Cross PC., 1993, CELL TISSUE ULTRASTR; Day R, 2003, TRENDS ENDOCRIN MET, V14, P10, DOI 10.1016/S1043-2760(02)00011-5; Dittie AS, 1996, J CELL BIOL, V132, P523, DOI 10.1083/jcb.132.4.523; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; Kim T, 2003, TRENDS ENDOCRIN MET, V14, P56, DOI 10.1016/S1043-2760(02)00041-3; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; KIRCHMAIR R, 1993, NEUROSCIENCE, V53, P359, DOI 10.1016/0306-4522(93)90200-Y; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LEITINGER B, 1994, J BIOL CHEM, V269, P8115; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Natori S, 1996, P NATL ACAD SCI USA, V93, P4431, DOI 10.1073/pnas.93.9.4431; Ninomiya Y, 1996, J BIOL CHEM, V271, P17751, DOI 10.1074/jbc.271.30.17751; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; Rustom A, 2002, TRAFFIC, V3, P279, DOI 10.1034/j.1600-0854.2002.030405.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; VOORBERG J, 1993, EMBO J, V12, P749, DOI 10.1002/j.1460-2075.1993.tb05709.x; Wacker I, 1997, J CELL SCI, V110, P1453	37	97	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20242	20249		10.1074/jbc.M310613200	http://dx.doi.org/10.1074/jbc.M310613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996840	hybrid			2022-12-27	WOS:000221164500101
J	Davis, J; Xu, F; Deane, R; Romanov, G; Previti, ML; Zeigler, K; Zlokovic, BV; Van Nostrand, WE				Davis, J; Xu, F; Deane, R; Romanov, G; Previti, ML; Zeigler, K; Zlokovic, BV; Van Nostrand, WE			Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; MOUSE MODEL; A-BETA; CEREBROSPINAL-FLUID; ANGIOPATHY; TRANSPORT; PEPTIDE; HEMORRHAGE; CLEARANCE	Cerebrovascular deposition of amyloid beta-protein (Abeta) is a common pathological feature of Alzheimer's disease and related disorders. In particular, the Dutch E22Q and Iowa D23N mutations in Abeta cause familial cerebrovascular amyloidosis with abundant diffuse amyloid plaque deposits. Both of these charge-altering mutations enhance the fibrillogenic and pathogenic properties of Abeta in vitro. Here, we describe the generation of several transgenic mouse lines (Tg-SwDI) expressing human neuronal Abeta precursor protein (AbetaPP) harboring the Swedish K670N/M671L and vasculotropic Dutch/Iowa E693Q/D694N mutations under the control of the mouse Thy1.2 promoter. Tg-SwDI mice expressed transgenic human AbetaPP only in the brain, but at levels below those of endogenous mouse AbetaPP. Despite the paucity of human AbetaPP expression, quantitative enzyme-linked immunosorbent assay measurements revealed that Tg-SwDI mice developed early-onset and robust accumulation of Abeta in the brain with high association with isolated cerebral microvessels. Tg-SwDI mice exhibited striking perivascular/vascular Abeta deposits that markedly increased with age. The vascular Abeta accumulations were fibrillar, exhibiting strong thioflavin S staining, and occasionally presented signs of microhemorrhage. In addition, numerous largely diffuse, plaque-like structures were observed starting at 3 months of age. In vivo transport studies demonstrated that Dutch/Iowa mutant Abeta was more readily retained in the brain compared with wild-type Abeta. These results with Tg-SwDI mice demonstrate that overexpression of human AbetaPP is not required for early-onset and robust accumulation of both vascular and parenchymal Abeta in mouse brain.	SUNY Stony Brook, Hlth Sci Ctr, Dept Med, Stony Brook, NY 11794 USA; Univ Rochester, Med Ctr, Dept Neurosurg, Frank P Smith Labs Neurosurg, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Div Neurovasc Biol, Rochester, NY 14642 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Rochester; University of Rochester	Van Nostrand, WE (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Med, T-15-081, Stony Brook, NY 11794 USA.	William.VanNostrand@stonybrook.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034467, R01NS036645, R01NS034467] Funding Source: NIH RePORTER; NIA NIH HHS [AG 16233] Funding Source: Medline; NINDS NIH HHS [NS 36645, NS 34467] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bading JR, 2002, J DRUG TARGET, V10, P359, DOI 10.1080/10611860290031831; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Carro E, 2002, NAT MED, V8, P1390, DOI 10.1038/nm793; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; DEMATTOS RB, 2003, ABETA METABOLISM ALZ, P123; DICKSON DW, 1990, ACTA NEUROPATHOL, V79, P486, DOI 10.1007/BF00296107; Fryer JD, 2003, J NEUROSCI, V23, P7889; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gomori G, 1936, AM J PATHOL, V12, P655; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Martel CL, 1997, J NEUROCHEM, V69, P1995; Matsuoka Y, 2003, J NEUROSCI, V23, P29; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Monro OR, 2002, NEUROBIOL AGING, V23, P405, DOI 10.1016/S0197-4580(01)00317-7; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; ROZEMULLER AJM, 1993, AM J PATHOL, V142, P1449; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; Van Dorpe J, 2000, AM J PATHOL, V157, P1283, DOI 10.1016/S0002-9440(10)64644-5; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; VANNOSTRAND WE, 1989, NATURE, V341, P546; Vinters Harry V, 2003, Adv Neurol, V92, P105; WATTENDORFF AR, 1995, J NEUROL NEUROSUR PS, V59, P699; Weller RO, 2002, ANN NY ACAD SCI, V977, P162, DOI 10.1111/j.1749-6632.2002.tb04812.x; Weller RO, 1998, AM J PATHOL, V153, P725, DOI 10.1016/S0002-9440(10)65616-7; Winkler DT, 2001, J NEUROSCI, V21, P1619, DOI 10.1523/JNEUROSCI.21-05-01619.2001; ZLOKOVIC BV, 1993, J BIOL CHEM, V268, P8019; Zlokovic BV, 2000, NAT MED, V6, P718, DOI 10.1038/77397; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	44	276	286	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20296	20306		10.1074/jbc.M312946200	http://dx.doi.org/10.1074/jbc.M312946200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985348	hybrid			2022-12-27	WOS:000221164500107
J	Ye, S; Vakonakis, I; Ioerger, TR; LiWang, AC; Sacchettini, JC				Ye, S; Vakonakis, I; Ioerger, TR; LiWang, AC; Sacchettini, JC			Crystal structure of circadian clock protein KaiA from Synechococcus elongatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN; PHOSPHORYLATION; EXPRESSION; PROGRAM; SYSTEMS	The circadian clock found in Synechococcus elongatus, the most ancient circadian clock, is regulated by the interaction of three proteins, KaiA, KaiB, and KaiC. While the precise function of these proteins remains unclear, KaiA has been shown to be a positive regulator of the expression of KaiB and KaiC. The 2.0-Angstrom structure of KaiA of S. elongatus reported here shows that the protein is composed of two independently folded domains connected by a linker. The NH2-terminal pseudo-receiver domain has a similar fold with that of bacterial response regulators, whereas the COOH-terminal four-helix bundle domain is novel and forms the interface of the 2-fold-related homodimer. The COOH-terminal four-helix bundle domain has been shown to contain the KaiC binding site. The structure suggests that the KaiB binding site is covered in the dimer interface of the KaiA "closed" conformation, observed in the crystal structure, which suggests an allosteric regulation mechanism.	Texas A&M Univ, Ctr Struct Biol, Dept Biochem & Biophys, College Stn, TX 77843 USA; Inst Biosci & Technol, Ctr Struct Biol, Houston, TX 77030 USA; Texas A&M Univ, Dept Comp Sci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	LiWang, AC (corresponding author), Texas A&M Univ, Ctr Struct Biol, Dept Biochem & Biophys, College Stn, TX 77843 USA.	andy-liwang@tamu.edu; sacchett@tamu.edu	LiWang, Andy/AAE-5205-2020	LiWang, Andy/0000-0003-4741-6946	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410, R56GM064576, R01GM064576] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 064576, GM 62410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BUNNING E, 1973, P NATL ACAD SCI USA, V70, P3387, DOI 10.1073/pnas.70.12.3387; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; Claridge-Chang A, 2001, NEURON, V32, P657, DOI 10.1016/S0896-6273(01)00515-3; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Durbin R., 1998, BIOL SEQUENCE ANAL P; Dvornyk V, 2003, P NATL ACAD SCI USA, V100, P2495, DOI 10.1073/pnas.0130099100; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI 10.1073/pnas.222467299; Iwasaki H, 1999, EMBO J, V18, P1137, DOI 10.1093/emboj/18.5.1137; Kageyama H, 2003, J BIOL CHEM, V278, P2388, DOI 10.1074/jbc.M208899200; Kitayama Y, 2003, EMBO J, V22, P2127, DOI 10.1093/emboj/cdg212; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leipe DD, 2000, GENOME RES, V10, P5; LIANG DC, 1994, BIOPHYS CHEM, V50, P63, DOI 10.1016/0301-4622(94)85020-8; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mori T, 2002, P NATL ACAD SCI USA, V99, P17203, DOI 10.1073/pnas.262578499; Nishimura H, 2002, MICROBIOL-SGM, V148, P2903, DOI 10.1099/00221287-148-9-2903; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAO GM, 1995, J MOL EVOL, V40, P136, DOI 10.1007/BF00167109; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Taniguchi Y, 2001, FEBS LETT, V496, P86, DOI 10.1016/S0014-5793(01)02408-5; Vakonakis L, 2004, P NATL ACAD SCI USA, V101, P1479, DOI 10.1073/pnas.0305516101; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; Williams SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI 10.1073/pnas.232517099; Xu Y, 2003, EMBO J, V22, P2117, DOI 10.1093/emboj/cdg168; Yan OY, 1998, P NATL ACAD SCI USA, V95, P8660, DOI 10.1073/pnas.95.15.8660	36	81	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20511	20518		10.1074/jbc.M400077200	http://dx.doi.org/10.1074/jbc.M400077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15007067	hybrid			2022-12-27	WOS:000221164500130
J	Suico, MA; Yoshida, H; Seki, Y; Uchikawa, T; Lu, Z; Shuto, T; Matsuzaki, K; Nakao, M; Li, JD; Kai, H				Suico, MA; Yoshida, H; Seki, Y; Uchikawa, T; Lu, Z; Shuto, T; Matsuzaki, K; Nakao, M; Li, JD; Kai, H			Myeloid Elf-1-like factor, an ETS transcription factor, up-regulates lysozyme transcription in epithelial cells through interaction with promyelocytic leukemia protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PML-NUCLEAR-BODIES; PRIMARY BILIARY-CIRRHOSIS; DNA-BINDING; TUMOR-SUPPRESSOR; FACTOR MEF; RAR-ALPHA; SP100; P53; DOMAINS; TARGET	Myeloid elf-1-like factor (MEF) or Elf4, which is a member of the ETS transcription factor family, up-regulates the basal expression of lysozyme gene in epithelial cells and is constitutively localized in the nucleus. The mammalian cell nucleus is organized into distinct nuclear domains or compartments that are essential for diverse physiological processes. Promyelocytic leukemia (PML) nuclear body or nuclear domain 10 is one of the nuclear domains and is involved in tumor suppression and regulation of transcription. Here, we investigate the role of PML nuclear body in MEF transactivation. We show that PML, but not Sp100, induced the accumulation of MEF in PML nuclear bodies and that MEF and PML physically interacted. This interaction stimulated MEF transcriptional activity, resulting in the up-regulation of endogenous lysozyme expression. Amino acids 348-517 of MEF were required for the accumulation of MEF in PML nuclear bodies and up-regulation of lysozyme transcription, which is enhanced by PML. Moreover, the C-terminal region of MEF spanning amino acids 477-517 was the putative region required for interaction between MEF and PML as determined with the use of the mammalian two-hybrid system. In addition, heat-shock treatment induced the accumulation of MEF in endogenous PML nuclear bodies and enhanced MEF transactivation of lysozyme gene. Thus, the recruitment of MEF to PML nuclear bodies may partly regulate lysozyme transcription in epithelial cells.	Kumamoto Univ, Fac Med & Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan; Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, Kumamoto 8600811, Japan; Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA USA	Kumamoto University; Kumamoto University; House Research Institute; University of Southern California	Kai, H (corresponding author), Kumamoto Univ, Fac Med & Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan.	hirokai@gpo.kumamoto-u.jp.ac		Li, Jian-Dong/0000-0002-5593-050X				Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Cowley DO, 2000, GENE DEV, V14, P366; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Eskiw CH, 2003, J CELL SCI, V116, P4455, DOI 10.1242/jcs.00758; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jiang WQ, 1996, EXP CELL RES, V229, P289, DOI 10.1006/excr.1996.0374; Kai H, 1999, J BIOL CHEM, V274, P20098, DOI 10.1074/jbc.274.29.20098; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Lacorazza HD, 2002, IMMUNITY, V17, P437, DOI 10.1016/S1074-7613(02)00422-3; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Matsuzaki K, 2003, GENES CELLS, V8, P275, DOI 10.1046/j.1365-2443.2003.00632.x; Miyazaki Y, 1996, ONCOGENE, V13, P1721; Muller S, 1999, J VIROL, V73, P5137; Nefkens I, 2003, J CELL SCI, V116, P513, DOI 10.1242/jcs.00253; Negorev D, 2001, J CELL SCI, V114, P59; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seki Y, 2002, CANCER RES, V62, P6579; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Spector DL, 2001, J CELL SCI, V114, P2891; STERNSDORF T, 1995, SCAND J IMMUNOL, V42, P257, DOI 10.1111/j.1365-3083.1995.tb03652.x; Suico MA, 2002, BBA-GENE STRUCT EXPR, V1577, P113, DOI 10.1016/S0167-4781(02)00370-6; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Topcu Z, 1999, ONCOGENE, V18, P7091, DOI 10.1038/sj.onc.1203201; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463	41	21	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19091	19098		10.1074/jbc.M312439200	http://dx.doi.org/10.1074/jbc.M312439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976184	hybrid			2022-12-27	WOS:000221041500122
J	Ivanina, T; Varon, D; Peleg, S; Rishal, I; Porozov, Y; Dessauer, CW; Keren-Raifman, T; Dascal, N				Ivanina, T; Varon, D; Peleg, S; Rishal, I; Porozov, Y; Dessauer, CW; Keren-Raifman, T; Dascal, N			G alpha(i1) and G alpha(i3) differentially interact with, and regulate, the G protein-activated K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; POTASSIUM CHANNEL; ATRIAL MYOCYTES; MOLECULAR-BASIS; BINDING-SITES; ALPHA-SUBUNIT; C-TERMINUS; RECEPTORS; IDENTIFICATION; GIRK1	G protein-activated K+ channels (GIRKs; Kir3) are activated by direct binding of Gbetagamma subunits released from heterotrimeric G proteins. In native tissues, only pertussis toxin-sensitive G proteins of the G(i/o) family, preferably Galpha(i3) and Galpha(i2), are donors of Gbetagamma for GIRK. How this specificity is achieved is not known. Here, using a pull-down method, we confirmed the presence of Galpha(i3-GDP) binding site in the N terminus of GIRK1 and identified novel binding sites in the N terminus of GIRK2 and in the C termini of GIRK1 and GIRK2. The non-hydrolyzable GTP analog, guanosine 5'-3-O-(thio) triphosphate, reduced the binding of Galpha(i3) by a factor of 2-4. Galpha(i1-GDP) bound to GIRK1 and GIRK2 much weaker than Galpha(i3-GDP). Titrated expression of components of signaling pathway in Xenopus oocytes and their activation by m2 muscarinic receptors revealed that G(i3) activates GIRK more efficiently than G(i1), as indicated by larger and faster agonist-evoked currents. Activation of GIRK by purified Gbetagamma in excised membrane patches was strongly augmented by coexpression of Galpha(i3) and less by Galpha(i1). Differences in physical interactions of GIRK with GDP-bound Galpha subunits, or Galphabetagamma heterotrimers, may dictate different extents of Galphabetagamma anchoring, influence the efficiency of GIRK activation by Gbetagamma, and play a role in determining signaling specificity.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Univ Texas, Houston Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	Tel Aviv University; Sackler Faculty of Medicine; University of Texas System; University of Texas Health Science Center Houston	Dascal, N (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.	dascaln@post.tau.ac.il	Porozov, Yuri/AAD-5285-2019; Porozov, Yuri/N-9088-2016; RISHAL, IDA/K-1691-2012; Dascal, Nathan/O-3915-2015; Dessauer, Carmen/N-6933-2018	Porozov, Yuri/0000-0002-5450-3135; Dascal, Nathan/0000-0002-5397-4146; Dessauer, Carmen/0000-0003-1210-4280	NIGMS NIH HHS [GM60419, GM68493, R01 GM060419-04, R01 GM060419] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068493, R01GM060419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benians A, 2003, J BIOL CHEM, V278, P10851, DOI 10.1074/jbc.M212299200; Bichet D, 2003, NAT REV NEUROSCI, V4, P957, DOI 10.1038/nrn1244; Chen L, 2002, P NATL ACAD SCI USA, V99, P8430, DOI 10.1073/pnas.122682899; Chidiac P, 1998, BIOCHEM PHARMACOL, V55, P549, DOI 10.1016/S0006-2952(97)00361-4; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Cohen NA, 1996, J BIOL CHEM, V271, P32301, DOI 10.1074/jbc.271.50.32301; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Dascal N, 2001, TRENDS ENDOCRIN MET, V12, P391, DOI 10.1016/S1043-2760(01)00475-1; Dobrev D, 2001, CIRCULATION, V104, P2551, DOI 10.1161/hc4601.099466; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Flagg TP, 2002, J PHYSIOL-LONDON, V544, P351, DOI 10.1113/jphysiol.2002.027581; FUNG BKK, 1983, J BIOL CHEM, V258, P503; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Guo Y, 2002, J BIOL CHEM, V277, P48289, DOI 10.1074/jbc.M207987200; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; He C, 2002, J BIOL CHEM, V277, P6088, DOI 10.1074/jbc.M104851200; Hille, 2002, ION CHANNELS EXCITAB; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ikeda K, 2002, NEUROSCI RES, V44, P121, DOI 10.1016/S0168-0102(02)00094-9; Ivanina T, 2003, J BIOL CHEM, V278, P29174, DOI 10.1074/jbc.M304518200; Jeong SW, 1998, NEURON, V21, P1201, DOI 10.1016/S0896-6273(00)80636-4; KANAHO Y, 1989, CELL SIGNAL, V1, P553, DOI 10.1016/0898-6568(89)90063-6; Kawai Y, 1996, J MOL CELL CARDIOL, V28, P1555, DOI 10.1006/jmcc.1996.0146; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Leaney JL, 2000, P NATL ACAD SCI USA, V97, P5651, DOI 10.1073/pnas.080572297; Leaney JL, 2000, J BIOL CHEM, V275, P921, DOI 10.1074/jbc.275.2.921; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; Logothetis DE, 1999, J PHYSIOL-LONDON, V520, P630, DOI 10.1111/j.1469-7793.1999.00630.x; LUETJE CW, 1988, J BIOL CHEM, V263, P13357; Medina I, 2000, J BIOL CHEM, V275, P29709, DOI 10.1074/jbc.M004989200; MIGEON JC, 1995, J BIOL CHEM, V270, P16070, DOI 10.1074/jbc.270.27.16070; Mitrovic I, 2003, P NATL ACAD SCI USA, V100, P271, DOI 10.1073/pnas.0136822100; Mullner C, 2003, BIOPHYS J, V84, P1399, DOI 10.1016/S0006-3495(03)74954-6; Mullner C., 2000, J GEN PHYSIOL, V115, P627; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; Sarvazyan NA, 2002, BIOCHEMISTRY-US, V41, P12858, DOI 10.1021/bi026212l; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Sorota S, 1999, J PHYSIOL-LONDON, V514, P413, DOI 10.1111/j.1469-7793.1999.413ae.x; Sowell MO, 1997, P NATL ACAD SCI USA, V94, P7921, DOI 10.1073/pnas.94.15.7921; Stanfield PR, 2002, REV PHYSIOL BIOCH P, V145, P47, DOI 10.1007/BFb0116431; Takano K, 1997, J PHYSIOL-LONDON, V502, P559, DOI 10.1111/j.1469-7793.1997.559bj.x; Valenzuela D, 1997, P NATL ACAD SCI USA, V94, P1727, DOI 10.1073/pnas.94.5.1727; Vorobiov D, 2000, J BIOL CHEM, V275, P4166, DOI 10.1074/jbc.275.6.4166; Wellner-Kienitz MC, 2001, J BIOL CHEM, V276, P37347, DOI 10.1074/jbc.M106234200; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang D., 2000, J DESERT RES, V20, P59	60	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17260	17268		10.1074/jbc.M313425200	http://dx.doi.org/10.1074/jbc.M313425200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963032	hybrid			2022-12-27	WOS:000220870400047
J	Shimura, H; Miura-Shimura, Y; Kosik, KS				Shimura, H; Miura-Shimura, Y; Kosik, KS			Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE 2A; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; NEURODEGENERATIVE DISORDERS; ALPHA-SYNUCLEIN; NEURON SURVIVAL; NERVOUS-SYSTEM; RAT-BRAIN; PHOSPHORYLATION	Pathological hyperphosphorylated tau is the principal component of paired helical filaments, a pathological hallmark of Alzheimer disease (AD) and a strong candidate for a neurotoxic role in AD and other neurodegenerative disorders. Here we show that heat shock protein 27 (Hsp27) preferentially binds pathological hyperphosphorylated tau and paired helical filaments tau directly but not non-phosphorylated tau. The formation of this complex altered the conformation of pathological hyperphosphorylated tau and reduced its concentration by facilitating its degradation and dephosphorylation. Moreover, Hsp27 rescues pathological hyperphosphorylated tau-mediated cell death. Therefore, Hsp27 is likely to provide a neuroprotective effect in AD and other tauopathies.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Inst Med,Dept Neurol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kosik, KS (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Inst Med,Dept Neurol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	kkosik@rics.bwh.harvard.edu	shimura, hideki/AAA-2864-2020					Armstrong CL, 2001, J COMP NEUROL, V434, P262, DOI 10.1002/cne.1176; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; Fath T, 2002, J NEUROSCI, V22, P9733; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Geschwind DH, 2003, NEURON, V40, P457, DOI 10.1016/S0896-6273(03)00681-0; Gong CX, 2001, BRAIN RES PROTOC, V6, P134, DOI 10.1016/S1385-299X(00)00046-5; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Hall Garth F., 1999, J Alzheimers Dis, V1, P379; Hopkins DA, 1998, EXP NEUROL, V153, P173, DOI 10.1006/exnr.1998.6870; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Jicha GA, 1997, J NEUROCHEM, V69, P2087; JOACHIM CL, 1987, ANN NEUROL, V22, P514, DOI 10.1002/ana.410220411; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kobayashi K, 2003, J NEUROL SCI, V208, P17, DOI 10.1016/S0022-510X(02)00410-0; Krueger-Naug A M R, 2002, Prog Mol Subcell Biol, V28, P235; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lewis SE, 1999, J NEUROSCI, V19, P8945, DOI 10.1523/JNEUROSCI.19-20-08945.1999; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Plumier JCL, 1997, MOL BRAIN RES, V45, P239, DOI 10.1016/S0169-328X(96)00255-0; Plumier JCL, 1996, NEUROSCIENCE, V75, P849, DOI 10.1016/0306-4522(96)00317-X; Price NE, 1999, MOL BRAIN RES, V73, P68, DOI 10.1016/S0169-328X(99)00237-5; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Sun L, 2003, NEUROSCIENCE, V118, P1175, DOI 10.1016/S0306-4522(02)00697-8; Tian Q, 2002, NEUROSIGNALS, V11, P262, DOI 10.1159/000067425; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Wagstaff MJD, 1999, J BIOL CHEM, V274, P5061, DOI 10.1074/jbc.274.8.5061; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	40	140	155	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17957	17962		10.1074/jbc.M400351200	http://dx.doi.org/10.1074/jbc.M400351200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963027	hybrid			2022-12-27	WOS:000220870400130
J	Chen, LG; Klass, C; Woods, A				Chen, LG; Klass, C; Woods, A			Syndecan-2 regulates transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TGF-BETA; CELL-SURFACE; GLYCOSAMINOGLYCAN CHAINS; PROTEOGLYCAN SYNTHESIS; SULFATE PROTEOGLYCAN; RECEPTOR EXPRESSION; CYTOPLASMIC DOMAIN; DOWN-REGULATION; LIGAND-BINDING	Transforming growth factor-beta (TGF-beta) has multiple functions including increasing extracellular matrix deposition in fibrosis. It functions through a complex family of cell surface receptors that mediate downstream signaling. We report here that a transmembrane heparan sulfate proteoglycan, syndecan-2 (S2), can regulate TGF-beta signaling. S2 protein increased in the renal interstitium in diabetes and regulated TGF-beta-mediated increased matrix deposition in vitro. Transfection of renal papillary fibroblasts with S2 or a S2 construct that has a truncated cytoplasmic domain (S2DeltaS) promoted TGF-beta binding and S2 core protein ectodomain directly bound TGF-beta. Transfection with S2 increased the amounts of type I and type II TGF-beta receptors (TbetaRI and TbetaRII), whereas S2DeltaS was much less effective. In contrast, S2DeltaS dramatically increased the level of type III TGF-beta receptor (TbetaRIII), betaglycan, whereas S2 resulted in a decrease. Syndecan-2 specifically co-immunoprecipitated with betaglycan but not with TbetaRI or TbetaRII. This is a novel mechanism of control of TGF-beta action that may be important in fibrosis.	Univ Alabama, Dept Cell Biol, THT 946, Birmingham, AL 35294 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30303 USA	University of Alabama System; University of Alabama Birmingham; Emory University	Woods, A (corresponding author), Univ Alabama, Dept Cell Biol, THT 946, 1530 3rd Ave S, Birmingham, AL 35294 USA.	anwoods@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054605] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54605] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashcroft GS, 1999, MICROBES INFECT, V1, P1275, DOI 10.1016/S1286-4579(99)00257-9; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; Chen LG, 2002, BIOCHEM J, V366, P481, DOI 10.1042/BJ20020711; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; Couchman JR, 2001, INT REV CYTOL, V207, P113; De Iongh RU, 2001, EXP EYE RES, V72, P649, DOI 10.1006/exer.2001.1001; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Echtermeyer F, 1999, J CELL SCI, V112, P3433; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Gebken J, 1999, J ENDOCRINOL, V161, P503, DOI 10.1677/joe.0.1610503; GILBERT SF, 2000, DEV BIOL, P152; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Kaji T, 2000, J BIOL CHEM, V275, P1463, DOI 10.1074/jbc.275.2.1463; Klass CM, 2000, J CELL SCI, V113, P493; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Koli KM, 1997, J BIOL CHEM, V272, P6423, DOI 10.1074/jbc.272.10.6423; Kramer KL, 2002, CELL, V111, P981, DOI 10.1016/S0092-8674(02)01200-X; Kramer KL, 2002, DEV CELL, V2, P115, DOI 10.1016/S1534-5807(01)00107-1; Kusano Y, 2000, EXP CELL RES, V256, P434, DOI 10.1006/excr.2000.4802; Livne E, 1997, MICROSC RES TECHNIQ, V37, P314; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MCCARTHY KJ, 1993, J HISTOCHEM CYTOCHEM, V41, P401, DOI 10.1177/41.3.8429203; Modrowski D, 2000, J BIOL CHEM, V275, P9178, DOI 10.1074/jbc.275.13.9178; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; OH ES, 1997, ARCH BIOCHEM BIOPHYS, V344, P64; Philip A, 1999, EUR J BIOCHEM, V261, P618, DOI 10.1046/j.1432-1327.1999.00298.x; Prud'homme GJ, 2000, J AUTOIMMUN, V14, P23, DOI 10.1006/jaut.1999.0339; Ripley D, 2001, GYNECOL ONCOL, V81, P301, DOI 10.1006/gyno.2001.6161; Sebestyen A, 2000, CYTOKINE, V12, P1557, DOI 10.1006/cyto.2000.0754; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Van Osch GJVM, 1998, MATRIX BIOL, V17, P413, DOI 10.1016/S0945-053X(98)90101-9; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wiesmann C, 1999, STRUCT FOLD DES, V7, pR251, DOI 10.1016/S0969-2126(00)80018-0; Worapamorn W, 2001, J CELL PHYSIOL, V186, P448, DOI 10.1002/1097-4652(2001)9999:9999<000::AID-JCP1047>3.0.CO;2-V; Zwaagstra JC, 1999, EXP CELL RES, V252, P352, DOI 10.1006/excr.1999.4640	41	100	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15715	15718		10.1074/jbc.C300430200	http://dx.doi.org/10.1074/jbc.C300430200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14976204	hybrid			2022-12-27	WOS:000220747900003
J	Webb, AI; Dunstone, MA; Chen, WS; Aguilar, MI; Chen, QY; Jackson, H; Chang, L; Kjer-Nielsen, L; Beddoe, T; McCluskey, J; Rossjohn, J; Purcell, AW				Webb, AI; Dunstone, MA; Chen, WS; Aguilar, MI; Chen, QY; Jackson, H; Chang, L; Kjer-Nielsen, L; Beddoe, T; McCluskey, J; Rossjohn, J; Purcell, AW			Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; T-CELL RESPONSES; REDUCED PEPTIDE-BOND; HISTOCOMPATIBILITY MOLECULE HLA-A2; CHORIOMENINGITIS VIRUS-INFECTION; TESTIS ANTIGEN NY-ESO-1; VACCINE DESIGN; CRYSTAL-STRUCTURES; IMMUNE-RESPONSES; ANTIBODY-RESPONSES	NY-ESO-1, a commonly expressed tumor antigen of the cancer-testis family, is expressed by a wide range of tumors but not found in normal adult somatic tissue, making it an ideal cancer vaccine candidate. Peptides derived from NY-ESO-1 have shown preclinical and clinical trial promise; however, biochemical features of these peptides have complicated their formulation and led to heterogeneous immune responses. We have taken a rational approach to engineer an HLA A2-restricted NY-ESO-1-derived T cell epitope with improved formulation and immunogenicity to the wild type peptide. To accomplish this, we have solved the x-ray crystallographic structures of HLA A2 complexed to NY-ESO (157-165) and two analogues of this peptide in which the C-terminal cysteine residue has been substituted to alanine or serine. Substitution of cysteine by serine maintained peptide conformation yet reduced complex stability, resulting in poor cytotoxic T lymphocyte recognition. Conversely, substitution with alanine maintained complex stability and cytotoxic T lymphocyte recognition. Based on the structures of the three HLA A2 complexes, we incorporated 2-aminoisobutyric acid, an isostereomer of cysteine, into the epitope. This analogue is impervious to oxidative damage, cysteinylation, and dimerization of the peptide epitope upon formulation that is characteristic of the wild type peptide. Therefore, this approach has yielded a potential therapeutic molecule that satiates the hydrophobic F pocket of HLA A2 and exhibited superior immunogenicity relative to the wild type peptide.	Monash Univ, Sch Biomed Sci, Prot Crystallog Unit, Clayton, Vic 3800, Australia; Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Austin & Repatriat Med Ctr, Ludwig Inst Canc Res, T Cell Lab, Heidelberg, Vic 3084, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Univ Melbourne, ImmunoID, Parkville, Vic 3010, Australia	Monash University; Monash University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; University of Melbourne; University of Melbourne	Rossjohn, J (corresponding author), Monash Univ, Sch Biomed Sci, Prot Crystallog Unit, Clayton, Vic 3800, Australia.	jamie.rossjohn@med.monash.edu.au; apurcell@unimelb.edu.au	Purcell, Anthony/AAH-1942-2019; Beddoe, Travis/F-3415-2014; Chen, Weisan/E-7828-2012; Rossjohn, Jamie/F-9032-2013; McCluskey, James/A-1291-2007; Dunstone, Michelle/I-2895-2014	Purcell, Anthony/0000-0003-0532-8331; Beddoe, Travis/0000-0003-4550-2277; Chen, Weisan/0000-0002-5221-9771; Rossjohn, Jamie/0000-0002-2020-7522; McCluskey, James/0000-0002-8597-815X; Dunstone, Michelle/0000-0002-6026-648X				Apostolopoulos V, 2002, J MOL BIOL, V318, P1293, DOI 10.1016/S0022-2836(02)00196-1; Baratin M, 2002, J PEPT SCI, V8, P327, DOI 10.1002/psc.391; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Blanchet JS, 2001, J IMMUNOL, V167, P5852, DOI 10.4049/jimmunol.167.10.5852; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Bouvier M, 1998, PROTEINS, V33, P97, DOI 10.1002/(SICI)1097-0134(19981001)33:1<97::AID-PROT9>3.0.CO;2-I; Brooks JM, 1998, J IMMUNOL, V161, P5252; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calbo S, 2000, J IMMUNOTHER, V23, P125, DOI 10.1097/00002371-200001000-00015; Chang L, 2003, TISSUE ANTIGENS, V62, P408, DOI 10.1034/j.1399-0039.2003.00122.x; Chen JL, 2000, J IMMUNOL, V165, P948, DOI 10.4049/jimmunol.165.2.948; Chen WS, 1999, J EXP MED, V189, P1757, DOI 10.1084/jem.189.11.1757; Collaborative Computational Project No. 4, 1994, ACTA CRYSTALLOGR D, V50, P750; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Deng YP, 1997, J IMMUNOL, V158, P1507; Dutoit V, 2002, J CLIN INVEST, V110, P1813, DOI 10.1172/JCI200216428; Engelhard VH, 2002, IMMUNOL REV, V188, P136, DOI 10.1034/j.1600-065X.2002.18812.x; Ercolini AM, 2003, J IMMUNOL, V170, P4273, DOI 10.4049/jimmunol.170.8.4273; GARBOCZI DN, 1994, J MOL BIOL, V239, P581, DOI 10.1006/jmbi.1994.1398; Gnjatic S, 2003, P NATL ACAD SCI USA, V100, P8862, DOI 10.1073/pnas.1133324100; Gnjatic S, 2002, P NATL ACAD SCI USA, V99, P11813, DOI 10.1073/pnas.142417699; Gold JS, 2003, J IMMUNOL, V170, P5188, DOI 10.4049/jimmunol.170.10.5188; GUICHARD G, 1995, J BIOL CHEM, V270, P26057, DOI 10.1074/jbc.270.44.26057; Guichard G, 1996, J MED CHEM, V39, P2030, DOI 10.1021/jm9509511; Guichard G, 2000, J MED CHEM, V43, P3803, DOI 10.1021/jm000909s; Hillig RC, 2001, J MOL BIOL, V310, P1167, DOI 10.1006/jmbi.2001.4816; Huarte E, 2002, CLIN CANCER RES, V8, P2336; Jager D, 2001, J CLIN PATHOL, V54, P669, DOI 10.1136/jcp.54.9.669; Jager E, 2000, P NATL ACAD SCI USA, V97, P12198, DOI 10.1073/pnas.220413497; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Jager E, 2000, P NATL ACAD SCI USA, V97, P4760, DOI 10.1073/pnas.97.9.4760; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Kjer-Nielsen L, 2002, J IMMUNOL, V169, P5153, DOI 10.4049/jimmunol.169.9.5153; Kourilsky P, 2001, Int Rev Immunol, V20, P575, DOI 10.3109/08830180109045579; Krebs S, 1998, J BIOL CHEM, V273, P19072, DOI 10.1074/jbc.273.30.19072; Krebs S, 1998, J PEPT SCI, V4, P378, DOI 10.1002/(SICI)1099-1387(199809)4:6<378::AID-PSC157>3.0.CO;2-B; Lamas JR, 1998, INT IMMUNOL, V10, P259, DOI 10.1093/intimm/10.3.259; Levitsky V, 1996, J EXP MED, V183, P915, DOI 10.1084/jem.183.3.915; LIPFORD GB, 1995, VACCINE, V13, P313, DOI 10.1016/0264-410X(95)93320-9; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Meziere C, 1997, J IMMUNOL, V159, P3230; Micheletti F, 1999, IMMUNOLOGY, V96, P411; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; Ostankovitch M, 1998, J IMMUNOL, V161, P200; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Platsoucas CD, 2003, ANTICANCER RES, V23, P1969; Poenaru S, 1999, J MED CHEM, V42, P2318, DOI 10.1021/jm981123l; Purcell AW, 2003, J PEPT SCI, V9, P255, DOI 10.1002/psc.456; Reid SW, 1996, J EXP MED, V184, P2279, DOI 10.1084/jem.184.6.2279; Reinelt S, 2001, J BIOL CHEM, V276, P24525, DOI 10.1074/jbc.M102772200; Romero P, 2001, CLIN CANCER RES, V7, p766S; Rudolph MG, 2001, IMMUNITY, V14, P231, DOI 10.1016/S1074-7613(01)00105-4; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9; SETTE A, 1994, J IMMUNOL, V153, P5586; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Sliz P, 2001, J IMMUNOL, V167, P3276, DOI 10.4049/jimmunol.167.6.3276; Stemmer C, 1999, J BIOL CHEM, V274, P5550, DOI 10.1074/jbc.274.9.5550; Sylvester-Hvid C, 2002, TISSUE ANTIGENS, V59, P251, DOI 10.1034/j.1399-0039.2002.590402.x; Tangri S, 2001, J EXP MED, V194, P833, DOI 10.1084/jem.194.6.833; Terasawa H, 2002, CLIN CANCER RES, V8, P41; Valmori D, 2000, CANCER RES, V60, P4499; vanderBurg SH, 1996, J IMMUNOL, V156, P3308; vanderMost RG, 1996, J IMMUNOL, V157, P5543; Zarour HM, 2002, CANCER RES, V62, P213; Zeng G, 2002, CANCER RES, V62, P3630	68	57	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23438	23446		10.1074/jbc.M314066200	http://dx.doi.org/10.1074/jbc.M314066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15004033	hybrid			2022-12-27	WOS:000221570900080
J	Courageot, MP; Lepine, S; Hours, M; Giraud, F; Sulpice, JC				Courageot, MP; Lepine, S; Hours, M; Giraud, F; Sulpice, JC			Involvement of sodium in early phosphatidylserine exposure and phospholipid scrambling induced by P2X7 purinoceptor activation in thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SURFACE EXPOSURE; APOPTOTIC CELLS; TRANSVERSE REDISTRIBUTION; MURINE THYMOCYTES; FLIP-FLOP; CALCIUM; PHAGOCYTOSIS; ASYMMETRY	Extracellular ATP ( ATP(ec)), a possible effector in thymocyte selection, induces thymocyte death via purinoceptor activation. We show that ATPec induced cell death by apoptosis, rather than lysis, and early phosphatidylserine ( PS) exposure and phospholipid scrambling in a limited thymocyte population ( 35 - 40%). PS externalization resulted from the activation of the cationic channel P2X7 ( formerly P2Z) receptor and was triggered in all thymocyte subsets although to different proportions in each one. Phospholipid movement was dependent on ATP(ec)- induced Ca2+ and/ or Na+ influx. At physiological external Na+ concentration, without external Ca2+, PS was exposed in all ATP(ec)- responsive cells. In contrast, without external Na+, physiological external Ca2+ concentration promoted a submaximal response. Altogether these data show that Na+ influx plays a major role in the rapid PS exposure induced by P2X7 receptor activation in thymocytes.	Univ Paris 11, CNRS, UMR 8619, Lab Biomembranes & Messagers Cellulaires, F-91405 Orsay, France; Univ Paris 11, Inst Federatif Rech, Serv Cytometrie, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Sulpice, JC (corresponding author), Univ Paris 11, CNRS, UMR 8619, Lab Biomembranes & Messagers Cellulaires, Bat 440, F-91405 Orsay, France.	Jean-Claude.Sulpice@ibaic.u-psud.fr						Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Apasov SG, 1997, J IMMUNOL, V158, P5095; BELEZNAY Z, 1993, BIOCHEMISTRY-US, V32, P3146, DOI 10.1021/bi00063a029; Blom WM, 2003, J BIOL CHEM, V278, P12467, DOI 10.1074/jbc.M201264200; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Bortner CD, 2003, J BIOL CHEM, V278, P39176, DOI 10.1074/jbc.M303516200; Bratton DL, 1999, J BIOL CHEM, V274, P28113, DOI 10.1074/jbc.274.40.28113; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Bucki R, 2000, BIOCHEMISTRY-US, V39, P5838, DOI 10.1021/bi992403l; Bucki R, 2001, BIOCHEMISTRY-US, V40, P15752, DOI 10.1021/bi010899c; Chused TM, 1996, J IMMUNOL, V157, P1371; Chvatchko Y, 1996, IMMUNITY, V5, P275, DOI 10.1016/S1074-7613(00)80322-2; Courageot MP, 2002, ANN NY ACAD SCI, V973, P186, DOI 10.1111/j.1749-6632.2002.tb04630.x; Das P, 2003, LIFE SCI, V72, P2617, DOI 10.1016/S0024-3205(03)00163-2; de Jong K, 2001, BLOOD, V98, P860, DOI 10.1182/blood.V98.3.860; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Dubyak GR, 2000, J AUTONOM NERV SYST, V81, P64, DOI 10.1016/S0165-1838(00)00155-7; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; Freedman BD, 1999, EUR J IMMUNOL, V29, P1635, DOI 10.1002/(SICI)1521-4141(199905)29:05<1635::AID-IMMU1635>3.3.CO;2-2; Gleiss B, 2002, FEBS LETT, V519, P153, DOI 10.1016/S0014-5793(02)02743-6; Hampton MB, 1996, FEBS LETT, V399, P277, DOI 10.1016/S0014-5793(96)01341-5; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Khoshbouei H, 2003, J BIOL CHEM, V278, P12070, DOI 10.1074/jbc.M212815200; KOJIMA H, 1994, J CLIN INVEST, V94, P2237, DOI 10.1172/JCI117586; Kuroki DW, 1997, J BIOL CHEM, V272, P23905, DOI 10.1074/jbc.272.38.23905; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Martinez MC, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-20; Nagy PV, 2000, IMMUNOL LETT, V72, P23, DOI 10.1016/S0165-2478(00)00168-1; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; PIZZO P, 1991, BIOCHEM J, V274, P139, DOI 10.1042/bj2740139; Ross PE, 1997, J CELL BIOL, V138, P987, DOI 10.1083/jcb.138.5.987; Samson J, 2001, PLATELETS, V12, P436, DOI 10.1080/09537100120078395; Schlegel RA, 2000, ANN NY ACAD SCI, V926, P217; Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; Stout JG, 1997, J CLIN INVEST, V99, P2232, DOI 10.1172/JCI119397; Stuart MCA, 1998, EUR J CELL BIOL, V76, P77, DOI 10.1016/S0171-9335(98)80019-8; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Uthaisang W, 2003, FEBS LETT, V545, P110, DOI 10.1016/S0014-5793(03)00508-8; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Waring P, 1999, CELL DEATH DIFFER, V6, P624, DOI 10.1038/sj.cdd.4400540; Williamson P, 2001, METHOD CELL BIOL, V66, P339; Williamson P, 2001, BIOCHEMISTRY-US, V40, P8065, DOI 10.1021/bi001929z; Wurth GA, 2002, BIOCHEM J, V362, P701, DOI 10.1042/bj3620701; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	55	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21815	21823		10.1074/jbc.M401426200	http://dx.doi.org/10.1074/jbc.M401426200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14996828	hybrid			2022-12-27	WOS:000221417100019
J	Dong, JB; Chen, W; Welford, A; Wandinger-Ness, A				Dong, JB; Chen, W; Welford, A; Wandinger-Ness, A			The proteasome alpha-subunit XAPC7 interacts specifically with Rab7 and late endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; GTP-BINDING-PROTEINS; LYSOSOMAL TRANSPORT; CYTOPLASMIC DOMAIN; C-TERMINUS; X PROTEIN; RECEPTOR; DEGRADATION; MEMBRANE; EXPRESSION	Rab7 is a key regulatory protein governing early to late endocytic membrane transport. In this study the proteasome alpha-subunit XAPC7 (also known as PSMA7, RC6-1, and HSPC in mammals) was identified to interact specifically with Rab7 and was recruited to multivesicular late endosomes through this interaction. The protein interaction domains were localized to the C terminus of XAPC7 and the N terminus of Rab7. XAPC7 was not found on early or recycling endosomes, but could be recruited to recycling endosomes by expression of a Rab7-(1-174) Rab11-(160-202) chimera, establishing a central role for Rab7 in the membrane recruitment of XAPC7. Although XAPC7 could be shown to associate with membranes bearing ubiquitinated cargo, overexpression had no impact on steady-state ubiquitinated protein levels. Most notably, overexpression of XAPC7 was found to impair late endocytic transport of two different membrane proteins, including EGFR known to be highly dependent on ubiquitination and proteasome activity for proper endocytic sorting and lysosomal transport. Decreased late endocytic transport caused by XAPC7 overexpression was partially rescued by coexpression of wild-type Rab7, suggesting a negative regulatory role for XAPC7. Nevertheless, Rab7 itself was not subject to XAPC7-dependent proteasomal degradation. Together the data establish the first direct molecular link between the endocytic trafficking and cytosolic degradative machineries.	Univ New Mexico, Sch Med, HSC, Dept Pathol,Mol Trafficking Lab, Albuquerque, NM 87131 USA	University of New Mexico	Wandinger-Ness, A (corresponding author), Univ New Mexico, Sch Med, HSC, Dept Pathol,Mol Trafficking Lab, 2325 Camino Salud NE,CRF 225, Albuquerque, NM 87131 USA.	wness@unm.edu	Wandinger-Ness, Angela/J-9104-2012	Wandinger-Ness, Angela/0000-0003-0613-3157	NCI NIH HHS [R24 CA 88339] Funding Source: Medline; NCRR NIH HHS [P20 RR 11830, S10 RR 14668, S10 RR 01698] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA088339] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011830, S10RR014668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Cagney G, 2001, PHYSIOL GENOMICS, V7, P27, DOI 10.1152/physiolgenomics.2001.7.1.27; Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Denzer K, 2000, J CELL SCI, V113, P3365; Desjardins M, 2003, CURR OPIN CELL BIOL, V15, P498, DOI 10.1016/S0955-0674(03)00083-8; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Feng Y, 2001, METHOD ENZYMOL, V329, P175; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Golubnitschaja-Labudova O, 2000, CURR EYE RES, V21, P867, DOI 10.1076/ceyr.21.5.867.5534; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; JONASSEN I, 1995, PROTEIN SCI, V4, P1587, DOI 10.1002/pro.5560040817; Jordens I, 2001, CURR BIOL, V11, P1680, DOI 10.1016/S0960-9822(01)00531-0; JORDENS I, 2003, PIGMENT CELL RES, V16, P583; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Kruger M, 2001, MOL CELL BIOL, V21, P8357, DOI 10.1128/MCB.21.24.8357-8364.2001; LEFRANCOIS L, 1982, VIROLOGY, V121, P168, DOI 10.1016/0042-6822(82)90126-X; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Melman L, 2002, MOL BIOL CELL, V13, P3325, DOI 10.1091/mbc.E02-03-0152; Mizuno K, 2003, MOL BIOL CELL, V14, P3741, DOI 10.1091/mbc.E02-08-0495; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Ohnami S, 1999, CANCER RES, V59, P5565; Orlowski M, 2000, ARCH BIOCHEM BIOPHYS, V383, P1, DOI 10.1006/abbi.2000.2036; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Rodman JS, 2000, J CELL SCI, V113, P183; Ryo A, 2000, AIDS RES HUM RETROV, V16, P995, DOI 10.1089/08892220050058416; SCHAUER TM, 1993, J STRUCT BIOL, V111, P135, DOI 10.1006/jsbi.1993.1044; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Stein MP, 2003, ADV DRUG DELIVER REV, V55, P1421, DOI 10.1016/j.addr.2003.07.009; Stein MP, 2003, TRAFFIC, V4, P754, DOI 10.1034/j.1600-0854.2003.00133.x; Stenmark H, 1999, J CELL SCI, V112, P4175; Tipler CP, 1997, MOL HUM REPROD, V3, P1053, DOI 10.1093/molehr/3.12.1053; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang TL, 2004, MOL BIOL CELL, V15, P815, DOI 10.1091/mbc.E03-06-0413; WHITT MA, 1989, J VIROL, V63, P3569, DOI 10.1128/JVI.63.9.3569-3578.1989; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang ZS, 2000, J BIOL CHEM, V275, P15157, DOI 10.1074/jbc.M910378199	63	61	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21334	21342		10.1074/jbc.M401022200	http://dx.doi.org/10.1074/jbc.M401022200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14998988	hybrid			2022-12-27	WOS:000221273800096
J	Shah, OJ; Hunter, T				Shah, OJ; Hunter, T			Critical role of T-Loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TARGET; PROTEIN-KINASE; CELL-GROWTH; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; IN-VITRO; TSC2; RAPAMYCIN; P70(S6K); ACTIVATION	The tuberous sclerosis gene products Tsc1 and Tsc2 behave as tumor suppressors by restricting cell growth, a function conserved among metazoans. Recent evidence has indicated that hyperactivation of S6 kinase 1 (S6K1) may represent an important biochemical change in the development of tuberous sclerosis-associated lesions. We show here that deletion of either Tsc1 or Tsc2 or expression of the Rheb (Ras homolog enriched in brain) GTPase leads to hyperphosphorylation of S6K1 at a subset of regulatory sites, particularly those of two essential residues functionally conserved among AGC superfamily serine/threonine kinases, i.e. the activation loop (T-loop; Thr-229) and the hydrophobic motif (H-motif; Thr-389). These sites are reciprocally and dose-dependently regulated when S6K1 is coexpressed with the Tsc1-Tsc2 complex. Mutations that render S6K1 mTOR ( mammalian target of rapamycin)-resistant also protect S6K1 activity and phosphorylation from down-regulation by Tsc1/2. We demonstrate that two disease-associated mutations in Tsc2 fail to negatively regulate S6K1 activity concomitant with a failure to modify T-loop and H-motif phosphorylation. Finally, we identify one pathological Tsc2 mutation that retains its ability to negatively regulate S6K1, suggesting that, in some cases, tuberous sclerosis may develop independently of S6K1 hyperactivation. These results also highlight the importance of dual control of T-loop and H-motif phosphorylation of S6K1 by the Tsc1-Tsc2 complex.	Salk Inst Biol Studies, Mol & Cellular Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hunter@salk.edu			NCI NIH HHS [T32 CA 09523-18] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Choy YS, 1999, ANN HUM GENET, V63, P383, DOI 10.1046/j.1469-1809.1999.6350383.x; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gilbert JR, 1998, NEUROGENETICS, V1, P267, DOI 10.1007/s100480050039; Gomez MR, 1988, TUBEROUS SCLEROSIS; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hyman MH, 2000, ARCH NEUROL-CHICAGO, V57, P662, DOI 10.1001/archneur.57.5.662; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Jones AC, 1999, AM J HUM GENET, V64, P1305, DOI 10.1086/302381; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; NELLIST M, 1993, CELL, V75, P1305; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Niida Y, 1999, HUM MUTAT, V14, P412, DOI 10.1002/(SICI)1098-1004(199911)14:5<412::AID-HUMU7>3.0.CO;2-K; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rennebeck G, 1998, P NATL ACAD SCI USA, V95, P15629, DOI 10.1073/pnas.95.26.15629; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shah OJ, 2000, BIOCHEM J, V347, P389, DOI 10.1042/0264-6021:3470389; Sugiyama H, 1996, J IMMUNOL, V157, P656; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Zhang H, 1999, J HUM GENET, V44, P391, DOI 10.1007/s100380050185; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	53	23	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20816	20823		10.1074/jbc.M400957200	http://dx.doi.org/10.1074/jbc.M400957200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14993219	hybrid			2022-12-27	WOS:000221273800033
J	Deval, E; Salinas, M; Baron, A; Lingueglia, E; Lazdunski, M				Deval, E; Salinas, M; Baron, A; Lingueglia, E; Lazdunski, M			ASIC2b-dependent regulation of ASIC3, an essential acid-sensing ion channel subunit in sensory neurons via the partner protein PICK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; FUNCTIONAL ROLES; BRADYKININ; DOMAIN; RECEPTORS; EXPRESSION; BRAIN; ION-CHANNEL-3; CONTRIBUTES; AMPA	ASIC3, an acid-sensing ion channel subunit expressed essentially in sensory neurons, has been proposed to be involved in pain. We show here for the first time that native ASIC3-like currents were increased in cultured dorsal root ganglion (DRG) neurons following protein kinase C (PKC) stimulation. This increase was induced by the phorbol ester PDBu and by pain mediators, such as serotonin, which are known to activate the PKC pathway through their binding to G protein-coupled receptors. We demonstrate that this regulation involves the silent ASIC2b subunit, an ASIC subunit also expressed in sensory neurons. Indeed, heteromultimeric ASIC3/ASIC2b channels, but not homomeric ASIC3 channels, are positively regulated by PKC. The increase of ASIC3/ASIC2b current is accompanied by a shift in its pH dependence toward more physiological pH values and may lead to an increase of sensory neuron excitability. This regulation by PKC requires PICK-1 (protein interacting with C kinase), a PDZ domain-containing protein, which interacts with the ASIC2b C terminus.	Inst Paul Hamel, UNSA, CNRS, UMR 6097,Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), Inst Paul Hamel, UNSA, CNRS, UMR 6097,Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	LINGUEGLIA, Eric/F-5509-2013; DEVAL, Emmanuel/N-6280-2016; SALINAS, Miguel/N-6380-2016; BARON, Anne/N-5691-2016	LINGUEGLIA, Eric/0000-0003-3902-3405; DEVAL, Emmanuel/0000-0002-0215-9379; SALINAS, Miguel/0000-0002-7445-123X; BARON, Anne/0000-0002-8026-6380				Aley KO, 1999, J NEUROSCI, V19, P2181; Aley KO, 2001, J NEUROSCI, V21, P6933, DOI 10.1523/JNEUROSCI.21-17-06933.2001; Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Banik RK, 2001, J NEUROPHYSIOL, V86, P2727, DOI 10.1152/jn.2001.86.6.2727; Baron A, 2002, J BIOL CHEM, V277, P50463, DOI 10.1074/jbc.M208848200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; BASSLER EL, 2001, J BIOL CHEM, V11, P11; Benson CJ, 1999, CIRC RES, V84, P921; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Bhave G, 2001, NAT NEUROSCI, V4, P417, DOI 10.1038/86075; Bolshakov KV, 2002, NEUROSCIENCE, V110, P723, DOI 10.1016/S0306-4522(01)00582-6; Carlton S M, 2001, Curr Opin Pharmacol, V1, P52, DOI 10.1016/S1471-4892(01)00002-9; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Chen JJ, 1998, J PHARMACOL EXP THER, V287, P1119; Collingridge GL, 2003, NEUROSCI RES, V47, P3, DOI 10.1016/S0168-0102(03)00160-3; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; Dev KK, 2001, TRENDS PHARMACOL SCI, V22, P355, DOI 10.1016/S0165-6147(00)01684-9; Deval E, 2003, NEUROPHARMACOLOGY, V44, P662, DOI 10.1016/S0028-3908(03)00047-9; DRAY A, 1995, BRIT J ANAESTH, V75, P125, DOI 10.1093/bja/75.2.125; Dray A, 1997, CAN J PHYSIOL PHARM, V75, P704, DOI 10.1139/cjpp-75-6-704; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Fox A, 2003, PAIN, V104, P683, DOI 10.1016/S0304-3959(03)00141-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Kamei J, 2001, EXPERT OPIN INV DRUG, V10, P1653, DOI 10.1517/13543784.10.9.1653; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Khasar SG, 1999, J NEUROPHYSIOL, V81, P1104, DOI 10.1152/jn.1999.81.3.1104; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; KVANTA A, 1991, FEBS LETT, V283, P321, DOI 10.1016/0014-5793(91)80618-D; Li P, 1999, NAT NEUROSCI, V2, P972, DOI 10.1038/14771; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Ma QP, 2000, NEUROREPORT, V11, P4003, DOI 10.1097/00001756-200012180-00020; Mamet J, 2003, J BIOL CHEM, V278, P48907, DOI 10.1074/jbc.M309468200; Mamet J, 2002, J NEUROSCI, V22, P10662; MCGUIRK SM, 1992, NEUROSCIENCE, V49, P117, DOI 10.1016/0306-4522(92)90079-H; Neugebauer Volker, 2002, Expert Opin Ther Targets, V6, P349; Nicholson R, 2003, NEUROSCI LETT, V337, P119, DOI 10.1016/S0304-3940(02)01256-9; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Perroy J, 2002, EMBO J, V21, P2990, DOI 10.1093/emboj/cdf313; Petruska JC, 2002, NEUROSCIENCE, V115, P15, DOI 10.1016/S0306-4522(02)00409-8; Prado GN, 2002, J CELL PHYSIOL, V193, P275, DOI 10.1002/jcp.10175; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Reeh P W, 2001, Curr Opin Pharmacol, V1, P45, DOI 10.1016/S1471-4892(01)00014-5; RICHARDSON BP, 1990, ANN N Y ACAD SCI, V600, P511; Seabrook GR, 1997, NEUROPHARMACOLOGY, V36, P1009, DOI 10.1016/S0028-3908(97)00065-8; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Wotherspoon G, 2000, NEUROSCI LETT, V294, P175, DOI 10.1016/S0304-3940(00)01561-5; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Zhou ST, 2001, BRAIN RES, V913, P18, DOI 10.1016/S0006-8993(01)02747-0	66	83	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19531	19539		10.1074/jbc.M313078200	http://dx.doi.org/10.1074/jbc.M313078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14976185	hybrid			2022-12-27	WOS:000221164500020
J	Tu, XM; Wang, CC				Tu, XM; Wang, CC			The involvement of two cdc2-related kinases (CRKs) in Trypanosoma brucei cell cycle regulation and the distinctive stage-specific phenotypes caused by CRK3 depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-MEXICANA; RNA INTERFERENCE; PROTEIN-KINASE; LIFE-CYCLE; FUNCTIONAL-CHARACTERIZATION; AFRICAN TRYPANOSOMES; GENOME SEGREGATION; DNA-REPLICATION; GENE-EXPRESSION; CYTOKINESIS	Cyclin-dependent protein kinases are among the key regulators of eukaryotic cell cycle progression. Potential functions of the five cdc2-related kinases (CRK) in Trypanosoma brucei were analyzed using the RNA interference (RNA(i)) technique. In both the procyclic and bloodstream forms of T. brucei, CRK1 is apparently involved in controlling the G(1)/S transition, whereas CRK3 plays an important role in catalyzing cells across the G(2)/M junction. A knockdown of CRK1 caused accumulation of cells in the G(1) phase without apparent phenotypic change, whereas depletion of CRK3 enriched cells of both forms in the G(2)/M phase. However, two distinctive phenotypes were observed between the CRK3-deficient procyclic and bloodstream forms. The procyclic form has a majority of the cells containing a single enlarged nucleus plus one kinetoplast. There is also an enhanced population of anucleated cells, each containing a single kinetoplast known as the zoids (0N1K). The CRK3-depleted bloodstream form has an increased number of one nucleus-two kinetoplast cells (1N2K) and a small population containing aggregated multiple nuclei and multiple kinetoplasts. Apparently, these two forms have different mechanisms in cell cycle regulation. Although the procyclic form can be driven into cytokinesis and cell division by kinetoplast segregation without a completed mitosis, the bloodstream form cannot enter cytokinesis under the same condition. Instead, it keeps going through another G(1) phase and enters a new S phase resulting in an aggregate of multiple nuclei and multiple kinetoplasts in an undivided cell. The different leakiness in cell cycle regulation between two stage-specific forms of an organism provides an interesting and useful model for further understanding the evolution of cell cycle control among the eukaryotes.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu	Tu, Xiaoming/G-5090-2018		NIAID NIH HHS [R01 AI 2178] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bastin P, 2000, J CELL SCI, V113, P3321; DAS A, 1994, J CELL SCI, V107, P3477; Gomez EB, 1998, MOL BIOCHEM PARASIT, V91, P337, DOI 10.1016/S0166-6851(97)00218-1; Gomez EB, 2001, MOL BIOCHEM PARASIT, V113, P97, DOI 10.1016/S0166-6851(00)00382-0; Grant KM, 1998, J BIOL CHEM, V273, P10153, DOI 10.1074/jbc.273.17.10153; Hammarton Tansy C, 2003, Prog Cell Cycle Res, V5, P91; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Hassan P, 2001, MOL BIOCHEM PARASIT, V113, P189, DOI 10.1016/S0166-6851(01)00220-1; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Kohl L, 2003, EMBO J, V22, P5336, DOI 10.1093/emboj/cdg518; Kuntzel H, 1996, BIOL CHEM, V377, P481; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Li ZY, 2002, J BIOL CHEM, V277, P15486, DOI 10.1074/jbc.M109029200; Lillico SG, 2002, FEMS MICROBIOL LETT, V211, P123, DOI 10.1111/j.1574-6968.2002.tb11213.x; MATTHEWS KR, 1995, J CELL SCI, V108, P2231; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; Mottram JC, 1996, MOL MICROBIOL, V22, P573, DOI 10.1046/j.1365-2958.1996.00136.x; MOTTRAM JC, 1995, GENE, V162, P147, DOI 10.1016/0378-1119(95)00350-F; MOTTRAM JC, 1993, J BIOL CHEM, V268, P21044; Mutomba MC, 1997, MOL BIOCHEM PARASIT, V90, P491, DOI 10.1016/S0166-6851(97)00197-7; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ploubidou A, 1999, J CELL SCI, V112, P4641; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Timms MW, 2002, MOL BIOL CELL, V13, P3747, DOI 10.1091/mbc.E02-05-0266; Van Hellemond JJ, 2000, J BIOL CHEM, V275, P8315, DOI 10.1074/jbc.275.12.8315; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; Wang YX, 1998, MOL BIOCHEM PARASIT, V96, P139, DOI 10.1016/S0166-6851(98)00121-2; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49	36	90	90	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20519	20528		10.1074/jbc.M312862200	http://dx.doi.org/10.1074/jbc.M312862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15010459	hybrid			2022-12-27	WOS:000221164500131
J	Vilfan, ID; Conwell, CC; Hud, NV				Vilfan, ID; Conwell, CC; Hud, NV			Formation of native-like mammalian sperm cell chromatin with folded bull protamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; SINGLE DNA-MOLECULES; X-RAY-DIFFRACTION; NUCLEOPROTAMINE STRUCTURE; ROOSTER SPERMATOGENESIS; NUCLEAR PROTEINS; TROUT TESTIS; SPERMATOZOA; COMPLEXES; PEPTIDES	The DNA of most vertebrate sperm cells is packaged by protamines. The primary structure of mammalian protamine I can be divided into three domains, a central DNA binding domain that is arginine-rich and amino and carboxyl-terminal domains that are rich in cysteine residues. In native bull sperm chromatin, intramolecular disulfide bonds hold the terminal domains of bull protamine folded back onto the central DNA binding domain, whereas intermolecular disulfide bonds between DNA-bound protamines help stabilize the chromatin of mature mammalian sperm cells. Folded bull protamine was used to condense DNA in vitro under various solution conditions. Using transmission electron microscopy and light scattering, we show that bull protamine forms particles with DNA that are morphologically similar to the subunits of native bull sperm chromatin. In addition, the stability provided by intermolecular disulfide bonds formed between bull protamine molecules within in vitro DNA condensates is comparable with that observed for native bull sperm chromatin. The importance of the bull protamine terminal domains in controlling the bull sperm chromatin morphology is indicated by our observation that DNA condensates formed under identical conditions with a fish protamine, which lacks cysteine-rich terminal domains, do not produce as uniform structures as bull protamine. A model is also presented for the bull protamine.DNA complex in native sperm cell chromatin that provides an explanation for the positions of the cysteine residues in bull protamine that form intermolecular disulfide bonds.	Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Sch Chem & Biochem, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Hud, NV (corresponding author), Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Sch Chem & Biochem, Atlanta, GA 30332 USA.	hud@chemistry.gatech.edu	Hud, Nicholas V/T-7017-2017	Hud, Nicholas/0000-0001-7711-6472	NIGMS NIH HHS [GM 62873] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062873] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADROER R, 1992, NUCLEIC ACIDS RES, V20, P609, DOI 10.1093/nar/20.3.609; AGELL N, 1983, FEBS LETT, V155, P209, DOI 10.1016/0014-5793(82)80604-2; ALFERT M, 1956, J BIOPHYS BIOCHEM CY, V2, P109, DOI 10.1083/jcb.2.2.109; Allen MJ, 1997, NUCLEIC ACIDS RES, V25, P2221, DOI 10.1093/nar/25.11.2221; ALLEN MJ, 1993, CHROMOSOMA, V102, P623, DOI 10.1007/BF00352310; ALLEN MJ, 1995, J STRUCT BIOL, V114, P197, DOI 10.1006/jsbi.1995.1019; AMMER H, 1987, BIOL CHEM H-S, V368, P1619, DOI 10.1515/bchm3.1987.368.2.1619; BALHORN R, 1977, BIOCHEMISTRY-US, V16, P4074, DOI 10.1021/bi00637a021; BALHORN R, 1992, ARCH BIOCHEM BIOPHYS, V296, P384, DOI 10.1016/0003-9861(92)90588-N; Balhorn R., 1989, P366; Balhorn R, 1999, MALE GAMETE: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS, P55; Balhorn R, 2000, MOL REPROD DEV, V56, P230, DOI 10.1002/(SICI)1098-2795(200006)56:2+<230::AID-MRD3>3.3.CO;2-M; BALHORN R, 1982, J CELL BIOL, V93, P298, DOI 10.1083/jcb.93.2.298; BALHORN R, 1991, BIOCHEMISTRY-US, V30, P175, DOI 10.1021/bi00215a026; Bench GS, 1996, CYTOMETRY, V23, P263, DOI 10.1002/(SICI)1097-0320(19960401)23:4<263::AID-CYTO1>3.3.CO;2-9; BERNE BJ, 2000, DYNAMIC LIGHT SCATTE, P316; BIANCHI F, 1994, BIOCHEM BIOPH RES CO, V201, P1197, DOI 10.1006/bbrc.1994.1832; Blanc NS, 2001, J STRUCT BIOL, V134, P76, DOI 10.1006/jsbi.2001.4365; Bloomfield VA, 2000, BIOPOLYMERS, V54, P168, DOI 10.1002/1097-0282(200009)54:3<168::AID-BIP20>3.0.CO;2-9; Brewer L, 2003, J BIOL CHEM, V278, P42403, DOI 10.1074/jbc.M303610200; COROMINAS M, 1985, J BIOL CHEM, V260, P6269; Creighton T. E., 1993, PROTEINS STRUCTURES; Dadoune JP, 1995, MICRON, V26, P323, DOI 10.1016/0968-4328(95)00007-0; DASILVA LB, 1992, SCIENCE, V258, P269, DOI 10.1126/science.1411525; Fernandez-Barbero A, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.051803; FITA I, 1983, J MOL BIOL, V167, P157, DOI 10.1016/S0022-2836(83)80039-4; Gimenez-Bonafe P, 2002, EUR J CELL BIOL, V81, P341, DOI 10.1078/0171-9335-00253; HONDA BM, 1975, J BIOL CHEM, V250, P8681; HUD NV, 1993, BIOCHEM BIOPH RES CO, V193, P1347, DOI 10.1006/bbrc.1993.1773; HUD NV, 1994, BIOCHEMISTRY-US, V33, P7528, DOI 10.1021/bi00190a005; KOEHLER J K, 1970, Journal of Ultrastructure Research, V33, P598, DOI 10.1016/S0022-5320(70)90184-X; KOEHLER JK, 1983, GAMETE RES, V8, P357, DOI 10.1002/mrd.1120080406; KOEHLER JK, 1966, J ULTRA MOL STRUCT R, V16, P359, DOI 10.1016/S0022-5320(66)80068-0; Lewis JD, 2003, CHROMOSOMA, V111, P473, DOI 10.1007/s00412-002-0226-0; Lin XM, 1999, J PHYS CHEM B, V103, P5488, DOI 10.1021/jp990729y; LOIR M, 1985, CHROMOSOMA, V92, P304, DOI 10.1007/BF00329814; LOUIE AJ, 1972, P NATL ACAD SCI USA, V69, P1975, DOI 10.1073/pnas.69.7.1975; LOUIE AJ, 1972, J BIOL CHEM, V247, P7962; MARUSHIGE K, 1969, DEV BIOL, V19, P397, DOI 10.1016/0012-1606(69)90050-5; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; Prieto MC, 1997, BIOCHEMISTRY-US, V36, P11944, DOI 10.1021/bi971061l; Quintanilla-Vega B, 2000, AM J IND MED, V38, P324; Raukas E, 1999, BIOESSAYS, V21, P440, DOI 10.1002/(SICI)1521-1878(199905)21:5<440::AID-BIES11>3.0.CO;2-V; Rooney AP, 1999, MOL BIOL EVOL, V16, P706, DOI 10.1093/oxfordjournals.molbev.a026153; Rooney AP, 2000, MOL BIOL EVOL, V17, P278, DOI 10.1093/oxfordjournals.molbev.a026307; Saenger W., 1984, PRINCIPLES NUCL ACID; SANTI S, 1994, BIOL CELL, V81, P47, DOI 10.1016/0248-4900(94)90054-X; Sorgi FL, 1997, GENE THER, V4, P961, DOI 10.1038/sj.gt.3300484; SUAU P, 1977, J MOL BIOL, V117, P909, DOI 10.1016/S0022-2836(77)80005-3; SUWALSKY M, 1972, BIOPOLYMERS, V11, P2223, DOI 10.1002/bip.1972.360111103; Tecle M, 2003, BIOCHEMISTRY-US, V42, P10343, DOI 10.1021/bi034325e; Torgerson DG, 2002, MOL BIOL EVOL, V19, P1973, DOI 10.1093/oxfordjournals.molbev.a004021; VERDAGUER N, 1993, EUR J BIOCHEM, V214, P879, DOI 10.1111/j.1432-1033.1993.tb17991.x; Zintchenko A, 2003, LANGMUIR, V19, P2507, DOI 10.1021/la0265427	54	79	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20088	20095		10.1074/jbc.M312777200	http://dx.doi.org/10.1074/jbc.M312777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14990583	hybrid			2022-12-27	WOS:000221164500085
J	Alexander, DC; Jones, JRW; Tan, T; Chen, JM; Liu, J				Alexander, DC; Jones, JRW; Tan, T; Chen, JM; Liu, J			PimF, a mannosyltransferase of mycobacteria, is involved in the biosynthesis of phosphatidylinositol mannosides and lipoarabinomannan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; DC-SIGN; TUBERCULOSIS H37RV; ACYLATION STATE; MATURATION; PHAGOSOME; IDENTIFICATION; RECEPTOR; DEFINITION; LIPOMANNAN	Phosphatidylinositol mannosides (PIMs) and their related molecules lipomannan (LM) and lipoarabinomannan ( LAM) are important components of the mycobacterial cell wall. These molecules mediate host-pathogen interactions and exhibit immunomodulatory activities. The biosynthesis of these lipoglycans is not fully understood. In this study, we have identified a mycobacterial gene (Rv1500) that is involved in the synthesis of PIMs. We have named this gene pimF. Transposon mutagenesis of pimF of Mycobacterium marinum resulted in multiple phenotypes, including altered colony morphology, disappearance of tetracyl-PIM7, and accumulation of tetraacyl-PIM5. The syntheses of LAM and LM were also affected. In addition, the pimF mutant exhibited a defect during infection of cultured macrophage cells. Although the mutant was able to replicate and persist within macrophages, the initial cell entry step was inefficient. Transformation of the M. marinum mutant with the pimF homolog of Mycobacterium tuberculosis complemented all of the above mentioned phenotypes. These results provide evidence that PimF is a mannosyltransferase. However, sequence analysis indicates that PimF is distinct from mannosyltransferases involved in the early steps of PIM synthesis. PimF catalyzes the formation of high molecular weight PIMs, which are precursors for the synthesis of LAM and LM. As such, this work marks the first analysis of a mannosyltransferase involved in the later stages of PIM synthesis.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Liu, J (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 4382 Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	jun.liu@utoronto.ca	Liu, Jun/AAC-9209-2019	Liu, Jun/0000-0002-0522-6733; Chen, Jeffrey/0000-0001-8431-3802	NIAID NIH HHS [N01-AI-75320] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI075320] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdian PL, 2000, J BIOL CHEM, V275, P40568, DOI 10.1074/jbc.M007496200; Apostolou I, 1999, P NATL ACAD SCI USA, V96, P5141, DOI 10.1073/pnas.96.9.5141; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Besra GS, 1998, METH MOL B, V101, P91, DOI 10.1385/0-89603-471-2:91; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Ernst JD, 1998, INFECT IMMUN, V66, P1277, DOI 10.1128/IAI.66.4.1277-1281.1998; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Fratti RA, 2003, P NATL ACAD SCI USA, V100, P5437, DOI 10.1073/pnas.0737613100; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; Gurcha SS, 2002, BIOCHEM J, V365, P441, DOI 10.1042/BJ20020107; HOWARD NS, 1995, GENE, V166, P181, DOI 10.1016/0378-1119(95)00597-X; Kaur D, 2002, MICROBIOL-SGM, V148, P3049, DOI 10.1099/00221287-148-10-3049; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Kordulakova J, 2003, J BIOL CHEM, V278, P36285, DOI 10.1074/jbc.M303639200; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; Liu J, 1999, MYCOBACTERIA MOL BIO, P220; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; MORITA YS, 2003, BIOCH J; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; Platt R, 2000, PLASMID, V43, P12, DOI 10.1006/plas.1999.1433; RAMAKRISHNAN L, 1994, INFECT IMMUN, V62, P3222, DOI 10.1128/IAI.62.8.3222-3229.1994; Sassetti CM, 2001, P NATL ACAD SCI USA, V98, P12712, DOI 10.1073/pnas.231275498; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; Strohmeier GR, 1999, MICROBES INFECT, V1, P709, DOI 10.1016/S1286-4579(99)80072-0; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Vergne I, 2003, J EXP MED, V198, P653, DOI 10.1084/jem.20030527; XU SM, 1994, J IMMUNOL, V153, P2568	40	51	55	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18824	18833		10.1074/jbc.M400791200	http://dx.doi.org/10.1074/jbc.M400791200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14960574	hybrid			2022-12-27	WOS:000221041500091
J	Askwith, CC; Wemmie, JA; Price, MP; Rokhlina, T; Welsh, MJ				Askwith, CC; Wemmie, JA; Price, MP; Rokhlina, T; Welsh, MJ			Acid-sensing ion channel 2 (ASIC2) modulates ASIC1 H+-activated currents in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED NA+ CHANNEL; EPITHELIAL SODIUM-CHANNEL; ROOT GANGLION-CELLS; ION-CHANNEL; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; SENSORY NEURONS; CATION CHANNEL; CHROMOSOMAL LOCALIZATION; CAENORHABDITIS-ELEGANS	Hippocampal neurons express subunits of the acid-sensing ion channel (ASIC1 and ASIC2) and exhibit large cation currents that are transiently activated by acidic extracellular solutions. Earlier work indicated that ASIC1 contributed to the current in these neurons and suggested its importance for normal behavior. However, the specific contribution of ASIC1 and ASIC2 subunits to acid-evoked currents in hippocampal neurons remained uncertain. To decipher the individual role of the ASIC subunits, we studied H+-gated currents in neurons from both ASIC1 and ASIC2 null mice. We found that much of the current was produced by ASIC1a/2a heteromultimeric channels, and individual subunits made distinct contributions. The ASIC1a subunit was key in establishing current amplitude. The ASIC2a subunit had little effect on amplitude but influenced desensitization, recovery from desensitization, pH sensitivity, and the response to modulatory agents. We also found heterogeneity in the contribution of ASIC2 throughout the neuronal population, with individual neurons expressing both ASIC1a homomultimeric and ASIC1a/2a heteromultimeric channels. Studies of neurons heterozygous for disrupted ASIC alleles indicated that the properties of H+-gated currents are dependent on the proportion of the individual subunits. These findings indicate that the absolute and relative amounts of ASIC subunits determine the amplitude and properties of hippocampal H+-gated currents and therefore may contribute to normal physiology and pathophysiology.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Welsh, MJ (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Howard Hughes Med Inst, 500 EMRB, Iowa City, IA 52242 USA.	michael-welsh@uiowa.edu		Wemmie, John/0000-0001-7531-9065; Welsh, Michael/0000-0002-1646-6206	NHLBI NIH HHS [HL61234] Funding Source: Medline; NIDDK NIH HHS [DK54759] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL061234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; AKAIKE N, 1990, J NEUROPHYSIOL, V63, P805, DOI 10.1152/jn.1990.63.4.805; Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; Berdiev BK, 2001, J BIOL CHEM, V276, P38755, DOI 10.1074/jbc.M107266200; Biagini G, 2001, NEUROBIOL DIS, V8, P45, DOI 10.1006/nbdi.2000.0331; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Catarsi S, 2001, NEUROPHARMACOLOGY, V41, P592, DOI 10.1016/S0028-3908(01)00107-1; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; de la Rosa DA, 2003, J PHYSIOL-LONDON, V546, P77, DOI 10.1113/jphysiol.2002.030692; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; Deval E, 2003, NEUROPHARMACOLOGY, V44, P662, DOI 10.1016/S0028-3908(03)00047-9; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Grunder S, 2000, NEUROREPORT, V11, P1607; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V245, P589, DOI 10.1006/bbrc.1998.8483; Ji HJ, 2002, J BIOL CHEM, V277, P8395, DOI 10.1074/jbc.M109465200; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; Jovov B, 2003, HISTOCHEM CELL BIOL, V119, P437, DOI 10.1007/s00418-003-0525-4; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Mehta AK, 1999, BRAIN RES REV, V29, P196, DOI 10.1016/S0165-0173(98)00052-6; MENNERICK S, 1995, J NEUROPHYSIOL, V73, P320, DOI 10.1152/jn.1995.73.1.320; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Sakai H, 1999, J PHYSIOL-LONDON, V519, P323, DOI 10.1111/j.1469-7793.1999.0323m.x; Schaefer L, 2000, FEBS LETT, V471, P205, DOI 10.1016/S0014-5793(00)01403-4; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Ueda T, 2003, J NEUROSCI, V23, P7376; Ugawa S, 2001, NEUROREPORT, V12, P2865, DOI 10.1097/00001756-200109170-00022; Varming T, 1999, NEUROPHARMACOLOGY, V38, P1875, DOI 10.1016/S0028-3908(99)00079-9; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Welsh MJ, 2002, J BIOL CHEM, V277, P2369, DOI 10.1074/jbc.R100060200; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Xie JH, 2002, J NEUROPHYSIOL, V87, P2835, DOI 10.1152/jn.2002.87.6.2835; Zhang P, 2001, J GEN PHYSIOL, V117, P563, DOI 10.1085/jgp.117.6.563	60	176	184	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18296	18305		10.1074/jbc.M312145200	http://dx.doi.org/10.1074/jbc.M312145200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14960591	hybrid			2022-12-27	WOS:000221041500026
J	Thomas, T; Telford, D; Laird, DW				Thomas, T; Telford, D; Laird, DW			Functional domain mapping and selective trans-dominant effects exhibited by Cx26 disease-causing mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; DOMINANT CONNEXIN DISORDERS; BREAST-TUMOR CELLS; INTERCELLULAR COMMUNICATION; HEARING-LOSS; DIFFERENTIAL EXPRESSION; VOLTAGE-DEPENDENCE; MISSENSE MUTATION; RAT EPIDERMIS; GENE DELIVERY	Mutations in Cx26 are a major cause of autosomal dominant and recessive forms of sensorineural deafness. Some mutations in Cx26 are associated not only with deafness but also with skin disease. We examined the subcellular localization and function of two green fluorescent protein (GFP)-tagged Cx26 point mutants that exhibit both phenotypes, G59A-GFP and D66H-GFP. D66H-GFP was retained within the brefeldin A-insensitive trans-Golgi network, whereas a population of G59A-GFP was transported to the cell surface. Neither G59A nor D66H formed gap junctions that were permeable to small fluorescent dyes, suggesting they are loss-of-function mutations. When co-expressed with wild-type Cx26, both G59A and D66H exerted dominant-negative effects on Cx26 function. G59A also exerted a trans-dominant negative effect on co-expressed wild type Cx32 and Cx43, whereas D66H exerted a trans-dominant negative effect on Cx43 but not Cx32. We propose that the severity of the skin disease is dependent on the specific nature of the Cx26 mutation and the trans-dominant selectivity of the Cx26 mutants on co-expressed connexins. Additional systematic mutations at residue D66, in which the overall charge of this motif was altered, suggested that the first extracellular loop is critical for Cx26 transport to the cell surface as well as function of the resulting gap junction channels.	Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Laird, DW (corresponding author), Dent Sci Bldg,Rm 00077, London, ON N6A 5C1, Canada.	dwlaird@uwo.ca	Laird, Dale W/AAL-2407-2020; Laird, Dale w/E-4176-2015	Laird, Dale W/0000-0002-4568-3285; 				Ahmad S, 1999, BIOCHEM J, V339, P247, DOI 10.1042/0264-6021:3390247; Bakirtzis G, 2003, HUM MOL GENET, V12, P1737, DOI 10.1093/hmg/ddg183; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Beyer EC, 2001, CELL COMMUN ADHES, V8, P199, DOI 10.3109/15419060109080723; Brink PR, 1997, AM J PHYSIOL-CELL PH, V273, pC1386, DOI 10.1152/ajpcell.1997.273.4.C1386; BRUZZONE R, 1994, J CELL SCI, V107, P955; Bruzzone R, 1996, BIOESSAYS, V18, P709, DOI 10.1002/bies.950180906; BUTTERWECK A, 1994, EUR J CELL BIOL, V65, P152; Choudhry R, 1997, DEV DYNAM, V210, P417, DOI 10.1002/(SICI)1097-0177(199712)210:4<417::AID-AJA6>3.3.CO;2-0; Cohen-Salmon M, 2002, CURR BIOL, V12, P1106, DOI 10.1016/S0960-9822(02)00904-1; Cohn ES, 1999, PEDIATRICS, V103, P546, DOI 10.1542/peds.103.3.546; Cottrell GT, 2001, CELL COMMUN ADHES, V8, P193, DOI 10.3109/15419060109080722; De Maio A, 2002, J CELL PHYSIOL, V191, P269, DOI 10.1002/jcp.10108; Di WL, 2001, CELL COMMUN ADHES, V8, P415, DOI 10.3109/15419060109080763; Di WL, 2001, J INVEST DERMATOL, V117, P958, DOI 10.1046/j.0022-202x.2001.01468.x; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; FUJIKURA Y, 1993, ANAT REC, V235, P335, DOI 10.1002/ar.1092350302; Gabriel HD, 1998, J CELL BIOL, V140, P1453, DOI 10.1083/jcb.140.6.1453; Galipeau J, 1999, CANCER RES, V59, P2384; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; GOLIGER JA, 1995, MOL BIOL CELL, V6, P1491, DOI 10.1091/mbc.6.11.1491; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; He DS, 1999, P NATL ACAD SCI USA, V96, P6495, DOI 10.1073/pnas.96.11.6495; Heathcote K, 2000, J MED GENET, V37, P50, DOI 10.1136/jmg.37.1.50; HENNEMANN H, 1992, EUR J CELL BIOL, V57, P51; Kelley PM, 2000, BRAIN RES REV, V32, P184, DOI 10.1016/S0165-0173(99)00080-6; Kelsell DP, 2000, EUR J HUM GENET, V8, P468, DOI 10.1038/sj.ejhg.5200510; Kelsell DP, 2001, TRENDS CELL BIOL, V11, P2, DOI 10.1016/S0962-8924(00)01866-3; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; Labarthe MP, 1998, J INVEST DERMATOL, V111, P72, DOI 10.1046/j.1523-1747.1998.00248.x; Laird DW, 1999, CANCER RES, V59, P4104; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Lee MJ, 1998, MOL CELLS, V8, P295; Lefebvre PP, 2000, BRAIN RES REV, V32, P159; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; Lucke T, 1999, J INVEST DERMATOL, V112, P354, DOI 10.1046/j.1523-1747.1999.00512.x; Maestrini E, 1999, HUM MOL GENET, V8, P1237, DOI 10.1093/hmg/8.7.1237; Mao AJ, 2000, J BIOL CHEM, V275, P34407, DOI 10.1074/jbc.M003917200; Marziano NK, 2003, HUM MOL GENET, V12, P805, DOI 10.1093/hmg/ddg076; MasgrauPeya E, 1997, J HISTOCHEM CYTOCHEM, V45, P1207, DOI 10.1177/002215549704500904; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; Nicholson BJ, 2000, BRAZ J MED BIOL RES, V33, P369, DOI 10.1590/S0100-879X2000000400002; Niessen H, 2000, J CELL SCI, V113, P1365; Oshima A, 2003, J BIOL CHEM, V278, P1807, DOI 10.1074/jbc.M207713200; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Qin H, 2003, J BIOL CHEM, V278, P30005, DOI 10.1074/jbc.M300614200; Rabionet R, 2000, HUM MUTAT, V16, P190, DOI 10.1002/1098-1004(200009)16:3<190::AID-HUMU2>3.3.CO;2-9; Richard G, 1998, HUM GENET, V103, P393, DOI 10.1007/s004390050839; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Risek B, 1998, J CELL SCI, V111, P1395; Rouan F, 2001, J CELL SCI, V114, P2105; RUBIN JB, 1992, BIOPHYS J, V62, P183, DOI 10.1016/S0006-3495(92)81804-0; RUBIN JB, 1992, P NATL ACAD SCI USA, V89, P3820, DOI 10.1073/pnas.89.9.3820; SALOMON D, 1994, J INVEST DERMATOL, V103, P240, DOI 10.1111/1523-1747.ep12393218; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; WHITE TW, 1994, J CELL BIOL, V125, P879, DOI 10.1083/jcb.125.4.879; White TW, 1996, J BIOENERG BIOMEMBR, V28, P339, DOI 10.1007/BF02110110; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Wiszniewski L, 2000, J INVEST DERMATOL, V115, P278, DOI 10.1046/j.1523-1747.2000.00043.x; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X	62	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19157	19168		10.1074/jbc.M314117200	http://dx.doi.org/10.1074/jbc.M314117200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978038	hybrid			2022-12-27	WOS:000221041500129
J	Vora, A; Bera, S; Grandgenett, D				Vora, A; Bera, S; Grandgenett, D			Structural organization of avian retrovirus integrase in assembled intasomes mediating full-site integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; TO-AUTOINTEGRATION FACTOR; VIRAL-DNA ENDS; TYPE-1 PREINTEGRATION COMPLEXES; IN-VITRO; HIV-1 INTEGRASE; STRAND-TRANSFER; REVERSE TRANSCRIPTION; CONCERTED INTEGRATION; CRYSTAL-STRUCTURE	Retrovirus preintegration complexes (PIC) purified from virus-infected cells are competent for efficient concerted integration of the linear viral DNA ends by integrase (IN) into target DNA (full-site integration). In this report, we have shown that the assembled complexes (intasomes) formed in vitro with linear 3.6-kbp DNA donors possessing 3'-OH-recessed attachment (att) site sequences and avian myeloblastosis virus IN (4 nM) were as competent for full-site integration as isolated retrovirus PIC. The att sites on DNA with 3'-OH-recessed ends were protected by IN in assembled intasomes from DNase I digestion up to similar to20 bp from the terminus. Several DNA donors containing either normal blunt-ended att sites or different end mutations did not allow assembly of complexes that exhibit the similar to20-bp DNase I footprint at 14 degreesC. At 50 and 100 mM NaCl, the similar to 20-bp DNase I footprints were produced with wild type (wt) U3 and gain-of-function att site donors for full-site integration as previously observed at 320 mM NaCl. Although the wt U5 att site donors were fully competent for full-site integration at 37 degreesC, the similar to20-bp DNase I footprint was not observed under a variety of assembly conditions including low NaCl concentrations at 14 degreesC. Under suboptimal assembly conditions for intasomes using U3 att DNA, DNase I probing demonstrated an enhanced cleavage site 9 bp from the end of U3 suggesting that a transient structural intasome intermediate was identified. Using a single nucleotide change at position 7 from the end and a series of small size deletions of wt U3 att site sequences, we determined that sequences upstream of the 11th nucleotide position were not required by IN to produce the similar to 20-bp DNase I footprint and full-site integration. The results suggest the structural organization of IN at the att sites in reconstituted intasomes was similar to that observed in PIC.	St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Grandgenett, D (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA.	Grandgdp@slu.edu			NATIONAL CANCER INSTITUTE [R01CA016312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031334] Funding Source: NIH RePORTER; NCI NIH HHS [CA16312] Funding Source: Medline; NIAID NIH HHS [AI31334] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beitzel B, 2003, NUCLEIC ACIDS RES, V31, P5025, DOI 10.1093/nar/gkg684; Brin E, 2002, J BIOL CHEM, V277, P18357, DOI 10.1074/jbc.M201354200; Brown HEV, 1999, J VIROL, V73, P9011, DOI 10.1128/JVI.73.11.9011-9020.1999; Brown P. O., 1997, P161; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; Chaconas G, 1996, CURR BIOL, V6, P817, DOI 10.1016/S0960-9822(02)00603-6; Chen HM, 2000, J VIROL, V74, P8188, DOI 10.1128/JVI.74.17.8188-8193.2000; Chen HM, 2001, MOL CELL BIOL, V21, P6758, DOI 10.1128/MCB.21.20.6758-6767.2001; Chen HM, 1999, J BIOL CHEM, V274, P17358, DOI 10.1074/jbc.274.24.17358; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; Chiu R, 2003, J VIROL, V77, P6482, DOI 10.1128/JVI.77.11.6482-6492.2003; Chiu R, 2000, J VIROL, V74, P8292, DOI 10.1128/JVI.74.18.8292-8298.2000; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; Craigie R, 2002, MOBILE DNA, P613; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Hindmarsh P, 2001, J VIROL, V75, P1132, DOI 10.1128/JVI.75.3.1132-1141.2001; KNAUS RJ, 1984, BIOCHEMISTRY-US, V23, P350, DOI 10.1021/bi00297a026; Leclercq I, 2003, J VIROL METHODS, V109, P105, DOI 10.1016/S0166-0934(03)00052-1; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; Lin CW, 2003, J VIROL, V77, P5030, DOI 10.1128/JVI.77.8.5030-5036.2003; Mansharamani M, 2003, J VIROL, V77, P13084, DOI 10.1128/JVI.77.24.13084-13092.2003; Masuda T, 1998, J VIROL, V72, P8396, DOI 10.1128/JVI.72.10.8396-8402.1998; McCord M, 1999, VIROLOGY, V259, P392, DOI 10.1006/viro.1999.9782; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MURPHY JE, 1989, J VIROL, V63, P319, DOI 10.1128/JVI.63.1.319-327.1989; REICIN AS, 1995, J VIROL, V69, P5904, DOI 10.1128/JVI.69.9.5904-5907.1995; Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166; Suzuki Y, 2002, J VIROL, V76, P12376, DOI 10.1128/JVI.76.23.12376-12380.2002; Villanueva RA, 2003, VIROLOGY, V316, P146, DOI 10.1016/S0042-6822(03)00559-2; Vora A, 2001, J VIROL, V75, P3556, DOI 10.1128/JVI.75.8.3556-3567.2001; VORA AC, 1995, J VIROL, V69, P7483, DOI 10.1128/JVI.69.12.7483-7488.1995; Vora AC, 1997, J BIOL CHEM, V272, P23938, DOI 10.1074/jbc.272.38.23938; VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wang T, 1999, BIOCHEMISTRY-US, V38, P3624, DOI 10.1021/bi982124i; Wei SQ, 1997, EMBO J, V16, P7511, DOI 10.1093/emboj/16.24.7511; Wei SQ, 1998, P NATL ACAD SCI USA, V95, P10535, DOI 10.1073/pnas.95.18.10535; Williams TL, 2000, SCIENCE, V289, P73, DOI 10.1126/science.289.5476.73; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Zhou HB, 2001, J VIROL, V75, P1359, DOI 10.1128/JVI.75.3.1359-1370.2001	50	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18670	18678		10.1074/jbc.M314270200	http://dx.doi.org/10.1074/jbc.M314270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14990573	hybrid			2022-12-27	WOS:000221041500072
J	Chand, HS; Schmidt, AE; Bajaj, SP; Kisiel, W				Chand, HS; Schmidt, AE; Bajaj, SP; Kisiel, W			Structure-function analysis of the reactive site in the first Kunitz-type domain of human tissue factor pathway inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; FACTOR ACTIVATOR INHIBITOR; PROTEASE INHIBITOR; MESSENGER-RNA; CRYSTAL-STRUCTURE; PROTEINASE-INHIBITORS; MOLECULAR-CLONING; BOVINE TRYPSIN; CDNA CLONING; HUMAN SKIN	Human tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type proteinase inhibitor that regulates a variety of serine proteinases involved in coagulation and fibrinolysis through their non-productive interaction with a P-1 residue (Arg-24) in its first Kunitz-type domain (KD1). Previous kinetic studies revealed that TFPI-2 was a more effective inhibitor of plasmin than several other serine proteinases, but the molecular basis for this specificity was unclear. In this study, we employed molecular modeling and mutagenesis strategies to produce several variants of human TFPI-2 KD1 in an effort to identify interactive site residues other than the P-1 Arg that contribute significantly to its inhibitory activity and specificity. Molecular modeling of KD1 based on the crystal structure of bovine pancreatic trypsin inhibitor revealed that KD1 formed a more energetically favorable complex with plasmin versus trypsin and/or the factor VIIa-tissue factor complex primarily due to strong ionic interactions between Asp-19 (P-6) and Arg residues in plasmin (Arg-644, Arg-719, and Arg-767), Arg-24 (P-1) with Asp- 735 in plasmin, and Arg-29 (P-5') with Glu-606 in plasmin. In addition, Leu-26 through Leu-28 (P-2'-P-4') in KD1 formed strong van der Waals contact with a hydrophobic cluster in plasmin (Phe-583, Met-585, and Phe-587). Mutagenesis of Asp-19, Tyr-20, Arg-24, Arg-29, and Leu-26 in KD1 resulted in substantial reductions in plasmin inhibitory activity relative to wild-type KD1, but the Asp-19 and Tyr-20 mutations revealed the importance of these residues in the specific inhibition of plasmin. In addition to the reactive site residues in the P-6-P-5' region of KD1, mutation of a highly conserved Phe at the P-18' position revealed the importance of this residue in the inhibition of serine proteinases by KD1. Thus, together with the P-1 residue, the nature of other residues flanking the P-1 residue, particularly at P-6 and P-5', strongly influences the inhibitory activity and specificity of human TFPI-2.	Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ Calif Los Angeles, Orthopaed Hosp, Dept Orthopaed Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kisiel, W (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pathol, MSC08,4640M,1 Univ New Mexico, Albuquerque, NM 87131 USA.	wkisiel@salud.unm.edu	Chand, Hitendra/AAE-7975-2020	Chand, Hitendra/0000-0002-0574-9307	NHLBI NIH HHS [HL70369, HL64119] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070369, R01HL064119] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajaj MS, 2001, THROMB HAEMOSTASIS, V86, P959; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; Burgering MJM, 1997, J MOL BIOL, V269, P395, DOI 10.1006/jmbi.1997.1029; Castro MJM, 1996, BIOCHEMISTRY-US, V35, P11435, DOI 10.1021/bi960515w; Chand HS, 2004, BLOOD, V103, P1069, DOI 10.1182/blood-2003-06-1930; Cottrell GS, 2004, J BIOL CHEM, V279, P13532, DOI 10.1074/jbc.M312090200; CREIGHTON TE, 1987, J MOL BIOL, V194, P11, DOI 10.1016/0022-2836(87)90711-X; DROBNICKOSOROK M, 1990, BIOL CHEM H-S, V371, P57, DOI 10.1515/bchm3.1990.371.1.57; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; Grzesiak A, 2000, J BIOL CHEM, V275, P33346, DOI 10.1074/jbc.M006085200; Herman MP, 2001, J CLIN INVEST, V107, P1117, DOI 10.1172/JCI10403; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; JANIN J, 1990, J BIOL CHEM, V265, P16027; Kamei S, 1999, THROMB RES, V94, P147, DOI 10.1016/S0049-3848(98)00205-9; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Kobayashi H, 2004, CANCER-AM CANCER SOC, V100, P869, DOI 10.1002/cncr.20034; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Kraunsoe JAE, 1996, FEBS LETT, V396, P108, DOI 10.1016/0014-5793(96)01081-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nirmala X, 2001, EUR J BIOCHEM, V268, P2064, DOI 10.1046/j.1432-1327.2001.02084.x; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; RAO CN, 1995, J INVEST DERMATOL, V104, P379, DOI 10.1111/1523-1747.ep12665851; Sambrook J., 2001, MOL CLONING LAB MANU; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; STALLINGSMANN ML, 1994, J BIOL CHEM, V269, P24090; STASSEN JM, 1995, THROMB HAEMOSTASIS, V74, P655; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sugiyama T, 2002, FEBS LETT, V517, P121, DOI 10.1016/S0014-5793(02)02588-7; TSCHESCHE H, 1987, BIOCHIM BIOPHYS ACTA, V913, P97, DOI 10.1016/0167-4838(87)90238-X; Udagawa K, 1998, PLACENTA, V19, P217, DOI 10.1016/S0143-4004(98)90011-X; VANNOSTRAND WE, 1995, J BIOL CHEM, V270, P22827, DOI 10.1074/jbc.270.39.22827; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WENZEL HR, 1982, FEBS LETT, V140, P53, DOI 10.1016/0014-5793(82)80519-X; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; WLODAWER A, 1987, J MOL BIOL, V193, P145, DOI 10.1016/0022-2836(87)90633-4; WUN TC, 1988, J BIOL CHEM, V263, P6001; Xu YB, 1998, J MOL BIOL, V276, P955, DOI 10.1006/jmbi.1997.1582; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452	59	52	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17500	17507		10.1074/jbc.M400802200	http://dx.doi.org/10.1074/jbc.M400802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970225	hybrid			2022-12-27	WOS:000220870400077
J	Yuan, C; Kent, C				Yuan, C; Kent, C			Identification of critical residues of choline kinase A2 from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ATP-BINDING; CHOLINE/ETHANOLAMINE KINASE; ESCHERICHIA-COLI; PHOSPHATIDYLCHOLINE METABOLISM; ETHANOLAMINE KINASE; NUCLEOTIDE-BINDING; CATALYTIC SUBUNIT	Choline kinase catalyzes the phosphorylation of choline by ATP, the first committed step in the CDP-choline pathway for phosphatidylcholine biosynthesis. To begin to elucidate the mechanism of catalysis by this enzyme, choline kinase A-2 from Caenorhabditis elegans was analyzed by systematic mutagenesis of highly conserved residues followed by analysis of kinetic and structural parameters. Specifically, mutants were analyzed with respect to K-m and k(cat) values for each substrate and Mg2+, inhibitory constants for Mg2+ and Ca2+, secondary structure as monitored by circular dichroism, and sensitivity to unfolding in guanidinium hydrochloride. The most severe impairment of catalysis occurred with the modification of Asp-255 and Asn-260, which are located in the conserved Brenner's phosphotransferase motif, and Asp-301 and Glu-303, in the signature choline kinase motif. For example, mutation of Asp-255 or Asp-301 to Ala eliminated detectable catalytic activity, and mutation of Asn-260 and Glu-303 to Ala decreased k(cat) by 300- and 10-fold, respectively. Additionally, the K-m for Mg2+ for mutants N260A and E303A was approximately 30-fold higher than that of wild type. Several other residues (Ser-86, Arg-111, Glu-125, and Trp-387) were identified as being important: Catalytic efficiencies (k(cat)/K-m) for the enzymes in which these residues were mutated to Ala were reduced to 2-25% of wild type. The high degree of structural similarity among choline kinase A-2, aminoglycoside phosphotransferases, and protein kinases, together with the results from this mutational analysis, indicates it is likely that these conserved residues are located at the catalytic core of choline kinase.	Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kent, C (corresponding author), 1497 Vista Claridad, La Jolla, CA 92037 USA.	ckent@umich.edu			NIGMS NIH HHS [GM60510] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060510] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyama C, 1998, BBA-LIPID LIPID MET, V1390, P1, DOI 10.1016/S0005-2760(97)00177-X; Aoyama C, 2000, J LIPID RES, V41, P452; BAIROCH A, 1988, NATURE, V331, P22, DOI 10.1038/331022a0; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; Boehr DD, 2001, J BIOL CHEM, V276, P23929, DOI 10.1074/jbc.M100540200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; Brown M, 2000, J EXP MED, V191, P2101, DOI 10.1084/jem.191.12.2101; Burk DL, 2001, BIOCHEMISTRY-US, V40, P8756, DOI 10.1021/bi010504p; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CUADRADO A, 1993, ONCOGENE, V8, P2959; de Molina AR, 2001, BIOCHEM BIOPH RES CO, V285, P873, DOI 10.1006/bbrc.2001.5250; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Deyrup AT, 1998, J BIOL CHEM, V273, P9450, DOI 10.1074/jbc.273.16.9450; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fernandez-Tornero C, 2002, J MOL BIOL, V321, P163, DOI 10.1016/S0022-2836(02)00596-X; Gee P, 2003, BBA-PROTEINS PROTEOM, V1648, P33, DOI 10.1016/S1570-9639(03)00106-7; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hishida T, 1999, J BIOL CHEM, V274, P25335, DOI 10.1074/jbc.274.36.25335; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; Hutter MC, 1999, PROTEIN SCI, V8, P2728; Ishidate K, 1997, BBA-LIPID LIPID MET, V1348, P70, DOI 10.1016/S0005-2760(97)00118-5; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; Kim KH, 1998, J BIOL CHEM, V273, P6844, DOI 10.1074/jbc.273.12.6844; Kim KS, 1999, J BIOL CHEM, V274, P14857, DOI 10.1074/jbc.274.21.14857; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Lykidis A, 2001, J BIOL CHEM, V276, P2174, DOI 10.1074/jbc.M008794200; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P14115, DOI 10.1021/bi00251a021; Monks DE, 1996, PLANT PHYSIOL, V110, P1197, DOI 10.1104/pp.110.4.1197; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; PAVLIDIS P, 1994, CELL, V79, P23, DOI 10.1016/0092-8674(94)90397-2; Peisach D, 2003, STRUCTURE, V11, P703, DOI 10.1016/S0969-2126(03)00094-7; PORTER TJ, 1990, J BIOL CHEM, V265, P414; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; Runquist JA, 2001, BIOCHEMISTRY-US, V40, P14530, DOI 10.1021/bi010778c; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; Thompson PR, 2002, BIOCHEMISTRY-US, V41, P7001, DOI 10.1021/bi0256680; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; WITTENBERG J, 1953, J BIOL CHEM, V202, P431; Yu Y, 2002, J BIOL CHEM, V277, P34978, DOI 10.1074/jbc.M205316200; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	50	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17801	17809		10.1074/jbc.M401382200	http://dx.doi.org/10.1074/jbc.M401382200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960577	hybrid			2022-12-27	WOS:000220870400112
J	Gardner, LA; Delos Santos, NM; Matta, SG; Whitt, MA; Bahouth, SW				Gardner, LA; Delos Santos, NM; Matta, SG; Whitt, MA; Bahouth, SW			Role of the cyclic AMP-dependent protein kinase in homologous resensitization of the beta(1)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DOWN-REGULATION; BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; DIFFERENTIAL REGULATION; BETA-ARRESTINS; MESSENGER-RNA; ENDOCYTOSIS; DESENSITIZATION; INTERNALIZATION; AGONIST	A fundamental question in biology is how the various motifs in G protein-coupled receptors participate in the divergent functions orchestrated by these molecules. Here we describe a fundamental role for a serine residue at position 312 in the third intracellular loop of the human beta(1)-adrenergic receptor (beta(1)-AR) in endocytic recycling of the agonist-internalized receptor. In receptor recycling experiments that were monitored by confocal microscopy, the agonist-internalized wild-type (WT) beta(1)-AR recycled with a t(0.5) of 14 +/- 3 min. Mutagenesis of Ser(312) to alanine (Ser(312) --> Ala beta(1)-AR) or to the phosphoserine mimic aspartic acid (Ser(312 -->) Asp beta(1)-AR) resulted in beta(1)-AR constructs that were pharmacologically indistinguishable from the WT beta(1)-AR. The internalized Ser(312) --> Asp beta(1)-AR recycled efficiently with a t(0.5) of 11 +/- 3 min, whereas the internalized Ser(312) --> Ala beta(1)-AR was not recycled or functionally resensitized through the endosomal pathway. Because this serine is a putative residue for phosphorylation by the cyclic AMP-dependent protein kinase (PKA), we examined the role of this kinase in recycling of the internalized beta(1)-AR. Inhibition of PKA biochemically or genetically using a dominant negative PKA construct blocked the recycling of the internalized WT beta(1)-AR. Phosphorylation studies revealed that the beta(1)-AR is partially phosphorylated by PKA and that phosphorylation of the beta(1)-AR by the catalytic subunit of PKA occurs exclusively at Ser(312). Our results identify a new signaling paradigm in which homologous activation of a kinase provides a reversible modification that shifts the itinerary of the internalized receptor toward recycling and resensitization. Therefore, PKA-mediated phosphorylation of G protein-coupled receptors might result in motif-dependent desensitization or resensitization.	Univ Tennessee, Hlth Sci Ctr, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Bahouth, SW (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	sbahouth@utmem.edu			NCRR NIH HHS [S10 RR 13725] Funding Source: Medline; NHLBI NIH HHS [F32 HL 71419] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013725] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL071419] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiyama C, 1999, JPN J PHARMACOL, V81, P12, DOI 10.1254/jjp.81.12; Bahouth SW, 1996, MOL PHARMACOL, V49, P1049; BAHOUTH SW, 1995, BIOCHEM J, V307, P831, DOI 10.1042/bj3070831; Bahouth SW, 2001, BIOCHEM PHARMACOL, V62, P1211, DOI 10.1016/S0006-2952(01)00789-4; Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Clark RB, 2002, METHOD ENZYMOL, V343, P506; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dunigan CD, 2002, BIOCHEMISTRY-US, V41, P8019, DOI 10.1021/bi025538r; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Garland AM, 1996, MOL PHARMACOL, V49, P438; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HERTEL C, 1985, J BIOL CHEM, V260, P2547; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Katsura T, 1997, Am J Physiol, V272, pF817; Kirigiti P, 2001, MOL PHARMACOL, V60, P1308, DOI 10.1124/mol.60.6.1308; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; ROGERS KV, 1990, P NATL ACAD SCI USA, V87, P8975, DOI 10.1073/pnas.87.22.8975; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; VON ZM, 1992, J BIOL CHEM, V267, P3530; WALDO GL, 1983, J BIOL CHEM, V258, P3900; WALSH DA, 1991, METHOD ENZYMOL, V201, P304; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Wolf R, 1999, MOL PHARMACOL, V55, P263, DOI 10.1124/mol.55.2.263; WU JZ, 1994, BIOCHEMISTRY-US, V33, P14825, DOI 10.1021/bi00253a022; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; YU SS, 1993, J BIOL CHEM, V268, P337; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	47	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21135	21143		10.1074/jbc.M313652200	http://dx.doi.org/10.1074/jbc.M313652200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14990580	hybrid			2022-12-27	WOS:000221273800071
J	Gille, A; Lushington, GH; Mou, TC; Doughty, MB; Johnson, RA; Seifert, R				Gille, A; Lushington, GH; Mou, TC; Doughty, MB; Johnson, RA; Seifert, R			Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; G-PROTEIN ACTIVATION; CATALYTIC MECHANISM; GTP ANALOGS; SF9 CELLS; NUCLEOSIDE 3-POLYPHOSPHATES; BORDETELLA-PERTUSSIS; LIGAND INTERACTIONS; BACILLUS-ANTHRACIS; CYTOSOLIC DOMAINS	Mammals express nine membranous adenylyl cyclase isoforms (ACs 1-9), a structurally related soluble guanylyl cyclase (sGC) and a soluble AC (sAC). Moreover, Bacillus anthracis and Bacillus pertussis produce the AC toxins, edema factor (EF), and adenylyl cyclase toxin (ACT), respectively. 2'(3')-O-(N-methylanthraniloyl)guanosine 5'-[gamma-thio]triphosphate is a potent competitive inhibitor of AC in S49 lymphoma cell membranes. These data prompted us to study systematically the effects of 24 nucleotides on AC in S49 and Sf9 insect cell membranes, ACs 1, 2, 5, and 6, expressed in Sf9 membranes and purified catalytic subunits of membranous ACs (C1 of AC5 and C2 of AC2), sAC, sGC, EF, and ACT in the presence of MnCl2. N-Methylanthraniloyl (MANT)-GTP inhibited C1.C2 with a K-i of 4.2 nM. Phe-889 and Ile-940 of C2 mediate hydrophobic interactions with the MANT group. MANT-inosine 5'-[gamma-thio]triphosphate potently inhibited C1.C2 and ACs 1, 5, and 6 but exhibited only low affinity for sGC, EF, ACT, and G-proteins. Inosine 5'-[gamma-thio]triphosphate and uridine 5'-[thio] triphosphate were mixed G-protein activators and AC inhibitors. AC5 was up to 15-fold more sensitive to inhibitors than AC2. EF and ACT exhibited unique inhibitor profiles. At sAC, 2',5'-dideoxyadenosine 3'-triphosphate was the most potent compound (IC50, 690 nM). Several MANT-adenine and MANT-guanine nucleotides inhibited sGC with Ki values in the 200-400 nM range. UTP and ATP exhibited similar affinities for sGC as GTP and were mixed sGC substrates and inhibitors. The exchange of MnCl2 against MgCl2 reduced inhibitor potencies at ACs and sGC 1.5-250-fold, depending on the nucleotide and cyclase studied. The omission of the NTP-regenerating system from cyclase reactions strongly reduced the potencies of MANT-ADP, indicative for phosphorylation to MANT-ATP by pyruvate kinase. Collectively, AC isoforms and sGC are differentially inhibited by purine and pyrimidine nucleotides.	Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA; Univ Kansas, Mol Graph & Modeling Lab, Lawrence, KS 66045 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; SE Louisiana Univ, Dept Physiol & Biophys, Hammond, LA 70402 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	University of Kansas; University of Kansas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Louisiana System; Southeastern Louisiana University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Seifert, R (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, 1251 Wescoe Hall Dr,Malott Hall,Rm 5064, Lawrence, KS 66045 USA.	rseifert@ku.edu	Gille, Andreas/E-1531-2011; Seifert, Roland/G-3189-2013; Lushington, Gerald/P-8421-2019; Lushington, Gerald/AAH-3205-2020	Gille, Andreas/0000-0001-5235-8897; Lushington, Gerald/0000-0001-5821-4253				Abdel-Majid RM, 1998, NAT GENET, V19, P289, DOI 10.1038/980; ALVAREZ R, 1990, ANAL BIOCHEM, V187, P98, DOI 10.1016/0003-2697(90)90423-7; Balint GA, 2001, J PHYSIOL-PARIS, V95, P243, DOI 10.1016/S0928-4257(01)00032-8; BRANDWEIN HJ, 1982, J BIOL CHEM, V257, P1309; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1998, J BIOL CHEM, V273, P24972, DOI 10.1074/jbc.273.38.24972; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; DURHAM JP, 1976, EUR J BIOCHEM, V61, P535, DOI 10.1111/j.1432-1033.1976.tb10048.x; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545; Gallois-Montbrun S, 2003, MOL PHARMACOL, V63, P538, DOI 10.1124/mol.63.3.538; GARBERS DL, 1975, BIOCHIM BIOPHYS ACTA, V377, P174, DOI 10.1016/0005-2744(75)90298-3; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Gille A, 2003, N-S ARCH PHARMACOL, V368, P210, DOI 10.1007/s00210-003-0783-7; Gille A, 2003, J BIOL CHEM, V278, P12672, DOI 10.1074/jbc.M211292200; Gille A, 2003, J BIOL CHEM, V278, P7822, DOI 10.1074/jbc.M210162200; Gille A, 2002, J BIOL CHEM, V277, P34434, DOI 10.1074/jbc.M204259200; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; HILDEBRANDT JD, 1982, J BIOL CHEM, V257, P4723; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Houston C, 2002, J NEUROCHEM, V80, P678, DOI 10.1046/j.0022-3042.2001.00746.x; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; JAKOBS KH, 1983, EUR J BIOCHEM, V130, P605, DOI 10.1111/j.1432-1033.1983.tb07192.x; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; JOHNSON RA, 1980, J BIOL CHEM, V255, P8252; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; JOHNSON RA, 1990, J BIOL CHEM, V265, P19035; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kawabe J, 1996, J BIOL CHEM, V271, P20132, DOI 10.1074/jbc.271.33.20132; Klinker JF, 1997, BIOCHEM PHARMACOL, V54, P551, DOI 10.1016/S0006-2952(97)00205-0; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; Laux WHG, 2004, J BIOL CHEM, V279, P13317, DOI 10.1074/jbc.M309535200; Lucas KA, 2000, PHARMACOL REV, V52, P375; McEwen DP, 2001, ANAL BIOCHEM, V291, P109, DOI 10.1006/abio.2001.5011; Mitterauer T, 1998, BIOCHEMISTRY-US, V37, P16183, DOI 10.1021/bi981441m; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Muegge I, 1999, J MED CHEM, V42, P791, DOI 10.1021/jm980536j; NEER EJ, 1979, J BIOL CHEM, V254, P2089; NEWTON RP, 1986, BIOCHEM J, V236, P431, DOI 10.1042/bj2360431; Okumura S, 2003, P NATL ACAD SCI USA, V100, P9986, DOI 10.1073/pnas.1733772100; Onda T, 2001, J BIOL CHEM, V276, P47785, DOI 10.1074/jbc.M107233200; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; Patel TB, 2001, GENE, V269, P13, DOI 10.1016/S0378-1119(01)00448-6; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Remmers AE, 1996, J BIOL CHEM, V271, P4791; SARFATI RS, 1990, J BIOL CHEM, V265, P18902; Schaefer ML, 2000, J NEUROSCI, V20, P4809; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Shen YQ, 2002, EMBO J, V21, P6721, DOI 10.1093/emboj/cdf681; Shoshani I, 1999, J BIOL CHEM, V274, P34735, DOI 10.1074/jbc.274.49.34735; Soelaiman S, 2003, J BIOL CHEM, V278, P25990, DOI 10.1074/jbc.M301232200; Storm DR, 1998, NEURON, V20, P1199, DOI 10.1016/S0896-6273(00)80500-0; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SYBYL, 2002, SYBYL VERS 6 9; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAO M, 1970, ARCH BIOCHEM BIOPHYS, V141, P236, DOI 10.1016/0003-9861(70)90127-X; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; Wang RX, 2003, J MED CHEM, V46, P2287, DOI 10.1021/jm0203783; WATSON PA, 1994, J BIOL CHEM, V269, P28893; Wedel BJ, 2001, ANNU REV PHYSIOL, V63, P215, DOI 10.1146/annurev.physiol.63.1.215; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650; ZWILLER J, 1981, BIOCHIM BIOPHYS ACTA, V658, P64, DOI 10.1016/0005-2744(81)90250-3	85	88	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19955	19969		10.1074/jbc.M312560200	http://dx.doi.org/10.1074/jbc.M312560200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14981084	hybrid			2022-12-27	WOS:000221164500070
J	Tang, J; Wu, SB; Liu, HT; Stratt, R; Barak, OG; Shiekhattar, R; Picketts, DJ; Yang, XL				Tang, J; Wu, SB; Liu, HT; Stratt, R; Barak, OG; Shiekhattar, R; Picketts, DJ; Yang, XL			A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-INDUCED APOPTOSIS; PML NUCLEAR-BODIES; PROMYELOCYTIC LEUKEMIA; DAXX; CHROMATIN; ACTIVATION; MUTATIONS; INHIBITION; BINDING; ALPHA	Death domain-associated protein (Daxx) is a multifunctional protein that modulates both apoptosis and transcription. Within the nucleus, Daxx is a component of the promyelocytic leukemia protein (PML) nuclear bodies (NBs) and interacts with a number of transcription factors, yet its precise role in transcription remains elusive. To further define the function of Daxx, we have isolated its interacting proteins in the nucleus using epitope-tagged affinity purification and identified X-linked mental retardation and alpha-thalassaemia syndrome protein (ATRX), a putative member of the SNF2 family of ATP-dependent chromatin remodeling proteins that is mutated in several X-linked mental retardation disorders. We show that substantial amounts of endogenous Daxx and ATRX exist in a nuclear complex. Daxx binds to ATRX through its paired amphipathic alpha helices domains. ATRX has ATPase activity that is stimulated by mononucleosomes, and patient mutations in the ATPase domain attenuate this activity. ATRX strongly represses transcription when tethered to a promoter. Daxx does not affect the ATPase activity of ATRX, however, it alleviates its transcription repression activity. In addition, ATRX is found in the PML-NBs, and this localization is mediated by Daxx. These results show that the ATRX.Daxx complex is a novel ATP-dependent chromatin-remodeling complex, with ATRX being the core ATPase subunit and Daxx being the targeting subunit. Moreover, the localization of ATRX to the PML-NBs supports the notion that these structures may play an important role in transcription regulation.	Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; The Wistar Institute	Picketts, DJ (corresponding author), Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada.	dpicketts@ohri.ca; xyang@mail.med.upenn.edu			NCI NIH HHS [CA 88868, T32 CA 09140] Funding Source: Medline; NIGMS NIH HHS [GM 60911] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009140, R01CA088868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060911] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Berube NG, 2000, HUM MOL GENET, V9, P539, DOI 10.1093/hmg/9.4.539; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Everett RD, 1999, J CELL SCI, V112, P3443; Fyodorov DV, 2002, MOL CELL BIOL, V22, P6344, DOI 10.1128/MCB.22.18.6344-6353.2002; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lin DY, 2003, J BIOL CHEM, V278, P15958, DOI 10.1074/jbc.M300387200; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Picketts DJ, 1996, HUM MOL GENET, V5, P1899, DOI 10.1093/hmg/5.12.1899; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	33	141	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20369	20377		10.1074/jbc.M401321200	http://dx.doi.org/10.1074/jbc.M401321200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14990586	hybrid			2022-12-27	WOS:000221164500115
J	Oita, E; Harada, K; Chiba, K				Oita, E; Harada, K; Chiba, K			Degradation of polyubiquitinated cyclin B is blocked by the MAPK pathway at the metaphase I arrest in starfish oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; BETA-GAMMA-SUBUNIT; CLEAVING XENOPUS-EMBRYOS; PROTEIN-KINASE P90(RSK); GTP-BINDING PROTEIN; CYTOSTATIC FACTOR; SIGNALING PATHWAY; MEIOSIS REINITIATION; INTRACELLULAR PH; UBIQUITIN LIGASE	In the starfish ovary, maturing oocytes stimulated by 1-methyladenine undergo synchronous germinal vesicle breakdown and then arrest in metaphase of the first meiotic division ( metaphase I). Immediately after spawning, an increase of intracellular pH (pH(i)) from similar to 7.0 to similar to 7.3 is induced by Na+/H+ antiporter in oocytes, and meiosis reinitiation occurs. Here we show that an endogenous substrate of the proteasome, polyubiquitinated cyclin B, was stable at pH 7.0, whereas it was degraded at pH 7.3. When the MAPK pathway was blocked by MEK inhibitor U0126, degradation of polyubiquitinated cyclin B occurred even at pH 7.0 without an increase of the peptidase activity of the proteasome. These results indicate that the proteasome activity at pH 7.0 is sufficient for degradation of polyubiquitinated cyclin B and that the MAPK pathway blocks the degradation of polyubiquitinated cyclin B in the maturing oocytes in the ovary. Immediately after spawning, the increase in pHi mediated by Na+/H+ antiporter cancels the inhibitory effects of the MAPK pathway, resulting in the degradation of polyubiquitinated cyclin B and the release of the arrest. Thus, the key step of metaphase I arrest in starfish oocytes occurs after the polyubiqutination of cyclin B but before cyclin B proteolysis by the proteasome.	Ochanomizu Univ, Dept Biol, Tokyo 1128610, Japan	Ochanomizu University	Chiba, K (corresponding author), Ochanomizu Univ, Dept Biol, 2-1-1 Ohtsuka, Tokyo 1128610, Japan.	kchiba@cc.ocha.ac.jp						Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; CHIBA K, 1992, EUR J BIOCHEM, V207, P833, DOI 10.1111/j.1432-1033.1992.tb17114.x; Chiba K, 1999, DEV BIOL, V205, P217, DOI 10.1006/dbio.1998.9118; Chiba K, 2000, ZOOL SCI, V17, P413, DOI 10.2108/0289-0003(2000)17[413:MRISO]2.0.CO;2; CHIBA K, 1993, MOL BIOL CELL, V4, P1027, DOI 10.1091/mbc.4.10.1027; Chiba K, 1997, J BIOCHEM-TOKYO, V122, P286; Chiba K, 1999, DEV BIOL, V209, P52, DOI 10.1006/dbio.1999.9239; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; Frank-Vaillant M, 2001, DEV BIOL, V231, P279, DOI 10.1006/dbio.2000.0142; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; Harada K, 2003, DEVELOPMENT, V130, P4581, DOI 10.1242/dev.00649; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEIJER L, 1984, INT REV CYTOL, V86, P129, DOI 10.1016/S0074-7696(08)60179-5; Nakano T, 1999, DEV BIOL, V209, P200, DOI 10.1006/dbio.1999.9248; Nishiyama A, 2000, GENE DEV, V14, P2344, DOI 10.1101/gad.823200; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; PICKART CM, 1986, J BIOL CHEM, V261, P210; Reimann JDR, 2002, NATURE, V416, P850, DOI 10.1038/416850a; Sadler KC, 1998, DEV BIOL, V197, P25, DOI 10.1006/dbio.1998.8869; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Schwab MS, 2001, CURR BIOL, V11, P141, DOI 10.1016/S0960-9822(01)00045-8; SHILLING F, 1989, DEV BIOL, V133, P605, DOI 10.1016/0012-1606(89)90063-8; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TADENUMA H, 1992, BIOCHEM BIOPH RES CO, V186, P114, DOI 10.1016/S0006-291X(05)80782-X; TADENUMA H, 1991, ARCH BIOCHEM BIOPHYS, V290, P411, DOI 10.1016/0003-9861(91)90560-6; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; Tunquist BJ, 2002, CURR BIOL, V12, P1027, DOI 10.1016/S0960-9822(02)00894-1; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543	51	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18633	18640		10.1074/jbc.M311122200	http://dx.doi.org/10.1074/jbc.M311122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985367	hybrid			2022-12-27	WOS:000221041500067
J	Parker, BS; Buley, T; Evison, BJ; Cutts, SM; Neumann, GM; Iskander, MN; Phillips, DR				Parker, BS; Buley, T; Evison, BJ; Cutts, SM; Neumann, GM; Iskander, MN; Phillips, DR			A molecular understanding of mitoxantrone-DNA adduct formation - Effect of cytosine methylation and flanking sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTRAND CROSS-LINKS; ANTITUMOR DRUGS ADRIAMYCIN; BREAST-CANCER; CELLS; TOPOISOMERASES; ANTHRACYCLINE; METABOLITES; DAUNOMYCIN; ACTIVATION; ALKYLATION	When mitoxantrone is activated by formaldehyde it can form adducts with DNA. These occur preferentially at CpG and CpA sequences and are enhanced 2-3-fold at methylated CpG sequences compared with non-methylated sites. We sought to understand the molecular factors involved in enhanced adduct formation at these methylated sites. This required, first, clarification of factors that contributed to the formation of adducts at CpG sites. For this purpose mass spectrometry of an oligonucleotide duplex ( containing a single CpG adduct site) was used to confirm the presence of an additional carbon atom ( derived from formaldehyde) on the drug-DNA complex. The effect of 3'-flanking sequences was revealed by electrophoretic analysis of oligonucleotide-drug adducts, and the preferred adduct-forming site was identified as 5'-CGG-3'. Radiolabeled studies of drug-DNA adducts confirmed that the site of attachment involved the exocyclic amino of guanine. Molecular modeling analysis of the relative stability of the intercalated form of mitoxantrone was consistent with observed adduct-forming potential of CG sites with varying flanking sequences. The known preference for adduct formation at methylated CG sites was confirmed by energetics calculations and shown to be due to a shift of equilibrium of the intercalated form of the drug from the major groove ( at CG sites) to the minor groove ( at methylated CG sites). This increases the relative amount of drug that is located adjacent to the N-2 exocyclic amino of guanine in the minor groove, where covalent linkage is facilitated. These results account for the enhanced covalent binding of mitoxantrone to methylated CG sequences and provide a molecular model of the interactions.	Monash Univ, Victorian Coll Pharm, Dept Med Chem, Parkville, Vic 3052, Australia; La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia	Monash University; La Trobe University	Iskander, MN (corresponding author), Monash Univ, Victorian Coll Pharm, Dept Med Chem, 381 Royal Parade, Parkville, Vic 3052, Australia.	magdy.iskander@vcp.monash.edu.au; d.phillips@latrobe.edu.au	Cutts, Suzanne/B-2467-2012	Cutts, Suzanne/0000-0002-6055-0405; Parker, Belinda/0000-0002-8333-1926				Capranico G, 1998, BBA-GENE STRUCT EXPR, V1400, P185, DOI 10.1016/S0167-4781(98)00135-3; CORNBLEET MA, 1984, EUR J CANCER CLIN ON, V20, P1141, DOI 10.1016/0277-5379(84)90122-6; Cullinane C, 2000, NUCLEIC ACIDS RES, V28, P1019, DOI 10.1093/nar/28.4.1019; CULLINANE C, 1994, BIOCHEMISTRY-US, V33, P4632, DOI 10.1021/bi00181a025; Cutts SM, 2001, CANCER RES, V61, P8194; DiPaola RS, 2001, CANCER, V92, P2065, DOI 10.1002/1097-0142(20011015)92:8<2065::AID-CNCR1546>3.0.CO;2-K; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; GUPTA M, 1995, MOL PHARMACOL, V48, P658; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X; Halgren TA, 1999, J COMPUT CHEM, V20, P720, DOI 10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; LOWN JW, 1985, J BIOMOL STRUCT DYN, V2, P1097, DOI 10.1080/07391102.1985.10507626; Panousis C, 1997, CANCER LETT, V113, P173, DOI 10.1016/S0304-3835(97)04611-9; Panousis C, 1995, ANTI-CANCER DRUG DES, V10, P593; Parker BS, 2003, CANCER BIOL THER, V2, P259, DOI 10.4161/cbt.2.3.364; Parker BS, 1999, NUCLEIC ACIDS RES, V27, P2918, DOI 10.1093/nar/27.14.2918; Parker BS, 2000, NUCLEIC ACIDS RES, V28, P982, DOI 10.1093/nar/28.4.982; Parker BS, 2001, J BIOL CHEM, V276, P15953, DOI 10.1074/jbc.M009216200; Perez-Gracia JL, 2001, CANCER-AM CANCER SOC, V92, P2508, DOI 10.1002/1097-0142(20011115)92:10<2508::AID-CNCR1601>3.0.CO;2-#; Phillips D. R., 1999, ENCY MOL BIOL, V1, P68; RESZKA K, 1989, BIOCHEM PHARMACOL, V38, P4253, DOI 10.1016/0006-2952(89)90523-6; Robak T, 2001, NEOPLASMA, V48, P203; Skladanowski A, 2000, BRIT J CANCER, V82, P1300; Taatjes DJ, 1997, J MED CHEM, V40, P1276, DOI 10.1021/jm960835d; Taatjes DJ, 1996, J MED CHEM, V39, P4135, DOI 10.1021/jm960519z; VANROSMALEN A, 1995, NUCLEIC ACIDS RES, V23, P42, DOI 10.1093/nar/23.1.42; Warnecke PM, 2000, CURR OPIN ONCOL, V12, P68, DOI 10.1097/00001622-200001000-00012; Zeman SM, 1998, P NATL ACAD SCI USA, V95, P11561, DOI 10.1073/pnas.95.20.11561	29	59	60	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18814	18823		10.1074/jbc.M400931200	http://dx.doi.org/10.1074/jbc.M400931200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14963025	hybrid			2022-12-27	WOS:000221041500090
J	Sokolov, M; Strissel, KJ; Leskov, IB; Michaud, NA; Govardovskii, VI; Arshavsky, VY				Sokolov, M; Strissel, KJ; Leskov, IB; Michaud, NA; Govardovskii, VI; Arshavsky, VY			Phosducin facilitates light-driven transducin translocation in rod photoreceptors - Evidence from the phosducin knockout mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENTS; GAMMA-SUBUNIT; CGMP CASCADE; BETA-GAMMA; PROTEIN; PHOSPHORYLATION; EXPRESSION; VERTEBRATE; COMPLEX; CELLS	Phosducin is a photoreceptor-specific protein known to interact with the betagamma subunits of G proteins. In pursuit of the function of phosducin, we tested the hypothesis that it regulates the light-driven translocation of G protein transducin from the outer segments of rod photoreceptors to other compartments of the rod cell. Transducin translocation has been previously shown to contribute to rod adaptation to bright illumination, yet the molecular mechanisms underlying the translocation phenomenon remain unknown. In this study we provide two major lines of evidence in support of the role of phosducin in transducin translocation. First, we have demonstrated that transducin betagamma subunits interact with phosducin along their entire intracellular translocation route, as evident from their co-precipitation in serial tangential sections from light-adapted but not dark-adapted retinas. Second, we generated a phosducin knockout mouse and found that the degree of light-driven transducin translocation in the rods of these mice was significantly reduced as compared with that observed in the rods of wild type animals. In knockout animals the translocation of transducin betagamma subunits was affected to a larger degree than the translocation of the alpha subunit. We also found that the amount of phosducin in rods is sufficient to interact with practically all of the transducin present in these cells and that the subcellular distribution of phosducin is consistent with that of a soluble protein evenly distributed throughout the entire rod cytoplasm. Together, these data indicate that phosducin binding to transducin betagamma subunits facilitates transducin translocation. We suggest that the mechanism of phosducin action is based on the reduction of transducin affinity to the membranes of rod outer segments, achieved by keeping the transducin betagamma subunits apart from the alpha subunit. This increased solubility of transducin would make it more susceptible to translocation from the outer segments.	Harvard Univ, Sch Med, Dept Ophthalmol, Howe Labs MEEI, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	Arshavsky, VY (corresponding author), Harvard Univ, Sch Med, Dept Ophthalmol, Howe Labs MEEI, 243 Charles St, Boston, MA 02114 USA.	vadim_arshavsky@meei.harvard.edu	Govardovskii, Victor I/K-2655-2018		NEI NIH HHS [EY-10336] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010336] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE T, 1993, GENE, V133, P179; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BRANN MR, 1987, SCIENCE, V235, P585, DOI 10.1126/science.3101175; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gropp KE, 1997, EXP EYE RES, V64, P875, DOI 10.1006/exer.1996.0257; Ho YK, 2002, METHOD ENZYMOL, V344, P126; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KUO CH, 1989, NEUROSCI LETT, V103, P8, DOI 10.1016/0304-3940(89)90476-X; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; LEE RH, 1992, J BIOL CHEM, V267, P25104; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Lyubarsky AL, 1999, J NEUROSCI, V19, P442, DOI 10.1523/JNEUROSCI.19-01-00442.1999; Margulis A, 2002, MOL VIS, V8, P477; Nakano K, 2001, P NATL ACAD SCI USA, V98, P4693, DOI 10.1073/pnas.071067198; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; Obin M, 2002, J BIOL CHEM, V277, P44566, DOI 10.1074/jbc.M205308200; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; ORGANISCIAK DT, 1991, EXP EYE RES, V53, P773, DOI 10.1016/0014-4835(91)90113-S; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; Pulvermuller A, 2002, MOL CELL BIOL, V22, P2194, DOI 10.1128/MCB.22.7.2194-2203.2002; ROOF DJ, 1988, SCIENCE, V241, P845, DOI 10.1126/science.3136548; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; Thulin CD, 1999, MOL VIS, V5, pU13; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Zhang HB, 2003, MOL VIS, V9, P231; Zhu X, 1998, Mol Vis, V4, P13; Zhu XM, 2000, MOL CELL BIOL, V20, P5216, DOI 10.1128/MCB.20.14.5216-5226.2000; Zhu XM, 2000, BIOCHEM BIOPH RES CO, V270, P504, DOI 10.1006/bbrc.2000.2414	45	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19149	19156		10.1074/jbc.M311058200	http://dx.doi.org/10.1074/jbc.M311058200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14973130	hybrid			2022-12-27	WOS:000221041500128
J	Wu, YH; Shih, SF; Lin, JY				Wu, YH; Shih, SF; Lin, JY			Ricin triggers apoptotic morphological changes through caspase-3 cleavage of BAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR LEAK SYNDROME; PROGRAMMED CELL-DEATH; CYTOCHROME-C; ENDOTHELIAL-CELLS; A-CHAIN; SHIGA TOXIN; IN-VITRO; SCYTHE; BCL-2; MITOCHONDRIA	Ricin, one of type II ribosomal inactivating proteins, inhibits protein biosynthesis by its RNA N-glycosidase activity. By yeast two-hybrid screening, the human BAT3 (HLA-B-associated transcript 3) was isolated as a ricin A-chain interacting protein. A canonical caspase-3 cleavage site, DEQD(1001) was found at the C-terminal region of BAT3. Ricin induced the apoptosis by activating caspase-3 and leading to the cleavage of BAT3 at 4 h after treatment while DNA laddering at 24 h. The cleavage is completely inhibited by zDEVD-fmk, a caspase-3 specific inhibitor. In addition, cleavage of BAT3 is blocked in caspase-3-deficient MCF-7 cells, indicating that BAT3 is a novel caspase-3 substrate. Evidence indicates that caspase-3 activated by ricin acts on BAT3 at the caspase cleavage site, DEQD(1001) to release a C-terminal fragment designated CTF-131. The CTF-131 induces phosphatidylserine exposure, cell rounding, and chromatin condensation as ricin does. Moreover, silencing expression of endogenous BAT3 concomitantly suppresses ricin-induced apoptosis. Together, our results suggest a model that ricin triggers morphological changes of apoptosis by caspase-3-mediated proteolytic activation of BAT3.	Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 10063, Taiwan	National Taiwan University	Lin, JY (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 10063, Taiwan.	jylin@ha.mc.ntu.edu.tw	Lin, Jung-Yaw/AGW-9336-2022	Lin, Jung-Yaw/0000-0002-6341-1160				Baluna R, 1997, IMMUNOPHARMACOLOGY, V37, P117, DOI 10.1016/S0162-3109(97)00041-6; Baluna R, 2000, EXP CELL RES, V258, P417, DOI 10.1006/excr.2000.4954; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brigotti M, 2002, FASEB J, V16, DOI 10.1096/fj.01-0521com; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; ENDO Y, 1988, J BIOL CHEM, V263, P8735; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Ghetie V, 2001, MOL BIOTECHNOL, V18, P251, DOI 10.1385/MB:18:3:251; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hughes JN, 1996, HUM EXP TOXICOL, V15, P443, DOI 10.1177/096032719601500513; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Keppler-Hafkemeyer A, 2000, INT J CANCER, V87, P86, DOI 10.1002/1097-0215(20000701)87:1<86::AID-IJC13>3.0.CO;2-I; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Komatsu N, 1998, J BIOCHEM-TOKYO, V124, P1038, DOI 10.1093/oxfordjournals.jbchem.a022197; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIN JY, 1970, NATURE, V227, P292, DOI 10.1038/227292a0; Lindstrom AL, 1997, BLOOD, V90, P2323; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Manchen ST, 2001, BIOCHEM BIOPH RES CO, V287, P1075, DOI 10.1006/bbrc.2001.5701; Martelli AM, 2001, J CELL BIOCHEM, V82, P634, DOI 10.1002/jcb.1186; Miller J. H, 1972, EXPT MOL GENETICS; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; Ozaki T, 1999, DNA CELL BIOL, V18, P503, DOI 10.1089/104454999315222; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; Sandvig K, 2002, HISTOCHEM CELL BIOL, V117, P131, DOI 10.1007/s00418-001-0346-2; Schindler J, 2001, CLIN CANCER RES, V7, P255; Schnell R, 2002, CLIN CANCER RES, V8, P1779; SOLERRODRIGUEZ AM, 1993, EXP CELL RES, V206, P227, DOI 10.1006/excr.1993.1142; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Takemoto K, 2003, J CELL BIOL, V160, P235, DOI 10.1083/jcb.200207111; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Thress K, 1999, EMBO J, V18, P5486, DOI 10.1093/emboj/18.20.5486; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; Thress K, 2001, EMBO J, V20, P1033, DOI 10.1093/emboj/20.5.1033; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	47	59	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19264	19275		10.1074/jbc.M307049200	http://dx.doi.org/10.1074/jbc.M307049200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14960581	hybrid			2022-12-27	WOS:000221041500140
J	Oh, JS; Manzerra, P; Kennedy, MB				Oh, JS; Manzerra, P; Kennedy, MB			Regulation of the neuron-specific ras GTPase-activating protein, synGAP, by Ca2+/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY FRACTION; SYNAPTIC PLASTICITY; NMDA RECEPTOR; GLUTAMATERGIC SYNAPSES; INTRINSIC DISORDER; PSD-95	synGAP is a neuron-specific Ras GTPase-activating protein found in high concentration in the postsynaptic density fraction from mammalian forebrain. Proteins in the postsynaptic density, including synGAP, are part of a signaling complex attached to the cytoplasmic tail of the N-methyl-D-aspartate-type glutamate receptor. synGAP can be phosphorylated by a second prominent component of the complex, Ca2+/calmodulin-dependent protein kinase II. Here we show that phosphorylation of synGAP by Ca2+/calmodulin-dependent protein kinase II increases its Ras GTPase-activating activity by 70-95%. We identify four major sites of phosphorylation, serines 1123, 1058, 750/751/756, and 764/765. These sites together with other minor phosphorylation sites in the carboxyl tail of synGAP control stimulation of GTPase-activating activity. When three of these sites and four other serines in the carboxyl tail are mutated, stimulation of GAP activity after phosphorylation is reduced to 21 +/- 5% compared with 70-95% for the wild type protein. We used phosphosite-specific antibodies to show that, as predicted, phosphorylation of serines 765 and 1123 is increased in cultured cortical neurons after exposure of the neurons to the agonist N-methyl-D-aspartate.	CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA	California Institute of Technology	Kennedy, MB (corresponding author), CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA.	kennedym@its.caltech.edu		Kennedy, Mary/0000-0003-1369-0525	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028710, R01NS017660] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS017660-23A2, R01 NS017660-24, R01 NS017660-21, NS17660, R01 NS017660-22, NS28710, R01 NS017660] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; BOLLAG G, 1995, METHOD ENZYMOL, V255, P161; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHEN HJ, 1997, ABSTR SOC NEUROSCI, V23, P1466; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim JH, 2003, J NEUROSCI, V23, P1119; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Komiyama NH, 2002, J NEUROSCI, V22, P9721; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Li X, 2000, Genome Inform Ser Workshop Genome Inform, V11, P172; MCCORMICK F, 1991, COLD SH Q B, V56, P237; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; Oh JS, 2002, NEURON, V33, P151; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Rose Kamala, 1993, P46; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Sjostrom PJ, 2002, CURR OPIN NEUROBIOL, V12, P305, DOI 10.1016/S0959-4388(02)00325-2; SMITH DB, 1995, CURRENT PROTOCOLS MO, V2, P1671; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	33	90	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17980	17988		10.1074/jbc.M314109200	http://dx.doi.org/10.1074/jbc.M314109200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970204	hybrid, Green Accepted			2022-12-27	WOS:000220870400133
J	Huang, FT; Khvorova, A; Marshall, W; Sorkin, A				Huang, FT; Khvorova, A; Marshall, W; Sorkin, A			Analysis of clathrin-mediated endocytosis of epidermal growth factor receptor by RNA interference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED PITS; BINDING; PROTEIN; CELLS; INTERNALIZATION; TRAFFICKING; EXPRESSION; DYNAMIN; EPS15R	To identify proteins that participate in clathrin-mediated endocytosis of the epidermal growth factor receptor (EGFR), 13 endocytic proteins were depleted in HeLa cells using highly efficient small interfering RNAs that were designed using a novel selection algorithm. The effects of small interfering RNAs on the ligand-induced endocytosis of EGFR were compared with those effects on the constitutive internalization of the transferrin receptor. The knock-downs of clathrin heavy chain and dynamin produced maximal inhibitory effects on the internalization of both receptors. Depletion of alpha, beta(2), or mu2 subunits of AP-2 reduced EGF and transferrin internalization rates by 40-60%. Down-regulation of several accessory proteins individually had no effect on endocytosis but caused significant inhibition of EGF and transferrin endocytosis when the homologous proteins were depleted simultaneously. Surprisingly, knockdown of clathrin-assembly lymphoid myeloid leukemia protein, CALM, did not influence transferrin endocytosis but considerably affected EGFR internalization. Thus, CALM is the second protein besides Grb2 that appears to play a specific role in EGFR endocytosis. This study demonstrates that the efficient gene silencing by rationally designed small interfering RNA can be used as an approach to functionally analyze the entire cellular machineries, such as the clathrin-coated pits and vesicles.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80111 USA; Dharmacon Inc, Lafayette, CO 80026 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sorkin, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80111 USA.	alexander.sorkin@uchsc.edu		Sorkin, Alexander/0000-0002-4446-1920				Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Carbone R, 1997, CANCER RES, V57, P5498; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; Confalonieri S, 2002, FEBS LETT, V513, P24, DOI 10.1016/S0014-5793(01)03241-0; Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069; DAMKE H, 1995, METHOD ENZYMOL, V257, P209; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; Galperin E, 2003, J CELL SCI, V116, P4799, DOI 10.1242/jcs.00801; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; LUND KA, 1990, J BIOL CHEM, V265, P15713; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Scaringe SA, 2000, METHOD ENZYMOL, V317, P3; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299	31	353	360	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16657	16661		10.1074/jbc.C400046200	http://dx.doi.org/10.1074/jbc.C400046200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14985334	hybrid			2022-12-27	WOS:000220747900117
J	Miyauchi, S; Gopal, E; Fei, YJ; Ganapathy, V				Miyauchi, S; Gopal, E; Fei, YJ; Ganapathy, V			Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na+-coupled transporter for short-chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLISM; APOPTOSIS; BUTYRATE	SLC5A8, a tumor suppressor gene down-regulated in human colon cancer, codes for a transporter in the Na+/ glucose cotransporter gene family, but the definitive functional identity of the transporter protein is not known. Since this gene is expressed abundantly in the colon where short-chain fatty acids are generated by bacterial fermentation, we tested the hypothesis that it codes for a Na+-coupled transporter for these fatty acids. The coding region of SLC5A8 mRNA was amplified from human intestine and expressed heterologously in Xenopus laevis oocytes. Transport function was monitored by uptake of radiolabeled substrates and by substrate-induced currents under voltage-clamp conditions. Uptake of short-chain fatty acids ( lactate, pyruvate, acetate, propionate, and butyrate) in oocytes expressing SLC5A8 was severalfold higher than in uninjected oocytes. Exposure of SLC5A8-expressing oocytes to these fatty acids induced inward currents under voltage-clamp conditions in a Na+-dependent manner. These currents were saturable and the substrate concentrations needed for half-maximal induction of the current were in the range of 0.08 - 2.5 mM. The substrate-induced currents decreased as the carbon chain length of the substrates increased. The Na+-activation kinetics indicated involvement of more than one Na+ ion in the activation process. Direct measurements of substrate ( propionate) and charge transfer showed that three positive charges are transferred into oocytes per substrate molecule. These studies establish the functional identity of SLC5A8 as a Na+-coupled transporter for short-chain fatty acids.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, 1149 Laney Walker Blvd, Augusta, GA 30912 USA.	vganapat@mail.mcg.edu			NHLBI NIH HHS [HL64196] Funding Source: Medline; NIAID NIH HHS [AI49849] Funding Source: Medline; NICHD NIH HHS [HD44404] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD044404] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049849] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Augenlicht LH, 1999, CANCER RES, V59, P6005; BARACNIETO M, 1980, AM J PHYSIOL, V239, pF496, DOI 10.1152/ajprenal.1980.239.5.F496; BARBARAT B, 1988, J BIOL CHEM, V263, P12190; Basson MD, 2000, J GASTROINTEST SURG, V4, P501, DOI 10.1016/S1091-255X(00)80093-1; Blottiere HM, 2003, P NUTR SOC, V62, P101, DOI 10.1079/PNS2002215; Bongaerts GPA, 1997, MICROB PATHOGENESIS, V22, P285, DOI 10.1006/mpat.1996.0122; Chen JS, 2003, CURR CANCER DRUG TAR, V3, P219, DOI 10.2174/1568009033481994; Emenaker NJ, 2001, J NUTR, V131, p3041S, DOI 10.1093/jn/131.11.3041S; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012; Inoue K, 2004, BIOCHEM J, V378, P949, DOI 10.1042/BJ20031261; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100; Mortensen PB, 1996, SCAND J GASTROENTERO, V31, P132, DOI 10.3109/00365529609094568; Rajendran VM, 2000, ANN NY ACAD SCI, V915, P15; Rodriguez AM, 2002, J CLIN ENDOCR METAB, V87, P3500, DOI 10.1210/jc.87.7.3500; Sellin JH, 1999, NEWS PHYSIOL SCI, V14, P58; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; Uribarri J, 1998, MEDICINE, V77, P73, DOI 10.1097/00005792-199803000-00001; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P123; Wachtershauser A, 2000, EUR J NUTR, V39, P164, DOI 10.1007/s003940070020; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019, DOI 10.1152/ajpcell.2000.278.5.C1019; Wang JP, 1998, GASTROENTEROLOGY, V114, P940, DOI 10.1016/S0016-5085(98)70313-0; WRIGHT EM, 2003, PFLUGERS ARCH E 0514	25	207	223	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13293	13296		10.1074/jbc.C400059200	http://dx.doi.org/10.1074/jbc.C400059200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14966140	hybrid			2022-12-27	WOS:000220478500003
J	Price, KL; Lummis, SCR				Price, KL; Lummis, SCR			The role of tyrosine residues in the extracellular domain of the 5-hydroxytryptamine(3) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; LIGAND-BINDING DOMAIN; AGONIST-BINDING; 5-HT3 RECEPTOR; SUBUNIT; SITE; IDENTIFICATION; ANTAGONISTS; GAMMA; CONDUCTANCE	Aromatic residues play an important role in the ligand-binding domain of Cys loop receptors. Here we examine the role of the 11 tyrosines in this domain of the 5-HT3 receptor in ligand binding and receptor function by substituting them for alanine, for serine, and, for some residues, also for phenylalanine. The mutant receptors were expressed in HEK293 cells and Xenopus oocytes and examined using radioligand binding, Ca2+ imaging, electrophysiology, and immunochemistry. The data suggest that Tyr(50) and Tyr(91) are critical for receptor assembly and/or structure, Tyr(141) is important for antagonist binding and/or the structure of the binding pocket, Tyr(143) plays a critical role in receptor gating and/or agonist binding, and Tyr(153) and Tyr(234) are involved in ligand binding and/or receptor gating. Tyr(73), Tyr(88), Tyr(94), Tyr(167), and Tyr(240) do not appear to play major roles either in the structure of the extracellular domain or in ligand binding. The data support the location of these residues on a model of 5-HT docked into the ligand-binding domain and also provide evidence for the structural similarity of the extracellular domain to AChBP and the homologous regions of other Cys loop ligand-gated ion channels.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Lummis, SCR (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	sl120@mole.bio.cam.ac.uk		Price, Kerry/0000-0002-5563-4567				Akk G, 1999, BIOPHYS J, V76, P207, DOI 10.1016/S0006-3495(99)77190-0; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; AYLWIN ML, 1994, MOL PHARMACOL, V46, P1149; AYLWIN ML, 1994, FEBS LETT, V349, P99, DOI 10.1016/0014-5793(94)00649-0; Breitinger HGA, 2001, BIOCHEMISTRY-US, V40, P8419, DOI 10.1021/bi0106890; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; Chio CL, 2002, NEUROSCI LETT, V334, P49, DOI 10.1016/S0304-3940(02)01068-6; COCKCROFT V, 1995, ANN NY ACAD SCI, V757, P40, DOI 10.1111/j.1749-6632.1995.tb17463.x; Cooper ST, 1997, J NEUROCHEM, V68, P2140; Deane CM, 2001, J BIOL CHEM, V276, P37962; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FU DX, 1994, J BIOL CHEM, V269, P26152; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; Gunthorpe MJ, 2000, J PHYSIOL-LONDON, V522, P187, DOI 10.1111/j.1469-7793.2000.00187.x; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; Hargreaves AC, 1996, MOL PHARMACOL, V50, P1284; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kearney PC, 1996, MOL PHARMACOL, V50, P1401; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LUMMIS SCR, 1993, EUR J PHARMACOL, V243, P7, DOI 10.1016/0014-2999(93)90160-J; MIHIC SJ, 1994, J BIOL CHEM, V269, P32768; MIQUEL MC, 1991, BIOCHEM PHARMACOL, V42, P1453, DOI 10.1016/0006-2952(91)90459-I; Molles BE, 2002, J BIOL CHEM, V277, P5433, DOI 10.1074/jbc.M109232200; Mu TW, 2003, J AM CHEM SOC, V125, P6850, DOI 10.1021/ja0348086; Ohno K, 1996, NEURON, V17, P157, DOI 10.1016/S0896-6273(00)80289-5; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; Spier AD, 2000, J BIOL CHEM, V275, P5620, DOI 10.1074/jbc.275.8.5620; Spier AD, 2002, J MOL NEUROSCI, V18, P169, DOI 10.1385/JMN:18:3:169; Spier AD, 1999, MOL BRAIN RES, V67, P221; Steward LJ, 2000, MOL PHARMACOL, V57, P1249; Sullivan D, 2002, MOL PHARMACOL, V61, P463, DOI 10.1124/mol.61.2.463; Turchin A, 1999, BIOTECHNIQUES, V26, P672, DOI 10.2144/99264st02; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; Venkataraman P, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-15; Willcockson IU, 2002, J BIOL CHEM, V277, P42249, DOI 10.1074/jbc.M205383200; Yan D, 1999, J BIOL CHEM, V274, P5537, DOI 10.1074/jbc.274.9.5537	45	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23294	23301		10.1074/jbc.M314075200	http://dx.doi.org/10.1074/jbc.M314075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	14998995	hybrid			2022-12-27	WOS:000221570900063
J	Beauchemin, H; Blouin, MJ; Trudel, M				Beauchemin, H; Blouin, MJ; Trudel, M			Differential regulatory and compensatory responses in hematopoiesis/erythropoiesis in alpha- and beta-globin hemizygous mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW TRANSPLANTATION; SICKLE-CELL-DISEASE; INEFFECTIVE ERYTHROPOIESIS; THALASSEMIC ERYTHROCYTES; MOUSE MODEL; STEM-CELLS; HEMOGLOBIN; GENE; CHAINS; MUTATIONS	Characterization of hematopoiesis/erythropoiesis in thalassemias from multipotent primitive cells to mature erythrocytes is of fundamental importance and clinical relevance. We investigated this process in alpha- and beta-globin hemizygous mice, lacking the two adult tandemly organized genes from either the alpha- or beta-globin locus. Although both mice backcrossed on a homogeneous background exhibited similar reduced red blood cell (RBC) survival, beta-globin hemizygous mice had less severe reticulocyte loss and globin chain imbalance, suggesting an apparently milder thalassemia than for alpha-globin hemizygous mice. In contrast, however, beta-globin hemizygous mice displayed a more marked perturbation of hematologic parameters. Quantification of erythroid precursor subpopulations in marrow and spleen of beta-globin hemizygous mice showed more severely impaired maturation from the basophilic to orthochromatophilic erythroblasts and substantial loss of these late precursors probably as a consequence of a greater susceptibility to an excess of free alpha-chain than beta-chain. Hence, only erythroid precursors exhibiting stochastically moderate chain imbalance would escape death and mature to reticulocyte/RBC stage, leading to survival and minimal loss of reticulocytes in the beta-globin hemizygous mice. Furthermore, in response to the ineffective erythropoiesis in beta-globin hemizygous mice, a dynamic compensatory hematopoiesis was observed at earlier differentiation stage as evidenced by a significant increase of erythroid progenitors (erythroid colony-forming units similar to100-fold) as well as of multipotent primitive cells (day 12 spleen colony-forming units similar to7-fold). This early compensatory mechanism was less pronounced in alpha-globin hemizygous mice. The expansion of multipotent primitive and potentially stem cell populations, taken together with ineffective erythropoiesis and increased reticulocyte/RBC destruction could confer major cumulative advantage for gene targeting/bone marrow transplantation. Therefore, this study not only corroborated the strong potential effectiveness of transplantation for thalassemic hematopoietic therapy but also demonstrated the existence of a differential regulatory response for alpha- and beta-thalassemia.	Univ Montreal, Fac Med, Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Trudel, M (corresponding author), Univ Montreal, Fac Med, Inst Rech Clin Montreal, 110 Ouest Ave Pins, Montreal, PQ H2W 1R7, Canada.	trudelm@IRCM.qc.ca		Trudel, Marie/0000-0003-0057-2669				Ayala S, 1997, BRIT J HAEMATOL, V98, P47, DOI 10.1046/j.1365-2141.1997.1822999.x; BANK A, 1969, NATURE, V222, P295, DOI 10.1038/222295a0; BARON MH, 1991, MOL CELL BIOL, V11, P1239, DOI 10.1128/MCB.11.3.1239; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; Blouin MJ, 1999, BLOOD, V94, P1451, DOI 10.1182/blood.V94.4.1451.416k02_1451_1459; Blouin MJ, 2000, NAT MED, V6, P177, DOI 10.1038/72279; BOTHWELL TH, 1979, IRON METABOLISM MAN, P190; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P322; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; COLEMAN MB, 1995, J CLIN INVEST, V95, P503, DOI 10.1172/JCI117691; de Krom M, 2002, MOL CELL, V9, P1319, DOI 10.1016/S1097-2765(02)00558-0; Fabry ME, 2001, BLOOD, V97, P410, DOI 10.1182/blood.V97.2.410; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; FINCH CA, 1970, MEDICINE, V49, P17, DOI 10.1097/00005792-197001000-00002; Gell D, 2002, J BIOL CHEM, V277, P40602, DOI 10.1074/jbc.M206084200; GIARDINI C, 1995, ANNU REV MED, V46, P319; HANASH SM, 1978, P NATL ACAD SCI USA, V75, P3427, DOI 10.1073/pnas.75.7.3427; Harteveld CL, 1996, BRIT J HAEMATOL, V95, P461, DOI 10.1046/j.1365-2141.1996.d01-1926.x; HEYWOOD JD, 1966, J LAB CLIN MED, V67, P246; Imren S, 2002, P NATL ACAD SCI USA, V99, P14380, DOI 10.1073/pnas.212507099; KAPELUSHNIK J, 1995, BLOOD, V86, P3241, DOI 10.1182/blood.V86.8.3241.bloodjournal8683241; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; La Nasa G, 2002, BLOOD, V99, P4350, DOI 10.1182/blood.V99.12.4350; LOUKOPOULOS D, 1991, ANN HEMATOL, V62, P85, DOI 10.1007/BF01702920; MARTINELL J, 1981, P NATL ACAD SCI-BIOL, V78, P5056, DOI 10.1073/pnas.78.8.5056; MASALA B, 1994, METHOD ENZYMOL, V231, P21; Mathias LA, 2000, EXP HEMATOL, V28, P1343, DOI 10.1016/S0301-472X(00)00555-5; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; Pootrakul P, 2000, BLOOD, V96, P2606, DOI 10.1182/blood.V96.7.2606.h8002606_2606_2612; ROUYERFESSARD P, 1990, J BIOL CHEM, V265, P20247; RUSSELL LB, 1976, P NATL ACAD SCI USA, V73, P2843, DOI 10.1073/pnas.73.8.2843; SCHRIER SL, 1989, BLOOD, V74, P2194; SCHRIER SL, 1994, ANNU REV MED, V45, P211; SCOTT MD, 1993, J CLIN INVEST, V91, P1706, DOI 10.1172/JCI116380; SCOTT MD, 1995, BRIT J HAEMATOL, V91, P811, DOI 10.1111/j.1365-2141.1995.tb05394.x; SHAEFFER JR, 1983, J BIOL CHEM, V258, P3172; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; SKOW LC, 1983, CELL, V34, P1043, DOI 10.1016/0092-8674(83)90562-7; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; TRUDEL M, 1994, BLOOD, V84, P3189; VANDENBOS C, 1993, EXP HEMATOL, V21, P350; WAGEMAKER G, 1986, EXP HEMATOL, V14, P303; WONG C, 1989, BLOOD, V73, P914	44	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19471	19480		10.1074/jbc.M309989200	http://dx.doi.org/10.1074/jbc.M309989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004025	hybrid			2022-12-27	WOS:000221164500013
J	Dhakshinamoorthy, S; Porter, AG				Dhakshinamoorthy, S; Porter, AG			Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NAD(P)H-QUINONE OXIDOREDUCTASE1 GENE; DETOXIFYING ENZYME GENES; HEME OXYGENASE-1 GENE; OXIDATIVE STRESS; MEDIATED EXPRESSION; NF-E2-RELATED FACTOR-2; QUINONE OXIDOREDUCTASE; SERUM DEPRIVATION; SH-SY5Y CELLS	Nitric oxide (NO) is a signaling molecule that in excess causes cell death. Here we report a mechanism of NO-induced transcriptional up-regulation of genes encoding detoxifying enzymes and protective proteins and their role in counteracting NO-induced apoptosis of neuroblastoma cells. Promoter analysis using reporter assays identified the antioxidant response element (ARE) located in the promoter region of NAD(P)H:quinone oxidoreductase 1 (Nqo1) and other detoxifying enzyme genes as responsible for NO-mediated gene induction. The transcription factors NF-E2-related factor 2 (Nrf2) and small maf proteins were detected in NO-induced nuclear protein-ARE complexes. Nrf2 augmented NO-induced, ARE-dependent gene expression, which was blocked by dominant-negative Nrf2 (DN-Nrf2) lacking the transcriptional activation domain. Consistent with these results, Nrf2 was localized in the cytoplasm in unstimulated cells, and NO triggered its rapid nuclear accumulation. Neuroblastoma cells were stably transfected with DN-Nrf2, which repressed both the expression of protective genes and their induction by NO. These DN-Nrf2 cells exhibited reduced NQO1 enzymatic activity and were sensitized to NO-induced apoptosis. Similar results were obtained when Nrf2 expression was blocked by RNA interference. Conversely, stable cells expressing higher levels of Nrf2 protein had elevated NQO1 activity and were protected from NO. Finally, NO-mediated ARE-dependent gene induction occurred well before apoptosis as judged by caspase activation. These results together suggest that NO signals the transcriptional up-regulation of NQO1 and other detoxifying enzyme and protective genes through Nrf2 via the ARE to counteract NO-induced apoptosis of neuroblastoma cells.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Dhakshinamoorthy, S (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	saravanad@imcb.a-star.edu.sg; mcbagp@imcb.a-star.edu.sg						Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; Berendji D, 1999, MOL MED, V5, P721, DOI 10.1007/BF03402096; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Bogdan C, 1998, J EXP MED, V187, P1361, DOI 10.1084/jem.187.9.1361; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Buckley BJ, 2003, BIOCHEM BIOPH RES CO, V307, P973, DOI 10.1016/S0006-291X(03)01308-1; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Choi BM, 2003, FREE RADICAL BIO MED, V34, P1136, DOI 10.1016/S0891-5849(03)00064-9; Ciani E, 2002, J BIOL CHEM, V277, P49896, DOI 10.1074/jbc.M206177200; Dennis J, 2003, J NEUROSCI RES, V72, P89, DOI 10.1002/jnr.10540; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2; Feng ZW, 2002, MOL CELL BIOL, V22, P5357, DOI 10.1128/MCB.22.15.5357-5366.2002; Gaikwad A, 2001, J BIOL CHEM, V276, P22559, DOI 10.1074/jbc.M101053200; Gegg ME, 2003, J NEUROCHEM, V86, P228, DOI 10.1046/j.1471-4159.2003.01821.x; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Hemish J, 2003, J BIOL CHEM, V278, P42321, DOI 10.1074/jbc.M308192200; Hentze H, 2003, CELL DEATH DIFFER, V10, P956, DOI 10.1038/sj.cdd.4401264; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; Jaiswal AK, 2000, ARCH BIOCHEM BIOPHYS, V375, P62, DOI 10.1006/abbi.1999.1650; Johnson DA, 2002, J NEUROCHEM, V81, P1233, DOI 10.1046/j.1471-4159.2002.00913.x; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kroncke KD, 2000, FASEB J, V14, P166; Kuo PC, 2000, GASTROENTEROLOGY, V118, P608, DOI 10.1016/S0016-5085(00)70268-X; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; Li L, 2004, J BIOL CHEM, V279, P4058, DOI 10.1074/jbc.M310415200; Lucas KA, 2000, PHARMACOL REV, V52, P375; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Moriya R, 2000, FEBS LETT, V484, P253, DOI 10.1016/S0014-5793(00)02167-0; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MURPHY TH, 1991, J NEUROCHEM, V56, P990, DOI 10.1111/j.1471-4159.1991.tb02019.x; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Okada S, 1998, J IMMUNOL, V160, P2590; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sekhar KR, 2002, FREE RADICAL BIO MED, V32, P650, DOI 10.1016/S0891-5849(02)00755-4; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Shiraishi F, 2000, AM J PHYSIOL-RENAL, V278, pF726, DOI 10.1152/ajprenal.2000.278.5.F726; Siegel D, 1997, MOL PHARMACOL, V52, P300, DOI 10.1124/mol.52.2.300; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; Tosetti F, 2003, MOL PHARMACOL, V63, P565, DOI 10.1124/mol.63.3.565; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; Uehara T, 1999, J NEUROCHEM, V72, P196, DOI 10.1046/j.1471-4159.1999.0720196.x; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	69	132	139	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20096	20107		10.1074/jbc.M312492200	http://dx.doi.org/10.1074/jbc.M312492200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985350	hybrid			2022-12-27	WOS:000221164500086
J	Ruiz-Ruiz, C; de Almodovar, CR; Rodriguez, A; Ortiz-Ferron, G; Redondo, JM; Lopez-Rivas, A				Ruiz-Ruiz, C; de Almodovar, CR; Rodriguez, A; Ortiz-Ferron, G; Redondo, JM; Lopez-Rivas, A			The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; TRAIL-INDUCED APOPTOSIS; GENE-EXPRESSION; DEATH RECEPTOR; IFN-GAMMA; P53-DEPENDENT MECHANISM; TUMORICIDAL ACTIVITY; MEDIATED APOPTOSIS; LEUKEMIA CELLS; T-LYMPHOCYTES	Treatment of human breast tumor cells with interferon-gamma (IFN-gamma) elevates caspase-8 expression and sensitizes these cells to death receptor-mediated apoptosis through the increased processing and activation of apical procaspase-8. We have characterized the human caspase-8 gene promoter and studied the transcriptional regulation of caspase-8 gene expression in MCF-7 breast tumor cells treated with IFN-gamma. Our findings show that IFN-gamma induces the up-regulation of caspase-8 mRNA expression through a protein synthesis-dependent mechanism involving the action of the IFN-gamma-inducible transcription factor interferon regulatory factor-1 (IRF-1) and without altering mRNA stability. The human caspase-8 gene promoter lacks recognizable TATA and CAAT boxes but contains a consensus Sp1 binding site. We have identified two major IFN-gamma-inducible transcriptional start sites in these cells by S1 nuclease mapping, confirmed by primer extension analysis. Deletion analysis of the promoter defined an 82-bp minimal region responsible for IFN-gamma-inducible promoter activity. In this region, we have identified an IFN-stimulated response element that is important for both the basal and IFN-gamma-enhanced transcriptional activities. Electrophoretic mobility shift assay analysis demonstrated that IFN-gamma induces a complex between an oligonucleotide probe containing the ISRE motif and IRF-1 over a similar time scale to the induction of caspase-8 mRNA. Exogenously expressed IRF-1 in MCF-7 cells up-regulated the activity of a luciferase reporter plasmid containing an 82-bp region of the caspase-8 promoter. These data define a new pathway through which IFN-gamma might control the sensitivity of tumor cell to death receptor-mediated apoptosis.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Ctr Nacl Invest Cardiovasc, Madrid 28760, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.	alrivas@ipb.csic.es	Redondo, Juan Miguel/H-6351-2015; Ruiz-Ruiz, Carmen/I-8792-2017; Marquez, Antonio A. Rodriguez/L-2422-2013; Lopez-Rivas, Abelardo/E-5115-2015	Redondo, Juan Miguel/0000-0001-5779-9122; Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Marquez, Antonio A. Rodriguez/0000-0003-2455-6583; Ruiz de Almodovar, Carmen/0000-0001-5975-7815; Lopez-Rivas, Abelardo/0000-0002-9351-9690				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; CELADA A, 1986, J IMMUNOL, V137, P2373; Collins M, 1996, NUCLEIC ACIDS RES, V24, P3661, DOI 10.1093/nar/24.19.3661; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Fallarino F, 1996, J IMMUNOL, V156, P1095; Ferreira CG, 2000, CANCER RES, V60, P7133; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Gongora C, 2000, NUCLEIC ACIDS RES, V28, P2333, DOI 10.1093/nar/28.12.2333; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; Harada K, 2002, CANCER RES, V62, P5897; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Iwase S, 1999, FEBS LETT, V450, P263, DOI 10.1016/S0014-5793(99)00515-3; Jones DT, 2001, BLOOD, V98, P2800, DOI 10.1182/blood.V98.9.2800; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kontny HU, 2001, CELL DEATH DIFFER, V8, P506, DOI 10.1038/sj.cdd.4400836; Langaas V, 2001, ANTICANCER RES, V21, P3733; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; Liu BL, 2002, J BIOL CHEM, V277, P30159, DOI 10.1074/jbc.M203566200; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NASTALA CL, 1994, J IMMUNOL, V153, P1697; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Refaeli Y, 2002, J EXP MED, V196, P999, DOI 10.1084/JEM.20020666; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 2002, BIOCHEM J, V365, P825, DOI 10.1042/BJ20020184; Ruiz-Ruiz MD, 1999, CELL DEATH DIFFER, V6, P271, DOI 10.1038/sj.cdd.4400490; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shyu RY, 2000, J SURG ONCOL, V75, P122, DOI 10.1002/1096-9098(200010)75:2<122::AID-JSO9>3.0.CO;2-4; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Varela N, 2001, J BIOL CHEM, V276, P17779, DOI 10.1074/jbc.M100815200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang Q, 1998, GENE, V222, P83, DOI 10.1016/S0378-1119(98)00476-4; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yang XZ, 2003, CANCER RES, V63, P1122; ZAHEDI K, 1994, J BIOL CHEM, V269, P9669; Zuzak TJ, 2002, EUR J CANCER, V38, P83, DOI 10.1016/S0959-8049(01)00355-0	55	71	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19712	19720		10.1074/jbc.M313023200	http://dx.doi.org/10.1074/jbc.M313023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14993214	hybrid			2022-12-27	WOS:000221164500041
J	Salvat, C; Wang, GL; Dastur, A; Lyon, N; Huibregtse, JM				Salvat, C; Wang, GL; Dastur, A; Lyon, N; Huibregtse, JM			The-4 phenylalanine is required for substrate ubiquitination catalyzed by HECT ubiquitin ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGELMAN-SYNDROME GENE; PROTEIN LIGASE; UBE3A; FAMILY; MUTATIONS; COMPLEX; PATHWAY; CASCADE; DOMAINS; LIGANDS	The reaction cycle of HECT domain ubiquitin ligases consists of three steps: 1) binding of an E2 protein, 2) transfer of ubiquitin from E2 to the HECT domain, and 3) transfer of ubiquitin to the substrate. We report the identification of a determinant that is specifically required for the last step of this cycle, a phenylalanine residue located four amino acids from the C terminus of most HECT domains, referred to here as the -4F. Alteration of this residue in human E6AP and Saccharomyces cerevisae Rsp5p did not affect ubiquitin-thioester formation, but effectively blocked substrate ubiquitination. Alteration of the -4F to alanine with concomitant substitution of a nearby residue to phenylalanine only partially restored Rsp5p activity, indicating that precise spatial placement of this residue is important. C-terminally extended E6AP and Rsp5p proteins were also defective for substrate ubiquitination, providing a likely biochemical understanding of a previously isolated Angelman syndrome-associated mutation of E6AP that alters the stop codon of an otherwise wild-type gene. We propose that the -4F may play a role in orienting ubiquitin when it is tethered to the HECT active site cysteine. This may be necessary to allow for approach of the incoming lysine epsilon-amino group of the substrate.	Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Huibregtse, JM (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.	huibreg@icmb.utexas.edu			NATIONAL CANCER INSTITUTE [R01CA072943] Funding Source: NIH RePORTER; NCI NIH HHS [CA-72943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albrecht U, 1997, NAT GENET, V17, P75, DOI 10.1038/ng0997-75; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Fang P, 1999, HUM MOL GENET, V8, P129, DOI 10.1093/hmg/8.1.129; GIROD PA, 1993, PLANT J, V3, P545, DOI 10.1046/j.1365-313X.1993.03040545.x; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kishino T, 1998, GENOMICS, V47, P101, DOI 10.1006/geno.1997.5093; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Vu TH, 1997, NAT GENET, V17, P12, DOI 10.1038/ng0997-12; Wang GL, 1999, MOL CELL BIOL, V19, P342; Yamamoto Y, 1997, GENOMICS, V41, P263, DOI 10.1006/geno.1997.4617; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	28	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18935	18943		10.1074/jbc.M312201200	http://dx.doi.org/10.1074/jbc.M312201200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966115	hybrid			2022-12-27	WOS:000221041500104
J	Wang, QB; Udayakumar, TS; Vasaitis, TS; Brodie, AM; Fondell, JD				Wang, QB; Udayakumar, TS; Vasaitis, TS; Brodie, AM; Fondell, JD			Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; AMINO-TERMINAL DOMAIN; CHROMATIN-REMODELING COMPLEX; CAG REPEAT POLYMORPHISM; TRINUCLEOTIDE REPEATS; NUCLEAR RECEPTORS; MOLECULAR-BIOLOGY; RESPONSE ELEMENT; GENE-EXPRESSION	Androgen receptor (AR) signaling pathways mediate critical events in normal and neoplastic prostate growth. Shortening of the polymorphic N-terminal polyglutamine (poly(Q)) tract of the AR gene leads to transcriptional hyperactivity and has been correlated with an increased risk of prostate cancer. The underlying mechanisms for these effects are poorly understood. We show here that androgen-dependent cellular proliferation and transcription in prostate cancer cells is inversely correlated to the length of the AR poly(Q) region. We further show that AR proteins containing a shortened poly(Q) region functionally respond to lower concentrations of androgens than wild type AR. Whereas DNA binding activity is relatively unaffected by AR poly(Q) variation, we found that ligand binding affinity and the ligand-induced NH2- to COOH-terminal intramolecular interaction is enhanced when the poly(Q) region is shortened. Importantly, we show that AR proteins containing a shortened poly(Q) region associate in vivo with higher levels of specific p160 coactivators and components of the SWI/SNF chromatin remodeling complex as compared with the wild type AR. Collectively, our findings suggest that the AR transcriptional hyperactivity associated with shortened poly(Q) length stems from altered ligand-induced conformational changes that enhance coactivator recruitment.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Maryland; University of Maryland Baltimore	Fondell, JD (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.	fondeljd@umdnj.edu	Wang, Qianben/E-4267-2011		NIDDK NIH HHS [DK60883] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060883] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alen P, 1999, MOL CELL BIOL, V19, P6085; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Beilin J, 2000, J MOL ENDOCRINOL, V25, P85, DOI 10.1677/jme.0.0250085; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bright RK, 1997, CANCER RES, V57, P995; Callewaert L, 2003, BIOCHEM BIOPH RES CO, V306, P46, DOI 10.1016/S0006-291X(03)00902-1; Casella R, 2001, UROLOGY, V58, P651, DOI 10.1016/S0090-4295(01)01401-7; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Choong CS, 1998, J MOL ENDOCRINOL, V21, P235, DOI 10.1677/jme.0.0210235; Christiaens V, 2002, J BIOL CHEM, V277, P49230, DOI 10.1074/jbc.M209322200; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; Clark Peter E, 2003, Methods Mol Med, V81, P255; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Glass CK, 2000, GENE DEV, V14, P121; Hardy DO, 1996, J CLIN ENDOCR METAB, V81, P4400, DOI 10.1210/jc.81.12.4400; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Huang ZQ, 2003, EMBO J, V22, P2146, DOI 10.1093/emboj/cdg219; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Ingles SA, 1997, J NATL CANCER I, V89, P166, DOI 10.1093/jnci/89.2.166; Inoue H, 2002, J BIOL CHEM, V277, P41674, DOI 10.1074/jbc.M205961200; Irvine RA, 2000, HUM MOL GENET, V9, P267, DOI 10.1093/hmg/9.2.267; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; Jenster G, 1999, SEMIN ONCOL, V26, P407; Kantoff P, 1998, BBA-REV CANCER, V1378, pC1; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Lobaccaro JM, 1999, ENDOCRINOLOGY, V140, P350, DOI 10.1210/en.140.1.350; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; Montgomery JS, 2001, J PATHOL, V195, P138, DOI 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nelson KA, 2002, AM J EPIDEMIOL, V155, P883, DOI 10.1093/aje/155.10.883; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Stanford JL, 1997, CANCER RES, V57, P1194; Trapman J, 1996, PATHOL RES PRACT, V192, P752, DOI 10.1016/S0344-0338(96)80097-5; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Tut TG, 1997, J CLIN ENDOCR METAB, V82, P3777, DOI 10.1210/jc.82.11.3777; Vivat V, 1997, J MOL ENDOCRINOL, V18, P147, DOI 10.1677/jme.0.0180147; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Wang QB, 2001, ANAL BIOCHEM, V289, P217, DOI 10.1006/abio.2000.4960; WONG CI, 1993, J BIOL CHEM, V268, P19004; Zhu ZX, 2001, BIOCHEMISTRY-US, V40, P10756, DOI 10.1021/bi010525j	68	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17319	17328		10.1074/jbc.M400970200	http://dx.doi.org/10.1074/jbc.M400970200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966121	hybrid			2022-12-27	WOS:000220870400055
J	El-Tanani, M; Platt-Higgins, A; Rudland, PS; Campbell, FC				El-Tanani, M; Platt-Higgins, A; Rudland, PS; Campbell, FC			Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; METASTASIS-INDUCING DNA; PROTEIN S100A4 P9KA; BETA-CATENIN; NEOPLASTIC TRANSFORMATION; METALLOPROTEINASE MATRILYSIN; PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CARCINOMA; ACTIVATION DOMAIN; INTESTINAL TUMORS	Osteopontin (OPN) is a multifunctional protein implicated in mammary development, neoplastic change, and metastasis. OPN is a target gene for beta-catenin-T cell factor signaling, which is commonly disturbed during mammary oncogenesis, but the understanding of OPN regulation is incomplete. Data base-assisted bioinformatic analysis of the OPN promoter region has revealed the presence of T cell factor-, Ets-, and AP-1-binding motifs. Here we report that beta-catenin, Lef-1, Ets transcription factors, and the AP-1 protein c-Jun each weakly enhanced luciferase expression from a OPN promoter-luciferase reporter construct, transiently transfected into a rat mammary cell line. OPN promoter responsiveness to beta-catenin and Lef-1, however, was considerably enhanced by Ets transcription factors including Ets-1, Ets-2, ERM, and particularly PEA3. PEA3 also enhanced promoter responsiveness to the AP-1 protein c-Jun. Co-transfection of cells with beta-catenin, Lef-1, PEA3, and c-Jun in combination increased luciferase expression by up to 280-fold and induced expression of endogenous rat OPN. In six human breast cell lines, those that highly expressed OPN also expressed PEA3 and Ets-1. Moreover, there was a significant association of immunocytochemical staining for OPN and one of beta-catenin, Ets-1, Ets-2, PEA3, or c-Jun, in the 29 human breast carcinomas tested. This study shows that beta-catenin/ Lef-1, Ets, and AP-1 transcription factors can cooperate in a rat mammary cell line in stimulating transcription of OPN and that their independent presence is associated with that of OPN in a group of human breast cancers. These results suggest that the presence of these transcription factors in human breast cancer is responsible in part for the overexpression of OPN that, in turn, is implicated in mammary neoplastic progression and metastasis.	Queens Univ Belfast, Canc Res Ctr, Dept Surg, Belfast BT12 6BJ, Antrim, North Ireland; Univ Liverpool, Sch Biol Sci, Canc & Polio Res Labs, Liverpool L69 7ZB, Merseyside, England	Queens University Belfast; University of Liverpool	El-Tanani, M (corresponding author), Queens Univ Belfast, Canc Res Ctr, Dept Surg, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.	m.el-tanani@qub.ac.uk						Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Agrawal D, 2002, J NATL CANCER I, V94, P513; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BEHREND EI, 1994, CANCER RES, V54, P832; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boyd KE, 1999, P SOC EXP BIOL MED, V222, P9, DOI 10.1111/j.1525-1373.1999.09992.x; Buttice G, 1996, ONCOGENE, V13, P2297; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Devoll RE, 1999, J ORAL PATHOL MED, V28, P97; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200; El-Tanani MK, 2001, ONCOGENE, V20, P1793, DOI 10.1038/sj.onc.1204358; ElTanani MKK, 1996, MOL CELL ENDOCRINOL, V121, P29, DOI 10.1016/0303-7207(96)03844-0; ElTanani MKK, 1997, J STEROID BIOCHEM, V60, P269, DOI 10.1016/S0960-0760(96)00226-9; Foos G, 2000, ONCOGENE, V19, P5507, DOI 10.1038/sj.onc.1203946; Giese K, 1997, P NATL ACAD SCI USA, V94, P12845, DOI 10.1073/pnas.94.24.12845; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Howe LR, 2003, CANCER RES, V63, P1906; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6; Kao LC, 2002, ENDOCRINOLOGY, V143, P2119, DOI 10.1210/en.143.6.2119; Kim HJ, 2002, J CELL BIOCHEM, V87, P93, DOI 10.1002/jcb.10280; Kinoshita J, 2002, SURGERY, V131, pS222, DOI 10.1067/msy.2002.119792; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koszewski NJ, 1996, J STEROID BIOCHEM, V59, P377, DOI 10.1016/S0960-0760(96)00127-6; Li GH, 2002, CIRCULATION, V106, P854, DOI 10.1161/01.CIR.0000024113.26985.CC; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nagai S, 2001, INT IMMUNOL, V13, P367, DOI 10.1093/intimm/13.3.367; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Oates AJ, 1996, ONCOGENE, V13, P97; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Oyama Y, 2002, CIRC RES, V90, P348, DOI 10.1161/hh0302.105098; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; RIDALL AL, 1995, ANN NY ACAD SCI, V760, P59, DOI 10.1111/j.1749-6632.1995.tb44620.x; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rudland PS, 2000, CANCER RES, V60, P1595; Rudland PS, 2002, CANCER RES, V62, P3417; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; Sabattini E, 1998, J CLIN PATHOL, V51, P506, DOI 10.1136/jcp.51.7.506; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Sato T, 2002, APMIS, V110, P347, DOI 10.1034/j.1600-0463.2002.100410.x; SENGER DR, 1985, CANCER RES, V45, P5818; SENGER DR, 1988, CANCER RES, V48, P5770; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; SU LC, 1995, ONCOGENE, V10, P2163; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Walunas TL, 2000, J IMMUNOL, V164, P2857, DOI 10.4049/jimmunol.164.6.2857; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wu Y, 2000, BRIT J CANCER, V83, P156; Yamagiwa H, 1999, BONE, V25, P197, DOI 10.1016/S8756-3282(99)00157-X; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065	76	89	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20794	20806		10.1074/jbc.M311131200	http://dx.doi.org/10.1074/jbc.M311131200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14990565	hybrid			2022-12-27	WOS:000221273800031
J	Zhao, J; Zhang, LH; Jia, LT; Zhang, L; Xu, YM; Wang, Z; Yu, CJ; Peng, WD; Wen, WH; Wang, CJ; Chen, SY; Yang, AG				Zhao, J; Zhang, LH; Jia, LT; Zhang, L; Xu, YM; Wang, Z; Yu, CJ; Peng, WD; Wen, WH; Wang, CJ; Chen, SY; Yang, AG			Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN ANTIBODY; BREAST-CANCER-CELLS; GRANZYME-B; PSEUDOMONAS EXOTOXIN; ANTITUMOR-ACTIVITY; INDUCED APOPTOSIS; TARGET-CELLS; KILLER-CELLS; GROWTH; TRANSLOCATION	Targeted cell killing is required for effective treatment of cancers. We previously described the generation of a chimeric immunocasp-3 protein and its potent selective antitumor activity (Jia, L.T., Zhang, L.H., Yu, C.J., Zhao, J., Xu, Y.M., Gui, J.H., Jin, M., Ji, Z.L., Wen, W.H., Wang, C.J., Chen, S.Y., and Yang, A.G. (2003) Cancer Res. 63, 3257-3262). Here we extend the repertoire of another chimeric pro-apoptotic protein immunoGrB, which comprises an anti-HER2 single-chain antibody, a Pseudomonas exotoxin A translocation domain and active granzyme B. Human lymphoma Jurkat cells transfected with the immunoGrB gene expression vector were able to produce and secrete the chimeric protein. The immunoGrB molecule selectively recognized and destroyed HER2-overexpressing tumor cells both in vitro and in nude mouse after intramuscular injection of the immunoGrB expression plasmid. Further in vivo study showed that intravenous administration of immunoGrB gene-modified lymphocytes led to suppression of HER2-overexpressing tumor growth and prolonged animal survival because of continuous secretion of immunoGrB molecules into blood and lymph fluid. These results demonstrate that the chimeric immunoGrB molecule, which is capable of antibody-directed targeting and granzyme B-mediated killing, has therapeutic potential against HER2 tumors, especially in cases in which caspase-dependent apoptosis is inhibited.	Fourth Mil Med Univ, Dept Biochem & Mol Biol, Xian 710032, Peoples R China; Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA	Air Force Military Medical University; Air Force Military Medical University; Baylor College of Medicine	Yang, AG (corresponding author), Fourth Mil Med Univ, Dept Biochem & Mol Biol, Xian 710032, Peoples R China.	agyang@fmmu.edu.cn	温, 家琦/GYV-3177-2022					Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; BATRA JK, 1992, P NATL ACAD SCI USA, V89, P5867, DOI 10.1073/pnas.89.13.5867; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; Chen SY, 1997, NATURE, V385, P78, DOI 10.1038/385078a0; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Dela Cruz JS, 2000, J IMMUNOL, V165, P5112, DOI 10.4049/jimmunol.165.9.5112; Edwards KM, 1999, IMMUNOL CELL BIOL, V77, P76, DOI 10.1046/j.1440-1711.1999.00799.x; Elliott MJ, 1999, CANCER CHEMOTH PHARM, V44, P1, DOI 10.1007/s002800050938; Fokkema E, 2003, VIRCHOWS ARCH, V442, P349, DOI 10.1007/s00428-003-0763-9; Foy TM, 2002, SEMIN ONCOL, V29, P53, DOI 10.1053/sonc.2002.34056; Frankel AE, 2000, CLIN CANCER RES, V6, P326; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HEAD JF, 2002, EXPER OPIN THER TAR, V6, P375; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Iwasaka T, 1996, ACTA OBSTET GYN SCAN, V75, P797, DOI 10.3109/00016349609054706; Jia LT, 2003, CANCER RES, V63, P3257; Kam CM, 2000, BBA-PROTEIN STRUCT M, V1477, P307, DOI 10.1016/S0167-4838(99)00282-4; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; Keefe DL, 2002, CANCER-AM CANCER SOC, V95, P1592, DOI 10.1002/cncr.10854; Kolenko VM, 2000, APOPTOSIS, V5, P17, DOI 10.1023/A:1009677307458; Kreitman R J, 2001, Curr Opin Investig Drugs, V2, P1282; Leyland-Jones B, 2002, LANCET ONCOL, V3, P137, DOI 10.1016/S1470-2045(02)00676-9; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Neve RM, 2001, BIOCHEM BIOPH RES CO, V280, P274, DOI 10.1006/bbrc.2000.4104; OGATA M, 1992, J BIOL CHEM, V267, P25396; OSBORNE CK, 1985, CANCER RES, V45, P584; Pelegrin M, 1998, HUM GENE THER, V9, P2165, DOI 10.1089/hum.1998.9.15-2165; Pinkoski MJ, 2000, CELL DEATH DIFFER, V7, P17, DOI 10.1038/sj.cdd.4400604; Pinkoski MJ, 1998, BLOOD, V92, P1044; Plunkett TA, 2002, INT J CLIN PRACT, V56, P261; PRESS MF, 1994, CANCER RES, V54, P5675; PRESS MF, 1990, ONCOGENE, V5, P953; PRIOR TI, 1992, BIOCHEMISTRY-US, V31, P3555, DOI 10.1021/bi00129a001; Ranson M, 2002, ONCOLOGY-BASEL, V63, P17, DOI 10.1159/000066203; Rosenblum MG, 1999, CLIN CANCER RES, V5, P865; Rosenblum MG, 2000, INT J CANCER, V88, P267, DOI 10.1002/1097-0215(20001015)88:2<267::AID-IJC19>3.0.CO;2-G; Tan-Chiu E, 2002, ONCOLOGY-BASEL, V63, P57, DOI 10.1159/000066201; Taupiac MP, 1999, MOL MICROBIOL, V31, P1385, DOI 10.1046/j.1365-2958.1999.01280.x; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Trapani JA, 2001, GENOME BIOL, V2; Wright M, 1997, GENE THER, V4, P317, DOI 10.1038/sj.gt.3300372; Yang AG, 1997, NAT BIOTECHNOL, V15, P46, DOI 10.1038/nbt0197-46	45	44	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21343	21348		10.1074/jbc.M312648200	http://dx.doi.org/10.1074/jbc.M312648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004021	hybrid			2022-12-27	WOS:000221273800097
J	Chao, JI; Kuo, PC; Hsu, TS				Chao, JI; Kuo, PC; Hsu, TS			Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 GENE-MUTATIONS; P38 MAP KINASE; MAMMALIAN-CELLS; EXPRESSION; PROTEIN; CANCER; LINES; CYCLE; PHOSPHORYLATION; FAMILY	Survivin is expressed in most tumor cells and has been associated with both anti-apoptosis and mitotic progression. However, the mechanism of regulation of the survivin expression remains unclear. In this study we investigated the expression and regulation of survivin in the nitric oxide (NO)-exposed human lung carcinoma cells. The lung carcinoma cell lines CL3, H1299, and A549 but not normal lung fibroblast expressed high levels of survivin proteins. NO donors S-nitroso-N-acetyl-penicillamine (SNAP) and sodium nitroprusside (SNP) decreased the survivin expression. SNAP (0.4mM, 24 h) and SNP (1 mM, 24 h) significantly induced cytotoxicity and apoptosis in lung carcinoma cells. Furthermore, SNAP inhibited the cell growth and increased the fractions of G(2)/M phase. The levels of cyclin B1 and phospho-cdc2-(Thr-161) proteins were inhibited in the NO-exposed cells. The cdc25 phosphatase inhibitors (Cpd 5 and NSC 663284) and the cdc2 kinase inhibitors (alsterpaullone and purvalanol A) enhanced SNP-induced cytotoxicity and the decrease in survivin expression. However, overexpression of survivin by a pOTB7-survivin vector reduced SNP-induced cell growth inhibition and cytotoxicity. In addition, SNP activated the phosphorylation of p38 mitogen-activated protein (MAP) kinase. The specific p38 MAP kinase inhibitor, SB202190, significantly decreased the cytotoxicity and increased the survivin levels in NO donor-treated and inducible NOS-transfected cells. Conversely, anticancer agents including quercetin, arsenite, and cisplatin but not genistein increased the levels of survivin protein. Our results indicated for the first time that NO inhibited the expression of survivin, which was down-regulated by the p38 MAP kinase pathway.	Tzu Chi Univ, Coll Life Sci, Inst Pharmacol & Toxicol, Mol Toxicol Lab, Hualien 970, Taiwan	Tzu Chi University	Chao, JI (corresponding author), Tzu Chi Univ, Coll Life Sci, Inst Pharmacol & Toxicol, Mol Toxicol Lab, 701,Sect 3,Chung Yang Rd, Hualien 970, Taiwan.	chaoji@mail.tcu.edu.tw						AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aramaki Y, 2001, BIOCHEM BIOPH RES CO, V280, P982, DOI 10.1006/bbrc.2000.4204; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Chao JI, 2001, CHEM RES TOXICOL, V14, P1193, DOI 10.1021/tx010041o; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; CUI SJ, 1994, CANCER RES, V54, P2462; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Ikeguchi M, 2002, CLIN CANCER RES, V8, P3131; Ishida A, 1997, J BIOL CHEM, V272, P10050; Kawamura K, 2003, DEV BIOL, V256, P331, DOI 10.1016/S0012-1606(02)00135-5; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Lazo JS, 2001, J MED CHEM, V44, P4042, DOI 10.1021/jm0102046; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Messmer UK, 1996, FEBS LETT, V384, P162; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MONCADA S, 1991, PHARMACOL REV, V43, P109; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; PLUMB JA, 1989, CANCER RES, V49, P4435; Rodel C, 2003, INT J RADIAT ONCOL, V55, P1341, DOI 10.1016/S0360-3016(02)04618-7; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tamura K, 2000, CANCER RES, V60, P1317; Temme A, 2003, MOL BIOL CELL, V14, P78, DOI 10.1091/mbc.E02-04-0182; Tendler DS, 2001, CANCER RES, V61, P3682; Tsai CM, 1996, CANCER RES, V56, P206; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verhagen AM, 2001, GENOME BIOL, V2; Wall NR, 2003, CANCER RES, V63, P230; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE QW, 1994, J BIOL CHEM, V269, P28500; YANG PC, 1992, AM J RESP CELL MOL, V7, P161, DOI 10.1165/ajrcmb/7.2.161	56	90	95	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20267	20276		10.1074/jbc.M312381200	http://dx.doi.org/10.1074/jbc.M312381200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14988404	hybrid			2022-12-27	WOS:000221164500104
J	Dentin, R; Pegorier, JP; Benhamed, F; Foufelle, F; Ferre, P; Fauveau, V; Magnuson, MA; Girard, J; Postic, C				Dentin, R; Pegorier, JP; Benhamed, F; Foufelle, F; Ferre, P; Fauveau, V; Magnuson, MA; Girard, J; Postic, C			Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1C; FATTY-ACID-SYNTHASE; PYRUVATE-KINASE GENE; CARNITINE-PALMITOYLTRANSFERASE-I; CARBOHYDRATE RESPONSE ELEMENT; RAT HEPATOCYTES; TRANSCRIPTION FACTOR; GLUCOSE-HOMEOSTASIS; STEROL REGULATION; TRANSGENIC MICE	Hepatic glucokinase (GK) catalyzes the phosphorylation of glucose to glucose 6-phosphate (G6P), a step which is essential for glucose metabolism in liver as well as for the induction of glycolytic and lipogenic genes. The sterol regulatory element-binding protein-1c (SREBP-1c) has emerged as a major mediator of insulin action on hepatic gene expression, but the extent to which its transcriptional effect is caused by an increased glucose metabolism remains unclear. Through the use of hepatic GK knockout mice (hGK-KO) we have shown that the acute stimulation by glucose of L-pyruvate kinase (L-PK), fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), and Spot 14 genes requires GK expression. To determine whether the effect of SREBP-1c requires GK expression and subsequent glucose metabolism, a transcriptionally active form of SREBP-1c was overexpressed both in vivo and in primary cultures of control and hGK-KO hepatocytes. Our results demonstrate that the synergistic action of SREBP-1c and glucose metabolism via GK is necessary for the maximal induction of L-PK, ACC, FAS, and Spot 14 gene expression. Indeed, in hGK-KO hepatocytes overexpressing SREBP-1c, the effect of glucose on glycolytic and lipogenic genes is lost because of the impaired ability of these hepatocytes to efficiently metabolize glucose, despite a marked increase in low Km hexokinase activity. Our studies also reveal that the loss of glucose effect observed in hGK-KO hepatocytes is associated with a decreased in the carbohydrate responsive element-binding protein (ChREBP) gene expression, a transcription factor suggested to mediate glucose signaling in liver. Decreased ChREBP gene expression, achieved using small interfering RNA, results in a loss of glucose effect on endogenous glycolytic (L-PK) and lipogenic ( FAS, ACC) gene expression, thereby demonstrating the direct implication of ChREBP in glucose action. Together these results support a model whereby both SREBP-1c and glucose metabolism, acting via ChREBP, are necessary for the dietary induction of glycolytic and lipogenic gene expression in liver.	Univ Paris 05, Inst Cochin, Dept Endocrinol, CNRS,UMR8104,INSERM,U567, F-75014 Paris, France; Univ Paris 05, EA1833, F-75014 Paris, France; Univ Paris 06, Ctr Rech Biomed Cordeliers, INSERM, U465, F-75006 Paris, France; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Vanderbilt University	Postic, C (corresponding author), Univ Paris 05, Inst Cochin, Dept Endocrinol, CNRS,UMR8104,INSERM,U567, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	postic@cochin.inserm.fr	Magnuson, Mark A/B-1335-2009; Postic, Catherine/P-2271-2017; Dentin, Renaud/AAV-5818-2020; Ferré, Pascal/K-1250-2013; Magnuson, Mark/AAY-7172-2021; dentin, Renaud/P-4939-2017	Magnuson, Mark A/0000-0002-8824-6499; Postic, Catherine/0000-0002-1875-6960; Dentin, Renaud/0000-0003-0988-4458; Ferré, Pascal/0000-0003-0115-7045; Magnuson, Mark/0000-0002-8824-6499; dentin, Renaud/0000-0003-0988-4458; FOUFELLE, Fabienne/0000-0002-0752-622X				Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Becard D, 2001, DIABETES, V50, P2425, DOI 10.2337/diabetes.50.11.2425; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Gosmain Y, 2004, DIABETES, V53, P321, DOI 10.2337/diabetes.53.2.321; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; Guillet-Deniau I, 2002, DIABETES, V51, P1722, DOI 10.2337/diabetes.51.6.1722; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Horton JD, 2002, BIOCHEM SOC T, V30, P1091, DOI 10.1042/bst0301091; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; Li JP, 2003, P NATL ACAD SCI USA, V100, P9476, DOI 10.1073/pnas.1133426100; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Louet JF, 2001, BIOCHEM J, V354, P189, DOI 10.1042/0264-6021:3540189; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Mourrieras F, 1997, BIOCHEM J, V326, P345, DOI 10.1042/bj3260345; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; O'Callaghan BL, 2001, J BIOL CHEM, V276, P16033, DOI 10.1074/jbc.M101557200; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; PRIPBUUS C, 1995, BIOCHEM SOC T, V23, P500, DOI 10.1042/bst0230500; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Rufo C, 2001, J BIOL CHEM, V276, P21969, DOI 10.1074/jbc.M100461200; Sebastian S, 2000, BIOCHEM BIOPH RES CO, V270, P886, DOI 10.1006/bbrc.2000.2527; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; THUMELIN S, 1994, BIOCHEM J, V300, P583, DOI 10.1042/bj3000583; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Wang HY, 2002, J BIOL CHEM, V277, P32746, DOI 10.1074/jbc.M201635200; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298	57	337	355	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20314	20326		10.1074/jbc.M312475200	http://dx.doi.org/10.1074/jbc.M312475200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985368	hybrid			2022-12-27	WOS:000221164500109
J	Dos Santos, PC; Smith, AD; Frazzon, J; Cash, VL; Johnson, MK; Dean, DR				Dos Santos, PC; Smith, AD; Frazzon, J; Cash, VL; Johnson, MK; Dean, DR			Iron-sulfur cluster assembly - NifU-directed activation of the nitrogenase Fe protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE DESULFURASE ACTIVITY; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; GENE-CLUSTER; S CLUSTER; 2FE-2S CLUSTER; BIOSYNTHESIS; SYSTEM; IDENTIFICATION; SCAFFOLD	The NifU protein is a homodimer that is proposed to provide a molecular scaffold for the assembly of [Fe-S] clusters uniquely destined for the maturation of the nitrogenase catalytic components. There are three domains contained within NifU, with the N-terminal domain exhibiting a high degree of primary sequence similarity to a related family of [Fe-S] cluster biosynthetic scaffolds designated IscU. The C-terminal domain of NifU exhibits sequence similarity to a second family of proposed [Fe-S] cluster biosynthetic scaffolds designated Nfu. Genetic experiments described here involving amino acid substitutions within the N-terminal and C-terminal domains of NifU indicate that both domains can separately participate in nitrogenase-specific [Fe-S] cluster formation, although the N-terminal domain appears to have the dominant function. These in vivo experiments were supported by in vitro [Fe-S] cluster assembly and transfer experiments involving the activation of an apo-form of the nitrogenase Fe protein.	Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA	Virginia Polytechnic Institute & State University; University System of Georgia; University of Georgia	Dean, DR (corresponding author), Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA.	deandr@vt.edu	Frazzon, Jeverson/L-6402-2013	Dos Santos, Patricia/0000-0002-3364-0931	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062542] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 62542 4] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; BEYNON J, 1987, J BACTERIOL, V169, P4024, DOI 10.1128/jb.169.9.4024-4029.1987; CAGNON C, 1991, PROTEIN ENG, V4, P843, DOI 10.1093/protein/4.7.843; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CHROMY V, 1974, CLIN CHEM, V20, P1362; DENK D, 1987, J GEN MICROBIOL, V133, P515; Dos Santos PC, 2004, CHEM REV, V104, P1159, DOI 10.1021/cr020608l; FORTUNE WB, 1938, IND ENG CHEM ANAL ED, V10, P61; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; Hwang DM, 1996, J MOL EVOL, V43, P536, DOI 10.1007/PL00006114; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leon S, 2003, BIOCHEM J, V371, P823, DOI 10.1042/BJ20021946; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Nishio K, 2000, J BIOL CHEM, V275, P22615, DOI 10.1074/jbc.C000279200; Ollagnier-De-Choudens S, 2003, FEBS LETT, V555, P263, DOI 10.1016/S0014-5793(03)01244-4; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; PETERS JW, 1994, J BIOL CHEM, V269, P28076; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; Wu SP, 2002, BIOCHEMISTRY-US, V41, P8876, DOI 10.1021/bi0256781; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	36	93	93	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19705	19711		10.1074/jbc.M400278200	http://dx.doi.org/10.1074/jbc.M400278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14993221	hybrid			2022-12-27	WOS:000221164500040
J	Faustin, B; Rossignol, R; Rocher, C; Benard, G; Malgat, M; Letellier, T				Faustin, B; Rossignol, R; Rocher, C; Benard, G; Malgat, M; Letellier, T			Mobilization of adenine nucleotide translocators as molecular bases of the biochemical threshold effect observed in mitochondrial diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; BLUE NATIVE ELECTROPHORESIS; BEEF-HEART MITOCHONDRIA; CYTOCHROME-C-OXIDASE; OXIDATIVE-PHOSPHORYLATION; ADP/ATP CARRIER; RESPIRATORY-CHAIN; FLUX CONTROL; COMPLEX-I; WILD-TYPE	The existence of a biochemical threshold effect in the metabolic expression of oxidative phosphorylation deficiencies has considerable implications for the understanding of mitochondrial bioenergetics and the study of mitochondrial diseases. However, the molecular bases of this phenomenon remain unclear. We report here a new mechanism to explain this threshold effect, based on a reserve of enzymes not initially participating in the respiratory rate that can be activated either to respond to a flux increase or to compensate for a defect induced by a mutation. We show that this mobilization occurs through 1) the assembly of inactive adenine nucleotide translocator isoform 1 subunits into oligomeric active carriers or 2) conformational changes in the adenine nucleotide translocator isoform 1 in a permeability transition pore-like structure. We discuss how these transitions are sensitive to the steady state of oxidative phosphorylation functioning or tissue and analyze their consequences on the threshold effect.	Univ Bordeaux 2, INSERM, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Letellier, T (corresponding author), 146 Rue Leo Saignat, F-33076 Bordeaux, France.	tletel@u-bordeaux2.fr	Bénard, Giovanni/M-3485-2014	Bénard, Giovanni/0000-0003-0036-9425; Rocher, Christophe/0000-0003-1859-9704				Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055; BLOCK MR, 1984, BIOCHIM BIOPHYS ACTA, V767, P369, DOI 10.1016/0005-2728(84)90207-X; BOULAY F, 1986, BIOCHEMISTRY-US, V25, P7567, DOI 10.1021/bi00371a046; BRANDOLIN G, 1985, BIOCHEMISTRY-US, V24, P1991, DOI 10.1021/bi00329a029; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; Cabezon E, 2003, NAT STRUCT BIOL, V10, P744, DOI 10.1038/nsb966; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CLARK JB, 1970, J BIOL CHEM, V245, P4724; DAVIDSON AM, 1987, BIOCHEM J, V246, P715, DOI 10.1042/bj2460715; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Doerner A, 1997, FEBS LETT, V414, P258, DOI 10.1016/S0014-5793(97)01000-4; Dorner A, 1999, BBA-BIOMEMBRANES, V1417, P16, DOI 10.1016/S0005-2736(98)00245-4; DOUSSIERE J, 1984, BIOCHIM BIOPHYS ACTA, V766, P492, DOI 10.1016/0005-2728(84)90265-2; DYALL SD, 2003, J BIOL CHEM; GELLERICH FN, 1990, FEBS LETT, V274, P167, DOI 10.1016/0014-5793(90)81355-R; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; Gnaiger E, 1998, J EXP BIOL, V201, P1129; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Grivennikova VG, 2003, BIOCHEM J, V369, P619, DOI 10.1042/BJ20021165; GRIVENNIKOVA VG, 2002, BIOCH J, V14; GROEN AK, 1982, J BIOL CHEM, V257, P2754; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HOLZHUTTER HG, 1990, COMPUT APPL BIOSCI, V6, P23; Huang SG, 2001, ARCH BIOCHEM BIOPHYS, V394, P67, DOI 10.1006/abbi.2001.2520; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KLINGENBERG M, 1975, EUR J BIOCHEM, V52, P351, DOI 10.1111/j.1432-1033.1975.tb04003.x; KRAMER R, 1979, BIOCHEMISTRY-US, V18, P4209; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KUNZ W, 1988, FEBS LETT, V233, P17, DOI 10.1016/0014-5793(88)81347-4; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; LEMASTERS JJ, 1979, J BIOL CHEM, V254, P1248; LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171; LETELLIER T, 1992, PEDIATR RES, V32, P17, DOI 10.1203/00006450-199207000-00004; LETELLIER T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P58, DOI 10.1016/0005-2728(93)90189-M; Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490; Majima E, 1998, BIOCHEMISTRY-US, V37, P424, DOI 10.1021/bi9710683; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MORGANHUGHES JA, 1977, BRAIN, V100, P617, DOI 10.1093/brain/100.4.617; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426; Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schagger H, 2001, J BIOL CHEM, V276, P37861; Schulenberg B, 2003, J BIOL CHEM, V278, P27251, DOI 10.1074/jbc.C300189200; STREICHERSCOTT J, 1993, ANAL BIOCHEM, V210, P69, DOI 10.1006/abio.1993.1152; Taylor RW, 2001, ADV DRUG DELIVER REV, V49, P121, DOI 10.1016/S0169-409X(01)00130-2; TORRONI A, 1990, J BIOL CHEM, V265, P20589; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Zaid A, 2001, EUR J BIOCHEM, V268, P5497, DOI 10.1046/j.0014-2956.2001.02453.x; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	61	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20411	20421		10.1074/jbc.M314259200	http://dx.doi.org/10.1074/jbc.M314259200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14976187	hybrid			2022-12-27	WOS:000221164500120
J	Gafni, J; Hermel, E; Young, JE; Wellington, CL; Hayden, MR; Ellerby, LM				Gafni, J; Hermel, E; Young, JE; Wellington, CL; Hayden, MR; Ellerby, LM			Inhibition of calpain cleavage of huntingtin reduces toxicity - Accumulation of calpain/caspase fragments in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTOR; MUTANT HUNTINGTIN; CASPASE CLEAVAGE; MOUSE MODEL; POLYGLUTAMINE TRACT; CELL-DEATH; IN-VITRO; CYSTEINE PROTEASE; TRANSGENIC MICE; CROSS-TALK	Huntington's disease (HD) is a neurodegenerative disorder caused by a polyglutamine (polyQ) tract expansion near the N terminus of huntingtin (Htt). Proteolytic processing of mutant Htt and abnormal calcium signaling may play a critical role in disease progression and pathogenesis. Recent work indicates that calpains may participate in the increased and/or altered patterns of Htt proteolysis leading to the selective toxicity observed in HD striatum. Here, we identify two calpain cleavage sites in Htt and show that mutation of these sites renders the polyQ expanded Htt less susceptible to proteolysis and aggregation, resulting in decreased toxicity in an in vitro cell culture model. In addition, we found that calpain- and caspase-derived Htt fragments preferentially accumulate in the nucleus without the requirement of further cleavage into smaller fragments. Calpain family members, calpain- 1, -5, -7, and -10, have increased levels or are activated in HD tissue culture and transgenic mouse models, suggesting they may play a key role in Htt proteolysis and disease pathology. Interestingly, calpain- 1, -5, -7, and -10 localize to the cytoplasm and the nucleus, whereas the activated forms of calpain-7 and -10 are found only in the nucleus. These results support the role of calpain- derived Htt fragmentation in HD and suggest that aberrant activation of calpains may play a role in HD pathogenesis.	Buck Inst Age Res, Novato, CA 94945 USA; Touro Univ Coll Osteopath Med, Vallejo, CA 94592 USA; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	Buck Institute for Research on Aging; Touro University California; University of British Columbia; University of British Columbia	Ellerby, LM (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	lellerby@buckinstitute.org	Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419	NINDS NIH HHS [NS 40251 A, F32 NS 043937] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040251, F32NS043937] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN RD, 1993, EUR J IMMUNOL, V23, P333, DOI 10.1002/eji.1830230205; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen NS, 1999, J NEUROCHEM, V72, P1890, DOI 10.1046/j.1471-4159.1999.0721890.x; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; Guttmann RP, 2002, J PHARMACOL EXP THER, V302, P1023, DOI 10.1124/jpet.102.036962; Hackam AS, 1999, HUM MOL GENET, V8, P25, DOI 10.1093/hmg/8.1.25; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; HEDREEN JC, 1991, NEUROSCI LETT, V133, P257, DOI 10.1016/0304-3940(91)90583-F; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Huntington G, 2003, J NEUROPSYCH CLIN N, V15, P109, DOI 10.1176/appi.neuropsych.15.1.109; Kamei M, 1998, GENOMICS, V51, P197, DOI 10.1006/geno.1998.5395; Kaytor MD, 1999, HUM MOL GENET, V8, P1657, DOI 10.1093/hmg/8.9.1657; Kegel KB, 2002, J BIOL CHEM, V277, P7466, DOI 10.1074/jbc.M103946200; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Lin CH, 2001, HUM MOL GENET, V10, P137, DOI 10.1093/hmg/10.2.137; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Nucifora FC, 2003, J BIOL CHEM, V278, P13047, DOI 10.1074/jbc.M211224200; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Panov AV, 2003, ARCH BIOCHEM BIOPHYS, V410, P1, DOI 10.1016/S0003-9861(02)00585-4; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Ray SK, 2000, ANN NY ACAD SCI, V914, P275, DOI 10.1111/j.1749-6632.2000.tb05202.x; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAPP E, 1995, NEUROSCIENCE, V64, P397, DOI 10.1016/0306-4522(94)00427-7; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Shields DC, 1998, P NATL ACAD SCI USA, V95, P5768, DOI 10.1073/pnas.95.10.5768; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Sun Y, 2001, J BIOL CHEM, V276, P24713, DOI 10.1074/jbc.M103501200; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; Xia JR, 2003, HUM MOL GENET, V12, P1393, DOI 10.1093/hmg/ddg156; YOSHIMURA N, 1984, J BIOL CHEM, V259, P9847; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3; Zeron MM, 2001, MOL CELL NEUROSCI, V17, P41, DOI 10.1006/mcne.2000.0909	59	211	222	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20211	20220		10.1074/jbc.M401267200	http://dx.doi.org/10.1074/jbc.M401267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14981075	hybrid			2022-12-27	WOS:000221164500098
J	Reszko, AE; Kasumov, T; David, F; Jobbins, KA; Thomas, KR; Hoppel, CL; Brunengraber, H; Rosiers, CD				Reszko, AE; Kasumov, T; David, F; Jobbins, KA; Thomas, KR; Hoppel, CL; Brunengraber, H; Rosiers, CD			Peroxisomal fatty acid oxidation is a substantial source of the acetyl moiety of malonyl-CoA in rat heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; COENZYME-A; LIVER MITOCHONDRIA; SKELETAL-MUSCLE; HUMAN-TISSUES; PPAR-ALPHA; CITRATE; METABOLISM; DECARBOXYLASE; PURIFICATION	Little is known about the sources of acetyl-CoA used for the synthesis of malonyl-CoA, a key regulator of mitochondrial fatty acid oxidation in the heart. In perfused rat hearts, we previously showed that malonyl-CoA is labeled from both carbohydrates and fatty acids. This study was aimed at assessing the mechanisms of incorporation of fatty acid carbons into malonyl-CoA. Rat hearts were perfused with glucose, lactate, pyruvate, and a fatty acid (palmitate, oleate or docosanoate). In each experiment, substrates were C-13-labeled to yield singly or/and doubly labeled acetyl-CoA. The mass isotopomer distribution of malonyl-CoA was compared with that of the acetyl moiety of citrate, which reflects mitochondrial acetyl-CoA. In the presence of labeled glucose or lactate/pyruvate, the C-13 labeling of malonyl-CoA was up to 2-fold lower than that of mitochondrial acetyl-CoA. However, in the presence of a fatty acid labeled in its first acetyl moiety, the C-13 labeling of malonyl-CoA was up to 10-fold higher than that of mitochondrial acetyl-CoA. The labeling of malonyl-CoA and of the acetyl moiety of citrate is compatible with peroxisomal beta-oxidation forming C-12 and C-14 acyl-CoAs and contributing >50% of the fatty acid-derived acetyl groups that end up in malonyl-CoA. This fraction increases with the fatty acid chain length. By supplying acetyl-CoA for malonyl-CoA synthesis, peroxisomal beta-oxidation may participate in the control of mitochondrial fatty acid oxidation in the heart. In addition, this pathway may supply some acyl groups used in protein acylation, which is increasingly recognized as an important regulatory mechanism for many biochemical processes.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Montreal, Dept Nutr, Montreal, PQ H3C 3J7, Canada	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Universite de Montreal	Brunengraber, H (corresponding author), Case Western Reserve Univ, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxb8@cwru.edu	Rosiers, Christine Des/O-6285-2014		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG 15585] Funding Source: Medline; NIDDK NIH HHS [DK 07319, R01 DK 35543] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbas AS, 1998, J MOL CELL CARDIOL, V30, P1305, DOI 10.1006/jmcc.1998.0693; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; BRADY PS, 1982, J BIOL CHEM, V257, P9290; Brunengraber H, 1997, ANNU REV NUTR, V17, P559, DOI 10.1146/annurev.nutr.17.1.559; Campbell FM, 2002, J BIOL CHEM, V277, P4098, DOI 10.1074/jbc.M106054200; CHEEMADHADLI S, 1976, CAN J BIOCHEM CELL B, V54, P561, DOI 10.1139/o76-082; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; Comte B, 1997, J BIOL CHEM, V272, P26117, DOI 10.1074/jbc.272.42.26117; DeMar JC, 1999, PROG LIPID RES, V38, P49, DOI 10.1016/S0163-7827(98)00020-4; Dyck JRB, 2000, BIOCHEM J, V350, P599, DOI 10.1042/0264-6021:3500599; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; Finck BN, 2003, P NATL ACAD SCI USA, V100, P1226, DOI 10.1073/pnas.0336724100; FINK G, 1988, J BIOL CHEM, V263, P18036; Hasselbaink DM, 2002, MOL CELL BIOCHEM, V239, P101, DOI 10.1023/A:1020584808730; HUTH W, 1973, H-S Z PHYSIOL CHEM, V354, P635, DOI 10.1515/bchm2.1973.354.1.635; IZAI K, 1992, J BIOL CHEM, V267, P1027; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LINCOLN BC, 1987, ARCH BIOCHEM BIOPHYS, V259, P149, DOI 10.1016/0003-9861(87)90480-2; LINN TC, 1979, J BIOL CHEM, V254, P1691; Longnus SL, 2001, AM J PHYSIOL-HEART C, V281, pH1561, DOI 10.1152/ajpheart.2001.281.4.H1561; LOPASCHUK GD, 1994, CAN J PHYSIOL PHARM, V72, P1101, DOI 10.1139/y94-156; Mannaerts GP, 2000, CELL BIOCHEM BIOPHYS, V32, P73, DOI 10.1385/CBB:32:1-3:73; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; Poirier M, 2002, AM J PHYSIOL-HEART C, V283, pH1379, DOI 10.1152/ajpheart.00244.2002; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Reszko AE, 2001, ANAL BIOCHEM, V298, P69, DOI 10.1006/abio.2001.5349; ROBINSON IN, 1982, BIOCHEM J, V206, P177, DOI 10.1042/bj2060177; ROBISHAW JD, 1985, AM J PHYSIOL, V248, pE1, DOI 10.1152/ajpendo.1985.248.1.E1; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Saha AK, 1997, AM J PHYSIOL-ENDOC M, V272, pE641, DOI 10.1152/ajpendo.1997.272.4.E641; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; VEERKAMP JH, 1986, BIOCHIM BIOPHYS ACTA, V875, P301, DOI 10.1016/0005-2760(86)90180-3; Vincent G, 2000, AM J PHYSIOL-ENDOC M, V278, pE846, DOI 10.1152/ajpendo.2000.278.5.E846; Vincent GV, 2004, AM J PHYSIOL-HEART C, V286, pH257, DOI 10.1152/ajpheart.00717.2003; WATSON JA, 1969, ARCH BIOCHEM BIOPHYS, V135, P209, DOI 10.1016/0003-9861(69)90532-3; Young ME, 2001, AM J PHYSIOL-ENDOC M, V280, pE471, DOI 10.1152/ajpendo.2001.280.3.E471; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; ZHANG Y, 1994, J BIOL CHEM, V269, P11025	40	53	54	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19574	19579		10.1074/jbc.M400162200	http://dx.doi.org/10.1074/jbc.M400162200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14982940	hybrid			2022-12-27	WOS:000221164500025
J	Catley, MC; Cambridge, LM; Nasuhara, Y; Ito, K; Chivers, JE; Beaton, A; Holden, NS; Bergmann, MW; Barnes, PJ; Newton, R				Catley, MC; Cambridge, LM; Nasuhara, Y; Ito, K; Chivers, JE; Beaton, A; Holden, NS; Bergmann, MW; Barnes, PJ; Newton, R			Inhibitors of protein kinase C (PKC) prevent activated transcription - Role of events downstream of NF-kappa B DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; DEPENDENT TRANSCRIPTION; ZETA-PKC; RELA/P65 SUBUNIT; GENE-EXPRESSION; P65 SUBUNIT; A549 CELLS; PHOSPHORYLATION; DEGRADATION; INDUCTION	In pulmonary A549 cells, the protein kinase C (PKC) inhibitor, Ro 31-8220, and the phosphotidylcholine-specific phospholipase C inhibitor, D609, prevent NF-kappaB-dependent transcription, yet NF-kappaB DNA binding is unaffected (Bergmann, M., Hart, L., Lindsay, M., Barnes, P. J., and Newton, R. (1998) J. Biol. Chem. 273, 6607-6610). We now show that this effect also occurs in BEAS-2B bronchial epithelial cells as well as with other PKC inhibitors (G? 6976, GF109203X, and calphostin C) in A549 cells. Similarly, phorbol ester, a diacylglycerol mimetic, activates NF-kappaB-dependent transcription and potentiates tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB-dependent transcription, yet unlike TNFalpha, poorly activates IkappaB kinase (IKK) activity, IkappaBalpha degradation, or NF-kappaB DNA binding in both A549 and BEAS-2B cells. As phorbol ester-induced NF-kappaB-dependent transcription was relatively insensitive to the proteasome inhibitor, MG-132, PKC may affect NF-kappaB-dependent transcription via mechanisms other than the core IKK-IkappaB pathway. This is supported by Gal4 one hybrid analysis of p65/RelA transactivation, which was potentiated by TNFalpha and phorbol ester and was inhibited by Ro 31-8220 and D609. Additionally, a number of PKC isoforms, particularly the novel isoform PKCepsilon, induced p65/RelA transactivation. Phosphorylation of p65/RelA and cAMP-responsive element-binding protein (CREB)-binding protein (CBP) was increased by TNFalpha treatment and, in the case of CBP, was prevented by Ro 31-8220 or D609. However, p65/RelA-CBP interactions were unaffected by either compound. As this effect was not limited to NF-kappaB, but was a more general feature of inducible gene transcription, we suggest PKC isoforms may provide a point of intervention in diseases such as inflammation, or cancer, where activated gene expression is prominent.	Univ Warwick, Inst Biomed Res, Coventry CV4 7AL, W Midlands, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England; Humboldt Univ, Charite, Max Delbruck Ctr, Berlin, Germany	University of Warwick; Imperial College London; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Newton, R (corresponding author), Univ Warwick, Inst Biomed Res, Coventry CV4 7AL, W Midlands, England.	r.newton@warwick.ac.uk	Nasuhara, Yasuyuki/G-1647-2012; Ito, Kazuhiro/AAF-5994-2019; Newton, Robert/C-6814-2012	Newton, Robert/0000-0002-4919-8498; Holden, Neil/0000-0001-5824-3417; Barnes, Peter/0000-0002-5122-4018				Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Catley MC, 2003, FEBS LETT, V547, P75, DOI 10.1016/S0014-5793(03)00672-0; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Fiedler MA, 1998, AM J RESP CELL MOL, V19, P259, DOI 10.1165/ajrcmb.19.2.3149; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Goodman RH, 2000, GENE DEV, V14, P1553; HIMMLER A, 1993, J RECEPTOR RES, V13, P79, DOI 10.3109/10799899309073647; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lum H, 1999, AM J PHYSIOL-CELL PH, V277, pC580, DOI 10.1152/ajpcell.1999.277.3.C580; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MEJA KK, 2002, AM J RESP CRIT CARE, V165, pA64; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Newton R, 2000, BIOCHEM BIOPH RES CO, V277, P675, DOI 10.1006/bbrc.2000.3722; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; Newton R, 2001, BIOCHEM BIOPH RES CO, V287, P249, DOI 10.1006/bbrc.2001.5569; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Soh JW, 1999, MOL CELL BIOL, V19, P1313; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; STRATOWA C, 1995, J RECEPT SIGNAL TR R, V15, P617, DOI 10.3109/10799899509045244; Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432-1033.2002.03157.x; Vancurova I, 2001, J BIOL CHEM, V276, P19746, DOI 10.1074/jbc.M100234200; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Zanger K, 2001, MOL CELL, V7, P551, DOI 10.1016/S1097-2765(01)00202-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	63	68	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18457	18466		10.1074/jbc.M400765200	http://dx.doi.org/10.1074/jbc.M400765200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976190	hybrid			2022-12-27	WOS:000221041500045
J	Kanekura, K; Hashimoto, Y; Niikura, T; Aiso, S; Matsuoka, M; Nishimoto, I				Kanekura, K; Hashimoto, Y; Niikura, T; Aiso, S; Matsuoka, M; Nishimoto, I			Alsin, the product of ALS2 gene, suppresses SOD1 mutant neurotoxicity through RhoGEF domain by interacting with SOD1 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOTIDE EXCHANGE FACTOR; SUPEROXIDE-DISMUTASE GENE; NEURONAL CELL-DEATH; ALZHEIMERS-DISEASE; LINKED SOD1; TRANSGENIC MICE; ONCOGENIC DBL; MOTOR-NEURONS	Mutation of the ALS2 gene encoding alsin is linked to the onset of autosomal recessive motor neuron diseases, including juvenile-onset amyotrophic lateral sclerosis (ALS). Alsin long form (LF) belongs to the family of the guanine nucleotide exchanging factor (GEF) for small GTPases. Expression of alsin LF, but not alsin short form, protected motor neuronal cells from toxicity induced by mutants of the Cu/Zn-superoxide dismutase (SOD1) gene, which cause autosomal dominant ALS. In contrast, expression of alsin did not suppress neurotoxicity by other neurodegenerative insults such as Alzheimer's disease-related genes. Deletion analysis of alsin LF demonstrated that the RhoGEF domain is essential for alsin-mediated neuroprotection. Furthermore, we found that alsin LF bound to SOD1 mutants, but not to wtSOD1, via the RhoGEF domain. Such functional and physical interaction between two ALS-related genes will become a promising clue to clarify the pathogenesis of ALS and other motor neuron diseases.	Keio Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Anat, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University	Niikura, T (corresponding author), Keio Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, Life Sci Res Bldg,6th Floor,35 Shinanomachi, Tokyo 1608582, Japan.	niikurat@sc.itc.keio.ac.jp	Hashimoto, Yuichi/N-1508-2015	Hashimoto, Yuichi/0000-0001-5863-3618				Bogdanov MB, 1998, J NEUROCHEM, V71, P1321; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DURHAM HD, 1993, NEUROTOXICOLOGY, V14, P387; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; Ghadge GD, 1997, J NEUROSCI, V17, P8756; Gros-Louis F, 2003, ANN NEUROL, V53, P144, DOI 10.1002/ana.10422; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; Hashimoto Y, 2003, J NEUROCHEM, V84, P864, DOI 10.1046/j.1471-4159.2003.01585.x; Hashimoto Y, 2002, J NEUROCHEM, V80, P426, DOI 10.1046/j.0022-3042.2001.00722.x; Hashimoto Y, 2002, J PHARMACOL EXP THER, V300, P736, DOI 10.1124/jpet.300.3.736; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P12854; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; MATSUMOTO S, 1993, J NEUROL SCI, V115, P208, DOI 10.1016/0022-510X(93)90226-O; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Radunovic A, 1996, J NEUROL NEUROSUR PS, V61, P565, DOI 10.1136/jnnp.61.6.565; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zhang B, 1997, J CELL BIOL, V139, P1307, DOI 10.1083/jcb.139.5.1307; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	34	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19247	19256		10.1074/jbc.M313236200	http://dx.doi.org/10.1074/jbc.M313236200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970233	Green Submitted, hybrid			2022-12-27	WOS:000221041500138
J	Out, R; Kruijt, JK; Rensen, PCN; Hildebrand, RB; de Vos, P; Van Eck, M; Van Berkel, TJC				Out, R; Kruijt, JK; Rensen, PCN; Hildebrand, RB; de Vos, P; Van Eck, M; Van Berkel, TJC			Scavenger receptor BI plays a role in facilitating chylomicron metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LIPOLYSIS-STIMULATED RECEPTOR; TRIGLYCERIDE-RICH LIPOPROTEINS; HEPARAN-SULFATE PROTEOGLYCANS; MEMBRANE-BINDING PROTEINS; PARENCHYMAL LIVER-CELLS; APOE-DEFICIENT MICE; I SR-BI; APOLIPOPROTEIN-E; REMNANT RECEPTOR	The function of scavenger receptor class B type I (SR-BI) in mediating the selective uptake of high density lipoprotein (HDL) cholesterol esters is well established. However, the potential role of SR-BI in chylomicron and chylomicron remnant metabolism is largely unknown. In the present investigation, we report that the cell association of 160 nm-sized triglyceride-rich chylomicron-like emulsion particles to freshly isolated hepatocytes from SR-BI-deficient mice is greatly reduced (>70%), as compared with wild-type littermate mice. Competition experiments show that the association of emulsion particles with isolated hepatocytes is efficiently competed for (>70%) by the well established SR-BI ligands, HDL and oxidized low density lipoprotein (LDL), whereas LDL is ineffective. Upon injection into SR-BI-deficient mice the hepatic association of emulsion particles is markedly decreased (similar to80%) as compared with wild-type mice. The relevance of these findings for in vivo chylomicron ( remnant) metabolism was further evaluated by studying the effect of SR-BI deficiency on the intragastric fat load-induced postprandial triglyceride response. The postprandial triglyceride response is 2-fold higher in SR-BI-deficient mice as compared with wild-type littermates (area-under-the-curve 39.6 +/- 1.2 versus 21.1 +/- 3.6; p < 0.005), with a 4-fold increased accumulation of chylomicron (remnant)-associated triglycerides in plasma at 6 h after intragastric fat load. We conclude that SR-BI is important in facilitating chylomicron ( remnant) metabolism and might function as an initial recognition site for chylomicron remnants whereby the subsequent internalization can be exerted by additional receptor systems like the LDL receptor and LDL receptor-related protein.	Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Out, R (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, POB 9502, NL-2300 RA Leiden, Netherlands.	r.out@lacdr.leidenuniv.nl	Eckhardt, Erik/G-1567-2010; Van Berkel, Theo/ABD-7677-2021; Rensen, Patrick C.N./D-7176-2018	Rensen, Patrick C.N./0000-0002-8455-4988; van Eck, Miranda/0000-0003-3936-3194				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Bultel-Brienne S, 2002, J BIOL CHEM, V277, P36092, DOI 10.1074/jbc.M201943200; CHOI SY, 1993, J BIOL CHEM, V268, P15804; Cooper AD, 1997, J LIPID RES, V38, P2173; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; Fluiter K, 1999, J BIOL CHEM, V274, P8893, DOI 10.1074/jbc.274.13.8893; Fu T, 2003, J BIOL CHEM, V278, P52559, DOI 10.1074/jbc.M310892200; GIANTURCO SH, 1994, J LIPID RES, V35, P1674; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Hoekstra M, 2003, J BIOL CHEM, V278, P25448, DOI 10.1074/jbc.M301189200; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahley RW, 1999, J LIPID RES, V40, P1; MANN CJ, 1995, BIOCHEMISTRY-US, V34, P10421, DOI 10.1021/bi00033a014; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Martins IJ, 2000, J LIPID RES, V41, P205; MORTIMER BC, 1995, J BIOL CHEM, V270, P28767, DOI 10.1074/jbc.270.48.28767; RAMPRASAD MP, 1995, BIOCHEMISTRY-US, V34, P9126, DOI 10.1021/bi00028a023; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Redgrave TG, 1995, J LIPID RES, V36, P2670; REDGRAVE TG, 1985, BIOCHIM BIOPHYS ACTA, V835, P104, DOI 10.1016/0005-2760(85)90036-0; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; Rensen PCN, 1997, J LIPID RES, V38, P1070; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; Riddle TM, 2002, J LIPID RES, V43, P1458, DOI 10.1194/jlr.M200129-JLR200; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHAFI S, 1994, J LIPID RES, V35, P709; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; TROUSSARD AA, 1995, J BIOL CHEM, V270, P17068, DOI 10.1074/jbc.270.29.17068; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANDIJK MCM, 1992, J BIOL CHEM, V267, P17732; VANDIJK MCM, 1992, EUR J BIOCHEM, V205, P775, DOI 10.1111/j.1432-1033.1992.tb16842.x; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Webb NR, 2004, J LIPID RES, V45, P272, DOI 10.1194/jlr.M300319-JLR200; Webb NR, 2002, J LIPID RES, V43, P1421, DOI 10.1194/jlr.M200026-JLR200; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WINDLER E, 1991, BIOCHEM J, V276, P79, DOI 10.1042/bj2760079; Xu SZ, 1997, J LIPID RES, V38, P1289; YEN FT, 1994, BIOCHEMISTRY-US, V33, P1172, DOI 10.1021/bi00171a017; Yu KCW, 2001, FRONT BIOSCI-LANDMRK, V6, pD332, DOI 10.2741/Yu; Ziere GJ, 1996, EUR J BIOCHEM, V242, P703, DOI 10.1111/j.1432-1033.1996.0703r.x	56	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18401	18406		10.1074/jbc.M401170200	http://dx.doi.org/10.1074/jbc.M401170200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970197	hybrid, Green Published			2022-12-27	WOS:000221041500038
J	Dick, RA; Kensler, TW				Dick, RA; Kensler, TW			The catalytic and kinetic mechanisms of NADPH-dependent alkenal/one oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALCOHOL-DEHYDROGENASE; QUINONE OXIDOREDUCTASE; ZETA-CRYSTALLIN; GENOME SEQUENCE; IDENTIFICATION; CELLS; 12-HYDROXYDEHYDROGENASE; INACTIVATION; PURIFICATION; 13-REDUCTASE	NADPH-dependent alkenal/one oxidoreductase (AOR) from the rat is a phase 2/antioxidative enzyme that is known to catalyze the reduction of the carbon-carbon double bond of alpha,beta-unsaturated aldehydes and ketones. It is also known for its leukotriene B-4 12-hydroxydehydrogenase activity. In order to begin to understand these dual catalytic activities and validate its classification as a reductase of the medium-chain dehydrogenase/ reductase family, an investigation of the mechanism of its NADPH-dependent activity was undertaken. Recombinant AOR and a 3-nonen-2-one substrate were used to perform steady-state initial velocity, product inhibition, and dead end inhibition experiments, which elucidated an ordered Theorell-Chance kinetic mechanism with NADPH binding first and NADP(+) leaving last. A nearly 20-fold preference for NADPH over NADH was also observed. The dependence of kinetic parameters V and V/K on pH suggests the involvement of a general acid with a pK of 9.2. NADPH isomers stereospecifically labeled with deuterium at the 4-position were used to determine that AOR catalyzes the transfer of the pro-R hydride to the beta-carbon of an alpha,beta-unsaturated ketone, illudin M. Two-dimensional nuclear Overhauser effect NMR spectra demonstrate that this atom becomes the R-hydrogen at this position on the metabolite. Using [4R-H-2] NADPH, small primary kinetic isotope effects of 1.16 and 1.73 for V and V/K, respectively, were observed and suggest that hydride transfer is not rate-limiting. Atomic absorption spectroscopy indicated an absence of Zn2+ from active preparations of AOR. Thus, AOR fits predictions made for medium-chain reductases and bears similar characteristics to well known medium-chain alcohol dehydrogenases.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Div Toxicol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Kensler, TW (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Div Toxicol Sci, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.	tkensler@jhsph.edu	Kensler, Thomas W/D-8686-2014	Kensler, Thomas W/0000-0002-6676-261X	NCI NIH HHS [T32CA09243, CA39416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009243, R01CA039416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABIYCHUK E, 1995, J BIOL CHEM, V270, P26224, DOI 10.1074/jbc.270.44.26224; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200; Dick RA, 2004, CLIN CANCER RES, V10, P1492, DOI 10.1158/1078-0432.CCR-03-0162; Dick RA, 2001, J BIOL CHEM, V276, P40803, DOI 10.1074/jbc.M105487200; EDER E, 1991, CHEM RES TOXICOL, V4, P50, DOI 10.1021/tx00019a007; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; Ensor CM, 1998, BIOCHEM J, V330, P103, DOI 10.1042/bj3300103; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fillgrove KL, 2001, BIOCHEMISTRY-US, V40, P12412, DOI 10.1021/bi0111606; Fromm HJ, 1983, CONT ENZYME KINETICS, P233; GROMAN EV, 1976, EUR J BIOCHEM, V63, P427, DOI 10.1111/j.1432-1033.1976.tb10244.x; Haynes RL, 2000, MOL PHARMACOL, V58, P788, DOI 10.1124/mol.58.4.788; Hirata T, 2000, PHYTOCHEMISTRY, V55, P297, DOI 10.1016/S0031-9422(00)00326-5; LILLEY PE, 1993, GENE, V129, P9; Mano J, 2002, PLANT CELL PHYSIOL, V43, P1445, DOI 10.1093/pcp/pcf187; Mano J, 2000, EUR J BIOCHEM, V267, P3661, DOI 10.1046/j.1432-1327.2000.01398.x; Nordling E, 2002, EUR J BIOCHEM, V269, P4267, DOI 10.1046/j.1432-1033.2002.03114.x; ORR GA, 1984, ANAL BIOCHEM, V142, P232, DOI 10.1016/0003-2697(84)90544-X; PERSSON B, 1994, EUR J BIOCHEM, V226, P15, DOI 10.1111/j.1432-1033.1994.tb20021.x; Pocker Y, 2001, CHEM-BIOL INTERACT, V130, P383, DOI 10.1016/S0009-2797(00)00263-5; Primiano T, 1996, CARCINOGENESIS, V17, P2297, DOI 10.1093/carcin/17.11.2297; RAO PV, 1992, J BIOL CHEM, V267, P96; RUDOLPH FB, 1983, CONT ENZYME KINETICS, P207; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; SEKHAR VC, 1988, BIOCHEMISTRY-US, V27, P5082, DOI 10.1021/bi00414a020; TANAKA K, 1990, XENOBIOTICA, V20, P671, DOI 10.3109/00498259009046883; THORN JM, 1995, J MOL BIOL, V249, P785, DOI 10.1006/jmbi.1995.0337; Uchida K, 2000, MECH AGEING DEV, V116, P135, DOI 10.1016/S0047-6374(00)00129-9; WRATTEN CC, 1963, BIOCHEMISTRY-US, V2, P935, DOI 10.1021/bi00905a007; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128; Zheng RJ, 2000, BIOCHEMISTRY-US, V39, P3708, DOI 10.1021/bi992676g	32	33	35	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17269	17277		10.1074/jbc.M400427200	http://dx.doi.org/10.1074/jbc.M400427200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966122	hybrid			2022-12-27	WOS:000220870400048
J	Imamura, H; Ikeda, C; Yoshida, M; Yokoyama, K				Imamura, H; Ikeda, C; Yoshida, M; Yokoyama, K			The F subunit of Thermus thermophilus V-1-ATPase promotes ATPase activity but is not necessary for rotation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-SUBUNIT; V-ATPASE; ENDOGENOUS INHIBITOR; 14-KDA SUBUNIT; ROTARY MOTOR; PURIFICATION; F-1-ATPASE; EUBACTERIUM; RESOLUTION; ENCODES	V-1-ATPase from the thermophilic bacterium Thermus thermophilus is a molecular rotary motor with a subunit composition of A(3)B(3)DF, and its central rotor is composed of the D and F subunits. To determine the role of the F subunit, we generated an A(3)B(3)D subcomplex and compared it with A(3)B(3)DF. The ATP hydrolyzing activity of A(3)B(3)D (V-max = 20 s(-1)) was lower than that of A(3)B(3)DF (V-max = 31 s(-1)) and was more susceptible to MgADP inhibition during ATP hydrolysis. A3B3D was able to bind the F subunit to form A(3)B(3)DF. The C-terminally truncated F(Delta85-106) subunit was also bound to A(3)B(3)D, but the F(Delta69-106) subunit was not, indicating the importance of residues 69 - 84 of the F subunit for association with A(3)B(3)D. The ATPase activity of A(3)B(3)DF((Delta85-106)) (V-max = 24 s(-1)) was intermediate between that of A(3)B(3)D and A(3)B(3)DF. A single molecule experiment showed the rotation of the D subunit in A(3)B(3)D, implying that the F subunit is a dispensable component for rotation itself. Thus, the F subunit binds peripherally to the D subunit, but promotes V-1-ATPase catalysis.	Japan Sci & Technol Agcy, Explorat Res Adv Technol, ATP Syst Project, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology	Yokoyama, K (corresponding author), Japan Sci & Technol Agcy, Explorat Res Adv Technol, ATP Syst Project, Midori Ku, 5800-3 Nagatsuta, Yokohama, Kanagawa 2260026, Japan.	kyokoyama-ra@res.titech.ac.jp	Yokoyama, Ken/AAJ-3582-2020; Imamura, Hiromi/AAD-5109-2019	Yokoyama, Ken/0000-0002-6813-1096; Imamura, Hiromi/0000-0002-1896-0443				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Jones RPO, 2001, MOL MEMBR BIOL, V18, P283; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Kato-Yamada Y, 1999, J BIOL CHEM, V274, P33991, DOI 10.1074/jbc.274.48.33991; Kato-Yamada Y, 2000, J BIOL CHEM, V275, P35746, DOI 10.1074/jbc.M006575200; Lolkema JS, 2003, J BIOENERG BIOMEMBR, V35, P323, DOI 10.1023/A:1025776831494; Murata T, 1997, J BIOL CHEM, V272, P24885, DOI 10.1074/jbc.272.40.24885; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON N, 1972, J BIOL CHEM, V247, P7657; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; TSUTSUMI S, 1991, BIOCHIM BIOPHYS ACTA, V1098, P13, DOI 10.1016/0005-2728(91)90003-7; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; Yokoyama K, 2003, J BIOL CHEM, V278, P42686, DOI 10.1074/jbc.M305853200; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; YOKOYAMA K, 1994, J BIOL CHEM, V269, P12248; YOKOYAMA K, 1990, J BIOL CHEM, V265, P21946; Yokoyama K, 1998, J BIOL CHEM, V273, P20504, DOI 10.1074/jbc.273.32.20504; Yokoyama K, 2000, J BIOL CHEM, V275, P13955, DOI 10.1074/jbc.275.18.13955	32	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					18085	18090		10.1074/jbc.M314204200	http://dx.doi.org/10.1074/jbc.M314204200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963028	hybrid			2022-12-27	WOS:000220870400144
J	Smit, L; Baas, A; Kuipers, J; Korswagen, H; van de Wetering, M; Clevers, H				Smit, L; Baas, A; Kuipers, J; Korswagen, H; van de Wetering, M; Clevers, H			Wnt activates the Tak1/Nemo-like kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA SIGNAL-TRANSDUCTION; KAPPA-B ACTIVATION; N-TERMINAL KINASE; C-ELEGANS EMBRYOS; PROTEIN-KINASE; CAENORHABDITIS-ELEGANS; MAP KINASE; CATENIN DEGRADATION; POLARITY SIGNALS; GENE-EXPRESSION	Genetic studies on endoderm-mesoderm specification in Caenorhabditis elegans have demonstrated a role for several Wnt cascade components as well as for a MAPK-like pathway in this process. The latter pathway includes the MAPK kinase kinase-like MOM-4/Tak1, its adaptor TAP-1/Tab1, and the MAPK-like LIT-1/Nemolike kinase. A model has been proposed in which the Tak1 kinase cascade counteracts the Wnt cascade at the level of beta-catenin/TCF phosphorylation. In this model, the signal that activates the Tak1 kinase cascade is unknown. As an alternative explanation of these genetic data, we have explored whether Tak1 is directly activated by Wnt. We find that Wnt1 stimulation results in autophosphorylation and activation of MOM-4/Tak1 in a TAP-1/Tab1-dependent fashion. Wnt1-induced Tak1 stimulation activates Nemo-like kinase, resulting in the phosphorylation of TCF. Our results combined with the genetic data from C. elegans imply a mechanism whereby Wnt directly activates the MOM-4/Tak1 kinase signaling pathway. Thus, Wnt signal transduction through the canonical pathway activates beta-catenin/TCF, whereas Wnt signal transduction through the Tak1 pathway phosphorylates and inhibits TCF, which might function as a feedback mechanism.	Ctr Biomed Genet, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Clevers, H (corresponding author), Ctr Biomed Genet, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	clevers@niob.knaw.nl	Korswagen, Hendrik/I-8782-2012	Smit, Linda/0000-0003-0025-269X				Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Calvo D, 2001, EMBO J, V20, P7197, DOI 10.1093/emboj/20.24.7197; Golan T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GOLDSTEIN B, 1993, DEVELOPMENT, V121, P1221; GUMBINER BM, 1997, CURR BIOL, V7, P443; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Herman MA, 2001, DEVELOPMENT, V128, P581; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kaletta T, 1997, NATURE, V390, P294, DOI 10.1038/36869; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Korswagen HC, 2000, NATURE, V406, P527, DOI 10.1038/35020099; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Maloof JN, 1999, DEVELOPMENT, V126, P37; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Rocheleau CE, 1999, CELL, V97, P717, DOI 10.1016/S0092-8674(00)80784-9; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shin TH, 1999, MOL CELL, V4, P275, DOI 10.1016/S1097-2765(00)80375-5; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Siegfried KR, 2002, DEVELOPMENT, V129, P443; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xu Z, 2003, J BIOL CHEM, V278, P24767, DOI 10.1074/jbc.M302454200; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zeng WL, 2000, NATURE, V403, P789, DOI 10.1038/35001615	49	92	103	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17232	17240		10.1074/jbc.M307801200	http://dx.doi.org/10.1074/jbc.M307801200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960582	hybrid			2022-12-27	WOS:000220870400044
J	Yang, QH; Du, CY				Yang, QH; Du, CY			Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE OMI/HTRA2; APOPTOSIS PROTEIN; IAP PROTEINS; CASPASE ACTIVATION; BINDING XIAP; CONTAINS 2; INHIBITOR; UBIQUITIN; DEGRADATION; REAPER	The inhibitor of apoptosis (IAP) proteins bind and inhibit caspases via their baculovirus IAP repeat domains. Some of these IAPs are capable of ubiquitinating themselves and their interacting proteins through the ubiquitin-protein isopeptide ligase activity of their RING domain. The Drosophila IAP antagonists Reaper, Hid, and Grim can accelerate the degradation of Drosophila IAP1 and some mammalian IAPs by promoting their ubiquitin-protein isopeptide ligase activity. Here we show that Smac/DIABLO, a mammalian functional homolog of Reaper/Hid/Grim, selectively causes the rapid degradation of c-IAP1 and c-IAP2 but not XIAP and Livin in HeLa cells, although it efficiently promotes the auto-ubiquitination of them all. Smac binding to c-IAP via its N-terminal IAP-binding motif is the prerequisite for this effect, which is further supported by the findings that Smac N-terminal peptide is sufficient to enhance c-IAP1 ubiquitination, and Smac no longer promotes the ubiquitination of mutant c-IAP1 lacking all three baculovirus IAP repeat domains. In addition, different IAPs require the same ubiquitin-conjugating enzymes UbcH5a and UbcH6 for their ubiquitination. Taken together, Smac may serve as a key molecule in vivo to selectively reduce the protein level of c-IAPs through the ubiquitin/proteasome pathway.	Stowers Inst Med Res, Kansas City, MO 64110 USA	Stowers Institute for Medical Research	Du, CY (corresponding author), Stowers Inst Med Res, 1000E 50th St, Kansas City, MO 64110 USA.	cdu@stowers-institute.org						Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Ashhab Y, 2001, FEBS LETT, V495, P56, DOI 10.1016/S0014-5793(01)02366-3; BAKER RT, 1994, J BIOL CHEM, V269, P25381; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Fu J, 2003, J BIOL CHEM, V278, P52660, DOI 10.1074/jbc.M308036200; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hagglund R, 2002, P NATL ACAD SCI USA, V99, P631, DOI 10.1073/pnas.022531599; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Kuai J, 2003, J BIOL CHEM, V278, P14363, DOI 10.1074/jbc.M208672200; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Silke J, 2004, J BIOL CHEM, V279, P4313, DOI 10.1074/jbc.M305661200; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Varshavsky A, 2000, METHOD ENZYMOL, V327, P578, DOI 10.1016/S0076-6879(00)27303-5; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; Yang LL, 2003, CANCER RES, V63, P831; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2003, FASEB J, V17, P790, DOI 10.1096/fj.02-0654rev; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	61	158	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16963	16970		10.1074/jbc.M401253200	http://dx.doi.org/10.1074/jbc.M401253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960576	hybrid			2022-12-27	WOS:000220870400011
J	del Re, E; Babitt, JL; Pirani, A; Schneyer, AL; Lin, HY				del Re, E; Babitt, JL; Pirani, A; Schneyer, AL; Lin, HY			In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; SERINE THREONINE KINASE; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; EXPRESSION CLONING; HIGH-AFFINITY; MEMBRANE; DEFECTS; COMPLEX; MICE	Transforming growth factor beta( TGF-beta) ligands exert their biological effects through type II ( TbetaRII) and type I receptors ( TbetaRI). Unlike TGF-beta1 and - beta3, TGF- beta2 appears to require the co- receptor betaglycan ( type III receptor, TbetaRIII) for high affinity binding and signaling. Recently, the TbetaRIII null mouse was generated and revealed significant non- overlapping phenotypes with the TGF-beta2 null mouse, implying the existence of TbetaRIII independent mechanisms for TGF-beta2 signaling. Because a variant of the type II receptor, the type II- B receptor ( TbetaRII- B), has been suggested to mediate TGF-beta2 signaling in the absence of TbetaRIII, we directly tested the ability of TbetaRII- B to bind TGF-beta2. Here we show that the soluble extracellular domain of the type II- B receptor ( sTbetaRII- B. Fc) bound TGF- beta1 and TGF- beta3 with high affinity ( K-d values = 31.7 +/- 22.8 and 74.6 +/- 15.8 pM, respectively), but TGF-beta2 binding was undetectable at corresponding doses. Similar results were obtained for the soluble type II receptor ( sTbetaRII. Fc). However, sTbetaRII. Fc or sTbetaRII- B. Fc in combination with soluble type I receptor ( sTbetaRI. Fc) formed a high affinity complex that bound TGF-beta2, and this complex inhibited TGF-beta2 in a biological inhibition assay. These results show that TGF-beta2 has the potential to signal in the absence of TbetaRIII when sufficient TGF-beta2, TbetaRI, and TbetaRII or TbetaRII- B are present. Our data also support a cooperative model for receptor- ligand interactions, as has been suggested by crystallization studies of TGF-beta receptors and ligands. Our cell- free binding assay system will allow for testing of models of receptor- ligand complexes prior to actual solution of crystal structures.	Harvard Univ, Sch Med, Program Membrane Biol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Renal Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Reprod Endocrine Unit, Charlestown, MA 02129 USA	Harvard University; Harvard University; Harvard University; Massachusetts General Hospital	Lin, HY (corresponding author), 149 13th St,MHG-E,CNY-8216, Charlestown, MA 02129 USA.	hlin@partners.org	del Re, Elisabetta C./AAW-8913-2020	del Re, Elisabetta C./0000-0002-9645-4845	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007540, K08DK002716, P30DK043351] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK-07540-17, DK-43351, DK-02716] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boesen CC, 2002, STRUCTURE, V10, P913, DOI 10.1016/S0969-2126(02)00780-3; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; De Crescenzo G, 2003, J MOL BIOL, V328, P1173, DOI 10.1016/S0022-2836(03)00360-7; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Docagne F, 2001, J BIOL CHEM, V276, P46243, DOI 10.1074/jbc.M010915200; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hirai R, 1996, EXP CELL RES, V223, P135, DOI 10.1006/excr.1996.0066; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; Rotzer D, 2001, EMBO J, V20, P480, DOI 10.1093/emboj/20.3.480; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Schneyer A, 2003, ENDOCRINOLOGY, V144, P1671, DOI 10.1210/en.2002-0203; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; SUZUKI A, 1994, FEBS LETT, V355, P19, DOI 10.1016/0014-5793(94)01156-7; TENDIJKE P, 1993, ONCOGENE, V8, P2879; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	37	44	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22765	22772		10.1074/jbc.M401350200	http://dx.doi.org/10.1074/jbc.M401350200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14996829	hybrid			2022-12-27	WOS:000221417100128
J	Gerber, D; Sal-Man, N; Shai, Y				Gerber, D; Sal-Man, N; Shai, Y			Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PORE-FORMING DOMAIN; THURINGIENSIS DELTA-ENDOTOXIN; CELL ANTIGEN RECEPTOR; GLYCOPHORIN-A; IN-VIVO; BIOLOGICAL MEMBRANE; ERBB RECEPTORS; HUMAN-BREAST; HELIX 4	Protein assembly is a critical process involved in a wide range of cellular events and occurs through extra-cellular and/or transmembrane domains (TMs). Previous studies demonstrated that a GXXXG motif is crucial for homodimer formation. Here we selected the TMs of ErbB1 and ErbB2 as a model since these receptors function both as homodimers and as heterodimers. Both TMs contain two GXXXG-like motifs located at the C and N termini. The C-terminal motifs were implicated previously in homodimer formation, but the role of the N-terminal motifs was not clear. We used the ToxR system and expressed the TMs of both ErbB1 and ErbB2 containing only the N-terminal GXXXG motifs. The data revealed that the ErbB2 but not the ErbB1 construct formed homodimers. Importantly, a synthetic ErbB1 TM peptide was able to form a heterodimer with ErbB2, by displacing the ErbB2 TM homodimer. The specificity of the interaction was demonstrated by using three controls: (i) Two single mutations within the GXXXG-like motif of the ErbB1 peptide reduced or preserved its activity, in agreement with similar mutations in glycophorin A. (ii) A TM peptide of the bacterial Tar receptor did not assemble with the ErbB2 construct. (iii) The ErbB1 peptide had no effect on the dimerization of a construct containing the TM-1 domain of the Tar receptor. Fluorescence microscopy demonstrated that all the peptides localized on the membrane. Furthermore, incubation with the peptides had no effect on bacterial growth and protein expression levels. Our results suggest that the N-terminal GXXXG-like motif of the ErbB1 TM plays a role in heterodimerization with the ErbB2 transmembrane domain. To our knowledge, this is the first demonstration of a transmembrane domain with two distinct recognition motifs, one for homodimerization and the other for heterodimerization.	Weizmann Inst Sci, Dept Biol Chem, Harold S & Harriet B Brady Profess Chair Canc Res, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, Harold S & Harriet B Brady Profess Chair Canc Res, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il		Sal-Man, Neta/0000-0002-1109-479X				ADAIR BD, 1994, BIOCHEMISTRY-US, V33, P5539, DOI 10.1021/bi00184a024; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Brandt BH, 1999, FASEB J, V13, P1939, DOI 10.1096/fasebj.13.14.1939; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Brosig B, 1998, PROTEIN SCI, V7, P1052; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; GAZIT E, 1995, J BIOL CHEM, V270, P2571, DOI 10.1074/jbc.270.6.2571; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gerber D, 2002, J MOL BIOL, V322, P491, DOI 10.1016/S0022-2836(02)00807-0; Gerber D, 2001, J BIOL CHEM, V276, P31229, DOI 10.1074/jbc.M101889200; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; Hurwitz E, 2000, CANCER IMMUNOL IMMUN, V49, P226, DOI 10.1007/s002620000112; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Laage R, 1997, EUR J BIOCHEM, V249, P540, DOI 10.1111/j.1432-1033.1997.00540.x; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LOFTS FJ, 1993, ONCOGENE, V8, P2813; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; Masson L, 1999, J BIOL CHEM, V274, P31996, DOI 10.1074/jbc.274.45.31996; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; Sal-Man N, 2004, BIOCHEMISTRY-US, V43, P2309, DOI 10.1021/bi0356294; SCHECHTER B, 1991, INT J CANCER, V48, P167, DOI 10.1002/ijc.2910480203; Schneider D, 2003, J BIOL CHEM, V278, P3105, DOI 10.1074/jbc.M206287200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	35	82	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21177	21182		10.1074/jbc.M400847200	http://dx.doi.org/10.1074/jbc.M400847200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985340	hybrid			2022-12-27	WOS:000221273800076
J	Pimanda, JE; Ganderton, T; Maekawa, A; Yap, CL; Lawler, J; Kershaw, G; Chesterman, CN; Hogg, PJ				Pimanda, JE; Ganderton, T; Maekawa, A; Yap, CL; Lawler, J; Kershaw, G; Chesterman, CN; Hogg, PJ			Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; PLATELET-FUNCTION ANALYZER; VONWILLEBRAND-FACTOR MULTIMERS; BINDING COMPETITIVE INHIBITOR; PRIMARY HEMOSTASIS; NORMAL INDIVIDUALS; ENDOTHELIAL-CELLS; FACTOR-VIII; DISEASE	Plasma von Willebrand factor (VWF) is a multimeric glycoprotein from endothelial cells and platelets that mediates adhesion of platelets to sites of vascular injury. In the shear force of flowing blood, however, only the very large VWF multimers are effective in capturing platelets. The multimeric size of VWF can be controlled by proteolysis at the Tyr(842)-Met(843) peptide bond by ADAMTS13 or cleavage of the disulfide bonds that hold VWF multimers together by thrombospondin-1 (TSP-1). The average multimer size of plasma VWF in TSP-1 null mice was significantly smaller than in wild type mice. In addition, the multimer size of VWF released from endothelium in vivo was reduced more rapidly in TSP-1 null mice than in wild type mice. TSP-1, like ADAMTS13, bound to the VWF A3 domain. TSP-1 in the wild type mice, therefore, may compete with ADAMTS13 for interaction with the A3 domain and slow the rate of VWF proteolysis. TSP-1 is stored in platelet alpha-granules and is released upon platelet activation. Significantly, platelet VWF multimer size was reduced upon lysis or activation of wild type murine platelets but not TSP-1 null platelets. This difference had functional consequences in that there was an increase in collagen- and VWF-mediated aggregation of the TSP-1 null platelets under both static and shear conditions. These findings indicate that TSP-1 influences plasma and platelet VWF multimeric size differently and may be more relevant for control of the VWF released from platelets.	Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia; Monash Univ, Box Hill Hosp, Dept Med, Australian Ctr Blood Dis, Clayton, Vic 3128, Australia; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Royal Prince Alfred Hosp, Dept Haematol, Sydney, NSW 2050, Australia	University of New South Wales Sydney; Box Hill Hospital; Monash University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Sydney	Hogg, PJ (corresponding author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.	p.hogg@unsw.edu.au	Lawler, Jack/AAJ-1379-2020	Ganderton, Timothy Richard/0000-0002-3949-4795; Hogg, Philip/0000-0001-6486-2863	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068003] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 68003] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATLLE J, 1987, BLOOD, V70, P173; Bonnefoy A, 2001, J BIOL CHEM, V276, P5605, DOI 10.1074/jbc.M010091200; COUNTS RB, 1978, J CLIN INVEST, V62, P702, DOI 10.1172/JCI109178; CRUZ MA, 1995, J BIOL CHEM, V270, P19668; Dong JF, 2003, J BIOL CHEM, V278, P29633, DOI 10.1074/jbc.M301385200; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Dong Jing-fei, 2002, Blood, V100, P457; Favaloro EJ, 1999, AM J HEMATOL, V62, P165, DOI 10.1002/(SICI)1096-8652(199911)62:3<165::AID-AJH6>3.0.CO;2-C; FAVALORO EJ, 1995, AM J CLIN PATHOL, V104, P264; FAVALORO EJ, 1991, BLOOD COAGUL FIBRIN, V2, P285, DOI 10.1097/00001721-199104000-00011; Fressinaud E, 1998, BLOOD, V91, P1325, DOI 10.1182/blood.V91.4.1325; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Furlan M, 1996, ANN HEMATOL, V72, P341, DOI 10.1007/s002770050184; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; GALVIN NJ, 1987, J CELL BIOL, V104, P1413, DOI 10.1083/jcb.104.5.1413; Harrison P, 1999, BLOOD COAGUL FIBRIN, V10, P25, DOI 10.1097/00001721-199901000-00004; HOGG PJ, 1993, J BIOL CHEM, V268, P7139; HOGG PJ, 1992, BIOCHEMISTRY-US, V31, P265, DOI 10.1021/bi00116a036; HOGG PJ, 1993, J BIOL CHEM, V268, P21811; JAFFE EA, 1974, P NATL ACAD SCI USA, V71, P1906, DOI 10.1073/pnas.71.5.1906; KAO KJ, 1986, AM J CLIN PATHOL, V86, P317, DOI 10.1093/ajcp/86.3.317; Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569; KUNDU SK, 1995, SEMIN THROMB HEMOST, V21, P106; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; LAWLER J, 1986, ANN NY ACAD SCI, V485, P273, DOI 10.1111/j.1749-6632.1986.tb34589.x; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Leng XH, 2004, ARTERIOSCL THROM VAS, V24, P376, DOI 10.1161/01.ATV.0000110445.95304.91; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; MANNUCCI PM, 1995, P NATL ACAD SCI USA, V92, P2428, DOI 10.1073/pnas.92.7.2428; MANNUCCI PM, 1985, BLOOD, V66, P796; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; MOSHER DF, 1992, ANN NY ACAD SCI, V667, P64, DOI 10.1111/j.1749-6632.1992.tb51598.x; MURPHYULLRICH JE, 1985, BLOOD, V66, P1098; NICHOLS TC, 1995, P NATL ACAD SCI USA, V92, P2455, DOI 10.1073/pnas.92.7.2455; Pimanda JE, 2002, BLOOD, V100, P2832, DOI 10.1182/blood-2002-03-0770; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICHARDSON DW, 1985, ANN INTERN MED, V103, P228, DOI 10.7326/0003-4819-103-2-228; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Schmitt A, 2001, EXP HEMATOL, V29, P1295, DOI 10.1016/S0301-472X(01)00733-0; Soejima K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; SUZUKI H, 1990, HISTOCHEMISTRY, V94, P337; SWEENEY JD, 1990, BLOOD, V76, P2258; TSAI HM, 1989, BLOOD, V73, P2074; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Watala C, 2003, THROMB RES, V109, P299, DOI 10.1016/S0049-3848(03)00238-X; WENCELDRAKE JD, 1985, BLOOD, V65, P929; Xie LJ, 2001, J EXP MED, V193, P1341, DOI 10.1084/jem.193.12.1341; Xie LJ, 2000, THROMB HAEMOSTASIS, V84, P506; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200; ZIMMERMAN TS, 1986, J CLIN INVEST, V77, P947, DOI 10.1172/JCI112394	58	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21439	21448		10.1074/jbc.M313560200	http://dx.doi.org/10.1074/jbc.M313560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14981081	hybrid			2022-12-27	WOS:000221273800109
J	Gavva, NR; Klionsky, L; Qu, YS; Shi, LC; Tamir, R; Edenson, S; Zhang, TJ; Viswanadhan, VN; Toth, A; Pearce, LV; Vanderah, TW; Porreca, F; Blumberg, PM; Lile, J; Sun, Y; Wildt, K; Louis, JC; Treanor, JJS				Gavva, NR; Klionsky, L; Qu, YS; Shi, LC; Tamir, R; Edenson, S; Zhang, TJ; Viswanadhan, VN; Toth, A; Pearce, LV; Vanderah, TW; Porreca, F; Blumberg, PM; Lile, J; Sun, Y; Wildt, K; Louis, JC; Treanor, JJS			Molecular determinants of vanilloid sensitivity in TRPV1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; CAPSAICIN RECEPTOR VR1; ACTIVATED ION-CHANNEL; PROTEIN-KINASE-C; DIRECT PHOSPHORYLATION; ANALGESIC PROPERTIES; ANTAGONIST; BINDING; CELLS; PAIN	Vanilloid receptor 1 (TRPV1), a membrane-associated cation channel, is activated by the pungent vanilloid from chili peppers, capsaicin, and the ultra potent vanilloid from Euphorbia resinifera, resiniferatoxin (RTX), as well as by physical stimuli (heat and protons) and proposed endogenous ligands (anandamide, N-arachidonyldopamine, N-oleoyldopamine, and products of lipoxygenase). Only limited information is available in TRPV1 on the residues that contribute to vanilloid activation. Interestingly, rabbits have been suggested to be insensitive to capsaicin and have been shown to lack detectable [H-3]RTX binding in membranes prepared from their dorsal root ganglia. We have cloned rabbit TRPV1 (oTRPV1) and report that it exhibits high homology to rat and human TRPV1. Like its mammalian orthologs, oTRPV1 is selectively expressed in sensory neurons and is sensitive to protons and heat activation but is 100-fold less sensitive to vanilloid activation than either rat or human. Here we identify key residues (Met(547) and Thr(550)) in transmembrane regions 3 and 4 (TM3/4) of rat and human TRPV1 that confer vanilloid sensitivity, [H-3]RTX binding and competitive antagonist binding to rabbit TRPV1. We also show that these residues differentially affect ligand recognition as well as the assays of functional response versus ligand binding. Furthermore, these residues account for the reported pharmacological differences of RTX, PPAHV (phorbol 12-phenyl-acetate 13-acetate 20-homovanillate) and capsazepine between human and rat TRPV1. Based on our data we propose a model of the TM3/4 region of TRPV1 bound to capsaicin or RTX that may aid in the development of potent TRPV1 antagonists with utility in the treatment of sensory disorders.	Amgen Inc, Dept Neurosci, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Mol Struct, Thousand Oaks, CA 91320 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA	Amgen; Amgen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Arizona	Gavva, NR (corresponding author), Amgen Inc, Dept Neurosci, MS 29-2-B,1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	ngavva@amgen.com	Tóth, Attila/F-4859-2010	Tóth, Attila/0000-0001-6503-3653	NATIONAL CANCER INSTITUTE [ZIABC005270, Z01BC005270] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acs G, 1996, MOL BRAIN RES, V35, P173, DOI 10.1016/0169-328X(95)00204-6; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chu CJ, 2003, J BIOL CHEM, V278, P13633, DOI 10.1074/jbc.M211231200; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; EDENSON S, 2000, SOC NEUR ABSTR, V26; GLINSUKON T, 1980, TOXICON, V18, P215, DOI 10.1016/0041-0101(80)90076-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayes P, 2000, PAIN, V88, P205, DOI 10.1016/S0304-3959(00)00353-5; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Jung J, 1999, J NEUROSCI, V19, P529; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; McIntyre P, 2001, BRIT J PHARMACOL, V132, P1084, DOI 10.1038/sj.bjp.0703918; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Olah Z, 2001, J BIOL CHEM, V276, P31163, DOI 10.1074/jbc.M101607200; Pomonis JD, 2003, J PHARMACOL EXP THER, V306, P387, DOI 10.1124/jpet.102.046268; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; QU Y, 2003, BIOPHYS J S, V84, P434; Savidge J, 2002, NEUROPHARMACOLOGY, V43, P450, DOI 10.1016/S0028-3908(02)00122-3; Shin JS, 2001, NEUROSCI LETT, V299, P135, DOI 10.1016/S0304-3940(00)01777-8; Szallasi A, 1999, MOL PHARMACOL, V56, P581, DOI 10.1124/mol.56.3.581; SZALLASI A, 1993, N-S ARCH PHARMACOL, V347, P84; Szallasi A, 1999, PHARMACOL REV, V51, P159; Toth A, 2004, MOL PHARMACOL, V65, P282, DOI 10.1124/mol.65.2.282; Valenzano KJ, 2003, J PHARMACOL EXP THER, V306, P377, DOI 10.1124/jpet.102.045674; Vlachova V, 2003, J NEUROSCI, V23, P1340, DOI 10.1523/JNEUROSCI.23-04-01340.2003; Wahl P, 2001, MOL PHARMACOL, V59, P9, DOI 10.1124/mol.59.1.9; WALPOLE CSJ, 1993, J MED CHEM, V36, P2362, DOI 10.1021/jm00068a014; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419	39	268	284	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20283	20295		10.1074/jbc.M312577200	http://dx.doi.org/10.1074/jbc.M312577200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996838	hybrid			2022-12-27	WOS:000221164500106
J	Lin, PW; Simon, PO; Gewirtz, AT; Neish, AS; Ouellette, AJ; Madara, JL; Lencer, WI				Lin, PW; Simon, PO; Gewirtz, AT; Neish, AS; Ouellette, AJ; Madara, JL; Lencer, WI			Paneth cell cryptdins act in vitro as apical paracrine regulators of the innate inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EPITHELIAL IL-8 EXPRESSION; STAPHYLOCOCCAL ALPHA-TOXIN; SALMONELLA-TYPHIMURIUM; NECROTIZING ENTEROCOLITIS; ANTIMICROBIAL PEPTIDES; ULCERATIVE-COLITIS; HOST-DEFENSE; INTERLEUKIN-8; ACTIVATION	Intestinal-specific antimicrobial alpha-defensins, termed cryptdins, are secreted into the intestinal lumen by mouse Paneth cells in response to microbial pathogens. Cryptdins kill microbes by forming pores in their limiting membranes. The cryptdin isoforms 2 and 3 also can form anion-conductive pores in eukaryotic cell membranes, thus affecting cell physiology. Here, we find that when applied to apical membranes of the human intestinal cell line T84, cryptdin 3 (Cr3) induces secretion of the proinflammatory cytokine interleukin 8 (IL-8) in a dose-dependent manner. The induction of IL-8 secretion is specific to the cryptdins that form channels in mammalian cell membranes because cryptdin 4, which does not form pores in T84 cells, does not induce IL-8 secretion. Cr3 induces inflammatory cytokine secretion by activating NF-kappaB and p38 mitogen-activated protein kinase in a Ca2+-dependent manner, but influx by extracellular Ca2+ is not involved. Unlike other known inflammatory agonists, signal transduction by Cr3 occurs slowly, suggesting a novel mechanism of action. These results show that selective cryptdins may amplify their roles in innate immunity by acting as novel paracrine agonists to coordinate an inflammatory response with the antimicrobial secretions of Paneth cells.	Harvard Univ, Sch Med,Childrens Hosp, Gastrointestinal Cell Biol Dept, Combined Program Pediat Gastroenterol & Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Div, Atlanta, GA 30322 USA; Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Harvard Univ, Ctr Digest Dis, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Emory University; Emory University; University of California System; University of California Irvine; University of Chicago; Harvard University	Lencer, WI (corresponding author), GI Cell Biol, 300 Longwood Ave,Enders 1220, Boston, MA 02115 USA.	wayne.lencer@tch.harvard.edu	Neish, Andrew/B-3895-2009; Denning, Patricia W/G-4485-2011	Lencer, Wayne/0000-0001-7346-2730	NICHD NIH HHS [HD 07466] Funding Source: Medline; NIDDK NIH HHS [DK 57827, L40 DK065555, DK 43854, K08 DK062851, DK 062851, DK 35932, DK 47662, DK 48106, DK 44632] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048106, R01DK035932, K08DK062851, R01DK044632, R01DK047662, R37DK048106, R37DK035932, R01DK057827, R55DK044632] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; Collier-Hyams LS, 2002, J IMMUNOL, V169, P2846, DOI 10.4049/jimmunol.169.6.2846; Coutinho HB, 1998, J CLIN PATHOL, V51, P512, DOI 10.1136/jcp.51.7.512; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; Dragneva Y, 2001, INFECT IMMUN, V69, P2630, DOI 10.1128/IAI.69.4.2630-2635.2001; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Gewirtz AT, 1999, INFECT IMMUN, V67, P608, DOI 10.1128/IAI.67.2.608-617.1999; Guimbaud R, 1998, AM J GASTROENTEROL, V93, P2397, DOI 10.1016/S0002-9270(98)00575-9; Huttner KM, 1999, PEDIATR RES, V45, P785, DOI 10.1203/00006450-199906000-00001; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; Keshavarzian A, 1999, AM J GASTROENTEROL, V94, P704, DOI 10.1111/j.1572-0241.1999.00940.x; Kilgore KS, 1997, AM J PATHOL, V150, P2019; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; Lencer WI, 1997, P NATL ACAD SCI USA, V94, P8585, DOI 10.1073/pnas.94.16.8585; Mallow EB, 1996, J BIOL CHEM, V271, P4038; MCCORMICK BA, 1995, J CELL BIOL, V131, P1599, DOI 10.1083/jcb.131.6.1599; MCCORMICK BA, 1993, J CELL BIOL, V123, P895, DOI 10.1083/jcb.123.4.895; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Ouellette AJ, 1999, AM J PHYSIOL-GASTR L, V277, pG257, DOI 10.1152/ajpgi.1999.277.2.G257; Porter EM, 1997, INFECT IMMUN, V65, P2389, DOI 10.1128/IAI.65.6.2389-2395.1997; Porter EM, 1998, FEBS LETT, V434, P272, DOI 10.1016/S0014-5793(98)00994-6; Rose F, 2002, AM J PHYSIOL-LUNG C, V282, pL207, DOI 10.1152/ajplung.00156.2001; Salzman NH, 1998, PEDIATR RES, V44, P20, DOI 10.1203/00006450-199807000-00003; Satchell DP, 2003, J BIOL CHEM, V278, P13838, DOI 10.1074/jbc.M212115200; Shirafuji Y, 2003, J BIOL CHEM, V278, P7910, DOI 10.1074/jbc.M210600200; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Walev I, 2001, FASEB J, V15, P237, DOI 10.1096/fj.01-0572fje; Walev I, 2000, J IMMUNOL, V164, P5120, DOI 10.4049/jimmunol.164.10.5120; Yu YM, 2003, AM J PHYSIOL-GASTR L, V285, pG282, DOI 10.1152/ajpgi.00503.2002; Yue G, 2002, AM J PHYSIOL-GASTR L, V282, pG757, DOI 10.1152/ajpgi.00152.2001	33	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19902	19907		10.1074/jbc.M311821200	http://dx.doi.org/10.1074/jbc.M311821200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14990585	hybrid			2022-12-27	WOS:000221164500064
J	Griparic, L; van der Wel, NN; Orozco, IJ; Peters, PJ; van der Bliek, AM				Griparic, L; van der Wel, NN; Orozco, IJ; Peters, PJ; van der Bliek, AM			Loss of the intermembrane space protein Mgm1/OPA1 induces swelling and localized constrictions along the lengths of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; DOMINANT OPTIC ATROPHY; TRANSMEMBRANE GTPASE; SUBCELLULAR-LOCALIZATION; OPA1 MUTATIONS; YEAST REQUIRES; CYTOCHROME-C; FUSION; MEMBRANE; MGM1P	Mgm1 is a member of the dynamin family of GTP-binding proteins. Mgm1 was first identified in yeast, where it affects mitochondrial morphology. The human homologue of Mgm1 is called OPA1. Mutations in the OPA1 gene are the prevailing cause of dominant optic atrophy, a hereditary disease in which progressive degeneration of the optic nerve can lead to blindness. Here we investigate the properties of the Mgm1/OPA1 protein in mammalian cells. We find that Mgm1/OPA1 is localized to the mitochondrial intermembrane space, where it is tightly bound to the outer surface of the inner membrane. Overexpression of wild type or mutant forms of the Mgm1/OPA1 protein cause mitochondria to fragment and, in some cases, cluster near the nucleus, whereas the loss of protein caused by small interfering RNA ( siRNA) leads to dispersal of mitochondrial fragments throughout the cytosol. The cristae of these fragmented mitochondria are disorganized. At early time points after transfection with Mgm1/OPA1 siRNA, the mitochondria are not yet fragmented. Instead, the mitochondria swell and stretch, after which they form localized constrictions similar to the mitochondrial abnormalities observed during the early stages of apoptosis. These abnormalities might be the earliest effects of losing Mgm1/OPA1 protein.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Netherlands Cancer Institute	van der Bliek, AM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, 33-257 CHS,POB 951737, Los Angeles, CA 90095 USA.	avan@mednet.ucla.edu	Van Der Wel, Nicole/AAE-7569-2020	van der Wel, Nicole/0000-0001-6392-3417	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051866] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM051866] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; BAUMGART E, 1987, LAB INVEST, V56, P554; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; CHANG TS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1254, DOI 10.1001/archopht.1993.01090090106028; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KJER P, 1983, ACTA OPHTHALMOL, V61, P300; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; Misaka T, 2002, J BIOL CHEM, V277, P15834, DOI 10.1074/jbc.M109260200; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X; Pelloquin L, 1999, J CELL SCI, V112, P4151; PENTTILA A, 1975, LAB INVEST, V32, P690; Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359; Peters PJ, 2001, METHOD ENZYMOL, V329, P210; Rojo M, 2002, J CELL SCI, V115, P1663; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; Schapira AHV, 2002, J INHERIT METAB DIS, V25, P207, DOI 10.1023/A:1015629912477; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sesaki H, 2003, MOL BIOL CELL, V14, P2342, DOI 10.1091/mbc.E02-12-0788; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; SKINNIDER LF, 1976, ARCH PATHOL LAB MED, V100, P601; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; SMITH U, 1970, J CELL SCI, V7, P501; Sternlieb I, 1995, HEPATOLOGY, V22, P1782, DOI 10.1002/hep.1840220626; Toomes C, 2001, HUM MOL GENET, V10, P1369, DOI 10.1093/hmg/10.13.1369; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341	43	331	345	5	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18792	18798		10.1074/jbc.M400920200	http://dx.doi.org/10.1074/jbc.M400920200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970223	hybrid			2022-12-27	WOS:000221041500087
J	Hou, BD; Eren, M; Painter, CA; Covington, JW; Dixon, JD; Schoenhard, JA; Vaughan, DE				Hou, BD; Eren, M; Painter, CA; Covington, JW; Dixon, JD; Schoenhard, JA; Vaughan, DE			Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappa B site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-CHEMOATTRACTANT PROTEIN-1; PLASMINOGEN-ACTIVATOR-INHIBITOR-1 GENE; HORMONE REGULATION; RESPONSE ELEMENT; PAI-1 PROMOTER; DIRECT BINDING; EXPRESSION; IDENTIFICATION; TISSUE; FIBRINOLYSIS	Plasminogen activator inhibitor-1 (PAI-1) is the major inhibitor of plasminogen activation and likely plays important roles in coronary thrombosis and arteriosclerosis. Tumor necrosis factor-alpha (TNFalpha) is one of many recognized physiological regulators of PAI-1 expression and may contribute to elevated plasma PAI-1 levels in sepsis and obesity. Although TNFalpha is a potent inducer of PAI-1 expression in vitro and in vivo, the precise location of the TNFalpha response site in the PAI-1 promoter has yet to be determined. Transient transfection studies using luciferase reporter constructs containing PAI-1 promoter sequence up to 6.4 kb failed to detect a response to TNFalpha. Moreover, TNFalpha failed to induce expression of enhanced green fluorescent protein under the control of a 2.9-kb human PAI-1 promoter in transgenic mice, although endogenous murine PAI-1 was strongly induced. These data suggested that the TNFalpha response element in the PAI-1 gene is remote from the proximal promoter region. In this study, seven candidate regulatory regions were identified using cross-species sequence homology analysis as well as DNase I-hypersensitive site analysis. We identified a 5' distal TNFalpha-responsive enhancer of the PAI-1 gene located 15 kb upstream of the transcription start site containing a conserved NFkappaB-binding site that mediates the response to TNFalpha. This newly recognized site is fully capable of binding NFkappaB subunits p50 and p65, whereas overexpression of the NFkappaB inhibitor IkappaB prevents TNFalpha-induced activation of this enhancer element.	Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Nashville, TN 37232 USA	Vanderbilt University	Vaughan, DE (corresponding author), Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, 2220 Pierce Ave,PRB,Rm 383, Nashville, TN 37232 USA.	doug.vaughan@vanderbilt.edu	Eren, Mesut/J-3818-2016	Hou, Baidong/0000-0002-0892-0181; Painter, Corrie/0000-0001-6174-1548	PHS HHS [R01 65192, R01 60906] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alessi MC, 2000, DIABETES, V49, P1374, DOI 10.2337/diabetes.49.8.1374; Alessi MC, 2000, HORM METAB RES, V32, P504, DOI 10.1055/s-2007-978677; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; Chen YQ, 2001, THROMB HAEMOSTASIS, V86, P1563, DOI 10.1055/s-0037-1616763; Daneri-Navarro A, 1998, EUR J CANCER, V34, P566, DOI 10.1016/S0959-8049(97)10038-7; DAWSON S, 1992, ATHEROSCLEROSIS, V95, P105, DOI 10.1016/0021-9150(92)90014-8; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Eren M, 2003, J THROMB HAEMOST, V1, P2389, DOI 10.1046/j.1538-7836.2003.00437.x; Eriksson P, 1998, ARTERIOSCL THROM VAS, V18, P20, DOI 10.1161/01.ATV.18.1.20; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Fink T, 2002, BLOOD, V99, P2077, DOI 10.1182/blood.V99.6.2077; Gandolfo GM, 1996, ANTICANCER RES, V16, P2155; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; Gottgens B, 2000, NAT BIOTECHNOL, V18, P181, DOI 10.1038/72635; Gozal E, 2002, AM J RESP CELL MOL, V27, P91, DOI 10.1165/ajrcmb.27.1.4790; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; Hermans PWM, 1999, LANCET, V354, P556, DOI 10.1016/S0140-6736(99)02220-5; Koh SCL, 1999, J PERINAT MED, V27, P458, DOI 10.1515/JPM.1999.061; Kohler HP, 2000, NEW ENGL J MED, V342, P1792, DOI 10.1056/NEJM200006153422406; Kordula T, 2000, J NEUROSCI, V20, P7510; Kornelisse RF, 1996, J INFECT DIS, V173, P1148, DOI 10.1093/infdis/173.5.1148; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; Leithauser B, 1996, INTENS CARE MED, V22, P631, DOI 10.1007/BF01709738; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; LIU YX, 1991, EUR J BIOCHEM, V195, P549, DOI 10.1111/j.1432-1033.1991.tb15736.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Loskutoff DJ, 2000, ANN NY ACAD SCI, V902, P272; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Mesters RM, 1996, THROMB HAEMOSTASIS, V75, P902; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; PODOR TJ, 1993, J IMMUNOL, V150, P225; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ruef J, 1999, THROMB HAEMOSTASIS, V82, P109, DOI 10.1055/s-0037-1614638; Sambrook J., 2001, MOL CLONING LAB MANU; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; Schoenhard JA, 2003, J MOL CELL CARDIOL, V35, P473, DOI 10.1016/S0022-2828(03)00051-8; Shanmugam N, 2003, J BIOL CHEM, V278, P34834, DOI 10.1074/jbc.M302828200; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; STEWART AF, 1991, NUCLEIC ACIDS RES, V19, P3157, DOI 10.1093/nar/19.11.3157; STRANDBERG L, 1988, EUR J BIOCHEM, V176, P609, DOI 10.1111/j.1432-1033.1988.tb14320.x; Suzuki S, 2003, P NATL ACAD SCI USA, V100, P8276, DOI 10.1073/pnas.0932598100; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; Wagner K, 2001, GENOMICS, V78, P113, DOI 10.1006/geno.2001.6660; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Westendorp RGJ, 1999, LANCET, V354, P561, DOI 10.1016/S0140-6736(98)09376-3; Yamashita M, 1997, THROMB RES, V87, P165, DOI 10.1016/S0049-3848(97)00116-3; Zhu N, 2002, J IMMUNOL, V168, P744, DOI 10.4049/jimmunol.168.2.744	54	114	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18127	18136		10.1074/jbc.M310438200	http://dx.doi.org/10.1074/jbc.M310438200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14963043	hybrid			2022-12-27	WOS:000221041500007
J	Higashi, H; Nakaya, A; Tsutsumi, R; Yokoyama, K; Fujii, Y; Ishikawa, S; Higuchi, M; Takahashi, A; Kurashima, Y; Teishikata, Y; Tanaka, S; Azuma, T; Hatakeyama, M				Higashi, H; Nakaya, A; Tsutsumi, R; Yokoyama, K; Fujii, Y; Ishikawa, S; Higuchi, M; Takahashi, A; Kurashima, Y; Teishikata, Y; Tanaka, S; Azuma, T; Hatakeyama, M			Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GASTRIC EPITHELIAL-CELLS; SIGNAL-REGULATED KINASE; MET RECEPTOR; IN-VIVO; PHOSPHORYLATION SITES; PATHOGENICITY ISLAND; MONGOLIAN GERBILS; ADAPTER PROTEINS; FOCAL ADHESION	The CagA protein of Helicobacter pylori, which is injected from the bacteria into bacteria-attached gastric epithelial cells, is associated with gastric carcinoma. CagA is tyrosine-phosphorylated by Src family kinases, binds the SH2 domain-containing SHP-2 phosphatase in a tyrosine phosphorylation-dependent manner, and deregulates its enzymatic activity. We established AGS human gastric epithelial cells that inducibly express wildtype or a phosphorylation-resistant CagA, in which tyrosine residues constituting the EPIYA motifs were substituted with alanines. Upon induction, wild-type CagA, but not the mutant CagA, elicited strong elongation of cell shape, termed the "hummingbird" phenotype. Time-lapse video microscopic analysis revealed that the CagA-expressing cells exhibited a marked increase in cell motility with successive rounds of elongation-contraction processes. Inhibition of CagA phosphorylation by an Src kinase inhibitor, PP2, or knockdown of SHP-2 expression by small interference RNA ( siRNA) abolished the CagA-mediated hummingbird phenotype. The morphogenetic activity of CagA also required Erk MAPK but was independent of Ras or Grb2. In AGS cells, CagA prolonged duration of Erk activation in response to serum stimulation. Conversely, inhibition of SHP-2 expression by siRNA abolished the sustained Erk activation. Thus, SHP-2 acts as a positive regulator of Erk activity in AGS cells. These results indicate that SHP-2 is involved in the Ras-independent modification of Erk signals that is necessary for the morphogenetic activity of CagA. Our work therefore suggests a key role of SHP-2 in the pathological activity of H. pylori virulence factor CagA.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido, Japan; Univ Fukui, Sch Med, Dept Internal Med 2, Fukui 9101193, Japan	Hokkaido University; Hokkaido University; University of Fukui	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kta 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Higashi, Hideaki/F-6872-2012; Tanaka, Shinya/D-3586-2011	Kanemitsu, Atsushi/0000-0002-4156-9522				Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLASER MJ, 1995, CANCER RES, V55, P2111; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Danesh J, 1999, ALIMENT PHARM THERAP, V13, P851; FENG GS, 1993, SCIENCE, V259, P1611; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gutch MJ, 1998, GENE DEV, V12, P571, DOI 10.1101/gad.12.4.571; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatakeyama M, 2003, MICROBES INFECT, V5, P143, DOI 10.1016/S1286-4579(02)00085-0; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Honda S, 1998, CANCER RES, V58, P4255; Huang JQ, 1998, GASTROENTEROLOGY, V114, P1169, DOI 10.1016/S0016-5085(98)70422-6; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Manes S, 1999, MOL CELL BIOL, V19, P3125; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Pagliocca A, 2002, AM J PHYSIOL-GASTR L, V283, pG292, DOI 10.1152/ajpgi.00056.2002; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; Peek RM, 1995, LAB INVEST, V73, P760; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Rugge M, 1999, CANCER-AM CANCER SOC, V85, P2506, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2506::AID-CNCR3>3.3.CO;2-9; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2003, EMBO J, V22, P515, DOI 10.1093/emboj/cdg050; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Tsutsumi R, 2003, J BIOL CHEM, V278, P3664, DOI 10.1074/jbc.M208155200; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Wessler S, 2002, FASEB J, V16, P417, DOI 10.1096/fj.01-0766fje; Yamaoka Y, 2000, EPIDEMIOL INFECT, V124, P91, DOI 10.1017/S0950268899003209; Yamaoka Y, 1999, GASTROENTEROLOGY, V117, P342, DOI 10.1053/gast.1999.0029900342; Yamaoka Y, 1998, J CLIN MICROBIOL, V36, P2258, DOI 10.1128/JCM.36.8.2258-2263.1998; Yamazaki S, 2003, J INFECT DIS, V187, P334, DOI 10.1086/367807; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	67	214	226	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17205	17216		10.1074/jbc.M309964200	http://dx.doi.org/10.1074/jbc.M309964200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963045	hybrid			2022-12-27	WOS:000220870400041
J	Liu, T; Nakashima, S; Hirose, K; Shibasaka, M; Katsuhara, M; Ezaki, B; Giedroc, DP; Kasamo, K				Liu, T; Nakashima, S; Hirose, K; Shibasaka, M; Katsuhara, M; Ezaki, B; Giedroc, DP; Kasamo, K			A novel cyanobacterial SmtB/ArsR family repressor regulates the expression of a CPx-ATPase and a metallothionein in response to both Cu(I)/Ag(I) and Zn(II)/Cd(II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ENCODES; METAL-ION SELECTIVITY; SACCHAROMYCES-CEREVISIAE; STAPHYLOCOCCUS-AUREUS; ZINC HOMEOSTASIS; SENSOR PROTEINS; BINDING-SITES; HEAVY-METALS; METALLOREGULATORY PROTEINS; COPPER CHAPERONE	A novel SmtB/ArsR family metalloregulator, denoted BxmR, has been identified and characterized from the cyanobacterium Oscillatoria brevis. Genetic and biochemical evidence reveals that BxmR represses the expression of both bxa1, encoding a CPx-ATPase metal transporter, as well as a divergently transcribed operon encoding bxmR and bmtA, a heavy metal sequestering metallothionein. Derepression of the expression of all three genes is mediated by both monovalent (Ag(I) and Cu(I)) and divalent (Zn(II) and Cd(II)) heavy metal ions, a novel property among SmtB/ArsR metal sensors. Electrophoretic gel mobility shift experiments reveal that apoBxmR forms multiple resolvable complexes with oligonucleotides containing a single 12-2-12 inverted repeat derived from one of the two operator/promoter regions with similar apparent affinities. Preincubation with either monovalent or divalent metal ions induces disassembly of both the BxmR-bxa1 and BxmR-bxmR/bmtA operator/promoter complexes. Interestingly, the temporal regulation of expression of bxa1 and bmtA mRNAs is different in O. brevis with bxa1 induced first upon heavy metal treatment, followed by bmtA/bxmR. A dynamic interplay among Bxa1, BmtA, and BxmR is proposed that maintains metal homeostasis in O. brevis by balancing the relative rates of metal storage and efflux of multiple heavy metal ions.	Okayama Univ, Res Inst Bioresources, Okayama 7100046, Japan; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Okayama University; Texas A&M University System; Texas A&M University College Station	Nakashima, S (corresponding author), Okayama Univ, Res Inst Bioresources, Okayama 7100046, Japan.	snakashi@rib.okayama-u.ac.jp; giedroc@tamu.edu	Giedroc, David/A-8608-2018; EZAKI, Bunichi/B-2510-2011	Giedroc, David/0000-0002-2342-1620; Katsuhara, Maki/0000-0002-8264-3063	NIGMS NIH HHS [GM042569] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042569, R29GM042569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews GK, 2001, BIOMETALS, V14, P223, DOI 10.1023/A:1012932712483; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Blindauer CA, 2002, MOL MICROBIOL, V45, P1421, DOI 10.1046/j.1365-2958.2002.03109.x; Brown KR, 2002, BIOCHEMISTRY-US, V41, P6469, DOI 10.1021/bi0160664; Brown NL, 2003, FEMS MICROBIOL REV, V27, P145, DOI 10.1016/S0168-6445(03)00051-2; Busenlehner LS, 2003, FEMS MICROBIOL REV, V27, P131, DOI 10.1016/S0168-6445(03)00054-8; Busenlehner LS, 2002, J MOL BIOL, V319, P685, DOI 10.1016/S0022-2836(02)00299-1; Cave JS, 2002, J BIOL CHEM, V277, P38441, DOI 10.1074/jbc.M207677200; Cavet JS, 2003, J BIOL CHEM, V278, P44560, DOI 10.1074/jbc.M307877200; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; Cousins RJ, 2003, P NATL ACAD SCI USA, V100, P6952, DOI 10.1073/pnas.0732111100; Eicken C, 2003, J MOL BIOL, V333, P683, DOI 10.1016/j.jmb.2003.09.007; Eide DJ, 2003, J NUTR, V133, p1532S, DOI 10.1093/jn/133.5.1532S; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; ERBE JL, 1995, NUCLEIC ACIDS RES, V23, P2472, DOI 10.1093/nar/23.13.2472; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Glasfeld A, 2003, NAT STRUCT BIOL, V10, P652, DOI 10.1038/nsb951; HUCKLE JW, 1993, MOL MICROBIOL, V7, P177, DOI 10.1111/j.1365-2958.1993.tb01109.x; Jensen LT, 2003, J BIOL CHEM, V278, P42036, DOI 10.1074/jbc.M307413200; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; Kar SR, 2001, BIOCHEMISTRY-US, V40, P13378, DOI 10.1021/bi011289f; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Liu T, 2003, FEBS LETT, V542, P159, DOI 10.1016/S0014-5793(03)00370-3; LIU T, 2002, J BACTERIOL, V184, P5027; LUCHINAT C, 1994, ENCY INORGANIC CHEM, P4406; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Pennella MA, 2003, P NATL ACAD SCI USA, V100, P3713, DOI 10.1073/pnas.0636943100; Peterson CW, 1996, FEBS LETT, V379, P85, DOI 10.1016/0014-5793(95)01492-6; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Robinson NJ, 2001, ADV MICROB PHYSIOL, V44, P183, DOI 10.1016/S0065-2911(01)44014-8; Rosen BP, 2002, COMP BIOCHEM PHYS A, V133, P689, DOI 10.1016/S1095-6433(02)00201-5; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; SHI WP, 1994, J BIOL CHEM, V269, P19826; Silver S, 1996, GENE, V179, P9, DOI 10.1016/S0378-1119(96)00323-X; SILVER S, 1989, TRENDS BIOCHEM SCI, V14, P76, DOI 10.1016/0968-0004(89)90048-0; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Tarsac N. T. de, 1987, The Cyanobacteria., P251; Thelwell C, 1998, P NATL ACAD SCI USA, V95, P10728, DOI 10.1073/pnas.95.18.10728; Turner JS, 1996, NUCLEIC ACIDS RES, V24, P3714, DOI 10.1093/nar/24.19.3714; VanZile ML, 2002, BIOCHEMISTRY-US, V41, P9776, DOI 10.1021/bi020178t; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Xiong AM, 1998, J BACTERIOL, V180, P4024, DOI 10.1128/JB.180.16.4024-4029.1998; Xu C, 1996, J BIOL CHEM, V271, P2427, DOI 10.1074/jbc.271.5.2427; Zhang B, 2003, MOL CELL BIOL, V23, P8471, DOI 10.1128/MCB.23.23.8471-8485.2003; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713	58	47	52	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17810	17818		10.1074/jbc.M310560200	http://dx.doi.org/10.1074/jbc.M310560200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960585	hybrid			2022-12-27	WOS:000220870400113
J	Mounier, CM; Ghomashchi, F; Lindsay, MR; James, S; Singer, AG; Parton, RG; Gelb, MH				Mounier, CM; Ghomashchi, F; Lindsay, MR; James, S; Singer, AG; Parton, RG; Gelb, MH			Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A(2) occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A(2)-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-V; CROSS-TALK; LEUKOTRIENE BIOSYNTHESIS; ANTIINFLAMMATORY DRUGS; PYRROLIDINE INHIBITORS; EICOSANOID GENERATION; HUMAN NEUTROPHILS; A(2); BINDING; EXPRESSION	Stable expression of human groups IIA and X secreted phospholipases A(2) (hGIIA and hGX) in CHO-K1 and HEK293 cells leads to serum- and interleukin-1beta-promoted arachidonate release. Using mutant CHO-K1 cell lines, it is shown that this arachidonate release does not require heparan sulfate proteoglycan- or glycosylphosphatidylinositol-anchored proteins. It is shown that the potent secreted phospholipase A(2) inhibitor Me-Indoxam is cell-impermeable. By use of Me-Indoxam and the cell-impermeable, secreted phospholipase A(2) trapping agent heparin, it is shown that hGIIA liberates free arachidonate prior to secretion from the cell. With hGX-transfected CHO-K1 cells, arachidonate release occurs before and after enzyme secretion, whereas all of the arachidonate release from HEK293 cells occurs prior to enzyme secretion. Immunocytochemical studies by confocal laser and electron microscopies show localization of hGIIA to the cell surface and Golgi compartment. Additional results show that the interleukin-1beta-dependent release of arachidonate is promoted by secreted phospholipase A(2) expression and is completely dependent on cytosolic (group IVA) phospholipase A(2). These results along with additional data resolve the paradox that efficient arachidonic acid release occurs with hGIIA-transfected cells, and yet exogenously added hGIIA is poorly able to liberate arachidonic acid from mammalian cells.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Queensland; University of Queensland; University of Queensland	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Campus Box 351700, Seattle, WA 98195 USA.	gelb@chem.washington.edu	Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL36835, HL50040] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balboa MA, 2003, J BIOL CHEM, V278, P48059, DOI 10.1074/jbc.M305904200; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Bezzine S, 2002, J BIOL CHEM, V277, P48523, DOI 10.1074/jbc.M203137200; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Breuza L, 2002, J CELL SCI, V115, P4457, DOI 10.1242/jcs.00130; Connolly S, 2002, J MED CHEM, V45, P1348, DOI 10.1021/jm011050x; Das S, 2003, J BIOL CHEM, V278, P41431, DOI 10.1074/jbc.M304897200; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Edwards SH, 2002, BIOCHEMISTRY-US, V41, P15468, DOI 10.1021/bi020485z; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Gargalovic P, 2001, J BIOL CHEM, V276, P26164, DOI 10.1074/jbc.M011291200; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; KASSIS AI, 1980, J NUCL MED, V21, P88; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; Mihelich ED, 1999, BBA-MOL CELL BIOL L, V1441, P223, DOI 10.1016/S1388-1981(99)00157-2; MORGAN BP, 1991, J AM CHEM SOC, V113, P297, DOI 10.1021/ja00001a043; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2003, J BIOL CHEM, V278, P10657, DOI 10.1074/jbc.M211325200; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2002, J BIOL CHEM, V277, P19145, DOI 10.1074/jbc.M112385200; Murakami M, 2002, BIOCHEM BIOPH RES CO, V292, P689, DOI 10.1006/bbrc.2002.6716; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Ono T, 2002, BIOCHEM J, V363, P727, DOI 10.1042/0264-6021:3630727; Osterhout JL, 2000, J BIOL CHEM, V275, P8248, DOI 10.1074/jbc.275.11.8248; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Seno K, 2000, J MED CHEM, V43, P1041, DOI 10.1021/jm9905155; Seno K, 2001, BIOORG MED CHEM LETT, V11, P587, DOI 10.1016/S0960-894X(01)00003-8; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snyder DW, 1999, J PHARMACOL EXP THER, V288, P1117; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P12400, DOI 10.1021/bi962972i; Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461	59	128	133	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25024	25038		10.1074/jbc.M313019200	http://dx.doi.org/10.1074/jbc.M313019200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15007070	hybrid			2022-12-27	WOS:000221827900017
J	Ancsin, JB; Kisilevsky, R				Ancsin, JB; Kisilevsky, R			A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein - Significance for malarial sporozoite attachment to hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-E; FUNCTIONAL-PROPERTIES; FIBROBLAST-GROWTH; CELL-SURFACE; II-PLUS; GLYCOSAMINOGLYCAN; PROTEOGLYCANS; DOMAIN; CLEARANCE; INVASION	Circumsporozoite protein ( CSP) coats the malarial sporozoite and functions to target the liver for infection, which is the first step to developing malaria. An important tissue ligand for CSP is the glycosaminoglycan heparan sulfate ( HS) found on the surface of hepatocytes and in the basement membrane of the space of Disse. To better understand this efficient targeting process, we set out to identify and characterize the HS binding site( s) of CSP. We synthesized a series of peptides corresponding to five regions of Plasmodium falciparum CSP containing basic residues, a common requirement of HS binding sites, and screened them for heparin and HS binding activity. Only one of these peptides ( Pf 2), which contains a motif we have named region I- plus, demonstrated both high affinity heparin/ HS binding activity and the ability to block the binding of recombinant CSP to heparin- Sepharose 4B. Analysis by isothermal titration calorimetry revealed that region I- plus has a binding constant of K-d = 5.0 mum M and a stoichiometry of n = 7.8 binding sites/ heparin chain. Heparin binding was dependent on the amino acid sequence of region I- plus, and the binding sites on heparin/ HS are contained within a decasaccharide. Furthermore, HS oligosaccharides rich in sulfate and iduronic acid content ( heparin- like) are required for efficient binding. Because liver HS is exceptionally high in both these components relative to the HS of other organs, the HS structural requirements for efficient region I- plus/ HS binding are consistent with this peptide sequence functioning to target sporozoites to the liver for attachment to hepatocytes. Finally, the region I- plus heparin/ HS binding site was also discovered for two other species that infect humans, Plasmodium malariae and Plasmodium vivax, further supporting the existence of a HS binding domain in the N- terminal portion of CSP.	Queens Univ, Dept Pathol & Lab Med, Kingston, ON K7L 3N6, Canada; Kingston Gen Hosp, Syl & Molly Apps Res Ctr, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Ancsin, JB (corresponding author), Queens Univ, Dept Pathol & Lab Med, Kingston, ON K7L 3N6, Canada.	3jba1@post.queensu.ca						BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Caldwell EEO, 1996, INT J BIOCHEM CELL B, V28, P203, DOI 10.1016/1357-2725(95)00123-9; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1994, J EXP MED, V179, P695, DOI 10.1084/jem.179.2.695; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; GRESSNER AM, 1989, J CLIN CHEM CLIN BIO, V27, P141; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JI ZS, 1995, J LIPID RES, V36, P583; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; LAWLER J, 1986, BLOOD, V67, P1197; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; MILLET P, 1994, J PARASITOL, V80, P384, DOI 10.2307/3283408; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; Pinzon-Ortiz C, 2001, J BIOL CHEM, V276, P26784, DOI 10.1074/jbc.M104038200; Pradel G, 2002, MOL MICROBIOL, V45, P637, DOI 10.1046/j.1365-2958.2002.03057.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rathore D, 2000, P NATL ACAD SCI USA, V97, P8530, DOI 10.1073/pnas.140224597; Rathore D, 2002, J BIOL CHEM, V277, P7092, DOI 10.1074/jbc.M106862200; Rathore D, 2001, BIOCHEMISTRY-US, V40, P11518, DOI 10.1021/bi0105476; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Shakibaei M, 1996, J EXP MED, V184, P1699, DOI 10.1084/jem.184.5.1699; SHIN SCJ, 1982, J PROTOZOOL, V29, P448, DOI 10.1111/j.1550-7408.1982.tb05431.x; Silverstein RL, 2002, J CELL BIOL, V159, P203, DOI 10.1083/jcb.200209138; Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Sinnis P, 1996, INFECT AGENT DIS, V5, P182; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SMITH PK, 1980, ANAL BIOCHEM, V109, P466, DOI 10.1016/0003-2697(80)90679-X; SOBEL M, 1992, J BIOL CHEM, V267, P8857; TAYLOR RL, 1973, BIOCHEMISTRY-US, V12, P3633, DOI 10.1021/bi00743a010; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; UNGUREANU E, 1976, T ROY SOC TROP MED H, V70, P482, DOI 10.1016/0035-9203(76)90133-4; Wadstrom T, 1999, J MED MICROBIOL, V48, P223, DOI 10.1099/00222615-48-3-223; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Ying P, 1997, EXP PARASITOL, V85, P168, DOI 10.1006/expr.1996.4134; Zhu H, 2001, MOL MED, V7, P517, DOI 10.1007/BF03401857; [No title captured]	52	66	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21824	21832		10.1074/jbc.M401979200	http://dx.doi.org/10.1074/jbc.M401979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15007056	hybrid			2022-12-27	WOS:000221417100020
J	Fiorani, P; Reid, RJD; Schepis, A; Jacquiau, HR; Guo, H; Thimmaiah, P; Benedetti, P; Bjornsti, MA				Fiorani, P; Reid, RJD; Schepis, A; Jacquiau, HR; Guo, H; Thimmaiah, P; Benedetti, P; Bjornsti, MA			The deubiquitinating enzyme Doa4p protects cells from DNA topoisomerase I poisons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPTOTHECIN RESISTANCE; ACTIN CYTOSKELETON; S-PHASE; CATALYTIC-ACTIVITY; SINGLE MUTATION; POINT MUTATION; YEAST GENE; REPLICATION; SITE; MECHANISM	DNA topoisomerase I (Top1p) catalyzes changes in DNA topology via the formation of an enzyme-DNA covalent complex that is reversibly stabilized by the antitumor drug, camptothecin (CPT). During S-phase, collisions with replication forks convert these complexes into cytotoxic DNA lesions that trigger cell cycle arrest and cell death. To investigate cellular responses to CPT-induced DNA damage, a yeast genetic screen identified conditional tah mutants with enhanced sensitivity to self-poisoning DNA topoisomerase I mutant (Top1T722Ap), which mimics the action of CPT. Mutant alleles of three genes, DOA4, SLA1 and SLA2, were recovered. A nonsense mutation in DOA4 eliminated the catalytic residues of the Doa4p deubiquitinating enzyme, yet retained the rhodanase domain. At 36degreesC, this doa4-10 mutant exhibited increased sensitivity to CPT, osmotic stress, and hydroxyurea, and a reversible petite phenotype. However, the accumulation of pre-vacuolar class E vesicles that was observed in doa4Delta cells was not detected in the doa4-10 mutant. Mutations in SLA1 or SLA2, which alter actin cytoskeleton architecture, induced a conditional synthetic lethal phenotype in combination with doa4-10 in the absence of DNA damage. Here actin cytoskeleton defects coincided with the enhanced fragility of large-budded cells. In contrast, the enhanced sensitivity of doa4-10 mutant cells to Top1T722Ap was unrelated to alterations in endocytosis and was selectively suppressed by increased dosage of the ribonucleotide reductase inhibitor Sml1p. Additional studies suggest a role for Doa4p in the Rad9p checkpoint response to Top1p poisons. These findings indicate a functional link between ubiquitin-mediated proteolysis and cellular resistance to CPT-induced DNA damage.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Univ Padua, Dept Biol, I-35131 Padua, Italy; CNR, Inst Cell Biol, I-00016 Monterotondo, Italy	St Jude Children's Research Hospital; Jefferson University; University of Padua; Consiglio Nazionale delle Ricerche (CNR)	Bjornsti, MA (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	Mary-Ann.Bjornsti@stjude.org	Reid, Robert/AAR-1560-2020	Reid, Robert/0000-0002-7424-3537	NCI NIH HHS [CA 58755, CA 70406, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058755, P30CA021765, R01CA070406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Ayscough KR, 1999, MOL BIOL CELL, V10, P1061, DOI 10.1091/mbc.10.4.1061; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bastin-Shanower SA, 2003, MOL CELL BIOL, V23, P3487, DOI 10.1128/MCB.23.10.3487-3496.2003; BENEDETTI P, 1993, CANCER RES, V53, P4343; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Bordo D, 2002, EMBO REP, V3, P741, DOI 10.1093/embo-reports/kvf150; BYERS B, 1991, METHOD ENZYMOL, V194, P602; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; CLARK MW, 1991, METHOD ENZYMOL, V194, P608; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Desai SD, 2000, ANN NY ACAD SCI, V922, P306; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Fiorani P, 2003, J BIOL CHEM, V278, P43268, DOI 10.1074/jbc.M303899200; Fiorani P, 2000, ANN NY ACAD SCI, V922, P65; FUJIMORI A, 1995, CANCER RES, V55, P1339; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gourlay CW, 2003, J CELL SCI, V116, P2551, DOI 10.1242/jcs.00454; Hann CL, 1998, J BIOL CHEM, V273, P31519, DOI 10.1074/jbc.273.47.31519; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Kohn KW, 2000, ANN NY ACAD SCI, V922, P11; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Li XG, 1997, BIOCHEM PHARMACOL, V53, P1019, DOI 10.1016/S0006-2952(96)00899-4; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redon C, 2003, EMBO REP, V4, P678, DOI 10.1038/sj.embor.embor871; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; Reid RJD, 1999, P NATL ACAD SCI USA, V96, P11440, DOI 10.1073/pnas.96.20.11440; RUBIN E, 1994, J BIOL CHEM, V269, P2433; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SIKORSKI RS, 1989, GENETICS, V122, P19; Simon JA, 2000, CANCER RES, V60, P328; Singer JD, 1996, MOL CELL BIOL, V16, P1356; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Tang HY, 2000, MOL CELL BIOL, V20, P12, DOI 10.1128/MCB.20.1.12-25.2000; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Walowsky C, 1999, J BIOL CHEM, V274, P7302, DOI 10.1074/jbc.274.11.7302; Wan S, 2001, CURR GENET, V38, P299, DOI 10.1007/s002940000172; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Wang LF, 1997, CANCER RES, V57, P1516; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	73	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21271	21281		10.1074/jbc.M312338200	http://dx.doi.org/10.1074/jbc.M312338200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14990574	hybrid			2022-12-27	WOS:000221273800088
J	Pilon, G; Dallaire, P; Marette, A				Pilon, G; Dallaire, P; Marette, A			Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase - A new mechanism of action of insulin-sensitizing drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; FATTY-ACID OXIDATION; SKELETAL-MUSCLE; INOS EXPRESSION; MULTIPLE-SCLEROSIS; GLUCOSE-TRANSPORT; ADIPOSE-TISSUE; DEFICIENT MICE; OBESITY; RESISTANCE	AMP-activated protein kinase (AMPK), an energy-sensing enzyme that is activated in response to cellular stress, is a critical signaling molecule for the regulation of multiple metabolic processes. AMPK has recently emerged as an attractive novel target for the treatment of obesity and type 2 diabetes because its activation increases fatty acid oxidation and improves glucose homeostasis. Here we show that pharmacological activation of AMPK by insulin-sensitizing drugs markedly inhibits inducible nitric-oxide synthase (iNOS), a proinflammatory mediator in endotoxic shock and in chronic inflammatory states including obesity-linked diabetes. AMPK-mediated iNOS inhibition was observed in several cell types (myocytes, adipocytes, macrophages) and primarily resulted from post-transcriptional regulation of the iNOS protein. AMPK activation in vivo also blunted iNOS induction in muscle and adipose tissues of endotoxin-challenged rats. Reduction of AMPK expression by small interfering RNA reversed the inhibitory effects of AMPK activators on iNOS expression and nitric oxide production in myocytes. These results indicate that AMPK is a novel anti-inflammatory signaling pathway and thus represents a promising therapeutic target for immune-inflammatory disorders.	Laval Univ Hosp Res Ctr, Dept Anat & Physiol, Ste Foy, PQ G1V 4G2, Canada; Laval Univ Hosp Res Ctr, Lipid Res Unit, Ste Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Marette, A (corresponding author), Laval Univ Hosp Res Ctr, Dept Physiol, 2705 Laurier Blvd, Ste Foy, PQ G1V 4G2, Canada.	andre.marette@crchul.ulaval.ca	Marette, Andre/E-9342-2013	Marette, Andre/0000-0003-3950-5973				Adams V, 2002, CARDIOVASC RES, V54, P95, DOI 10.1016/S0008-6363(02)00228-6; Angele MK, 1999, AM J PHYSIOL-CELL PH, V276, pC285, DOI 10.1152/ajpcell.1999.276.2.C285; Bachmaier K, 1997, CIRCULATION, V96, P585; Bauer Anthony J, 2002, Curr Opin Crit Care, V8, P152, DOI 10.1097/00075198-200204000-00011; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; Behr-Roussel D, 2000, CIRCULATION, V102, P1033, DOI 10.1161/01.CIR.102.9.1033; Bender AT, 2000, J BIOL CHEM, V275, P17407, DOI 10.1074/jbc.M000155200; Blanchette J, 2003, IMMUNOLOGY, V108, P513, DOI 10.1046/j.1365-2567.2003.01620.x; Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Cromheeke KM, 1999, CARDIOVASC RES, V43, P744, DOI 10.1016/S0008-6363(99)00148-0; Fiedler M, 2001, DIABETOLOGIA, V44, P2180, DOI 10.1007/s001250100027; Forget G, 2001, EUR J IMMUNOL, V31, P3185, DOI 10.1002/1521-4141(200111)31:11&lt;3185::AID-IMMU3185&gt;3.0.CO;2-J; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Gielen S, 2003, J AM COLL CARDIOL, V42, P861, DOI 10.1016/S0735-1097(03)00848-9; GRUBER HE, 1989, CIRCULATION, V80, P1400, DOI 10.1161/01.CIR.80.5.1400; Halseth AE, 2002, BIOCHEM BIOPH RES CO, V294, P798, DOI 10.1016/S0006-291X(02)00557-0; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Kapur S, 1997, DIABETES, V46, P1691, DOI 10.2337/diabetes.46.11.1691; Kapur S, 1999, AM J PHYSIOL-ENDOC M, V276, pE635, DOI 10.1152/ajpendo.1999.276.4.E635; Kolodziejski PJ, 2002, P NATL ACAD SCI USA, V99, P12315, DOI 10.1073/pnas.192345199; Kwon G, 1999, J BIOL CHEM, V274, P18702, DOI 10.1074/jbc.274.26.18702; Le Roy D, 1998, SHOCK, V10, P37, DOI 10.1097/00024382-199807000-00007; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marette A, 2002, CURR OPIN CLIN NUTR, V5, P377, DOI 10.1097/00075197-200207000-00005; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074; Musi Nicolas, 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P119; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Qian ZP, 2001, CIRCULATION, V104, P2369, DOI 10.1161/hc4401.098471; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Sakamoto K, 2002, J APPL PHYSIOL, V93, P369, DOI 10.1152/japplphysiol.00167.2002; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Smith KJ, 2002, LANCET NEUROL, V1, P232, DOI 10.1016/S1474-4422(02)00102-3; Southey A, 1997, INT J IMMUNOPHARMACO, V19, P669; Stichtenoth DO, 1998, BRIT J RHEUMATOL, V37, P246; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Welch JS, 2003, P NATL ACAD SCI USA, V100, P6712, DOI 10.1073/pnas.1031789100; WILDHIRT SM, 1995, INT J CARDIOL, V50, P253, DOI 10.1016/0167-5273(95)02385-A; Winder W W, 2000, Diabetes Technol Ther, V2, P441, DOI 10.1089/15209150050194305; Winder WW, 2001, J APPL PHYSIOL, V91, P1017, DOI 10.1152/jappl.2001.91.3.1017; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Yamasaki K, 1998, J CLIN INVEST, V101, P967, DOI 10.1172/JCI2067; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	59	135	142	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20767	20774		10.1074/jbc.M401390200	http://dx.doi.org/10.1074/jbc.M401390200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985344	hybrid			2022-12-27	WOS:000221273800028
J	Toso, R; Camire, RM				Toso, R; Camire, RM			Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; BOVINE FACTOR-V; COAGULATION FACTOR-V; FACTOR-VIII VARIANT; FACTOR XA-BINDING; PROTHROMBINASE COMPLEX; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; PROTEIN-C; SITE	Factor V, the precursor of factor Va, circulates in plasma with little or no procoagulant activity. Activity is generated following limited proteolysis indicating that the conversion of factor V to factor Va results in appropriate structural changes, which impart cofactor function. We have produced recombinant partial B-domain-truncated derivatives of factor V (FVdes811-1491 and FVdes811-1491 with Arg(709) and Arg(1545) mutated to Gln) to investigate whether discrete proteolysis within the B-domain followed by a conformational transition is responsible for activation. Direct binding fluorescence measurements as well as steady-state kinetic assays were employed to assess the ability of these factor V derivatives to assemble and function in prothrombinase. In contrast to human factor V, single-chain B-domain-truncated factor V bound to FXa membranes with an affinity that was identical to factor Va. Additionally, it was found that, once this modified derivative was assembled in prothrombinase, it functioned in an equivalent manner to factor Va. Taken together these data support the hypothesis that proteolysis within the B-domain of factor V, although necessary, is incidental to the mechanism by which cofactor function is realized. Instead, our results are more consistent with the interpretation that proteolytic activation of factor V simply eliminates steric and/or conformational constraints contributed by the B-domain that otherwise interfere with discrete binding interactions that govern the eventual function of factor Va.	Childrens Hosp Philadelphia, Div Hematol, Abramson Res Ctr 302E, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Camire, RM (corresponding author), Childrens Hosp Philadelphia, Div Hematol, Abramson Res Ctr 302E, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	rcamire@mail.med.upenn.edu	Toso, Raffaella/I-5202-2012		NHLBI NIH HHS [P01 HL 74124-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington PR., 2002, DATA REDUCTION ERROR; BRUIN T, 1987, EUR J BIOCHEM, V170, P305, DOI 10.1111/j.1432-1033.1987.tb13700.x; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; CHEN J, 1994, J BIOL CHEM, V269, P16041; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DONATH MJSH, 1995, BIOCHEM J, V312, P49, DOI 10.1042/bj3120049; Doolittle RF, 2003, J THROMB HAEMOST, V1, P1559, DOI 10.1046/j.1538-7836.2003.00278.x; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1973, BIOCHIM BIOPHYS ACTA, V310, P289, DOI 10.1016/0005-2795(73)90034-2; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; Kalafatis M, 2003, J BIOL CHEM, V278, P33550, DOI 10.1074/jbc.M303153200; Kalafatis M, 1997, ARTERIOSCL THROM VAS, V17, P620, DOI 10.1161/01.ATV.17.4.620; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; Kemball-Cook G, 1998, NUCLEIC ACIDS RES, V26, P216, DOI 10.1093/nar/26.1.216; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim SW, 1999, BIOCHEMISTRY-US, V38, P11448, DOI 10.1021/bi991275y; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1981, METHOD ENZYMOL, V80, P286; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MANN KG, 1990, BLOOD, V76, P1; MARQUETTE KA, 1995, BLOOD, V86, P3026; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; ORTEL TL, 1995, MOL BIOL THROMBOSIS, P119; Pipe SW, 1997, P NATL ACAD SCI USA, V94, P11851, DOI 10.1073/pnas.94.22.11851; PITTMAN DD, 1993, BLOOD, V81, P2925; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; Sandberg H, 2001, THROMB HAEMOSTASIS, V85, P93; SEGAL IH, 1975, ENZYME KINETICS BEHA; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Steen M, 2002, J BIOL CHEM, V277, P38424, DOI 10.1074/jbc.M204972200; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939	61	66	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21643	21650		10.1074/jbc.M402107200	http://dx.doi.org/10.1074/jbc.M402107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004010	hybrid			2022-12-27	WOS:000221273800131
J	Alexa, A; Bozoky, Z; Farkas, A; Tompa, P; Friedrich, P				Alexa, A; Bozoky, Z; Farkas, A; Tompa, P; Friedrich, P			Contribution of distinct structural elements to activation of calpain by Ca2+ ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; CA2+-BINDING DOMAIN; MU-CALPAIN; EF-HAND; BINDING; PROTEASE; CALCIUM; CALPASTATIN; PROTEINS	The effect of Ca2+ in calpain activation is mediated via several binding sites in the enzyme molecule. To test the contribution of structural elements suspected to be part of this Ca2+ relay system, we made a site-directed mutagenesis study on calpains, measuring consequential changes in Ca2+ binding and Ca2+ sensitivity of enzyme activity. Evidence is provided for earlier suggestions that an acidic loop in domain III and the transducer region connecting domains III and IV are part of the Ca2+ relay system. Wild-type Drosophila Calpain B domain III binds two to three Ca2+ ions with a K-d of 3400 muM. Phospholipids lower this value to 220 muM. Ca2+ binding decreases in parallel with the number of mutated loop residues. Deletion of the entire loop abolishes binding of the ion. The Ca2+ dependence of enzyme activity of various acidic-loop mutants of Calpain B and rat m-calpain suggests the importance of the loop in regulating activity. Most conspicuously, the replacement of two adjacent acidic residues in the N-terminal half of the loop evokes a dramatic decrease in the Ca2+ need of both enzymes, lowering half-maximal Ca2+ concentration from 8.6 to 1.3 mM for Calpain B and from 250 to 7 muM for m-calpain. Transducer-region mutations in m-calpain also facilitate Ca2+ activation with the most profound effect seen upon shortening the region by deletion mutagenesis. All of these data along with structural considerations suggest that the acidic loop and the transducer region form an interconnected, extended structural unit that has the capacity to integrate and transduce Ca2+-evoked conformational changes over a long distance. A schematic model of this "extended transducer" mechanism is presented.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Friedrich, P (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	friedric@enzim.hu		Alexa, Anita/0000-0002-5740-7835				Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CRAWFORD C, 1993, BIOCHEM J, V296, P135, DOI 10.1042/bj2960135; Dutt P, 2000, BIOCHEM J, V348, P37, DOI 10.1042/0264-6021:3480037; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Hosfield CM, 2001, J BIOL CHEM, V276, P7404, DOI 10.1074/jbc.M007352200; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Jekely G, 1999, J BIOL CHEM, V274, P23893, DOI 10.1074/jbc.274.34.23893; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lid SE, 2002, P NATL ACAD SCI USA, V99, P5460, DOI 10.1073/pnas.042098799; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Linke WA, 2002, J STRUCT BIOL, V137, P194, DOI 10.1006/jsbi.2002.4468; Moldoveanu T, 2004, J BIOL CHEM, V279, P6106, DOI 10.1074/jbc.M310460200; Moldoveanu T, 2001, BBA-PROTEIN STRUCT M, V1545, P245, DOI 10.1016/S0167-4838(00)00286-7; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Mukhopadhyay R, 2001, FEBS LETT, V505, P374, DOI 10.1016/S0014-5793(01)02844-7; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Schad E, 2002, BIOCHEM J, V362, P383, DOI 10.1042/0264-6021:3620383; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; Tompa P, 1996, J BIOL CHEM, V271, P33161, DOI 10.1074/jbc.271.52.33161; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279	29	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20118	20126		10.1074/jbc.M311969200	http://dx.doi.org/10.1074/jbc.M311969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14976200	hybrid			2022-12-27	WOS:000221164500088
J	de Jong, AS; Melchers, WJG; Glaudemans, DHRF; Willems, PHGM; van Kuppeveld, FJM				de Jong, AS; Melchers, WJG; Glaudemans, DHRF; Willems, PHGM; van Kuppeveld, FJM			Mutational analysis of different regions in the coxsackievirus 2B protein - Requirements for homo-multimerization, membrane permeabilization, subcellular localization, and virus replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEINS; POLIOVIRUS INFECTION; ENDOPLASMIC-RETICULUM; HYDROPHOBIC DOMAIN; VIRAL REPLICATION; AMPHIPATHIC HELIX; KIN RECOGNITION; RNA REPLICATION; ANIMAL VIRUSES; GOLGI-COMPLEX	The coxsackievirus 2B protein is a small hydrophobic protein (99 amino acids) that increases host cell membrane permeability, possibly by forming homo-multimers that build membrane-integral pores. Previously, we defined the functional role of the two hydrophobic regions HR1 and HR2. Here, we investigated the importance of regions outside HR1 and HR2 for multimerization, increasing membrane permeability, subcellular localization, and virus replication through analysis of linker insertion and substitution mutants. From these studies, the following conclusions could be drawn. (i) The hydrophilic region ((RNHDD62)-R-58) between HR1 and HR2 is critical for multimerization and increasing membrane permeability. Substitution analysis of Asn(61) and Asn(62) demonstrated the preference for short polar side chains (Asp, Asn), residues that are often present in turns, over long polar side chains (Glu, Gln). This finding supports the idea that the hydrophilic region is involved in pore formation by facilitating a turn between HR1 and HR2 to reverse chain direction. (ii) Studies undertaken to define the downstream boundary of HR2 demonstrated that the aromatic residues Trp(80) and Trp(82), but not the positively charged residues Arg(81), Lys(84), and Lys(86) are important for increasing membrane permeability. (iii) The N terminus is not required for multimerization but does contribute to the membrane-active character of 2B. (iv) The subcellular localization of 2B does not rely on regions outside HR1 and HR2 and does not require multimerization. (v) Virus replication requires both the membrane-active character and an additional function of 2B that is not connected to this activity.	Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	van Kuppeveld, FJM (corresponding author), Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Med Microbiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	f.vankuppeveld@ncmls.kun.nl	Willems, P.H.G.M./L-4759-2015; Melchers, Willem/C-8819-2015; Jong, A.S./L-4416-2015	Willems, P.H.G.M./0000-0002-0915-1599; Melchers, Willem/0000-0002-5446-2230; van Kuppeveld, Frank/0000-0001-5800-749X				Agirre A, 2002, J BIOL CHEM, V277, P40434, DOI 10.1074/jbc.M205393200; Aldabe R, 1997, J VIROL, V71, P6214, DOI 10.1128/JVI.71.8.6214-6217.1997; ALDABE R, 1995, BIOCHEM BIOPH RES CO, V206, P64, DOI 10.1006/bbrc.1995.1010; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; Barco A, 1998, J VIROL, V72, P3560, DOI 10.1128/JVI.72.5.3560-3570.1998; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; BIENZ K, 1994, ARCH VIROL, P147; Binder H, 2003, BIOPHYS J, V85, P982, DOI 10.1016/S0006-3495(03)74537-8; Burgoyne RD, 2003, BBA-MOL CELL RES, V1641, P137, DOI 10.1016/S0167-4889(03)00089-2; Campanella M, 2004, J BIOL CHEM, V279, P18440, DOI 10.1074/jbc.M309494200; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; CARRASCO L, 1989, PHARMACOL THERAPEUT, V40, P171, DOI 10.1016/0163-7258(89)90096-X; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Cuconati A, 1998, J VIROL, V72, P1297, DOI 10.1128/JVI.72.2.1297-1307.1998; de Jong AS, 2003, J BIOL CHEM, V278, P1012, DOI 10.1074/jbc.M207745200; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; de Planque MRR, 2002, BIOCHEMISTRY-US, V41, P8396, DOI 10.1021/bi0257686; DEPLANQUE MR, 1932, BIOCHEMISTRY-US, V42, P5341; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Gonzalez ME, 2003, FEBS LETT, V552, P28, DOI 10.1016/S0014-5793(03)00780-4; Gunasekaran K, 1997, PROTEIN ENG, V10, P1131, DOI 10.1093/protein/10.10.1131; Ibrahim HR, 2001, J BIOL CHEM, V276, P43767, DOI 10.1074/jbc.M106317200; JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042; JOHNSON KL, 1991, J VIROL, V65, P4341, DOI 10.1128/JVI.65.8.4341-4349.1991; KLUMP WM, 1990, J VIROL, V64, P1573, DOI 10.1128/JVI.64.4.1573-1583.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMA J, 1992, J BIOL CHEM, V267, P15932; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Nieva JL, 2003, FEBS LETT, V552, P68, DOI 10.1016/S0014-5793(03)00852-4; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; Northey JGB, 2002, J MOL BIOL, V320, P389, DOI 10.1016/S0022-2836(02)00445-X; Persson S, 1998, BIOPHYS J, V75, P1365, DOI 10.1016/S0006-3495(98)74054-8; PORTER AG, 1993, J VIROL, V67, P6917, DOI 10.1128/JVI.67.12.6917-6921.1993; REED L. J., 1938, AMER JOUR HYG, V27, P493; ROSE GD, 1978, NATURE, V272, P586, DOI 10.1038/272586a0; Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001; Sandoval IV, 1997, J VIROL, V71, P4679, DOI 10.1128/JVI.71.6.4679-4693.1997; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Strandberg E, 2003, FEBS LETT, V544, P69, DOI 10.1016/S0014-5793(03)00475-7; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; Towner JS, 2003, VIROLOGY, V314, P432, DOI 10.1016/S0042-6822(03)00448-3; van Kuppeveld FJM, 2002, J VIROL, V76, P9446, DOI 10.1128/JVI.76.18.9446-9456.2002; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; VanKuppeveld FJM, 1996, J VIROL, V70, P7632, DOI 10.1128/JVI.70.11.7632-7640.1996; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; VANKUPPEVELD FJM, 1995, J VIROL, V69, P7782, DOI 10.1128/JVI.69.12.7782-7790.1995; vanKuppeveld FJM, 1996, J VIROL, V70, P3876, DOI 10.1128/JVI.70.6.3876-3886.1996; vanKuppeveld FJM, 1997, J GEN VIROL, V78, P1833, DOI 10.1099/0022-1317-78-8-1833; Vijayakumar M, 1999, PROTEINS, V34, P497, DOI 10.1002/(SICI)1097-0134(19990301)34:4<497::AID-PROT9>3.3.CO;2-7; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033	56	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19924	19935		10.1074/jbc.M314094200	http://dx.doi.org/10.1074/jbc.M314094200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14976211	hybrid			2022-12-27	WOS:000221164500067
J	Faudry, E; Lozzi, SP; Santana, JM; D'Souza-Ault, M; Kieffer, S; Felix, CR; Ricart, CAO; Sousa, MV; Vernet, T; Teixeira, ARL				Faudry, E; Lozzi, SP; Santana, JM; D'Souza-Ault, M; Kieffer, S; Felix, CR; Ricart, CAO; Sousa, MV; Vernet, T; Teixeira, ARL			Triatoma infestans apyrases belong to the 5 '-Nucleotidase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOSQUITO AEDES-AEGYPTI; RHODNIUS-PROLIXUS; SALIVARY-GLAND; DROSOPHILA-MELANOGASTER; LUTZOMYIA-LONGIPALPIS; PLATELET-AGGREGATION; 2-DIMENSIONAL GELS; EXPRESSION; PURIFICATION; CLONING	Apyrases are nucleoside triphosphate-diphosphohydrolases (EC 3.6.1.5) present in a variety of organisms. The apyrase activity found in the saliva of hematophagous insects is correlated with the prevention of ADP-induced platelet aggregation of the host during blood sucking. Purification of apyrase activity from the saliva of the triatomine bug Triatoma infestans was achieved by affinity chromatography on oligo(dT)-cellulose and gel filtration chromatography. The isolated fraction includes five N-glycosylated polypeptides of 88, 82, 79, 68 and 67 kDa apparent molecular masses. The isolated apyrase mixture completely inhibited aggregation of human blood platelets. Labeling with the ATP substrate analogue 5'-p-fluorosulfonylbenzoyladenosine showed that the five species have ATP-binding characteristic of functional apyrases. Furthermore, tandem mass spectroscopy peptide sequencing showed that the five species share sequence similarities with the apyrase from Aedes aegypti and with 5'-nucleotidases from other species. The complete cDNA of the 79-kDa enzyme was cloned, and its sequence confirmed that it encodes for an apyrase belonging to the 5'-nucleotidase family. The gene multiplication leading to the unusual salivary apyrase diversity in T. infestans could represent an important mechanism amplifying the enzyme expression during the insect evolution to hematophagy, in addition to an escape from the host immune response, thus enhancing acquisition of a meal by this triatomine vector of Chagas' disease.	Univ Brasilia, Fac Med, Dept Pathol, Chagas Dis Multidisciplinary Res Lab, BR-70910900 Brasilia, DF, Brazil; Univ Brasilia, Inst Biol, Enzymol Lab, BR-70910900 Brasilia, DF, Brazil; Univ Brasilia, Inst Biol, Ctr Prot Res & Serv, BR-70910900 Brasilia, DF, Brazil; CEA Grenoble, Dept Reponse & Dynam Cellulaire, Lab Chim Prot, F-38054 Grenoble 9, France; UJF, Inst Biol Struct JP Ebel, Lab Ingn Macromol, CNRS,CEA, F-38027 Grenoble 1, France	Universidade de Brasilia; Universidade de Brasilia; Universidade de Brasilia; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Teixeira, ARL (corresponding author), Univ Brasilia, Fac Med, Dept Pathol, Chagas Dis Multidisciplinary Res Lab, BR-70910900 Brasilia, DF, Brazil.	ateixeir@unb.br	Vernet, Thierry/G-1118-2012; Santana, Jaime/H-5319-2013; Faudry, Eric/I-9154-2014; de Sousa, Marcelo Valle/H-1838-2016	Faudry, Eric/0000-0001-9958-6029; de Sousa, Marcelo Valle/0000-0002-2871-4430				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Arocha-Pinango CL, 1999, THROMB HAEMOSTASIS, V81, P647; Biederbick A, 2000, J BIOL CHEM, V275, P19018, DOI 10.1074/jbc.M001245200; BORN GVR, 1965, NATURE, V206, P1121, DOI 10.1038/2061121a0; CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694; Charlab R, 1999, P NATL ACAD SCI USA, V96, P15155, DOI 10.1073/pnas.96.26.15155; DIXON M, 1979, ENZYMES, P72; Failer BU, 2002, J BIOL CHEM, V277, P36978, DOI 10.1074/jbc.M201656200; Fiske CH, 1925, J BIOL CHEM, V66, P375; Francischetti IMB, 2000, J BIOL CHEM, V275, P12639, DOI 10.1074/jbc.275.17.12639; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; Jung SM, 2000, J BIOL CHEM, V275, P8016, DOI 10.1074/jbc.275.11.8016; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; Knofel T, 2001, J MOL BIOL, V309, P239, DOI 10.1006/jmbi.2001.4656; Lanzaro GC, 1999, INSECT MOL BIOL, V8, P267, DOI 10.1046/j.1365-2583.1999.820267.x; LAW JH, 1992, ANNU REV BIOCHEM, V61, P87, DOI 10.1146/annurev.bi.61.070192.000511; Lombardo F, 2000, J BIOL CHEM, V275, P23861, DOI 10.1074/jbc.M909547199; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Marinotti O, 1996, COMP BIOCHEM PHYS B, V113, P675, DOI 10.1016/0305-0491(95)02035-7; Mathews GV, 1996, AM J TROP MED HYG, V55, P417, DOI 10.4269/ajtmh.1996.55.417; Milburn D, 1998, PROTEIN ENG, V11, P855, DOI 10.1093/protein/11.10.855; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NOESKEJUNGBLUT C, 1994, J BIOL CHEM, V269, P5050; NOESKEJUNGBLUT C, 1995, J BIOL CHEM, V270, P28629, DOI 10.1074/jbc.270.48.28629; OKAMURA S, 1978, J BIOL CHEM, V253, P3765; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Ribeiro JMC, 1999, J EXP BIOL, V202, P1551; RIBEIRO JMC, 1982, J INSECT PHYSIOL, V28, P655, DOI 10.1016/0022-1910(82)90142-1; RIBEIRO JMC, 1981, EXPERIENTIA, V37, P384, DOI 10.1007/BF01959876; RIBEIRO JMC, 1980, J INSECT PHYSIOL, V26, P303, DOI 10.1016/0022-1910(80)90138-9; Ribeiro JMC, 1998, INSECT BIOCHEM MOLEC, V28, P1051, DOI 10.1016/S0965-1748(98)00096-4; Ribeiro JMC, 1998, J MED ENTOMOL, V35, P599, DOI 10.1093/jmedent/35.4.599; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; SAMBROOK J, 2001, MOL CLONING LAB MANU, V6, P7; SCHADECK RJG, 1989, BRAZ J MED BIOL RES, V22, P303; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SMITH JJB, 1980, EXPERIENTIA, V36, P898, DOI 10.1007/BF01953780; Smith TM, 2002, ARCH BIOCHEM BIOPHYS, V406, P105, DOI 10.1016/S0003-9861(02)00420-4; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; Valenzuela JG, 2003, INSECT BIOCHEM MOLEC, V33, P717, DOI 10.1016/S0965-1748(03)00067-5; Valenzuela JG, 2002, J EXP BIOL, V205, P2843; Valenzuela JG, 2002, INSECT BIOCHEM MOLEC, V32, P1101, DOI 10.1016/S0965-1748(02)00047-4; Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583; Valenzuela JG, 2001, J EXP BIOL, V204, P229; VALENZUELA JG, 1996, INSECT BIOCHEM MOLEC, V21, P557; VOLKNANDT W, 1991, EUR J BIOCHEM, V202, P855, DOI 10.1111/j.1432-1033.1991.tb16443.x; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	48	63	63	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19607	19613		10.1074/jbc.M401681200	http://dx.doi.org/10.1074/jbc.M401681200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985353	hybrid			2022-12-27	WOS:000221164500029
J	Fujii, M; Matsumoto, Y; Tanaka, N; Miki, K; Suzuki, T; Ishii, N; Ayusawa, D				Fujii, M; Matsumoto, Y; Tanaka, N; Miki, K; Suzuki, T; Ishii, N; Ayusawa, D			Mutations in chemosensory cilia cause resistance to paraquat in nematode Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROGRADE INTRAFLAGELLAR TRANSPORT; EXTENDS LIFE-SPAN; STRESS RESISTANCE; OXIDATIVE STRESS; INSULIN-RECEPTOR; CALORIC RESTRICTION; SENSITIVE MUTANT; GROWTH-HORMONE; FAMILY-MEMBER; LONGEVITY	The relationship between oxidative stress and longevity is a matter of concern in various organisms. We isolated mutants resistant to paraquat from nematode Caenorhabditis elegans. One mutant named mev-4 was long-lived and showed cross-resistance to heat and Dyf phenotype (defective in dye filling). Genetic and sequence analysis revealed that mev-4 had a nonsense mutation on the che-11 gene, homologues of which are involved in formation of cilia and flagella in other organisms. The paraquat resistance was commonly observed in various Dyf mutants and did not depend on the daf-16 gene, whereas the extension of life span did depend on it. Expression of antioxidant enzyme genes seemed normal. These results suggest that chemosensory neurons are a target of oxidative stress and influence longevity dependent on the daf-16 signaling in C. elegans.	Yokohama City Univ, Kihara Inst Biol Res, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Tokai Univ, Sch Med, Dept Mol Biol, Kanagawa 2591193, Japan	Yokohama City University; Tokai University	Ayusawa, D (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Totsuka Ku, Maioka Cho 641-12, Yokohama, Kanagawa 2440813, Japan.	dayusawa@yokohama-cu.ac.jp	Suzuki, Toshikazu/F-4387-2011	Suzuki, Toshikazu/0000-0002-4398-4762				Ailion M, 1999, P NATL ACAD SCI USA, V96, P7394, DOI 10.1073/pnas.96.13.7394; ALBERT PS, 1981, J COMP NEUROL, V198, P435, DOI 10.1002/cne.901980305; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Arantes-Oliveira N, 2002, SCIENCE, V295, P502, DOI 10.1126/science.1065768; Bargmann CI, 1998, ANNU REV NEUROSCI, V21, P279, DOI 10.1146/annurev.neuro.21.1.279; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; Barsyte D, 2001, FASEB J, V15, P627, DOI 10.1096/fj.99-0966com; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; BRENNER S, 1974, GENETICS, V77, P71; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Carter CS, 2002, TRENDS GENET, V18, P295, DOI 10.1016/S0168-9525(02)02696-3; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; FUJII M, 1995, FEBS LETT, V375, P263, DOI 10.1016/0014-5793(95)01223-2; Fujii M, 1998, DNA Res, V5, P25, DOI 10.1093/dnares/5.1.25; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; HOSONO R, 1989, EXP GERONTOL, V24, P251, DOI 10.1016/0531-5565(89)90016-8; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Munoz MJ, 2003, GENETICS, V163, P171; Murakami S, 2001, CURR BIOL, V11, P1517, DOI 10.1016/S0960-9822(01)00453-5; Murakami S, 1996, GENETICS, V143, P1207; Murakami S, 1998, CURR BIOL, V8, P1091, DOI 10.1016/S0960-9822(98)70448-8; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Piperno G, 1998, J CELL BIOL, V143, P1591, DOI 10.1083/jcb.143.6.1591; Qin HM, 2001, CURR BIOL, V11, P457, DOI 10.1016/S0960-9822(01)00122-1; Riddle DL, 1997, C ELEGANS; Schafer JC, 2003, MOL BIOL CELL, V14, P2057, DOI 10.1091/mbc.E02-10-0677; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Uchida O, 2003, DEVELOPMENT, V130, P1215, DOI 10.1242/dev.00341; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Wolkow CA, 2002, TRENDS NEUROSCI, V25, P212, DOI 10.1016/S0166-2236(02)02133-1; Yamamoto K, 1996, MUTAT RES-FUND MOL M, V358, P1, DOI 10.1016/0027-5107(96)00070-X; Yang YL, 2000, MECH AGEING DEV, V113, P101, DOI 10.1016/S0047-6374(99)00100-1; Yokoyama K, 2002, FEBS LETT, V516, P53, DOI 10.1016/S0014-5793(02)02470-5	66	22	57	2	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20277	20282		10.1074/jbc.M313119200	http://dx.doi.org/10.1074/jbc.M313119200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14982934	hybrid			2022-12-27	WOS:000221164500105
J	Fujiuchi, N; Aglipay, JA; Ohtsuka, T; Maehara, N; Sahin, F; Su, GH; Lee, SW; Ouchi, T				Fujiuchi, N; Aglipay, JA; Ohtsuka, T; Maehara, N; Sahin, F; Su, GH; Lee, SW; Ouchi, T			Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-INDUCIBLE PROTEIN; EPITHELIAL-CELLS; TRANSCRIPTION; FAMILY; DOMAIN; MEMBER; P202; METHYLATION; INHIBITION; COMPLEXITY	IFI16 is a member of the PYRIN superfamily that has been implicated in BRCA1-mediated apoptosis and inflammation signaling pathways. Here we report that most breast cancer cell lines examined expressed decreased mRNA and protein levels of IFI16, although IFI16 is expressed in human primary normal mammary epithelial cells. Significantly, immunohistochemical analysis of tissues from 25 breast cancer patients demonstrated that carcinoma cells showed negative or weaker staining of IFI16 compared with positive nuclear staining in normal mammary duct epithelium. siRNA-mediated reduction of IFI16 resulted in perturbation of p53 activation when treated with ionizing radiation (IR). Expression of IFI16 enhanced p53 transcriptional activity in cells exposed to IR. Adenovirus expression of IFI16 in IFI16-deficient MCF7 induced apoptosis, which was enhanced by radiomimetic neocarcinostatin treatment. Tetracycline-regulated IFI16 also induced apoptosis when coexpressed with p53 in p53-deficient EJ cells subjected to IR, suggesting that IFI16 is involved in p53-mediated transmission of apoptosis signaling. Consistent with these results, expression of IFI16 enhanced activation of the known p53 target genes, including p21, Hdm2, and bax in MCF7 cells. These results suggest that loss of IFI16 results in deregulation of p53-mediated apoptosis, leading to cancer development.	NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA	Icahn School of Medicine at Mount Sinai; New York University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Ouchi, T (corresponding author), NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	Toru.Ouchi@mssm.edu		Su, Gloria/0000-0002-5158-6019	NATIONAL CANCER INSTITUTE [R01CA079892, R01CA078356, R01CA090631, R01CA085681, U01CA090631] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85681, CA 78356, CA 90631, CA 79892] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Gariglio M, 2002, J INTERF CYTOK RES, V22, P815, DOI 10.1089/107999002320271413; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HOWLEY PM, 1991, CANCER RES, V51, pS5019; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Kwak JC, 2003, J BIOL CHEM, V278, P40899, DOI 10.1074/jbc.M308012200; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Min W, 1996, MOL CELL BIOL, V16, P359; MIYASHITA T, 1995, CELL, V80, P293; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WATKINS S, 1993, CURRENT PROTOCOLS MO, V1; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0; YUTSUDO M, 1988, VIROLOGY, V166, P594, DOI 10.1016/0042-6822(88)90532-6	36	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20339	20344		10.1074/jbc.M400344200	http://dx.doi.org/10.1074/jbc.M400344200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14990579	hybrid			2022-12-27	WOS:000221164500111
J	Gruber, K; Gartler, G; Krammer, B; Schwab, H; Kratky, C				Gruber, K; Gartler, G; Krammer, B; Schwab, H; Kratky, C			Reaction mechanism of hydroxynitrile lyases of the alpha/beta-hydrolase superfamily - The three-dimensional structure of the transient enzyme-substrate complex certifies the crucial role of LYS236	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; HEVEA-BRASILIENSIS; MANIHOT-ESCULENTA; ACTIVE-SITE; MOLECULAR-CLONING; (R)-(+)-MANDELONITRILE LYASE; (S)-HYDROXYNITRILE LYASE; CRYSTAL-STRUCTURE; IDENTIFICATION; CYANOGENESIS	The hydroxynitrile lyases (HNLs) from Hevea brasiliensis (HbHNL) and from Manihot esculenta (MeHNL) are both members of the alpha/beta-hydrolase superfamily. Mechanistic proposals have been put forward in the past for both enzymes; they differed with respect to the role of the active-site lysine residue for which a catalytic function was claimed for the Hevea enzyme but denied for the Manihot enzyme. We applied a freeze-quench method to prepare crystals of the complex of HbHNL with the biological substrate acetone cyanohydrin and determined its three-dimensional structure. Site-directed mutagenesis was used to prepare the mutant K236L, which is inactive although its three-dimensional structure is similar to the wild-type enzyme. However, the structure of the K236L-acetone cyanohydrin complex shows the substrate in a different orientation from the wild-type complex. Finite difference Poisson-Boltzmann calculations show that in the absence of Lys(236) the catalytic base His(235) would be protonated at neutral pH. All of this suggests that Lys(236) is instrumental for catalysis in several ways, i.e. by correctly positioning the substrate, by stabilizing the negatively charged reaction product CN-, and by modulating the basicity of the catalytic base. These data complete the elucidation of the reaction mechanism of alpha/beta-hydrolase HNLs, in which the catalytic triad acts as a general base rather than as a nucleophile; proton abstraction from the substrate is performed by the serine, and reprotonation of the product cyanide is performed by the histidine residues. Together with a threonine side chain, the active-site serine and lysine are also involved in substrate binding.	Karl Franzens Univ Graz, Inst Chem Phys Chem, A-8010 Graz, Austria; Graz Univ Technol, Inst Mol Biotechnol, A-8010 Graz, Austria; Angew Biokatalyse Kompetenzzentrum GmbH, A-8010 Graz, Austria	University of Graz; Graz University of Technology	Kratky, C (corresponding author), Karl Franzens Univ Graz, Inst Chem Phys Chem, Univ Heinrichstr 28, A-8010 Graz, Austria.	Christoph.Kratky@uni-graz.at	Gruber, Karl/GPP-6706-2022; Krammer, Barbara/L-4058-2015	Gruber, Karl/0000-0002-3485-9740; Schwab, Helmut/0000-0003-2746-0624; Krammer, Barbara/0000-0001-5972-5258				Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer M, 1999, BIOTECHNOL BIOENG, V62, P20, DOI 10.1002/(SICI)1097-0290(19990105)62:1&lt;20::AID-BIT3&gt;3.0.CO;2-I; BECKER W, 1966, BIOCHEM Z, V346, P301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG IP, 1993, PLANT CELL PHYSIOL, V34, P1139; CHING WM, 1978, J AM CHEM SOC, V100, P6119, DOI 10.1021/ja00487a025; Conn EE, 1981, BIOCH PLANTS COMPREH, P479; EFFENBERGER F, 1994, ANGEW CHEM INT EDIT, V33, P1555, DOI 10.1002/anie.199415551; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fleming SM, 2000, BIOCHEMISTRY-US, V39, P1522, DOI 10.1021/bi9923095; Griengl H, 1997, CHEM COMMUN, P1933, DOI 10.1039/a700907k; Gruber K, 2001, PROTEINS, V44, P26, DOI 10.1002/prot.1068; Gruber K, 1999, BIOL CHEM, V380, P993, DOI 10.1515/BC.1999.123; HAINBUCHER M, 1997, THESIS K FRANZENS U; Hasslacher M, 1997, PROTEIN EXPRES PURIF, V11, P61, DOI 10.1006/prep.1997.0765; Hasslacher M, 1997, PROTEINS, V27, P438; Hasslacher M, 1996, J BIOL CHEM, V271, P5884, DOI 10.1074/jbc.271.10.5884; Hickel A, 1996, PHYSIOL PLANTARUM, V98, P891, DOI 10.1111/j.1399-3054.1996.tb06700.x; Hofmann B, 1998, J MOL BIOL, V279, P889, DOI 10.1006/jmbi.1998.1802; Holmquist M, 2000, CURR PROTEIN PEPT SC, V1, P209, DOI 10.2174/1389203003381405; Hu ZH, 1997, PLANT PHYSIOL, V115, P1359, DOI 10.1104/pp.115.4.1359; *INV CORP, 2002, INSTR MAN MAN METH E; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEMPIER N, 1995, TETRAHEDRON-ASYMMETR, V6, P845, DOI 10.1016/0957-4166(95)00085-4; KLEMPIER N, 1993, TETRAHEDRON LETT, V34, P4769, DOI 10.1016/S0040-4039(00)74084-6; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSE CG, 1992, CHIRALITY IND, P279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauble H, 2002, PROTEIN SCI, V11, P65, DOI 10.1110/ps.ps.33702; Lauble H, 2001, PROTEIN SCI, V10, P1015, DOI 10.1110/ps.01301; Lauble H, 2001, ACTA CRYSTALLOGR D, V57, P194, DOI 10.1107/S0907444900015766; LIEBEREI R, 1985, PLANT SYST EVOL, V150, P49, DOI 10.1007/BF00985567; MCMAHON JM, 1995, J EXP BOT, V46, P731, DOI 10.1093/jxb/46.7.731; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Selmar D, 1993, ACS SYM SER, V13, P191; Stranzl GR, 2004, J BIOL CHEM, V279, P3699, DOI 10.1074/jbc.M306814200; STRYER L, 1995, BIOCHEMISTRY-US, P42; Trummler K, 1997, J BIOL CHEM, V272, P4770, DOI 10.1074/jbc.272.8.4770; Wagner UG, 1996, ACTA CRYSTALLOGR D, V52, P591, DOI 10.1107/S0907444995016830; Wagner UG, 1996, STRUCTURE, V4, P811, DOI 10.1016/S0969-2126(96)00088-3; WAJANT H, 1994, PLANT MOL BIOL, V26, P735, DOI 10.1007/BF00013758; Wajant H, 1996, BIOL CHEM, V377, P611; Wajant H, 1996, J BIOL CHEM, V271, P25830, DOI 10.1074/jbc.271.42.25830; Zuegg J, 1999, PROTEIN SCI, V8, P1990, DOI 10.1110/ps.8.10.1990	53	62	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20501	20510		10.1074/jbc.M401575200	http://dx.doi.org/10.1074/jbc.M401575200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14998991	hybrid			2022-12-27	WOS:000221164500129
J	Kethidi, DR; Perera, SC; Zheng, S; Feng, QL; Krell, P; Retnakaran, A; Palli, SR				Kethidi, DR; Perera, SC; Zheng, S; Feng, QL; Krell, P; Retnakaran, A; Palli, SR			Identification and characterization of a juvenile hormone (JH) response region in the JH esterase gene from the spruce budworm, Choristoneura fumiferana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; MANDUCA-SEXTA; DEVELOPMENTAL EXPRESSION; NUCLEAR RECEPTOR; BINDING-PROTEIN; VITELLOGENIN GENE; MOLECULAR ACTIONS; TOBACCO HORNWORM; LIGAND-BINDING; MESSENGER-RNA	Using a differential display of mRNA technique we discovered that the juvenile hormone (JH) esterase gene (Cfjhe) from Choristoneura fumiferana is directly induced by juvenile hormone I ( JH I), and the JH I induction is suppressed by 20-hydroxyecdysone (20E). To study the mechanism of action of these two hormones in the regulation of expression of this gene, we cloned the 1270-bp promoter region of the Cfjhe gene and identified a 30-bp region that is located between - 604 and - 574 and is sufficient to support both JH I induction and 20E suppression. This 30-bp region contains two conserved hormone response element half-sites separated by a 4-nucleotide spacer similar to the direct repeat 4 element and is designated as a putative juvenile hormone response element (JHRE). In CF-203 cells, a luciferase reporter placed under the control of JHRE and a minimal promoter was induced by JH I in a dose- and time-dependent manner. Moreover, 20E suppressed this JH I-induced luciferase activity in a dose- and time-dependent manner. Nuclear proteins isolated from JH I-treated CF-203 cells bound to JHRE and the binding was competed by a 100-fold excess of the cold probe but not by 100-fold excess of double-stranded oligonucleotides of unrelated sequence. JH I induced/modified nuclear proteins prior to their binding to JHRE and 20E suppressed this JH I induction/modification. These results suggest that the 30-bp JHRE identified in the Cfjhe gene promoter is sufficient to support JH induction and 20E suppression of the Cfjhe gene.	Univ Kentucky, Coll Agr, Dept Entomol, Lexington, KY 40546 USA; Canadian Forestry Serv, Great Lakes Forestry Ctr, Sault Ste Marie, ON P6E 2E5, Canada; Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	University of Kentucky; Natural Resources Canada; Canadian Forest Service; Great Lakes Forestry Centre; University of Guelph	Palli, SR (corresponding author), Univ Kentucky, Coll Agr, Dept Entomol, Lexington, KY 40546 USA.	rpalli@uky.edu	PALLI, SUBBA REDDY/AAU-8289-2020	PALLI, SUBBA REDDY/0000-0002-0873-3247				Ashok M, 1998, P NATL ACAD SCI USA, V95, P2761, DOI 10.1073/pnas.95.6.2761; Charles JP, 1996, ARCH INSECT BIOCHEM, V31, P371, DOI 10.1002/(SICI)1520-6327(1996)31:4&lt;371::AID-ARCH2&gt;3.0.CO;2-Z; Comas D, 1999, INSECT BIOCHEM MOLEC, V29, P821, DOI 10.1016/S0965-1748(99)00058-2; Cusson M, 2000, CAN ENTOMOL, V132, P263, DOI 10.4039/Ent132263-3; DREVET JR, 1994, J BIOL CHEM, V269, P10660; Dubrovsky EB, 2000, DEV BIOL, V224, P486, DOI 10.1006/dbio.2000.9800; Feng QL, 1999, MOL CELL ENDOCRINOL, V148, P95, DOI 10.1016/S0303-7207(98)00228-7; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Gilbert LI, 2000, INSECT BIOCHEM MOLEC, V30, P617, DOI 10.1016/S0965-1748(00)00034-5; GLINKA AV, 1995, BIOCHEM MOL BIOL INT, V35, P323; HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157; Hirai M, 1998, INSECT BIOCHEM MOLEC, V28, P181, DOI 10.1016/S0965-1748(97)00116-1; IYENGAR AR, 1995, DEV BIOL, V170, P314, DOI 10.1006/dbio.1995.1217; Jones G, 1997, P NATL ACAD SCI USA, V94, P13499, DOI 10.1073/pnas.94.25.13499; JONES G, 1995, ANNU REV ENTOMOL, V40, P147, DOI 10.1146/annurev.en.40.010195.001051; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; Kokoza VA, 2001, GENE, V274, P47, DOI 10.1016/S0378-1119(01)00602-3; Orth AP, 1999, MOL CELL ENDOCRINOL, V149, P61, DOI 10.1016/S0303-7207(98)00258-5; PALLI SR, 1992, DEV BIOL, V150, P306, DOI 10.1016/0012-1606(92)90244-B; Palli SR, 1996, INSECT BIOCHEM MOLEC, V26, P485, DOI 10.1016/0965-1748(96)00004-5; PALLI SR, 1991, INSECT BIOCHEM, V21, P7, DOI 10.1016/0020-1790(91)90059-N; Palli SR, 1997, DEV GENET, V20, P36, DOI 10.1002/(SICI)1520-6408(1997)20:1&lt;36::AID-DVG5&gt;3.0.CO;2-A; PALLI SR, 1994, P NATL ACAD SCI USA, V91, P6191, DOI 10.1073/pnas.91.13.6191; Pursley S, 2000, INSECT BIOCHEM MOLEC, V30, P839, DOI 10.1016/S0965-1748(00)00056-4; RIDDIFORD LM, 1994, ADV INSECT PHYSIOL, V24, P213, DOI 10.1016/S0065-2806(08)60084-3; SEVALA VL, 1989, EXPERIENTIA, V45, P355, DOI 10.1007/BF01957476; SHEMSHEDINI L, 1990, J BIOL CHEM, V265, P1913; Sohi S S, 1995, Methods Mol Biol, V39, P397; VENKATARAMAN V, 1994, DEV GENET, V15, P391, DOI 10.1002/dvg.1020150502; Wang SF, 1998, J BIOL CHEM, V273, P27531, DOI 10.1074/jbc.273.42.27531; Wilson TG, 1998, P NATL ACAD SCI USA, V95, P14040, DOI 10.1073/pnas.95.24.14040; WILSON TG, 1986, DEV BIOL, V118, P190, DOI 10.1016/0012-1606(86)90087-4; WROBLEWSKI VJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P461, DOI 10.1016/0003-9861(90)90285-7; Wyatt GR, 1996, ADV INSECT PHYSIOL, V26, P1, DOI 10.1016/S0065-2806(08)60030-2; Xu Y, 2002, EUR J BIOCHEM, V269, P6026, DOI 10.1046/j.1432-1033.2002.03293.x; Zhang JZ, 1996, MOL CELL ENDOCRINOL, V122, P15, DOI 10.1016/0303-7207(96)03884-1; Zhou BH, 1998, DEV BIOL, V203, P233, DOI 10.1006/dbio.1998.9059; Zhou S, 2002, MOL CELL ENDOCRINOL, V190, P177, DOI 10.1016/S0303-7207(01)00602-5; Zhou XF, 2002, DEVELOPMENT, V129, P2259	39	49	54	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19634	19642		10.1074/jbc.M311647200	http://dx.doi.org/10.1074/jbc.M311647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14990570	hybrid			2022-12-27	WOS:000221164500032
J	Naryzhny, SN; Lee, H				Naryzhny, SN; Lee, H			The post-translational modifications of proliferating cell nuclear antigen - Acetylation, not phosphorylation, plays an important role in the regulation of its function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; PROTEINS; CYCLE; REPAIR; PCNA; ASSOCIATION; CHROMATIN; SITES; CLAMP	The diverse function of proliferating cell nuclear antigen (PCNA) is thought to be due, in large part, to post-translational modifications. Here we show by high resolution two-dimensional PAGE analysis that there are three distinct PCNA isoforms that differ in their acetylation status. The moderately acetylated main (M) form was found in all of the subcellular compartments of cycling cells, whereas the highly acetylated acidic form was primarily found in the nucleoplasm, nuclear matrix, and chromatin. Interestingly, the deacetylated basic form was most pronounced in the nucleoplasm of cycling cells. The cells in G(0) and the cytoplasm of cycling cells contained primarily the M form only. Because p300 and histone deacetylase (HDAC1) were co-immunoprecipitated with PCNA, they are likely responsible for the acetylation and deacetylation of PCNA, respectively. We also found that deacetylation reduced the ability of PCNA to bind to DNA polymerases beta and delta. Taken together, our data support a model where the acidic and M forms participate in DNA replication, whereas the basic form is associated with the termination of DNA replication.	NE Ontario Reg Canc Ctr, Dept Res, Sudbury, ON P3E 5J1, Canada		Lee, H (corresponding author), NE Ontario Reg Canc Ctr, Dept Res, 41 Ramsey Lake Rd, Sudbury, ON P3E 5J1, Canada.	hlee@hrsrh.on.ca	Naryzhny, Stanislav/D-1683-2012	Naryzhny, Stanislav/0000-0002-4102-3423				BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRAND SR, 1994, J IMMUNOL, V153, P3070; BRAVO R, 1985, FEBS LETT, V182, P435, DOI 10.1016/0014-5793(85)80349-5; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; MANSFIELD M, 1999, TN051 MILL; MCCORMICK D, 1992, HISTOPATHOLOGY, V21, P591, DOI 10.1111/j.1365-2559.1992.tb00454.x; Milutinovic S, 2002, J BIOL CHEM, V277, P20974, DOI 10.1074/jbc.M202504200; Naryzhny SN, 2001, ELECTROPHORESIS, V22, P1764, DOI 10.1002/1522-2683(200105)22:9&lt;1764::AID-ELPS1764&gt;3.0.CO;2-V; Naryzhny SN, 2003, PROTEOMICS, V3, P930, DOI 10.1002/pmic.200300400; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; PROSPERI E, 1994, EXP CELL RES, V215, P257, DOI 10.1006/excr.1994.1341; RABILLOUD T, 1992, ELECTROPHORESIS, V13, P429, DOI 10.1002/elps.1150130190; Ramsby ML, 1999, METH MOL B, V112, P53; SPECTOR DL, 1998, NUCL MATRIX PREPARAT; Stucki M, 2001, PROG NUCLEIC ACID RE, V65, P261; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tanno M, 1999, EXP MOL PATHOL, V67, P192, DOI 10.1006/exmp.1999.2281; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849	29	103	106	17	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20194	20199		10.1074/jbc.M312850200	http://dx.doi.org/10.1074/jbc.M312850200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14988403	hybrid			2022-12-27	WOS:000221164500096
J	Ray, K; Hines, CS; Coll-Rodriguez, J; Rodgers, DW				Ray, K; Hines, CS; Coll-Rodriguez, J; Rodgers, DW			Crystal structure of human thimet oligopeptidase provides insight into substrate recognition, regulation, and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOENDOPEPTIDASE EC 3.4.24.15; ENKEPHALIN-CONTAINING PEPTIDES; RAT-BRAIN; SOLUBLE METALLOENDOPEPTIDASE; CRYSTALLOGRAPHIC ANALYSIS; NEUROLYSIN EC-3.4.24.16; ENDOPEPTIDASE 24.15; ANTIGENIC PEPTIDES; MOLECULAR-CLONING; NATURAL PEPTIDES	Thimet oligopeptidase ( TOP) is a zinc metallopeptidase that metabolizes a number of bioactive peptides and degrades peptides released by the proteasome, limiting antigenic presentation by MHC class I molecules. We present the crystal structure of human TOP at 2.0-Angstrom resolution. The active site is located at the base of a deep channel that runs the length of the elongated molecule, an overall fold first seen in the closely related metallopeptidase neurolysin. Comparison of the two related structures indicates hinge-like flexibility and identifies elements near one end of the channel that adopt different conformations. Relatively few of the sequence differences between TOP and neurolysin map to the proposed substrate-binding site, and four of these variable residues may account for differences in substrate specificity. In addition, a loop segment ( residues 599 - 611) in TOP differs in conformation and degree of order from the corresponding neurolysin loop, suggesting it may also play a role in activity differences. Cysteines thought to mediate covalent oligomerization of rat TOP, which can inactivate the enzyme, are found to be surface-accessible in the human enzyme, and additional cysteines ( residues 321,350, and 644) may also mediate multimerization in the human homolog. Disorder in the N terminus of TOP indicates it may be involved in subcellular localization, but a potential nuclear import element is found to be part of a helix and, therefore, unlikely to be involved in transport. A large acidic patch on the surface could potentially mediate a protein-protein interaction, possibly through formation of a covalent linkage.	Univ Kentucky, Dept Mol & Cellular Biol, Lexington, KY 40536 USA; Univ Kentucky, Ctr Struct Biol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Rodgers, DW (corresponding author), Univ Kentucky, Dept Mol & Cellular Biol, Lexington, KY 40536 USA.	david.rodgers@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038041, R56NS038041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F30DA014596] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 14596] Funding Source: Medline; NINDS NIH HHS [NS 38041] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; Arndt JW, 2002, STRUCTURE, V10, P215, DOI 10.1016/S0969-2126(02)00698-6; BARRETT AJ, 1990, BIOCHEM J, V271, P701, DOI 10.1042/bj2710701; BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brown CK, 2001, P NATL ACAD SCI USA, V98, P3127, DOI 10.1073/pnas.051633198; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camargo ACM, 1997, BIOCHEM J, V324, P517, DOI 10.1042/bj3240517; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHECLER F, 1995, METHOD ENZYMOL, V248, P593; CHECLER F, 1993, METHODS NEUROTRANSMI, V2, P375; CHEN JM, 1995, EXP CELL RES, V216, P80, DOI 10.1006/excr.1995.1010; CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Crack PJ, 1999, BRAIN RES, V835, P113, DOI 10.1016/S0006-8993(99)01494-8; DAHMS P, 1992, EUR J BIOCHEM, V208, P145, DOI 10.1111/j.1432-1033.1992.tb17168.x; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; DAUCH P, 1995, J BIOL CHEM, V270, P27266, DOI 10.1074/jbc.270.45.27266; Dendorfer A, 1997, BRIT J PHARMACOL, V120, P121, DOI 10.1038/sj.bjp.0700874; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; FERRO ES, 1995, J CELL BIOCHEM, V57, P311, DOI 10.1002/jcb.240570215; Ferro ES, 1999, DNA CELL BIOL, V18, P781, DOI 10.1089/104454999314926; Fontenele-Neto JD, 2001, J COMP NEUROL, V438, P399, DOI 10.1002/cne.1323; Garrido PAG, 1999, DNA CELL BIOL, V18, P323, DOI 10.1089/104454999315385; Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEALY DP, 1992, BRAIN RES, V571, P121, DOI 10.1016/0006-8993(92)90517-D; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; Jiracek J, 1996, J BIOL CHEM, V271, P19606, DOI 10.1074/jbc.271.32.19606; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; Kim HM, 2003, FEBS LETT, V538, P65, DOI 10.1016/S0014-5793(03)00128-5; Kim SI, 2003, BIOCHEM J, V375, P111, DOI 10.1042/BJ20030490; Koike H, 1999, J BIOCHEM-TOKYO, V126, P235, DOI 10.1093/oxfordjournals.jbchem.a022428; Lew RA, 1997, J NEUROENDOCRINOL, V9, P707, DOI 10.1046/j.1365-2826.1997.00628.x; Massarelli EE, 1999, BRAIN RES, V851, P261, DOI 10.1016/S0006-8993(99)02135-6; MATTHEWS BW, 1974, J BIOL CHEM, V249, P8030; McCool S, 1998, BIOCHEM SOC T, V26, pS15, DOI 10.1042/bst026s015; McCool S, 2000, DNA CELL BIOL, V19, P729, DOI 10.1089/104454900750058099; MCPHERSON A, 1999, CRYSTALLIZATION BIOL, P188; MENTLEIN R, 1994, J NEUROCHEM, V62, P27; MORALES TI, 1977, J BIOL CHEM, V252, P4855; Morrison LS, 2003, BIOCHEM J, V376, P189, DOI 10.1042/BJ20030792; Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oliveira V, 2003, FEBS LETT, V541, P89, DOI 10.1016/S0014-5793(03)00310-7; Oliveira V, 2001, BIOCHEMISTRY-US, V40, P4417, DOI 10.1021/bi002715k; Oliveira V, 2001, ANAL BIOCHEM, V292, P257, DOI 10.1006/abio.2001.5083; Oliveira V, 2000, J CELL BIOCHEM, V76, P478, DOI 10.1002/(SICI)1097-4644(20000301)76:3<478::AID-JCB14>3.0.CO;2-H; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; Portaro FCV, 2001, EUR J BIOCHEM, V268, P887, DOI 10.1046/j.1432-1327.2001.01978.x; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Ray K, 2002, PROTEIN SCI, V11, P2237, DOI 10.1110/ps.0216302; Rioli V, 1998, BIOCHEM BIOPH RES CO, V250, P5, DOI 10.1006/bbrc.1998.8941; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; Shrimpton CN, 2003, J NEUROSCI RES, V74, P474, DOI 10.1002/jnr.10698; Shrimpton CN, 2002, ENDOCR REV, V23, P647, DOI 10.1210/er.2001-0032; Shrimpton CN, 1997, J BIOL CHEM, V272, P17395, DOI 10.1074/jbc.272.28.17395; Sigman JA, 2003, PROTEIN ENG, V16, P623, DOI 10.1093/protein/gzg073; Tullai JW, 2000, J BIOL CHEM, V275, P36514, DOI 10.1074/jbc.M001843200; VINCENT B, 1995, BRIT J PHARMACOL, V115, P1053, DOI 10.1111/j.1476-5381.1995.tb15918.x; Vincent B, 1997, EUR J PHARMACOL, V334, P49, DOI 10.1016/S0014-2999(97)01209-0; Wu TJ, 1997, J NEUROENDOCRINOL, V9, P813, DOI 10.1046/j.1365-2826.1997.00637.x; XU GY, 1991, INT J PEPT PROT RES, V37, P528; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; YANG XP, 1994, HYPERTENSION, V23, P1235; York IA, 2003, IMMUNITY, V18, P429, DOI 10.1016/S1074-7613(03)00058-X	73	69	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20480	20489		10.1074/jbc.M400795200	http://dx.doi.org/10.1074/jbc.M400795200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14998993	hybrid			2022-12-27	WOS:000221164500127
J	Leahy, M; Lyons, A; Krause, D; O'Connor, R				Leahy, M; Lyons, A; Krause, D; O'Connor, R			Impaired Shc, Ras, and MAPK activation but normal Akt activation in FL5.12 cells expressing an insulin-like growth factor I receptor mutated at tyrosines 1250 and 1251	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; PROTEIN-KINASE ACTIVATION; N-TERMINAL KINASES; SIGNALING PATHWAY; IGF-1 RECEPTOR; PHOSPHORYLATION SITES; INOSITOL PHOSPHATASE; GLIOBLASTOMA CELLS; TRANSFORMATION; APOPTOSIS	The Y1250F/Y1251F mutant of the insulin-like growth factor I receptor (IGF-IR) has tyrosines 1250 and 1251 mutated to phenylalanines and is deficient in IGF-I-mediated suppression of apoptosis in FL5.12 lymphocytic cells. To address the mechanism of loss of function in this mutant we investigated signaling responses in FL5.12 cells overexpressing either a wild-type (WT) or Y1250F/Y1251F ( mutant) IGF-IR. Cells expressing the mutant receptor were deficient in IGF-I-induced phosphorylation of the JNK pathway and had decreased ERK and p38 phosphorylation. IGF-I induced phosphorylation of Akt was comparable in WT and mutant expressing cells. The decreased activation of the mitogen-activated protein kinase ( MAPK) pathways was accompanied by greatly decreased Ras activation in response to IGF-I. Although phosphorylation of Gab2 was similar in WT and mutant cell lines, phosphorylation of Shc on Tyr(313) in response to IGF-I was decreased in cells expressing the mutant receptor, as was recruitment of Grb2 and Ship to Shc. However, phosphorylation of Shc on Tyr(239), the Src phosphorylation site, was normal. A role for JNK in the survival of FL5.12 cells was supported by the observation that the JNK inhibitor SP600125 suppressed IGF-I-mediated protection from apoptosis. Altogether these data demonstrate that phosphorylation of Shc, and assembly of the Shc complex necessary for activation of Ras and the MAPK pathways are deficient in cells expressing the Y1250F/Y1251F mutant IGF-IR. This would explain the loss of IGF-I-mediated survival in FL5.12 cells expressing this mutant and may also explain why this mutant IGF-IR is deficient in functions associated with cellular transformation and cell migration in fibroblasts and epithelial tumor cells.	Natl Univ Ireland Univ Coll Cork, Dept Biochem, Biosci Inst, Cell Biol Lab, Cork, Ireland	University College Cork	O'Connor, R (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Biochem, Biosci Inst, Cell Biol Lab, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014	O'Connor, Rosemary/0000-0002-0687-3422				Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; Blakesley VA, 1998, J BIOL CHEM, V273, P18411, DOI 10.1074/jbc.273.29.18411; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Crespo P, 1996, ONCOGENE, V13, P455; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dunn SE, 1998, CANCER RES, V58, P3353; Esposito DL, 1997, ENDOCRINOLOGY, V138, P2979, DOI 10.1210/en.138.7.2979; Gatzka M, 2000, CANCER RES, V60, P4222; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Hellawell GO, 2002, CANCER RES, V62, P2942; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hochbaum D, 2003, J BIOL CHEM, V278, P33738, DOI 10.1074/jbc.M305208200; Hongo A, 1996, ONCOGENE, V12, P1231; Ingham RJ, 1999, J IMMUNOL, V163, P5891; Ishihara H, 1998, BIOCHEM BIOPH RES CO, V252, P139, DOI 10.1006/bbrc.1998.9621; JHUN BH, 1994, J BIOL CHEM, V269, P5699; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Koval AP, 1998, BIOCHEM J, V330, P923; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Liu L, 1997, J BIOL CHEM, V272, P8983; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Miura M, 1997, BIOCHEM BIOPH RES CO, V239, P182, DOI 10.1006/bbrc.1997.7449; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Ott VL, 2002, J IMMUNOL, V168, P4430, DOI 10.4049/jimmunol.168.9.4430; Oxford G, 2003, CANCER LETT, V189, P117, DOI 10.1016/S0304-3835(02)00510-4; PELICCI G, 1995, ONCOGENE, V11, P899; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; RESNICOFF M, 1994, CANCER RES, V54, P2218; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Sato K, 1997, BIOCHEM BIOPH RES CO, V240, P399, DOI 10.1006/bbrc.1997.7667; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Tang YC, 2003, CANCER RES, V63, P1166; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Walsh PT, 2002, IMMUNOLOGY, V107, P461, DOI 10.1046/j.1365-2567.2002.01525.x; Weber MM, 2002, CANCER-AM CANCER SOC, V95, P2086, DOI 10.1002/cncr.10945; Winnay JN, 2000, J BIOL CHEM, V275, P10545, DOI 10.1074/jbc.275.14.10545; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000; Zhu WJ, 1998, ONCOGENE, V17, P565, DOI 10.1038/sj.onc.1201979	65	25	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18306	18313		10.1074/jbc.M309234200	http://dx.doi.org/10.1074/jbc.M309234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14963047	hybrid			2022-12-27	WOS:000221041500027
J	Plageman, TF; Yutzey, KE				Plageman, TF; Yutzey, KE			Differential expression and function of Tbx5 and Tbx20 in cardiac development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLT-ORAM-SYNDROME; ATRIAL-NATRIURETIC-FACTOR; T-BOX GENES; TRANSCRIPTION FACTORS; CHAMBER FORMATION; HEART DEVELOPMENT; MAMMALIAN HEART; MOUSE HEART; MUTATIONS; NKX2-5	The T-box transcription factors play critical roles in embryonic development including cell type specification, tissue patterning, and morphogenesis. Several T-box genes are expressed in the heart and are regulators of cardiac development. At the earliest stages of heart development, two of these genes, Tbx5 and Tbx20, are co-expressed in the heart-forming region but then become differentially expressed as heart morphogenesis progresses. Although Tbx5 and Tbx20 belong to the same gene family and share a highly conserved DNA-binding domain, their transcriptional activities are distinct. The C-terminal region of the Tbx5 protein is a transcriptional activator, while the C terminus of Tbx20 can repress transcription. Tbx5, but not Tbx20, activates a cardiac- specific promoter (atrial natriuretic factor (ANF)) alone and synergistically with other transcription factors. In contrast, Tbx20 represses ANF promoter activity and also inhibits the activation mediated by Tbx5. Of the two T-box binding consensus sequences in the promoter of ANF, only T-box binding element 1 (TBE1) is required for the synergistic activation of ANF by Tbx5 and GATA4, but TBE2 is required for repression by Tbx20. To elucidate upstream signaling pathways that regulate Tbx5 and Tbx20 expression, recombinant bone morphogenetic protein-2 was added to cardiogenic explants from chick embryos. Using real time reverse transcription-PCR, it was demonstrated that Tbx20, but not Tbx5, is induced by bone morphogenetic protein-2. Collectively these data demonstrate clear differences in both the expression and function of two related transcription factors and suggest that the modulation of cardiac gene expression can occur as a result of combinatorial regulatory interactions of T-box proteins.	Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Yutzey, KE (corresponding author), Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, ML 7020,3333 Burnet Ave, Cincinnati, OH 45229 USA.	yutzey@cchmc.org	Plageman, Timothy/C-6638-2013	Plageman, Timothy/0000-0001-6565-2577; Yutzey, Katherine/0000-0002-1444-7124	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066051] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07752, HL66051] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGENTIN S, 1985, J BIOL CHEM, V260, P4568; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Bruneau BG, 1999, DEV BIOL, V211, P100, DOI 10.1006/dbio.1999.9298; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Christoffels VM, 2000, DEV BIOL, V223, P266, DOI 10.1006/dbio.2000.9753; Delot EC, 2003, DEVELOPMENT, V130, P209, DOI 10.1242/dev.00181; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; Ehrman LA, 1999, DEV BIOL, V207, P163, DOI 10.1006/dbio.1998.9167; Fan C, 2003, J BIOL CHEM, V278, P8780, DOI 10.1074/jbc.M208120200; FAN C, 2003, J MED GENET; Firnberg N, 2002, DEV BIOL, V247, P237, DOI 10.1006/dbio.2002.0696; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Garrity DM, 2002, DEVELOPMENT, V129, P4635; Ghosh TK, 2001, HUM MOL GENET, V10, P1983, DOI 10.1093/hmg/10.18.1983; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRIFFIN K, 1995, DEVELOPMENT, V121, P2983; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Houweling AC, 2002, ANAT RECORD, V266, P93, DOI 10.1002/ar.10042; Huang J, 1998, MOL CELL BIOL, V18, P5478, DOI 10.1128/MCB.18.9.5478; Iio A, 2001, DEV GENES EVOL, V211, P559, DOI 10.1007/s00427-001-0187-y; Isaac A, 2000, MECH DEVELOP, V93, P41, DOI 10.1016/S0925-4773(00)00261-6; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; Jiao K, 2003, GENE DEV, V17, P2362, DOI 10.1101/gad.1124803; Kim RY, 2001, DEV BIOL, V235, P449, DOI 10.1006/dbio.2001.0284; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Kraus F, 2001, MECH DEVELOP, V100, P87, DOI 10.1016/S0925-4773(00)00499-8; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Li QY, 1997, NAT GENET, V15, P21; Liberatore CM, 2000, DEV BIOL, V223, P169, DOI 10.1006/dbio.2000.9748; LINCOLN J, 2004, DEV DYN; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; Papaioannou VE, 2001, INT REV CYTOL, V207, P1; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Rodriguez-Esteban C, 1999, NATURE, V398, P814, DOI 10.1038/19769; Ryan Kenneth, 2003, Birth Defects Research, V69, P25, DOI 10.1002/bdrc.10001; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SCHULTEMERKER S, 1995, CURR BIOL, V5, P62, DOI 10.1016/S0960-9822(95)00017-0; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Searcy RD, 1998, DEV DYNAM, V213, P82; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Showell C, 2004, DEV DYNAM, V229, P201, DOI 10.1002/dvdy.10480; Stennard FA, 2003, DEV BIOL, V262, P206, DOI 10.1016/S0012-1606(03)00385-3; Szeto DP, 2002, DEVELOPMENT, V129, P5093; Takeuchi JK, 2003, DEVELOPMENT, V130, P5953, DOI 10.1242/dev.00797; Wilkinson D.G., 1993, ESSENTIAL DEV BIOL P, P257; Yamada M, 2000, DEV BIOL, V228, P95, DOI 10.1006/dbio.2000.9927; Yamagishi T, 1998, ANN NY ACAD SCI, V857, P276, DOI 10.1111/j.1749-6632.1998.tb10131.x; YUTZEY KE, 1995, DEV BIOL, V170, P531, DOI 10.1006/dbio.1995.1234; Zaman Z, 2001, P NATL ACAD SCI USA, V98, P2550, DOI 10.1073/pnas.041611198; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	62	103	106	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19026	19034		10.1074/jbc.M314041200	http://dx.doi.org/10.1074/jbc.M314041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978031	hybrid			2022-12-27	WOS:000221041500115
J	Shao, H; Xu, XJ; Mastrangelo, MAA; Jing, NJ; Cook, RG; Legge, GB; Tweardy, DJ				Shao, H; Xu, XJ; Mastrangelo, MAA; Jing, NJ; Cook, RG; Legge, GB; Tweardy, DJ			Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FACTOR-RECEPTOR; SH2 DOMAINS; HIGH-AFFINITY; EGF RECEPTOR; CELL-TRANSFORMATION; STAT3 ACTIVATION; GENE-REGULATION; INTACT-CELLS; IDENTIFICATION	Stat3 is an Src homology (SH)2-containing protein constitutively activated in a wide variety of human cancers following its recruitment to YXXQ-containing motifs, which results in resistance to apoptosis. Despite resolution of the crystal structure of Stat3 homodimer bound to DNA, the structural basis for the unique specificity of Stat3 SH2 for YXXQ-containing phosphopeptides remains unresolved. We tested three models of this interaction based on computational analysis of available structures and sequence alignments, two of which assumed an extended peptide configuration and one in which the peptide had a beta-turn. By using peptide immunoblot affinity assays and mirror resonance affinity analysis, we demonstrated that only phosphotyrosine (Tyr(P)) peptides containing +3 Gln (not Leu, Met, Glu, or Arg) bound to wild type Stat3. Examination of a series of wild type and mutant Stat3 proteins demonstrated loss of binding to pYXXQ-containing peptides only in Stat3 mutated at Lys-591 or Arg-609, whose side chains interact with the Tyr(P) residue, and Stat3 mutated at Glu-638, whose amide hydrogen bonds with oxygen within the +3 Gln side chain when the peptide ligand assumes a beta-turn. These findings support a model for Stat3 SH2 interactions that could form the basis for anticancer drugs that specifically target Stat3.	Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Univ Houston, Dept Biochem, Houston, TX 77204 USA	Baylor College of Medicine; Baylor College of Medicine; University of Houston System; University of Houston	Tweardy, DJ (corresponding author), Baylor Coll Med, Infect Dis Sect, Dept Med, 1 Baylor Plaza,BCM 286,Rm 1319, Houston, TX 77030 USA.	dtweardy@bcm.tmc.edu	Tweardy, David/L-3929-2019		NCI NIH HHS [R01 CA86430] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086430] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CANTLEY LC, 1994, J CELL SCI, P121; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRANDIS JR, 1993, CANCER RES, V53, P3579; Guruprasad K, 2000, J BIOSCIENCES, V25, P143, DOI 10.1007/BF03404909; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Leatherbarrow R. J, 1998, GRAFIT VERSION 4; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Ogura K, 1999, J MOL BIOL, V289, P439, DOI 10.1006/jmbi.1999.2792; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Ouali M, 2000, PROTEIN SCI, V9, P1162, DOI 10.1110/ps.9.6.1162; Rahuel J, 1998, J MOL BIOL, V279, P1013, DOI 10.1006/jmbi.1998.1790; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; Ren ZY, 2003, BIOORG MED CHEM LETT, V13, P633, DOI 10.1016/S0960-894X(02)01050-8; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Schuenke KW, 1998, HUM IMMUNOL, V59, P783, DOI 10.1016/S0198-8859(98)00072-X; Shao H, 2003, CANCER RES, V63, P3923; Sheinerman FB, 2003, J MOL BIOL, V334, P823, DOI 10.1016/j.jmb.2003.09.075; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Wiederkehr-Adam M, 2003, J BIOL CHEM, V278, P16117, DOI 10.1074/jbc.M300261200; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	41	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18967	18973		10.1074/jbc.M314037200	http://dx.doi.org/10.1074/jbc.M314037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966128	hybrid			2022-12-27	WOS:000221041500108
J	Syme, CD; Nadal, RC; Rigby, SEJ; Viles, JH				Syme, CD; Nadal, RC; Rigby, SEJ; Viles, JH			Copper binding to the amyloid-beta (A beta) peptide associated with Alzheimer's disease - Folding, coordination geometry, pH dependence, stoichiometry, and affinity of A beta-(1-28): Insights from a range of complementary spectroscopic techniques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRION PROTEIN; FREE-RADICALS; STRUCTURAL IMPLICATIONS; SUPEROXIDE-DISMUTASE; CEREBROSPINAL-FLUID; CIRCULAR-DICHROISM; PRECURSOR PROTEIN; HYDROGEN-PEROXIDE; METAL-BINDING; ZINC	There is now direct evidence that copper is bound to amyloid-beta peptide (Abeta) in senile plaque of Alzheimer's disease. Copper is also linked with the neurotoxicity of Abeta and free radical damage, and Cu2+ chelators represent a possible therapy for Alzheimer's disease. We have therefore used a range of complementary spectroscopies to characterize the coordination of Cu2+ to Abeta in solution. The mode of copper binding is highly pH-dependent. EPR spectroscopy indicates that both coppers have axial, Type II coordination geometry, square-planar or square-pyramidal, with nitrogen and oxygen ligands. Circular dichroism studies indicate that copper chelation causes a structural transition of Abeta. Competition studies with glycine and L-histidine indicate that copper binds to Abeta- (1 -28) at pH 7.4 with an affinity of K-a similar to10(7) M-1. H-1 NMR indicates that histidine residues are involved in Cu2+ coordination but that Tyr(10) is not. Studies using analogues of Abeta- (1 - 28) in which each of the histidine residues have been replaced by alanine or in which the N terminus is acetylated suggest that the N terminus and His(13) are crucial for Cu2+ binding and that His(6) and His(14) are also implicated. Evidence for the link between Alzheimer's disease and Cu2+ is growing, and our studies have made a significant contribution to understanding the mode of Cu2+ binding to Abeta in solution.	Univ London, Queen Mary, Sch Biol Sci, London E1 4NS, England	University of London; Queen Mary University London	Viles, JH (corresponding author), Univ London, Queen Mary, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	j.viles@qmul.ac.uk		Syme, Christopher/0000-0002-0913-1141; Nadal, Rebecca/0000-0002-5526-3508				Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Atwood CS, 1999, MET IONS BIOL SYST, V36, P309; Bondy SC, 1998, BRAIN RES, V799, P91, DOI 10.1016/S0006-8993(98)00461-2; Brown AM, 1997, J NEUROCHEM, V69, P1204; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Bush AI, 2003, P NATL ACAD SCI USA, V100, P11193, DOI 10.1073/pnas.2135061100; Bush AI, 2002, NEUROBIOL AGING, V23, P1031, DOI 10.1016/S0197-4580(02)00120-3; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Cuajungco MP, 1997, BRAIN RES REV, V23, P219, DOI 10.1016/S0165-0173(97)00002-7; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Dikalov SI, 1999, J BIOL CHEM, V274, P9392, DOI 10.1074/jbc.274.14.9392; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; FAWCETT TG, 1980, J AM CHEM SOC, V102, P2598, DOI 10.1021/ja00528a013; Garnett AP, 2003, J BIOL CHEM, V278, P6795, DOI 10.1074/jbc.M209280200; Garzon-Rodriguez W, 1999, BIOORG MED CHEM LETT, V9, P2243, DOI 10.1016/S0960-894X(99)00357-1; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HORI F, 1979, B CHEM SOC JPN, V52, P1076, DOI 10.1246/bcsj.52.1076; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kontush A, 2001, FREE RADICAL BIO MED, V31, P1120, DOI 10.1016/S0891-5849(01)00688-8; Kowalik-Jankowska T, 2003, J INORG BIOCHEM, V95, P270, DOI 10.1016/S0162-0134(03)00128-4; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Marx J, 2003, SCIENCE, V301, P905; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; PEISACH J, 1974, ARCH BIOCHEM BIOPHYS, V165, P691, DOI 10.1016/0003-9861(74)90298-7; Roses AD, 1996, CURR OPIN NEUROBIOL, V6, P644, DOI 10.1016/S0959-4388(96)80098-5; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; SIGEL H, 1982, CHEM REV, V82, P385, DOI 10.1021/cr00050a003; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Sparks DL, 2003, P NATL ACAD SCI USA, V100, P11065, DOI 10.1073/pnas.1832769100; Suzuki K, 2001, BIOCHEM BIOPH RES CO, V285, P991, DOI 10.1006/bbrc.2001.5263; TSANGARIS JM, 1970, J AM CHEM SOC, V92, P4255, DOI 10.1021/ja00717a020; VALENTINE JS, 1979, P NATL ACAD SCI USA, V76, P4245, DOI 10.1073/pnas.76.9.4245; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042	47	386	400	1	92	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18169	18177		10.1074/jbc.M313572200	http://dx.doi.org/10.1074/jbc.M313572200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978032	hybrid			2022-12-27	WOS:000221041500011
J	Zlateva, T; Quaroni, L; Que, L; Stankovich, MT				Zlateva, T; Quaroni, L; Que, L; Stankovich, MT			Redox studies of subunit interactivity in aerobic ribonucleotide reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYL RADICAL-DIIRON(III) COFACTOR; PROTEIN R2; DIPHOSPHATE REDUCTASE; FE2+ REACTION; MECHANISM; BINDING; SITE; EPR; GENERATION; KINETICS	Ribonucleotide reductase is a heterodimeric (alpha(2)beta(2)) allosteric enzyme that catalyzes the conversion of ribonucleotides to deoxyribonucleotides, an essential step in DNA biosynthesis and repair. In the enzymatically active form aerobic Escherichia coli ribonucleotide reductase is a complex of homodimeric R1 and R2 proteins. We use electrochemical studies of the dinuclear center to clarify the interplay of subunit interaction, the binding of allosteric effectors and substrate selectivity. Our studies show for the first time that electrochemical reduction of active R2 generates a distinct Met form of the diiron cluster, with a midpoint potential ( - 163 +/- 3 mV) different from that of R2(Met) produced by hydroxyurea ( - 115 +/- 2 mV). The redox potentials of both Met forms experience negative shifts when measured in the presence of R1, becoming - 223 +/- 6 and - 226 +/- 3 mV, respectively, demonstrating that R1-triggered conformational changes favor one configuration of the diiron cluster. We show that the association of a substrate analog and specificity effector (dGDP/dTTP or GMP/dTTP) with R1 regulates the redox properties of the diiron centers in R2. Their midpoint potential in the complex shifts to - 192 +/- 2mV for dGDP/ dTTP and to - 203 +/- 3 mV for GMP/dTTP. In contrast, reduction potential measurements show that the diiron cluster is not affected by ATP (0.35 - 1.45 mM) and dATP (0.3 - 0.6 mM) binding to R1. Binding of these effectors to the R1-R2 complex does not perturb the normal docking modes between R1 and R2 as similar redox shifts are observed for ATP or dATP associated with the R1-R2 complex.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Met Biocatalysis, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Stankovich, MT (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	stankovi@chem.umn.edu	Quaroni, Luca/O-4629-2019; Quaroni, Luca/G-3604-2013; Quaroni, Luca/I-3027-2014	Quaroni, Luca/0000-0002-0225-9775; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029344] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29344] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKES G, 1989, BIOCHEMISTRY-US, V28, P1923, DOI 10.1021/bi00430a074; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; Davydov R, 1996, BIOCHEMISTRY-US, V35, P5571, DOI 10.1021/bi952836y; Dobbing AM, 2000, J AM CHEM SOC, V122, P2206, DOI 10.1021/ja993412k; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; ERIKSSON S, 1983, J BIOL CHEM, V258, P5674; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1990, J BIOL CHEM, V265, P10919; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; GEREZ C, 1992, BIOCHEMISTRY-US, V31, P780, DOI 10.1021/bi00118a020; Han JY, 1996, INORG CHEM, V35, P4629, DOI 10.1021/ic9515012; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3209, DOI 10.1073/pnas.0536684100; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; LARSSON A, 1988, J BIOL CHEM, V263, P17780; Logan DT, 1996, STRUCTURE, V4, P1053, DOI 10.1016/S0969-2126(96)00112-8; Miller MA, 1999, J AM CHEM SOC, V121, P1096, DOI 10.1021/ja9826845; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; RAVI N, 1994, J AM CHEM SOC, V116, P8007, DOI 10.1021/ja00097a007; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SILVA KE, 1995, BIOCHEMISTRY-US, V34, P14093, DOI 10.1021/bi00043a014; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; STANKOVICH MT, 1990, ANAL BIOCHEM, V109, P295; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; THELANDER L, 1973, J BIOL CHEM, V248, P4591; Tong W, 1998, BIOCHEMISTRY-US, V37, P5840, DOI 10.1021/bi9728811; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0	37	4	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18742	18747		10.1074/jbc.M311355200	http://dx.doi.org/10.1074/jbc.M311355200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966112	hybrid			2022-12-27	WOS:000221041500081
J	Thiyagarajan, MM; Stracquatanio, RP; Pronin, AN; Evanko, DS; Benovic, JL; Wedegaertner, PB				Thiyagarajan, MM; Stracquatanio, RP; Pronin, AN; Evanko, DS; Benovic, JL; Wedegaertner, PB			A predicted amphipathic helix mediates plasma membrane localization of GRK5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; RIBOSYLATION FACTOR-1; SPLICE VARIANTS; KINASE GRK5; BETA-GAMMA; PALMITOYLATION; BINDING; DOMAIN; GDP; DESENSITIZATION	G protein-coupled receptor kinases (GRKs) specifically phosphorylate agonist-occupied G protein-coupled receptors at the inner surface of the plasma membrane (PM), leading to receptor desensitization. GRKs utilize a variety of mechanisms to bind tightly, and sometimes reversibly, to cellular membranes. Previous studies demonstrated the presence of a membrane binding domain in the C terminus of GRK5. Here we define a mechanism by which this short C-terminal stretch of amino acids of GRK5 mediates PM localization. Secondary structure predictions suggest that a region contained within amino acids 546 - 565 of GRK5 forms an amphipathic helix, with the key features of the predicted helix being a hydrophobic patch of amino acids on one face of the helix, hydrophilic amino acids on the opposite face, and a number of basic amino acids surrounding the hydrophobic patch. We show that amino acids 546 - 565 of GRK5 are sufficient to target the cytoplasmic green fluorescent protein (GFP) to the PM, and the hydrophobic amino acids are necessary for PM targeting of GFP-546-565. Moreover, full-length GRK5-GFP is localized to the PM, but mutation of the hydrophobic patch or the surrounding basic amino acids prevents PM localization of GRK5-GFP. Last, we show that mutation of the hydrophobic residues severely diminishes phospholipid-dependent autophosphorylation of GRK5 and phosphorylation of membrane-bound rhodopsin by GRK5. The findings in this report thus suggest the presence of a membrane binding motif in GRK5 and define the importance of a group of hydrophobic amino acids within this motif in mediating its PM localization.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St,839 BLSB, Philadelphia, PA 19107 USA.	P_Wedegaertner@mail.jci.tju.edu			NIGMS NIH HHS [GM44944, GM62884, GM56444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM056444, R01GM056444, R55GM056444, R01GM062884, R01GM044944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Firsov D, 1997, AM J PHYSIOL-CELL PH, V273, pC953, DOI 10.1152/ajpcell.1997.273.3.C953; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P3804, DOI 10.1021/bi9923050; Loudon RP, 1997, J BIOL CHEM, V272, P27422, DOI 10.1074/jbc.272.43.27422; Noble B, 2003, J BIOL CHEM, V278, P47466, DOI 10.1074/jbc.M308257200; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; Pronin AN, 1998, J BIOL CHEM, V273, P31510, DOI 10.1074/jbc.273.47.31510; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; Stoffel RH, 1998, BIOCHEMISTRY-US, V37, P16053, DOI 10.1021/bi981432d; Thiyagarajan MM, 2002, BIOCHEMISTRY-US, V41, P9470, DOI 10.1021/bi025533u	29	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17989	17995		10.1074/jbc.M310738200	http://dx.doi.org/10.1074/jbc.M310738200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14976207	hybrid			2022-12-27	WOS:000220870400134
J	Westhoff, CM; Siegel, DL; Burd, CG; Foskett, JK				Westhoff, CM; Siegel, DL; Burd, CG; Foskett, JK			Mechanism of genetic complementation of ammonium transport in yeast by human erythrocyte Rh-associated glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; H+-ATPASE; EXPRESSION; PROTEINS; MEMBRANE; KIDNEY; POLYPEPTIDES; NH3; PH	The Rh blood group proteins are erythrocyte proteins important in neonatal and transfusion medicine. Recent studies have shed new light on the possible biological function of Rh proteins as members of a conserved family of proteins involved in ammonium transport. The erythrocyte Rh-associated glycoprotein (RhAG) mediates uptake of ammonium when expressed in Xenopus laevis oocytes, and functional studies indicate that RhAG might function as an NH4+-H+-exchanger. To further delineate the functional properties of RhAG, in this study we have expressed RhAG in both a Saccharomyces cerevisiae ammonium-transport mutant (mep1Delta mep2Delta mep3Delta) and a wild-type strain. RhAG was able to complement the transport mutant, with complementation strictly pH-dependent, requiring pH 6.2-6.5. RhAG also conferred resistance to methylamine (MA), a toxic analog of ammonium, and expression in wild-type cells revealed that resistance was correlated with efflux of MA. RhAG-mediated resistance was pH-dependent, being optimal at acid pH. The opposite pH dependence of ammonium complementation (uptake) and MA resistance (efflux) is consistent with bidirectional movement of substrate counter to the direction of the proton gradient. This report clarifies and expands previous observations of RhAG-mediated transport in yeast and supports the hypothesis that ammonium transport is coupled to the H+ gradient and that RhAG functions as a NH4+/H+ exchanger.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Westhoff, CM (corresponding author), 510 Stellar Chance, Philadelphia, PA 19104 USA.	westhoff@mail.med.upenn.edu	Foskett, Kevin/R-2549-2019	Burd, Christopher/0000-0003-1831-8706; Foskett, J. Kevin/0000-0002-8854-0268	NIDDK NIH HHS [DK02751] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002751] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carmelo V, 1996, ARCH MICROBIOL, V166, P315, DOI 10.1007/s002030050389; CIMPRICH P, 1995, FEMS MICROBIOL LETT, V130, P245; Eladari D, 2002, J AM SOC NEPHROL, V13, P1999, DOI 10.1097/01.ASN.0000025280.02386.9D; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; KANE PM, 1995, J BIOL CHEM, V270, P17025; KLEINER D, 1981, BIOCHIM BIOPHYS ACTA, V639, P41, DOI 10.1016/0304-4173(81)90004-5; Liu Z, 2000, J BIOL CHEM, V275, P25641, DOI 10.1074/jbc.M003353200; Liu Z, 2001, J BIOL CHEM, V276, P1424, DOI 10.1074/jbc.M007528200; Lorenz MC, 1998, GENETICS, V150, P1443; MALLINSON G, 1990, TRANSFUSION, V30, P222, DOI 10.1046/j.1537-2995.1990.30390194341.x; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Race RR., 1975, BLOOD GROUPS MAN; ROON RJ, 1975, J BACTERIOL, V122, P502, DOI 10.1128/JB.122.2.502-509.1975; Serrano R., 1991, MOL CELLULAR BIOL YE, P523; Soupene E, 2001, MOL CELL BIOL, V21, P5733, DOI 10.1128/MCB.21.17.5733-5741.2001; Verlander JW, 2003, AM J PHYSIOL-RENAL, V284, pF323, DOI 10.1152/ajprenal.00050.2002; von Wiren N, 2000, CURR OPIN PLANT BIOL, V3, P254, DOI 10.1016/S1369-5266(00)00073-X; Weiner ID, 2003, ACTA PHYSIOL SCAND, V179, P331, DOI 10.1046/j.0001-6772.2003.01210.x; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200	21	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17443	17448		10.1074/jbc.M311853200	http://dx.doi.org/10.1074/jbc.M311853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966114	hybrid			2022-12-27	WOS:000220870400070
J	Avisar, D; Keller, M; Gazit, E; Prudovsky, E; Sneh, B; Zilberstein, A				Avisar, D; Keller, M; Gazit, E; Prudovsky, E; Sneh, B; Zilberstein, A			The role of Bacillus thuringiensis Cry1C and Cry1E separate structural domains in the interaction with Spodoptera littoralis gut epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; MIDGUT AMINOPEPTIDASE-N; DELTA-ENDOTOXIN; MANDUCA-SEXTA; HELIOTHIS-VIRESCENS; INSECTICIDAL TOXIN; PORE FORMATION; CRYSTAL-STRUCTURE; LOOP 2; BINDING	The Bacillus thuringiensis delta-endotoxins Cry1C and Cry1E share toxicity against several important lepidopteran species. Their combined use to delay development of resistance in target insects depends on their differential interaction with the gut epithelial cells. The three structural domains and combinations of two consecutive domains of Cry1C and Cry1E were separately expressed in Escherichia coli, and their interactions with the brush border membrane vesicles (BBMV) of Cry1E-tolerant and -susceptible Spodoptera littoralis larvae were studied. About 80% reduction in binding of Cry1E and each of its separate domains to BBMV of Cry1E-tolerant larvae was observed, whereas Cry1C was toxic to all larvae and bound equally to BBMV derived from both Cry1E-tolerant and -susceptible larvae. These results suggest differential interactions of the two toxins with BBMV encompassing all three domains. Comparable binding assays performed with fluorescent Cry1C and Cry1C domain II showed that Cry1C has higher B-max and lower K-d than Cry1C domain II and further supported the existence of toxin multisite interactions. Competitive binding assays were used to estimate the sequence of interaction events. Cry1C domain II could compete with domain III binding, whereas domain III did not interfere with domain II binding, indicating sequential interactions of domain III and then domain II with the same membrane site. No competition between domain II of Cry1C and Cry1E was observed, confirming the existence of different domain II binding sites for the two toxins. Taken together, all three domains specifically interact with the epithelial cell membrane. The folding of the three-domain toxin probably dictates the sequence of interaction events.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Agr Res Org, Volcani Ctr, Dept Field & Garden Crops, IL-50250 Bet Dagan, Israel	Tel Aviv University; Tel Aviv University; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Zilberstein, A (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel.	aviah@post.tau.ac.il	Gazit, Ehud/M-8026-2019; Gazit, Ehud/C-3715-2011; Gazit, Ehud/AHE-9332-2022	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; 				Abdul-Rauf M, 1999, CURR MICROBIOL, V39, P94, DOI 10.1007/s002849900425; Agrawal N, 2002, APPL ENVIRON MICROB, V68, P4583, DOI 10.1128/AEM.68.9.4583-4592.2002; Aronson AI, 2001, FEMS MICROBIOL LETT, V195, P1, DOI 10.1111/j.1574-6968.2001.tb10489.x; Banks DJ, 2003, INSECT BIOCHEM MOLEC, V33, P499, DOI 10.1016/S0965-1748(03)00022-5; Burton SL, 1999, J MOL BIOL, V287, P1011, DOI 10.1006/jmbi.1999.2649; Coux F, 2001, J BIOL CHEM, V276, P35546, DOI 10.1074/jbc.M101887200; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; de Maagd RA, 1999, MOL MICROBIOL, V31, P463, DOI 10.1046/j.1365-2958.1999.01188.x; de Maagd RA, 2000, APPL ENVIRON MICROB, V66, P1559, DOI 10.1128/AEM.66.4.1559-1563.2000; Denolf P, 1997, EUR J BIOCHEM, V248, P748, DOI 10.1111/j.1432-1033.1997.t01-1-00748.x; Dorsch JA, 2002, INSECT BIOCHEM MOLEC, V32, P1025, DOI 10.1016/S0965-1748(02)00040-1; Flores H, 1997, FEBS LETT, V414, P313, DOI 10.1016/S0014-5793(97)01015-6; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gomez I, 2003, BIOCHEMISTRY-US, V42, P10482, DOI 10.1021/bi034440p; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Hara H, 2003, FEBS LETT, V538, P29, DOI 10.1016/S0014-5793(03)00117-0; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; Jenkins JL, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-12; Jenkins JL, 2000, J BIOL CHEM, V275, P14423, DOI 10.1074/jbc.275.19.14423; Jurat-Fuentes JL, 2001, APPL ENVIRON MICROB, V67, P323, DOI 10.1128/AEM.67.1.323-329.2001; Keller M, 1996, INSECT BIOCHEM MOLEC, V26, P365, DOI 10.1016/0965-1748(95)00102-6; Lee MK, 2000, MOL MICROBIOL, V38, P289, DOI 10.1046/j.1365-2958.2000.02109.x; Lee MK, 1999, APPL ENVIRON MICROB, V65, P4513; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LIANG YZ, 1995, J BIOL CHEM, V270, P24719, DOI 10.1074/jbc.270.42.24719; Luo K, 1996, INSECT BIOCHEM MOLEC, V26, P783, DOI 10.1016/S0965-1748(96)00027-6; Luo K, 1999, APPL ENVIRON MICROB, V65, P457; Masson L, 1999, J BIOL CHEM, V274, P31996, DOI 10.1074/jbc.274.45.31996; MOAR WJ, 1995, APPL ENVIRON MICROB, V61, P2086, DOI 10.1128/AEM.61.6.2086-2092.1995; Morse RJ, 2001, STRUCTURE, V9, P409, DOI 10.1016/S0969-2126(01)00601-3; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Oltean DI, 1999, APPL ENVIRON MICROB, V65, P4760; Rajagopal R, 2002, J BIOL CHEM, V277, P46849, DOI 10.1074/jbc.C200523200; Rang C, 1999, APPL ENVIRON MICROB, V65, P2918; Schwartz JL, 1997, FEBS LETT, V412, P270, DOI 10.1016/S0014-5793(97)00801-6; Simpson RM, 2000, INSECT BIOCHEM MOLEC, V30, P1069, DOI 10.1016/S0965-1748(00)00082-5; Strizhov N, 1996, MOL GEN GENET, V253, P11, DOI 10.1007/s004380050290; Strizhov N, 1996, P NATL ACAD SCI USA, V93, P15012, DOI 10.1073/pnas.93.26.15012; Vachon V, 2002, BIOCHEMISTRY-US, V41, P6178, DOI 10.1021/bi011572e; Vie V, 2001, J MEMBRANE BIOL, V180, P195, DOI 10.1007/s002320010070; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; Zhao JZ, 2000, APPL ENVIRON MICROB, V66, P3784, DOI 10.1128/AEM.66.9.3784-3789.2000; Zhao JZ, 2003, NAT BIOTECHNOL, V21, P1493, DOI 10.1038/nbt907; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	45	14	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15779	15786		10.1074/jbc.M312597200	http://dx.doi.org/10.1074/jbc.M312597200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14963036	hybrid			2022-12-27	WOS:000220747900012
J	Bradley, AL; Chobot, SE; Arciero, DM; Hooper, AB; Elliott, SJ				Bradley, AL; Chobot, SE; Arciero, DM; Hooper, AB; Elliott, SJ			A distinctive electrocatalytic response from the cytochrome c peroxidase of Nitrosomonas europaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-FILM VOLTAMMETRY; PSEUDOMONAS-AERUGINOSA; CATALASE-PEROXIDASES; CRYSTAL-STRUCTURE; REDUCTION; OXIDATION; ENZYMES; STATES; MUTANT; HEMES	Here the cytochrome c peroxidase (CcP) from Nitrosomonas europaea is examined using the technique of catalytic protein film voltammetry. Submonolayers of the bacterial diheme enzyme at a pyrolytic graphite edge electrode give catalytic, reductive signals in the presence of the substrate hydrogen peroxide. The resulting waveshapes indicate that CcP is bound non-covalently in a highly active configuration. The native enzyme has been shown to possess two heme groups of low and high potential ( L and H, - 260 and + 450 mV versus hydrogen, respectively), and here we find that the catalytic waves of the N. europaea enzyme have a midpoint potential of > 500 mV and a shape that corresponds to a 1-electron process. The signals increase in magnitude with hydrogen peroxide concentration, revealing Michaelis-Menten kinetics and K-m = 55 muM. The midpoint potentials shift with substrate concentration, indicating the electrochemically active species observed in our data corresponds to a catalytic species. The potentials also shift with respect to pH, and the pH dependence is interpreted in terms of a two pK(a) model for proton binding. Together the data show that the electrochemistry of the N. europaea cytochrome c peroxidase is unlike other peroxidases studied to date, including other bacterial enzymes. This is discussed in terms of a catalytic model for the N. europaea enzyme and compared with other cytochrome c peroxidases.	Boston Univ, Dept Chem, Boston, MA 02215 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA	Boston University; University of Minnesota System; University of Minnesota Twin Cities	Elliott, SJ (corresponding author), Boston Univ, Dept Chem, 590 Commonwealth Ave, Boston, MA 02215 USA.	elliott@bu.edu		Hokanson, Sarah Chobot/0000-0002-7348-4312; Elliott, Sean/0000-0003-0096-9551	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072663] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM072663-01A1, R01 GM072663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alves T, 1999, BBA-PROTEIN STRUCT M, V1434, P248, DOI 10.1016/S0167-4838(99)00188-0; ARCIERO DM, 1994, J BIOL CHEM, V269, P11878; Armstrong FA, 1997, CHEM SOC REV, V26, P169, DOI 10.1039/cs9972600169; Battistuzzi G, 2001, ARCH BIOCHEM BIOPHYS, V388, P100, DOI 10.1006/abbi.2001.2281; BRETON JL, 1995, EUR J BIOCHEM, V233, P937, DOI 10.1111/j.1432-1033.1995.937_3.x; CLARK HW, 1960, OXIDATION REDUCTION; COLLINS MJ, 1993, J BIOL CHEM, V268, P14655; ELLFOLK N, 1983, BIOCHIM BIOPHYS ACTA, V743, P23, DOI 10.1016/0167-4838(83)90413-2; Elliott SJ, 2004, BIOCHEMISTRY-US, V43, P799, DOI 10.1021/bi035869j; Elliott SJ, 2002, J AM CHEM SOC, V124, P11612, DOI 10.1021/ja027776f; Fulop V, 2001, ADV INORG CHEM, V51, P163; FULOP V, 1995, STRUCTURE, V3, P1225, DOI 10.1016/S0969-2126(01)00258-1; GILMOUR R, 1994, BIOCHEM J, V300, P907, DOI 10.1042/bj3000907; GREENWOOD C, 1988, CHEM SCRIPTA, V28A, P79; Hu W, 1998, EUR J BIOCHEM, V258, P29, DOI 10.1046/j.1432-1327.1998.2580029.x; Isaac IS, 1999, ESSAYS BIOCHEM, V34, P51, DOI 10.1042/bse0340051; Leger C, 2003, BIOCHEMISTRY-US, V42, P8653, DOI 10.1021/bi034789c; Lopes H, 1998, J BIOL INORG CHEM, V3, P632, DOI 10.1007/s007750050277; Mondal MS, 1998, J AM CHEM SOC, V120, P6270, DOI 10.1021/ja980197j; Mondal MS, 1996, J AM CHEM SOC, V118, P263, DOI 10.1021/ja952489f; Redaelli C, 2002, CHEMBIOCHEM, V3, P226, DOI 10.1002/1439-7633(20020301)3:2/3<226::AID-CBIC226>3.0.CO;2-7; Shimizu H, 2001, BIOCHEMISTRY-US, V40, P13483, DOI 10.1021/bi011481h; Timoteo CG, 2003, J BIOL INORG CHEM, V8, P29, DOI 10.1007/s00775-002-0382-y; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Zamocky M, 2000, GENE, V256, P169, DOI 10.1016/S0378-1119(00)00358-9	25	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13297	13300		10.1074/jbc.C400026200	http://dx.doi.org/10.1074/jbc.C400026200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14973133	hybrid			2022-12-27	WOS:000220478500004
J	Huang, W; Dedousis, N; Bhatt, BA; O'Doherty, RM				Huang, W; Dedousis, N; Bhatt, BA; O'Doherty, RM			Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; REVERSES INSULIN-RESISTANCE; SKELETAL-MUSCLE; RECEPTOR; TRIGLYCERIDE; MICE; RATS; PHOSPHODIESTERASE; HYPOTHALAMUS; STIMULATION	Obesity is associated with the development of leptin resistance. However, the effects of leptin resistance on leptin- regulated metabolic processes and the biochemical defects that cause leptin resistance are poorly understood. We have addressed in rats the effect of diet-induced obesity ( DIO), a situation of elevated tissue lipid levels, on the well described lipid- lowering effect of leptin in liver, an action that is proposed to be important for the prevention of tissue lipotoxicity and insulin resistance. In addition, we have addressed the role of phosphatidylinositol 3- kinase ( PI 3- kinase) in mediating the acute effects of leptin on hepatic lipid levels in lean and DIO animals. A 90- min leptin ( similar to 10 ng/ ml) perfusion of isolated livers from lean animals decreased triglyceride levels by 42 +/- 5% ( p = 0.006). However, leptin concentrations ranging from similar to 10 to similar to 90 ng/ ml had no effect on triglyceride levels in livers from DIO animals. The acute lipid- lowering effect of leptin on livers from lean animals was mediated by a PI 3- kinase- dependent mechanism, because wortmannin and LY294002, the PI 3- kinase inhibitors, blocked the effects of leptin on hepatic triglyceride levels and leptin increased liver PI 3- kinase activity by 183 +/- 6% ( p = 0.003) and insulin receptor substrate 1 tyrosine phosphorylation by 185 +/- 30% ( p = 0.02) in the absence of PI 3- kinase inhibitors. Contrary to the effects of leptin in lean livers, leptin did not activate PI 3- kinase in livers from DIO rats. These data present evidence for a role for 1) leptin resistance in contributing to the excessive accumulation of tissue lipid in obesity, 2) PI 3- kinase in mediating the acute lipid- lowering effects of leptin in liver, and 3) defective leptin activation of PI 3- kinase as a novel mechanism of leptin resistance.	Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	O'Doherty, RM (corresponding author), Univ Pittsburgh, Med Ctr, Dept Med, E1112 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	odohertyr@msx.dept-med.pitt.edu			NIDDK NIH HHS [R01 DK58855-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058855] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Anderwald C, 2002, MOL ENDOCRINOL, V16, P1612, DOI 10.1210/me.16.7.1612; Atkinson LL, 2002, J BIOL CHEM, V277, P29424, DOI 10.1074/jbc.M203813200; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bryson JM, 1999, AM J PHYSIOL-ENDOC M, V277, pE417, DOI 10.1152/ajpendo.1999.277.3.E417; Buettner R, 2000, AM J PHYSIOL-ENDOC M, V278, pE563, DOI 10.1152/ajpendo.2000.278.3.E563; Burcelin R, 1999, DIABETES, V48, P1264, DOI 10.2337/diabetes.48.6.1264; Cases JA, 2001, DIABETES, V50, P348, DOI 10.2337/diabetes.50.2.348; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; FRIEDMAN JM, 2002, NUTR REV, V84, P85; GORES GJ, 1986, HEPATOLOGY, V6, P511, DOI 10.1002/hep.1840060331; Grundy SM, 2000, ENDOCRINE, V13, P155, DOI 10.1385/ENDO:13:2:155; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON RL, 1974, J LIPID RES, V15, P182; HIDAKA H, 1984, ADV CYCLIC NUCL PROT, V16, P245; Hoggard N, 1997, BIOCHEM BIOPH RES CO, V232, P383, DOI 10.1006/bbrc.1997.6245; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kelley DE, 2002, ANNU REV NUTR, V22, P325, DOI 10.1146/annurev.nutr.22.010402.102912; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS516; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Lee Y, 2001, J BIOL CHEM, V276, P5629, DOI 10.1074/jbc.M008553200; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Meijer D K, 1981, Methods Enzymol, V77, P81; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Muoio DM, 2002, BEST PRACT RES CL EN, V16, P653, DOI 10.1053/beem.2002.0223; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; O'Doherty RM, 1999, AM J PHYSIOL-ENDOC M, V277, pE544, DOI 10.1152/ajpendo.1999.277.3.E544; Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI [10.1172/JCI0215001, 10.1172/JCI200215001]; Rizk NM, 2001, ENDOCRINOLOGY, V142, P3027, DOI 10.1210/en.142.7.3027; Roden M, 2000, HEPATOLOGY, V32, P1045, DOI 10.1053/jhep.2000.18712; Sahu A, 2002, J NEUROENDOCRINOL, V14, P887, DOI 10.1046/j.1365-2826.2002.00856.x; SCHMUCKER DL, 1975, LAB INVEST, V33, P168; Sebokova E, 2003, DIABETES, V52, pA302; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Simha V, 2003, DIABETES CARE, V26, P30, DOI 10.2337/diacare.26.1.30; Steinberg GR, 2000, AM J PHYSIOL-ENDOC M, V279, pE1374, DOI 10.1152/ajpendo.2000.279.6.E1374; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V283, pE187, DOI 10.1152/ajpendo.00542.2001; Unger RH, 2003, ANNU REV PHYSIOL, V65, P333, DOI 10.1146/annurev.physiol.65.092101.142622; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Wang JL, 2001, DIABETES, V50, P2786, DOI 10.2337/diabetes.50.12.2786; Wang ZW, 1999, BIOCHEM BIOPH RES CO, V260, P653, DOI 10.1006/bbrc.1999.0918; Wang ZW, 1999, P NATL ACAD SCI USA, V96, P10373, DOI 10.1073/pnas.96.18.10373; Yaspelkis BB, 2001, AM J PHYSIOL-ENDOC M, V280, pE130, DOI 10.1152/ajpendo.2001.280.1.E130; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	55	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21695	21700		10.1074/jbc.M401546200	http://dx.doi.org/10.1074/jbc.M401546200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14993225	hybrid			2022-12-27	WOS:000221417100003
J	Relic, B; Benoit, R; Franchimont, N; Ribbens, C; Kaiser, MJ; Gillet, P; Merville, MP; Bours, V; Malaise, MG				Relic, B; Benoit, R; Franchimont, N; Ribbens, C; Kaiser, MJ; Gillet, P; Merville, MP; Bours, V; Malaise, MG			15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; NITRIC-OXIDE; EXPERIMENTAL OSTEOARTHRITIS; TRANSCRIPTION FACTORS; GAMMA AGONISTS; IN-VIVO; PATHWAYS; ERK; GROWTH	We have previously shown that nuclear factor-kappaB inhibition by adenovirus expressing mutated IkappaB-alpha or by proteasome inhibitor increases human articular chondrocytes sensibility to apoptosis. Moreover, the nuclear factor-kappaB inhibitor BAY11-7085, a potent anti-inflammatory drug in rat adjuvant arthritis, is itself a proapoptotic agent for chondrocytes. In this work, we show that BAY 11-7085 but not the proteasome inhibitor MG-132 induced a rapid and sustained phosphorylation of extracellular signal-regulated kinases (ERK1/2) in human articular chondrocytes. The level of ERK1/2 phosphorylation correlated with BAY 11-7085 concentration and chondrocyte apoptosis. 15-Deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) and its precursor prostaglandin (PG) D2 but not PGE2 and PGF2alpha rescued chondrocytes from BAY 11-7085-induced apoptosis. 15d-PGJ2 markedly inhibited BAY 11-7085-induced phosphorylation of ERK1/2. BAY 11-7085 also induced ERK1/2 phosphorylation and apoptosis in human synovial fibroblasts, and these reactions were down-regulated by 15d-PGJ2. Further analysis in synovial fibroblasts showed that only molecules that suppressed BAY 11-7085-induced phosphorylation of ERK1/2 (i.e. 15d-PGJ2, PGD2, and to a lesser extent, MEK1/2 inhibitor UO126, but not prostaglandins E2 and F2alpha or peroxisome proliferator-activated receptor-gamma agonist ciglitazone) were able protect cells from apoptosis. These results suggested that the antiapoptotic effect of 15d-PGJ2 on chondrocytes and synovial fibroblasts might involve inhibition of ERK1/2 phosphorylation.	Univ Liege, Ctr Cellular & Mol Therapy, B-4000 Liege, Belgium; Univ Liege, Dept Orthoped Surg, B-4000 Liege, Belgium	University of Liege; University of Liege	Malaise, MG (corresponding author), CHU Sart Tilman B35, Dept Rheumatol, B-4000 Liege, Belgium.	michel.malaise@ulg.ac.be		BENOIT, Valerie/0000-0002-1098-9452				Aigner T, 2002, ARTHRITIS RHEUM-US, V46, P1986, DOI 10.1002/art.10554; Aoun P, 2003, EUR J PHARMACOL, V472, P65, DOI 10.1016/S0014-2999(03)01867-3; Asada S, 2001, INFLAMM RES, V50, P19, DOI 10.1007/s000110050719; Bapat S, 2001, FEBS LETT, V499, P21, DOI 10.1016/S0014-5793(01)02511-X; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Boyault S, 2001, FEBS LETT, V501, P24, DOI 10.1016/S0014-5793(01)02614-X; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Calabrese C, 2003, J BIOL CHEM, V278, P24951, DOI 10.1074/jbc.M211600200; Choi YJ, 2003, BIOCHEM BIOPH RES CO, V305, P176, DOI 10.1016/S0006-291X(03)00719-8; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kim HA, 2002, BIOCHEM BIOPH RES CO, V295, P937, DOI 10.1016/S0006-291X(02)00789-1; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pelletier JP, 2003, ARTHRITIS RHEUM-US, V48, P1582, DOI 10.1002/art.11014; Pelletier JP, 2001, J RHEUMATOL, V28, P2509; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Relic B, 2002, LAB INVEST, V82, P1661, DOI 10.1097/01.LAB.0000041714.05322.C0; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Subramaniam S, 2003, J BIOL CHEM, V278, P8904, DOI 10.1074/jbc.M210037200; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Tsubouchi Y, 2001, BIOCHEM BIOPH RES CO, V283, P750, DOI 10.1006/bbrc.2001.4847; van der Kraan PM, 2002, OSTEOARTHR CARTILAGE, V10, P631, DOI 10.1053/joca.2002.0806; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Ward C, 2002, J IMMUNOL, V168, P6232, DOI 10.4049/jimmunol.168.12.6232; Xiao D, 2002, CANCER RES, V62, P3615; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Zheng B, 2003, BLOOD, V102, P1019, DOI 10.1182/blood-2002-11-3507; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	36	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22399	22403		10.1074/jbc.M314118200	http://dx.doi.org/10.1074/jbc.M314118200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15004016	hybrid			2022-12-27	WOS:000221417100088
J	Casalino-Matsuda, SM; Monzon, ME; Conner, GE; Salathe, M; Forteza, RM				Casalino-Matsuda, SM; Monzon, ME; Conner, GE; Salathe, M; Forteza, RM			Role of hyaluronan and reactive oxygen species in tissue kallikrein-mediated epidermal growth factor receptor activation in human airways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING-ENZYME; MUCIN SYNTHESIS; EXPRESSION; EGF; INCREASES; ACID; INFLAMMATION; MECHANISMS; RESPONSES; LIGANDS	In human airways, oxidative stress-induced submucosal gland cell hypertrophy and hyperplasia, histological features of chronic bronchitis, have been linked to epidermal growth factor receptor ( EGFR) activation. To explore mechanisms of oxidative stress-induced EGFR activation and signaling, primary cultures of human tracheal submucosal gland (SMG) cells were used to assess EGFR ligand release, EGFR phosphorylation, p44/42 MAPK phosphorylation, and mucin 5AC synthesis in response to reactive oxygen species generated by xanthine/ xanthine oxidase (X/XO). Exposure to X/XO increased release of epidermal growth factor (EGF) from these cells, thereby activating EGFR, phosphorylating MAPK, and increasing mucin 5AC production. The importance of EGF was confirmed by transfection of small interfering RNA inhibiting pro-EGF production, which resulted in inhibition of EGFR and MAPK phosphorylation despite X/XO exposure. Blocking signaling by using specific protease inhibitors showed that tissue kallikrein (TK) processed pro-EGF in response to X/XO. Airway TK is bound and inactivated by luminal hyaluronan ( HA), and treatment of submucosal gland cells with X/XO induced HA depolymerization and TK activation. These events were blocked by reactive oxygen species scavengers and addition of exogenous excess HA and TK inhibitors. Thus, HA plays a crucial role in regulating airway TK activity and thereby TK-mediated release of active EGF from human SMG cells. Sustained HA depolymerization is expected to cause TK activation, EGF release, and EGFR signaling and to lead to SMG cell hypertrophy and hyperplasia as well as mucus hypersecretion with subsequent airflow obstruction.	Univ Miami, Sch Med, Div Pulm & Crit Care Med R47, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	University of Miami; University of Miami	Forteza, RM (corresponding author), Univ Miami, Sch Med, Div Pulm & Crit Care Med R47, 1600 NW 10th Ave,RMSB 7072A, Miami, FL 33136 USA.	rforteza@miami.edu	Matsuda, Marina/AAH-2959-2019; Conner, Gregory/AAI-1285-2021	Matsuda, Marina/0000-0002-7566-4560; Conner, Gregory/0000-0003-2217-2252; Salathe, Matthias/0000-0001-9092-4861	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073156, R01HL060644, R01HL066125, R01HL068992] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60644, HL 68992, HL 73156, HL 66125] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agren UM, 1997, FREE RADICAL BIO MED, V23, P996, DOI 10.1016/S0891-5849(97)00098-1; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BALAZS EA, 1967, ARTHRITIS RHEUM, V10, P357, DOI 10.1002/art.1780100407; Basbaum C, 2002, NOVART FDN SYMP, V248, P171; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; BASBAUM C, 2002, NOVART FDN SYMP, V180, P277; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BRAY BA, 1994, EXP LUNG RES, V20, P317, DOI 10.3109/01902149409064390; Cagliari CI, 2003, BIOCHEM BIOPH RES CO, V311, P241, DOI 10.1016/j.bbrc.2003.09.203; Calabro A, 2000, GLYCOBIOLOGY, V10, P283, DOI 10.1093/glycob/10.3.283; Chan H, 1998, PROTEIN EXPRES PURIF, V12, P361, DOI 10.1006/prep.1997.0854; CHOW CK, 1993, ANN NY ACAD SCI, V686, P289, DOI 10.1111/j.1749-6632.1993.tb39189.x; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; Comhair SAA, 2002, AM J PHYSIOL-LUNG C, V283, pL246, DOI 10.1152/ajplung.00491.2001; Davies JR, 2002, NOVART FDN SYMP, V248, P76; DAVIES JR, 2002, NOVART FDN SYMP, V93, P277; Forteza R, 2001, FASEB J, V15, P2179, DOI 10.1096/fj.01-0036com; Forteza R, 1999, AM J RESP CELL MOL, V21, P666, DOI 10.1165/ajrcmb.21.6.3651; Garach-Jehoshua O, 1999, ENDOCRINOLOGY, V140, P713, DOI 10.1210/en.140.2.713; GEIGER R, 1988, METHOD ENZYMOL, V163, P102; HALLIWELL B, 1988, FASEB J, V2, P2867, DOI 10.1096/fasebj.2.13.2844616; Hisaka T, 1999, INT J ONCOL, V14, P453; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JAHNKE GD, 1994, ENDOCRINOLOGY, V135, P2022, DOI 10.1210/en.135.5.2022; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; JORGENSEN PE, 1991, BIOCHIM BIOPHYS ACTA, V1074, P284, DOI 10.1016/0304-4165(91)90165-D; JORGENSEN PE, 1994, GROWTH FACTORS, V11, P113, DOI 10.3109/08977199409001053; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; MacNee W, 2001, NOVART FDN SYMP, V234, P169; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATSUMURA G, 1966, RADIAT RES, V28, P735, DOI 10.2307/3572179; Miyazaki Y, 1996, BIOCHEM BIOPH RES CO, V226, P542, DOI 10.1006/bbrc.1996.1391; Nadel JA, 2000, CHEST, V117, p262S, DOI 10.1378/chest.117.5_suppl_1.262S-a; Neelam B, 1998, BIOCHEMISTRY-US, V37, P4884, DOI 10.1021/bi972548x; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; PROUD D, 1993, AM J RESP CELL MOL, V8, P16, DOI 10.1165/ajrcmb/8.1.16; SPURZEM JR, 1991, CHEST, V100, P389, DOI 10.1378/chest.100.2.389; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Takeyama K, 2000, J IMMUNOL, V164, P1546, DOI 10.4049/jimmunol.164.3.1546; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165, DOI 10.1152/ajplung.2001.280.1.L165; TREVISANI L, 1992, RESPIRATION, V59, P136; Zhang M, 1997, EUR RESPIR J, V10, P1747, DOI 10.1183/09031936.97.10081747	48	58	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21606	21616		10.1074/jbc.M309950200	http://dx.doi.org/10.1074/jbc.M309950200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14988406	hybrid			2022-12-27	WOS:000221273800127
J	Hua, QX; Weiss, MA				Hua, QX; Weiss, MA			Mechanism of insulin fibrillation - The structure of insulin under amyloidogenic conditions resembles a protein-folding intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY SYSTEMIC AMYLOIDOSIS; RECEPTOR-BINDING SURFACE; CRYSTAL-STRUCTURE; HUMAN LYSOZYME; FIBRILS; HEXAMER; ANALOG; RESOLUTION; TRANSTHYRETIN; SPECTROSCOPY	Insulin undergoes aggregation-coupled misfolding to form a cross-beta assembly. Such fibrillation has long complicated its manufacture and use in the therapy of diabetes mellitus. Of interest as a model for disease-associated amyloids, insulin fibrillation is proposed to occur via partial unfolding of a monomeric intermediate. Here, we describe the solution structure of human insulin under amyloidogenic conditions (pH 2.4 and 60degreesC). Use of an enhanced sensitivity cryogenic probe at high magnetic field avoids onset of fibrillation during spectral acquisition. A novel partial fold is observed in which the N-terminal segments of the A- and B-chains detach from the core. Unfolding of the N-terminal alpha-helix of the A- chain exposes a hydrophobic surface formed by native-like packing of the remaining alpha-helices. The C-terminal segment of the B-chain, although not well ordered, remains tethered to this partial helical core. We propose that detachment of N-terminal segments makes possible aberrant protein-protein interactions in an amyloidogenic nucleus. Non-cooperative unfolding of the N-terminal A-chain alpha-helix resembles that observed in models of proinsulin folding intermediates and foreshadows the extensive alpha-->beta transition characteristic of mature fibrils.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Weiss, MA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	michael.weiss@case.edu			NIDDK NIH HHS [R01 DK 054622] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054622] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad A, 2003, BIOCHEMISTRY-US, V42, P11404, DOI 10.1021/bi034868o; Arai M, 2000, ADV PROTEIN CHEM, V53, P209; BADGER J, 1991, ACTA CRYSTALLOGR B, V47, P127, DOI 10.1107/S0108768190009570; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; Baldwin RL, 1997, NAT STRUCT BIOL, V4, P965, DOI 10.1038/nsb1297-965; Bao SJ, 1997, P NATL ACAD SCI USA, V94, P2975, DOI 10.1073/pnas.94.7.2975; BENTLEY G, 1976, NATURE, V261, P166, DOI 10.1038/261166a0; BI RC, 1984, BIOPOLYMERS, V23, P391, DOI DOI 10.1002/BIP.360230302; BLUNDELL TL, 1971, NATURE, V231, P506, DOI 10.1038/231506a0; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bouchard M, 2000, PROTEIN SCI, V9, P1960, DOI 10.1110/ps.9.10.1960; BRADER ML, 1991, TRENDS BIOCHEM SCI, V16, P341; Brange I., 1987, GALENICS INSULIN PHY; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; Brange J, 1997, J PHARM SCI, V86, P517, DOI 10.1021/js960297s; Brange J, 1997, PROTEINS, V27, P507, DOI 10.1002/(SICI)1097-0134(199704)27:4<507::AID-PROT4>3.3.CO;2-H; Brange J, 1997, DIABETOLOGIA, V40, pS48, DOI 10.1007/s001250051400; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; Chang XQ, 1997, BIOCHEMISTRY-US, V36, P9409, DOI 10.1021/bi9631069; DAI JB, 1987, SCI CHINA SER B, V30, P55; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; Diao JS, 1997, ACTA CRYSTALLOGR D, V53, P507, DOI 10.1107/S0907444997004034; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2001, BIOCHEM SOC SYMP, V68, P1; Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7; Dong J, 2003, J MOL BIOL, V330, P431, DOI 10.1016/S0022-2836(03)00536-9; FESIK SW, 1990, Q REV BIOPHYS, V23, P97, DOI 10.1017/S0033583500005515; Hawkins PN, 2003, J NEPHROL, V16, P443; Hirschfield GM, 2003, INT J BIOCHEM CELL B, V35, P1608, DOI 10.1016/S1357-2725(03)00169-9; HUA QX, 1991, BIOCHEMISTRY-US, V30, P5505, DOI 10.1021/bi00236a025; Hua QX, 2003, GENE DEV, V17, P826, DOI 10.1101/gad.1058003; Hua QX, 2002, BIOCHEMISTRY-US, V41, P14700, DOI 10.1021/bi0202981; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; Hua QX, 1996, J MOL BIOL, V264, P390, DOI 10.1006/jmbi.1996.0648; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HUA QX, 1990, BIOCHEMISTRY-US, V29, P10545, DOI 10.1021/bi00498a018; Jacoby E, 1996, J MOL BIOL, V258, P136, DOI 10.1006/jmbi.1996.0239; Jimenez JL, 2002, P NATL ACAD SCI USA, V99, P9196, DOI 10.1073/pnas.142459399; KAARSHOLM NC, 1993, BIOCHEMISTRY-US, V32, P10773, DOI 10.1021/bi00091a031; Kelly JW, 2000, NAT STRUCT BIOL, V7, P824, DOI 10.1038/82815; LANHAM JG, 1982, Q J MED, V51, P25; Liu K, 2000, NAT STRUCT BIOL, V7, P754; Liu K, 2000, J MOL BIOL, V303, P555, DOI 10.1006/jmbi.2000.4164; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; Nettleton EJ, 2000, BIOPHYS J, V79, P1053, DOI 10.1016/S0006-3495(00)76359-4; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P8397, DOI 10.1021/bi0105983; Olsen HB, 1996, BIOCHEMISTRY-US, V35, P8836, DOI 10.1021/bi960292+; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Vajo Z, 2001, ENDOCR REV, V22, P706, DOI 10.1210/er.22.5.706; WAUGH DF, 1946, J AM CHEM SOC, V68, P247, DOI 10.1021/ja01206a030; WAUGH DF, 1946, FED PROC, V5, P111; Waugh DF, 1944, J AM CHEM SOC, V66, P663, DOI 10.1021/ja01232a516; WAUGH DF, 1941, AM J PHYSIOL, V133, pP484; Weiss MA, 2002, BIOCHEMISTRY-US, V41, P809, DOI 10.1021/bi011839+; Weiss MA, 2000, BIOCHEMISTRY-US, V39, P15429, DOI 10.1021/bi001905s; Whittingham JL, 1997, BIOCHEMISTRY-US, V36, P2826, DOI 10.1021/bi9625105; Whittingham JL, 2002, J MOL BIOL, V318, P479, DOI 10.1016/S0022-2836(02)00021-9; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xu B, 2002, J MOL BIOL, V316, P435, DOI 10.1006/jmbi.2001.5377; YU NT, 1974, ARCH BIOCHEM BIOPHYS, V160, P614, DOI 10.1016/0003-9861(74)90438-X; YU NT, 1972, J MOL BIOL, V70, P117, DOI 10.1016/0022-2836(72)90167-2; YUNT, 1972, J AM CHEM SOC, V94, P3250, DOI 10.1021/ja00764a068	71	190	199	2	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21449	21460		10.1074/jbc.M314141200	http://dx.doi.org/10.1074/jbc.M314141200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14988398	hybrid			2022-12-27	WOS:000221273800110
J	Kuronuma, K; Sano, H; Kato, K; Kudo, K; Hyakushima, N; Yokota, S; Takahashi, H; Fujii, N; Suzuki, H; Kodama, T; Abe, S; Kuroki, Y				Kuronuma, K; Sano, H; Kato, K; Kudo, K; Hyakushima, N; Yokota, S; Takahashi, H; Fujii, N; Suzuki, H; Kodama, T; Abe, S; Kuroki, Y			Pulmonary surfactant protein A augments the phagocytosis of streptococcus pneumoniae by alveolar macrophages through a casein kinase 2-dependent increase of cell surface localization of scavenger receptor A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG COLLECTINS; II CELLS; ALPHA SECRETION; DEFICIENT MICE; BINDING; EXPRESSION; INFECTION; PHOSPHORYLATION; SUPERFAMILY; ACTIVATION	Pulmonary surfactant proteins A (SP-A) and D (SP-D), members of the collectin family, play important roles in the innate immune system of the lung. Here, we show that SP-A but not SP-D augmented phagocytosis of Streptococcus pneumoniae by alveolar macrophages, independent of its binding to the bacteria. Analysis of the SP-A/SP-D chimeras, in which progressively longer carboxyl-terminal regions of SP-A were replaced with the corresponding SP-D regions, has revealed that the SP-D region Gly(346)-Phe(355) can be substituted for the SP-A region Leu(219)-Phe(228) without altering the SP-A activity of enhancing the phagocytosis and that the SP-A region Cys(204)-Cys(218) is required for the SP-A-mediated phagocytosis. Acetylated low density lipoprotein significantly reduced the SP-A-stimulated uptake of the bacteria. SP-A failed to enhance the phagocytosis of S. pneumoniae by alveolar macrophages derived from scavenger receptor A (SR-A)-deficient mice, demonstrating that SP-A augments SRA-mediated phagocytosis. Preincubation of macrophages with SP-A at 37degreesC but not at 4degreesC stimulated the phagocytosis. The SP-A-mediated enhanced phagocytosis was not inhibited by the presence of cycloheximide. SP-A increased cell surface localization of SR-A that was inhibitable by apigenin, a casein kinase 2 (CK2) inhibitor. SP-A-treated macrophages exhibited significantly greater binding of acetylated low density lipoprotein than nontreated cells. The SP-A-stimulated phagocytosis was also abolished by apigenin. In addition, SP-A stimulated CK2 activity. These results demonstrate that SP-A enhances the phagocytosis of S. pneumoniae by alveolar macrophages through a CK2-dependent increase of cell surface SR-A localization. This study reveals a novel mechanism of bacterial clearance by alveolar macrophages.	Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Microbiol, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Mol Med, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 3, Sapporo, Hokkaido 0608556, Japan; Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido 0808555, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo 1538904, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Obihiro University of Agriculture & Veterinary Medicine; University of Tokyo; Japan Science & Technology Agency (JST)	Kuroki, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 0608556, Japan.	kurokiy@sapmed.ac.jp	Yokota, Shin-ichi/K-8139-2019	Yokota, Shin-ichi/0000-0002-0831-3429				BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Borron P, 2000, AM J PHYSIOL-LUNG C, V278, pL840, DOI 10.1152/ajplung.2000.278.4.L840; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; Dietrich J, 1998, J BIOL CHEM, V273, P24232, DOI 10.1074/jbc.273.37.24232; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; Fong LG, 1999, J BIOL CHEM, V274, P36808, DOI 10.1074/jbc.274.51.36808; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; GEERTSMA MF, 1994, AM J PHYSIOL-LUNG C, V267, pL578, DOI 10.1152/ajplung.1994.267.5.L578; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; Hartshorn KL, 1998, AM J PHYSIOL-LUNG C, V274, pL958, DOI 10.1152/ajplung.1998.274.6.L958; Heider H, 2001, FEBS LETT, V505, P185, DOI 10.1016/S0014-5793(01)02819-8; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Kabha K, 1997, AM J PHYSIOL-LUNG C, V272, pL344, DOI 10.1152/ajplung.1997.272.2.L344; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279, DOI 10.1165/ajrcmb.20.2.3303; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; Mead JR, 2003, J BIOL CHEM, V278, P17741, DOI 10.1074/jbc.M301602200; Murakami S, 2002, J BIOL CHEM, V277, P6830, DOI 10.1074/jbc.M106671200; NAITO M, 1991, AM J PATHOL, V139, P1411; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Ritter M, 2001, EUR J IMMUNOL, V31, P999, DOI 10.1002/1521-4141(200104)31:4<999::AID-IMMU999>3.0.CO;2-R; Saitoh M, 2000, BIOCHEMISTRY-US, V39, P1059, DOI 10.1021/bi9917939; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; Thomas CA, 2000, J EXP MED, V191, P147, DOI 10.1084/jem.191.1.147; TINO MJ, 1996, AM J PHYSIOL, V270, P677; Tsunezawa W, 1998, BBA-PROTEIN STRUCT M, V1387, P433, DOI 10.1016/S0167-4838(98)00159-9	38	95	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21421	21430		10.1074/jbc.M312490200	http://dx.doi.org/10.1074/jbc.M312490200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14993215	hybrid			2022-12-27	WOS:000221273800107
J	Vozza, A; Blanco, E; Palmieri, L; Palmieri, F				Vozza, A; Blanco, E; Palmieri, L; Palmieri, F			Identification of the mitochondrial GTP/GDP transporter in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 HUMAN ISOFORMS; BACTERIAL EXPRESSION; FUNCTIONAL-CHARACTERIZATION; TISSUE DISTRIBUTION; BOVINE MITOCHONDRIA; YEAST MITOCHONDRIA; CARRIER PROTEINS; ADP/ATP CARRIER; INNER MEMBRANE; RECONSTITUTION	The genome of Saccharomyces cerevisiae contains 35 members of a family of transport proteins that, with a single exception, are found in the inner membranes of mitochondria. The transport functions of the 16 biochemically identified mitochondrial carriers are concerned with shuttling substrates, biosynthetic intermediates, and cofactors across the inner membrane. Here the identification and functional characterization of the mitochondrial GTP/GDP carrier (Ggc1p) is described. The ggc1 gene was overexpressed in bacteria. The purified protein was reconstituted into liposomes, and its transport properties and kinetic parameters were characterized. It transported GTP and GDP and, to a lesser extent, the corresponding deoxynucleotides and the structurally related ITP and IDP by a counter-exchange mechanism. Transport was saturable with an apparent K-m of 1 muM for GTP and 5 muM for GDP. It was strongly inhibited by pyridoxal 5'-phosphate, bathophenanthroline, tannic acid, and bromcresol purple but little affected by the inhibitors of the ADP/ATP carrier carboxyatractyloside and bongkrekate. Furthermore, in contrast to the ADP/ATP carrier, the Ggc1p-mediated GTP/GDP heteroexchange is H+-compensated and thus electroneutral. Cells lacking the ggc1 gene had reduced levels of GTP and increased levels of GDP in their mitochondria. Furthermore, the knock-out of ggc1 results in lack of growth on nonfermentable carbon sources and complete loss of mitochondrial DNA. The physiological role of Ggc1p in S. cerevisiae is probably to transport GTP into mitochondria, where it is required for important processes such as nucleic acid and protein synthesis, in exchange for intramitochondrially generated GDP.	Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR)	Palmieri, F (corresponding author), Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, Via E Orabona 4, I-70125 Bari, Italy.	fpalm@farmbiol.uniba.it	Blanco, Emanuela/ABF-8934-2020	Vozza, Angelo/0000-0002-2433-465X; BLANCO, EMANUELA/0000-0001-9541-7148				ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; Amutha B, 2003, BIOCHEM J, V370, P805, DOI 10.1042/BJ20021415; Barrientos A, 2003, MOL BIOL CELL, V14, P2292, DOI 10.1091/mbc.E02-10-0636; Brachmann CB, 1998, YEAST, V14, P115; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; Fiermonte G, 2003, J BIOL CHEM, V278, P32778, DOI 10.1074/jbc.M302317200; Fiermonte G, 2002, J BIOL CHEM, V277, P19289, DOI 10.1074/jbc.M201572200; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; Hoyos ME, 2003, PLANT J, V33, P1027, DOI 10.1046/j.1365-313X.2003.01685.x; Kao LR, 1996, YEAST, V12, P1239, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1239::AID-YEA17>3.0.CO;2-8; KLEINEKE J, 1979, FEBS LETT, V107, P198, DOI 10.1016/0014-5793(79)80494-9; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; KRAMER R, 1980, BIOCHEMISTRY-US, V19, P556; LANOUE KF, 1974, ARCH BIOCHEM BIOPHYS, V161, P544, DOI 10.1016/0003-9861(74)90337-3; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; LESUISSE E, 2004, IN PRESS BIOCH J; Marlovits TC, 2002, P NATL ACAD SCI USA, V99, P16243, DOI 10.1073/pnas.242338299; Marobbio CMT, 2003, EMBO J, V22, P5975, DOI 10.1093/emboj/cdg574; Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; OHASHI A, 1980, J BIOL CHEM, V255, P7740; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; Palmieri L, 2000, BBA-BIOENERGETICS, V1459, P363, DOI 10.1016/S0005-2728(00)00173-0; Palmieri L, 2000, J BIOENERG BIOMEMBR, V32, P67, DOI 10.1023/A:1005564429242; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Picault N, 2002, J BIOL CHEM, V277, P24204, DOI 10.1074/jbc.M202702200; Prohl C, 2001, MOL CELL BIOL, V21, P1089, DOI 10.1128/MCB.21.4.1089-1097.2001; Przybyla-Zawislak B, 1998, EUR J BIOCHEM, V258, P736, DOI 10.1046/j.1432-1327.1998.2580736.x; Roussel D, 2002, J BIOENERG BIOMEMBR, V34, P165, DOI 10.1023/A:1016027302232; Schricker R, 1995, J BIOL CHEM, V270, P31103, DOI 10.1074/jbc.270.52.31103; Sepuri NBV, 1998, J BIOL CHEM, V273, P20941, DOI 10.1074/jbc.273.33.20941; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; Thomson M, 2002, CELL BIOCHEM FUNCT, V20, P273, DOI 10.1002/cbf.974; Zara V, 1996, MOL CELL BIOL, V16, P6524	40	95	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20850	20857		10.1074/jbc.M313610200	http://dx.doi.org/10.1074/jbc.M313610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14998997	hybrid			2022-12-27	WOS:000221273800036
J	Orfeo, T; Brufatto, N; Nesheim, ME; Xu, H; Butenas, S; Mann, KG				Orfeo, T; Brufatto, N; Nesheim, ME; Xu, H; Butenas, S; Mann, KG			The factor V activation paradox	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; FACTOR-XA; PROTHROMBIN ACTIVATION; BLOOD-COAGULATION; HUMAN MEIZOTHROMBIN; BOVINE PROTHROMBIN; CATHEPSIN-G; CLEAVAGE; MEMBRANE; BINDING	The prothrombinase complex consists of the protease factor Xa, Ca2+, and factor Va assembled on an anionic membrane. Factor Va functions both as a receptor for factor Xa and a positive effector of factor Xa catalytic efficiency and thus is key to efficient conversion of prothrombin to thrombin. The activation of the procofactor, factor V, to factor Va is an essential reaction that occurs early in the process of tissue factor-initiated blood coagulation; however, the catalytic sequence leading to formation of factor Va is a subject of disagreement. We have used biophysical and biochemical approaches to establish the second order rate constants and reaction pathways for the activation of phospholipid-bound human factor V by native and recombinant thrombin and meizothrombin, by mixtures of prothrombin activation products, and by factor Xa. We have also reassessed the activation of phospholipid-bound human prothrombin by factor Xa. Numerical simulations were performed incorporating the various pathways of factor V activation including the presence or absence of the pathway of factor V-independent prothrombin activation by factor Xa. Reaction pathways for factor V activation are similar for all thrombin forms. Empirical rate constants and the simulations are consistent with the following mechanism for factor Va formation. alpha-Thrombin, derived from factor Xa cleavage of phospholipid-bound prothrombin via the prethrombin 2 pathway, catalyzes the initial activation of factor V; generation of factor Va in a milieu already containing factor Xa enables prothrombinase formation with consequent meizothrombin formation; and meizothrombin functions as an amplifier of the process of factor V activation and thus has an important procoagulant role. Direct activation of factor V by factor Xa at physiologically relevant concentrations does not appear to be a significant contributor to factor Va formation.	Univ Vermont, Dept Biochem, Burlington, VT 05405 USA; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	University of Vermont; Queens University - Canada; Queens University - Canada	Mann, KG (corresponding author), Univ Vermont, Dept Biochem, 89 Beaumont Ave,Given Bldg,Rm C401, Burlington, VT 05405 USA.	Kenneth.Mann@uvm.edu			NHLBI NIH HHS [R01 HL 34475] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams TE, 2003, J THROMB HAEMOST, V1, P1024, DOI 10.1046/j.1538-7836.2003.00127.x; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BOVILL EG, 1995, ARTERIOSCL THROM VAS, V15, P754, DOI 10.1161/01.ATV.15.6.754; BRADFORD HN, 1988, BLOOD, V71, P388; Brufatto N, 2003, J BIOL CHEM, V278, P6755, DOI 10.1074/jbc.M206413200; Brummel KE, 2002, BLOOD, V100, p696A; Brummel KE, 2002, BLOOD, V100, P148, DOI 10.1182/blood.V100.1.148; BUTENAS S, 1992, BIOCHEMISTRY-US, V31, P5399, DOI 10.1021/bi00138a023; Butenas S, 2002, BLOOD, V100, p488A; Butenas S, 1997, J BIOL CHEM, V272, P21527, DOI 10.1074/jbc.272.34.21527; Butenas S, 1997, THROMB HAEMOSTASIS, V78, P1193; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; Cawthern KM, 1998, BLOOD, V91, P4581, DOI 10.1182/blood.V91.12.4581.412k12_4581_4592; COTE HCF, 1994, J BIOL CHEM, V269, P11374; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; DOMBROSE FA, 1979, J BIOL CHEM, V254, P5027; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1979, J BIOL CHEM, V254, P964; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; Gomori G, 1942, J LAB CLIN MED, V27, P955; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; Hockin MF, 1999, BIOCHEMISTRY-US, V38, P6918, DOI 10.1021/bi981966e; Hockin MF, 2002, J BIOL CHEM, V277, P18322, DOI 10.1074/jbc.M201173200; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Kalafatis M, 2003, J BIOL CHEM, V278, P33550, DOI 10.1074/jbc.M303153200; Kalafatis M, 2001, J BIOL CHEM, V276, P18614, DOI 10.1074/jbc.M007134200; KANE WH, 1982, J BIOL CHEM, V257, P3963; KANE WH, 1981, J BIOL CHEM, V256, P1002; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KUNG C, 1994, J BIOL CHEM, V269, P25838; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1988, J BIOL CHEM, V263, P1037; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OATES AM, 1987, BLOOD, V70, P846; Petrovan RJ, 1998, BIOCHEMISTRY-US, V37, P1185, DOI 10.1021/bi971948h; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; Steen M, 2002, J BIOL CHEM, V277, P38424, DOI 10.1074/jbc.M204972200; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANS G, 1994, J BIOL CHEM, V269, P15969; TANS G, 1991, J BIOL CHEM, V266, P21864; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; TIJBURG PNM, 1991, J BIOL CHEM, V266, P4017; TRACY PB, 1983, J BIOL CHEM, V258, P662; TRACY PB, 1982, BLOOD, V60, P59; TURKINGTON PT, 1993, THROMB RES, V72, P333, DOI 10.1016/0049-3848(93)90142-B; Undas A, 2001, BLOOD, V98, P2423, DOI 10.1182/blood.V98.8.2423; vantVeer C, 1997, J BIOL CHEM, V272, P20721, DOI 10.1074/jbc.272.33.20721	68	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19580	19591		10.1074/jbc.M400727200	http://dx.doi.org/10.1074/jbc.M400727200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14982929	hybrid			2022-12-27	WOS:000221164500026
J	Shen, Q; Cline, GW; Shulman, GI; Leibowitz, MD; Davies, PJA				Shen, Q; Cline, GW; Shulman, GI; Leibowitz, MD; Davies, PJA			Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; PROTEIN-KINASE B; TYROSINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; ACID-TRANSPORT; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; SERINE/THREONINE PHOSPHORYLATION; GLUT4 TRANSLOCATION; GENE-EXPRESSION; ADIPOSE-TISSUE	Rexinoids and thiazolidinediones (TZDs) are two classes of nuclear receptor ligands that induce insulin sensitization in diabetic rodents. TZDs are peroxisome proliferator-activated receptor gamma (PPARgamma) activators, whereas rexinoids are selective ligands for the retinoid X receptors ( RXRs). Activation of both the insulin receptor substrates (IRSs)/Akt and the c-Cbl-associated protein (CAP)/c-Cbl pathways are important in regulating insulin-stimulated glucose transport. We have compared the effects of a rexinoid (LG268) and a TZD ( rosiglitazone) on these two signal pathways in skeletal muscle of diabetic (db/db) mice. The results we have obtained show that treatment of db/db mice with either LG268 or rosiglitazone for 2 weeks results in a significant increase in insulin-stimulated glucose transport activity in skeletal muscle. Treatment with LG268 increases insulin-stimulated IRS-1 tyrosine phosphorylation and Akt phosphorylation in skeletal muscle without affecting the activity of the CAP/c-Cbl pathway. In contrast, rosiglitazone increases the levels of CAP expression and insulin-stimulated c-Cbl phosphorylation without affecting the IRS-1/Akt pathway. The effects of LG268 on the IRS-1/Akt pathway were associated with a decrease in the level of IRS-1 Ser(307) phosphorylation. Taken together, these data suggest that rexinoids improve insulin sensitivity via changes in skeletal muscle metabolism that are distinct from those induced by TZDs. Rexinoids represent a novel class of insulin sensitizers with potential applications in the treatment of insulin resistance.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77225 USA; Ligand Pharmaceut Inc, San Diego, CA 92121 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	University of Texas System; Ligand Pharmaceuticals; Yale University	Davies, PJA (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, 6431 Fannin St,MSB 5-111, Houston, TX 77225 USA.	Peter.J.Davies@uth.tmc.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, R01DK060045] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 60045, R01 DK040936] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Ahuja HS, 2001, MOL PHARMACOL, V59, P765, DOI 10.1124/mol.59.4.765; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; Davies PJA, 2001, MOL PHARMACOL, V59, P170, DOI 10.1124/mol.59.2.170; Del Aguila LF, 2000, AM J PHYSIOL-ENDOC M, V279, pE206, DOI 10.1152/ajpendo.2000.279.1.E206; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; Ellis BA, 2000, AM J PHYSIOL-ENDOC M, V279, pE554, DOI 10.1152/ajpendo.2000.279.3.E554; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Houmard JA, 2002, DIABETES, V51, P2959, DOI 10.2337/diabetes.51.10.2959; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; Kausch C, 2001, BIOCHEM BIOPH RES CO, V280, P664, DOI 10.1006/bbrc.2000.4216; Kayali AG, 2000, DIABETES, V49, P1783, DOI 10.2337/diabetes.49.11.1783; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Martin G, 2000, J BIOL CHEM, V275, P12612, DOI 10.1074/jbc.275.17.12612; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Oakes ND, 1997, METABOLISM, V46, P935, DOI 10.1016/S0026-0495(97)90083-4; Oku A, 2001, AM J PHYSIOL-ENDOC M, V280, pE816, DOI 10.1152/ajpendo.2001.280.5.E816; Park KS, 1998, J CLIN ENDOCR METAB, V83, P2830, DOI 10.1210/jc.83.8.2830; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Song XM, 1999, DIABETES, V48, P664, DOI 10.2337/diabetes.48.3.664; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Turcotte LP, 2001, DIABETES, V50, P1389, DOI 10.2337/diabetes.50.6.1389; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Yonemitsu S, 2001, DIABETES, V50, P1093, DOI 10.2337/diabetes.50.5.1093; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	49	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19721	19731		10.1074/jbc.M311729200	http://dx.doi.org/10.1074/jbc.M311729200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14998989	hybrid			2022-12-27	WOS:000221164500042
J	Lagace, DC; Nachtigal, MW				Lagace, DC; Nachtigal, MW			Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING PROTEINS; ADIPOCYTE DIFFERENTIATION; PPAR-GAMMA; PREADIPOCYTE DIFFERENTIATION; SODIUM VALPROATE; GENE-EXPRESSION; C/EBP-ALPHA; TRANSCRIPTION; ANTICONVULSANT; MODULATION	Adipogenesis is dependent on the sequential activation of transcription factors including the CCAAT/ enhancer-binding proteins (C/EBP), peroxisome proliferator-activated receptor gamma (PPARgamma), and steroid regulatory element-binding protein ( SREBP). We show that the mood stabilizing drug valproic acid (VPA; 0.5 - 2 mM) inhibits mouse 3T3 L1 and human preadipocyte differentiation, likely through its histone deacetylase ( HDAC) inhibitory properties. The HDAC inhibitor trichostatin A (TSA) also inhibited adipogenesis, whereas the VPA analog valpromide, which does not possess HDAC inhibitory effects, did not prevent adipogenesis. Acute or chronic VPA treatment inhibited differentiation yet did not affect mitotic clonal expansion. VPA ( 1 mM) inhibited PPARgamma induced differentiation but does not activate a PPARgamma reporter gene, suggesting that it is not a PPARgamma ligand. VPA or TSA treatment reduced mRNA and protein levels of PPARgamma and SREBP1a. TSA reduced C/EBPalpha mRNA and protein levels, whereas VPA only produced a decrease in C/EBPalpha protein expression. Overall our results highlight a role for HDAC activity in adipogenesis that can be blocked by treatment with VPA.	Dalhousie Univ, Fac Med, Dept Pharmacol, Halifax, NS B3H 1X5, Canada	Dalhousie University	Nachtigal, MW (corresponding author), Dalhousie Univ, Fac Med, Dept Pharmacol, 5850 Coll St, Halifax, NS B3H 1X5, Canada.	Mark.Nachtigal@Dal.Ca		Nachtigal, Mark/0000-0003-3291-8628				Aronne LJ, 2003, J CLIN PSYCHIAT, V64, P22; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Camp HS, 2002, TRENDS MOL MED, V8, P442, DOI 10.1016/S1471-4914(02)02396-1; CHAPMAN JB, 1984, PSYCHOPHARMACOLOGY, V83, P390, DOI 10.1007/BF00428553; Chen G, 1999, MOL BRAIN RES, V64, P52, DOI 10.1016/S0169-328X(98)00303-9; Coyle JT, 2003, NEURON, V38, P157, DOI 10.1016/S0896-6273(03)00195-8; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Elberg G, 2000, J BIOL CHEM, V275, P27815; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Ferin M, 2003, J CLIN ENDOCR METAB, V88, P2908, DOI 10.1210/jc.2002-021614; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; Inoue J, 2001, BIOCHEM BIOPH RES CO, V283, P1157, DOI 10.1006/bbrc.2001.4915; Jallon P, 2001, DRUG SAFETY, V24, P969, DOI 10.2165/00002018-200124130-00004; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; KASTURI I, 1982, J BIOL CHEM, V257, P12224; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; KUNTZSIMON G, 1995, J GEN VIROL, V76, P1409, DOI 10.1099/0022-1317-76-6-1409; Lagace DC, 2003, PROG NEURO-PSYCHOPH, V27, P587, DOI 10.1016/S0278-5846(03)00045-9; Lampen A, 2001, EUR J PHARMACOL, V431, P25, DOI 10.1016/S0014-2999(01)01423-6; Lu Q, 2004, J MED CHEM, V47, P467, DOI 10.1021/jm0303655; Macrithie K, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD004052; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Ntambi JM, 2000, J NUTR, V130, p3122S, DOI 10.1093/jn/130.12.3122S; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Vanina Y, 2002, PSYCHIATR SERV, V53, P842, DOI 10.1176/appi.ps.53.7.842; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Wolden-Hanson T, 1998, PHARMACOTHERAPY, V18, P1075; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8	43	85	91	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18851	18860		10.1074/jbc.M312795200	http://dx.doi.org/10.1074/jbc.M312795200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985358	hybrid			2022-12-27	WOS:000221041500094
J	Malagarie-Cazenave, S; Segui, B; Leveque, S; Garcia, V; Carpentier, S; Altie, MF; Brouchet, A; Gouaze, V; Andrieu-Abadie, N; Barreira, Y; Benoist, H; Levade, T				Malagarie-Cazenave, S; Segui, B; Leveque, S; Garcia, V; Carpentier, S; Altie, MF; Brouchet, A; Gouaze, V; Andrieu-Abadie, N; Barreira, Y; Benoist, H; Levade, T			Role of FAN in tumor necrosis factor-alpha and lipopolysaccharide-induced interleukin-6 secretion and lethality in D-galactosaminesensitized mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL SPHINGOMYELINASE ACTIVATION; P55 TNF-RECEPTOR; GENE-EXPRESSION; HEPATOCYTE APOPTOSIS; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; RAT HEPATOCYTES; ENDOTOXIN-SHOCK; SENSITIZED MICE; LIVER-FAILURE	Tumor necrosis factor (TNF) alpha-induced neutral sphingomyelinase-mediated generation of ceramide, a bioactive lipid molecule, is transduced by the adaptor protein FAN, which binds to the intracellular region of the CD120a TNFalpha receptor. FAN-deficient mice do not exhibit any gross abnormality. To further explore the functions of FAN in vivo and because CD120a-deficient mice are resistant to endotoxin-induced liver failure and lethality, we investigated the susceptibility of FAN-deficient animals to lipopolysaccharide (LPS). We show that after D-galactosamine sensitization, FAN-deficient mice were partially resistant to LPS- and TNFalpha-induced lethality. Although LPS challenge resulted in a hepatic ceramide content lower in mutant mice than in control animals, it triggered similar histological alterations, caspase activation, and DNA fragmentation in the liver. Interestingly, LPS- induced elevation of IL-6 ( but not TNFalpha) serum concentrations was attenuated in FAN-deficient mice. A less pronounced secretion of IL-6 was also observed after LPS or TNFalpha treatment of cultured peritoneal macrophages and embryonic fibroblasts isolated from FAN-deficient mice, as well as in human fibroblasts expressing a mutated FAN. Finally, we show that D-galactosamine-sensitized IL-6-deficient mice were partially resistant to endotoxin-induced liver apoptosis and lethality. These findings highlight the role of FAN and IL-6 in the inflammatory response initiated by endotoxin, implicating TNFalpha.	CHU Rangueil, INSERM,U466, Inst Louis Bugnard, Biochim Lab, F-31059 Toulouse 9, France; CHU Rangueil, Inst Louis Bugnard, Anim Facil, F-31059 Toulouse 9, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Levade, T (corresponding author), CHU Rangueil, INSERM,U466, Inst Louis Bugnard, Biochim Lab, 1 Ave Jean Poulhes,TSA 50032, F-31059 Toulouse 9, France.	levade@toulouse.inserm.fr	Benoist, Hervé/P-2927-2014; Ségui, Bruno/O-8957-2014; Levade, Thierry/O-8948-2014; GARCIA, Virginie/W-8313-2019; Gouaze-Andersson, Valerie/O-9180-2014; Andrieu-Abadie, Nathalie/N-6793-2013	Ségui, Bruno/0000-0002-6119-1889; GARCIA, Virginie/0000-0002-9761-7036; Gouaze-Andersson, Valerie/0000-0002-1797-515X; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; malagarie-cazenave, sophie/0000-0001-8380-5223				Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; Adam-Klages S, 1998, J LEUKOCYTE BIOL, V63, P678, DOI 10.1002/jlb.63.6.678; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Amtmann E, 2003, DRUG EXP CLIN RES, V29, P5; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BARTON BE, 1993, INFECT IMMUN, V61, P1496, DOI 10.1128/IAI.61.4.1496-1499.1993; Barton BE, 1996, INFECT IMMUN, V64, P714, DOI 10.1128/IAI.64.3.714-718.1996; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; Boer U, 2003, J HEPATOL, V38, P728, DOI 10.1016/S0168-8278(03)00090-4; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; Deaciuc IV, 2000, ALCOHOL CLIN EXP RES, V24, P1557, DOI 10.1111/j.1530-0277.2000.tb04575.x; Delogu G, 1999, CRIT CARE MED, V27, P2413, DOI 10.1097/00003246-199911000-00015; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Fiebich BL, 1995, J NEUROIMMUNOL, V63, P207, DOI 10.1016/0165-5728(95)00145-X; Galun E, 2002, BBA-MOL CELL RES, V1592, P345, DOI 10.1016/S0167-4889(02)00326-9; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hedlund M, 1998, MOL MICROBIOL, V29, P1297, DOI 10.1046/j.1365-2958.1998.01017.x; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kozawa O, 1997, J BIOL CHEM, V272, P25099, DOI 10.1074/jbc.272.40.25099; Kreder D, 1999, EMBO J, V18, P2472, DOI 10.1093/emboj/18.9.2472; LAULEDERKIND SJF, 1995, J EXP MED, V182, P599, DOI 10.1084/jem.182.2.599; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; LEIST M, 1995, AM J PATHOL, V146, P1220; LIBERT C, 1994, EUR J IMMUNOL, V24, P2237, DOI 10.1002/eji.1830240945; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luschen S, 2000, BIOCHEM BIOPH RES CO, V274, P506, DOI 10.1006/bbrc.2000.3173; MALAGARIECAZENA.S, 2002, EXPERT REV MOL MED, P1; McDermott MF, 2001, CELL MOL BIOL, V47, P619; Memon RA, 1998, ARTERIOSCL THROM VAS, V18, P1257, DOI 10.1161/01.ATV.18.8.1257; Morikawa A, 1996, INFECT IMMUN, V64, P734, DOI 10.1128/IAI.64.3.734-738.1996; Naka T, 2002, ARTHRITIS RES THER, V4, pS233, DOI 10.1186/ar565; Nakamura A, 2003, J EXP MED, V197, P669, DOI 10.1084/jem.20021824; Nowak M, 2000, AM J PHYSIOL-REG I, V278, pR1202, DOI 10.1152/ajpregu.2000.278.5.R1202; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Osawa Y, 2001, LIVER, V21, P309, DOI 10.1034/j.1600-0676.2001.210503.x; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Plumpe J, 1999, ITAL J GASTROENTEROL, V31, P235; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sanchez C, 2001, MOL PHARMACOL, V59, P955, DOI 10.1124/mol.59.5.955; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Segui B, 1999, J BIOL CHEM, V274, P37251, DOI 10.1074/jbc.274.52.37251; Shinoda J, 1999, CELL SIGNAL, V11, P435, DOI 10.1016/S0898-6568(99)00013-3; Streetz K, 2000, GASTROENTEROLOGY, V119, P446, DOI 10.1053/gast.2000.9364; Taub R, 2003, J CLIN INVEST, V112, P978, DOI 10.1172/JCI20031200319974; TIEGS G, 1989, BIOCHEM PHARMACOL, V38, P627, DOI 10.1016/0006-2952(89)90208-6; Tokuda H, 1999, J CELL BIOCHEM, V72, P262, DOI 10.1002/(SICI)1097-4644(19990201)72:2<262::AID-JCB10>3.0.CO;2-N; Tominaga K, 1997, MOL IMMUNOL, V34, P1147, DOI 10.1016/S0161-5890(97)00145-4; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Tsugane K, 1999, J HEPATOL, V31, P8, DOI 10.1016/S0168-8278(99)80158-5; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANDEVOORDE V, 1992, FEBS LETT, V302, P235, DOI 10.1016/0014-5793(92)80449-Q; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WRIGHT SD, 1995, IMMUNOL TODAY, V16, P297, DOI 10.1016/0167-5699(95)80185-5; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499	76	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18648	18655		10.1074/jbc.M314294200	http://dx.doi.org/10.1074/jbc.M314294200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985352	hybrid			2022-12-27	WOS:000221041500069
J	Osmanagic-Myers, S; Wiche, G				Osmanagic-Myers, S; Wiche, G			Plectin-RACK1 (receptor for activated C kinase 1) scaffolding - A novel mechanism to regulate protein kinase C activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-II; TYROSINE PHOSPHORYLATION; CULTURED-CELLS; GROWTH-FACTOR; PKC-DELTA; RACK1; BINDING; DYNAMICS; EPSILON; ASSOCIATION	Agonist-induced translocation of protein kinase C (PKC) isozymes is mediated by receptors for the activated form of the kinase, shuttling it from one intracellular site to another and enhancing its catalytic activity. It is however unknown whether the receptors themselves are anchored to certain intracellular structures prior to their engagement with PKC. We show here sequestering of receptor for activated C kinase 1 (RACK1) to the cytoskeleton through the cytoskeletal linker protein plectin during the initial stages of cell adhesion. We found that upon PKC activation, RACK1 was released from the cytoskeleton and transferred to the detergent-soluble cell compartment, where it formed an inducible triple complex with one of the PKC isozymes, PKCdelta, and with plectin. In plectin-deficient cells the cytoskeleton-associated RACK1 fraction was reduced, and the protein was found predominantly at sites to which it normally translocated upon PKC activation. Concomitantly, dislocation of PKCdelta and elevated enzymatic activity were observed in these cells. PKCdelta was also more rapidly degraded, likely due to its overactivation. We propose a previously unrecognized function of plectin as cytoskeletal regulator of PKC signaling, and possibly other signaling events, through sequestration of the scaffolding protein RACK1.	Univ Vienna, Vienna Bioctr, Inst Biochem & Mol Cell Biol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Wiche, G (corresponding author), Univ Vienna, Vienna Bioctr, Inst Biochem & Mol Cell Biol, Dr Bohrgasse 9, A-1030 Vienna, Austria.	gerhard.wiche@univie.ac.at	WICHE, Gerhard/AAA-3227-2021; Osmanagic-Myers, Selma/AAI-8921-2020	Osmanagic-Myers, Selma/0000-0002-3834-1332; Wiche, Gerhard/0000-0001-9550-5463				Andra K, 2003, J INVEST DERMATOL, V120, P189, DOI 10.1046/j.1523-1747.2003.12027.x; Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; BARRY ST, 1994, J CELL SCI, V107, P2033; Battaini F, 1999, EXP NEUROL, V159, P559, DOI 10.1006/exnr.1999.7151; Battaini F, 1997, TRENDS NEUROSCI, V20, P410, DOI 10.1016/S0166-2236(97)01084-9; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; BORNER C, 1992, J BIOL CHEM, V267, P12892; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Janda L, 2001, BIOESSAYS, V23, P1064, DOI 10.1002/bies.1151; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Lunter PC, 2002, BIOCHEM BIOPH RES CO, V296, P904, DOI 10.1016/S0006-291X(02)02007-7; Massoumi R, 2002, J CELL SCI, V115, P3509; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; NOZAKI M, 1988, BIOCHEM BIOPH RES CO, V154, P890, DOI 10.1016/0006-291X(88)90223-9; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pass JM, 2001, AM J PHYSIOL-HEART C, V281, pH2500, DOI 10.1152/ajpheart.2001.281.6.H2500; RAMSBY ML, 1994, ELECTROPHORESIS, V15, P265, DOI 10.1002/elps.1150150146; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rouan F, 2000, J INVEST DERMATOL, V114, P381, DOI 10.1046/j.1523-1747.2000.00880.x; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Tall EG, 2000, CURR BIOL, V10, P743, DOI 10.1016/S0960-9822(00)00541-8; Watters D, 1996, EXP CELL RES, V229, P327, DOI 10.1006/excr.1996.0378; Wiche G, 1998, J CELL SCI, V111, P2477; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607	38	93	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18701	18710		10.1074/jbc.M312382200	http://dx.doi.org/10.1074/jbc.M312382200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966116	hybrid			2022-12-27	WOS:000221041500076
J	Petrel, C; Kessler, A; Dauban, P; Dodd, RH; Rognan, D; Ruat, M				Petrel, C; Kessler, A; Dauban, P; Dodd, RH; Rognan, D; Ruat, M			Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; PROTEIN-COUPLED RECEPTORS; CA2+ RECEPTOR; RAT; IDENTIFICATION; PROLIFERATION; CALCIMIMETICS; RECOGNITION; EXPRESSION; SECRETION	A three-dimensional model of the human extracellular Ca2+-sensing receptor (CaSR) has been used to identify specific residues implicated in the recognition of two negative allosteric CaSR modulators of different chemical structure, NPS 2143 and Calhex 231. To demonstrate the involvement of these residues, we have analyzed dose-inhibition response curves for the effect of these calcilytics on Ca2+-induced [H-3]inositol phosphate accumulation for the selected CaSR mutants transiently expressed in HEK293 cells. These mutants were further used for investigating the binding pocket of two chemically unrelated positive allosteric CaSR modulators, NPS R-568 and (R)-2-[1-(1-naphthyl)ethylaminomethyl]-1H-indole (Calindol), a novel potent calcimimetic that stimulates (EC50 = 0.31 muM) increases in [H-3]inositol phosphate levels elicited by activating the wild-type CaSR by 2 mM Ca2+. Our data validate the involvement of Trp-818(6.48), Phe-821(6.51), Glu-837(7.39), and Ile- 841(7.43) located in transmembranes (TM) 6 and TM7, in the binding pocket for both calcimimetics and calcilytics, despite important differences observed between each family of compounds. The TMs involved in the recognition of both calcilytics include residues located in TM3 (Arg-680(3.28), Phe-684(3.32), and Phe-688(3.36)). However, our study indicates subtle differences between the binding of these two compounds. Importantly, the observation that some mutations that have no effect on calcimimetics recognition but which affect the binding of calcilytics in TM3 and TM5, suggests that the binding pocket of positive and negative allosteric modulators is partially overlapping but not identical. Our CaSR model should facilitate the development of novel drugs of this important therapeutic target and the identification of the molecular determinants involved in the binding of allosteric modulators of class 3 G-protein-coupled receptors.	CNRS, UPR 9040, Neurobiol Cellulaire & Mol Lab, IFR 2118,Inst Neurobiol Alfred Fessard, F-91198 Gif Sur Yvette, France; CNRS, UPR 2301, Inst Chim Subst Nat, F-91198 Gif Sur Yvette, France; CNRS, UMR 7981, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Ruat, M (corresponding author), CNRS, UPR 9040, Neurobiol Cellulaire & Mol Lab, IFR 2118,Inst Neurobiol Alfred Fessard, Batiment 33,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	ruat@nbcm.cnrs-gif.fr	Ruat, Martial/E-5544-2016; Centeno, Patricia Pacios/O-8368-2016; Rognan, Didier/B-9939-2014					Archer E, 2003, TRENDS PHARMACOL SCI, V24, P36, DOI 10.1016/S0165-6147(02)00009-3; Bissantz C, 2003, PROTEINS, V50, P5, DOI 10.1002/prot.10237; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2003, OSTEOPOROSIS INT, V14, pS25, DOI 10.1007/s00198-002-1343-6; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Bukoski RD, 1998, AM J HYPERTENS, V11, P1117, DOI 10.1016/S0895-7061(97)00499-8; Chattopadhyay N, 1998, GLIA, V24, P449, DOI 10.1002/(SICI)1098-1136(199812)24:4<449::AID-GLIA10>3.3.CO;2-0; Coulombe J, 2002, OSTEOPOROSIS INT, V13, pS25; Dauban P, 2000, BIOORG MED CHEM LETT, V10, P2001, DOI 10.1016/S0960-894X(00)00382-6; Doggrell SA, 2002, DRUG FUTURE, V27, P140, DOI 10.1358/dof.2002.027.02.656406; Faure H, 2002, OSTEOPOROSIS INT, V13, pS29; Ferry S, 1997, BIOCHEM BIOPH RES CO, V238, P866, DOI 10.1006/bbrc.1997.7401; Ferry S, 2000, EUR J NEUROSCI, V12, P872, DOI 10.1046/j.1460-9568.2000.00980.x; Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200; Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h; Jingami H, 2003, CURR OPIN NEUROBIOL, V13, P271, DOI 10.1016/S0959-4388(03)00067-9; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Mailland M, 1997, ENDOCRINOLOGY, V138, P3601, DOI 10.1210/en.138.9.3601; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323; Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273; Nemeth EF, 2002, CURR PHARM DESIGN, V8, P2077, DOI 10.2174/1381612023393387; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Ruppert J, 1997, PROTEIN SCI, V6, P524; Schaffhauser H, 2003, MOL PHARMACOL, V64, P798, DOI 10.1124/mol.64.4.798; Schwalbe H, 2002, CHEMBIOCHEM, V3, P915, DOI 10.1002/1439-7633(20021004)3:10<915::AID-CBIC915>3.0.CO;2-L	35	175	184	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18990	18997		10.1074/jbc.M400724200	http://dx.doi.org/10.1074/jbc.M400724200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976203	hybrid			2022-12-27	WOS:000221041500111
J	Schweizer, RAS; Zurcher, M; Balazs, Z; Dick, B; Odermatt, A				Schweizer, RAS; Zurcher, M; Balazs, Z; Dick, B; Odermatt, A			Rapid hepatic metabolism of 7-ketocholesterol by 11 beta-hydroxysteroid dehydrogenase type 1 - Species-specific differences between the rat, human, and hamster enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL-OXIDATION-PRODUCTS; GENE-EXPRESSION; INSULIN SENSITIVITY; ADIPOSE-TISSUE; HUMAN LIVER; BILE-ACIDS; IN-VITRO; CARBENOXOLONE; MICE; OXYSTEROLS	The role of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in the local activation of the glucocorticoid receptor by converting inactive 11-ketoglucocorticoids to active 11beta-hydroxyglucocorticoids is well established. Currently, 11beta-HSD1 is considered a promising target for treatment of obese and diabetic patients. Here, we demonstrate a role of 11beta-HSD1 in the metabolism of 7-ketocholesterol (7KC), the major dietary oxysterol. Comparison of recombinant 11beta-HSD1, transiently expressed in human embryonic kidney 293 cells, revealed the stereo-specific interconversion of 7KC and 7beta-hydroxycholesterol by rat and human 11beta-HSD1, whereas the hamster enzyme interconverted 7alpha-hydroxycholesterol, 7beta-hydroxycholesterol, and 7KC. In contrast to lysates, which efficiently catalyzed both oxidation and reduction, intact cells exclusively reduced 7KC. These findings were confirmed using rat and hamster liver homogenates, intact rat hepatocytes, and intact hamster liver tissue slices. Reduction of 7KC was abolished upon inhibition of 11beta-HSD1 by carbenoxolone (CBX) or 2'-hydroxyflavanone. In vivo, after gavage feeding rats, 7KC rapidly appeared in the liver and was converted to 7beta-hydroxycholesterol. CBX significantly decreased the ratio of 7beta-hydroxycholesterol to 7KC, supporting the evidence from cell culture experiments for 11beta-HSD1-dependent reduction of 7KC to 7beta-hydroxycholesterol. Upon inhibition of 11beta-HSD1 by CBX, 7KC tended to accumulate in the liver, and plasma 7KC concentration increased. Together, our results suggest that 11beta-HSD1 efficiently catalyzes the first step in the rapid hepatic metabolism of dietary 7KC, which may explain why dietary 7KC has little or no effect on the development of atherosclerosis.	Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland	University of Bern	Odermatt, A (corresponding author), Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, Freiburgstr 15, CH-3010 Bern, Switzerland.	alex.odermatt@dkf2.unibe.ch		Odermatt, Alex/0000-0002-6820-2712				Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Ando M, 2002, BRIT J NUTR, V88, P339, DOI 10.1079/BJN2002670; Andrews RC, 2003, J CLIN ENDOCR METAB, V88, P285, DOI 10.1210/jc.2002-021194; Audige A, 2002, EUR J CLIN INVEST, V32, P411, DOI 10.1046/j.1365-2362.2002.01003.x; Barf T, 2002, J MED CHEM, V45, P3813, DOI 10.1021/jm025530f; BJORKHEM I, 1968, ACTA CHEM SCAND, V22, P1595, DOI 10.3891/acta.chem.scand.22-1595; BREUER O, 1993, EUR J BIOCHEM, V215, P705, DOI 10.1111/j.1432-1033.1993.tb18082.x; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Brown AJ, 2000, J BIOL CHEM, V275, P27627; de Groot JR, 2003, CARDIOVASC RES, V60, P288, DOI 10.1016/j.cardiores.2003.07.004; DOGTEROM P, 1993, DRUG METAB DISPOS, V21, P705; ERICKSON SK, 1977, J BIOL CHEM, V252, P5186; Fitzpatrick JL, 2001, ARCH BIOCHEM BIOPHYS, V389, P278, DOI 10.1006/abbi.2001.2341; FUJIYAMA J, 1991, CLIN CHIM ACTA, V200, P1, DOI 10.1016/0009-8981(91)90328-A; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; HODIS HN, 1991, ATHEROSCLEROSIS, V89, P117, DOI 10.1016/0021-9150(91)90051-4; Iuliano L, 2003, ANAL BIOCHEM, V312, P217, DOI 10.1016/S0003-2697(02)00467-0; JAVITT NB, 1994, FASEB J, V8, P1308, DOI 10.1096/fasebj.8.15.8001744; Lindsay RS, 2003, J CLIN ENDOCR METAB, V88, P2738, DOI 10.1210/jc.2002-030017; Livingstone DEW, 2003, J PHARMACOL EXP THER, V305, P167, DOI 10.1124/jpet.102.044842; Lyons MA, 1999, INT J BIOCHEM CELL B, V31, P369, DOI 10.1016/S1357-2725(98)00123-X; Lyons MA, 2002, BBA-MOL CELL BIOL L, V1581, P119, DOI 10.1016/S1388-1981(02)00156-7; Lyons MA, 2001, BBA-MOL CELL BIOL L, V1530, P209, DOI 10.1016/S1388-1981(01)00083-X; Lyons MA, 1999, J LIPID RES, V40, P1846; Maeda Y, 2002, STEROIDS, V67, P703, DOI 10.1016/S0039-128X(02)00027-2; MARSCHALL HU, 1992, J CLIN INVEST, V89, P1981, DOI 10.1172/JCI115806; MARSCHALL HU, 1994, J LIPID RES, V35, P1599; Maser E, 2003, CHEM-BIOL INTERACT, V143, P435, DOI 10.1016/S0009-2797(02)00180-1; Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI17845; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; NIELSEN JH, 1995, J DAIRY RES, V62, P101, DOI 10.1017/S0022029900033719; NORII T, 1970, STEROIDS, V15, P303; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; OSADA K, 1994, LIPIDS, V29, P555, DOI 10.1007/BF02536627; Paulmyer-Lacroix O, 2002, J CLIN ENDOCR METAB, V87, P2701, DOI 10.1210/jc.87.6.2701; Peng SK, 1996, ARTERY, V22, P61; Rask E, 2002, J CLIN ENDOCR METAB, V87, P3330, DOI 10.1210/jc.87.7.3330; REDGRAVE TG, 1983, INT REV PHYSIOL, V28, P103; Robinzon B, 2003, ARCH BIOCHEM BIOPHYS, V412, P251, DOI 10.1016/S0003-9861(03)00056-0; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Schweizer RAS, 2003, MOL CELL ENDOCRINOL, V212, P41, DOI 10.1016/j.mce.2003.09.027; Song W, 1998, J BIOL CHEM, V273, P16223, DOI 10.1074/jbc.273.26.16223; Stewart PM, 1999, VITAM HORM, V57, P249; Takeuchi K, 1998, GEN PHARMACOL, V30, P739, DOI 10.1016/S0306-3623(97)00339-X; TAMASAWA N, 1994, BBA-LIPID LIPID MET, V1214, P20, DOI 10.1016/0005-2760(94)90004-3; Uyama N, 2003, J HEPATOL, V39, P749, DOI 10.1016/S0168-8278(03)00375-1; Vine DF, 1997, LIPIDS, V32, P887, DOI 10.1007/s11745-997-0114-0; Vine DF, 2002, LIPIDS, V37, P455, DOI 10.1007/s11745-002-0917-z; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Wsol V, 2003, CHEM-BIOL INTERACT, V143, P459, DOI 10.1016/S0009-2797(02)00221-1	50	108	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18415	18424		10.1074/jbc.M313615200	http://dx.doi.org/10.1074/jbc.M313615200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14973125	Green Submitted, hybrid			2022-12-27	WOS:000221041500040
J	Bocharov, EV; Sobol, AG; Pavlov, KV; Korzhnev, DM; Jaravine, VA; Gudkov, AT; Arseniev, AS				Bocharov, EV; Sobol, AG; Pavlov, KV; Korzhnev, DM; Jaravine, VA; Gudkov, AT; Arseniev, AS			From structure and dynamics of protein L7/L12 to molecular switching in ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR TU; NUCLEAR-MAGNETIC-RESONANCE; ESCHERICHIA-COLI RIBOSOME; N-15 NMR RELAXATION; BIOLOGICAL MACROMOLECULES; CONFORMATIONAL-CHANGES; HETERONUCLEAR NMR; HUMAN UBIQUITIN; PROGRAM; TRANSLOCATION	Based on the H-1-N-15 NMR spectroscopy data, the three-dimensional structure and internal dynamic properties of ribosomal protein L7 from Escherichia coli were derived. The structure of L7 dimer in solution can be described as a set of three distinct domains, tumbling rather independently and linked via flexible hinge regions. The dimeric N-terminal domain (residues 1-32) consists of two antiparallel alpha-alpha-hairpins forming a symmetrical four-helical bundle, whereas the two identical C-terminal domains (residues 52-120) adopt a compact alpha/beta-fold. There is an indirect evidence of the existence of transitory helical structures at least in the first part (residues 33-43) of the hinge region. Combining structural data for the ribosomal protein L7/L12 from NMR spectroscopy and x-ray crystallography, it was suggested that its hinge region acts as a molecular switch, initiating "ratchet-like" motions of the L7/L12 stalk with respect to the ribosomal surface in response to elongation factor binding and GTP hydrolysis. This hypothesis allows an explanation of events observed during the translation cycle and provides useful insights into the role of protein L7/L12 in the functioning of the ribosome.	Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Russian Acad Sci, AN Frumkin Electrochem Inst, Moscow 117071, Russia; Univ Toronto, Dept Med Genet, Toronto, ON M5S 1A8, Canada; Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Frumkin Institute of Physical Chemistry & Electrochemistry; University of Toronto; Russian Academy of Sciences	Arseniev, AS (corresponding author), Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Ul Miklukho Maklaya 16-10, Moscow 117997, Russia.	aars@nmr.ru	Pavlov, Konstantin/T-6515-2017; Pavlov, Konstantin V./Y-8481-2018	Pavlov, Konstantin/0000-0003-1637-8000; Pavlov, Konstantin V./0000-0003-1637-8000				Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bax A, 1997, J BIOMOL NMR, V10, P289, DOI 10.1023/A:1018308717741; Bocharov EV, 1996, FEBS LETT, V379, P291, DOI 10.1016/0014-5793(95)01531-0; Bocharov EV, 1998, FEBS LETT, V423, P347, DOI 10.1016/S0014-5793(98)00121-5; BUBUNENKO MG, 1992, FEBS LETT, V313, P232, DOI 10.1016/0014-5793(92)81198-U; BUSHUEV VN, 1988, METHOD ENZYMOL, V164, P148; BUSHUEV VN, 1989, J BIOL CHEM, V264, P4498; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; CONZALO P, 2003, BIOL CELL, V95, P179; Daragan VA, 1997, PROG NUCL MAG RES SP, V31, P63, DOI 10.1016/S0079-6565(97)00006-X; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; Dey D, 1998, J BIOL CHEM, V273, P1670, DOI 10.1074/jbc.273.3.1670; Doudna JA, 2002, CELL, V109, P153, DOI 10.1016/S0092-8674(02)00725-0; EFREMOV RG, 1995, J PHYS CHEM-US, V99, P10658, DOI 10.1021/j100026a033; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; Griaznova O, 2000, BIOCHEMISTRY-US, V39, P4075, DOI 10.1021/bi992621e; Gudkov AT, 1997, FEBS LETT, V407, P253, DOI 10.1016/S0014-5793(97)00361-X; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; GUDKOV AT, 1980, FEBS LETT, V109, P34, DOI 10.1016/0014-5793(80)81305-6; GUDKOV AT, 1995, FEBS LETT, V367, P280, DOI 10.1016/0014-5793(95)00564-P; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Guntert P, 1998, J BIOMOL NMR, V12, P543, DOI 10.1023/A:1008391403193; Hamman BD, 1996, BIOCHEMISTRY-US, V35, P16672, DOI 10.1021/bi9615001; Hamman BD, 1996, BIOCHEMISTRY-US, V35, P16680, DOI 10.1021/bi9624189; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korzhnev DM, 2000, J BIOMOL NMR, V17, P231, DOI 10.1023/A:1008348827208; Korzhnev DM, 2001, PROG NUCL MAG RES SP, V38, P197, DOI 10.1016/S0079-6565(00)00028-5; Kristensen O, 2002, CURR PROTEIN PEPT SC, V3, P133, DOI 10.2174/1389203023380837; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEIJONMARCK M, 1987, J MOL BIOL CHEM, V247, P3622; LILJAS A, 1987, BIOCHIMIE, V69, P1043, DOI 10.1016/0300-9084(87)90004-6; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; Mohr D, 2002, BIOCHEMISTRY-US, V41, P12520, DOI 10.1021/bi026301y; Montesano-Roditis L, 2001, J BIOL CHEM, V276, P14117, DOI 10.1074/jbc.M008430200; Mumenthaler C, 1997, J BIOMOL NMR, V10, P351, DOI 10.1023/A:1018383106236; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; OLEINIKOV AV, 1993, J BIOL CHEM, V268, P917; Oleinikov AV, 1998, P NATL ACAD SCI USA, V95, P4215, DOI 10.1073/pnas.95.8.4215; Orekhov VY, 1995, APPL MAGN RESON, V9, P581, DOI 10.1007/BF03162365; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Sanyal SC, 2000, CURR OPIN STRUC BIOL, V10, P633, DOI 10.1016/S0959-440X(00)00143-3; Savelsbergh A, 2003, MOL CELL, V11, P1517, DOI 10.1016/S1097-2765(03)00230-2; SCHAUMANN T, 1990, BIOPOLYMERS, V29, P679, DOI 10.1002/bip.360290403; Spirin AS, 2002, FEBS LETT, V514, P2, DOI 10.1016/S0014-5793(02)02309-8; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Tjandra N, 1996, J AM CHEM SOC, V118, P6264, DOI 10.1021/ja960106n; Valle M, 2003, CELL, V114, P123, DOI 10.1016/S0092-8674(03)00476-8; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; Wahl MC, 2002, CURR PROTEIN PEPT SC, V3, P93, DOI 10.2174/1389203023380756; Wieden HJ, 2001, J MOL EVOL, V52, P129, DOI 10.1007/s002390010141; Wilson DN, 2002, CURR PROTEIN PEPT SC, V3, P1, DOI 10.2174/1389203023380846; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	63	86	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17697	17706		10.1074/jbc.M313384200	http://dx.doi.org/10.1074/jbc.M313384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960595	hybrid			2022-12-27	WOS:000220870400100
J	Liu, ZJ; Boles, E; Rosen, BP				Liu, ZJ; Boles, E; Rosen, BP			Arsenic trioxide uptake by hexose permeases in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDCK CELLS; TRANSPORTERS; GLUCOSE; OXOPHENYLARSINE; ANTIMONITE; OXIDE	Arsenic trioxide is a toxic metalloid and carcinogen that is also used as an anticancer drug, and for this reason it is important to identify the routes of arsenite uptake by cells. In this study the ability of hexose transporters to facilitate arsenic trioxide uptake in Saccharomyces cerevisiae was examined. In the absence of glucose, strains with disruption of the arsenite efflux gene ACR3 accumulated high levels of As-73(OH)(3). The addition of glucose inhibited uptake by similar to80%. Disruption of FPS1, the aquaglyceroporin gene, reduced glucose-independent uptake by only about 25%, and the residual uptake was nearly completely inhibited by hexoses, including glucose, galactose, mannose, and fructose but not pentoses or disaccharides. A strain lacking FPS1, ACR3, and all genes for hexose permeases except for HXT3, HXT6, HXT7, and GAL2 exhibited hexose-inhibitable As-73(OH)(3) uptake, whereas a strain lacking all 18 hexose transport-related genes (HXT1 to HXT17 and GAL2), FPS1 and ACR3, exhibited <10% of wild type As-73(OH)(3) transport. When HXT1, HXT3, HXT4, HXT5, HXT7, or HXT9 was individually expressed in that strain, hexose-inhibitable As-73(OH)(3) uptake was restored. In addition, the transport of [C-14] glucose was inhibited by As(OH)(3). These results clearly demonstrate that hexose permeases catalyze the majority of the transport of the trivalent metalloid arsenic trioxide.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany	Wayne State University; Goethe University Frankfurt	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu		Rosen, Barry P./0000-0002-5230-4271; Boles, Eckhard/0000-0002-5713-1883	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055425, R37GM055425] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES10344] Funding Source: Medline; NIGMS NIH HHS [GM55425] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; FROST SC, 1990, BIOCHEM J, V269, P589, DOI 10.1042/bj2690589; Ghosh M, 1999, P NATL ACAD SCI USA, V96, P5001, DOI 10.1073/pnas.96.9.5001; Hamacher T, 2002, MICROBIOL-SGM, V148, P2783, DOI 10.1099/00221287-148-9-2783; HAMSON GC, 1938, J AM CHEM SOC, V60, P1814; HOFFMAN RD, 1992, J BIOL CHEM, V267, P14005; Krampe S, 1998, FEBS LETT, V441, P343, DOI 10.1016/S0014-5793(98)01583-X; LIEBL B, 1995, FUND APPL TOXICOL, V27, P1, DOI 10.1006/faat.1995.1103; LIEBL B, 1995, ARCH TOXICOL, V69, P421, DOI 10.1007/s002040050194; Liu ZJ, 2002, P NATL ACAD SCI USA, V99, P6053, DOI 10.1073/pnas.092131899; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Nourani A, 1997, MOL CELL BIOL, V17, P5453, DOI 10.1128/MCB.17.9.5453; Reifenberger E, 1997, EUR J BIOCHEM, V245, P324, DOI 10.1111/j.1432-1033.1997.00324.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanders OI, 1997, J BACTERIOL, V179, P3365, DOI 10.1128/jb.179.10.3365-3367.1997; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Tseng CH, 2002, TOXICOL LETT, V133, P69, DOI 10.1016/S0378-4274(02)00085-1; Wieczorke R, 2003, CELL PHYSIOL BIOCHEM, V13, P123, DOI 10.1159/000071863; Wieczorke R, 1999, FEBS LETT, V464, P123, DOI 10.1016/S0014-5793(99)01698-1; Wysocki R, 2001, MOL MICROBIOL, V40, P1391, DOI 10.1046/j.1365-2958.2001.02485.x	23	92	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17312	17318		10.1074/jbc.M314006200	http://dx.doi.org/10.1074/jbc.M314006200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966117	hybrid			2022-12-27	WOS:000220870400054
J	Sambade, M; Kane, PM				Sambade, M; Kane, PM			The yeast vacuolar proton-translocating ATPase contains a subunit homologous to the Manduca sexta and bovine e subunits that is essential for function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; V-ATPASE; GENE; PROTEIN; MANIPULATION; VERSATILE; DELETION; COMPLEX; MUTANTS	The yeast cwh36Delta mutant was identified in a screen for yeast mutants exhibiting a Vma(-) phenotype suggestive of loss of vacuolar proton-translocating ATPase (V-ATPase) activity. The mutation disrupts two genes, CWH36 and a recently identified open reading frame on the opposite strand, YCL005W-A. We demonstrate that disruption of YCL005W-A is entirely responsible for the Vma(-) growth phenotype of the cwh36Delta mutant. YCL005W-A encodes a homolog of proteins associated with the Manduca sexta and bovine chromaffin granule V-ATPase. The functional significance of these proteins for V-ATPase activity had not been tested, but we show that the protein encoded by YCL005W-A, which we call Vma9p, is essential for V-ATPase activity in yeast. Vma9p is localized to the vacuole but fails to reach the vacuole in a mutant lacking one of the integral membrane subunits of the V-ATPase. Vma9p is associated with the yeast V-ATPase complex in vacuolar membranes, as demonstrated by co-immunoprecipitation with known V-ATPase subunits and glycerol gradient fractionation of solubilized vacuolar membranes. Based on this evidence, we propose that Vma9p is a genuine subunit of the yeast V-ATPase and that e subunits may be a functionally essential part of all eukaryotic V-ATPases.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.	kanepm@upstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM50322, R01 GM050322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; Davis-Kaplan SR, 2004, J BIOL CHEM, V279, P4322, DOI 10.1074/jbc.M310680200; Geer LY, 2002, GENOME RES, V12, P1619, DOI 10.1101/gr.278202; Graham LA, 2003, J BIOENERG BIOMEMBR, V35, P301, DOI 10.1023/A:1025772730586; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Inoue T, 2003, J BIOENERG BIOMEMBR, V35, P291, DOI 10.1023/A:1025720713747; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ludwig J, 1998, J BIOL CHEM, V273, P10939, DOI 10.1074/jbc.273.18.10939; Merzendorfer H, 1999, J BIOL CHEM, V274, P17372, DOI 10.1074/jbc.274.24.17372; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SHERMAN F, 1982, METHODS YEAST GENETI, P177; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SIKORSKI RS, 1989, GENETICS, V122, P19; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stothard P, 2000, BIOTECHNIQUES, V28, P1102, DOI 10.2144/00286ir01; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C	30	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17361	17365		10.1074/jbc.M314104200	http://dx.doi.org/10.1074/jbc.M314104200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970230	hybrid			2022-12-27	WOS:000220870400059
J	Joo, M; Park, GY; Wright, JG; Blackwell, TS; Atchison, ML; Christman, JW				Joo, M; Park, GY; Wright, JG; Blackwell, TS; Atchison, ML; Christman, JW			Transcriptional regulation of the cyclooxygenase-2 gene in macrophages by PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; BINDING-PROTEIN; C/EBP-BETA; MESSENGER-RNA; FAMILY-MEMBER; FACTOR GATA-1; EXPRESSION; PHOSPHORYLATION; P300	Macrophages are an abundant source of cyclooxygenase-2 (COX-2) enzymatic products, but a specific mechanism for macrophage COX-2 gene expression has not been described. We examined whether PU.1, a myeloid-specific Ets family transcription factor, is involved. Sequence analysis revealed two potential c-Ets binding sites in the COX-2 promoter (COX-2p) which bind to immunoreactive PU.1. Chromatin immunoprecipitation analysis shows inducible PU.1 binding to these sites in response to lipopolysaccharide, and COX-2 protein production is augmented by ectopic expression of PU.1 but not by pU.1(S148A), indicating that PU.1 phosphorylation is likely involved. Interestingly, expression of PU.1 results in acetylation of CCAAT/enhancer-binding protein-beta (C/EBP-beta) and increased production of COX-2 protein. Coimmunoprecipitation experiments suggest a role for p300 in C/EBP-beta acetylation and COX-2 expression. In contrast, E1A inhibits acetylation of C/EBP-beta and is correlated with decreased COX-2 expression. Together, these data suggest that PU.1 is activated by phosphorylation of Ser(148) in response to lipopolysaccharide treatment and subsequently binds to sequences in the endogenous COX-2p in a time-dependent manner. Concomitantly, C/EBP-beta becomes acetylated, and expression of the COX-2 gene increases. We speculate that a combinatorial role of PU.1 and C/EBP-beta mediates the robust production of COX-2 products by macrophages which occurs in Gram-negative bacterial sepsis.	Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37203 USA; Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of Pennsylvania	Christman, JW (corresponding author), Vanderbilt Univ, Sch Med, Dept Allergy Pulm & Crit Care Med, 1161 21st Ave S,Suite T-1217 MCN, Nashville, TN 37232 USA.	john.christman@vanderbilt.edu			NHLBI NIH HHS [HL 68121, HL 07123, HL 66196] Funding Source: Medline; NIGMS NIH HHS [GM 42415] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066196, R01HL068121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042415] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL F, 1999, SHORT PROTOCOLS MOL, pA1; Blackwell TS, 1997, J IMMUNOL, V158, P5934; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Ermert L, 2000, AM J PATHOL, V156, P1275, DOI 10.1016/S0002-9440(10)64998-X; FLETCHER JR, 1993, ARCH SURG-CHICAGO, V128, P1192; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; Goodman RH, 2000, GENE DEV, V14, P1553; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; HROMAS R, 1993, BLOOD, V82, P2998; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Jones KA, 2000, GENE DEV, V14, P1992; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Lodie TA, 1997, J IMMUNOL, V158, P1848; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Polevoda B, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-5-reviews0006; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rieske P, 2001, J BIOL CHEM, V276, P8460, DOI 10.1074/jbc.M007482200; Rosenbauer F, 1999, BLOOD, V94, P4274, DOI 10.1182/blood.V94.12.4274.424k05_4274_4281; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Walsh JC, 2002, IMMUNITY, V17, P665, DOI 10.1016/S1074-7613(02)00452-1; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; Williams JA, 1997, J BIOL CHEM, V272, P25693, DOI 10.1074/jbc.272.41.25693; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhang P, 2000, BLOOD, V96, P2641	53	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6658	6665		10.1074/jbc.M306267200	http://dx.doi.org/10.1074/jbc.M306267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14966110	hybrid			2022-12-27	WOS:000188969200056
J	Li, SN; Perlman, DM; Peterson, MS; Burrichter, D; Avdulov, S; Polunovsky, VA; Bitterman, PB				Li, SN; Perlman, DM; Peterson, MS; Burrichter, D; Avdulov, S; Polunovsky, VA; Bitterman, PB			Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; UNFOLDED PROTEIN RESPONSE; MYC-DEPENDENT APOPTOSIS; CASPASE-9 ACTIVATION; DEATH RECEPTORS; STRESS; MITOCHONDRIA; BAX; CASCADE; CA2+	Eukaryotic translation initiation factor 4E (eIF4E) is the mRNA cap-binding protein required for translation of cellular mRNAs utilizing the 5' cap structure. The rate-limiting factor for mRNA recruitment to ribosomes, eIF4E is a major target for regulation of translation by growth factors, hormones, and other extracellular stimuli. When overexpressed, eIF4E exerts profound effects on cell growth and survival, leading to suppression of oncogene-dependent apoptosis, causing malignant transformation and conferring tumors with multiple drug resistance. We found previously that overexpressed eIF4E interdicts the apoptotic pathway induced by growth factor withdrawal and cytotoxic drugs by selectively activating the expression of Bcl-X-L, thus preventing mitochondrial release of cytochrome c. In this study, we examined the impact of ectopic eIF4E expression on apoptosis mediated by the endoplasmic reticulum (ER). Here we show that eIF4E rescued cells from the ER stressors brefeldin A, tunicamycin, thapsigargin, and the Ca2+ ionophore A23187. In addition, we found that cells rescued from Ca2+ ionophore-triggered apoptosis did not release calcium from their ER nor did they translocate caspase-12 from the ER to the cytoplasm. These data lend strong support to the concept that eIF4E functions as a pleiotropic regulator of cell viability and that integration of critical organelle-mediated checkpoints for apoptosis can be controlled by the cap-dependent translation apparatus.	Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Bitterman, PB (corresponding author), Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.	bitte001@umn.edu		Perlman, David/0000-0001-7055-0970; BITTERMAN, PETER/0000-0002-7995-7117	NATIONAL CANCER INSTITUTE [U01CA091220] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050152, R01HL073719] Funding Source: NIH RePORTER; NCI NIH HHS [1U01 CA 91220] Funding Source: Medline; NHLBI NIH HHS [1P50 HL 50152, HL 07741-07, 1R01 HL 073719] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; He LH, 2003, P NATL ACAD SCI USA, V100, P1022, DOI 10.1073/pnas.0333594100; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Liu CY, 2003, J CELL SCI, V116, P1861, DOI 10.1242/jcs.00408; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Mehmet H, 2000, NATURE, V403, P29, DOI 10.1038/47377; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Talapatra S, 2002, CELL DEATH DIFFER, V9, P856, DOI 10.1038/sj.cdd.4401078; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	39	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21312	21317		10.1074/jbc.M312467200	http://dx.doi.org/10.1074/jbc.M312467200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14990584	hybrid			2022-12-27	WOS:000221273800093
J	Ryan, RM; Mitrovic, AD; Vandenberg, RJ				Ryan, RM; Mitrovic, AD; Vandenberg, RJ			The chloride permeation pathway of a glutamate transporter and its proximity to the glutamate translocation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; TRANSMEMBRANE CONDUCTANCE REGULATOR; ANION-SELECTIVITY; RAT-BRAIN; CYSTEINE MUTAGENESIS; SUBSTRATE-BINDING; SENSITIVE RESIDUE; INDUCED CURRENTS; REENTRANT LOOP; ION FLUXES	Excitatory amino acid transporters (EAATs) regulate glutamate concentrations in the brain to maintain normal excitatory synaptic transmission. A widely accepted view of transporters is that they consist of a pore with alternating access to the intracellular and extracellular solutions, which serves to couple ion movement to the movement of substrate. However, recent observations that EAATs, and also a number of other neurotransmitter transporters, can also function as ligand-gated chloride channels have blurred the distinctions between transporters and ion channels. Here we show that mutations in the second transmembrane domain (TM2) of EAAT1 alter anion permeation properties without affecting glutamate transport and that a number of TM2 residues are accessible to the external aqueous solution. Furthermore, we demonstrate that the extracellular edge of TM2 is in close proximity to a membrane-associated domain that influences glutamate transport. This study will provide the foundation for beginning to understand how transporters can function as both transporters and ion channels.	Univ Sydney, Biomed Res Inst, Dept Pharmacol, Sydney, NSW 2006, Australia	University of Sydney	Vandenberg, RJ (corresponding author), Univ Sydney, Biomed Res Inst, Dept Pharmacol, Sydney, NSW 2006, Australia.	robv@pharmacol.usyd.edu.au	Ryan, Renae/AAC-3540-2021; Vandenberg, Robert John/E-6018-2016	Ryan, Renae/0000-0002-8680-4610; Vandenberg, Robert John/0000-0003-1523-4814				ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Auger C, 2000, NEURON, V28, P547, DOI 10.1016/S0896-6273(00)00132-X; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Billups B, 1996, J NEUROSCI, V16, P6722; Borre L, 2002, J BIOL CHEM, V277, P13501, DOI 10.1074/jbc.M110861200; Borre L, 2001, J BIOL CHEM, V276, P40396, DOI 10.1074/jbc.M104926200; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; GALLI A, 1995, J EXP BIOL, V198, P2197; GRANT GB, 1995, J NEUROSCI, V15, P3852; Grewer C, 2000, P NATL ACAD SCI USA, V97, P9706, DOI 10.1073/pnas.160170397; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hill, 2001, ION CHANNELS EXCITAB, P441; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Leighton BH, 2002, J BIOL CHEM, V277, P29847, DOI 10.1074/jbc.M202508200; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; Melzer N, 2003, J BIOL CHEM, V278, P50112, DOI 10.1074/jbc.M307990200; Mitrovic AD, 2001, J BIOL CHEM, V276, P26071, DOI 10.1074/jbc.M011318200; Motulsky H., 1999, ANAL DATA GRAPHPAD P; Otis TS, 1998, J NEUROSCI, V18, P7099; Otis TS, 1997, SCIENCE, V277, P1515, DOI 10.1126/science.277.5331.1515; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Poulsen MV, 2001, J PHYSIOL-LONDON, V534, P159, DOI 10.1111/j.1469-7793.2001.00159.x; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Risso S, 1996, J PHYSIOL-LONDON, V490, P691, DOI 10.1113/jphysiol.1996.sp021178; Ryan RM, 2002, J BIOL CHEM, V277, P13494, DOI 10.1074/jbc.M109970200; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Seal RP, 2001, P NATL ACAD SCI USA, V98, P15324, DOI 10.1073/pnas.011400198; Smith SS, 1999, J GEN PHYSIOL, V114, P799, DOI 10.1085/jgp.114.6.799; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751; Zuniga FA, 2001, J BIOL CHEM, V276, P44970, DOI 10.1074/jbc.M107350200	54	94	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20742	20751		10.1074/jbc.M304433200	http://dx.doi.org/10.1074/jbc.M304433200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14982939	hybrid			2022-12-27	WOS:000221273800026
J	Bougdour, A; Lelong, C; Geiselmann, J				Bougdour, A; Lelong, C; Geiselmann, J			Crl, a low temperature-induced protein in Escherichia coli that binds directly to the stationary phase sigma subunit of RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN-BINDING; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; INORGANIC POLYPHOSPHATE; SALMONELLA-TYPHIMURIUM; PROMOTER SELECTIVITY; INTRACELLULAR LEVELS; BIOFILM FORMATION; H-NS; RPOS	The alternative sigma factor sigma(S) (RpoS) of Escherichia coli RNA polymerase regulates the expression of stationary phase and stress-response genes. sigma(S) is also required for the transcription of the cryptic genes csgBA that encode the subunits of the curli proteins. The expression of the csgBA genes is regulated in response to a multitude of physiological signals. In stationary phase, these genes are transcribed by the sigma(S) factor, and expression of the operon is enhanced by the small protein Crl. It has been shown that Crl stimulates the activity of sigma(S), leading to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase. However, the underlying molecular mechanism has remained elusive. We show here that Crl interacts directly with sigma(S) and that this interaction promotes binding of the sigma(S) holoenzyme (Esigma(S)) to the csgBA promoter. Expression of Crl is increased during the transition from growing to stationary phase. Crl accumulates in stationary phase cells at low temperature (30degreesC) but not at 37degreesC. We therefore propose that Crl is a second thermosensor, besides DsrA, controlling sigma(S) activity.	Univ Grenoble 1, CNRS, UMR 5163, Lab Adaptat & Pathogenie Microorganismes, F-38041 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Lelong, C (corresponding author), Univ Grenoble 1, CNRS, UMR 5163, Lab Adaptat & Pathogenie Microorganismes, BP53, F-38041 Grenoble 9, France.	cecile.lelong@ujf-grenoble.fr	Geiselmann, Hans/GVT-8876-2022; Bougdour, Alexandre/K-3795-2014	Geiselmann, Hans/0000-0002-1329-7558; Bougdour, Alexandre/0000-0002-5895-0020				ARNQVIST A, 1992, MOL MICROBIOL, V6, P2443; ARNQVIST A, 1994, MOL MICROBIOL, V13, P1021, DOI 10.1111/j.1365-2958.1994.tb00493.x; BACHMANN BJ, 1976, BACTERIOL REV, V40, P116, DOI 10.1128/MMBR.40.1.116-167.1976; Balandina A, 2001, MOL MICROBIOL, V39, P1069, DOI 10.1046/j.1365-2958.2001.02305.x; Becker G, 1999, P NATL ACAD SCI USA, V96, P6439, DOI 10.1073/pnas.96.11.6439; BOHANNON DE, 1991, J BACTERIOL, V173, P4482, DOI 10.1128/JB.173.14.4482-4492.1991; BOHRINGER J, 1995, J BACTERIOL, V177, P413; Brombacher E, 2003, MICROBIOL-SGM, V149, P2847, DOI 10.1099/mic.0.26306-0; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; DING QQ, 1995, MOL MICROBIOL, V16, P649, DOI 10.1111/j.1365-2958.1995.tb02427.x; Dorel C, 1999, FEMS MICROBIOL LETT, V178, P169, DOI 10.1016/S0378-1097(99)00347-X; FAURE D, 2004, DIVERSIFICATION ADAP; Gaal T, 2001, MOL MICROBIOL, V42, P939, DOI 10.1046/j.1365-2958.2001.02703.x; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; Gerstel U, 2003, MOL MICROBIOL, V49, P639, DOI 10.1046/j.1365-2958.2003.03594.x; Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024; Hammar M, 1995, MOL MICROBIOL, V18, P661, DOI 10.1111/j.1365-2958.1995.mmi_18040661.x; Hammar M, 1996, P NATL ACAD SCI USA, V93, P6562, DOI 10.1073/pnas.93.13.6562; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Hengge-Aronis R, 2002, MICROBIOL MOL BIOL R, V66, P373, DOI 10.1128/MMBR.66.3.373-395.2002; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; HenggeAronis R, 1996, MOL MICROBIOL, V21, P887, DOI 10.1046/j.1365-2958.1996.511405.x; HUISMAN GW, 1994, SCIENCE, V265, P537, DOI 10.1126/science.7545940; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; Jishage M, 1997, J BACTERIOL, V179, P959, DOI 10.1128/jb.179.3.959-963.1997; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; JISHAGE M, 1995, J BACTERIOL, V177, P6832, DOI 10.1128/jb.177.23.6832-6835.1995; Kusano S, 1996, J BIOL CHEM, V271, P1998, DOI 10.1074/jbc.271.4.1998; Kusano S, 1997, J BACTERIOL, V179, P3649, DOI 10.1128/jb.179.11.3649-3654.1997; Kusano S, 1997, GENES CELLS, V2, P433, DOI 10.1046/j.1365-2443.1997.13203301320330.x; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413; Maeda H, 2000, NUCLEIC ACIDS RES, V28, P3497, DOI 10.1093/nar/28.18.3497; Miller JH, 1972, EXPT MOL GENETICS, P201; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; OLSEN A, 1993, INFECT AGENT DIS, V2, P272; OLSEN A, 1993, MOL MICROBIOL, V7, P523, DOI 10.1111/j.1365-2958.1993.tb01143.x; Pratt LA, 1996, P NATL ACAD SCI USA, V93, P2488, DOI 10.1073/pnas.93.6.2488; Pratt LA, 1998, MOL MICROBIOL, V29, P1225, DOI 10.1046/j.1365-2958.1998.01007.x; Prigent-Combaret C, 1999, J BACTERIOL, V181, P5993, DOI 10.1128/JB.181.19.5993-6002.1999; Reischl S, 2002, J BIOL CHEM, V277, P32659, DOI 10.1074/jbc.M201372200; Repoila F, 2001, J BACTERIOL, V183, P4012, DOI 10.1128/JB.183.13.4012-4023.2001; Romling U, 1998, MOL MICROBIOL, V28, P249, DOI 10.1046/j.1365-2958.1998.00791.x; Romling U, 1998, J BACTERIOL, V180, P722; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schnetz K, 2002, MICROBIOL-SGM, V148, P2573, DOI 10.1099/00221287-148-8-2573; Shiba T, 1997, P NATL ACAD SCI USA, V94, P11210, DOI 10.1073/pnas.94.21.11210; Silhavy T. J., 1984, EXPT GENE FUSIONS; SJOBRING U, 1994, MOL MICROBIOL, V14, P443, DOI 10.1111/j.1365-2958.1994.tb02179.x; Sledjeski DD, 1996, EMBO J, V15, P3993, DOI 10.1002/j.1460-2075.1996.tb00773.x; SMALL P, 1994, J BACTERIOL, V176, P1729, DOI 10.1128/jb.176.6.1729-1737.1994; Studemann A, 2003, EMBO J, V22, P4111, DOI 10.1093/emboj/cdg411; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401	57	101	105	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19540	19550		10.1074/jbc.M314145200	http://dx.doi.org/10.1074/jbc.M314145200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14978043	hybrid			2022-12-27	WOS:000221164500021
J	Cho, JY; Akbarali, Y; Zerbini, LF; Gu, XS; Boltax, J; Wang, YH; Oettgen, P; Zhang, DE; Libermann, TA				Cho, JY; Akbarali, Y; Zerbini, LF; Gu, XS; Boltax, J; Wang, YH; Oettgen, P; Zhang, DE; Libermann, TA			Isoforms of the Ets transcription factor NERF/ELF-2 physically interact with AML1 and mediate opposing effects on AML1-mediated transcription of the B cell-specific blk gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC TRANSACTIVATION DOMAIN; PROTEIN-PROTEIN INTERACTIONS; FACTOR-RECEPTOR PROMOTER; MURINE MYELOPEROXIDASE; ANTIGEN RECEPTOR; MYELOID-LEUKEMIA; TYROSINE KINASE; C/EBP-ALPHA; FAMILY; ENHANCER	We previously isolated different isoforms of a new Ets transcription factor family member, NERF/ELF-2, NERF-2, NERF-1a, and NERF-1b. In contrast to the inhibitory isoforms NERF-1a and NERF-1b, NERF-2 acts as a transactivator of the B cell-specific blk promoter. We now report that NERF-2 and NERF-1 physically interact with AML1 (RUNX1), a frequent target for chromosomal translocations in leukemia. NERF-2 bound to AML1 via an interaction site located in a basic region upstream of the Ets domain. This is in contrast to most other Ets factors such as Ets-1 that bind to AML1 via the Ets domain, suggesting that different Ets factors utilize different domains for interaction with AML1. The interaction between AML1 and NERF-2 led to cooperative transactivation of the blk promoter, whereas the interaction between AML1 and NERF-1a led to repression of AML1-mediated transactivation. To delineate the differences in function of the different NERF isoforms, we determined that the transactivation domain of NERF-2 is encoded by the N-terminal 100 amino acids, which have been replaced in NERF-1a by a 19-amino acid transcriptionally inactive sequence. Furthermore, acidic domains A and B, which are conserved in NERF-2 and the related proteins ELF-1 and MEF/ELF-4, but not in NERF-1a, are largely responsible for NERF-2-mediated transactivation. Because translocation of the Ets factor Tel to AML1 is a frequent event in childhood pre-B leukemia, understanding the interaction of Ets factors with AML1 in the context of a B cell-specific promoter might help to determine the function of Ets factors and AML1 in leukemia.	Beth Israel Deaconess Med Ctr, BIDMC Genom Ctr, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Harvard Medical School; Scripps Research Institute	Libermann, TA (corresponding author), Beth Israel Deaconess Med Ctr, BIDMC Genom Ctr, 4 Blackfan Circle, Boston, MA 02115 USA.	tliberma@bidmc.harvard.edu	Oettgen, Peter/AAF-5026-2021; Zerbini, Luiz/B-7720-2015; Libermann, Towia/F-9866-2010	Zerbini, Luiz/0000-0003-0736-9508; Libermann, Towia/0000-0002-4006-8179	NATIONAL CANCER INSTITUTE [P01CA072009, R01CA076323] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 76323, P01 CA 72009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akbarali Y, 1996, J BIOL CHEM, V271, P26007, DOI 10.1074/jbc.271.42.26007; ALBAGLI O, 1994, ONCOGENE, V9, P3259; BURCKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410; BURG DL, 1994, J BIOL CHEM, V269, P28136; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; Carlsson R, 2003, MOL IMMUNOL, V39, P1035, DOI 10.1016/S0161-5890(03)00032-4; Christensen RA, 2002, J CELL BIOCHEM, V85, P505, DOI 10.1002/jcb.10148; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Frank R, 1995, ONCOGENE, V11, P2667; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Hromas R, 2001, BLOOD, V97, P2168, DOI 10.1182/blood.V97.7.2168; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; KLAUS GGB, 1987, IMMUNOL REV, V99, P19, DOI 10.1111/j.1600-065X.1987.tb01170.x; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; Laget MP, 1996, ONCOGENE, V12, P1325; LEUNG S, 1993, ONCOGENE, V8, P989; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; LIN JJ, 1992, J IMMUNOL, V149, P1548; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Malek SN, 1998, P NATL ACAD SCI USA, V95, P7351, DOI 10.1073/pnas.95.13.7351; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1995, BLOOD, V86, P1; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Ramsey H, 2003, LEUKEMIA, V17, P1665, DOI 10.1038/sj.leu.2403048; RILEY LK, 1988, P NATL ACAD SCI USA, V85, P2489, DOI 10.1073/pnas.85.8.2489; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Suico MA, 2002, BBA-GENE STRUCT EXPR, V1577, P113, DOI 10.1016/S0167-4781(02)00370-6; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310	56	24	26	4	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19512	19522		10.1074/jbc.M309074200	http://dx.doi.org/10.1074/jbc.M309074200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14970218	hybrid			2022-12-27	WOS:000221164500018
J	Daoudi, M; Lavergne, E; Garin, A; Tarantino, N; Debre, P; Pincet, F; Combadiere, C; Deterre, P				Daoudi, M; Lavergne, E; Garin, A; Tarantino, N; Debre, P; Pincet, F; Combadiere, C; Deterre, P			Enhanced adhesive capacities of the naturally occurring Ile(249)-Met(280) variant of the chemokine receptor CX3CR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; 7-TRANSMEMBRANE RECEPTORS; SIGNAL-TRANSDUCTION; PHYSIOLOGICAL FLOW; DENDRITIC CELLS; IFN-GAMMA; RAT-BRAIN; T-CELL; FRACTALKINE; CX(3)CR1	It was recently shown that individuals carrying the naturally occurring mutant CX3CR1-Ile(249)-Met(280) (hereafter called CX3CR1-IM) have a lower risk of cardiovascular disease than individuals homozygous for the wildtype CX3CR1-Val(249) - Thr(280) (CX3CR1-VT). We report here that peripheral blood mononuclear cells (PBMC) from individuals with the CX3CR1-IM haplotype adhered more potently to membrane-bound CX3CL1 than did PBMC from homozygous CX3CR1-VT donors. Similar excess adhesion was observed with CX3CR1-IM-transfected human embryonic kidney (HEK) cell lines tested with two different methods: the parallel plate laminar flow chamber and the dual pipette aspiration technique. Suppression of the extra adhesion in the presence of pertussis toxin indicates that G-protein mediated the underlying transduction pathway, in contrast to the G-protein-independent adhesion previously described for CX3CR1-VT. Surprisingly, HEK and PBMC that expressed CX3CR1-IM and - VT were indistinguishable when tested with the soluble form of CX3CL1 for chemotaxis, calcium release, and binding capacity. In conclusion, only the membrane-anchored form of CX3CL1 functionally discriminated between these two allelic isoforms of CX3CR1. These results suggest that each form of this ligand may lead to a different signaling pathway. The extra adhesion of CX3CR1-IM may be related to immune defenses and to atherogenesis, both of which depend substantially on adhesive intercellular events.	Univ Paris 06, INSERM, U543, Lab Immunol Cellulaire, F-75013 Paris, France; Ecole Normale Super, Lab Phys Stat, CNRS, UMR 8550, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Sorbonne Universite; Universite Paris Cite	Deterre, P (corresponding author), Univ Paris 06, INSERM, U543, Lab Immunol Cellulaire, 91 Blvd Hop, F-75013 Paris, France.	deterre@ccr.jussieu.fr	Deterre, Philippe/O-8984-2017; Combadiere, Christophe/I-5639-2013	Deterre, Philippe/0000-0001-9303-0791; Combadiere, Christophe/0000-0002-1755-4531; PINCET, FREDERIC/0000-0002-4243-2157				Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brand S, 2002, GASTROENTEROLOGY, V122, P166, DOI 10.1053/gast.2002.30329; Brumme ZL, 2003, AIDS, V17, P201, DOI 10.1097/00002030-200301240-00010; Cambien B, 2001, BLOOD, V97, P2031, DOI 10.1182/blood.V97.7.2031; Combadiere B, 2003, AIDS, V17, P1279, DOI 10.1097/00002030-200306130-00002; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Decaillot FM, 2003, NAT STRUCT BIOL, V10, P629, DOI 10.1038/nsb950; DEVRIES ME, 2003, J BIOL CHEM, V27, P27; Dichmann S, 2001, INFLAMM RES, V50, P529, DOI 10.1007/PL00000230; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274; Faure S, 2003, JAIDS-J ACQ IMM DEF, V32, P335, DOI 10.1097/00126334-200303010-00014; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Foussat A, 2001, BLOOD, V98, P1678, DOI 10.1182/blood.V98.6.1678; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gugl A, 2003, ATHEROSCLEROSIS, V166, P339, DOI 10.1016/S0021-9150(02)00362-3; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Haskell CA, 2000, J BIOL CHEM, V275, P34183, DOI 10.1074/jbc.M005731200; Hendel H, 2001, J ACQ IMMUN DEF SYND, V26, P507, DOI 10.1097/00126334-200104150-00019; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Ludwig A, 2002, J IMMUNOL, V168, P604, DOI 10.4049/jimmunol.168.2.604; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; McDermott D H, 2000, Science, V290, P2031; McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790; McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Nakayama T, 2003, J IMMUNOL, V170, P1136, DOI 10.4049/jimmunol.170.3.1136; Nishimura M, 2002, J IMMUNOL, V168, P6173, DOI 10.4049/jimmunol.168.12.6173; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; Ollivier W, 2003, CYTOKINE, V21, P303, DOI 10.1016/S1043-4666(03)00112-1; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Papadopoulos EJ, 1999, EUR J IMMUNOL, V29, P2551, DOI 10.1002/(SICI)1521-4141(199908)29:08<2551::AID-IMMU2551>3.0.CO;2-T; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pierres A, 1998, P NATL ACAD SCI USA, V95, P9256, DOI 10.1073/pnas.95.16.9256; Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUNG KLP, 1986, SCIENCE, V234, P1405, DOI 10.1126/science.3491426; TOZEREN A, 1989, BIOPHYS J, V55, P479, DOI 10.1016/S0006-3495(89)82841-3; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Umehara H, 2001, IMMUNOL CELL BIOL, V79, P298, DOI 10.1046/j.1440-1711.2001.01004.x; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Yoneda O, 2003, EUR J IMMUNOL, V33, P53, DOI 10.1002/immu.200390007	54	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19649	19657		10.1074/jbc.M313457200	http://dx.doi.org/10.1074/jbc.M313457200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14990582	hybrid			2022-12-27	WOS:000221164500034
J	Serrano, R; Bernal, D; Simon, E; Arino, J				Serrano, R; Bernal, D; Simon, E; Arino, J			Copper and iron are the limiting factors for growth of the yeast Saccharomyces cerevisiae in an alkaline environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-ION TRANSPORTERS; CANDIDA-ALBICANS; SUPEROXIDE-DISMUTASE; GENE-EXPRESSION; UNEXPECTED ROLE; PROTEIN; CHAPERONE; DISEASE; GENOME; CELLS	Exposure of the yeast Saccharomyces cerevisiae to an alkaline environment represents a stress situation that negatively affects growth and results in an adaptive transcriptional response. We screened a collection of 4825 haploid deletion mutants for their ability to grow at mild alkaline pH, and we identified 118 genes, involved in numerous cellular functions, whose absence results in reduced growth. The list includes several key genes in copper and iron homeostasis, such as CCC2, RCS1, FET3, LYS7, and CTR1. In contrast, a screen of high-copy number plasmid libraries for clones able to increase tolerance to alkaline pH revealed only two genes: FET4 ( encoding a low affinity transporter for copper, iron, and zinc) and CTR1 ( encoding a high affinity copper transporter). The beneficial effect of overexpression of CTR1 requires a functional high affinity iron transport system, as it was abolished by deletion of FET3, a component of the high affinity transport system, or CCC2, which is required for assembly of the transport system. The growth-promoting effect of FET4 was not modified in these mutants. These results suggest that the observed tolerance to alkaline pH is because of improved iron uptake and indicate that both iron and copper are limiting factors for growth under alkaline pH conditions. Addition to the medium of micromolar concentrations of copper or iron ions drastically improved growth at high pH. Supplementation with iron improved somewhat the tolerance of a fet3 strain but was ineffective in a ctr1 mutant, suggesting the existence of additional copper-requiring functions important for tolerance to an alkaline environment.	Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain	Autonomous University of Barcelona	Arino, J (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Ed 5, E-08193 Barcelona, Spain.	Joaquin.Arino@uab.es	Arino, Joaquin/D-3756-2011	Arino, Joaquin/0000-0002-6774-2987; Arino Carmona, Joaquin/0000-0002-0390-4270				ADAMS A, 1997, METHODS YEAST GENETI, P145; Aldea Marti, 1994, Microbiologia (Madrid), V10, P27; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Bush AI, 2003, P NATL ACAD SCI USA, V100, P11193, DOI 10.1073/pnas.2135061100; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Chung JH, 2003, J BIOL CHEM, V278, P28872, DOI 10.1074/jbc.M300943200; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Davis D, 2003, CURR GENET, V44, P58, DOI [10.1007/s00294-003-0415-2, 10.1007/s00294-003-0431-2]; Davis-Kaplan SR, 2004, J BIOL CHEM, V279, P4322, DOI 10.1074/jbc.M310680200; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; Heese-Peck A, 2002, MOL BIOL CELL, V13, P2664, DOI 10.1091/mbc.E02-04-0186; Heymann P, 2002, INFECT IMMUN, V70, P5246, DOI 10.1128/IAI.70.9.5246-5255.2002; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jensen LT, 2002, J MOL BIOL, V318, P251, DOI 10.1016/S0022-2836(02)00093-1; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kosman DJ, 2003, MOL MICROBIOL, V47, P1185, DOI 10.1046/j.1365-2958.2003.03368.x; Laage R, 2001, MOL BIOL CELL, V12, P3375, DOI 10.1091/mbc.12.11.3375; Lamb TM, 2003, MOL CELL BIOL, V23, P677, DOI 10.1128/MCB.23.2.677-686.2003; Lamb TM, 2001, J BIOL CHEM, V276, P1850, DOI 10.1074/jbc.M008381200; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lin SJ, 1997, J BIOL CHEM, V272, P9215; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Nelson N, 2000, J EXP BIOL, V203, P89; Noor Rana, 2002, Med Sci Monit, V8, pRA210; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Penalva MA, 2002, MICROBIOL MOL BIOL R, V66, P426, DOI 10.1128/MMBR.66.3.426-446.2002; Philpott CC, 2002, BIOCHEM SOC T, V30, P698, DOI 10.1042/bst0300698; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ramanan N, 2000, SCIENCE, V288, P1062, DOI 10.1126/science.288.5468.1062; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Sacher A, 2001, J EXP BIOL, V204, P1053; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Swain E, 2002, J BIOL CHEM, V277, P36152, DOI 10.1074/jbc.M206624200; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; Weinberg ED, 1999, J EUKARYOT MICROBIOL, V46, P231, DOI 10.1111/j.1550-7408.1999.tb05119.x; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	57	99	103	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19698	19704		10.1074/jbc.M313746200	http://dx.doi.org/10.1074/jbc.M313746200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14993228	hybrid			2022-12-27	WOS:000221164500039
J	Eggert, S; Paliga, K; Soba, P; Evin, G; Masters, CL; Weidemann, A; Beyreuther, K				Eggert, S; Paliga, K; Soba, P; Evin, G; Masters, CL; Weidemann, A; Beyreuther, K			The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages - Modulation of APLP-1 processing by N-glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; TRANSMEMBRANE DOMAIN; SECRETASE CLEAVAGE; INTRACELLULAR DOMAIN; ASPARTYL PROTEASE; METALLOPROTEASE INHIBITORS; INTRAMEMBRANE CLEAVAGE; NUCLEAR TRANSLOCATION; CEREBROSPINAL-FLUID; CONVERTING-ENZYME	Amyloid precursor protein (APP) processing is of major interest in Alzheimer's disease research, since sequential cleavages by beta- and gamma-secretase lead to the formation of the 4-kDa amyloid Abeta protein peptide that accumulates in Alzheimer's disease brain. The processing of APP involves proteolytic conversion by different secretases leading to alpha-, beta-, gamma-, delta-, and epsilon-cleavages. Since modulation of these cleavages represents a rational therapeutic approach to control amyloid formation, its interference with the processing of the members of the APP gene family is of considerable importance. By using C-terminally tagged constructs of APLP-1 and APLP-2 and the untagged proteins, we have characterized their proteolytic C-terminal fragments produced in stably transfected SH-SY5Y cells. Pharmacological manipulation with specific protease inhibitors revealed that both homologues are processed by alpha- and gamma-secretase-like cleavages, and that their intracellular domains can be released by cleavage at epsilon-sites. APLP-2 processing appears to be the most elaborate and to involve alternative cleavage sites. We show that APLP-1 is the only member of the APP gene family for which processing can be influenced by N-glycosylation. Additionally, we were able to detect p3-like fragments of APLP-1 and p3-like and Abeta-like fragments of APLP-2 in the media of stably transfected SH-SY5Y cells.	Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany; Univ Kiel, Fac Med, Inst Biochem, D-24098 Kiel, Germany; Univ Melbourne, Mental Hlth Res Inst, Dept Pathol, Parkville, Vic 3010, Australia	Ruprecht Karls University Heidelberg; University of Kiel; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Eggert, S (corresponding author), Zentrum Mol Biol Heidelberg, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	s.eggert@zmbh.uni-heidelberg.de	Evin, Genevieve M/E-5891-2013; Soba, Peter/AAK-1134-2021; Soba, Peter/AAC-8143-2020	Soba, Peter/0000-0002-6163-4686; Soba, Peter/0000-0002-6163-4686				Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; Coulson EJ, 2000, NEUROCHEM INT, V36, P175, DOI 10.1016/S0197-0186(99)00125-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; DYRKS T, 1994, FEBS LETT, V349, P210, DOI 10.1016/0014-5793(94)00671-7; ELBEIN AD, 1987, METHOD ENZYMOL, V138, P661; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Grziwa B, 2003, J BIOL CHEM, V278, P6803, DOI 10.1074/jbc.M210047200; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Heber S, 2000, J NEUROSCI, V20, P7951; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lichtenthaler SF, 2002, P NATL ACAD SCI USA, V99, P1365, DOI 10.1073/pnas.032395699; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Lyckman AW, 1998, J BIOL CHEM, V273, P11100, DOI 10.1074/jbc.273.18.11100; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Paliga K, 1997, EUR J BIOCHEM, V250, P354, DOI 10.1111/j.1432-1033.1997.0354a.x; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Parvathy S, 1998, BIOCHEM SOC T, V26, pS242, DOI 10.1042/bst026s242; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Simons M, 1996, J NEUROSCI, V16, P899; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Urban S, 2002, EMBO J, V21, P4277, DOI 10.1093/emboj/cdf434; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; WANG R, 1991, J BIOL CHEM, V266, P16960; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEBSTER MT, 1995, BIOCHEM J, V310, P95, DOI 10.1042/bj3100095; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang JM, 2002, J BIOL CHEM, V277, P15069, DOI 10.1074/jbc.M105375200; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X; ZHONG ZY, 1994, J BIOL CHEM, V269, P627	90	178	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18146	18156		10.1074/jbc.M311601200	http://dx.doi.org/10.1074/jbc.M311601200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970212	hybrid			2022-12-27	WOS:000221041500009
J	Girotti, M; Evans, JH; Burke, D; Leslie, CC				Girotti, M; Evans, JH; Burke, D; Leslie, CC			Cytosolic phospholipase A(2) translocates to forming phagosomes during phagocytosis of zymosan in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PATTERN-RECOGNITION RECEPTORS; ACTIVATED PROTEIN-KINASE; MOLECULAR CHARACTERIZATION; PHOSPHORYLATION SITES; MEDIATED PHAGOCYTOSIS; NUCLEAR-ENVELOPE; C2 DOMAIN; CALCIUM; DECTIN-1	Resident tissue macrophages mediate early innate immune responses to microbial infection. Cytosolic phospholipase A(2)alpha (cPLA(2)alpha) is activated in macrophages during phagocytosis of non-opsonized yeast (zymosan) triggering arachidonic acid release and eicosanoid production. cPLA(2)alpha translocates from cytosol to membrane in response to intracellular calcium concentration ([Ca2+](i)) increases. Enhanced green fluorescent protein (EGFP)-cPLA(2)alpha translocated to forming phagosomes, surrounding the zymosan particle by 5 min and completely overlapping with early endosome (Rab5) and plasma membrane (F4/80) markers but only partially overlapping with resident endoplasmic reticulum proteins (GRP78 and cyclooxygenase 2). EGFP-cPLA(2)alpha also localized to membrane ruffles during phagocytosis. Zymosan induced an initial high amplitude calcium transient that preceded particle uptake followed by a low amplitude sustained calcium increase. Both phases were required for optimal phagocytosis. Extracellular calcium chelation prevented only the sustained phase but allowed a limited number of phagocytic events, which were accompanied by translocation of cPLA(2)alpha to the phagosome although [Ca2+](i) remained at resting levels. The results demonstrate that cPLA(2)alpha targets the phagosome membrane, which may serve as a source of arachidonic acid for eicosanoid production.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80206 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org			NHLBI NIH HHS [HL34303, HL61378] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061378] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aderem A, 2002, CELL, V110, P5, DOI 10.1016/S0092-8674(02)00819-X; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; ADEREM AA, 1986, J EXP MED, V163, P139, DOI 10.1084/jem.163.1.139; AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; Anes E, 2003, NAT CELL BIOL, V5, P793, DOI 10.1038/ncb1036; Balla Tamas, 2002, Sci STKE, V2002, ppl3, DOI 10.1126/stke.2002.125.pl3; BONNEY RJ, 1978, BIOCHEM J, V176, P433, DOI 10.1042/bj1760433; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Desjardins M, 2003, NAT REV IMMUNOL, V3, P280, DOI 10.1038/nri1053; DICARLO FJ, 1958, SCIENCE, V127, P756, DOI 10.1126/science.127.3301.756-a; DOHERTY NS, 1985, PROSTAGLANDINS, V30, P769, DOI 10.1016/0090-6980(85)90006-1; Duclos S, 2000, J CELL SCI, V113, P3531; EMILSSON A, 1986, BIOCHIM BIOPHYS ACTA, V876, P533, DOI 10.1016/0005-2760(86)90041-X; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Evans JH, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-30; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gijon MA, 2000, ADV ENZYME REGUL, V40, P255, DOI 10.1016/S0065-2571(99)00031-X; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; GORDON S, 1986, CIBA F SYMP, V118, P54, DOI 10.1002/9780470720998.ch5; Greenberg S, 1999, J LEUKOCYTE BIOL, V66, P712, DOI 10.1002/jlb.66.5.712; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; HISHIKAWA T, 1991, J CELL BIOL, V115, P59, DOI 10.1083/jcb.115.1.59; Hume DA, 2002, J LEUKOCYTE BIOL, V72, P621; HUMES JL, 1977, NATURE, V269, P149, DOI 10.1038/269149a0; Larsen EC, 2000, J IMMUNOL, V165, P2809, DOI 10.4049/jimmunol.165.5.2809; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LUNDY SR, 1990, J IMMUNOL, V144, P2671; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1993, J BIOL CHEM, V268, P24506; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; Shmelzer Z, 2003, J CELL BIOL, V162, P683, DOI 10.1083/jcb.200211056; SierraHonigmann R, 1996, LAB INVEST, V74, P684; Six DA, 2003, J BIOL CHEM, V278, P23842, DOI 10.1074/jbc.M301386200; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Stewart A, 2002, J BIOL CHEM, V277, P29526, DOI 10.1074/jbc.M204856200; Taylor PR, 2003, EUR J IMMUNOL, V33, P2090, DOI 10.1002/eji.200324003; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691; Xia Y, 1999, J IMMUNOL, V162, P2281	68	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19113	19121		10.1074/jbc.M313867200	http://dx.doi.org/10.1074/jbc.M313867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14963030	hybrid			2022-12-27	WOS:000221041500124
J	Meng, YL; Liu, ZJ; Rosen, BP				Meng, YL; Liu, ZJ; Rosen, BP			As(III) and Sb(III) uptake by G1pF and efflux by ArsB in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; PROTON ANTIPORT SYSTEMS; ARSENITE TRANSPORT; MEMBRANE-VESICLES; RESISTANCE; NEUROSPORA; PROTEIN; SUBUNIT; OPERON; GENES	The toxicity of the metalloids arsenic and antimony is related to uptake, whereas detoxification requires efflux. In this report we show that uptake of the trivalent inorganic forms of arsenic and antimony into cells of Escherichia coli is facilitated by the aquaglyceroporin channel GlpF and that transport of Sb(III) is catalyzed by the ArsB carrier protein; everted membrane vesicles accumulated Sb( III) with energy supplied by NADH oxidation, reflecting efflux from intact cells. Dissipation of either the membrane potential or the pH gradient did not prevent Sb( III) uptake, whereas dissipation of both completely uncoupled the carrier protein, suggesting that transport is coupled to either the electrical or the chemical component of the electrochemical proton gradient. Reciprocally, Sb( III) transport via ArsB dissipated both the pH gradient and the membrane potential. These results strongly indicate that ArsB is an antiporter that catalyzes metalloid-proton exchange. Unexpectedly, As( III) inhibited ArsB-mediated Sb( III) uptake, whereas Sb( III) stimulated ArsB-mediated As( III) transport. We propose that the actual substrate of ArsB is a polymer of (AsO)(n), (SbO)(n), or a co-polymer of the two metalloids.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu		Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM52216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK JC, 1979, ARCH BIOCHEM BIOPHYS, V194, P208, DOI 10.1016/0003-9861(79)90611-8; BREY RN, 1978, BIOCHEM BIOPH RES CO, V83, P1588, DOI 10.1016/0006-291X(78)91403-1; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; CHEN CM, 1986, J BIOL CHEM, V261, P5030; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; DEY S, 1994, J BIOL CHEM, V269, P25442; Driessen AJM, 2000, TRENDS BIOCHEM SCI, V25, P397, DOI 10.1016/S0968-0004(00)01634-0; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; HAMSON GC, 1938, J AM CHEM SOC, V60, P1814; Kuroda M, 1997, J BIOL CHEM, V272, P326; Liu ZJ, 2004, J BIOL CHEM, V279, P17312, DOI 10.1074/jbc.M314006200; Liu ZJ, 2002, P NATL ACAD SCI USA, V99, P6053, DOI 10.1073/pnas.092131899; Mukhopadhyay R, 2002, FEMS MICROBIOL REV, V26, P311, DOI 10.1016/S0168-6445(02)00112-2; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; PERLIN DS, 1984, J BIOL CHEM, V259, P7884; Prakash S, 2003, BBA-BIOMEMBRANES, V1618, P79, DOI 10.1016/j.bbamem.2003.10.010; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; ROSEN BP, 1992, ANN NY ACAD SCI, V671, P257, DOI 10.1111/j.1749-6632.1992.tb43801.x; Rosen BP, 1999, TRENDS MICROBIOL, V7, P207, DOI 10.1016/S0966-842X(99)01494-8; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanders OI, 1997, J BACTERIOL, V179, P3365, DOI 10.1128/jb.179.10.3365-3367.1997; SLONCZEWSKI JL, 1981, P NATL ACAD SCI-BIOL, V78, P6271, DOI 10.1073/pnas.78.10.6271; WU JH, 1992, J BIOL CHEM, V267, P12570	24	199	212	6	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18334	18341		10.1074/jbc.M400037200	http://dx.doi.org/10.1074/jbc.M400037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970228	hybrid			2022-12-27	WOS:000221041500030
J	Seki, K; Hata, A				Seki, K; Hata, A			Indian hedgehog gene is a target of the bone morphogenetic protein signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN IMMUNOPRECIPITATION; CHONDROCYTE PROLIFERATION; SMAD PROTEINS; BMP; DIFFERENTIATION; BINDING; DNA; TRANSDUCTION; REGULATORS; ACTIVATION	Bone morphogenetic proteins (BMPs), a large subgroup of the transforming growth factor-beta family of growth factors, are key mediators of many fundamental processes in embryonic development. The BMP target genes mediating these effects and the mechanism of their selective regulation are poorly characterized. In this study, we used a chromatin immunoprecipitation-based gene cloning method to identify BMP target genes in a mouse embryonic carcinoma cell line. We identified the Indian hedgehog (Ihh) gene as a target of BMP signaling. Both reporter and reverses transcription-PCR assays revealed that Ihh is up-regulated in embryonic cells upon BMP treatment. The BMP response element of the Ihh promoter contains multiple GC-rich motifs known as the "Mad/Medea binding box" found in the Drosophila tinman gene and in the mouse Id1 gene. DNA binding studies revealed that Smad4 binds to these GC-rich motifs. These findings indicate that BMP stimulates Ihh expression. We also suggest expression of the Ihh gene, which contains multiple Smad binding sites, might be finely regulated by a gradient of BMP concentrations.	Tufts Univ, Sch Med, Dept Biochem, Tufts New England Med Ctr Mol Cardiol Res Inst, Boston, MA 02111 USA	Tufts University	Hata, A (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Tufts New England Med Ctr Mol Cardiol Res Inst, 750 Washington St,Box 8486, Boston, MA 02111 USA.	akiko.hata@tufts.edu						Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; Minina E, 2001, DEVELOPMENT, V128, P4523; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Rushlow C, 2001, GENE DEV, V15, P340, DOI 10.1101/gad.861401; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	22	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18544	18549		10.1074/jbc.M311592200	http://dx.doi.org/10.1074/jbc.M311592200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14981086	hybrid			2022-12-27	WOS:000221041500056
J	Zoppi, N; Gardella, R; De Paepe, A; Barlati, S; Colombi, M				Zoppi, N; Gardella, R; De Paepe, A; Barlati, S; Colombi, M			Human fibroblasts with mutations in COL5A1 and COL3A1 genes do not organize collagens and fibronectin in the extracellular matrix, down-regulate alpha(2)beta(1) integrin, and recruit alpha(v)beta(3) instead of alpha(5)beta(1) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS-SYNDROME; SKIN FIBROBLASTS; CELL-SURVIVAL; V COLLAGEN; ADHESION; RECEPTOR; CYTOSKELETON; ACTIVATION; INDUCTION	Dermal fibroblasts derived from types I and IV Ehlers-Danlos syndrome (EDS) patients, carrying mutations in COL5A1 and COL3A1 genes, respectively, synthesize aberrant types V and III collagen (COLL) and show defective organization of these proteins into the extracellular matrix (ECM) and high reduction of their functional receptor, the alpha(2)beta(1) integrin, compared with control fibroblasts. EDS cells also show reduced levels of fibronectin (FN) in the culture medium and lack an FN fibrillar network. Finally, EDS cells prevalently organize alpha(v)beta(3) integrin instead of alpha(5)beta(1) integrin. The alpha(v)beta(3) integrin, distributed on the whole EDS cell surface, shows FN binding and assembly properties when the cells are treated with purified FN. Treatment of EDS cells with purified COLLV or COLLIII, but not with FN, restores the control phenotype (COLL+, FN+, alpha(v)beta(3)(-), alpha(5)beta(1)(+), alpha(2)beta(1)(+)). Function-blocking antibodies to COLLV, COLLIII, or alpha(2)beta(1) integrin induce in control fibroblasts an EDS-like phenotype (COLL-, FN-, alpha(v)beta(3)(+), alpha(5)beta(1)(-), alpha(2)beta(1)(-)). These results show that in human fibroblasts alpha(2)beta(1) integrin organization and function are controlled by its ligand, and that the alpha(2)beta(1)-COLL interaction, in turn, regulates FN integrin receptor recruitment: high alpha(2)beta(1) integrin levels induce alpha(5)beta(1) integrin organization, while low alpha(2)beta(1) integrin levels lead to alpha(v)beta(3) integrin organization.	Univ Brescia, Fac Med, Dept Biomed Sci & Biotechnol, Div Biol & Genet, I-25123 Brescia, Italy; Ghent Univ Hosp, Ctr Genet Med, B-9000 Ghent, Belgium	University of Brescia; Ghent University; Ghent University Hospital	Colombi, M (corresponding author), Univ Brescia, Fac Med, Dept Biomed Sci & Biotechnol, Div Biol & Genet, Viale Europa 11, I-25123 Brescia, Italy.	colombi@med.unibs.it	Barlati, Sergio/A-2666-2010	Colombi, Marina/0000-0002-3105-5990; ZOPPI, Nicoletta/0000-0003-0197-8927				Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; BARLATI S, 1991, CELL BIOL INT REP, V15, P1183, DOI 10.1016/0309-1651(91)90090-6; BeauvaisJouneau A, 1997, BIOL CELL, V89, P5, DOI 10.1016/S0248-4900(99)80076-8; Birk DE, 2001, MICRON, V32, P223, DOI 10.1016/S0968-4328(00)00043-3; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; Bouma P, 2001, J BIOL CHEM, V276, P13356, DOI 10.1074/jbc.M011742200; BYERS PH, 1990, EXTRACELLULAR MATRIX, P251; Chernousov MA, 1998, J CELL SCI, V111, P2763; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colombi M, 2003, J BIOL CHEM, V278, P14346, DOI 10.1074/jbc.M211997200; COLVIN RB, 1989, FIBRONECTIN, P213; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DELCOMMENNE M, 1995, J BIOL CHEM, V270, P26794, DOI 10.1074/jbc.270.45.26794; DePaepe A, 1997, AM J HUM GENET, V60, P547; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; Feng XD, 1999, J INVEST DERMATOL, V113, P913, DOI 10.1046/j.1523-1747.1999.00786.x; Gailit J, 1996, J INVEST DERMATOL, V106, P102, DOI 10.1111/1523-1747.ep12328177; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Greiling D, 1997, J CELL SCI, V110, P861; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hangan D, 1996, CANCER RES, V56, P3142; HEDMAN K, 1979, J CELL BIOL, V81, P83, DOI 10.1083/jcb.81.1.83; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILAUTALA T, 1993, GENOMICS, V15, P399; Kielty Cay M., 1993, P103; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Michalickova K, 1998, HUM MOL GENET, V7, P249, DOI 10.1093/hmg/7.2.249; MORO L, 1994, CELL BIOL INT, V18, P29, DOI 10.1006/cbir.1994.1004; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; OLIVER N, 1992, J INVEST DERMATOL, V99, P579, DOI 10.1111/1523-1747.ep12667776; Pope FM, 1997, J MED GENET, V34, P400, DOI 10.1136/jmg.34.5.400; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Retta SF, 2001, MOL BIOL CELL, V12, P3126, DOI 10.1091/mbc.12.10.3126; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sabatelli P, 2001, MATRIX BIOL, V20, P475, DOI 10.1016/S0945-053X(01)00160-3; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Steinmann Beat, 1993, P351; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; TEMPLE AS, 1988, BRIT J DERMATOL, V118, P17, DOI 10.1111/j.1365-2133.1988.tb01745.x; THIERY JP, 1989, FIBRONECTIN, P181; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Vogel WF, 2001, EUR J DERMATOL, V11, P506; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; Wu CY, 1996, CELL ADHES COMMUN, V4, P149, DOI 10.3109/15419069609014219; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zoppi N, 1998, CELL BIOL INT, V22, P499, DOI 10.1006/cbir.1998.0283	60	78	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18157	18168		10.1074/jbc.M312609200	http://dx.doi.org/10.1074/jbc.M312609200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970208	hybrid			2022-12-27	WOS:000221041500010
J	Harrow, F; Amuta, JU; Hutchinson, SR; Akwaa, F; Ortiz, BD				Harrow, F; Amuta, JU; Hutchinson, SR; Akwaa, F; Ortiz, BD			Factors binding a non-classical cis-element prevent heterochromatin effects on locus control region activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; T-CELL-RECEPTOR; TRANSGENIC MICE; GENE-EXPRESSION; TRANSCRIPTION FACTORS; ALPHA LOCUS; DEVELOPMENTAL REGULATION; CHROMOSOMAL INTEGRATION; HISTONE DEACETYLASE; CHROMATIN MODIFIERS	A locus control region (LCR) is a cis-acting gene-regulatory element capable of transferring the expression characteristics of its gene locus of origin to a linked transgene. Furthermore, it can do this independently of the site of integration in the genome of transgenic mice. Although most LCRs contain subelements with classical transcriptional enhancer function, key aspects of LCR activity are supported by cis-acting sequences devoid of the ability to act as direct transcriptional enhancers. Very few of these "non-enhancer" LCR components have been characterized. Consequently, the sequence requirements and molecular bases for their functions, as well as their roles in LCR activity, are poorly understood. We have investigated these questions using the LCR from the mouse T cell receptor (TCR) alpha/Dad1 gene locus. Here we focus on DNase hypersensitive site (HS) 6 of the TCRalpha LCR. HS6 does not support classical enhancer activity, yet has gene regulatory activity in an in vivo chromatin context. We have identified three in vivo occupied factor-binding sites within HS6, two of which interact with Runx1 and Elf-1 factors. Deletion of these sites from the LCR impairs its activity in vivo. This mutation renders the transgene locus abnormally inaccessible in chromatin, preventing the normal function of other LCR subelements and reducing transgene mRNA levels. These data show these factor-binding sites are required for preventing heterochromatin formation and indicate that they function to maintain an active TCRalpha LCR assembly in vivo.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Ortiz, BD (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave,Rm 927-N, New York, NY 10021 USA.	ortiz@genectr.hunter.cuny.edu			NIAID NIH HHS [AI-053050] Funding Source: Medline; NIGMS NIH HHS [GM-060665, GM-007823] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053050, R01AI053050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T34GM007823, R25GM060665] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Anderson MK, 1999, DEVELOPMENT, V126, P3131; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Chauveau C, 1999, J IMMUNOL, V163, P4637; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAZ P, 1994, IMMUNITY, V1, P207, DOI 10.1016/1074-7613(94)90099-X; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Eszterhas SK, 2002, MOL CELL BIOL, V22, P469, DOI 10.1128/MCB.22.2.469-479.2002; Feng YQ, 1999, J MOL BIOL, V292, P779, DOI 10.1006/jmbi.1999.3113; Festenstein R, 2000, CURR OPIN GENET DEV, V10, P199, DOI 10.1016/S0959-437X(00)00060-5; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; Fraser P, 1998, CURR OPIN CELL BIOL, V10, P361, DOI 10.1016/S0955-0674(98)80012-4; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hernandez-Munain C, 1999, IMMUNITY, V10, P723, DOI 10.1016/S1074-7613(00)80071-0; HO IC, 1989, P NATL ACAD SCI USA, V86, P6714, DOI 10.1073/pnas.86.17.6714; Ho YG, 2002, MOL CELL, V9, P291, DOI 10.1016/S1097-2765(02)00447-1; Hong NA, 1997, MOL CELL BIOL, V17, P2151, DOI 10.1128/MCB.17.4.2151; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JIMENEZ G, 1993, MOL CELL ENDOCRINOL, V96, P53, DOI 10.1016/0303-7207(93)90094-Z; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; Kiekhaefer CM, 2004, J BIOL CHEM, V279, P7456, DOI 10.1074/jbc.M309750200; Li QL, 2002, BLOOD, V100, P3077, DOI 10.1182/blood-2002-04-1104; MAGRAM J, 1985, NATURE, V315, P338, DOI 10.1038/315338a0; McMorrow T, 2000, EMBO J, V19, P4986, DOI 10.1093/emboj/19.18.4986; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Molete JM, 2002, GENE, V283, P185, DOI 10.1016/S0378-1119(01)00858-7; Molete JM, 2001, MOL CELL BIOL, V21, P2969, DOI 10.1128/MCB.21.9.2969-2980.2001; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ortiz BD, 1999, MOL CELL BIOL, V19, P1901; Ortiz BD, 1997, EMBO J, V16, P5037, DOI 10.1093/emboj/16.16.5037; Ortiz BD, 2001, J IMMUNOL, V167, P3836, DOI 10.4049/jimmunol.167.7.3836; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PETERSON KR, 1993, MOL CELL BIOL, V13, P4836, DOI 10.1128/MCB.13.8.4836; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; Santoso B, 2000, J BIOL CHEM, V275, P1952, DOI 10.1074/jbc.275.3.1952; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Schubeler D, 2001, P NATL ACAD SCI USA, V98, P11432, DOI 10.1073/pnas.201394698; Sutter NB, 2003, P NATL ACAD SCI USA, V100, P1105, DOI 10.1073/pnas.242732999; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; Vassilopoulos G, 1999, BLOOD, V93, P703, DOI 10.1182/blood.V93.2.703.402k07_703_712; Westendorf JJ, 1999, J CELL BIOCHEM, P51; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; Wolffe AP, 1996, TRENDS GENET, V12, P58, DOI 10.1016/0168-9525(96)81401-6; WU C, 1989, METHOD ENZYMOL, V170, P269; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; Zhuma T, 1999, EMBO J, V18, P6396, DOI 10.1093/emboj/18.22.6396	57	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17842	17849		10.1074/jbc.M401258200	http://dx.doi.org/10.1074/jbc.M401258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966120	hybrid			2022-12-27	WOS:000220870400117
J	Liu, EB; Li, XH; Yan, F; Zhao, QP; Wu, XH				Liu, EB; Li, XH; Yan, F; Zhao, QP; Wu, XH			Cyclin-dependent kinases phosphorylate human Cdt1 and induce its degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; S-PHASE; LICENSING FACTOR; PROTEIN; PROTEOLYSIS; P65(CDC18); TRANSITION; INITIATION	Eukaryotic cells tightly control DNA replication so that replication origins fire only once during S phase within the same cell cycle. Cell cycle-regulated degradation of the replication licensing factor Cdt1 plays important roles in preventing more than one round of DNA replication per cell cycle. We have previously shown that the SCFSkp2-mediated ubiquitination pathway plays an important role in Cdt1 degradation. In this study, we demonstrate that human Cdt1 is a substrate of Cdk2 and Cdk4 both in vivo and in vitro. Overexpression of cyclin-dependent kinase inhibitors such as p21 and p27 dramatically suppresses the phosphorylation of Cdt1, disrupts the interaction of Cdt1 with the F-box protein Skp2, and blocks the degradation of Cdt1. Further analysis reveals that Cdt1 interacts with cyclin/cyclin-dependent kinase (Cdk) complexes through a cyclin/Cdk binding consensus site, located at the N terminus of Cdt1. A Cdt1 mutant carrying four amino acid substitutions at the Cdk binding site dramatically reduces associations with cyclin/Cdk complexes. This mutant is not phosphorylated, fails to bind Skp2 and is more stable than wild-type Cdt1. These data suggest that cyclin/Cdk-mediated Cdt1 phosphorylation is required for the association of Cdt1 with the SCFSkp2 ubiquitin ligase and thus is important for the cell cycle dependent degradation of Cdt1 in mammalian cells.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Wu, XH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	xiaohwu@scripps.edu						Adams PD, 1996, MOL CELL BIOL, V16, P6623; Baum B, 1998, EMBO J, V17, P5689, DOI 10.1093/emboj/17.19.5689; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Rialland M, 2002, J CELL SCI, V115, P1435; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089	26	148	151	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17283	17288		10.1074/jbc.C300549200	http://dx.doi.org/10.1074/jbc.C300549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	15004027	hybrid			2022-12-27	WOS:000220870400050
J	Sutovsky, H; Gazit, E				Sutovsky, H; Gazit, E			The von Hippel-Lindau tumor suppressor protein is a molten globule under native conditions - Implications for its physiological activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIRES DIRECT BINDING; WILD-TYPE; THERMODYNAMIC STABILITY; UBIQUITIN LIGASE; MOLECULAR-BASIS; GENE-PRODUCT; DNA-BINDING; COMPLEX; DOMAIN; P53	The von-Hippel Lindau tumor suppressor protein (pVHL) is conserved throughout evolution, as its homologues are found in organisms ranging from mammals to the Drosophila melanogaster and Anopheles gambiae insects and the Caenorhabditis elegans nematode. Although the physiological role of pVHL is not fully understood, it has been shown to interact with a large number of unrelated proteins and was suggested to play a role in protein degradation as an E3 ubiquitin ligase component in the ubiquitin pathway. To gain insight into the molecular basis of pVHL activity, we analyzed its folding and stability in solution under physiologically relevant conditions. Dynamic light-scattering and gel filtration chromatography of the purified pVHL clearly indicated that the Stokes radius of the protein is larger than what would be expected from its crystal structure. However, under these conditions, the protein shows a clear secondary structure as determined by far-UV circular dichroism. Yet, the near-UV CD experiments show an absence of a tertiary structure. Upon the addition of urea, even at very low concentrations, the protein unfolds in a non-reversible manner, leading to the formation of amorphous aggregates. Furthermore, a large increase in fluorescence (>50-fold) is observed upon the addition of pVHL into a solution containing 8-anilino-1-naphthalene sulfonic acid. We therefore conclude that, under native conditions, the non-bound pVHL has a molten globule configuration with marginal stability. Although molten globular structures can be induced in many proteins under extreme conditions, this is one of the few reported cases of such a structure under the physiological conditions of pH, ionic strength, and temperature. The significance of the pVHL structural properties is being discussed in the context of its physiological activities.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gazit, E (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	ehudg@post.tau.ac.il	Gazit, Ehud/C-3715-2011; Gazit, Ehud/AHE-9332-2022; Gazit, Ehud/M-8026-2019	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720				ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Bychkova VE, 1998, FOLD DES, V3, P285, DOI 10.1016/S1359-0278(98)00039-X; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conaway JW, 1998, BBA-REV CANCER, V1377, pM49, DOI 10.1016/S0304-419X(97)00035-8; Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Esteban-Barragan MA, 2002, CANCER RES, V62, P2929; Farrell HM, 2002, J DAIRY SCI, V85, P459, DOI 10.3168/jds.S0022-0302(02)74096-4; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Gazit E, 1997, BIOCHEMISTRY-US, V36, P15546, DOI 10.1021/bi9707584; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamura T, 2002, J BIOL CHEM, V277, P30388, DOI 10.1074/jbc.M203344200; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KISHIDA T, 1995, CANCER RES, V55, P4544; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Melville MW, 2003, MOL CELL BIOL, V23, P3141, DOI 10.1128/MCB.23.9.3141-3151.2003; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pioli PA, 2001, J BIOL CHEM, V276, P40346, DOI 10.1074/jbc.M105391200; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Shutova T, 2000, FEBS LETT, V467, P137, DOI 10.1016/S0014-5793(00)01115-7; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tang KS, 1999, J MOL BIOL, V285, P1869, DOI 10.1006/jmbi.1998.2420; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Zhou MI, 2002, J BIOL CHEM, V277, P39887, DOI 10.1074/jbc.M205040200	50	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17190	17196		10.1074/jbc.M311225200	http://dx.doi.org/10.1074/jbc.M311225200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963040	hybrid			2022-12-27	WOS:000220870400039
J	Boussac, A; Rappaport, F; Carrier, P; Verbavatz, JM; Gobin, R; Kirilovsky, D; Rutherford, AW; Sugiura, M				Boussac, A; Rappaport, F; Carrier, P; Verbavatz, JM; Gobin, R; Kirilovsky, D; Rutherford, AW; Sugiura, M			Biosynthetic Ca2+/Sr2+ exchange in the photosystem II oxygen-evolving enzyme of Thermosynechococcus elongatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE Y-Z; CYANOBACTERIUM SYNECHOCOCCUS-ELONGATUS; PHOTOSYNTHETIC WATER OXIDATION; AMINO-ACID-RESIDUES; MANGANESE CLUSTER; MN CLUSTER; OXIDIZING COMPLEX; CRYSTAL-STRUCTURE; PSII MEMBRANES; EVOLUTION	The thermophilic cyanobacterium, Thermosynechococcus elongatus, has been grown in the presence of Sr2+ instead of Ca2+ with the aim of biosynthetically replacing the Ca2+ of the oxygen-evolving enzyme with Sr2+. Not only were the cells able to grow normally with Sr2+, they actively accumulated the ion to levels higher than those of Ca2+ in the normal cultures. A protocol was developed to purify a fully active Sr2+-containing photosystem II (PSII). The modified enzyme contained a normal polypeptide profile and 1 strontium/4 manganese, indicating that the normal enzyme contains 1 calcium/4 manganese. The Sr2+- and Ca2+-containing enzymes were compared using EPR spectroscopy, UV-visible absorption spectroscopy, and O-2 polarography. The Ca2+/Sr2+ exchange resulted in the modification of the EPR spectrum of the manganese cluster and a slower turnover of the redox cycle (the so-called S-state cycle), resulting in diminished O-2 evolution activity under continuous saturating light: all features reported previously by biochemical Ca2+/Sr2+ exchange in plant PSII. This allays doubts that these changes could be because of secondary effects induced by the biochemical treatments themselves. In addition, the Sr2+-containing PSII has other kinetics modifications: 1) it has an increased stability of the S-3 redox state; 2) it shows an increase in the rate of electron donation from Tyr(D), the redox-active tyrosine of the D-2 protein, to the oxygen-evolving complex in the S-3-state forming S-2; 3) the rate of oxidation of the S-0-state to the S-1-state by Tyr(D)(.) is increased; and 4) the release of O-2 is slowed down to an extent similar to that seen for the slow-down of the S(3)Tyr(Z)(.) to S(0)Tyr(Z) transition, consistent with the latter constituting the limiting step of the water oxidation mechanism in Sr2+-substituted enzyme as well as in the normal enzyme. The replacement of Ca2+ by Sr2+ appears to have multiple effects on kinetics properties of the enzyme that may be explained by S-state-dependent shifts in the redox properties of both the manganese complex and Tyr(Z) as well as structural effects.	CEA Saclay, Serv Bioenerget, DBJC, URA 2096,CNRS, F-91191 Gif Sur Yvette, France; Inst Biol Physicochim, CNRS, UPR 1261, F-75005 Paris, France; CEA Cadarache, Lab Ecool Photosynthese, DEVM, F-13108 St Paul Les Durance, France; CEA Saclay, Serv Biophys Fonct Membranaires, DBJC, F-91191 Gif Sur Yvette, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CEA; CEA; UDICE-French Research Universities; Universite Paris Saclay	Boussac, A (corresponding author), CEA Saclay, Serv Bioenerget, DBJC, URA 2096,CNRS, F-91191 Gif Sur Yvette, France.	alain.boussac@cea.fr	Rutherford, Alfred W/A-7831-2019; Kirilovsky, Diana/I-2359-2014	Rutherford, Alfred W/0000-0002-3124-154X; Kirilovsky, Diana/0000-0003-2146-3103; Verbavatz, Jean-Marc/0000-0002-4654-1174; Rappaport, Fabrice/0000-0001-9377-4934				ADELROTH P, 1995, BIOCHEMISTRY-US, V34, P9021, DOI 10.1021/bi00028a010; Ananyev GM, 2001, BBA-BIOENERGETICS, V1503, P52, DOI 10.1016/S0005-2728(00)00215-2; Barber J, 2002, CURR OPIN STRUC BIOL, V12, P523, DOI 10.1016/S0959-440X(02)00357-3; Beal D, 1999, REV SCI INSTRUM, V70, P202, DOI 10.1063/1.1149566; BECKER DW, 1985, PLANT PHYSIOL, V79, P552, DOI 10.1104/pp.79.2.552; Bernat G, 2002, BIOCHEMISTRY-US, V41, P5830, DOI 10.1021/bi011691u; Boussac A, 1999, BIOCHEMISTRY-US, V38, P11942, DOI 10.1021/bi990845r; Boussac A, 2000, BIOCHEMISTRY-US, V39, P13788, DOI 10.1021/bi001159r; BOUSSAC A, 1992, BIOCHEMISTRY-US, V31, P1224, DOI 10.1021/bi00119a036; BOUSSAC A, 1995, BBA-BIOENERGETICS, V1230, P195, DOI 10.1016/0005-2728(95)00061-M; BOUSSAC A, 1989, BIOCHEMISTRY-US, V28, P8984, DOI 10.1021/bi00449a005; Boussac A, 1998, BIOCHEMISTRY-US, V37, P8995, DOI 10.1021/bi980195b; BOUSSAC A, 1988, BIOCHEMISTRY-US, V27, P3476, DOI 10.1021/bi00409a052; BOUSSAC A, 1992, PHOTOSYNTH RES, V32, P207, DOI 10.1007/BF00034796; BOUSSAC A, 1990, NATURE, V347, P303, DOI 10.1038/347303a0; BOUSSAC A, 1988, FEBS LETT, V236, P432, DOI 10.1016/0014-5793(88)80071-1; Boussac A, 1998, BIOCHEMISTRY-US, V37, P4001, DOI 10.1021/bi9728710; BRITT RD, 2004, IN PRESS BIOCH BIOPH; Carrier P, 2003, PLANTA, V216, P939, DOI 10.1007/s00425-002-0947-6; Chen THH, 2002, CURR OPIN PLANT BIOL, V5, P250, DOI 10.1016/S1369-5266(02)00255-8; Chu HA, 2000, BIOCHEMISTRY-US, V39, P14371, DOI 10.1021/bi001751g; Cinco RM, 1998, J PHYS CHEM B, V102, P8248, DOI 10.1021/jp981658q; Cinco RM, 2002, BIOCHEMISTRY-US, V41, P12928, DOI 10.1021/bi026569p; CLAUSEN J, 2004, IN PRESS BIOCH BIOPH; Debus RJ, 2001, BBA-BIOENERGETICS, V1503, P164, DOI 10.1016/S0005-2728(00)00221-8; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEKKER JP, 1984, BIOCHIM BIOPHYS ACTA, V767, P515, DOI 10.1016/0005-2728(84)90050-1; Diner BA, 2001, BBA-BIOENERGETICS, V1503, P147, DOI 10.1016/S0005-2728(00)00220-6; Douglas S, 1998, CAN J MICROBIOL, V44, P128, DOI 10.1139/cjm-44-2-128; Enami I, 2003, PLANT CELL PHYSIOL, V44, P820, DOI 10.1093/pcp/pcg106; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; GHANOTAKIS DF, 1984, FEBS LETT, V167, P120; GILCHRIST ML, 1995, P NATL ACAD SCI USA, V92, P9545, DOI 10.1073/pnas.92.21.9545; HAN K, 1993, PLANT CELL PHYSIOL, V34, P585; Haumann M, 1999, BBA-BIOENERGETICS, V1411, P121, DOI 10.1016/S0005-2728(99)00045-6; Hendry G, 2003, BIOCHEMISTRY-US, V42, P6209, DOI 10.1021/bi034279i; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; Isgandarova S, 2003, BIOCHEMISTRY-US, V42, P8929, DOI 10.1021/bi034744b; Jegerschold C, 2000, J BIOL CHEM, V275, P12781, DOI 10.1074/jbc.275.17.12781; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; KARNOVSKY MJ, 1971, J CELL BIOL, V51, P146; Kimura Y, 2002, BIOCHEMISTRY-US, V41, P5844, DOI 10.1021/bi016093u; KODERA Y, 1995, BBA-BIOENERGETICS, V1232, P43, DOI 10.1016/0005-2728(95)00108-3; Kretschmann H, 1996, BBA-BIOENERGETICS, V1274, P1, DOI 10.1016/0005-2728(95)00150-6; Kuhl H, 1999, EUR J BIOCHEM, V266, P453, DOI 10.1046/j.1432-1327.1999.00877.x; LAVERGNE J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P175, DOI 10.1016/S0005-2728(09)91005-2; LAVOREL J, 1976, J THEOR BIOL, V57, P171, DOI 10.1016/S0022-5193(76)80011-2; LAVOREL J, 1992, BIOCHIM BIOPHYS ACTA, V1101, P33, DOI 10.1016/0167-4838(92)90463-N; MIYAO M, 1987, BIOCHIM BIOPHYS ACTA, V890, P151, DOI 10.1016/0005-2728(87)90016-8; Noguchi T, 2002, BIOCHEMISTRY-US, V41, P15706, DOI 10.1021/bi020603i; Olesen K, 2003, BIOCHEMISTRY-US, V42, P2025, DOI 10.1021/bi026175y; PAULY S, 1992, BIOCHIM BIOPHYS ACTA, V1099, P203, DOI 10.1016/0304-4173(92)90029-E; Pecoraro VL, 1998, PURE APPL CHEM, V70, P925, DOI 10.1351/pac199870040925; Peloquin JM, 2001, BBA-BIOENERGETICS, V1503, P96, DOI 10.1016/S0005-2728(00)00219-X; Porra RJ., 1991, CHLOROPHYLLS, P31; RAPPAPORT F, 1994, BBA-BIOENERGETICS, V1184, P178, DOI 10.1016/0005-2728(94)90222-4; Razeghifard MR, 1997, BBA-BIOENERGETICS, V1322, P141; Robblee JH, 2001, BBA-BIOENERGETICS, V1503, P7, DOI 10.1016/S0005-2728(00)00217-6; Roncel M, 2003, J BIOL INORG CHEM, V8, P206, DOI 10.1007/s00775-002-0406-7; RUTHERFORD AW, 1989, TRENDS BIOCHEM SCI, V14, P227, DOI 10.1016/0968-0004(89)90032-7; SCHULTZELAM S, 1994, APPL ENVIRON MICROB, V60, P447, DOI 10.1128/AEM.60.2.447-453.1994; SHEN JR, 1988, BIOCHIM BIOPHYS ACTA, V933, P358, DOI 10.1016/0005-2728(88)90043-6; SHEN JR, 1991, PLANT CELL PHYSIOL, V32, P439, DOI 10.1093/oxfordjournals.pcp.a078099; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; Sugiura M, 1999, PLANT CELL PHYSIOL, V40, P1219, DOI 10.1093/oxfordjournals.pcp.a029510; Tang XS, 1996, J AM CHEM SOC, V118, P7638, DOI 10.1021/ja9610592; VANDERMEULEN KA, 2004, IN PRESS BIOCH BIOPH; VOELKER M, 1987, Biochimica et Biophysica Acta, V890, P66; Vrettos JS, 2002, PHILOS T R SOC B, V357, P1395, DOI 10.1098/rstb.2002.1136; Vrettos JS, 2001, BIOCHEMISTRY-US, V40, P7937, DOI 10.1021/bi010679z; Vrettos JS, 2001, BBA-BIOENERGETICS, V1503, P229, DOI 10.1016/S0005-2728(00)00214-0; Westphal KL, 2000, BIOCHEMISTRY-US, V39, P16220, DOI 10.1021/bi0018077; YERKES CT, 1981, BIOCHIM BIOPHYS ACTA, V634, P19, DOI 10.1016/0005-2728(81)90124-9; YOCUM CF, 1991, BIOCHIM BIOPHYS ACTA, V1059, P1, DOI 10.1016/S0005-2728(05)80182-3; ZIMMERMANN JL, 1986, BIOCHIM BIOPHYS ACTA, V851, P416, DOI 10.1016/0005-2728(86)90078-2; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	76	131	132	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22809	22819		10.1074/jbc.M401677200	http://dx.doi.org/10.1074/jbc.M401677200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	14990562	hybrid			2022-12-27	WOS:000221570900006
J	Suzuki, M; Mizuno, A				Suzuki, M; Mizuno, A			A novel human Cl- channel family related to Drosophila flightless locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDUCTANCE CHLORIDE CHANNELS; SMOOTH-MUSCLE; CURRENTS; SELECTIVITY; ACTIVATION; MYOCYTES; CELLS; GENE	Large conductance chloride (maxi-Cl-) currents have been recorded in some cells, but there is still little information on the molecular nature of the channel underlying this conductance. We report here that tweety, a gene located in Drosophila flightless, has a structure similar to those of known channels and that human homologues of tweety (hTTYH1-3) are novel maxi-Cl- channels. hTTYH3 mRNA was found to be distributed in excitable tissues. The whole cell current of hTTYH3 was large enough to be discriminated from the control but emerged only after treatment with ionomycin. Analysis of pore mutants suggested that positively charged amino acids contributed to anion selectivity. Like a maxi-Cl- channel in situ, the hTTYH3 single channel showed 26-picosiemen linear current voltage, complex kinetics, 4,4'-diisothiocyanato-stilbene-2,2'-disulfonic acid sensitivity, subconductance, and the permeability order of I- > Br- > Cl-. Similarly, hTTYH2 encoded an ionomycin-induced maxi-Cl- channel, but TTYH1 encoded a Ca2+-independent and swelling-activated maxi-Cl- channel. Therefore, the hTTYH family encoded maxi-Cl- channels of mammals. Further studies on the hTTYH family should lead to the elucidation of physiological and pathophysiological roles of novel Cl- channel molecules.	Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University	Suzuki, M (corresponding author), Jichi Med Sch, Dept Pharmacol, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	macsuz@jichi.ac.jp						Bell PD, 2003, P NATL ACAD SCI USA, V100, P4322, DOI 10.1073/pnas.0736323100; Campbell HD, 2000, GENOMICS, V68, P89, DOI 10.1006/geno.2000.6259; COULOMBE A, 1992, PFLUG ARCH EUR J PHY, V422, P143, DOI 10.1007/BF00370413; Diaz M, 2001, J PHYSIOL-LONDON, V536, P79, DOI 10.1111/j.1469-7793.2001.00079.x; DIXON DM, 1993, J MEMBRANE BIOL, V131, P143, DOI 10.1007/BF02791323; FAHMI M, 1995, AM J PHYSIOL-ENDOC M, V269, pE969, DOI 10.1152/ajpendo.1995.269.5.E969; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; GROSCHNER K, 1992, PFLUG ARCH EUR J PHY, V421, P209, DOI 10.1007/BF00374829; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Hille B., 1992, IONIC CHANNELS EXCIT, P337, DOI 10.1016/0014-5793(92)81020-M; HURNAK O, 1993, GEN PHYSIOL BIOPHYS, V12, P171; HUSSY N, 1992, J NEUROPHYSIOL, V68, P2042, DOI 10.1152/jn.1992.68.6.2042; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; KEMP PJ, 1993, AM J PHYSIOL, V265, pL323, DOI 10.1152/ajplung.1993.265.4.L323; KOKUBUN S, 1991, PFLUG ARCH EUR J PHY, V418, P204, DOI 10.1007/BF00370515; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; PACAUD P, 1992, PFLUG ARCH EUR J PHY, V421, P125, DOI 10.1007/BF00374818; PAHAPILL PA, 1992, J MEMBRANE BIOL, V125, P171; Piskorowski R, 2002, NATURE, V420, P499, DOI 10.1038/nature01199; Sabirov RZ, 2001, J GEN PHYSIOL, V118, P251, DOI 10.1085/jgp.118.3.251; Schreiber M, 1999, NAT NEUROSCI, V2, P416, DOI 10.1038/8077; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SUN XP, 1993, AM J PHYSIOL, V264, pG774, DOI 10.1152/ajpgi.1993.264.4.G774; SUN XP, 1992, J PHYSIOL-LONDON, V448, P355, DOI 10.1113/jphysiol.1992.sp019046; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; SUZUKI M, 1991, J CLIN INVEST, V88, P735, DOI 10.1172/JCI115370; THORN P, 1987, Q J EXP PHYSIOL CMS, V72, P31, DOI 10.1113/expphysiol.1987.sp003053; WRIGHT EM, 1977, PHYSIOL REV, V57, P109, DOI 10.1152/physrev.1977.57.1.109; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	34	111	119	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22461	22468		10.1074/jbc.M313813200	http://dx.doi.org/10.1074/jbc.M313813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15010458	hybrid			2022-12-27	WOS:000221417100095
J	Irshad, S; Pedley, RB; Anderson, J; Latchman, DS; Budhram-Mahadeo, V				Irshad, S; Pedley, RB; Anderson, J; Latchman, DS; Budhram-Mahadeo, V			The Brn-3b transcription factor regulates the growth, behavior, and invasiveness of human neuroblastoma cells in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING SYNAPTIC PROTEINS; NEURONAL PROCESS OUTGROWTH; PEDIATRIC-ONCOLOGY-GROUP; RETINOIC ACID; POU DOMAIN; EXPRESSION; GENE; AMPLIFICATION; ONCOGENE; ASSOCIATION	Neuroblastomas are the second most common solid tumor in children but the molecular mechanisms underlying the initiation and progression of this disease are poorly understood. We previously showed that the Brn-3b transcription factor is highly expressed in actively proliferating neuroblastoma cells but is significantly decreased when these cells are induced to differentiate. In this study, we analyzed the effects of manipulating Brn-3b levels in the human neuroblastoma cell line, IMR-32 and showed that constitutive overexpression of Brn-3b consistently increased cellular growth and proliferation in monolayer as well as in an anchorage-independent manner compared with controls whereas stably decreasing Brn-3b can reduce the rate of growth of these cells. Cells with high Brn-3b also fail to respond to growth inhibitory retinoic acid, as they continue to proliferate. Moreover, Brn-3b levels significantly modified tumor growth in vivo with elevated Brn-3b resulting in faster tumor growth in xenograft models whereas decreasing Brn-3b resulted in slower growth compared with controls. Interestingly, elevated Brn-3b levels also enhances the invasive capacity of these neuroblastoma cells with significantly larger numbers of migrating cells observed in overexpressing clones compared with controls. Because invasion and metastasis influence morbidity and mortality in neuroblastoma and so significantly affect the course and outcome of neuroblastomas, this finding is very important. Our results therefore suggest that Brn-3b transcription factor contributes to proliferation of neuroblastoma cells in vivo and in vitro but may also influence progression and/or invasion during tumorigenesis. It is possible that decreasing Brn-3b levels may reverse some effects on growth and proliferation of these cells.	Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; Inst Child Hlth, Unit Mol Haematol, London WC1N 1EH, England; UCL Royal Free & Univ Coll Med Sch, Dept Oncol, Canc Res UK Targeting & Imaging Grp, London NW3 2PF, England	University of London; University College London; University of London; University College London; Cancer Research UK; University of London; University College London; UCL Medical School	Budhram-Mahadeo, V (corresponding author), Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	v.mahadeo@ich.ucl.ac.uk		Anderson, William/0000-0001-7509-3203				Alvarado CS, 2000, J PEDIAT HEMATOL ONC, V22, P197, DOI 10.1097/00043426-200005000-00003; Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; Brodeur G M, 1985, Prog Clin Biol Res, V175, P105; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Budhram-Mahadeo V, 2001, INT J BIOCHEM CELL B, V33, P1027, DOI 10.1016/S1357-2725(01)00069-3; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; Castleberry RP, 1997, EUR J CANCER, V33, P1430, DOI 10.1016/S0959-8049(97)00308-0; CHRISTIANSEN H, 1988, BRIT J CANCER, V57, P121, DOI 10.1038/bjc.1988.24; Dachs GU, 2000, BRIT J CANCER, V83, P662, DOI 10.1054/bjoc.2000.1318; Dennis JH, 2001, ONCOGENE, V20, P4961, DOI 10.1038/sj.onc.1204491; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; Hart SL, 1998, HUM GENE THER, V9, P575, DOI 10.1089/hum.1998.9.4-575; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; Katzenstein HM, 1998, J CLIN ONCOL, V16, P2007, DOI 10.1200/JCO.1998.16.6.2007; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; Latchman DS, 1998, INT J BIOCHEM CELL B, V30, P1153, DOI 10.1016/S1357-2725(98)00090-9; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Maniatis T, MOL CLONING LAB MANU; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Morris PJ, 1996, MOL BRAIN RES, V43, P279, DOI 10.1016/S0169-328X(96)00207-0; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Smith MD, 1997, J BIOL CHEM, V272, P21325, DOI 10.1074/jbc.272.34.21325; Smith MD, 1997, J BIOL CHEM, V272, P1382, DOI 10.1074/jbc.272.2.1382; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Theil T, 1995, J BIOL CHEM, V270, P30958, DOI 10.1074/jbc.270.52.30958; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Zaizen Y, 1998, J PEDIATR SURG, V33, P1765, DOI 10.1016/S0022-3468(98)90281-0	36	28	31	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21617	21627		10.1074/jbc.M312506200	http://dx.doi.org/10.1074/jbc.M312506200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14970234	hybrid			2022-12-27	WOS:000221273800128
J	Asai, T; Takahashi, T; Esaki, M; Nishikawa, S; Ohtsuka, K; Nakai, M; Endo, T				Asai, T; Takahashi, T; Esaki, M; Nishikawa, S; Ohtsuka, K; Nakai, M; Endo, T			Reinvestigation of the requirement of cytosolic ATP for mitochondrial protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; PRECURSOR PROTEINS; YEAST MITOCHONDRIA; NUCLEOSIDE TRIPHOSPHATES; CYTOPLASMIC CHAPERONES; INTERMEMBRANE SPACE; INNER MEMBRANE; RECEPTOR TOM70; TRANSLOCATION; PREPROTEINS	Protein import into mitochondria requires the energy of ATP hydrolysis inside and/or outside mitochondria. Although the role of ATP in the mitochondrial matrix in mitochondrial protein import has been extensively studied, the role of ATP outside mitochondria (external ATP) remains only poorly characterized. Here we developed a protocol for depletion of external ATP without significantly reducing the import competence of precursor proteins synthesized in vitro with reticulocyte lysate. We tested the effects of external ATP on the import of various precursor proteins into isolated yeast mitochondria. We found that external ATP is required for maintenance of the import competence of mitochondrial precursor proteins but that, once they bind to mitochondria, the subsequent translocation of presequence-containing proteins, but not the ADP/ATP carrier, proceeds independently of external ATP. Because depletion of cytosolic Hsp70 led to a decrease in the import competence of mitochondrial precursor proteins, external ATP is likely utilized by cytosolic Hsp70. In contrast, the ADP/ATP carrier requires external ATP for efficient import into mitochondria even after binding to mitochondria, a situation that is only partly attributed to cytosolic Hsp70.	Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Chubu Univ, Dept Environm Biol, Aichi 4878501, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolutional Sci & Technol, Kawaguchi, Saitama 3320012, Japan	Nagoya University; Chubu University; Osaka University; Japan Science & Technology Agency (JST)	Endo, T (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Esaki, Masatoshi/L-6591-2017; Esaki, Masatoshi/ABS-6645-2022					Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; DAUM G, 1982, J BIOL CHEM, V257, P3028; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Esaki M, 1999, P NATL ACAD SCI USA, V96, P11770, DOI 10.1073/pnas.96.21.11770; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; Herrmann JM, 2000, BBA-BIOENERGETICS, V1459, P331, DOI 10.1016/S0005-2728(00)00169-9; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Horst M, 1997, BBA-BIOENERGETICS, V1318, P71, DOI 10.1016/S0005-2728(96)00131-4; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; Kanamori T, 1999, P NATL ACAD SCI USA, V96, P3634, DOI 10.1073/pnas.96.7.3634; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; Kubo Y, 1999, J MOL BIOL, V286, P447, DOI 10.1006/jmbi.1998.2465; LAIN B, 1994, J BIOL CHEM, V269, P15588; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1990, J BIOL CHEM, V265, P16324; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; Terada K, 1996, MOL CELL BIOL, V16, P6103; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	40	17	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19464	19470		10.1074/jbc.M401291200	http://dx.doi.org/10.1074/jbc.M401291200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15001571	hybrid			2022-12-27	WOS:000221164500012
J	Becamel, C; Gavarini, S; Chanrion, B; Alonso, G; Galeotti, N; Dumuis, A; Bockaert, J; Marin, P				Becamel, C; Gavarini, S; Chanrion, B; Alonso, G; Galeotti, N; Dumuis, A; Bockaert, J; Marin, P			The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of PDZ proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; SIGNAL-TRANSDUCTION; DOMAIN PROTEIN; 2C RECEPTORS; ADULT-RAT; COMPLEX; PSD-95; LOCALIZATION; BRAIN; 5-HYDROXYTRYPTAMINE(2C)	The 5-hydroxytryptamine type 2A (5-HT2A) receptor and the 5-HT2C receptor are closely related members of the G-protein-coupled receptors activated by serotonin that share very similar pharmacological profiles and cellular signaling pathways. These receptors express a canonical class I PDZ ligand (SXV) at their C-terminal extremity. Here, we have identified proteins that interact with the PDZ ligand of the 5-HT2A and 5-HT2C receptors by a proteomic approach associating affinity chromatography using immobilized synthetic peptides encompassing the PDZ ligand and mass spectrometry. We report that both receptor C termini interact with specific sets of PDZ proteins in vitro. The 5-HT2C receptor but not the 5-HT2A receptor binds to the Veli-3.CASK.Mint1 ternary complex and to SAP102. In addition, the 5-HT2C receptor binds more strongly to PSD-95 and MPP-3 than the 5-HT2A receptor. In contrast, a robust interaction between the 5-HT2A receptor and the channel-interacting PDZ protein CIPP was found, whereas CIPP did not significantly associate with the 5-HT2C receptor. We also show that residues located at the -1 position and upstream the PDZ ligand in the C terminus of the 5-HT2A and 5-HT2C receptors are major determinants in their interaction with specific PDZ proteins. Immunofluorescence and electron microscopy studies strongly suggested that these specific interactions also take place in living cells and that the 5-HT2 receptor-PDZ protein complexes occur in intracellular compartments. The interaction of the 5-HT2A and the 5-HT2C receptor with specific sets of PDZ proteins may contribute to their different signal transduction properties.	CNRS, UPR 2580, F-34094 Montpellier 5, France; CNRS, UMR 5101, F-34094 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Marin, P (corresponding author), CNRS, UPR 2580, 141 Rue Cardonille, F-34094 Montpellier 5, France.	philippe.marin@ccipe.cnrs.fr	Galeotti, Nicoletta/Y-1720-2019; Galeotti, Nicoletta/N-1093-2015	Galeotti, Nicoletta/0000-0002-1812-9844; Galeotti, Nicoletta/0000-0002-1812-9844				Abramowski D, 1995, NEUROPHARMACOLOGY, V34, P1635, DOI 10.1016/0028-3908(95)00138-7; Aghajanian GK, 2000, BRAIN RES REV, V31, P302, DOI 10.1016/S0165-0173(99)00046-6; Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Aoki C, 2001, SYNAPSE, V40, P239, DOI 10.1002/syn.1047; Backstrom JR, 2000, J BIOL CHEM, V275, P23620, DOI 10.1074/jbc.M000922200; Becamel C, 2002, EMBO J, V21, P2332, DOI 10.1093/emboj/21.10.2332; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Becamel Carine, 2002, Biological Procedures Online, V4, P94, DOI 10.1251/bpo39; BERG KA, 1994, MOL PHARMACOL, V46, P477; Berg KA, 2001, J PHARMACOL EXP THER, V299, P593; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Birrane G, 2003, J BIOL CHEM, V278, P1399, DOI 10.1074/jbc.C200571200; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Christopherson KS, 2003, J CELL SCI, V116, P3213, DOI 10.1242/jcs.00617; Cornea-Hebert V, 2002, NEUROSCIENCE, V113, P23, DOI 10.1016/S0306-4522(02)00146-X; Cornea-Hebert V, 1999, J COMP NEUROL, V409, P187, DOI 10.1002/(SICI)1096-9861(19990628)409:2<187::AID-CNE2>3.0.CO;2-P; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Fujita A, 2000, BIOCHEM BIOPH RES CO, V269, P1, DOI 10.1006/bbrc.1999.1893; Grotewiel MS, 1999, N-S ARCH PHARMACOL, V359, P21, DOI 10.1007/PL00005318; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Karnak D, 2002, J BIOL CHEM, V277, P46730, DOI 10.1074/jbc.M208781200; Kreienkamp HJ, 2002, CURR OPIN PHARMACOL, V2, P581, DOI 10.1016/S1471-4892(02)00203-5; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Lin LH, 1998, BBA-GENE STRUCT EXPR, V1443, P211, DOI 10.1016/S0167-4781(98)00209-7; Long JF, 2003, J MOL BIOL, V327, P203, DOI 10.1016/S0022-2836(03)00113-X; MELTZER HY, 1989, J PHARMACOL EXP THER, V251, P238; Miner LAH, 2003, NEUROSCIENCE, V116, P107, DOI 10.1016/S0306-4522(02)00580-8; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; NOURRY C, 2003, SCI STKE; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Parker LL, 2003, J BIOL CHEM, V278, P21576, DOI 10.1074/jbc.M210973200; Phelan SA, 1999, ANTIOXID REDOX SIGN, V1, P571, DOI 10.1089/ars.1999.1.4-571; Roth BL, 1998, PHARMACOL THERAPEUT, V79, P231, DOI 10.1016/S0163-7258(98)00019-9; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Van Oekelen D, 2003, LIFE SCI, V72, P2429, DOI 10.1016/S0024-3205(03)00141-3; Xia ZQ, 2003, J BIOL CHEM, V278, P21901, DOI 10.1074/jbc.M301905200	47	135	146	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20257	20266		10.1074/jbc.M312106200	http://dx.doi.org/10.1074/jbc.M312106200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14988405	hybrid			2022-12-27	WOS:000221164500103
J	Harris, ES; Li, F; Higgs, HN				Harris, ES; Li, F; Higgs, HN			The mouse formin, FRL alpha, slows actin filament barbed end elongation, competes with capping protein, accelerates polymerization from monomers, and severs filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARP2/3 COMPLEX; NUCLEATION; MECHANISM; PROFILIN; REORGANIZATION; CYTOSKELETON; ACTIVATION; NETWORK; YEAST; MDIA1	Formins are a conserved class of proteins expressed in all eukaryotes, with known roles in generating cellular actin-based structures. The mammalian formin, FRLalpha, is enriched in hematopoietic cells and tissues, but its biochemical properties have not been characterized. We show that a construct composed of the C-terminal half of FRLalpha (FRLalpha-C) is a dimer and has multiple effects on muscle actin, including tight binding to actin filament sides, partial inhibition of barbed end elongation, inhibition of barbed end binding by capping protein, acceleration of polymerization from monomers, and actin filament severing. These multiple activities can be explained by a model in which FRLalpha-C binds filament sides but prefers the topology of sides at the barbed end (end-sides) to those within the filament. This preference allows FRLalpha-C to nucleate new filaments by side stabilization of dimers, processively advance with the elongating barbed end, block interaction between C-terminal tentacles of capping protein and filament end-sides, and sever filaments by preventing subunit re-association as filaments bend. Another formin, mDia1, does not reduce the barbed end elongation rate but does block capping protein, further supporting an end-side binding model for formins. Profilin partially relieves barbed end elongation inhibition by FRLalpha-C. When non-muscle actin is used, FRLalpha-C's effects are largely similar. FRLalpha-C's ability to sever filaments is the first such activity reported for any formin. Because we find that mDia1-C does not sever efficiently, severing may not be a property of all formins.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Higgs, HN (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	henry.n.higgs@dartmouth.edu		Higgs, Henry/0000-0002-2917-9644	NCRR NIH HHS [P20 RR 16437] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016437] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Andrianantoandro E, 2001, J MOL BIOL, V312, P721, DOI 10.1006/jmbi.2001.5005; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; COOPER JA, 1985, BIOCHEMISTRY-US, V24, P793, DOI 10.1021/bi00324a039; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Ichetovkin I, 2000, CELL MOTIL CYTOSKEL, V45, P293, DOI 10.1002/(SICI)1097-0169(200004)45:4<293::AID-CM5>3.0.CO;2-1; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; McRorie D. K., 1993, SELF ASS SYSTEMS ANA; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Yamashita A, 2003, EMBO J, V22, P1529, DOI 10.1093/emboj/cdg167; Yayoshi-Yamamoto S, 2000, MOL CELL BIOL, V20, P6872, DOI 10.1128/MCB.20.18.6872-6881.2000; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057	29	158	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20076	20087		10.1074/jbc.M312718200	http://dx.doi.org/10.1074/jbc.M312718200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14990563	hybrid			2022-12-27	WOS:000221164500084
J	Lou, Y; Yao, JH; Zereshki, A; Dou, Z; Ahmed, K; Wang, HM; Hu, JB; Wang, YZ; Yao, XB				Lou, Y; Yao, JH; Zereshki, A; Dou, Z; Ahmed, K; Wang, HM; Hu, JB; Wang, YZ; Yao, XB			NEK2A interacts with MAD1 and possibly functions as a novel integrator of the spindle checkpoint signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHECKPOINT; CENP-E; PROTEIN-KINASE; KINETOCHORE LOCALIZATION; UNATTACHED KINETOCHORES; ASSEMBLY CHECKPOINT; PREMATURE ANAPHASE; MAMMALIAN-CELLS; BUDDING YEAST; PHOSPHORYLATION	Chromosome segregation in mitosis is orchestrated by protein kinase signaling cascades. A biochemical cascade named spindle checkpoint ensures the spatial and temporal order of chromosome segregation during mitosis. Here we report that spindle checkpoint protein MAD1 interacts with NEK2A, a human orthologue of the Aspergillus nidulans NIMA kinase. MAD1 interacts with NEK2A in vitro and in vivo via a leucine zipper-containing domain located at the C terminus of MAD1. Like MAD1, NEK2A is localized to HeLa cell kinetochore of mitotic cells. Elimination of NEK2A by small interfering RNA does not arrest cells in mitosis but causes aberrant premature chromosome segregation. NEK2A is required for MAD2 but not MAD1, BUB1, and HEC1 to associate with kinetochores. These NEK2A-eliminated or -suppressed cells display a chromosome bridge phenotype with sister chromatid inter-connected. Moreover, loss of NEK2A impairs mitotic checkpoint signaling in response to spindle damage by nocodazole, which affected mitotic escape and led to generation of cells with multiple nuclei. Our data demonstrate that NEK2A is a kinetochore-associated protein kinase essential for faithful chromosome segregation. We hypothesize that NEK2A links MAD2 molecular dynamics to spindle checkpoint signaling.	Univ Sci & Technol China, Lab Cell Dynam, Sch Life Sci, Hefei 230027, Peoples R China; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA	Chinese Academy of Sciences; University of Science & Technology of China, CAS; University of California System; University of California Berkeley; Morehouse School of Medicine	Yao, XB (corresponding author), Univ Sci & Technol China, Lab Cell Dynam, Sch Life Sci, Hefei 230027, Peoples R China.	yaoxb@ustc.edu.cn	Yao, Xuebiao/P-5771-2014; DOU, ZHEN/N-2022-2013; Yao, Jianhui/D-1952-2014	DOU, ZHEN/0000-0003-3303-9393				BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Campbell MS, 2001, J CELL SCI, V114, P953; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Dou Z, 2003, CELL RES, V13, P443, DOI 10.1038/sj.cr.7290186; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li XT, 1997, J CELL SCI, V110, P537; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Liu ST, 2003, NAT CELL BIOL, V5, P341, DOI 10.1038/ncb953; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Martinez-Exposito MJ, 1999, P NATL ACAD SCI USA, V96, P8493, DOI 10.1073/pnas.96.15.8493; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; ROOS UP, 1976, CHROMOSOMA, V54, P363, DOI 10.1007/BF00292816; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Wassmann K, 2003, EMBO J, V22, P797, DOI 10.1093/emboj/cdg071; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; ZHANG J, 2002, SCI B, V119, P345; Zhou RH, 2003, J BIOL CHEM, V278, P35651, DOI 10.1074/jbc.M303416200	37	101	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20049	20057		10.1074/jbc.M314205200	http://dx.doi.org/10.1074/jbc.M314205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14978040	hybrid			2022-12-27	WOS:000221164500081
J	Ohashi, S; Abe, H; Takahashi, T; Yamamoto, Y; Takeuchi, M; Arai, H; Nagata, K; Kita, T; Okamoto, H; Yamamoto, H; Doi, T				Ohashi, S; Abe, H; Takahashi, T; Yamamoto, Y; Takeuchi, M; Arai, H; Nagata, K; Kita, T; Okamoto, H; Yamamoto, H; Doi, T			Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MOLECULAR CHAPERONE; MESANGIAL CELLS; TRANSCRIPTIONAL ACTIVATION; ADVANCED GLYCOSYLATION; GLOMERULAR-LESIONS; TRANSGENIC MICE; HSP47; EXPRESSION; RECEPTOR	Advanced glycation end products (AGEs) appear to contribute to the diabetic complications. This study reports the inhibitory effect of OPB-9195 (OPB), an inhibitor of AGEs formation, and the role of a collagen-specific molecular chaperone, a 47-kDa heat shock protein (HSP47) in diabetic nephropathy. Transgenic mice carrying nitric-oxide synthase cDNA fused with insulin promoter (iNOSTg) leads to diabetes mellitus. The iNOSTg mice at 6 months of age represented diffuse glomerulosclerosis, and the expression of HSP47 was markedly increased in the mesangial area in parallel with increased expression of types I and IV collagens. OPB treatment ameliorated glomerulosclerosis in the iNOSTg mice associated with the decreased expression of HSP47 and types I and IV collagens. The expression of transforming growth factor-beta (TGF-beta) was increased in glomeruli of iNOSTg mice and decreased after treatment with OPB. To confirm these mechanisms, cultured mesangial cells were stimulated with AGEs. AGEs significantly increased the expression of HSP47, type IV collagen, and TGF-beta mRNA. Neutralizing antibody for TGF-beta inhibited the overexpression of both HSP47 and type IV collagen in vitro. In conclusion, AGEs increase the expression of HSP47 in association with collagens, both in vivo and in vitro. The processes may be mediated by TGF-beta.	Univ Tokushima, Sch Med, Dept Clin Biol & Med, Course Biol Med, Tokushima 7708503, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Biochem & Mol Vasc Biol, Kanazawa, Ishikawa 9208640, Japan; Hokuriku Univ, Fac Pharmaceut Sci, Dept Biochem, Kanazawa, Ishikawa 9201181, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Kyoto 6068575, Japan; Kyoto Univ, Dept Cardiovasc Med, Kyoto 6068575, Japan; Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 9808575, Japan	Tokushima University; Kanazawa University; Hokuriku University; Kyoto University; Kyoto University; Tohoku University	Doi, T (corresponding author), Univ Tokushima, Sch Med, Dept Clin Biol & Med, Course Biol Med, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	doi@clin.med.tokushima-u.ac.jp	Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849				Abe H, 2004, J BIOL CHEM, V279, P14201, DOI 10.1074/jbc.M310427200; Abe H, 1999, J BIOL CHEM, V274, P20874, DOI 10.1074/jbc.274.30.20874; BOJESTIG M, 1994, NEW ENGL J MED, V330, P15, DOI 10.1056/NEJM199401063300103; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; DOI T, 1990, LAB INVEST, V63, P204; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; DOI T, 1990, AM J PATHOL, V137, P541; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Hirata H, 1999, J BIOL CHEM, V274, P35703, DOI 10.1074/jbc.274.50.35703; Iehara N, 1996, KIDNEY INT, V50, P1166, DOI 10.1038/ki.1996.424; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; Makibayashi K, 2001, AM J PATHOL, V158, P1733, DOI 10.1016/S0002-9440(10)64129-6; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; NAGATA K, 1988, BIOCHEM BIOPH RES CO, V153, P428, DOI 10.1016/S0006-291X(88)81242-7; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Razzaque MS, 1998, NEPHRON, V80, P434, DOI 10.1159/000045217; Schutze K, 1998, NAT BIOTECHNOL, V16, P737, DOI 10.1038/nbt0898-737; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; Sunamoto M, 1998, INT J EXP PATHOL, V79, P133, DOI 10.1046/j.1365-2613.1998.00061.x; Sunamoto M, 1998, LAB INVEST, V78, P967; Takamura T, 1998, J BIOL CHEM, V273, P2493, DOI 10.1074/jbc.273.5.2493; Takeuchi M, 1999, MOL MED, V5, P393, DOI 10.1007/BF03402128; Tsuji H, 1998, BIOCHEM BIOPH RES CO, V245, P583, DOI 10.1006/bbrc.1998.8489; VELASQUEZ MT, 1990, FASEB J, V4, P2850, DOI 10.1096/fasebj.4.11.2199283; VLASSARA H, 1994, LAB INVEST, V70, P138; Weigert C, 2003, BIOCHEM BIOPH RES CO, V304, P301, DOI 10.1016/S0006-291X(03)00599-0; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; Yamamura I, 1998, BIOCHEM BIOPH RES CO, V244, P68, DOI 10.1006/bbrc.1998.8216; Yasuda K, 2002, J BIOL CHEM, V277, P44613, DOI 10.1074/jbc.M208558200	30	44	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19816	19823		10.1074/jbc.M310428200	http://dx.doi.org/10.1074/jbc.M310428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004023	hybrid			2022-12-27	WOS:000221164500053
J	Sarkar, S; Leaman, DW; Gupta, S; Sil, P; Young, D; Morehead, A; Mukherjee, D; Ratliff, N; Sun, YP; Rayborn, M; Hollyfield, J; Sen, S				Sarkar, S; Leaman, DW; Gupta, S; Sil, P; Young, D; Morehead, A; Mukherjee, D; Ratliff, N; Sun, YP; Rayborn, M; Hollyfield, J; Sen, S			Cardiac overexpression of myotrophin triggers myocardial hypertrophy and heart failure in transgenic mice (Publication with Expression of Concern. See vol. 295, pg. 3385, 2020) (Publication with Expression of Concern. See vol. 295, pg. 3385, 2020) (Withdrawn Publication. See vol. 295, pg. 15424, 2020) (Publication with Expression of Concern. See vol. 295, pg. 3385, 2020) (Withdrawn Publication. See vol. 295, pg. 15424, 2020)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Withdrawn Publication							GENE-EXPRESSION; KAPPA-B; ACTIVATION; PATTERNS; DISTINCT	Cardiac hypertrophy and heart failure remain leading causes of death in the United States. Many studies have suggested that, under stress, myocardium releases factors triggering protein synthesis and stimulating myocyte growth. We identified and cloned myotrophin, a 12-kDa protein from hypertrophied human and rat hearts. Myotrophin ( whose gene is localized on human chromosome 7q33) stimulates myocyte growth and participates in cellular interaction that initiates cardiac hypertrophy in vitro. In this report, we present data on the pathophysiological significance of myotrophin in vivo, showing the effects of overexpression of cardiospecific myotrophin in transgenic mice in which cardiac hypertrophy occurred by 4 weeks of age and progressed to heart failure by 9 - 12 months. This hypertrophy was associated with increased expression of proto-oncogenes, hypertrophy marker genes, growth factors, and cytokines, with symptoms that mimicked those of human cardiomyopathy, functionally and morphologically. This model provided a unique opportunity to analyze gene clusters that are differentially upregulated during initiation of hypertrophy versus transition of hypertrophy to heart failure. Importantly, changes in gene expression observed during initiation of hypertrophy were significantly different from those seen during its transition to heart failure. Our data show that overexpression of myotrophin results in initiation of cardiac hypertrophy that progresses to heart failure, similar to changes in human heart failure. Knowledge of the changes that take place as a result of overexpression of myotrophin at both the cellular and molecular levels will suggest novel strategies for treatment to prevent hypertrophy and its progression to heart failure.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; University of Toledo	Sen, S (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol NB 50, 9500 Euclid Ave, Cleveland, OH 44195 USA.	sens@ccf.org	Mukherjee, Debabrata/AAG-1486-2019	Mukherjee, Debabrata/0000-0002-5131-3694				Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Gupta S, 2002, J CELL BIOL, V159, P1019, DOI 10.1083/jcb.200207149; IWAKI K, 1990, J BIOL CHEM, V265, P13809; James JF, 1998, CIRC RES, V82, P407, DOI 10.1161/01.RES.82.4.407; Kang YJ, 1999, P SOC EXP BIOL MED, V222, P263, DOI 10.1046/j.1525-1373.1999.d01-143.x; Masutomo K, 1999, J MOL CELL CARDIOL, V31, P1607, DOI 10.1006/jmcc.1999.0997; Mitra S, 2001, CYTOGENET CELL GENET, V93, P151, DOI 10.1159/000056974; MUKHERJEE DP, 1993, HYPERTENSION, V21, P142, DOI 10.1161/01.HYP.21.2.142; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SCHAPER J, 1991, CIRCULATION, V83, P504, DOI 10.1161/01.CIR.83.2.504; SEN S, 1990, J BIOL CHEM, V265, P16635; SEN S, 1987, CIRCULATION, V75, P81; SEN S, 1974, CIRC RES, V35, P775, DOI 10.1161/01.RES.35.5.775; Sil P, 1998, CIRC RES, V82, P1173, DOI 10.1161/01.RES.82.11.1173; SIL P, 1995, CIRC RES, V76, P1020, DOI 10.1161/01.RES.76.6.1020; Sivasubramanian N, 1996, J BIOL CHEM, V271, P2812, DOI 10.1074/jbc.271.5.2812; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tan FL, 2002, P NATL ACAD SCI USA, V99, P11387, DOI 10.1073/pnas.162370099; Vikstrom KL, 1998, CIRC RES, V82, P773, DOI 10.1161/01.RES.82.7.773	20	48	50	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20422	20434		10.1074/jbc.M308488200	http://dx.doi.org/10.1074/jbc.M308488200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14970239	hybrid			2022-12-27	WOS:000221164500121
J	Xi, J; Liu, RY; Asbury, GR; Eckenhoff, MF; Eckenhoff, RG				Xi, J; Liu, RY; Asbury, GR; Eckenhoff, MF; Eckenhoff, RG			Inhalational anesthetic-binding proteins in rat neuronal membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOTHANE BINDING; BENZODIAZEPINE-RECEPTOR; INHALED ANESTHETICS; ANALYTICAL SHAPE; MITOCHONDRIAL; CAVITIES; BRAIN; MACROMOLECULES; COMPUTATION; MECHANISMS	Molecular targets of inhaled anesthetics must be represented in the group that specifically bind these drugs, but the paucity of direct binding data has limited the number of candidates for further evaluation. To find candidate targets, we used a combination of photolabeling, two-dimensional gel electrophoresis, and mass spectrometry to identify halothane-binding targets in rat neuronal membranes. Of the 265 spots detected on the two-dimensional gels, 90 were labeled by [C-14] halothane, and 34 were identified. Mitochondrial proteins, especially respiratory complex and voltage-dependent anion channels, dominated the labeled group, and there were several examples of subunit-and state-dependent binding. A significant correlation was found between internal protein cavities and binding in a group of proteins with high resolution structures. Therefore, in addition to identifying novel neuronal targets, these data suggest a general molecular feature, the buried cavity, as a dominant attribute of volatile anesthetic-binding sites found in a limited number of neuronal membrane proteins.	Univ Penn Hlth Syst, Dept Anesthesia, Philadelphia, PA 19104 USA; Amersham Biosci, Piscataway, NJ 08855 USA	University of Pennsylvania	Eckenhoff, RG (corresponding author), Univ Penn Hlth Syst, Dept Anesthesia, 305 John Morgan,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	roderic.eckenhoff@uphs.upenn.edu		Eckenhoff, Roderic/0000-0002-5581-746X	NIGMS NIH HHS [GM 51595, GM 55876] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; BOHNEN N, 1994, INT J NEUROSCI, V77, P181, DOI 10.3109/00207459408986029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Chan K, 2002, ANAL BIOCHEM, V301, P308, DOI 10.1006/abio.2001.5506; COHEN PJ, 1973, ANESTHESIOLOGY, V39, P153, DOI 10.1097/00000542-197308000-00007; Darbandi-Tonkabon R, 2003, J BIOL CHEM, V278, P13196, DOI 10.1074/jbc.M213168200; Darbandi-Tonkabon R, 2004, J PHARMACOL EXP THER, V308, P502, DOI 10.1124/jpet.103.058123; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Eckenhoff ME, 2002, J PHARMACOL EXP THER, V300, P172, DOI 10.1124/jpet.300.1.172; Eckenhoff MF, 1998, J PHARMACOL EXP THER, V285, P371; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; ECKENHOFF RG, 1991, ANN NY ACAD SCI, V625, P755, DOI 10.1111/j.1749-6632.1991.tb33910.x; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Eckenhoff RG, 1996, P NATL ACAD SCI USA, V93, P2807, DOI 10.1073/pnas.93.7.2807; Eckenhoff RG, 2001, BIOCHEMISTRY-US, V40, P10819, DOI 10.1021/bi010691r; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; Fountoulakis M, 1999, ELECTROPHORESIS, V20, P3572; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; HANLEY PJ, 2002, J PHYSL, V544, P3; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HUBBARD SJ, 1994, PROTEIN SCI, V3, P2194, DOI 10.1002/pro.5560031205; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Johansson JS, 2001, PHARM TOXIC, P37; Jonas EA, 1999, SCIENCE, V286, P1347, DOI 10.1126/science.286.5443.1347; Krapfenbauer K, 2003, ELECTROPHORESIS, V24, P1847, DOI 10.1002/elps.200305401; Liang J, 1998, PROTEINS, V33, P18, DOI 10.1002/(SICI)1097-0134(19981001)33:1<18::AID-PROT2>3.3.CO;2-X; Liang J, 1998, PROTEINS, V33, P1; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MELVIN MA, 1982, ANESTHESIOLOGY, V57, P238, DOI 10.1097/00000542-198209000-00018; MICHENFELDER JD, 1975, AM J PHYSIOL, V229, P1050, DOI 10.1152/ajplegacy.1975.229.4.1050; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MORGAN PG, 1994, ANESTHESIOLOGY, V81, P888, DOI 10.1097/00000542-199410000-00016; Morgan PG, 2002, ANESTHESIOLOGY, V96, P1268, DOI 10.1097/00000542-200205000-00036; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Warltier DC, 2000, ANESTHESIOLOGY, V92, P253, DOI 10.1097/00000542-200001000-00038	38	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19628	19633		10.1074/jbc.M313864200	http://dx.doi.org/10.1074/jbc.M313864200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14988400	hybrid			2022-12-27	WOS:000221164500031
J	Loegering, D; Arlander, SJH; Hackbarth, J; Vroman, BT; Roos-Mattjus, P; Hopkins, KM; Lieberman, HB; Karnitz, LM; Kaufmann, SH				Loegering, D; Arlander, SJH; Hackbarth, J; Vroman, BT; Roos-Mattjus, P; Hopkins, KM; Lieberman, HB; Karnitz, LM; Kaufmann, SH			Rad9 protects cells from topoisomerase poison-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; S-PHASE CHECKPOINT; CYTO-TOXICITY; TUMOR-CELLS; ARA-C; CAMPTOTHECIN CYTOTOXICITY; RADIOSENSITIZING AGENT; REPLICATION CHECKPOINT; CHROMATIN ASSOCIATION; POLYMERASE-ALPHA	Previous studies have suggested two possible roles for Rad9 in mammalian cells subjected to replication stress or DNA damage. One model suggests that a Rad9-containing clamp is loaded onto damaged DNA, where it participates in Chk1 activation and subsequent events that contribute to cell survival. The other model suggests that Rad9 translocates to mitochondria, where it triggers apoptosis by binding to and inhibiting Bcl-2 and Bcl-x(L). To further study the role of Rad9, parental and Rad9 -/- murine embryonic stem (ES) cells were treated with camptothecin, etoposide, or cytarabine, all prototypic examples of three classes of widely used anticancer agents. All three agents induced Rad9 chromatin binding. Each of these agents also triggered S-phase checkpoint activation in parental ES cells, as indicated by a caffeine-inhibitable decrease in [H-3] thymidine incorporation into DNA and Cdc25A down-regulation. Interestingly, the ability of cytarabine to activate the S-phase checkpoint was severely compromised in Rad9-/- cells, whereas activation of this checkpoint by camptothecin and etoposide was unaltered, suggesting that the action of cytarabine is readily distinguished from that of classical topoisomerase poisons. Nonetheless, Rad9 deletion sensitized ES cells to the cytotoxic effects of all three agents, as evidenced by enhanced apoptosis and diminished colony formation. Collectively, these results suggest that the predominant role of Rad9 in ES cells is to promote survival after replicative stress and topoisomerase-mediated DNA damage.	Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Mol Pharmacol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Mol Biol, Rochester, MN 55905 USA; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Columbia University	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Oncol Res, Guggenheim 1301,200 1st St SW, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu; Kaufmann.Scott@Mayo.edu		Kaufmann, Scott/0000-0002-4900-7145; Roos-Mattjus, Pia/0000-0002-7187-2012	NATIONAL CANCER INSTITUTE [R01CA073709, R01CA089816, R01CA084321, R56CA084321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052493] Funding Source: NIH RePORTER; NCI NIH HHS [CA73709, CA84321, R01 CA073709, CA89816] Funding Source: Medline; NIGMS NIH HHS [GM52493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Busby EC, 2000, CANCER RES, V60, P2108; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Chabner BA, 1996, CANC CHEMOTHERAPY BI, P213; Chen JG, 2002, CANCER RES, V62, P1935; Chreneik JE, 2003, J BIOL CHEM, V278, P12461, DOI 10.1074/jbc.M212930200; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; COVEY JM, 1989, CANCER RES, V49, P5016; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GOTTLIEB JA, 1970, CANCER CHEMOTH REP 1, V54, P461; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; HANDE KR, 1984, CANCER RES, V44, P379; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; KUFE D, 1984, BLOOD, V64, P54; KUFE DW, 1980, J BIOL CHEM, V255, P8997; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Liu QH, 2000, GENE DEV, V14, P1448; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MATTERN MR, 1987, CANCER RES, V47, P1793; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Momparler R L, 1969, Biochem Biophys Res Commun, V34, P464; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Rhind N, 2000, J CELL SCI, V113, P3889; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Sagata N, 2002, SCIENCE, V298, P1905, DOI 10.1126/science.1079225; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Sampath D, 2001, CURR OPIN ONCOL, V13, P484, DOI 10.1097/00001622-200111000-00011; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shao RG, 1997, CANCER RES, V57, P4029; Shi Z, 2001, CANCER RES, V61, P1065; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; SLICHENMYER WJ, 1993, JNCI-J NATL CANCER I, V85, P271, DOI 10.1093/jnci/85.4.271; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	72	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18641	18647		10.1074/jbc.M313536200	http://dx.doi.org/10.1074/jbc.M313536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14988409	hybrid			2022-12-27	WOS:000221041500068
J	Luo, WQ; Williams, J; Smallwood, PM; Touchman, JW; Roman, LM; Nathans, J				Luo, WQ; Williams, J; Smallwood, PM; Touchman, JW; Roman, LM; Nathans, J			Proximal and distal sequences control UV cone pigment gene expression in transgenic zebrafish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; VISUAL PIGMENTS; RHODOPSIN PROMOTER; HOMEOBOX GENE; ROD; CRX; UPSTREAM; PHOTORECEPTORS; REQUIREMENTS; HOMEODOMAIN	The molecular basis of cone photoreceptor-specific gene expression is largely unknown. In this study, we define cis-acting DNA sequences that control the cell type-specific expression of the zebrafish UV cone pigment gene by transient expression of green fluorescent protein transgenes following their injection into zebrafish embryos. These experiments show that 4.8 kb of 5'-flanking sequences from the zebrafish UV pigment gene direct expression specifically to UV cones and that this activity requires both distal and proximal sequences. In addition, we demonstrate that a proximal region located between -215 and -110 bp (with respect to the initiator methionine codon) can function in the context of a zebrafish rhodopsin promotor to convert its specificity from rod-only expression to rod and UV cone expression. These experiments demonstrate the power of transient transgenesis in zebrafish to efficiently define cis-acting regulatory sequences in an intact vertebrate.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; NHGRI, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460				AMSTERDAM A, 1995, DEV BIOL, V171, P123, DOI 10.1006/dbio.1995.1265; Asaoka Y, 2002, P NATL ACAD SCI USA, V99, P15456, DOI 10.1073/pnas.232444199; BRANCHEK T, 1984, J COMP NEUROL, V224, P107, DOI 10.1002/cne.902240109; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Chinen A, 2003, GENETICS, V163, P663; CHIU MI, 1994, J NEUROSCI, V14, P3426; CHIU MI, 1994, VISUAL NEUROSCI, V11, P773, DOI 10.1017/S0952523800003072; Fadool JM, 2003, DEV BIOL, V258, P277, DOI 10.1016/S0012-1606(03)00125-8; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Higashijima S, 1997, DEV BIOL, V192, P289, DOI 10.1006/dbio.1997.8779; Kennedy BN, 2001, J BIOL CHEM, V276, P14037, DOI 10.1074/jbc.M010490200; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LARISON KD, 1990, DEVELOPMENT, V109, P567; Mani SS, 2001, J BIOL CHEM, V276, P36557, DOI 10.1074/jbc.M101685200; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; NAWROCKI L, 1985, VISION RES, V25, P1569, DOI 10.1016/0042-6989(85)90127-0; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; RAYMOND PA, 1993, NEURON, V10, P1161, DOI 10.1016/0896-6273(93)90064-X; RAYMOND PA, 1995, J COMP NEUROL, V359, P537, DOI 10.1002/cne.903590403; Schmitt EA, 1999, J COMP NEUROL, V404, P515; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; Tahayato A, 2003, DEV CELL, V5, P391, DOI 10.1016/S1534-5807(03)00239-9; Takechi M, 2003, FEBS LETT, V553, P90, DOI 10.1016/S0014-5793(03)00977-3; Vihtelic TS, 1999, VISUAL NEUROSCI, V16, P571, DOI 10.1017/S0952523899163168; Wang XK, 2000, BIOTECHNIQUES, V29, P814, DOI 10.2144/00294st09; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	33	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19286	19293		10.1074/jbc.M400161200	http://dx.doi.org/10.1074/jbc.M400161200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966125	hybrid			2022-12-27	WOS:000221041500142
J	Schrader, N; Kim, EY; Winking, J; Paulukat, J; Schindelin, H; Schwarz, G				Schrader, N; Kim, EY; Winking, J; Paulukat, J; Schindelin, H; Schwarz, G			Biochemical characterization of the high affinity binding between the glycine receptor and gephyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; ESCHERICHIA-COLI MOEA; PROTEIN GEPHYRIN; CRYSTAL-STRUCTURE; SPLICE VARIANTS; SPINAL NEURONS; BETA-SUBUNIT; MOLYBDOPTERIN; CYTOSKELETON; ACTIVATION	Gephyrin is an essential and instructive molecule for the formation of inhibitory synapses. Gephyrin binds directly to the large cytoplasmic loop located between transmembrane helices three and four of the beta-subunit of the glycine receptor and to microtubules, thus promoting glycine receptor ( GlyR) anchoring to the cytoskeleton and clustering in the postsynaptic membrane. Besides its structural role, gephyrin is involved in the biosynthesis of the molybdenum cofactor that is essential for all molybdenum-dependent enzymes in mammals. Gephyrin can be divided into an N-terminal trimeric G domain and a C-terminal E domain, which are connected by a central linker region. Here we have studied the in vitro interaction of gephyrin and its domains with the large cytoplasmic loop of the GlyR beta-subunit (GlyRbeta-loop). Binding of gephyrin to the GlyR is exclusively mediated by the E domain, and the binding site was mapped to one of its sub-domains ( residues 496 - 654). By using isothermal titration calorimetry, a high affinity (K-d = 0.2 - 0.4 muM) and low affinity (K-d = 11 - 30 muM) binding site for the GlyRbeta-loop was found on holo-gephyrin and the E domain, respectively, with a binding stoichiometry of two GlyRbeta-loops per E domain in both cases. Binding of the GlyRbeta-loop does not change the oligomeric state of either full-length gephyrin or the isolated E domain.	SUNY Stony Brook, Dept Biochem, Ctr Struct Biol, Stony Brook, NY 11794 USA; Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Braunschweig University of Technology	Schindelin, H (corresponding author), SUNY Stony Brook, Dept Biochem, Ctr Struct Biol, Stony Brook, NY 11794 USA.	hermann.schindelin@sunysb.edu; g.schwarz@tu-bs.de	Schwarz, Guenter/ABE-9643-2021; Schindelin, Hermann/Q-2697-2019	Schwarz, Guenter/0000-0002-2118-9338; 	NIDDK NIH HHS [DK54835] Funding Source: Medline; NINDS NIH HHS [NS48605] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048605] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Fuhrmann JC, 2002, J NEUROSCI, V22, P5393; Giesemann T, 2003, J NEUROSCI, V23, P8330; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Johnson JL., 2001, METABOLIC MOL BASES, P3163; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; Kirsch J, 1998, NATURE, V392, P717, DOI 10.1038/33694; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Kneussel M, 1999, J NEUROCHEM, V72, P1323, DOI 10.1046/j.1471-4159.1999.0721323.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Mammoto A, 1998, BIOCHEM BIOPH RES CO, V243, P86, DOI 10.1006/bbrc.1997.8068; Meier J, 2000, MOL CELL NEUROSCI, V16, P566, DOI 10.1006/mcne.2000.0899; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; Ramming M, 2000, P NATL ACAD SCI USA, V97, P10266, DOI 10.1073/pnas.97.18.10266; Rees MI, 2003, J BIOL CHEM, V278, P24688, DOI 10.1074/jbc.M301070200; Reiss J, 2001, AM J HUM GENET, V68, P208, DOI 10.1086/316941; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; SASSOEPOGNETTO M, 1995, J COMP NEUROL, V357, P1, DOI 10.1002/cne.903570102; SCHMITT B, 1987, BIOCHEMISTRY-US, V26, P805, DOI 10.1021/bi00377a022; Schrag JD, 2001, J MOL BIOL, V310, P419, DOI 10.1006/jmbi.2001.4771; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Schwarz G, 2001, J MOL BIOL, V312, P405, DOI 10.1006/jmbi.2001.4952; Sola M, 2001, J BIOL CHEM, V276, P25294, DOI 10.1074/jbc.M101923200; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3	35	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18733	18741		10.1074/jbc.M311245200	http://dx.doi.org/10.1074/jbc.M311245200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976213	hybrid			2022-12-27	WOS:000221041500080
J	Weinreb, PH; Simon, KJ; Rayhorn, P; Yang, WJ; Leone, DR; Dolinski, BM; Pearse, BR; Yokota, Y; Kawakatsu, H; Atakilit, A; Sheppard, D; Violette, SM				Weinreb, PH; Simon, KJ; Rayhorn, P; Yang, WJ; Leone, DR; Dolinski, BM; Pearse, BR; Yokota, Y; Kawakatsu, H; Atakilit, A; Sheppard, D; Violette, SM			Function-blocking integrin alpha(v)beta(6) monoclonal antibodies - Distinct ligand-mimetic and nonligand-mimetic classes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; GLY-ASP LIGAND; I DOMAIN; PLATELET ACTIVATION; CRYSTAL-STRUCTURE; CELL ATTACHMENT; FAB FRAGMENT; TGF-BETA; BINDING; ALPHA-V-BETA-6	We have generated a panel of potent, selective monoclonal antibodies that bind human and mouse alpha(v)beta(6) integrin with high affinity (up to 15 pM). A subset of these antibodies blocked the binding of alpha(v)beta(6) to the transforming growth factor-beta1 latency-associated peptide with IC50 values as low as 18 pM, and prevented the subsequent alpha(v)beta(6)-mediated activation of transforming growth factor-beta1. The antibodies also inhibited alpha(v)beta(6) binding to fibronectin. The blocking antibodies form two biochemical classes. One class, exemplified by the ligand-mimetic antibody 6.8G6, bound to the integrin in a divalent cation-dependent manner, contained an RGD motif or a related sequence in CDR3 of the heavy chain, was blocked by RGD-containing peptides, and was internalized by alpha(v)beta(6)-expressing cells. Despite containing an RGD sequence, 6.8G6 was specific for alpha(v)beta(6) and showed no cross-reactivity with the RGD-binding integrins alpha(v)beta(3), alpha(v)beta(8), or alpha(IIb)beta(3). The nonligand-mimetic blocking antibodies, exemplified by 6.3G9, were cation-independent, were not blocked by RGD-containing peptides, were not internalized, and did not contain RGD or related sequences. These two classes of antibody were unable to bind simultaneously to alpha(v)beta(6), suggesting that they may bind overlapping epitopes. The "ligand-mimetic" antibodies are the first to be described for alpha(v)beta(6) and resemble those described for alpha(IIb)beta(3). We also report for the first time the relative abilities of divalent cations to promote alpha(v)beta(6) binding to latency-associated peptide and to the ligand-mimetic antibodies. These antibodies should provide valuable tools to study the ligand-receptor interactions of alpha(v)beta(6) as well as the role of alpha(v)beta(6) in vivo.	Biogen Idec Inc, Cambridge, MA 02142 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Lung Biol Ctr, San Francisco, CA 94143 USA	Biogen; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weinreb, PH (corresponding author), Biogen Idec Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.	Paul.Weinreb@Biogenidec.com		Weinreb, Paul/0000-0002-0802-0052				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Agrez MV, 1996, BRIT J CANCER, V73, P887, DOI 10.1038/bjc.1996.158; Annes JP, 2002, FEBS LETT, V511, P65, DOI 10.1016/S0014-5793(01)03280-X; Arend LJ, 2000, J AM SOC NEPHROL, V11, P2297, DOI 10.1681/ASN.V11122297; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Blake RC, 1999, ANAL BIOCHEM, V272, P123, DOI 10.1006/abio.1999.4176; BREUSS JM, 1995, J CELL SCI, V108, P2241; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; Brezinsky SCG, 2003, J IMMUNOL METHODS, V277, P141, DOI 10.1016/S0022-1759(03)00108-X; CUNNINGHAM BA, 1970, BIOCHEMISTRY-US, V9, P3161, DOI 10.1021/bi00818a008; DECKMYN H, 1994, BRIT J HAEMATOL, V87, P562, DOI 10.1111/j.1365-2141.1994.tb08313.x; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; GOLDBERG ME, 1993, CURR OPIN IMMUNOL, V5, P278, DOI 10.1016/0952-7915(93)90018-N; Gotwals PJ, 1999, BIOCHEMISTRY-US, V38, P8280, DOI 10.1021/bi982860m; Hakkinen L, 2000, J HISTOCHEM CYTOCHEM, V48, P985; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; Huang XZ, 1998, J CELL SCI, V111, P2189; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Karpusas M, 2003, J MOL BIOL, V327, P1031, DOI 10.1016/S0022-2836(03)00203-1; Kemperman H, 1997, EXP CELL RES, V234, P156, DOI 10.1006/excr.1997.3599; Koivisto L, 2000, EXP CELL RES, V255, P10, DOI 10.1006/excr.1999.4769; Kraft S, 1999, J BIOL CHEM, V274, P1979, DOI 10.1074/jbc.274.4.1979; Kunicki TJ, 1997, J BIOL CHEM, V272, P4103, DOI 10.1074/jbc.272.7.4103; KUNICKI TJ, 1995, J BIOL CHEM, V270, P16660, DOI 10.1074/jbc.270.28.16660; Lawrence DA, 2001, MOL CELL BIOCHEM, V219, P163, DOI 10.1023/A:1010819716023; Liddington R, 1998, STRUCT FOLD DES, V6, P937, DOI 10.1016/S0969-2126(98)00094-X; Lobb RR, 1995, CELL ADHES COMMUN, V3, P385, DOI 10.3109/15419069509081293; Lu M, 2002, J CELL SCI, V115, P4641, DOI 10.1242/jcs.00145; Ludbrook SB, 2003, BIOCHEM J, V369, P311, DOI 10.1042/BJ20020809; Mehta RJ, 1998, BIOCHEM J, V330, P861; Memmo LM, 1998, J CELL SCI, V111, P425; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; Mousa SA, 2002, CURR OPIN CHEM BIOL, V6, P534, DOI 10.1016/S1367-5931(02)00350-2; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; NIIYA K, 1987, BLOOD, V70, P475; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; Rahman S, 2000, BIOCHEM J, V345, P701, DOI 10.1042/0264-6021:3450701; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHAW LM, 1993, J CELL BIOL, V123, P1017, DOI 10.1083/jcb.123.4.1017; SMITH JW, 1994, J BIOL CHEM, V269, P32788; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; TAUB R, 1989, J BIOL CHEM, V264, P259; Thomas GJ, 1997, ORAL ONCOL, V33, P381, DOI 10.1016/S0964-1955(97)00021-3; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; Wattam B, 2001, BIOCHEM J, V356, P11, DOI 10.1042/0264-6021:3560011; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	58	116	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17875	17887		10.1074/jbc.M312103200	http://dx.doi.org/10.1074/jbc.M312103200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960589	hybrid			2022-12-27	WOS:000220870400121
J	Xu, Z; Balsara, RD; Gorlatova, NV; Lawrence, DA; Castellino, FJ; Ploplis, VA				Xu, Z; Balsara, RD; Gorlatova, NV; Lawrence, DA; Castellino, FJ; Ploplis, VA			Conservation of critical functional domains in murine plasminogen activator inhibitor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; SOMATOMEDIN-B DOMAIN; CELL-ADHESION; STRUCTURAL REQUIREMENTS; UROKINASE RECEPTOR; ENDOTHELIAL-CELLS; VITRONECTIN; BINDING; PAI-1; MIGRATION	Plasminogen activator inhibitor-1 is the main physiological regulator of tissue-type plasminogen activator in normal plasma. In addition to its critical function in fibrinolysis, plasminogen activator inhibitor-1 has been implicated in roles in other physiological and pathophysiological processes. To investigate structure-function aspects of mouse plasminogen activator inhibitor-1, the recombinant protein was expressed in Escherichia coli and purified. Five variant recombinant murine proteins (R76E, Q123K, R346A, R101A, and Q123K/R101A) were also generated using site-directed mutagenesis. The variant (R346A) was found to be defective in its inhibitory activity against tissue plasminogen activator relative to its wild-type counterpart. Enzyme-linked immunosorbent assay and surface plasmon resonance experiments demonstrated reduced vitronectin-binding affinity of the (Q123K) variant (K-D = 1800 nM) relative to the wild-type protein (K-D = 5.4 nM). Kinetic analyses indicated that the (Q123K) variant had a slower association (k(on) = 2.92 x 10(4) M-1 s(-1)) to, and a faster dissociation from, vitronectin (k(off) = 5.3 x 10(-2) s(-1)), (wild-type k(on) = 1.03 x 10(6) M-1 s(-1) and k(off) = 5.27 x 10(-3) s(-1)). The Q123K/R101A variant demonstrated an even lower vitronectin-binding ability. Low density lipoprotein receptor-related protein binding was decreased for the (R76E) variant. It was also demonstrated that the plasminogen activator inhibitor-1/vitronectin complex decreased the interaction of plasminogen activator inhibitor-1 with low density lipoprotein receptor-related protein. These results indicate that the complex interactions traditionally associated with different plasminogen activator inhibitor-1 functions apply to the murine system, thus showing a commonality of subtle functions among different species and evolutionary conservation of this protein. Further, this study provides additional evidence that the human hemostasis system can be studied effectively in the mouse, which is a great asset for investigations with gene-altered mice.	Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	University of Notre Dame; University of Notre Dame; American Red Cross	Ploplis, VA (corresponding author), Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA.	vploplis@nd.edu		Lawrence, Daniel/0000-0003-3126-1935	NHLBI NIH HHS [HL-13423, HL-63682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013423, R01HL063682, R37HL013423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1997, CIRCULATION, V96, P2772; Chan JCY, 2001, AM J PATHOL, V159, P1681, DOI 10.1016/S0002-9440(10)63015-5; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; De Prada NA, 2002, EUR J BIOCHEM, V269, P184, DOI 10.1046/j.0014-2956.2002.02639.x; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; Eitzman DT, 2000, BLOOD, V96, P4212; Eitzman DT, 1996, BLOOD, V87, P4718; FRANCIS CW, 1987, HEMOSTASIS THROMBOSI, P358; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GRIMSLEY PG, 1995, THROMB RES, V79, P353, DOI 10.1016/0049-3848(95)00123-9; Gutierrez LS, 2000, CANCER RES, V60, P5839; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Ploplis VA, 2001, AM J PATHOL, V158, P107, DOI 10.1016/S0002-9440(10)63949-1; Rezaie AR, 1999, BIOCHEMISTRY-US, V38, P14592, DOI 10.1021/bi9913303; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; VONMOURIK JA, 1984, J BIOL CHEM, V259, P14914; WEI Y, 1994, J BIOL CHEM, V269, P32380; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943	37	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17914	17920		10.1074/jbc.M314197200	http://dx.doi.org/10.1074/jbc.M314197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963029	hybrid			2022-12-27	WOS:000220870400125
J	Kotzka, J; Lehr, S; Roth, G; Avci, H; Knebel, B; Muller-Wieland, D				Kotzka, J; Lehr, S; Roth, G; Avci, H; Knebel, B; Muller-Wieland, D			Insulin-activated Erk-mitogen-activated protein kinases phosphorylate sterol regulatory element-binding protein-2 at serine residues 432 and 455 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR PROMOTER; LEUCINE ZIPPER PROTEIN; NUCLEAR-PROTEIN; TRANSCRIPTION; SREBP-1; DOMAIN; MAX; IDENTIFICATION; HETERODIMERS; (SREBP)-1A	The transcription factor sterol regulatory element binding protein (SREBP)-2 plays a pivotal role in lipid metabolism. Previously, we have shown that the mature form of SREBP-2 is a substrate of Erk-mitogen-activated protein kinases (MAPK). The aim of the present study was to identify Erk-specific phosphorylation sites. Using a protein chemistry approach, we could identify Ser-432 and Ser-455 as major phosphorylation sites. Further characterization by electrophoretic mobility shift assay and promoter reporter gene analyses revealed that phosphorylation does not influence protein/DNA interaction, but enhances trans-activity. In intact cells, SREBP-2 is phosphorylated by insulin, which seems to be related to their bio-responses on low density lipoprotein receptor activity. These results suggest that activation of Erk-MAPK pathways by hormones such as insulin might be related to a novel regulatory principle of SREBP-2.	Univ Dusseldorf, Inst Clin Biochem & Pathobiochem, German Diabet Ctr, D-40225 Dusseldorf, Germany	Deutsches Diabetes-Zentrum (DDZ); Heinrich Heine University Dusseldorf	Muller-Wieland, D (corresponding author), Univ Dusseldorf, Inst Clin Biochem & Pathobiochem, German Diabet Ctr, Hennekamp 65, D-40225 Dusseldorf, Germany.	mueller-wieland@ddfi.uni-duesseldorf.de		Kotzka, Jorg/0000-0003-1173-9372				Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Atchley WR, 1999, J MOL EVOL, V48, P501, DOI 10.1007/PL00006494; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOUSSET K, 1993, ONCOGENE, V8, P3211; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KIM JB, 1995, MOL CELL BIOL, V15, P2582; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; Kotzka J, 2000, J LIPID RES, V41, P99; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; MEYER HE, 1991, METHOD ENZYMOL, V201, P206; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Prasad KSS, 1997, J BIOL CHEM, V272, P11457; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WADMAN IA, 1994, ONCOGENE, V9, P3713; WANG XD, 1993, J BIOL CHEM, V268, P14497; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	26	77	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22404	22411		10.1074/jbc.M401198200	http://dx.doi.org/10.1074/jbc.M401198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14988395	hybrid			2022-12-27	WOS:000221417100089
J	Guo, DF; Tardif, V; Ghelima, K; Chan, JSD; Ingelfinger, JR; Chen, XM; Chenier, I				Guo, DF; Tardif, V; Ghelima, K; Chan, JSD; Ingelfinger, JR; Chen, XM; Chenier, I			A novel angiotensin II type 1 receptor-associated protein induces cellular hypertrophy in rat vascular smooth muscle and renal proximal tubular cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED INTERNALIZATION; SPONTANEOUSLY HYPERTENSIVE RAT; GUANINE-NUCLEOTIDE EXCHANGE; TRUNCATED AT(1A) RECEPTOR; AKT/PROTEIN KINASE-B; CARDIAC FIBROBLASTS; NUCLEAR-PROTEIN; GROWTH-FACTOR; EXPRESSION; RCC1	Angiotensin II stimulates cellular hypertrophy in cultured vascular smooth muscle and renal proximal tubular cells. This effect is believed to be one of earliest morphological changes of heart and renal failure. However, the precise molecular mechanism involved in angiotensin II-induced hypertrophy is poorly understood. In the present study we report the isolation of a novel angiotensin II type 1 receptor-associated protein. It encodes a 531-amino acid protein. Its mRNA is detected in all human tissues examined but highly expressed in the human kidney, pancreas, heart, and human embryonic kidney cells as well as rat vascular smooth muscle and renal proximal tubular cells. Protein synthesis and relative cell size analyzed by flow cytometry studies indicate that overexpression of the novel angiotensin II type 1 receptor-associated protein induces cellular hypertrophy in cultured rat vascular smooth muscle and renal proximal tubular cells. In contrast, the hypertrophic effects was reversed in renal proximal tubular cell lines expressing the novel gene in the antisense orientation and its dominant negative mutant, which lacks the last 101 amino acids in its carboxyl-terminal tail. The hypertrophic effects are at least in part mediated via protein kinase B activation or cyclin-dependent kinase inhibitor, p27(kip1) protein expression level in vascular smooth muscle, and renal proximal tubular cells. Moreover, angiotensin II could not stimulate cellular hypertrophy in renal proximal tubular cells expressing the novel gene in the antisense orientation and its mutant. These findings may provide new molecular mechanisms to understand hypertrophic agents such as angiotensin II-induced cellular hypertrophy.	Univ Montreal, Dept Med, Montreal, PQ H2W 1T8, Canada; CHUM Hotel Dieu Hosp, Res Ctr, Montreal, PQ H2W 1T8, Canada; Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA; Gen Hosp People Liberty Army, Dept Nephrol, Beijing 100853, Peoples R China	Universite de Montreal; Universite de Montreal; Harvard University; Massachusetts General Hospital	Guo, DF (corresponding author), Univ Montreal, Dept Med, 3850 St Urbain, Montreal, PQ H2W 1T8, Canada.	guod@magellan.umontreal.ca						Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BISCHOFF FR, 1995, METHOD ENZYMOL, V257, P135; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; CHELLAPPAN SP, 1998, CIRCULATION, V98, P82; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; Conchon S, 1998, AM J PHYSIOL-ENDOC M, V274, pE336, DOI 10.1152/ajpendo.1998.274.2.E336; Cui TX, 2000, BIOCHEM BIOPH RES CO, V279, P938, DOI 10.1006/bbrc.2000.4055; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; Dinh DT, 2001, CLIN SCI, V100, P481, DOI 10.1042/CS20000263; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; Gorin Y, 2001, FASEB J, V15, P1909, DOI 10.1096/fj..01-0165com; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Guo DF, 2003, BIOCHEM BIOPH RES CO, V310, P1254, DOI 10.1016/j.bbrc.2003.09.154; Hannken T, 1998, KIDNEY INT, V54, P1923, DOI 10.1046/j.1523-1755.1998.00212.x; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Hughes AD, 1998, J HUM HYPERTENS, V12, P275, DOI 10.1038/sj.jhh.1000635; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; INGELFINGER JR, 1990, J CLIN INVEST, V85, P417, DOI 10.1172/JCI114454; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; MACKOVICBASIC M, 1992, J AM SOC NEPHROL, V3, P1124; METSARINNE KP, 1994, ANGIOTENSIN RECEPTOR, P235; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIZUNO K, 1992, LIFE SCI, V51, P367, DOI 10.1016/0024-3205(92)90589-H; MORTON JJ, 1992, J VASC RES, V29, P264, DOI 10.1159/000158941; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PFEFFER JM, 1982, P NATL ACAD SCI-BIOL, V79, P3310, DOI 10.1073/pnas.79.10.3310; PHILLIPS MI, 1987, ANNU REV PHYSIOL, V49, P413, DOI 10.1146/annurev.physiol.49.1.413; PRATT RE, 1993, CELLULAR MOL BIOL RE, P471; RIBEIRO AB, 1985, DRUGS, V30, P6, DOI 10.2165/00003495-198500301-00003; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SAITOH H, 1995, J BIOL CHEM, V270, P10658, DOI 10.1074/jbc.270.18.10658; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pC113, DOI 10.1152/ajpcell.1987.253.1.C113; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Solban N, 2000, J BIOL CHEM, V275, P32234, DOI 10.1074/jbc.M001352200; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; Takahashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1927, DOI 10.1152/ajpheart.1999.276.6.H1927; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; TANG SS, 1995, AM J PHYSIOL-RENAL, V268, pF435, DOI 10.1152/ajprenal.1995.268.3.F435; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; WANG DH, 1990, HYPERTENSION, V15, P68, DOI 10.1161/01.HYP.15.1.68; WOLF G, 1991, BIOCHEM BIOPH RES CO, V176, P902, DOI 10.1016/S0006-291X(05)80271-2; WOLF G, 1991, CELL REGUL, V2, P219, DOI 10.1091/mbc.2.3.219; Wolf G, 1999, KIDNEY INT, V56, P1262, DOI 10.1046/j.1523-1755.1999.00695.x; WOLF G, 1990, AM J PHYSIOL, V259, pF768, DOI 10.1152/ajprenal.1990.259.5.F768; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488; Zhang JS, 1996, J BIOL CHEM, V271, P15026, DOI 10.1074/jbc.271.25.15026; Zhang SL, 2002, ENDOCRINOLOGY, V143, P4627, DOI 10.1210/en.2002-220408	73	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21109	21120		10.1074/jbc.M401544200	http://dx.doi.org/10.1074/jbc.M401544200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985364	hybrid			2022-12-27	WOS:000221273800068
J	Morel, JL; Rakotoarisoa, L; Jeyakumar, LH; Fleischer, S; Mironneau, C; Mironneau, J				Morel, JL; Rakotoarisoa, L; Jeyakumar, LH; Fleischer, S; Mironneau, C; Mironneau, J			Decreased expression of ryanodine receptors alters calcium-induced calcium release mechanism in mdx duodenal myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; PORTAL-VEIN MYOCYTES; DYSTROPHIC MDX; CA2+ RELEASE; MUSCULAR-DYSTROPHY; MICE; MOUSE; CHANNELS; PROTEIN; PURIFICATION	It is generally believed that alterations of calcium homeostasis play a key role in skeletal muscle atrophy and degeneration observed in Duchenne's muscular dystrophy and mdx mice. Mechanical activity is also impaired in gastrointestinal muscles, but the cellular and molecular mechanisms of this pathological state have not yet been investigated. We showed, in mdx duodenal myocytes, that both caffeine- and depolarization-induced calcium responses were inhibited, whereas acetylcholine- and thapsigargin-induced calcium responses were not significantly affected compared with control mice. Calcium-induced calcium release efficiency was impaired in mdx duodenal myocytes depending only on inhibition of ryanodine receptor expression. Duodenal myocytes expressed both type 2 and type 3 ryanodine receptors and were unable to produce calcium sparks. In control and mdx duodenal myocytes, both caffeine- and depolarization-induced calcium responses were dose-dependently and specifically inhibited with the anti-type 2 ryanodine receptor antibody. A strong inhibition of type 2 ryanodine receptor in mdx duodenal myocytes was observed on the mRNA as well as on the protein level. Taken together, our results suggest that inhibition of type 2 ryanodine receptor expression in mdx duodenal myocytes may account for the decreased calcium release from the sarcoplasmic reticulum and reduced mechanical activity.	Univ Bordeaux 2, CNRS, UMR 5017, Lab Signalisat & Interact Cellulaires, F-33076 Bordeaux, France; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Vanderbilt University	Mironneau, J (corresponding author), Univ Bordeaux 2, CNRS, UMR 5017, Lab Signalisat & Interact Cellulaires, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	jean.mironneau@umr5017.u-bordeaux2.fr	Morel, Jean-Luc/AAY-9235-2020	morel, jean-luc/0000-0001-8079-6851				ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; Arnaudeau S, 1997, CELL CALCIUM, V22, P399, DOI 10.1016/S0143-4160(97)90024-5; Baccari MC, 2000, NEUROSCI LETT, V282, P105, DOI 10.1016/S0304-3940(00)00879-X; BAKKER AJ, 1993, J PHYSIOL-LONDON, V460, P1; BAROHN RJ, 1988, NEW ENGL J MED, V319, P15, DOI 10.1056/NEJM198807073190103; Boittin FX, 2000, BIOCHEM J, V349, P323, DOI 10.1042/0264-6021:3490323; Boittin FX, 1999, AM J PHYSIOL-CELL PH, V277, pC139, DOI 10.1152/ajpcell.1999.277.1.C139; BOLAND B, 1993, J MUSCLE RES CELL M, V14, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Collet C, 1999, J PHYSIOL-LONDON, V520, P417, DOI 10.1111/j.1469-7793.1999.00417.x; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; ESCOBAR AL, 1995, FEBS LETT, V364, P335, DOI 10.1016/0014-5793(95)00425-9; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; Gillis JM, 1999, J MUSCLE RES CELL M, V20, P605, DOI 10.1023/A:1005545325254; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEAD SI, 1992, P ROY SOC B-BIOL SCI, V248, P163, DOI 10.1098/rspb.1992.0058; Jeyakumar LH, 2001, BIOCHEM BIOPH RES CO, V281, P979, DOI 10.1006/bbrc.2001.4444; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; Mallouk N, 2000, P NATL ACAD SCI USA, V97, P4950, DOI 10.1073/pnas.97.9.4950; Mironneau J, 2002, J PHYSIOL-LONDON, V538, P707, DOI 10.1113/jphysiol.2001.013046; Mironneau J, 2001, J BIOL CHEM, V276, P11257, DOI 10.1074/jbc.M005994200; Monnier N, 2000, HUM MOL GENET, V9, P2599, DOI 10.1093/hmg/9.18.2599; Morel JL, 1997, AM J PHYSIOL-HEART C, V273, pH2867, DOI 10.1152/ajpheart.1997.273.6.H2867; Morel JL, 1997, MOL PHARMACOL, V51, P1042, DOI 10.1124/mol.51.6.1042; Morel JL, 1997, BRIT J PHARMACOL, V121, P451, DOI 10.1038/sj.bjp.0701157; Mule F, 2001, GASTROENTEROLOGY, V120, P1430, DOI 10.1053/gast.2001.24054; Plant DR, 2003, AM J PHYSIOL-CELL PH, V285, pC522, DOI 10.1152/ajpcell.00369.2002; RIVETBASTIDE M, 1993, CELL CALCIUM, V14, P563, DOI 10.1016/0143-4160(93)90077-J; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685	31	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21287	21293		10.1074/jbc.M311124200	http://dx.doi.org/10.1074/jbc.M311124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985349	hybrid			2022-12-27	WOS:000221273800090
J	Puranik, M; Nielsen, SB; Youn, H; Hvitved, AN; Bourassa, JL; Case, MA; Tengroth, C; Balakrishnan, G; Thorsteinsson, MV; Groves, JT; McLendon, GL; Roberts, GP; Olson, JS; Spiro, TG				Puranik, M; Nielsen, SB; Youn, H; Hvitved, AN; Bourassa, JL; Case, MA; Tengroth, C; Balakrishnan, G; Thorsteinsson, MV; Groves, JT; McLendon, GL; Roberts, GP; Olson, JS; Spiro, TG			Dynamics of carbon monoxide binding to CooA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING TRANSCRIPTION ACTIVATOR; RESONANCE RAMAN-SPECTROSCOPY; RHODOSPIRILLUM-RUBRUM; REGULATOR COOA; LIGAND-BINDING; HISTIDINE 77; HEME; IDENTIFICATION; ABSORPTION; MECHANISM	CooA is a dimeric CO-sensing heme protein from Rhodospirillum rubrum. The heme iron in reduced CooA is six-coordinate; the axial ligands are His-77 and Pro-2. CO displaces Pro-2 and induces a conformation change that allows CooA to bind DNA and activate transcription of coo genes. Equilibrium CO binding is cooperative, with a Hill coefficient of n = 1.4, P-50 = 2.2 muM, and estimated Adair constants K-1 = 0.16 and K-2 = 1.3 muM(-1). The rates of CO binding and release are both strongly biphasic, with roughly equal amplitudes for the fast and slow phases. The association rates show a hyperbolic dependence on [CO], consistent with Pro-2 dissociation being rate-limiting. The kinetic characteristics of the transiently formed five-coordinate heme are probed via flash photolysis. These observations are integrated into a kinetic model, in which CO binding to one subunit decreases the rate of Pro-2 rebinding in the second, leading to a net increase in affinity for the second CO. The CO adduct exists in slowly interconverting "open" and "closed" forms. This interconversion probably involves the large-scale motions required to bring the DNA-binding domains into proper orientation. The combination of low CO affinity, slow CO binding, and slow conformational transitions ensures that activation of CooA only occurs at high (micromolar) and sustained (greater than or equal to1 min) levels of CO. When micromolar levels do occur, positive cooperativity allows efficient activation over a narrow range of CO concentrations.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77025 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Rice University; Princeton University; University of Wisconsin System; University of Wisconsin Madison	Olson, JS (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS 140,6100 Main St, Houston, TX 77025 USA.	olson@rice.edu; spiro@princeton.edu	Groves, John T./GPP-7588-2022; Nielsen, Steen Brondsted/G-5844-2016	Groves, John T./0000-0002-9944-5899; Olson, John/0000-0002-0760-5403	NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM 08280, GM 53228, GM 35649, GM 33576, T32 GM008280, GM 36928] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033576, T32GM008280, R01GM035649, R01GM053228, R01GM036928] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; Coyle CM, 2003, J BIOL CHEM, V278, P35384, DOI 10.1074/jbc.M301000200; GIBSON QH, 1986, J BIOL CHEM, V261, P228; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; HOFRICHTER J, 1994, METHOD ENZYMOL, V232, P387; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; Kerby RL, 2003, J MOL BIOL, V325, P809, DOI 10.1016/S0022-2836(02)01203-2; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; Kumazaki S, 2000, J BIOL CHEM, V275, P38378, DOI 10.1074/jbc.M005533200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Moffet DA, 2001, J AM CHEM SOC, V123, P2109, DOI 10.1021/ja0036007; Reynolds MF, 2000, BIOCHEMISTRY-US, V39, P388, DOI 10.1021/bi991378g; Rubtsov IV, 2001, J AM CHEM SOC, V123, P10056, DOI 10.1021/ja011023w; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Youn H, 2003, J BIOL CHEM, V278, P2333, DOI 10.1074/jbc.M210825200; Zhao XJ, 1999, APPL SPECTROSC, V53, P1200, DOI 10.1366/0003702991945669; Zhao XJ, 2000, J RAMAN SPECTROSC, V31, P349, DOI 10.1002/(SICI)1097-4555(200004)31:4<349::AID-JRS548>3.0.CO;2-6	28	58	58	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21096	21108		10.1074/jbc.M400613200	http://dx.doi.org/10.1074/jbc.M400613200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14990568	hybrid			2022-12-27	WOS:000221273800067
J	Shi, Z; Ferreira, GC				Shi, Z; Ferreira, GC			Probing the active site loop motif of murine ferrochelatase by random mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE FERROCHELATASE; RANDOM SEQUENCE MUTAGENESIS; AMINO-ACID SUBSTITUTIONS; BINDING-SITE; MAMMALIAN FERROCHELATASE; METAL-BINDING; ESCHERICHIA-COLI; ERYTHROPOIETIC PROTOPORPHYRIA; DIRECTED MUTAGENESIS; HEME-BIOSYNTHESIS	Ferrochelatase catalyzes the terminal step of the heme biosynthetic pathway by inserting ferrous iron into protoporphyrin IX. A conserved loop motif was shown to form part of the active site and contact the bound porphyrin by molecular dynamics calculations and structural analysis. We applied a random mutagenesis approach and steady-state kinetic analysis to assess the role of the loop motif in murine ferrochelatase function, particularly with respect to porphyrin interaction. Functional substitutions in the 10 consecutive loop positions Gln(248)-Leu(257) were identified by genetic complementation in Escherichia coli strain Deltavis. Lys(250), Val(251), Pro(253), Val(254), and Pro(255) tolerated a variety of replacements including single substitutions and contained low informational content. Gln(248), Ser(249), Gly(252), Trp(256), and Leu(257) possessed high informational content, since permissible replacements were limited and only observed in multiply substituted mutants. Selected active loop variants exhibited k(cat) values comparable with or higher than that of wild-type murine ferrochelatase. The K-m values for porphyrin increased, except for the single mutant V251L. Other than a moderate increase observed in the triple mutant S249A/K250Q/V251C, the K-m values for Fe2+ were lowered. The k(cat)/K-m for porphyrin remained largely unchanged, with the exception of a 10-fold reduction in the triple mutant K250M/V251L/W256Y. The k(cat)/K-m for Fe2+ was improved. Molecular modeling of these active loop variants indicated that loop mutations resulted in alterations of the active site architecture. However, despite the plasticity of the loop primary structure, the relative spatial positioning of the loop in the active site appeared to be maintained in functional variants, supporting a role for the loop in ferrochelatase function.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Ferreira, GC (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA.	gferreir@hsc.usf.edu	Shi, Zhen/B-6358-2014; Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217				ABBAS A, 1993, J BIOL CHEM, V268, P8541; Al-Karadaghi S, 1997, STRUCTURE, V5, P1501, DOI 10.1016/S0969-2126(97)00299-2; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Blackwood ME, 1997, J AM CHEM SOC, V119, P12170, DOI 10.1021/ja971619c; Blackwood ME, 1998, BIOCHEMISTRY-US, V37, P779, DOI 10.1021/bi972616f; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; Dailey HA, 2000, CELL MOL LIFE SCI, V57, P1909, DOI 10.1007/PL00000672; Dailey TA, 2002, J BACTERIOL, V184, P2460, DOI 10.1128/JB.184.9.2460-2464.2002; Ferreira GC, 1999, INT J BIOCHEM CELL B, V31, P995, DOI 10.1016/S1357-2725(99)00066-7; FERREIRA GC, 1994, J BIOL CHEM, V269, P7062; FERREIRA GC, 1994, J BIOL CHEM, V269, P4396; Ferreira GC, 2002, BIOCHEMISTRY-US, V41, P4809, DOI 10.1021/bi015814m; FERREIRA GC, 1993, J BIOL CHEM, V268, P584; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P221, DOI 10.1007/BF02110037; Fodje MN, 2002, PROTEIN ENG, V15, P353, DOI 10.1093/protein/15.5.353; Franco R, 2001, BIOCHEM J, V356, P217, DOI 10.1042/0264-6021:3560217; FRANCO R, 1995, J BIOL CHEM, V270, P26352, DOI 10.1074/jbc.270.44.26352; Franco R, 2000, BIOCHEMISTRY-US, V39, P2517, DOI 10.1021/bi991346t; GONG J, 1995, BIOCHEMISTRY-US, V34, P1678, DOI 10.1021/bi00005a024; Gora M, 1996, J BIOL CHEM, V271, P11810, DOI 10.1074/jbc.271.20.11810; Gora M, 1996, BIOCHIMIE, V78, P144, DOI 10.1016/0300-9084(96)82647-2; Gouya L, 2002, NAT GENET, V30, P27, DOI 10.1038/ng809; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Huntley JJA, 2003, PROTEIN SCI, V12, P1368, DOI 10.1110/ps.0305303; Karlberg T, 2002, BIOCHEMISTRY-US, V41, P13499, DOI 10.1021/bi0260785; KOHNO H, 1994, BBA-PROTEIN STRUCT M, V1209, P95, DOI 10.1016/0167-4838(94)90142-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landis DM, 1998, J BIOL CHEM, V273, P25809, DOI 10.1074/jbc.273.40.25809; Lecerof D, 2003, J BIOL INORG CHEM, V8, P452, DOI 10.1007/s00775-002-0436-1; Lecerof D, 2000, J MOL BIOL, V297, P221, DOI 10.1006/jmbi.2000.3569; Lloyd SG, 1996, J AM CHEM SOC, V118, P9892, DOI 10.1021/ja954000o; Medlock AE, 2000, BIOCHEMISTRY-US, V39, P7461, DOI 10.1021/bi000134p; MUNIR KM, 1992, J BIOL CHEM, V267, P6584; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; Osborne MJ, 2001, BIOCHEMISTRY-US, V40, P9846, DOI 10.1021/bi010621k; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; Rufenacht UB, 1998, AM J HUM GENET, V62, P1341, DOI 10.1086/301870; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sellers VM, 2001, BIOCHEMISTRY-US, V40, P9821, DOI 10.1021/bi010012c; Shi Z, 2003, ANAL BIOCHEM, V318, P18, DOI 10.1016/S0003-2697(03)00175-1; Shin DH, 2003, PROTEIN SCI, V12, P1464, DOI 10.1110/ps.0302703; TARTOF KD, 1987, FOCUS, V9, P12; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Weaver TM, 2000, PROTEIN SCI, V9, P201; Wu CK, 2001, NAT STRUCT BIOL, V8, P156, DOI 10.1038/84152; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	47	20	20	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19977	19986		10.1074/jbc.M313821200	http://dx.doi.org/10.1074/jbc.M313821200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14981080	hybrid			2022-12-27	WOS:000221164500072
J	Zhang, X; Wehbi, H; Roberts, MF				Zhang, X; Wehbi, H; Roberts, MF			Cross-linking phosphatidylinositol-specific phospholipase C traps two activating phosphatidylcholine molecules on the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFACIAL BINDING; BACILLUS-CEREUS; CRYSTAL-STRUCTURE; PHOSPHOTRANSFERASE; MECHANISM; PHOSPHATE; RESIDUES; KINETICS; HELIX	Bacillus thuringiensis phosphatidylinositol-specific phospholipase C (PI-PLC), a bacterial model for the catalytic domain of mammalian PI-PLC enzymes, was cross-linked by 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride to probe for the aggregation and/or conformational changes of PI-PLC when bound to activating phosphatidylcholine ( PC) interfaces. Dimers and higher order multimers ( up to 31% of the total protein when cross-linked at pH 7) were observed when the enzyme was cross-linked in the presence of PC vesicles. Aggregates were also detected with PI-PLC bound to diheptanoyl-PC (diC(7)PC) micelles, although the fraction of cross-linked multimers (19% at pH 7) was lower than when the enzyme was cross-linked in the presence of vesicles. PI-PLC cross-linked in the presence of a diC(7)PC interface exhibited an enhanced specific activity for PI cleavage. The extent of this cross-linking-enhanced activation was reduced in PI-PLC mutants lacking either tryptophan in the rim (W47A and W242A) of this (betaalpha)(8)-barrel protein. The higher activity of the native protein cross-linked in the presence of diC(7)PC correlated with an increased affinity of the protein for two diC(7)PC molecules as detected by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry. In contrast to wild type protein, W47A and W242A had only a single diC7PC tightly associated when cross-linked in the presence of that activator molecule. These results indicate that (i) each rim tryptophan residue is involved in binding a PC molecule at interfaces, (ii) the affinity of the enzyme for an activating PC molecule is enhanced when the protein is bound to a surface, and (iii) this conformation of the enzyme with at least two PC bound that is stabilized by chemical cross-linking interacts more effectively with activating interfaces, leading to higher observed specific activities for the phosphotransferase reaction.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA	Boston College	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.	mary.roberts@bc.edu		Zhang, Xin/0000-0003-3023-664X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060418] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 60418] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berg OG, 2004, BIOCHEMISTRY-US, V43, P2080, DOI 10.1021/bi035063j; BIAN JR, 1992, J COLLOID INTERF SCI, V153, P420, DOI 10.1016/0021-9797(92)90333-H; Birrell GB, 2003, BIOPHYS J, V84, P3264; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P19; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Feng JW, 2003, J BIOL CHEM, V278, P24651, DOI 10.1074/jbc.M301207200; Feng JW, 2002, J BIOL CHEM, V277, P19867, DOI 10.1074/jbc.M200938200; Fichmann J, 1999, METH MOL B, V112, P1; GOLDFINE H, 1992, INFECT IMMUN, V60, P4059, DOI 10.1128/IAI.60.10.4059-4067.1992; Griffith OH, 1999, BBA-MOL CELL BIOL L, V1441, P237, DOI 10.1016/S1388-1981(99)00153-5; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HENDRICKSON HS, 1992, BIOCHEMISTRY-US, V31, P12169, DOI 10.1021/bi00163a028; Hondal RJ, 1998, BIOCHEMISTRY-US, V37, P4568, DOI 10.1021/bi972646i; Hondal RJ, 1997, BIOCHEMISTRY-US, V36, P6633, DOI 10.1021/bi962866g; LEWIS KA, 1993, BIOCHEMISTRY-US, V32, P8836, DOI 10.1021/bi00085a014; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHINSON C, 1989, BIOCHEMISTRY-US, V28, P4807, DOI 10.1021/bi00437a043; Qian XQ, 1998, BIOCHEMISTRY-US, V37, P6513, DOI 10.1021/bi972650u; Sahoo D, 2002, J MOL BIOL, V321, P201, DOI 10.1016/S0022-2836(02)00618-6; Stieglitz K, 1999, J BIOL CHEM, V274, P35367, DOI 10.1074/jbc.274.50.35367; Tsou LK, 2002, J AM CHEM SOC, V124, P14917, DOI 10.1021/ja026721a; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; Wallace BA, 1999, ADV EXP MED BIOL, V467, P789; Wehbi H, 2003, BIOCHEMISTRY-US, V42, P9374, DOI 10.1021/bi034195+; Wehbi H, 2003, BBA-BIOMEMBRANES, V1613, P15, DOI 10.1016/S0005-2736(03)00134-2; Wu YQ, 1997, BIOCHEMISTRY-US, V36, P11223, DOI 10.1021/bi971039s; Yang HY, 2003, PROTEIN SCI, V12, P2087, DOI 10.1110/ps.03192503; Zhou C, 1997, BIOCHEMISTRY-US, V36, P347, DOI 10.1021/bi960601w; Zhou C, 1997, BIOCHEMISTRY-US, V36, P10089, DOI 10.1021/bi970846o; Zhou C, 1998, BIOCHEMISTRY-US, V37, P16430, DOI 10.1021/bi980601r	33	16	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20490	20500		10.1074/jbc.M401016200	http://dx.doi.org/10.1074/jbc.M401016200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996830	hybrid			2022-12-27	WOS:000221164500128
J	Quinton, TM; Kim, S; Derian, CK; Jin, JG; Kunapuli, SP				Quinton, TM; Kim, S; Derian, CK; Jin, JG; Kunapuli, SP			Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN RECEPTOR; MOLECULAR-CLONING; AGGREGATION; PEPTIDES; CALCIUM; PAR4; DETERMINANTS; HEMOSTASIS; INHIBITION; MECHANISM	The activation of plasmin from its circulating precursor plasminogen is the mechanism of several clot-busting drugs used to clinically treat patients who have suffered a stroke; however, plasmin thus generated has been shown to activate platelets directly. There has been speculation as to whether plasmin interacts with the protease-activated receptors (PARs) because of its similarity in amino acid specificity with the classic platelet activator thrombin. We have investigated whether plasmin activates platelets via PAR activation through multiple complementary approaches. At concentrations sufficient to induce human platelet aggregation, plasmin released very little calcium compared with that induced by thrombin, the PAR-1 agonist peptide SFLLRN, or the PAR-4 agonist peptide AYPGKF. Stimulation of platelets with plasmin initially failed to desensitize additional stimulation with SFLLRN or AYPGKF, but a prolonged incubation with plasmin desensitized platelets to further stimulation by thrombin. The desensitization of PAR-1 had no effect on plasmin-induced platelet aggregation and yielded an aggregation profile that was similar to plasmin in response to a low dose of thrombin. However, PAR-4 desensitization completely eliminated aggregation in response to plasmin. Inclusion of the PAR-1-specific antagonist BMS-200261 inhibited platelet aggregation induced by a low dose of thrombin but not by plasmin. Additionally, mouse platelets naturally devoid of PAR-1 showed a full aggregation response to plasmin in comparison to thrombin. Furthermore, human and mouse platelets treated with a PAR-4 antagonist, as well as platelets isolated from PAR-4 homozygous null mice, failed to aggregate in response to plasmin. Finally, a protease-resistant recombinant PAR-4 was refractory to activation by plasmin. We conclude that plasmin induces platelet aggregation primarily through slow cleavage of PAR-4.	Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Physiol, Sch Med, Philadelphia, PA 19140 USA; Johnson & Johnson Pharmaceut Res & Dev, Spring House, PA 19477 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Johnson & Johnson; Johnson & Johnson USA	Quinton, TM (corresponding author), Rm 224OMS,3420 N Broad St, Philadelphia, PA 19140 USA.	tquinton@temple.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060683, P01HL064943] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64943, HL60683] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dubois C, 2003, THROMB HAEMOSTASIS, V89, P853, DOI 10.1055/s-0037-1613473; Ervin AL, 2001, BLOOD COAGUL FIBRIN, V12, P415, DOI 10.1097/00001721-200109000-00001; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hollenberg MD, 2001, CAN J PHYSIOL PHARM, V79, P439, DOI 10.1139/cjpp-79-5-439; Hollenberg MD, 1999, TRENDS PHARMACOL SCI, V20, P271, DOI 10.1016/S0165-6147(99)01333-4; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Ishii-Watabe A, 2000, BIOCHEM PHARMACOL, V59, P1345, DOI 10.1016/S0006-2952(00)00279-3; Kahn ML, 1998, J BIOL CHEM, V273, P23290, DOI 10.1074/jbc.273.36.23290; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; NAKAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC958, DOI 10.1152/ajpcell.1995.268.4.C958; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; NIEWIAROWSKI S, 1973, J CLIN INVEST, V52, P1647, DOI 10.1172/JCI107345; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Parry MAA, 1996, BIOCHEM J, V320, P335, DOI 10.1042/bj3200335; PASCHE B, 1994, BLOOD, V83, P404; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; SCHAFER AI, 1987, BLOOD, V69, P1504; Schweizer J, 2000, J AM COLL CARDIOL, V36, P1336, DOI 10.1016/S0735-1097(00)00863-9; TURNER JS, 1994, BIOCHEM J, V297, P175, DOI 10.1042/bj2970175; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Watabe A, 1997, RES COMMUN MOL PATH, V96, P341; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	27	73	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18434	18439		10.1074/jbc.M401431200	http://dx.doi.org/10.1074/jbc.M401431200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14973136	hybrid			2022-12-27	WOS:000221041500042
J	Scarlatti, F; Bauvy, C; Ventruti, A; Sala, G; Cluzeaud, F; Vandewalle, A; Ghidoni, R; Codogno, P				Scarlatti, F; Bauvy, C; Ventruti, A; Sala, G; Cluzeaud, F; Vandewalle, A; Ghidoni, R; Codogno, P			Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PROGRAMMED CELL-DEATH; HUMAN COLON-CANCER; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; AUTOPHAGIC VACUOLES; TUMOR-SUPPRESSOR; HT-29 CELLS; GROWTH ARREST; AKT KINASE	The sphingolipid ceramide is involved in the cellular stress response. Here we demonstrate that ceramide controls macroautophagy, a major lysosomal catabolic pathway. Exogenous C-2-ceramide stimulates macroautophagy (proteolysis and accumulation of autophagic vacuoles) in the human colon cancer HT-29 cells by increasing the endogenous pool of long chain ceramides as demonstrated by the use of the ceramide synthase inhibitor fumonisin B-1. Ceramide reverted the interleukin 13-dependent inhibition of macroautophagy by interfering with the activation of protein kinase B. In addition, C-2-ceramide stimulated the expression of the autophagy gene product beclin 1. Ceramide is also the mediator of the tamoxifen-dependent accumulation of autophagic vacuoles in the human breast cancer MCF-7 cells. Monodansylcadaverine staining and electron microscopy showed that this accumulation was abrogated by myriocin, an inhibitor of de novo synthesis ceramide. The tamoxifen-dependent accumulation of vacuoles was mimicked by 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthase. 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol, tamoxifen, and C-2-ceramide stimulated the expression of beclin 1, whereas myriocin antagonized the tamoxifen-dependent up-regulation. Tamoxifen and C-2-ceramide interfere with the activation of protein kinase B, whereas myriocin relieved the inhibitory effect of tamoxifen. In conclusion, the control of macroautophagy by ceramide provides a novel function for this lipid mediator in a cell process with major biological outcomes.	INSERM, U504, F-94807 Villejuif, France; San Paolo Med Sch, Biochem & Mol Biol Lab, I-20142 Milan, Italy; INSERM, U478, F-75870 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	codogno@vjf.inserm.fr	Codogno, Patrice/G-1384-2013	Codogno, Patrice/0000-0002-5492-3180; GHIDONI, RICCARDO/0000-0002-6300-5867				Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413; Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Alesse E, 1998, CELL DEATH DIFFER, V5, P381, DOI 10.1038/sj.cdd.4400358; AMES BN, 1960, J BIOL CHEM, V235, P769; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Baehrecke EH, 2003, CELL DEATH DIFFER, V10, P940, DOI 10.1038/sj.cdd.4401280; Bergamini E, 2003, BIOMED PHARMACOTHER, V57, P203, DOI 10.1016/S0753-3322(03)00048-9; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Bleicher RJ, 2002, BBA-MOL CELL BIOL L, V1585, P172, DOI 10.1016/S1388-1981(02)00338-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; Bursch W, 2000, J CELL SCI, V113, P1189; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402; Furuya N., 2004, AUTOPHAGY, P244; Ghidoni R, 1996, EUR J BIOCHEM, V237, P454, DOI 10.1111/j.1432-1033.1996.0454k.x; Ghidoni R, 1999, BBA-MOL CELL BIOL L, V1439, P17, DOI 10.1016/S1388-1981(99)00074-8; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levade T, 2002, NEUROCHEM RES, V27, P601, DOI 10.1023/A:1020215815013; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0; Nishino Ichizo, 2003, Curr Neurol Neurosci Rep, V3, P64, DOI 10.1007/s11910-003-0040-y; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Paglin S, 2001, CANCER RES, V61, P439; Pelled D, 2002, J BIOL CHEM, V277, P1957, DOI 10.1074/jbc.M104677200; Perry DK, 1999, TRENDS BIOCHEM SCI, V24, P226, DOI 10.1016/S0968-0004(99)01407-3; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; PREISS J, 1986, J BIOL CHEM, V261, P8597; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; Saftig P, 2001, TRENDS MOL MED, V7, P37, DOI 10.1016/S1471-4914(00)01868-2; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Selzner M, 2001, CANCER RES, V61, P1233; Stefanis DD, 2002, BIOL CHEM, V383, P989, DOI 10.1515/BC.2002.106; STROMHAUG PE, 1993, BIOCHEM J, V291, P115, DOI 10.1042/bj2910115; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	77	357	385	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18384	18391		10.1074/jbc.M313561200	http://dx.doi.org/10.1074/jbc.M313561200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970205	hybrid			2022-12-27	WOS:000221041500036
J	Tapias, A; Auriol, J; Forget, D; Enzlin, JH; Scharer, OD; Coin, F; Coulombe, B; Egly, JM				Tapias, A; Auriol, J; Forget, D; Enzlin, JH; Scharer, OD; Coin, F; Coulombe, B; Egly, JM			Ordered conformational changes in damaged DNA induced by nucleotide excision repair factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; PHOTO-CROSS-LINKING; GROUP-C PROTEIN; TRANSCRIPTION FACTOR IIH; OPEN COMPLEX-FORMATION; XPG PROTEIN; BINDING; ENDONUCLEASE; TFIIH; NUCLEASE	In response to genotoxic attacks, cells activate sophisticated DNA repair pathways such as nucleotide excision repair (NER), which consists of damage removal via dual incision and DNA resynthesis. Using permanganate footprinting as well as highly purified factors, we show that NER is a dynamic process that takes place in a number of successive steps during which the DNA is remodeled around the lesion in response to the various NER factors. XPC/HR23B first recognizes the damaged structure and initiates the opening of the helix from position -3 to +6. TFIIH is then recruited and, in the presence of ATP, extends the opening from position -6 to +6; it also displaces XPC downstream from the lesion, thereby providing the topological structure for recruiting XPA and RPA, which will enlarge the opening. Once targeted by XPG, the damaged DNA is further melted from position -19 to +8. XPG and XPF/ERCC1 endonucleases then cut the damaged DNA at the limit of the opened structure that was previously "labeled" by the positioning of XPC/HR23B and TFIIH.	ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; Univ Zurich, Inst Mol Canc Res, CH-8008 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Zurich	Coulombe, B (corresponding author), ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 10142, F-67404 Illkirch Graffenstaden, France.	coulomb@ircm.qc.ca; egly@igbmc.u-strasbg.fr	Schärer, Orlando D./AAF-8613-2021; Coin, Frédéric/F-5925-2013; Scharer, Orlando/B-8908-2008	Coin, Frédéric/0000-0002-5620-8519; Scharer, Orlando/0000-0003-2425-2715	Canadian Institutes of Health Research [14309-2] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANIN MF, 1990, NUCLEIC ACIDS RES, V18, P4395, DOI 10.1093/nar/18.15.4395; Araujo SJ, 2000, GENE DEV, V14, P349; Araujo SJ, 2001, MOL CELL BIOL, V21, P2281, DOI 10.1128/MCB.21.7.2281-2291.2001; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; Constantinou A, 1999, J BIOL CHEM, V274, P5637, DOI 10.1074/jbc.274.9.5637; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Enzlin JH, 2002, EMBO J, V21, P2045, DOI 10.1093/emboj/21.8.2045; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Forget D, 2004, MOL CELL BIOL, V24, P1122, DOI 10.1128/MCB.24.3.1122-1131.2004; Frit P, 2002, MOL CELL, V10, P1391, DOI 10.1016/S1097-2765(02)00732-3; GERARD M, 1991, J BIOL CHEM, V266, P20940; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hermanson-Miller IL, 2002, BIOCHEMISTRY-US, V41, P2402, DOI 10.1021/bi0112863; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hohl M, 2003, J BIOL CHEM, V278, P19500, DOI 10.1074/jbc.M213155200; Houtsmuller AB, 1999, SCIENCE, V284, P958, DOI 10.1126/science.284.5416.958; JIANG Y, 1995, J BIOL CHEM, V270, P1277, DOI 10.1074/jbc.270.3.1277; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Missura M, 2001, EMBO J, V20, P3554, DOI 10.1093/emboj/20.13.3554; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Nocentini S, 1997, J BIOL CHEM, V272, P22991, DOI 10.1074/jbc.272.37.22991; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; Persinger J, 2000, METH MOL B, V148, P363; Reardon JT, 2002, MOL CELL BIOL, V22, P5938, DOI 10.1128/MCB.22.16.5938-5945.2002; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; Robert F, 2000, METH MOL B, V148, P383; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Schweizer U, 1999, NUCLEIC ACIDS RES, V27, P3183, DOI 10.1093/nar/27.15.3183; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; VANGARDEREN CJ, 1994, EUR J BIOCHEM, V225, P1169; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258; Yokoi M, 2000, J BIOL CHEM, V275, P9870, DOI 10.1074/jbc.275.13.9870; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	59	108	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19074	19083		10.1074/jbc.M312611200	http://dx.doi.org/10.1074/jbc.M312611200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14981083	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000221041500120
J	Tu, HP; Tang, TS; Wang, ZN; Bezprozvanny, I				Tu, HP; Tang, TS; Wang, ZN; Bezprozvanny, I			Association of type 1 inositol 1,4,5-trisphosphate receptor with AKAP9 (Yotiao) and protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-DEPENDENT PHOSPHORYLATION; (1,4,5)-TRISPHOSPHATE RECEPTOR; SPLICE VARIANTS; FUNCTIONAL-CHARACTERIZATION; MUTATIONAL ANALYSIS; RYANODINE RECEPTOR; SKELETAL-MUSCLE; NMDA RECEPTOR; CALCIUM; TRISPHOSPHATE	Inositol 1,4,5-trisphosphate receptors (InsP(3)R) play a key role in intracellular calcium (Ca2+) signaling. Three InsP(3)R isoforms are expressed in mammals. Type 1 InsP(3)R (InsP(3)R1) is a predominant neuronal isoform. Neuronal InsP(3)R1 is one of the major substrates of protein kinase A (PKA) phosphorylation. In our previous study (Tang, T. S., Tu, H., Wang, Z., and Bezprozvanny, I. (2003) J. Neurosci. 23, 403-415) we discovered a direct association between InsP(3)R1 and protein phosphatase 1alpha (PP1alpha). In functional experiments we demonstrated that phosphorylation by PKA activates InsP(3)R1 and that dephosphorylation by PP1alpha inhibits InsP(3)R1. To extend these findings, here we investigated the possibility of InsP(3)R1-PKA association. In a series of biochemical experiments we demonstrate the following findings. 1) InsP(3)R1 and PKA associate in the brain. 2) InsP(3)R1-PKA association is mediated by the AKAP9 (Yotiao) multifunctional PKA anchoring protein. 3) InsP(3)R1-AKAP9 association is mediated via the leucine/isoleucine zipper (LIZ) motif in the InsP3R1 coupling domain and the fourth LIZ motif in AKAP9. 4) The InsP3R association with AKAP9 is specific for type 1 InsP3R. 5) Both the SII(+) and the SII(-) coupling domain splice variants of InsP(3)R1 bind to AKAP9. 6) Binding to AKAP9 promotes association of neuronal InsP(3)R1 with the NR1 NMDA receptor; and 7) neuronal InsP(3)R1 associate with PP1 directly via carboxy-terminus and indirectly via AKAP9. The obtained results advance our understanding of cross-talk between cAMP and InsP(3)/Ca2+ signaling pathways in the brain.	Univ Texas, SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bezprozvanny, I (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA.	Ilya.Bezprozvanny@UTSouthwestern.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038082] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS38082] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Brown JH, 1996, PROTEINS, V26, P134; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; deSouza N, 2002, J BIOL CHEM, V277, P39397, DOI 10.1074/jbc.M207059200; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Feliciello A, 1999, FEBS LETT, V464, P174, DOI 10.1016/S0014-5793(99)01585-9; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Galvan DL, 2002, J BIOL CHEM, V277, P48248, DOI 10.1074/jbc.M209990200; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Hulme JT, 2002, J BIOL CHEM, V277, P4079, DOI 10.1074/jbc.M109814200; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; Lin JW, 1998, J NEUROSCI, V18, P2017; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; Maes K, 2000, CELL CALCIUM, V27, P257, DOI 10.1054/ceca.2000.0121; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Maximov A, 2003, MOL CELL NEUROSCI, V22, P271, DOI 10.1016/S1044-7431(02)00027-1; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NAKAGAWA T, 1991, J NEUROCHEM, V57, P1807, DOI 10.1111/j.1471-4159.1991.tb06385.x; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; Pieper AA, 2001, NEUROSCIENCE, V102, P433, DOI 10.1016/S0306-4522(00)00470-X; Rodriguez P, 2003, J BIOL CHEM, V278, P38593, DOI 10.1074/jbc.C301180200; Ruehr ML, 2003, J BIOL CHEM, V278, P24831, DOI 10.1074/jbc.M213279200; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; Tu HP, 2002, BIOPHYS J, V82, P1995, DOI 10.1016/S0006-3495(02)75548-3; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Wagner LE, 2003, J BIOL CHEM, V278, P45811, DOI 10.1074/jbc.M306270200; WALAAS SI, 1986, J NEUROSCI, V6, P954; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	43	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19375	19382		10.1074/jbc.M313476200	http://dx.doi.org/10.1074/jbc.M313476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14982933	hybrid			2022-12-27	WOS:000221041500150
J	Khundmiri, SJ; Bertorello, AM; Delamere, NA; Lederer, ED				Khundmiri, SJ; Bertorello, AM; Delamere, NA; Lederer, ED			Clathrin-mediated endocytosis of Na+,K+-ATPase in response to parathyroid hormone requires ERK-dependent phosphorylation of Ser-11 within the alpha(1)-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; SODIUM-PHOSPHATE COTRANSPORTERS; PROTEIN-KINASE-C; ALPHA-SUBUNIT; PROXIMAL TUBULE; TRANSPORT; PATHWAYS; DOPAMINE; KIDNEY; RECRUITMENT	Parathyroid hormone (PTH) inhibits Na+, K+-ATPase activity through protein kinase C- (PKC) and extracellular signal-regulated kinase- (ERK) dependent pathways and increases serine phosphorylation of the alpha(1)-subunit. To determine whether specific serine phosphorylation sites within the Na+, K+-ATPase alpha(1)-subunit are involved in the Na+, K+-ATPase responses to PTH, we examined the effect of PTH in opossum kidney cells stably transfected with wild type rat Na+, K+-ATPase alpha(1)-subunit (WT), serine 11 to alanine mutant alpha(1)-subunit (S11A), or serine 18 to alanine mutant alpha(1)-subunit (S18A). PTH increased phosphorylation and endocytosis of the Na+, K+-ATPase alpha(1)-subunit into clathrin-coated vesicles in cells transfected with WT and S18A rat Na+, K+-ATPase alpha(1)-subunits. PTH did not increase the level of phosphorylation or stimulate translocation of Na+, K+-ATPase alpha(1)-subunits into clathrin-coated vesicles in cells transfected with the S11A mutant. PTH inhibited ouabain-sensitive Rb-86 uptake and Na+, K+-ATPase activity (ouabain-sensitive ATP hydrolysis) in WT- and S18A-transfected opossum kidney cells but not in S11A-transfected cells. Pretreatment of the cells with the PKC inhibitors and ERK inhibitor blocked PTH inhibition of Rb-86 uptake, Na+, K+-ATPase activity, alpha(1)-subunit phosphorylation, and endocytosis in WT and S18A cells. Consistent with the notion that ERK phosphorylates Na+, K+-ATPase alpha(1)-subunit, ERK was shown to be capable of causing phosphorylation of Na+, K+-ATPase alpha(1)-subunit immunoprecipitated from WT and S18A but not from S11A-transfected cells. These results suggest that PTH regulates Na+, K+-ATPase by PKC and ERK-dependent alpha(1)-subunit phosphorylation and that the phosphorylation requires the expression of a serine at the 11 position of the Na+, K+-ATPase alpha(1)-subunit.	Univ Louisville, Kidney Dis Program, Dept Med, Louisville, KY 40202 USA; Univ Louisville, Dept Ophthalmol, Louisville, KY 40202 USA; Louisville Vet Affairs Hosp, Louisville, KY USA; Karolinska Inst, Karolinska Hosp, Dept Med, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden	University of Louisville; University of Louisville; Karolinska Institutet; Karolinska University Hospital	Lederer, ED (corresponding author), Univ Louisville, Kidney Dis Program, Dept Med, 615 S Preston, Louisville, KY 40202 USA.	e.lederer@louisville.edu		Delamere, Nicholas/0000-0002-3018-1645; Khundmiri, Syed/0000-0002-0364-0412	NATIONAL EYE INSTITUTE [R01EY009532] Funding Source: NIH RePORTER; NEI NIH HHS [EY09532, EY06915] Funding Source: Medline; BLRD VA [I01 BX000610] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); BLRD VA		Bacic D, 2003, PFLUG ARCH EUR J PHY, V446, P52, DOI 10.1007/s00424-002-0969-8; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; Brismar H, 2000, CLIN EXP HYPERTENS, V22, P303, DOI 10.1081/CEH-100100079; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; Derrickson BH, 1997, AM J PHYSIOL-RENAL, V272, pF781, DOI 10.1152/ajprenal.1997.272.6.F781; Done SC, 2002, J BIOL CHEM, V277, P17108, DOI 10.1074/jbc.M201326200; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HAMMOND TG, 1994, AM J PHYSIOL, V266, pF554, DOI 10.1152/ajprenal.1994.266.4.F554; Khundmiri SJ, 2003, J BIOL CHEM, V278, P10134, DOI 10.1074/jbc.M211775200; Khundmiri SJ, 2002, AM J PHYSIOL-RENAL, V282, pF512, DOI 10.1152/ajprenal.00111.2000; Lederer ED, 1998, AM J PHYSIOL-RENAL, V275, pF270, DOI 10.1152/ajprenal.1998.275.2.F270; Lederer ED, 1998, J AM SOC NEPHROL, V9, P975; Lederer ED, 2000, J AM SOC NEPHROL, V11, P222, DOI 10.1681/ASN.V112222; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Magyar CE, 2000, CURR OPIN NEPHROL HY, V9, P149, DOI 10.1097/00041552-200003000-00009; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; Okafor MC, 2002, INVEST OPHTH VIS SCI, V43, P790; RIBEIRO CMP, 1994, AM J PHYSIOL, V266, pF497, DOI 10.1152/ajprenal.1994.266.3.F497; RIBEIRO CP, 1992, AM J PHYSIOL, V262, pF209, DOI 10.1152/ajprenal.1992.262.2.F209; SZCZEPANSKAKONKEL M, 1986, J BIOL CHEM, V261, P6375; Vasilets LA, 2003, ANN NY ACAD SCI, V986, P543, DOI 10.1111/j.1749-6632.2003.tb07248.x; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zhang YB, 1999, AM J PHYSIOL-RENAL, V276, pF711, DOI 10.1152/ajprenal.1999.276.5.F711	29	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17418	17427		10.1074/jbc.M311715200	http://dx.doi.org/10.1074/jbc.M311715200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14976217	hybrid			2022-12-27	WOS:000220870400067
J	Irsch, T; Krauth-Siegel, RL				Irsch, T; Krauth-Siegel, RL			Glyoxalase II of African trypanosomes is trypanothione-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; D-LACTATE; IN-VITRO; TRIOSEPHOSPHATE ISOMERASE; SACCHAROMYCES-CEREVISIAE; LEISHMANIA-BRAZILIENSIS; HETEROLOGOUS EXPRESSION; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; CRYSTAL-STRUCTURE	The glyoxalase system is a ubiquitous pathway catalyzing the glutathione-dependent detoxication of ketoaldehydes such as methylglyoxal, which is mainly formed as a by-product of glycolysis. The gene encoding a glyoxalase II has been cloned from Trypanosoma brucei, the causative agent of African sleeping sickness. The deduced protein sequence contains the highly conserved metal binding motif THXHXDH but lacks three basic residues shown to fix the glutathione-thioester substrate in the crystal structure of human glyoxalase II. Recombinant T. brucei glyoxalase II hydrolyzes lactoylglutathione, but does not show saturation kinetics up to 5 mM with the classical substrate of glyoxalases II. Instead, the parasite enzyme strongly prefers thioesters of trypanothione (bis(glutathionyl) spermidine), which were prepared from methylglyoxal and trypanothione and analyzed by high performance liquid chromatography and mass spectrometry. Mono-(lactoyl) trypanothione and bis-(lactoyl) trypanothione are hydrolyzed by T. brucei glyoxalase II with k(cat)/K-m values of 5x10(5) M-1 s(-1) and 7x10(5) M-1 s(-1), respectively, yielding D-lactate and regenerating trypanothione. Glyoxalase II occurs in the mammalian bloodstream and insect procyclic form of T. brucei and is the first glyoxalase II of the order of Kinetoplastida characterized so far. Our results show that the glyoxalase system is another pathway in which the nearly ubiquitous glutathione is replaced by the unique trypanothione in trypanosomatids.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Krauth-Siegel, RL (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 504, D-69120 Heidelberg, Germany.	krauth-siegel@urz.uni-heidelberg.de						Ahmed N, 2003, BBA-MOL BASIS DIS, V1639, P121, DOI 10.1016/j.bbadis.2003.08.002; ALLEN RE, 1993, EUR J BIOCHEM, V213, P1261, DOI 10.1111/j.1432-1033.1993.tb17877.x; Bito A, 1999, PROTEIN EXPRES PURIF, V17, P456, DOI 10.1006/prep.1999.1151; BRANDT RB, 1982, METHOD ENZYMOL, V89, P35; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; Cameron AD, 1997, EMBO J, V16, P3386, DOI 10.1093/emboj/16.12.3386; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; DARLING TN, 1988, MOL BIOCHEM PARASIT, V28, P121, DOI 10.1016/0166-6851(88)90059-X; DARLING TN, 1987, P NATL ACAD SCI USA, V84, P7129, DOI 10.1073/pnas.84.20.7129; de Bari L, 2002, BIOCHEM J, V365, P391, DOI 10.1042/BJ20020139; ELIA AC, 1995, BIOCHEM MOL BIOL INT, V35, P763; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Ferguson GP, 1998, ARCH MICROBIOL, V170, P209, DOI 10.1007/s002030050635; Freire AP, 2003, BIOCHEM SOC T, V31, P1409; GHOSHAL K, 1989, MOL BIOCHEM PARASIT, V35, P21, DOI 10.1016/0166-6851(89)90138-2; Grunfelder CG, 2002, TRAFFIC, V3, P547, DOI 10.1034/j.1600-0854.2002.30805.x; GUHA MK, 1988, BIOCHEMISTRY-US, V27, P8818, DOI 10.1021/bi00424a020; Gutheil WG, 1998, ANAL BIOCHEM, V259, P62, DOI 10.1006/abio.1998.2642; HAMILTON DS, 1992, BIOCHIM BIOPHYS ACTA, V1159, P203, DOI 10.1016/0167-4838(92)90026-A; Helfert S, 2001, BIOCHEM J, V357, P117, DOI 10.1042/0264-6021:3570117; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Kang JH, 2003, TOXICOL LETT, V145, P181, DOI 10.1016/S0378-4274(03)00305-9; Kavarana MJ, 1999, J MED CHEM, V42, P221, DOI 10.1021/jm9708036; Krauth-Siegel RL, 2003, BIOL CHEM, V384, P539, DOI 10.1515/BC.2003.062; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Maiti MK, 1997, PLANT MOL BIOL, V35, P471, DOI 10.1023/A:1005891123344; Martins AM, 2001, EUR J BIOCHEM, V268, P3930, DOI 10.1046/j.1432-1327.2001.02304.x; Melville SE, 1998, MOL BIOCHEM PARASIT, V94, P155, DOI 10.1016/S0166-6851(98)00054-1; Muller S, 2003, TRENDS PARASITOL, V19, P320, DOI 10.1016/S1471-4922(03)00141-7; NORTON SJ, 1990, BIOCHEM INT, V22, P411; OPPERDOES FR, 1984, J CELL BIOL, V98, P1178, DOI 10.1083/jcb.98.4.1178; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; RACKER E, 1951, J BIOL CHEM, V190, P685; RAE C, 1994, BIOCHEMISTRY-US, V33, P3548, DOI 10.1021/bi00178a011; Ridderstrom M, 1997, BIOCHEM J, V322, P449, DOI 10.1042/bj3220449; Ridderstrom M, 2000, BBA-PROTEIN STRUCT M, V1481, P344, DOI 10.1016/S0167-4838(00)00178-3; Ridderstrom M, 1996, J BIOL CHEM, V271, P319, DOI 10.1074/jbc.271.1.319; Schilling O, 2003, BIOCHEMISTRY-US, V42, P11777, DOI 10.1021/bi034672o; Schmidt H, 2003, J BIOL CHEM, V278, P46329, DOI 10.1074/jbc.M305338200; Shahi SK, 2002, MOL MICROBIOL, V43, P1129, DOI 10.1046/j.1365-2958.2002.02831.x; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; TABOR H, 1975, J BIOL CHEM, V250, P2648; TALESA V, 1990, BIOCHEM INT, V21, P397; TALESA V, 1990, BIOCHEM INT, V22, P1115; TALESA V, 1989, BIOCHIM BIOPHYS ACTA, V993, P7, DOI 10.1016/0304-4165(89)90135-9; TALESA V, 1990, BIOCHEM INT, V20, P53; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thornalley PJ, 1998, CHEM-BIOL INTERACT, V112, P137, DOI 10.1016/S0009-2797(97)00157-9; THORNALLEY PJ, 1994, BIOCHEM PHARMACOL, V47, P418, DOI 10.1016/0006-2952(94)90035-3; UOTILA L, 1973, BIOCHEMISTRY-US, V12, P3938, DOI 10.1021/bi00744a024; UOTILA L, 1973, BIOCHEMISTRY-US, V12, P3944, DOI 10.1021/bi00744a025; Vander Jagt D.L., 1989, GLUTATHIONE CHEM, P597; Zang TM, 2001, J BIOL CHEM, V276, P4788, DOI 10.1074/jbc.M005090200	55	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22209	22217		10.1074/jbc.M401240200	http://dx.doi.org/10.1074/jbc.M401240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14976196	hybrid			2022-12-27	WOS:000221417100067
J	Nakamura, Y; Suzuki, H; Sakaguchi, M; Mihara, K				Nakamura, Y; Suzuki, H; Sakaguchi, M; Mihara, K			Targeting and assembly of rat mitochondrial translocase of outer membrane 22 (TOM22) into the TOM complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; TAIL-ANCHORED PROTEINS; GENERAL INSERTION PORE; RECEPTOR COMPLEX; PREPROTEIN TRANSLOCASE; INNER MEMBRANE; AMINO-ACIDS; IMPORT PORE; SIGNAL; COMPONENT	Tom22 is a preprotein receptor and organizer of the mitochondrial outer membrane translocase complex (TOM complex). Rat Tom22 (rTOM22) is a 142-residue protein, embedded in the outer membrane through the internal transmembrane domain (TMD) with 82 N-terminal residues in the cytosol and 41 C-terminal residues in the intermembrane space. We analyzed the signals that target rTOM22 to the mitochondrial outer membrane and assembly into the TOM complex in cultured mammalian cells. Deletions or mutations were systematically introduced into the molecule, and the intracellular localization of the mutant constructs in HeLa cells was examined by confocal microscopy and cell fractionation. Their assembly into the TOM complex was also examined using blue native gel electrophoresis. These experiments revealed three separate structural elements: a cytoplasmic 10-residue segment with an acidic alpha-helical structure located 30 residues upstream of the TMD (the import sequence), TMD with an appropriate hydrophobicity, and a 20-residue C-terminal segment located 22 residues downstream of the TMD (C-tail signal). The import sequence and TMD were both essential for targeting and integration into the TOM complex, whereas the C-tail signal affected the import efficiency. The import sequence combined with foreign TMD functioned as a mitochondrial targeting and anchor signal but failed to integrate the construct into the TOM complex. Thus, the mitochondrial-targeting and TOM integration signal could be discriminated. A yeast two-hybrid assay revealed that the import sequence interacted with two intramolecular elements, the TMD and C-tail signal, and that it also interacted with the import receptor Tom20.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8120054, Japan	Kyushu University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8120054, Japan.	mihara@cell.med.kyushu-u.ac.jp						Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Allen R, 2002, FEBS LETT, V514, P347, DOI 10.1016/S0014-5793(02)02433-X; CAO W, 1995, J BIOL CHEM, V270, P5674, DOI 10.1074/jbc.270.10.5674; Cao W, 1996, BIOCHEM BIOPH RES CO, V224, P457, DOI 10.1006/bbrc.1996.1048; Chacinska A, 2003, EMBO J, V22, P5370, DOI 10.1093/emboj/cdg532; Court DA, 1996, MOL CELL BIOL, V16, P4035; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Egan B, 1999, FEBS LETT, V451, P243, DOI 10.1016/S0014-5793(99)00581-5; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Horie C, 2002, MOL BIOL CELL, V13, P1615, DOI 10.1091/mbc.01-12-0570; Horie C, 2003, J BIOL CHEM, V278, P41462, DOI 10.1074/jbc.M307047200; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; Isenmann S, 1998, MOL BIOL CELL, V9, P1649, DOI 10.1091/mbc.9.7.1649; Ishihara N, 1998, J BIOCHEM-TOKYO, V123, P722; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; KEIL P, 1993, J BIOL CHEM, V268, P19177; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; NISHINO H, 1990, BIOCHEM INT, V20, P1059; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P11527, DOI 10.1074/jbc.273.19.11527; Saeki K, 2000, J BIOL CHEM, V275, P31996, DOI 10.1074/jbc.M004794200; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; STANLEY S, 1995, J BIOL CHEM, V270, P16694, DOI 10.1074/jbc.270.28.16694; Steenaart NAE, 1996, BIOCHEMISTRY-US, V35, P3764, DOI 10.1021/bi9528053; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Yano M, 2000, MOL CELL BIOL, V20, P7205, DOI 10.1128/MCB.20.19.7205-7213.2000	46	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21223	21232		10.1074/jbc.M314156200	http://dx.doi.org/10.1074/jbc.M314156200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14985332	hybrid			2022-12-27	WOS:000221273800082
J	Tompa, P; Buzder-Lantos, P; Tantos, A; Farkas, A; Szilagyi, A; Banoczi, Z; Hudecz, F; Friedrich, P				Tompa, P; Buzder-Lantos, P; Tantos, A; Farkas, A; Szilagyi, A; Banoczi, Z; Hudecz, F; Friedrich, P			On the sequential determinants of calpain cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; CALCIUM-DEPENDENT PROTEASE; RESONANCE ENERGY-TRANSFER; MYELIN BASIC-PROTEIN; LIMITED PROTEOLYSIS; MU-CALPAIN; IN-VITRO; ENDOGENOUS INHIBITOR; MEDIATED PROTEOLYSIS; CYTOPLASMIC DOMAINS	The structural clues of substrate recognition by calpain are incompletely understood. In this study, 106 cleavage sites in substrate proteins compiled from the literature have been analyzed to dissect the signal for calpain cleavage and also to enable the design of an ideal calpain substrate and interfere with calpain action via site-directed mutagenesis. In general, our data underline the importance of the primary structure of the substrate around the scissile bond in the recognition process. Significant amino acid preferences were found to extend over 11 residues around the scissile bond, from P-4 to P-7'. In compliance with earlier data, preferred residues in the P-2 position are Leu, Thr, and Val, and in P-1 Lys, Tyr, and Arg. In position P-1', small hydrophilic residues, Ser and to a lesser extent Thr and Ala, occur most often. Pro dominates the region flanking the P-2-P-1' segment, i.e. positions P-3 and P-2'- P-4'; most notable is its occurrence 5.59 times above chance in P-3'. Intriguingly, the segment C-terminal to the cleavage site resembles the consensus inhibitory region of calpastatin, the specific inhibitor of the enzyme. Further, the position of the scissile bond correlates with certain sequential attributes, such as secondary structure and PEST score, which, along with the amino acid preferences, suggests that calpain cleaves within rather disordered segments of proteins. The amino acid preferences were confirmed by site-directed mutagenesis of the autolysis sites of Drosophila calpain B; when amino acids at key positions were changed to less preferred ones, autolytic cleavage shifted to other, adjacent sites. Based on these preferences, a new fluorogenic calpain substrate, DABCYL-TPLKSPPPSPR-EDANS, was designed and synthesized. In the case of mu- and m-calpain, this substrate is kinetically superior to commercially available ones, and it can be used for the in vivo assessment of the activity of these ubiquitous mammalian calpains.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary; Eotvos Lorand Univ, Hungarian Acad Sci, Res Grp Peptide Chem, H-1528 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Hungarian Academy of Sciences	Friedrich, P (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	friedric@enzim.hu	Tantos, Agnes/C-7187-2015; Banoczi, Zoltan/I-8505-2017; Banoczi, Zoltan/AAU-7974-2021; Szilagyi, Andras/A-3561-2008; Tantos, Agnes/GWD-0372-2022	Banoczi, Zoltan/0000-0003-1880-4042; Banoczi, Zoltan/0000-0003-1880-4042; Szilagyi, Andras/0000-0002-1773-6861; 				ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; Alexa A, 1996, J NEUROSCI RES, V44, P438, DOI 10.1002/(SICI)1097-4547(19960601)44:5<438::AID-JNR4>3.0.CO;2-G; ANDO Y, 1989, J BIOL CHEM, V264, P6948; AZARIAN SM, 1995, J BIOL CHEM, V270, P24375, DOI 10.1074/jbc.270.41.24375; BANIK NL, 1994, J NEUROSCI RES, V37, P489, DOI 10.1002/jnr.490370408; Bi X, 1996, NEUROSCIENCE, V73, P903, DOI 10.1016/0306-4522(96)00157-1; Buki KG, 1997, BBA-PROTEIN STRUCT M, V1338, P100, DOI 10.1016/S0167-4838(96)00189-6; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; CRAWFORD C, 1987, BIOCHEM J, V248, P579, DOI 10.1042/bj2480579; DAVID LL, 1993, FEBS LETT, V324, P265, DOI 10.1016/0014-5793(93)80131-D; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Elce JS, 1997, J BIOL CHEM, V272, P11268; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; EMORI Y, 1988, J BIOL CHEM, V263, P2364; Farkas A, 2004, BIOCHEM J, V378, P299, DOI 10.1042/BJ20031310; FISCHER S, 1986, BIOL CHEM H-S, V367, P1147, DOI 10.1515/bchm3.1986.367.2.1147; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; GREGORIOU M, 1994, EUR J BIOCHEM, V223, P455, DOI 10.1111/j.1432-1033.1994.tb19013.x; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; Hayashi M, 1999, ARCH BIOCHEM BIOPHYS, V371, P133, DOI 10.1006/abbi.1999.1427; HIRAO T, 1984, J BIOCHEM-TOKYO, V96, P775, DOI 10.1093/oxfordjournals.jbchem.a134895; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; JAMES P, 1989, J BIOL CHEM, V264, P8289; Jekely G, 1999, J BIOL CHEM, V274, P23893, DOI 10.1074/jbc.274.34.23893; Kakkar R, 1998, ARCH BIOCHEM BIOPHYS, V358, P320, DOI 10.1006/abbi.1998.0858; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KIUCHI K, 1991, BIOCHEMISTRY-US, V30, P10416, DOI 10.1021/bi00107a008; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lin JS, 1997, EUR J CELL BIOL, V73, P141; LITERSKY JM, 1995, J NEUROCHEM, V65, P903; MAKI M, 1988, J BIOL CHEM, V263, P10254; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; MELLGREN RL, 1986, ARCH BIOCHEM BIOPHYS, V246, P233, DOI 10.1016/0003-9861(86)90468-6; MELLONI E, 1984, BIOCHIM BIOPHYS ACTA, V788, P11, DOI 10.1016/0167-4838(84)90291-7; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; Mittoo S, 2003, ANAL BIOCHEM, V319, P234, DOI 10.1016/S0003-2697(03)00324-5; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MOLINARI M, 1995, J BIOL CHEM, V270, P14576, DOI 10.1074/jbc.270.24.14576; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; NOZAKI H, 1987, Tokai Journal of Experimental and Clinical Medicine, V12, P223; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PARK DG, 1993, J BIOL CHEM, V268, P3710; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pete MJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P104, DOI 10.1006/abbi.1999.1256; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAKAI K, 1987, J BIOCHEM-TOKYO, V101, P911, DOI 10.1093/oxfordjournals.jbchem.a121959; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Schey KL, 1999, INVEST OPHTH VIS SCI, V40, P657; Schroder E, 1998, BBA-PROTEIN STRUCT M, V1383, P279, DOI 10.1016/S0167-4838(97)00217-3; SEUBERT P, 1987, SYNAPSE, V1, P20, DOI 10.1002/syn.890010105; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Stabach PR, 1997, BIOCHEMISTRY-US, V36, P57, DOI 10.1021/bi962034i; Straubinger AF, 1999, GENE, V236, P273, DOI 10.1016/S0378-1119(99)00274-7; TAKAHASHI K, 1990, CALPAIN SUBSTRATE SP; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; TOMPA P, 1995, ANAL BIOCHEM, V228, P287, DOI 10.1006/abio.1995.1352; TSUBATA T, 1989, J BIOCHEM-TOKYO, V105, P23, DOI 10.1093/oxfordjournals.jbchem.a122611; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; Villa PG, 1998, J CELL SCI, V111, P713; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1999, CALPAIN PHARM TOXICO, P77; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; YANG HQ, 1994, J BIOL CHEM, V269, P18977; YANG LS, 1995, EUR J BIOCHEM, V233, P9, DOI 10.1111/j.1432-1033.1995.009_1.x; YOSHIDA M, 1992, J BIOCHEM-TOKYO, V112, P433, DOI 10.1093/oxfordjournals.jbchem.a123918; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; [No title captured]	86	257	261	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20775	20785		10.1074/jbc.M313873200	http://dx.doi.org/10.1074/jbc.M313873200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14988399	hybrid			2022-12-27	WOS:000221273800029
J	Park, CS; Kim, SI; Lee, MS; Youn, CY; Kim, DJ; Jho, EH; Song, WK				Park, CS; Kim, SI; Lee, MS; Youn, CY; Kim, DJ; Jho, EH; Song, WK			Modulation of beta-catenin phosphorylation/degradation by cyclin-dependent kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; WNT SIGNALING PATHWAY; F-BOX PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR LEF-1; XENOPUS EGG EXTRACTS; APC TUMOR-SUPPRESSOR; CENTROSOME DUPLICATION; CELL-CYCLE; AXIS FORMATION	beta-Catenin functions as a downstream component of the Wnt/Wingless signal transduction pathway, and inappropriate control of cytosolic beta-catenin is a crucial step in the genesis of several human cancers. Here we demonstrate that cyclin-dependent kinase 2 (CDK2) in association with cyclin A or cyclin E directly binds to beta-catenin. In vivo and in vitro kinase assays with cyclin-CDK2 demonstrate beta-catenin phosphorylation on residues Ser(33), Ser(37), Thr(41), and Ser(45). This phosphorylation promotes rapid degradation of cytosolic beta-catenin via the beta-TrCP-mediated proteasome pathway. Moreover, cyclin E-CDK2 contributes to rapid degradation of cytosolic beta-catenin levels during G(1) phase by regulating beta-catenin phosphorylation and subsequent degradation. In this way, CDK2 may "finetune" beta-catenin levels over the course of the cell cycle.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Vanderbilt Univ, Sch Med, Vanderbilt Brain Inst, Nashville, TN 37232 USA; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea	Gwangju Institute of Science & Technology (GIST); Vanderbilt University; University of Seoul	Song, WK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	wksong@kjist.ac.kr		Jho, Eek-hoon/0000-0003-2414-6234; Park, Chun Shik/0000-0002-4329-3953				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ABERLE H, 1994, J CELL SCI, V107, P3655; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Easwaran V, 1999, J BIOL CHEM, V274, P16641, DOI 10.1074/jbc.274.23.16641; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Sarcevic B, 2002, EMBO J, V21, P2009, DOI 10.1093/emboj/21.8.2009; Sasaki T, 2002, J BIOL CHEM, V277, P36032, DOI 10.1074/jbc.M206674200; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Voeller HJ, 1998, CANCER RES, V58, P2520; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	72	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19592	19599		10.1074/jbc.M314208200	http://dx.doi.org/10.1074/jbc.M314208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985333	hybrid			2022-12-27	WOS:000221164500027
J	Xu, JK; Liu, Y; Yang, YY; Bates, S; Zhang, JT				Xu, JK; Liu, Y; Yang, YY; Bates, S; Zhang, JT			Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER RESISTANCE PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; MINIMUM FUNCTIONAL UNIT; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; DROSOPHILA-MELANOGASTER; DRUG-TRANSPORT; CELLS; MEMBRANES; DIMERIZATION	Human ATP-binding cassette G2 (ABCG2, also known as mitoxantrone resistance protein, breast cancer-resistance protein, ABC placenta) is a member of the superfamily of ATP-binding cassette ( ABC) transporters that have a wide variety of substrates. Overexpression of human ABCG2 in model cancer cell lines causes multidrug resistance by actively effluxing anticancer drugs. Unlike most of the other ABC transporters which usually have two nucleotide-binding domains and two transmembrane domains, ABCG2 consists of only one nucleotide-binding domain followed by one transmembrane domain. Thus, ABCG2 has been thought to be a half-transporter that may function as a homodimer. In this study, we characterized the oligomeric feature of human ABCG2 using non-denaturing detergent perfluorooctanoic acid and Triton X-100 in combination with gel filtration, sucrose density gradient sedimentation, and gel electrophoresis. Unexpectedly, we found that human ABCG2 exists mainly as a tetramer, with a possibility of a higher form of oligomerization. Monomeric and dimeric ABCG2 did not appear to be the major form of the protein. Further immunoprecipitation analysis showed that the oligomeric ABCG2 did not contain any other proteins. Taken together, we conclude that human ABCG2 likely exists and functions as a homotetramer.	Indiana Univ, Sch Med, Ctr Canc,Walther Canc Inst, Walther Oncol Ctr,Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; NCI, Canc Therapeut Branch, Bethesda, MD 20892 USA; NIH, Pathol Lab, Bethesda, MD 20892 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	Zhang, JT (corresponding author), Indiana Univ, Sch Med, Ctr Canc,Walther Canc Inst, Walther Oncol Ctr,Dept Pharmacol & Toxicol, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Bates, Susan/AFP-9514-2022; Zhang, Jian-Ting/L-8334-2015		NATIONAL CANCER INSTITUTE [R29CA064539, Z01BC010622, R01CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64539] Funding Source: Medline; NIGMS NIH HHS [GM 59475] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JD, 2002, MOL CANCER THER, V1, P427; Allikmets R, 1998, CANCER RES, V58, P5337; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Ewart GD, 1998, METHOD ENZYMOL, V292, P213; GEORGES E, 1993, J BIOL CHEM, V268, P1792; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; Jette L, 1997, BIOCHEMISTRY-US, V36, P13929, DOI 10.1021/bi970737+; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Litman T, 2002, BBA-BIOMEMBRANES, V1565, P6, DOI 10.1016/S0005-2736(02)00492-3; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Maliepaard M, 2001, CANCER RES, V61, P3458; Mitic LL, 2003, PROTEIN SCI, V12, P218, DOI 10.1110/ps.0233903; Miyake K, 1999, CANCER RES, V59, P8; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; Ozvegy C, 2001, BIOCHEM BIOPH RES CO, V285, P111, DOI 10.1006/bbrc.2001.5130; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Ramjeesingh M, 2003, BIOCHEM J, V374, P793, DOI 10.1042/BJ20030683; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Soszynski M, 1998, ARCH BIOCHEM BIOPHYS, V354, P311, DOI 10.1006/abbi.1998.0687; SULLIVAN DT, 1975, BIOCHEM GENET, V13, P603, DOI 10.1007/BF00484918; Taylor JC, 2001, J BIOL CHEM, V276, P36075, DOI 10.1074/jbc.C100345200; Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200; Yang ZG, 2002, BIOCHEMISTRY-US, V41, P13012, DOI 10.1021/bi026064z; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s	36	209	223	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19781	19789		10.1074/jbc.M310785200	http://dx.doi.org/10.1074/jbc.M310785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15001581	hybrid			2022-12-27	WOS:000221164500049
J	El Fakhry, Y; Bouillon, M; Leveille, C; Brunet, A; Khalil, H; Thibodeau, J; Mourad, W				El Fakhry, Y; Bouillon, M; Leveille, C; Brunet, A; Khalil, H; Thibodeau, J; Mourad, W			Delineation of the HLA-DR region and the residues involved in the association with the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; CELL ANTIGEN RECEPTOR; GPI-ANCHORED PROTEINS; NECROSIS-FACTOR-ALPHA; HUMAN B-CELLS; LIPID RAFTS; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; MONOCLONAL-ANTIBODIES; INVARIANT CHAIN	Whereas the association of major histocompatibility complex (MHC) class II molecules with the cytoskeleton and their recruitment into lipid rafts play a critical role during cognate T/antigen-presenting cell interactions, MHC class II-induced signals, regions, and residues involved in their association and recruitment have not yet been fully deciphered. In this study, we show that oligomerization of HLA-DR molecules induces their association with the cytoskeleton and their recruitment into lipid rafts. The association of oligomerized HLA-DR molecules with the cytoskeleton and their recruitment into lipid rafts occur independently. Furthermore, the association with the cytoskeleton is HLA-DR-specific, since oligomerization of HLA-DP triggers its recruitment only into lipid rafts. HLA-DR molecules devoid of both alpha and beta cytoplasmic tails did not associate with the cytoskeleton, but their recruitment into lipid rafts was unimpeded. Deletion of either the alpha or beta cytoplasmic tail did not affect the association of HLA-DR with the cytoskeleton and/or recruitment into lipid rafts. HLA-DR molecules that were devoid of the alpha cytoplasmic chain and that had their beta cytoplasmic chain replaced with the HLA-DP beta chain or with a beta chain in which the residues at positions Gly(226)-His(227)-Ser(228) were substituted by alanine no longer associated with the cytoskeleton. They were, however, still recruited into lipid rafts. Together, these results support the involvement of different regions of the cytoplasmic tails in the association and the recruitment of HLA-DR into different compartments. The differential behavior of HLA-DP and -DR with respect to their association with the cytoskeleton may explain the previously described difference in their transduced signals.	Univ Laval, Dept Med, CHU Laval, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Univ Montreal, Fac Med, Dept Microbiol & Immunol, Lab Immunol Mol, Montreal, PQ H3C 3J7, Canada	Laval University; Universite de Montreal	Mourad, W (corresponding author), Univ Laval, Dept Med, CHU Laval, Ctr Rech Rhumatol & Immunol, 2705 Blvd Laurier,T1-49, Quebec City, PQ G1V 4G2, Canada.	Walid.Mourad@crchul.ulaval.ca		Mourad, Walid/0000-0002-1859-9387				ALTOMONTE M, 1993, J IMMUNOL, V151, P5115; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; ANDRE P, 1994, J EXP MED, V179, P763, DOI 10.1084/jem.179.2.763; Andreae S, 2003, BLOOD, V102, P2130, DOI 10.1182/blood-2003-01-0273; Becart S, 2003, J CELL SCI, V116, P2565, DOI 10.1242/jcs.00449; Bertho N, 2000, J IMMUNOL, V164, P2379, DOI 10.4049/jimmunol.164.5.2379; Bishop GA, 2001, CURR OPIN IMMUNOL, V13, P278, DOI 10.1016/S0952-7915(00)00216-8; Bouillon M, 2003, J BIOL CHEM, V278, P7099, DOI 10.1074/jbc.M211566200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Cheng PC, 2001, J IMMUNOL, V166, P3693, DOI 10.4049/jimmunol.166.6.3693; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; CHIA CP, 1994, J IMMUNOL, V153, P3398; Dolan BP, 2004, J IMMUNOL, V172, P907, DOI 10.4049/jimmunol.172.2.907; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Fernandez EM, 2003, HUM IMMUNOL, V64, P327, DOI 10.1016/S0198-8859(02)00803-0; GRIFFITH IJ, 1988, P NATL ACAD SCI USA, V85, P4847, DOI 10.1073/pnas.85.13.4847; HARTON JA, 1993, J IMMUNOL, V151, P5282; HARTON JA, 1995, IMMUNITY, V3, P349, DOI 10.1016/1074-7613(95)90119-1; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hiltbold EM, 2003, J IMMUNOL, V170, P1329, DOI 10.4049/jimmunol.170.3.1329; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWARD DR, 1986, EXP HEMATOL, V14, P887; Huby RDJ, 1999, J BIOL CHEM, V274, P22591, DOI 10.1074/jbc.274.32.22591; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; KANSAS GS, 1992, EUR J IMMUNOL, V22, P147, DOI 10.1002/eji.1830220122; Khalil H, 2003, INT IMMUNOL, V15, P1249, DOI 10.1093/intimm/dxg124; Lang P, 2001, SCIENCE, V291, P1537, DOI 10.1126/science.291.5508.1537; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Laufer TM, 1997, J IMMUNOL, V159, P5914; Leveille C, 2002, EUR J IMMUNOL, V32, P2282, DOI 10.1002/1521-4141(200208)32:8<2282::AID-IMMU2282>3.0.CO;2-M; Leveille C, 1999, INT IMMUNOL, V11, P719, DOI 10.1093/intimm/11.5.719; Leveille C, 1999, EUR J IMMUNOL, V29, P3516, DOI 10.1002/(SICI)1521-4141(199911)29:11<3516::AID-IMMU3516>3.3.CO;2-4; LONG EO, 1991, HUM IMMUNOL, V31, P229, DOI 10.1016/0198-8859(91)90092-N; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Lynch GW, 1999, EUR J IMMUNOL, V29, P2590, DOI 10.1002/(SICI)1521-4141(199908)29:08<2590::AID-IMMU2590>3.0.CO;2-R; Matsuoka T, 2001, J IMMUNOL, V166, P2202, DOI 10.4049/jimmunol.166.4.2202; MATSUYAMA S, 1993, EUR J IMMUNOL, V23, P3194, DOI 10.1002/eji.1830231223; MEHINDATE K, 1995, J IMMUNOL, V155, P3570; Moldovan MC, 2002, J IMMUNOL, V169, P6261, DOI 10.4049/jimmunol.169.11.6261; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MOURAD W, 1990, J EXP MED, V172, P1513, DOI 10.1084/jem.172.5.1513; Munnelly HM, 2000, INT IMMUNOL, V12, P1319, DOI 10.1093/intimm/12.9.1319; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NEWELL MK, 1988, J IMMUNOL, V140, P1930; PALACIOS R, 1983, P NATL ACAD SCI-BIOL, V80, P3456, DOI 10.1073/pnas.80.11.3456; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Rich T, 1997, J IMMUNOL, V159, P3792; Robadey C, 1997, J IMMUNOL, V159, P3238; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; Setterblad N, 2003, J LEUKOCYTE BIOL, V74, P40, DOI 10.1189/jlb.0103045; Setterblad N, 2001, SCAND J IMMUNOL, V54, P87, DOI 10.1046/j.1365-3083.2001.00969.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; STPIERRE Y, 1991, J IMMUNOL, V147, P2875; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; Truman JP, 1996, EXP HEMATOL, V24, P1409; VAICKUS L, 1989, CELL IMMUNOL, V119, P445, DOI 10.1016/0008-8749(89)90257-8; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297; Wakatsuki T, 2001, J CELL SCI, V114, P1025; WATT TH, 1997, LYMPHOCYTE SIGNALLIN, P141; WODA BA, 1984, J IMMUNOL, V133, P2767; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741	67	13	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18472	18480		10.1074/jbc.M401159200	http://dx.doi.org/10.1074/jbc.M401159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976194	hybrid			2022-12-27	WOS:000221041500047
J	Price, PA; June, HH; Hamlin, NJ; Williamson, MK				Price, PA; June, HH; Hamlin, NJ; Williamson, MK			Evidence for a serum factor that initiates the re-calcification of demineralized bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERY CALCIFICATION; WARFARIN; RAT; MATRIX; VITRO	The present studies show for the first time that demineralized bone re-calcifies rapidly when incubated at 37 degreesC in rat serum: re-calcification can be demonstrated by Alizarin Red and von Kossa stains, by depletion of serum calcium, and by uptake of calcium and phosphate by bone matrix. Re-calcification is specific for the type I collagen matrix structures that were calcified in the original bone, with no evidence for calcification in periosteum or cartilage. Re-calcification ceases when the amount of calcium and phosphate introduced into the matrix is comparable to that present in the original bone prior to demineralization, and the re-calcified bone is palpably hard. Re-calcified bone mineral is comparable to the original bone mineral in calcium to phosphate ratio and in Fourier transform infrared and x-ray diffraction spectra. The serum activity responsible for re-calcification is sufficiently potent that the addition of only 1.5% serum to Dulbecco's modified Eagle's medium causes bone re-calcification. This putative serum calcification factor has an apparent molecular mass of 55-150 kDa and is inactivated by trypsin or chymotrypsin. The serum calcification factor must act on bone for 12 h before re-calcification can be detected by Alizarin Red or von Kossa staining and before the subsequent growth of calcification will occur in the absence of serum. The speed, matrix-type specificity, and extent of the serum-induced re-calcification of demineralized bone suggest that the serum calcification factor identified in these studies may participate in the normal calcification of bone.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Price, PA (corresponding author), Univ Calif San Diego, Div Biol Sci, 0368, La Jolla, CA 92093 USA.	pprice@ucsd.edu			NHLBI NIH HHS [HL58090] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058090] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHRA BN, 1972, CALC TISS RES, V8, P287; BACHRA BN, 1968, CALC TISS RES, V2, P343, DOI 10.1007/BF02279222; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CURREY JD, 2002, BONES STRUCTURE MECH, P4; DESTENO CV, 1975, CALC TISS RES, V17, P161, DOI 10.1007/BF02547288; DRIESSENS FCM, 1990, BIOMINERALS, P183; ELLIOTT JC, 1994, STRUCTURE CHEM APATI, P260; Hamaya M, 2002, CALCIFIED TISSUE INT, V70, P117, DOI 10.1007/s002230010021; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400; Price PA, 2002, CIRC RES, V91, P547, DOI 10.1161/01.RES.0000033987.22436.50; Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817; Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317; Price PA, 2001, ARTERIOSCL THROM VAS, V21, P1610, DOI 10.1161/hq1001.097102	15	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19169	19180		10.1074/jbc.M307880200	http://dx.doi.org/10.1074/jbc.M307880200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978037	hybrid			2022-12-27	WOS:000221041500130
J	Yamaoka, S; Miyaji, M; Kitano, T; Umehara, H; Okazaki, T				Yamaoka, S; Miyaji, M; Kitano, T; Umehara, H; Okazaki, T			Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective lymphoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; CERAMIDE; MEMBRANE; PROTEIN; RESISTANT; BINDING; DIACYLGLYCEROL; IDENTIFICATION; ACCUMULATION; TRAFFICKING	Sphingomyelin (SM) synthase has been assumed to be involved in both cell death and survival by regulating pro-apoptotic mediator ceramide and pro-survival mediator diacylglycerol. However, its precise functions are ambiguous due to the lack of molecular cloning of SM synthase gene(s). We isolated WR19L/Fas-SM(-) mouse lymphoid cells, which show a defect of SM at the plasma membrane due to the lack of SM synthase activity and resistance to cell death induced by an SM-directed cytolytic protein lysenin. WR19L/Fas-SM(-) cells were also highly susceptible to methyl-beta-cyclodextrin (MbetaCD) as compared with the WR19L/Fas-SM(+) cells, which are capable of SM synthesis. By expression cloning method using WR19L/Fas-SM(-) cells and MbetaCD-based selection, we have succeeded in cloning of a human cDNA responsible for SM synthase activity. The cDNA encodes a peptide of 413 amino acids named SMS1 ( putative molecular mass, 48.6 kDa), which contains a sterile alpha motif domain near the N-terminal region and four predicted transmembrane domains. WR19L/Fas-SM(-) cells expressing SMS1 cDNA (WR19L/Fas-SMS1) restored the resistance against MbetaCD, the accumulation of SM at the plasma membrane, and SM synthesis by transferring phosphocholine from phosphatidylcholine to ceramide. Furthermore, WR19L/Fas-SMS1 cells, as well as WR19L/ Fas-SM(-) cells supplemented with exogenous SM, restored cell growth ability in serum-free conditions, where the growth of WR19L/ Fas-SM(-) cells was severely inhibited. The results suggest that SMS1 is responsible for SM synthase activity in mammalian cells and plays a critical role in cell growth of mouse lymphoid cells.	Kyoto Univ, Grad Sch Med, Dept Hematol Oncol & Clin Immunol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Outpatient Oncol Unit, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Okazaki, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol Oncol & Clin Immunol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	toshiroo@kuhp.kyoto-u.ac.jp		Yamaoka, Shohei/0000-0003-4154-9967				Albi E, 1999, FEBS LETT, V460, P369, DOI 10.1016/S0014-5793(99)01378-2; Allan D, 1999, BBA-MOL CELL RES, V1450, P277, DOI 10.1016/S0167-4889(99)00057-9; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barrera FN, 2003, J BIOL CHEM, V278, P46878, DOI 10.1074/jbc.M307846200; Bork P, 1998, NAT GENET, V18, P313, DOI 10.1038/ng0498-313; Chatterjee S, 1999, CHEM PHYS LIPIDS, V102, P79, DOI 10.1016/S0009-3084(99)00077-8; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; DILLEHAY DL, 1994, J NUTR, V124, P615, DOI 10.1093/jn/124.5.615; ELMENDORF HG, 1994, J CELL BIOL, V124, P449, DOI 10.1083/jcb.124.4.449; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAMPTON RY, 1989, SCIENCE, V246, P1050, DOI 10.1126/science.2555921; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; HANADA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P151, DOI 10.1016/0005-2760(91)90002-Y; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; Itoh M, 2003, CLIN CANCER RES, V9, P415; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Luberto C, 2003, J BIOL CHEM, V278, P32733, DOI 10.1074/jbc.M300932200; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Lucas L, 2000, ONCOGENE, V19, P431, DOI 10.1038/sj.onc.1203323; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MIROOBRADORS MJ, 1993, CARCINOGENESIS, V14, P941, DOI 10.1093/carcin/14.5.941; MOSCAT J, 1989, BIOCHEM SOC T, V17, P988, DOI 10.1042/bst0170988; Moschetta A, 2003, DIGEST DIS SCI, V48, P1094, DOI 10.1023/A:1023712712025; Okazaki T, 1998, CELL SIGNAL, V10, P685, DOI 10.1016/S0898-6568(98)00035-7; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Riboni Laura, 2002, Cerebellum, V1, P129, DOI 10.1080/147342202753671268; Schultz J, 1997, PROTEIN SCI, V6, P249; Shakor ABA, 2003, FEBS LETT, V542, P1, DOI 10.1016/S0014-5793(03)00330-2; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; van Helvoort A, 1997, J CELL SCI, V110, P781; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; Watanabe M, 2004, CANCER RES, V64, P1000, DOI 10.1158/0008-5472.CAN-03-1383; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; Yamaji-Hasegawa A, 2003, J BIOL CHEM, V278, P22762, DOI 10.1074/jbc.M213209200	45	178	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18688	18693		10.1074/jbc.M401205200	http://dx.doi.org/10.1074/jbc.M401205200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976195	hybrid			2022-12-27	WOS:000221041500074
J	Zhang, YL; Hernandez-Ono, A; Ko, C; Yasunaga, K; Huang, LS; Ginsberg, HN				Zhang, YL; Hernandez-Ono, A; Ko, C; Yasunaga, K; Huang, LS; Ginsberg, HN			Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids - I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; HEPG2 CELLS; INTRACELLULAR DEGRADATION; INSULIN-RESISTANCE; OLEIC-ACID; TRANSPORT KINETICS; RICH LIPOPROTEINS; VLDL-TRIGLYCERIDE	The in vivo effects of increased delivery of fatty acids ( FA) to the liver are poorly defined. Therefore, we compared the effects of infusing either 6 mM oleic acid (OA) bound to albumin, 0.5-20% Intralipid, or saline for 3 or 6 h into male C57BL/6J mice. Infusions were followed by studies of triglyceride (TG) and apoB secretion. Although plasma FA levels increased similarly after either 20% Intralipid or 6 mM OA, TG secretion increased only after infusion of 4-20% Intralipid; TG secretion was unchanged by 6 mM OA. By contrast, 6-h infusions of either 6 mM OA or 4-20% Intralipid increased apoB secretion. 6 mM OA and 20% Intralipid each increased secretion of apoB from primary hepatocytes ex vivo. Importantly, 0.5-2% Intralipid, which delivered more FA to the liver than 6 mM OA, did not stimulate apoB secretion. Hepatic apoB mRNA levels were unaffected by either 6 mM OA or 20% Intralipid, but microsomal triglyceride transfer protein mRNA was significantly lower after 6-h infusions with 6 mM OA versus either saline or 20% Intralipid. Lower microsomal triglyceride transfer protein mRNA levels were associated with reduced hepatic TG mass after 6-h infusions of 6 mM OA. We conclude that 1) increased FA delivery to the liver in vivo increases secretion of apoB-lipoproteins via post-transcriptional mechanisms, 2) OA-induced apoB-lipoprotein secretion occurred at least in part via mechanisms other than by providing substrate for TG synthesis, and 3) the route of delivery of FA is important for its effects on apoB secretion.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	Ginsberg, HN (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, PH 10-305,630 W 168th St, New York, NY 10032 USA.	hng1@columbia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062583] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62583, HL 55368] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARBEENY CM, 1992, J LIPID RES, V33, P843; Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; BARR J E, 1979, Pharmacology Biochemistry and Behavior, V11, P115, DOI 10.1016/0091-3057(79)90307-1; Bartels ED, 2002, DIABETES, V51, P1233, DOI 10.2337/diabetes.51.4.1233; BARTER PJ, 1973, METABOLISM, V22, P779, DOI 10.1016/0026-0495(73)90048-6; BENNETT AJ, 1995, BIOCHEM BIOPH RES CO, V212, P473, DOI 10.1006/bbrc.1995.1994; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; CABEZAS MC, 1993, J CLIN INVEST, V92, P160, DOI 10.1172/JCI116544; Carpentier A, 1999, AM J PHYSIOL-ENDOC M, V276, pE1055, DOI 10.1152/ajpendo.1999.276.6.E1055; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; COHN JS, 1990, J CLIN INVEST, V85, P804, DOI 10.1172/JCI114507; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; DASHTI N, 1989, J LIPID RES, V30, P1365; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DAVIS RA, 1982, J BIOL CHEM, V257, P908; Diraison F, 1998, AM J PHYSIOL-ENDOC M, V274, pE321, DOI 10.1152/ajpendo.1998.274.2.E321; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ELLSWORTH JL, 1986, J LIPID RES, V27, P858; ERICKSON SK, 1986, J LIPID RES, V27, P875; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIBBONS GF, 2001, BIOCH BIOPHY ACTA, V1483, P37; GINSBERG H N, 1987, Diabetes Metabolism Reviews, V3, P571; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; HAVEL RJ, 1970, J CLIN INVEST, V49, P2017, DOI 10.1172/JCI106422; KISSEBAH AH, 1974, CLIN SCI MOL MED, V47, P259, DOI 10.1042/cs0470259; KISSEBAH AH, 1982, DIABETES, V31, P217, DOI 10.2337/diabetes.31.3.217; KISSEBAH AH, 1976, ATHEROSCLEROSIS, V24, P199, DOI 10.1016/0021-9150(76)90076-9; Lewis G F, 1999, Curr Opin Lipidol, V10, P475, DOI 10.1097/00041433-199910000-00013; LEWIS GF, 1995, J CLIN INVEST, V95, P158, DOI 10.1172/JCI117633; LEWIS GF, 1993, DIABETES, V42, P833, DOI 10.2337/diabetes.42.6.833; Liang JS, 2001, NAT MED, V7, P1327, DOI 10.1038/nm1201-1327; LIN MCM, 1995, J LIPID RES, V36, P1073; LUDWIG EH, 1991, DNA CELL BIOL, V10, P329, DOI 10.1089/dna.1991.10.329; Malmstrom R, 1999, ATHEROSCLEROSIS, V146, P381, DOI 10.1016/S0021-9150(99)00153-7; Malmstrom R, 1997, ARTERIOSCL THROM VAS, V17, P1454, DOI 10.1161/01.ATV.17.7.1454; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; Marsh JB, 2002, ATHEROSCLEROSIS, V162, P227, DOI 10.1016/S0021-9150(01)00709-2; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; OTWAY S, 1967, J PHYSIOL-LONDON, V190, P321, DOI 10.1113/jphysiol.1967.sp008211; Packard CJ, 1997, ARTERIOSCL THROM VAS, V17, P3542, DOI 10.1161/01.ATV.17.12.3542; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; Parks EJ, 1999, J CLIN INVEST, V104, P1087, DOI 10.1172/JCI6572; PATSCH W, 1983, J CLIN INVEST, V72, P371, DOI 10.1172/JCI110977; PATSCH W, 1981, DIABETES, V30, P530, DOI 10.2337/diab.30.6.530; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SALAM WH, 1988, BIOCHEM J, V251, P809, DOI 10.1042/bj2510809; SCANU ANGELO M., 1965, ADVANCE LIPID RES, V3, P63; Siri P, 2001, J BIOL CHEM, V276, P46064, DOI 10.1074/jbc.M108909200; SMITH SG, 1974, METHODS NARCOTICS RE, P3; Sparks JD, 1996, BIOCHEM J, V313, P567, DOI 10.1042/bj3130567; SPARKS JD, 1994, BIOCHEM BIOPH RES CO, V205, P417, DOI 10.1006/bbrc.1994.2681; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; Sparks JD, 1997, BBA-LIPID LIPID MET, V1347, P51, DOI 10.1016/S0005-2760(97)00050-7; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; Taghibiglou C, 2000, J LIPID RES, V41, P499; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; van Bennekum AM, 1999, J LIPID RES, V40, P565; WETTERAU JR, 1992, SCIENCE, V258, P999; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WU XJ, 1994, J LIPID RES, V35, P1200; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	72	72	74	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19362	19374		10.1074/jbc.M400220200	http://dx.doi.org/10.1074/jbc.M400220200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970200	hybrid			2022-12-27	WOS:000221041500149
J	Bai, HD; Doray, B; Kornfeld, S				Bai, HD; Doray, B; Kornfeld, S			GGA1 interacts with the adaptor protein AP-1 through a WNSF sequence in its hinge region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EAR HOMOLOGY DOMAIN; GAMMA-ADAPTIN; APPENDAGE DOMAIN; STRUCTURAL BASIS; BINDING-SITE; VHS DOMAINS; CLATHRIN; FAMILY; MOTIF; RECRUITMENT	The Golgi-associated gamma-adaptin-related ADP-ribosylation factor-binding proteins (GGAs) are critical components of the transport machinery that mediates the trafficking of the mannose 6-phosphate receptors and associated cargo from the trans-Golgi network to the endosomes. The GGAs colocalize in vivo with the clathrin adaptor protein AP-1 and bind to AP-1 in vitro, suggesting that the two proteins may cooperate in packaging the mannose 6-phosphate receptors into clathrin-coated vesicles at the trans-Golgi network. Here, we demonstrate that the sequence, (WNSF385)-W-382, in the hinge region of GGA1 mediates its interaction with the AP-1 gamma-ear. The Trp and Phe constitute critical amino acids in this interaction. The binding of Rabaptin5 to the AP-1 gamma-ear, which occurs through a FXXPhi motif, is inhibited by a peptide encoding the GGA1 (WNSF385)-W-382 sequence. Moreover, mutations in the AP-1 gamma-ear that abolish its interaction with Rabaptin5 also preclude its association with GGA1. These results suggest that the GGA1 WXXF-type and Rabaptin5 FXXPhi-type motifs bind to the same or highly overlapping sites in the AP-1 gamma-ear. This binding is modulated by residues adjacent to the core motifs.	Washington Univ, Sch Med, Div Hematol, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Internal Med, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.	skornfel@im.wustl.edu		Doray, Balraj/0000-0003-3347-5013	NATIONAL CANCER INSTITUTE [R01CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Collins BM, 2003, NAT STRUCT BIOL, V10, P607, DOI 10.1038/nsb955; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Doray B, 2002, P NATL ACAD SCI USA, V99, P8072, DOI 10.1073/pnas.082235699; Doray B, 2002, J BIOL CHEM, V277, P18477, DOI 10.1074/jbc.M201879200; Doray B, 2001, MOL BIOL CELL, V12, P1925, DOI 10.1091/mbc.12.7.1925; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Jha A, 2004, J BIOL CHEM, V279, P2281, DOI 10.1074/jbc.M305644200; Kent HM, 2002, STRUCTURE, V10, P1139, DOI 10.1016/S0969-2126(02)00801-8; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Mattera R, 2004, J BIOL CHEM, V279, P8018, DOI 10.1074/jbc.M311873200; Miller GJ, 2003, NAT STRUCT BIOL, V10, P599, DOI 10.1038/nsb953; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Nogi T, 2002, NAT STRUCT BIOL, V9, P527, DOI 10.1038/nsb808; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Ritter B, 2003, EMBO REP, V4, P1089, DOI 10.1038/sj.embor.7400004; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Wasiak S, 2003, FEBS LETT, V555, P437, DOI 10.1016/S0014-5793(03)01299-7; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	28	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17411	17417		10.1074/jbc.M401158200	http://dx.doi.org/10.1074/jbc.M401158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14973137	hybrid			2022-12-27	WOS:000220870400066
J	Liao, WX; Moore, RK; Shimasaki, S				Liao, WX; Moore, RK; Shimasaki, S			Functional and molecular characterization of naturally occurring mutations in the oocyte-secreted factors bone morphogenetic protein-15 and growth and differentiation factor-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASED OVULATION RATE; BETA SUPERFAMILY; SHEEP; GENE; FOLLICULOGENESIS; SYSTEM; BMP-15; BMP15; OVARY; GDF-9	Bone morphogenetic protein-15 (BMP-15) and growth and differentiation factor-9 (GDF-9) are oocyte-secreted factors that are critical local regulators of ovarian physiology. Recent studies have identified a number of mutations in these genes that cause increased fertility and infertility in heterozygous or homozygous ewes carrying the mutations, respectively. Interestingly, heterozygous ewes with a mutation in both BMP-15 and GDF-9 exhibit higher fertility than those having mutation in only one of the genes. Here, we have produced recombinant human BMP-15 and GDF-9 that carry the mutations identified in those sheep, i.e. I31D and S99I in BMP-15 and S77F in GDF-9. We found that when individually expressed, both BMP-15 mutations had no effect on the processing, secretion, and dimerization of the mature proteins or on the biological activity of the molecules. However, when mutant BMP-15 was co-expressed with wild-type GDF-9, the secretion of BMP-15 and GDF-9 was significantly reduced, suggesting that the mechanisms by which the BMP-15 mutations affect sheep fertility occurs at the level of protein secretion rather than dimerization and biological activity. Moreover, when mutant GDF-9 was co-expressed with mutant BMP-15, the secretion levels of both proteins were significantly lower than those of cells co-expressing wildtype GDF-9 and mutant BMP-15, suggesting a possible mechanism for the extreme fertility observed in the compound heterozygous mutant sheep.	Univ Calif San Diego, Sch Med, Dept Reprod Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Shimasaki, S (corresponding author), Univ Calif San Diego, Sch Med, Dept Reprod Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sshimasaki@ucsd.edu			NICHD NIH HHS [F32 HD41320, R01 HD41494, U54HD12303] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD041494, U54HD012303] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD041320] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Belville C, 2004, MOL ENDOCRINOL, V18, P708, DOI 10.1210/me.2003-0358; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1018, DOI 10.1210/me.13.6.1018; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; Hanrahan JP, 2004, BIOL REPROD, V70, P900, DOI 10.1095/biolreprod.103.023093; Juengel JL, 2002, BIOL REPROD, V67, P1777, DOI 10.1095/biolreprod.102.007146; Juengel JL, 2004, BIOL REPROD, V70, P557, DOI 10.1095/biolreprod.103.023333; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Laitinen M, 1998, MECH DEVELOP, V78, P135, DOI 10.1016/S0925-4773(98)00161-0; Liao WX, 2003, J BIOL CHEM, V278, P3713, DOI 10.1074/jbc.M210598200; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; Montgomery GW, 2001, REPRODUCTION, V121, P843, DOI 10.1530/rep.0.1210843; Moore RK, 2003, J BIOL CHEM, V278, P304, DOI 10.1074/jbc.M207362200; Otsuka F, 2000, J BIOL CHEM, V275, P39523, DOI 10.1074/jbc.M007428200; Otsuka F, 2001, J BIOL CHEM, V276, P32889, DOI 10.1074/jbc.M103212200; Otsuka F, 2001, J BIOL CHEM, V276, P11387, DOI 10.1074/jbc.M010043200; Otsuka F, 2002, P NATL ACAD SCI USA, V99, P8060, DOI 10.1073/pnas.122066899; Otsuka F, 2002, ENDOCRINOLOGY, V143, P4938, DOI 10.1210/en.2002-220929; Otsuka F, 2001, BIOCHEM BIOPH RES CO, V289, P961, DOI 10.1006/bbrc.2001.6103; Shimasaki S, 2003, REPRODUCTION, P323; Shimasaki S, 2004, ENDOCR REV, V25, P72, DOI 10.1210/er.2003-0007; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854	28	72	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17391	17396		10.1074/jbc.M401050200	http://dx.doi.org/10.1074/jbc.M401050200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970198	hybrid			2022-12-27	WOS:000220870400063
J	Peshenko, IV; Dizhoor, AM				Peshenko, IV; Dizhoor, AM			Guanylyl cyclase-activating proteins (GCAPs) are Ca2+/Mg2+ sensors - Implications for photoreceptor guanylyl cyclase (RetGC) regulation in mammalian photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CONCENTRATION; OUTER SEGMENTS; LIGHT ADAPTATION; CLONING; BINDING; MUTANT; RODS	Guanylyl cyclase-activating proteins (GCAP) are EF-hand Ca2+-binding proteins that activate photoreceptor guanylyl cyclase (RetGC) in the absence of Ca2+ and inhibit RetGC in a Ca2+-sensitive manner. The reported data for the RetGC inhibition by Ca2+/GCAPs in vitro are in disagreement with the free Ca2+ levels found in mammalian photoreceptors (Woodruff, M. L., Sampath, A. P., Matthews, H. R., Krasnoperova, N. V., Lem, J., and Fain, G. L. (2002) J. Physiol. (Lond.) 542, 843-854). We have found that binding of Mg2+ dramatically affects both Ca2+-dependent conformational changes in GCAP-1 and Ca2+ sensitivity of RetGC regulation by GCAP-1 and GCAP-2. Lowering free Mg2+ concentrations ([Mg](f)) from 5.0 mM to 0.5 mM decreases the free Ca2+ concentration required for half-maximal inhibition of RetGC ([Ca](1/2)) by recombinant GCAP-1 and GCAP-2 from 1.3 and 0.2 muM to 0.16 and 0.03 muM, respectively. A similar effect of Mg2+ on Ca2+ sensitivity of RetGC by endogenous GCAPs was observed in mouse retina. Analysis of the [Ca](1/2) changes as a function of [Mg](f) in mouse retina shows that the [Ca](1/2) becomes consistent with the range of 23-250 nM free Ca2+ found in mouse photoreceptors only if the [Mg](f) in the photoreceptors is near 1 mM. Our data demonstrate that GCAPs are Ca2+/Mg2+ sensor proteins. While Ca2+ binding is essential for cyclase activation and inhibition, Mg2+ binding to GCAPs is critical for setting the actual dynamic range of RetGC regulation by GCAPs at physiological levels of free Ca2+.	Penn Coll Optometry, Hafter Res Lab, Elkins Pk, PA 19027 USA		Peshenko, IV (corresponding author), Penn Coll Optometry, Hafter Res Lab, 8360 Old York Rd, Elkins Pk, PA 19027 USA.	adizhoor@pco.edu		Dizhoor, Alexander/0000-0001-6770-9186	NEI NIH HHS [EY11522] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Calvert PD, 1998, J GEN PHYSIOL, V111, P39, DOI 10.1085/jgp.111.1.39; Chen CH, 2003, J PHYSIOL-LONDON, V553, P125, DOI 10.1113/jphysiol.2003.053280; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; Dizhoor AM, 2000, CELL SIGNAL, V12, P711, DOI 10.1016/S0898-6568(00)00134-0; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1999, METHODS, V19, P521, DOI 10.1006/meth.1999.0894; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Hwang JY, 2003, EUR J BIOCHEM, V270, P3814, DOI 10.1046/j.1432-1033.2003.03770.x; Hwang JY, 2002, BIOCHEMISTRY-US, V41, P13021, DOI 10.1021/bi026618y; KOUTALOS Y, 1995, J GEN PHYSIOL, V106, P863, DOI 10.1085/jgp.106.5.863; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; NAKATANI K, 1995, J PHYSIOL-LONDON, V484, P69, DOI 10.1113/jphysiol.1995.sp020648; Nakatani K, 2002, ADV EXP MED BIOL, V514, P1; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; Ozawa T, 2000, BIOCHEMISTRY-US, V39, P14495, DOI 10.1021/bi001930y; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; Ramamurthy V, 2001, J BIOL CHEM, V276, P26218, DOI 10.1074/jbc.M010495200; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sokal I, 2001, J BIOL CHEM, V276, P43361, DOI 10.1074/jbc.M103614200; Sokal I, 1999, J BIOL CHEM, V274, P19829, DOI 10.1074/jbc.274.28.19829; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987	31	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16903	16906		10.1074/jbc.C400065200	http://dx.doi.org/10.1074/jbc.C400065200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14993224	hybrid			2022-12-27	WOS:000220870400003
J	Gentry, JJ; Rutkoski, NJ; Burke, TL; Carter, BD				Gentry, JJ; Rutkoski, NJ; Burke, TL; Carter, BD			A functional interaction between the p75 neurotrophin receptor interacting factors, TRAF6 and NRIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NECROSIS-FACTOR RECEPTOR; ZINC-FINGER PROTEINS; NF-KAPPA-B; TRANSCRIPTIONAL REPRESSION; DEFECTIVE INTERLEUKIN-1; MEDIATED APOPTOSIS; GENE-EXPRESSION; CELL-SURVIVAL; PC12 CELLS	Neurotrophin signaling through the p75 receptor regulates apoptosis within the nervous system both during development and in response to injury. Whereas a number of p75 interacting factors have been identified, how these upstream factors function in a coordinated manner to mediate receptor signaling is still unclear. Here, we report a functional interaction between TRAF6 and the neurotrophin receptor interacting factor (NRIF), two proteins known to associate with the intracellular domain of the p75 neurotrophin receptor. The association between NRIF and TRAF6 was direct and occurred with both endogenous and ectopically expressed proteins. A KRAB repressor domain of NRIF and the carboxyl-terminal, receptor-binding region of TRAF6 were required for the interaction. Co-expression of TRAF6 increased the levels of NRIF protein and induced its nuclear translocation. Reciprocally, NRIF enhanced TRAF6-mediated activation of the c-Jun NH2-terminal kinase (JNK) by 3-fold, while only modestly increasing the stimulation of NF-kappaB. The expression of both NRIF and TRAF6 was required for reconstituting p75 activation of JNK in HEK293 cells, whereas NRIF mutants lacking the TRAF6 interaction domain were unable to substitute for the full-length protein in facilitating activation of the kinase. These results suggest that NRIF and TRAF6 functionally interact to facilitate neurotrophin signaling through the p75 receptor.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Carter, BD (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 655 Light Hall, Nashville, TN 37232 USA.	bruce.carter@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038220] Funding Source: NIH RePORTER; NIMH NIH HHS [MH19732] Funding Source: Medline; NINDS NIH HHS [NS38220] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Benzel I, 2001, GENE, V281, P19, DOI 10.1016/S0378-1119(01)00730-2; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Bui NT, 2002, J NEUROCHEM, V81, P594, DOI 10.1046/j.1471-4159.2002.00841.x; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Chung JY, 2002, J CELL SCI, V115, P679; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; de Haan G, 2000, J BIOL CHEM, V275, P13493, DOI 10.1074/jbc.275.18.13493; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Foehr ED, 2000, J NEUROSCI, V20, P7556; Frankowski H, 2002, NEUROMOL MED, V1, P153; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; GENTRY JJ, 2001, 31 ANN M SOC NEUR SA; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; Harrington AW, 2002, J NEUROSCI, V22, P156, DOI 10.1523/JNEUROSCI.22-01-00156.2002; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; Ling L, 2000, P NATL ACAD SCI USA, V97, P9567, DOI 10.1073/pnas.170279097; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lomaga MA, 2000, J NEUROSCI, V20, P7384; Lorenz P, 2001, BIOL CHEM, V382, P637, DOI 10.1515/BC.2001.075; Mamidipudi V, 2002, J BIOL CHEM, V277, P28010, DOI 10.1074/jbc.M109730200; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Matsuda E, 2001, J BIOL CHEM, V276, P14222, DOI 10.1074/jbc.M010663200; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Park JA, 2000, J NEUROSCI, V20, P9096; PENGUE G, 1995, J VIROL, V69, P6577, DOI 10.1128/JVI.69.10.6577-6580.1995; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tcherpakov M, 2002, J BIOL CHEM, V277, P49101, DOI 10.1074/jbc.C200533200; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yoon SO, 1998, J NEUROSCI, V18, P3273	54	34	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16646	16656		10.1074/jbc.M309209200	http://dx.doi.org/10.1074/jbc.M309209200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14960584	hybrid			2022-12-27	WOS:000220747900116
J	Mangeat, B; Turelli, P; Liao, SY; Trono, D				Mangeat, B; Turelli, P; Liao, SY; Trono, D			A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to vif action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROVIRAL DNA-SYNTHESIS; HIV-1 VIF; ENZYME APOBEC3G; DEGRADATION; PROTEIN; INFECTION; PRIMATE	APOBEC3G (also known as CEM15) is an innate intracellular antiretroviral factor that is counteracted by the Vif protein of lentiviruses. While APOBEC3G orthologues from several species are active against a broad range of retroviruses, given Vif proteins have a narrow spectrum of activity. For instance, HIV-1 Vif efficiently blocks APOBEC3G from human but not African green monkey (AGM), whereas the reverse is observed with SIVAGM Vif. Here, we demonstrate that a single amino acid at position 128 of human and AGM APOBEC3G governs the virus-specific sensitivity of these proteins to Vif-mediated inhibition. Furthermore, we show that this phenotype correlates with the ability of Vif to bind APOBEC3G and interfere with its incorporation into virions. These results shed light on an important determinant of the tropism of primate lentiviruses.	CMU, Dept Microbiol & Mol Med, CH-1211 Geneva 4, Switzerland; CMU, Frontiers Genet Res Program, CH-1211 Geneva 4, Switzerland	University of Geneva	Trono, D (corresponding author), CMU, Dept Microbiol & Mol Med, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	didier.trono@medecine.unige.ch		Mangeat, Bastien/0000-0003-2592-0236				AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; TURELLI P, 2004, IN PRESS SCIENCE; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	17	217	220	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14481	14483		10.1074/jbc.C400060200	http://dx.doi.org/10.1074/jbc.C400060200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14966139	hybrid			2022-12-27	WOS:000220594700003
J	Akiyama, TE; Lambert, G; Nicol, CJ; Matsusue, K; Peters, JM; Brewer, HB; Gonzalez, FJ				Akiyama, TE; Lambert, G; Nicol, CJ; Matsusue, K; Peters, JM; Brewer, HB; Gonzalez, FJ			Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOPOIETIN-LIKE PROTEIN-3; PPAR-GAMMA; GENE-EXPRESSION; LIPID-METABOLISM; FATTY-ACIDS; BETA-OXIDATION; DEFICIENT MICE; TARGETED DISRUPTION; INSULIN-RESISTANCE; ADIPOSE-TISSUE	The results of recent studies using selective agonists for peroxisome proliferator-activated receptor beta (PPARbeta) suggest that this receptor may have a role in regulating levels of serum lipids in animal models of obesity and insulin resistance. To further examine this possibility, serum lipid profiles of mice lacking a functional PPARbeta receptor were determined. PPARbeta-null mice maintained on either normal chow or a 10-week high fat (HF) diet, a condition that has been shown to induce insulin resistance and obesity in mice, have elevated levels of serum triglycerides primarily associated with very low density lipoprotein (VLDL) with no difference in either total cholesterol or phospholipids. Consistent with this finding, PPARbeta-null mice on a HF-diet were shown to have an increased rate of hepatic VLDL production as well as lowered lipoprotein lipase activity in serum compared with wild-type controls. The latter parallels an increase in the hepatic expression of the genes encoding angiopoietin-like proteins 3 and 4 in PPARbeta-null mice on a HF diet, both proteins of which have recently been shown to inhibit lipoprotein lipase (LPL) activity in vivo. Consistent with elevated VLDL production, a marked increase in plasma VLDL apoB48, -E, -AI, and -AII, as well as a sharp depletion of the hepatic lipid stores was also found in PPARbeta-null mice. In addition, PPARbeta-null mice on a HF diet were shown to have increased adiposity, despite lower total body weight. Together, these results indicate a clear role for PPARbeta in regulating levels of serum triglycerides in mice on a high fat Western diet by modulating both VLDL production and LPL-mediated catabolism of VLDL-triglycerides and also suggest a potential therapeutic role for PPARbeta in the improvement of serum lipids in the setting of metabolic syndrome.	NCI, Lab Metab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NHLBI, Mol Dis Branch, NIH, Bethesda, MD 20892 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol, University Pk, PA 16802 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Gonzalez, FJ (corresponding author), NCI, Lab Metab, Div Basic Sci, NIH, Bldg 37,Rm 3106B, Bethesda, MD 20892 USA.	fjgonz@helix.nih.gov	Peters, Jeffrey/D-8847-2011	Lambert, Gilles/0000-0001-5632-0685; Peters, Jeffrey/0000-0003-2782-2998	NATIONAL CANCER INSTITUTE [ZIABC005708, Z01BC005708] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonucci T, 1997, DIABETES CARE, V20, P188, DOI 10.2337/diacare.20.2.188; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Chaput E, 2000, BIOCHEM BIOPH RES CO, V271, P445, DOI 10.1006/bbrc.2000.2647; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; DREXEL H, 1994, CIRCULATION, V90, P2230, DOI 10.1161/01.CIR.90.5.2230; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1984, ENDOCRINOLOGY, V134, P264; Imai T, 2001, P NATL ACAD SCI USA, V98, P224, DOI 10.1073/pnas.011528898; Infante JP, 2002, MOL GENET METAB, V75, P108, DOI 10.1006/mgme.2001.3279; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; Kaplan R, 2003, J LIPID RES, V44, P136, DOI 10.1194/jlr.M200367-JLR200; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lambert G, 2001, J BIOL CHEM, V276, P15090, DOI 10.1074/jbc.M008466200; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; Leibowitz MD, 2000, FEBS LETT, V473, P333, DOI 10.1016/S0014-5793(00)01554-4; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Peters JM, 2003, BBA-MOL CELL BIOL L, V1632, P80, DOI 10.1016/S1388-1981(03)00065-9; PHILLIPS NR, 1993, CIRCULATION, V88, P2762, DOI 10.1161/01.CIR.88.6.2762; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; RUSSELL JC, 1970, CLIN CHEM, V16, P900; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V301, P604, DOI 10.1016/S0006-291X(02)03058-9; Shimizugawa T, 2002, J BIOL CHEM, V277, P33742, DOI 10.1074/jbc.M203215200; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Spiegelman BM, 1997, BIOCHIMIE, V79, P111, DOI 10.1016/S0300-9084(97)81500-3; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; Tan NS, 2003, AM J CLIN DERMATOL, V4, P523, DOI 10.2165/00128071-200304080-00001; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Yoshida K, 2002, J LIPID RES, V43, P1770, DOI 10.1194/jlr.C200010-JLR200	57	78	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20874	20881		10.1074/jbc.M312802200	http://dx.doi.org/10.1074/jbc.M312802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15001574	hybrid			2022-12-27	WOS:000221273800039
J	Li, JY; Cui, YM; Chen, LL; Gu, M; Li, J; Nan, FJ; Ye, QZ				Li, JY; Cui, YM; Chen, LL; Gu, M; Li, J; Nan, FJ; Ye, QZ			Mutations at the S1 sites of methionine aminopeptidases from Escherichia coli and Homo sapiens reveal the residues critical for substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PYROCOCCUS-FURIOSUS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; INHIBITORS; GENE; FUMAGILLIN; PROTEINS; OVEREXPRESSION; TRANSFERASE	Methionine aminopeptidase (MetAP) catalyzes the removal of methionine from newly synthesized polypeptides. MetAP carries out this cleavage with high precision, and Met is the only natural amino acid residue at the N terminus that is accepted, although type I and type II MetAPs use two different sets of residues to form the hydrophobic S1 site. Characteristics of the S1 binding pocket in type I MetAP were investigated by systematic mutation of each of the seven S1 residues in Escherichia coli MetAP type I (EcMetAP1) and human MetAP type I (HsMetAP1). We found that Tyr-65 and Trp-221 in EcMetAP1, as well as the corresponding residues Phe-197 and Trp-352 in HsMetAP1, were essential for the hydrolysis of a thiopeptolide substrate, Met-S-Gly-Phe. Mutation of Phe-191 to Ala in HsMetAP1 caused inactivity in contrast to the full activity of EcMetAP1(Y62A), which may suggest a subtle difference between the two type I enzymes. The more striking finding is that mutation of Cys-70 in EcMetAP1 or Cys-202 in HsMetAP1 opens up the S1 pocket. The thiopeptolides Leu-S-Gly-Phe and Phe-S-Gly-Phe, with previously unacceptable Leu or Phe as the N-terminal residue, became efficient substrates of EcMetAP1(C70A) and HsMetAP1(C202A). The relaxed specificity shown in these S1 site mutants for the N-terminal residues was confirmed by hydrolysis of peptide substrates and inhibition by reaction products. The structural features at the enzyme active site will be useful information for designing specific MetAP inhibitors for therapeutic applications.	Univ Kansas, Hight Throughput Screening Lab, Higuchi Biosci Ctr, Lawrence, KS 66047 USA; Chinese Acad Sci, Chinese Natl Ctr Drug Screening, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China	University of Kansas; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Nan, FJ (corresponding author), Univ Kansas, Hight Throughput Screening Lab, Higuchi Biosci Ctr, 1501 Wakarusa Dr, Lawrence, KS 66047 USA.	fjnan@mail.shcnc.ac.cn; qye@ku.edu	Chen, Ling-Ling/AAY-3547-2021; Li, Jia/F-9116-2011; Ye, Qizhuang/B-3147-2009	chen, ling ling/0000-0001-9501-0305	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR 015563] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; CHANG SYP, 1989, J BACTERIOL, V171, P4071, DOI 10.1128/jb.171.7.4071-4072.1989; CHANG YH, 1992, J BIOL CHEM, V267, P8007; Chiu CH, 1999, J BACTERIOL, V181, P4686, DOI 10.1128/JB.181.15.4686-4689.1999; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Keding SJ, 1998, SYNTHETIC COMMUN, V28, P4463, DOI 10.1080/00397919808004481; Kruger EA, 2000, EXPERT OPIN INV DRUG, V9, P1383, DOI 10.1517/13543784.9.6.1383; Larrabee JA, 1999, ANAL BIOCHEM, V269, P194, DOI 10.1006/abio.1998.3086; Li JY, 2003, BIOCHEM BIOPH RES CO, V307, P172, DOI 10.1016/S0006-291X(03)01144-6; LI JY, 2004, IN PRESS BIOCHEMISTR; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Lowther WT, 1999, BIOCHEMISTRY-US, V38, P14810, DOI 10.1021/bi991711g; Lowther WT, 1998, P NATL ACAD SCI USA, V95, P12153, DOI 10.1073/pnas.95.21.12153; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; Lowther WT, 1999, BIOCHEMISTRY-US, V38, P7678, DOI 10.1021/bi990684r; Luo QL, 2003, J MED CHEM, V46, P2631, DOI 10.1021/jm0300532; MILLER CG, 1989, J BACTERIOL, V171, P5215, DOI 10.1128/jb.171.9.5215-5217.1989; Oefner C, 2003, J MOL BIOL, V332, P13, DOI 10.1016/S0022-2836(03)00862-3; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Solbiati J, 1999, J MOL BIOL, V290, P607, DOI 10.1006/jmbi.1999.2913; Tahirov TH, 1998, J MOL BIOL, V284, P101, DOI 10.1006/jmbi.1998.2146; Towbin H, 2003, J BIOL CHEM, V278, P52964, DOI 10.1074/jbc.M309039200; Tsunasawa S, 1997, J BIOCHEM-TOKYO, V122, P843; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Vaughan MD, 2002, CURR MED CHEM, V9, P385, DOI 10.2174/0929867023371102; Walker KW, 1999, J BIOL CHEM, V274, P13403, DOI 10.1074/jbc.274.19.13403; Yang G, 2001, BIOCHEMISTRY-US, V40, P10645, DOI 10.1021/bi010806r; Zhou Y, 2000, ANAL BIOCHEM, V280, P159, DOI 10.1006/abio.2000.4513	31	18	23	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21128	21134		10.1074/jbc.M401679200	http://dx.doi.org/10.1074/jbc.M401679200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14976199	hybrid			2022-12-27	WOS:000221273800070
J	Townsend, PA; Cutress, RI; Carroll, CJ; Lawrence, KM; Scarabelli, TM; Packham, G; Stephanou, A; Latchman, DS				Townsend, PA; Cutress, RI; Carroll, CJ; Lawrence, KM; Scarabelli, TM; Packham, G; Stephanou, A; Latchman, DS			BAG-1 proteins protect cardiac myocytes from simulated ischemia/reperfusion-induced apoptosis via an alternate mechanism of cell survival independent of the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; E3 UBIQUITIN LIGASE; ENDOTHELIAL-CELLS; ISOFORMS; PATHWAY; COMPLEX; GROWTH; HSP90; DEATH	BAG-1 ((B) under bar cl-2-associated (a) under bar thano (g) under bar ene-(a) under bar) proteins interact with the HSC70 and HSP70 heat shock proteins and have been proposed to promote cell survival by coordinating the function of these chaperones with the proteasome to facilitate protein degradation. Consistent with this proposal, previous analyses in cancer cells have demonstrated that BAG-1 requires protein domains important for HSC70/HSP70 and proteasome binding in order to interfere with the growth inhibition induced by heat shock (Townsend, P.A., Cutress, R.I., Sharp, A., Brimmell, M., and Packham, G. (2003) Cancer Res., 63, 4150-4157). Moreover, cellular stress triggered the relocalization of the cytoplasmic BAG-1S (similar to36 kDa) isoform to the nucleus, and both BAG-1S and the constitutively nuclear localized BAG-1L (similar to50 kDa) isoform suppressed heat shock-induced apoptosis to the same extent, suggesting a critical role in the nucleus. Because ischemia (I) and reperfusion (R) are important stress signals in acute and chronic heart disease, we have examined the expression and function of BAG-1 proteins in primary cardiac myocytes (CMs) and the Langendorff-perfused intact heart. The expression of both BAG-1 isoforms, BAG-1S and BAG-1L, was rapidly induced following ischemia in rat CM, and this was maintained during subsequent reperfusion. In control hearts, BAG-1S and BAG-1L were readily detectable in both the nucleus and the cytoplasm. However, BAG-1S did not relocate to the nucleus following simulated I/R. BAG-1 interacted with both RAF-1 and HSC70 in CMs and the whole heart, and binding to HSC70 was increased following I/R. Overexpression of the human BAG-1S and BAG-1 M isoforms significantly reduced CM apoptosis following simulated I/R. By contrast, BAG-1L or BAG-1S fused to a heterologous nuclear localization sequence failed to protect CM. Finally, overexpression of BAG-1 deletion and point mutants unable to bind HSC70/HSP70 failed to offer cardioprotection. Surprisingly, a deletion mutant lacking the N-terminal ubiquitin-like domain, which mediates interaction with the proteasome, still promoted cardioprotection. Therefore, BAG-1 has a novel cardioprotective role, mediated via association with HSC70/HSP70, which is critical upon cytoplasmic localization but independent of the BAG-1 ubiquitin-like domain. Our studies demonstrate that BAG-1 can influence cellular response to stress by multiple mechanisms, potentially influenced by the cell type and nature of the stress signal.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; Univ Southampton, Sch Med, Canc Sci Div, Canc Res UK Oncol Unit, Southampton SO16 6YD, Hants, England; St Johns Hosp, Div Cardiochirurg, Detroit, MI USA	University of London; University College London; University of Southampton	Townsend, PA (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	p.townsend@ich.ucl.ac.uk	Carroll, Christopher/AAV-8023-2021; Townsend, Paul/AAF-8234-2020; Carroll, Christopher/AAJ-6185-2021	Carroll, Christopher/0000-0002-2814-6955; Townsend, Paul/0000-0001-8956-9508; Packham, Graham/0000-0002-9232-5691				*AM HEART ASS, 2002, HEART DIS STROK STAT; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; *BRIT HEART FDN HL, 2003, COR HEART DIS STAT; Chen J, 2002, ONCOGENE, V21, P7050, DOI 10.1038/sj.onc.1205845; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cutress RI, 2003, ONCOGENE, V22, P4973, DOI 10.1038/sj.onc.1206688; Cutress RI, 2002, BRIT J CANCER, V87, P834, DOI 10.1038/sj.bjc.6600538; Davidson SM, 2003, J MOL CELL CARDIOL, V35, P1359, DOI 10.1016/J.yjmcc.2003.08.001; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; ESUMI K, 1991, AM J PHYSIOL, V260, pH1743, DOI 10.1152/ajpheart.1991.260.6.H1743; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; HEADS RJ, 1994, J MOL CELL CARDIOL, V26, P695, DOI 10.1006/jmcc.1994.1084; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Scarabelli T, 2001, CIRCULATION, V104, P253, DOI 10.1161/01.CIR.104.3.253; Scarabelli TM, 2002, CIRC RES, V90, P745, DOI 10.1161/01.RES.0000015224.07870.9A; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tang SC, 2002, IUBMB LIFE, V53, P99, DOI 10.1080/15216540211473; Townsend PA, 2003, CANCER RES, V63, P4150; Townsend PA, 2003, BBA-REV CANCER, V1603, P83, DOI 10.1016/S0304-419X(03)00002-7; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899	30	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20723	20728		10.1074/jbc.M400399200	http://dx.doi.org/10.1074/jbc.M400399200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14978028	hybrid			2022-12-27	WOS:000221273800024
J	Walter, M; Forsyth, NR; Wright, WE; Shay, JW; Roth, MG				Walter, M; Forsyth, NR; Wright, WE; Shay, JW; Roth, MG			The establishment of telomerase-immortalized Tangier disease cell lines indicates the existence of an apolipoprotein A-I-inducible but ABCA1-independent cholesterol efflux pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER 1; HUMAN FIBROBLASTS; LIFE-SPAN; INTRACELLULAR CHOLESTEROL; MEDIATED REMOVAL; LIPID EFFLUX; ABCA1; EXPRESSION; AGE	Tangier disease (TD) is a human genetic disorder associated with defective apolipoprotein-I-induced lipid efflux and increased atherosclerotic susceptibility. It has been linked to mutations in the ATP-binding cassette protein A1 (ABCA1). Here we describe the establishment of permanent Tangier cell lines using telomerase. Ectopic expression of the catalytic subunit of human telomerase extended the life span of control and TD skin fibroblasts, and ( in contrast to immortalization procedures using viral oncogenes) did not impair apolipoprotein A-I-induced lipid efflux. The key characteristics of TD fibroblasts ( reduced cholesterol and phospholipid efflux) were observed both in primary and telomerase-immortalized fibroblasts from two unrelated homozygous patients. Surprisingly, the apolipoprotein-inducible cholesterol efflux in TD cells was significantly improved after immortalization ( up to 40% of normal values). In contrast to ABCA1-dependent cholesterol efflux, this efflux was not inhibited by brefeldin A, glybenclamide, or intracellular ATP depletion but was inhibited in the presence of cytochalasin D. Apolipoprotein A-I-dependent cholesterol efflux was inversely correlated with the population doubling number in cell culture and was inhibited up to 40% in near-senescent normal diploid fibroblasts. This inhibition was completely reversed by telomerase. Thus ectopic expression of telomerase is a way to circumvent the lack of critical experimental material and represents a major improvement for studying cholesterol efflux pathways in lipid disorders. Our findings indicate the existence of an ABCA1-independent but cytoskeleton-dependent cholesterol removal pathway that may help to prevent early atherosclerosis in Tangier disease but may also be sensitive to aging phenomena ex vivo and possibly in vivo.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Roth, MG (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	michael.roth@utsouthwestern.edu	Shay, Jerry W/F-7878-2011	Roth, Michael/0000-0002-9056-332X				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brewer HB, 2003, AM J CARDIOL, V91, p3E, DOI 10.1016/S0002-9149(02)03382-9; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; Drobnik W, 1999, ARTERIOSCL THROM VAS, V19, P28, DOI 10.1161/01.ATV.19.1.28; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Garcia GG, 2002, J IMMUNOL, V169, P5021, DOI 10.4049/jimmunol.169.9.5021; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Leitinger B, 2002, J CELL SCI, V115, P963; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; OPPENHEIMER MJ, 1987, ARTERIOSCLEROSIS, V7, P325, DOI 10.1161/01.ATV.7.4.325; Oram JF, 1999, J LIPID RES, V40, P1769; Oram JF, 1996, J LIPID RES, V37, P2473; Oram JF, 2001, J LIPID RES, V42, P1173; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; RADER DJ, 1993, LANCET, V342, P1455, DOI 10.1016/0140-6736(93)92933-K; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; SINGARAJA RR, 2004, IN PRESS ARTERIOSCLE; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; Tall AR, 2003, ARTERIOSCL THROM VAS, V23, P710, DOI 10.1161/01.ATV.0000068683.51375.59; Utech M, 2001, BIOCHEM BIOPH RES CO, V280, P229, DOI 10.1006/bbrc.2000.4061; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; WALTER M, 1994, ATHEROSCLEROSIS, V110, P203, DOI 10.1016/0021-9150(94)90205-4; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	45	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20866	20873		10.1074/jbc.M401714200	http://dx.doi.org/10.1074/jbc.M401714200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15001567	hybrid			2022-12-27	WOS:000221273800038
J	Guilbault, B; Kay, RJ				Guilbault, B; Kay, RJ			RasGRP1 sensitizes an immature B cell line to antigen receptor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL-BINDING MOTIFS; NUCLEOTIDE-RELEASING PROTEIN; CD40 LIGAND RESCUE; MEDIATED APOPTOSIS; SIGNALING PATHWAY; CALCIUM-BINDING; CYCLE ARREST; KAPPA-B/REL; IG-ALPHA; BCL-X	RasGRP1 is a guanine nucleotide exchange factor that activates Ras GTPases and is activated downstream of antigen receptors on both T and B lymphocytes. RasGRP1 provides signals to immature T cells that confer survival and proliferation, but RasGRP1 also promotes T cell receptor-mediated deletion of mature T cells. We used the WEHI-231 cell line as an experimental system to determine whether RasGRP1 can serve as a quantitative modifier of B cell receptor-induced deletion of immature B cells. A 2-fold elevation in RasGRP1 expression markedly increased apoptosis of WEHI-231 cells following B cell receptor ligation, whereas a dominant negative mutant of RasGRP1 suppressed B cell receptor-induced apoptosis. Activation of ERK1 or ERK2 kinases was not required for RasGRP1-mediated apoptosis. Instead, elevated RasGRP1 expression caused down-regulation of NF-kappaB and Bcl-xL, which provide survival signals counter-acting apoptosis induction by B cell receptor. Inhibition of NF-kappaB was sufficient to enhance B cell receptor-induced apoptosis of WEHI-231 cells, and ligation of co-stimulatory receptors that activate NF-kappaB suppressed the ability of RasGRP1 to promote B cell receptor-induced apoptosis. These experiments define a novel apoptosis-promoting pathway leading from B cell receptor to the inhibition of NF-kappaB and demonstrate that differential expression of RasGRP1 has the potential to modulate the sensitivities of B cells to negative selection following antigen encounter.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency; University of British Columbia	Kay, RJ (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	rkay@bccrc.ca						Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Caloca MJ, 2003, J BIOL CHEM, V278, P33465, DOI 10.1074/jbc.M302807200; Caloca MJ, 2003, EMBO J, V22, P3326, DOI 10.1093/emboj/cdg316; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Gauld SB, 2002, J IMMUNOL, V168, P3855, DOI 10.4049/jimmunol.168.8.3855; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; GOTTSCHALK AR, 1995, IMMUNOL CELL BIOL, V73, P8, DOI 10.1038/icb.1995.2; Goudeau B, 2003, P NATL ACAD SCI USA, V100, P15800, DOI 10.1073/pnas.2535880100; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Iritani BM, 1999, IMMUNITY, V10, P713, DOI 10.1016/S1074-7613(00)80070-9; ISHIDA T, 1995, J IMMUNOL, V155, P5527; JAKWAY JP, 1986, J IMMUNOL, V137, P2225; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kraus M, 1999, IMMUNITY, V11, P537, DOI 10.1016/S1074-7613(00)80129-6; Krebs Danielle L., 1999, Methods in Cell Science, V21, P57, DOI 10.1023/A:1009843325770; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Layer K, 2003, IMMUNITY, V19, P243, DOI 10.1016/S1074-7613(03)00209-7; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JR, 1998, J IMMUNOL, V161, P1637; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu Qingyan, 2001, Molecular Cell Biology Research Communications, V4, P381, DOI 10.1006/mcbr.2001.0304; Lorenzo PS, 2001, CANCER RES, V61, P943; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; MERINO R, 1995, J IMMUNOL, V155, P3830; Monroe JG, 1996, J IMMUNOL, V156, P2657; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nemazee D, 2003, CURR OPIN IMMUNOL, V15, P182, DOI 10.1016/S0952-7915(03)00008-6; Norment AM, 2003, J IMMUNOL, V170, P1141, DOI 10.4049/jimmunol.170.3.1141; Oh-Hora M, 2003, J EXP MED, V198, P1841, DOI 10.1084/jem.20031547; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Reuther GW, 2002, J BIOL CHEM, V277, P30508, DOI 10.1074/jbc.M111330200; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Schauer SL, 1998, J IMMUNOL, V160, P4398; Schauer SL, 1996, J IMMUNOL, V157, P81; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Torres RM, 1999, IMMUNITY, V11, P527, DOI 10.1016/S1074-7613(00)80128-4; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com; WANG ZH, 1995, J IMMUNOL, V155, P3722; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yang Y, 2002, J BIOL CHEM, V277, P25756, DOI 10.1074/jbc.M202575200; Zhu N, 2002, J IMMUNOL, V168, P744, DOI 10.4049/jimmunol.168.2.744	59	17	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19523	19530		10.1074/jbc.M314273200	http://dx.doi.org/10.1074/jbc.M314273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14970203	hybrid			2022-12-27	WOS:000221164500019
J	Lauhon, CT; Skovran, E; Urbina, HD; Downs, DM; Vickery, LE				Lauhon, CT; Skovran, E; Urbina, HD; Downs, DM; Vickery, LE			Substitutions in an active site loop of Escherichia coli IscS result in specific defects in Fe-S cluster and thionucleoside biosynthesis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; IRON-SULFUR CLUSTERS; PERFORMANCE LIQUID-CHROMATOGRAPHY; THIOLATED NUCLEOSIDES PRESENT; NIFS-LIKE PROTEIN; TRANSFER-RNA; CYSTEINE DESULFURASE; SALMONELLA-TYPHIMURIUM; AZOTOBACTER-VINELANDII; SELENOCYSTEINE LYASE	IscS catalyzes the fragmentation of L-cysteine to L-alanine and sulfane sulfur in the form of a cysteine persulfide in the active site of the enzyme. In Escherichia coli IscS, the active site cysteine Cys(328) resides in a flexible loop that potentially influences both the formation and stability of the cysteine persulfide as well as the specificity of sulfur transfer to protein substrates. Alanine-scanning substitution of this 14 amino acid region surrounding Cys(328) identified additional residues important for IscS function in vivo. Two mutations, S326A and L333A, resulted in strains that were severely impaired in Fe-S cluster synthesis in vivo. The mutant strains were deficient in Fe-S cluster-dependent tRNA thionucleosides (s(2)C and ms(2)i(6)A) yet showed wild type levels of Fe-S-independent thionucleosides (s(4)U and mnm(5)s(2)U) that require persulfide formation and transfer. In vitro, the mutant proteins were similar to wild type in both cysteine desulfurase activity and sulfur transfer to IscU. These results indicate that residues in the active site loop can selectively affect Fe-S cluster biosynthesis in vivo without detectably affecting persulfide delivery and suggest that additional assays may be necessary to fully represent the functions of IscS in Fe-S cluster formation.	Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53705 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Irvine	Lauhon, CT (corresponding author), Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA.	clauhon@facstaff.wisc.edu		Skovran, Elizabeth/0000-0002-1737-5621	NIGMS NIH HHS [GM 57002, GM 47296, GM 54264] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047296, R01GM057002] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; Beinert H, 2000, EUR J BIOCHEM, V267, P5657, DOI 10.1046/j.1432-1327.2000.01637.x; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; Cupp-Vickery JR, 2003, J MOL BIOL, V330, P1049, DOI 10.1016/S0022-2836(03)00690-9; Esberg B, 1999, J BACTERIOL, V181, P7256, DOI 10.1128/JB.181.23.7256-7265.1999; Flint DH, 1996, J BIOL CHEM, V271, P16068; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; GARDNER PR, 1991, J BIOL CHEM, V266, P1468; GEHRKE CW, 1982, J CHROMATOGR, V230, P297, DOI 10.1016/S0378-4347(00)80479-X; Jager G, 2004, J BACTERIOL, V186, P750, DOI 10.1128/JB.186.3.750-757.2004; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Leipuviene R, 2004, J BACTERIOL, V186, P758, DOI 10.1128/JB.186.3.758-766.2004; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Marquet A, 2001, CURR OPIN CHEM BIOL, V5, P541, DOI 10.1016/S1367-5931(00)00249-0; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; Mihara H, 2002, P NATL ACAD SCI USA, V99, P6679, DOI 10.1073/pnas.102176099; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; Olson JW, 2000, BIOCHEMISTRY-US, V39, P16213, DOI 10.1021/bi001744s; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	45	33	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19551	19558		10.1074/jbc.M401261200	http://dx.doi.org/10.1074/jbc.M401261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14978044	hybrid			2022-12-27	WOS:000221164500022
J	Sudha, R; Anantharaman, L; Sivaram, MVS; Mirsamadi, N; Choudhury, D; Lohiya, NK; Gupta, RB; Roy, RP				Sudha, R; Anantharaman, L; Sivaram, MVS; Mirsamadi, N; Choudhury, D; Lohiya, NK; Gupta, RB; Roy, RP			Linkage of interactions in sickle hemoglobin fiber assembly - Inhibitory effect emanating from mutations in the AB region of the alpha-chain is annulled by a mutation at its EF corner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; DEOXYHEMOGLOBIN-S; BETA-CHAIN; INTERMOLECULAR CONTACTS; POLYMERIZATION; MUTANT; SUBSTITUTIONS; PARTICIPATION; SEMISYNTHESIS; HAEMOGLOBIN	The AB and GH regions of the alpha-chain are located in spatial proximity and contain a cluster of intermolecular contact residues of the sickle hemoglobin (HbS) fiber. We have examined the role of dynamics of AB/GH region on HbS polymerization through simultaneous replacement of non-contact Ala(19) and Ala(21) of the AB corner with more flexible Gly or rigid alpha-aminoisobutyric acid (Aib) residues. The polymerization behavior of HbS with Aib substitutions was similar to the native HbS. In contrast, Gly substitutions inhibited HbS polymerization. Molecular dynamics simulation studies of alpha-chains indicated that coordinated motion of AB and GH region residues present in native ( Ala) as well as in Aib mutant was disrupted in the Gly mutant. The inhibitory effect due to Gly substitutions was further explored in triple mutants that included mutation of an inter-double-strand contact (alphaAsn(78) --> His or Gln) at the EF corner. Although the inhibitory effect of Gly substitutions in the triple mutant was unaffected in the presence of alphaGln(78), His at this site almost abrogated its inhibitory potential. The polymerization studies of point mutants (alphaGln(78) --> His) indicated that the inhibitory effect due to Gly substitutions in the triple mutant was synergistically compensated for by the polymerization-enhancing activity of His(78). Similar synergistic coupling, between alphaHis(78) and an intra-double-strand contact point (alpha16) mutation located in the AB region, was also observed. Thus, two conclusions are made: (i) Gly mutations at the AB corner inhibit HbS polymerization by perturbing the dynamics of the AB/GH region, and (ii) perturbations of AB region (through changes in dynamics of the AB/GH region or abolition of a specific fiber contact site) that influence HbS polymerization do so in concert with alpha78 site at the EF corner. The overall results provide insights about the interaction-linkage between distant regions of the HbS tetramer in fiber assembly.	Natl Inst Immunol, New Delhi 110067, India; Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India; Univ Rajasthan, Dept Zool, Jaipur 302004, Rajasthan, India; Reg Med Res Ctr Tribals, Jabalpur 482003, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Jawaharlal Nehru University, New Delhi; University of Rajasthan; Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tribal Health (NIRTH)	Roy, RP (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	rproy@nii.res.in						Balaram P., 1992, CURR OPIN STRUC BIOL, V2, P845, DOI [10.1016/0959-440X(92)90110-S, DOI 10.1016/0959-440X(92)90110-S]; BENESCH RE, 1978, BIOCHEM BIOPH RES CO, V81, P1307, DOI 10.1016/0006-291X(78)91278-0; BENESCH RE, 1982, NATURE, V299, P231, DOI 10.1038/299231a0; BENESCH RE, 1977, NATURE, V269, P772, DOI 10.1038/269772a0; BENESCH RE, 1979, J BIOL CHEM, V254, P8169; Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658, DOI 10.1007/978-94-015-7658]; Bookchin RM, 1999, J BIOL CHEM, V274, P6689, DOI 10.1074/jbc.274.10.6689; BOOKCHIN RM, 1977, NATURE, V269, P526, DOI 10.1038/269526a0; BOOKCHIN RM, 1974, SEMIN HEMATOL, V11, P577; BOOKCHIN RM, 1967, J BIOL CHEM, V242, P248; Bucci E, 1981, Methods Enzymol, V76, P97; CRETEGNY I, 1993, J MOL BIOL, V230, P733, DOI 10.1006/jmbi.1993.1195; Dumoulin A, 1998, J BIOL CHEM, V273, P35032, DOI 10.1074/jbc.273.52.35032; DYKES GW, 1979, J MOL BIOL, V130, P451, DOI 10.1016/0022-2836(79)90434-0; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; Harrington DJ, 1997, J MOL BIOL, V272, P398, DOI 10.1006/jmbi.1997.1253; HARTE WE, 1990, P NATL ACAD SCI USA, V87, P8864, DOI 10.1073/pnas.87.22.8864; Himanen JP, 1996, J BIOL CHEM, V271, P25152, DOI 10.1074/jbc.271.41.25152; Himanen JP, 1997, BLOOD, V89, P4196, DOI 10.1182/blood.V89.11.4196; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; Karle IL, 1999, ACCOUNTS CHEM RES, V32, P693, DOI 10.1021/ar9702942; Li XF, 2002, J BIOL CHEM, V277, P13479, DOI 10.1074/jbc.M108149200; Li XF, 1999, BIOTECHNOL APPL BIOC, V29, P165; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Manning JM, 1998, J BIOL CHEM, V273, P19359, DOI 10.1074/jbc.273.31.19359; MATSUDA G, 1973, INT J PEPT PROT RES, V5, P423; McCammon JA., 1987, DYNAMICS PROTEINS NU; Nacharaju P, 1997, J BIOL CHEM, V272, P27869, DOI 10.1074/jbc.272.44.27869; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; Rao MJ, 2000, J MOL BIOL, V300, P1389, DOI 10.1006/jmbi.2000.3898; RHODA MD, 1984, BIOCHIM BIOPHYS ACTA, V786, P62, DOI 10.1016/0167-4838(84)90154-7; ROY RP, 1993, J BIOL CHEM, V268, P16406; ROY RP, 1994, METHOD ENZYMOL, V231, P194; Sivaram MVS, 2001, J BIOL CHEM, V276, P18209, DOI 10.1074/jbc.M101788200; WATOWICH SJ, 1993, J STRUCT BIOL, V111, P161, DOI 10.1006/jsbi.1993.1047; YIP YK, 1977, P NATL ACAD SCI USA, V74, P64, DOI 10.1073/pnas.74.1.64	40	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20018	20027		10.1074/jbc.M311562200	http://dx.doi.org/10.1074/jbc.M311562200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14982923	hybrid			2022-12-27	WOS:000221164500077
J	Sugimoto, N; Tatsumi, Y; Tsurumi, T; Matsukage, A; Kiyono, T; Nishitani, H; Fujita, M				Sugimoto, N; Tatsumi, Y; Tsurumi, T; Matsukage, A; Kiyono, T; Nishitani, H; Fujita, M			Cdt1 phosphorylation by cyclin A-dependent kinases negatively regulates its function without affecting geminin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; S-PHASE; CELL-CYCLE; MEDIATED PROTEOLYSIS; LICENSING FACTOR; CDC2 MUTANT; INITIATION; CHROMATIN; CDK	The current concept regarding cell cycle regulation of DNA replication is that Cdt1, together with origin recognition complex and CDC6 proteins, constitutes the machinery that loads the minichromosome maintenance complex, a candidate replicative helicase, onto chromatin during the G(1) phase. The actions of origin recognition complex and CDC6 are suppressed through phosphorylation by cyclin-dependent kinases (Cdks) after S phase to prohibit rereplication. It has been suggested in metazoan cells that the function of Cdt1 is blocked through binding to an inhibitor protein, geminin. However, the functional relationship between the Cdt1-geminin system and Cdks remains to be clarified. In this report, we demonstrate that human Cdt1 is phosphorylated by cyclin A-dependent kinases dependent on its cyclin-binding motif. Cdk phosphorylation resulted in the binding of Cdt1 to the F-box protein Skp2 and subsequent degradation. In contrast, in vitro DNA binding activity of Cdt1 was inhibited by the phosphorylation. However, geminin binding to Cdt1 was not affected by the phosphorylation. Finally we provide evidence that inactivation of Cdk1 results in Cdt1 dephosphorylation and rebinding to chromatin in murine FT210 cells synchronized around the G(2)/M phase. Taken together, these findings suggest that Cdt1 function is also negatively regulated by the Cdk phosphorylation independent of geminin binding.	Natl Canc Ctr, Res Inst, Div Virol, Chuoh Ku, Tokyo 1040045, Japan; Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Japan Womens Univ, Fac Sci, Bunkyou Ku, Tokyo 1128679, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan	National Cancer Center - Japan; Aichi Cancer Center; Japan Womens University; Kyushu University	Fujita, M (corresponding author), Natl Canc Ctr, Res Inst, Div Virol, Chuoh Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	mafujita@gan2.res.ncc.go.jp	Kiyono, Tohru/H-5834-2011	Sugimoto, Nozomi/0000-0002-4313-5728; Tatsumi, Yasutoshi/0000-0003-2646-7410; Fujita, Masatoshi/0000-0001-6617-2452; Nishitani, Hideo/0000-0001-5907-9380				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; Fujita M, 1996, J BIOL CHEM, V271, P4349; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; FUJITA M, 1999, FRONT BIOSCI, V4, P816; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; Herbig U, 2000, MOL BIOL CELL, V11, P4117, DOI 10.1091/mbc.11.12.4117; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; MASUMOTO H, 2002, NATURE, V713, P1; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Rowles A, 1999, J CELL SCI, V112, P2011; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	41	146	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19691	19697		10.1074/jbc.M313175200	http://dx.doi.org/10.1074/jbc.M313175200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14993212	hybrid			2022-12-27	WOS:000221164500038
J	Atreya, CE; Anderson, KS				Atreya, CE; Anderson, KS			Kinetic characterization of bifunctional thymidylate Synthase-dihydrofolate reductase (TS-DHFR) from Cryptosporidium hominis - A paradigm shift for TS activity and channeling behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS EXPRESSION; ANTIFOLATE RESISTANCE; ENZYME; BINDING; MECHANISM; DOMAIN; GENE	This study presents a kinetic characterization of the recently crystallized bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) enzyme from the apicomplexa parasite, Cryptosporidium hominis. Our study focuses on determination of the C. hominis TS-DHFR kinetic mechanism, substrate channeling behavior, and domain-domain communication. Unexpectedly, the unique mechanistic features of C. hominis TS-DHFR involve the highly conserved TS domain. At 45 s(-1), C. hominis TS activity is 10-40- fold faster than other TS enzymes studied and a new kinetic mechanism was required to simulate C. hominis TS behavior. A large accumulation of dihydrofolate produced at TS and a lag in product formation at DHFR were observed. These observations make C. hominis TS-DHFR the first bifunctional TS-DHFR enzyme studied for which there is clear evidence against dihydrofolate substrate channeling. Furthermore, whereas with Leishmania major TS-DHFR there are multiple lines of evidence for domain-domain communication ( ligand binding at one active site affecting activity of the other enzyme), no such effects were observed with C. hominis TS-DHFR.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	karen.anderson@yale.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044630] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44630] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson AC, 1999, BIOCHEMISTRY-US, V38, P13829, DOI 10.1021/bi991610i; Atreya CE, 2003, J BIOL CHEM, V278, P28901, DOI 10.1074/jbc.M212689200; Atreya CE, 2003, J BIOL CHEM, V278, P14092, DOI 10.1074/jbc.M212690200; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DEV IK, 1994, J BIOL CHEM, V269, P1873; Elcock AH, 1996, J MOL BIOL, V262, P370, DOI 10.1006/jmbi.1996.0520; Ferreira MS, 2002, MEM I OSWALDO CRUZ, V97, P443, DOI 10.1590/S0074-02762002000400001; Finer-Moore JS, 2003, BIOCHEMISTRY-US, V42, P248, DOI 10.1021/bi020599a; FINERMOORE JS, 1990, BIOCHEMISTRY-US, V29, P6977, DOI 10.1021/bi00482a005; GRUMONT R, 1988, BIOCHEMISTRY-US, V27, P3776, DOI 10.1021/bi00410a039; Guerrant RL, 1997, EMERG INFECT DIS, V3, P51, DOI 10.3201/eid0301.970106; Johnson EF, 2002, J BIOL CHEM, V277, P43126, DOI 10.1074/jbc.M206523200; KAMB A, 1992, BIOCHEMISTRY-US, V31, P12876, DOI 10.1021/bi00166a024; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; Liu J, 2002, BBA-MOL BASIS DIS, V1587, P174, DOI 10.1016/S0925-4439(02)00080-7; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; O'Neil RH, 2003, J BIOL CHEM, V278, P52980, DOI 10.1074/jbc.M310328200; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; SCHLICHTING I, 1994, J BIOL CHEM, V269, P26591; Shallom S, 1999, J BIOL CHEM, V274, P37781, DOI 10.1074/jbc.274.53.37781; STROUD RM, 1994, NAT STRUCT BIOL, V1, P131, DOI 10.1038/nsb0394-131; Trujillo M, 1996, BIOCHEMISTRY-US, V35, P6366, DOI 10.1021/bi952923q; Tzipori S, 1998, ADV PARASIT, V40, P187, DOI 10.1016/S0065-308X(08)60121-9; Vasquez JR, 1996, MOL BIOCHEM PARASIT, V79, P153, DOI 10.1016/0166-6851(96)02647-3; Wattanarangsan J, 2003, MOL BIOCHEM PARASIT, V126, P97, DOI 10.1016/S0166-6851(02)00240-2; Yuvaniyama J, 2003, NAT STRUCT BIOL, V10, P357, DOI 10.1038/nsb921; Zhang K, 2002, SCIENCE, V296, P545, DOI 10.1126/science.1068274	31	24	24	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18314	18322		10.1074/jbc.M400009200	http://dx.doi.org/10.1074/jbc.M400009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966126	hybrid			2022-12-27	WOS:000221041500028
J	Cox, KH; Tate, JJ; Cooper, TG				Cox, KH; Tate, JJ; Cooper, TG			Actin cytoskeleton is required for nuclear accumulation of Gln3 in response to nitrogen limitation but not rapamycin treatment in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE HOMOLOG; DISRUPT MICROFILAMENT ORGANIZATION; RETROGRADE GENE-EXPRESSION; CATABOLITE REPRESSION; CELL-GROWTH; ENDOPLASMIC-RETICULUM; TOR PROTEINS; YEAST; LOCALIZATION; TARGET	Saccharomyces cerevisiae selectively utilizes good nitrogen sources in preference to poor ones by down-regulating transcription of genes encoding proteins that transport and degrade poor nitrogen sources when excess nitrogen is available. This regulation is designated nitrogen catabolite repression (NCR). When cells are transferred from a good to a poor nitrogen source ( glutamine to proline) or treated with rapamycin, an inhibitor of the protein kinases Tor1/2, Gln3 (NCR-sensitive transcription activator) moves from the cytoplasm into the nucleus. Gln3 re-accumulates in the cytoplasm when cells are returned to a good nitrogen source. However, Gln3 is not uniformly distributed in the cytoplasm. Such non-uniform distribution could result from a variety of interactions including association with a cytoplasmic vesicular system or components of the cytoskeleton. We used latrunculin, a drug that disrupts the actin cytoskeleton by inhibiting actin polymerization, to determine whether the actin cytoskeleton participates in intracellular Gln3 movement. Latrunculin-treatment prevents nuclear accumulation of Gln3 and NCR-sensitive transcription in cells transferred from ammonia to proline medium but does not prevent its accumulation in the cytoplasm of cells transferred from proline to glutamine medium. In contrast, rapamycin-induced nuclear accumulation of Gln3 is not demonstrably affected by latrunculin treatment. These data indicate the actin cytoskeleton is required for nuclear localization of Gln3 in response to limiting nitrogen but not rapamycin-treatment. Therefore, the actin cytoskeleton either participates in the response of Gln3 intracellular localization to nitrogen limitation before Tor1/2, or Tor1/2 inhibition only mimics the outcome of nitrogen limitation rather than directly regulating it.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NIGMS NIH HHS [R01 GM035642, GM-35642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Ayscough KR, 2000, CURR BIOL, V10, P1587, DOI 10.1016/S0960-9822(00)00859-9; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Belmont LD, 1998, J CELL BIOL, V142, P1289, DOI 10.1083/jcb.142.5.1289; Belmont LD, 1999, J CELL SCI, V112, P1325; Berg P, 2002, J BIOL CHEM, V277, P32310, DOI 10.1074/jbc.M203351200; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; Carvalho J, 2003, J BIOL CHEM, V278, P16878, DOI 10.1074/jbc.M300429200; Carvalho J, 2001, J BIOL CHEM, V276, P25359, DOI 10.1074/jbc.M103050200; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; Cooper TG, 1996, MYCOTA, V3, P139; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Cox KH, 2004, J BIOL CHEM, V279, P10270, DOI 10.1074/jbc.M312023200; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Dewar H, 2002, MOL BIOL CELL, V13, P3646, DOI 10.1091/mbc.E02-05-0262; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Fehrenbacher KL, 2002, MOL BIOL CELL, V13, P854, DOI 10.1091/mbc.01-04-0184; Garber PM, 2002, GENETICS, V161, P521; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kaminska J, 2002, MOL CELL BIOL, V22, P6946, DOI 10.1128/MCB.22.20.6946-6958.2002; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kulkarni AA, 2001, J BIOL CHEM, V276, P32136, DOI 10.1074/jbc.M104580200; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; Rai R, 2003, J BIOL CHEM, V278, P12826, DOI 10.1074/jbc.M212186200; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Tate JJ, 2003, J BIOL CHEM, V278, P36924, DOI 10.1074/jbc.M301829200; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; Zheng XF, 1997, P NATL ACAD SCI USA, V94, P3070, DOI 10.1073/pnas.94.7.3070; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	60	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19294	19301		10.1074/jbc.M309240200	http://dx.doi.org/10.1074/jbc.M309240200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970238	Green Accepted, hybrid			2022-12-27	WOS:000221041500143
J	Kevil, CG; Orr, AW; Langston, W; Mickett, K; Murphy-Ullrich, J; Patel, RP; Kucik, DF; Bullard, DC				Kevil, CG; Orr, AW; Langston, W; Mickett, K; Murphy-Ullrich, J; Patel, RP; Kucik, DF; Bullard, DC			Intercellular adhesion molecule-1 (ICAM-1) regulates endothelial cell motility through a nitric oxide-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; E-SELECTIN; IN-VITRO; ACTIN CYTOSKELETON; MONOCYTE ADHESION; MIGRATION SPEED; DEFICIENT MICE; KNOCKOUT MICE; ANGIOGENESIS; SYNTHASE	Coordinated regulation of endothelial cell migration is an integral process during angiogenesis. However, molecular mechanisms regulating endothelial cell migration remain largely unknown. Increased expression of cell adhesion molecules has been implicated during angiogenesis, yet the precise role of these molecules is unclear. Here, we examined the hypothesis that intercellular adhesion molecule-1 (ICAM-1) is important for endothelial cell migration. Total cell displacement and directional migration were significantly attenuated in ICAM-1-deficient endothelium. Closer examination of ICAM-1-deficient cells revealed decreased Akt Thr(308) and endothelial nitric-oxide synthase Ser(1177) phosphorylation and NO bioavailability, increased actin stress fiber formation, and a lack of distinct cell polarity compared with wild-type endothelium. Supplementation of ICAM-1 mutant cells with the NO donor DETA NONOate (0.1 muM) corrected the migration defect, diminished stress fiber formation, and enhanced pseudopod and uropod formation. These data demonstrate that ICAM-1 facilitates the development of cell polarity and modulates endothelial cell migration through a pathway regulating endothelial nitric-oxide synthase activation and organization of the actin cytoskeleton.	Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; Univ Alabama Birmingham, Dept Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Gen & Pathobiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Res Serv, Birmingham, AL 35294 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kevil, CG (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, 1501 Kings Highway, Shreveport, LA 71130 USA.	ckevil@lsuhsc.edu	Orr, Anthony/P-8927-2015; Kevil, Christopher/G-9318-2011	Orr, Anthony/0000-0002-2377-213X; Patel, Rakesh/0000-0002-1526-4303; Kevil, Christopher/0000-0003-0863-7260	NCRR NIH HHS [RR-17009] Funding Source: Medline; NHLBI NIH HHS [HL-010312, HL-70146, HL-07918, HL-44575] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR017009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010312, R01HL070146, R01HL044575] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baldwin AL, 1998, AM J PHYSIOL-HEART C, V274, pH1776, DOI 10.1152/ajpheart.1998.274.5.H1776; Bauer PM, 2003, J BIOL CHEM, V278, P14841, DOI 10.1074/jbc.M211926200; Boyle JJ, 2000, J PATHOL, V192, P234; Brandes RP, 2000, HYPERTENSION, V35, P231, DOI 10.1161/01.HYP.35.1.231; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Dedio J, 2001, FASEB J, V15, P79, DOI 10.1096/fj.00-0078com; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DUNN GA, 1980, EUR J CANCER, V16, P6, DOI 10.1016/0014-2964(80)90096-1; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Federici C, 1996, EUR J BIOCHEM, V238, P173, DOI 10.1111/j.1432-1033.1996.0173q.x; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gho YS, 1999, CANCER RES, V59, P5128; Goligorsky MS, 1999, AM J PHYSIOL-CELL PH, V276, pC1271, DOI 10.1152/ajpcell.1999.276.6.C1271; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Hussain MB, 1999, BRIT J PHARMACOL, V128, P1082, DOI 10.1038/sj.bjp.0702874; JIANYING L, 1999, BLOOD, V93, P3785; Ke XC, 2001, BBA-MOL CELL RES, V1539, P101, DOI 10.1016/S0167-4889(01)00090-8; Kevil CG, 2000, AM J PHYSIOL-CELL PH, V279, pC21, DOI 10.1152/ajpcell.2000.279.1.C21; Kevil CG, 2001, ACTA PHYSIOL SCAND, V173, P151, DOI 10.1046/j.1365-201X.2001.00901.x; Kevil CG, 2001, ENDOTHELIUM-J ENDOTH, V8, P107, DOI 10.3109/10623320109165320; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1442, DOI 10.1152/ajpcell.2001.281.5.C1442; Kevil Christopher G., 2003, Pathophysiology, V9, P63, DOI 10.1016/S0928468002000834; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; KWEE L, 1995, DEVELOPMENT, V121, P489; Kwon HM, 1998, J CLIN INVEST, V101, P1551, DOI 10.1172/JCI1568; Lee PC, 1999, AM J PHYSIOL-HEART C, V277, pH1600, DOI 10.1152/ajpheart.1999.277.4.H1600; Marley R, 2001, FREE RADICAL BIO MED, V31, P688, DOI 10.1016/S0891-5849(01)00627-X; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Montrucchio G, 1997, AM J PATHOL, V151, P557; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Noiri E, 1998, AM J PHYSIOL-CELL PH, V274, pC236, DOI 10.1152/ajpcell.1998.274.1.C236; Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Papapetropoulos A, 1997, AM J PATHOL, V150, P1835; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rikitake Y, 2002, ARTERIOSCL THROM VAS, V22, P108, DOI 10.1161/hq0102.101843; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Scotland RS, 2002, CIRC RES, V90, P904, DOI 10.1161/01.RES.0000016506.04193.96; Skidgel RA, 2002, AM J PHYSIOL-LUNG C, V282, pL1179, DOI 10.1152/ajplung.00045.2002; Su YC, 2003, AM J PHYSIOL-CELL PH, V284, pC1542, DOI 10.1152/ajpcell.00248.2002; Tilghman RW, 2002, FASEB J, V16, P1257, DOI 10.1096/fj.01-0969fje; Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Yasuda M, 2002, AM J PHYSIOL-CELL PH, V282, pC917, DOI 10.1152/ajpcell.00223.2001; Yasuda M, 2000, LIFE SCI, V66, P2113, DOI 10.1016/S0024-3205(00)00537-3; Zharikov SI, 2001, AM J PHYSIOL-LUNG C, V280, pL465, DOI 10.1152/ajplung.2001.280.3.L465; Zicha D, 1997, Methods Mol Biol, V75, P449; ZICHA D, 1991, J CELL SCI, V99, P769; Ziche M, 2000, J NEURO-ONCOL, V50, P139, DOI 10.1023/A:1006431309841; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; Zimmermann K, 2002, P NATL ACAD SCI USA, V99, P17167, DOI 10.1073/pnas.252345399	62	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19230	19238		10.1074/jbc.M312025200	http://dx.doi.org/10.1074/jbc.M312025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985356	hybrid			2022-12-27	WOS:000221041500136
J	Liu, Q; Liang, XH; Uliel, S; Belahcen, M; Unger, R; Michaeli, S				Liu, Q; Liang, XH; Uliel, S; Belahcen, M; Unger, R; Michaeli, S			Identification and functional characterization of Lsm proteins in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SM-LIKE PROTEINS; MESSENGER-RNA DEGRADATION; SMALL NUCLEAR RIBONUCLEOPROTEINS; SNRNP CORE; U6 SNRNA; CRYSTAL-STRUCTURE; LA PROTEIN; IN-VITRO; COMPLEX; GENE	RNA interference of Sm proteins in Trypanosoma brucei demonstrated that the stability of the small nuclear RNAs (U1, U2, U4, U5) and the spliced leader RNA, but not U6 RNA, were affected upon Sm depletion (Mandelboim, M., Barth, S., Biton, M., Liang, X. H., and Michaeli, S. ( 2003) J. Biol. Chem. 278, 51469 - 51478), suggesting that Lsm proteins that bind and stabilize U6 RNA in other eukaryotes should exist in trypanosomes. In this study, we identified seven Lsm proteins (Lsm2p to Lsm8p) and examined the function of Lsm3p and Lsm8p by RNA interference silencing. Both Lsm proteins were found to be essential for U6 stability and mRNA decay. Silencing was lethal, and cis- and trans-splicing were inhibited. Importantly, silencing also affected the level of U4. U6 and the U4. U6/U5 tri-small nuclear ribonucleoprotein complexes. The presence of Lsm proteins in trypanosomes that diverged early in the eukaryotic lineage suggests that these proteins are highly conserved in both structure and function among eukaryotes. Interestingly, however, Lsm1p that is specific to the mRNA decay complex was not identified in the genome data base of any kinetoplastidae, and the Lsm8p that in other eukaryotes exclusively functions in U6 stability was found to function in trypanosomes also in mRNA decay. These data therefore suggest that in trypanosomes only a single Lsm complex may exist.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	michaes@mail.biu.ac.il	Michaeli, Shulamit/AAC-8255-2022					Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Arluison V, 2002, J MOL BIOL, V320, P705, DOI 10.1016/S0022-2836(02)00548-X; Boeck R, 1998, MOL CELL BIOL, V18, P5062, DOI 10.1128/MCB.18.9.5062; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Campbell DA, 2000, PARASITOL TODAY, V16, P78, DOI 10.1016/S0169-4758(99)01545-8; Collins BM, 2001, J MOL BIOL, V309, P915, DOI 10.1006/jmbi.2001.4693; COOPER M, 1995, EMBO J, V14, P2066, DOI 10.1002/j.1460-2075.1995.tb07198.x; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; Goncharov I, 1999, J BIOL CHEM, V274, P12217, DOI 10.1074/jbc.274.18.12217; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; He WH, 2000, CURR OPIN CELL BIOL, V12, P346, DOI 10.1016/S0955-0674(00)00098-3; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; KASTNER B, 1990, P NATL ACAD SCI USA, V87, P1710, DOI 10.1073/pnas.87.5.1710; Kufel J, 2003, J BIOL CHEM, V278, P2147, DOI 10.1074/jbc.M208856200; Kufel J, 2002, MOL CELL BIOL, V22, P5248, DOI 10.1128/MCB.22.14.5248-5256.2002; Liang XH, 2003, EUKARYOT CELL, V2, P830, DOI 10.1128/EC.2.5.830-840.2003; Liang XH, 2002, RNA, V8, P237, DOI 10.1017/S1355838202018290; Lucke S, 1997, EMBO J, V16, P4433, DOI 10.1093/emboj/16.14.4433; Mair G, 2000, RNA, V6, P163, DOI 10.1017/S135583820099229X; Mandelboim M, 2003, J BIOL CHEM, V278, P51469, DOI 10.1074/jbc.M308997200; Marchetti MA, 2000, J CELL SCI, V113, P899; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; Mura C, 2001, P NATL ACAD SCI USA, V98, P5532, DOI 10.1073/pnas.091102298; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; Palfi Z, 2000, P NATL ACAD SCI USA, V97, P8967, DOI 10.1073/pnas.150236097; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; Pillai RS, 2001, EMBO J, V20, P5470, DOI 10.1093/emboj/20.19.5470; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Stevens JR, 1999, PARASITOL TODAY, V15, P432, DOI 10.1016/S0169-4758(99)01532-X; TERNS MP, 1992, MOL CELL BIOL, V12, P3032, DOI 10.1128/MCB.12.7.3032; Tomasevic N, 2002, MOL CELL BIOL, V22, P4101, DOI 10.1128/MCB.22.12.4101-4112.2002; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; Xu YX, 2001, J BIOL CHEM, V276, P14289, DOI 10.1074/jbc.M007007200; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3	47	189	206	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18210	18219		10.1074/jbc.M400678200	http://dx.doi.org/10.1074/jbc.M400678200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14990572	hybrid			2022-12-27	WOS:000221041500016
J	Shin, JH; Namkung, W; Choi, JY; Yoon, JH; Lee, MG				Shin, JH; Namkung, W; Choi, JY; Yoon, JH; Lee, MG			Purinergic stimulation induces Ca2+-dependent activation of Na+-K+-2Cl(-) cotransporter in human nasal epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; SUBMANDIBULAR-GLAND ACINAR; K-CL COTRANSPORTER; DUCT CELLS; CHLORIDE SECRETION; P-2 RECEPTORS; EXPRESSION; MEMBRANE; MECHANISMS; CHANNELS	Increasing evidence suggests that P2 receptors (P2Rs) in airway epithelial cells perform critical functions in auto- or paracrine regulation of fluid and mucus secretion. In the present study, we characterized the effects of P2R stimulation on Na+-K+-2Cl(-) cotransporter (NKCC) activity in normal human nasal epithelial (NHNE) cells. [Ca2+](i) and pH(i) were measured in primary cultures of NHNE cells using a double perfusion chamber, which enabled us to analyze membrane-specific transporter activities. NKCC activities were estimated by the pHi reduction due to Na+-dependent and bumetanide-sensitive intracellular uptake of NH4+. NKCC activities were observed in the basolateral membrane, but not in the luminal membrane, of NHNE cells. Interestingly, P2Rs were expressed in both membranes, and the stimulation of either luminal or basolateral P2R increased NKCC activity. Blockades of luminal Cl- channels, basolateral K+ channels, or protein kinase C did not affect the activation of NKCC by basolateral P2R stimulation. The effects of luminal P2R stimulation were partially reduced by Cl- channel blockers. However, chelation of intracellular Ca2+ by 1,2-bis(2-aminophenoxy) ethane- N, N, N', N'-tetraacetic acid (BAPTA) treatment completely blocked the stimulatory effects of luminal and basolateral P2Rs on NKCC. In addition, increasing [Ca2+](i) by treatment with ionomycin-stimulated NKCC activity. These results provide evidence that stimulation of P2Rs directly activates basolateral NKCC by Ca2+-dependent pathways in NHNE cells, which is an important aspect of the purinergic regulation of ion and fluid secretions in human airway epithelia under physiologic and pathologic conditions.	Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Lee, MG (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, 134 Sinchon Dong, Seoul 120752, South Korea.	mlee@yumc.yonsei.ac.kr	Lee, Min Goo/D-5635-2012; Yoon, Joo-Heon/E-5781-2016; Lee, Min Goo/AAS-4636-2020	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X; choi, jae young/0000-0001-9493-3458; Yoon, Joo-Heon/0000-0003-2404-7156				Bergeron MJ, 2003, AM J PHYSIOL-RENAL, V285, pF68, DOI 10.1152/ajprenal.00032.2003; Brindikova TA, 2003, AM J PHYSIOL-CELL PH, V285, pC1445, DOI 10.1152/ajpcell.00386.2002; Donaldson SH, 2003, CURR OPIN PULM MED, V9, P486, DOI 10.1097/00063198-200311000-00007; Eccles R, 2000, AM J RHINOL, V14, P335, DOI 10.2500/105065800781329528; Evans RL, 1997, J PHYSIOL-LONDON, V499, P351, DOI 10.1113/jphysiol.1997.sp021932; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; HAAS M, 1993, AM J PHYSIOL, V264, pC189, DOI 10.1152/ajpcell.1993.264.1.C189; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Jun ES, 2001, LIFE SCI, V68, P827, DOI 10.1016/S0024-3205(00)00985-1; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Lee JH, 2003, HUM MOL GENET, V12, P2321, DOI 10.1093/hmg/ddg243; Lee MG, 1998, J PHYSIOL-LONDON, V513, P341, DOI 10.1111/j.1469-7793.1998.341bb.x; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; Liedtke CM, 2002, AM J PHYSIOL-LUNG C, V282, pL1151, DOI 10.1152/ajplung.00143.2001; Matthews JB, 2002, WORLD J SURG, V26, P826, DOI 10.1007/s00268-002-4059-z; MUALLEM S, 1990, J BIOL CHEM, V265, P12813; Namkung W, 2003, J BIOL CHEM, V278, P200, DOI 10.1074/jbc.M207199200; ONEILL WC, 1995, AM J PHYSIOL-CELL PH, V269, pC267, DOI 10.1152/ajpcell.1995.269.1.C267; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; QUINTON PM, 1994, 2 J LEV LECT CYST FI, P26; QUINTON PM, 1999, PHYSIOL REV, V79, P3; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; Song KS, 2003, J BIOL CHEM, V278, P34890, DOI 10.1074/jbc.M303911200; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252; Yoon JH, 2000, ANN OTO RHINOL LARYN, V109, P594, DOI 10.1177/000348940010900612; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956	29	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18567	18574		10.1074/jbc.M400639200	http://dx.doi.org/10.1074/jbc.M400639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14982922	hybrid			2022-12-27	WOS:000221041500059
J	Cheong, CG; Wolan, DW; Greasley, SE; Horton, PA; Beardsley, GP; Wilson, IA				Cheong, CG; Wolan, DW; Greasley, SE; Horton, PA; Beardsley, GP; Wilson, IA			Crystal structures of human bifunctional enzyme aminoimidazole-4-carboxamide ribonucleotide transformylase/IMP cyclohydrolase in complex with potent sulfonyl-containing antifolates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN AICAR TRANSFORMYLASE; CATALYTIC MECHANISM; GAR TFASE; IMP CYCLOHYDROLASE; INHIBITOR; ACID; DOMAIN; 10-FORMYL-TDAF; METHOTREXATE; INSIGHTS	Aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase/IMP cyclohydrolase (ATIC) is a bifunctional enzyme with folate-dependent AICAR transformylase and IMP cyclohydrolase activities that catalyzes the last two steps of purine biosynthesis. The AICAR transformylase inhibitors BW1540 and BW2315 are sulfamido-bridged 5,8-dideazafolate analogs with remarkably potent K-i values of 8 and 6 nM, respectively, compared with most other antifolates. Crystal structures of ATIC at 2.55 and 2.60 Angstrom with each inhibitor, in the presence of substrate AICAR, revealed that the sulfonyl groups dominate inhibitor binding and orientation through interaction with the proposed oxyanion hole. These agents then appear to mimic the anionic transition state and now implicate Asn(431') in the reaction mechanism along with previously identified key catalytic residues Lys(266) and His(267). Potent and selective inhibition of the AICAR transformylase active site, compared with other folate-dependent enzymes, should therefore be pursued by further design of sulfonyl-containing antifolates.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Yale Univ, Sch Med, Dept Pediat & Pharmacol, New Haven, CT 06520 USA	Scripps Research Institute; Scripps Research Institute; Yale University	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu		Wolan, Dennis/0000-0001-9879-8353	NATIONAL CANCER INSTITUTE [P01CA063536] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA63536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; American Cancer Society, 2002, CANC FACTS FIG 2002; Andersson J, 2001, J BIOL CHEM, V276, P40457, DOI 10.1074/jbc.M106863200; BAGGOTT JE, 1986, BIOCHEM J, V236, P193, DOI 10.1042/bj2360193; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beardsley GP, 1998, ADV EXP MED BIOL, V431, P221; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BEARDSLEY GP, 1997, PURINE PYRIMIDINE ME, P221; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boger DL, 2000, BIOORGAN MED CHEM, V8, P1075, DOI 10.1016/S0968-0896(00)00051-1; Boger DL, 1997, BIOORGAN MED CHEM, V5, P1847, DOI 10.1016/S0968-0896(97)00123-5; Boger DL, 1997, BIOORGAN MED CHEM, V5, P1853, DOI 10.1016/S0968-0896(97)00124-7; Boger DL, 1997, BIOORGAN MED CHEM, V5, P1817, DOI 10.1016/S0968-0896(97)00120-X; Boger DL, 1997, BIOORGAN MED CHEM, V5, P1831, DOI 10.1016/S0968-0896(97)00121-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulock KG, 2002, J BIOL CHEM, V277, P22168, DOI 10.1074/jbc.M111964200; Calvert H, 1999, SEMIN ONCOL, V26, P3; Cambillau C, 1996, CURR OPIN STRUC BIOL, V6, P449, DOI 10.1016/S0959-440X(96)80108-4; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DeLano W.L, PYMOL MOL GRAPHICS S; ERBA E, 1994, BRIT J CANCER, V69, P205, DOI 10.1038/bjc.1994.40; Greasley SE, 2001, NAT STRUCT BIOL, V8, P402, DOI 10.1038/87555; Hallberg BM, 2000, STRUCT FOLD DES, V8, P79, DOI 10.1016/S0969-2126(00)00082-4; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jackson RC., 1981, NUCLEOSIDES CANC TRE, P18; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIDE DR, 1995, CRC HDB CHEM PHYS, V9, P15; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Rotsaert FAJ, 2003, BIOCHEMISTRY-US, V42, P4049, DOI 10.1021/bi027092k; Roussel A., 1991, SILICON GRAPHICS GEO, V86; Shim JH, 2001, J AM CHEM SOC, V123, P4687, DOI 10.1021/ja010014k; SMITH GK, 1982, BIOCHEMISTRY-US, V21, P2870, DOI 10.1021/bi00541a010; STURA EA, 1991, J CRYST GROWTH, V110, P270, DOI 10.1016/0022-0248(91)90896-D; Su Y, 1998, J MOL BIOL, V281, P485, DOI 10.1006/jmbi.1998.1931; Sugita T, 1997, J BIOCHEM-TOKYO, V122, P309; Vergis JM, 2004, BIOCHEMISTRY-US, V43, P1184, DOI 10.1021/bi035139b; Wlodawer A, 2003, ACTA BIOCHIM POL, V50, P81; Wolan DW, 2004, BIOCHEMISTRY-US, V43, P1171, DOI 10.1021/bi030162i; Wolan DW, 2003, BIOCHEMISTRY-US, V42, P10904, DOI 10.1021/bi030106h; Wolan DW, 2002, BIOCHEMISTRY-US, V41, P15505, DOI 10.1021/bi020505x; Zhang Y, 2003, BIOCHEMISTRY-US, V42, P6043, DOI 10.1021/bi034219c	45	36	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					18034	18045		10.1074/jbc.M313691200	http://dx.doi.org/10.1074/jbc.M313691200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14966129	hybrid			2022-12-27	WOS:000220870400139
J	Shi, CS; Kehrl, JH				Shi, CS; Kehrl, JH			Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; TYROSINE KINASE; ANGIOTENSIN-II; PROTEIN-KINASE; RAC ACTIVATION; PHOSPHORYLATION; FAMILY; CELLS; TRANSFORMATION; TRANSCRIPTION	Signal transducers and activators of transcription factors (STATs) mediate many of the cellular responses that occur following cytokine, growth factor, and hormone signaling. STATs are activated by tyrosine and serine phosphorylation, which normally occurs as a tightly regulated process. Dysregulated STAT activity may facilitate oncogenesis, as constitutively activated STATs have been found in many human tumors as well as in v-abl- and v-src-transformed cell lines. Pyk2 is a member of the focal adhesion kinase family and can be activated by c-Src, epidermal growth factor receptor ( EGFR), Janus kinase 1, tyrosine kinases, and G-protein-coupled receptor signaling. Although Pyk2 has been implicated in Janus kinase-dependent activation of MAPK and Stat1, no role for Pyk2 in the activation of other STAT proteins has been ascribed. Here, we provide evidence that Pyk2, along with c-Src, facilitates EGFR-mediated Stat3 activation. Pyk2 expression in HeLa cells induces Stat3 reporter gene activation and Stat3 phosphorylation on amino acid residues Tyr-705 and Ser-727. Together Pyk2 and c-Src potently activate Stat3, and Pyk2 enhances Stat3-induced cell proliferation. Moreover, the expression of a dominant negative version of Pyk2 impairs c-Src-induced Stat3 activation and cell proliferation. The treatment of A431 cells with EGF results in the recruitment of c-Src, Pyk2, and Stat3 to the EGFR and the phosphorylation of c-Src, Pyk2, and Stat3. Expression of constructs for dominant negative forms of either Pyk2 or c-Src impair EGF-induced Stat3 phosphorylation. These results indicate that Pyk2 facilitates EGFR- and c-Src-mediated Stat3 activation, thereby implicating Pyk2 activation as a potential co-mediator in triggering Stat3-induced oncogenesis.	NIAID, Cell Mol Immunol Sect, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kehrl, JH (corresponding author), NIAID, Cell Mol Immunol Sect, Immunoregulat Lab, NIH, Bldg 10,Rm 11B08,10 Ctr DR MSC 1876, Bethesda, MD 20892 USA.	jkehrl@atlas.niaid.nih.gov	Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000739, ZIAAI000739] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akaishi H, 1998, INT IMMUNOL, V10, P1747, DOI 10.1093/intimm/10.11.1747; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; Frank GD, 2002, MOL ENDOCRINOL, V16, P367, DOI 10.1210/me.16.2.367; Gismondi A, 2003, J IMMUNOL, V170, P3065, DOI 10.4049/jimmunol.170.6.3065; Guinamard R, 2000, NAT IMMUNOL, V1, P31, DOI 10.1038/76882; Haq R, 2002, J BIOL CHEM, V277, P17359, DOI 10.1074/jbc.M201842200; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Lukashova V, 2003, J IMMUNOL, V171, P3794, DOI 10.4049/jimmunol.171.7.3794; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Pelletier S, 2003, MOL CELL BIOL, V23, P1316, DOI 10.1128/MCB.23.4.1316-1333.2003; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Sano S, 2001, IMMUNITY, V15, P261, DOI 10.1016/S1074-7613(01)00180-7; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Schweizer U, 2002, J CELL BIOL, V156, P287, DOI 10.1083/jcb.200107009; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu EHT, 2003, BIOCHEM BIOPH RES CO, V303, P920, DOI 10.1016/S0006-291X(03)00451-0; Xu B, 2003, MOL CELL BIOL, V23, P3918, DOI 10.1128/MCB.23.11.3918-3928.2003; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	62	36	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17224	17231		10.1074/jbc.M311875200	http://dx.doi.org/10.1074/jbc.M311875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14963038	hybrid			2022-12-27	WOS:000220870400043
J	Xu, C; Ma, HL; Inesi, G; Al-Shawi, MK; Toyoshima, C				Xu, C; Ma, HL; Inesi, G; Al-Shawi, MK; Toyoshima, C			Specific structural requirements for the inhibitory effect of thapsigargin on the Ca2+ ATPase SERCA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; HUMAN P-GLYCOPROTEIN; TRANSITION-STATE ANALYSIS; TRANSPORT ATPASE; CALCIUM-PUMP; MEDIATE RESISTANCE; THAPSIA-GARGANICA; DRUG-BINDING; MECHANISM; EXPRESSION	Mutational analysis of amino acid residues lining the thapsigargin (TG) binding cavity at the interface of the membrane surface and cytosolic headpiece was performed in the Ca2+ ATPase (SERCA-1). Specific mutations such as F256V, I765A, and Y837A reduce not only the apparent affinity of the ATPase for TG but also the maximal inhibitory effect. The effect of mutations is dependent on the type and size of the substitute side chain, indicating that hydrophobic partitioning of TG and complementary molecular shapes are involved not only in binding but also in the inhibitory mechanism. A major factor determining the inhibitory effect of bound TG is its interference with conformational changes that are required for the progress of the ATPase cycle. Most prominent and specific is the TG interference with a wide displacement of the Phe-256 side chain that is associated with the E2 to E1.2Ca(2+) transition. The specificity of the TG inhibitory mechanism is emphasized by the finding that the F256V mutation does not interfere at all with the effect of 2,5-di-(t-butyl)-hydroquinone, which is another SERCA inhibitor bound by hydrophobic partitioning. The specificity of the inhibitory mechanism is also emphasized by the observation that within the concentration range producing total inhibition of wild-type SERCA-1, TG produces a 4-fold stimulation of the P-glycoprotein (multidrug transporter) ATPase.	Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA; Univ Virginia Syst, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan	University System of Maryland; University of Maryland Baltimore; University of Virginia; University of Tokyo	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA.	ginesi@umaryland.edu	Toyoshima, Chikashi/R-4153-2019	Toyoshima, Chikashi/0000-0001-9640-0778	NHLBI NIH HHS [R01HL69380] Funding Source: Medline; PHS HHS [R01-52502] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Al-Shawi MK, 2003, J BIOL CHEM, V278, P52629, DOI 10.1074/jbc.M308175200; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12961, DOI 10.1021/bi971478r; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; CHRISTENSEN SB, 1982, J ORG CHEM, V47, P649; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; Denmeade SR, 2003, J NATL CANCER I, V95, P990, DOI 10.1093/jnci/95.13.990; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Figler RA, 2000, ARCH BIOCHEM BIOPHYS, V376, P34, DOI 10.1006/abbi.2000.1712; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GUTHEIL JC, 1994, J BIOL CHEM, V269, P7976; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUA SM, 1995, BIOCHEMISTRY-US, V34, P5137, DOI 10.1021/bi00015a026; Hua SM, 1997, BIOCHEMISTRY-US, V36, P11865, DOI 10.1021/bi970105n; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; KHAN YM, 1995, BIOCHEMISTRY-US, V34, P14385, DOI 10.1021/bi00044a015; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lee AG, 2002, BBA-BIOMEMBRANES, V1565, P246, DOI 10.1016/S0005-2736(02)00573-4; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; LYTTON J, 1991, J BIOL CHEM, V266, P17067; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; Raeymaekers Luc, 2002, Novartis Found Symp, V246, P71; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; ZHANG Z, 1995, J BIOL CHEM, V270, P16283; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	42	52	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17973	17979		10.1074/jbc.M313263200	http://dx.doi.org/10.1074/jbc.M313263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970206	hybrid			2022-12-27	WOS:000220870400132
J	Sanchez-Martin, L; Sanchez-Sanchez, N; Gutierrez-Lopez, MD; Rojo, AI; Vicente-Manzanares, M; Perez-Alvarez, MJ; Sanchez-Mateos, P; Bustelo, XR; Cuadrado, A; Sanchez-Madrid, F; Rodriguez-Fernandez, JL; Cabanas, C				Sanchez-Martin, L; Sanchez-Sanchez, N; Gutierrez-Lopez, MD; Rojo, AI; Vicente-Manzanares, M; Perez-Alvarez, MJ; Sanchez-Mateos, P; Bustelo, XR; Cuadrado, A; Sanchez-Madrid, F; Rodriguez-Fernandez, JL; Cabanas, C			Signaling through the leukocyte integrin LFA-1 in T cells induces a transient activation of Rac-1 that is regulated by Vav and PI3K/Akt-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; TYROSINE KINASE PYK2; RHO FAMILY GTPASES; HUMAN NEUTROPHILS; PHOSPHATIDYLINOSITOL 3-KINASE; INTERCELLULAR-ADHESION; PROTOONCOGENE PRODUCT; BIOLOGICAL-ACTIVITY; PHOSPHORYLATION; LYMPHOCYTES	Integrin LFA-1 is a receptor that is able to transmit multiple intracellular signals in leukocytes. Herein we show that LFA-1 induces a potent and transient increase in the activity of the small GTPase Rac-1 in T cells. Maximal Rac-1 activity peaked 10-15 min after LFA-1 stimulation and rapidly declined to basal levels at longer times. We have identified Vav, a guanine nucleotide exchange factor for Rac-1, and PI3K/Akt, as regulators of the activation and inactivation phases of the activity of Rac-1, respectively, in the context of LFA-1 signaling based on the following experimental evidence: (i) LFA-1 induced activation of Vav and PI3K/Akt with kinetics consistent with a regulatory role for these molecules on Rac-1, (ii) overexpression of a constitutively active Vav mutant induces activation of Rac independently of LFA-1 stimulation whereas overexpression of a dominant-negative Vav mutant blocks LFA-1-mediated Rac activation, (iii) pharmacological inhibition of PI3K/Akt prevented the fall in the activity of Rac-1 after its initial activation but had no effect on Vav activity, and (iv) overexpression of a dominant-negative or a constitutively active Akt-1 induced or inhibited, respectively, Rac-1 activity. Finally, we show that T cells with a sustained Rac activity have impaired capacity to elongate onto ICAM-1. These results demonstrate that down-regulation of the activity of this GTPase is a requirement for the regulation of T cell morphology and motility and highlight the importance of temporal regulation of the signaling triggered from this integrin.	Univ Complutense Madrid, Fac Med, CSIC, Inst Farmacol & Toxicol, E-28040 Madrid, Spain; Univ Autonoma Madrid, Fac Med, CSIC, Dept Bioquim, E-28029 Madrid, Spain; Hosp Gen Gregorio Maranon, Secc Inmunooncol, Madrid 28007, Spain; Hosp Princesa, Serv Inmunol, Madrid 28006, Spain; Univ Salamanca, CSIC, Ctr Invest Canc, Salamanca 37007, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); General University Gregorio Maranon Hospital; Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Cabanas, C (corresponding author), Univ Complutense Madrid, Fac Med, CSIC, Inst Farmacol & Toxicol, Pabellon 3, E-28040 Madrid, Spain.	cacabagu@med.ucm.es	Vicente-Manzanares, Miguel/H-1010-2018; Bustelo, Xose R./AAD-2081-2022; Alvarez, Maria Jose Pérez/B-9768-2012; Sanchez-Mateos, Paloma/E-8931-2013; Sanchez-Madrid, Francisco/M-7889-2016; Rodriguez-Fernandez, Jose Luis/Q-5021-2019; Rojo, Ana I/AAA-5203-2019; Bustelo, Xose R./A-9526-2010; CABAÑAS, CARLOS/J-4595-2012; MD, Gutierrez-Lopez/P-2965-2014	Vicente-Manzanares, Miguel/0000-0001-5943-3220; Bustelo, Xose R./0000-0001-9398-6072; Alvarez, Maria Jose Pérez/0000-0001-8334-8085; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Rodriguez-Fernandez, Jose Luis/0000-0001-8874-1425; Bustelo, Xose R./0000-0001-9398-6072; CABAÑAS, CARLOS/0000-0002-8767-060X; Rojo, Ana I/0000-0002-0312-5867; Cuadrado, Antonio/0000-0002-4039-7140; Sanchez-Mateos, Paloma/0000-0001-6589-4445; Cuadrado, Antonio/0000-0002-3444-9012				Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DEL PL, 1997, SCIENCE, V278, P687; del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; Dib K, 2003, J BIOL CHEM, V278, P24181, DOI 10.1074/jbc.M302300200; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Gahmberg CG, 1998, CELL MOL LIFE SCI, V54, P549, DOI 10.1007/s000180050183; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Jones GE, 1998, CELL ADHES COMMUN, V6, P237, DOI 10.3109/15419069809004479; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Niggli V, 1997, EUR J PHARMACOL, V335, P43, DOI 10.1016/S0014-2999(97)01169-2; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; Porter JC, 2002, J IMMUNOL, V168, P6330, DOI 10.4049/jimmunol.168.12.6330; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, FEBS LETT, V498, P168, DOI 10.1016/S0014-5793(01)02481-4; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Rodriguez-Fernandez JL, 1999, MOL BIOL CELL, V10, P1891, DOI 10.1091/mbc.10.6.1891; Rodriguez-Fernandez JL, 2002, J LEUKOCYTE BIOL, V71, P520; Rodriguez-Fernandez JL, 2001, J BIOL CHEM, V276, P40518, DOI 10.1074/jbc.M102896200; Salinas M, 2001, MOL CELL NEUROSCI, V17, P67, DOI 10.1006/mcne.2000.0921; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Serrador JM, 1999, TRENDS CELL BIOL, V9, P228, DOI 10.1016/S0962-8924(99)01553-6; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; Vicente-Manzanares M, 1999, J IMMUNOL, V163, P4001; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	63	52	53	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16194	16205		10.1074/jbc.M400905200	http://dx.doi.org/10.1074/jbc.M400905200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14960575	Green Published, hybrid			2022-12-27	WOS:000220747900062
J	Duda, K; Chi, YI; Shoelson, SE				Duda, K; Chi, YI; Shoelson, SE			Structural basis for HNF-4 alpha activation by ligand and coactivator binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; NUCLEAR FACTOR-4-ALPHA GENE; UPSTREAM PROMOTER REGION; CRYSTAL-STRUCTURE; RESPONSE ELEMENT; NATURAL LIGAND; RETINOIC ACID; TRANSCRIPTIONAL REGULATION; ANDROGEN RECEPTOR; VISCERAL ENDODERM	In addition to suggesting that fatty acids are endogenous ligands, our recent crystal structure of HNF-4alpha showed an unusual degree of structural flexibility in the AF-2 domain (helix alpha12). Although every molecule contained a fatty acid within its ligand binding domain, one molecule in each homodimer was in an open inactive conformation with alpha12 fully extended and colinear with alpha10. By contrast, the second molecule in each homodimer was in a closed conformation with alpha12 folded against the body of the domain in what is widely considered to be the active state. This indicates that although ligand binding is necessary, it is not sufficient to induce an activating structural transition in HNF-4alpha as is commonly suggested to occur for nuclear receptors. To further assess potential mechanisms of activation, we have solved a structure of human HNF-4alpha bound to both fatty acid ligand and a coactivator sequence derived from SRC-1. The mode of coactivator binding is similar to that observed for other nuclear receptors, and in this case, all of the molecules adopt the closed active conformation. We conclude that for HNF-4alpha, coactivator rather than ligand binding locks the active conformation.	Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Shoelson, SE (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	Steven.Shoelson@joslin.harvard.edu			NIDDK NIH HHS [T32 DK07260, R01 DK43123, DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, T32DK007260, R01DK043123] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Duncan SA, 1997, DEVELOPMENT, V124, P279; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Love-Gregory LD, 2004, DIABETES, V53, P1134, DOI 10.2337/diabetes.53.4.1134; Malecki MT, 1999, DIABETIC MED, V16, P193, DOI 10.1046/j.1464-5491.1999.00073.x; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Silander K, 2004, DIABETES, V53, P1141, DOI 10.2337/diabetes.53.4.1141; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Watkins RE, 2003, J MOL BIOL, V331, P815, DOI 10.1016/S0022-2836(03)00795-2; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198	41	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23311	23316		10.1074/jbc.M400864200	http://dx.doi.org/10.1074/jbc.M400864200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	14982928	hybrid			2022-12-27	WOS:000221570900065
J	Lindquist, JN; Parsons, CJ; Stefanovic, B; Brenner, DA				Lindquist, JN; Parsons, CJ; Stefanovic, B; Brenner, DA			Regulation of alpha 1(I) collagen messenger RNA decay by interactions with alpha CP at the 3 '-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; 3' UNTRANSLATED REGION; POLY(C) BINDING-PROTEIN; KH-DOMAIN PROTEINS; FAT-STORING CELLS; MAMMALIAN-CELLS; IN-VITRO; STABILITY COMPLEX; RAT-LIVER; ENDORIBONUCLEASE ACTIVITY	Liver fibrosis is characterized by an increased deposition of extracellular matrix proteins, including collagen type I, by activated hepatic stellate cells (HSCs). Previous studies have shown that this increase is mediated primarily by a post-transcriptional mechanism. In particular, the RNA-binding protein alphaCP binds to the alpha1(I) collagen 3'-untranslated region (UTR) and stabilizes this RNA in activated, but not quiescent, HSCs. This study examines the role of alphaCP in the decay of transcripts containing the collagen 3'-UTR in extracts obtained from NIH fibroblasts and quiescent and activated HSCs. Using an in vitro decay system, alphaCP binding activity was competed out with the addition of wild type oligonucleotides, but not with mutant oligonucleotides. Competition of alphaCP binding activity increased the rate of decay of wild type transcripts containing the alphaCP 3'-UTR binding site, but not of transcripts containing a mutated binding site. Quiescent HSC extracts contain no alphaCP binding activity and have no difference in the rate of decay of transcripts with wild type and mutant binding sites for alphaCP. The addition of recombinant alphaCP was sufficient to increase the half-life of the wild type transcript, whereas that of the mutant transcript was minimally changed. In vitro decay assays performed with activated HSC extracts that contain alphaCP binding activity demonstrate a markedly reduced decay rate of wild type compared with mutant transcripts. In vivo small interfering RNA experiments targeting alphaCP showed a reduction of the binding activity of alphaCP and a concomitant reduction in intracellular levels of alpha1( I) collagen messenger RNA. In conclusion, this study demonstrates the direct role of alphaCP in the stabilization of alpha1( I) collagen messenger RNA by blocking RNA degradation in activated HSCs.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Florida State Univ, Dept Biomed Sci, Tallahassee, FL 32306 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Columbia University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; State University System of Florida; Florida State University; Scripps Research Institute	Brenner, DA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	dab2106@columbia.edu		Brenner, David/0000-0003-2573-525X	NIAAA NIH HHS [AA12586-03] Funding Source: Medline; NIDDK NIH HHS [DK34987] Funding Source: Medline; NIGMS NIH HHS [GM41804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012586] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AYCOCK RS, 1989, CONNECT TISSUE RES, V23, P19, DOI 10.3109/03008208909103901; Baber JL, 1999, J MOL BIOL, V289, P949, DOI 10.1006/jmbi.1999.2818; BRENNER DA, 1993, HEPATOLOGY, V17, P287, DOI 10.1016/0270-9139(93)90090-A; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; Dejgaard K, 1996, EUR J BIOCHEM, V241, P425, DOI 10.1111/j.1432-1033.1996.00425.x; DELEEUW AM, 1984, HEPATOLOGY, V4, P392; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Ford LP, 1999, METHODS, V17, P21, DOI 10.1006/meth.1998.0703; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Friedman SL, 1999, ALCOHOL CLIN EXP RES, V23, P904, DOI 10.1097/00000374-199905000-00020; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; Funke B, 1996, NUCLEIC ACIDS RES, V24, P3821, DOI 10.1093/nar/24.19.3821; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hellerbrand C, 1996, HEPATOLOGY, V24, P670; HENDRIKS HFJ, 1985, EXP CELL RES, V160, P138, DOI 10.1016/0014-4827(85)90243-5; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; Lindquist Jeffrey N., 2000, Journal of Gastroenterology, V35, P80; Lindquist JN, 2000, NUCLEIC ACIDS RES, V28, P4306, DOI 10.1093/nar/28.21.4306; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Maniatis T., 1982, MOL CLONING; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; PYPE S, 1994, J BIOL CHEM, V269, P31457; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Safadi Rifaat, 2002, MedGenMed, V4, P27; SCHUPPAN D, 1990, SEMIN LIVER DIS, V10, P1, DOI 10.1055/s-2008-1040452; Stefanovic A, 2000, NUCLEIC ACIDS RES, V28, P641, DOI 10.1093/nar/28.2.641; Stefanovic B, 1999, MOL CELL BIOL, V19, P4334; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; Stefanovic B, 2003, J BIOL CHEM, V278, P927, DOI 10.1074/jbc.M209175200; Stefanovic B, 2002, J BIOL CHEM, V277, P18229, DOI 10.1074/jbc.M108065200; WANG XM, 1995, MOL CELL BIOL, V15, P1769; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374	53	43	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23822	23829		10.1074/jbc.M314060200	http://dx.doi.org/10.1074/jbc.M314060200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	14973140	hybrid			2022-12-27	WOS:000221570900126
J	Grgic, L; Zwicker, K; Kashani-Poor, N; Kerscher, S; Brandt, U				Grgic, L; Zwicker, K; Kashani-Poor, N; Kerscher, S; Brandt, U			Functional significance of conserved histidines and arginines in the 49-kDa subunit of mitochondrial complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; IRON-SULFUR CLUSTER; YARROWIA-LIPOLYTICA; CATALYTIC CORE; N2; HYDROGENASES; SITE	We have studied the ubiquinone-reducing catalytic core of NADH: ubiquinone oxidoreductase ( complex I) from Yarrowia lipolytica by a series of point mutations replacing conserved histidines and arginines in the 49-kDa subunit. Our results show that histidine 226 and arginine 141 probably do not ligate iron-sulfur cluster N2 but that exchanging these residues specifically influences the properties of this redox center. Histidines 91 and 95 were found to be essential for ubiquinone reductase activity of complex I. Mutations at the C-terminal arginine 466 affected ubiquinone affinity and inhibitor sensitivity but also destabilized complex I. These results provide further support for a high degree of structural conservation between the 49-kDa subunit of complex I and its ancestor, the large subunit of water-soluble [NiFe] hydrogenases. In several mutations of histidine 226, arginine 141, and arginine 466 the characteristic EPR signatures of iron-sulfur cluster N2 became undetectable, but specific, inhibitor-sensitive ubiquinone reductase activity was only moderately reduced. As we could not find spectroscopic indications for a modified cluster N2, we concluded that these complex I mutants were lacking most of this redox center but were still capable of catalyzing inhibitor-resistant ubiquinone reduction at near normal rates. We discuss that this at first surprising scenario may be explained by electron transfer theory; after removal of a single redox center in a chain, electron transfer rates are predicted to be still much faster than steady-state turnover of complex I. Our results question some of the central mechanistic functions that have been put forward for iron-sulfur cluster N2.	Goethe Univ Frankfurt, Facbereich Med, Inst Biochem 1, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Brandt, U (corresponding author), Goethe Univ Frankfurt, Facbereich Med, Inst Biochem 1, Theodor Stern Kai 7,Haus 25B, D-60590 Frankfurt, Germany.	brandt@zbc.kgu.de	Brandt, Ulrich/C-4406-2008; Brandt, Ulrich/GLV-1242-2022	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; BOHM R, 1990, MOL MICROBIOL, V4, P231, DOI 10.1111/j.1365-2958.1990.tb00590.x; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Byrdin M, 2003, P NATL ACAD SCI USA, V100, P8676, DOI 10.1073/pnas.1531645100; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Duarte M, 2002, BIOCHEM J, V364, P833, DOI 10.1042/BJ20011750; Duderstadt RE, 1999, FEBS LETT, V454, P21, DOI 10.1016/S0014-5793(99)00766-8; Flemming D, 2003, J BIOL CHEM, V278, P47602, DOI 10.1074/jbc.M308967200; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Friedrich T, 2000, BBA-BIOENERGETICS, V1459, P305, DOI 10.1016/S0005-2728(00)00165-1; Garofano A, 2003, J BIOL CHEM, V278, P42435, DOI 10.1074/jbc.M305819200; Kashani-Poor N, 2001, BBA-BIOENERGETICS, V1504, P363, DOI 10.1016/S0005-2728(00)00266-8; Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200; Kerscher S, 2002, BBA-BIOENERGETICS, V1555, P83, DOI 10.1016/S0005-2728(02)00259-1; Kerscher S, 2001, J BIOENERG BIOMEMBR, V33, P187, DOI 10.1023/A:1010726818165; Kerscher SJ, 1999, J CELL SCI, V112, P2347; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magnitsky S, 2002, J BIOENERG BIOMEMBR, V34, P193, DOI 10.1023/A:1016083419979; Montet Y, 1997, NAT STRUCT BIOL, V4, P523, DOI 10.1038/nsb0797-523; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Schagger H., 2003, MEMBRANE PROTEIN PUR, P105, DOI DOI 10.1016/B978-012361776-7/50006-1; Videira A, 1998, BBA-BIOENERGETICS, V1364, P89, DOI 10.1016/S0005-2728(98)00020-6; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200	26	65	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21193	21199		10.1074/jbc.M313180200	http://dx.doi.org/10.1074/jbc.M313180200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15004020	hybrid			2022-12-27	WOS:000221273800078
J	Thuerauf, DJ; Morrison, L; Glembotski, CC				Thuerauf, DJ; Morrison, L; Glembotski, CC			Opposing roles for ATF6 alpha and ATF6 beta in endoplasmic reticulum stress response gene induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; TRANSCRIPTION FACTOR; MESSENGER-RNA; ATF6; IDENTIFICATION; DEGRADATION; PROTEOLYSIS; COMPLEX; DOMAIN; IRE1	The endoplasmic reticulum ( ER) transmembrane proteins, ATF6alpha and ATF6beta, are cleaved in response to ER stress, which can be induced by tunicamycin. The resulting N-terminal fragments of both ATF6 isoforms, which have conserved basic leucine-zipper and DNA binding domains but divergent transcriptional activation domains, translocate to the nucleus where they bind to ER stress-response elements (ERSE) in ER stress-response genes (ERSRG), such as GRP78. Although it is known that ATF6alpha is a potent activator of ERSRGs, the transcriptional potency and functions of ATF6beta remain to be explored. Accordingly, N-terminal fragments of each ATF6 isoform (N-ATF6alpha and N-ATF6beta) were overexpressed in HeLa cells and the effects on GRP78 induction were assessed. When expressed at similar levels, N-ATF6alpha conferred similar to200-fold greater GRP78 promoter activation than N-ATF6beta. Because ER stress activates nuclear translocation of both ATF6alpha and beta and because both bind to ERSEs, the effect of co-expressing them on GRP78 induction was assessed. Surprisingly, N-ATF6alpha inhibited N-ATF6alpha-mediated GRP78 promoter activation in a dominant-negative manner. Moreover, N-ATF6beta inhibited TN-mediated GRP78 promoter activation, which requires endogenous ATF6alpha. ATF6 isoform-specific small inhibitory RNAs were used to show that, as expected, endogenous ATF6alpha was required for maximal ERSRG induction; however, endogenous ATF6beta moderated ERSRG induction. These results indicate that compared with ATF6alpha, ATF6beta is a very poor activator of ERSRG induction and it represses ATF6alpha-mediated ERSRG induction. Thus, ATF6beta may serve as a transcriptional repressor functioning in part to regulate the strength and duration of ATF6alpha-mediated ERSRG activation during the ER stress response.	San Diego State Univ, San Diego State Univ Heart Inst, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Glembotski, CC (corresponding author), San Diego State Univ, San Diego State Univ Heart Inst, San Diego, CA 92182 USA.	cglembotski@sciences.sdsu.edu			NHLBI NIH HHS [HL 075573] Funding Source: Medline; NINDS NIH HHS [NS 025037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Clauss IM, 1996, NUCLEIC ACIDS RES, V24, P1855, DOI 10.1093/nar/24.10.1855; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Liu CY, 2003, J CELL SCI, V116, P1861, DOI 10.1242/jcs.00408; Mori K, 2003, TRAFFIC, V4, P519, DOI 10.1034/j.1600-0854.2003.00112.x; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Spear E, 2001, TRAFFIC, V2, P515, DOI 10.1034/j.1600-0854.2001.20801.x; Thuerauf DJ, 2002, J BIOL CHEM, V277, P20734, DOI 10.1074/jbc.M201749200; Thuerauf DJ, 2001, J BIOL CHEM, V276, P48309, DOI 10.1074/jbc.M107146200; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	22	107	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21078	21084		10.1074/jbc.M400713200	http://dx.doi.org/10.1074/jbc.M400713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14973138	hybrid			2022-12-27	WOS:000221273800065
J	Ostrom, RS; Bundey, RA; Insel, PA				Ostrom, RS; Bundey, RA; Insel, PA			Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CARDIAC MYOCYTES; HEART-FAILURE; SYNTHASE; PROTEIN; ISOFORMS; RECEPTOR; CAMP; COMPARTMENTATION; PHOSPHORYLATION	Several cell types, including cardiac myocytes and vascular endothelial cells, produce nitric oxide (NO) via both constitutive and inducible isoforms of NO synthase. NO attenuates cardiac contractility and contributes to contractile dysfunction in heart failure, although the precise molecular mechanisms for these effects are poorly defined. Adenylyl cyclase (AC) isoforms type 5 and 6, which are preferentially expressed in cardiac myocytes, may be inhibited via a direct nitrosylation by NO. Because endothelial NO synthase (eNOS and NOS3), beta-adrenergic (betaAR) receptors, and AC6 all can localize in lipid raft/caveolin-rich microdomains, we sought to understand the role of lipid rafts in organizing components of betaAR-G(s)-AC signal transduction together with eNOS. Using neonatal rat cardiac myocytes, we found that disruption of lipid rafts with beta-cyclodextrin inhibited forskolin-stimulated AC activity and cAMP production, eliminated caveolin-3-eNOS interaction, and increased NO production. betaAR- and G(s)-mediated activation of AC activity were inhibited by beta-cyclodextrin treatment, but prostanoid receptor-stimulated AC activity, which appears to occur outside caveolin-rich microdomains, was unaffected unless eNOS was overexpressed and lipid rafts were disrupted. An NO donor, SNAP, inhibited basal and forskolin-stimulated cAMP production in both native cardiac myocytes and cardiac myocytes and pulmonary artery endothelial cells engineered to overexpress AC6. These effects of SNAP were independent of guanylyl cyclase activity and were mimicked by overexpression of eNOS. The juxtaposition of eNOS with betaAR and AC types 5 and 6 results in selective regulation of betaAR by eNOS activity in lipid raft domains over other G(s)-coupled receptors localized in nonraft domains. Thus co-localization of multiple signaling components in lipid rafts provides key spatial regulation of AC activity.	Univ Calif San Diego, Dept Pharmacol, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Vasc Biol Ctr Excellence, Memphis, TN 38163 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, Sch Med, 0636, La Jolla, CA 92093 USA.	pinsel@ucsd.edu		Ostrom, Rennolds/0000-0002-7204-0357	NHLBI NIH HHS [HL 53773, HL 63885, HL 71781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071781, R01HL063885, P50HL053773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Billington CK, 1999, AM J RESP CELL MOL, V21, P597, DOI 10.1165/ajrcmb.21.5.3759; Bundey RA, 2003, ANAL BIOCHEM, V319, P318, DOI 10.1016/S0003-2697(03)00325-7; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gao MH, 1998, P NATL ACAD SCI USA, V95, P1038, DOI 10.1073/pnas.95.3.1038; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gustafsson AB, 2002, AM J PHYSIOL-CELL PH, V283, pC463, DOI 10.1152/ajpcell.00299.2001; Hare JM, 2000, CIRC RES, V86, P1085, DOI 10.1161/01.RES.86.10.1085; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; HARE JM, 1995, CIRCULATION, V92, P2198, DOI 10.1161/01.CIR.92.8.2198; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; Hill J, 2000, CELL SIGNAL, V12, P233, DOI 10.1016/S0898-6568(99)00082-0; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Keaney JF, 1996, AM J PHYSIOL-HEART C, V271, pH2646, DOI 10.1152/ajpheart.1996.271.6.H2646; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; McVey M, 1999, J BIOL CHEM, V274, P18887, DOI 10.1074/jbc.274.27.18887; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Ooboshi H, 1997, AM J PHYSIOL-HEART C, V273, pH265, DOI 10.1152/ajpheart.1997.273.1.H265; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Ostrom RS, 2003, J BIOL CHEM, V278, P24461, DOI 10.1074/jbc.M212659200; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Rong JX, 2003, P NATL ACAD SCI USA, V100, P13531, DOI 10.1073/pnas.1735526100; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; Ziolo MT, 2001, AM J PHYSIOL-HEART C, V281, pH2295, DOI 10.1152/ajpheart.2001.281.6.H2295	44	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19846	19853		10.1074/jbc.M313440200	http://dx.doi.org/10.1074/jbc.M313440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15007069	hybrid, Green Published			2022-12-27	WOS:000221164500057
J	Zhang, H; Wu, W; Du, Y; Santos, SJ; Conrad, SE; Watson, JT; Grammatikakis, N; Gallo, KA				Zhang, H; Wu, W; Du, Y; Santos, SJ; Conrad, SE; Watson, JT; Grammatikakis, N; Gallo, KA			Hsp90/p50(cdc37) is required for mixed-lineage kinase (MLK) 3 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DEATH-DOMAIN KINASE; MOLECULAR CHAPERONES; HSP90 FUNCTION; NEURONAL APOPTOSIS; ANSAMYCINS CAUSES; BREAST-CANCER; IN-VIVO; COMPLEX; CDC37	Mixed-lineage kinase 3 (MLK3) is a mitogen-activated protein kinase (MAPK) kinase kinase that activates MAPK pathways, including the c-Jun NH2-terminal kinase (JNK) and p38 pathways. MLK3 and its family members have been implicated in JNK-mediated apoptosis. A survey of human cell lines revealed high levels of MLK3 in breast cancer cells. To learn more about MLK3 regulation and its signaling pathways in breast cancer cells, we engineered the estrogen-responsive human breast cancer cell line, MCF-7, to stably, inducibly express FLAG epitope-tagged MLK3. FLAG.MLK3 complexes were isolated by affinity purification, and associated proteins were identified by in-gel trypsin digestion followed by liquid chromatography/tandem mass spectrometry. Among the proteins identified were heat shock protein 90alpha,beta (Hsp90) and its kinase-specific cochaperone p50(cdc37). We show that endogenous MLK3 complexes with Hsp90 and p50(cdc37). Further experiments demonstrate that MLK3 associates with Hsp90/p50(cdc37) through its catalytic domain in an activity-independent manner. Upon treatment of MCF-7 cells with geldanamycin, an ansamycin antibiotic that inhibits Hsp90 function, MLK3 levels decrease dramatically. Furthermore, tumor necrosis factor alpha-induced activation of MLK3 and JNK in MCF-7 cells is blocked by geldanamycin treatment. Our finding that geldanamycin treatment does not affect the cellular levels of the downstream signaling components, MAPK kinase 4, MAPK kinase 7, and JNK, suggests that Hsp90/p50(cdc37) regulates JNK signaling at the MAPK kinase kinase level. Previously identified Hsp90/p50(cdc37) clients include oncoprotein kinases and protein kinases that promote cellular proliferation and survival. Our findings reveal that Hsp90/p50(cdc37) also regulates protein kinases involved in apoptotic signaling.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Boston Univ, Sch Med, Boston, MA 02118 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University; Boston University	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, 4180 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	gallok@msu.edu			NATIONAL CANCER INSTITUTE [R01CA076647, R29CA076306] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76306, CA 76647] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 2000, CELL GROWTH DIFFER, V11, P355; Bagatell R, 2001, CLIN CANCER RES, V7, P2076; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Chavany C, 1996, J BIOL CHEM, V271, P4974; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Dunn FB, 2002, J NATL CANCER I, V94, P1194; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gross EA, 2002, J BIOL CHEM, V277, P13873, DOI 10.1074/jbc.M111994200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Miyata Y, 2001, J BIOL CHEM, V276, P21841, DOI 10.1074/jbc.M010944200; Mota M, 2001, J NEUROSCI, V21, P4949, DOI 10.1523/JNEUROSCI.21-14-04949.2001; Munster PN, 2001, CANCER RES, V61, P2945; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nollen EAA, 2002, J CELL SCI, V115, P2809; Pollock R, 2002, NAT BIOTECHNOL, V20, P729, DOI 10.1038/nbt0702-729; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Saporito MS, 2002, PROGR MED CHEM, V40, P23, DOI 10.1016/S0079-6468(08)70081-X; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schoorlemmer J, 2002, J BIOL CHEM, V277, P49111, DOI 10.1074/jbc.M205520200; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Srethapakdi M, 2000, CANCER RES, V60, P3940; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Westermarck J, 2002, EMBO J, V21, P451, DOI 10.1093/emboj/21.3.451; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200	48	25	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19457	19463		10.1074/jbc.M311377200	http://dx.doi.org/10.1074/jbc.M311377200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15001580	hybrid			2022-12-27	WOS:000221164500011
J	Ivaska, KK; Hentunen, TA; Vaaraniemi, J; Ylipahkala, H; Pettersson, K; Vaananen, K				Ivaska, KK; Hentunen, TA; Vaaraniemi, J; Ylipahkala, H; Pettersson, K; Vaananen, K			Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-CONTAINING PROTEIN; K-DEPENDENT BONE; GLA-PROTEIN; IMMUNOREACTIVE FORMS; SERUM; METABOLISM; DIFFERENTIATION; EXPRESSION; BOVINE; MARKER	Osteocalcin detected from serum samples is considered a specific marker of osteoblast activity and bone formation rate. However, osteocalcin embedded in bone matrix must also be released during bone resorption. To understand the contribution of each type of bone cell in circulating osteocalcin levels, we used immunoassays detecting different molecular forms of osteocalcin to monitor bone resorption in vitro. Osteoclasts were obtained from rat long bones and cultured on bovine bone slices using osteocalcin-depleted fetal bovine serum. In addition, human osteoclasts differentiated from peripheral blood mononuclear cells were used. Both rat and human osteoclasts released osteocalcin from bovine bone into medium. The amount of osteocalcin increased in the presence of parathyroid hormone, a stimulator of resorption, and decreased in the presence of bafilomycin A1, an inhibitor of resorption. The amount of osteocalcin in the medium correlated with a well characterized marker of bone resorption, the C-terminal telopeptide of type I collagen (r > 0.9, p < 0.0001). The heterogeneity of released osteocalcin was determined using reverse phase high performance liquid chromatography, and several molecular forms of osteocalcin, including intact molecule, were identified in the culture medium. In conclusion, osteocalcin is released from the bone matrix during bone resorption as intact molecules and fragments. In addition to the conventional use as a marker of bone formation, osteocalcin can be used as a marker of bone resorption in vitro. Furthermore, bone matrix-derived osteocalcin may contribute to circulating osteocalcin levels, suggesting that serum osteocalcin should be considered as a marker of bone turnover rather than bone formation.	Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, Dept Biotechnol, FIN-20520 Turku, Finland	University of Turku; University of Turku	Ivaska, KK (corresponding author), Univ Turku, Inst Biomed, Dept Anat, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	kaisa.ivaska@utu.fi	Ivaska, Kaisa/G-1406-2012	Ivaska, Kaisa/0000-0001-7482-7623				Alatalo SL, 2000, CLIN CHEM, V46, P1751; Aliberti G, 2000, CLIN PHYSIOL, V20, P122; Baumgrass R, 1997, J BONE MINER RES, V12, P447, DOI 10.1359/jbmr.1997.12.3.447; Bellows CG, 1999, CELL TISSUE RES, V297, P249, DOI 10.1007/s004410051353; BERESFORD JN, 1984, METAB BONE DIS RELAT, V5, P229, DOI 10.1016/0221-8747(84)90064-X; Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756-3282(98)00092-1; BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313; BROWN JP, 1984, LANCET, V1, P1091; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CHAMBERS TJ, 1984, J CELL SCI, V66, P383; CHARLES P, 1985, J CLIN INVEST, V76, P2254, DOI 10.1172/JCI112234; Chen JT, 1996, J BONE MINER RES, V11, P1784; Christenson RH, 1997, CLIN BIOCHEM, V30, P573, DOI 10.1016/S0009-9120(97)00113-6; DIMUZIO MT, 1983, BIOCHEM J, V216, P249, DOI 10.1042/bj2160249; Dowd TL, 2003, BIOCHEMISTRY-US, V42, P7769, DOI 10.1021/bi034470s; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; DUDA RJ, 1986, J BONE MINER RES, V1, P91; FARRUGIA W, 1986, CALCIFIED TISSUE INT, V39, P234, DOI 10.1007/BF02555210; Fohr B, 2003, J CLIN ENDOCR METAB, V88, P5059, DOI 10.1210/jc.2003-030910; GALLOP PM, 1980, NEW ENGL J MED, V302, P1460, DOI 10.1056/NEJM198006263022608; GARNERO P, 1994, J BONE MINER RES, V9, P255; Gundberg CM, 2002, J BONE MINER RES, V17, pS406; GUNDBERG CM, 1991, J CLIN ENDOCR METAB, V72, P438, DOI 10.1210/jcem-72-2-438; GUNDBERG CM, 1986, J CLIN INVEST, V77, P1762, DOI 10.1172/JCI112499; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HAUSCHKA PV, 1977, CALCIUM BINDING PROT, P338; Hellman J, 1996, J BONE MINER RES, V11, P1165; Hentunen TA, 2001, J BONE MINER RES, V16, pS377; Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079; Ivaska KK, 2002, J BONE MINER RES, V17, pS407; Ivaska KK, 2003, BIOCHEM BIOPH RES CO, V306, P973, DOI 10.1016/S0006-291X(03)01093-3; Jung CY, 2001, GENE, V271, P143, DOI 10.1016/S0378-1119(01)00513-3; Kalume DE, 2000, J MASS SPECTROM, V35, P145, DOI 10.1002/(SICI)1096-9888(200002)35:2<145::AID-JMS922>3.0.CO;2-I; Kurihara N, 1998, J BONE MINER METAB, V16, P11, DOI 10.1007/s007740050022; LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; LIAN JB, 1985, J BIOL CHEM, V260, P8706; Mason DJ, 1996, J BONE MINER RES, V11, P350; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; Novak JF, 1997, J BONE MINER RES, V12, P1035, DOI 10.1359/jbmr.1997.12.7.1035; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; POWER MJ, 1991, CRIT REV CL LAB SCI, V28, P287, DOI 10.3109/10408369109106867; PRICE PA, 1980, J CLIN INVEST, V66, P878, DOI 10.1172/JCI109954; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P3374, DOI 10.1073/pnas.73.10.3374; PRICE PA, 1980, P NATL ACAD SCI-BIOL, V77, P2234, DOI 10.1073/pnas.77.4.2234; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; PRICE PA, 1980, J BIOL CHEM, V255, P1660; PRICE PA, 1981, J BIOL CHEM, V256, P2760; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; TAYLOR AK, 1990, J CLIN ENDOCR METAB, V70, P467, DOI 10.1210/jcem-70-2-467; THIEDE MA, 1994, ENDOCRINOLOGY, V135, P929, DOI 10.1210/en.135.3.929	52	142	149	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18361	18369		10.1074/jbc.M314324200	http://dx.doi.org/10.1074/jbc.M314324200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970229	hybrid			2022-12-27	WOS:000221041500033
J	Kaya, Y; Del Campo, M; Ofengand, J; Malhotra, A				Kaya, Y; Del Campo, M; Ofengand, J; Malhotra, A			Crystal structure of TruD, a novel pseudouridine synthase with a new protein fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; ESCHERICHIA-COLI; RIBOSOMAL-RNA; RECOGNITION; ENZYME; ALIGNMENT; BINDING; GROWTH; MODE; RLUD	TruD, a recently discovered novel pseudouridine synthase in Escherichia coli, is responsible for modifying uridine13 in tRNA(Glu) to pseudouridine. It has little sequence homology with the other 10 pseudouridine synthases in E. coli which themselves have been grouped into four related protein families. Crystal structure determination of TruD revealed a two domain structure consisting of a catalytic domain that differs in sequence but is structurally very similar to the catalytic domain of other pseudouridine synthases and a second large domain (149 amino acids, 43% of total) with a novel alpha/beta fold that up to now has not been found in any other protein.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Malhotra, A (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.	malhotra@miami.edu	Malhotra, Arun/A-3916-2008; Malhotra, Arun/Z-5140-2019	Malhotra, Arun/0000-0001-6656-7841; Malhotra, Arun/0000-0001-6656-7841	NIGMS NIH HHS [GM58879, GM66374] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058879, F31GM066374] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Behm-Ansmant I, 2003, RNA, V9, P1371, DOI 10.1261/rna.5520403; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Del Campo M, 2004, RNA, V10, P231, DOI 10.1261/rna.5187404; Del Campo M, 2003, ACTA CRYSTALLOGR D, V59, P1871, DOI 10.1107/S0907444903018468; Del Campo M, 2001, RNA, V7, P1603; DeLano W.L, PYMOL MOL GRAPHICS S; Ferre-D'Amare AR, 2003, CURR OPIN STRUC BIOL, V13, P49, DOI 10.1016/S0959-440X(02)00002-7; Foster PG, 2000, NAT STRUCT BIOL, V7, P23; Hoang C, 2001, CELL, V107, P929, DOI 10.1016/S0092-8674(01)00618-3; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ishitani R, 2003, CELL, V113, P383, DOI 10.1016/S0092-8674(03)00280-0; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaya Y, 2003, RNA, V9, P711, DOI 10.1261/rna.5230603; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Mueller EG, 2002, NAT STRUCT BIOL, V9, P320, DOI 10.1038/nsb0502-320; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Ofengand J, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P175; Ofengand J, 2002, FEBS LETT, V514, P17, DOI 10.1016/S0014-5793(02)02305-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan H, 2003, P NATL ACAD SCI USA, V100, P12648, DOI 10.1073/pnas.2135585100; Sekine S, 2003, EMBO J, V22, P676, DOI 10.1093/emboj/cdg053; Sivaraman J, 2004, J MOL BIOL, V335, P87, DOI 10.1016/j.jmb.2003.10.003; Sivaraman J, 2002, NAT STRUCT BIOL, V9, P353, DOI 10.1038/nsb788; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Xie W, 2003, NAT STRUCT BIOL, V10, P781, DOI 10.1038/nsb976	32	29	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18107	18110		10.1074/jbc.C400072200	http://dx.doi.org/10.1074/jbc.C400072200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14999002	hybrid			2022-12-27	WOS:000221041500003
J	Kishida, T; Kostetskii, I; Zhang, ZB; Martinez, F; Liu, P; Walkley, SU; Dwyer, NK; Blanchette-Mackie, EJ; Radice, GL; Strauss, JF				Kishida, T; Kostetskii, I; Zhang, ZB; Martinez, F; Liu, P; Walkley, SU; Dwyer, NK; Blanchette-Mackie, EJ; Radice, GL; Strauss, JF			Targeted mutation of the MLN64 START domain causes only modest alterations in cellular sterol metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; PHOSPHATIDYLCHOLINE TRANSFER PROTEIN; PICK C1-DEFICIENT NEURONS; CHOLESTEROL HOMEOSTASIS; GENE-EXPRESSION; DISTAL AXONS; C1 PROTEIN; DISEASE; STEROIDOGENESIS; TRAFFICKING	The StAR-related lipid transfer (START) domain, first identified in the steroidogenic acute regulatory protein (StAR), is involved in the intracellular trafficking of lipids. Sixteen mammalian START domain-containing proteins have been identified to date. StAR, a protein targeted to mitochondria, stimulates the movement of cholesterol from the outer to the inner mitochondrial membranes, where it is metabolized into pregnenolone in steroidogenic cells. MLN64, the START domain protein most closely related to StAR, is localized to late endosomes along with other proteins involved in sterol trafficking, including NPC1 and NPC2, where it has been postulated to participate in sterol distribution to intracellular membranes. To investigate the role of MLN64 in sterol metabolism, we created mice with a targeted mutation in the Mln64 START domain, expecting to find a phenotype similar to that in humans and mice lacking NPC1 or NPC2 (progressive neurodegenerative symptoms, free cholesterol accumulation in lysosomes). Unexpectedly, mice homozygous for the Mln64 mutant allele were viable, neurologically intact, and fertile. No significant alterations in plasma lipid levels, liver lipid content and distribution, and expression of genes involved in sterol metabolism were observed, except for an increase in sterol ester storage in mutant mice fed a high fat diet. Embryonic fibroblast cells transfected with the cholesterol side-chain cleavage system and primary cultures of granulosa cells from Mln64 mutant mice showed defects in sterol trafficking as reflected in reduced conversion of endogenous cholesterol to steroid hormones. These observations suggest that the Mln64 START domain is largely dispensable for sterol metabolism in mice.	Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; NIDDK, Lipid Cell Biol Sect, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; Pennsylvania Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Strauss, JF (corresponding author), Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, 1354 BRB,421 Curie Blvd, Philadelphia, PA 19104 USA.	jfs3@mail.med.upenn.edu			FIC NIH HHS [D43 TW00671] Funding Source: Medline; NICHD NIH HHS [HD06274] Funding Source: Medline; NIDDK NIH HHS [P30 DK 19525] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003, ZIADK060003, P30DK019525] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpy F, 2002, J BIOL CHEM, V277, P50780, DOI 10.1074/jbc.M208290200; Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; BARTLETT EM, 1970, ANAL BIOCHEM, V36, P159, DOI 10.1016/0003-2697(70)90343-X; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cheema SK, 1997, J LIPID RES, V38, P315; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; Frolov A, 2001, J BIOL CHEM, V276, P46414, DOI 10.1074/jbc.M108099200; GEORGE EL, 1994, METHOD ENZYMOL, V245, P386; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; Karten B, 2002, J NEUROCHEM, V83, P1154, DOI 10.1046/j.1471-4159.2002.01220.x; Karten B, 2003, J BIOL CHEM, V278, P4168, DOI 10.1074/jbc.M205406200; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MATSUO H, 1994, ENDOCRINOLOGY, V135, P1135, DOI 10.1210/en.135.3.1135; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; Shen WJ, 2003, J BIOL CHEM, V278, P43870, DOI 10.1074/jbc.M303934200; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; van Helvoort A, 1999, P NATL ACAD SCI USA, V96, P11501, DOI 10.1073/pnas.96.20.11501; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Wiegand V, 2003, FASEB J, V17, P782, DOI 10.1096/fj.02-0818fje; Xie CL, 1999, AM J PHYSIOL-ENDOC M, V276, pE336, DOI 10.1152/ajpendo.1999.276.2.E336; Zervas M, 2001, J NEUROPATH EXP NEUR, V60, P49, DOI 10.1093/jnen/60.1.49; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200	37	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19276	19285		10.1074/jbc.M400717200	http://dx.doi.org/10.1074/jbc.M400717200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14963026	hybrid			2022-12-27	WOS:000221041500141
J	Laganiere, J; Tremblay, GB; Dufour, CR; Giroux, S; Rousseau, F; Giguere, V				Laganiere, J; Tremblay, GB; Dufour, CR; Giroux, S; Rousseau, F; Giguere, V			A polymorphic autoregulatory hormone response element in the human estrogen-related receptor alpha (ERR alpha) promoter dictates peroxisome proliferator-activated receptor gamma coactivator-1 alpha control of ERR alpha expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LACTOFERRIN GENE; CHAIN ACYL-COENZYME; NUCLEAR RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; HEPATIC GLUCONEOGENESIS; ORPHAN RECEPTOR; DEHYDROGENASE GENE; PGC-1-ALPHA; PGC-1; IDENTIFICATION	The orphan nuclear estrogen-related receptor alpha (ERRalpha) and transcriptional cofactor peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) are involved in the regulation of energy metabolism. Recently, extensive cross-talk between PGC-1alpha and ERRalpha has been demonstrated. The presence of PGC-1alpha is associated with an elevated expression of ERRalpha, and the two proteins can influence the transcriptional activities of one another. Using a candidate gene approach to detect regulatory variants within genes encoding nuclear receptors, we have identified a 23-bp sequence (ESRRA23) containing two nuclear receptor recognition half-site motifs that is present in 1-4 copies within the promoter of the human ESRRA gene encoding ERRalpha. The ESRRA23 sequence contains a functional ERR response element that is specifically bound by ERRalpha, and chromatin immunoprecipitation shows that endogenous ERRalpha occupies its own promoter in vivo. Strikingly, introduction of PGC-1alpha in HeLa cells by transient transfection induces the activity of the ESRRA promoter in a manner that is dependent on the presence of the ESRRA23 element and on its dosage. Coexpression of ERRalpha and PGC-1alpha results in a synergistic activation of the ESRRA promoter. In experiments using ERRalpha null fibroblasts, the ability of PGC-1alpha to stimulate the ESRRA promoter is considerably reduced but can be restored by addition of ERRalpha. Taken together, these results demonstrate that an interdependent ERRalpha/PGC-1alpha-based transcriptional pathway targets the ESRRA23 element to dictate the level of ERRalpha expression. This study further suggests that this regulatory polymorphism may provide differential responses to ERRalpha/PGC-1alpha-mediated metabolic cues in the human population.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; Alethia Biotherapeut Inc, Montreal, PQ H2M 2N9, Canada; Hop St Francois Assise, Ctr Rech, Unite Rech Genet Humaine & Mol, Quebec City, PQ G1L 3L5, Canada	McGill University; McGill University; McGill University; McGill University; Laval University	Giguere, V (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Rm H5-21,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	vincent.giguere@mcgill.ca		Dufour, Catherine Rosa/0000-0001-7324-3458; Laganiere, Josee/0000-0003-0775-3331; Giguere, Vincent/0000-0001-9567-3694				Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Chen S, 2001, J BIOL CHEM, V276, P28465, DOI 10.1074/jbc.M102638200; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200; Laganiere J, 2003, METHOD ENZYMOL, V364, P339; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Liu DX, 2003, ENDOCRINOLOGY, V144, P4894, DOI 10.1210/en.2003-0432; Lu DS, 2001, CANCER RES, V61, P6755; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Maehara K, 2003, J MOL ENDOCRINOL, V31, P47, DOI 10.1677/jme.0.0310047; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Trapp T, 1996, J BIOL CHEM, V271, P9879, DOI 10.1074/jbc.271.17.9879; Tremblay GB, 1998, CANCER RES, V58, P877; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Vanacker JM, 1998, ONCOGENE, V17, P2429, DOI 10.1038/sj.onc.1202167; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang ZP, 2000, J BIOL CHEM, V275, P20837, DOI 10.1074/jbc.M001880200	37	133	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18504	18510		10.1074/jbc.M313543200	http://dx.doi.org/10.1074/jbc.M313543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978033	hybrid			2022-12-27	WOS:000221041500051
J	Paukert, M; Sidi, S; Russell, C; Siba, M; Wilson, SW; Nicolson, T; Grunder, S				Paukert, M; Sidi, S; Russell, C; Siba, M; Wilson, SW; Nicolson, T; Grunder, S			A family of acid-sensing ion channels from the zebrafish - Widespread expression in the central nervous system suggests a conserved role in neuronal communication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED NA+ CHANNEL; SODIUM-CHANNELS; PROTEIN PICK1; TOUCH; CONTRIBUTES; VERTEBRATE; SUBUNIT; MEMBER; BRAIN; BNAC1	Acid-sensing ion channels (ASICs) are excitatory receptors for extracellular H+. Proposed functions include synaptic transmission, peripheral perception of pain, and mechanosensation. Despite the physiological importance of these functions, the precise role of ASICs has not yet been established. In order to increase our understanding of the physiological role and basic structure-function relationships of ASICs, we report here the cloning of six new ASICs from the zebrafish (zASICs). zASICs possess the basic functional properties of mammalian ASICs: activation by extracellular H+, Na+ selectivity, and block by micromolar concentrations of amiloride. The zasic genes are broadly expressed in the central nervous system, whereas expression in the peripheral nervous system is scarce. This pattern suggests a predominant role for zASICs in neuronal communication. Our results suggest a conserved function for receptors of extracellular H+ in the central nervous system of vertebrates.	Dept Physiol 2, D-72076 Tubingen, Germany; Max Planck Inst Dev Biol, D-72076 Tubingen, Germany; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England	Max Planck Society; University of London; University College London	Grunder, S (corresponding author), Dept Physiol 2, Gmelinstr 5, D-72076 Tubingen, Germany.	stefan.gruender@uni-tuebingen.de	Zebrafish, UCL/A-3125-2009; Russell, Claire/A-4879-2012; Gründer, Stefan/I-2495-2019; Wilson, Stephen W/B-9404-2008	Russell, Claire/0000-0002-6748-9301; Gründer, Stefan/0000-0002-7635-9883; Wilson, Stephen W/0000-0002-8557-5940				Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; Barbazuk WB, 2000, GENOME RES, V10, P1351, DOI 10.1101/gr.144700; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; BERNHARDT RR, 1990, J COMP NEUROL, V302, P603, DOI 10.1002/cne.903020315; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; CLARKE JDW, 1984, J PHYSIOL-LONDON, V348, P511, DOI 10.1113/jphysiol.1984.sp015122; Concha ML, 2003, NEURON, V39, P423, DOI 10.1016/S0896-6273(03)00437-9; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; de la Rosa DA, 2003, J PHYSIOL-LONDON, V546, P77, DOI 10.1113/jphysiol.2002.030692; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; EICHLER VB, 1981, J COMP NEUROL, V203, P121, DOI 10.1002/cne.902030110; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Geisler R, 1999, NAT GENET, V23, P86, DOI 10.1038/12692; Grunder S, 2000, NEUROREPORT, V11, P1607; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; GRUNWALD DJ, 1988, DEV BIOL, V126, P115, DOI 10.1016/0012-1606(88)90245-X; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Olson TH, 1998, NEUROREPORT, V9, P1109, DOI 10.1097/00001756-199804200-00028; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Ribera AB, 1998, J NEUROSCI, V18, P9181; Sneddon LU, 2003, P ROY SOC B-BIOL SCI, V270, P1115, DOI 10.1098/rspb.2003.2349; Sneddon LU, 2003, BRAIN RES, V972, P44, DOI 10.1016/S0006-8993(03)02483-1; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Welsh MJ, 2002, J BIOL CHEM, V277, P2369, DOI 10.1074/jbc.R100060200; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X	39	60	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18783	18791		10.1074/jbc.M401477200	http://dx.doi.org/10.1074/jbc.M401477200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970195	Green Published, hybrid			2022-12-27	WOS:000221041500086
J	Suzuki, N; Shibata, Y; Urano, T; Murohara, T; Muramatsu, T; Kadomatsu, K				Suzuki, N; Shibata, Y; Urano, T; Murohara, T; Muramatsu, T; Kadomatsu, K			Proteasomal degradation of the nuclear targeting growth factor midkine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; ACID-RESPONSIVE GENE; MITOGENIC ACTIVITY; CARCINOMA-CELLS; TRANSLOCATION; UBIQUITINATION; TRANSPORT; SYSTEM; FAMILY; ALPHA	It is widely held that growth factor signaling is terminated by lysosomal degradation of its activated receptor and the endocytosed growth factor is transported to lysosomes. Nuclear targeting is another important pathway through which signals of growth factors are mediated. However, mechanisms underlying desensitization of nuclear targeting growth factors are poorly understood. Here we report that the nuclear targeting pathway is down-regulated by the proteasome system. Degradation of endocytosed midkine, a heparin-binding growth factor, was suppressed by both proteasome and lysosome inhibitors to similar extents. By contrast, a proteasome inhibitor, but not lysosome ones, accelerated the nuclear accumulation of midkine. An expression vector of signal sequence-less midkine, which is produced in the cytosol, was constructed because endocytosed midkine may be translocated to the cytosol from cellular compartments before entering the nucleus. The cytosol-produced midkine underwent proteasomal degradation and accumulated in the nucleus as did the endocytosed midkine. It was polyubiquitinated, and its nuclear accumulation was enhanced by a proteasome inhibitor. We further dissected the midkine molecule to investigate roles in degradation and trafficking. The N-terminal half-domain of midkine was significantly more susceptible to proteasomal degradation, whereas the C-terminal half-domain was sufficient for nuclear localization. Together, these data highlight the desensitization of nuclear targeting by growth factors and indicate a critical role of the proteasome system in it.	Nagoya Univ, Grad Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Cardiol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Nagoya University	Kadomatsu, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	kkadoma@med.nagoya-u.ac.jp	Kadomatsu, Kenji/G-8083-2012; Murohara, Toyoaki/M-4958-2014	Urano, Takeshi/0000-0003-3383-3554				BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; Cao D, 2003, CELL, V113, P533, DOI 10.1016/S0092-8674(03)00353-2; Deeks ED, 2002, BIOCHEMISTRY-US, V41, P3405, DOI 10.1021/bi011580v; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Horiba M, 2000, J CLIN INVEST, V105, P489, DOI 10.1172/JCI7208; Ikematsu S, 2000, BRIT J CANCER, V83, P701, DOI 10.1054/bjoc.2000.1339; Ikematsu S, 2003, BRIT J CANCER, V88, P1522, DOI 10.1038/sj.bjc.6600938; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Malecki J, 2002, EMBO J, V21, P4480, DOI 10.1093/emboj/cdf472; Martinez-Moczygemba M, 2001, J CLIN INVEST, V108, P1797, DOI 10.1172/JCI200113877; Melman L, 2002, MOL BIOL CELL, V13, P3325, DOI 10.1091/mbc.E02-03-0152; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Owada K, 1999, J NEUROCHEM, V73, P2084; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Rodighiero C, 2002, EMBO REP, V3, P1222, DOI 10.1093/embo-reports/kvf239; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Salama RHM, 2001, EXP CELL RES, V270, P13, DOI 10.1006/excr.2001.5341; Sato W, 2001, J IMMUNOL, V167, P3463, DOI 10.4049/jimmunol.167.6.3463; Shibata Y, 2002, MOL CELL BIOL, V22, P6788, DOI 10.1128/MCB.22.19.6788-6796.2002; Takei Y, 2001, CANCER RES, V61, P8486; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006-291X(05)80255-4; TSUTSUI J, 1993, CANCER RES, V53, P1281; UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P4063; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WILLNOW TE, 1994, J CELL SCI, V107, P719; YOSHIDA Y, 1995, DEV BRAIN RES, V85, P25, DOI 10.1016/0165-3806(94)00183-Z; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N	48	18	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17785	17791		10.1074/jbc.M310772200	http://dx.doi.org/10.1074/jbc.M310772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14970216	hybrid			2022-12-27	WOS:000220870400110
J	Gassel, M; Breitenlechner, CB; Konig, N; Huber, R; Engh, RA; Bossemeyer, D				Gassel, M; Breitenlechner, CB; Konig, N; Huber, R; Engh, RA; Bossemeyer, D			The protein kinase C inhibitor bisindolyl maleimide 2 binds with reversed orientations to different conformations of protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; SELECTIVE INHIBITORS; COMPLEX; STAUROSPORINE; POTENT; FLEXIBILITY; PEPTIDE; UCN-01	As the key mediators of eukaryotic signal transduction, the protein kinases often cause disease, and in particular cancer, when disregulated. Appropriately selective protein kinase inhibitors are sought after as research tools and as therapeutic drugs; several have already proven valuable in clinical use. The AGC subfamily protein kinase C (PKC) was identified early as a cause of cancer, leading to the discovery of a variety of PKC inhibitors. Despite its importance and early discovery, no crystal structure for PKC has yet been reported. Therefore, we have co-crystallized PKC inhibitor bisindolyl maleimide 2 (BIM2) with PKA variants to study its binding interactions. BIM2 co-crystallized as an asymmetric pair of kinase-inhibitor complexes. In this asymmetric unit, the two kinase domains have different lobe configurations, and two different inhibitor conformers bind in different orientations. One kinase molecule ( A) is partially open with respect to the catalytic conformation, the other ( B) represents the most open conformation of PKA reported so far. In monomer A, the BIM2 inhibitor binds tightly via an induced fit in the ATP pocket. The indole moieties are rotated out of the plane with respect to the chemically related but planar inhibitor staurosporine. In molecule B a different conformer of BIM2 binds in a reversed orientation relative to the equivalent maleimide atoms in molecule A. Also, a critical active site salt bridge is disrupted, usually indicating the induction of an inactive conformation. Molecular modeling of the clinical phase III PKC inhibitor LY333531 into the electron density of BIM2 reveals the probable binding mechanism and explains selectivity properties of the inhibitor.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; German Canc Res Ctr, Dept Pathochem, D-69120 Heidelberg, Germany; Roche Diagnost GmbH, Dept Med Chem, D-82372 Penzberg, Germany	Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ); Roche Holding	Engh, RA (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany.	engh@biochem.mpg.de; d.bossemeyer@dkfz-heidelberg.de		Engh, Richard/0000-0002-6207-0560				Akamine P, 2003, J MOL BIOL, V327, P159, DOI 10.1016/S0022-2836(02)01446-8; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Breitenlechner C, 2003, STRUCTURE, V11, P1595, DOI 10.1016/j.str.2003.11.002; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DAVIS PD, 1992, J MED CHEM, V35, P177, DOI 10.1021/jm00079a024; De Moliner E, 2003, EUR J BIOCHEM, V270, P3174, DOI 10.1046/j.1432-1033.2003.03697.x; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; Engh RA, 2002, PHARMACOL THERAPEUT, V93, P99, DOI 10.1016/S0163-7258(02)00180-8; Engh RA, 2001, ADV ENZYME REGUL, V41, P121, DOI 10.1016/S0065-2571(00)00010-8; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; Frank RN, 2002, AM J OPHTHALMOL, V133, P693, DOI 10.1016/S0002-9394(02)01321-1; Gassel M, 2003, J MOL BIOL, V329, P1021, DOI 10.1016/S0022-2836(03)00518-7; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; Johnson LN, 2002, PHARMACOL THERAPEUT, V93, P113, DOI 10.1016/S0163-7258(02)00181-X; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; Komander D, 2003, BIOCHEM J, V375, P255, DOI 10.1042/BJ20031119; Komander D, 2004, STRUCTURE, V12, P215, DOI 10.1016/j.str.2004.01.005; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; Li F, 2002, J MOL BIOL, V315, P459, DOI 10.1006/jmbi.2001.5256; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Nakashima S, 2002, J BIOCHEM, V132, P669, DOI 10.1093/oxfordjournals.jbchem.a003272; Narayana N, 1997, STRUCTURE, V5, P921, DOI 10.1016/S0969-2126(97)00246-3; Narayana N, 1999, BIOCHEMISTRY-US, V38, P2367, DOI 10.1021/bi9820659; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; Prade L, 1997, STRUCTURE, V5, P1627, DOI 10.1016/S0969-2126(97)00310-9; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Stubbs MT, 2002, CHEMBIOCHEM, V3, P246, DOI 10.1002/1439-7633(20020301)3:2/3<246::AID-CBIC246>3.0.CO;2-#; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	46	37	38	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23679	23690		10.1074/jbc.M314082200	http://dx.doi.org/10.1074/jbc.M314082200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	14996846	hybrid			2022-12-27	WOS:000221570900110
J	Boskovic, DS; Troxler, T; Krishnaswamy, S				Boskovic, DS; Troxler, T; Krishnaswamy, S			Active site-independent recognition of substrates and product by bovine prothrombinase - A fluorescence resonance energy transfer study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHLOROMETHYL KETONES; COAGULATION-FACTOR-VA; FACTOR-XA; MACROMOLECULAR SUBSTRATE; SERINE PROTEASES; EXOSITE-I; CONFORMATIONAL SENSITIVITY; PHOSPHOLIPID-VESICLES; CRYSTAL-STRUCTURE; ENZYME COMPLEXES	The conversion of prothrombin to thrombin is catalyzed by prothrombinase, an enzyme complex composed of the serine proteinase factor Xa and a cofactor protein, factor Va, assembled on membranes. Kinetic studies indicate that interactions with extended macromolecular recognition sites (exosites) rather than the active site of prothrombinase are the principal determinants of binding affinity for substrate or product. We now provide a model-independent evaluation of such ideas by physical studies of the interaction of substrate derivatives and product with prothrombinase. The enzyme complex was assembled using Xa modified with a fluorescent peptidyl chloromethyl ketone to irreversibly occlude the active site. Binding was inferred by prethrombin 2-dependent perturbations in the fluorescence of Oregon Green(488) at the active site of prothrombinase. Active site-independent binding was also unequivocally established by fluorescence resonance energy transfer between 2,6-dansyl tethered to the active site of Xa and eosin tethered to the active sites of either thrombin or meizothrombin des fragment 1. Comparable interprobe distances obtained from these measurements suggest that substrate and product interact equivalently with the enzyme. Competition established the ability of a range of substrate or product derivatives to bind in a mutually exclusive fashion to prothrombinase. Equilibrium dissociation constants obtained for the active site-independent binding of prothrombin, prethrombin 2, meizothrombin des fragment 1 and thrombin to prothrombinase were comparable with their affinities inferred from kinetic studies using active enzyme. Our findings directly establish that binding affinity is principally determined by the exosite-mediated interaction of either the substrate, both possible intermediates, or product with prothrombinase. A single type of exosite binding interaction evidently drives affinity and binding specificity through the stepwise reactions necessary for the two cleavage reactions of prothrombin activation and product release.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Reg Laser & Biotechnol Lab, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310A Abramson,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Krishnaswamy, Sriram/Z-4380-2019; Boskovic, Danilo/D-4670-2012	Boskovic, Danilo/0000-0001-6919-3726; Troxler, Thomas/0000-0003-2373-6902	NCRR NIH HHS [P41 RR 001348] Funding Source: Medline; NHLBI NIH HHS [HL 74124, HL 62523] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001348] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124, R01HL062523] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aktimur A, 2003, J BIOL CHEM, V278, P7981, DOI 10.1074/jbc.M212748200; Anderson PJ, 2003, J BIOL CHEM, V278, P44482, DOI 10.1074/jbc.M306917200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington PR., 2002, DATA REDUCTION ERROR; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BRANNON JH, 1978, J PHYS CHEM-US, V82, P705, DOI 10.1021/j100495a018; Brufatto N, 2003, J BIOL CHEM, V278, P6755, DOI 10.1074/jbc.M206413200; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P433; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; ESMON CT, 1974, J BIOL CHEM, V249, P7791; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; HOLTOM GR, 1990, P SOC PHOTO-OPT INS, V1204, P2, DOI 10.1117/12.17680; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Lakowicz JR., 1999, PRINCIPLES FLUORESCE, P25; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NISHIDA S, 1995, BIOCHEMISTRY-US, V34, P1771, DOI 10.1021/bi00005a034; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; Rose T, 2002, J BIOL CHEM, V277, P19243, DOI 10.1074/jbc.C200132200; SCOTT TG, 1970, J AM CHEM SOC, V92, P687, DOI 10.1021/ja00706a043; SEGEL IH, 1975, ENZYME KINETICS, P18; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WALKER RK, 1994, J BIOL CHEM, V269, P27441; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200	60	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20786	20793		10.1074/jbc.M400469200	http://dx.doi.org/10.1074/jbc.M400469200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14988397	hybrid			2022-12-27	WOS:000221273800030
J	Wang, D; Lippard, SJ				Wang, D; Lippard, SJ			Cisplatin-induced post-translational modification of histones H3 and H4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-INDUCED PHOSPHORYLATION; P38 MAP KINASES; CELL-DEATH; CHROMOSOME CONDENSATION; EXCISION-REPAIR; STRESS; ACETYLATION; ACTIVATION; CHROMATIN; INDUCTION	The anti-cancer drug cisplatin kills cells by damaging DNA and inducing apoptosis. Understanding the detailed mechanisms by which cancer cells respond to cisplatin has the potential to improve substantially platinum-based therapy. Post-translational modification of histones alters chromatin structure, facilitating the binding of nuclear factors that mediate DNA repair, transcription, and other processes. In the present study, we have investigated the effects of cisplatin treatment on histone post-translational modification in cancer cells. We discovered that specific phosphorylation of histone H3 at Ser-10, mediated by the p38 MAPK pathway, is induced in response to cisplatin treatment. In addition, hyperacetylation of histone H4 was caused by drug treatment. These findings revealed a link between cisplatin administration and chromosomal structural alterations, providing mechanistic information about how cells respond to platinum-induced stress.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu	Wang, Dong/C-8943-2012		NATIONAL CANCER INSTITUTE [R01CA034992, R37CA034992] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.0.CO;2-D; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Labrador M, 2003, GENE DEV, V17, P43, DOI 10.1101/gad.1021403; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Miyata Y, 2001, BIOCHEM BIOPH RES CO, V283, P655, DOI 10.1006/bbrc.2001.4840; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; ROSENBERG B, 1985, CANCER, V55, P2303, DOI 10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; SORENSON CM, 1988, CANCER RES, V48, P6703; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strelkov IS, 2002, CANCER RES, V62, P75; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Wang D, 2003, BIOCHEMISTRY-US, V42, P6747, DOI 10.1021/bi034264k; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2003, ONCOGENE, V22, P5291, DOI 10.1038/sj.onc.1206507; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200	49	47	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20622	20625		10.1074/jbc.M402547200	http://dx.doi.org/10.1074/jbc.M402547200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15010460	hybrid			2022-12-27	WOS:000221273800011
J	Li, HD; Ayer, LM; Polyak, MJ; Mutch, CM; Petrie, RJ; Gauthier, L; Shariat, N; Hendzel, MJ; Shaw, AR; Patel, KD; Deans, JP				Li, HD; Ayer, LM; Polyak, MJ; Mutch, CM; Petrie, RJ; Gauthier, L; Shariat, N; Hendzel, MJ; Shaw, AR; Patel, KD; Deans, JP			The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts - Antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING ELECTRON-MICROSCOPY; LIPID RAFTS; B-LYMPHOCYTES; T-CELL; ACTIVATION; PHOSPHORYLATION; COLOCALIZATION; IMMUNOGLOBULIN; REDISTRIBUTION; IDENTIFICATION	CD20 is a B cell-specific membrane protein that functions in store-operated calcium entry and serves as a useful target for antibody-mediated therapeutic depletion of B cells. Antibody binding to CD20 induces a diversity of biological effects, some of which are dependent on lipid rafts. Rafts are isolated as low density detergent-resistant membranes, initially characterized using Triton X-100. We have previously reported that CD20 is soluble in 1% Triton but that antibodies induce the association of CD20 with Triton-resistant rafts. However, by using several other detergents to isolate rafts and by microscopic co-localization with a glycosylphosphatidylinositol-linked protein, we show in this report that CD20 is constitutively raft-associated. CD20 was distributed in a punctate pattern on the cell surface as visualized by fluorescence imaging and was also localized to microvilli by electron microscopy. The mechanism underlying antibody-induced association of CD20 with Triton-resistant rafts was investigated and found not to require cellular ATP, kinase activity, actin polymerization, or antibody cross-linking but was dependent on the epitope recognized. Thus, antibody-induced insolubility in 1% Triton most likely reflects a transition from relatively weak to strong raft association that occurs as a result of a conformational change in the CD20 protein.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Alberta	Deans, JP (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jdeans@ucalgary.ca	Patel, Kamala D/AAX-1245-2021; Hendzel, Michael/C-3391-2009	Hendzel, Michael/0000-0002-9603-7945				Braccia A, 2003, J BIOL CHEM, V278, P15679, DOI 10.1074/jbc.M211228200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Cragg MS, 2003, BLOOD, V101, P1045, DOI 10.1182/blood-2002-06-1761; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DEANS JP, 1993, J IMMUNOL, V151, P4494; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; Deans JP, 2002, IMMUNOLOGY, V107, P176, DOI 10.1046/j.1365-2567.2002.01495.x; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; GONATAS NK, 1972, LAB INVEST, V26, P253; HASSLEN SR, 1995, HISTOCHEM J, V27, P547; Hooijberg E, 1996, HYBRIDOMA, V15, P23, DOI 10.1089/hyb.1996.15.23; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; KANSAS GS, 1991, J IMMUNOL, V147, P4094; Kusumi A, 1996, CURR OPIN CELL BIOL, V8, P566, DOI 10.1016/S0955-0674(96)80036-6; Li HD, 2003, J BIOL CHEM, V278, P42427, DOI 10.1074/jbc.M308802200; LIN PS, 1973, NEW ENGL J MED, V289, P548, DOI 10.1056/NEJM197309132891102; LINTHICUM DS, 1975, J ULTRA MOL STRUCT R, V51, P55, DOI 10.1016/S0022-5320(75)80008-6; Maloney DG, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30156; PERKINS WD, 1972, J EXP MED, V135, P267, DOI 10.1084/jem.135.2.267; Petrie RJ, 2002, J IMMUNOL, V169, P2886, DOI 10.4049/jimmunol.169.6.2886; PETRIS SD, 1978, NATURE, V272, P66, DOI 10.1038/272066a0; Phong MC, 2003, BIOCHEM BIOPH RES CO, V300, P563, DOI 10.1016/S0006-291X(02)02886-3; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; POLLIACK A, 1973, J EXP MED, V138, P607, DOI 10.1084/jem.138.3.607; Polyak MJ, 2003, LEUKEMIA, V17, P1384, DOI 10.1038/sj.leu.2402978; Polyak MJ, 2002, BLOOD, V99, P3256, DOI 10.1182/blood.V99.9.3256; Polyak MJ, 1998, J IMMUNOL, V161, P3242; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Schreiner G F, 1976, Adv Immunol, V24, P37, DOI 10.1016/S0065-2776(08)60329-6; SCHUCK S, 2003, P NATL ACAD SCI US; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; VALENTINE MA, 1989, J BIOL CHEM, V264, P11282; von Haller PD, 2001, PROTEOMICS, V1, P1010	35	53	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19893	19901		10.1074/jbc.M400525200	http://dx.doi.org/10.1074/jbc.M400525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14976189	hybrid			2022-12-27	WOS:000221164500063
J	Newberry, KJ; Brennan, RG				Newberry, KJ; Brennan, RG			The structural mechanism for transcription activation by MerR family member multidrug transporter activation, N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DNA; REGULATOR; CRYSTALLOGRAPHY; MTAN; ZNTR	Transcription regulators of the MerR family respond to myriad stress signals to activate sigma(70)/sigma(A)-targeted genes, which contain suboptimal 19-bp spacers between their -35 and -10 promoter elements. The crystal structure of a BmrR-TPP+-DNA complex provided initial insight into the transcription activation mechanism of the MerR family, which involves base pair distortion, DNA undertwisting and shortening of the spacer, and realignment of the -35 and -10 boxes. Here, we describe the crystal structure of MerR family member MtaN bound to the mta promoter. Although the global DNA binding modes of MtaN and BmrR differ somewhat, homologous protein-DNA interactions are maintained. Moreover, despite their different sequences, the mta promoter conformation is essentially identical to that of the BmrR-TPP+-bound bmr promoter, indicating that this DNA distortion mechanism is common to the entire MerR family. Interestingly, DNA binding experiments reveal that the identity of the two central bases of the mta and bmr promoters, which are conserved as either a thymidine or an adenine in nearly all MerR promoters, is not important for DNA affinity. Comparison of the free and DNA-bound MtaN structures reveals that a conformational hinge, centered at residues N-terminal to the ubiquitous coiled coil, is key for mta promoter binding. Analysis of the structures of BmrR, CueR, and ZntR indicates that this hinge may be common to all MerR family members.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Brennan, RG (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	brennanr@ohsu.edu		Brennan, Richard/0000-0001-7647-485X	NIAID NIH HHS [T32 AI 07472, AI 48593] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007472, R01AI048593] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSARI AZ, 1995, NATURE, V374, P371; Baranova NN, 1999, MOL MICROBIOL, V31, P1549, DOI 10.1046/j.1365-2958.1999.01301.x; Brocklehurst KR, 1999, MOL MICROBIOL, V31, P893, DOI 10.1046/j.1365-2958.1999.01229.x; Brown NL, 2003, FEMS MICROBIOL REV, V27, P145, DOI 10.1016/S0168-6445(03)00051-2; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Godsey MH, 2000, ACTA CRYSTALLOGR D, V56, P1456, DOI 10.1107/S0907444900010295; Godsey MH, 2001, J BIOL CHEM, V276, P47178, DOI 10.1074/jbc.M105819200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; HELLMANN EE, 2002, BACILLUS SUBTILIS IT, P289; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; Outten CE, 1999, J BIOL CHEM, V274, P37517, DOI 10.1074/jbc.274.53.37517; RECORD JMT, 1996, ESCHERICHIA COLI SAL, V1, P792; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	22	101	105	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20356	20362		10.1074/jbc.M400960200	http://dx.doi.org/10.1074/jbc.M400960200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14985361	hybrid			2022-12-27	WOS:000221164500113
J	Rao, SK; Huynh, C; Proux-Gillardeaux, V; Galli, T; Andrews, NW				Rao, SK; Huynh, C; Proux-Gillardeaux, V; Galli, T; Andrews, NW			Identification of SNAREs involved in synaptotagmin VII-regulated lysosomal exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; CLOSTRIDIAL NEUROTOXINS; NEUROTRANSMITTER RELEASE; MOLECULAR-MECHANISMS; PLATELET EXOCYTOSIS; EPITHELIAL-CELLS; 3T3-L1 CELLS; CA2+ SENSOR	Ca2+-regulated exocytosis of lysosomes has been recognized recently as a ubiquitous process, important for the repair of plasma membrane wounds. Lysosomal exocytosis is regulated by synaptotagmin VII, a member of the synaptotagmin family of Ca2+-binding proteins localized on lysosomes. Here we show that Ca2+-dependent interaction of the synaptotagmin VII C(2)A domain with SNAP-23 is facilitated by syntaxin 4. Specific interactions also occurred in cell lysates between the plasma membrane t-SNAREs SNAP-23 and syntaxin 4 and the lysosomal v-SNARE TI-VAMP/VAMP7. Following cytosolic Ca2+ elevation, SDS-resistant complexes containing SNAP-23, syntaxin 4, and TI-VAMP/VAMP7 were detected on membrane fractions. Lysosomal exocytosis was inhibited by the SNARE domains of syntaxin 4 and TI-VAMP/VAMP7 and by cleavage of SNAP-23 with botulinum neurotoxin E, thereby functionally implicating these SNAREs in Ca2+-regulated exocytosis of conventional lysosomes.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06536 USA; Inst Fer Moulin, INSERM, U536, F-75005 Paris, France	Yale University; Yale University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Andrews, NW (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, 295 Congress Ave, New Haven, CT 06536 USA.	norma.andrews@yale.edu	Galli, Thierry/G-8842-2011; Galli, Thierry/Q-2249-2019	Galli, Thierry/0000-0001-8514-7455; Galli, Thierry/0000-0001-8514-7455; Andrews, Norma/0000-0002-0611-2412	NIGMS NIH HHS [R01 GM064625, GM 07499-24] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; Banerjee A, 2001, AM J PHYSIOL-CELL PH, V280, pC775; BLASI J, 1994, J PHYSIOLOGY-PARIS, V88, P235, DOI 10.1016/0928-4257(94)90086-8; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; Caler EV, 2001, J EXP MED, V193, P1097, DOI 10.1084/jem.193.9.1097; Chakrabarti S, 2003, J CELL BIOL, V162, P543, DOI 10.1083/jcb.200305131; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chieregatti E, 2004, MOL BIOL CELL, V15, P1918, DOI 10.1091/mbc.E03-09-0684; Craxton M, 1999, FEBS LETT, V460, P417, DOI 10.1016/S0014-5793(99)01382-4; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Filippini F, 2001, TRENDS BIOCHEM SCI, V26, P407, DOI 10.1016/S0968-0004(01)01861-8; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hibi T, 2000, BIOCHEM BIOPH RES CO, V271, P36, DOI 10.1006/bbrc.2000.2591; Huang XH, 2001, PANCREAS, V23, P125, DOI 10.1097/00006676-200108000-00002; Jaiswal JK, 2002, J CELL BIOL, V159, P625, DOI 10.1083/jcb.200208154; Koh TW, 2003, TRENDS NEUROSCI, V26, P413, DOI 10.1016/S0166-2236(03)00195-4; Lawrence GW, 2002, J CELL SCI, V115, P667; Lemons PP, 2000, BIOCHEM BIOPH RES CO, V267, P875, DOI 10.1006/bbrc.1999.2039; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Macaulay SL, 1997, BIOCHEM BIOPH RES CO, V237, P388, DOI 10.1006/bbrc.1997.7143; Martin-Martin B, 2000, BLOOD, V96, P2574; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; Martinez-Arca S, 2000, J CELL BIOL, V149, P889, DOI 10.1083/jcb.149.4.889; Martinez-Arca S, 2003, P NATL ACAD SCI USA, V100, P9011, DOI 10.1073/pnas.1431910100; Muzerelle A, 2003, NEUROSCIENCE, V122, P59, DOI 10.1016/S0306-4522(03)00567-0; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rickman C, 2004, J BIOL CHEM, V279, P644, DOI 10.1074/jbc.M310879200; Rickman C, 2004, J BIOL CHEM, V279, P12574, DOI 10.1074/jbc.M310710200; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; St-Denis JF, 1999, BIOCHEM J, V338, P709, DOI 10.1042/0264-6021:3380709; Steegmaier M, 1999, MOL BIOL CELL, V10, P1957, DOI 10.1091/mbc.10.6.1957; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Tucker WC, 2003, J CELL BIOL, V162, P199, DOI 10.1083/jcb.200302060; Vaidyanathan VV, 2001, J BIOL CHEM, V276, P25101, DOI 10.1074/jbc.M103536200; Vaidyanathan VV, 1999, J NEUROCHEM, V72, P327, DOI 10.1046/j.1471-4159.1999.0720327.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	54	234	243	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20471	20479		10.1074/jbc.M400798200	http://dx.doi.org/10.1074/jbc.M400798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14993220	hybrid			2022-12-27	WOS:000221164500126
J	Raychowdhury, MK; Ibarra, C; Damiano, A; Jackson, GR; Smith, PR; McLaughlin, M; Prat, AG; Ausiello, DA; Lader, AS; Cantiello, HF				Raychowdhury, MK; Ibarra, C; Damiano, A; Jackson, GR; Smith, PR; McLaughlin, M; Prat, AG; Ausiello, DA; Lader, AS; Cantiello, HF			Characterization of Na+-permeable cation channels in LLC-PK1 renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULAR CELLS; SENSITIVE SODIUM-CHANNEL; LINE LLC-PK1; PROTEIN-KINASE; XENOPUS-LAEVIS; PIG-KIDNEY; AMILORIDE; LOCALIZATION; VASOPRESSIN; EXPRESSION	In this study, the presence of Na+-permeable cation channels was determined and characterized in LLC-PK1 cells, a renal tubular epithelial cell line with proximal tubule characteristics derived from pig kidney. Patch-clamp analysis under cell-attached conditions indicated the presence of spontaneously active Na+-permeable cation channels. The channels displayed nonrectifying single channel conductance of 11 pS, substates, and an similar to3:1 Na+/K+ permeability-selectivity ratio. The Na+-permeable cation channels were inhibited by pertussis toxin and reactivated by G protein agonists. Cation channel activity was observed in quiescent cell-attached patches after vasopressin stimulation. The addition of protein kinase A and ATP to excised patches also induced Na+ channel activity. Spontaneous and vasopressin-induced Na+ channel activity were inhibited by extracellular amiloride. To begin assessing potential molecular candidates for this cation channel, both reverse transcription-PCR and immunocytochemical analyses were conducted in LLC-PK1 cells. Expression of porcine orthologs of the alphaENaC and ApxL genes were found in LLC-PK1 cells. The expression of both gene products was confirmed by immunocytochemical analysis. Although alphaENaC labeling was mostly intracellular, ApxL labeled to both the apical membrane and cytoplasmic compartments of subconfluent LLC-PK1 cells. Vasopressin stimulation had no effect on alphaENaC immunolabeling but modified the cellular distribution of ApxL, consistent with an increased membrane-associated ApxL. The data indicate that proximal tubular LLC-PK1 renal epithelial cells express amiloride-sensitive, Na+-permeable cation channels, which are regulated by the cAMP pathway, and G proteins. This channel activity may implicate previously reported epithelial channel proteins, although this will require further experimentation. The evidence provides new clues as to potentially relevant Na+ transport mechanisms in the mammalian proximal nephron.	Massachusetts Gen Hosp E, Renal Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Buenos Aires, Fac Med, Dept Fisiol, RA-1121 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Farm & Bioquim, Dept Fisicoquim, Lab Canales Ion Quim Gen & Inorgan, RA-1113 Buenos Aires, DF, Argentina; Univ Alabama, Dept Physiol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biophys, Birmingham, AL 35294 USA	Harvard University; Harvard Medical School; University of Buenos Aires; University of Buenos Aires; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Cantiello, HF (corresponding author), Massachusetts Gen Hosp E, Renal Unit, 149 13th St, Charlestown, MA 02129 USA.	cantiello@helix.mgh.harvard.edu			NIDDK NIH HHS [DK 48040, T32 DK 07540 C15] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048040, T32DK007540] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; AUSIELLO DA, 1980, BIOCHEM J, V186, P773, DOI 10.1042/bj1860773; BENOS DJ, 1986, P NATL ACAD SCI USA, V83, P8525, DOI 10.1073/pnas.83.22.8525; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1986, J BIOL CHEM, V261, P3252; CANTIELLO HF, 1987, AM J PHYSIOL, V252, pF590, DOI 10.1152/ajprenal.1987.252.4.F590; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CANTIELLO HF, 1991, AM J PHYSIOL, V261, P882; Ciampolillo F, 1996, AM J PHYSIOL-CELL PH, V271, pC1303, DOI 10.1152/ajpcell.1996.271.4.C1303; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; ELGAVISH GA, 1985, BIOCHEM BIOPH RES CO, V128, P746, DOI 10.1016/0006-291X(85)90110-X; FULLER CM, 1995, AM J PHYSIOL-CELL PH, V269, pC641, DOI 10.1152/ajpcell.1995.269.3.C641; GOGELEIN H, 1986, PFLUG ARCH EUR J PHY, V406, P198, DOI 10.1007/BF00586683; GOLDRING SR, 1978, BIOCHEM BIOPH RES CO, V83, P434, DOI 10.1016/0006-291X(78)91009-4; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Hager H, 2001, AM J PHYSIOL-RENAL, V280, pF1093, DOI 10.1152/ajprenal.2001.280.6.F1093; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; Loffing J, 2000, AM J PHYSIOL-RENAL, V278, pF530, DOI 10.1152/ajprenal.2000.278.4.F530; MORAN A, 1984, FED PROC, V43, P447; MORAN A, 1988, J BIOL CHEM, V263, P19586; OHARA A, 1993, AM J PHYSIOL, V264, P352; Prat AG, 1996, J BIOL CHEM, V271, P18045, DOI 10.1074/jbc.271.30.18045; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; PRAT AG, 1993, AM J PHYSIOL, V265, pC218, DOI 10.1152/ajpcell.1993.265.1.C218; RABITO CA, 1982, J BIOL CHEM, V257, P6802; RABITO CA, 1986, AM J PHYSIOL, V250, pF734, DOI 10.1152/ajprenal.1986.250.4.F734; RABITO CA, 1980, J MEMBRANE BIOL, V54, P31, DOI 10.1007/BF01875374; RABITO CA, 1983, AM J PHYSIOL, V245, pF22, DOI 10.1152/ajprenal.1983.245.1.F22; SARIBANSOHRABY S, 1992, AM J PHYSIOL, V263, pC1111, DOI 10.1152/ajpcell.1992.263.5.C1111; SCHIAFFINO MV, 1995, HUM MOL GENET, V4, P373, DOI 10.1093/hmg/4.3.373; Smith PR, 1998, AM J PHYSIOL-RENAL, V274, pF91, DOI 10.1152/ajprenal.1998.274.1.F91; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; VOLKL H, 1988, BIOCHIM BIOPHYS ACTA, V946, P5, DOI 10.1016/0005-2736(88)90450-6; WEINSTEIN AM, 2000, KIDNEY PHYSL PATHOPH, V3, P1287; Willmann JK, 1997, PFLUG ARCH EUR J PHY, V434, P173, DOI 10.1007/s004240050380; Zuckerman JB, 1999, J BIOL CHEM, V274, P23286, DOI 10.1074/jbc.274.33.23286	37	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20137	20146		10.1074/jbc.M311946200	http://dx.doi.org/10.1074/jbc.M311946200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14982925	hybrid			2022-12-27	WOS:000221164500090
J	Sommer, F; Drepper, F; Haehnel, W; Hippler, M				Sommer, F; Drepper, F; Haehnel, W; Hippler, M			The hydrophobic recognition site formed by residues PsaA-Trp(651) and PsaB-Trp(627) of photosystem I in Chlamydomonas reinhardtii confers distinct selectivity for binding of plastocyanin and cytochrome c(6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST-ELECTRON TRANSFER; DIRECTED MUTAGENESIS; ANGSTROM RESOLUTION; PSAF; SUBUNIT; REDUCTION; PROTEINS; DONOR; CHLOROPLAST; EXPRESSION	On the lumenal side of photosystem I (PSI), each of the two large core subunits, PsaA and PsaB, expose a conserved tryptophan residue to the surface. PsaB-Trp(627) is part of the hydrophobic recognition site that is essential for tight binding of the two electron donors plastocyanin and cytochrome c(6) to the donor side of PSI (Sommer, F., Drepper, F., and Hippler, M. (2002) J. Biol. Chem. 277, 6573-6581). To examine the function of PsaA-Trp(651) in binding and electron transfer of both donors to PSI, we generated the mutants PsaA-W651F and PsaA-W651S by site-directed mutagenesis and biolistic transformation of Chlamydomonas reinhardtii. The protein-protein interaction and the electron transfer between the donors and PSI isolated from the mutants were analyzed by flash absorption spectroscopy. The mutation PsaA-W651F completely abolished the formation of a first order electron transfer complex between plastocyanin (pc) and the altered PSI and increased the dissociation constant for binding of cytochrome (cyt) c(6) by more than a factor of 10 as compared with wild type. Mutation of PsaA-Trp(651) to Ser had an even larger impact on the dissociation constant. The K-D value increased another 2-fold when the values obtained for the interaction and electron transfer between cyt c(6) and PSI from PsaA-W651S and PsaA-W651F are compared. In contrast, binding and electron transfer of pc to PSI from PsaA-W651S improved as compared with PSI from PsaA-W651F and admitted the formation of an intermolecular electron transfer complex, resulting in a K-D value of about 554 muM that is still five times higher than observed for wild type. These results demonstrate that PsaA-Trp(651) is, such as PsaB-Trp(627), crucial for high affinity binding of pc and cyt c(6) to PSI. Our results also indicate that the highly conserved structural recognition motif that is formed by PsaA-Trp(651) and PsaB-Trp(627) confers a differential selectivity in binding of both donors to PSI.	Univ Jena, Lehrstuhl Pflanzenphysiol, D-07743 Jena, Germany; Univ Freiburg, D-79104 Freiburg, Germany	Friedrich Schiller University of Jena; University of Freiburg	Hippler, M (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	mhippler@sas.upenn.edu		Michael, Hippler/0000-0001-9670-6101; Drepper, Friedel/0000-0002-2043-5795				Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; De la Cerda B, 1999, J BIOL CHEM, V274, P13292, DOI 10.1074/jbc.274.19.13292; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; Haldrup A, 2000, J BIOL CHEM, V275, P31211, DOI 10.1074/jbc.M002933200; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; Hippler M, 1999, J BIOL CHEM, V274, P4180, DOI 10.1074/jbc.274.7.4180; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Hippler M, 2002, PROTIST, V153, P197, DOI 10.1078/1434-4610-00098; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KERFELD CA, 1995, J MOL BIOL, V250, P627, DOI 10.1006/jmbi.1995.0404; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; Molina-Heredia FP, 1999, J BIOL CHEM, V274, P33565, DOI 10.1074/jbc.274.47.33565; Molina-Heredia FP, 2001, J BIOL CHEM, V276, P601, DOI 10.1074/jbc.M007081200; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Ramesh VM, 2002, BIOCHEMISTRY-US, V41, P14652, DOI 10.1021/bi026392z; Redding K, 1998, EMBO J, V17, P50, DOI 10.1093/emboj/17.1.50; REDINBO MR, 1994, J BIOENERG BIOMEMBR, V26, P49, DOI 10.1007/BF00763219; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDMANN G, 1986, ARCH MICROBIOL, V21, P6366; Setif P, 2001, BBA-BIOENERGETICS, V1507, P161, DOI 10.1016/S0005-2728(01)00205-5; Sommer F, 2003, PLANT CELL ENVIRON, V26, P1881, DOI 10.1046/j.1365-3040.2003.01105.x; Sommer F, 2002, J BIOL CHEM, V277, P6573, DOI 10.1074/jbc.M110633200; Sun J, 1999, J BIOL CHEM, V274, P19048, DOI 10.1074/jbc.274.27.19048; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; XU QA, 1994, J BIOL CHEM, V269, P3205	35	41	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20009	20017		10.1074/jbc.M313986200	http://dx.doi.org/10.1074/jbc.M313986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14996834	hybrid			2022-12-27	WOS:000221164500076
J	Twiddy, D; Brown, DG; Adrain, C; Jukes, R; Martin, SJ; Cohen, GM; MacFarlane, M; Cain, K				Twiddy, D; Brown, DG; Adrain, C; Jukes, R; Martin, SJ; Cohen, GM; MacFarlane, M; Cain, K			Pro-apoptotic proteins released from the mitochondria regulate the protein composition and caspase-processing activity of the native Apaf-1/caspase-9 apoptosome complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C BINDING; APAF-1 APOPTOSOME; STRUCTURAL BASIS; MEDIATED OLIGOMERIZATION; DEPENDENT FORMATION; NEGATIVE REGULATION; ELEGANS CED-4; ACTIVATION; XIAP; PROCASPASE-9	The apoptosome is a large caspase-activating ( similar to 700 1400 kDa) complex, which is assembled from Apaf-1 and caspase-9 when cytochrome c is released during mitochondrial-dependent apoptotic cell death. Apaf-1 the core scaffold protein is similar to 135 kDa and contains CARD ( caspase recruitment domain), CED-4, and multiple (13) WD40 repeat domains, which can potentially interact with a variety of unknown regulatory proteins. To identify such proteins we activated THP.1 lysates with dATP/cytochrome c and used sucrose density centrifugation and affinity-based methods to purify the apoptosome for analysis by MALDI-TOF mass spectrometry. First, we used a glutathione S-transferase (GST) fusion protein ( GST-casp9(1-130)) containing the CARD domain of caspase-9-(1-130), which binds to the CARD domain of Apaf-1 when it is in the apoptosome and blocks recruitment/activation of caspase-9. This affinity-purified apoptosome complex contained only Apaf-1XL and GST-casp9(1-130), demonstrating that the WD40 and CED-4 domains of Apaf-1 do not stably bind other cytosolic proteins. Next we used a monoclonal antibody to caspase-9 to immunopurify the native active apoptosome complex from cell lysates, containing negligible levels of cytochrome c, second mitochondria-derived activator of caspase ( Smac), or Omi/HtrA2. This apoptosome complex exhibited low caspase-processing activity and contained four stably associated proteins, namely Apaf-1, pro-p35/34 forms of caspase-9, pro-p20 forms of caspase-3 ,X-linked inhibitor of apoptosis ( XIAP), and cytochrome c, which was only bound transiently to the complex. However, in lysates containing Smac and Omi/HtrA2, the caspase-processing activity of the purified apoptosome complex increased 6-8-fold and contained only Apaf-1 and the p35/p34-processed subunits of caspase-9. During apoptosis, Smac, Omi/HtrA2, and cytochrome c are released simultaneously from mitochondria, and thus it is likely that the functional apoptosome complex in apoptotic cells consists primarily of Apaf-1 and processed caspase-9.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Dublin 2, Ireland	University of Leicester; Trinity College Dublin	Cain, K (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg, Leicester LE1 9HN, Leics, England.	kc5@le.ac.uk	Cohen, Gerald M/A-1687-2008; Adrain, Colin/I-6259-2013	Adrain, Colin/0000-0001-7597-4393; Martin, Seamus/0000-0002-8539-3143				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Almond JB, 2001, LEUKEMIA, V15, P1388, DOI 10.1038/sj.leu.2402201; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Bratton SB, 2002, CELL DEATH DIFFER, V9, P881, DOI 10.1038/sj.cdd.4401069; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Hengartner M, 1998, SCIENCE, V281, P1298, DOI 10.1126/science.281.5381.1298; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Purring-Koch C, 2000, P NATL ACAD SCI USA, V97, P11928, DOI 10.1073/pnas.220416197; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Rehm M, 2003, J CELL BIOL, V162, P1031, DOI 10.1083/jcb.200303123; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	49	91	101	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19665	19682		10.1074/jbc.M311388200	http://dx.doi.org/10.1074/jbc.M311388200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14993223	hybrid			2022-12-27	WOS:000221164500036
J	Wang, JZ; Wei, QQ; Wang, CY; Hill, WD; Hess, DC; Dong, Z				Wang, JZ; Wei, QQ; Wang, CY; Hill, WD; Hess, DC; Dong, Z			Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CEREBELLAR GRANULE NEURONS; MICROGLIAL ACTIVATION; BAX TRANSLOCATION; FAMILY-MEMBERS; MOUSE MODEL; APOPTOSIS; DISEASE; NEUROTOXICITY; INHIBITION	Robust neuroprotective effects have been shown for minocycline. Whether it also protects nonneuronal cells or tissues is unknown. More importantly, the mechanisms of minocylcine protection appear multifaceted and remain to be clarified. Here we show that minocycline can protect kidney epithelial cells in vitro and protect the kidneys from ischemic injury in vivo. We further show that Bcl-2 is a key molecular determinant of minocycline protection. Minocycline protected kidney epithelial cells against apoptosis induced by hypoxia, azide, cisplatin, and staurosporine. The protection occurred at mitochondria, involving the suppression of Bax accumulation, outer membrane damage, and cytochrome c release. Minocycline induced Bcl-2, which accumulated in mitochondria and interacted with death-promoting molecules including Bax, Bak, and Bid. Down-regulation of Bcl-2 by specific antisense oligonucleotides abolished the cytoprotective effects of minocycline. Thus, minocycline can protect neuronal as well as nonneuronal cells and tissues. One mechanism for minocycline protection involves the induction of Bcl-2, an antiapoptotic protein.	Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USA; Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Dong, Z (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	zdong@mail.mcg.edu		Wang, Cong-Yi/0000-0001-7914-168X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058831] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58831] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Dong Z, 2000, BIOCHEM J, V347, P669, DOI 10.1042/0264-6021:3470669; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Dong Z, 2003, EXP CELL RES, V288, P301, DOI 10.1016/S0014-4827(03)00214-3; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; KLEIN NC, 1995, MED CLIN N AM, V79, P789, DOI 10.1016/S0025-7125(16)30039-6; Lin SZ, 2003, LIFE SCI, V72, P1635, DOI 10.1016/S0024-3205(02)02442-6; Lin SZ, 2001, NEUROSCI LETT, V315, P61, DOI 10.1016/S0304-3940(01)02324-2; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Ryan Maria E., 1996, Current Opinion in Rheumatology, V8, P238, DOI 10.1097/00002281-199605000-00013; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF184, DOI 10.1152/ajprenal.1996.271.1.F184; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka TM, 2002, BRAIN, V125, P722, DOI 10.1093/brain/awf068; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wang XD, 2001, GENE DEV, V15, P2922; Wei QQ, 2004, AM J PHYSIOL-RENAL, V286, pF803, DOI 10.1152/ajprenal.00093.2003; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	40	200	211	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19948	19954		10.1074/jbc.M313629200	http://dx.doi.org/10.1074/jbc.M313629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004018	hybrid			2022-12-27	WOS:000221164500069
J	Nishiya, T; DeFranco, AL				Nishiya, T; DeFranco, AL			Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the toll-like receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN DENDRITIC CELLS; CPG-DNA; CONTAINING ADAPTER; C57BL/10SCCR MICE; IMMUNE-RESPONSES; INTERFERON-BETA; NITRIC-OXIDE; CUTTING EDGE; TLR4	Toll-like receptors (TLRs) are sensors for the detection of invading infectious agents and can initiate innate immune responses. Because the innate immune system induces an appropriate defense against different pathogens, different TLR signaling domains may have unique properties that are responsible for eliciting distinctive responses to different types of pathogens. To test this hypothesis, we created ligand-regulated TLR chimeric receptors composed of the extracellular region of TLR4 and the transmembrane and cytoplasmic regions of other TLRs and expressed these chimeras in macrophages lacking endogenous TLR4. Interestingly, the chimeras between TLR4 and either TLR3, TLR7, or TLR9 were localized completely intracellularly whereas other chimeras were expressed on the cell surface. Lipopolysaccharide (LPS), a ligand for these chimeras, induced the activation of nuclear factor kappaB and mitogen-activated protein kinases and the subsequent production of pro-inflammatory cytokines in macrophages expressing TLR4, TLR4/TLR5, or TLR4/TLR8 chimeras but not in macrophages expressing TLR4/TLR1, TLR4/TLR2, or TLR4/TLR6 chimeras. Co-expression of unresponsive chimeras in some combinations (chimeras with TLR1+TLR2 or TLR2+TLR6 but not TLR1+TLR6) resulted in LPS responsiveness, indicating functional complementarity. Furthermore, the pair of TLR2+TLR6 chimera required approximately 10-fold less LPS to induce the same responses compared with the TLR1+TLR2 pair. Finally, LPS induced effective interferon-beta production and subsequent Stat1 phosphorylation in macrophages expressing full-length TLR4 but not other cell surface TLR chimeras. These results suggest that the functions of TLRs are diversified not only in their extracellular regions for ligand recognition but also in their transmembrane and cytoplasmic regions for subcellular localization and signaling properties.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	DeFranco, AL (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, Box 0414,HSE1001F,513 Parnassus Ave, San Francisco, CA 94143 USA.	defranco@cgl.ucsf.edu			NIAID NIH HHS [AI33442, AI20038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020038, R37AI020038, R01AI033442] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arima T, 1996, NEUROSCI LETT, V212, P1, DOI 10.1016/0304-3940(96)12758-0; Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Beutler B, 2003, ANNU REV PHARMACOL, V43, P609, DOI 10.1146/annurev.pharmtox.43.100901.135729; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Onishi M, 1996, EXP HEMATOL, V24, P324; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 2000, J ENDOTOXIN RES, V6, P51, DOI 10.1177/09680519000060010701; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Sandor F, 2003, J CELL BIOL, V162, P1099, DOI 10.1083/jcb.200304093; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554; Zhang HF, 2002, FEBS LETT, V532, P171, DOI 10.1016/S0014-5793(02)03669-4	49	194	214	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19008	19017		10.1074/jbc.M311618200	http://dx.doi.org/10.1074/jbc.M311618200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976215	hybrid			2022-12-27	WOS:000221041500113
J	O'Mahony, AM; Montano, M; Van Beneden, K; Chen, LF; Greene, WC				O'Mahony, AM; Montano, M; Van Beneden, K; Chen, LF; Greene, WC			Human T-cell lymphotropic virus type 1 tax induction of biologically active NF-kappa B requires I kappa B kinase-1-mediated phosphorylation of RelA/p65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-ALPHA; KINASE-ALPHA; TRANSCRIPTIONAL ACTIVITY; MICE LACKING; P65 SUBUNIT; LIVER DEGENERATION; ACTIVATION; BETA; PROTEIN; ONCOPROTEIN	Activation of the NF-kappaB/Rel family of transcription factors proceeds through a catalytic complex containing IkappaB kinase (IKK)-1 and IKK2. Targeted disruption of each of the IKK genes suggests that these two kinases may mediate distinct functions in the activation pathway. In our studies of the human T-cell lymphotropic virus type 1 (HTLV-1) Tax oncoprotein, we have uncovered a new function of IKK1 required for complete activation of the NF-kappaB transcriptional program. In IKK1(-/-) murine embryonic fibroblasts (MEFs), Tax normally induced early NF-kappaB activation events. However, NF-kappaB induced by Tax in these IKK1(-/-) cells was functionally impaired. In IKK1(-/-) (but not wild-type) MEFs, Tax failed to activate several different kappaB reporter constructs or to induce the endogenous IkappaBalpha gene. In contrast, Tax normally activated the cAMP-responsive element-binding protein/activating transcription factor pathway, leading to full stimulation of an HTLV-1 long terminal repeat reporter construct in IKK1(-/-) cells. Furthermore, reconstitution of IKK1(-/-) cells with kinase-proficient ( but not kinase-deficient) forms of IKK1 restored the Tax induction of full NF-kappaB transactivation. We further found that the defect in NF-kappaB action in IKK1(-/-) cells correlated with a failure of Tax to induce phosphorylation of the RelA/p65 subunit of NF-kappaB at Ser(529) and Ser(536). Such phosphorylation of RelA/p65 was readily detected in wild-type MEFs. Phosphorylation of Ser(536) was required for a complete response to Tax expression, whereas phosphorylation of Ser(529) appeared to be less critical. Together, these findings highlight distinct roles for the IKK1 and IKK2 kinases in the activation of NF-kappaB in response to HTLV-1 Tax. IKK2 plays a dominant role in signaling for IkappaBalpha degradation, whereas IKK1 appears to play an important role in enhancing the transcriptional activity of NF-kappaB by promoting RelA/p65 phosphorylation.	Univ Calif San Francisco, Dept Med, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes	Greene, WC (corresponding author), Univ Calif San Francisco, Dept Med, Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.	wgreene@gladstone.ucsf.edu	Van Beneden, Katrien/E-2282-2011		NATIONAL CANCER INSTITUTE [R01CA089001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008637] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA89001] Funding Source: Medline; NIAMS NIH HHS [F32AR08637] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Barmak K, 2003, VIROLOGY, V308, P1, DOI 10.1016/S0042-6822(02)00091-0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 1999, GENE EXPRESSION, V7, P233; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	58	88	93	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18137	18145		10.1074/jbc.M401397200	http://dx.doi.org/10.1074/jbc.M401397200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14963024	hybrid			2022-12-27	WOS:000221041500008
J	Panda, K; Adak, S; Konas, D; Sharma, M; Stuehr, DJ				Panda, K; Adak, S; Konas, D; Sharma, M; Stuehr, DJ			A conserved aspartate (Asp-1393) regulates NADPH reduction of neuronal nitric-oxide synthase - Implications for catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P450 OXIDOREDUCTASE; SITE-DIRECTED MUTAGENESIS; ELECTRON FLOW-THROUGH; NO COMPLEX-FORMATION; FERREDOXIN-NADP(+) REDUCTASE; CRYSTAL-STRUCTURE; FLAVIN DOMAIN; ANGSTROM RESOLUTION; CONTROL ELEMENT; BINDING DOMAIN	Nitric-oxide synthases (NOSs) are flavo-heme enzymes whose electron transfer reactions are controlled by calmodulin (CaM). The NOS flavoprotein domain includes a ferredoxin-NADP(+) reductase (FNR)-like module that contains NADPH- and FAD-binding sites. FNR-like modules in related flavoproteins have three conserved residues that regulate electron transfer between bound NAD(P)H and FAD. To investigate the function of one of these residues in neuronal NOS ( nNOS), we generated and characterized mutants that had Val, Glu, or Asn substituted for the conserved Asp-1393. All three mutants exhibited normal composition, spectral properties, and binding of cofactors, substrates, and CaM. All had slower NADPH- dependent cytochrome c and ferricyanide reductase activities, which were associated with proportionally slower rates of NADPH- dependent flavin reduction in the CaM-free and CaM-bound states. Rates of NO synthesis were also proportionally slower in the mutants and were associated with slower rates of CaM-dependent ferric heme reduction. However, a D1393V mutant whose flavins had been prereduced with NADPH had a normal rate of heme reduction. This indicated that the kinetic defect was restricted to flavin reduction step(s) in the mutants and suggested that this limited their catalytic activities. Together, our results show the following. 1) The presence and positioning of the Asp-1393 carboxylate side chain are critical to enable NADPH-dependent reduction of the nNOS flavoprotein. 2) Control of flavin reduction is important because it ensures that the rate of heme reduction is sufficiently fast to enable NO synthesis by nNOS.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org	Panda, Koustubh/E-5273-2017	Panda, Koustubh/0000-0002-4783-2221	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; Abu-Soud HM, 1999, BIOCHEMISTRY-US, V38, P12446, DOI 10.1021/bi990698x; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Aliverti A, 1998, J BIOL CHEM, V273, P34008, DOI 10.1074/jbc.273.51.34008; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; Bewley MC, 2001, BIOCHEMISTRY-US, V40, P13574, DOI 10.1021/bi0106336; Bishop CD, 2003, EVOL DEV, V5, P542, DOI 10.1046/j.1525-142X.2003.03059.x; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Daff S, 2001, BIOCHEM SOC T, V29, P147, DOI 10.1042/0300-5127:0290147; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Finn RD, 2003, EUR J BIOCHEM, V270, P1164, DOI 10.1046/j.1432-1033.2003.03474.x; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Gorren ACF, 2002, BIOCHEMISTRY-US, V41, P7819, DOI 10.1021/bi025675o; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Guan ZW, 2003, ARCH BIOCHEM BIOPHYS, V412, P65, DOI 10.1016/S0003-9861(03)00009-2; Gutierrez A, 2003, BIOCHEM SOC T, V31, P497, DOI 10.1042/BST0310497; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; IGNARRO LJ, 2000, NITRIX OXIDE BIOL PA; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Munro AW, 2002, TRENDS BIOCHEM SCI, V27, P250, DOI 10.1016/S0968-0004(02)02086-8; Nishida CR, 2002, DRUG METAB REV, V34, P479, DOI 10.1081/DMR-120005648; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Olteanu H, 2001, J BIOL CHEM, V276, P35558, DOI 10.1074/jbc.M103707200; OPRIAN DD, 1982, J BIOL CHEM, V257, P8935; Panda K, 2003, J BIOL CHEM, V278, P37122, DOI 10.1074/jbc.M304456200; Panda Satya P., 2002, Nitric Oxide, V6, P445; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; Roitel O, 2003, BIOCHEMISTRY-US, V42, P10809, DOI 10.1021/bi034562h; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Senda T, 2000, J MOL BIOL, V304, P397, DOI 10.1006/jmbi.2000.4200; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; Shen AL, 1999, J BIOL CHEM, V274, P5391, DOI 10.1074/jbc.274.9.5391; Shen AL, 1996, BIOCHEMISTRY-US, V35, P9451, DOI 10.1021/bi960587n; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Witteveen CFB, 1998, BIOCHEM BIOPH RES CO, V250, P36, DOI 10.1006/bbrc.1998.8807; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	64	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18323	18333		10.1074/jbc.M310391200	http://dx.doi.org/10.1074/jbc.M310391200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14966111	hybrid			2022-12-27	WOS:000221041500029
J	Su, SV; Hong, P; Baik, S; Negrete, OA; Gurney, KB; Lee, B				Su, SV; Hong, P; Baik, S; Negrete, OA; Gurney, KB; Lee, B			DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; C-TYPE-LECTIN; HUMAN DENDRITIC CELLS; INTERCELLULAR-ADHESION MOLECULE-3; SELECTIVE RECOGNITION; EBOLA-VIRUS; (ICAM-3)-GRABBING NONINTEGRIN; ICAM-3-GRABBING NONINTEGRIN; CARBOHYDRATE-RECOGNITION; MANNOSE RECEPTOR	DC-SIGN is a C-type lectin that binds to endogenous adhesion molecules ICAM-2 and ICAM-3 as well as the viral envelope glycoprotein human immunodeficiency virus, type 1, glycoprotein (gp) 120. We wished to determine whether DC-SIGN binds differently to its endogenous ligands ICAM-2 and ICAM-3 versus HIV-1 gp120. We found that recombinant soluble DC-SIGN bound to gp120-Fc more than 100- and 50-fold better than ICAM-2-Fc and ICAM-3-Fc, respectively. This relative difference was maintained using DC-SIGN expressed on three different CD4-negative cell lines. Although the cell surface affinity for gp120 varied by up to 4-fold on the cell lines examined, the affinity for gp120 was not a correlate of the ability of the cell line to transfer virus. Monosaccharides with equatorial 4-OH groups competed as well as D-mannose for gp120 binding to DC-SIGN, regardless of how the other hydroxyl groups were positioned. Disaccharide competitors and glycan chip analysis showed that DC-SIGN has a preference for oligosaccharides linked in an alpha-anomeric configuration. Alanine-scanning mutagenesis of DC-SIGN revealed that highly conserved residues that coordinate calcium (Asp-366) and/or are involved in both calcium and specific carbohydrate interactions (Glu-347, Asn-349, Glu-354, and Asp-355) significantly compromised binding to all three ligands. Mutating non-conserved residues (Asn-311, Arg-345, Val-351, Gly-352, Glu-353, Ser-360, Gly-361, and Asn-362) minimally affected binding except for the Asp-367 mutant, which enhanced gp120 binding but diminished ICAM-2 and ICAM-3 binding. Conversely, mutating the moderately conserved residue (Gly-346) abrogated gp120 binding but enhanced ICAM-2 and ICAM-3 binding. Thus, DC-SIGN appears to bind in a distinct but overlapping manner to gp120 when compared with ICAM-2 and ICAM-3.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, UCLA AIDS Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lee, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, 3821 Mol Sci Bldg,609 Charles E Young Dr E, Los Angeles, CA 90095 USA.	benhurL@microbio.ucla.edu	Lee, Benhur/A-8554-2016	Lee, Benhur/0000-0003-0760-1709	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697, R01AI052021, R21AI055305] Funding Source: NIH RePORTER; NIAID NIH HHS [R21-AI055305, R01 AI052021, AI-28697, R01-AI52021] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; Astoul CH, 2000, BIOCHEM BIOPH RES CO, V274, P455, DOI 10.1006/bbrc.2000.3166; Baribaud F, 2002, J VIROL, V76, P9135, DOI 10.1128/JVI.76.18.9135-9142.2002; Baribaud F, 2001, VIROLOGY, V286, P1, DOI 10.1006/viro.2001.0975; Baribaud FD, 2001, J VIROL, V75, P10281, DOI 10.1128/JVI.75.21.10281-10289.2001; Clapham PR, 2001, BRIT MED BULL, V58, P43, DOI 10.1093/bmb/58.1.43; CLAUSEN H, 1985, BIOCHEMISTRY-US, V24, P3578, DOI 10.1021/bi00335a028; Colmenares M, 2002, J BIOL CHEM, V277, P36766, DOI 10.1074/jbc.M205270200; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; de Parseval A, 2004, J VIROL, V78, P2597, DOI 10.1128/JVI.78.5.2597-2600.2004; Dove A, 2001, NAT BIOTECHNOL, V19, P913, DOI 10.1038/nbt1001-913; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200; Gardner JP, 2003, P NATL ACAD SCI USA, V100, P4498, DOI 10.1073/pnas.0831128100; Geider S, 1996, J BIOL CHEM, V271, P26302, DOI 10.1074/jbc.271.42.26302; Geijtenbeek TBH, 2003, CURR TOP MICROBIOL, V276, P31; Geijtenbeek TBH, 2002, J BIOL CHEM, V277, P11314, DOI 10.1074/jbc.M111532200; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; GURNEY K, 2003, 20 YEARS HIV RES DIS, P236; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; HESTER G, 1995, NAT STRUCT BIOL, V2, P472, DOI 10.1038/nsb0695-472; Hong PWP, 2002, J VIROL, V76, P12855, DOI 10.1128/JVI.76.24.12855-12865.2002; Jameson B, 2002, J VIROL, V76, P1866, DOI 10.1128/JVI.76.4.1866-1875.2002; Kijimoto-Ochiai S, 2002, CELL MOL LIFE SCI, V59, P648, DOI 10.1007/s00018-002-8455-1; Lasala F, 2003, ANTIMICROB AGENTS CH, V47, P3970, DOI 10.1128/AAC.47.12.3970-3972.2003; Lee B, 2001, J VIROL, V75, P12028, DOI 10.1128/JVI.75.24.12028-12038.2001; Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Lue J, 2002, J VIROL, V76, P10299, DOI 10.1128/JVI.76.20.10299-10306.2002; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Matsumoto N, 1998, IMMUNITY, V8, P245, DOI 10.1016/S1074-7613(00)80476-8; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519; Natarajan K, 2002, ANNU REV IMMUNOL, V20, P853, DOI 10.1146/annurev.immunol.20.100301.064812; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Nimrichter L, 2004, GLYCOBIOLOGY, V14, P197, DOI 10.1093/glycob/cwh022; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; Schwartz AJ, 2002, AIDS RES HUM RETROV, V18, P1021, DOI 10.1089/08892220260235380; Schwarz M, 2003, GLYCOBIOLOGY, V13, P749, DOI 10.1093/glycob/cwg091; Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Trumpfheller C, 2003, INT IMMUNOL, V15, P289, DOI 10.1093/intimm/dxg030; van Die I, 2003, GLYCOBIOLOGY, V13, P471, DOI 10.1093/glycob/cwg052; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wu L, 2002, J VIROL, V76, P5905, DOI 10.1128/JVI.76.12.5905-5914.2002; Zamze S, 2002, J BIOL CHEM, V277, P41613, DOI 10.1074/jbc.M207057200; Zelensky AN, 2003, PROTEINS, V52, P466, DOI 10.1002/prot.10626	59	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19122	19132		10.1074/jbc.M400184200	http://dx.doi.org/10.1074/jbc.M400184200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970226	hybrid			2022-12-27	WOS:000221041500125
J	Zzaman, S; Abhyankar, MM; Bastia, D				Zzaman, S; Abhyankar, MM; Bastia, D			Reconstitution of F factor DNA replication in vitro with purified proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; INITIATOR PROTEIN; CRYSTAL-STRUCTURE; PLASMID; ORIGIN; REPE; REGION; HU	Jacob, Brenner, and Cuzin pioneered the development of the F plasmid as a model system to study replication control, and these investigations led to the development of the "replicon model" (Jacob, F., Brenner, S., and Cuzin, F. (1964) Cold Spring Harbor Symp. Quant. Biol. 28, 329-348). To elucidate further the mechanism of initiation of replication of this plasmid and its control, we have reconstituted its replication in vitro with 21 purified host-encoded proteins and the plasmid-encoded initiator RepE. The replication in vitro was specifically initiated at the F ori (oriV) and required both the bacterial initiator protein DnaA and the plasmid-encoded initiator RepE. The wild type dimeric RepE was inactive in catalyzing replication, whereas a monomeric mutant form called RepE* (R118P) was capable of catalyzing vigorous replication. The replication topology was mostly of the Cairns form, and the fork movement was unidirectional and mostly from right to left. The replication was dependent on the HU protein, and the structurally and functionally related DNA bending protein IHF could not efficiently substitute for HU. The priming was dependent on DnaG primase. Many of the characteristics of the in vitro replication closely mimicked those of in vivo replication. We believe that the in vitro system should be very useful in unraveling the mechanism of replication initiation and its control.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Bastia, D (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	bastia@musc.edu						Abhyankar MM, 2004, J BIOL CHEM, V279, P6711, DOI 10.1074/jbc.M312052200; Abhyankar MM, 2003, J BIOL CHEM, V278, P45476, DOI 10.1074/jbc.M308516200; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; Crooke E, 1995, METHOD ENZYMOL, V262, P500; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; EICHENLAUB R, 1977, P NATL ACAD SCI USA, V74, P1138, DOI 10.1073/pnas.74.3.1138; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; HIASA H, 1994, J BIOL CHEM, V269, P6058; HUPP TR, 1993, J BIOL CHEM, V268, P13137; ISHIAI M, 1992, J BACTERIOL, V174, P5597, DOI 10.1128/JB.174.17.5597-5603.1992; ISHIAI M, 1994, P NATL ACAD SCI USA, V91, P3839, DOI 10.1073/pnas.91.9.3839; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KOGOMA T, 1984, P NATL ACAD SCI-BIOL, V81, P7845, DOI 10.1073/pnas.81.24.7845; Komori H, 1999, EMBO J, V18, P4597, DOI 10.1093/emboj/18.17.4597; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; LEDERBERG J, 1953, SCIENCE, V118, P169, DOI 10.1126/science.118.3059.169; LEDERBERG J, 1946, NATURE, V158, P558, DOI 10.1038/158558a0; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; MACALLISTER TW, 1991, J BIOL CHEM, V266, P16056; Matsunaga F, 1997, J MOL BIOL, V274, P27, DOI 10.1006/jmbi.1997.1373; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MURAISO K, 1987, MOL GEN GENET, V206, P519, DOI 10.1007/BF00428895; MUROTSU T, 1984, MOL GEN GENET, V196, P373, DOI 10.1007/BF00328075; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Pellegrini O, 2000, BIOCHIMIE, V82, P693, DOI 10.1016/S0300-9084(00)01151-2; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Seitz H, 2000, MOL MICROBIOL, V37, P1270, DOI 10.1046/j.1365-2958.2000.02096.x; Sharma R, 2001, EMBO J, V20, P4577, DOI 10.1093/emboj/20.16.4577; STENZEL TT, 1991, GENE DEV, V5, P1453, DOI 10.1101/gad.5.8.1453; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; TOLUN A, 1981, CELL, V24, P687, DOI 10.1016/0092-8674(81)90095-7; Uga H, 1999, EMBO J, V18, P3856, DOI 10.1093/emboj/18.13.3856; White SW, 1999, ACTA CRYSTALLOGR D, V55, P801, DOI 10.1107/S0907444999000578	42	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17404	17410		10.1074/jbc.M400021200	http://dx.doi.org/10.1074/jbc.M400021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14973139	hybrid			2022-12-27	WOS:000220870400065
J	Shi, R; Lin, SX				Shi, R; Lin, SX			Cofactor hydrogen bonding onto the protein main chain is conserved in the short chain dehydrogenase/reductase family and contributes to nicotinamide orientation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGENIC 17-BETA-HYDROXYSTEROID-DEHYDROGENASE; HUMAN-PLACENTA; ESTRADIOL; SPECIFICITY; SUBSTRATE; RECEPTOR; NADP(+); COMPLEX; TYPE-1; BREAST	Human estrogenic 17beta-hydroxysteroid dehydrogenase (17beta-HSD1), a member of the short chain dehydrogenase/ reductase (SDR) family, is responsible for the biosynthesis of all active estrogens. The crystal structures of two C19-steroid ternary complexes (17beta- HSD1-androstanedione- NADP and 17beta- HSD1-androstenedione-NADP) reveal the critical role of Leu(149) in regulating the substrate specificity and provide novel insight into the different fates of a conserved glutamate residue in the estrogen-specific proteins upon the binding of the keto and hydroxyl groups of steroids. The whole NADP molecule can be unambiguously defined in the NADP binary complex, whereas both ternary complexes show that the nicotinamide moiety of NADP cannot be located in the density maps. In both ternary complexes, the expected position of carboxamide oxygen of NADP is occupied by a water molecule, which makes a bifurcated hydrogen bond with the O3 of C19-steroid and the main chain nitrogen of Val(188). These results demonstrate that the hydrogen bonding interaction between the main chain amide group and the carboxamide group of NAD(P)(H) plays an important role in anchoring the nicotinamide ring to the enzyme. This finding is substantiated by structural analyses of all 33 NAD( P)( H) complexes of different SDR proteins, because 29 structures of 33 show this interaction. This common feature reveals a general mechanism among the SDR family, providing a rational basis for inhibitor design against biologically relevant SDR targets.	Univ Laval, Med Ctr, CHUQ, Oncol & Mol Endocrinol Res Ctr, Ste Foy, PQ G1V 4G2, Canada	Laval University	Lin, SX (corresponding author), Univ Laval, Med Ctr, CHUQ, Oncol & Mol Endocrinol Res Ctr, 2705 laurier Blvd, Ste Foy, PQ G1V 4G2, Canada.	sxlin@crchul.ulaval.ca		Lin, Sheng-Xiang/0000-0001-9149-375X				Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BONNEY RC, 1986, J STEROID BIOCHEM, V24, P361, DOI 10.1016/0022-4731(86)90082-8; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chavez B, 2001, J HUM GENET, V46, P560, DOI 10.1007/s100380170021; Ekena K, 1998, J BIOL CHEM, V273, P693, DOI 10.1074/jbc.273.2.693; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; Gangloff A, 2002, FASEB J, V16, P274, DOI 10.1096/fj.02-0397fje; Gangloff A, 2001, BIOCHEM J, V356, P269, DOI 10.1042/0264-6021:3560269; GHOSH D, 1994, STRUCTURE, V2, P973, DOI 10.1016/S0969-2126(94)00099-9; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN SX, 1992, J BIOL CHEM, V267, P16182; Luu The V, 1989, Mol Endocrinol, V3, P1301; Mazza C, 1998, J BIOL CHEM, V273, P8145, DOI 10.1074/jbc.273.14.8145; MENDOZAHERNANDEZ G, 1984, BIOCHEM BIOPH RES CO, V119, P83, DOI 10.1016/0006-291X(84)91621-8; Miyoshi Y, 2001, INT J CANCER, V94, P685, DOI 10.1002/ijc.1525; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nahoum V, 2003, FASEB J, V17, P1334, DOI 10.1096/fj.02-0524fje; Negishi M, 1996, FASEB J, V10, P683, DOI 10.1096/fasebj.10.7.8635685; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petrotchenko EV, 1999, J BIOL CHEM, V274, P30019, DOI 10.1074/jbc.274.42.30019; Poutanen M, 1995, J STEROID BIOCHEM, V55, P525, DOI 10.1016/0960-0760(95)00201-4; Sawicki MW, 1999, P NATL ACAD SCI USA, V96, P840, DOI 10.1073/pnas.96.3.840; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; VIHKO R, 1989, CRIT REV ONCOL HEMAT, V9, P1, DOI 10.1016/S1040-8428(89)80012-5; Whitlow M, 2001, J MED CHEM, V44, P2928, DOI 10.1021/jm0101444; YANG F, 1992, J CHROMATOGR-BIOMED, V582, P71, DOI 10.1016/0378-4347(92)80304-9; Zhou HP, 1999, BIOCHEM BIOPH RES CO, V257, P414, DOI 10.1006/bbrc.1999.0356; ZHU DW, 1993, J MOL BIOL, V234, P242, DOI 10.1006/jmbi.1993.1578	37	66	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16778	16785		10.1074/jbc.M313156200	http://dx.doi.org/10.1074/jbc.M313156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14966133	hybrid			2022-12-27	WOS:000220747900130
J	Bernstein, LS; Ramineni, S; Hague, C; Cladman, W; Chidiac, P; Levey, AI; Hepler, JR				Bernstein, LS; Ramineni, S; Hague, C; Cladman, W; Chidiac, P; Levey, AI; Hepler, JR			RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate G(q/11 alpha) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; PLASMA-MEMBRANE; ALPHA-SUBUNITS; G(Q ALPHA); IDENTIFICATION; SPECIFICITY; REGULATOR; DOMAIN; BETA; LOCALIZATION	RGS proteins serve as GTPase-activating proteins and/or effector antagonists to modulate Galpha signaling events. In live cells, members of the B/R4 subfamily of RGS proteins selectively modulate G protein signaling depending on the associated receptor (GPCR). Here we examine whether GPCRs selectively recruit RGS proteins to modulate linked G protein signaling. We report the novel finding that RGS2 binds directly to the third intracellular (i3) loop of the G(q/11)-coupled M1 muscarinic cholinergic receptor (M1 mAChR; M1i3). This interaction is selective because closely related RGS16 does not bind M1i3, and neither RGS2 nor RGS16 binds to the G(i/o)-coupled M2i3 loop. When expressed in cells, RGS2 and M1 mAChR co-localize to the plasma membrane whereas RGS16 does not. The N-terminal region of RGS2 is both necessary and sufficient for binding to M1i3, and RGS2 forms a stable heterotrimeric complex with both activated G(q)alpha and M1i3. RGS2 potently inhibits M1 mAChR-mediated phosphoinositide hydrolysis in cell membranes by acting as an effector antagonist. Deletion of the N terminus abolishes this effector antagonist activity of RGS2 but not its GTPase-activating protein activity toward G(11)alpha in membranes. These findings predict a model where the i3 loops of GPCRs selectively recruit specific RGS protein(s) via their N termini to regulate the linked G protein. Consistent with this model, we find that the i3 loops of the mAChR subtypes (M1-M5) exhibit differential profiles for binding distinct B/R4 RGS family members, indicating that this novel mechanism for GPCR modulation of RGS signaling may generally extend to other receptors and RGS proteins.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	Emory University; Emory University; Emory University; Western University (University of Western Ontario)	Hepler, JR (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	jhepler@emory.edu	Levey, Allan/F-2104-2011; Chidiac, Peter/L-5906-2015	Levey, Allan/0000-0002-3153-502X; Chidiac, Peter/0000-0001-8365-6109	NIGMS NIH HHS [R01 GM 61847] Funding Source: Medline; NINDS NIH HHS [R01 NS 30454, R01 NS 37112] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030454, R01NS037112] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anger T, 2004, J BIOL CHEM, V279, P3906, DOI 10.1074/jbc.M309496200; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Cladman W, 2002, MOL PHARMACOL, V62, P654, DOI 10.1124/mol.62.3.654; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Dowal L, 2001, BIOCHEMISTRY-US, V40, P414, DOI 10.1021/bi001923+; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 2003, MOL PHARMACOL, V64, P547, DOI 10.1124/mol.64.3.547; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Herlitze X, 1999, J PHYSIOL-LONDON, V517, P341, DOI 10.1111/j.1469-7793.1999.0341t.x; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Ingi T, 1998, J NEUROSCI, V18, P7178; Jeong SW, 2001, J PHYSIOL-LONDON, V535, P335, DOI 10.1111/j.1469-7793.2001.00335.x; LEVEY AI, 1991, J NEUROSCI, V11, P3218; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; McClatchy DB, 2002, J BIOL CHEM, V277, P29268, DOI 10.1074/jbc.M203081200; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587; Sierra DA, 2000, TRENDS CARDIOVAS MED, V10, P263, DOI 10.1016/S1050-1738(00)00072-4; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; van Koppen CJ, 2003, PHARMACOL THERAPEUT, V98, P197, DOI 10.1016/S0163-7258(03)00032-9; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	39	187	191	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21248	21256		10.1074/jbc.M312407200	http://dx.doi.org/10.1074/jbc.M312407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14976183	hybrid			2022-12-27	WOS:000221273800085
J	Hwang, R; Lee, EJ; Kim, MH; Li, SZ; Jin, YJ; Rhee, YM; Kim, YM; Lim, SK				Hwang, R; Lee, EJ; Kim, MH; Li, SZ; Jin, YJ; Rhee, YM; Kim, YM; Lim, SK			Calcyclin, a Ca2+ ion-binding protein, contributes to the anabolic effects of simvastatin on bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST DIFFERENTIATION; PARATHYROID-HORMONE; S100 PROTEINS; IN-VITRO; CELLS; OSTEOPOROSIS; THERAPY; MINERALIZATION; OSTEOSARCOMA; ALENDRONATE	In vitro treatment with a pharmacological dose of simvastatin, a potent pro-drug of a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, stimulates bone formation. In our study, simvastatin stimulated differentiation of osteoblasts remarkably in a dose-dependent manner, with minimal effect on proliferation. To identify the mediators of the anabolic effects of simvastatin on osteoblasts, we tried to identify and characterize simvastatin-induced proteins by using proteomic analysis. Calcyclin was significantly up-regulated by more than 10 times, and annexin I was also up-regulated by simvastatin. However, annexin III, vimentin, and tropomyosin were down-regulated. Up-regulated calcyclin mRNA by simvastatin was validated by reverse transcription in mouse calvarial cells. In confocal microscope analysis, green fluorescence protein-calcyclin fusion protein was ubiquitously observed in the of MC3T3-E1 cells transfected with green fluorescence protein-calcyclin cDNA containing plasmid and was quickly concentrated in the nucleus 20 min after simvastatin treatment. Overexpression of calcyclin cDNA stimulated both the proliferation and expression of alkaline phosphatase mRNA significantly, without exposure to simvastatin in MC3T3-E1 cells. However, both the rate of proliferation of the osteoblasts and the expression of alkaline phosphatase mRNA were suppressed significantly 1 day after treatment with the calcyclin-specific small interference RNA, and furthermore, simvastatin did not overcome this suppression in the small interference RNA-pretreated MC3T3-E1 cells. In conclusion, calcyclin is one of the candidate proteins that plays a role in osteoblasto-genesis in response to simvastatin, although the precise functions of calcyclin in osteoblast remain to be verified.	Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Anat, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Lim, SK (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea.	lsk@yumc.yonsei.ac.kr	Rhee, Yumie/L-8020-2019	Rhee, Yumie/0000-0003-4227-5638; Lee, Eun-Jin/0000-0001-5718-542X; Kim, Myoung Hee/0000-0001-5652-1452				Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; Betancourt M, 2003, J BONE MINER RES, V18, P163, DOI 10.1359/jbmr.2003.18.1.163; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jcem.85.3.6476; Corsini Alberto, 2000, Journal of Cardiovascular Pharmacology and Therapeutics, V5, P161, DOI 10.1177/107424840000500304; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Duarte WR, 2003, J BONE MINER RES, V18, P493, DOI 10.1359/jbmr.2003.18.3.493; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; HAGIWARA M, 1988, J BIOL CHEM, V263, P6438; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Herbert B, 2001, ELECTROPHORESIS, V22, P2046, DOI 10.1002/1522-2683(200106)22:10<2046::AID-ELPS2046>3.0.CO;2-C; Horwitz M, 2000, J CLIN ENDOCR METAB, V85, P2127, DOI 10.1210/jc.85.6.2127; Langer A, 2003, CAN J CARDIOL, V19, P921; Laufs U, 1997, J BIOL CHEM, V272, P31725, DOI 10.1074/jbc.272.50.31725; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Niki I, 1996, J BIOCHEM, V120, P685; Nowotny M, 2003, J BIOL CHEM, V278, P26923, DOI 10.1074/jbc.M211518200; PECK WA, 1993, AM J MED, V94, P646; Rosen CJ, 2001, J CLIN ENDOCR METAB, V86, P957, DOI 10.1210/jc.86.3.957; Sakou T, 1998, BONE, V22, P591, DOI 10.1016/S8756-3282(98)00053-2; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; Seth A, 2000, J BONE MINER RES, V15, P1683, DOI 10.1359/jbmr.2000.15.9.1683; Stulik J, 2000, EUR J CANCER, V36, P1050, DOI 10.1016/S0959-8049(00)00043-5; Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; Tu QS, 2003, J BONE MINER RES, V18, P1825, DOI 10.1359/jbmr.2003.18.10.1825; Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882; 2001, S MED J, V94, P569	35	49	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21239	21247		10.1074/jbc.M312771200	http://dx.doi.org/10.1074/jbc.M312771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14973129	hybrid			2022-12-27	WOS:000221273800084
J	Monslow, J; Williams, JD; Guy, CA; Price, IK; Craig, KJ; Williams, HJ; Williams, NM; Martin, J; Coleman, SL; Topley, N; Spicer, AP; Buckland, PR; Davies, M; Bowen, T				Monslow, J; Williams, JD; Guy, CA; Price, IK; Craig, KJ; Williams, HJ; Williams, NM; Martin, J; Coleman, SL; Topley, N; Spicer, AP; Buckland, PR; Davies, M; Bowen, T			Identification and analysis of the promoter region of the human hyaluronan synthase 2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; IN-VITRO; CELLS; ACCUMULATION; TRANSLATION; GENERATION; INDUCTION; CLONING; GROWTH; CANCER	Hyaluronan (HA) is a linear glycosaminoglycan of the vertebrate extracellular matrix that is synthesized at the plasma membrane by the HA synthase (HAS) enzymes HAS1, -2 and -3. The regulation of HA synthesis has been implicated in a variety of extracellular matrix-mediated and pathological processes, including renal fibrosis. We have recently described the genomic structures of each of the human HAS genes. In the present study, we analyzed the HAS2 promoter region. In 5'-rapid amplification of cDNA ends analysis of purified mRNA from human renal epithelial proximal tubular cells, we detected an extended sequence for HAS2 exon 1, relocating the transcription initiation site 130 nucleotides upstream of the reference HAS2 mRNA sequence, GenBank(TM) accession number NM_005328. A luciferase reporter gene assay of nested fragments spanning the 5' terminus of NM_005328 demonstrated the constitutive promoter activity of sequences directly upstream of the repositioned transcription initiation site but not of the newly designated exonic nucleotides. Using reverse transcription-PCR, expression of this extended HAS2 mRNA was demonstrated in a variety of human cell types, and orthologous sequences were detected in mouse and rat kidney. Alignment of human, murine, and equine genomic DNA sequences upstream of the repositioned HAS2 exon 1 provided evidence for the evolutionary conservation of specific transcription factor binding sites. The location of the HAS2 promoter will facilitate analysis of the transcriptional regulation of this gene in a variety of pathological contexts as well as in developmental models in which HAS2 null animals have an embryonic lethal phenotype.	Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales; Cardiff Medictr, Cardiff Inst Tissue Engn & Repair, Cardiff CF14 4UJ, S Glam, Wales; Cardiff Univ, Dept Psychol Med, Cardiff CF14 4XN, S Glam, Wales; Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	Cardiff University; Cardiff University; Cardiff University; Texas A&M University System	Bowen, T (corresponding author), Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales.	bowent@cf.ac.uk	Williams, Hywel/AAL-2440-2021	Williams, Hywel/0000-0001-7758-0312; Newton-Bishop, Julia/0000-0001-9147-6802				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bowen T, 1998, MOL PSYCHIATR, V3, P67, DOI 10.1038/sj.mp.4000293; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2000, AM J RESP CELL MOL, V23, P431, DOI 10.1165/ajrcmb.23.4.f201; Clayton A, 1998, J CELL SCI, V111, P443; Coleman SL, 2002, HUM MOL GENET, V11, P1817, DOI 10.1093/hmg/11.16.1817; Grobe K, 2002, J BIOL CHEM, V277, P30699, DOI 10.1074/jbc.M111904200; Hoogendoorn B, 2003, HUM MOL GENET, V12, P2249, DOI 10.1093/hmg/ddg246; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Jones S, 2001, KIDNEY INT, V59, P1739, DOI 10.1046/j.1523-1755.2001.0590051739.x; Jones SG, 2003, INT J BIOCHEM CELL B, V35, P1361, DOI 10.1016/S1357-2725(03)00040-2; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Knudson CB, 2001, SEMIN CELL DEV BIOL, V12, P69, DOI 10.1006/scdb.2000.0243; Knudson W, 2002, CELL MOL LIFE SCI, V59, P36, DOI 10.1007/s00018-002-8403-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAURENT TC, 1995, ANN RHEUM DIS, V54, P429, DOI 10.1136/ard.54.5.429; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Mack JA, 2003, FASEB J, V17, P1352, DOI 10.1096/fj.02-0959fje; Monslow J, 2003, INT J BIOCHEM CELL B, V35, P1272, DOI 10.1016/S1357-2725(03)00048-7; Mummert ME, 2002, J IMMUNOL, V169, P4322, DOI 10.4049/jimmunol.169.8.4322; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; Nilsson ABM, 2001, ACTA PHYSIOL SCAND, V173, P343, DOI 10.1046/j.1365-201X.2001.00897.x; PHILLIPS AO, 1995, AM J PATHOL, V147, P362; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Spicer AP, 1997, GENOMICS, V41, P493, DOI 10.1006/geno.1997.4696; Spicer AP, 1997, J BIOL CHEM, V272, P8957; Stock AE, 2002, ENDOCRINOLOGY, V143, P4375, DOI 10.1210/en.2002-220563; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Strutz F, 2001, EXPERT OPIN INV DRUG, V10, P1989, DOI 10.1517/13543784.10.11.1989; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yamada Y, 2003, ONCOL REP, V10, P1919; Yung S, 1998, KIDNEY INT, V54, P2160, DOI 10.1046/j.1523-1755.1998.00177.x; Yung S, 1996, KIDNEY INT, V50, P1337, DOI 10.1038/ki.1996.446; Yung S, 2000, KIDNEY INT, V58, P1953, DOI 10.1111/j.1523-1755.2000.00367.x; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	42	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20576	20581		10.1074/jbc.M312666200	http://dx.doi.org/10.1074/jbc.M312666200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14988410	hybrid			2022-12-27	WOS:000221273800006
J	Unno, M; Matsui, T; Chu, GC; Couture, M; Yoshida, T; Rousseau, DL; Olson, JS; Ikeda-Saito, M				Unno, M; Matsui, T; Chu, GC; Couture, M; Yoshida, T; Rousseau, DL; Olson, JS; Ikeda-Saito, M			Crystal structure of the dioxygen-bound heme oxygenase from Corynebacterium diphtheriae - Implications for heme oxygenase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; CATALYTIC PATHWAY; DISTAL POCKET; HMU O; COMPLEX; MYOGLOBIN; DEGRADATION; EPR; MECHANISM; SYSTEM	HmuO, a heme oxygenase of Corynebacterium diphtheriae, catalyzes degradation of heme using the same mechanism as the mammalian enzyme. The oxy form of HmuO, the precursor of the catalytically active ferric hydroperoxo species, has been characterized by ligand binding kinetics, resonance Raman spectroscopy, and x-ray crystallography. The oxygen association and dissociation rate constants are 5 muM(-1) s(-1) and 0.22 s(-1), respectively, yielding an O-2 affinity of 21 muM(-1), which is similar to20 times greater than that of mammalian myoglobins. However, the affinity of HmuO for CO is only 3-4-fold greater than that for mammalian myoglobins, implying the presence of strong hydrogen bonding interactions in the distal pocket of HmuO that preferentially favor O-2 binding. Resonance Raman spectra show that the Fe-O-2 vibrations are tightly coupled to porphyrin vibrations, indicating the highly bent Fe-O-O geometry that is characteristic of the oxy forms of heme oxygenases. In the crystal structure of the oxy form the Fe-O-O angle is 110degrees, the O-O bond is pointed toward the heme alpha-meso-carbon by direct steric interactions with Gly-135 and Gly-139, and hydrogen bonds occur between the bound O-2 and the amide nitrogen of Gly-139 and a distal pocket water molecule, which is a part of an extended hydrogen bonding network that provides the solvent protons required for oxygen activation. In addition, the O-O bond is orthogonal to the plane of the proximal imidazole side chain, which facilitates hydroxylation of the porphyrin alpha-meso-carbon by preventing premature O-O bond cleavage.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 9909585, Japan; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Tohoku University; Case Western Reserve University; Yeshiva University; Albert Einstein College of Medicine; Yamagata University; Rice University	Unno, M (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan.	unno19@tagen.tohoku.ac.jp; mis2@tagen.tohoku.ac.jp	Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015; Matsui, Toshitaka/B-1570-2008; Couture, Manon/F-8326-2015	Matsui, Toshitaka/0000-0003-3865-8468; Couture, Manon/0000-0001-8296-8055; Olson, John/0000-0002-0760-5403	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806, R01GM035649, R01GM057272] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40720] Funding Source: Medline; NIGMS NIH HHS [GM 35649, GM 54806, GM 57272] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; Brucker EA, 1996, J BIOL CHEM, V271, P25419, DOI 10.1074/jbc.271.41.25419; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; Colas C, 2003, CHEM REV, V103, P2305, DOI 10.1021/cr0204303; CONDON PJ, 1994, J BIOL CHEM, V269, P25259; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Davydov R, 2003, J AM CHEM SOC, V125, P16208, DOI 10.1021/ja038923s; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; de Montellano PRO, 2000, CURR OPIN CHEM BIOL, V4, P221; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Denisov IG, 2002, FEBS LETT, V532, P203, DOI 10.1016/S0014-5793(02)03674-8; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fujii H, 1998, J AM CHEM SOC, V120, P8251, DOI 10.1021/ja973925w; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Genco CA, 2001, MOL MICROBIOL, V39, P1, DOI 10.1046/j.1365-2958.2001.02231.x; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; HARUTYUNYAN EH, 1995, J MOL BIOL, V251, P104, DOI 10.1006/jmbi.1995.0419; Hirotsu S, 2004, J BIOL CHEM, V279, P11937, DOI 10.1074/jbc.M311631200; Ikeda-Saito M, 2003, ACS SYM SER, V858, P97; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krzywda S, 1998, BIOCHEMISTRY-US, V37, P15896, DOI 10.1021/bi9812470; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; Migita CT, 1998, J BIOL CHEM, V273, P945, DOI 10.1074/jbc.273.2.945; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; SCHEIDT WR, 1986, J AM CHEM SOC, V108, P1163, DOI 10.1021/ja00266a008; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Suematsu M, 2000, HEPATOLOGY, V31, P3, DOI 10.1002/hep.510310102; Sugishima M, 2002, BIOCHEMISTRY-US, V41, P7293, DOI 10.1021/bi025662a; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Zhang XH, 2003, BIOCHEMISTRY-US, V42, P7418, DOI 10.1021/bi027173g; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	58	100	101	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21055	21061		10.1074/jbc.M400491200	http://dx.doi.org/10.1074/jbc.M400491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14966119	hybrid			2022-12-27	WOS:000221273800062
J	Hardwidge, PR; Rodriguez-Escudero, I; Goode, D; Donohoe, S; Eng, J; Goodlett, DR; Aebersold, R; Finlay, BB				Hardwidge, PR; Rodriguez-Escudero, I; Goode, D; Donohoe, S; Eng, J; Goodlett, DR; Aebersold, R; Finlay, BB			Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; CODED AFFINITY TAGS; GTP-BINDING PROTEIN; KINASE; ACTIN; DIFFERENTIATION; CYTOSKELETON; EXPRESSION; EFFACEMENT; ACTIVATION	We present the first large scale proteomic analysis of a human cellular response to a pathogen. Enteropathogenic Escherichia coli (EPEC) is an enteric human pathogen responsible for much childhood morbidity and mortality worldwide. EPEC uses a type III secretion system (TTSS) to inject bacterial proteins into the cytosol of intestinal epithelial cells, resulting in diarrhea. We analyzed the host response to TTSS-delivered EPEC effector proteins by infecting polarized intestinal epithelial monolayers with either wild-type or TTSS-deficient EPEC. Host proteins were isolated and subjected to quantitative profiling using isotope-coded affinity tagging (ICAT) combined with electrospray ionization tandem mass spectrometry. We identified over 2000 unique proteins from infected Caco-2 monolayers, of which similar to13% are expressed differentially in the presence of TTSS-delivered EPEC effector proteins. We validated these data in silico and through immunoblotting and immunofluorescence microscopy. The identified changes extend cytoskeletal observations made in less relevant cell types and generate testable hypotheses with regard to host proteins potentially involved in EPEC-induced diarrhea. These data provide a framework for future biochemical analyses of host-pathogen interactions.	Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ Complutense Madrid, Dept Microbiol 2, E-28040 Madrid, Spain; Inst Syst Biol, Seattle, WA 98103 USA	University of British Columbia; Complutense University of Madrid; Institute for Systems Biology (ISB)	Finlay, BB (corresponding author), Univ British Columbia, Biotechnol Lab, Rm 237 Wesbrook Bldg,6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	bfinlay@interchange.ubc.ca	Rodríguez, Isabel/I-5955-2017; Eng, Jimmy K/I-4202-2012	Rodríguez, Isabel/0000-0002-1792-1143; Eng, Jimmy K/0000-0001-6352-6737; Goode, David/0000-0002-3277-6562				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BALDWIN TJ, 1991, INFECT IMMUN, V59, P1599, DOI 10.1128/IAI.59.5.1599-1604.1991; Ben-Ami G, 1998, INFECT IMMUN, V66, P1755, DOI 10.1128/IAI.66.4.1755-1758.1998; Bertrand CA, 2004, AM J PHYSIOL-CELL PH, V286, pC247, DOI 10.1152/ajpcell.00593.2002; Bierne H, 2001, J CELL BIOL, V155, P101, DOI 10.1083/jcb.200104037; CANIL C, 1993, INFECT IMMUN, V61, P2755, DOI 10.1128/IAI.61.7.2755-2762.1993; COOMBES BK, 2004, IN PRESS ADV APPL MI; Crane JK, 1997, INFECT IMMUN, V65, P3277, DOI 10.1128/IAI.65.8.3277-3285.1997; DANNENBERG MS, 1993, J CLIN INVEST, V92, P1117; De Grado M, 2001, INFECT IMMUN, V69, P6217, DOI 10.1128/IAI.69.10.6217-6224.2001; Donnenberg MS, 1997, TRENDS MICROBIOL, V5, P109, DOI 10.1016/S0966-842X(97)01000-7; Elliott SJ, 1998, MOL MICROBIOL, V28, P1, DOI 10.1046/j.1365-2958.1998.00783.x; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gauthier A, 2003, INFECT IMMUN, V71, P3310, DOI 10.1128/IAI.71.6.3310-3319.2003; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Goosney DL, 2001, INFECT IMMUN, V69, P3315, DOI 10.1128/IAI.69.5.3315-3322.2001; Gormley K, 2003, BIOCHEM J, V371, P1, DOI 10.1042/BJ20021375; Gruenheid S, 2003, NATURE, V422, P775, DOI 10.1038/nature01603; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; Hecht G, 2001, AM J PHYSIOL-GASTR L, V281, pG1, DOI 10.1152/ajpgi.2001.281.1.G1; Hecht G, 1999, AM J PHYSIOL-GASTR L, V276, pG781, DOI 10.1152/ajpgi.1999.276.3.G781; Henry PC, 2003, J BIOL CHEM, V278, P20019, DOI 10.1074/jbc.M211153200; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hojo M, 2003, J GASTROEN HEPATOL, V18, P815, DOI 10.1046/j.1440-1746.2003.03053.x; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; Hou P, 2003, HUM MOL GENET, V12, P1981, DOI 10.1093/hmg/ddg209; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jepson MA, 2003, CELL MICROBIOL, V5, P773, DOI 10.1046/j.1462-5822.2003.00315.x; Kanzaki M, 2002, MOL BIOL CELL, V13, P2334, DOI 10.1091/mbc.01-10-0490; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lee K, 2001, BIOCHEM J, V353, P377, DOI 10.1042/0264-6021:3530377; LEVINE MM, 1978, LANCET, V1, P1119; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Peiffer I, 2001, CELL MICROBIOL, V3, P341, DOI 10.1046/j.1462-5822.2001.00121.x; Potter DA, 2003, J BIOL CHEM, V278, P30403, DOI 10.1074/jbc.M304616200; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; Santos RL, 2002, J INFECT DIS, V186, P372, DOI 10.1086/341509; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; SWIMM A, 2003, 43 M AM SOC CELL BIO; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Tu XL, 2003, MOL MICROBIOL, V47, P595, DOI 10.1046/j.1365-2958.2003.03329.x; von Haller PD, 2003, MOL CELL PROTEOMICS, V2, P428, DOI 10.1074/mcp.M300041-MCP200; Watarai M, 1997, J EXP MED, V185, P281, DOI 10.1084/jem.185.2.281; Yi EC, 2003, RAPID COMMUN MASS SP, V17, P2093, DOI 10.1002/rcm.1150; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	51	67	70	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20127	20136		10.1074/jbc.M401228200	http://dx.doi.org/10.1074/jbc.M401228200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14988394	hybrid			2022-12-27	WOS:000221164500089
J	Kopp, JL; Wilder, PJ; Desler, M; Kim, JH; Hou, JW; Nowling, T; Rizzino, A				Kopp, JL; Wilder, PJ; Desler, M; Kim, JH; Hou, JW; Nowling, T; Rizzino, A			Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; MEDIATED CELLULAR-TRANSFORMATION; DNA-BINDING SPECIFICITIES; TRANSCRIPTION FACTOR; TGF-BETA; AUTO-INHIBITION; FACTORS ELK-1; CANCER CELLS; EXPRESSION; PROTEIN	Previous studies have shown that the promoter of the type II TGF-beta receptor gene (TbetaR-II) is strongly stimulated by Elf3, a member of the Ets transcription factor family. The TbetaR-II gene behaves as a tumor suppressor and it is expressed in nearly all cell types, whereas Elf3 is expressed primarily in epithelial cells. Hence, the TbetaR-II gene is likely to be regulated by other Ets proteins in nonepithelial cells. In this study, we examined the effects of four other Ets family members (Ets1, Ets2, PEA3, and PU.1) on TbetaR-II promoter/reporter constructs that contain the two essential ets sites of this gene. These studies employed F9 embryonal carcinoma cells and their differentiated cells, because transcription of the TbetaR-II gene increases after F9 cells differentiate. Here we demonstrate that Ets2, which is expressed in F9-differentiated cells along with Elf3, does not stimulate or bind to the TbetaR-II promoter in these cells. In contrast, PEA3 stimulates the TbetaR-II promoter in F9-differentiated cells, but it inhibits this promoter in F9 cells. Thus, the effects of PEA3 on the TbetaR-II promoter are cell context-dependent. We also show that the effects of Elf3 are cell context-dependent. Elf3 strongly stimulates the TbetaR-II promoter in F9-differentiated cells, but not in F9 cells. In contrast to Elf3 and PEA3, Ets1 strongly stimulates this promoter in both F9 cells and F9-differentiated cells. Finally, we show that PU.1 exerts little or no effect on the activity of the TbetaR-II promoter. Together, our findings indicate that Elf3 is not the only Ets protein capable of stimulating the TbetaR-II promoter. Importantly, our findings also indicate that each of the five Ets proteins influences the TbetaR-II promoter in a unique manner because of important differences in their biochemical properties or their patterns of cellular expression.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	arizzino@unmc.edu			NATIONAL CANCER INSTITUTE [P30CA036727, R01CA074771] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74771, CA 36727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bernadt CT, 2003, MOL REPROD DEV, V65, P353, DOI 10.1002/mrd.10313; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Denkinger DJ, 2002, J CELL BIOCHEM, V84, P772, DOI 10.1002/jcb.10089; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; GRAHAM CF, 1980, RESULTS PROBL CELL D, V11, P290; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HUMPHRIES DE, 1994, BIOCHEM BIOPH RES CO, V203, P1020, DOI 10.1006/bbrc.1994.2284; Jackson RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P290, DOI 10.1006/abbi.1999.1459; Jennings R, 2001, ONCOGENE, V20, P6899, DOI 10.1038/sj.onc.1204808; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; Kelly DL, 1999, ANTICANCER RES, V19, P4791; Kim JH, 2002, J BIOL CHEM, V277, P17520, DOI 10.1074/jbc.M110434200; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KULKARNI AB, 1993, AM J PATHOL, V143, P3; Laget MP, 1996, ONCOGENE, V12, P1325; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; Leveen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; MAO XH, 1994, J BIOL CHEM, V269, P18216; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MARTIN ME, 1992, MOL CELL BIOL, V12, P2213, DOI 10.1128/MCB.12.5.2213; MIZEL SB, 1980, P NATL ACAD SCI-BIOL, V77, P2205, DOI 10.1073/pnas.77.4.2205; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; Ng AYN, 2002, GASTROENTEROLOGY, V122, P1455, DOI 10.1053/gast.2002.32990; Nowling T, 2002, MOL REPROD DEV, V63, P309, DOI 10.1002/mrd.90014; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PARIA BC, 1992, DEV BIOL, V151, P91, DOI 10.1016/0012-1606(92)90216-4; Park SH, 2001, CELL GROWTH DIFFER, V12, P9; PIO F, 1995, J BIOL CHEM, V270, P24258, DOI 10.1074/jbc.270.41.24258; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Prud'homme GJ, 2000, J AUTOIMMUN, V14, P23, DOI 10.1006/jaut.1999.0339; RAYNER MJ, 1984, J CELL SCI, V72, P227; RAYNER MJ, 1982, J CELL SCI, V58, P331; RIZZINO A, 1987, CANCER RES, V47, P4386; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Shah AH, 2002, CANCER RES, V62, P7135; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; Wilder PJ, 2002, MOL REPROD DEV, V63, P282, DOI 10.1002/mrd.10165	71	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19407	19420		10.1074/jbc.M314115200	http://dx.doi.org/10.1074/jbc.M314115200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14976186	hybrid			2022-12-27	WOS:000221164500006
J	Salih, E; Fluckiger, R				Salih, E; Fluckiger, R			Complete topographical distribution of both the in vivo and in vitro phosphorylation sites of bone sialoprotein and their biological implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATIONS; RAT OSTEOCLASTS; CELL ATTACHMENT; MASS-SPECTROMETRY; PROTEIN-KINASES; MATRIX PROTEINS; MESSENGER-RNA; DENTAL-PULP; RGD DOMAIN; OSTEOPONTIN	Bone sialoprotein (BSP) is a multifunctional, highly phosphorylated, and glycosylated protein with key roles in biomineralization and tissue remodeling. This work identifies the complete topographical distribution and precise location of both the in vitro and in vivo phosphorylation sites of bovine BSP by a combination of state-of-the-art techniques and approaches. In vitro phosphorylation of native and deglycosylated BSPs by casein kinase II identified seven phosphorylation sites by solid-phase N-terminal peptide sequencing that were within peptides 12 - 22 (LEDS(P) EENGVFK), 42-62 (FAVQSSSD-SS( P) EENGNGDS(P) S(P) EE), 80 - 91 (EDS(P) DENEDEES( P) E), and 135 - 145 (EDES(P) DEEEEEE). The in vivo phosphorylation regions and sites were identified by use of a novel thiol reagent, 1-S-mono[C-14] carboxy-methyldithiothreitol. This approach identified all of the phosphopeptides defined by in vitro phosphorylation, but two additional phosphopeptides were defined at residues, 250 - 264 (DNGYEIYES(P) ENGDPR), and 282 - 289 (GYDS( P) YDGQ). Furthermore, use of native BSP and matrix-assisted laser desorption ionization time-of-flight mass spectrometry identified several of the above peptides, including an additional phosphopeptide at residues 125 - 130 (AGAT(P) GK) that was not defined in either of the in vitro and in vivo studies described above. Overall, 7 in vitro and 11 in vivo phosphorylation sites were identified unequivocally, with natural variation in the quantitative extent of phosphorylation at each in vivo phosphorylation site.	Childrens Hosp, Dept Orthoped Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Orthoped Surg, Lab Study Skeletal Disorders & Rehabil, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Salih, E (corresponding author), Childrens Hosp, Dept Orthoped Res, 300 Longwood Ave, Boston, MA 02115 USA.	erdjan.salih@tch.harvard.edu		Fluckiger, Rudolf/0000-0002-4655-2244; Salih, Erdjan/0000-0003-3322-2323	NATIONAL INSTITUTE ON AGING [R01AG017969] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG 17969] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; CHAMBERS TJ, 1986, BONE MINER, V1, P127; CHEN JK, 1992, J BONE MINER RES, V7, P987; Cooper LF, 1998, J BONE MINER RES, V13, P620, DOI 10.1359/jbmr.1998.13.4.620; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Decup F, 2000, Clin Oral Investig, V4, P110, DOI 10.1007/s007840050126; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; ENDO A, 1989, CONNECT TISSUE RES, V21, P509, DOI 10.3109/03008208909050008; FISHER LW, 1990, J BIOL CHEM, V265, P2347; GLIMCHER MJ, 1984, PHILOS T R SOC B, V304, P479, DOI 10.1098/rstb.1984.0041; Goldberg M, 2003, AM J DENT, V16, P66; Goldberg M, 2002, PATHOL BIOL, V50, P194, DOI 10.1016/S0369-8114(02)00288-2; Goldberg M, 2001, Adv Dent Res, V15, P91; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; Harris NL, 2000, BONE, V27, P795, DOI 10.1016/S8756-3282(00)00392-6; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; Katayama Y, 1998, J CELL PHYSIOL, V176, P179, DOI 10.1002/(SICI)1097-4652(199807)176:1<179::AID-JCP19>3.3.CO;2-M; MIKUNITAKAGAKI Y, 1990, BIOCHEM J, V268, P585, DOI 10.1042/bj2680585; MINTZ KP, 1993, J BONE MINER RES, V8, P985; Mizuno M, 2000, CALCIFIED TISSUE INT, V66, P388, DOI 10.1007/s002230010078; NESBITT S, 1993, J BIOL CHEM, V268, P16737; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OLDBERG A, 1989, J CELL BIOL, V109, P3183, DOI 10.1083/jcb.109.6.3183; Raynal C, 1996, ENDOCRINOLOGY, V137, P2347, DOI 10.1210/en.137.6.2347; Razzouk S, 2002, BONE, V30, P40, DOI 10.1016/S8756-3282(01)00637-8; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROSS FP, 1993, J BIOL CHEM, V268, P9901; Salih E, 1996, J BIOL CHEM, V271, P16897, DOI 10.1074/jbc.271.28.16897; Salih E, 2003, CONNECT TISSUE RES, V44, P223, DOI 10.1080/03008200390181708; Salih E, 2003, ANAL BIOCHEM, V319, P143, DOI 10.1016/S0003-2697(03)00254-9; Salih E, 2002, BIOCHEM J, V364, P465, DOI 10.1042/BJ20011272; Salih E, 1997, J BIOL CHEM, V272, P13966, DOI 10.1074/jbc.272.21.13966; Salih E, 1996, J BONE MINER RES, V11, P1461; Salih E, 1996, CONNECT TISSUE RES, V35, P207, DOI 10.3109/03008209609029193; Samoto H, 2003, J BIOL CHEM, V278, P28659, DOI 10.1074/jbc.M300671200; SHANKAR G, 1995, EXP CELL RES, V219, P364, DOI 10.1006/excr.1995.1240; SHANKAR G, 1993, J CELL SCI, V105, P61; Six N, 2002, J MATER SCI-MATER M, V13, P225, DOI 10.1023/A:1013846516693; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; Stubbs JT, 1997, J BONE MINER RES, V12, P1210, DOI 10.1359/jbmr.1997.12.8.1210; Stubbs JT, 1996, CONNECT TISSUE RES, V35, P393, DOI 10.3109/03008209609029217; Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; VEIS A, 1984, CHEM BIOL MINERALIZE, P170; Wang J, 1998, BONE, V22, P621, DOI 10.1016/S8756-3282(98)00057-X; WANG J, 1999, ORTHOP T, V22, P951; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; Zaia J, 2001, BIOCHEMISTRY-US, V40, P12983, DOI 10.1021/bi010887r; ZHOU HY, 1995, CALCIFIED TISSUE INT, V56, P403, DOI 10.1007/BF00301610	52	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19808	19815		10.1074/jbc.M310299200	http://dx.doi.org/10.1074/jbc.M310299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15004024	hybrid			2022-12-27	WOS:000221164500052
J	Xiao, ZS; Hjelmeland, AB; Quarles, LD				Xiao, ZS; Hjelmeland, AB; Quarles, LD			Selective deficiency of the "bone-related" Runx2-II unexpectedly preserves osteoblast-mediated skeletogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCALCIN GENE-EXPRESSION; TRANSCRIPTION FACTOR; CHONDROCYTE DIFFERENTIATION; MORPHOGENETIC PROTEIN-2; CBFA1; PROMOTER; OVEREXPRESSION; CBFA1/RUNX2; ISOFORMS; MOUSE	Runx2 (runt-related transcription factor 2) is a master regulator of skeletogenesis. Distinct promoters in the Runx2 gene transcribe the "bone-related" Runx2-II and non-osseous Runx2-I isoforms that differ only in their respective N termini. Existing mutant mouse models with both isoforms deleted exhibit an arrest of osteoblast and chondrocyte maturation and the complete absence of mineralized bone, but they do not distinguish the separate functions of the two N-terminal isoforms. To elucidate the function of the bone-related isoform, we generated selective Runx2-II-deficient mice by the targeted deletion of the distal promoter and exon 1. Homozygous Runx2-II-deficient (Runx2-II-/-) mice unexpectedly formed axial, appendicular, and craniofacial bones derived from either intramembranous ossification or mesenchymal cells of the bone collar, but they failed to form the posterior cranium and other bones derived from endochondral ossification. Heterozygous Runx2-II-deficient mice had grossly normal skeletons, but were osteopenic. The commitment of mesenchymal cells ex vivo to the osteoblast lineage occurred in Runx2-II-/- mice, but osteoblastic gene expression was impaired. Chondrocyte maturation appeared normal, but the zone of hypertrophic chondrocytes was not transformed into metaphyseal bone, leading to widened growth plates in Runx2-II-/- mice. Compensatory increments in Runx2-I expression occurred in Runx2-II-/- mice but were not sufficient to normalize osteoblastic maturation or transcriptional activity. Our findings support distinct functions of Runx2-II and -I in the control of skeletogenesis. Runx2-I is sufficient for early osteoblastogenesis and intramembranous bone formation, whereas Runx2-II is necessary for complete osteoblastic maturation and endochondral bone formation.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Bone & Mineral Disorders, Durham, NC 27710 USA	Duke University; Duke University	Quarles, LD (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3036, Durham, NC 27710 USA.	Quarl001@mc.duke.edu		Quarles, L. Darryl/0000-0002-5082-7896; Hjelmeland, Anita/0000-0003-2200-3248	NIAMS NIH HHS [R01 AR 049712] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049712] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; Caplan AI, 1987, BONE MINERAL RES, P117; Choi KY, 2002, EXP MOL MED, V34, P426, DOI 10.1038/emm.2002.60; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Enomoto H, 2004, J CELL SCI, V117, P417, DOI 10.1242/jcs.00866; Enomoto H, 2003, J BIOL CHEM, V278, P23971, DOI 10.1074/jbc.M302457200; Fujita T, 2001, BIOCHEM BIOPH RES CO, V280, P348, DOI 10.1006/bbrc.2000.4108; Fujiwara M, 1999, BBA-GENE STRUCT EXPR, V1446, P265, DOI 10.1016/S0167-4781(99)00113-X; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Inoue K, 2003, BLOOD CELL MOL DIS, V30, P157, DOI 10.1016/S1079-9796(03)00032-9; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Levanon D, 2001, GENE, V262, P23, DOI 10.1016/S0378-1119(00)00532-1; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168-9525(03)00176-8; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Park MH, 2001, J BONE MINER RES, V16, P885, DOI 10.1359/jbmr.2001.16.5.885; Rennert J, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-4; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Telfer JC, 2001, DEV BIOL, V229, P363, DOI 10.1006/dbio.2000.9991; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Tu QS, 2003, J CLIN INVEST, V111, P1029, DOI 10.1172/JCI200317054; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xiao ZS, 2003, J CELL BIOCHEM, V88, P493, DOI 10.1002/jcb.10375; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2	58	81	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20307	20313		10.1074/jbc.M401109200	http://dx.doi.org/10.1074/jbc.M401109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	15007057	hybrid			2022-12-27	WOS:000221164500108
J	Alberto, F; Bignon, C; Sulzenbacher, G; Henrissat, B; Czjzek, M				Alberto, F; Bignon, C; Sulzenbacher, G; Henrissat, B; Czjzek, M			The three-dimensional structure of invertase (beta-fructosidase) from Thermotoga maritima reveals a bimodular arrangement and an evolutionary relationship between retaining and inverting glycosidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; DENSITY MODIFICATION; YEAST INVERTASE; ACTIVE-SITE; SEQUENCE; FOLD; MECHANISMS; GENE; NEURAMINIDASE	Thermotoga maritima invertase (beta-fructosidase) hydrolyzes sucrose to release fructose and glucose, which are major carbon and energy sources for both prokaryotes and eukaryotes. The name "invertase" was given to this enzyme over a century ago, because the 1: 1 mixture of glucose and fructose that it produces was named "invert sugar." Despite its name, the enzyme operates with a mechanism leading to the retention of the anomeric configuration at the site of cleavage. The enzyme belongs to family GH32 of the sequence-based classification of glycosidases. The crystal structure, determined at 2-Angstrom resolution, reveals two modules, namely a five-bladed beta-propeller with structural similarity to the beta-propeller structures of glycosidase from families GH43 and GH68 connected to a beta-sandwich module. Three carboxylates at the bottom of a deep, negatively charged funnel-shaped depression of the beta-propeller are essential for catalysis and function as nucleophile, general acid, and transition state stabilizer, respectively. The catalytic machinery of invertase is perfectly superimposable to that of the enzymes of families GH43 and GH68. The variation in the position of the furanose ring at the site of cleavage explains the different mechanisms evident in families GH32 and GH68 ( retaining) and GH43 ( inverting) furanosidases.	CNRS, F-13402 Marseille 20, France; Univ Aix Marseille 1 & 2, Inst Biol Struct & Microbiol, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS)	Czjzek, M (corresponding author), CNRS, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	czjzek@afmb.cnrs-mrs.fr	Sulzenbacher, Gerlind/A-6801-2018; Henrissat, Bernard/J-2475-2012	Sulzenbacher, Gerlind/0000-0003-4844-2820; Henrissat, Bernard/0000-0002-3434-8588; Alberto, Francois/0000-0002-0596-6694				Ackerman SJ, 2002, J BIOL CHEM, V277, P14859, DOI 10.1074/jbc.M200221200; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; BRAUN C, 1993, ANAL BIOCHEM, V212, P259, DOI 10.1006/abio.1993.1320; BURMEISTER WP, 1992, EMBO J, V11, P49, DOI 10.1002/j.1460-2075.1992.tb05026.x; Cho SW, 2001, J MOL BIOL, V311, P863, DOI 10.1006/jmbi.2001.4919; *COMP COLL PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; GASKELL A, 1995, STRUCTURE, V3, P1197, DOI 10.1016/S0969-2126(01)00255-6; GEBLER J, 1992, J BIOL CHEM, V267, P12559; GUNASEKARAN P, 1990, J BACTERIOL, V172, P6727, DOI 10.1128/jb.172.12.6727-6735.1990; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; *INV, 2002, GAT TECHN UN TECHN C; Jawad Z, 2002, STRUCTURE, V10, P447, DOI 10.1016/S0969-2126(02)00750-5; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KERSTERSHILDERSON H, 1976, CARBOHYD RES, V47, P269, DOI 10.1016/S0008-6215(00)84192-0; KIDBY DK, 1973, ANAL BIOCHEM, V55, P312; KOSHLAND DE, 1954, J BIOL CHEM, V208, P139; Lee HS, 1996, PLANT PHYSIOL, V112, P1513, DOI 10.1104/pp.112.4.1513; Li Y, 1996, MICROBIOL-UK, V142, P1651, DOI 10.1099/13500872-142-7-1651; Liebl W, 1998, APPL MICROBIOL BIOT, V50, P55, DOI 10.1007/s002530051256; Meng GY, 2003, NAT STRUCT BIOL, V10, P935, DOI 10.1038/nsb974; Michel G, 2001, J BIOL CHEM, V276, P40202, DOI 10.1074/jbc.M100670200; Naumoff DG, 2001, PROTEINS, V42, P66, DOI 10.1002/1097-0134(20010101)42:1<66::AID-PROT70>3.0.CO;2-4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nurizzo D, 2002, NAT STRUCT BIOL, V9, P665, DOI 10.1038/nsb835; OSULLIVAN C, 1890, J CHEM SOC, V57, P854; Pitson SM, 1996, FEBS LETT, V398, P7, DOI 10.1016/S0014-5793(96)01153-2; Pons T, 1998, PROTEINS, V33, P383, DOI 10.1002/(SICI)1097-0134(19981115)33:3<383::AID-PROT7>3.0.CO;2-R; Reddy A, 1996, J BIOL CHEM, V271, P13953, DOI 10.1074/jbc.271.24.13953; REDDY AV, 1990, BIOCHEMISTRY-US, V29, P2482, DOI 10.1021/bi00462a007; REDDY VA, 1990, J BIOL CHEM, V265, P10817; ROUSSEL A, 1991, SILICON GRAPHICS GEO, V88; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Schell MA, 2002, P NATL ACAD SCI USA, V99, P14422, DOI 10.1073/pnas.212527599; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Sturm A, 1999, TRENDS PLANT SCI, V4, P401, DOI 10.1016/S1360-1385(99)01470-3; Sturm A, 1999, PLANT PHYSIOL, V121, P1, DOI 10.1104/pp.121.1.1; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029	48	172	187	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18903	18910		10.1074/jbc.M313911200	http://dx.doi.org/10.1074/jbc.M313911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14973124	hybrid, Green Published			2022-12-27	WOS:000221041500100
J	Cakouros, D; Daish, TJ; Mills, K; Kumar, S				Cakouros, D; Daish, TJ; Mills, K; Kumar, S			An arginine-histone methyltransferase, CARMER, coordinates ecdysone-mediated apoptosis in drosophila cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN METHYLATION; CASPASE DRONC; DEATH; METAMORPHOSIS; EXPRESSION; ACTIVATION; COMPLEX	Developmentally programmed cell death is regulated by a balance between pro- and anti-death signaling. During Drosophila metamorphosis, the removal of larval tissues is dependent on the steroid hormone ecdys one, which controls the levels of pro- and anti-death molecules. Ecdysone binds to its heterodimeric receptor ecdysone receptor/ultraspiracle to mediate transcription of primary response genes. Here we show that CARMER, an arginine-histone methyltransferase, is critical in coordinating ecdysone-induced expression of Drosophila cell death genes. Ablation of CARMER blocks ecdysone-induced cell death in Drosophila cells, but not apoptosis induced by cell stress. We demonstrate that CARMER associates with the ecdysone receptor complex and modulates the ecdysone-induced transcription of a number of apoptotic genes. Thus, the chromatin-modifying protein, CARMER, modulates cell death by controlling the hormone-dependent expression of the core cell death machinery.	Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Inst, POB 14,Rundle Mall, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814				Baehrecke EH, 2000, CELL DEATH DIFFER, V7, P1057, DOI 10.1038/sj.cdd.4400753; Cakouros D, 2002, J CELL BIOL, V157, P985, DOI 10.1083/jcb.200201034; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Daish TJ, 2003, CELL DEATH DIFFER, V10, P1348, DOI 10.1038/sj.cdd.4401312; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; Jiang CA, 2000, MOL CELL, V5, P445, DOI 10.1016/S1097-2765(00)80439-6; Jiang CG, 1997, DEVELOPMENT, V124, P4673; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; KUMAR S, 2004, IN PRESS TRENDS BIOC; Lee CY, 2000, MOL CELL, V6, P433, DOI 10.1016/S1097-2765(00)00042-3; Ress C, 2000, TISSUE CELL, V32, P464, DOI 10.1016/S0040-8166(00)80003-8; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Teyssier C, 2002, J BIOL CHEM, V277, P46066, DOI 10.1074/jbc.M207623200; Truman JW, 2002, ANNU REV ENTOMOL, V47, P467, DOI 10.1146/annurev.ento.47.091201.145230; Xu W, 2004, GENE DEV, V18, P144, DOI 10.1101/gad.1141704; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100	21	30	33	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18467	18471		10.1074/jbc.M400972200	http://dx.doi.org/10.1074/jbc.M400972200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14976192	hybrid			2022-12-27	WOS:000221041500046
J	Dorner, A; Xiong, DD; Couch, K; Yajima, T; Knowlton, KU				Dorner, A; Xiong, DD; Couch, K; Yajima, T; Knowlton, KU			Alternatively spliced soluble coxsackie-adenovirus receptors inhibit coxsackievirus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR DYSFUNCTION; CELLULAR RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; CHROMOSOMAL LOCALIZATION; ADHESION MOLECULES; EXPRESSION; PROTEIN; MECHANISM; GENE; CAR	The coxsackie-adenovirus receptor (CAR) is a transmembrane receptor of the immunoglobulin superfamily whose expression is altered in myocardial and malignant diseases. Soluble isoforms of other adhesion molecules and cytokine receptors have been proven to have significant agonist and antagonist effects on their full-length receptors; however, little is known about soluble CAR receptors. Using reverse transcription-PCR, we identified three CAR isoforms that lack the transmembrane domain and are the result of alternative RNA splicing events between exons IV and VII (CAR4/7), exons III and VII (CAR3/7), and exons II and VII (CAR2/7). The three CAR isoforms contain different regions of the extracellular domain of CAR and have C termini that are distinct from the full-length receptors. These alternatively spliced CAR proteins are released from transfected HeLa cells confirming that they are soluble proteins. In addition, the soluble CAR proteins are able to interact with the bacterially expressed extracellular domain of CAR. In addition, CAR4/7 but not CAR2/7 was found to bind to coxsackievirus B3 (CVB3). Each of the three soluble CAR isoforms is able to inhibit CVB3 infection of transfected HeLa cells. Given that soluble CAR isoforms can bind to the extracellular domain of CAR and the CVB3 capsid, they may have significant inhibitory or stimulatory effects on CAR signaling and may have an important role in the host defense against viral infection.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Charite, Dept Cardiol, D-12200 Berlin, Germany	University of California System; University of California San Diego; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Knowlton, KU (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	KKnowlton@ucsd.edu			NHLBI NIH HHS [5R01HL57365-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bernal RM, 2002, CLIN CANCER RES, V8, P1915; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Blankenberg S, 2001, CIRCULATION, V104, P1336, DOI 10.1161/hc3701.095949; Bowles KR, 1999, HUM GENET, V105, P354, DOI 10.1007/s004390051114; Chen JW, 2003, DNA CELL BIOL, V22, P253, DOI 10.1089/104454903321908647; Cohen CJ, 2001, J BIOL CHEM, V276, P25392, DOI 10.1074/jbc.M009531200; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Fechner H, 1999, GENE THER, V6, P1520, DOI 10.1038/sj.gt.3301030; Fechner H, 2003, CIRCULATION, V107, P876, DOI 10.1161/01.CIR.0000050150.27478.C5; FernandezBotran R, 1996, ADV IMMUNOL, V63, P269, DOI 10.1016/S0065-2776(08)60858-5; HALE KK, 1995, CYTOKINE, V7, P26, DOI 10.1006/cyto.1995.1004; Haudenschild D, 2002, J BIOL CHEM, V277, P4309, DOI 10.1074/jbc.M109372200; He YN, 2001, NAT STRUCT BIOL, V8, P874, DOI 10.1038/nsb1001-874; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Honda T, 2000, MOL BRAIN RES, V77, P19, DOI 10.1016/S0169-328X(00)00036-X; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; Knowlton KU, 1996, J VIROL, V70, P7811, DOI 10.1128/JVI.70.11.7811-7818.1996; Lee GH, 2000, CIRC RES, V87, P489; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; Nordoy I, 1996, CLIN IMMUNOL IMMUNOP, V81, P16, DOI 10.1006/clin.1996.0151; Noutsias M, 2001, CIRCULATION, V104, P275; Okegawa T, 2001, CANCER RES, V61, P6592; Pauschinger M, 1999, CIRCULATION, V99, P1348, DOI 10.1161/01.CIR.99.10.1348; Pauschinger M, 1999, CIRCULATION, V99, P889, DOI 10.1161/01.CIR.99.7.889; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; SHAFREN DR, 1995, J VIROL, V69, P3873, DOI 10.1128/JVI.69.6.3873-3877.1995; Soldan SS, 2001, ANN NEUROL, V50, P486, DOI 10.1002/ana.1135; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Thoelen I, 2001, BIOCHEM BIOPH RES CO, V287, P216, DOI 10.1006/bbrc.2001.5535; Tomko RP, 2000, EXP CELL RES, V255, P47, DOI 10.1006/excr.1999.4761; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; van't Hof W, 2002, J VIROL, V76, P6382, DOI 10.1128/JVI.76.12.6382-6386.2002; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	38	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18497	18503		10.1074/jbc.M311754200	http://dx.doi.org/10.1074/jbc.M311754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14978041	hybrid			2022-12-27	WOS:000221041500050
J	Heller, WT; Vigil, D; Brown, S; Blumenthal, DK; Taylor, SS; Trewhella, J				Heller, WT; Vigil, D; Brown, S; Blumenthal, DK; Taylor, SS; Trewhella, J			C Subunits binding to the protein kinase a RI alpha dimer induce a large conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA REGULATORY SUBUNIT; AMIDE H/H-2 EXCHANGE; CATALYTIC-SUBUNIT; I-ALPHA; TROPONIN-C; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; CAMP BINDING; X-RAY; COMPLEX	We present structural data on the RIalpha isoform of the cAMP-dependent protein kinase A that reveal, for the first time, a large scale conformational change within the RIalpha homodimer upon catalytic subunit binding. This result infers that the inhibition of catalytic subunit activity is not the result of a simple docking process but rather is a multi-step process involving local conformational changes both in the cAMP-binding domains as well as in the linker region of the regulatory subunit that impact the global structure of the regulatory homodimer. The results were obtained using small-angle neutron scattering with contrast variation and deuterium labeling. From these experiments we derived information on the shapes and dispositions of the catalytic subunits and regulatory homodimer within a holoenzyme reconstituted with a deuterated regulatory subunit. The scattering data also show that, despite extensive sequence homology between the isoforms, the overall structure of the type Ialpha holoenzyme is significantly more compact than the type IIalpha isoform. We present a model of the type Ialpha holoenzyme, built using available high-resolution structures of the component subunits and domains, which best fits the neutron-scattering data. In this model, the type Ialpha holoenzyme forms a flattened V shape with the RIalpha dimerization domain at the point of the V and the cAMP-binding domains of the RIalpha subunits with their bound catalytic subunits at the ends.	Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92037 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Trewhella, J (corresponding author), Los Alamos Natl Lab, Biosci Div, POB 1663, Los Alamos, NM 87545 USA.	jtrewhella@lanl.gov	Brown, Simon/A-3261-2009; Heller, William/ABE-1104-2020	Brown, Simon/0000-0003-3997-4614; Heller, William/0000-0001-6456-2975; Blumenthal, Donald/0000-0002-8614-1167; Trewhella, Jill/0000-0002-8555-6766	NIGMS NIH HHS [GM19301, GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921, R01GM019301, R37GM019301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amieux PS, 2002, ANN NY ACAD SCI, V968, P75, DOI 10.1111/j.1749-6632.2002.tb04328.x; Anand GS, 2003, P NATL ACAD SCI USA, V100, P13264, DOI 10.1073/pnas.2232255100; Anand GS, 2002, J MOL BIOL, V323, P377, DOI 10.1016/S0022-2836(02)00919-1; Banky P, 2003, J MOL BIOL, V330, P1117, DOI 10.1016/S0022-2836(03)00552-7; BEVINGTON PR, 1969, DATA REDUCTION ERROR, P164; Canaves JM, 2002, J MOL EVOL, V54, P17, DOI 10.1007/s00239-001-0013-1; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; Diller TC, 2000, PROTEIN EXPRES PURIF, V20, P357, DOI 10.1006/prep.2000.1312; ERLICHMA.J, 1973, J BIOL CHEM, V248, P7607; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; HAMMOUDA B, 1996, SMALL ANGLE NEUTRON; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; Heller WT, 2002, BIOCHEMISTRY-US, V41, P15654, DOI 10.1021/bi026687c; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; IBEL K, 1975, J MOL BIOL, V93, P255, DOI 10.1016/0022-2836(75)90131-X; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRIGBAUM WR, 1970, BIOCHEMISTRY-US, V9, P1216, DOI 10.1021/bi00807a024; Laxminarayana D, 2000, INT IMMUNOL, V12, P1521, DOI 10.1093/intimm/12.11.1521; Li F, 2000, BIOCHEMISTRY-US, V39, P15626, DOI 10.1021/bi002196l; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P8233, DOI 10.1021/bi00193a009; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SLICE LW, 1989, J BIOL CHEM, V264, P20940; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Tung CS, 2002, J BIOL CHEM, V277, P12423, DOI 10.1074/jbc.M110298200; Vigil D, 2004, J MOL BIOL, V337, P1183, DOI 10.1016/j.jmb.2004.02.028; Zhao JK, 1998, J BIOL CHEM, V273, P30448, DOI 10.1074/jbc.273.46.30448; ZOLLER MJ, 1979, J BIOL CHEM, V254, P2408	34	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19084	19090		10.1074/jbc.M313405200	http://dx.doi.org/10.1074/jbc.M313405200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14985329	hybrid			2022-12-27	WOS:000221041500121
J	Rybin, VO; Guo, JF; Sabri, A; Elouardighi, H; Schaefer, E; Steinberg, SF				Rybin, VO; Guo, JF; Sabri, A; Elouardighi, H; Schaefer, E; Steinberg, SF			Stimulus-specific differences in protein kinase C delta localization and activation mechanisms in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; PKC-DELTA; ISOFORM EXPRESSION; PHOSPHORYLATION; HYPERTROPHY; EPSILON; APOPTOSIS; CELLS	Protein kinase C (PKC) isoforms play key roles in the regulation of cardiac contraction, ischemic preconditioning, and hypertrophy/failure. Models of PKC activation generally focus on lipid cofactor-induced PKC translocation to membranes. This study identifies tyrosine phosphorylation as an additional mechanism that regulates PKCdelta actions in cardiomyocytes. Using immunoblot analysis with antibodies to total PKCdelta and PKCdelta-pY(311), we demonstrate that PKCdelta partitions between soluble and particulate fractions (with little Tyr(311) phosphorylation) in resting cardiomyocytes. Phorbol 12-myristate 13-acetate (PMA) promotes PKCdelta translocation to membranes and phosphorylation at Tyr(311). H2O2 also increases PKCdelta-pY(311) in association with its release from membranes. Both PMA- and H2O2-dependent increases in PKCdelta-pY(311) are mediated by Src family kinases, but they occur via different mechanisms. The H2O2-dependent increase in PKCdelta-pY(311) results from Src activation and increased Src-PKCdelta complex formation. The PMA-dependent increase in PKCdelta-pY(311) results from a lipid cofactor-induced conformational change that renders PKCdelta a better substrate for phosphorylation by precomplexed Src kinases (without Src activation). PKCalpha-Y-311 phosphorylation does not grossly alter the kinetics of PMA- dependent PKCdelta down-regulation. Rather, tyrosine phosphorylation regulates PKCdelta kinase activity. PKCdelta is recovered from the soluble fraction of H2O2-treated cardiomyocytes as a tyrosine-phosphorylated, lipid-independent enzyme with altered substrate specificity. In vitro PKCdelta phosphorylation by Src also increases lipid-independent kinase activity. The magnitude of this effect varies, depending upon the substrate, suggesting that tyrosine phosphorylation fine-tunes PKCdelta substrate specificity. The stimulus-specific modes for PKCdelta signaling identified in this study allow for distinct PKCdelta-mediated phosphorylation events and responses during growth factor stimulation and oxidant stress in cardiomyocytes.	Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; BioSource Int, Hopkinton, MA 01748 USA	Columbia University	Steinberg, SF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.	sfs1@columbia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064639] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64639] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acs P, 2000, CARCINOGENESIS, V21, P887, DOI 10.1093/carcin/21.5.887; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Clerk A, 2001, CIRC RES, V89, P847, DOI 10.1161/res.89.10.847; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Heidkamp MC, 2001, CIRC RES, V89, P882, DOI 10.1161/hh2201.099434; Hernandez OM, 2000, CIRC RES, V86, P198, DOI 10.1161/01.RES.86.2.198; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Kovacic B, 1998, J BIOL CHEM, V273, P35185; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Kwon SH, 2003, J MOL CELL CARDIOL, V35, P615, DOI 10.1016/S0022-2828(03)00084-1; Leitges M, 2002, MOL CELL BIOL, V22, P3970, DOI 10.1128/MCB.22.12.3970-3980.2002; LI WQ, 1994, J BIOL CHEM, V269, P2349; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Rybin V, 1996, CIRC RES, V79, P388, DOI 10.1161/01.RES.79.3.388; Rybin VO, 1997, AM J PHYSIOL-HEART C, V272, pH1636, DOI 10.1152/ajpheart.1997.272.4.H1636; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Sabri A, 2003, MOL CELL BIOCHEM, V251, P97, DOI 10.1023/A:1025490017780; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Sawai H, 1997, J BIOL CHEM, V272, P2452; Sawyer DB, 2002, J MOL CELL CARDIOL, V34, P379, DOI 10.1006/jmcc.2002.1526; Solaro RJ, 2002, J MOL CELL CARDIOL, V34, P689, DOI 10.1006/jmcc.2002.2028; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Yasuda K, 2002, J IMMUNOL, V169, P2813, DOI 10.4049/jimmunol.169.6.2813	40	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19350	19361		10.1074/jbc.M311096200	http://dx.doi.org/10.1074/jbc.M311096200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14970215	hybrid			2022-12-27	WOS:000221041500148
J	Wu, HJ; Lima, WF; Zhang, H; Fan, A; Sun, H; Crooke, ST				Wu, HJ; Lima, WF; Zhang, H; Fan, A; Sun, H; Crooke, ST			Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; THERMUS-THERMOPHILUS HB8; LUNG-CARCINOMA CELLS; ESCHERICHIA-COLI; RIBONUCLEASE-H; MOLECULAR-CLONING; IN-VITRO; EXPRESSION; KINASE	Although ribonuclease H activity has long been implicated as a molecular mechanism by which DNA-like oligonucleotides induce degradation of target RNAs, definitive proof that one or more RNase H is responsible is lacking. To date, two RNase H enzymes (H1 and H2) have been cloned and shown to be expressed in human cells and tissues. To determine the role of RNase H1 in the mechanism of action of DNA-like antisense drugs, we varied the levels of the enzyme in human cells and mouse liver and determined the correlation of those levels with the effects of a number of DNA-like antisense drugs. Our results demonstrate that in human cells RNase H1 is responsible for most of the activity of DNA-like antisense drugs. Further, we show that there are several additional previously undescribed RNases H in human cells that may participate in the effects of DNA-like antisense oligonucleotides.	ISIS Pharmaceut Inc, Dept Core Technol, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Wu, HJ (corresponding author), ISIS Pharmaceut Inc, Dept Core Technol, 2292 Faraday Ave, Carlsbad, CA 92008 USA.	hwu@isisph.com						Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; BUSEN W, 1980, J BIOL CHEM, V255, P9434; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Cerritelli SM, 1998, GENOMICS, V53, P300, DOI 10.1006/geno.1998.5497; Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; Crooke ST, 2003, BURGERS MED CHEM, V5, P115; Crooke ST, 1999, BIOCHIM BIOPHYS ACTA, V1489, P30; CROUCH RJ, 1982, COLD SPRING HARBOR M, V14, P211; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDER PS, 1991, J BIOL CHEM, V266, P6472; EDER PS, 1993, BIOCHIMIE PARIS, V75, P6472; FRANK P, 1994, NUCLEIC ACIDS RES, V22, P5247, DOI 10.1093/nar/22.24.5247; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; Frank P, 1998, BIOL CHEM, V379, P1407, DOI 10.1515/bchm.1998.379.12.1407; Geary RS, 1997, DRUG METAB DISPOS, V25, P1272; GILES RV, 1995, ANTISENSE RES DEV, V5, P23, DOI 10.1089/ard.1995.5.23; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; KANAYA S, 1992, J BIOL CHEM, V267, P10184; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lima WF, 1997, J BIOL CHEM, V272, P18191, DOI 10.1074/jbc.272.29.18191; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; Lima WF, 2003, J BIOL CHEM, V278, P14906, DOI 10.1074/jbc.M211279200; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Monia BP, 1997, ANTI-CANCER DRUG DES, V12, P327; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; RONG YW, 1990, BIOCHEMISTRY-US, V29, P383, DOI 10.1021/bi00454a012; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; ten Asbroek ALMA, 2002, EUR J BIOCHEM, V269, P583, DOI 10.1046/j.0014-2956.2001.02686.x; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Vickers TA, 2003, J BIOL CHEM, V278, P7108, DOI 10.1074/jbc.M210326200; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 2001, J BIOL CHEM, V276, P23547, DOI 10.1074/jbc.M009676200; Wu HJ, 1998, ANTISENSE NUCLEIC A, V8, P53, DOI 10.1089/oli.1.1998.8.53; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475	45	210	215	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17181	17189		10.1074/jbc.M311683200	http://dx.doi.org/10.1074/jbc.M311683200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960586	hybrid			2022-12-27	WOS:000220870400038
